[
    {
        "input": "Brittle nails, hair loss, and fatigue",
        "output": "Iron deficiency anemia",
        "instruction": "Given the list of symptoms, suggest a possible dietary deficiency or condition that might be the cause.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The trial aims to assess the efficacy and safety of a new hypertension drug compared to a placebo. Primary endpoint: blood pressure reduction after 12 weeks of treatment. Secondary endpoints: improvement in quality of life and a reduction in cardiovascular events.",
        "output": "Primary endpoint: \"blood pressure reduction after 12 weeks of treatment\", Secondary endpoints: \"improvement in quality of life\" and \"reduction in cardiovascular events\"",
        "instruction": "Given a description of a medical trial, identify the primary endpoint and secondary endpoints of the study.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms: fever, sore throat, swollen lymph nodes, fatigue\nDiagnostics: strep throat, mononucleosis, tonsillitis",
        "output": "Fever, sore throat, swollen lymph nodes: Mononucleosis\nFatigue, sore throat: Tonsillitis",
        "instruction": "Given a list of symptoms and a set of diagnostic possibilities, match each symptom with the most likely diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient: 32-year-old female complaining of lower abdominal pain and vaginal discharge. Medical history includes an STD diagnosis six months ago, which was successfully treated.",
        "output": "Additional Testing: A pelvic exam, including a Pap smear and testing for sexually transmitted infections and bacterial vaginosis, would be appropriate to evaluate the cause of the symptoms and determine if any additional treatment is necessary. An ultrasound may also be recommended to assess the reproductive organs and identify any abnormalities.",
        "instruction": "Given a patient's medical history and current symptoms, determine if any additional diagnostic tests or imaging studies are necessary to make a diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Genetic analysis report of a patient's DNA profile.",
        "output": "The patient's DNA profile contains the APOE4 allele, which is a known genetic marker associated with an increased risk of developing Alzheimer's disease. The patient should consult with a healthcare professional to discuss potential preventive measures and regular check-ups.",
        "instruction": "Identify any genetic markers associated with the risk of developing Alzheimer's disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Procedure: Colonoscopy \\nPatient History: Age 55, no history of GI bleeding or colon cancer \\nAre there any potential complications of a colonoscopy? If yes, provide recommendations to mitigate them.",
        "output": "Yes, there are potential complications of a colonoscopy, including bleeding, infection, perforation, or adverse reactions to sedation. Adequate bowel preparation and careful selection of the sedation agent may reduce the risk of adverse events. Patients at higher risk, such as those with a history of bleeding disorders or bowel obstruction, may need additional evaluation or alternative procedures.",
        "instruction": "Given a medical procedure and patient history, identify any potential complications and provide recommendations to mitigate them.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Therapy: CAR-T Cell Therapy",
        "output": "CAR-T cell therapy targets T cells, a type of immune cell.",
        "instruction": "Identify the type of cells targeted by the given therapy.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical guidelines: American Heart Association's Blood Pressure Guidelines",
        "output": "Key points: The guidelines recommend that blood pressure should be measured at every regular healthcare visit, with treatment goals set based on the patient's risk factors and overall health status. Lifestyle changes, such as diet, exercise, and limiting alcohol and salt intake, are recommended for all patients with high blood pressure. Medication may also be necessary, with specific treatment goals outlined for different patient populations.\nPotential benefits: Improved long-term health outcomes and reduced risk of heart attack, stroke, and other cardiovascular diseases.\nPotential risks: Side effects associated with medication use and lifestyle changes, as well as the possibility of overtreatment in certain patients.",
        "instruction": "Given a set of medical guidelines or recommendations, provide a summary of the key points and potential benefits or risks.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medication order: 10mg of amlodipine daily. Electronic health record shows that the patient has a known allergy to amlodipine and is currently taking lisinopril for hypertension.",
        "output": "There is a discrepancy between the medication order and the patient's medication history. The patient has a known allergy to amlodipine and is currently taking lisinopril for hypertension. The medication order should be cancelled and the prescribing physician should be notified. Consider alternative medications for hypertension.",
        "instruction": "Identify any discrepancies between the medication orders and the patient's medication history as provided in the electronic health record and suggest actions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Situation: Treating a patient with a suspected airborne infectious disease",
        "output": "Appropriate PPE: N95 respirator or higher, eye protection (goggles or face shield), gloves, and a gown.",
        "instruction": "Determine the appropriate personal protective equipment (PPE) for a healthcare worker based on a specific situation.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Clinical case study: A 45-year-old male with a history of alcohol abuse presents with abdominal pain, nausea, and yellowing of the skin and eyes.",
        "output": "Key clinical findings include abdominal pain, nausea, and jaundice. Possible diagnosis may include alcoholic liver disease, hepatitis, or cirrhosis.",
        "instruction": "Given a clinical case study, identify the key clinical findings and suggest a possible diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "OBJECTIVE: To compare the effectiveness of compression stockings and pneumatic compression devices for the prevention of deep vein thrombosis in patients after total hip replacement surgery.\nMETHODS: We conducted a randomized controlled trial of 300 patients, with allocation to either compression stockings (n=150) or pneumatic compression devices (n=150). The primary outcome was the incidence of deep vein thrombosis within 30 days post-surgery, as determined by a venogram or a duplex ultrasound.\nRESULTS: The incidence of deep vein thrombosis was significantly lower in the pneumatic compression group (1.3%) compared to the compression stockings group (6.0%) (p=0.02). No major complications or adverse events were reported in either group.\nCONCLUSION: The use of pneumatic compression devices is more effective than compression stockings in reducing the risk of deep vein thrombosis in patients after total hip replacement surgery.",
        "output": "Type of study: Randomized controlled trial\nPrimary outcome: Incidence of deep vein thrombosis within 30 days post-surgery",
        "instruction": "Given an article abstract, determine the type of study (e.g., observational, randomized controlled trial, systematic review) and the primary outcome of the study.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Disease: Alzheimer's disease",
        "output": "Biomarkers associated with Alzheimer's disease include amyloid-beta and tau proteins in cerebrospinal fluid (CSF) and brain imaging.",
        "instruction": "Identify the relevant biomarker(s) associated with a particular disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient reports unexplained weight loss, increased thirst, frequent urination, and blurred vision.",
        "output": "The patient's symptoms may indicate diabetes.",
        "instruction": "Classify the given patient's symptoms into potential medical conditions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "55-year-old male, smoker, sedentary lifestyle, hypertension, obesity, family history of heart disease",
        "output": "1. Age\n2. Smoking\n3. Sedentary lifestyle\n4. Hypertension (high blood pressure)\n5. Obesity\n6. Family history of heart disease",
        "instruction": "Assess the risk factors present in a patient's medical history.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Condition: Type 2 diabetes",
        "output": "Risk factors: Obesity, sedentary lifestyle, older age, family history, high blood pressure, high cholesterol levels, gestational diabetes, and certain ethnic backgrounds (such as African American, Hispanic, Native American, and Asian).",
        "instruction": "Identify potential risk factors for the condition described.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Total cholesterol: 165 mg/dL, HDL cholesterol: 62 mg/dL, LDL cholesterol: 95 mg/dL, Triglycerides: 80 mg/dL",
        "output": "Low risk lipid profile (Total cholesterol within desirable range, HDL cholesterol levels are considered protective, LDL cholesterol within optimal range, and Triglycerides within normal range)",
        "instruction": "Given values for cholesterol, classify the patient's lipid profile risk.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient showed signs of _________________________ in response to the medication.",
        "output": "Allergy",
        "instruction": "Given a medical scenario and a fill-in-the-blank sentence, provide the appropriate term for the blank.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Guidelines for diabetes management in primary care settings.",
        "output": "The guidelines do not include recommendations on nutritional counseling or exercise, which are important components of diabetes management.",
        "instruction": "Given a set of medical guidelines or protocols, identify any conflicts, inaccuracies, or areas for improvement.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient's weight is 75 kg and height is 1.7 meters.",
        "output": "The patient's BMI is 25.95.",
        "instruction": "Determine the patient's BMI from the given data.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A scientific study on a new cancer drug.",
        "output": "The study shows that the new cancer drug is effective in reducing the size and spread of certain types of tumors. However, it is important to note that the study was conducted on a small group of patients, and further studies on a larger population are needed to confirm the results. Additionally, the long-term effects and side effects of the drug are not fully understood and require further investigation.",
        "instruction": "Given a medical study, analyze the significance and reliability of the results and discuss potential limitations and implications.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A family gathering took place at a park where food was left out in the sun for several hours. The next day, attendees experienced abdominal cramps, diarrhea, vomiting, and fever, lasting about 48 hours.",
        "output": "Possible foodborne illness: Salmonella poisoning",
        "instruction": "Given a scenario and symptoms, suggest a possible foodborne illness.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical condition: Arthritis.\nSymptoms: joint pain, stiffness, swelling, decreased range of motion.",
        "output": "Diagnostic tests for arthritis may include X-rays, magnetic resonance imaging (MRI), blood tests, and synovial fluid analysis. Treatment options may include physical therapy, medication, and in severe cases, surgery. It is important to speak with a doctor to determine the appropriate diagnostic tests and treatment options for your specific needs.",
        "instruction": "Given a medical condition and a set of symptoms, identify the different types of diagnostic tests that may be used in the diagnosis and management of the condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "This clinical trial aims to evaluate the efficacy of a new drug for treating depression. Participants will be randomly assigned to either the experimental group receiving the new drug or the control group receiving a placebo. Neither the participants nor the researchers administering the drug will know which group they are in.",
        "output": "This clinical trial is a double-blind, randomized controlled trial.",
        "instruction": "Given a clinical trial description, identify the study design (e.g. double-blind, randomized controlled trial).",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "- Gene A: A gene that, when mutated, can lead to an increased rate of cell division and a higher chance of tumor formation.\n- Gene B: A gene that assists in repairing damaged DNA and helps prevent cells from becoming cancerous.\n- Gene C: A gene that encodes a protein involved in muscle contraction.",
        "output": "- Gene A: Oncogene\n- Gene B: Tumor suppressor gene\n- Gene C: Neither",
        "instruction": "Classify a given dataset of genes as either oncogenes, tumor suppressor genes, or neither based on their descriptions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Salmon",
        "output": "Omega-3 fatty acids",
        "instruction": "Given a food product, identify which nutrient it is primarily known for.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient reports experiencing occasional headaches.",
        "output": "Mild",
        "instruction": "Evaluate the given symptom's severity for a patient with hypertension, classifying it as mild, moderate, or severe.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Title: \"Effects of Vitamin D Supplementation on Cognitive Function in Older Adults: A Randomized Controlled Trial\"\nObjective: Determine if Vitamin D supplementation improves cognitive function in older adults.\nMethods: A double-blind, randomized, placebo-controlled trial with 120 participants aged 60 and older who had mild cognitive impairment.\nResults: There was no significant difference in cognitive function between the Vitamin D and placebo groups after 24 weeks.\nConclusion: This study found no substantial evidence supporting the hypothesis that Vitamin D supplementation improves cognitive function in older adults with mild cognitive impairment.",
        "output": "The purpose of the study was to determine if Vitamin D supplementation improves cognitive function in older adults with mild cognitive impairment. The researchers conducted a randomized, double-blind, placebo-controlled trial with 120 participants aged 60 and older. After 24 weeks, the study did not find any significant difference in cognitive function between the Vitamin D and placebo groups, concluding that there is no substantial evidence to support the hypothesis that Vitamin D supplementation improves cognitive function in this population.",
        "instruction": "Summarize the findings and main points of a given biomedical research article or study, making sure to highlight the study's purpose, methodology, results, and conclusions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "This imaging method uses high-frequency sound waves to produce live images of the inside of the body.",
        "output": "Ultrasound (US)",
        "instruction": "Given the brief description, classify the medical imaging technique: \"Computed Tomography (CT), Ultrasound (US), Magnetic Resonance Imaging (MRI), or X-ray\".",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Angiotensin-converting enzyme (ACE) inhibitors",
        "output": "Blood pressure medication",
        "instruction": "Indicate the type of medication based on the drug's classification.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient, a 45-year-old female, presented to the clinic today with a chief complaint of a persistent cough lasting for three weeks. She describes a dry cough with occasional clear sputum production. There is no associated fever, chills, or shortness of breath. Her vital signs were as follows: blood pressure 120/76 mmHg, heart rate 75 bpm, respiratory rate 16 breaths per minute, and temperature 98.6\u00b0F.",
        "output": "Clinic visit note",
        "instruction": "Classify the following passage as an example of a clinic visit note or a discharge summary.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Propranolol",
        "output": "{\"classification\": \"Beta-blocker\", \"main_uses\": [\"High blood pressure\", \"Angina\", \"Arrhythmias\", \"Migraine prophylaxis\", \"Essential tremor\"], \"possible_side_effects\": [\"Dizziness\", \"Fatigue\", \"Slow heart rate\", \"Low blood pressure\", \"Depression\", \"Nausea\", \"Diarrhea\", \"Erectile dysfunction\"]}",
        "instruction": "Identify the classification of a given drug, its main therapeutic uses, and possible side effects based on available drug information databases.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient name: John Smith",
        "output": "Primary care physician: Dr. Emily Johnson",
        "instruction": "Identify the primary care physician (PCP) associated with the given patient.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient Name: John Smith\nMedication: levothyroxine sodium\nDosage: 50 micrograms\nRoute: oral\nFrequency: once daily, in the morning, on an empty stomach",
        "output": "The medication being prescribed is levothyroxine sodium, with a dosage of 50 micrograms. The medication should be taken orally once daily in the morning on an empty stomach. It is important to follow the specific instructions provided by the healthcare professional, as taking this medication at the wrong time or with certain foods may affect its absorption and effectiveness.",
        "instruction": "Given a prescription, identify the medication(s) being prescribed and provide dosage instructions for a patient.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Article title: \"Efficacy of a new drug in the management of hypertension: a randomized controlled trial.\"",
        "output": "Study design: Randomized controlled trial. Quality assessment: Study methods were rigorous, with appropriate randomization and blinding. However, sample size was small and long-term effects were not evaluated. Results showing efficacy were promising but further studies needed for confirmation.",
        "instruction": "Given a biomedical article, identify the study design and evaluate the quality of the evidence presented.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In a recent study, Harvard Medical School researchers found that a new drug, fosfomycin, can combat antibiotic-resistant urinary tract infections (UTIs). Fosfomycin is widely available in Europe and Asia but not in the United States. In the study, researchers tested a high dose of fosfomycin against other commonly prescribed antibiotics and found that it was significantly more effective at killing drug-resistant bacteria. The study also found that fosfomycin has a low likelihood of developing resistance. This discovery could pave the way for the FDA to approve the use of fosfomycin to treat antibiotic-resistant UTIs in the United States.",
        "output": "- Harvard researchers found fosfomycin effective against antibiotic-resistant UTIs.\n- Fosfomycin is available in Europe and Asia but not in the US.\n- High dose fosfomycin was more effective than other common antibiotics.\n- Fosfomycin has a low likelihood of developing resistance.\n- The findings could lead to FDA approval for fosfomycin in the US.",
        "instruction": "Given a recent healthcare news article, list the main points.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient X has been prescribed the following medications: Lipitor, Plavix, and Lisinopril.",
        "output": "Medication Review for Patient X:\n- Lipitor: Potential side effects include muscle pain, weakness, and tenderness, as well as liver damage. Lipitor can interact with certain antibiotics, blood thinners, and antifungal medications.\n- Plavix: Potential side effects include bleeding, stomach pain, and headaches. Plavix can interact with certain antidepressants, antifungal medications, and blood thinners.\n- Lisinopril: Potential side effects include dizziness, cough, and kidney problems. Lisinopril can interact with certain pain medications, potassium supplements, and diuretics.\nIt's important to monitor patients closely for any adverse reactions and to adjust medication regimens if necessary.",
        "instruction": "Given a list of medications prescribed to a patient, confirm and document their potential drug interactions, side effects, and any other relevant medication information.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Psoriasis",
        "output": "Common symptoms of psoriasis include red, raised, scaly patches on the skin, itching and burning sensations, thickened nails, and joint pain in some cases.",
        "instruction": "Identify the common signs and symptoms of a specific medical condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Title: Effects of Aerobic Exercise on Cognitive Function in Older Adults with Mild Cognitive Impairment: A Systematic Review and Meta-analysis\nAbstract: Mild cognitive impairment (MCI) is a common condition among older adults, and an increased prevalence has been reported in recent years. Aerobic exercise (AE) has been suggested as a potential intervention for individuals with MCI. This systematic review and meta-analysis aimed to evaluate the effects of AE on cognitive function among older adults with MCI. A total of 24 studies were included, and the results indicated a significant positive effect of AE on global cognition, executive function and memory domains. The findings support AE as a potential intervention for older adults with MCI, and future studies should explore the optimal duration, frequency, and intensity of exercise to maximize the cognitive benefits.",
        "output": "The main purpose of the study is to evaluate the effects of aerobic exercise on cognitive function in older adults with mild cognitive impairment.",
        "instruction": "Given a medical article title and abstract, state the main purpose or objective of the study.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Clinical trial report:\n- Study title: A Randomized Double-blind Placebo-controlled Trial of Investigational Drug X in Patients with Moderate to Severe Rheumatoid Arthritis\n- Participants: 300 patients, ages 18-70, with moderate to severe RA\n- Primary outcomes: Improvement in patient's pain scores and reduction of joint swelling",
        "output": "This is a clinical trial that tested an investigational drug (Drug X) to see if it helps patients with moderate to severe rheumatoid arthritis. The study involved 300 patients between the ages of 18-70. The primary outcomes measured were an improvement in pain scores and a reduction in joint swelling.",
        "instruction": "Given a clinical trial report, provide a summary of the study design, participant characteristics, and primary outcomes.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A recent study published in the New England Journal of Medicine suggests that combination therapy of statins and ezetimibe can reduce the risk of cardiovascular events in patients with a history of heart disease.",
        "output": "The study found that the combination therapy of statins and ezetimibe was effective in reducing the incidence of major cardiovascular events in patients with a history of heart disease. This could have important implications for clinical practice and patient outcomes.",
        "instruction": "Given a sentence from a biomedical text, identify the key concepts and provide a brief summary.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patent description:\nThe new device is a wearable, continuous glucose monitoring system that uses a sensor to measure glucose levels in interstitial fluid. The data is transmitted wirelessly to a smartphone app, which displays glucose trends and alerts the user to high or low levels.",
        "output": "Key features:\n- Wearable\n- Continuous glucose monitoring\n- Sensor measurement of glucose levels in interstitial fluid\n- Wireless data transmission to smartphone app\nPotential applications:\n- Diabetes management\n- Prevention of hyperglycemia and hypoglycemia",
        "instruction": "Given a patent description of a new medical device, summarize its key features and potential applications.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Breast cancer screening involves looking for signs of breast cancer before a person has any symptoms. The goal of screening is to catch cancers at an early stage when the chances of successful treatment are highest. There are three main screening methods for breast cancer: mammography, clinical breast examination, and breast self-examination. Mammography is an imaging technique that uses low-energy X-rays to take pictures of the breast tissue to detect any abnormalities or changes. Clinical breast examination involves a healthcare professional gently feeling the breasts for any lumps or changes in size or shape. Breast self-examination is when a person checks their own breasts for lumps, swelling, or skin changes. Women aged 40 and older should discuss their breast cancer risk factors with their healthcare providers to decide when they should start screening and how often to have it.",
        "output": "Breast cancer screening aims to detect cancer early, increasing the chances of successful treatment. It involves mammography, clinical breast exams, and breast self-exams. Women aged 40 and older should discuss their risk factors with a healthcare provider to determine an appropriate screening schedule.",
        "instruction": "Summarize the key points about breast cancer screening from the given information.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms: Cough, fever, chills, muscle aches, headache, and fatigue",
        "output": "These symptoms can be caused by a number of different infections, but the most likely culprit is the flu. It is recommended to seek medical attention for proper diagnosis and treatment.",
        "instruction": "Based on a list of symptoms, identify the most likely causative agent of a patient's infection.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical report for a 46-year-old male patient who presents with chest pain and shortness of breath. Findings include high blood pressure, high cholesterol, and EKG indicating possible cardiac issues.",
        "output": "The patient has elevated blood pressure and cholesterol, and the EKG indicates possible cardiac issues. Further evaluation and diagnostic tests may be necessary to determine the potential cause and severity of the symptoms.",
        "instruction": "Given a patient's medical report, summarize the key findings for a physician consultation.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient electronic medical record",
        "output": "The patient is currently prescribed the following medications: losartan, metformin, and atorvastatin.",
        "instruction": "Given a patient's electronic medical record, identify the prescribed medications.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Diagnostic tests: EKG, MRI, CT scan, X-ray.",
        "output": "An EKG (electrocardiogram) is a diagnostic test that measures the electrical activity of the heart. An MRI (magnetic resonance imaging) uses a magnetic field and radio waves to produce detailed images of internal organs and tissues. A CT (computed tomography) scan uses X-rays and computer technology to produce detailed images of internal organs and structures. An X-ray uses a low level of radiation to create images of bones and other structures in the body.",
        "instruction": "Given a list of diagnostic tests, provide a summary and explanation of each test.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "CC: Chest pain. HPI: A 50-year-old male presents with intermittent chest pain that feels like a pressure and radiates to the left arm lasting for about 10 minutes, then resolves. Review of symptoms is otherwise negative. Vital signs are within normal limits. Physical exam is unremarkable. EKG shows ST segment depression in leads V1-V3. Troponin levels are within the normal range.",
        "output": "Suggest diagnostic tests including:\n- Stress test to evaluate for ischemia.\n- Coronary angiography to identify and locate any potential blockages or stenosis in the coronary arteries.",
        "instruction": "Given a medical chart note, provide a brief overview of the patient's condition and suggest appropriate diagnostic tests.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient symptoms: coughing, wheezing, shortness of breath, chest tightness\nPatient medical history: works in construction, smokes occasionally",
        "output": "Based on the patient's symptoms and medical history, potential environmental or occupational factors may include exposure to dust or other irritants at work. Smoking may also contribute to respiratory issues. Further evaluation may be needed to determine the specific cause and appropriate treatment.",
        "instruction": "Given a patient's symptoms and medical history, identify any potential environmental or occupational factors that may be contributing to the patient's condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Maltodextrin, citric acid, natural and artificial flavor, aspartame, magnesium oxide, ascorbic acid, red 40, blue 1, yellow 5",
        "output": "None",
        "instruction": "Given the provided ingredients list, identify any potential allergens present. If there are no allergens, respond with \"none.\"",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "ECG tracing provided.",
        "output": "Key features of the patient's ECG include the P wave, QRS complex, and T wave. Abnormalities may include arrhythmia, ischemia, or conduction abnormalities.",
        "instruction": "Identify the key features of the patient's electrocardiogram (ECG) and any potential abnormalities.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Total Cholesterol: 190 mg/dL, HDL: 55 mg/dL, LDL: 110 mg/dL, Triglycerides: 100 mg/dL",
        "output": "The patient's cholesterol levels are within the normal range. Normal levels are: Total Cholesterol below 200 mg/dL, HDL above 40 mg/dL, LDL below 130 mg/dL, and Triglycerides below 150 mg/dL.",
        "instruction": "Given a patient's lab report, identify if their cholesterol levels are within the normal range.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Salmonella",
        "output": "Salmonella is a bacterium often found in raw or undercooked poultry, eggs, and beef.",
        "instruction": "Identify the cause of this type of food poisoning.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Protein: Hemoglobin",
        "output": "The primary function of hemoglobin is to transport oxygen from the lungs to the tissues and to carry carbon dioxide from the tissues back to the lungs.",
        "instruction": "What is the primary function of a specific protein in the human body?",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Conditions:\n- Appendicitis\n- Pancreatitis\n- Gallstones\nSymptoms:\n- Severe abdominal pain\n- Nausea and vomiting\n- Elevated temperature",
        "output": "Appendicitis: Severe abdominal pain, nausea, and fever\nPancreatitis: Severe abdominal pain, nausea, and vomiting\nGallstones: Severe abdominal pain, nausea",
        "instruction": "Given a list of conditions and symptoms, match the symptoms to the appropriate condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient Symptoms: Severe abdominal pain, bloating, and constipation.",
        "output": "Based on the symptoms, the patient may be experiencing an obstruction in the colon or small intestine. Further evaluation with a colonoscopy or imaging studies, such as an abdominal CT scan, may be necessary to determine the location and severity of the obstruction. Treatment may involve medications to relieve the constipation, or surgery to remove the obstruction if the blockage is severe.",
        "instruction": "Identify the possible underlying cause of a patient's symptoms and recommend appropriate diagnostic tests or treatments.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc) patients. To determine whether noninvasive echocardiographic estimates of pulmonary arterial pressures could be predictors of future pulmonary hypertension development, we performed a longitudinal study in a cohort of SSc patients at risk for developing PH. Seventy-eight patients with SSc were followed up over a mean period of 3.8 years. Echocardiographic parameters, including tricuspid regurgitant velocity (TRV) and right ventricular systolic pressure (RVSP), were assessed at baseline and follow-up visits. PH was defined as mean pulmonary arterial pressure (mPAP) \u226525 mm Hg measured by right heart catheterization. The primary outcome was the development of PH. During follow-up, 21 patients (26.9%) developed PH. Baseline TRV independently predicted PH development, with a hazard ratio (HR) of 2.28 (95% CI: 1.39\u20133.74) for each 0.1 m/s increase in TRV. RVSP at follow-up was also a significant predictor of PH (HR 1.10; 95% CI: 1.03\u20131.17), while baseline RVSP was not. Our findings suggest that baseline TRV is an independent predictor of PH development in SSc patients at risk, and TRV and follow-up RVSP can be used as noninvasive markers for future development of PH.",
        "output": "The study aimed to determine if noninvasive echocardiographic estimates of pulmonary arterial pressures could predict future pulmonary hypertension development in systemic sclerosis patients. Over 3.8 years, the research found that 26.9% of patients developed pulmonary hypertension. Baseline tricuspid regurgitant velocity (TRV) was determined to be an independent predictor of pulmonary hypertension development, while follow-up right ventricular systolic pressure (RVSP) was also a significant predictor. This suggests that both baseline TRV and follow-up RVSP can serve as noninvasive markers for potential future pulmonary hypertension development in at-risk systemic sclerosis patients.",
        "instruction": "Summarize the main objectives and results of this research study on assessing pulmonary hypertension in systemic sclerosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "What is the role of an insurance provider in the healthcare system?",
        "output": "Insurance providers play a crucial role in the healthcare system by providing coverage for preventive and treatment services, and negotiating rates with healthcare providers and hospitals.",
        "instruction": "Identify and describe the role of key players in the healthcare system, such as physicians, nurses, and insurance providers.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "This paper investigates the effect of a yoga intervention on chronic lower back pain (CLBP) in a randomized controlled trial. The subjects were 60 participants suffering from CLBP aged between 30 and 60 years. The experimental group underwent a yoga intervention for 12 weeks, and the control group received no intervention. Pain intensity and functional disability were assessed using questionnaires. Results demonstrated a significant reduction in pain and improvement in function in the experimental group. Further research is recommended to explore the long-term benefits and the potential use of yoga in other populations.",
        "output": "Strengths: The abstract clearly explains the research purpose, identifies the population studied, and describes the methods used. It also summarizes the main findings, indicating improvements in pain and function after the yoga intervention. Weaknesses: The abstract does not mention specific assessment tools used for measuring pain intensity and functional disability. It also lacks information about the sample size for the experimental and control groups and does not provide numeric data related to the significant reduction in pain or improvement in function.",
        "instruction": "Evaluate the quality of a research paper's abstract by identifying the strengths and weaknesses.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Arthroscopy",
        "output": "Arthroscopy is a procedure used to examine and treat joint-related conditions, typically focusing on the knee, shoulder, ankle, hip, or wrist.",
        "instruction": "Identify the part of the body affected by the given medical term.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Chest X-ray reveals bilateral infiltrates and consolidation in the lower lobes.",
        "output": "Abnormalities present: Bilateral infiltrates and consolidation in the lower lobes.",
        "instruction": "Given a radiology report, identify any abnormalities present.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "CT scan shows a 5 cm mass in the right kidney, with no evidence of metastasis.",
        "output": "The 5 cm mass in the right kidney could suggest a renal cell carcinoma, the most common type of kidney cancer. Although there is no evidence of metastasis, the size of the mass and its location in the kidney would require further diagnostic tests, such as a biopsy or MRI, to confirm the diagnosis.",
        "instruction": "Based on the diagnostic imaging provided, list all of the potential abnormalities detected and explain the significance of each finding.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient presented with polydipsia, polyuria, and uncontrolled blood glucose levels which suggest poor glycemic control.",
        "output": "Polydipsia - excessive thirst; Polyuria - excessive urination; Blood glucose levels - the concentration of sugar in the blood; Glycemic control - management of blood sugar levels in a person with diabetes.",
        "instruction": "Identify any diabetes-related terms in the following sentence and provide brief explanations for each.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Data: blood glucose levels measured over the course of several weeks.",
        "output": "If the blood glucose levels consistently exceed normal ranges, this could indicate diabetes. However, other factors such as diet, medication, and physical activity should be taken into account when making a diagnosis.",
        "instruction": "Given a set of medical data, identify trends and patterns that may be indicative of a particular condition or disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Multiple research articles on the effectiveness of different vaccines.",
        "output": "Researchers have found that vaccines can be highly effective in preventing the spread of infectious diseases like polio, measles, and rubella. The most effective vaccines have high efficacy rates and produce long-lasting immunity. In addition, studies have found that regular vaccination can help to prevent outbreaks in high-risk populations.",
        "instruction": "Given medical research articles, identify the key findings and provide a brief summary.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Diagnosis: Type 2 diabetes mellitus; Treatment plan: Metformin 500mg twice daily, regular blood sugar monitoring, dietary consultation; Recommended lifestyle changes: regular exercise, maintaining a balanced diet, weight loss, smoking cessation, and stress management.",
        "output": "Diagnosed with Type 2 diabetes, the patient will take Metformin 500mg twice daily, monitor blood sugar, and attend dietary consultations. They are advised to exercise regularly, eat a balanced diet, lose weight, quit smoking, and manage stress.",
        "instruction": "Summarize the key points from a patient's medical records, mentioning the diagnosis, treatment plan, and any recommended lifestyle changes.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient presented with fatigue, fever, and enlarged lymph nodes. Medical history includes type 2 diabetes, hypertension, and multiple episodes of pneumonia. Physical exam showed hepatosplenomegaly, and laboratory testing revealed anemia and thrombocytopenia. CT scan showed multiple lymph nodes with the largest measuring 3 cm.",
        "output": "The patient's medical history includes type 2 diabetes, hypertension, and multiple episodes of pneumonia. The physical exam showed hepatosplenomegaly, and laboratory testing revealed anemia and thrombocytopenia. CT scan showed multiple enlarged lymph nodes with the largest node measuring 3 cm. The diagnosis is consistent with lymphoma, and further biopsy and imaging studies are recommended for treatment planning.",
        "instruction": "Given an electronic medical record (EMR) note describing a patient's medical history, summarize the key information and diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "What nerve controls the diaphragm?",
        "output": "The phrenic nerve controls the muscles in the diaphragm.",
        "instruction": "Identify the name of the nerve that controls the muscles in the diaphragm.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Type 2 diabetes is a common and chronic condition that affects the body's ability to process glucose (sugar) due to insufficient insulin production or insulin resistance. The primary causes of type 2 diabetes include genetic predisposition, obesity, physical inactivity, and unhealthy diet.",
        "output": "The primary causes of type 2 diabetes are genetic predisposition, obesity, physical inactivity, and unhealthy diet.",
        "instruction": "Identify the primary causes of type 2 diabetes from the given text.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A04.8, B52.9, J06.9, M00.9, R07.9",
        "output": "A04.8 - Enteritis due to Other Small Intestinal Organisms\nB52.9 - Vitamin B Deficiency, Unspecified\nJ06.9 - Acute Upper Respiratory Infection, Unspecified\nM00.9 - Pyogenic Arthritis, Unspecified\nR07.9 - Chest Pain, Unspecified",
        "instruction": "Given a set of medical codes, match them with their corresponding diagnoses.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms: headache, dry mouth, insomnia, and decreased appetite. \\n Medication: Adderall (amphetamine/dextroamphetamine).",
        "output": "Headache, dry mouth, insomnia, and decreased appetite may all be side effects of Adderall.",
        "instruction": "Identify which symptom(s) described may indicate a side effect of a specific medication.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "90 mL/min, 45 mL/min, 10 mL/min",
        "output": "Normal or High (Stage 1), Mild to Moderate Decrease (Stage 3a), Kidney Failure (Stage 5)",
        "instruction": "Identify the stages of chronic kidney disease according to the given estimated glomerular filtration rate (eGFR) levels.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "My doctor has recently diagnosed me with fibromyalgia, and I am not familiar with this condition.",
        "output": "Chronic widespread pain, Fatigue, Sleep disturbances",
        "instruction": "List at least three typical symptoms associated with the medical condition mentioned in the provided text.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A nurse discussing a patient's condition and treatment plan loudly in a hospital cafeteria during her lunch break.",
        "output": "Yes, there is a violation of HIPAA rules. The nurse is discussing the patient's condition and treatment plan in a public area, potentially disclosing protected health information to unauthorized individuals.",
        "instruction": "In the given scenario, determine if there is a violation of HIPAA (Health Insurance Portability and Accountability Act) rules and explain why.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient reports dizziness and nausea after starting a new medication.",
        "output": "These symptoms may be indicative of an adverse reaction to the new medication. The patient should be advised to speak with their healthcare provider before continuing with the medication.",
        "instruction": "Identify any potential adverse drug reactions or side effects based on the patient's reported symptoms and medication regimen.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms: fever, sore throat, fatigue, swollen lymph nodes, rash",
        "output": "These symptoms could be associated with several diseases, but one possible cause is infectious mononucleosis, also known as mono. Other possible causes could include strep throat or a virus. A doctor should be consulted to determine the exact cause of these symptoms.",
        "instruction": "From the given list of symptoms, identify the disease that they may be associated with.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Pulse oximeter",
        "output": "A pulse oximeter is a small, clip-like device that measures the level of oxygen saturation in your blood by shining a light through the skin, usually on a fingertip or earlobe. It works by detecting the color of oxygenated blood, which is brighter red than deoxygenated blood. The device calculates the percentage of oxygen saturation by comparing the levels of absorbed and unabsorbed light, and it also measures your pulse rate.",
        "instruction": "Explain the functioning of a specific medical device commonly used in healthcare settings.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "This medication is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, obsessive-compulsive disorder, and other mental health conditions.",
        "output": "Antidepressant",
        "instruction": "Given a description of a medication, provide its therapeutic classification.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "ECG Reading:\n- Sinus rhythm\n- P wave precedes each QRS complex\n- PR interval: 0.20 seconds\n- QRS duration: 0.08 seconds\n- QT interval: 0.38 seconds",
        "output": "No abnormalities detected. Normal sinus rhythm with normal intervals and durations.",
        "instruction": "Given an ECG reading, identify any abnormalities and their significance.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Chest x-ray revealed bilateral pleural effusions.",
        "output": "Condition: Pleural effusion\nDescription: Pleural effusion is the abnormal buildup of fluid in the space between the lungs and the chest cavity, which can make breathing difficult and cause chest pain.",
        "instruction": "Given a medical statement, identify the underlying medical condition and provide a brief description of the condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Genetic variant: BRCA1",
        "output": "Potential impact: increased risk of developing breast and ovarian cancer",
        "instruction": "Given a genetic variant, determine its potential impact on a patient's health.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Age: 45, BMI: 29, Family history of heart disease: Yes, Smoker: No, High blood pressure: Yes\nCondition: Cardiovascular disease",
        "output": "Yes, the patient is at risk of developing Cardiovascular disease due to their age, BMI, family history, and presence of high blood pressure.",
        "instruction": "Based on the given patient information, determine if the patient is at risk for the specified condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Warfarin, Simvastatin, Acetaminophen, Aspirin",
        "output": "Warfarin and Aspirin: This combination can increase the risk of bleeding. Consult your doctor regarding this potential drug interaction.",
        "instruction": "Red-flag a potential harmful drug interaction from a given list of medications a patient is taking.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Read the following study and provide a summary of the key findings: \"The Association between Vitamin D and Risk of Hypertension Among Middle-Aged and Older Women\"",
        "output": "This study found a significant association between vitamin D deficiency and increased risk of hypertension in middle-aged and older women. Adequate vitamin D intake may be important in helping to prevent hypertension.",
        "instruction": "Summarize a long and complex medical study or literature review into a few key points.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient is diagnosed with hepatitis. Which organ system(s) are affected?",
        "output": "Organ system affected: liver.",
        "instruction": "Given a medical report, identify the organ system(s) affected by the illness.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Endoscopic Retrograde Cholangiopancreatography (ERCP)",
        "output": "Minimally invasive surgery",
        "instruction": "Classify the following surgical procedure as either open surgery or minimally invasive surgery.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A procedure to remove a damaged or diseased kidney and replace it with a healthy donor kidney.",
        "output": "Nephrology/Transplant Surgery",
        "instruction": "Given a surgical procedure's description, identify the specialty it belongs to.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Lipid Panel, Complete Blood Count, Hemoglobin A1C",
        "output": "Lipid Panel: Fasting required, typically 9-12 hours before the test.\nComplete Blood Count: Fasting not required.\nHemoglobin A1C: Fasting not required.",
        "instruction": "Determine if the patient must fast before having the following laboratory tests.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Lab results:\n-Serum glucose: 110 mg/dL\n-HbA1c: 7.5%\n-Fasting insulin: 10 uIU/mL",
        "output": "Based on the lab results, the patient may have diabetes as shown by high HbA1c and serum glucose levels.",
        "instruction": "Given a patient's lab results, determine if the patient is in a specific disease state.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient's blood pressure is 180/110 mmHg, complaining of chest pain and shortness of breath.",
        "output": "These symptoms indicate a potential medical emergency like a heart attack or pulmonary embolism. The patient should be immediately transferred to the emergency department and treated for the underlying condition.",
        "instruction": "Given a patient's vital signs and symptoms, identify potential medical emergencies and recommend appropriate actions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The Impact of Telemedicine on Diabetes Management: A Systematic Review and Meta-Analysis - This review systematically analyzed 29 studies to evaluate the effectiveness of telemedicine interventions in managing diabetes. A significant overall reduction in HbA1c levels was observed among participants in the telemedicine group, compared to the control group. The review concluded that telemedicine interventions improve glycemic control among persons with diabetes and could serve as an effective approach for diabetes management.",
        "output": "The research article explores the effectiveness of telemedicine interventions in diabetes management, and it concludes that telemedicine improves glycemic control in diabetic patients and could be a valuable approach for managing the condition.",
        "instruction": "Summarize the main theme of the given research article, including the purpose and major conclusion.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient is a 34-year-old male with a history of hypertension and type I diabetes. He was prescribed Lipitor 10mg daily to manage his high blood pressure. Laboratory results: Glucose 192 mg/dL (fasting), HbA1c 8.5%, Total cholesterol 190 mg/dL, LDL 140 mg/dL, HDL 40 mg/dL, Triglycerides 210 mg/dL.",
        "output": "Issue 1: The patient has hypertension but is prescribed Lipitor, which is a cholesterol medication. Correction: The patient should be prescribed an antihypertensive medication (e.g., lisinopril) to manage high blood pressure. \n\nIssue 2: The patient has type I diabetes, but only glucose and HbA1c levels are mentioned. Correction: Include the result of a C-peptide test to better assess the patient's diabetes management.\n\nIssue 3: The patient's HbA1c level of 8.5% suggests poor glycemic control. Correction: Consider adjusting the patient's insulin regimen or discussing additional strategies to improve blood sugar management.",
        "instruction": "Review the given electronic medical record text and identify any apparent errors or inconsistencies that may have clinical impact. Suggest corrections for each identified issue.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical records of 50 patients, including their diagnoses.",
        "output": "Classification of patients' diagnoses:\n- 10 patients have diabetes type 2\n- 15 patients have hypertension\n- 5 patients have chronic obstructive pulmonary disease (COPD)\n- 7 patients have asthma\n- 13 patients have other conditions such as hyperlipidemia, hypothyroidism, or osteoporosis.",
        "instruction": "Given a set of medical records, classify patients based on their diagnoses.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Mrs. Smith, a 35-year-old female, presents to the clinic with persistent abdominal pain, bloating, nausea, and occasional diarrhea for the past four weeks.",
        "output": "The patient's chief complaint is persistent abdominal pain.",
        "instruction": "Based on the provided clinical notes, identify the patient's chief complaint.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "High blood sugar, increased thirst, frequent urination",
        "output": "Diabetes",
        "instruction": "Identify the medical condition associated with the following symptoms: high blood sugar, increased thirst, and frequent urination.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The study investigated the efficacy of a new immunotherapy treatment in 150 patients with advanced metastatic melanoma. The treatment involved inhibiting the PD-1 protein, which helps cancer cells evade detection by the immune system. The therapy showed efficacy in shrinking the tumors in 28% of the patients while increasing overall survival rates to 63% compared to the current standard of care, which has a survival rate of 40%. The side effects profile was favorable, and patients had fewer severe side effects than those receiving chemotherapy.",
        "output": "The new immunotherapy treatment for advanced metastatic melanoma successfully shrunk tumors in 28% of the patients and increased overall survival rates to 63%, compared to the current standard of care's 40% survival rate. Moreover, patients experienced fewer severe side effects than those on chemotherapy.",
        "instruction": "Summarize the main findings of this abstract about a new cancer treatment.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Asthma, type 2 diabetes, breast cancer, hypertension.",
        "output": "Breast cancer is the most likely to be hereditary, with a strong familial link.",
        "instruction": "Given a list of medical conditions, identify the one that is most likely to be hereditary.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A patient has suspected gallstones.",
        "output": "Imaging methods commonly used to diagnose gallstones include ultrasound and magnetic resonance imaging (MRI). These methods are effective in identifying and localizing gallstones within the gallbladder or other parts of the digestive tract.",
        "instruction": "Given a medical scenario, identify the appropriate imaging method for diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Procedure: Endotracheal intubation",
        "output": "Endotracheal tube, laryngoscope, suction catheter",
        "instruction": "Identify the proper medical equipment needed for this procedure.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Clinical trials for Parkinson's disease.",
        "output": "There are currently several clinical trials underway for Parkinson's disease, including studies exploring new treatments for the motor symptoms of the disease, as well as potential strategies for halting or reversing the underlying neurodegeneration. Patients interested in participating in a clinical trial should discuss the options with their healthcare provider.",
        "instruction": "Provide information about current clinical trials related to a specific medical condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Age 26: appendectomy. Age 32: Type 2 diabetes diagnosis. Age 35: knee surgery. Age 33: hypertension diagnosis. Age 42: total thyroidectomy.",
        "output": "1. Age 26: Appendectomy\n2. Age 32: Type 2 diabetes diagnosis\n3. Age 33: Hypertension diagnosis\n4. Age 35: Knee surgery\n5. Age 42: Total thyroidectomy",
        "instruction": "Organize the given medical history information of a patient into a detailed timeline.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "\"After taking my new pain relievers, I felt drowsy and experienced dry mouth.\"",
        "output": "Yes, report to the healthcare provider.",
        "instruction": "Based on the given text, categorize whether the signs noted should be reported to the healthcare provider.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In this study, we have investigated the potential benefits of Turmeric (Curcuma longa) extract supplementation in reducing inflammation and oxidative stress in patients with Type 2 diabetes. A total of 100 patients with Type 2 diabetes were randomly assigned to receive either 500 mg of Turmeric extract or placebo daily for three months. Blood samples were collected to measure glycemic control parameters, markers of inflammation, and oxidative stress. The Turmeric extract group showed significant reductions in markers of inflammation, improved glycemic control, and decreased levels of oxidative stress compared to the placebo group. Moreover, Turmeric extract supplementation was well tolerated with no adverse effects reported.",
        "output": "Main research question: Can Turmeric extract supplementation reduce inflammation and oxidative stress in patients with Type 2 diabetes?\nMain findings: Turmeric extract supplementation (500 mg daily for three months) significantly reduced inflammation markers, improved glycemic control, and decreased oxidative stress levels in Type 2 diabetes patients, with no reported adverse effects.",
        "instruction": "From the provided biomedical article, determine the main research question and briefly summarize the main findings of the article.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "What is the primary active ingredient in Tylenol?",
        "output": "Acetaminophen",
        "instruction": "Identify the primary active ingredient in a given medication.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Five separate codes related to diagnostic imaging services.",
        "output": "Organize the codes by imaging modality, such as X-rays, MRI, CT scans, PET scans, etc.",
        "instruction": "Given a set of medical billing codes, classify and organize them into appropriate categories.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A 55-year-old male with a family history of heart disease, who is a smoker, overweight, diabetic, and has uncontrolled hypertension.",
        "output": "1. Age (55 years old)\n2. Male sex\n3. Family history of heart disease\n4. Smoking\n5. Overweight\n6. Diabetes\n7. Uncontrolled hypertension",
        "instruction": "Based on the provided patient case, list key risk factors for cardiovascular disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Insulin pump.",
        "output": "Insulin pumps are a medical device used to manage insulin delivery for patients with type 1 or type 2 diabetes. They consist of a small pump worn on the body that delivers insulin through a catheter placed under the skin. Indications for use include better management of blood sugar levels and improved quality of life for patients. Risks include infection at the injection site, improper insulin dosing, and pump failure. Limitations include the need for regular maintenance and monitoring to ensure proper functioning.",
        "instruction": "Provide accurate and specific information about a given medical device, including its indications, risks, and limitations.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Osteoporosis",
        "output": "The appropriate diagnostic test for osteoporosis is a bone density test, also known as a dual-energy x-ray absorptiometry (DXA) test. This test measures bone mineral density and can indicate a patient's risk for fracture. It is used to diagnose osteoporosis or to determine the effectiveness of treatment.",
        "instruction": "Identify the appropriate diagnostic test for the given medical condition and explain its purpose.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In this study, we investigated the effects of combining metformin and statins on the risk of developing cardiovascular events in diabetic patients. We conducted a retrospective cohort study using medical claims data from a large nationwide insurer. The results showed that patients taking both metformin and statins had a lower risk of cardiovascular events compared to patients taking either drug alone.",
        "output": "Combining metformin and statins for reducing cardiovascular events in diabetic patients.",
        "instruction": "Identify the primary topic discussed in a given biomedical research abstract.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Avocado, butter, coconut oil, salmon, cheddar cheese, almonds, olive oil, bacon.",
        "output": "Butter, coconut oil, cheddar cheese, and bacon are high in saturated fats.",
        "instruction": "Given a list of food items, identify which ones are high in saturated fats.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medication: acetaminophen",
        "output": "Acetaminophen is considered safe to take during pregnancy when used at recommended doses.",
        "instruction": "Determine whether a medication is safe to take during pregnancy.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient medication regimen: 58-year-old male taking blood thinners for a history of blood clots, as well as medications to treat high blood pressure.",
        "output": "Potential side effects from blood thinners may include increased risk of bleeding or bruising, while high blood pressure medications can cause dizziness, fatigue, or dehydration. Interactions between the medications may also occur, and careful monitoring of the patient's symptoms and lab values may be necessary to prevent adverse effects.",
        "instruction": "Given a specific patient's medication regimen, identify potential side effects and interactions with other medications.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Furosemide is a loop diuretic that acts by inhibiting the luminal Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus increasing the urinary excretion of sodium, potassium, calcium, and water.",
        "output": "inhibiting the luminal Na-K-2Cl symporter in the thick ascending limb of the loop of Henle",
        "instruction": "Identify from the provided text, the mechanism of action for the given drug.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Diagnosis: Acute bronchitis",
        "output": "ICD-10 code: J20.9",
        "instruction": "Identify the ICD-10 code(s) associated with the given diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Lisinopril, Enalapril, Ramipril, and Captopril.",
        "output": "Angiotensin-converting enzyme (ACE) inhibitors.",
        "instruction": "Given a set of generic drug names, identify the primary therapeutic category they belong to.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Research article: \"Effectiveness of physical therapy interventions to reduce fear of movement in chronic low back pain patients: a systematic review and meta-analysis\"\nKeywords: physical therapy, fear of movement, low back pain",
        "output": "Physical therapy interventions can be effective in reducing fear of movement in patients with chronic low back pain, according to a systematic review and meta-analysis.",
        "instruction": "Given a medical research article and a set of keywords, identify and summarize the most relevant information using a limited number of words.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient Tom has been diagnosed with hypertension. The physician has prescribed him amlodipine and losartan.",
        "output": "Amlodipine is a calcium channel blocker used to treat high blood pressure and chest pain. Its side effects include swelling of the feet and ankles, dizziness, headaches, and flushing. Losartan is an angiotensin receptor blocker used to treat hypertension and heart failure. Its side effects include dry cough, back pain, and dizziness.",
        "instruction": "Given a medical text, identify the drugs prescribed for a given patient and explain their potential side effects.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient has a medical history of hypertension and diabetes. Criteria for diagnosis of metabolic syndrome: A patient must have three or more of the following: elevated waist circumference, high blood pressure, high fasting glucose, high triglycerides, low HDL cholesterol.",
        "output": "Yes, the patient meets the criteria for diagnosis of metabolic syndrome based on elevated waist circumference, high blood pressure, and high fasting glucose.",
        "instruction": "Given a patient's medical chart and a criteria, determine whether the patient meets the criteria for a specific medical condition or diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Potential diagnoses include viral gastroenteritis, food poisoning, and appendicitis. Symptoms include nausea, vomiting, diarrhea, and abdominal pain.",
        "output": "Based on the absence of symptoms such as fever and pain in the lower right abdomen, appendicitis is unlikely and can be ruled out as a potential diagnosis. The remaining diagnoses may require further examination or testing to determine the cause of the patient's symptoms.",
        "instruction": "Given a set of potential diagnoses and their associated symptoms, eliminate unlikely diagnoses based on the absence of certain symptoms.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Treatment: Chemotherapy for cancer",
        "output": "Chemotherapy can help decrease the size of cancerous tumor and prevent cancer from spreading to other parts of the body.",
        "instruction": "Identify the potential benefits of a specific treatment for the given medical condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "CBC with differential and platelets:\nWBC 5, HGB 11.5, HCT 35.9, PLT 120, NEUTS 21, LYMPHS 70.",
        "output": "The CBC with differential and platelets show a normal white blood cell count, a low hemoglobin level, low hematocrit level, and a low platelet count. The patient may be anemic and require further investigation. The differential shows a lower than normal neutrophil count and elevated lymphocyte count, which may indicate a viral infection.",
        "instruction": "Describe the given laboratory results and their implications for the patient's medical condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient History: 32-year-old male with a history of depression and anxiety.\nSymptoms: Difficulty sleeping, loss of appetite, and decreased energy levels.\nTreatment Option: Lexapro",
        "output": "Lexapro may be appropriate as a treatment option for the patient, given their history and symptom pattern. However, a thorough evaluation and consultation with a medical professional is necessary before making a final determination.",
        "instruction": "Given a patient's medical history and symptom pattern, determine whether a particular medication or treatment option is appropriate.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical history: diabetes, high blood pressure\nCurrent medications: metformin, lisinopril\nNewly prescribed medication: simvastatin",
        "output": "Potential adverse effects or drug interactions: increased risk of muscle pain and weakness, increased risk of developing rhabdomyolysis",
        "instruction": "Given a patient's medical history and current medications, determine if a newly prescribed medication has any potential adverse effects or drug interactions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Amoxicillin 500 mg, take one capsule every 8 hours for 10 days",
        "output": "The dosage is 500 mg, and the medication should be taken every 8 hours (three times a day) for a total of 10 days.",
        "instruction": "Given a prescription, determine the dosage and frequency of the medication.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A study was conducted to investigate the effects of a new drug on cognitive function in Alzheimer's patients.",
        "output": "Limitations: small sample size, lack of diversity in participants, short duration of the study",
        "instruction": "Given a medical research study, identify potential flaws or limitations in the study.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The presence of amyloid plaques in the brain is a key biomarker for Alzheimer's disease.",
        "output": "Amyloid plaques are a hallmark of Alzheimer's disease and are thought to contribute to the cognitive decline and memory loss associated with the disease. Early detection of amyloid plaques can aid in early diagnosis and treatment of Alzheimer's.",
        "instruction": "Identify and explain the importance of a key biomarker for diagnosing a specific disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The study found that patients with asthma who received regular treatment had fewer exacerbations and better overall lung function.",
        "output": "Main findings: Regular treatment of asthma leads to fewer exacerbations and better lung function.",
        "instruction": "Given a sentence from a biomedical text, extract and summarize the main findings or results reported.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medication: amoxicillin, Dosage: 500mg, Duration: 7 days",
        "output": "The patient needs to take a total of 3500mg of amoxicillin over a period of 7 days.",
        "instruction": "Given a medication and its prescribed dosage, calculate the total amount the patient needs to take over a specific duration.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Blood pressure",
        "output": "Millimeters of mercury (mmHg)",
        "instruction": "Identify the standard unit of measurement for the medical term given in the input.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Pain in the lower right abdomen",
        "output": "- Appendicitis\n- Ovarian cyst\n- Kidney stones\n- Hernia\n- Gastrointestinal issues\n- Muscular strain\nPlease consult a healthcare professional for a proper diagnosis.",
        "instruction": "Given the description of a patient's symptom, briefly list the potential causes for the symptom.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Drug name: Aspirin",
        "output": "Drug classification: Nonsteroidal Anti-Inflammatory Drug (NSAID)\nTherapeutic uses: Pain relief, fever reduction, anti-inflammatory properties, and prevention of heart attack and stroke in at-risk patients.",
        "instruction": "Given a drug name, describe the drug's classification and therapeutic uses.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In this double-blind, placebo-controlled trial, 248 patients with painful diabetic neuropathy were randomly assigned to receive either a new drug (124 patients) or placebo (124 patients). The primary endpoint was a change in pain intensity from baseline to week 12. The mean change in pain intensity in the drug group was -1.8, compared to -0.9 in the placebo group (p=0.038).",
        "output": "Yes, the study mentions a statistically significant result. The p-value (0.038) is less than 0.05, which indicates a significant difference between the drug and placebo groups.",
        "instruction": "Based on the provided abstract of a research paper, determine if the study mentions a statistically significant result.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A 45-year-old female patient reports experiencing joint pain, stiffness, and swelling in both hands and feet for the past several weeks. She has also been feeling fatigued and has experienced a low-grade fever. Lab results show elevated levels of rheumatoid factor and C-reactive protein.",
        "output": "Based on the symptoms and laboratory findings, the likely underlying condition is rheumatoid arthritis. The elevated levels of rheumatoid factor and C-reactive protein are consistent with this diagnosis. It is unclear at this point what may be causing the rheumatoid arthritis, and further diagnostic tests and evaluations may be necessary to determine the underlying cause.",
        "instruction": "Given a description of a patient's medical history, identify the underlying condition and its likely cause based on the reported symptoms and laboratory findings.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "65-year-old male, history of hypertension and diabetes.",
        "output": "Based on the patient's age, gender, and medical history, the estimated glomerular filtration rate (eGFR) should be calculated to determine kidney function. The presence of hypertension and diabetes may indicate the potential for kidney disease, and further testing such as creatinine or urine tests may be recommended.",
        "instruction": "Given a patient's demographics and medical history, calculate the estimated glomerular filtration rate (eGFR) and identify potential kidney disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Palliative care vs. Hospice care",
        "output": "Palliative care focuses on providing relief from the symptoms, pain, and stress of a serious illness at any stage in the treatment process. Hospice care is a specific type of palliative care provided to patients with a terminal illness nearing the end of life, focusing on comfort and support rather than curative treatment.",
        "instruction": "Differentiate between the two terms provided in the context of healthcare.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Title: Effects of mobile health app on bodyweight and health-related quality of life in overweight and obese individuals\nAim: To investigate if a mobile health app could help overweight and obese individuals lose weight and improve their quality of life.\nMethods: A randomized controlled trial was conducted with 100 participants, who were randomly assigned to receive either the mobile health app or usual care. The intervention group used the app to monitor their diet, physical activity, and receive feedback over a 12-week period.\nResults: At the end of 12 weeks, the intervention group had a statistically significant weight reduction compared to the control group (p < 0.001). They also showed significant improvements in health-related quality of life, with higher scores in physical and mental functioning (p < 0.001).\nConclusion: The mobile health app was effective in assisting overweight and obese individuals to lose weight and improve their health-related quality of life.",
        "output": "The study aimed to evaluate the effectiveness of a mobile health app for weight loss and quality of life improvement in overweight and obese individuals. A randomized controlled trial with 100 participants demonstrated that those using the app experienced significant weight reduction and better health-related quality of life compared to the control group after 12 weeks.",
        "instruction": "Summarize a medical study's findings, including its aims, methods, and conclusions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Objective: To determine the effectiveness of metformin and sulfonylureas for reducing the risk of major vascular events in patients with type 2 diabetes. Methods: We conducted a population-based cohort study of 523,620 patients with type 2 diabetes, who initiated oral antidiabetics between January 1, 2000, and December 31, 2010. Patients were matched on propensity score for treatment with metformin or sulfonylureas and followed up for the occurrence of major vascular events. Results: The risk of major vascular events was significantly lower among metformin initiators (hazard ratio 0.80, 95% CI 0.76-0.84) compared to sulfonylurea initiators. The risk reduction remained consistent across age, sex, and baseline CVD risk strata. Conclusion: Metformin is associated with a significant reduced risk of major vascular events compared to sulfonylureas in patients with type 2 diabetes.",
        "output": "This study aimed to compare metformin and sulfonylureas' effectiveness in reducing major vascular events risk in type 2 diabetes patients. A population-based cohort study involving 523,620 patients was conducted. Metformin initiators had a significantly lower risk of major vascular events compared to sulfonylurea initiators, and this risk reduction was consistent across different age, sex, and baseline CVD risk groups. The conclusion suggests that metformin is better than sulfonylureas for reducing major vascular events risk in type 2 diabetes patients.",
        "instruction": "Summarize the provided abstract from a medical research paper, highlighting the objective, methods, results, and conclusion.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A patient presents with frequent urination, a burning sensation during urination, and lower abdominal pain. The medical report includes a urinalysis showing the presence of bacteria, as well as a blood test showing elevated white blood cells.",
        "output": "The patient's most likely diagnosis is a urinary tract infection. Treatment options may include a course of antibiotics such as ciprofloxacin or nitrofurantoin, as well as increased fluid intake. A follow-up urine test should be done to ensure the infection has been successfully cleared.",
        "instruction": "Given a medical report, identify the patient's diagnosis and provide an overview of relevant treatment options.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "What are the major types of white blood cells and what are their functions?",
        "output": "The major types of white blood cells are neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Neutrophils are the most abundant and help fight bacterial infections. Lymphocytes include T-cells and B-cells and are important for the immune response. Monocytes help fight infections and eosinophils and basophils are involved in the allergic response.",
        "instruction": "Identify the major types of white blood cells and their functions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient A: Lower back pain, diagnosed with lumbar strain. Patient B: Suffering from chronic lower back pain, vertebral degeneration identified. Patient C: Recurring shoulder pain following a fall, muscle injury. Patient D: Headache after prolonged screen usage, eyestrain diagnosed. Patient E: Lower back pain, diagnosed with muscle strain.",
        "output": "The most common ailment in this sample of patient records is lower back pain.",
        "instruction": "Identify the most common ailment from a sample of patient records provided, using natural language processing techniques.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "What type of drug is X and what are the side effects?",
        "output": "Drug X is classified as an antipsychotic medication. Common side effects include drowsiness, weight gain, and increased risk of diabetes and high cholesterol.",
        "instruction": "What is the classification of drug X and what are some common side effects?",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A medication order has been entered for Patient A to receive 40mg of IV furosemide to treat congestive heart failure. The patient's medical history includes a history of sulfa allergy, and the current medication list includes lisinopril, metoprolol, and aspirin.",
        "output": "Administration of furosemide should be avoided in patients with a history of sulfa allergy, as furosemide contains a sulfa moiety. Alternative medications, such as ethacrynic acid or bumetanide, may be considered. The patient's other medications are not known to interact with furosemide and are safe to continue.",
        "instruction": "Given a medication order and a patient's electronic medical record, verify that the medication is safe to administer based on the patient's allergies, medical history, and other current medications.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The main objective of this randomized, double-blind, placebo-controlled clinical trial was to evaluate the efficacy and safety of a novel antiviral drug, XZ-25, in the treatment of patients with severe viral pneumonia. A total of 200 participants were enrolled and evenly distributed into the drug and placebo groups. The primary outcome measured improvement in oxygen saturation levels, and secondary outcomes included the duration of hospital stay and mortality rates. Patients receiving XZ-25 showed a statistically significant improvement in their oxygen saturation levels compared to the placebo group (p<0.001) and a shorter hospital stay (p=0.005). No significant difference was found in mortality rates between the two groups.",
        "output": "The clinical trial aimed to test the effectiveness and safety of a new antiviral drug, XZ-25, in treating severe viral pneumonia patients. In this study, patients treated with XZ-25 had significantly improved oxygen saturation levels and shorter hospital stays compared to the placebo group. However, there was no significant difference in the mortality rates between the two groups.",
        "instruction": "Summarize a clinical trial's purpose, methods, and results in a few sentences.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "What is the nutritional value of an avocado?",
        "output": "Avocado contains healthy fats, fiber, potassium, and vitamins C, K, and B6.",
        "instruction": "Provide a summary of the nutritional value of a particular food.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Parkinson's disease",
        "output": "Primary symptoms: Tremors, rigid muscles, impaired posture and balance, slow movements\nPrimary conditions: Neurodegenerative disorder, progressive disorder of the nervous system",
        "instruction": "Identify the primary symptoms and conditions associated with a certain disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "System: Urinary System",
        "output": "The urinary system consists of the kidneys, ureters, bladder, and urethra.",
        "instruction": "Identify the organs involved in the urinary system.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Mutation 1: c.67G>A; p.Trp23Ter. Mutation 2: c.1054G>A; p.Arg352Lys. Mutation 3: c.1466T>C; p.Ser489Pro.",
        "output": "Mutation 1 causes a premature stop codon in the corresponding mRNA, leading to a truncated protein. Mutation 2 causes a change in the amino acid sequence, potentially affecting protein function. Mutation 3 causes a substitution of the amino acid serine for proline, which could also affect protein function. These mutations could potentially be associated with various diseases, but further analysis is necessary.",
        "instruction": "Given a list of genetic mutations, determine their specific impact on gene function and potential disease associations.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient data: elderly male with a history of heart disease, currently taking aspirin and atorvastatin. \\n Treatment plan: daily aspirin and atorvastatin, lifestyle changes to reduce risk factors.",
        "output": "Based on the provided patient data and treatment plan, it is important to assess the patient's adherence to treatment and lifestyle changes. Any necessary changes to the treatment plan or personalized interventions may be recommended to improve adherence and reduce cardiovascular risk.",
        "instruction": "Given a patient's medical record and current treatment plan, assess the patient's adherence to treatment and recommend any necessary changes.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Biomarker: BRCA1",
        "output": "BRCA1 is a biomarker associated with breast and ovarian cancer.",
        "instruction": "Identify the specific type of cancer that a particular biomarker is associated with, based on available research.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "N/A",
        "output": "There are five types of malaria, each caused by a different parasite: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. The most common symptoms associated with malaria include fever, chills, headache, muscle and joint pain, nausea and vomiting. Symptoms can vary depending on the type of malaria contracted.",
        "instruction": "Identify and describe the different types of malaria and the most common symptoms associated with each type.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A heart-healthy lifestyle involves eating a balanced diet, incorporating regular physical activity, quitting smoking, managing stress, and limiting alcohol intake. If you're unsure where to start, consult with your healthcare provider for personalized guidance.",
        "output": "A heart-healthy lifestyle involves eating a balanced diet, incorporating regular physical activity, quitting smoking, managing stress, and limiting alcohol intake.",
        "instruction": "Highlight the most essential piece of advice from a text on heart health.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient has a history of anaphylactic shock.",
        "output": "The patient may be at risk for a severe allergic reaction to certain medications and should be closely monitored.",
        "instruction": "Identify any potential allergic reactions to a medication based on a patient's medical records.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "C6H12O6 + 6O2 -> 6CO2 + 6H2O + energy",
        "output": "This equation represents cellular respiration, a vital process in human metabolism where glucose (C6H12O6) and oxygen (O2) are converted into carbon dioxide (CO2), water (H2O), and energy. It is essential for providing the energy necessary for cells to function, grow, and maintain their structures.",
        "instruction": "Identify the type of chemical reaction represented by the chemical equation below and discuss its importance in human metabolism.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A randomized controlled trial aimed at determining the effects of a new antidiabetic medication on blood glucose levels compared to a placebo.",
        "output": "Primary objective: To determine the effects of a new antidiabetic medication on blood glucose levels.",
        "instruction": "Identify the primary objective of a clinical trial based on a brief description.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Data set: 25, 20, 30, 35, 22, 18, 40, 19, 21, 50, 15, 23, 24, 28, 29, 27, 19, 75, 26, 17",
        "output": "Outlier: 75. Investigate potential causes, such as data entry errors or actual data anomalies.",
        "instruction": "Given a set of patient data, identify any outliers and investigate potential causes.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "47-year-old male with a history of type 2 diabetes, hypertension, and atrial fibrillation presented to the ER with shortness of breath and fatigue for two days. Initial lab work indicated elevated troponin levels. The echocardiogram revealed a reduced ejection fraction of 30%. He was started on aggressive diuresis with furosemide, metoprolol, and amiodarone to manage his conditions. After five days of treatment, the patient's symptoms improved and he was discharged with instructions to follow up with his primary care physician.",
        "output": "A 47-year-old male with type 2 diabetes, hypertension, and atrial fibrillation experienced shortness of breath and fatigue. He had elevated troponin levels and a reduced ejection fraction, requiring treatment with diuretics, metoprolol, and amiodarone. After five days, his symptoms improved, and he was discharged with instructions to follow up with his doctor.",
        "instruction": "Provide a brief summary of the patient's health condition and main events in their hospital course.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient is a 52-year-old male with a family history of heart disease. He smokes a pack of cigarettes daily and has a sedentary lifestyle. His BMI is 28, and he has been diagnosed with hypertension and high cholesterol levels.",
        "output": "Family history of heart disease, smoking, sedentary lifestyle, BMI of 28 (overweight), hypertension, high cholesterol levels",
        "instruction": "Evaluate the patient's risk factors for developing cardiovascular disease based on the given information.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "COPD",
        "output": "Chronic Obstructive Pulmonary Disease",
        "instruction": "Interpret the given medical abbreviation.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms - persistent lower back pain, numbness, and tingling in the legs.\nMedical history - Age: 35, gender: male, no history of cancer or other significant conditions.",
        "output": "Recommended imaging test - Magnetic Resonance Imaging (MRI) of the lumbar spine and pelvis.",
        "instruction": "Given a list of symptoms and the patient's medical history, recommend the most appropriate imaging test.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Effects of a Low-Carbohydrate Diet on Weight Loss and Metabolic Health: A Randomized Controlled Trial",
        "output": "Does a low-carbohydrate diet lead to weight loss and improved metabolic health?",
        "instruction": "Identify the primary research question within a given research study title.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Computed tomography of the chest reveals an irregular mass in the right upper lobe, approximately 3 cm in diameter, with irregular margins. The mass seems to be infiltrating into the surrounding lung tissue. No mediastinal lymphadenopathy is detected. The left lung and other thoracic structures appear to be normal.",
        "output": "The CT scan report indicates a mass in the right upper lung with irregular margins, which might suggest malignancy. A radiologist should be consulted for further diagnosis and management.",
        "instruction": "Based on the CT scan report, identify any abnormal findings and consult a radiologist for a further diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient is taking lisinopril, simvastatin, and metformin for the treatment of hypertension, high cholesterol, and type 2 diabetes, respectively.",
        "output": "All three medications are generally safe to take together. However, lisinopril and simvastatin can increase the risk of muscle damage when taken together. Both can also cause lowered blood pressure as a side effect. Metformin can sometimes cause gastrointestinal side effects like nausea and diarrhea.",
        "instruction": "Given a list of medications that a patient is taking, identify any potential interactions or side effects between them.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical code: ICD-10-CM code T56.0X2A",
        "output": "The ICD-10-CM code T56.0X2A represents poisoning by unspecified narcotics, intentional self-harm, initial encounter.",
        "instruction": "Given a set of medical codes or terminology, provide a translation or definition for the code or term.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "True positives: 45,\nFalse positives: 10,\nTrue negatives: 80,\nFalse negatives: 5",
        "output": "Sensitivity: 90% (45 / (45 + 5))\nSpecificity: 88.9% (80 / (80 + 10))",
        "instruction": "Calculate the sensitivity and specificity of a diagnostic test using the provided data.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) aims to develop clinical, imaging, and biological markers for the early detection and progression tracking of Alzheimer\u2019s disease. ADNI includes MRI and PET scan data, genetics, cognitive tests, cerebrospinal fluid, and blood biomarker data.",
        "output": "Imaging",
        "instruction": "Given a biomedical dataset description, classify its primary type as 'genomics', 'clinical', or 'imaging'.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Gender: Male\nAge: 30\nHeight: 6 feet\nWeight: 165 pounds\nActivity level: Moderately active",
        "output": "Approximately 2800 calories per day",
        "instruction": "Recommend a daily caloric intake for the provided information.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient is a 72-year-old male with a history of hypertension and diabetes. Admission for shortness of breath and chest tightness. Echocardiogram showed moderate mitral regurgitation and dilated left atrium. Diagnosed with heart failure with preserved ejection fraction. Started on diuretics and beta blockers.",
        "output": "72-year-old male admitted for shortness of breath and chest tightness. Diagnosed with heart failure with preserved ejection fraction, started on diuretics and beta blockers. Moderate mitral regurgitation and dilated left atrium seen on echocardiogram.",
        "instruction": "Given a medical report, summarize and condense the information into 1-2 sentences.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical reports: Cardiologist evaluation, pulmonologist evaluation, primary care physician visit",
        "output": "The patient has been diagnosed with hypertension and mild sleep apnea, as well as early signs of cardiovascular disease. They should be monitored closely and treated with medication and lifestyle changes to prevent complications and improve their overall health.",
        "instruction": "Given a set of medical reports from different healthcare providers, organize and summarize the key findings and recommendations in a patient's medical record.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "None",
        "output": "Tiotropium is an anticholinergic bronchodilator.",
        "instruction": "Identify the class of the following drug based on its name: Tiotropium.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Laparoscopic surgery",
        "output": "Main Benefit: Less invasive and faster recovery time\nMain Drawback: Limited capability for complex surgeries",
        "instruction": "Identify the main benefit and main drawback of the given medical procedure.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Feeling dizzy or lightheaded, a rapid heartbeat, and shortness of breath.",
        "output": "The medical term for these symptoms is palpitations.",
        "instruction": "Identify the medical term that describes a given set of symptoms.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Multiple Sclerosis (MS)",
        "output": "The key symptoms of Multiple Sclerosis (MS) can include fatigue, difficulty walking, numbness or tingling in the limbs, muscle weakness, vision problems, and speech difficulties.",
        "instruction": "Identify the key symptoms associated with a given medical condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A study investigating the effects of exercise on blood sugar levels in children with type 1 diabetes found that moderate exercise helped reduce blood sugar levels, but excessive exercise could cause hypoglycemia. The study included 50 children aged 8-14, who were monitored while exercising on a stationary bike.",
        "output": "Q: What was the study design?\nA: The study was an observational study of 50 children with type 1 diabetes who exercised on a stationary bike.\n\nQ: What was the primary outcome measure?\nA: The primary outcome measure was blood sugar levels.\n\nQ: What were the study findings?\nA: Moderate exercise helped reduce blood sugar levels, but excessive exercise could cause hypoglycemia.",
        "instruction": "Given a medical report or article, answer specific questions related to the research findings and methodology.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient is taking Lisinopril for hypertension, and they have reported a persistent dry cough, dizziness upon standing, and headache since starting the medication.",
        "output": "[\"Persistent dry cough\", \"dizziness upon standing\", \"headache\"]",
        "instruction": "Identify the most likely side effects of a medication based on the given patient information.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Complete blood count (CBC) results:\n- Hemoglobin: 13.8 g/dL\n- Platelet count: 160,000/mm3\n- White blood cell (WBC) count: 7,500/mm3",
        "output": "All CBC results are within the normal reference range for hemoglobin, platelets, and WBC count.",
        "instruction": "Classify a set of laboratory test results as normal or abnormal based on established reference ranges.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Objective: To determine the effectiveness of a new digital cognitive behavioral therapy (dCBT) intervention for insomnia. Methods: A randomized controlled trial including 1,711 participants with insomnia. Participants were randomly assigned to either the dCBT group or the treatment as usual (TAU) group. The participants were assessed at baseline, post-treatment, and 3-month follow-up using the Insomnia Severity Index (ISI) as the primary outcome measure. Results: The dCBT group had statistically significant reductions in ISI scores compared to the TAU group at both post-treatment and follow-up.",
        "output": "The study aimed to evaluate a new digital cognitive behavioral therapy (dCBT) for insomnia. In a randomized controlled trial with 1,711 participants, the dCBT group showed significant improvements in Insomnia Severity Index scores compared to the treatment as usual group at both post-treatment and 3-month follow-up.",
        "instruction": "Provide a brief summary of a given clinical study's objective, methods, and results.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Pulse oximeter",
        "output": "1. Monitoring oxygen saturation levels in patients with respiratory conditions, such as asthma or COPD.\n2. Assessing the need for supplemental oxygen during or after surgical procedures.\n3. Evaluating a patient's response to a new medication or treatment affecting respiratory function.",
        "instruction": "List three potential uses of the specified medical device in healthcare settings.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Vitamin D",
        "output": "600 to 800 International Units (IU) or 15 to 20 micrograms (mcg) per day for adults",
        "instruction": "Provide the recommended daily dose for adults of the given supplement.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Headache, fever, muscle aches, fatigue, and sore throat.",
        "output": "Influenza (flu)",
        "instruction": "Given a list of symptoms, suggest a possible medical condition or illness they might be related to.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medication: Metformin",
        "output": "Dosage: Start with 500 mg once a day, gradually increase to 2000 mg daily in divided doses. Administration: With meals. Drug interactions: Increases risk of lactic acidosis with contrast agents or alcohol.",
        "instruction": "Identify the correct dosage and administration instructions for a particular medication, and highlight any drug interactions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "colonoscopy",
        "output": "A colonoscopy is a diagnostic procedure used to examine the inner lining of the large intestine for signs of inflammation, polyps, or other abnormalities. A thin, flexible tube with a camera is inserted through the rectum and guided through the colon to visualize and potentially remove any suspicious areas.",
        "instruction": "Given an input of a healthcare procedure, explain its purpose and how it works.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Sudden severe headache, multiple episodes in a short time span.",
        "output": "Possible medical conditions associated with this symptom include migraines, cluster headaches, or tension headaches.",
        "instruction": "Given a short description of a specific health symptom, identify the potential medical conditions that may be associated with it.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A 58-year-old male with a history of chest pain, high blood pressure, and high cholesterol levels.",
        "output": "The most appropriate specialist for the patient is a Cardiologist.",
        "instruction": "Given a brief patient history, determine the most appropriate type of specialist to be consulted.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medication: Levothyroxine, Use: Treatment of Hypothyroidism\nOther Medications: Warfarin, Furosemide, Simvastatin, Lisinopril",
        "output": "Levothyroxine may interact with Warfarin, resulting in an increased risk of bleeding. Furosemide may decrease the effectiveness of Levothyroxine, while Simvastatin and Lisinopril have no known interactions.",
        "instruction": "Given a medication name and use, identify potential drug interactions with other medications the patient is taking.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "This medication is typically prescribed for long-term management of chronic obstructive pulmonary disease (COPD).",
        "output": "0",
        "instruction": "Identify from the given sentence whether the medication is prescribed for short-term use or long-term use. '1' indicates short-term use, '0' indicates long-term use.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Aspirin, Ibuprofen, Lisinopril, Metformin.",
        "output": "There is a potential interaction between Aspirin and Ibuprofen. Taking these medications together may increase the risk of gastrointestinal bleeding. It is advisable to consult your healthcare provider for appropriate guidance.\n\nAnother potential interaction is between Lisinopril and Ibuprofen. Using them together may reduce the effectiveness of Lisinopril and increase the risk of kidney problems. Consult your healthcare provider for advice on how to manage these medications safely.",
        "instruction": "Given a list of medications, identify any possible drug interactions between them.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Speech difficulties in a child",
        "output": "Speech-language pathologist",
        "instruction": "Recommend a type of healthcare professional who could address the specific medical concern.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Chart note: \"Patient presents with complaints of fatigue and ongoing joint pain, concerning for possible rheumatoid arthritis. Pain has not improved with over-the-counter remedies. Previously diagnosed with hypertension and type 2 diabetes, both well controlled on medications. No significant changes in weight or blood pressure noted since last visit.\"",
        "output": "The patient is currently experiencing symptoms of fatigue and joint pain, possibly suggestive of rheumatoid arthritis. Blood pressure and diabetes remain well controlled. No significant changes in weight or blood pressure have been noted since the patient's last visit.",
        "instruction": "Given a medical chart note, summarize the patient's current condition and any changes since their last visit.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient has been prescribed medication for hypertension, high cholesterol, and acid reflux. Also taking over-the-counter aspirin for pain relief. Patient has a history of liver disease.",
        "output": "Potential drug interactions or contraindications based on the prescribed medications and patient history, including any risks or warnings.",
        "instruction": "Identify and list any potential drug interactions or contraindications based on the prescribed medications and patient history.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Name: John Doe\\nDOB: 01/01/1950\\nDOD: 02/15/2021\\nCause of death: Acute respiratory distress syndrome",
        "output": "Acute respiratory distress syndrome",
        "instruction": "Identify the cause of death mentioned in the given death certificate.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Fatigue, swollen lymph nodes, sore throat, fever, headaches, skin rash, and muscle aches.",
        "output": "Possible medical condition: Infectious mononucleosis (mono)",
        "instruction": "Given a list of symptoms, suggest a possible medical condition or disease that may be associated with the symptoms. If more information is needed, say \"additional information required.\"",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient presents with decreased visual acuity and bilateral eye pain.",
        "output": "Potential causes of these symptoms include cataracts, glaucoma, or optic neuritis. Further diagnostic testing is necessary to determine the specific condition.",
        "instruction": "Based on a patient's history and physical exam findings, identify potential underlying conditions or diseases.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "BP: Blood Pressure, HR: Heart Rate, CBC: Complete Blood Count, ECG: Electrocardiogram, BMI: Body Mass Index",
        "output": "The list contains common medical abbreviations, such as BP for Blood Pressure and HR for Heart Rate. It also includes diagnostic terms like CBC, ECG, and BMI.",
        "instruction": "Given a list of medical abbreviations and their meanings, summarize the contents in no more than two sentences.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Metformin",
        "output": "Classification: Biguanide; Indications: Type 2 diabetes mellitus, glucose regulation",
        "instruction": "Given this drug name, provide its general classification and indications for use.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In a study of elderly patients with pneumonia, an intervention group was given a multidisciplinary clinical pathway (MCP) that involved standardized assessments and care procedures, while a control group was treated by usual care. The intervention group had a significantly lower incidence of inpatient mortality, and a shorter duration of length of stay.",
        "output": "The use of a multidisciplinary clinical pathway (MCP) for elderly patients with pneumonia resulted in a significant improvement in outcomes compared to usual care.",
        "instruction": "Given a biomedical text, identify the author\u2019s main argument.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "\"In a randomized, double-blind, placebo-controlled trial involving 500 adults with moderate to severe Alzheimer's disease, the investigational drug XZP-123 was found to significantly improve cognitive function and reduce the rate of cognitive decline as compared to placebo. Participants received XZP-123 at a dose of 10 mg daily or placebo for 52 weeks, with assessments at 4, 12, 24, 36, and 52 weeks. Compared to placebo, XZP-123-treated patients showed a 5-point improvement on the 30-point Mini-Mental State Examination (MMSE) and a 30% reduction in the rate of cognitive decline over the study period. No serious adverse events were reported, and the drug was well-tolerated.\"",
        "output": "The clinical trial of new drug XZP-123 showed significant improvements in cognitive function and a reduced cognitive decline rate among Alzheimer's patients compared to a placebo group. The study lasted 52 weeks, and the drug proved to be safe and well-tolerated.",
        "instruction": "Provide a brief summary of the clinical trial findings for the new drug, XZP-123, based on the given abstract.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Email: Dear Doctor, For about three weeks now, I've had a persistent cough, and it's starting to become quite irritating. At first, I thought it was just a cold, but it's not going away. I'm also feeling more tired than usual and can't seem to shake off the fatigue, even after getting a good night's sleep. My appetite seems to have decreased as well. Could these symptoms be related to an ongoing issue? Please advise.",
        "output": "Patient's main concerns: Persistent cough, increased fatigue, and loss of appetite over the past three weeks.",
        "instruction": "Summarize a patient's main concerns as expressed in an email to their doctor.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Metformin, Lisinopril, Atorvastatin, Amoxicillin",
        "output": "{\"Metformin\": \"Antidiabetic\", \"Lisinopril\": \"ACE inhibitor\", \"Atorvastatin\": \"Statin\", \"Amoxicillin\": \"Antibiotic\"}",
        "instruction": "Given the list of medications, determine which class each drug belongs to.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A 35-year-old female presents with a 3-day history of fever, cough, and difficulty breathing. She works as a nurse in a local hospital and recently traveled to a region with a known outbreak of a respiratory illness.",
        "output": "- Age: 35\n- Gender: Female\n- Symptoms: fever, cough, difficulty breathing\n- Duration: 3 days\n- Occupation: Nurse\n- Travel history: Recently traveled to a region with a known respiratory illness outbreak",
        "instruction": "Given a brief patient history, list the relevant health data for making a differential diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Crohn's disease",
        "output": "Gastroenterologist",
        "instruction": "Identify the type of healthcare professional a patient should see for the management of a specific condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In a clinical trial of 1,000 patients, 800 patients experienced a significant reduction in symptoms after taking the drug.",
        "output": "80% efficacy rate",
        "instruction": "Based on the given clinical trial data, calculate and provide the drug\u2019s efficacy rate.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Epinephrine",
        "output": "Epinephrine is a medication used in emergency situations to treat severe allergic reactions (anaphylaxis) and cardiac arrest. It works by stimulating the heart and blood vessels, which increases blood flow and oxygen to the body's tissues. It can also relax the muscles in the airways, which can make breathing easier during an allergic reaction.",
        "instruction": "Identify and explain the clinical uses of the drug epinephrine.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "imaging report: MRI of the patient brain shows a small lesion, approximately 1 cm in diameter, located in the right parietal lobe.",
        "output": "The imaging report indicates the presence of a small tumor in the right parietal lobe, measuring about 1cm in diameter. Further evaluation is necessary to determine the exact nature of the tumor and associated risk factors.",
        "instruction": "Given a patient's imaging report, identify the location, size, and potential severity of a tumor.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A patient is presenting with symptoms of a headache and nausea. Which imaging study would be most appropriate to diagnose potential brain abnormalities?\n- CT scan\n- MRI scan\n- X-ray",
        "output": "MRI scan",
        "instruction": "From a list of imaging studies, select the appropriate one to diagnose a particular medical condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient presents with severe joint pain, swelling, and stiffness in multiple joints, fatigue, and occasional low-grade fever. Medical history includes an autoimmune disorder in their family.",
        "output": "The described symptoms and medical history suggest rheumatoid arthritis.",
        "instruction": "Identify the disease being described in the given symptoms and medical history.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Background: The use of probiotics has been proposed for patients with irritable bowel syndrome (IBS), but evidence supporting their use has been limited. This study aimed to determine the efficacy, safety, and tolerability of Bifidobacterium longum LSM1397 in improving IBS symptoms and quality of life. Methods: This randomized, double-blind, placebo-controlled trial involved 120 adults with IBS. Subjects received daily B. longum LSM1397 or placebo for 12 weeks. Results: Significant improvement in overall IBS symptoms and quality of life was observed in the B. longum LSM1397 group compared to the placebo group. No serious adverse events were reported. Conclusion: B. longum LSM1397 is effective, safe, and well-tolerated in improving IBS symptoms and quality of life.",
        "output": "Bifidobacterium longum LSM1397 was found to be effective, safe, and well-tolerated in improving irritable bowel syndrome (IBS) symptoms and quality of life in a randomized, double-blind, placebo-controlled trial involving 120 adults.",
        "instruction": "Summarize the main points of a medical study abstract.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient is taking the following medications: Warfarin, Aspirin, Metoprolol, and Simvastatin.",
        "output": "There is a major interaction between Warfarin and Aspirin as both increase the risk of bleeding. Additionally, a moderate interaction exists between Metoprolol and Simvastatin, which may slightly increase the risk of side effects like muscle pain.",
        "instruction": "Given a list of medications from a patient's medical history, identify possible drug interactions and their severity.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The latest research article titled \"Immunotherapy in Cancer Treatment: An Overview of Current Approaches and Emerging Strategies\" published in the Journal of Clinical Oncology.",
        "output": "Immunotherapy is an emerging field in cancer treatment that focuses on harnessing the immune system to fight cancer. The research article discusses the various types of immunotherapy currently available, including checkpoint inhibitors, adoptive cell transfer therapy, and cancer vaccines. It also outlines the challenges in developing and implementing immunotherapies, including identifying the most appropriate patient populations and overcoming immune system resistance.",
        "instruction": "Provide a brief overview of the latest research on the use of immunotherapy in cancer treatment.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Hemoglobin: 13.8 g/dL, Iron: 60 ug/dL, Total Cholesterol: 210 mg/dL, HDL Cholesterol: 60 mg/dL, LDL Cholesterol: 130 mg/dL",
        "output": "Hemoglobin: Normal, Iron: Low, Total Cholesterol: Borderline high, HDL Cholesterol: Normal, LDL Cholesterol: Borderline high",
        "instruction": "Interpret the given blood test results and indicate whether they are normal or abnormal.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A longitudinal study that collected participants' height and weight measurements, blood pressure readings, and blood samples to analyze cholesterol levels over a 5-year period.",
        "output": "Physiological data",
        "instruction": "Given a biomedical dataset description, identify the primary data type collected.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms: fever, cough, shortness of breath, fatigue, loss of smell\nVital signs: heart rate 110 beats per minute, SpO2 89%, body temperature 38.5\u00b0C, blood pressure 135/85 mmHg, respiratory rate 24 breaths per minute.",
        "output": "Possible conditions: [ \"COVID-19\", \"Pneumonia\", \"Influenza\", \"Bronchitis\", \"Asthma exacerbation\" ]",
        "instruction": "Given a patient's symptoms and vital signs, provide a list of possible medical conditions that could explain their presentation.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Total Cholesterol: 210 mg/dL, HDL: 55 mg/dL, LDL: 120 mg/dL, Triglycerides: 180 mg/dL",
        "output": "Total Cholesterol: Borderline High, HDL: Normal, LDL: Borderline High, Triglycerides: Normal",
        "instruction": "Based on the lab results provided, indicate whether the patient's cholesterol levels are within the normal range or not.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Atenolol, Simvastatin, Lisinopril, Omeprazole, Sertraline",
        "output": "Atenolol and Lisinopril are used to treat hypertension.",
        "instruction": "Given the provided list of medications, identify which ones are used to treat hypertension.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Diabetes, high blood pressure, obesity, insulin, fatigue, weakness, weight loss, pain medication, blurry vision, urinary tract infections, stress, unhealthy diet, regular exercise, high cholesterol",
        "output": "Diagnosis: Diabetes\nSymptoms: Fatigue, weakness, weight loss, blurry vision, urinary tract infections\nTreatments: Insulin, pain medication, regular exercise\nRisk factors: High blood pressure, obesity, stress, unhealthy diet, high cholesterol",
        "instruction": "Classify the following information into correct categories: diagnosis, symptom, treatment, and risk factor.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Collagen is the main structural protein found in skin and connective tissues, responsible for providing strength and elasticity.",
        "output": "Protein Name: Collagen\nFunction: Providing strength and elasticity in skin and connective tissues",
        "instruction": "Identify the protein name and function from the given sentence.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient has been diagnosed with breast cancer, and biopsy results indicate invasion of surrounding tissues.",
        "output": "The patient is in stage 2 breast cancer, and treatment may involve surgery, radiation therapy, or chemotherapy.",
        "instruction": "Given a medical report, identify the stage of cancer and the appropriate treatment plan.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Research article titled \"Impact of COVID-19 pandemic on mental health: An international study\" published in the Journal of Psychiatric Research. The study aimed to investigate the impact of COVID-19 on the mental health of individuals across different countries. The results showed a significant increase in symptoms of anxiety and depression among participants, particularly those living in areas with high COVID-19-related deaths. The study also found that individuals with pre-existing mental health conditions were more vulnerable to the negative effects of the pandemic.",
        "output": "The study found that COVID-19 has had a significant impact on the mental health of individuals, causing an increase in symptoms of anxiety and depression. Pre-existing mental health conditions also increased the vulnerability to these negative effects.",
        "instruction": "Summarize the key findings from the given research article related to COVID-19.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "(a) Aspirin, (b) Metformin, (c) Lisinopril, (d) Ibuprofen, (e) Amlodipine, (f) Insulin, (g) Acetaminophen, (h) Glipizide, (i) Losartan, (j) Naproxen",
        "output": "(a) Analgesic, (b) Antidiabetic, (c) Antihypertensive, (d) Analgesic, (e) Antihypertensive, (f) Antidiabetic, (g) Analgesic, (h) Antidiabetic, (i) Antihypertensive, (j) Analgesic",
        "instruction": "Identify whether the following drugs are classified as analgesics, antihypertensives, or antidiabetics.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In this clinical trial, 200 participants are assigned to one of two treatment groups without a predefined method or plan. Both participants and researchers do not know if they are receiving the active drug or an inactive substance.",
        "output": "Randomized, double-blind, and placebo-controlled trial",
        "instruction": "Given a short description of a clinical trial, determine whether the trial is randomized, double-blind, or placebo-controlled.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Drug: Warfarin (Coumadin)",
        "output": "Primary indication: Warfarin is an anticoagulant medication, primarily prescribed to prevent or treat blood clots and reduce the risk of stroke.\nCommon side effects: Bleeding, bruising, headache, and gastrointestinal discomfort.\nPrecautions and contraindications: Warfarin has numerous interactions with other medications and requires regular blood monitoring. It is contraindicated in patients with active bleeding or severe bleeding disorders and should be used cautiously in patients with liver or kidney disease, and during pregnancy.",
        "instruction": "Identify the primary indication for the given drug, its common side effects, and any important precautions or contraindications to be considered.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Drug: Aspirin",
        "output": "Aspirin is commonly used to reduce pain, fever, inflammation, and blood clotting. Adverse reactions may include stomach upset, bleeding, and allergic reactions. Contraindications include asthma, bleeding disorders, pregnancy, and certain medications.",
        "instruction": "Given a specific drug name, provide information on its therapeutic use, adverse reactions, and contraindications.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Title: \"The Role of MicroRNA in Inflammatory Bowel Disease Regulating Mucosal Immunity and Gut Microbiota.\"\nAbstract: \"Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic and relapsing inflammatory disorder of the gastrointestinal tract with complex pathogenesis and multifactorial etiology. MicroRNAs (miRNAs) have emerged as key regulators in cellular processes, and several studies have indicated their potential role in IBD development and progression. These non-coding RNA molecules regulate gene expression, the immune system, and gut microbiota interactions. This review discusses the role of miRNAs in IBD pathogenesis, focusing on their regulatory functions in mucosal immunity and gut microorganisms. Additionally, the article highlights the potential of miRNAs as biomarkers for IBD diagnosis, along with their therapeutic implications.\"",
        "output": "1. Inflammatory bowel disease\n2. MicroRNA\n3. Mucosal immunity\n4. Gut microbiota\n5. Biomarkers",
        "instruction": "Given a selected article, identify up to 5 main keywords related to the biomedical topic.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The risk factors for osteoporosis include age, female gender, low bodyweight, family history of osteoporosis, early menopause, history of fractures, lack of calcium and vitamin D, sedentary lifestyle, smoking, and excessive alcohol consumption.",
        "output": "- Age\n- Female gender\n- Low bodyweight\n- Family history of osteoporosis\n- Early menopause\n- History of fractures\n- Lack of calcium and vitamin D\n- Sedentary lifestyle\n- Smoking\n- Excessive alcohol consumption",
        "instruction": "Identify all the risk factors associated with a specific health condition mentioned in the given text, and provide a summary in a list format.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Surgery, physical therapy, diagnostic imaging, prescription for pain medications, post-operation follow-up",
        "output": "Diagnostic imaging, surgery, prescription for pain medications, post-operation follow-up, physical therapy",
        "instruction": "Arrange the following medical events in chronological order for a patient's treatment plan.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms include recurrent dizziness, vertigo, ringing in the ears, and hearing loss.",
        "output": "Yes, a referral to an ENT (ear, nose, and throat) specialist is recommended.",
        "instruction": "Given a list of patient symptoms, determine whether a referral to a specialist is necessary.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "- Age: 65 years\n- Gender: Male\n- Family history: Father died of a heart attack at age 50\n- Smoking history: Quit 10 years ago\n- BMI: 27 kg/m2\n- Blood pressure: 140/85 mmHg\n- Total cholesterol: 220 mg/dL\n- HDL cholesterol: 40 mg/dL",
        "output": "The patient is at high risk for a heart attack, based on their age, gender, family history, borderline hypertension, and elevated cholesterol levels.",
        "instruction": "Based on the provided medical history, determine if the patient is at high risk for a heart attack.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The body produces insulin, but the cells do not respond effectively to it, causing high blood sugar levels.",
        "output": "Type 2 diabetes",
        "instruction": "Identify the type of diabetes described: The body produces insulin, but the cells do not respond effectively to it, causing high blood sugar levels.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptom: Experiencing severe chest pain with shortness of breath.",
        "output": "Potential Health Issue: Heart attack",
        "instruction": "Classify the given medical symptom into the correct potential health issue.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "2 months: DTaP, Hib, IPV, PCV, RV\n4 months: DTaP, Hib, IPV, PCV, RV\n6 months: DTaP, Hib, PCV, RV\n12 months: MMR, Varicella, Hepatitis A, Hib, PCV",
        "output": "MMR, Varicella, Hepatitis A, Hib, PCV",
        "instruction": "Based on the given immunization schedule, identify the recommended vaccines for a 12-month-old child.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "This study aimed to evaluate whether the proportion of dietary protein intake from plant-based sources (plant protein) is associated with a reduced risk of cancer mortality. A prospective cohort study of US healthcare professionals frequency-matched on age, sex, and race/ethnicity, and followed for up to 32 years. Data were analyzed from December 2019 to October 2020. The primary outcome was cancer mortality, ascertained by state cancer registries and death certificates.",
        "output": "The hypothesis tested in the study: A higher proportion of dietary protein intake from plant-based sources is associated with a reduced risk of cancer mortality.",
        "instruction": "Given a medical research abstract, identify the hypothesis tested in the study.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Nutrition label on a food package",
        "output": "Main Components:\n1. Serving size\n2. Calories\n3. Macronutrients (Fat, Carbohydrates, Protein)\n4. Micronutrients (Vitamins, Minerals)\n5. Percent Daily Value\n\nSignificance: The serving size tells you how much of the food is considered a serving, and all subsequent nutritional information is based on that amount. Calories tell you how much energy you'll gain from eating one serving. Macronutrients provide essential building blocks for your body, while micronutrients help your body function properly. Percent Daily Value helps you determine how much of each nutrient in a serving of food contributes to your daily diet.",
        "instruction": "Identify the main components of a typical nutrition label and explain their significance.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient presents with a new medication list and reports taking medications from a previous doctor.",
        "output": "Gather medication information from the patient, including medication names, dosages, and frequencies. Complete a medication reconciliation to ensure current and new medications do not interact or cause adverse effects. Contact the previous doctor to verify medication information if necessary.",
        "instruction": "Gather relevant patient information and complete a medication reconciliation.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Case report of a patient with pancreatic adenocarcinoma",
        "output": "The patient presented with abdominal pain, weight loss, and elevated CA 19-9 levels. Imaging studies confirmed the presence of pancreatic adenocarcinoma. The patient underwent surgery, followed by chemotherapy and radiation therapy, and remains under surveillance.",
        "instruction": "Given a medical case report, summarize the main clinical findings and treatment approach.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "High levels of protein and blood in the urine and swelling in the hands and feet.",
        "output": "These symptoms may suggest that you have a kidney disease such as nephritis or glomerulonephritis. You should consult with a healthcare professional for a proper diagnosis and treatment plan.",
        "instruction": "Given a set of medical data, identify the possible disease or condition associated with it.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Blood pressure: 180/95 mmHg, heart rate: 96 bpm, respiratory rate: 20 breaths/min, oxygen saturation: 94% on room air, temperature: 99.1\u00b0F",
        "output": "The patient's blood pressure is elevated and heart rate is elevated, which may indicate hypertension and cardiac dysfunction. These results require further monitoring and potential intervention. The respiratory rate and oxygen saturation are within normal limits. The elevated temperature may indicate a possible infection, requiring further investigation to determine the cause.",
        "instruction": "Given a set of patient vitals, determine if there are any concerning abnormalities and recommend appropriate follow-up actions.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medical Article: A study published in the Journal of the American Medical Association found that a low-carbohydrate, high-fat diet was associated with significant weight loss and improved cardiovascular risk factors in overweight adults.",
        "output": "Please provide a brief summary of the findings and their implications for future research.",
        "instruction": "Given a medical article, summarize the findings and their implications for future research in two sentences or less.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Symptoms: fever, cough, fatigue, chest pain\nPotential diagnoses: pneumonia, bronchitis, asthma, COPD",
        "output": "Most likely symptoms per diagnosis: \n- pneumonia: fever, cough, chest pain\n- bronchitis: cough, fatigue\n- asthma: cough\n- COPD: fatigue, chest pain",
        "instruction": "Given a list of symptoms and potential diagnoses, determine which symptoms are most likely to be associated with each diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient is a 55-year-old female, with a past medical history significant for hypertension, hyperlipidemia, and type 2 diabetes. She presents with a one-week history of progressively worsening shortness of breath, chest pain, and swollen ankles.",
        "output": "55-year-old female patient with a history of hypertension, hyperlipidemia, and type 2 diabetes presenting with a one-week history of worsening shortness of breath, chest pain, and ankle swelling.",
        "instruction": "Summarize a patient's medical history and current symptoms to provide context for a healthcare provider.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "ICD-10 code: E10.9",
        "output": "Type 1 diabetes mellitus without complications",
        "instruction": "Given an ICD-10 code, provide the corresponding medical condition.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "I have started taking fish oil, vitamin D, and magnesium supplements as part of my daily routine.",
        "output": "fish oil, vitamin D, magnesium",
        "instruction": "Identify the dietary supplements mentioned in the given sentence.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A 45-year-old male patient presents to the emergency department with shortness of breath, chest pain, and fatigue, which have worsened over the past week. He has a medical history of hypertension and is a current smoker. On physical examination, the patient's blood pressure is found to be 170/100 mmHg, and his heart rate is 95 bpm. After further tests, including an electrocardiogram and blood tests, he is diagnosed with acute myocardial infarction.",
        "output": "A 45-year-old male with hypertension and a smoking habit experiences worsening shortness of breath, chest pain, and fatigue. He is found to have high blood pressure and is diagnosed with a heart attack after tests.",
        "instruction": "Given the medical case scenario, provide a brief summary without losing critical information.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "ECG",
        "output": "Electrocardiogram",
        "instruction": "Given a medical term or abbreviation, provide the full, unabbreviated version of the term.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Metformin",
        "output": "Metformin belongs to the drug class called biguanides.",
        "instruction": "Identify which drug class the given medication belongs to.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Martha is a 49-year-old woman who has come to her doctor's office complaining of fatigue, weight gain, and persistent headaches. She has a family history of heart disease and type 2 diabetes. Martha also mentions that she has been experiencing stiffness in her joints upon waking up in the mornings for the past month or so.",
        "output": "Fatigue, weight gain, persistent headaches, family history of heart disease and type 2 diabetes, and joint stiffness.",
        "instruction": "Identify the main health concerns of the patient mentioned in the provided text.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In the double-blinded, randomized, placebo-controlled clinical trial, 1000 patients with moderate to severe rheumatoid arthritis were recruited to establish the safety and efficacy of XYZ drug. The study aimed to evaluate the long-term effects of the drug on disease progression and quality of life measures, in comparison to placebo treatment.",
        "output": "Phase III",
        "instruction": "Given a paragraph describing a clinical trial, determine the phase of the trial. The output should be 'Phase I', 'Phase II', 'Phase III', or 'Phase IV'.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Title: Effect of Daily Vitamin D Supplementation on Mental Health in Adults\nMethods: A randomized, double-blind, placebo-controlled trial involving 200 participants\nResults: Statistically significant improvements in depression and anxiety symptoms in the vitamin D supplementation group compared to the placebo group\nConclusion: Daily vitamin D supplementation can be beneficial for mental health in adults",
        "output": "The study found that daily vitamin D supplementation leads to improved depression and anxiety symptoms in adults compared to a placebo group.",
        "instruction": "Provide a summary of the essential information presented in a research study.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Test results: elevated blood glucose, glycosuria, and polyuria.",
        "output": "The patient may have diabetes or prediabetes.",
        "instruction": "Given the medical test results, identify the potential diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medications: Warfarin, Aspirin, Lisinopril, Atorvastatin",
        "output": "There's a potential drug interaction between Warfarin and Aspirin, as both drugs have blood-thinning properties, which may increase the risk of bleeding. Consult with your healthcare provider to ensure the safety and appropriateness of this combination.",
        "instruction": "Identify a potential drug interaction given a patient's medication list.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Classify the following text into diagnosis, treatment, or prognosis: \"The patient was diagnosed with stage III breast cancer and is scheduled to begin chemotherapy next week.\"",
        "output": "The text describes a diagnosis of stage III breast cancer, which indicates a need for treatment in the form of chemotherapy. Therefore, this text could be classified as both diagnosis and treatment related.",
        "instruction": "Classify a given medical text into different categories, such as diagnosis, treatment, or prognosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medications:\n1. Aspirin \n2. Acetaminophen \n3. Ibuprofen \nSide Effects:\nA. Liver damage \nB. Stomach ulcers \nC. Bleeding",
        "output": "1. Aspirin - C. Bleeding \n2. Acetaminophen - A. Liver damage \n3. Ibuprofen - B. Stomach ulcers",
        "instruction": "Given a list of common medications and their side effects, match the medication to the appropriate side effect.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "In this randomized controlled trial, we investigated the efficacy of drug XYZ in treating type 2 diabetes patients by analyzing HbA1c levels and fasting plasma glucose (FPG) levels. A total of 200 participants were divided into two equal groups, with one group receiving drug XYZ and the other receiving a placebo. After 12 weeks, the group treated with drug XYZ showed a significant reduction in HbA1c levels and FPG levels compared to the placebo group (p < 0.05).",
        "output": "The study showed that drug XYZ effectively lowered blood sugar levels in type 2 diabetes patients as measured by HbA1c and fasting plasma glucose levels compared to a placebo.",
        "instruction": "Summarize the main points of the following medical research abstract in one to two sentences.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Text provided: \"The recent legislation that allows health insurance companies to deny coverage for pre-existing conditions is a gross violation of patients' rights and shows a clear disregard for the wellbeing of the people it is supposed to serve.\"",
        "output": "\"allows health insurance companies to deny coverage for pre-existing conditions\" and \"gross violation of patients' rights\" are both segments that indicate a strong negative sentiment towards the policy.",
        "instruction": "Identify and mark all segments of the text that indicate a strong sentiment towards a particular healthcare policy.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Lisinopril",
        "output": "Common side effects of lisinopril include cough, dizziness, headache, nausea, and diarrhea. More severe side effects may include low blood pressure, kidney problems, and angioedema (swelling of the face or neck).",
        "instruction": "Identify the side effects associated with the given medication based on the information provided by a reputable source.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Prescribed medication: metformin 1000 mg twice daily. Current medications: lisinopril, atorvastatin, and furosemide.",
        "output": "Metformin can interact with furosemide and lead to increased risk of lactic acidosis. It may also interact with atorvastatin and increase the risk of muscle pain or weakness. Regular monitoring of kidney function is recommended with metformin and lisinopril.",
        "instruction": "Identify the potential drug interactions between the prescribed medication and the patient's current medications.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Disease: Alzheimer's disease",
        "output": "Alzheimer's disease is caused by the accumulation of amyloid plaques and neurofibrillary tangles in the brain, leading to damage and death of nerve cells. This affects memory, thinking, and behavior, eventually leading to dementia.",
        "instruction": "Identify the biological mechanism responsible for a given disease.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Shortness of breath, chest pain, wheezing, fatigue, leg swelling, cough, rapid heartbeat, dizziness",
        "output": "Respiratory: Shortness of breath, wheezing, cough\nCardiovascular: Chest pain, fatigue, leg swelling, rapid heartbeat, dizziness",
        "instruction": "Categorize the following symptoms into either respiratory or cardiovascular.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Procedure: dental surgery\nMedical history: hypertension, Type 2 diabetes, heart attack 5 years ago, penicillin allergy",
        "output": "hypertension, Type 2 diabetes, heart attack 5 years ago, penicillin allergy",
        "instruction": "Identify the most relevant information from the patient's medical history for a specific medical procedure.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Metformin, Lisinopril, Ibuprofen, Atorvastatin",
        "output": "- Metformin: Oral antidiabetic drug (Biguanide)\n- Lisinopril: ACE inhibitor (Antihypertensive)\n- Ibuprofen: Nonsteroidal anti-inflammatory drug (NSAID)\n- Atorvastatin: Statin (Cholesterol-lowering)",
        "instruction": "Given a list of drugs, classify them based on their drug classes or categories.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Medications: ibuprofen, lisinopril, metformin, simvastatin, levothyroxine.",
        "output": "- Ibuprofen: a nonsteroidal anti-inflammatory drug used for pain relief and fever reduction.\n- Lisinopril: an angiotensin converting enzyme (ACE) inhibitor used to treat hypertension and congestive heart failure.\n- Metformin: an oral hypoglycemic drug used to control blood sugar levels in patients with type 2 diabetes.\n- Simvastatin: a statin drug used to lower cholesterol levels and reduce the risk of cardiovascular disease.\n- Levothyroxine: a synthetic thyroid hormone used to treat hypothyroidism.",
        "instruction": "Given a set of medication names, provide the indications for each medication.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "What are the disease targets of the new medication being developed?",
        "output": "The new medication is being developed to target specific disease indications such as cancer, autoimmune disorders, or infectious diseases. Its mechanism of action is specifically designed to address the molecular abnormalities associated with these conditions.",
        "instruction": "Provide a summary of the disease targets of a new medication development project:",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Many patients taking antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), experience weight gain as a side effect.",
        "output": "Weight gain",
        "instruction": "Identify the primary side effect described in the given sentence.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "A 36-year-old male presents with complaints of fatigue, excessive thirst, frequent urination, and blurred vision for the past month.",
        "output": "Based on the presented symptoms, I recommend the patient undergo a fasting blood glucose test and a Hemoglobin A1c test to assess for potential diabetes.",
        "instruction": "Given a case scenario of a patient with symptoms, recommend an appropriate medical examination to determine a potential diagnosis.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "The patient is a 45-year-old male with a history of hypertension and type 2 diabetes. He had a myocardial infarction 3 years ago and underwent a coronary artery bypass graft surgery. He has been compliant with his medications and follows a diabetic diet.",
        "output": "The patient has a history of hypertension, type 2 diabetes, myocardial infarction, and coronary artery bypass graft surgery. He is compliant with his medications and follows a diabetic diet.",
        "instruction": "Provide a summary of the patient's medical history, including any chronic conditions, surgeries, or hospitalizations.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Drowsiness, dizziness, dry mouth, constipation, urinary retention, blurred vision, and increased heart rate.",
        "output": "The medication being described is likely an anticholinergic drug, such as Benztropine or Atropine.",
        "instruction": "Given the side effects listed, identify the medication being described.",
        "domain": "med",
        "task": "ie"
    },
    {
        "input": "Patient A: Loss of appetite, nausea, vomiting, fatigue, jaundice\nPatient B: Abdominal pain, bloating, gas, diarrhea, constipation, fatigue",
        "output": "Patient A: Symptoms of liver disease or infection\nPatient B: Symptoms of irritable bowel syndrome",
        "instruction": "Classify a set of patient symptoms based on their description.",
        "domain": "med",
        "task": "ie"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 32-year-old nulliparous woman with polycystic ovary syndrome comes to the physician for a pelvic examination and Pap smear. Last year she had a progestin-releasing intrauterine device placed. Menarche occurred at the age of 10 years. She became sexually active at the age of 14 years. Her mother had breast cancer at the age of 51 years. She is 165 cm (5 ft 5 in) tall and weighs 79 kg (174 lb); BMI is 29 kg/m2. Examination shows mild facial acne. A Pap smear shows high-grade cervical intraepithelial neoplasia. Which of the following is this patient's strongest predisposing factor for developing this condition?\nA. Early onset of sexual activity\nB. Intrauterine device use\nC. Obesity\nD. Nulliparity\nE. Early menarche\nF. Family history of cancer\nG. Polycystic ovary syndrome\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 64-year-old male presents to the emergency room complaining of chest pain. He reports a pressure-like sensation over his sternum that radiates into his jaw. The pain came on suddenly 2 hours ago and has been constant since then. His past medical history is notable for a stable abdominal aortic aneurysm, hypertension, diabetes, and hyperlipidemia. He takes aspirin, enalapril, spironolactone, atorvastatin, canagliflozin, and metformin. His temperature is 99.1\u00b0F (37.3\u00b0C), blood pressure is 155/85 mmHg, pulse is 115/min, and respirations are 22/min. On exam, he is diaphoretic and in moderate distress. He is admitted for further management and does well after initial stabilization. He is seen two days later by the admitting team. This patient is at increased risk for a complication that is characterized by which of the following?\nA. Friction rub\nB. Cardiac tamponade\nC. Intra-cardiac shunt\nD. Mitral insufficiency\nE. Ventricular fibrillation\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 30-year-old man comes to the emergency department because of fever and productive cough for the past 4 days. During this period, he has had shortness of breath and chest pain that is worse on inspiration. He also reports fatigue and nausea. He has refractory schizophrenia and recurrent asthma attacks. He used to attend college but was expelled after threatening to harm one of his professors 2 months ago. His temperature is 38.5\u00b0C (101.3\u00b0F), pulse is 90/min, respirations are 20/min, and blood pressure is 120/80 mm Hg. Crackles and bronchial breath sounds are heard on auscultation of the left lung. Laboratory studies show:\nHemoglobin 13.5 g/dL\nLeukocyte count 1,100/mm3\nSegmented neutrophils 5%\nEosinophils 0%\nLymphocytes 93%\nMonocytes 2%\nPlatelet count 260,000/mm3\nWhich of the following medications is this patient most likely taking?\"\nA. Clozapine\nB. Olanzapine\nC. Haloperidol\nD. Risperidone\nE. Chlorpromazine\nF. Quetiapine\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A scientist is studying the replication sequences of a number of different viruses. He observes that one particular virus he is studying creates a single stranded DNA from an RNA template during its replication sequence. Which of the following viruses is he most likely observing?\nA. Hepatitis A virus\nB. Hepatitis B virus\nC. Hepatitis C virus\nD. HSV-1\nE. Norovirus\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old man presents to his physician on Monday morning complaining of a painful rash that developed over the last week. He does not have any other complaints. Past medical history is significant for occasional heartburn. Physical examination reveals a patchy erythematous lesion on the left side of his chest. Closer examination reveals that the rash follows a band like distribution across the chest just above the nipple and is made up of clusters of vesicles. Most of the vesicles appear to be filled with clear fluid, with a few having cloudy content, while some ruptured ones giving rise to ulcerations. The rash does not appear to cross the patient\u2019s midline. Below is a picture of the skin lesion. Which of the following best describes this rash?\nA. Erythematous, warm and painful\nB. Pruritic papules with erythematous base\nC. Patches of vesicles at different stages\nD. Ulcerative dermal lesions\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 39-year-old man presents to the emergency department for severe abdominal pain. His pain is located in the epigastric region of his abdomen, which he describes as sharp and persistent. His symptoms began approximately 2 days prior to presentation, and he has tried acetaminophen and ibuprofen, which did not improve his symptoms. He feels nauseated and has had 2 episodes of non-bloody, non-bilious emesis. He has a medical history of hypertension and hyperlipidemia for which he is on chlorthalidone and simvastatin. He has smoked 1 pack of cigarettes per day for the last 20 years and drinks 1 pint of vodka per day. On physical exam, there is tenderness to palpation of the upper abdomen, and the patient is noted to have tender hepatomegaly. Serum studies demonstrate:\n\nAmylase: 350 U/L (25-125 U/L)\nLipase: 150 U/L (12-53 U/L)\nAST: 305 U/L (8-20 U/L)\nALT: 152 U/L (8-20 U/L)\n\nHe is admitted to the hospital and started on intravenous fluids and morphine. Approximately 18 hours after admission the patient reports to feeling anxious, tremulous, and having trouble falling asleep. His blood pressure is 165/105 mmHg and pulse is 140/min. On exam, the patient appears restless and diaphoretic. Which of the following will most likely improve this patient's symptoms?\nA. Chlordiazepoxide\nB. Haloperidol\nC. Lorazepam\nD. Risperidone\nE. Thiamine\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 5-year-old girl is brought to the emergency department after sustaining an atraumatic tibial fracture while playing with her friends. This patient has a history of fractures in her upper and lower extremities. Children's services have investigated the family several times in the past and found no abuse. She was born at 39 weeks gestation via spontaneous vaginal delivery which resulted in several mild fractures. She is up to date on all vaccines and is meeting all developmental milestones. The mother has a brother with a similar history that is still living. Her vital signs show a heart rate of 90/min, respiratory rate of 22/min, blood pressure of 110/65 mm Hg, and temperature of 37.0\u00b0C (98.6\u00b0F). Physical exam reveals a regular heart rate, and her lungs are clear to auscultation bilaterally. The sclera of both eyes are blue. Additionally, her teeth are brown and distorted. Her leg is swollen, erythematous, and tender to palpation. An X-ray reveals a tibia fracture, while multiple fractures at various stages of healing are also seen on her arms. The physician suspects this is a genetic condition. Which of the inheritance patterns can be attributed to the girl\u2019s condition?\nA. Incomplete penetrance\nB. Pleiotropy\nC. Anticipation\nD. Locus heterogeneity\nE. De novo mutation\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 7-year-old boy presents with difficulty swallowing, diarrhea, itching, and weakness. He also complains of episodes of headaches, sweating, and palpitations, which are accompanied by fear and tend to end with micturition. His mother is concerned about the strange nodules on his lips and eyelids. The boy's younger brother had similar nodules and died at 10 years of age of unknown causes. The patient\u2019s vital signs are as follows: blood pressure 130/80 mm Hg, heart rate 107/min, respiratory rate 14/min, and temperature 36.9\u2103 (98.4\u2109). The child is tall, thin, has disproportionately long arms and legs, and increased thoracic spine kyphosis. There are multiple yellow-white, sessile, painless nodules on the patient\u2019s lips, and buccal and eyelid mucosa. There is a painless lump in the area of the left thyroid lobe and enlargement of the posterior cervical lymph nodes on the left side. What is the most probable embryonic origin of the cells in the lump?\nA. First pharyngeal groove\nB. First pharyngeal pouch\nC. Lateral plate mesoderm\nD. Neurogenic placodes\nE. Neural crest cells\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 22-year-old woman presents to her primary care doctor for a right breast mass that was found during self-exam. Her paternal aunt had been diagnosed with breast cancer 5 years ago, so she wishes to undergo further oncologic evaluation. She plays lacrosse in college but is not at the moment since it is currently off-season. She denies any sexual activity and reports that her last period was about 2 weeks ago. On physical exam, a small mobile non-tender mass is palpated in the inferolateral quadrant of her right breast. Mammography is shown in Figure A. The doctor recommends a fine needle aspiration biopsy, which is shown in Figure B demonstrating fat globules and foamy histiocytes. What is the most likely diagnosis?\nA. Breast abscess\nB. Breast cancer\nC. Breast fat necrosis\nD. Mastalgia\nE. Mondor's disease\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 40-year-old female presents to her gynecologist with dysmenorrhea, menorrhagia, and pelvic pain. The patient is not taking any medication and has no evidence of fever. Transvaginal sonogram reveals an enlarged, soft, and tender uterus, and uterine biopsy shows normal-appearing endometrial glands within the myometrium. Which of the following is the most likely diagnosis in this patient:\nA. Adenomyosis\nB. Endometriosis\nC. Endometritis\nD. Leiomyoma\nE. Endometrial carcinoma\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old previously healthy man presents to the primary care physician with the chief complaint of red colored urine over the past month. He states that he does not experience dysuria. On physical exam there is no costovertebral angle tenderness. With this presentation which is the most likely cause of this patient's hematuria?\nA. Bladder tumor\nB. Renal cell carcinoma\nC. Beeturia\nD. Urinary tract infection\nE. Urethral injury\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 27-year-old man is brought to the emergency department because of weakness, headache, and vomiting for 40 minutes. He is an amateur chef and his symptoms started 10 minutes after he ingested pufferfish that he had prepared. On arrival, he is lethargic. His temperature is 37\u00b0C (98.6\u00b0F), pulse is 120/min, respirations are 8/min, and blood pressure is 92/64 mm Hg. He is intubated and mechanical ventilation is begun. Intravenous fluid resuscitation is started. The cause of this patient's condition exerts its effect by which of the following mechanisms of action?\nA. Decrease in cell membrane permeability to sodium ions\nB. Increase in cell membrane permeability to chloride ions\nC. Decrease in cell membrane permeability to calcium ions\nD. Decrease in cell membrane permeability to potassium ions\nE. Increase in cell membrane permeability to calcium ions\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:Parents bring an 11-month-old baby to the clinic because the baby has a fever of 39.0\u00b0C (102.2\u00b0F). The baby is irritated and crying constantly. She is up to date on immunizations. A complete physical examination reveals no significant findings, and all laboratory tests are negative. Five days after resolution of her fever, she develops a transient maculopapular rash. What is the most likely diagnosis?\nA. Roseola\nB. Erythema infectiosum\nC. Rubella\nD. Measles\nE. Kawasaki disease\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 63-year-old man presents to the clinic concerned about numbness in his bilateral shoulders and arms for the past 8 weeks. The symptoms started when he fell from scaffolding at work and landed on his back. Initial workup was benign and he returned to normal duty. However, his symptoms have progressively worsened since the fall. He denies fever, back pain, limb weakness, preceding vomiting, and diarrhea. He has a history of type 2 diabetes mellitus, hypertension, hypercholesterolemia, ischemic heart disease, and a 48-pack-year cigarette smoking history. He takes atorvastatin, hydrochlorothiazide, lisinopril, labetalol, and metformin. His blood pressure is 132/82 mm Hg, the pulse is 72/min, and the respiratory rate is 15/min. All cranial nerves are intact. Muscle strength is normal in all limbs. Perception of sharp stimuli and temperature is reduced on his shoulders and upper arms. The vibratory sense is preserved. Sensory examination is normal in the lower limbs. What is the most likely diagnosis?\nA. Anterior cord syndrome\nB. Central cord syndrome\nC. Guillain-Barre syndrome\nD. Pontine infarction\nE. Vitamin B12 deficiency\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 3-year-old refugee with increasing pitting edema and abdominal swelling over the past 2 months is brought to the physician. Her family has been displaced several times over the last few years. Nutrition and housing were frequently inadequate. At the physician\u2019s clinic, the boy appears irritated and drowsy. He is difficult to arouse. Physical examination shows pitting edema over the ankles and feet and around his eyes. Abdominal examination is positive for ascites and hepatomegaly. Oral examination shows several missing teeth. Which of the following best explains these findings?\nA. Kwashiorkor\nB. Marasmus\nC. Beriberi\nD. Rickets\nE. Scurvy\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 61-year-old man presents to the clinic because of sinus congestion, dyspnea, fatigue, and a productive cough. He returned from a trip to Wuhan, China 3 weeks ago. He says that he received his annual influenza vaccine approximately 2 months ago and was in otherwise good health prior to the recent onset of symptoms. The heart rate is 92/min, respiratory rate is 20/min, temperature is 38.2\u00b0C (100.8\u00b0F), and blood pressure is 100/60 mm Hg. A chest X-ray shows a scant, bilateral patchy infiltrate. A sputum culture shows no gram-staining organisms and cold agglutinins are negative. Which of the following best describes the pathogen responsible for this patient\u2019s case?\nA. DNA | double-stranded | envelope: no | icosahedral\nB. DNA | double-stranded | envelope: yes | icosahedral\nC. DNA | single-stranded | envelope: no | icosahedral\nD. RNA | single-stranded | envelope: no | positive-sense, icosahedral\nE. RNA | single-stranded | envelope: yes | positive-sense, helical\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:You are trying to design a randomized controlled trial to evaluate the effectiveness of metoprolol in patients with heart failure. In preparing for the statistical analysis, you review some common types of statistical errors. Which of the following is true regarding a type 1 error in a clinical study?\nA. A type 1 error means the study is not significantly powered to detect a true difference between study groups.\nB. A type 1 error occurs when the null hypothesis is true but is rejected in error.\nC. A type 1 error occurs when the null hypothesis is false, yet is accepted in error.\nD. A type 1 error is a beta (\u03b2) error and is usually 0.1 or 0.2.\nE. A type 1 error is dependent on the confidence interval of a study.\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 40-year-old man with a past medical history of major depression presents to the clinic. He is interested in joining a research study on depression-related sleep disturbances. He had 2 episodes of major depression within the last 2 years, occurring once during the summer and then during the winter of the other year. He has been non-compliant with medication and has a strong desire to treat his condition with non-pharmacological methods. He would like to be enrolled in this study that utilizes polysomnography to record sleep-wave patterns. Which of the following findings is likely associated with this patient\u2019s psychiatric condition?\nA. Increased total REM sleep\nB. Increased slow wave sleep\nC. Late morning awakenings\nD. Increased REM sleep latency\nE. Associated with a seasonal pattern\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 75-year-old woman with late-onset autoimmune diabetes mellitus, rheumatoid arthritis, coronary artery disease, and idiopathic pulmonary fibrosis presents to the ship medic with altered mental status. While on her current cruise to the Caribbean islands, she experienced nausea, vomiting, and diarrhea. She takes aspirin, simvastatin, low-dose prednisone, glargine, and aspart. She is allergic to amoxicillin and shellfish. She works as a greeter at a warehouse and smokes 5 packs/day. Her temperature is 100.5\u00b0F (38.1\u00b0C), blood pressure is 90/55 mmHg, pulse is 130/min, and respirations are 30/min. Her pupils are equal and reactive to light bilaterally. Her lungs are clear to auscultation bilaterally, but her breath has a fruity odor. She has an early systolic murmur best appreciated at the left upper sternal border. She has reproducible peri-umbilical tenderness. Which of the following will most likely be present in this patient?\nA. Respiratory acidosis and contraction metabolic alkalosis\nB. Respiratory alkalosis and non-contraction metabolic alkalosis\nC. Respiratory alkalosis and anion-gap metabolic acidosis\nD. Respiratory alkalosis and non anion-gap metabolic acidosis\nE. Respiratory acidosis and anion-gap metabolic acidosis\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 4-year-old boy is brought to the emergency department by his parents for a sore throat and cough. The boy is very quiet, withdrawn, and frequently looks at his father before answering questions. Physical exam shows bruises in various states of healing on his buttocks and back. A rapid strep test returns positive for streptococcal pharyngitis. A chest radiograph is shown in Figure A. The boy's father explains that the bruising is from rough-housing with the boy's twin brother and that the rib fractures are from falling off a tricycle. Which of the following is the most appropriate next step?\nA. Admit the patient for hematologic work-up\nB. Interview the boy's brother regarding rough-housing\nC. Recommend outpatient family therapy to teach the boys how to play safely\nD. Notify Child Protective Services\nE. Prescribe penicillin for streptococcal pharyngitis and recommend follow-up to ensure child's safety\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 34-year-old woman is brought to the emergency department following a motor vehicle accident. She was walking on the sidewalk when a car traveling at high speed knocked her off her feet. She did not sustain any obvious injury but has painful breathing. An X-ray of the chest is taken to exclude a rib fracture and contusion of the lungs. The X-ray is found to be normal except for a solitary calcified nodule located in the left hilar region. The physician then asks the patient if she is or was a smoker, or has any pertinent medical history to explain the nodule. Her past medical history is insignificant, including any previous lung infections. Physical examination does not reveal any significant signs indicative of a tumor. A chest CT is ordered and a solitary nodule of 0.5 cm is confirmed. Which of the following is the most appropriate next step in the management of this patient?\nA. Positron emission scan\nB. Mediastinoscopy\nC. Sputum cytology\nD. CT scan of abdomen\nE. Repeat chest CT scan in 6 months\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 52-year-old male presents to his primary care physician at the insistence of his wife who reports that he has been complaining of vague abdominal pain over the last several months. She asks if you think her husband's skin appears yellow. Vitals signs and laboratory findings are as follows: T 98.7F, HR 73, BP 114/68, RR 14, O2 100%. Hemoglobin 9.7, Hematocrit 31.2, WBC 6, Platelets 146. Amylase and lipase are within normal limits. You order a CT scan (Figure A). Which of the following is the most likely diagnosis?\nA. Pancreatitis\nB. Cholangiocarcinoma\nC. Choledochal cyst\nD. Cholangitis\nE. Cholelithiasis\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 24-year-old man presents with a painless genital ulcer for the past 2 weeks. He reports that he recently has been having unprotected sex with multiple partners. Past medical history is unremarkable. On physical examination, a single ulcer is present on the dorsal shaft of the penis which is circumscribed, indurated, and partially healed. There is moderate inguinal lymphadenopathy but no buboes. Which of the following tests would confirm the most likely diagnosis in this patient?\nA. Viral and rickettsial disease research laboratory (VDRL) test\nB. Swab the chancre and perform a saline wet mount\nC. Fluorescent treponemal antibody absorption (FTA-ABS) test\nD. Frei test\nE. Perform a darkfield microscopic examination of a swab from the chancre\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 23-year-old patient with a past medical history of anxiety and appropriately treated schizophrenia presents to the emergency department for a first time seizure. The patient was at home eating dinner when he began moving abnormally and did not respond to his mother, prompting her to bring him in. His symptoms persisted in the emergency department and were successfully treated with diazepam. The patient is discharged and scheduled for a follow up appointment with neurology the next day for treatment. The patient returns to his neurologist 1 month later for a checkup. Physical exam is notable for carpopedal spasm when his blood pressure is being taken. Cranial nerves II-XII are grossly intact and his gait is stable. Which of the following is the most likely explanation of this patient's current presentation?\nA. Acute renal failure\nB. Elevated blood levels of a medication\nC. Increased water consumption\nD. P450 induction\nE. Sub-therapeutic dose\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 30-year-old woman presents complaining of shortness of breath, chest pain, and fatigue. The patient complains of dyspnea upon exertion, generalized fatigue, lethargy, and chest pain associated with strenuous activities. Her history is notable for an atrial septal defect at birth. Her temperature is 99.5\u00b0F (37.5\u00b0C), blood pressure is 147/98 mmHg, pulse is 90/min, respirations are 17/min, and oxygen saturation is 98% on room air. On exam, she has a wide, fixed splitting of S2. Which of the following medications most directly treats the underlying pathophysiology causing this patient's presentation?\nA. Bosentan\nB. Epoprostenol\nC. Lisinopril\nD. Metoprolol\nE. Nifedipine\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 8-year-old boy is brought to the clinic by his father for an annual well-check. His dad reports that he has been \u201cdifficult to handle\u201d as he would not listen and follow instructions at home. \u201cTelling him to sit still and do something is just so hard,\u201d the father says. His teacher also reports difficulties in the classroom where the child would talk out of turn and interrupt the class intermittently by doing something else. His grades have been suffering as a result. Otherwise, the patient has been healthy and up to date on his immunizations. What is the best course of management for this patient?\nA. Family therapy\nB. Haloperidol\nC. Methylphenidate\nD. Psychodynamic therapy\nE. Reassurance\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A pilot study is conducted to determine the therapeutic response of a new antidepressant drug in patients with persistent depressive disorder. Twelve participants are randomized into a control and a treatment group (n=6 patients in each). They are asked to subjectively rate the severity of their depression from 1 (low) to 10 (high) before and after taking a pill (control group = placebo; treatment group = antidepressant). The data from this study are shown in the following table:\nSubject Control group Treatment group\n  Depression ranking before intervention Depression ranking after intervention Depression ranking before intervention Depression ranking after intervention\n1 7 5 6 4\n2 8 6 8 4\n3 7 6 9 2\n4 5 5 7 5\n5 6 6 10 3\n6 9 7 6 4\nWhich of the following is the difference between the median of the depression scores before intervention in the treatment group and the control group?\nA. 0.7\nB. 0.5\nC. 1\nD. 2\nE. 2.1\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 28-year-old man presents to the emergency department after being rescued from his home. He was working at home alone on some renovations when 1 of his house's walls collapsed on him. His legs were trapped under the debris for about 30 hours before a neighbor came by, found him, and called an ambulance. He is very mildly confused and reports pain throughout both legs. The physical examination is notable for dry mucous membranes and tenderness to palpation throughout both legs with many superficial abrasions, but no active hemorrhage. The full-body computed tomography (CT) scan shows small fractures in both tibias, but no hematomas. He is admitted to the trauma service for observation. On hospital day 1, his urine appears very dark. Urine output over the preceding 24 hours is 200 mL. The laboratory studies show a creatinine of 2.7 mg/dL and serum creatine kinase (CK) of 29,700 IU/L. Which of the following is the next best step in the management of this patient?\nA. Order anti-nuclear antibody (ANA) titers\nB. Order anti-glomerular basement membrane (GBM) titers\nC. Order anti-streptolysin O titers\nD. Perform kidney biopsy\nE. Start dialysis\nF. Start IV fluids\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 35-year-old man with no known past medical history presents to his physician because he is applying for a job as a healthcare worker, which requires screening for the hepatitis B virus (HBV). The patient states that he is in good health and denies any symptoms. His vital signs and physical exam are unremarkable. Labs are drawn, and the patient's HBV serology shows the following:\n\nHBsAg: positive\nanti-HBsAg antibody: negative\nHBcAg: positive\nanti-HBcAg IgM: negative\nanti-HBcAg IgG: positive\nHBeAg: negative\nanti-HBeAg antibody: positive\n\nWhich of the following best describes this patient's results?\nA. Immune due to previous vaccination\nB. Immune due to previous infection\nC. Chronically infected, low infectivity\nD. Chronically infected, high infectivity\nE. Acutely infected\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 72-year-old man is admitted to the hospital because of a 2-day history of right-sided weakness and dysphagia. He is diagnosed with a thrombotic stroke and treatment with aspirin is initiated. A videofluoroscopic swallowing study is performed to determine his ability to swallow safely; he is found to be at increased risk of aspiration. Consequently, he is ordered not to have any food or liquids by mouth. A Dobhoff feeding tube is placed, tube feedings are ordered, and the patient starts receiving tube feedings. Shortly after, he develops a cough and dyspnea. An x-ray of the chest shows opacification of the right lower lobe and that the end of the Dobhoff tube is in his right lung instead of his stomach. Which of the following would most likely have prevented this medical error from occurring?\nA. Two patient identifiers\nB. Closed-loop communication\nC. Checklist\nD. Mortality and morbidity review\nE. Computerized physician order entry\nF. Fishbone diagram\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78-year-old woman living in New Jersey is brought to the emergency department in July with a fever for 5 days. Lethargy is present. She has had bloody urine over the last 48 hours but denies any nausea, vomiting, or abdominal pain. She has no history of serious illness and takes no medications. She has not traveled anywhere outside her city for the past several years. She appears ill. The temperature is 40.8\u2103 (105.4\u2109), the pulse is 108/min, the respiration rate is 20/min, and the blood pressure is 105/50 mm Hg. The abdominal exam reveals hepatosplenomegaly. Lymphadenopathy is absent. Petechiae are seen on the lower extremities. Laboratory studies show the following:\nLaboratory test\nHemoglobin 8 g/dL\nMean corpuscular volume (MCV) 98 \u00b5m3\nLeukocyte count 4,200/mm3\nSegmented neutrophils 32%\nLymphocytes 58%\nPlatelet count 108,000/mm3\nBilirubin, total 5.0 mg/dL\nDirect 0.7 mg/dL\nAspartate aminotransferase (AST) 51 U/L\nAlanine aminotransferase (ALT) 56 U/L\nAlkaline phosphatase 180 U/L\nLactate dehydrogenase (LDH) 640 U/L (N = 140\u2013280 U/L)\nHaptoglobin 20 mg/dL (N = 30\u2013200 mg/dL)\nUrine\nHemoglobin +\nUrobilinogen +\nProtein +\nA peripheral blood smear is shown (see image). Which of the following is the most likely diagnosis?\nA. Babesiosis\nB. Lyme disease\nC. Malaria\nD. Plague\nE. Leishmaniasis\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A previously healthy 5-year-old boy is brought to the emergency department because of a 1-day history of high fever. His temperature prior to arrival was 40.0\u00b0C (104\u00b0F). There is no family history of serious illness. Development has been appropriate for his age. He is administered rectal acetaminophen. While in the waiting room, he becomes unresponsive and starts jerking his arms and legs back and forth. A fingerstick blood glucose concentration is 86 mg/dL. After 5 minutes, he continues having jerky movements and is unresponsive to verbal and painful stimuli. Which of the following is the most appropriate next step in management?\nA. Intravenous administration of valproate\nB. Intravenous administration of lorazepam\nC. Intravenous administration of phenobarbital\nD. Obtain blood cultures\nE. Perform electroencephalogram\nF. Rectal administration of ibuprofen\nG. Repeat rectal administration of acetaminophen\nH. Rectal administration of lamotrigine\nI. Intravenous administration of fosphenytoin\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 42-year-old woman comes to the physician with acute, severe pain in the middle of her lower back. She also complains of constipation and trouble sleeping recently. Menses occur regularly at 28-day intervals. Examination shows localized tenderness to palpation over the lumbar spine. Serum calcium is 14 mg/dL and serum phosphorus is 1.5 mg/dL. An x-ray of the lumbar spine shows a compression fracture of the L4 vertebral body and osteopenia. Which of the following is the most likely underlying cause of this patient's decreased bone mineral density?\nA. Decrease in ovarian estrogen production\nB. Increase in calcitonin secretion\nC. Increase in interleukin-1 secretion\nD. Decrease in alkaline phosphatase secretion\nE. Decrease in RANKL receptor expression\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 23-year-old woman comes to the physician because of right-sided blurry vision and eye pain for 4 days. She has a 6-day history of low-grade fever, headache, and malaise. One year ago, she was diagnosed with Crohn disease. Her only medication is prednisone. Her temperature is 38\u00b0C (100.4\u00b0F), pulse is 84/min, and blood pressure is 112/75 mm Hg. The right eyelid is erythematous and tender; there are multiple vesicles over the right forehead and the tip of the nose. Visual acuity is 20/20 in the left eye and 20/80 in the right eye. Extraocular movements are normal. The right eye shows conjunctival injection and reduced corneal sensitivity. Fluorescein staining shows a corneal lesion with a tree-like pattern. Which of the following is the most likely diagnosis?\nA. Pseudomonas keratitis\nB. Anterior uveitis\nC. Orbital cellulitis\nD. Herpes zoster keratitis\nE. Angle-closure glaucoma\nF. Herpes simplex keratitis\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 67-year-old man with chronic kidney disease comes to the physician because of worsening fatigue and shortness of breath on exertion for 6 months. He has a 20-year history of poorly-controlled type 2 diabetes mellitus. Current medications include metformin and insulin. His pulse is 105/min. Examination shows conjunctival pallor and bounding pulses. Laboratory studies show:\nHemoglobin 8.6 g/dL\nMean corpuscular volume 90 \u03bcm3\nReticulocyte count 0.5%\nSerum\nFerritin 325 ng/mL\nUrea nitrogen 45 mg/dL\nCreatinine 2.2 mg/dL\nThe patient is prescribed a drug to treat the cause of his current symptoms. The drug's mechanism of action directly involves which of the following signaling pathways?\"\nA. PI3K/Akt/mTOR\nB. cAMP\nC. MAP kinase\nD. JAK/STAT\nE. IP3\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 19-year-old woman comes to the physician for a routine examination. She has one sexual partner, with whom she had unprotected sexual intercourse 3 days ago. She does not desire a pregnancy and is interested in a reliable and long-term contraceptive method. She has read in detail about the reliability, adverse-effects, health risks, and effective duration of intrauterine devices (IUD) as a birth control method. She requests the physician to prescribe and place an IUD for her. The physician feels that providing contraception would be a violation of her religious beliefs. Which of the following responses by the physician is most appropriate?\nA. \u201cPrescribing any means of contraception is against my religious beliefs, but as a doctor, I am obliged to place the IUD for you.\u201d\nB. \u201cI need to discuss this with my pastor before I decide whether to insert an IUD, as this is against my religious beliefs.\u201d\nC. \u201cI can understand your need for the IUD, but I cannot place it for you due to my religious beliefs. I would be happy to refer you to a colleague who could do it.\u201d\nD. \u201cI understand your concerns, but I cannot place the IUD for you due to my religious beliefs. I recommend you use condoms instead.\nE. \u201cFirst, I would like to perform an STD panel since you are sexually active.\u201d\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 28-year-old woman with a history of intravenous drug use is brought to the emergency department because of a 1-day history of fatigue, yellow eyes, confusion, and blood in her stools. She appears ill. Her temperature is 38.1\u00b0C (100.6\u00b0F). Physical examination shows pain in the right upper quadrant, diffuse jaundice with scleral icterus, and bright red blood in the rectal vault. Further evaluation demonstrates virions in her blood, some of which have a partially double-stranded DNA genome while others have a single-stranded RNA genome. They are found to share an identical lipoprotein envelope. This patient is most likely infected with which of the following pathogens?\nA. Picornavirus\nB. Calicivirus\nC. Flavivirus\nD. Filovirus\nE. Hepevirus\nF. Herpesvirus\nG. Deltavirus\nAnswer:",
        "output": "G",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 4-year-old boy presents the pediatrician with his parents for a consultation after his school teacher complained about his abnormal behavior and his inability to make friends in school. They mention that the boy does not interact well with others at home, school, or daycare. On physical examination, his vital signs are stable with normal weight, height, and head circumference for his age and sex. His general examination and systemic examination, including neurologic examination, are completely normal. His recent audiologic evaluation shows normal hearing, and intellectual disability has been ruled out by a clinical psychologist. Which of the following investigations is indicated as part of his diagnostic evaluation at present?\nA. Magnetic Resonance Imaging (MRI) of brain\nB. Positron Emission Tomography (SPECT) Scanning of head\nC. Electroencephalography\nD. Genetic testing for in MECP2 gene mutations\nE. No further testing is needed\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 57-year-old woman is brought to the emergency department by ambulance for dysarthria and left-sided facial droop. She is accompanied by her son, who states that the patient had just returned home an hour ago from walking the dog when suddenly the patient stated she felt \u201cstrange.\u201d When her son asked her what was wrong, her speech was slurred and her \"face looked funny.\u201d The son quickly called an ambulance. The paramedic upon arrival noted that the patient had left-sided facial droop. Her medical history includes asthma and sickle cell disease. She takes hydroxyurea, uses oxycodone as needed for pain, and an albuterol inhaler as needed for shortness of breath. The patient\u2019s temperature is 97\u00b0F (36.1\u00b0C), blood pressure is 145/72 mmHg, pulse is 93/min, and respirations are 14/min with an oxygen saturation of 96% on room air. On physical examination, a left-sided facial droop is appreciated. She has trouble articulating her words, and her speech is garbled. She is put on 2 L of oxygen by nasal cannula. Labs are obtained and pending. Which of the following therapies is most likely indicated?\nA. Alteplase\nB. Exchange transfusion\nC. Hydralazine\nD. Naloxone\nE. Warfarin\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 27-year-old woman presents to her family physician with pain on the front of her right knee. The pain started 2 months ago after she began training for a marathon, and it was gradual in onset and has slowly worsened. The pain increases with prolonged sitting and climbing stairs. She denies significant knee trauma. Her only medication is diclofenac sodium as needed for pain. Medical history is unremarkable. The vital signs include: temperature 36.9\u00b0C (98.4\u00b0F), blood pressure 100/70 mm Hg, and heart rate 78/min. Her body mass index is 26 kg/m2. The pain is reproduced by applying direct pressure to the right patella, and there is increased patellar laxity with medial and lateral displacement. The remainder of the examination is otherwise unremarkable. Which of the following is the most likely diagnosis?\nA. Patellar tendonitis\nB. Iliotibial band syndrome\nC. Prepatellar bursitis\nD. Patellofemoral pain syndrome\nE. Osgood-Schlatter's disease\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 58-year-old man is brought to the emergency department by his wife 30 minutes after the sudden onset of severe retrosternal chest pain radiating to his back. He has a history of hyperlipidemia, hypertension, and type 2 diabetes mellitus. He has smoked one-half pack of cigarettes daily for 20 years. Medications include aspirin, captopril, atorvastatin, and metformin. His pulse is 80/min and blood pressure is 160/60 mm Hg. A CT scan of the chest is shown. Which of the following is the strongest predisposing factor for this patient's current condition?\nA. Hyperlipidemia\nB. Diabetes mellitus\nC. Age\nD. Genetic collagen disorder\nE. Hypertension\nF. History of smoking\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 22-year-old woman is brought to the emergency department after being struck by a car while crossing the street. She has major depressive disorder with psychosis. Current medications include sertraline and haloperidol. Vital signs are within normal limits. X-ray of the lower extremity shows a mid-shaft femur fracture. The patient is taken to the operating room for surgical repair of the fracture. As the surgeon begins the internal fixation, the patient shows muscle rigidity and profuse diaphoresis. Her temperature is 39\u00b0C (102.2\u00b0F), pulse is 130/min, respirations are 24/min, and blood pressure is 146/70 mm Hg. The pupils are equal and reactive to light. The end tidal CO2 is 85 mm Hg. Which of the following is the most appropriate treatment for this patient's condition?\nA. Dantrolene therapy\nB. Fat embolectomy\nC. Cyproheptadine therapy\nD. Bromocriptine therapy\nE. Propranolol therapy\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 55-year-old man comes to the physician for a follow-up examination. For the past 6 months, he has had fatigue, headaches, and several episodes of dizziness. Three months ago, he was diagnosed with hypertension and started on medications. Since the diagnosis was made, his medications have been adjusted several times because of persistently high blood pressure readings. He also has hypercholesterolemia and peripheral arterial disease. He smoked one pack of cigarettes daily for 34 years but quit two months ago. His current medications include aspirin, atorvastatin, losartan, felodipine, and hydrochlorothiazide. He is 188 cm (6 ft 2 in) tall and weighs 109 kg (240 lb); BMI is 31 kg/m2. His pulse is 82/min and blood pressure is 158/98 mm Hg. Physical examination shows bilateral carotid bruits and normal heart sounds. Serum potassium concentration is 3.2 mEq/L, plasma renin activity is 4.5 ng/mL/h (N = 0.3\u20134.2 ng/mL/h), and serum creatinine concentration is 1.5 mg/dL. Further evaluation of this patient is most likely to show which of the following findings?\nA. Unilateral kidney atrophy\nB. Unilateral adrenal mass\nC. Unilateral parathyroid mass\nD. Bilateral kidney enlargement\nE. Pituitary mass\nF. Apneic episodes during sleep\nG. Diffuse thyroid enlargement\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A newborn presents with central cyanosis, nasal flaring, and subcostal retractions following a scheduled cesarean delivery. He was born to a healthy 29-year-old G-1-P-1 mother due to cervical incompetence at 34 weeks gestation; the pregnancy was otherwise uneventful. Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) scores were 6 and 8 at 1 and 5 minutes, respectively and his birth weight was 3,200 g. The umbilical cord had 3 vessels and the placenta was tan-red with all cotyledons intact. Fetal membranes were tan-white and semi-translucent. Currently, the vital signs include: temperature 36.9\u00b0C (98.4\u00b0F), blood pressure 70/40 mm Hg, pulse 190/min, and respiratory rate 68/min. On auscultation, breath sounds are decreased. Diffuse ground-glass opacifications are identified on chest X-ray. Which of the factors listed below most likely contributed to this infant\u2019s current condition?\nA. Gestational diabetes\nB. Alcohol abuse\nC. Cytomegalovirus infection\nD. Down syndrome\nE. Lithium\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 1-year-old girl is brought to the pediatrician because of a 6-month history of diarrhea. She has not received recommended well-child examinations. Her stools are foul-smelling and nonbloody. There is no family history of serious illness. She is at the 15th percentile for height and 5th percentile for weight. Physical examination shows abdominal distension. Her serum triglyceride concentration is 5 mg/dL. Genetic analysis shows a mutation in the gene that encodes microsomal triglyceride transfer protein. Which of the following is the most appropriate treatment for this patient's condition?\nA. Avoidance of dairy products\nB. Nicotinic acid supplementation\nC. Avoidance of dietary gluten\nD. Restriction of long-chain fatty acids\nE. Long-term antibiotic therapy\nF. Pancreatic enzyme replacement\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 64-year-old woman with osteoarthritis is brought to the emergency room because of a 2-day history of nausea and vomiting. Over the past few weeks, she has been taking acetaminophen frequently for worsening knee pain. Examination shows scleral icterus and tender hepatomegaly. She appears confused. Serum alanine aminotransferase (ALT) level is 845 U/L, aspartate aminotransferase (AST) is 798 U/L, and alkaline phosphatase is 152 U/L. Which of the following is the most likely underlying mechanism of this patient's liver failure?\nA. Glucuronide-conjugate formation\nB. Salicylic acid formation\nC. N-acetyl-p-benzoquinoneimine formation\nD. N-acetylcysteine formation\nE. Sulfate-conjugate formation\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 3855-g (8-lb 8-oz) newborn is examined shortly after birth. She was delivered at 40 weeks' gestation by cesarean delivery because of breech presentation. Pregnancy was otherwise uncomplicated. Physical examination shows asymmetric thigh creases. The left leg is shorter than the right leg and positioned in external rotation. Which of the following is the most likely underlying cause of this patient's findings?\nA. Avascular necrosis of the femoral head\nB. Fracture of the femoral neck\nC. Inflammation of the hip synovium\nD. Abnormal development of the acetabulum\nE. Traction apophysitis of the tibial tubercle\nF. Displacement of the femoral epiphysis\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78 -year-old gentleman presents to his primary care physician with progressive hearing loss over the last year. The patient has also been complaining of increasing pain in his legs over a similar time period. A radiograph of his right knee is shown in Figure A. Which of the following laboratory abnormalities is most likely in this patient?\nA. Decreased sodium\nB. Elevated alkaline phosphatase\nC. Elevated creatinine kinase\nD. Decreased phosphate\nE. Decreased calcium\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 26-year-old G1P0 woman presents for her first prenatal visit. Past medical history reveals the patient is blood type O negative, and the father is type A positive. The patient refuses Rho(D) immune globulin (RhoGAM), because it is derived from human plasma, and she says she doesn\u2019t want to take the risk of contracting HIV. Which of the following is correct regarding the potential condition her baby may develop?\nA. Rho(D) immune globulin is needed both before and immediately after delivery to protect this baby from developing the condition\nB. She should receive Rho(D) immune globulin to prevent the development of ABO incompatibility\nC. She should receive Rho(D) immune globulin to prevent the development of Rh(D) alloimmunization\nD. The Rho(D) immune globulin will also protect the baby against other Rh antigens aside from Rh(D)\nE. The injection can be avoided because the risk of complications of this condition is minimal\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A researcher discovers a new inhibitor for 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase that she believes will be more effective than current drugs. The compound she discovers uses the same mechanism of inhibiting the target enzyme as current drugs of this class; however, it has fewer off target effects and side effects. Therefore, she thinks that this drug can be used at higher concentrations. In order to study the effects of this compound on the enzyme, she conducts enzyme kinetics studies. Specifically, she plots the substrate concentration of the enzyme on the x-axis and its initial reaction velocity on the y-axis. She then calculates the Michaelis-Menten constant (Km) as well as the maximum reaction velocity (Vmax) of the enzyme. Compared to values when studying the enzyme alone, what will be the values seen after the inhibitor is added?\nA. Higher Km and lower Vmax\nB. Higher Km and same Vmax\nC. Same Km and higher Vmax\nD. Same Km and lower Vmax\nE. Same Km and same Vmax\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 35-year-old man presents to the general practitioner with a skin rash that has been present for 2 days. The rash appeared suddenly and has progressively gotten worse. It started off as an erythematous lesion on the back of his hands and also over his nose. The lesions over his hands have become bullous and tense. He has never experienced similar symptoms before. He just got back from a canoeing trip during a very hot and sunny weekend. Physical exam is significant for erythematous, vesicular lesions over the nape of the neck and bridge of the nose as well as tense bullae over the dorsum of both hands. The attending physician suspects a defect in the synthesis of heme and orders some blood tests. Which of the following precursors will most likely be elevated in this patient?\nA. Uroporphyrinogen III\nB. Hydroxymethylbilane\nC. Porphobilinogen\nD. \u03b4-Aminolevulinic acid\nE. Protoporphyrin IX\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:Six days after undergoing a left hemicolectomy for colorectal carcinoma, a 59-year-old man collapses in the hospital hallway and is unconscious for 30 seconds. Afterwards, he complains of shortness of breath and chest pain with deep inhalation. He has hypertension and hyperlipidemia. He smoked one pack of cigarettes daily for 35 years but quit prior to admission to the hospital. He does not drink alcohol. He is in distress and appears ill. His temperature is 36.5\u00b0C (97.7\u00b0F), blood pressure is 80/50 mm Hg, and pulse is 135/min and weak. Oxygen saturation is 88% on room air. Physical examination shows elevated jugular venous distention. Cardiac examination shows a regular, rapid heart rate and a holosystolic murmur that increases during inspiration. His abdomen is soft and mildly tender to palpation around the surgical site. Examination of his extremities shows pitting edema of the left leg. His skin is cold and clammy. Further examination is most likely to reveal which of the following findings?\nA. Rapid, aberrant contractions of the atria\nB. Collapsed inferior vena cava\nC. Stenosis of the carotid arteries\nD. Apical left ventricular ballooning\nE. Dilated right ventricular cavity\nF. Anechoic space between pericardium and epicardium\nG. Reduced regional ventricular wall motion\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 12-year-old boy is brought to the physician because of increased frequency of micturition over the past month. He has also been waking up frequently during the night to urinate. Over the past 2 months, he has had a 3.2-kg (7-lb) weight loss. There is no personal or family history of serious illness. He is at 40th percentile for height and weight. Vital signs are within normal limits. Physical examination shows no abnormalities. Serum concentrations of electrolytes, creatinine, and osmolality are within the reference range. Urine studies show:\nBlood negative\nProtein negative\nGlucose 1+\nLeukocyte esterase negative\nOsmolality 620 mOsmol/kg H2O\nWhich of the following is the most likely cause of these findings?\"\nA. Insulin resistance\nB. Elevated thyroxine levels\nC. Renal resistance to ADH\nD. Infection of the urinary tract\nE. Insulin deficiency\nF. Compulsive water intake\nG. Renal failure\nH. Inadequate ADH secretion\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-month-old boy is brought to the emergency department 25 minutes after having a seizure. He has had multiple seizures during the past week. His mother has noticed that he has become lethargic and has had a weak cry for the past month. He was born at 37 weeks' gestation. He is at the 20th percentile for height and 15th percentile for weight. His temperature is 36.7\u00b0C (98\u00b0F), respirations are 50/min, and pulse is 140/min. Examination shows a soft and nontender abdomen. The liver is palpated 4 cm below the right costal margin; there is no splenomegaly. Serum studies show:\nNa+ 137 mEq/L\nCl- 103 mEq/L\nK+ 3.9 mEq/L\nGlucose 32 mg/dL\nCalcium 9.6 mg/dL\nTotal cholesterol 202 mg/dL\nTriglycerides 260 mg/dL\nLactate 4.2 mEq/L (N = 0.5 - 2.2 mEq/L)\nA deficiency of which of the following enzymes is the most likely cause of this infant's symptoms?\"\nA. Glycogen branching enzyme\nB. Galactose 1-phosphate uridyltransferase\nC. Fructokinase\nD. Glucose 6-phosphatase\nE. Acid maltase\n\"\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 45-year-old male seismologist with a 10-year history of AIDS returns from a two-month long stay in Los Angeles three weeks ago and is hospitalized for concurrent pneumonia, meningitis, and vertebral osteomyelitis. A sputum sample was taken and shown to have spherules containing spores (Figure A). Treatment was initiated with a systemic medication that causes fever and chills upon infusion. Which of the following is the mechanism of action of this medication?\nA. Inhibits ergosterol synthesis\nB. Binds to ergosterol, forming destructive pores in cell membrane\nC. Inhibits squalene epoxidase\nD. Inhibits formation of beta glucan\nE. Inhibits pyrimidine synthesis\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 8-month-old boy is brought to the emergency room by his mother who notes that the child has not been passing stool regularly. Palpation and radiographic imaging of the umbilical region reveal the presence of fecal material in an abnormal out-pocketing of bowel. Which of the following is a common complication seen in this condition?\nA. Enlarged rugal folds\nB. Dysplasia\nC. Ulceration\nD. Megacolon\nE. Paneth cell metaplasia\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A hepatologist has learned about the survival benefit of Noxbinle (tumorolimus) in hepatocellular carcinoma (HCC) patients from a fellow physician. She is looking at a list of HCC patients on her hospital's hepatology consult service and trying to identify candidates who might derive more survival benefits from Noxbinle as opposed to Metalimus. Based on the information provided in the drug advertisement, which of the following patients with HCC would be an appropriate treatment candidate and benefit the most from treatment with Noxbinle 100 mg in comparison to Metalimus 100 mg?\nA. Non-cirrhotic patient with a history of hepatitis B and alcohol dependence\nB. Alcoholic patient with severe cirrhosis on immunosuppressive therapy\nC. Patient with severe cirrhosis, history of hepatitis C, and kidney stones\nD. Patient without cirrhosis, with a history of hepatitis C, and coronary artery disease\nE. Patient with severe cirrhosis, history of hepatitis C, and asthma\nF. Patient with moderate cirrhosis, alcoholism, and poor appetite\nG. Alcoholic patient with moderate cirrhosis and a necrotic foot ulcer\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A group of investigators is evaluating the diagnostic properties of a new blood test that uses two serum biomarkers, dityrosine and N\u03b5-carboxymethyl-lysine, for the clinical diagnosis of autism spectrum disorder (ASD) in children. The test is considered positive only if both markers are found in the serum. 50 children who have been diagnosed with ASD based on established clinical criteria and 50 children without the disorder undergo testing. The results show:\nDiagnosis of ASD No diagnosis of ASD\nTest positive 45 15\nTest negative 5 35\nWhich of the following is the specificity of this new test?\"\nA. 30%\nB. 10%\nC. 88%\nD. 70%\nE. 90%\nF. 75%\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 33-year-old man presents to his primary care physician for numbness and tingling in his hands. He does not typically see a physician, but states that he has had some worsening numbness and weakness in his hands that has been progressing over the past month. His temperature is 99\u00b0F (37.2\u00b0C), blood pressure is 120/66 mmHg, pulse is 80/min, respirations are 16/min, and oxygen saturation is 99% on room air. Physical exam is notable for a man with strange facial features including an enlarged mandible. The patient is tall and has very large hands with symptoms of numbness and pain reproduced when tapping over the flexor retinaculum of the wrist. Routine laboratory values demonstrate a fasting blood glucose of 155 mg/dL. Which of the following is the most likely cause of mortality in this patient?\nA. Adrenal failure\nB. Congestive heart failure\nC. Kidney failure\nD. Malignancy\nE. Stroke\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 63-year-old male is accompanied by his wife to his primary care doctor complaining of shortness of breath. He reports a seven-month history of progressively worsening dyspnea and a dry non-productive cough. He has also lost 15 pounds over the same time despite no change in diet. Additionally, over the past week, his wife has noticed that the patient appears confused and disoriented. His past medical history is notable for stable angina, hypertension, hyperlipidemia, and diabetes mellitus. He currently takes aspirin, metoprolol, lisinopril, atorvastatin, metformin, and glyburide. He has smoked 1 pack of cigarettes per day for 30 years and previously worked as a mechanic at a shipyard. Physical examination reveals no wheezes, rales, or rhonchi with slightly decreased aeration in the left lower lung field. Mucus membranes are moist with normal skin turgor and capillary refill. Laboratory analysis reveals the following:\n\nNa 121 mEq/L\nK 3.4 mEq/L\nCl 96 mEq/L\nHCO3 23 mEq/L\nCr 1.1 mg/dl\nBUN 17 mg/dl\n\nA biopsy of the responsible lesions will most likely demonstrate which of the following findings?\nA. Pleomorphic cells arising from the alveolar lining with disruption of the alveolar architecture\nB. Sheets of large pleomorphic cells containing keratin and intercellular bridges\nC. Undifferentiated small round blue cells\nD. Anaplastic pleomorphic giant cells\nE. Sheets of epithelial cells with papillary fragments, necrosis, and psammoma bodies\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 62-year-old man presents to the emergency department with sudden onset of severe left leg pain accompanied by numbness and weakness. His medical history is remarkable for hypertension and hyperlipidemia. His vital signs include a blood pressure of 155/92 mm Hg, a temperature of 37.1\u00b0C (98.7\u00b0F), and an irregular pulse of 92/min. Physical examination reveals absent left popliteal and posterior tibial pulses. His left leg is noticeably cold and pale. There is no significant tissue compromise, nerve damage, or sensory loss. Which of the following will most likely be required for this patient's condition?\nA. Amputation\nB. Thromboembolectomy\nC. Fasciotomy\nD. Warfarin\nE. Antibiotics\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 66-year-old woman comes to the physician because of a 1-week history of pruritic blister formation. Physical examination shows multiple 1\u20133 cm bullae on the palms, soles, lower legs, and inguinal folds. Gentle rubbing of the skin does not result in sloughing of the epidermis. Immunofluorescence studies of a perilesional skin biopsy specimen are most likely to show deposition of antibodies in which of the following areas?\nA. At the dermoepidermal junction\nB. Between epidermal keratinocytes\nC. No staining\nD. In dermal papillae\nE. In dermal vessel walls\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 24-year-old woman presents to the emergency department because she started experiencing dyspnea and urticaria after dinner. Her symptoms began approximately 15 minutes after eating a new type of shellfish that she has never had before. On physical exam her breathing is labored, and pulmonary auscultation reveals wheezing bilaterally. Given this presentation, she is immediately started on intramuscular epinephrine for treatment of her symptoms. If part of this patient's symptoms were related to the systemic release of certain complement components, which of the following is another function of the responsible component?\nA. Chemotaxis\nB. Clearance of immune complexes\nC. Direct cytolysis\nD. Inhibition of kallikrein activation\nE. Opsonization of pathogens\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:While in the ICU, a 62-year-old male undergoes placement of a Swan-Ganz catheter to evaluate his right heart pressures. All pressures are found to be within normal limits, and the cardiology fellow records a pulmonary wedge pressure of 10 mmHg. Which of the following are normal values for the pressures that will be obtained from this patient's right ventricle?\nA. 25/10 mmHg\nB. 25/5 mmHg\nC. 10/0 mmHg\nD. 100/5 mmHg\nE. 100/70 mmHg\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 18-year-old woman presents to the medical clinic 6 days after her boyfriend\u2019s condom broke during sexual intercourse. The patient states \u201cI do not wish to get pregnant at this point in my life.\u201d She has no other medical conditions and takes no prescription medications. Her family history is negative. She is a social drinker, drinking approx. 3\u20134 days every month. She is currently in a monogamous relationship with her boyfriend and she believes her boyfriend is monogamous as well. The heart rate is 104/min, and the blood pressure is 124/80 mm Hg. On physical examination, she appears tiresome and nervous. The heart auscultation is absent of murmur, and the lungs are clear to auscultation bilaterally. Her ovaries and uterus are palpable. Speculum exam shows no signs of trauma and a closed cervical os. Based on her history and physical examination, which of the following management strategies would you recommend?\nA. Mifepristone\nB. Ulipristal acetate\nC. Copper-IUD\nD. Levonorgestrel\nE. Ethinyl estradiol\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:Which of the following events is likely to occur in the germinal center?\nA. Development of early pro-B cells\nB. Development of immature B cells\nC. T-cell negative selection\nD. Isotype switching\nE. Formation of double-positive T cells\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 19-year-old man comes to the physician because of a 2 day history of blood-speckled stools and a protruding rectal mass. He has no abdominal pain, altered bowel habits, or fever. His mother has inflammatory bowel disease. His vital signs are within normal limits. Examination shows multiple, small, hyperpigmented maculae on the lips, buccal mucosa, palms, and soles. The abdomen is soft with no organomegaly. Rectal examination shows a 4-cm pedunculated polyp with superficial excoriations on the mucosa. A colonoscopy shows 14 polyps. A biopsy shows hamartomatous mucosal polyps. This patient's diagnosis is most likely associated with which of the following conditions?\nA. Medulloblastoma\nB. Enterovesicular fistula\nC. Mandibular osteoma\nD. Pancreatic carcinoma\nE. Esophageal varices\nF. Thyroid adenoma\nG. Alopecia\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 13-year-old Hispanic boy is brought to the physician by his mother because of left groin pain for 1 month. The pain radiates to his left knee and is aggravated on walking. He fell during soccer practice 5 weeks ago but did not see a doctor about it and does not recall any immediate and persistent pain after the event. He has hypothyroidism. His only medication is levothyroxine. His immunizations are up-to-date. He appears uncomfortable. He is at the 50th percentile for height and at the 95th percentile for weight. His temperature is 37.1\u00b0C (98.9\u00b0F), pulse is 77/min, respirations are 14/min, and blood pressure is 100/70 mm Hg. The patient has a left-sided, antalgic gait. The left lower extremity is externally rotated. The left hip is tender to palpation and internal rotation is limited by pain. Laboratory studies show:\nHemoglobin 13.1 g/dL\nLeukocyte count 9,100/mm3\nPlatelet count 250,000/mm3\nSerum\nTSH 3.6 \u03bcU/mL\nWhich of the following is the most likely diagnosis?\"\nA. Legg-Calv\u00e9-Perthes disease\nB. Septic arthritis of the left hip\nC. Slipped capital femoral epiphysis\nD. Osteomyelitis of the left hip\nE. Transient synovitis\nF. Developmental dysplasia of the left hip\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 6-year-old girl is brought to the physician by her parents because of concern that she is the shortest in her class. She has always been short for her age, but she is upset now that her classmates have begun teasing her for her height. She has no history of serious illness and takes no medications. She is 109 cm (3 ft 7 in) tall (10th percentile) and weighs 20 kg (45 lb) (50th percentile). Her blood pressure is 140/80 mm Hg. Vital signs are otherwise within normal limits. Physical examination shows a low-set hairline and a high-arched palate. Breast development is Tanner stage 1 and the nipples are widely spaced. Extremities are well perfused with strong peripheral pulses. Her hands are moderately edematous. This patient is at increased risk of developing which of the following complications?\nA. Renal cell carcinoma\nB. Precocious puberty\nC. Intellectual disability\nD. Aortic insufficiency\nE. Ectopia lentis\nF. Acute lymphoblastic leukemia\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 55-year-old man presents with fever, chills, fatigue, cough, sore throat, and breathlessness for the past 7 days. He describes the cough as productive and says he is fatigued all the time. He says he is a farmer with daily contact with rabbits, horses, sheep, pigeons, and chickens and reports cleaning the barn 3 days before his symptoms started. The patient denies any history of tick bites. Past medical history is irrelevant. His temperature is 39.4\u00b0C (103.0\u00b0F), pulse is 110/min, and respirations are 26/min. On physical examination, there are decreased breath sounds on the right side. A large tender node is palpable in the right axilla. A chest radiograph reveals multiple homogenous opacities in the lower lobe of the right lung and a right-sided pleural effusions. Gram staining of a sputum sample is negative for any organism. Serology tests are negative. Which of the following is the most likely causative organism for this patient\u2019s condition?\nA. Francisella tularensis\nB. Bacillus anthracis\nC. Staphylococcus aureus \nD. Yersinia pestis\nE. Mycoplasma pneumoniae\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 4-year-old male is brought to the pediatrician for a low-grade fever. His mother states that he has had a waxing and waning fever for the past 6 days with temperatures ranging from 99.8\u00b0F (37.7\u00b0C) to 101.0\u00b0F (38.3\u00b0C). She reports that he had a similar episode three months ago. She also reports symmetric joint swelling in the child\u2019s knees and wrists that has become increasingly noticeable over the past 8 weeks. He has not had a cough, difficulty breathing, or change in his bowel movements. The child was born at 40 weeks gestation. His height and weight are in the 45th and 40th percentiles, respectively. He takes no medications. His temperature is 100.1\u00b0F (37.8\u00b0C), blood pressure is 100/65 mmHg, pulse is 105/min, and respirations are 18/min. On examination, there is a non-pruritic, macular, salmon-colored truncal rash. Serological examination reveals the following:\n\nSerum:\nRheumatoid factor: Negative\nAnti-nuclear antibody: Negative\nAnti-double stranded DNA: Negative\nAnti-SSA: Negative\nAnti-SSB: Negative\nHuman leukocyte antigen B27: Positive\nErythrocyte sedimentation rate: 30 mm/h\n\nThis patient is most likely at increased risk of developing which of the following?\nA. Iridocyclitis\nB. Sacroiliitis\nC. Scoliosis\nD. Aortitis\nE. Dactylitis\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 42-year-old Caucasian woman presents to the emergency department with complaints of progressive weight loss, dizziness, nausea, and vomiting over the last several months. She returned from a 2-week international business trip 6 months ago where she reports being ill with a fever, diarrhea, and a cough. Her temperature is 97.7\u00b0F (36.5\u00b0C), blood pressure is 114/64 mmHg, pulse is 105/min, respirations are 72/min, and oxygen saturation is 99% on room air. Physical exam is significant for the finding in Figure A. Initial laboratory studies are ordered as seen below.\n\nSerum:\nNa+: 139 mEq/L\nCl-: 100 mEq/L\nK+: 6.3 mEq/L\nHCO3-: 15 mEq/L\nBUN: 20 mg/dL\nGlucose: 66 mg/dL\nCreatinine: 1.1 mg/dL\nCa2+: 10.2 mg/dL\n\nWhich of the following is the most likely underlying etiology of this patient's symptoms?\nA. Aldosteronoma\nB. Autoimmune adrenalitis\nC. SIADH\nD. Tuberculosis\nE. Viral gastroenteritis\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 68-year-old male with a history of chronic myelogenous leukemia presents to his oncologist complaining of shortness of breath. He reports developing progressively worsening dyspnea and a dry cough over the past 2 weeks. His past medical history is also notable for hypertension and gout. He takes imatinib, lisinopril, and allopurinol. He has a 40 pack-year smoking history and drinks 2-3 beers per day. He used to work in a foundry and is now a rancher working with sheep and goats. His temperature is 98.6\u00b0F (37\u00b0C), blood pressure is 135/75 mmHg, pulse is 90/min, and respirations are 22/min. On examination, he has slightly increased work of breathing and diffuse rales in the bilateral upper and lower lung fields. A chest radiograph demonstrates non-specific alveolar opacities. Endoscopic biopsy of the lung is performed with results shown in Figure A. This patient\u2019s condition is most likely caused by which of the following?\nA. Antibody-antigen complex deposition\nB. Defective surfactant clearance\nC. Idiopathic fibroblast proliferation\nD. Idiopathic granulomatous inflammation\nE. Reactive fibroblast proliferation due to silica inhalation\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old woman comes to the physician because of progressive weight loss for 3 months. Physical examination shows jaundice and a nontender, palpable gallbladder. A CT scan of the abdomen shows an ill-defined mass in the pancreatic head. She is scheduled for surgery to resect the pancreatic head, distal stomach, duodenum, early jejunum, gallbladder, and common bile duct and anastomose the jejunum to the remaining stomach, pancreas, and bile duct. Following surgery, this patient is at the greatest risk for which of the following?\nA. Hypercoagulable state\nB. Microcytic anemia\nC. Calcium oxalate kidney stones\nD. Wide-based gait\nE. Increased bile production\n\"\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 70-year-old caucasian woman presents to her primary care provider complaining of a heavy cough with blood-tinged sputum. Her cough has bothered her for the last 2 weeks. Over the counter medications are no longer alleviating her symptoms. She also reports that she has unintentionally lost 6.8 kg (15 lb) in the last 5 months. Her past medical history is significant for peptic ulcer disease that was positive for H. pylori on biopsy and was treated with triple-drug therapy. She is a lifetime non-smoker and worked as a teacher before retiring at the age of 60. Today, her temperature is 36.9\u00b0C (98.4\u00b0F), blood pressure is 128/82 mm Hg, pulse is 87/min, and pulse oximetry is 90% on room air. On physical exam, her heart has a regular rate and rhythm. Auscultation of the lungs revealed scattered crackles and wheezes. A CT scan of the lungs shows an irregular mass in the peripheral region of the inferior lobe of the right lung and a CT guided biopsy is positive for malignant tissue architecture and gland formation with a significant amount of mucus. Which of the following risk factors most likely predisposed this patient to her condition?\nA. Medication\nB. Occupational history\nC. Past medical history\nD. Race\nE. Gender\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 68-year-old man comes to the physician because of a 3-month history of a painless skin lesion on his neck. The lesion has gradually become darker in color. Sometimes it is itchy. He also noticed one similar lesion on his lower back. He is a retired gardener. He has smoked half a pack of cigarettes daily for 40 years. His temperature is 36.7\u00b0C (98\u00b0F), pulse is 72/min, and blood pressure is 123/78 mm Hg. Physical examination shows a 0.8-cm hyperpigmented papule on his neck and a 0.6-cm hyperpigmented papule on his lower back, both of which have a greasy and wax-like appearance. A photograph of the neck is shown. Which of the following is the most likely diagnosis?\nA. Actinic keratosis\nB. Dysplastic nevus\nC. Compound nevus\nD. Lentigo maligna\nE. Basal cell carcinoma\nF. Seborrheic keratosis\nG. Dermatofibroma\n\"\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 48-year-old woman presented to the hospital with a headache, intermittent fevers and chills, generalized arthralgias, excessive thirst, increased fluid intake, and a progressive rash that developed on her back. Three days before seeking evaluation at the hospital, she noticed a small, slightly raised lesion appearing like a spider or insect bite on her back, which she considered to be a scab covering the affected region. The patient's fever reached 39.4\u00b0C (102.9\u00b0F) 2 days before coming to the hospital, with an intensifying burning sensation on the affected site. When a family member examined the bite, it was noticed that the bump had transformed into a circular rash. The patient took over-the-counter ibuprofen for intense pain so she could sleep through the night. The day before her hospital visit, the patient felt exhausted but managed to complete a normal workday. On the day of the hospital visit, she awoke feeling very ill, with shooting joint pains, high fevers, and excessive thirst, which led to her to seek medical attention. On physical examination, her temperature was 40.1\u00b0C (104.2\u00b0F), and there was a large circular red rash with a bulls-eye appearance (17 \u00d7 19 cm in diameter) on her back. The rest of the physical examination was unremarkable. Her past medical and surgical histories were not significant apart from a history of anaphylaxis when taking a tetracycline. She recalled a walk in the woods 3 weeks before this exam but denied finding a tick or any other ectoparasite on her body. She denied any nutritional or inhalational allergies, although she emphasized that she is allergic to tetracyclines. Based on her symptoms, medical history, and physical examination findings, the attending physician decides to institute antimicrobial therapy immediately. Which antimicrobial drug did the physician prescribe?\nA. Cephalexin\nB. Amoxicillin\nC. Azithromycin\nD. Erythromycin\nE. Doxycycline\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 63-year-old woman, gravida 0, para 0 comes to the physician because of a 3-month history of abdominal distension, constipation, and weight loss. She has a history of endometriosis. Pelvic examination shows a nontender, irregular, left adnexal mass. Her serum level of CA-125 is elevated. Serum concentrations of human chorionic gonadotropin and alpha-fetoprotein are within the reference ranges. Microscopic examination of the mass is most likely to show which of the following findings?\nA. Large undifferentiated germ cells with clear cytoplasm\nB. Immature neuroectodermal tissue\nC. Flattened, cuboidal cells along with Schiller-Duval bodies\nD. Small, round cells that form Call-Exner bodies\nE. Atypical epithelial cells along with psammoma bodies\nF. Spindle-shaped stromal cells along with signet ring cells\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 23-year-old man presents to the emergency room with right flank pain. On physical examination, there is no rebound tenderness, guarding, and rigidity. The pain is radiating to the groin region and is associated with nausea. Plain X-ray of the kidney, ureter, and bladder is normal. Urinalysis showed the presence of mild hematuria, an absence of pus cells, and the following crystals (refer to image). What is the most likely composition of these crystals?\nA. Calcium carbonate\nB. Magnesium phosphate\nC. Uric acid\nD. Cysteine stones\nE. Calcium oxalate\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 27-year-old woman presents to your office complaining of difficulty swallowing, and she describes that \"there is something in the back of her throat\". Furthermore, she also feels an \"achy\" chest pain that has been getting progressively worse over the last few weeks. She denies having any fever, shortness of breath, cough, abdominal pain, heartburn, nausea, or vomiting. The patient has a history of wrist fracture as a child, migraines, and a recent diagnosis of myasthenia gravis. Which of the following is the most likely diagnosis?\nA. Benign tumor of the thymus\nB. Superior vena cava syndrome\nC. Anaplastic thyroid cancer\nD. Mediastinitis\nE. Thyroglossal duct cyst\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 35-year-old woman is started on a new experimental intravenous drug X. In order to make sure that she is able to take this drug safely, the physician in charge of her care calculates the appropriate doses to give to this patient. Data on the properties of drug X from a subject with a similar body composition to the patient is provided below:\n\nWeight: 100 kg\nDose provided: 1500 mg\nSerum concentration 15 mg/dL\nBioavailability: 1\n\nIf the patient has a weight of 60 kg and the target serum concentration is 10 mg/dL, which of the following best represents the loading dose of drug X that should be given to this patient?\nA. 150 mg\nB. 300mg\nC. 450 mg\nD. 600 mg\nE. 1000 mg\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 33-year-old man presents to the emergency department after he was struck by a motor vehicle. He was found unconscious and was brought in by ambulance. The patient\u2019s Glasgow Coma Scale is 7, and his temperature is 98.0\u00b0F (36.7\u00b0C), blood pressure is 84/44 mmHg, pulse is 140/min, respirations are 22/min, and oxygen saturation is 99% on room air. The patient is given IV fluids and blood products. A FAST exam is performed as seen in Figure A. As the patient is being set up to be intubated, it is noted that his blood pressure has improved to 100/60 mmHg. The patient is subsequently intubated and mechanically ventilated. His blood pressure sharply decreases to 80/40 mmHg. Which of the following is the most likely cause of this patient\u2019s hemodynamic status?\nA. Cardiac tamponade and tension pneumothorax\nB. Hemorrhagic shock and cardiac tamponade\nC. Hemorrhagic shock and increased intrathoracic pressure\nD. Hemorrhagic shock and neurogenic shock\nE. Hemorrhagic shock and septic shock\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 19-year-old G1P0000 presents for her first obstetric ultrasound after having a positive home pregnancy test. At her visit, she states that she is unsure but believes her last menstrual period was 6 weeks ago. She complains of several weeks of severe nausea with vomiting and has lost 4 pounds from her baseline weight. She also endorses some palpitations, increased perspiration, and a fine tremor of both hands. She denies vaginal bleeding. Ultrasound findings are shown in Figure A and Figure B, and her \u00df-hCG is 227,183 mIU/mL. Which of the following is the best next step in management?\nA. Propylthiouracil therapy\nB. Methotrexate therapy with serial serum \u00df-hCGlevels\nC. Misoprostol and mifepristone with serial serum \u00df-hCGlevels\nD. Dilation and curettage with serial serum \u00df-hCGlevels\nE. Laparoscopic removal of ovarian cysts\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 3-year-old girl is brought to her pediatrician with 2 days of fever and abdominal pain. She has also been crying and complaining of pain while urinating. She was born at term without incident and was previously healthy at regular checkups. On presentation, her temperature is 102.2\u00b0F (39\u00b0C), blood pressure is 137/85 mmHg, pulse is 122/min, and respirations are 24/min. Physical exam reveals a palpable, painless, abdominal mass that does not cross the midline. Which of the following additional findings would be associated with this patient's disorder?\nA. 11;22 chromosome translocation\nB. Aniridia\nC. Ash leaf spots\nD. Epstein-Barr virus\nE. Opsoclonus myoclonus\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 45-year-old man presents to his primary care physician for a wellness checkup. He states that he feels fatigued at times but feels near his baseline. The patient smokes 1 pack of cigarettes per day, drinks alcohol occasionally, and has a past medical history of poorly controlled diabetes. His temperature is 98.6\u00b0F (37.0\u00b0C), blood pressure is 167/108 mmHg, pulse is 80/min, respirations are 10/min, and oxygen saturation is 98% on room air. Physical exam reveals an overweight man with a ruddy complexion. Bilateral gynecomastia is noted for which the patient inquires about cosmetic surgery as a treatment. Laboratory values are ordered as seen below.\n\nHemoglobin: 14 g/dL\nHematocrit: 42%\nLeukocyte count: 6,500/mm^3 with normal differential\nPlatelet count: 185,000/mm^3\n\nSerum:\nNa+: 142 mEq/L\nCl-: 102 mEq/L\nK+: 3.2 mEq/L\nHCO3-: 31 mEq/L\nBUN: 27 mg/dL\nGlucose: 173 mg/dL\nCreatinine: 1.5 mg/dL\nCa2+: 9.8 mg/dL\n\nA CT scan demonstrates bilateral abnormal abdominal masses. Which of the following is the best next step in management?\nA. Eplerenone\nB. Hydrochlorothiazide\nC. Lisinopril\nD. Spironolactone\nE. Surgical excision\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 29-year-old woman (gravida 2, para 1) presents at 32 weeks gestation for routine follow-up care. Her previous pregnancy was complicated with preeclampsia, and she delivered at 35 weeks via cesarean delivery. Four years ago, she was diagnosed with arterial hypertension. Prior to pregnancy, she took amlodipine and hydrochlorothiazide; after she found out she was pregnant, she switched to methyldopa. The course of her current pregnancy has been unremarkable with normal laboratory values at each checkup. According to her blood pressure diary, her systolic blood pressure varies between 120 and 130 mm Hg, and her diastolic blood pressure is usually normal. At presentation, the blood pressure is 140/80 mm Hg, heart rate is 76/min, respiratory rate is 15/min, and temperature is 36.9\u00b0C (98.4\u00b0F). The fetal heart rate is 143/min. Examination shows a 1+ pitting lower leg edema. Dipstick test shows 2+ protein. 24-hour urine assessment demonstrates urinary protein excretion of 1 g/L. Which of the following laboratory values should be assessed next in this patient?\nA. Coagulogram\nB. Liver transaminases\nC. Total bilirubin\nD. Lipidogram\nE. Urinalysis\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 22-year-old man comes to the physician for a follow-up evaluation for chronic lower back pain. He has back stiffness that lasts all morning and slowly improves throughout the day. He has tried multiple over-the-counter medications, including ibuprofen, without any improvement in his symptoms. Physical examination shows tenderness over the iliac crest bilaterally and limited range of motion of the lumbar spine with forward flexion. The results of HLA-B27 testing are positive. An x-ray of the lumbar spine shows fusion of the lumbar vertebrae and sacroiliac joints. The physician plans to prescribe a new medication but first orders a tuberculin skin test to assess for the risk of latent tuberculosis reactivation. Inhibition of which of the following is the most likely primary mechanism of action of this drug?\nA. Inosine monophosphate dehydrogenase\nB. TNF-\u03b1\nC. NF-\u03baB\nD. Calcineurin\nE. mTOR kinase\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 52-year-old man with a history of gastric cancer that was treated with subtotal gastrectomy dies in a motor vehicle collision. At autopsy, examination of the spinal cord shows unilateral atrophy of the neurons in the area indicated by the arrow. Neurological examination of the patient when he was still alive would most likely have shown which of the following findings?\nA. Decreased sense of pain in the contralateral leg\nB. Decreased sense of temperature in the ipsilateral arm\nC. Decreased strength of the contralateral leg\nD. Decreased vibratory sense in the ipsilateral arm\nE. Decreased positional sense in the ipsilateral leg\nF. Decreased sense of crude touch in the contralateral arm\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 20-year-old male presents to the emergency department because of several days of back pain and fatigue. He is a college student who just returned from a study abroad program in Morocco. During his final week abroad he engaged in a number of recreational activities including swimming at the beach, eating local foods such as couscous and bean salad, and riding a camel into the desert. His temperature is 99\u00b0F (37\u00b0C), blood pressure is 121/79 mmHg, pulse is 70/min, and respirations are 11/min. He says that otherwise he has been healthy except for some episodes of dark urine. Upon physical exam, his skin is found to be more yellow than usual under his eyelids. Which of the following findings would most likely be seen in this patient?\nA. Absent urine bilirubin\nB. Elevated urine bilirubin\nC. Decreased urine urobilinogen\nD. Conjugated hyperbilirubinemia\nE. Elevated aspartate aminotransferase\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 22-year-old man is rushed to the emergency department after a motor vehicle accident. The patient states that he feels weakness and numbness in both of his legs. He also reports pain in his lower back. His airway, breathing, and circulation is intact, and he is conversational. Neurologic exam is significant for bilateral lower extremity flaccid paralysis and impaired pain and temperature sensation up to T10-T11 with normal vibration sense. A computerized tomography scan of the spine is performed which shows a vertebral burst fracture of the vertebral body at the level of T11. Which of the following findings is most likely present in this patient?\nA. Impaired proprioception sense\nB. Preserved fine touch\nC. Preserved crude touch\nD. Hyperreflexia at the level of the lesion\nE. Normal bladder function\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 32-year-old Greek man presents with a rash consistent with dermatitis herpetiformis and is treated with a course of oral dapsone. Over the following several days he becomes increasingly fatigued and experiences persistent back pain. Complete blood count reveals a normocytic anemia, and urinalysis shows hemoglobinuria. Results from a peripheral blood smear are shown in Figure A. Which of the following is most likely responsible for this patient\u2019s symptoms?\nA. Glucose-6-phosphate-dehydrogenase deficiency\nB. Pyruvate kinase deficiency\nC. Paroxysmal nocturnal hemoglobinuria\nD. Hereditary spherocytosis\nE. Cold immune hemolytic anemia\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 59-year-old man comes to the physician because of a 3-month history of frequent urination. He has to urinate every 1\u20132 hours during the day and wakes up at least 2\u20133 times at night to urinate. He also reports that over the last 2 months, he has difficulty initiating micturition and the urinary stream is weak, with prolonged terminal dribbling. His pulse is 72/min, and blood pressure is 158/105 mm Hg. Rectal exam shows a smooth, symmetrically enlarged prostate without any tenderness or irregularities. Prostate-specific antigen is within the reference range and urinalysis shows no abnormalities. A postvoid ultrasound shows a residual bladder volume of 110 mL. Which of the following is the most appropriate next step in management?\nA. Bladder catheterization\nB. Transurethral resection of the prostate\nC. Prostate biopsy\nD. Prostatectomy\nE. Terazosin therapy\nF. Finasteride therapy\nG. Cystoscopy\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 51-year-old man is brought to the emergency department because of a 2-day history of fever, abdominal pain, and confusion. His wife states that he has been unable to recall his birthday or her name. He was diagnosed with hepatitis C 3 years ago but refused treatment. He has been treated twice in the past year for acute pancreatitis. There is no family history of serious illness. His only medication is a calcium supplement. He emigrated from India 15 years ago. He appears ill. His temperature is 38.3\u00b0C (100.9\u00b0F), pulse is 101/min, and blood pressure is 104/68 mm Hg. He is confused and oriented only to person. Examination shows scleral icterus and spider angiomas. There are fine tremors of the hands bilaterally. The abdomen is distended and shifting dullness is present. There is diffuse tenderness to palpation with no guarding. Bowel sounds are absent. Laboratory studies show:\nHemoglobin 12.6 g/dL\nLeukocyte count 13,900/mm3\nPlatelet count 342,000/mm3\nSerum\nAlbumin 2.6 g/dL\nTotal bilirubin 2.56 mg/dL\nAlkaline phosphatase 54 U/L\nAST 17 U/L\nALT 44 U/L\nParacentesis is performed. Ascitic fluid analysis shows an albumin concentration of 0.8 g/dL, glucose concentration of 62 mg/dL, and a leukocyte count of 1900/mm3 with 60% neutrophils. Which of the following is the most likely explanation for these findings?\"\nA. Pancreatic fluid leakage\nB. Aseptic peritoneal inflammation\nC. Neoplastic growth\nD. Bacterial translocation\nE. Perforated viscus\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 59-year-old man presents to the health clinic for evaluation of severe itching for the past week. The itching is worse at night while lying in bed. The patient has a past medical history of hyperlipidemia, atrial fibrillation, and colon cancer. The patient takes rivaroxaban, simvastatin, and aspirin. The patient has a surgical history of colon resection, appendectomy, and tonsillectomy. He drinks a 6-pack of beer almost every night of the week. He smokes 2 packs of cigarettes daily and has been living at a homeless shelter for the past 6 months. Examination of the skin shows small crusted sores and superficial, wavy gray lines along the wrists and interdigital spaces of both hands as seen in the image. Small vesicles are also present along with excoriations. Which of the following is the most appropriate treatment option for this patient?\nA. Permethrin\nB. Ivermectin\nC. Acyclovir\nD. Penicillin G\nE. Dicloxacillin\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 10-year-old boy is brought to the pediatrician by his parents with complaints of short stature with small hands and skin hypopigmentation. A detailed development history reveals that he was born by normal vaginal delivery at full term and his neonatal period was uneventful. Until he was 6 months of age, he was breast-fed and then solid foods were started. At the age of 3 years, his parents noted that he had difficulty in sucking and swallowing. They also noted a weak cry. His motor milestones were delayed. His intelligence quotient (IQ) is 65. His temperature is 37.0\u00baC (98.6\u00b0F), pulse is 88/min, and respirations are 20/min. He has a short stature and falls in the obese category according to his body mass index. His neurologic examination shows the presence of hypotonia. Panoramic radiographic examination shows anterior teeth crowding and the presence of residual roots in some teeth. Which of the following is the most likely cause of this condition?\nA. Maternal inheritance\nB. Paternal inheritance\nC. Both paternal inheritance and maternal inheritance\nD. Infectious in origin\nE. Nutritional and metabolic in origin\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 16-year-old girl comes to her primary care physician for an annual check-up. She has no specific complaints. Her medical history is significant for asthma. She uses an albuterol inhaler as needed. She has no notable surgical history. Her mom had breast cancer and her grandfather died of colon cancer. She received all her childhood scheduled vaccinations up to age 8. She reports that she is doing well in school but hates math. She is sexually active with her boyfriend. They use condoms consistently, and they both tested negative recently for gonorrhea, chlamydia, syphilis and human immunodeficiency virus. She asks about birth control. In addition to educating the patient on her options for contraception, which of the following is the best next step in management?\nA. Cytology and human papilloma virus (HPV) testing now and then every 3 years\nB. Cytology and HPV testing now and then every 5 years\nC. Cytology now and then every 3 years\nD. No HPV-related screening as the patient is low risk\nE. No HPV-related screening and administer HPV vaccine\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 43-year-old woman comes to the physician because of tingling and weakness in her left arm for the past 2 days. An image of the brachial plexus is shown. Nerve conduction study shows decreased transmission of electrical impulses in the labeled structure. Physical examination is most likely to show impairment of which of the following movements?\nA. Extension of the wrist and fingers\nB. Opposition of the thumb\nC. Flexion of the metacarpophalangeal joints\nD. Flexion of the forearm\nE. Abduction of the shoulder above 100 degrees\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 23-year-old man presents to the office for a circular, itchy rash over the abdomen that has been slowly getting worse for the past 2 weeks. The patient has a medical history of chronic dermatitis and chronic sinusitis for which he has prescriptions of topical hydrocortisone and fexofenadine. He smokes one-half pack of cigarettes every day. His vital signs include: blood pressure 128/76 mm Hg, heart rate 78/min, and respirations 12/min. On physical examination, the patient appears tired but oriented. Examination of the skin reveals a 2 x 2 cm round and erythematous, annular plaque on the abdomen 3 cm to the left of the umbilicus. There are no vesicles, pustules, or papules. Auscultation of the heart reveals a 1/6 systolic murmur. Breath sounds are mildly coarse at the bases. A KOH preparation from the skin scraping confirms the presence of hyphae. Which of the following is the next best step in the management of this patient?\nA. Itraconazole\nB. Griseofulvin\nC. Topical clobetasol\nD. Topical clindamycin\nE. Doxycycline\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An obese 50-year-old woman presents to the emergency department of a rural hospital due to chest pain for the last 12 hours. The pain is substernal, crushing in nature, radiating into her neck, and accompanied by profuse sweating. Her history is significant for hypertension, and she admits poor compliance with her medications. An ECG done at the clinic confirmed the presence of STEMI, and the patient was given aspirin. The ambulance was in an accident on the way to the hospital and by the time the patient reached the angiography suite, the cardiologist decided intervention should be delayed due to the late presentation. Also, the patient\u2019s pain has improved. The patient is admitted and is stable for 3 nights with no dyspnea or edema. Her blood pressure is kept under control while in the hospital. On the fourth night, the patient becomes quite agitated and soon thereafter she is unresponsive. Her pulse cannot be palpated. She has an elevated JVP and upon auscultation, heart sounds are distant. What is the most likely diagnosis for this patient?\nA. Acute aortic dissection\nB. Acute pericarditis\nC. Ventricular septal rupture\nD. Left ventricular free wall rupture\nE. Papillary muscle rupture\nF. Pulmonary embolism\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 60-year-old woman presents to the physician with a 2-day history of fever and painful swelling of the left knee. She was diagnosed with rheumatoid arthritis about 15 years ago and has a 7-year history of diabetes mellitus. Over the past year, she has been admitted to the hospital twice for acute, painful swelling of the knees and hands. She is on insulin therapy and takes methotrexate, metformin, aspirin, and prednisolone 5 mg/day. Her temperature is 38.5\u00b0C (101.3\u00b0F), pulse is 86/min, respirations are 14/min, and blood pressure is 125/70 mm Hg. A finger-stick glucose test shows 230 mg/dL. Her left knee is diffusely swollen, warm, and painful on both active and passive motion. There is evidence of deformity in several small joints of the hands and feet without any acute swelling or pain. Physical examination of the lungs, abdomen, and perineum shows no abnormalities. The synovial fluid analysis shows the following:\nColor turbid, purulent, gray\nViscosity reduced\nWBC 25,000/\u00b5L\u2013250,000/\u00b5L\nNeutrophils > 90%\nCrystals may be present (presence indicates coexistence, but does not rule out infection)\nWhich of the following is the most appropriate initial pharmacotherapy in this patient?\nA. Intra-articular ceftriaxone\nB. Intra-articular triamcinolone acetonide\nC. Intravenous methylprednisolone\nD. Intravenous vancomycin\nE. Oral ciprofloxacin\nF. Oral prednisone\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A previously healthy 68-year-old woman is brought to the emergency department because of a 3-day history of nausea, anorexia, polyuria, and confusion. Her only medication is acetaminophen, which she takes daily for back pain that started 6 weeks ago. Physical examination shows conjunctival pallor. She is oriented to person but not to time or place. Laboratory studies show a hemoglobin concentration of 9.3 g/dL, a serum calcium concentration of 13.8 mg/dL, and a serum creatinine concentration of 2.1 mg/dL. Her erythrocyte sedimentation rate is 65 mm/h. Which of the following is the most likely underlying cause of this patient's condition?\nA. Excessive intake of calcium\nB. Overproliferation of plasma cells\nC. Ectopic release of PTHrP\nD. Decreased renal excretion of calcium\nE. Increased production of calcitriol\nF. Excess PTH secretion from parathyroid glands\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 16-year-old teenage boy is brought to the emergency room for severe left groin pain. He reports feeling feverish this morning but insisted on going to his basketball practice this afternoon. Shortly after the practice, he began experiencing severe pain at his left groin that is described as sharp and burning in quality. The pain does not radiate anywhere. He denies chest pain, shortness of breath, abdominal pain, hematuria, or abnormal discharge, but endorses fever and chills. He is sexually active with his girlfriend and reports consistent condom use. Per his mom, last week he had \u201ca weird flu episode\u201d where his left cheek was swollen but resolved within 4 days. He did not seek medical attention as his mother preferred natural/holistic management; the patient is not vaccinated. A physical examination demonstrates a relatively healthy patient in acute distress and an erythematous, swollen left scrotum. A Doppler ultrasound of the testicles is obtained and shown in Figure A. What is the most likely explanation for this patient\u2019s presentation?\nA. Bulging of soft tissue through the inguinal canal\nB. Inflammation of the testicles due to a viral infection\nC. Malignant growth of germ cells at the testicle\nD. Mutation of cystine-reabsorbing transporter at the proximal collecting tubule\nE. Rotation of the spermatic cord\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:\u0650A 62-year-old man comes to the emergency department because of colicky pain in the lower abdomen and abdominal distension for the past 12 hours. He has chronic constipation for which he takes lactulose and senna laxatives. His temperature is 37.1\u00b0C (98.7\u00b0F), blood pressure is 110/60 mm Hg and pulse is 85/min. On physical examination, there is diffuse abdominal distension and tenderness, and bowel sounds are faint. His plain abdominal radiograph is shown. Which of the following is the most likely diagnosis?\nA. Intussusception\nB. Infectious colitis\nC. Bowel adhesions\nD. Volvulus\nE. Acute diverticulitis\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A group of researchers from Italy conducted a case register study that included all patients from a city who had an International Classification of Diseases diagnosis and contacts with specialist psychiatric services over a 10-year period. Mortality was studied in relation to age, sex, diagnosis, care pattern, and registration interval. Standardized mortality ratios (SMRs) were calculated, with the overall SMR being 1.63 (lower when compared with studies that looked at hospitalized individuals). Men and those in younger age groups showed higher mortality rates (SMRs of 2.24 and 8.82, respectively), and mortality was also higher in the first year following registration (SMR = 2.32). Higher mortality was also found in patients with a diagnosis of alcohol and drug dependence (SMR = 3.87). The authors concluded that the overall mortality of psychiatric patients managed in a community-based setting was higher than expected; however, it was still lower than the mortality described in other psychiatric settings. The primary measure used in this study can be defined as which of the following?\nA. The total number of deaths divided by the mid-year population\nB. The number of deaths in a specific age group divided by a mid-year population in that age group\nC. The total number of expected deaths divided by a standard population\nD. The observed number of deaths divided by the expected number of deaths\nE. The number of deaths from a certain disease in 1 year divided by the total number of deaths in 1 year\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78-year-old woman is accompanied by her family for a routine visit to her primary care provider. The family states that 5 months prior, the patient had a stroke and is currently undergoing physical therapy. Today, her temperature is 98.2\u00b0F (36.8\u00b0C), blood pressure is 112/72 mmHg, pulse is 64/min, and respirations are 12/min. On exam, she is alert and oriented with no deficits in speech. Additionally, her strength and sensation are symmetric and preserved bilaterally. However, on further neurologic testing, she appears to have some difficulty with balance and a propensity to fall to her right side. Which of the following deficits does the patient also likely have?\nA. Contralateral eye deviation\nB. Hemiballismus\nC. Hemispatial neglect\nD. Intention tremor\nE. Truncal ataxia\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 31-year-old G3P2 woman gives birth to a newborn male at 38 weeks\u2019 gestation. Upon initial examination, the child\u2019s body and extremities are pink, his pulse is 110/min, and his arms and legs resist extension. He cries spontaneously with a weak, irregular, gasping cry. The pregnancy was complicated by polyhydramnios. The mother\u2019s past medical history is notable for non-insulin-dependent diabetes mellitus. The baby has a distended abdomen and vomits bilious fluid within an hour of birth. An abdominal radiograph is performed and shown in Figure A. This patient\u2019s condition is caused by which of the following?\nA. Failure of intestinal recanalization\nB. Failure of fusion of the dorsal and ventral pancreatic buds\nC. Failure of abdominal wall lateral fold fusion\nD. Muscularis externa hypertrophy\nE. Superior mesenteric artery ischemia\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 29-year-old man presents to his primary care provider complaining of testicular pain. He reports a four-day history of dull chronic pain in his left testicle that is worse with standing. His past medical history is notable for asthma and major depressive disorder. He takes inhaled albuterol as needed and sertraline. He is sexually active with a single female partner and always uses barrier protection. His temperature is 99.2\u00b0F (37.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 85/min, and respirations are 17/min. Physical examination reveals a non-tender twisted mass along the left spermatic cord that disappears when the patient lies supine. This patient\u2019s condition most likely stems from decreased laminar flow at which of the following vascular junctions?\nA. Left testicular vein \u2013 Left renal vein\nB. Left testicular vein \u2013 Inferior vena cava\nC. Left testicular vein \u2013 Left suprarenal vein\nD. Descending aorta \u2013 Left testicular artery\nE. Left testicular vein \u2013 Left internal iliac vein\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 33-year-old man presents to the emergency department after a motor vehicle collision. He is minimally responsive and is promptly intubated. His temperature is 97.5\u00b0F (36.4\u00b0C), blood pressure is 92/52 mmHg, and pulse is 185/min. A FAST exam is performed with an image of the right upper quadrant as seen in Figure A. Which of the following are the most likely systemic vascular resistance (SVR), wedge pressure (WP), and venous oxygen (SvO2) changes that would be seen in this patient in Figure B?\nA. A\nB. B\nC. C\nD. D\nE. E\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-month-old infant boy is brought into the clinic for a well-child check. Mom reports a healthy pregnancy with no complications. Though she said the ultrasound technician saw \u201csome white deposits in his brain\u201d during a prenatal check, mom was not concerned. The baby was delivered at 38 weeks of gestation during a home birth. When asked if there were any problems with the birthing process, mom denied any difficulties except that \u201che was small and had these blue dots all over.\u201d Physical exam was unremarkable except for the absence of object tracking. What other finding would you expect?\nA. Continuous machine-like murmur\nB. Hutchinson teeth\nC. Limb hypoplasia\nD. Sensorineural hearing loss\nE. Skin vesicles\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 29-year-old woman is hospitalized due to depression and suicidal ideation. She has a 5-year history of chaotic relationships that last only a few short weeks or months. Each relationship has left her feeling abandoned, empty, and extremely upset. During these periods, the patient confesses to shopping and making big purchases on impulse. She says she gets bored easily and moves on to the next adventure. The patient denies any changes in appetite, energy level, or concentration. On examination, multiple linear lacerations of varying phases of healing were noted on her forearms and trunk. Following consultation, she praises physicians to be \u2018the best people on the planet\u2019, but when the nurse came in to take her blood, she furiously stated that \u2018all nurses are incompetent and cruel\u2019. Which of the following is the most likely diagnosis?\nA. Major depressive disorder (MDD)\nB. Bipolar I disorder\nC. Borderline personality disorder\nD. Histrionic personality disorder\nE. Factitious disorder\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 32-year-old woman presents to her family physician with a long history of depression, irritability, and, more recently, personality changes. As her partner comments, she has stopped engaging in activities she used to enjoy like dancing, drumming lessons, and yoga. The patient denies changes in skin pigmentation and assures she keeps a balanced diet low in fat and carbohydrates. During the physical examination, jaundice and dark rings encircling the iris of the eye are noted, as well as hepatomegaly and gait disturbances. For a follow-up visit, the patient brings a battery of laboratory tests that includes a complete blood count showing normocytic normochromic anemia, a negative Coombs, normal iron levels, normal fasting glucose levels, elevated aminotransferases from the liver biochemical tests, bilirubin, and decreased serum ceruloplasmin levels. Antinuclear antibodies are negative. What is the most likely diagnosis?\nA. Wilson disease\nB. Hemochromatosis\nC. Autoimmune hepatitis\nD. Nonalcoholic fatty liver disease\nE. Primary sclerosing cholangitis\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 7-year-old girl is brought to the physician by her mother for a well-child examination. The mother reports that she had her first menstrual period 1 week ago. She has no history of serious illness. Immunizations are up-to-date. Physical examination shows Tanner stage 3 breast development and pubic hair. Without treatment, this patient is at greatest risk for which of the following as an adult?\nA. Delayed skeletal maturity\nB. Short stature\nC. Infertility\nD. Genu varum\nE. Osteoporosis\nF. Coarse facial features\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old homeless man with a history of hospitalization for alcohol intoxication is brought in confused. His serum glucose is 39mg/dl. Which of the following is likely true?\nA. He has also been using cocaine\nB. He has decreased activity of alcohol dehydrogenase\nC. Hepatic gluconeogenesis is elevated\nD. The next step in management is glucose repletion\nE. His hepatic NADH/NAD+ ratio is high\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 35-year-old obese man presents to the office complaining of chronic heartburn and nausea for the past 6 months. These symptoms are relieved when he takes 20 mg of omeprazole twice a day. The patient was prompted to come to the doctor when he recently experienced difficulty breathing and shortness of breath, symptoms which he believes underlies a serious health condition. The patient has no cardiac history but is concerned because his father recently died of a heart attack. Imaging of the patient\u2019s chest and abdomen would most likely reveal which of the following?\nA. Protrusion of fundus of the stomach through the diaphragm into the thoracic cavity\nB. Lung hypoplasia due to a defect in the diaphragm\nC. Widened mediastinum with evidence of esophageal rupture\nD. \"Hourglass stomach\" due to upward displacement of the gastroesophageal junction\nE. Cardiomegaly with pulmonary effusion\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78-year-old man with a history of myocardial infarction status post coronary artery bypass grafting and a 60-pack-year history of smoking is found deceased in his apartment after not returning calls to his family for the last 2 days. The man was last known to be alive 3 days ago, when his neighbor saw him getting his mail. The family requests an autopsy. On autopsy, the man is found to have a 100% blockage of his left anterior descending artery of his heart and likely passed from sudden cardiac death 2 days prior. Which of the following findings is expected to be found on histologic examination of his damaged myocardium?\nA. Cellular debris and lymphocytes\nB. Cellular debris and macrophages\nC. Cystic cavitation\nD. Fat saponification\nE. Uniform binding of acidophilic dyes\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 29-year-old woman presents with convulsions. The patient\u2019s brother says that he found her like that an hour ago and immediately called an ambulance. He also says that she has been extremely distraught and receiving supportive care from a social worker following a sexual assault by a coworker a few days ago. He says that the patient has no history of seizures. She has no significant past medical history and takes no medications. The patient\u2019s vital signs include: temperature 37.0\u00b0C (98.6\u00b0F), pulse 101/min, blood pressure 135/99 mm Hg, and respiratory rate 25/min. On physical examination, the patient is rolling from side to side, arrhythmically thrashing around, and muttering strangely. Her eyes are closed, and there is resistance to opening them. Which of the following is the most likely diagnosis in this patient?\nA. Somatization disorder\nB. Somatoform pain disorder\nC. Conversion disorder\nD. Hypochondriasis\nE. Body dysmorphic disorder\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 11-month-old boy is brought to the emergency department because of intermittent episodes of inconsolable crying for 4 hours. The parents report that the patient does not appear to be in discomfort between episodes, and moves and plays normally. The episodes have occurred at roughly 15-minute intervals and have each lasted a few minutes before subsiding. He has also vomited 3 times since these episodes began. The first vomitus appeared to contain food while the second and third appeared pale green in color. The patient was born at term and has been healthy. His immunizations are up-to-date. He has no history of recent travel. His older brother has Crohn's disease. The patient is at 50th percentile for height and 60th percentile for weight. He does not appear to be in acute distress. His temperature is 37.1\u00b0C (98.8\u00b0F), pulse is 125/min, respirations are 36/min, and blood pressure is 85/40 mm Hg. During the examination, the patient begins to cry and draws his knees up to his chest. Shortly thereafter, he passes stool with a mixture of blood and mucous; the patient's discomfort appears to resolve. Abdominal examination shows a sausage-shaped abdominal mass in the right upper quadrant. Which of the following is the most appropriate next step in the management of this patient?\nA. CT scan of the abdomen\nB. Exploratory laparotomy\nC. X-ray of the abdomen\nD. Stool cultures\nE. MRI of the abdomen\nF. Air enema\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 45-year-old male presents to the emergency room for toe pain. He reports that his right great toe became acutely painful, red, and swollen approximately five hours prior. He has had one similar prior episode six months ago that resolved with indomethacin. His medical history is notable for obesity, hypertension, and alcohol abuse. He currently takes hydrochlorothiazide (HCTZ). On physical examination, his right great toe is swollen, erythematous, and exquisitely tender to light touch. The patient is started on a new medication that decreases leukocyte migration and mitosis, and his pain eventually resolves; however, he develops nausea and vomiting as a result of therapy. Which of the following underlying mechanisms of action is characteristic of this patient\u2019s new medication?\nA. Inhibits microtubule polymerization\nB. Prevents conversion of xanthine to uric acid\nC. Decreases phospholipase A2-induced production of arachidonic acid\nD. Decreases cyclooxygenase-induced production of prostaglandins\nE. Metabolizes uric acid to water-soluble allantoin\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-month-old girl is brought to the pediatrician by her concerned father. He states that ever since her uncomplicated delivery she has failed to gain weight, has had chronic diarrhea, and has had multiple bacterial and viral infections. During the course of the workup, an absent thymic shadow is noted and a lymph node biopsy demonstrates the absence of germinal centers. Which of the following is the most likely cause of this patient's symptoms?\nA. Defect in WASP gene\nB. Defect in ATM gene\nC. Adenosine deaminase deficiency\nD. NADPH oxidase deficiency\nE. Defect in BTK gene\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 21-year-old woman presents with right eye irritation, redness, and watery discharge. These symptoms started abruptly 4 days ago. She is on summer vacation and does not report any contacts with evidently ill patients. However, during the vacation, she frequently visited crowded places. The patient denies any other symptoms. At the presentation, the patient\u2019s vital signs include: blood pressure 125/80 mm Hg, heart rate 75/min, respiratory rate 14/min, and temperature 36.7\u2103 (98\u2109). The physical examination shows conjunctival injection, watery discharge, and mild follicular transformation of the conjunctiva of the right eye. There are no corneal lesions. Ipsilateral preauricular lymph nodes are enlarged. Which of the following would be a proper medical therapy for this patient\nA. Oral erythromycin\nB. Acyclovir ointment\nC. No medical treatment required\nD. Levofloxacin drops\nE. Tetracycline ointment\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 38-year-old man is brought to the emergency department 35 minutes after an episode of loss of consciousness. He was having dinner with a client when his left arm suddenly became weak and numb. A few minutes later he became tense and his arms and legs began jerking violently, following which he lost consciousness. He has no recollection of this event. He works as a business consultant. He has a history of asthma and major depressive disorder. Current medication include an albuterol inhaler and doxepin. He increased the dose of doxepin one week ago because he felt the medication was not helping. He drinks two to three beers on the weekend. He admits to using cocaine 4\u20135 times per week. On arrival, he is alert and oriented to person, place, and time. His speech is slurred. His temperature is 37\u00b0C (98.6F), pulse is 96/min, and blood pressure is 155/90 mm Hg. The pupils are equal and reactive to light. Neurologic exam shows left facial droop. There is 3/5 strength in the left arm. Which of the following is the most likely underlying mechanism of this patient's symptoms?\nA. Antagonism on M3 receptor\nB. Ruptured berry aneurysm\nC. Tear in the carotid artery\nD. Patent foramen ovale\nE. Lowered seizure threshold\nF. Vasospasm of cerebral vessels\n\"\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A newborn male is evaluated 30 minutes after birth. He was born at 39 weeks gestation to a 27-year-old primigravid via cesarean section for cervical incompetence. The pregnancy was complicated by gestational diabetes, and the amniotic fluid was clear. Upon delivery, the patient had strong respiratory effort and a strong cry. His Apgar scores at 1 and 5 minutes were 7 and 8, respectively. The patient now is exhibiting increased work of breathing and is becoming progressively more tachypneic. His birth weight is 3,568 g (7 lb 14 oz). His temperature is 99.0\u00b0F (37.2\u00b0C), blood pressure is 60/44 mmHg, pulse is 146/min, and respirations are 72/min. On physical exam, the patient is grunting with nasal flaring and subcostal retractions. Breath sounds are decreased at the bases bilaterally. The patient has central cyanosis. His chest radiograph can be seen in Figure A.\n\nWhich of the following is the most likely etiology of this patient\u2019s presentation?\nA. Meconium aspiration syndrome\nB. Neonatal respiratory distress syndrome\nC. Persistent pulmonary hypertension\nD. Transient tachypnea of the newborn\nE. Viral pneumonia\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-year-old girl is brought to the doctor by her mother with persistent scratching of her perianal region. The patient\u2019s mother says that symptoms started 3 days ago and have progressively worsened until she is nearly continuously scratching even in public places. She says that the scratching is worse at night and disturbs her sleep. An anal swab and staining with lactophenol cotton blue reveal findings in the image (see image). Which of the following is the organism most likely responsible for this patient\u2019s condition?\nA. Enterobius vermicularis\nB. Wuchereria bancrofti\nC. Taenia saginata\nD. Ancylostoma duodenale\nE. Ascaris lumbricoides\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 15-year-old girl presents to her physician with dyspnea and fatigue for several months. Her past medical history is insignificant. She denies smoking, alcohol, and drug use and does not take any medications except for doxycycline for acne. Her temperature is 97.6\u00b0F (36.4\u00b0C), blood pressure is 120/81 mmHg, pulse is 95/min, respirations are 15/min, and oxygen saturation is 98% on room air. Physical examination is notable for a palpable spleen below the left seventh intercostal space and scleral icterus. Laboratory tests are ordered as seen below.\n\nHemoglobin: 10 g/dL\nHematocrit: 30%\nLeukocyte count: 7,500/mm^3 with normal differential\nPlatelet count: 207,000/mm^3\nTotal bilirubin: 7.0 mg/dL\nDirect bilirubin: 1.4 mg/dL\nLactate dehydrogenase: 450 U/L (normal value 80-280 U/L)\nHaptoglobin: 15 mg/dL (normal value is 30-220 mg/dL)\nReticulocyte count: 10%\n\nA peripheral blood smear is shown in Figure A. A direct Coomb test is negative. Which of the following is the most likely diagnosis?\nA. Autoimmune hemolytic anemia\nB. Disseminated intravascular coagulation\nC. Drug-induced hemolytic anemia\nD. Hereditary spherocytosis\nE. Sickle cell anemia\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-day-old boy is evaluated in the nursery for minimal movement in his left upper limb. He was born at 41 weeks gestation by an assisted forceps-vaginal delivery to a 42-year-old obese woman. Birth weight was 4.4 kg (9.7 lb). The mother had 4 previous vaginal deliveries, all requiring forceps. Examinations of the left upper limb show that the arm hangs by his side and is rotated medially. His forearm is extended and pronated, and his wrist and fingers are flexed. Moro reflex is present only on the right side. Which of the following muscles was spared from the injury sustained during delivery?\nA. Deltoid\nB. Biceps\nC. Triceps\nD. Supraspinatus\nE. Infraspinatus\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 32-year-old homeless woman is brought to the emergency department by ambulance 30 minutes after the police found her on the sidewalk. On arrival, she is unresponsive. Her pulse is 76/min, respirations are 6/min, and blood pressure is 110/78 mm Hg. Examination shows cool, dry skin. The pupils are pinpoint and react sluggishly to light. Intravenous administration of a drug is initiated. Two minutes after treatment is started, the patient regains consciousness and her respirations increase to 12/min. The drug that was administered has the strongest effect on which of the following receptors?\nA. M1 receptor\nB. Ryanodine receptor\nC. \u03bc-receptor\nD. GABAA receptor\nE. \u03b1-receptor\nF. 5-HT2A receptor\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78-year-old man is brought in to the emergency department by ambulance after his wife noticed that he began slurring his speech and had developed facial asymmetry during dinner approximately 30 minutes ago. His past medical history is remarkable for hypertension and diabetes. His temperature is 99.1\u00b0F (37.3\u00b0C), blood pressure is 154/99 mmHg, pulse is 89/min, respirations are 12/min, and oxygen saturation is 98% on room air. Neurologic exam reveals right upper and lower extremity weakness and an asymmetric smile. Which of the following is the next best step in management?\nA. Alteplase\nB. Aspirin\nC. CT head\nD. CTA head\nE. MRI brain\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 69-year-old man is brought to the emergency department for severe tearing lower back pain for 12 hours. The pain radiates to the flank and he describes it as 8 out of 10 in intensity. He has nausea and has vomited several times. He has no fever, diarrhea, or urinary symptoms. When he stands up suddenly, he becomes light-headed and has to steady himself for approximately 1 to 2 minutes before he is able to walk. He has hypertension and hyperlipidemia. Two years ago, he had a myocardial infarction and underwent coronary artery bypass grafting of his right coronary artery. He has smoked one and a half packs of cigarettes daily for 40 years and drinks 1 to 2 beers daily. His current medications include chlorthalidone, atorvastatin, lisinopril, and aspirin. He appears acutely ill. His temperature is 37.2\u00b0C (98.9\u00b0F), pulse is 130/min and regular, respirations are 35/min, and blood pressure is 80/55 mm Hg. Pulse oximetry on room air shows an oxygen saturation of 85%. Examination shows a pulsatile mass in the abdomen. Intravenous fluids and high-flow oxygen are started. Thirty minutes later, the patient dies. Which of the following was the strongest predisposing factor for the condition leading to this patient's death?\nA. Advanced age\nB. Hyperlipidemia\nC. Male sex\nD. Hypertension\nE. Smoking\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 11-month-old male presents to the emergency department with his father after \u201cpassing out\u201d at home. His father reports that the patient started crying after his older brother took a toy away from him. The patient was difficult to soothe and then suddenly stopped breathing. His father reports that his lips turned slightly blue, and the patient\u2019s entire body became limp. The episode lasted a few seconds, and the patient seemed to act normally afterwards. The patient\u2019s father notes that the patient\u2019s older brother had similar episodes as a child. He denies any family history of neurological disease. The patient\u2019s temperature is 98.5\u00b0F (36.9\u00b0C), blood pressure is 86/64 mmHg, pulse is 98/min, and respirations are 26/min. On physical exam, the patient is in no acute distress playing on his father\u2019s lap. The patient's neurological exam is unremarkable. Which of the following is the best next step in management?\nA. Arterial blood gas\nB. Echocardiogram\nC. Electroencephalogram (EEG)\nD. Electrocardiogram (ECG)\nE. Observation and reassurance\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 72-year-old man is brought to the emergency department with increasing fever and abdominal pain over the past week. The pain is constant and limited to the lower right part of his abdomen. He has nausea but no vomiting or diarrhea. His past medical history is unremarkable for any serious illnesses. He takes acetaminophen for knee arthritis. He is fully alert and oriented. His temperature is 39.5\u00b0C (103.1\u00b0F), pulse is 89/min, respirations are 15/min, and blood pressure is 135/70 mm Hg. Abdominal examination shows a tender mass in the right lower quadrant. CT shows obstruction of the appendiceal neck with a fecalith and the appendiceal tip leading to an irregular walled-off fluid collection. Stranding of the surrounding fat planes is also noted. Intravenous hydration is initiated. Which of the following is the most appropriate next step in management?\nA. Antibiotics + CT-guided drainage\nB. Antibiotics + interval appendectomy\nC. Appendectomy within 12 hours\nD. Early surgical drainage + interval appendectomy\nE. Emergency appendectomy\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 64-year-old man presents to the clinic complaining of low back pain. He was diagnosed with benign prostatic hypertrophy several years ago, which worsened last year. A hard nodule was felt on a digital rectal exam, which led to a prostate biopsy that revealed high-grade adenocarcinoma. A bone scan at that time showed small, focal abnormalities in the lumbar spine. He subsequently underwent radiation therapy to his prostate and pelvic lymph nodes. He was then placed on leuprolide and an anti-androgen. He was doing well until 2 months ago when he developed low back pain, which has worsened since then. He reports that the pain is 8/10 and nearly constant. He states that the pain not only affects his ability to fall asleep but also wakes him up at night. The pain is mildly alleviated by ibuprofen. In addition to prostate cancer, his medical history is significant for hypertension, hyperlipidemia, recurrent nephrolithiasis, and gastroesophageal reflux disease. He takes aspirin, lisinopril, rosuvastatin, and pantoprazole. Upon physical examination, there is midline tenderness within the lumbar region. Magnetic resonance imaging of the spine is obtained, which shows bony metastasis to the L2 and L3 spine without evidence of fracture or spinal cord compression. His prostate-specific antigen is 17.5 ng/mL. Which of the following is the best next step in management?\nA. Calcium and vitamin D supplementation\nB. External radiation therapy\nC. Flutamide\nD. Kyphoplasty\nE. Zoledronic acid\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old woman comes to the physician because of a 1-month history of persistent epigastric abdominal pain. She reports dull, aching pain that is worse after meals and wakes her up at night. She is afraid to eat, as it worsens the pain, and has had a 2-kg (4.4-lb) weight loss during this time. She has smoked a pack of cigarettes daily for the past 40 years. Her only medication is a calcium supplement. Her vital signs are within normal limits. She appears thin. Examination shows yellow discoloration of the sclera. The remainder of the examination shows no abnormalities. Laboratory studies show a total bilirubin of 9.8 mg/dL, direct bilirubin of 8.6 mg/dL, and an alkaline phosphatase of 120 IU/L. Abdominal ultrasonography shows dilation of the biliary and pancreatic ducts but no pancreatic or extrahepatic biliary lesions. Which of the following is the most appropriate next step in management?\nA. Colonoscopy\nB. Plain abdominal CT\nC. Contrast-enhanced abdominal CT\nD. Endoscopic ultrasonography\nE. Endoscopic retrograde cholangiopancreatography\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 52-year-old male presents with several months of fatigue, malaise, dry cough, and occasional episodes of painless hematuria. He recalls having had a sore throat several days prior to the onset of these symptoms that resolved without antibiotics. Physical exam is remarkable for diffusely coarse breath sounds bilaterally. Urinalysis reveals 2+ protein, 2+ blood, and numerous red blood cell casts are visible under light microscopy. Which is the most likely diagnosis?\nA. Diffuse membranous glomerulopathy\nB. Microscopic polyangiitis\nC. Focal segmental glomerulosclerosis\nD. Acute poststreptococcal glomerulonephritis\nE. Transitional cell bladder carcinoma\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 26-year-old woman, gravida 2, para 1, at 26 weeks\u2019 gestation, comes to the emergency department because of pain and swelling in her right calf. Physical examination shows an increased circumference of the right calf. The leg is warm and tender on palpation. Dorsiflexion of the right foot elicits calf pain. An ultrasound of the right leg shows a noncompressible popliteal vein. Which of the following is the most appropriate pharmacotherapy for this patient's condition?\nA. Aspirin\nB. Clopidogrel\nC. Heparin\nD. Rivaroxaban\nE. Alteplase\nF. Warfarin\nG. Argatroban\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 7-year-old male is admitted to the hospital with his fourth episode of wheezing and dyspnea. His symptoms are exacerbated by mold and pollen. Which of the following is most likely to be observed in this patient?\nA. Abnormal chest radiograph\nB. Normal FEV1\nC. Sputum eosinophils\nD. Normal FEV1/FVC\nE. Ground glass opacities on chest CT\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 32-year-old HIV positive female known to be non-adherent to her treatment regimen, presents to the hospital with the complaint of new-onset headaches. Her vital signs are only significant for a low-grade fever. Neurological examination reveals right-sided upper motor neuron signs, as well as a inattention and difficulty with concentration. The patient currently does not have a primary medical provider. A CT of the patients head is shown in the image below. What is the next best step in management for this patient?\nA. Perform a biopsy of the lesion\nB. Perform an analysis for 14-3-3 protein levels\nC. Begin treatment with pyrimethamine-sulfadiazine\nD. Begin treatment with albendazole and corticosteroids\nE. Begin treatment with acyclovir\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 76-year-old woman comes to the physician for evaluation of a 3-month history of vulvar itching and pain. She was diagnosed with lichen sclerosus 4 years ago. She has smoked 1 pack of cigarettes daily for 35 years. Physical examination shows a 2.5-cm nodular, ulcerative lesion on the vaginal introitus and left labia minora with surrounding erythema. Punch biopsy shows squamous cell carcinoma. A CT scan of the chest, abdomen, and pelvis shows enlarged lymph nodes concerning for metastatic disease. Which of the following lymph node regions is the most likely primary site of metastasis?\nA. Superficial inguinal\nB. Para-aortic\nC. Inferior mesenteric\nD. External iliac\nE. Internal iliac\nF. Deep inguinal\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 72-year-old African American man with a past medical history of hypertension, hyperlipidemia, chronic pancreatitis, and osteoarthritis presents to his primary care provider for fatigue. The patient reports that he has been so tired recently that he has struggled to get out of bed in the morning, and he has been calling out sick from his work as a prison guard. He denies any changes in sleep but endorses a depressed mood since his wife died suddenly six months ago. He reports that he has struggled to take on the household tasks that she used to manage, and his meals have suffered as a result. He is relying on a diet of mostly canned foods. Before the last few weeks, he had been relatively healthy other than a positive tuberculin skin test on routine screening last year, for which he recently completed nine months of treatment with isoniazid. His home medications are hydrochlorothiazide, atorvastatin, melatonin, and ibuprofen. His temperature is 97.2\u00b0F (36.2\u00b0C), blood pressure is 156/97 mmHg, pulse is 78/min, and respirations are 12/min. On physical exam, he appears older than his stated age and has conjunctival pallor. He has poor dentition and is wearing dentures. Physical exam is otherwise unremarkable. Laboratory tests are performed which reveal the following:\n\nLeukocyte count: 6,800/mm^3\nHemoglobin: 9.2 g/dL\nHematocrit: 29%\nMean corpuscular volume: 110 \u00b5m^3\nPlatelet count: 208,000/mm^3\n\nA peripheral smear is performed and can be seen in Figure A.\n\nWhich of the following is a risk factor for the development of this condition?\nA. Chronic pancreatitis\nB. Dark skin\nC. Isoniazid use\nD. Diet of highly processed foods\nE. Ingestion of denture cream\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 58-year-old female presents to her dermatologist complaining of a painful skin rash. She reports that the rash is red, itchy, and peeling. She also reports intermittent fatigue, night sweats, and chills. Her past medical history is notable for hypertension and diabetes mellitus for which she takes lisinopril and metformin. She has previously had two irregular skin lesions removed from her face and neck that eventually were shown to be squamous cell carcinoma. She has a 20 pack-year smoking history and drinks several alcoholic beverages per day. Her temperature is 98.9\u00b0F (37.1\u00b0C), blood pressure is 140/85 mmHg, pulse is 95/min, and respirations are 18/min. Physical examination reveals a red rash predominantly found on her trunk and thighs, inguinal lymphadenopathy, and hepatosplenomegaly. A notable physical examination finding is shown in Figure A. A biopsy of this patient's skin would most likely reveal which of the following?\nA. Keratinocyte acantholysis with preserved basal cell attachment\nB. Atypical keratinocytes with keratin pearls\nC. Pigmented cells with marked atypia and prominent nucleoli\nD. Nests of basaloid cells in the dermis with palisades\nE. Atypical lymphocytes with cerebriform nuclei\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:While playing the catcher position in baseball, a 27-year-old male sustained a blow to his left testes which required surgical removal. Upon awakening from anesthesia, he jokes to his wife that he is now half the man that she once knew. Which of the following scenarios is a similar ego defense as the one above?\nA. A religious woman with homosexual desires speaks out against gay marriage\nB. A husband angry at his wife takes out his anger on his employees\nC. A short-tempered male lifts weights to deal with his anger\nD. A cheating husband accuses his wife of doing the same\nE. A recently divorced man states he will finally be able to watch a football game without nagging\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 30-year-old G1P0 woman at 40 weeks gestation is admitted to the maternity ward for induction of labor. She has been taking her multivitamin daily. She feels fetal movement and denies any vaginal bleeding. Her temperature is 98.6\u00b0F (37\u00b0C), blood pressure is 110/60 mmHg, pulse is 85/min, respirations are 25/min, and oxygen saturation is 100%. The fetal heart monitor shows a heart rate of 120/min. A lumbar epidural catheter is placed without difficulty, followed by an amniotomy. No vaginal bleeding is observed. Thirty minutes later, the nurse reports fetal heart tracings shown in Figure A. The patient's vital signs have not changed. What is the most appropriate next step in management?\nA. Cesarean section\nB. Intravenous fluids\nC. Maternal repositioning\nD. Phenylephrine\nE. Supplementary oxygen\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 33-year-old woman comes to the physician because of a 1-year history of irregular menses and infertility. She has a history of an eating disorder and has received dietary and behavioral therapy over the past 6 months with minimal improvement in her symptoms. She is 170 cm (5 ft 7 in) tall and weighs 49 kg (104 lb); her BMI is 17 kg/m2. Physical examination is significant for pallor and thin, soft, depigmented hair on the arms and back. After an extensive workup, the physician recommends pulsatile GnRH therapy. One week after initiating therapy, a pelvic ultrasound shows a 24-mm hypoechogenic cavity in the right ovary. The patient subsequently receives a drug that results in the resumption of meiosis and the loss of gap junctions between the cumulus granulosa cells and the oocyte. This patient most likely received which of the following drugs?\nA. Follicle-stimulating hormone\nB. Mifepristone\nC. Human chorionic gonadotropin\nD. Ethinyl estradiol\nE. Medroxyprogesterone\nF. Cyproterone citrate\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:In 2006, three researchers from North Carolina wanted to examine the benefits of treating the risk of suicidality in children and adolescents by looking at randomized, multicenter, controlled trials of sertraline usage compared to placebo. Their analysis found clinically significant benefits of the drug and a positive benefit-to-risk ratio for sertraline in adolescents with major depressive disorder. They also found that 64 depressed children and adolescents need to receive the drug for 1 extra patient to experience suicidality as an adverse outcome. In other words, if 64 treated individuals received sertraline, some would experience suicidality due to their illness, some would not experience suicidality, and 1 individual would become suicidal due to the unique contribution of sertraline. Which of the following statements is true for this measure (defined as the inverse of the attributable risk), which aims to describe adverse outcomes this way?\nA. Input values must be probabilities of the events of interest.\nB. The final metric represents proportions in percentage terms.\nC. The measure can include multiple events at one time.\nD. Multiple risks can be contained and described within one result.\nE. Higher measures indicate greater risk.\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An inpatient psychiatrist recently had two patients who developed serious gastrointestinal infections while taking clozapine. He was concerned that his patients had developed agranulocytosis, a relatively rare but dangerous adverse event associated with clozapine. When the psychiatrist checked the absolute neutrophil count (ANC) of both patients, one was 450/mm3, while the other was 700/mm3 (N=1,500/mm3). According to the clozapine REMS (Risk Evaluation and Mitigation Strategy) program, severe neutropenia in clozapine recipients has often been defined as an absolute neutrophil count (ANC) less than 500/mm3. Changing the cutoff value to 750/mm3 would affect the test performance of ANC with regard to agranulocytosis in which of the following ways?\nA. Increased true negatives\nB. Increased positive predictive value\nC. Decreased true positives\nD. Unchanged specificity\nE. Increased false positives\nF. Decreased sensitivity\n\"\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 49-year-old woman presents to her primary care physician due to fatigue and shortness of breath. She finds herself being short of breath when climbing the stairs or walking uphill. Approximately 1 year ago, she was able to partake in long-distance running and weightlifting. Two weeks ago she noticed blood-tinged sputum after severely coughing during sleep. She emigrated from Mexico to the United States 3 years ago. Her temperature is 98\u00b0F (36.7\u00b0C), blood pressure is 100/62 mmHg, pulse is 135/min and irregularly irregular, and respirations are 21/min. On physical exam her speech is hoarse. She has bilateral crackles heard in the lung bases. Which of the following will most likely be found on cardiac auscultation?\nA. Crescendo-decrescendo systolic ejection murmur\nB. High-pitched, early diastolic decrescendo murmur\nC. Holosystolic, high-pitched murmur loudest at the apex\nD. Holosystolic, high-pitched murmur loudest at the left lower sternal border\nE. Opening snap with a mid-to-late diastolic murmur\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An investigator is studying the activity level of several different enzymes in human subjects from various demographic groups. An elevated level of activity of phosphoribosyl pyrophosphate synthetase is found in one of the study subjects. This patient is most likely to have which of the following conditions?\nA. Homocystinuria\nB. Gout\nC. Maple syrup urine disease\nD. Alkaptonuria\nE. Phenylketonuria\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:49-year-old man complains of no symptoms, but on a routine complete blood count (CBC) has a white blood cell count of 40,000 per uL. A peripheral blood smear demonstrates leukocytosis with myeloid cells present at various stages of differentiation, with more mature cells present at a greater percentage than less mature cells (Figure A). What is the likely diagnosis?\nA. Acute Lymphoblastic Leukemia (ALL)\nB. Acute Myelogenous Leukemia (AML)\nC. Chronic Lymphocytic Leukemia (CLL)\nD. Chronic Myelogenous Leukemia (CML)\nE. Acute Promyelocytic Leukemia (APL or APML)\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 4-year-old boy is brought to the physician because of non-fluent speech. His mother worries that his vocabulary is limited for his age and because he cannot use simple sentences to communicate. She says he enjoys playing with his peers and parents, but he has always lagged behind in his speaking and communication. His speech is frequently not understood by strangers. He physically appears normal. His height and weight are within the normal range for his age. He responds to his name, makes eye contact, and enjoys the company of his mother. Which of the following is the most appropriate next step in management?\nA. Audiology testing\nB. Evaluate response to methylphenidate\nC. Psychiatric evaluation\nD. Referral to speech therapist\nE. Thyroid-stimulating hormone\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 55-year-old patient with a history of alcoholism presents to the emergency department with cough and high fevers. The patient states that he has been admitted for this reason in the past, and that over the last four days, his cough has gotten worse and that he has also started having shortness of breath. His vitals are HR 95, T 102.3F, RR 20, and BP 135/85. His physical exam is significant for increased tactile fremitus over the right lung and 94% oxygen saturation on room air. His chest radiograph is shown in Figure A. What is the most likely organism responsible?\nA. Mycoplasma pneumonia\nB. Staphylococcus aureus\nC. Fusobacterium\nD. Streptococcus pyogenes\nE. Chlamydophila pneumoniae\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 20-year-old woman comes to the clinic for her first follow-up visit after being diagnosed with bipolar I disorder 1-month ago. At that time, she was acutely severely manic and was brought to the emergency department by her concerned boyfriend. She was started on lithium, and after subsequent improvement, she was discharged. A week after discharge, the patient forgot to take her medication for a few days and quickly began to manifest manic symptoms again which required brought her to the emergency department again. Since then, she has been compliant with her medications and currently has no significant complaints. Which of the following recommendations would be most helpful in minimizing the risk to the fetus in this patient?\nA. Adjust dosage of medication throughout the pregnancy\nB. Supplement all patients with 5mg of daily folic acid\nC. Low-dose polytherapy is preferred over monotherapy\nD. Discontinue the medication when conception is confirmed\nE. Switch to valproate as it has safest pregnancy profile\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An investigator studying the immunologic profile of various cells notices that the blood of a test subject agglutinates upon addition of a serum containing antibodies against P blood group antigens. Infection with which of the following pathogens would most likely be prevented by these antibodies?\nA. Parvovirus B19\nB. Babesia microti\nC. Plasmodium vivax\nD. Epstein Barr virus\nE. Influenza virus\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 20-year-old woman is brought to the emergency department by her parents after finding her seizing in her room at home. She has no known medical condition and this is her first witnessed seizure. She is stabilized in the emergency department. A detailed history reveals that the patient has been progressively calorie restricting for the past few years. Based on her last known height and weight, her body mass index (BMI) is 16.5 kg/m2. Which of the following electrolyte abnormalities would be of the most concern when this patient is reintroduced to food?\nA. Hypophosphatemia\nB. Hypercalcemia\nC. Hypermagnesemia\nD. Hyponatremia\nE. Hypokalemia\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 15-year-old boy is brought to the emergency department by ambulance after his mother found him having muscle spasms and stiffness in his room. His mother stated he scraped his foot on a rusty razor on the bathroom floor 2 days prior. On presentation, his temperature is 102.0\u00b0F (38.9\u00b0C), blood pressure is 108/73 mmHg, pulse is 122/min, and respirations are 18/min. On physical exam, he is found to have severe muscle spasms and rigid abdominal muscles. In addition, he has a dirty appearing wound on his right foot. The patient's mother does not recall any further vaccinations since age 12. Finally, he is found to have difficulty opening his mouth so he is intubated. Which of the following treatment(s) should be provided to this patient?\nA. Antitoxin\nB. Wound debridement\nC. Wound debridement and antitoxin\nD. Wound debridement and booster vaccine\nE. Wound debridement, antitoxin, and booster vaccine\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 69-year-old man presents to his primary care physician with hip and back pain. The patient states that this weekend he had a barbecue. When he was lifting a heavy object he suddenly felt pain in his lower back. He describes the pain as in his buttocks but states that at times it travels down his leg. The patient states that it feels, \"electrical.\" The patient has a past medical history of obesity, diabetes, depression, anxiety, diverticulosis, constipation, and a surgical repair of his anterior cruciate ligament. His current medications include metformin, insulin, lisinopril, fluoxetine, and sodium docusate. Which of the following is most likely to help confirm the diagnosis?\nA. Palpating the paraspinus muscle\nB. Flexion, abduction, and external rotation of the thigh\nC. Straight leg raise\nD. Internal rotation of the extended hip\nE. Radiography\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 26-year-old African American woman presents to the clinic with burning upon urination. The patient describes increased frequency, urgency, and a painful sensation at the urethra when urinating for the past 3 days. She also reports increased vaginal discharge and abnormal odor during the same time. The patient denies fever, flank pain, or hematuria (though the patient does report a dark brown color of the urine). Her past medical history is significant for Crohn disease that is controlled with sulfasalazine. Vital signs are within normal limits. What is the definitive treatment of the described condition?\nA. Bactrim\nB. IM ceftriaxone and oral azithromycin\nC. Increase in sulfasalazine dose\nD. IV ceftriaxone\nE. Surgery\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 34-year-old female presents to her ophthalmologist with 6 hours of blurry vision in her right eye. She reports severe pain with eye movement that has not been relieved with NSAIDs. She feels that she has been generally healthy all her life, although she does note one week of right arm weakness during the previous year that resolved without treatment. On exam, she has no noted ocular secretions, and her fundal exam is shown in Figure A. Which of the following additional findings is likely to be present in this patient?\nA. Polycythemia\nB. Elevated IgG in the cerebrospinal fluid (CSF)\nC. Multiple areas of periventricular hypointesnsity on T2 FLAIR imaging\nD. Subdural hematoma\nE. Small, punctate hypointensities on gradient echo MRI\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An newborn infant comes to the attention of the neonatal care unit because he started having heavy and rapid breathing. In addition, he was found to be very irritable with pale skin and profuse sweating. Finally, he was found to have cold feet with diminished lower extremity pulses. Cardiac auscultation reveals a harsh systolic murmur along the left sternal border. Notably, the patient is not observed to have cyanosis. Which of the following treatments would most likely be effective for this patient's condition?\nA. Leukotriene E4\nB. Prostaglandin E1\nC. Prostaglandin E2\nD. Prostaglandin I2\nE. Thromboxane A2\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 39-year-old female presents to her gynecologist complaining of a breast lump. Two weeks ago, while performing a breast self-examination she noticed a small firm nodule in her left breast. She is otherwise healthy and takes no medications. Her family history is notable for a history of breast cancer in her mother and maternal aunt. On physical examination, there is a firm immobile nodular mass in the superolateral quadrant of her left breast. A mammogram of her left breast is shown. Genetic analysis reveals a mutation on chromosome 17. This patient is at increased risk for which of the following conditions?\nA. Serous cystadenocarcinoma\nB. Endometrial carcinoma\nC. Granulosa-theca cell tumor\nD. Uterine leiomyosarcoma\nE. Transitional cell carcinoma\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 24-year-old woman gravida 2, para 1 at 24 weeks' gestation comes to the physician for a prenatal visit. She feels well. Her earlier pregnancy was uncomplicated. This is her 4th prenatal visit. She had an ultrasound scan 2 weeks ago that showed a live intrauterine pregnancy consistent with a 22-week gestation with no anomalies. She had a normal Pap smear 2 years ago. Vital signs are within normal limits. Pelvic examination shows a uterus consistent in size with a 24-week gestation. Her blood group and type is B positive. Which of the following is the most appropriate next step in management?\nA. Serum PAPP-A and HCG level\nB. Oral glucose challenge test\nC. Cardiotocography\nD. Rh antibody testing\nE. Swab for GBS culture\nF. Biophysical profile\nG. Tdap vaccination\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 71-year-old male presents to the emergency department after having a generalized tonic-clonic seizure. His son reports that he does not have a history of seizures but has had increasing confusion and weakness over the last several weeks. An electrolyte panel reveals a sodium level of 120 mEq/L and a serum osmolality of 248 mOsm/kg. His urine is found to have a high urine osmolality. His temperature is 37\u00b0 C (98.6\u00b0 F), respirations are 15/min, pulse is 67/min, and blood pressure is 122/88 mm Hg. On examination he is disoriented, his pupils are round and reactive to light and accommodation and his mucous membranes are moist. His heart has a regular rhythm without murmurs, his lungs are clear to auscultation bilaterally, the abdomen is soft, and his extremities have no edema but his muscular strength is 3/5 bilaterally. There is hyporeflexia of all four extremities. What is the most likely cause of his symptoms?\nA. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)\nB. Sheehan\u2019s syndrome\nC. Lithium use\nD. Diabetic ketoacidosis\nE. Hereditary diabetes insipidus\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 5-month-old male presents to the pediatrician with his mother for a well visit. The patient was born at 35 weeks gestation to a 30-year-old gravida 2 via vaginal delivery. The pregnancy and labor were uncomplicated. The patient required no resuscitation after delivery and was discharged from the hospital on day two of life. His mother now reports that the patient has been exclusively breastfed since birth, and she says that feedings have been going well, and that the patient appears satisfied afterwards. The patient feeds for 30 minutes every two hours and urinates 8-10 times per day. The patient\u2019s mother reports that she eats a varied diet that includes animal products, but she worries that the patient is not meeting his nutritional needs with breastmilk alone. The patient\u2019s height and weight at birth were in the 15th and 20th percentile, respectively. His height and weight are now in the 20th and 25th percentile, respectively. His temperature is 98.1\u00b0F (36.7\u00b0C), blood pressure is 58/46 mmHg, pulse is 128/min, and respirations are 34/min. On physical exam, the patient appears well-developed and well-nourished. He has mild conjunctival pallor.\n\nWhich of the following is the most appropriate guidance regarding this patient\u2019s nutritional needs?\nA. No changes are necessary to his diet\nB. Add cow's milk to his diet\nC. Add pureed foods to his diet\nD. Supplement his diet with formula\nE. Supplement his diet with iron and vitamin D\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old man with a past medical history of aortic stenosis presents to your office complaining of decreased energy and weakness for the past three years. Exam is notable for conjunctival and nail bed pallor, as well as a 3/5 crescendo-decrescendo murmur over the upper right sternal border. Laboratory workup reveals a hemoglobin of 9.1 g/dL. A colonoscopy is performed and reveals the finding on Figure A. What is the most likely source of this patient's anemia?\nA. Vascular malformation\nB. Cancerous growth\nC. Ischemia of the bowel wall\nD. Outpocketing of the mucosa\nE. Inflammation of the mucosa\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 6-month-old girl is brought to the hospital by her parents for evaluation due to poor feeding for the last month. Her parents say that she has not been eating well over the last two months, yet her abdomen has grown larger. Physical exam shows a thin female infant with an enlarged liver and palpable spleen. Eye exam reveals a red spot on the retina. She has an intact muscle tone and reflexes. Which of the following enzymes is deficient in this patient?\nA. Hexosaminidase A\nB. \u03b1-galactosidase A\nC. Glucocerebrosidase\nD. Sphingomyelinase\nE. Galactocerebrosidase\nF. Arylsulfatase A\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 55-year-old woman presents to the emergency department with recent onset confusion and photophobia. Upon questioning her husband, you discover the patient has been sick over the past week with fevers and productive sputum. Her vital signs are Temperature 102.6 Pulse 80 Respirations 18 Blood Pressure 110/70. The physical exam is significant for lethargy and nuchal rigidity. A lumbar puncture is performed and demonstrates cloudy fluid with an opening pressure of 35 cm H20, cell count of 1500 cells/uL (neutrophil predominant), protein level of 50 mg/dL and glucose of 30 mg/dL. Computed tomography scan demonstrates no space-occupying lesions. What is the most appropriate initial treatment for this patient?\nA. Acyclovir\nB. Supportive treatment, no antibiotics\nC. Ceftriaxone and dexamethasone\nD. Vancomycin, ceftriaxone, ampicillin and dexamethasone\nE. Vancomycin, ceftriaxone and ampicillin\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:Researchers are investigating oncogenes, specifically the KRAS gene that is associated with colon, lung, and pancreatic cancer. They have established that the gain-of-function mutation in this gene increases the chance of cancer development. They are also working to advance the research further to study tumor suppressor genes. Which of the genes below is considered a tumor suppressor gene?\nA. JAK2\nB. Her2/neu\nC. Rb\nD. BRAF\nE. BCL-2\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A newborn male is evaluated one minute after birth. He was born at 38 weeks gestation to a 28-year-old gravida 3 via vaginal delivery. The patient\u2019s mother received sporadic prenatal care, and the pregnancy was complicated by gestational diabetes. The amniotic fluid was clear. The patient\u2019s pulse is 70/min, and his breathing is irregular with a slow, weak cry. He whimpers in response to a soft pinch on the thigh, and he has moderate muscle tone with some flexion of his extremities. His body is pink and his extremities are blue. The patient is dried with a warm towel and then placed on his back on a flat warmer bed. His mouth and nose are suctioned with a bulb syringe.\n\nWhich of the following is the best next step in management?\nA. Chest compressions and bag-mask ventilation\nB. Intravenous epinephrine and reassessment of Apgar score at 5 minutes\nC. Positive pressure ventilation and reassessment of Apgar score at 5 minutes\nD. Supplemental oxygen via nasal cannula and reassessment of Apgar score at 5 minutes\nE. Endotracheal intubation and mechanical ventilation\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 1900-g (4-lb 3-oz) newborn is delivered at term to a 36-year-old primigravid woman. Pregnancy was complicated by polyhydramnios. Apgar scores are 7 and 7 at 1 and 5 minutes, respectively. He is at the 2nd percentile for head circumference and 15th percentile for length. Examination shows a prominent posterior part of the head. The ears are low-set and the jaw is small and retracted. The fists are clenched, with overlapping second and third fingers. The calcaneal bones are prominent and the plantar surface of the foot shows a convex deformity. Abdominal examination shows an omphalocele. Further evaluation of this patient is most likely to show which of the following findings?\nA. Cataracts\nB. Ventricular septal defect\nC. Ebstein's anomaly\nD. Macroorchidism\nE. Pheochromocytoma\nF. Holoprosencephaly\nG. Hirschsprung's disease\n\"\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 57-year-old patient comes to the physician for a 2-month history of progressive dyspnea and cough productive of large amounts of yellow, blood-tinged sputum. He has a history of COPD and recurrent upper respiratory tract infections. Examination of the lung shows bilateral crackles and end-expiratory wheezing. An x-ray of the chest shows thin-walled cysts and tram-track opacities in both lungs. The physician prescribes nebulized N-acetylcysteine. Which of the following is the most likely effect of this drug?\nA. Increase of ciliary beat rate\nB. Inhibition of peptidoglycan crosslinking\nC. Stimulation of vagus nerve\nD. Inhibition of phosphodiesterase\nE. Reduction of mucus hypersecretion\nF. Breaking of disulfide bonds\nG. Breakdown of leukocyte DNA\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 50-year-old man comes to the physician because of gradually worsening rhythmic movements of his right hand for the past 5 months. His symptoms worsen when he is in a meeting and he is concerned that people are noticing it more frequently. There is no personal or family history of serious illness, but the patient recalls that his father developed bobbing of the head in older age. He takes no medications. Neurological examination shows a tremor of the right hand when the limbs are relaxed. When the patient is asked to move his arm the tremor decreases. He has reduced arm swing while walking. Which of the following is the most appropriate pharmacotherapy?\nA. Donepezil\nB. Trihexyphenidyl\nC. Clonazepam\nD. Propranolol\nE. Methimazole\nF. Levodopa/carbidopa\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An investigator is studying bacterial adaptations to the environment in an infectious isolate and a noninfectious isolate of Hemophilus influenzae type B. Animals exposed to the noninfectious isolate do not develop symptoms of infection. The investigator cultivates the noninfectious isolate in a culture with lysed bacteria from the infectious isolate. Some of the animals exposed to these bacteria develop symptoms of infection. Which of the following processes is most likely responsible for the described findings?\nA. Transposition\nB. Specialized transduction\nC. Conjugation\nD. Reassortment\nE. Transformation\nF. Generalized transduction\nG. Recombination\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-year-old boy is brought to the physician because of decreased appetite and abdominal pain for the last several weeks. Physical examination shows a well-appearing toddler with a palpable left-sided abdominal mass that does not cross the midline. A CT of the abdomen shows a large, necrotic tumor on the left kidney. Histological examination of the kidney mass shows primitive blastemal cells and immature tubules and glomeruli. This tissue is most likely derived from the same embryological structure as which of the following?\nA. Carotid body\nB. Adrenal medulla\nC. Thyroid gland\nD. Papillary muscles\nE. Anterior pituitary\n\"\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 29-year-old man is brought to the emergency room 6 hours after the onset of severe epigastric pain and vomiting. His heart rate is 110/min and blood pressure is 98/72 mm Hg. He is diagnosed with acute pancreatitis, and fluid resuscitation with normal saline is initiated. Which of the following is the most likely immediate effect of fluid resuscitation in this patient?\nA. Increase in cardiac afterload\nB. Increase in volume of distribution\nC. Increase in myocardial oxygen demand\nD. Increase in plasma oncotic pressure\nE. Increase in glomerular filtration fraction\n\"\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 58-year-old woman presents to the physician with a cough that began 6 years ago, as well as intermittent difficulty in breathing for the last year. There is no significant sputum production. There is no history of rhinorrhea, sneezing or nose congestion. She has been a chronic smoker from early adulthood. Her temperature is 36.9\u00b0C (98.4\u00b0F), the heart rate is 80/min, the blood pressure is 128/84 mm Hg, and the respiratory rate is 22/min. A physical examination reveals diffuse end-expiratory wheezing with prolonged expiration on chest auscultation; breath sounds and heart sounds are diminished. There is no cyanosis, clubbing or lymphadenopathy. Her chest radiogram shows hyperinflated lungs bilaterally and a computed tomography scan of her chest is shown in the picture. Which of the following best describes the pathogenesis of the condition of this patient?\nA. Infiltration of the lower airway mucosa by activated eosinophils and T lymphocytes\nB. Increased release of matrix metalloproteinase 12 (MMP-12) by neutrophils\nC. Structural cell death mediated by Rtp801\nD. Depletion of the periciliary fluid layer in airway cells\nE. Activation of histone deacetylase-2\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 25-year-old woman comes to the physician because of periodic painful double vision for 3 days. Her symptoms occur only when looking sideways. She has myopia and has been wearing corrective lenses for 10 years. Ten days ago, she lost her balance and fell off her bike, for which she went to a hospital. A CT scan of the head at that time showed no abnormalities and she was released without further treatment. Her only medication is an oral contraceptive. Her vital signs are within normal limits. The pupils are equal and reactive to light. Her best corrected visual acuity is 20/40 in each eye. She has an adduction deficit in the right eye and nystagmus in the left eye when looking left; she has an adduction deficit in the left eye and nystagmus in the right eye when looking right. Fundoscopy reveals bilateral disc hyperemia. Which of the following is the most likely cause of this patient's findings?\nA. Caudal displacement of cerebellar vermis\nB. Demyelination of the medial longitudinal fasciculus\nC. Antibodies against acetylcholine receptors\nD. Compressive tumor of the pons\nE. Oxidative damage due to thiamine deficiency\nF. Subdural hematoma extending into the orbit\nG. Infarction of the brainstem\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 71-year-old man presents to his cardiologist with a 1-month history of increasing shortness of breath. He says that he is finding it very difficult to walk up the flight of stairs to his bedroom and he is no longer able to sleep flat on his bed because he wakes up choking for breath. His past medical history is significant for a myocardial infarction 3 years ago. On physical exam, he is found to have diffuse, moist crackles bilaterally on pulmonary auscultation and pitting edema in his lower extremities. Serum tests reveal an increased abundance of a product produced by cardiac myocytes. Which of the following most likely describes the function of this product?\nA. Binds to intracellular receptors in the collecting duct\nB. Increases conversion of angiotensin\nC. Increases water reabsorption in the kidney\nD. Inhibits release of renin\nE. Stimulates parasympathetic nerves\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78-year-old man is brought to the emergency department by ambulance 30 minutes after the sudden onset of speech difficulties and right-sided arm and leg weakness. Examination shows paralysis and hypoesthesia on the right side, positive Babinski sign on the right, and slurred speech. A CT scan of the head shows a hyperdensity in the left middle cerebral artery and no evidence of intracranial bleeding. The patient's symptoms improve rapidly after pharmacotherapy is initiated and his weakness completely resolves. Which of the following drugs was most likely administered?\nA. Rivaroxaban\nB. Alteplase\nC. Heparin\nD. Prasugrel\nE. Warfarin\n\"\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 64-year-old woman comes to the physician because of worsening intermittent nausea and burning pain in her upper abdomen for 4 hours. She has not had retrosternal chest pain, shortness of breathing, or vomiting. She has hypertension and type 2 diabetes mellitus. She has smoked one pack of cigarettes daily for 20 years. Her only medications are lisinopril and insulin. Her temperature is 37\u00b0C (98.6\u00b0F), pulse is 90/min, respirations are 12/min, and blood pressure is 155/75 mm Hg. The lungs are clear to auscultation. The abdomen is soft, with mild tenderness to palpation of the epigastrium but no guarding or rebound. Bowel sounds are normal. An ECG is shown. This patient's current condition is most likely to cause which of the following findings on cardiac examination?\nA. Decrescendo diastolic murmur\nB. Ventricular gallop\nC. Atrial gallop\nD. Mid-systolic click\nE. Fixed-split S2 sound\nF. Muffled heart sounds\nG. Elevated jugular venous pressure\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A medical student is reviewing dose-response curves of various experimental drugs. She is specifically interested in the different factors that cause the curve to shift in different directions. From her study, she plots the following graph (see image). She marks the blue curve for drug A, which acts optimally on a receptor. After drawing the second (green) curve, she discovers that this drug B has a lower ability to produce a reaction than the first one. She also discovers that more of the second drug B is required to produce the same response as the first one. Which of the following terms best describes the activity of drug B in comparison to drug A?\nA. Lower potency\nB. Higher efficacy\nC. Higher potency\nD. Increased affinity\nE. Decreased efficacy\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 25-year-old nulliparous woman at 8 weeks' gestation comes to her physician accompanied by her husband for her first prenatal visit. She has no personal or family history of serious illness. Her vaccinations are up-to-date and she takes no medications. She has no history of recreational drug use and does not drink alcohol. Her vital signs are within normal limits. She is 167 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24.3 kg/m2. She tested negative for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae 4 years ago. Which of the following tests should be done at this visit?\nA. Culture for group B streptococci, hepatitis C serology, and PPD skin test\nB. Serum TSH, CMV serology, and PCR for HSV-2\nC. PCR for HSV-2, culture for group B streptococci, and Western blot for HIV\nD. PPD skin test, ELISA for HIV, and VDRL\nE. VDRL, Western blot for HIV, and serum HBsAg\nF. Serum TSH, rapid plasma reagin test, and culture for group B streptococci\nG. ELISA for HIV, rapid plasma reagin test, and serum HBsAg\nH. CMV serology, hepatitis C serology, and serum HBsAg\n\"\nAnswer:",
        "output": "G",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A new assay for Lyme disease has been developed. While the assay has been tested extensively in Maine, a group of inventors are planning to test it in Southern California. In comparison to the assay's performance in Maine, testing the assay in Southern California would affect the performance of the assay in which of the following ways?\nA. Decrease negative likelihood ratio of the Lyme disease assay\nB. Lower likelihood that a patient without Lyme disease truly has a negative test\nC. Greater likelihood that an individual with a positive test will truly have Lyme disease\nD. Decreased positive likelihood ratio of the Lyme disease assay\nE. Lower likelihood that a patient with Lyme disease will truly have a positive test\nF. Greater likelihood that an individual with a negative test will truly not have Lyme disease\n\"\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 1-day-old infant born at full term by uncomplicated spontaneous vaginal delivery is noted to have cyanosis of the oral mucosa. The baby otherwise appears comfortable. On examination, his respiratory rate is 40/min and pulse oximetry is 80%. His left thumb is displaced and hypoplastic. A right ventricular lift is palpated, S1 is normal, S2 is single, and a harsh 3/6 systolic ejection murmur is heard at the left upper sternal border. Chest X-ray is shown. Which of the following is the most likely diagnosis?\nA. Transposition of great vessels\nB. Tetralogy of Fallot\nC. Ventricular septal defect\nD. Transient tachypnoea of the newborn\nE. Pneumothorax\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 39-year-old woman presents to her gynecologist for her annual exam. She missed her \"yearly exams\" over the past 5 years because she was \"too busy with work and family.\" She feels well and has no complaints. Her menses are regular, occurring every 29 days and lasting approximately 3 days. Menarche was at age 10. Her past medical history is notable for rheumatoid arthritis. She takes methotrexate. She has a 15-pack-year smoking history and drinks socially. She is married and has 2 children. She and her husband use condoms for protection. Her last Pap smear was 5 years ago and was normal. Her temperature is 98.8\u00b0F (37.1\u00b0C), blood pressure is 120/69 mmHg, pulse is 88/min, and respirations are 17/min. Pelvic examination demonstrates a normal appearing vagina with no adnexal or cervical motion tenderness. A Pap smear is performed, and a high-grade squamous intraepithelial lesion is identified. A cone biopsy is subsequently performed, and results are shown in Figure A. This patient most likely has which of the following conditions?\nA. Adenocarcinoma\nB. Cervical intraepithelial neoplasia I\nC. Cervical intraepithelial neoplasia II\nD. Cervical intraepithelial neoplasia III\nE. Squamous cell carcinoma\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 3-year-old boy presents to an urgent care clinic with his mother. She states that his behavior has been lethargic for the past 3 days. She also notes that he has had a runny nose, mild cough, and sore throat during this time. She does not believe that he has been febrile. His temperature is 99.1\u00b0F (37.2\u00b0C), blood pressure is 105/67 mmHg, pulse is 100/min, respirations are 18/min, and SpO2 97% on room air. Which nucleic acid structure most accurately describes the most likely virus responsible for this boy\u2019s clinical condition?\nA. Single-stranded, positive-sense RNA\nB. Single-stranded, negative-sense RNA\nC. Double-stranded RNA\nD. Single-stranded DNA\nE. Double-stranded DNA\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 36-year-old woman is brought to the emergency department after being involved in a motor vehicle collision. She is alert, awake, and oriented. There is no family history of serious illness and her only medication is an oral contraceptive. Her temperature is 37.3\u00b0C (99\u00b0F), pulse is 100/min, respirations are 20/min, and blood pressure is 102/80 mm Hg. Physical examination shows ecchymoses over the trunk and abdomen. A FAST scan of the abdomen is negative. An x-ray of the chest shows no fractures. A contrast-enhanced CT scan of the chest and abdomen is performed that shows a 4-cm sharply defined liver mass with a hypoattenuated central scar. Which of the following is the most appropriate next step in management?\nA. Reassurance and observation\nB. Biopsy of the mass\nC. Avoid contact sports\nD. Discontinue the oral contraceptive\nE. Percutaneous aspiration of the mass\nF. Surgical resection of the mass\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A husband returns from a three-month long business trip from Thailand, where he also engaged in extramarital affairs. He arrives back at home to find that his wife is distant and not as affectionate as she used to be. He then proceeds to argue with his wife stating that she must be cheating on him since she is so distant. Which of the following best explains the ego defense of the husband?\nA. Passive aggression\nB. Rationalization\nC. Projection\nD. Reaction formation\nE. Regression\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 9-month-old female infant presents with failure to thrive, repeated respiratory infections, and anemia refractory to administration of cobalamin, pyridoxine, folic acid, and iron (Figure A). Urinalysis demonstrates a crystalline sediment and a blood test shows normal ammonia levels. Which of the following enzymes is defective in this infant?\nA. Ornithine transcarbamoylase\nB. Adenosine deaminase\nC. Hypoxanthine-guanine phosphoribosyltransferase\nD. Xanthine oxidase\nE. UMP synthase\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 17-year-old girl comes in to her primary care physician's office for an athletic physical. She is on her school\u2019s varsity swim team. She states she is doing \u201cok\u201d in her classes. She is worried about her upcoming swim meet. She states, \u201cI feel like I\u2019m the slowest one on the team. Everyone is way more fit than I am.\u201d The patient has polycystic ovarian syndrome and irregular menses, and her last menstrual period was 5 weeks ago. She takes loratadine, uses nasal spray for her seasonal allergies, and uses ibuprofen for muscle soreness occasionally. The patient\u2019s body mass index (BMI) is 19 kg/m^2. On physical examination, the patient has dark circles under her eyes and calluses on the dorsum of her right hand. A beta-hCG is negative. Which of the following is associated with the patient\u2019s most likely condition?\nA. Dental cavities\nB. Galactorrhea\nC. Lanugo\nD. Metatarsal stress fractures\nE. Motor tics\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 23-year-old man presents with increasing neck pain for several months that does not improve with nonsteroidal anti-inflammatory drugs. The patient says he has had neck pain ever since he was involved in a motor vehicle accident 10 months ago. For the last 2 weeks, he says he has also noticed weakness and numbness in his hands and has difficulty gripping objects. Physical examination reveals a thermal injury that he says he got while holding a hot cup of coffee a week ago when he could not feel the warmth of the coffee mug. Strength is 4/5 bilaterally during elbow flexion and extension and wrist extension. He also has exaggerated deep tendon reflexes bilaterally and decreased sensation symmetrically on the dorsal and ventral surface of both forearms and hands. Which of the following additional findings would you expect to find in this patient?\nA. Fusion of cervical vertebrae\nB. Hypoplasia of the cerebellar vermis\nC. Bilateral carpal tunnel syndrome\nD. A cavitation in the cervical spinal cord\nE. Cervical spinal epidural abscess\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 35-year-old man presents with a 7 month history of insomnia. The patient admitted to having trouble sleeping from a young age but became more aware of how much this is affecting his health after attending a sleep conference earlier this year. He is worried that his health has suffered because of this, and he is also concerned that he will not be able to pay his bills if he were to get sick. He has no past medical or psychiatric condition and is not known to use any recreational drugs. The patient arrived for his appointment an hour early because he was afraid he might miss it. The patient is afebrile and his vital signs are within normal limits. Physical examination reveals an irritable middle age man who is tense and somewhat inattentive during the interview. Which of the following is the most likely diagnosis in this patient?\n \nA. Generalized anxiety disorder\nB. Adjustment disorder\nC. Social anxiety \nD. Agoraphobia\nE. Normal worry\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 24 year-old male presented to his physician with a homogenous, painless testicular swelling that he noticed for the past two weeks. After ultrasound and blood tests, he subsequently underwent a radical inguinal orchiectomy and pathology was consistent with seminoma. Which of the following would you expect to see in a tissue sample from the patient\u2019s orchiectomy?\nA. Lobules of large cells with prominent nuclei and watery cytoplasm\nB. Schiller-Duval bodies\nC. Reinke crystals\nD. Tubular papillary architecture with necrosis\nE. Mature derivatives of endoderm, mesoderm, and ectoderm\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78-year-old man comes to the physician for evaluation of progressive hearing loss in both ears over the past year. He has difficulties understanding conversations in crowded places and when more than one person talks at the same time. He has no dizziness, ear discharge, ringing noise, or ear pain. He has a history of hypertension, hypercholesterolemia, and type 2 diabetes mellitus. Medications include enalapril, metformin, and atorvastatin. Vital signs are within normal limits. Otoscopic examination shows pearly gray, translucent tympanic membranes with a normal light reflex. A vibrating 512 Hz tuning fork is placed on the left mastoid process. Once the patient no longer hears a tone, the fork is held over the ipsilateral ear and the patient reports to hear the tone again. The same test is repeated on the right side with similar results. There is no lateralization when a vibrating 512 Hz tuning fork is placed in the middle of the forehead. Which of the following is the most likely diagnosis?\nA. Cerumen impaction\nB. Ototoxicity\nC. Otosclerosis\nD. Cholesteatoma\nE. Vestibulocochlear nerve damage\nF. Presbycusis\nG. Acoustic neuroma\n\"\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 12-year-old boy is found on a routine auditory screening to have mild high frequency hearing impairment. On exam, he has no ear pain, no focal neurological deficits, and no cardiac murmurs. He has not had any recent illness. Laboratory studies show:\n\nSerum:\nCreatinine: 0.7 mg/dl\nProtein: 3.8 g/dl\nAntistreptolysin O titer: 60 Todd units (12-166 normal range)\n\nUrinalysis:\nMicroscopic heme\nProtein: 4+\nRBCs: 6/hpf\n\nA kidney biopsy is taken. Which of the following findings is most characteristic of this patient\u2019s disease?\nA. \u201cBasket-weave\u201d pattern of basement membrane on electron microscopy\nB. Crescent-moon shapes on light microscopy\nC. Large eosinophilic nodular lesions on light microscopy\nD. Thickened \u201ctram-track\u201d appearance of basement membrane on electron microscopy\nE. \u201cSpike and dome\u201d appearance on electron microscopy\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 32-year-old man comes to the physician because of a 3-month history of intermittent flank pain and reddish discoloration of urine. His blood pressure is 150/92 mm Hg. His serum creatinine concentration is 1.4 mg/dL. An abdominal CT scan is shown. This patient's condition is most likely caused by a genetic defect in which of the following locations?\nA. Short arm of chromosome 16\nB. Short arm of chromosome 3\nC. Long arm of chromosome 4\nD. Long arm of chromosome 10\nE. Short arm of chromosome 6\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 45-year-old Caucasian male with a history of chronic myeloid leukemia for which he is receiving chemotherapy presents to the emergency room with oliguria and colicky left flank pain. His serum creatinine is 3.0 mg/dL and is urine pH is 5.0. You diagnose nephrolithiasis. His kidney stones, however, are not visible on abdominal x-ray. His stone is most likely composed of which of the following?\nA. Calcium oxalate\nB. Calcium phosphate\nC. Magnesium ammonium phosphate\nD. Uric acid\nE. Cystine\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 24-year-old woman with a missed menstrual cycle has a positive pregnancy test. The estimated gestational age is 4 weeks. The patient questions the pregnancy test results and mentions that a urinary pregnancy test she took 3 weeks ago was negative. What is the explanation for the patient\u2019s first negative pregnancy test result?\nA. The embryonic liver has not yet developed to produce human chorionic gonadotropin at that term.\nB. The syncytiotrophoblast had not yet developed to produce human chorionic gonadotropin at that term.\nC. Pregnancy test becomes positive during organogenesis so should be expected positive no earlier than at week 4.\nD. Human chorionic gonadotropin starts to be produced by the uterus only after the embryonic implantation which has not yet occurred.\nE. Human chorionic gonadotropin can only be found in the urine after its placental production is started.\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 30-year-old woman comes to the emergency department because of fever, watery diarrhea, and abdominal cramping for the past 24 hours. She recently went to an international food fair. Her temperature is 39\u00b0C (102.2\u00b0F). Physical examination shows increased bowel sounds. Stool cultures grow gram-positive, spore-forming, anaerobic rods that produce alpha toxin. The responsible organism also causes which of the following physical examination findings?\nA. Diffuse, flaccid bullae\nB. Facial paralysis\nC. Subcutaneous crepitus\nD. Rose spots\nE. Petechial rash\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old woman presents with severe abdominal pain and bloody diarrhea. Past medical history is significant for a myocardial infarction 6 months ago. The patient reports a 25-pack-year smoking history and consumes 80 ounces of alcohol per week. Physical examination shows a diffusely tender abdomen with the absence of bowel sounds. Plain abdominal radiography is negative for free air under the diaphragm. Laboratory findings show a serum amylase of 115 U/L, serum lipase 95 U/L. Her clinical condition deteriorates rapidly, and she dies. Which of the following would most likely be the finding on autopsy in this patient?\nA. Small bowel obstruction\nB. Small bowel ischemia\nC. Ulcerative colitis\nD. Perforated appendicitis\nE. Acute pancreatitis\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 6-year-old boy is brought to the pediatrician by his foster father because he is concerned about the boy's health. He states that at seemingly random times he will have episodes of severe difficulty breathing and wheezing. Upon questioning, the pediatrician learns that these episodes do not appear to be associated with exercise, irritants, or infection. The pediatrician suspects the child has a type of asthma that is associated with eosinophils. In this type of asthma, what is released by the eosinophils to cause bronchial epithelial damage?\nA. IL-5\nB. Major basic protein\nC. IgM\nD. IL-8\nE. Interferon-gamma\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 78-year-old man comes to the physician because of progressively worsening fatigue and headache for 6 months and occasional abdominal pain. He has not had any changes in his weight. He has a history of hypertension, type 2 diabetes mellitus, and chronic shoulder pain. Current daily medications include hydrochlorothiazide, metformin, and ibuprofen. He does not drink alcohol and does not smoke. His diet has mostly consisted of potatoes and lean meats since his wife passed away 1 year ago. His pulse is 92/min and blood pressure is 135/80 mm Hg. Examination shows conjunctival and mucosal pallor. Abdominal and rectal examination shows no abnormalities. Neurological exam shows mild postural tremor. Peripheral blood smear shows red blood cells with increased zones of central pallor and anisocytosis. Which of the following is the most likely underlying cause of this patient\u2019s symptoms?\nA. Lead poisoning\nB. Folic acid deficiency\nC. Bone marrow failure\nD. Intravascular hemolysis\nE. Impaired erythropoietin production\nF. Vitamin B12 deficiency\nG. Iron deficiency\nAnswer:",
        "output": "G",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An endocervical swab is performed and nucleic acid amplification testing via polymerase chain reaction is conducted. It is positive for Chlamydia trachomatis and negative for Neisseria gonorrhoeae. Which of the following is the most appropriate pharmacotherapy?\nA. Oral amoxicillin\nB. Intravenous cefoxitin plus oral doxycycline\nC. Intramuscular ceftriaxone\nD. Oral levofloxacin\nE. Intramuscular ceftriaxone plus oral azithromycin\nF. Oral azithromycin\nG. Oral doxycycline\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 29-year-old woman comes to the office with her husband because she has had 4 spontaneous abortions. Regarding her medical history, she was diagnosed with systemic lupus erythematosus 9 years ago, had a stroke 3 years ago, and was diagnosed with deep vein thrombosis in the same year. She has no relevant family history. Her vital signs include: heart rate 78/min, respiratory rate 14/min, temperature 37.5\u00b0C (99.5\u00b0F), and blood pressure 120/85 mm Hg. The physical examination is unremarkable. The complete blood count results are as follows:\nHemoglobin 12.9 g/dL\nHematocrit 40%\nLeukocyte count 8,500/mm3\nNeutrophils 55%\nBands 2%\nEosinophils 1%\nBasophils 0%\nLymphocytes 29%\nMonocytes 2%\nPlatelet count 422,000/mm3\nHis coagulation test results are as follows:\nPartial thromboplastin time (activated) 50.9 s\nProthrombin time 13.0 s\nA VDRL test is done, and the result is positive. Mixing studies are performed, and they fail to correct aPTT. What is the most likely cause in this patient?\nA. Protein C deficiency\nB. Protein S deficiency\nC. Antiphospholipid syndrome\nD. Mutation of Leiden V factor\nE. Antithrombin deficiency\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 27-year-old G2P1 woman is diagnosed with an HIV infection after undergoing routine prenatal blood work testing. Her estimated gestational age by first-trimester ultrasound is 12 weeks. Her CD4 count is 150 cells/mm^3 and her viral load is 126,000 copies/mL. She denies experiencing any symptoms of HIV infection. Which of the following is appropriate management of this patient's pregnancy?\nA. Avoidance of antibiotic prophylaxis\nB. Breastfeeding\nC. HAART\nD. HAART after delivery\nE. Vaginal delivery\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 4-month-old male infant is brought in because he rejects food and is losing weight. He had several upper respiratory tract infections during the last 2 months. Upon examination, hepatosplenomegaly is noted, as well as mild hypotonia. During the next few weeks, hepatosplenomegaly progresses, the boy fails to thrive, and he continues to reject food. He has a blood pressure of 100/70 mm Hg and heart rate of 84/min. Blood tests show pancytopenia and elevated levels of transaminases. Slit lamp examination shows bilateral cherry-red spots on the macula. Chest X-ray shows a reticulonodular pattern and calcified nodules. Biopsy of the liver shows foamy histiocytes. What is the most likely diagnosis?\nA. Crigler-Najjar syndrome type I\nB. Niemann-Pick disease type A\nC. Gaucher disease\nD. Primary biliary cirrhosis\nE. Gilbert syndrome\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 18-month-old boy is brought to the physician because of a 2-day history of cough, fever, and lethargy. He has been admitted to the hospital twice during the past year for pneumonia. He can stand without support but has not started to walk. He speaks in bisyllables. He is at the 3rd percentile for height and 4th percentile for weight. Examination shows diffuse crackles over bilateral lung fields. Abdominal examination shows hepatosplenomegaly. Fundoscopy shows bright red macular spots. Despite being given appropriate antibiotic therapy, the patient dies. A photomicrograph of a section of the spleen obtained during autopsy is shown. Accumulation of which of the following substances is the most likely cause of this patient's condition?\nA. Limit dextrin\nB. Sphingomyelin\nC. Phenylalanine\nD. Galactitol\nE. Ceramide trihexoside\nF. Cerebroside sulfate\nG. GM2 ganglioside\nH. Glucocerebroside\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 72-year-old man presents to the emergency department after a fall. The patient was found lying down on the floor in his room in his retirement community. The patient has a past medical history of Alzheimer dementia and a prosthetic valve. His current medications include donepezil and warfarin. His temperature is 97.7\u00b0F (36.5\u00b0C), blood pressure is 85/50 mmHg, pulse is 160/min, respirations are 13/min, and oxygen saturation is 97% on room air. That patient is started on IV fluids and a type and screen is performed. Laboratory values are ordered as seen below.\n\nHemoglobin: 13 g/dL\nHematocrit: 39%\nLeukocyte count: 5,500 cells/mm^3 with normal differential\nPlatelet count: 225,000/mm^3\n\nINR: 2.5\nAST: 10 U/L\nALT: 12 U/L\n\nA chest radiograph and EKG are performed and are within normal limits. A full physical exam is within normal limits. The patient\u2019s vitals are repeated. His temperature is 99.5\u00b0F (37.5\u00b0C), blood pressure is 110/70 mmHg, pulse is 90/min, respirations are 10/min, and oxygen saturation is 98% on room air. Which of the following is the best next step in management?\nA. CT scan\nB. Exploratory laparoscopy\nC. Exploratory laparotomy\nD. Fresh frozen plasma\nE. Urgent blood transfusion\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 62-year-old man comes to the physician for a 1-month history of fever, malaise, and skin rash. He has had a 5-kg (11-lb) weight loss during this period. He does not smoke, drink alcohol, or use illicit drugs. He appears pale. His temperature is 39.1\u00b0C (102.3\u00b0F), pulse is 110/min, and blood pressure is 140/85 mm Hg. Physical examination shows nontender, erythematous macules on the palms and soles. A photograph of one of his fingernails is shown. Microscopic examination of the nail lesion is most likely to show which of the following?\nA. IgE immune complexes\nB. Aschoff granulomas\nC. Arteriovenous malformations\nD. Microemboli\nE. Non-caseating granulomas\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 45-year-old man is brought to the emergency department after a car accident with pain in the middle of his chest and some shortness of breath. He has sustained injuries to his right arm and leg. He did not lose consciousness. His temperature is 37\u00b0C (98.6\u00b0F), pulse is 110/min, respirations are 18/min, and blood pressure is 90/60 mm Hg. He is alert and oriented to person, place, and time. Examination shows several injuries to the upper extremities and chest. There are jugular venous pulsations 10 cm above the sternal angle. Heart sounds are faint on cardiac examination. The lungs are clear to auscultation. An ECG is shown. Which of the following is the most appropriate next step in management?\nA. Contrast esophagram with gastrografin\nB. X-ray of the chest\nC. Transesophageal echocardiography\nD. CT scan of the brain\nE. Contrast-enhanced CT angiography\nF. Emergency needle thoracostomy\nG. Transthoracic echocardiography\nAnswer:",
        "output": "G",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 56-year-old man comes to the physician for a follow-up examination. Physical examination shows hyperpigmented plaques on the posterior neck and in the axillae. His hemoglobin A1c concentration is 7.4% and fasting serum glucose concentration is 174 mg/dL. Which of the following is the strongest predisposing factor for this patient's laboratory findings?\nA. Elevated systolic blood pressure\nB. African-American ethnicity\nC. Increased BMI during childhood\nD. Increased serum testosterone level\nE. History of smoking\nF. High waist circumference\n\"\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old woman comes to the physician because of a 8-month history of worsening difficulties swallowing food and retrosternal chest discomfort. She reports that she sometimes has a feeling of \u201cfood getting stuck\u201d in her throat and hears a \u201cgurgling sound\u201d from her throat while eating. She says that she occasionally coughs up pieces of undigested food. She has noticed a bad taste in her mouth and bad breath. She has not had fever or weight loss. She has been visiting Mexico every year for the past 7 years. She has Raynaud disease treated with nifedipine. Her father died because of gastric cancer. She had smoked one-half pack of cigarettes daily for 20 years but stopped 25 years ago. Vital signs are within normal limits. Physical examination shows no abnormalities. Her hemoglobin concentration is 14 g/dL, leukocyte count is 9800/mm3, and platelet count is 215,000/mm3. An ECG shows sinus rhythm with no evidence of ischemia. Which of the following is most likely to confirm the diagnosis?\nA. Barium esophagram\nB. Esophageal manometry\nC. CT scan of the neck\nD. Serology and PCR\nE. Esophagogastroduodenoscopy\nF. Esophageal pH monitoring\nG. Endoscopic ultrasound\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An investigator is studying the regulation of adrenal hormone synthesis in rats. The investigator takes serum concentrations of different hormones before and after intravenous administration of metyrapone, which inhibits adrenal 11\u03b2-hydroxylase. The serum concentration of which of the following hormones is most likely to be decreased after administration of this agent?\nA. Adrenocorticotropic hormone\nB. Normetanephrine\nC. Epinephrine\nD. Norepinephrine\nE. Dopamine\nF. Dihydroxyphenylalanine\n\"\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 74-year-old African-American woman is brought to the emergency department by her home health aid. The patient was eating breakfast this morning when she suddenly was unable to lift her spoon with her right hand. She attempted to get up from the table, but her right leg felt weak. One hour later in the emergency department, her strength is 0/5 in the right upper and right lower extremities. Strength is normal in her left upper and lower extremities. Sensation is normal bilaterally. An emergency CT of the head does not show signs of hemorrhage. Subsequent brain MRI shows an infarct involving the internal capsule. Which of the following is true about her disease process?\nA. The most important risk factors are hypertension and diabetes\nB. The most common cause is embolism originating from the left atrium\nC. It is caused by ischemia to watershed areas\nD. IV thrombolysis cannot be used\nE. The most important risk factors are ethnicity and sex\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 11-year-old girl presents to the emergency department with a 12-hour history of severe abdominal pain. She says that the pain started near the middle of her abdomen and moved to the right lower quadrant after about 10 hours. Several hours after the pain started she also started experiencing nausea and loss of appetite. On presentation, her temperature is 102.5\u00b0F (39.2\u00b0C), blood pressure is 115/74 mmHg, pulse is 102/min, and respirations are 21/min. Physical exam reveals rebound tenderness in the right lower quadrant. Raising the patient's right leg with the knee flexed significantly increases the pain. Which of the following is the most common cause of this patient's symptoms in children?\nA. Fecalith obstruction\nB. Ingestion of indigestible object\nC. Lymphoid hyperplasia\nD. Meckel diverticulum\nE. Parasitic infection\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 56-year-old postmenopausal woman comes to the physician because of a 6-month history of worsening pain and swelling in her left knee. She has a history of peptic ulcer disease for which she takes cimetidine. Examination shows palpable crepitus and limited range of motion of the left knee. Which of the following is the most appropriate pharmacotherapy for this patient\u2019s symptoms?\nA. Ketorolac\nB. Diclofenac\nC. Acetylsalicylic acid\nD. Celecoxib\nE. Ibuprofen\nF. Meloxicam\nG. Indomethacin\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 49-year-old woman with a history of intravenous drug use comes to the physician because of a 6-month history of fatigue, joint pain, and episodic, painful discoloration in her fingers when exposed to cold weather. She takes no medications. She has smoked one pack of cigarettes daily for the past 22 years. She appears tired. Physical examination shows palpable, nonblanching purpura over the hands and feet. Neurological examination shows weakness and decreased sensation in all extremities. Serum studies show:\nAlanine aminotransferase 78 U/L\nAspartate aminotransferase 90 U/L\nUrea nitrogen 18 mg/dL\nCreatinine 1.5 mg/dL\nWhich of the following processes is the most likely explanation for this patient's current condition?\"\nA. Immune complex formation\nB. Granulomatous inflammation\nC. Spirochete infection\nD. Tobacco hypersensitivity\nE. Fibroblast proliferation\nF. Plasma cell malignancy\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 72-year-old man is diagnosed with multiple myeloma. His blood work shows mild anemia and urinalysis detects proteinuria at a level of 670 mg/24 h. A kidney biopsy is performed. Which of the following deposits would most likely be detected on the renal biopsy in this patient?\nA. \u0410\u03b2 amyloid\nB. Calcitonin\nC. AL amyloid\nD. Mutated transthyretin\nE. Amylin\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 77-year-old woman presents to a general medical clinic with progressive frontal headaches. Her symptoms began 2 months ago and have increased in intensity and frequency. She reports that her headaches are worse in the morning and often wake her from sleep. Her vital signs are stable. Neurologic examination reveals no focal deficits, but brain imaging reveals a mass lesion and biopsy is performed, with histology depicted in Figure A. Which of the following is true regarding this patient's illness?\nA. It is the most common primary brain tumor\nB. The specimen demonstrates psammoma bodies\nC. The patient's disease would be consistent with the MRI shown in Figure B\nD. The tumor arises from arachnoid cells external to the brain\nE. The patient's prognosis is good since the tumor is slow-growing\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 24-year-old man is rushed to the emergency room after he was involved in a motor vehicle accident. , He says that he is having difficulty breathing and has right-sided chest pain, which he describes as 8/10, sharp in character, and worse with deep inspiration. His vitals are: blood pressure 90/65 mm Hg, respiratory rate 30/min, pulse 120/min, temperature 37.2\u00b0C (99.0\u00b0F). On physical examination, patient is alert and oriented but in severe distress. There are multiple bruises over the anterior chest wall. There is also significant jugular venous distention and the presence of subcutaneous emphysema at the base of the neck. There is an absence of breath sounds on the right and hyperresonance to percussion. A bedside chest radiograph shows evidence of a collapsed right lung with a depressed right hemidiaphragm and tracheal deviation to the left. Which of the following findings is the strongest indicator of cardiogenic shock in this patient?\nA. Jugular veins distention\nB. Subcutaneous emphysema\nC. Hyperresonance to percussion\nD. No right chest raise\nE. Tracheal shift to the left\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 58-year-old male presents to his primary care doctor with the complaint of vision changes over the last several months. The patient's past medical history is notable for schizophrenia which has been well-controlled for the last 25 years on chlorpromazine. Which of the following is likely to be seen on ophthalmoscopy?\nA. Retinitis pigmentosa\nB. Macular degeneration\nC. Glaucoma\nD. Retinal hemorrhage\nE. Corneal deposits\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 27-year-old gentleman is brought into the ED after being stabbed in the back by a knife. In addition to the pain from the wound, he complains of weakness in his left leg. Upon physical examination you find that he has no other visible injuries; however, he has 2/5 strength in the left lower extremity. Complete neurologic exam also finds a deficit in vibration sense and light touch on the left lower extremity as well as a loss of pain and temperature sensation in the right lower extremity. Which of the following lesions would result in the syndrome described?\nA. Anterior cord lesion\nB. Posterior cord lesion\nC. Right cord hemisection\nD. Left cord hemisection\nE. Complete cord transection\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old man comes to the clinic complaining of abdominal pain for the past 2 months. He describes the pain as a dull, aching, 6/10 pain that is diffuse but worse in the right upper quadrant (RUQ). His past medical history is significant for diabetes controlled with metformin and a cholecystectomy 10 years ago. He reports fatigue and a 10-lb weight loss over the past month that he attributes to poor appetite; he denies fever, nausea/vomiting, palpitations, chest pain, or bowel changes. Physical examination is significant for mild scleral icterus and tenderness at the RUQ. Further workup reveals a high-grade malignant vascular neoplasm of the liver. What relevant detail would you expect to find in this patient\u2019s history?\nA. Chronic alcohol abuse\nB. Heavy ingestion of acetaminophen\nC. Infection with the hepatitis B virus\nD. Obesity\nE. Prior occupation in a chemical plastics manufacturing facility\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 24-year-old man is brought in to the emergency room after being retrieved by firefighters from a burning building. The patient is responding coherently to questions but reports pain secondary to a burn on his leg. He states he also has a headache and feels dizzy. His temperature is 98.5\u00b0F (36.9\u00b0C), blood pressure is 129/66 mmHg, pulse is 126/min, respirations are 14/min, and oxygen saturation is 99% on room air. Physical exam is notable for a confused young man with dry and flushed skin. Cardiopulmonary exam reveals a normal S1 and S2 as well as clear breath sounds bilaterally. The patient\u2019s neurological exam is within normal limits. Towards the end of his exam, the patient begins vomiting. Dermatologic exam reveals a superficial burn covering 1% of the patient\u2019s body over his right leg. Which of the following is the best next step in management for this patient?\nA. 100% oxygen\nB. CT scan of the head\nC. Hydroxocobalamin\nD. Normal saline\nE. Ondansetron\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 40-year-old man presents to the emergency department with a chief complaint of chest pain for the last 3 hours. His ECG shows normal sinus rhythm with ST-segment elevation in leads II, III, and aVF and reciprocal segment depression in leads V1\u2013V6. On physical examination, cardiac sounds are normal on auscultation. His blood pressure is 92/64 mm Hg and heart rate was 93/min. A tissue plasminogen activator is administered to the patient intravenously within 1 hour of hospital arrival due to a lack of available percutaneous coronary intervention. After 6 hours of therapy, the patient\u2019s clinical condition starts to deteriorate. ECG on the monitor shows accelerated idioventricular rhythm, which within a couple of minutes changes to ventricular fibrillation. Before any measures could be started, the patient deteriorates further and must be transferred to the ICU. What is the most likely etiology of the ECG findings in this patient?\nA. Increase in cellular pH\nB. Increased production of superoxide dismutase\nC. Calcium efflux\nD. Inhibition of lipid peroxidation\nE. Free radical formation\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 38-year-old woman makes an appointment with her family physician for a routine check-up after being away due to travel for 1 year. She recently had a screening Pap smear, which was negative for malignancy. Her past medical history is significant for a Pap smear 2 years ago that reported a low-grade squamous intraepithelial lesion (LSIL). A subsequent colposcopy diagnosed low-grade cervical intraepithelial neoplasia (CIN2). The patient is surprised by the differences in her diagnostic tests. You explain to her the basis for the difference and reassure her. With this in mind, which of the following HPV serotypes is most likely to be present in the patient?\nA. HPV 18\nB. HPV 6\nC. HPV 31\nD. HPV 16\nE. HPV 33\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 8-year-old boy is brought to the physician by his parents because of fever for 3 days. During the period, he has had fatigue, severe burning with urination, and increased urination. The mother reports that his urine has red streaks and a \u201cstrange\u201d odor. He has taken acetaminophen twice a day for the past two days with no improvement in his symptoms. He has had multiple ear infections in the past but has been healthy in the past year. His immunizations are up-to-date. He appears uncomfortable. His temperature is 39\u00b0C (102.2\u00b0F). Examination shows right-sided costovertebral angle tenderness. Laboratory studies show a leukocyte count of 16,000/cm3 and an erythrocyte sedimentation rate of 40 mm/hr. Urine dipstick shows leukocyte esterase and nitrites. Urinalysis shows:\nBlood 2+\nProtein 2+\nWBC 24/hpf\nRBC 50/hpf\nRBC casts none\nWBC casts numerous\nGranular casts none\nUrine cultures are sent to the laboratory. Damage to which of the following structures is the most likely cause of this patient's hematuria?\"\nA. Renal tubules\nB. Renal papilla\nC. Urethral epithelium\nD. Renal interstitium\nE. Renal glomerular basement membrane\nF. Mucosa of the bladder\n\"\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A healthy 22-year-old male participates in a research study you are leading to compare the properties of skeletal and cardiac muscle. You conduct a 3-phased experiment with the participant. In the first phase, you get him to lift up a 2.3 kg (5 lb) weight off a table with his left hand. In the second phase, you get him to do 20 burpees, taking his heart rate to 150/min. In the third phase, you electrically stimulate his gastrocnemius with a frequency of 50 Hz. You are interested in the tension and electrical activity of specific muscles as follows: Biceps in phase 1, cardiac muscle in phase 2, and gastrocnemius in phase 3. What would you expect to be happening in the phases and the respective muscles of interest?\nA. Recruitment of small motor units at the start of experiments 1 and 2\nB. Increase of tension in experiments 2 and 3, with the same underlying mechanism\nC. Recruitment of large motor units followed by small motor units in experiment 1\nD. Fused tetanic contraction at the end of all three experiments\nE. Increase of tension in all phases\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 21-year-old man presents to the emergency room with abdominal pain and nausea for the past 5 hours. The pain is diffusely spread and of moderate intensity. The patient also says he has not felt like eating since yesterday. He has no past medical history and is not on any medications. He regularly drinks 2\u20134 beers per day but does not smoke or use illicit substances. Vitals show a pulse of 120/min, a respiratory rate of 26/min, a blood pressure of 110/60 mm Hg, and a temperature of 37.8\u00b0C (100.0\u00b0F). Examination reveals a soft, diffusely tender abdomen with no guarding. Bowel sounds are present. His mucous membranes are slightly dry and there is a fruity smell to his breath. Laboratory tests show:\nLaboratory test\npH 7.31\nSerum glucose (random)  450 mg/dL\n    Serum electrolytes\nSodium 149 mEq/L\nPotassium 5 mEq/L\nChloride 99 mEq/L\nBicarbonate 16 mEq/L\n    Serum creatinine 1.0 mg/dL\nBlood urea nitrogen 15 mg/dL\n    Urinalysis\nProteins Negative\nGlucose Positive\nKetones Positive\nLeucocytes Negative\nNitrites Negative\nRed blood cells (RBC) Negative\nCasts Negative\nWhich of the following explains this patient's presentation?\nA. Anaerobic metabolism by products from skeletal muscles\nB. Blunt trauma to the abdomen\nC. Burn out of pancreatic beta cells\nD. Effects of alcohol on mitochondrial metabolic activity\nE. Fecalith in the caecum\nF. Presence of gut contents in the abdominal cavity\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 51-year-old man presents to his primary care provider complaining of malaise. He returned from a research trip to Madagascar 2 weeks ago and has since developed a worsening fever with a maximum temperature of 102.2\u00b0F (39\u00b0C). He also reports some swelling around his neck and groin. He works as a zoologist and was in rural Madagascar studying a rare species of lemur. His past medical history is notable for hypertension and gout. He takes lisinopril and allopurinol. His temperature is 101.9\u00b0F (38.3\u00b0C), blood pressure is 145/85 mmHg, pulse is 110/min, and respirations are 22/min. On exam, he has painful erythematous cervical, axillary, and inguinal lymphadenopathy. Black hemorrhagic eschars are noted on his fingertips bilaterally. The pathogen responsible for this patient\u2019s condition produces a virulence factor that has which of the following functions?\nA. Cleave immunoglobulin\nB. Inhibit leukocyte migration\nC. Inhibit phagocytosis\nD. Inhibit ribosomal function\nE. Trigger widespread inflammation\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old man presents with left-sided numbness, diplopia, and blurring of vision. The diplopia is more prominent on his left-side lateral gaze. He denies having fever, headache, ocular pain, lacrimation, changes in color vision, or limb weakness. He has a past medical history of type-2 diabetes mellitus, hypertension, hypercholesterolemia, and ischemic heart disease. In addition, he had an ischemic stroke 9 years ago, from which he recovered completely with physiotherapy and rehabilitation. He has a history of a 56-pack-year cigarette smoking habit. His medications include aspirin, atorvastatin, glimepiride, metformin, metoprolol, and ramipril. The mental status examination is unremarkable. His muscle strength is normal in all 4 limbs. His sensations are decreased on his left side, including his face. The examination of extraocular movements is shown in the image. A lesion in which of the following locations explains the findings during eye examination?\nA. Cavernous sinus\nB. Corticospinal tract before pyramidal decussation\nC. Dorsal column-medial lemniscus\nD. Frontal eye field\nE. Medial longitudinal fasciculus\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 40-year-old construction worker comes to your office complaining of lower back pain. The patient reports that the pain first started 6 months ago, and that he thought it was from lifting heavy objects at work. Initially his symptoms occurred only when he woke up and then slowly improved at the end of the workday, but now his symptoms last almost his entire shift. A review of systems is notable for fatigue, palpitations, and dyspnea. He notes that the fatigue has also been getting progressively worse. The patient\u2019s past medical history is significant for eczema and inflammatory bowel disease. His only medications are NSAIDs to help his lower back pain. He smokes cigars socially. On physical exam, you note mild bilateral lower extremity edema and restricted anterior flexion of the lower spine. Straight leg raises of both legs elicits no lower back pain. The neurological exam is otherwise unremarkable. His temperature is 99\u00b0F (37.2\u00b0C), blood pressure is 121/82 mmHg, pulse is 94/min, reapirations are 15/min, and oxygen saturation is 97% O2 on room air. An EKG is performed, as shown in Figure A. Which of the following results would you expect on this patient\u2019s pulmonary function test?\nA. Normal vital capacity, normal total lung capacity, normal FEV1/FVC ratio, low DLCO\nB. Normal vital capacity, normal total lung capacity, decreased FEV1/FVC ratio, low DLCO\nC. Normal vital capacity, normal total lung capacity, decreased FEV1/FVC ratio, high DLCO\nD. Decreased vital capacity, decreased total lung capacity, normal FEV1/FVC ratio, normal DLCO\nE. Decreased vital capacity, decreased total lung capacity, normal FEV1/FVC ratio, low DLCO\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 52-year-old female presents to clinic complaining of sudden onset of flank tenderness that was fluctuating and radiating into her groin. Laboratory analysis reveals a serum calcium of 12.4 (normal 8.4-10.2) and a serum phosphorous of 2.5 (normal 2.7-4.5) and a chloride:phosphorous ratio >33. You suspect primary hyperparathyroidism. Which of the following mechanisms is responsible for the patient\u2019s current condition?\nA. PTH binding to receptors on osteoclasts\nB. Parafollicular, or C-cell, synthesis of calcitonin\nC. Increased RANK-L production\nD. Decreased M-CSF production\nE. Increased synthesis of osteoid by osteoblasts\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 47-year-old woman is admitted to the hospital because of a 2-week history of low-grade fever, fatigue, and a 3-kg (6.6-lb) weight loss. Her temperature is 38\u00b0C (100.4\u00b0F). Physical examination shows pallor and a cardiac murmur. Her serum creatinine is 1.8 mg/dL. Urinalysis shows red cell casts and 2+ protein. A CT scan of the abdomen with contrast shows no abnormalities. Despite appropriate medical therapy, the patient dies. A photograph of the heart taken during autopsy is shown. Which of the following is the most likely explanation for the laboratory findings in this patient?\nA. Occlusion of renal arteries by cholesterol crystals\nB. Deposition of antigen-antibody complexes\nC. Embolization by an infected thrombus\nD. Intravascular fragmentation of red blood cells\nE. Hypersensitivity to penicillin haptens\nF. Tubular cell damage by a nephrotoxic drug\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 3-year-old boy is brought to the emergency room by his parents due to noisy, difficult breathing. They are concerned that he may have swallowed something when they were not looking. The parents note that he has had a fever and runny nose for the past few days. On physical exam, the patient has a cough and exhibits breathing with inspiratory stridor. A chest radiograph is obtained and shows the finding seen in Figure A. The physician explains that no treatment is needed, though nebulized epinephrine may be used to alleviate symptoms. What is the most likely cause of this patient\u2019s difficulty breathing?\nA. Foreign body aspiration\nB. Haemophilus influenza\nC. Laryngomalacia\nD. Parainfluenza virus\nE. Respiratory syncytial virus\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 5-year-old girl is brought to the physician because of watery discharge from her right eye for 2 weeks. She and her parents, who are refugees from Sudan, arrived in Texas a month ago. Her immunization status is not known. She is at the 25th percentile for weight and the 50th percentile for height. Her temperature is 37.2\u00b0C (99\u00b0F), pulse is 90/min, and respirations are 18/min. Examination of the right eye shows matting of the eyelashes. Everting the right eyelid shows hyperemia, follicles, and papillae on the upper tarsal conjunctiva. Slit-lamp examination of the right eye shows follicles in the limbic region and the bulbar conjunctiva. There is corneal haziness with neovascularization at the 12 o'clock position. Examination of the left eye is unremarkable. Direct opthalmoscopy of both eyes shows no abnormalities. Right pre-auricular lymphadenopathy is present. Which of the following is the most likely diagnosis in this patient?\nA. Vernal conjunctivitis\nB. Adenoviral conjunctivitis\nC. Giant papillary conjuctivitis\nD. Phlyctenular conjunctivitis\nE. Angular conjunctivitis\nF. Acute hemorrhagic conjuctivitis\nG. Neisserial conjunctivitis\nH. Acute herpetic conjunctivitis\nI. Trachoma conjunctivitis\nAnswer:",
        "output": "I",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 19-month-old girl is brought for a well-child examination. She was born at term and has been healthy. On physical examination, the child is alert and active. Her temperature is 37.3 \u00b0C (99.1 \u00b0F), pulse is 102/min, respirations are 24/min, and blood pressure is 102/54 mm Hg. She is at the 75th percentile for height and 80th percentile for weight. Cardiac examination shows a normal S1 and a split S2 during inspiration. A grade 2/6 soft mid-systolic murmur is heard maximally at the lower left sternal border. A contrast echocardiogram is performed and reveals a mild transient right-to-left interatrial shunt that becomes apparent when the child coughs. Which of the following is the most appropriate next step in management?\nA. Percutaneous closure\nB. No intervention\nC. Warfarin therapy\nD. Aspirin therapy\nE. Surgical closure\nF. Regular echocardiographies\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 71-year-old male is admitted to the hospital with a Staphylococcal aureus infection of his decubitus ulcers. He is diabetic and has a body mass index of 45. His temperature is 37\u00b0C (98.6\u00b0F), respirations are 15/min, pulse is 67/min and blood pressure is 122/98 mm Hg. The nurse is monitoring his blood glucose and records it as 63 mg/dL. She then asks the resident on call if the patient should receive glargine insulin as ordered seeing his glucose levels. Which of the following would be the most appropriate response by the resident?\nA. Yes, glargine insulin is a long-acting insulin and should still be given to control his blood glucose over the next 24 hours.\nB. No, glargine insulin should not be given during an episode of hypoglycemia as it will further lower blood glucose.\nC. No, glargine insulin was probably ordered in error as it is not recommended in type 2 diabetes.\nD. No, due to his S. aureus infection he is more likely to have low blood glucose and glargine insulin should be held until he has recovered.\nE. No, glargine insulin should be stopped and replaced with lispro insulin until his blood glucose increases.\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 31-year-old woman, gravida 1, para 0, at 28 weeks' gestation comes to the obstetrician for a prenatal visit. She has had a tingling pain in the thumb, index finger, and middle finger of her right hand for the past 6 weeks. Physical examination shows decreased sensation to pinprick touch on the thumb, index finger, middle finger, and lateral half of the ring finger of the right hand. The pain is reproduced when the dorsal side of each hand is pressed against each other. Which of the following additional findings is most likely in this patient?\nA. Palmar nodule\nB. Thenar atrophy\nC. Interosseus wasting\nD. Wrist drop\nE. Hypothenar weakness\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 5-year-old boy is brought to the physician because of facial swelling that started 5 days ago. Two weeks ago, he had a sore throat that resolved spontaneously. His temperature is 37\u00b0C (98.6\u00b0F), pulse is 107/min, and blood pressure is 94/67 mm Hg. Examination shows pitting edema of the upper and lower extremities as well as periorbital edema. The abdomen is mildly distended. Laboratory studies show:\nHemoglobin 13.1 g/dL\nSerum\nAlbumin 2.1 g/dL\nTotal cholesterol 270 mg/dL\nTriglycerides 175 mg/dL\nUrine\nBlood negative\nGlucose negative\nProtein 4+\nLeukocyte esterase negative\nA renal biopsy of this patient is most likely to show which of the following findings?\"\nA. Splitting of the glomerular basement membrane on electron microscopy\nB. Mesangial proliferation on light microscopy\nC. Subepithelial dense deposits on electron microscopy\nD. Deposits of IgG and C3 at the glomerular basement membrane on immunofluoresence\nE. Linear deposition of anti-GBM antibodies on immunofluorescence\nF. Normal light microscopy findings\nG. Granular subepithelial deposits of IgG, IgM, and C3 on immunofluorescence\nH. Apple-green birefringence with Congo red stain\nI. Effacement of foot processes of podocytes on light microscopy\nJ. Segmental sclerosis on light microscopy\n\"\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 54-year-old woman comes to the emergency department because of sharp chest pain and shortness of breath for 1 day. She has been coughing intermittently, which worsens the pain. She has osteoporosis, for which she takes raloxifene. Arterial blood gas analysis on room air shows:\npH 7.52\nPCO2 25 mm Hg\nPO2 65 mm Hg\nO2 saturation 92%\nPhysical examination is most likely to show which of the following findings?\"\nA. Unilateral swelling of the leg\nB. Increased anteroposterior diameter of the thorax\nC. Grouped vesicles on the right hemithorax\nD. Pericardial friction rub\nE. Absent left radial pulse\nF. Increased tactile fremitus\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An experiment to determine the effects of gravity on blood pressure is conducted on 3 individuals of equal height and blood pressure oriented in different positions in space. Participant A is strapped in a supine position on a bed turned upside down in a vertical orientation with his head towards the floor and his feet towards the ceiling. Participant B is strapped in a supine position on a bed turned downwards in a vertical orientation with his head towards the ceiling and his feet just about touching the floor. Participant C is strapped in a supine position on a bed in a horizontal orientation. Blood pressure readings are then taken at the level of the head, heart, and feet from all 3 participants. Which of these positions will have the lowest recorded blood pressure reading?\nA. Participant A: at the level of the head\nB. Participant B: at the level of the feet\nC. Participant C: at the level of the heart\nD. Participant A: at the level of the feet\nE. Participant B: at the level of the head\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:An 8-year-old boy is brought to the physician by his parents for short stature. Neither his clothing nor his shoe size have changed over the past year. He also frequently bumps into obstacles such as furniture and has headaches at night. He is always thirsty for cold water and has been urinating more frequently. Three years ago, he had an asthma attack that was treated with albuterol and a one-week course of steroids. His mother has Hashimoto's thyroiditis and had precocious puberty. His mother's height is 147 cm (4 ft 10 in) and his father's height is 160 cm (5 ft 3 in). He is at the 5th percentile for height and 5th percentile for weight. His temperature is 37\u00b0C (98.6\u00b0F), pulse is 98/min, respirations are 16/min, and blood pressure is 100/64 mm Hg. Examination shows a soft and nontender abdomen. The genitals and pubic hair are both Tanner stage 1. Axillary hair is absent. Patellar reflexes are 1+ bilaterally. Laboratory studies show:\nNa+ 145 mEq/L\nK+ 4.1 mEq/L\nCl- 102 mEq/L\nHCO3- 25 mEq/L\nCa2+ 9.4 mg/dL\nGlucose 110 mg/dL\nThyroid-stimulating hormone 0.3 \u03bcU/mL\nThyroxine 3.9 \u03bcg/dL\nInsulin-like growth factor 1 24 ng/mL (N=61\u2013356 ng/mL)\nInsulin-like growth factor binding protein 3 2.1 mcg/mL (N=1.6\u20136.5 \u03bcg/mL)\nWhich of the following is the most likely diagnosis?\"\nA. Medication side effect\nB. Rathke cleft cyst\nC. Autoimmune polyendocrine syndrome\nD. Constitutional growth delay\nE. Familial short stature\nF. Craniopharyngioma\nG. Multiple endocrine neoplasia\nH. Pituitary adenoma\nAnswer:",
        "output": "F",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 73-year-old man is brought to the physician by his daughter for evaluation of increasing forgetfulness during the past 6 months. The daughter reports that he recently got lost while walking home from the grocery store. He has also been more irritable recently. On mental status examination, he has a normal affect. He is oriented to person and place but cannot recall which month it is. He recalls memories from more than 20 years ago in great detail but cannot state his home address or the name of his recently born grandson. His gait is normal and there is no nystagmus. An MRI of the brain is shown. Which of the following is the most likely underlying cause of the radiologic findings?\nA. Inflammation of the choroid plexus\nB. Atrophy of the cortex\nC. Demyelination of periventricular structures\nD. Bleeding into the ventricular system\nE. Obstruction of the foramen of Monro\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 52-year-old man comes to the physician for a routine health maintenance examination. He feels well. His blood pressure is 125/70 mm Hg. His glomerular filtration rate is calculated to be 105 mL/min/1.73 m2 and glucose clearance is calculated to be 103 mL/min. This patient is most likely being treated with which of the following agents?\nA. Metformin\nB. Canagliflozin\nC. Ifosfamide\nD. Glipizide\nE. Linagliptin\nF. Acarbose\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 10-year-old male is taken to his physician by his parents due to a sore throat. A throat swab and culture reveal the growth seen in Figure A. The bacteria are gram-positive and bacitracin inhibits their growth. The child is given treatment and sent home. Twenty years later, the patient presents to the emergency department with dyspnea on exertion and CXR showed an enlarged cardiac silhouette and pulmonary edema. The patient's current symptomatology most likely occurred secondary to which of the following?\nA. Type III hypersensitivity reaction\nB. Coagulase activity\nC. Leukocidin activity\nD. Type I hypersensitivty reaction\nE. Molecular mimicry\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 46-year-old woman presents to her primary care physician with complaints of increasing left upper quadrant discomfort. She has a known history of type 1 Gaucher disease. On physical examination, her spleen is palpable 8 cm below the costal margin. Routine laboratory work reveals severe pancytopenia. After consultation with the patient on the risks of her condition, the patient decides to undergo a splenectomy. Which of the following is more likely to occur as a consequence of splenectomy in this patient?\nA. Anemia\nB. Pneumococcal septicemia\nC. Thrombocytopenia\nD. Staphylococcal septicemia\nE. Leukopenia\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 25-year-old male graduate student is brought to the emergency department for respiratory distress after he was found by his roommate coughing and severely short of breath. He was diagnosed with HIV infection 3 months ago but is not compliant with his antiretroviral therapy. He is from Chile and moved here 5 years ago. He appears unwell and is unable to speak in full sentences. His temperature is 38.2\u00b0C (100.7\u00b0F), pulse is 127/min, respirations are 32/min, and blood pressure is 95/65 mm Hg. Pulse oximetry shows an oxygen saturation of 86% on room air. No oral thrush is seen. The patient is placed on supplemental oxygen. Serum studies show:\nLactate dehydrogenase 364 IU/L\nCD4 cell count 98/mm3\nBeta-D-glucan elevated\nArterial blood gas analysis shows:\npH 7.50\nPaCO2 22 mm Hg\nPaO2 60 mm Hg\nHCO3 20 mEq/L\nAn x-ray of the chest is shown. Standard antibiotic therapy is begun immediately. The most appropriate next step in management is administration of which of the following?\"\nA. Amphotericin B\nB. Prednisone\nC. Isoniazid\nD. Azithromycin\nE. Filgrastim\nF. Antiretroviral therapy\n\"\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A clinical trial is being run with patients that have a genetic condition characterized by abnormal hemoglobin that can undergo polymerization when exposed to hypoxia, acidosis, or dehydration. This process of polymerization is responsible for the distortion of the red blood cell (RBC) that acquires a crescent shape and the hemolysis of RBCs. Researchers are studying the mechanisms of the complications commonly observed in these patients such as stroke, aplastic crisis, and auto-splenectomy. What kind of mutation leads to the development of the disease?\nA. Missense mutation\nB. Nonsense mutation\nC. Splice site\nD. Frameshift mutation\nE. Silent mutation\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-year-old girl is brought to a geneticist for evaluation after suffering a deterioration of physical and mental capabilities for the last year. She had developed normally for the first 6 months but then began to have progressive developmental delay. She was also found to have an exaggerated startle reflex. Physical exam reveals the finding shown in Figure A but is otherwise unremarkable. Electron microscopy of neurons and phagocytic cells, if performed, would have revealed the finding shown in Figure B. Which of the following enzymes is most likely deficient in this patient?\nA. Galactocerebrosidase\nB. Glucocerebrosidase\nC. Hexosaminidase A\nD. Iduronate sulfatase\nE. Sphingomyelinase\nAnswer:",
        "output": "C",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 74-year-old woman presents to the emergency department for shortness of breath and bilateral lower extremity pitting edema. She has had exacerbations like this in the past and notes that she has not been taking her home heart medications as scheduled. Review of systems is negative for any other symptoms including GI, urinary, and musculoskeletal symptoms. Physical exam reveals bilateral pulmonary crackles, lower extremity pitting edema that extends to the hip, and no abdominal tenderness. Neurological exam is unremarkable and the patient is at her baseline mental status. She is subsequently started on BiPAP, given furosemide, and admitted to the hospital. Routine admission workup includes urinalysis, which shows >100,000 cfu/mL of E. coli. She has no known drug allergies. Which of the following is the most appropriate treatment for this patient for this finding?\nA. Ceftriaxone\nB. Levofloxacin\nC. Nitrofurantoin\nD. No treatment\nE. Trimethoprim-sulfamethoxazole\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 27-year-old gravida 2, para 1 presents to her physician at 21 weeks gestation with decreased sensitivity, tingling, and pain in her right hand that is worse at night and is partially relieved by shaking her hand. She developed these symptoms gradually over the past month. She does not report any trauma to her extremities, neck, or spine. The physical examination shows a normal range of motion of the neck, spine, and extremities. On neurologic examination, the patient has 2+ biceps and triceps reflexes. She has decreased pressure and temperature sensitivity over the palmar surface of the 1st, 2nd, and 3rd fingers. Wrist flexion and tapping the skin over the flexor retinaculum trigger exacerbation of the symptoms. Which of the following statements about the patient\u2019s condition is correct?\nA. This is a fairly uncommon condition in pregnant women.\nB. Pre-pregnancy obesity increases risk of developing this condition during pregnancy.\nC. Corticosteroid injections are contraindicated in pregnant women for management of this condition.\nD. If this condition has occurred in the second or third trimester of pregnancy, it is unlikely to resolve after the completion of pregnancy.\nE. Immobilization (for example, splinting) should improve the reported outcome in this patient.\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old man with a history of coronary artery disease presents to your office complaining of ongoing chest pain with exertion. The patient has had a recent cardiac work-up that showed no areas of acute ischemia. At the last visit, the patient was prescribed sublingual nitroglycerin for symptom relief of stable angina. On further questioning, the patient states that he has been swallowing the tablet whole instead of allowing it to dissolve because he \u201cdoes not like the taste\u201d. What is the cause of the persistent symptoms?\nA. Coronary steal syndrome\nB. Nitroglycerin tolerance\nC. Unstable angina\nD. First pass metabolism of nitroglycerin\nE. Concomitant use of sildenafil\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 37-year-old woman comes to the physician because of a 10-month history of excessive daytime sleepiness and fatigue. She says she has difficulty concentrating and has fallen asleep at work on numerous occasions. She also reports having frequent headaches during the day. She has no difficulty falling asleep at night, but wakes up gasping for breath at least once. She has always snored loudly and began using an oral device to decrease her snoring a year ago. She has occasional lower back pain, for which she takes tramadol tablets 1\u20132 times per week. She also began taking one rabeprazole tablet daily 3 weeks ago. She does not smoke. She is 175 cm (5 ft 7 in) tall and weighs 119 kg (262 lb); BMI is 38.8 kg/m2. Her vital signs are within normal limits. Physical and neurologic examinations show no other abnormalities. Arterial blood gas analysis on room air shows:\npH 7.35\nPCO2 51 mm Hg\nPO2 64 mm Hg\nHCO3- 29 mEq/L\nO2 saturation 92%\nAn x-ray of the chest and ECG show no abnormalities. Which of the following is the most likely cause of this patient's condition?\"\nA. Apneic episodes with obstructed upper airways\nB. Drug-induced respiratory depression\nC. Reduced oxygen carrying capacity of blood\nD. Skeletal abnormality of the chest wall\nE. Chronic inflammatory airflow limitation\nF. Thickening of alveolar membranes\nG. Diurnal alveolar hypoventilation\n\"\nAnswer:",
        "output": "G",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 45-year-old woman comes to the emergency department with her 17-year-old son because she believes she has been poisoned by her ex-husband. She reports that her coffee tasted \u201cstrange\u201d this morning. After breakfast, she then saw a black car drive by the house, which she concludes must have been her ex-husband, who also drives a black car. She says that since the divorce 3 years ago, her ex-husband has been seeking revenge and thinks that he has installed cameras in her apartment to spy on her and their son. She has never seen any of these cameras but when she is alone in the apartment, she can sometimes hear them beeping and feel them recording her. The son also reports his mother's coffee mug smelled of bitter almonds, which he suspects was cyanide. He agrees with the mother's distrust towards his father and reports that he has also occasionally heard a camera beeping but has not been able to find any cameras yet. The mother's vital signs are within normal limits. Physical examination shows no abnormalities. Arterial blood gas analysis on room air shows a pH of 7.4. Toxicology screening is negative. Which of the following is the best initial step in management?\nA. Ziprasidone therapy\nB. Fluphenazine treatment\nC. Repetitive transcranial magnetic stimulation\nD. Examine mother and son separately\nE. Family therapy\nF. Cognitive behavioral therapy\nG. Report the case to the authorities\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 2-week-old infant is brought to the physician by her father because of a 1-week history of vaginal discharge. The discharge was initially clear, but now he notices that it is tinged with blood. The father is also concerned about \u201cbruises\u201d on his daughter's back and buttocks. Both parents work so that the infant spends most of her time in daycare or with her aunt. She was born at term following a pregnancy complicated by maternal gonococcal infection that was treated with antibiotics. She appears well. Physical examination shows mild acne across her cheeks and forehead. There are multiple large flat gray-blue patches on her back and buttocks. An image of one of the lesions is shown. Firm breast buds are present. Genitourinary examination shows erythema and swelling of the vulva and vagina with an odorless, blood-stained white discharge. Which of the following is the most appropriate next step in management?\nA. Contact Child Protective Services\nB. Reassurance\nC. Ceftriaxone and doxycycline therapy\nD. Leuprolide therapy\nE. Fluconazole therapy\nF. Ceftriaxone therapy\nG. MRI of the brain\nH. Order coagulation studies\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 4-month-old girl with Down syndrome is brought into the pediatrician\u2019s office by her father for her first well-child visit. The father states she was a home birth at 39 weeks gestation after an uneventful pregnancy without prenatal care. The child has not received any routine immunizations. The father states that sometimes when she is crying or nursing she \"gets a little blue\", but otherwise the patient is healthy. The patient is within the normal range of weight and height. Her blood pressure is 110/45 mm Hg, the pulse is 185/min, the respiratory rate is 25/min, and the temperature is 37.1\u00b0C (98.7\u00b0F). The physician notes an elevated heart rate, widened pulse pressure, and some difficulty breathing. On exam, the patient is playful and in no apparent distress. On lung exam, some faint crackles are heard at the lung bases without wheezing. Cardiac exam is significant for a harsh, machine-like murmur. An echocardiogram verifies the diagnosis. What is the next step in treatment of this patient?\nA. Antibiotics\nB. Indomethacin\nC. PGE2\nD. Emergent open heart surgery\nE. Heart transplant\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 58-year-old female, being treated on the medical floor for community-acquired pneumonia with levofloxacin, develops watery diarrhea. She reports at least 9 episodes of diarrhea within the last two days, with lower abdominal discomfort and cramping. Her temperature is 98.6\u00b0 F (37\u00b0 C), respiratory rate is 15/min, pulse is 67/min, and blood pressure is 122/98 mm Hg. Her physical examination is unremarkable. Laboratory testing shows:\nHb%   13 gm/dL\nTotal count (WBC):   13,400/mm3\nDifferential count:    \n  Neutrophils: 80%\n  Lymphocytes: 15%\n  Monocytes: 5%\nESR:   33 mm/hr\nWhat is the most likely diagnosis?\nA. Ulcerative colitis\nB. C. difficile colitis\nC. Irritable bowel syndrome\nD. Osmotic diarrhea\nE. Giardiasis\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 33-year-old woman is brought to the emergency department when she experienced sudden chest pain. The patient was visiting her husband on the oncology floor when she suddenly felt chest pain and became short of breath. The patient has a past medical history of asthma. Her temperature is 98.3\u00b0F (36.8\u00b0C), blood pressure is 129/61 mmHg, pulse is 129/min, respirations are 15/min, and oxygen saturation is 98% on room air. An ECG is performed as seen in Figure A, and a chest radiograph is performed as seen in Figure B. An initial set of cardiac troponins is notable for a value of 0.8 ng/mL and a D-dimer is elevated. Which of the following is the most likely diagnosis?\nA. Anxiety\nB. Myocardial infarction\nC. Prinzmetal angina\nD. Pulmonary embolism\nE. Stress cardiomyopathy\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 28-year-old woman comes to the emergency department because of increasing weakness and numbness of her legs for 3 days. She noticed that the weakness was more severe after she had a hot shower that morning. A year ago, she had an episode of partial vision loss in her left eye that resolved within 3 weeks. She is sexually active with 3 male partners and uses condoms inconsistently. She appears anxious. Her temperature is 37\u00b0C (98.6\u00b0F), pulse is 80/min, and blood pressure is 108/77 mm Hg. Examination shows spasticity and decreased muscle strength in bilateral lower extremities. Deep tendon reflexes are 4+ bilaterally. Plantar reflex shows an extensor response bilaterally. The abdominal reflex is absent. Sensation to vibration and position over the lower extremities shows no abnormalities. Tandem gait is impaired. MRI of the brain and spine is inconclusive. Further evaluation is most likely to show which of the following?\nA. Positive rapid plasma reagin test\nB. Demyelination on nerve biopsy\nC. Slow nerve conduction velocity\nD. Elevated intrinsic factor antibody level\nE. Oligoclonal bands in cerebral spinal fluid\nF. Positive ELISA for HIV\n\"\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 43-year-old man with a history of hepatitis C and current intravenous drug use presents with 5 days of fever, chills, headache, and severe back pain. On physical exam, temperature is 100.6 deg F (38.1 deg C), blood pressure is 109/56 mmHg, pulse is 94/min, and respirations are 18/min. He is thin and diaphoretic with pinpoint pupils, poor dentition, and track marks on his arms and legs. A high-pitched systolic murmur is heard, loudest in the left sternal border and with inspiration. He is admitted to the hospital and started on broad-spectrum antibiotics. One of the blood cultures drawn 12 hours ago returns positive for Staphylococcus aureus. Which of the following is the most appropriate next step to confirm the diagnosis?\nA. Repeat blood cultures now\nB. Repeat blood cultures 24 hours after initial cultures were drawn\nC. Repeat blood cultures 36 hours after initial cultures were drawn\nD. Repeat blood cultures 48 hours after initial cultures were drawn\nE. Do not repeat blood cultures\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 67-year-old man is brought to the physician because of increasing forgetfulness, unsteadiness, and falls over the past year. He reports that these symptoms seem to worsen with each fall. Initially, he could not remember directions to his home but now cannot remember recent conversations or appointments he has made. He often repeats questions that he asked shortly before. He has long-standing hypertension, coronary artery disease, and hypercholesterolemia. Current medications include aspirin, carvedilol, enalapril, and atorvastatin. Examination shows a bruise over the left temple and an unsteady gait. On mental status examination, he is oriented to place and person only. Short-term memory is impaired; he can recall 0 out of 5 objects after 10 minutes. Long-term memory is intact. He has no delusions or hallucinations. Muscle strength is decreased in the left lower extremity. The Babinski sign is present on the left. A CT scan of the head is shown. Which of the following is the most appropriate next step in management?\nA. Warfarin therapy\nB. Vitamin E therapy\nC. Cerebral shunting\nD. Tetrabenazine therapy\nE. Cognitive training\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 32-year-old woman comes to the physician for a screening health examination that is required for scuba diving certification. The physician asks her to perform a breathing technique: following deep inspiration, she is instructed to forcefully exhale against a closed airway and contract her abdominal muscles while different cardiovascular parameters are evaluated. Which of the following effects is most likely after 10 seconds in this position?\nA. Increased venous return to right atrium\nB. Increased venous return to left atrium\nC. Decreased systemic vascular resistance\nD. Decreased left ventricular stroke volume\nE. Decreased intra-abdominal pressure\nF. Decreased pulse rate\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 29-year-old man comes in for evaluation of infertility. He has been trying to conceive for over 2 years with his wife and previous evaluation of his wife's fertility revealed no abnormalities. Physical exam reveals a tall man with long extremities, sparse body hair, gynecomastia, and small testes. Laboratory studies reveal increased serum follicle-stimulating hormone concentration and an increased estradiol:testosterone ratio. Genetic studies reveal a cytogenetic abnormality. If this abnormality was inherited from the patient's father, at which stage of spermatogenesis did this error most likely occur?\nA. Primary spermatocyte\nB. Secondary spermatocyte\nC. Spermatid\nD. Spermatogonium\nE. Spermatozoon\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 62-year-old woman comes to the physician because of a 6-month history of progressive pain and stiffness of the fingers of her right hand. The stiffness is worse at the end of the day. She recently retired after working for 28 years as a typist at a data entry firm. Physical examination shows swelling, joint-line tenderness, and decreased range of motion of the first metacarpophalangeal joint and the distal interphalangeal joints of the right hand. Discrete, hard, mildly tender nodules are palpated over the 2nd and 4th distal interphalangeal joints of the right hand. An x-ray of her right hand shows narrowing of the interphalangeal joint spaces with subchondral sclerosis and osteophytes. Which of the following is the most likely underlying mechanism of this patient's condition?\nA. Monosodium urate crystal precipitation in the joints\nB. Bacterial infection of the joint space\nC. Autoimmune-mediated cartilage erosion\nD. Calcium pyrophosphate dihydrate crystal precipitation in the joints\nE. Degenerative disease of the joints\nAnswer:",
        "output": "E",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 65-year-old African-American man presents to your office with dysphagia. He reports that he has found it progressively more difficult to swallow food over the past year. At the time of presentation, he is able to eat only soup. Social history is significant for asbestos exposure, multiple daily drinks of hard alcohol, and a 70 pack-year smoking history. What would you most expect to see on an esophageal biopsy of this patient?\nA. Keratin nests and pearls\nB. Ferruginous bodies\nC. Glandular metaplasia\nD. Mucosal abrasions\nE. Esophageal varices\nAnswer:",
        "output": "A",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 34-year-old man comes to the physician for a routine health maintenance examination. He was diagnosed with HIV 8 years ago. He is currently receiving triple antiretroviral therapy. He is sexually active and uses condoms consistently. He is planning a trip to Thailand with his partner to celebrate his 35th birthday in 6 weeks. His last tetanus and diphtheria booster was given 4 years ago. He received three vaccinations against hepatitis B 5 years ago. He had chickenpox as a child. Other immunization records are unknown. Vital signs are within normal limits. Cardiopulmonary examination shows no abnormalities. Leukocyte count shows 8,700/mm3, and CD4+ T-lymphocyte count is 480 cells/mm3 (Normal \u2265 500); anti-HBs is 150 mIU/mL. Which of the following recommendations is most appropriate at this time?\nA. Hepatitis B vaccine\nB. Bacillus Calmette Guerin vaccine\nC. Tetanus, diphtheria vaccine\nD. Measles, mumps, rubella vaccine\nE. Yellow fever vaccine\nF. No vaccination\nAnswer:",
        "output": "D",
        "domain": "med",
        "task": "mc"
    },
    {
        "instruction": "The following are multiple choice questions (with answers) about medicine.",
        "input": "Question:A 57-year-old man presents with acute-onset nausea and left flank pain. He says his symptoms suddenly started 10 hours ago and have not improved. He describes the pain as severe, colicky, intermittent, and localized to the left flank. The patient denies any fever, chills, or dysuria. His past medical history is significant for nephrolithiasis, incidentally diagnosed 10 months ago on a routine ultrasound, for which he has not been treated. His family history is unremarkable. The patient is afebrile, and his vital signs are within normal limits. On physical examination, he is writhing in pain and moaning. Severe left costovertebral angle tenderness is noted. Gross hematuria is present on urinalysis. A non-contrast CT of the abdomen and pelvis reveals a 12-mm obstructing calculus at the left ureterovesical junction. Initial management, consisting of IV fluid resuscitation, antiemetics, and analgesia, is administered. Which of the following is the best next step in the management of this patient?\nA. Percutaneous nephrostomy\nB. Ureteroscopy\nC. Percutaneous nephrostolithotomy (PCNL)\nD. Extracorporeal shockwave lithotripsy (ESWL)\nE. 24-hour urine chemistry\nAnswer:",
        "output": "B",
        "domain": "med",
        "task": "mc"
    },
    {
        "input": "Patient is taking warfarin to prevent blood clots and has recently started taking amiodarone for heart arrhythmias.",
        "output": "Recommend dosage adjustments for warfarin due to its narrow therapeutic index. Potentially reducing warfarin dosage by 30-50% and monitoring blood clotting levels closely.",
        "instruction": "Given a patient's medical history and current medication regimen, recommend appropriate dosage adjustments for a medication with a narrow therapeutic index.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 30-year-old female presents with fatigue, joint pain, and a butterfly rash on her face. Potential diagnoses include lupus, rheumatoid arthritis, and Lyme disease.",
        "output": "The symptoms and risk factors suggest a potential diagnosis of lupus. Diagnostic tests include blood tests for antinuclear antibodies and lupus-specific biomarkers. Treatment options depend on the diagnosis and may include medication, physical therapy, and lifestyle changes.",
        "instruction": "Given a medical scenario and a list of potential diagnoses, evaluate the likelihood of each diagnosis based on the presented symptoms and recommend appropriate diagnostic tests and treatment options.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient's Current Condition and Medical History: A patient with mobility impairment due to multiple sclerosis. \\nQuestion: What type of assistive device or medical equipment should be recommended for this patient?",
        "output": "Based on the patient's condition and medical history, a mobility aid such as a cane, walker, or wheelchair may be recommended to improve the patient's independence and quality of life. It may also be helpful to provide training or support for using the device safely and effectively.",
        "instruction": "Given a patient's current condition and medical history, recommend a specific type of assistive device or medical equipment.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient was recently diagnosed with osteoporosis and is beginning treatment with medication.",
        "output": "Follow-up testing that may be recommended includes bone density scans and monitoring of calcium and vitamin D levels to ensure the medication is effectively reducing the risk of fractures.",
        "instruction": "Given a medical scenario and patient information, suggest appropriate follow-up testing.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical case history:\nAge: 65\nGender: Male\nMedical symptoms: Chest pain, shortness of breath, fatigue\nLaboratory values: Elevated troponin levels",
        "output": "Based on the medical case history provided, appropriate diagnostic tests to confirm a suspected myocardial infarction might include electrocardiogram, echocardiogram, stress test, coronary angiography, or cardiac magnetic resonance imaging.",
        "instruction": "Given a medical case history, suggest appropriate diagnostic tests to confirm a suspected medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient is a 60-year-old female with a history of smoking and a family history of heart disease.",
        "output": "Smoking cessation and regular exercise can significantly reduce the risk of heart disease. Limiting unhealthy foods, maintaining a healthy weight, and monitoring blood pressure and cholesterol levels can also help reduce risk. The patient should also consider medications such as aspirin or cholesterol-lowering drugs if recommended by their healthcare provider.",
        "instruction": "Based on the patient's medical history, suggest preventative measures or lifestyle changes that could reduce the patient's risk of heart disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical test results: \n- Serum creatinine levels: 1.5 mg/dL\n- Elevated blood pressure \n- Urine protein levels: 300 mg/day \nMedical history: A patient with a history of hypertension",
        "output": "These findings suggest the possibility of kidney damage due to hypertension. Further evaluation, including imaging studies such as ultrasound, is necessary to confirm the diagnosis. Blood pressure control is essential in this case, and adjustments to medication regimes may be necessary if the current medication is not effectively controlling blood pressure. The patient should also be advised on lifestyle interventions to manage hypertension, such as dietary modifications and increased physical activity. Referral to a nephrologist may be necessary for more specialized care if the condition is confirmed.",
        "instruction": "Given a set of medical test results and a patient's medical history, provide an interpretation of the findings and any recommended follow-up actions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Osteoarthritis (OA) affects millions of people worldwide, causing joint pain and reduced mobility. Although the precise mechanisms underlying OA development are not fully understood, several factors contribute to the progression of this disease. In this study, we investigated the role of a specific protein, Sirt1, in the development of OA and explored potential therapeutic strategies. Our results show that Sirt1 activates essential autophagy pathways responsible for maintaining cartilage health and inhibiting cellular stress mechanisms that contribute to OA progression. Furthermore, we found that the upregulation of Sirt1 in OA animal models significantly reduced the disease's severity, suggesting that targeting Sirt1 could be a potential therapeutic strategy for OA treatment.",
        "output": "This study shows that the protein Sirt1 plays a critical role in maintaining cartilage health in osteoarthritis and that upregulation of Sirt1 in animal models reduces disease severity, indicating its potential as a therapeutic target.",
        "instruction": "Summarize a given biomedical research abstract into a single, concise statement that highlights the main finding of the study.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "The main difference between a random control trial (RCT) and a cohort study is the study design. An RCT is an experimental study where participants are randomly assigned to either the treatment or control group, allowing researchers to evaluate the effectiveness of an intervention. A cohort study, on the other hand, is an observational study where a group of individuals with a particular exposure (or risk factor) is compared to another group without the exposure to evaluate the relationship between the exposure and the outcome of interest over time.",
        "instruction": "Describe the main difference between a random control trial and a cohort study in the context of medical research.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Condition: Coronary artery disease",
        "output": "Common risk factors for coronary artery disease include smoking, high blood pressure, high cholesterol, diabetes, obesity, physical inactivity, and family history of heart disease.",
        "instruction": "Find common risk factors for a given health condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient has been experiencing a headache for two days that gets worse when moving their head and is accompanied by vomiting and blurred vision.",
        "output": "Possible causes of the headache include tension headache, migraine, or more serious conditions such as subarachnoid hemorrhage. The patient should be immediately admitted to the hospital for further evaluation. Diagnostic tests may include CT scan or MRI of the brain, lumbar puncture, and tests to evaluate blood pressure and heart health.",
        "instruction": "Given a symptom or complaint, provide information about the possible causes and recommend further diagnostic tests or treatments.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The pathophysiology of chronic obstructive pulmonary disease (COPD) involves chronic inflammation and structural changes in the airways and lungs.",
        "output": "The underlying causes of chronic obstructive pulmonary disease (COPD) include long-term inflammation and changes to the structure of breathing passages and lungs.",
        "instruction": "Rewrite the provided sentence, removing any unnecessary medical jargon to make it more accessible to the general public.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A patient presents with a persistent cough, chest pain, and a low-grade fever. Chest x-ray shows an infiltrate in the left lower lobe of the lung.",
        "output": "The symptoms and x-ray findings are consistent with several potential diagnoses, including pneumonia, tuberculosis, or lung cancer. Diagnostic tests that might be used to confirm or rule out these diagnoses include sputum culture, chest CT or MRI, or a biopsy of the lung tissue. Further evaluation by a healthcare provider is recommended to determine the appropriate diagnostic tests and treatment plan.",
        "instruction": "Given a medical case, provide a differential diagnosis with explanations of potential diagnoses and relevant diagnostic tests to confirm or rule out the diagnoses.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "In vitro fertilization (IVF) is a complex series of procedures used to help with fertility or prevent genetic problems and assist with the conception of a child.",
        "output": "In vitro fertilization (IVF) is a process that helps people have a baby when they have trouble getting pregnant naturally. It involves joining a woman's egg and a man's sperm together in a laboratory, and then placing the fertilized egg back in the woman's womb to grow into a baby.",
        "instruction": "Explain the process of in vitro fertilization in a simplified manner suitable for a middle school student.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Wound location: on the patient's knee.",
        "output": "Wash your hands before touching the wound. Clean the wound with soap and warm water. Apply an antibiotic ointment and cover the wound with a sterile bandage. Change the bandage daily or sooner if it becomes wet or dirty.",
        "instruction": "Provide instructions on how to properly clean and care for a wound.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Type 2 diabetes medications: Metformin vs. Sulfonylureas",
        "output": "Metformin typically has fewer side effects and helps reduce blood sugar levels mainly by decreasing glucose production in the liver. It may also improve insulin sensitivity. Sulfonylureas work by stimulating the pancreas to release more insulin, but they have a greater risk of causing low blood sugar levels and weight gain compared to Metformin.",
        "instruction": "Give a comparison of two medications for the same medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Antibiotic resistance",
        "output": "Antibiotic resistance occurs when bacteria evolve to become resistant to the antibiotics that are used to treat infections caused by the bacteria, making it more difficult or impossible to treat the infection.",
        "instruction": "Provide a straightforward explanation of a commonly used medical term or phrase for a general audience.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A patient interested in understanding the role of the kidneys in the body, as well as potential health concerns related to kidney function.",
        "output": "The kidneys are responsible for filtering waste products from the blood and regulating the body's fluid balance. Symptoms of kidney disease can include fatigue, swelling in the feet or ankles, and changes in urination patterns. Kidney disease can be caused by a number of factors, including high blood pressure, diabetes, and infections. Treatment options can include medication to manage symptoms and slow the progression of the disease, as well as lifestyle changes such as dietary modifications.",
        "instruction": "Explain the function of the kidneys, and identify potential causes and symptoms of kidney disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "35-year-old female with no significant medical history, but has a family history of heart disease and smokes half a pack of cigarettes a day.",
        "output": "This patient has an increased risk of heart disease due to family history and smoking. Further evaluation and intervention are recommended.",
        "instruction": "Assess the risk level of a patient based on their age, medical history, and lifestyle factors.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "-",
        "output": "The interpretation and critical analysis of a medical study require a thorough understanding of statistical methods, research design, and the clinical implications of the results. It should involve a detailed evaluation of the study's methodology, sample size, data collection, and analysis, and a consideration of potential sources of bias and limitations of the study. Finally, it should provide a comprehensive and objective critique of the study's conclusions.",
        "instruction": "Interpret the results of a medical study and provide a critical analysis of the study's methodology and conclusions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What should a person with diabetes avoid eating to manage their blood sugar levels?",
        "output": "A person with diabetes should avoid foods high in added sugars, such as candy, pastries, and sugary drinks, as well as refined carbohydrates like white bread, pasta, and rice. It's also best to limit high-fat and high-sodium processed foods, as they can contribute to other health issues related to diabetes.",
        "instruction": "Given a food-related question, provide dietary advice for a specific medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "Type 1 diabetes is an autoimmune disorder where the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in little or no insulin production. It usually begins in childhood or adolescence. Type 2 diabetes is a metabolic disorder, characterized by insulin resistance and insufficient insulin production, usually developed in adulthood. Lifestyle factors, such as obesity, poor diet, and lack of exercise, contribute significantly to the development of type 2 diabetes.",
        "instruction": "Explain the difference between type 1 and type 2 diabetes.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "BRCA1",
        "output": "The BRCA1 gene produces a protein that helps repair damaged DNA and ensures the stability of a cell's genetic material, playing a critical role in preventing the development of certain cancers, such as breast and ovarian cancer.",
        "instruction": "Explain the function of the following gene in simple terms.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Symptoms: Sudden onset headaches, nausea, vomiting\nPast medical history: Hypertension, diabetes",
        "output": "The sudden onset of headaches, nausea, and vomiting suggest that the patient may be experiencing a serious medical condition, such as a stroke or meningitis. The patient's medical history of hypertension and diabetes further raises concern for a more severe condition. Therefore, urgent diagnostic tests such as CT scan or lumbar puncture must be carried out to quickly identify the possible causes of the headache.",
        "instruction": "Identify the potential causes of a patient's sudden onset of headaches and recommend appropriate diagnostic tests.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "Smoking increases the risk of cardiovascular diseases by damaging blood vessels and causing the buildup of plaque in the arteries. This can lead to atherosclerosis, a narrowing of the arteries, which restricts blood flow and can result in angina, heart attack, or stroke. Additionally, smoking reduces oxygen levels in the blood, forcing the heart to work harder to pump blood, and increases the risk of blood clotting, further raising the risk of cardiovascular events.",
        "instruction": "Explain how smoking can increase the risk of cardiovascular diseases.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A male patient aged 55 years old with a family history of heart disease.",
        "output": "Risk score: High risk for cardiovascular disease. \nRisk management strategies: Modify lifestyle and prescribe treatments to reduce risk factors, such as smoking cessation, blood pressure control, cholesterol-lowering medications, and aspirin therapy.",
        "instruction": "Given a patient\u2019s demographics and medical history, calculate their risk score for a specific condition and determine the appropriate risk management strategies.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient data comprising age, body mass index (BMI), family history of diabetes, and diet and exercise habits.",
        "output": "Predict the onset of diabetes based on the patient's data, recommend appropriate lifestyle changes, and advise on preventative or management strategies for the condition.",
        "instruction": "Given a set of patient data, predict the onset of diabetes and recommend lifestyle changes to prevent or manage the condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What should a patient with chronic obstructive pulmonary disease (COPD) know about the condition and potential treatments?",
        "output": "COPD is a chronic respiratory condition typically caused by long-term exposure to irritants such as cigarette smoke or environmental pollutants. Symptoms may include coughing, wheezing, shortness of breath, and chest tightness. Treatment options may include medications to manage symptoms and slow disease progression, lifestyle changes such as quitting smoking or avoiding environmental triggers, and pulmonary rehabilitation to improve lung function and overall health.",
        "instruction": "Given a complex medical diagnosis or condition, provide clear and concise patient education on potential causes, symptoms, and treatment options.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "In the study titled \"Stem Cell-Derived Exosomes for Wound Healing: Current Status and Promising Directions,\" researchers isolated exosomes derived from mesenchymal stem cells (MSCs) as a promising regenerative medicine treatment for severe wound healing. The study results indicated MSC-derived exosomes significantly promoted wound closure and accelerated tissue regeneration, showing excellent potential for clinical application in wound healing.",
        "output": "Researchers studied the potential of mesenchymal stem cell-derived exosomes as a treatment for severe wound healing and found promising results. The treatment accelerated tissue regeneration and promoted wound closure, indicating potential for clinical application.",
        "instruction": "Summarize a recent research study in regenerative medicine in two sentences.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What are some foods that should be avoided if I have celiac disease?",
        "output": "Foods that should be avoided if you have celiac disease include wheat, barley, and rye, as well as any products that contain these ingredients. Gluten-free alternatives are available for many common foods.",
        "instruction": "Provide a list of foods to avoid for a patient with a specific medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Beta-blockers",
        "output": "Main side effects of beta-blockers include fatigue, dizziness, slow heart rate (bradycardia), low blood pressure (hypotension), cold hands and feet, depression, and in some cases, breathing difficulties, particularly in patients with asthma or chronic obstructive pulmonary disease (COPD).",
        "instruction": "For the given drug class, list the main side effects.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical condition: Seasonal allergies.\nSymptom: Runny nose.",
        "output": "Over-the-counter medications like loratadine and cetirizine can be taken to alleviate runny nose caused by seasonal allergies.",
        "instruction": "Given a medical condition and symptom, recommend over-the-counter medications to alleviate the symptom.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "Foods that may contribute to increased inflammation in the body include refined carbohydrates like white bread and pastries, fried foods, processed meats, sugary drinks, red meat, and trans fats found in processed foods and margarine.",
        "instruction": "Provide a list of common foods that may contribute to increased inflammation in the body.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Scenario: A patient has ingested a toxic substance.",
        "output": "Call emergency services immediately and provide as much information about the substance ingested as possible. If the patient is conscious and able to swallow, give them a small amount of water to dilute the toxin. Do not induce vomiting unless instructed to do so by a medical professional. Keep the patient calm and monitor for any changes in their condition until medical help arrives.",
        "instruction": "Given a medical scenario, provide first aid or emergency treatment instructions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Diagnostic Tests: Electrocardiogram (ECG), Chest X-Ray, Lipid Profile",
        "output": "Recommendation: Based on the diagnostic tests, the patient may be at risk of cardiovascular disease. Further testing may include stress testing, echocardiography, or coronary angiography, depending on the clinical findings. Additionally, referral to a cardiologist or specialist in lipid management may be necessary for optimization of care.",
        "instruction": "Given a set of diagnostic tests, recommend appropriate follow-up actions, such as further testing or referral to specialty care.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient has recently undergone hip replacement surgery. What are the potential complications associated with this procedure, and how can the patient monitor for those complications?",
        "output": "Potential complications associated with hip replacement surgery may include infection, blood clots, nerve damage, or implant failure. The patient can monitor for signs of infection, such as fever, increased pain or redness at the surgical site, or discharge from the site. They should also monitor for any signs of blood clots, such as swelling or pain in the affected leg, shortness of breath, or chest pain. Any signs of nerve damage, such as numbness or weakness in the leg or foot, should be reported to the healthcare provider immediately. Finally, any signs of implant failure, such as pain or instability in the joint, should also be reported to the healthcare provider.",
        "instruction": "Given a list of potential complications associated with a medical condition or procedure, advise the patient on how to monitor for those complications.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Risk factor: High blood pressure",
        "output": "High blood pressure increases the likelihood of developing cardiovascular disease as it puts extra strain on the blood vessels and heart, causing them to work harder than necessary. This continuous strain increases the risk of damage to the blood vessels and heart tissue, leading to conditions such as heart attack, stroke, heart failure, or kidney disease. Additionally, consistently high blood pressure can cause the arteries to stiffen and narrow from a buildup of plaque, further increasing the risk of cardiovascular events.",
        "instruction": "Given a risk factor, explain how it increases the likelihood of developing cardiovascular disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 45-year-old patient has a family history of heart disease and is a smoker with high cholesterol.",
        "output": "To reduce the patient's risk of cardiovascular disease, it's recommended that they quit smoking, maintain a healthy diet, and exercise regularly. Medications may also be prescribed to lower cholesterol and blood pressure. Regular monitoring and follow-up visits are important for assessing progress and adjusting the treatment plan as needed.",
        "instruction": "Given a patient's medical history and lifestyle factors, provide recommendations for reducing the risk of cardiovascular disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Dosage instructions: Take one 500 mg tablet orally every 8 hours for 7 days.",
        "output": "Take one pill every 8 hours for a week.",
        "instruction": "Convert the given dosage instructions into simpler terms for a patient to understand.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Term: Peripheral neuropathy",
        "output": "Peripheral neuropathy refers to a condition in which the nerves outside the central nervous system (brain and spinal cord) are damaged or not functioning properly, often causing weakness, numbness, and pain, usually in the hands and feet.",
        "instruction": "Given a medical term from a text, provide its simplified explanation intended for a non-medical person.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Symptoms: Joint pain and stiffness in the hands and feet. Medical history includes a family history of rheumatoid arthritis.",
        "output": "The symptoms and medical history suggest the possibility of rheumatoid arthritis. Further testing and evaluation such as a rheumatoid factor blood test or joint imaging may be necessary to confirm the diagnosis and determine the appropriate course of treatment.",
        "instruction": "Given a set of symptoms and medical history, suggest any necessary testing or evaluations.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient takes Simvastatin for high cholesterol and Metformin for type 2 diabetes. They are also allergic to penicillin.",
        "output": "It is important to avoid taking medications that may interact negatively with Simvastatin or Metformin, such as certain antibiotics and antifungal medications. Possible alternatives may need to be explored, based on the patient's medical conditions and allergies.",
        "instruction": "Given a medication history and medical conditions, identify potential medication interactions and recommend alternatives.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 45-year-old woman presents with recurrent migraines. She experiences a migraine attack every week and has tried over-the-counter analgesics without improvement. She has been previously diagnosed with mild hypertension.",
        "output": "For this patient, we would recommend a treatment plan that includes lifestyle changes and medication. Suggested lifestyle changes include stress management, adequate sleep, and regular exercise. For acute migraine attacks, triptans or nonsteroidal anti-inflammatory drugs (NSAIDs) would be appropriate. For prophylactic treatment, beta-blockers, calcium channel blockers, or angiotensin receptor blockers may be used for hypertension control and migraine prevention. Additionally, botox injections or nerve stimulation may be considered in refractory cases.",
        "instruction": "Given a patient case and standard guidelines, recommend a treatment plan for a common condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient's medical case: 55-year-old male with a diagnosis of hypertension, hypercholesterolemia, and atrial fibrillation.",
        "output": "Follow-up/referral care: Frequent monitoring of the blood pressure, lipid levels, and anticoagulation therapy. Referral to an electrophysiologist for further evaluation and management of atrial fibrillation. Lifestyle modification and medication adherence counseling should also be provided.",
        "instruction": "Given a patient's medical case, suggest any necessary follow-up or referral care.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Scenario: A patient with type 2 diabetes presents with hypoglycemia.\nSymptoms: sweating, tremors, and confusion.",
        "output": "The appropriate intervention for hypoglycemia in a patient with type 2 diabetes is to provide a source of glucose, such as a glucose tablet or a sugary drink. If the patient is unable to consume anything orally, glucagon should be administered by an injectable form, which would increase the glucose levels in the patient's blood. The patient's blood glucose levels should be monitored closely after the intervention.",
        "instruction": "Given a medical scenario and a set of symptoms, provide the appropriate medical intervention to manage the condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Drug X may cause dizziness, nausea, headache, fatigue, dry mouth, muscle pain, and blurred vision.",
        "output": "Side effects of drug X include dizziness, nausea, headache, fatigue, dry mouth, muscle pain, and blurred vision.",
        "instruction": "Summarize the side effects of drug X.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "The key principles of the Hippocratic Oath include treating patients to the best of one's ability, maintaining patient confidentiality, respecting the boundaries between patients and healthcare providers, avoiding harm, and prioritizing the welfare and dignity of the patient.",
        "instruction": "Explain the key principles of the Hippocratic Oath, an ethical guide for medical professionals.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient has a family history of heart disease.",
        "output": "It is recommended that the patient take preventative measures such as maintaining a healthy diet, exercising regularly, quitting smoking, and managing stress to reduce their risk of developing heart disease.",
        "instruction": "Recommend a preventative action or measure a patient can take to improve their health.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient has recently been diagnosed with neoplasm of uncertain behavior of endocrine glands.",
        "output": "The patient has recently been diagnosed with an abnormal growth in the hormone-producing glands, but it's unclear if it's cancerous or not.",
        "instruction": "Translate complex medical jargon or terminology into simpler language that patients can understand.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical history of a patient with elevated blood pressure, family history of cardiovascular disease, and current symptoms of chest pain and shortness of breath.",
        "output": "Based on the patient's medical history and current symptoms, further testing and evaluation are necessary to rule out any underlying cardiovascular conditions. Possible tests and treatments might include an electrocardiogram (ECG), echocardiogram, or stress test. An appropriate referral to a cardiologist is recommended.",
        "instruction": "Given a patient's medical history and current symptoms, identify any potential underlying conditions or diseases and recommend further testing or treatment.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical alert: Patient has a severe allergy to penicillin.",
        "output": "The healthcare provider should avoid prescribing penicillin and consider alternative antibiotics if necessary. They should also inform other healthcare providers involved in the patient's care about the allergy to avoid the risk of an allergic reaction.",
        "instruction": "Given a medical alert, recommend appropriate actions for the healthcare provider.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Avoid taking your hypertension medication concomitantly with grapefruit or grapefruit products.",
        "output": "Don't take your blood pressure medicine at the same time as eating or drinking grapefruit or grapefruit products.",
        "instruction": "Paraphrase the given medical instruction to make it more understandable for patients.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The stages of Alzheimer's disease include preclinical, mild cognitive impairment (MCI), mild dementia, moderate dementia, and severe dementia.",
        "output": "The stages of Alzheimer's disease are:\n1. No symptoms but changes developing in the brain.\n2. Minor memory problems, but not affecting daily life.\n3. Mild memory loss and struggles with daily tasks.\n4. More serious memory loss and trouble with daily activities.\n5. Severe memory loss and needing help with nearly all activities.",
        "instruction": "Express the stages of a specific disease in simpler terms, focusing on symptoms and progression.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Avoid close contact with people who are sick. Stay at home when you are unwell. Wear a mask when social distancing measures are difficult to maintain. Wash your hands regularly for at least 20 seconds with soap and water.",
        "output": "Stay away from those who are unwell to protect yourself. Prioritize your health by staying home when you're not feeling well. Always wear a mask to safeguard yourself and others when you can't keep your distance. Keep your hands clean by washing them frequently and thoroughly using soap and water for a full 20 seconds.",
        "instruction": "Identify the key points in the given public health campaign message and rephrase them in a persuasive manner.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Adult patient with frequent ear infections",
        "output": "Recurring ear infections in adults can be caused by a variety of factors, such as allergies, smoking, or exposure to irritants like polluted air or swimming pools. To prevent future infections, patients should avoid these triggers, keep ears dry, and practice good hygiene, such as washing hands regularly and avoiding sharing personal items like earbuds or headphones.",
        "instruction": "Identify potential causes of a patient's recurring ear infections and suggest preventative measures.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient: My doctor prescribed me an antidepressant medication. What are some potential risks I should be aware of?",
        "output": "Antidepressants can have several potential risks, including increased suicidal thoughts in young adults, sexual dysfunction, weight gain, and interactions with other medications or substances. It is important to closely monitor your symptoms and notify your doctor if you experience any unwanted side effects.",
        "instruction": "Summarize the potential risks of a specific medication for a patient.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Current probiotics research papers",
        "output": "Recent research suggests that probiotics can have a positive effect on gut health, particularly in alleviating symptoms of irritable bowel syndrome. However, more research is needed to fully understand the benefits and optimal usage of probiotics as a supplement.",
        "instruction": "Provide a summary of the latest research on the effectiveness of probiotics for improving gut health.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient was diagnosed with gastroesophageal reflux disease (GERD).",
        "output": "The patient has acid reflux.",
        "instruction": "Simplify a long medical term for a patient.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Reducing salt intake",
        "output": "Effective; reducing salt intake helps lower blood pressure and can be an important part of managing hypertension.",
        "instruction": "Evaluate the effectiveness of the given lifestyle modification for managing hypertension.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Risk factor: Obesity. Disease: Type 2 diabetes.",
        "output": "Obesity is a major risk factor for developing type 2 diabetes because excess body fat, particularly in the abdominal area, can cause the body to become resistant to insulin, a hormone that regulates blood sugar levels. Over time, this insulin resistance can result in consistently high blood sugar levels, leading to the development of type 2 diabetes.",
        "instruction": "Explain the connection between a risk factor and a specific disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Scenario: A patient with diabetes presents with uncontrolled blood sugar and concerns about their ability to manage their condition.",
        "output": "Plan of Care:\n- Assess the patient's current blood sugar levels and determine appropriate medication adjustments or changes.\n- Provide patient education and resources for diabetes management, including meal planning, glucose monitoring, and medication adherence.\n- Refer the patient to a diabetes educator or other healthcare professional for additional support and follow-up.",
        "instruction": "Given a medical scenario, outline a plan of care that addresses the patient's needs and concerns.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Health issue: Common cold",
        "output": "To manage the common cold, get plenty of rest, drink fluids to stay hydrated, use a humidifier to ease congestion, take over-the-counter pain relievers and decongestants as needed, and soothe a sore throat with warm liquids like tea or soup. Additionally, practice good hygiene, such as washing your hands frequently, to avoid spreading the cold to others.",
        "instruction": "Provide self-care recommendations for a minor health issue.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Disease: Parkinson's disease",
        "output": "Parkinson's disease is a progressive, nervous system disorder that affects movement. Common symptoms include tremors or shaking, trouble with balance and coordination, and stiff muscles. Some risk factors for Parkinson's disease include age, gender, genetics and exposure to certain toxins.",
        "instruction": "Provide a brief overview of the given disease or condition. Include common symptoms and potential risk factors.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Condition: Insomnia",
        "output": "Management: Establish a regular sleep schedule, avoid caffeine and alcohol, create a relaxing sleep environment, practice relaxation techniques such as deep breathing or meditation, cognitive behavioral therapy for insomnia (CBT-I).",
        "instruction": "Provide recommendations for managing insomnia, including non-pharmacological approaches.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "1. Gastroesophageal reflux disease (GERD)\n2. Myocardial infarction (MI)",
        "output": "1. Acid reflux or heartburn\n2. Heart attack",
        "instruction": "Simplify the provided complex medical terms for a layperson to understand better.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Procedure: Colonoscopy.",
        "output": "1. Follow a low-fiber diet a few days before the procedure 2. Complete a prescribed bowel preparation the day before 3. Stay hydrated by drinking clear liquids 4. Avoid solid food the day before the procedure 5. Arrange for someone to drive you home after the colonoscopy.",
        "instruction": "Provide advice on how a patient can prepare for a specific medical procedure.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The study revealed that participants who received the experimental drug showed a significant increase in high-density lipoprotein (HDL) levels, also known as \"good cholesterol,\" and a decrease in triglycerides. These effects suggest that the drug might have potential benefits in improving the lipid profile and overall cardiovascular health in patients with dyslipidemia.",
        "output": "The study found that the experimental drug helped increase \"good cholesterol\" levels and reduce unhealthy fats in the blood. This could lead to better heart health for patients with abnormal lipid levels.",
        "instruction": "Summarize the findings of a given biomedical research study in simple language.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 35-year-old male with severe chest pain and difficulty breathing.",
        "output": "The patient should be immediately triaged as a level 1 emergency due to the severity of his symptoms, which may indicate a heart attack or other life-threatening condition.",
        "instruction": "Given a medical scenario, determine the appropriate triage level based on the severity of the patient's condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Male patient, 35 years old, weight: 80 kg, height: 1.8 m",
        "output": "BMI = 80/(1.8^2) = 24.69",
        "instruction": "Given the age and sex of a patient, calculate BMI by filling in the blanks in the following formula: BMI = weight (kg) / (height (m))^2.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What are the best practices for healthcare settings to prevent the spread of infectious diseases like COVID-19?",
        "output": "The best practices to prevent the spread of infectious diseases in a healthcare setting include frequent handwashing, wearing appropriate personal protective equipment, disinfection of surfaces and equipment, social distancing, and screening of patients for symptoms before any treatment.",
        "instruction": "Provide a list of best practices for preventing the spread of a highly infectious disease in a healthcare setting.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Myocardial infarction, commonly referred to as a heart attack, occurs when blood flow to a part of the heart is blocked, usually by a blood clot, causing damage or death to the heart muscle cells due to the lack of oxygen and nutrients.",
        "output": "A heart attack, or myocardial infarction, happens when the blood supply to a part of the heart gets blocked, often by a blood clot. This blockage can damage or even kill the heart muscle cells because they don't get enough oxygen and nutrients.",
        "instruction": "Rewrite the following scientific statement in plain language without losing the main information.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What is diabetes and what are common symptoms?",
        "output": "Diabetes is a condition in which the body is unable to properly regulate blood sugar levels. Common symptoms include increased thirst and urination, fatigue, blurry vision, and slow healing of cuts and wounds.",
        "instruction": "Given a specific health condition or disease, provide a brief definition and common symptoms.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient has a history of GERD and takes omeprazole daily. They are currently experiencing a headache and stuffy nose.",
        "output": "For temporary relief of headaches, acetaminophen (Tylenol) is safe for most people with GERD. It's important to avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil) or aspirin, which can worsen GERD symptoms. For a stuffy nose, an antihistamine like loratadine (Claritin) or cetirizine (Zyrtec) may be helpful.",
        "instruction": "Given a patient's current medication list and medical conditions, recommend over-the-counter medications to manage their symptoms.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Lab results: Hemoglobin A1C 9%, fasting blood sugar 165 mg/dL, LDL cholesterol 160 mg/dL, triglycerides 200 mg/dL.\nClinical history: Patient with type 2 diabetes, overweight, sedentary lifestyle.",
        "output": "Interpretation: Poorly controlled diabetes with elevated LDL cholesterol and triglycerides.\nRecommendations: Optimize diabetes management with medications and lifestyle changes, initiate statin therapy for LDL control, and encourage healthy eating and regular exercise to improve cholesterol and triglyceride levels. Additional testing for complications of diabetes may also be necessary.",
        "instruction": "Given a patient's lab results and clinical history, provide an interpretation of the results and recommend further testing or treatment.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "Eat smaller, more frequent meals; avoid spicy, fatty, or acidic foods; limit caffeine, chocolate, and alcohol; eat slowly and chew food thoroughly; and avoid lying down for at least 2-3 hours after eating. Drinking water or herbal tea after meals may also help.",
        "instruction": "Develop dietary recommendations for a patient with gastroesophageal reflux disease (GERD).",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "None needed.",
        "output": "Vaccines work by introducing a small, harmless piece of a pathogen (like a virus or bacteria) to the body. This piece stimulates an immune response in the body, which then learns how to recognize and fight off the actual pathogen if it enters the body in the future. Different vaccines work in slightly different ways, depending on the pathogen they're designed to protect against. Some vaccines contain weakened or inactivated pathogens, while others contain pieces of a pathogen's proteins called antigens.",
        "instruction": "Explain the differences between vaccines and how they work in the body to prevent infection.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Lab test: fasting blood glucose level of 150 mg/dL",
        "output": "A fasting blood glucose level of 150 mg/dL indicates that the patient may have hyperglycemia, potentially indicating diabetes. Follow-up testing and evaluation may be warranted to confirm the diagnosis and determine the appropriate course of treatment.",
        "instruction": "Given a specific lab test result, interpret the result and provide any necessary follow-up or recommendations for treatment.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "This is a medical consent form for a colonoscopy procedure.",
        "output": "A colonoscopy is an exam where a small camera is used to look inside the colon. The procedure may be uncomfortable for some patients and generally requires a special diet. The potential benefits include detecting and preventing colon cancer at an early stage. However, rare complications such as bleeding, puncture of the intestine, and infection are possible risks.",
        "instruction": "Given a medical consent form, summarize the key information and possible risks and benefits of the medical procedure in an understandable language for the patient.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Complaint: Persistent cough \\nSymptoms: Cough with yellow-green phlegm, shortness of breath, wheezing, chest tightness, fever",
        "output": "Possible Diagnoses: Bronchitis, pneumonia, or asthma flare-up\\nFollow-up Tests: Chest X-ray, sputum culture, lung function tests",
        "instruction": "Given a patient's complaint and specific symptoms, suggest possible diagnoses and follow-up tests.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Suspected diagnosis: Multiple sclerosis\nSymptoms and findings: vision problems, difficulty walking, abnormal brain MRI showing demyelinating lesions",
        "output": "Based on the patient's symptoms and MRI findings, a spinal tap or lumbar puncture would be an appropriate diagnostic test to confirm the suspected diagnosis of multiple sclerosis. The test involves taking a sample of cerebrospinal fluid from the lower back and analyzing it for signs of inflammation and immune system activity.",
        "instruction": "Based on the patient's current symptoms and test results, recommend an appropriate diagnostic test to confirm the suspected diagnosis.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "(No input)",
        "output": "- \"Type 1 Diabetes\": \"Onset: Typically in childhood or adolescence; Main causes: Autoimmune destruction of insulin-producing beta cells; Treatment options: Insulin injections or pump, blood glucose monitoring, carbohydrate counting, and healthy diet\"\n- \"Type 2 Diabetes\": \"Onset: Typically in adulthood, but can occur in children; Main causes: Insulin resistance and reduced insulin secretion; Treatment options: Lifestyle changes (diet, exercise), oral medications (like metformin), insulin injections (if needed), blood glucose monitoring\"",
        "instruction": "Describe the major differences between type 1 and type 2 diabetes, including onset, main causes, and treatment options.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Symptoms: diarrhea, abdominal pain, and fever",
        "output": "Based on the symptoms presented, the most probable diagnosis is acute gastroenteritis. Treatment options include rehydration, anti-diarrheal medications, and symptomatic relief for pain and fever. If symptoms persist or worsen, further evaluation may be necessary to rule out other potential causes.",
        "instruction": "Given a list of symptoms, identify the most probable diagnosis and provide the relevant treatment options.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Type 2 Diabetes",
        "output": "1. Assess symptoms: frequent urination, increased thirst, unexplained weight loss, and fatigue. 2. Fasting plasma glucose test: measure blood sugar levels after an eight-hour fast. 3. Oral glucose tolerance test: check blood sugar levels two hours after consuming a glucose-containing beverage. 4. HbA1c test: measure average blood sugar levels for the past two to three months. 5. Evaluate risk factors: family history, obesity, physical inactivity, high blood pressure, and age.",
        "instruction": "List five key steps in diagnosing a specific medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Irritable bowel syndrome (IBS)",
        "output": "Symptoms of IBS include abdominal pain, bloating, gas, diarrhea or constipation, or alternating between the two. Treatment options include dietary changes, such as eating low-FODMAP foods, stress management techniques, regular exercise, and medications (like antispasmodics, laxatives, or antidiarrheals)",
        "instruction": "Summarize the typical symptoms and treatment options for patients diagnosed with irritable bowel syndrome (IBS).",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient is taking a combination of insulin and metformin for type 2 diabetes and enalapril for high blood pressure.",
        "output": "Potential side effects or drug interactions to be aware of include hypoglycemia (low blood sugar) from the insulin and metformin, and kidney damage or electrolyte imbalance from the enalapril. Regular monitoring and follow-up with the patient's healthcare provider is necessary to ensure the medications are safe and effective.",
        "instruction": "Given a patient's medical history and prescribed medications, suggest potential side effects or drug interactions to be aware of.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A groundbreaking new drug for Alzheimer's disease was recently approved by the FDA. The drug, called Aducanumab, is a monoclonal antibody that targets amyloid-beta plaques in the brain, which are believed to contribute to the development of Alzheimer's disease. In clinical trials, the drug showed a significant reduction in amyloid plaques and a slight improvement in cognitive function in some patients. However, the drug's approval was not without controversy, as some experts argue that the evidence of its effectiveness is inconclusive. The new medication is expensive and requires monthly infusions, potentially limiting its accessibility to some patients.",
        "output": "The FDA recently approved Aducanumab, a new Alzheimer's drug that targets amyloid-beta plaques in the brain. Clinical trials showed reduced plaques and slight cognitive improvement in some patients, but the drug's effectiveness is debated. The expensive medication requires monthly infusions, potentially affecting patient accessibility.",
        "instruction": "Provide a concise summary of the recent study about the new Alzheimer's drug.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Title: \"Effectiveness of a mindfulness-based stress reduction intervention in patients with chronic pain\"",
        "output": "The study aimed to investigate the effectiveness of a mindfulness-based stress reduction intervention in reducing chronic pain in patients. Results showed that the intervention was associated with significant decreases in pain severity and pain interference, as well as improvements in various measures of psychological well-being.",
        "instruction": "Given a journal article or medical study, provide a summary of the main findings.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What is a health promotion strategy for preventing obesity in children?",
        "output": "A health promotion strategy for preventing obesity in children includes encouraging regular physical activity, promoting healthy eating habits with balanced meals, limiting screen time, and educating both children and parents about the importance of a healthy lifestyle.",
        "instruction": "Summarize a health promotion or disease prevention strategy for a specific population.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "1. Unhealthy diet (high in salt or saturated fats)\n2. Physical inactivity\n3. Family history of hypertension",
        "instruction": "Provide three examples of risk factors for high blood pressure.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Clinical guideline for the use of anticoagulation in atrial fibrillation states that patients with a CHA2DS2-VASc score of 2 or more should receive anticoagulation therapy unless contraindicated. The same guideline recommends the use of direct oral anticoagulants (DOACs) as first-line therapy in eligible patients.",
        "output": "The patient's CHA2DS2-VASc score and comorbidities should be considered when making anticoagulation decisions. DOACs are generally preferred over warfarin due to their similar efficacy and reduced risk of bleeding and drug interactions. However, individual patient factors such as renal function, other medications, and bleeding risk should be taken into account when selecting a specific DOAC and dosing regimen. Additionally, patient education and monitoring are crucial to ensure compliance, correct dosing, and timely follow-up for potential adverse effects.",
        "instruction": "Given a set of clinical guidelines for a medical procedure or intervention, interpret the guidelines and suggest appropriate adjustments for individual patient factors.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Context: Define the term \"myocardial infarction.\" \\nExample of use: \"Myocardial infarction, also known as a heart attack, may cause chest pain, sudden fatigue or shortness of breath.\"",
        "output": "Myocardial infarction is a serious medical condition referring to the death or damage of heart muscle tissue. An example of use is \"Myocardial infarction, also known as a heart attack, may cause chest pain, sudden fatigue or shortness of breath.\"",
        "instruction": "Define the following medical terms and provide an example of their use in a clinical setting.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient has a history of breast cancer and has undergone surgery and chemotherapy. A recent PET/CT scan shows no evidence of metastasis but reveals new suspicious lesions in the lungs.",
        "output": "The presence of new suspicious lesions in the lungs may indicate disease progression or metastasis of breast cancer. The prognoses and long-term outcomes depend on various factors, such as the stage of the cancer, the response to previous treatments, and the overall health status of the patient. Further diagnostic tests, such as biopsy or MRI, may be necessary to confirm the diagnosis and determine the appropriate treatment options.",
        "instruction": "Given a patient's clinical history and imaging test result, provide potential prognoses and long-term outcomes.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient presents with cough, fever, and shortness of breath for the past five days. They also report fatigue and muscle aches.",
        "output": "Based on the symptoms, the likely diagnosis is acute bronchitis. The recommended treatment plan includes rest, plenty of fluid intake, cough suppressants, and over-the-counter pain relievers. Antibiotics are not usually required for this condition as it is often viral and resolves within two to three weeks.",
        "instruction": "Given a list of symptoms and their duration, provide a likely diagnosis and the appropriate treatment plan.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "In a recent study published in the New England Journal of Medicine, researchers found that the combination of drug A and B demonstrated significant efficacy in fighting pancreatic cancer, reducing tumor size and increasing survival rates in patients during the clinical trials.",
        "output": "A recent study showed that combining two drugs could help fight pancreatic cancer by shrinking tumors and increasing patients' chances of living longer.",
        "instruction": "Summarize a medical research article into a concise statement suitable for a layman.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient was administered intravenous immunoglobulin to palliate their autoimmune-mediated thrombocytopenic purpura symptoms.",
        "output": "The patient was given a special medicine through their veins to relieve the symptoms of their rare blood disorder caused by an immune system problem.",
        "instruction": "Rewrite the following medical sentence in a simpler and more understandable way for a general audience.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Blood glucose: 210 mg/dL (Normal: 70-100 mg/dL)\nBlood pressure: 150/95 mm Hg (Normal: <120/80 mm Hg)\nCholesterol: 250 mg/dL (Normal: <200 mg/dL)",
        "output": "The patient has elevated blood glucose, high blood pressure, and high cholesterol levels, indicating potential issues like diabetes, hypertension, and an increased risk of heart disease.",
        "instruction": "Analyze a patient's lab results and provide a general interpretation.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient experiences prolonged fatigue, weight gain, and hair thinning.",
        "output": "These symptoms may be indicative of hypothyroidism. To confirm the diagnosis, the patient should undergo a thyroid function test and consult with a doctor for further evaluation and treatment.",
        "instruction": "Given a description of a patient's symptoms, provide information on potential causes and how to proceed for diagnosis.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient presents with severe abdominal pain, nausea, and vomiting. Medical history includes a history of ulcers and recent use of pain medication.",
        "output": "The patient's symptoms suggest a possible gastrointestinal emergency and require urgent medical attention. Treatment could include medication to manage symptoms and possible surgical intervention, if necessary.",
        "instruction": "Given a patient's symptoms and medical history, determine the severity of their condition and recommend an appropriate course of action.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient diagnosed with type 2 diabetes and hypertension.",
        "output": "To improve their condition, the patient should adopt a healthier diet low in sugar and sodium, increase physical activity, maintain a healthy weight, and manage stress effectively.",
        "instruction": "Given the diagnosis of a patient, suggest lifestyle changes that may improve their condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Research findings related to effective interventions for substance abuse treatment",
        "output": "Effective substance abuse treatment interventions may include cognitive-behavioral therapy, medication-assisted treatment, and peer support groups. It's important for healthcare providers to provide individualized and culturally sensitive care, as well as ongoing support and follow-up to prevent relapse. Consult with established guidelines for more detailed recommendations and strategies for treating substance abuse.",
        "instruction": "Given a set of medical guidelines or research findings, summarize key points and provide recommendations for healthcare providers.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 45-year-old male patient with a family history of colon cancer is concerned about his risk of developing the disease. He does not have any current symptoms.",
        "output": "Based on the patient's family history and age, he is at an increased risk of developing colon cancer. Recommended preventative measures include regular colon cancer screenings, maintaining a healthy weight, incorporating plenty of fiber into the diet, decreasing alcohol intake, quit smoking, and increasing physical activity.",
        "instruction": "Given a patient history, provide preventative recommendations to reduce the risk of developing a specific condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Parkinson's disease",
        "output": "Common signs and symptoms of Parkinson's disease include tremors, slow movement, stiffness, and difficulties with balance and coordination. Patients may also experience changes in speech and handwriting, reduced ability to smell, depression, anxiety, and sleep disturbances.",
        "instruction": "Given a medical condition or disease, explain the signs and symptoms that a patient may experience.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient presents with persistent cough, hemoptysis, weight loss, and chest pain.",
        "output": "1. \"Potential cause\": \"Lung cancer\", \"Follow-up tests\": \"Chest X-ray, CT scan, bronchoscopy, and biopsy\"\n2. \"Potential cause\": \"Tuberculosis\", \"Follow-up tests\": \"Chest X-ray, sputum culture, and interferon-gamma release assay (IGRA)\"\n3. \"Potential cause\": \"Pneumonia\", \"Follow-up tests\": \"Chest X-ray, blood cultures, and sputum gram stain\"",
        "instruction": "List three potential causes for the given symptoms and provide appropriate follow-up tests or examinations to confirm each potential cause.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Clinical guideline for the prevention of postoperative infections.",
        "output": "Critique of implementation reveals some discrepancies between the guideline and actual practice, including inadequate use of prophylactic antibiotics, improper surgical technique, and poor infection control measures. Potential improvements include better education and training for healthcare providers, increased surveillance and monitoring of infections, and improved use of evidence-based recommendations.",
        "instruction": "Given a clinical guideline or protocol, provide a critique of its implementation in practice and recommend potential improvements.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "In the US, paracetamol is known as acetaminophen, and a common brand name is Tylenol.",
        "instruction": "Convert the generic drug name to its corresponding US brand name: paracetamol.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Diagnosis: Rheumatoid arthritis. Current treatment plan includes methotrexate.",
        "output": "Potential side effects or interactions with this medication may include liver toxicity or interactions with other medications. Appropriate follow-up care may include regular blood tests and close monitoring for any potential adverse reactions.",
        "instruction": "Given a patient's diagnosis and current treatment plan, recommend potential side effects or interactions and appropriate follow-up care.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "Osmosis is a natural process where water moves across a barrier, like a cell membrane, to balance the concentration of dissolved substances on both sides. Water will flow from an area with fewer dissolved substances to an area with more dissolved substances until the concentration is equal on both sides. This process helps maintain proper balance and hydration within cells and tissues.",
        "instruction": "Explain the process of osmosis in simple language that a non-expert can understand.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "An 18-year-old female with no significant medical history presented with a two-week history of severe headache, photophobia, and neck stiffness. Physical examination was significant for nuchal rigidity and positive Kernig's and Brudzinski's signs. A lumbar puncture was performed, revealing an elevated opening pressure and a predominant lymphocytic pleocytosis with increased proteins and slightly low glucose levels. The patient was diagnosed with aseptic meningitis, and after intensive supportive treatment, she had a complete resolution of her symptoms within a week.",
        "output": "A previously healthy 18-year-old female experienced severe headache, photophobia, and neck stiffness for two weeks. Doctors found signs of meningitis on physical examination and confirmed the diagnosis through a lumbar puncture. Despite intensive supportive treatment, the patient fully recovered within a week.",
        "instruction": "Summarize the main points of the medical case report.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Breast cancer",
        "output": "\"Breast cancer treatment\" OR \"breast cancer screening\" OR \"breast cancer surgery\" OR \"breast cancer diagnosis\" OR \"breast cancer incidence\" OR \"breast cancer risk factors\" OR \"breast cancer prevention\"",
        "instruction": "Generate a search query for finding relevant research articles on a given medical topic.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medication: Aspirin\nMedical History: History of gastric ulcers",
        "output": "Aspirin is generally not recommended for individuals with a history of gastric ulcers as it can exacerbate the condition. Consult with a healthcare provider for alternative options.",
        "instruction": "Given a specific medication name and patient medical history, provide recommendations on whether the medication is safe for use.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Regularly engaging in physical exercise can help maintain good health and improve overall well-being.",
        "output": "Exercising often helps you stay healthy, makes you feel better, and helps you live a longer, happier life.",
        "instruction": "Explain the benefits of a healthy habit in a simple, easy-to-understand manner.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Title: \"Case study: Advanced pancreatic cancer\"",
        "output": "Plan of Care: In a case of advanced pancreatic cancer, treatment goals typically focus on symptom management and maintenance of quality of life. Palliative care should be initiated early in the disease course to address symptoms such as pain, malnutrition, and psychological distress. Chemotherapy and other systemic agents may be used to prolong survival and symptom control when appropriate. The patient and family should be counseled on end-of-life issues and given appropriate psychological support. Additionally, referral to hospice or supportive care services may be considered to provide comprehensive management and symptom control.",
        "instruction": "Given a medical case study, develop a plan of care that takes into account the patient's medical history, diagnosis, and overall health goals.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient has a history of arthritis and experiences joint pain and stiffness.",
        "output": "Low-impact exercises such as swimming, yoga, or cycling may be recommended to improve mobility and manage arthritis pain. Physical therapy may also be recommended to develop a personalized plan for stretching and strengthening muscles and joints.",
        "instruction": "Given a patient's medical history and current condition, recommend appropriate exercises or physical therapy to improve mobility and manage pain.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Scientific articles and peer-reviewed research studies related to the surgical procedure in question.",
        "output": "The surgical procedure may be associated with potential risks and side effects such as bleeding, infection, pain, or damage to surrounding structures. Depending on the procedure, there may also be risks associated with anesthesia or post-operative recovery. Patients should discuss these risks and potential complications with their surgeon prior to undergoing the procedure.",
        "instruction": "Summarize the potential side effects and risks associated with a specific surgical procedure.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What is the role of the cerebellum in the human brain?",
        "output": "The cerebellum, located at the back of the brain, is responsible for coordinating muscle movements, maintaining balance, and regulating posture. It ensures that movements are smooth, precise, and well-timed.",
        "instruction": "Given a question about a specific aspect of human anatomy, provide a brief and clear explanation.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Mrs. Thompson, a 72-year-old female, has a history of hypertension and was recently diagnosed with depression. She is currently taking lisinopril for hypertension. What are the potential interactions with an antidepressant and lisinopril? What alternative medications can she take?",
        "output": "There are potential interactions between antidepressants and lisinopril that can lead to hypotensive effects. Alternative antidepressant medications that are safer to take with lisinopril include SSRIs. Medical advice should still be sought before making any changes to medication.",
        "instruction": "Given a patient's medication history and current medical condition, determine any potential interactions and recommend alternative medications.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "QID, PO, PRN.",
        "output": "QID means four times a day, PO means by mouth, and PRN means as needed. These are common medical terms used to indicate medication dosages and frequency.",
        "instruction": "Given a set of medical terminology or abbreviations, explain their meaning to a layperson.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Breakfast: Bagel with cream cheese, orange juice. Lunch: Cheeseburger, fries, and a soda. Dinner: Fried chicken, mashed potatoes with gravy, and chocolate cake for dessert. Snack: Potato chips.",
        "output": "The current plan has several issues: simple carbohydrates, high-fat food, and sugary drinks. Suggested improvements: \n\nBreakfast: Replace the bagel with whole-grain bread, and choose a side of fruit instead of orange juice. \nLunch: Swap the cheeseburger for a grilled chicken sandwich, replace fries with a side salad, and drink water.\nDinner: Opt for grilled chicken, use steamed vegetables as a side, and select a fruit-based dessert.\nSnack: Choose nuts or low-fat yogurt instead of potato chips.",
        "instruction": "Assess the given dietary plan for a diabetic patient, and provide suggestions for improvements based on key diabetes dietary guidelines.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient is a 25-year-old female with a history of depression and anxiety. She presents with fatigue, insomnia, and poor appetite. She reports using marijuana daily to manage her symptoms.",
        "output": "Marijuana use can have significant effects on mental health, including worsening depression and anxiety symptoms, as well as impacting sleep and appetite. The patient should be evaluated for substance use disorder and referred to a mental health specialist for further treatment and support. Non-pharmacological interventions such as cognitive-behavioral therapy and mindfulness-based interventions may be recommended to improve coping strategies and overall well-being. In addition, lifestyle modifications such as regular exercise, healthy diet, and stress reduction techniques should be emphasized.",
        "instruction": "Given a patient's medical history and symptoms, identify any potential contributing factors to the patient's health and provide appropriate recommendations.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Warfarin",
        "output": "1. Monitor the patient's International Normalized Ratio (INR) regularly to ensure they are within the therapeutic range and adjust the dosage as needed to prevent over- or under-anticoagulation.\n2. Educate the patient to avoid over-the-counter medications, herbal supplements, or sudden changes in their diet without consulting their healthcare provider, as these may interact with warfarin and affect its efficacy or cause adverse reactions.",
        "instruction": "Provide two precautions that should be taken when administering the given medication.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "TITLE: Prenatal exposure to maternal smoking and ADHD in offspring\\n\\nABSTRACT: This prospective study aimed to examine the association between maternal smoking during pregnancy and the risk of ADHD in offspring. A total of 4,731 mother-child pairs from a population-based cohort in the Netherlands were followed from early pregnancy through 6 years of age. Mothers were interviewed during pregnancy regarding smoking habits, and children were followed up with questionnaires mailed to their parents at ages 2, 3, and 6. The adjusted odds ratio for ADHD in children prenatally exposed to maternal smoking was 1.71 (95% CI: 1.22-2.39) compared with unexposed children. No association was seen for paternal smoking. The results suggest that prenatal exposure to maternal smoking is associated with an increased risk for ADHD in offspring, independent of paternal smoking and other confounders.",
        "output": "Children exposed to maternal smoking during pregnancy have an increased risk of ADHD, according to a study of 4,731 mother-child pairs in the Netherlands.",
        "instruction": "Create a summary of the given medical abstract.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Pathology report with biopsy results",
        "output": "Based on the biopsy results, the pathology report classifies the tumor as malignant. Further evaluation and treatment is recommended.",
        "instruction": "Classify a given pathology report as benign or malignant.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Surgical Procedure: Appendectomy",
        "output": "An appendectomy is a surgical procedure in which the appendix is removed. Prior to the procedure, the patient will likely need to fast and undergo various diagnostic tests such as ultrasounds or CT scans. During the procedure, general anesthesia will be administered and the surgeon will either make several small incisions or one larger incision in the abdomen to remove the appendix. After the procedure, the patient will need to rest and follow doctor's orders for pain management and wound care.",
        "instruction": "Provide a brief overview of a specific surgical procedure, including what preparations are necessary and what the patient can expect during and after the procedure.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "None required",
        "output": "Type 1 diabetes is an autoimmune condition where the body's immune system attacks and destroys the cells in the pancreas that make insulin, leading to an insulin deficiency. Type 2 diabetes, on the other hand, is a condition where the body becomes resistant to the effects of insulin or does not produce enough insulin to maintain normal blood glucose levels.",
        "instruction": "Provide a simplified explanation of the difference between Type 1 and Type 2 diabetes, tailored to a layman's understanding.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Test: Hemoglobin",
        "output": "The normal hemoglobin range is typically 12.0-15.5 g/dL for adult women and 13.5-17.5 g/dL for adult men.",
        "instruction": "Express the normal range for a specific laboratory test.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Atrial fibrillation",
        "output": "Atrial fibrillation is a type of irregular heartbeat, where the upper chambers of the heart beat rapidly and out of sync with the lower chambers.",
        "instruction": "Explain the provided medical term in simple, non-technical language.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient\u2019s medical history: Family history of diabetes, BMI of 30, elevated fasting blood glucose levels.",
        "output": "Based on the patient\u2019s risk factors, they may be at increased risk for developing diabetes. Preventive measures may include lifestyle changes such as a healthy diet, exercise, and weight loss, as well as regular monitoring of blood sugar levels. Medications such as metformin may also be recommended to reduce the risk of diabetes.",
        "instruction": "Given a patient\u2019s medical history and test results, calculate their risk for certain health conditions and recommend appropriate preventive measures.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Demographics: 28 year old female, non-smoker, non-drinker, healthy weight. Medical history: generally healthy, but has a family history of cancer.",
        "output": "It is recommended that you maintain a healthy lifestyle and continue to stay at a healthy weight. Due to your family history of cancer, regular screenings and check-ups are recommended. Please consult with your healthcare provider to determine the appropriate types and frequency of screenings.",
        "instruction": "Given a patient's demographics and medical history, provide personalized health advice.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "For a person with iron-deficiency anemia, it is recommended to consume a diet rich in iron sources such as red meat, poultry, fish, beans, lentils, tofu, fortified cereals, and dark leafy greens. Additionally, they should incorporate foods high in vitamin C, like citrus fruits, tomatoes, or bell peppers, to enhance iron absorption. Avoid excessive caffeinated beverages, as they may hinder iron absorption.",
        "instruction": "Provide general dietary advice for a person with iron-deficiency anemia.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "High blood pressure, blurry vision, frequent urination, excessive thirst",
        "output": "The symptoms suggest a possible case of uncontrolled hypertension and undiagnosed diabetes mellitus. A healthcare professional should be consulted for further evaluation and appropriate tests.",
        "instruction": "Analyze these symptoms and provide a possible diagnosis: consistently high blood pressure readings, blurry vision, frequent urination, and excessive thirst.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "\u03b2-Amyloid (A\u03b2) peptide is a key pathological hallmark of Alzheimer's disease. A\u03b2 accumulates mainly in the form of extracellular amyloid plaques, which disrupt synapses and promote neuroinflammation. Reducing A\u03b2 aggregation and deposition could be a key therapeutic strategy for Alzheimer's disease. Various factors, including astrocytes and microglia, regulate amyloidogenic pathways, and targeting those factors could represent novel therapeutic interventions.",
        "output": "The buildup of a protein called \u03b2-amyloid is closely linked to Alzheimer's disease. This protein forms clumps outside brain cells, causing harmful effects such as damage to connections between cells and brain inflammation. Treatment that helps reduce these clumps might be an effective way to treat Alzheimer's. Some cells in the brain can control the processes that lead to \u03b2-amyloid clumps, so targeting these cells might open up new ways to treat the disease.",
        "instruction": "Rewrite the given passage for a lay audience by simplifying the technical terms and concepts.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "Benefits of telemedicine:\n1. Improved access: Telemedicine allows patients in remote or underserved areas to receive care without having to travel long distances.\n2. Cost savings: Virtual visits can be more cost-effective for both patients and healthcare providers, as they eliminate travel expenses and can reduce the need for in-person visits.\n3. Convenience: Patients can receive a consultation from the comfort of their own homes, which may be particularly advantageous for individuals with limited mobility or chronic conditions.\n4. Increased patient engagement: Telemedicine provides an opportunity for better communication and follow-up between healthcare providers and patients, which may improve adherence to treatment plans and overall health outcomes.\n\nPotential drawbacks of telemedicine:\n1. Limited physical examination: Some conditions may require a hands-on physical assessment that is not possible through a virtual visit.\n2. Technical challenges: Patients and providers may face difficulties with technology, internet connectivity, or lack of familiarity with telemedicine platforms.\n3. Privacy concerns: There are potential risks to patient privacy and security if telemedicine platforms are not adequately protected.\n4. Reimbursement and regulatory issues: Disparities in reimbursement policies and varying state telemedicine regulations may impact the availability or consistency of telemedicine services.",
        "instruction": "Summarize the key benefits and potential drawbacks of telemedicine.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical reports show elevated liver enzymes and ultrasound reveals gallstones. Patient has no symptoms.",
        "output": "Further evaluation is needed to determine the best course of treatment. Options may include monitoring the patient's symptoms, recommending a low-fat diet, or referring the patient to a gastroenterologist for further evaluation and possible surgical intervention.",
        "instruction": "Given a set of medical reports, determine the next steps in the patient's treatment plan.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Alzheimer's disease",
        "output": "Alzheimer's disease typically progresses through three stages: early (mild), middle (moderate), and late (severe) stage. In the early stage, the person may experience mild memory loss and difficulty concentrating. In the middle stage, memory loss worsens, and the person may have difficulty recognizing family members, performing daily tasks, or making decisions. In the late stage, the person requires full-time care, loses the ability to communicate, and experiences severe cognitive decline.",
        "instruction": "Describe the various stages of a specific illness or disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient is taking Warfarin, 5mg and Aspirin, 81mg.",
        "output": "Combining warfarin and aspirin can increase the risk of bleeding, as both medications can interfere with the body's ability to form blood clots. Patients taking both medications should be closely monitored for signs of bleeding, and the dosage of one or both medications may need to be adjusted to minimize the risk of complications. It is important to discuss any potential medication interactions with a healthcare provider to ensure safe and effective treatment.",
        "instruction": "Given a list of medications and dosages, check for potential drug interactions and explain the potential risks and implications of any interactions found.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Use of corticosteroids for managing chronic inflammatory diseases.",
        "output": "Potential risks associated with long-term use of corticosteroids can include osteoporosis, diabetes, hypertension, and susceptibility to infections.",
        "instruction": "Identify the potential risks associated with long-term use of corticosteroids for managing chronic inflammatory diseases.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Social anxiety disorder",
        "output": "Social anxiety disorder is a mental health condition characterized by a persistent, intense fear of being judged, embarrassed, or negatively evaluated in social situations, which can significantly interfere with daily life activities.",
        "instruction": "Provide a brief definition of the given psychological disorder.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "Kidneys are bean-shaped organs that have the job of filtering waste and excess substances from the blood. They produce urine to remove these substances from the body, help control blood pressure, and keep the right balance of water, salts, and minerals in the blood. Kidneys also help in producing hormones necessary for various body functions, including making red blood cells and keeping bones healthy.",
        "instruction": "Explain the role of kidneys in the human body in simple language without using scientific jargon.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Mammogram",
        "output": "Preparation may include avoiding using deodorant or antiperspirant on the day of the mammogram and wearing comfortable, accessible clothing. Follow-up care may include a breast examination or biopsy depending on the results of the mammogram and individual factors.",
        "instruction": "Given a medical procedure, explain the necessary preparation and follow-up care for patients.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient presents with persistent cough and shortness of breath. Chest x-ray is inconclusive.",
        "output": "Based on the symptoms and inconclusive chest x-ray, the appropriate testing method to rule out or diagnose a potential respiratory condition may be a CT scan of the chest. Please consult a healthcare provider for further evaluation and testing.",
        "instruction": "Given a medical scenario, identify the appropriate testing or imaging method to diagnose or rule out a particular medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Symptoms: Nausea, vomiting, diarrhea, abdominal pain, fever.\nConditions: Hypertension, hypothyroidism, depression.\nCurrent medications: Lisinopril, levothyroxine, sertraline.",
        "output": "Potential medication contraindications or interactions: Sertraline can cause gastrointestinal side effects and interact with levothyroxine. Modification to the treatment plan: Consider switching to an alternative antidepressant with less gastrointestinal side effects, monitor thyroid function and adjust levothyroxine dose if necessary.",
        "instruction": "Given a set of patient-provided symptoms and conditions, identify potential medication contraindications or interactions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Condition: Rheumatoid Arthritis \\n Treatments: Non-steroidal anti-inflammatory drugs (NSAIDs), Corticosteroids, Disease-modifying antirheumatic drugs (DMARDs), Biologic agents \\n Patient: 45-year-old female, active lifestyle, no prior history of gastrointestinal issues",
        "output": "Recommended treatment: Disease-modifying antirheumatic drugs (DMARDs) or Biologic agents, as they target the underlying disease process and can help prevent joint damage, allowing the patient to maintain an active lifestyle. Consult a rheumatologist for a specific treatment plan.",
        "instruction": "Given a list of medical treatments for a specific condition, recommend the most appropriate treatment option based on a patient's individual profile.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient's history: 65-year-old female with a history of stage 3 chronic kidney disease, hypertension, and gout. Allergy to sulfa drugs. Current medications: hydrochlorothiazide, lisinopril, and allopurinol.",
        "output": "Alternative medication: Losartan. It is an angiotensin receptor blocker (ARB) that can help control blood pressure without affecting the kidneys. It is not a sulfa drug and does not interact with allopurinol (a medication commonly used to treat gout).",
        "instruction": "Given a patient's medical history, allergies and current medication list, suggest a potential alternative medication.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Title: The Role of Gut Microbiome in the Development of Obesity and Diabetes\nAbstract: The human gut microbiome plays a significant role in maintaining host health through its metabolic, immunological, and endocrine functions. Recent studies have shown that alterations in gut microbiota composition, referred to as dysbiosis, are associated with the development of obesity and diabetes. The underlying mechanisms include increased energy extraction, altered gut hormone secretion, increased intestinal permeability, and systemic inflammation. This review article provides an overview of the current understanding of the role of gut microbiome in obesity and diabetes pathogenesis and discusses potential therapeutic strategies for targeting gut microbiota to combat these metabolic disorders.",
        "output": "This review discusses how alterations in the gut microbiome contribute to obesity and diabetes development and explores potential therapies targeting gut microbiota to combat these disorders.",
        "instruction": "Summarize the provided biomedical article title and abstract into a single sentence.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient's TSH level is 7.5 mIU/L (normal range: 0.4-5.0 mIU/L).",
        "output": "The patient's TSH level is elevated, suggesting possible hypothyroidism. Recommend checking free T4 levels to confirm the diagnosis and consider thyroid ultrasound if necessary.",
        "instruction": "Provide a suggestion for further investigation based on a lab result.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Heart failure",
        "output": "Heart failure occurs when the heart is unable to pump enough blood to meet the body's needs. Current treatment options can include medication, lifestyle changes, and in severe cases, surgical intervention or heart transplant. Close monitoring and management of symptoms is important to prevent complications and improve quality of life.",
        "instruction": "Provide an overview of a specific disease and current treatment options.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Treatment option 1: Surgery\nTreatment option 2: Physical therapy",
        "output": "The better treatment option depends on the specific medical condition and patient factors, but both surgery and physical therapy can be effective. Generally, physical therapy is less invasive and has fewer potential side effects than surgery and can be a good first-line treatment option.",
        "instruction": "Given two potential treatment options for a medical condition, recommend the better option based on established efficacy and side effect profiles.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Why is it recommended to get a flu shot every year?",
        "output": "The flu virus changes every year, and getting a flu shot helps to protect against the strains of the virus that are currently in circulation.",
        "instruction": "Given a medical recommendation, explain the reason for it.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Depression",
        "output": "Supportive therapies and self-care practices such as psychotherapy, cognitive-behavioral therapy, group therapy, regular exercise, and maintaining a healthy diet may help to alleviate symptoms of depression. Medications may also be prescribed by a healthcare provider as part of the treatment plan. It is important to regularly follow up with a healthcare provider to ensure the treatment plan is effective.",
        "instruction": "Given a diagnosis or condition, provide recommendations for supportive therapies or self-care practices.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Endocrinologist",
        "output": "An endocrinologist is a doctor who specializes in diagnosing and treating hormone-related disorders and conditions in the body.",
        "instruction": "Describe the given healthcare professional's role in simple terms.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medication: Warfarin",
        "output": "For safe use, take Warfarin at the same time each day, as prescribed by your doctor. Avoid sudden changes in dietary habits or vitamin K intake, and inform your healthcare professionals about any other medications, supplements, or over-the-counter drugs you take. Store Warfarin in its original container, away from heat, moisture, and light, and keep it out of reach of children and pets.",
        "instruction": "Offer guidance for the safe use and storage of a medication.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient is a 50-year-old male with no history of cancer. Family history of colon cancer.",
        "output": "Based on the patient's demographic information and medical history, the patient may benefit from cancer screening for colon cancer. Screening options may include colonoscopy, fecal occult blood testing, or stool DNA testing. Further evaluation and consultation with a healthcare provider is recommended to determine the appropriate screening frequency and modality based on individual risk factors.",
        "instruction": "Given a set of patient demographic information and medical history, provide guidelines for cancer screening.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Describe the primary function of a colonoscopy.",
        "output": "The primary function of a colonoscopy is to visually examine the inner lining of the colon and rectum to check for pre-cancerous polyps, cancers, or other abnormalities in the large intestine. It helps in the early detection, diagnosis, and prevention of colorectal cancer and can also be used to diagnose inflammatory bowel disease and other gastrointestinal conditions.",
        "instruction": "Describe the primary function or purpose of a specific medical examination.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Terms- Atherosclerosis, ischemia, hypertension, hyperlipidemia, thrombosis.",
        "output": "Atherosclerosis- a buildup of plaque within the arteries that can lead to circulation issues and heart problems. Ischemia- a lack of oxygen flow to an area of the body, which can cause tissue damage or death. Hypertension- high blood pressure, which can lead to heart disease, stroke, or organ damage. Hyperlipidemia- high levels of \u201cbad\u201d cholesterol in the body, which can increase the risk of heart disease. Thrombosis- an abnormal blood clot formation that can lead to blockages and serious health complications. These medical terms all play a significant role in understanding and treating cardiovascular disease.",
        "instruction": "Given a set of medical terminology, provide a brief overview of each term and their relevance in the biomedical domain.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "45-year-old female with abdominal pain and bloating",
        "output": "Common medical tests include blood tests, abdominal ultrasound, pelvic ultrasound, CT scan, colonoscopy, and endoscopy. Consult a healthcare professional for appropriate diagnosis and testing.",
        "instruction": "Given a patient's age, gender, and symptom, provide a list of common medical tests that could help diagnose their condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What precautionary measures can be followed in a healthcare setting to prevent the transmission of COVID-19?",
        "output": "To prevent the transmission of COVID-19 in a healthcare setting, the following measures are recommended: frequent hand washing, using hand sanitizer with at least 60% alcohol, wearing personal protective equipment like masks and gloves, maintaining proper distancing when possible, disinfecting surfaces regularly, proper disposal of waste, following respiratory hygiene/cough etiquette, and adhering to infection control guidelines specified by health authorities.",
        "instruction": "Suggest appropriate precautionary measures to follow in a healthcare setting to prevent the spread of infection.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Metformin, 500 mg twice daily, for the management of type 2 diabetes.",
        "output": "Metformin is a medication that helps to lower blood sugar levels in people with type 2 diabetes. It should be taken twice a day, with meals, as prescribed by your doctor.",
        "instruction": "Given a medication and dosage, explain to the patient the purpose of the medication and how to take it.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Obesity is a major public health problem and a significant risk factor for the development of diseases such as type 2 diabetes, cardiovascular diseases, and various types of cancer. Recent studies suggest that changes in the gut microbiota may play an important role in the onset of obesity; however, the mechanisms through which these microbial alterations contribute to obesity remain largely unexplored. In this study, we examined the effects of gut microbiota transplantation from lean donors to mice with diet-induced obesity. Our results show that gut microbiota transplantation significantly improved glucose tolerance, increased good bacteria, and reduced body weight gain in recipient mice. These findings suggest that modulating the gut microbiota may represent a promising therapeutic strategy for obesity and related metabolic diseases.",
        "output": "The study investigates the role of gut microbiota in obesity by transplanting it from lean donors to diet-induced obese mice. Results show improved glucose tolerance, increased good bacteria, and reduced weight gain in recipient mice, suggesting that gut microbiota modulation may be a potential therapy for obesity and related diseases.",
        "instruction": "Summarize the abstract of a scientific paper from the biomedical field.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient is a 45-year-old smoker with a family history of heart disease, high blood pressure, and high cholesterol. The patient has no significant medical problems but is concerned about long-term health risks.",
        "output": "Recommendation for the patient should include quitting smoking, regular physical activity, and a heart-healthy diet to lower the risk of heart disease, high blood pressure, and high cholesterol. Screening tests such as a lipid panel, blood pressure checks, and cardiac stress tests should be performed regularly. The patient should also be advised to receive vaccinations for influenza and pneumonia to prevent respiratory infections.",
        "instruction": "Given a patient's personal and medical history, provide recommendations for preventive health measures, such as diet and lifestyle changes, screenings, and immunizations.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "HPI, ROS, PMH, FH, SH",
        "output": "HPI - History of Present Illness - a summary of the patient's current symptoms and how they developed. \\n ROS - Review of Systems - a checklist of symptoms in different body systems to assess the patient's overall health. \\n PMH - Past Medical History - a record of the patient's previous and ongoing health conditions. \\n FH - Family History - a record of the patient's family members and their known medical conditions. \\n SH - Social History - a record of the patient's lifestyle factors, such as smoking, alcohol use, and occupation.",
        "instruction": "Given a list of common abbreviations used in electronic health records (EHR), expand and explain each one in simple language.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical instructions: use an inhaler to treat asthma symptoms",
        "output": "To use an inhaler to treat asthma symptoms, remove the cap and shake the inhaler. Hold the inhaler about one inch from your mouth and breathe out fully. As you start to breathe in slowly, press down on the button on the inhaler to release a puff of medication. Hold your breath for 10 seconds, then breathe out slowly. Repeat as needed, but follow your healthcare provider's instructions for when and how often to use your inhaler.",
        "instruction": "Given a set of medical instructions, explain them to a patient in clear and concise language.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Positron emission tomography (PET) scan",
        "output": "A positron emission tomography (PET) scan is an imaging technique that uses a small amount of radioactive material, called tracers, to visualize body tissues and show how organs and tissues are functioning. It is commonly used to detect cancer, evaluate response to cancer treatment, and examine brain function in neurological disorders.",
        "instruction": "Provide a concise definition of a specific diagnostic imaging technique.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What is hospital readmission rate?",
        "output": "Hospital readmission rate is a measure of the percentage of patients who are hospitalized within a certain period of time (usually 30 days) after being discharged from an initial hospitalization. High readmission rates may indicate poor care coordination, inadequate discharge planning, or other systemic issues. It may also lead to increased healthcare costs, patient dissatisfaction, and poor health outcomes. Healthcare providers and leaders can use this measure to identify areas for improvement and implement interventions to reduce readmissions and improve patient care.",
        "instruction": "Given a healthcare quality measure or performance metric, describe the importance and implications for healthcare providers and patients.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Myocardial infarction",
        "output": "Heart attack",
        "instruction": "Simplify the given medical term by providing its everyday counterpart or a more easily understood description.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Diagnosis: Gout\nMedical History: Obesity, high blood pressure",
        "output": "Appropriate lifestyle modifications may include weight loss, limiting alcohol intake, decreasing intake of purine-rich foods, and increasing hydration. Follow-up care may include ongoing monitoring of uric acid levels and medications to manage gout attacks.",
        "instruction": "Given a diagnosis and relevant medical history, suggest appropriate lifestyle modifications or follow-up care.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The study aimed to investigate the effects of a 12-week aerobic exercise program in patients with mild cognitive impairment (MCI). 80 participants aged 55-75 were randomly assigned to an exercise group or control group. The exercise group participated in an aerobic exercise program with moderate intensity, three times a week for 12 weeks. The control group received no additional intervention beyond standard care. The researchers assessed cognitive function, processing speed, and memory performance before and after the intervention using a battery of tests. The findings revealed a significant improvement in cognitive function, processing speed, and memory performance in the exercise group compared to the control group.",
        "output": "A 12-week aerobic exercise program with moderate intensity for patients with mild cognitive impairment (MCI) resulted in significant improvements in cognitive function, processing speed, and memory performance compared to a control group who received standard care.",
        "instruction": "Summarize the findings and results of a given biomedical research study or clinical trial.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient medical record: 70-year-old male admitted for pneumonia in the ICU. On the sixth day of hospitalization, he develops a fever and skin rash.",
        "output": "The patient may have acquired a hospital-acquired infection, such as sepsis or a catheter-related bloodstream infection. Antibiotic treatment and supportive care, such as IV fluids and oxygen therapy, should be initiated immediately.",
        "instruction": "Given a patient's medical record, identify potential hospital-acquired infections and recommend appropriate treatment.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "patient_info: Patient is allergic to penicillin and is currently taking a medication for hypertension. \\n",
        "output": "There are no known interactions or adverse reactions between the patient's medication for hypertension and their allergy to penicillin.",
        "instruction": "Given a patient's medication allergies and current prescriptions, verify that there are no potential adverse reactions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A patient is diagnosed with diabetes.",
        "output": "To improve blood sugar control in patients with diabetes, it is important to make dietary changes such as reducing refined carbohydrates, adding more fruits and vegetables, increasing fiber intake, and reducing saturated and trans fats. Patients should work closely with a registered dietitian to develop a personalized meal plan that meets their specific needs and goals.",
        "instruction": "Identify the appropriate dietary changes for a specific health condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A patient is 50 years old, overweight, and has a family history of diabetes and heart disease.",
        "output": "The patient is at an increased risk of developing diabetes and heart disease. To prevent these conditions, the patient should consider making lifestyle modifications such as increasing physical activity, incorporating more whole foods into their diet, and reducing sugary and processed foods. A healthcare provider may also want to monitor the patient's blood sugar and cholesterol levels regularly and prescribe medications if necessary.",
        "instruction": "Given a patient's health risk factors, recommend lifestyle modifications or interventions to prevent chronic diseases.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Lab results show a high fasting blood glucose level of 300 mg/dL.",
        "output": "Identify abnormal levels and recommend immediate hospitalization for management of hyperglycemia and initiation of insulin therapy to lower blood glucose levels.",
        "instruction": "Given a list of laboratory values, identify and interpret abnormal results and recommend appropriate follow-up actions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient presents with a history of smoking, a high-fat diet, a sedentary lifestyle, and a family history of heart disease and cancer.",
        "output": "The patient may be at increased risk for developing chronic conditions such as heart disease and cancer due to their lifestyle and medical history. Recommendations may include lifestyle changes, regular monitoring, and preventative screening measures to help mitigate these risks.",
        "instruction": "Given a patient's medical history and lifestyle, determine potential risk factors for the development of chronic conditions such as heart disease or cancer.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Atherosclerosis",
        "output": "Atherosclerosis is the build-up of fatty deposits (plaque) in the walls of your arteries, which can narrow and even block the blood flow, increasing the risk of heart attacks, strokes, and other complications.",
        "instruction": "Provide a plain language explanation for the given medical term, making it more accessible to a non-medical audience.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 50-year-old male patient plans to travel to South America for a week-long trip. He has no history of travel to these areas before. His vaccine record shows that he has received MMR, Tdap, Hepatitis A, Hepatitis B vaccines.",
        "output": "Based on the patient's travel plans and existing vaccinations, the following vaccines are recommended for the South America trip according to the CDC: 1) Yellow Fever vaccine, due to the presence of the disease in certain areas. 2) Typhoid vaccine, particularly if traveling to smaller cities or rural areas. 3) Rabies vaccine, if the patient will be spending a significant amount of time outdoors or will come into close contact with animals. 4) Influenza vaccine, if traveling during flu season (May to October in South America).",
        "instruction": "Based on patient information, recommend appropriate vaccinations according to the latest CDC guidelines.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "mRNA vaccines (e.g., Pfizer-BioNTech and Moderna COVID-19 vaccines)",
        "output": "mRNA vaccines work by introducing a piece of genetic material called messenger RNA (mRNA) into the body, which provides instructions for cells to produce a harmless protein found on the surface of the targeted virus. In the case of Pfizer-BioNTech and Moderna COVID-19 vaccines, this is the spike protein found on the coronavirus. Once the protein is produced, the immune system recognizes it as foreign and creates a defensive response, including antibodies. If the person is later exposed to the actual virus, their immune system is prepared to recognize and fight it, helping to prevent disease.",
        "instruction": "Explain how a specific type of vaccine works and its significance in preventing disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient has chronic back pain and has exhausted conservative treatment options.",
        "output": "Treatment options: Physical therapy, spinal injections, spinal cord stimulation, surgery.\nPros and cons: Physical therapy is non-invasive and can improve function and strength but may take several weeks before improvement is seen. Spinal injections can provide pain relief but are not a long-term solution and may have side effects. Spinal cord stimulation may be effective in reducing pain, but it is invasive and may require lead placement; in some cases, it may not be covered by insurance. Surgery can provide long-term pain relief but requires a prolonged recovery period and may come with risks such as nerve damage, infection, and failed back surgery syndrome.",
        "instruction": "Identify and rank the treatment options for a patient based on their condition, and explain the pros and cons of each treatment option.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Symptoms: fatigue, weight loss, joint pain, skin rashes.",
        "output": "Potential differential diagnoses may include rheumatoid arthritis, lupus, or other autoimmune disorders, as well as cancer or other systemic diseases. Further evaluation and testing will be necessary to determine the underlying condition.",
        "instruction": "Given a set of patient symptoms, provide differential diagnoses for the underlying condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medications: Citalopram, aspirin",
        "output": "There is a potential drug interaction between Citalopram and aspirin, as both medications can increase the risk of bleeding. Patients should be monitored closely for signs of bleeding or bruising, and dosage may need to be adjusted or alternative medications prescribed to reduce the risk of adverse effects. It's important to discuss any potential interactions or concerns with a healthcare provider.",
        "instruction": "Identify possible drug or medication interactions and provide recommendations to reduce the risk of adverse effects.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Gluten-free diet",
        "output": "Grilled chicken with quinoa and steamed vegetables (like broccoli and carrots), served with a side of mixed greens dressed in olive oil and lemon juice.",
        "instruction": "Provide an example of a healthy meal suitable for someone following a specific dietary restriction mentioned in the input text.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "An abnormal liver function test result.",
        "output": "A follow-up liver function test may be recommended to confirm the abnormal result. Additional tests or treatments may be necessary depending on the underlying cause, such as hepatitis or alcohol abuse.",
        "instruction": "Identify the cause of abnormal laboratory test results and recommend appropriate follow-up tests or treatments.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient exhibited symptoms of dyspnea and tachycardia, leading to a diagnosis of congestive heart failure.",
        "output": "The patient showed signs of trouble breathing and a fast heart rate, which led to a diagnosis of heart failure.",
        "instruction": "Rewrite the given medical text in a manner that is easy to understand by the general public.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "\"Investigation of the efficacy of probiotics in the alleviation of irritable bowel syndrome symptoms in a randomized, double-blind, placebo-controlled trial\"",
        "output": "Do probiotics help relieve irritable bowel syndrome symptoms when tested in a carefully controlled study?",
        "instruction": "Simplify the following biomedical research title into a plain English question.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What is Hypertension?",
        "output": "Hypertension, or high blood pressure, means that the force of blood pushing against the walls of blood vessels is consistently too high. This can damage organs over time, and increase the risk of heart disease, stroke, and other complications. There are many factors that can contribute, including diet, lifestyle, and genetics.",
        "instruction": "Given a medical scenario and a question, provide a brief explanation of a medical condition or disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "\"According to recent studies, inhibition of the NLRP3 inflammasome exerts neuroprotective effects in rodent models of Parkinson's disease by suppressing the production of pro-inflammatory cytokines and reactive microglial activation.\"",
        "output": "Recent research suggests that blocking a specific part of the immune system, called NLRP3 inflammasome, can protect brain cells in animal models of Parkinson's disease. This mechanism works by reducing inflammation and stopping harmful immune cells from becoming overactive.",
        "instruction": "Convert a complex biomedical research finding into a plain-English statement suitable for a non-expert audience.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Glaucoma, myocardial infarction, pulmonary embolism, cirrhosis, URI",
        "output": "- Glaucoma: a group of eye diseases that can cause permanent vision loss by damaging the optic nerve\n- Myocardial infarction: a heart attack, when blood flow to the heart is blocked and causes damage to the heart muscle\n- Pulmonary embolism: a blood clot that forms in the lungs and can cause shortness of breath, chest pain, and even death\n- Cirrhosis: a chronic liver disease characterized by scar tissue and damage to the liver, often caused by alcohol abuse or hepatitis B or C\n- URI: upper respiratory infection, a common illness that affects the nose, throat, and sinuses",
        "instruction": "Given a list of medical terms, create a glossary with definitions for each term.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Age: 45 years, Weight: 75 kg, Height: 170 cm, Blood Pressure: 130/85 mmHg",
        "output": "Overall, the patient appears to be in fairly good health. Their BMI is within the normal weight range, but their blood pressure is slightly elevated, indicating a possible risk for hypertension. Regular check-ups and monitoring are recommended.",
        "instruction": "Given a patient's age, weight, height, and blood pressure readings, provide a brief overall health assessment.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient with skin rash, itching, and difficulty breathing after eating seafood.",
        "output": "Immediate medical attention is necessary. The patient may be having an allergic reaction, and emergency treatment is required to prevent further complications.",
        "instruction": "Analyze the given medical record and determine the appropriate course of action for a patient with a suspected food allergy.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Hypertension",
        "output": "Hypertension, also known as high blood pressure, is a condition where the pressure in your blood vessels is consistently too high. It can cause damage to your arteries and increase your risk of heart disease, stroke, and other health problems.",
        "instruction": "Simplify the given medical term or phrase and provide an easily understandable definition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical term: Rhinorrhea",
        "output": "A runny nose",
        "instruction": "Read the given medical term and provide a more understandable definition for non-medical professionals.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient is prescribed fluoxetine for depression and hydrochlorothiazide for hypertension.",
        "output": "Fluoxetine can interact with hydrochlorothiazide and increase the risk of low sodium levels. Patients taking these medications should be carefully monitored for this potential side effect.",
        "instruction": "Given a medication order, describe potential drug-interaction concerns or possible adverse reactions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The contraceptive implant is a small, flexible rod that is inserted under the skin of the upper arm and provides up to 3 years of continuous protection against pregnancy. It is more than 99% effective and does not require daily attention like other forms of birth control. However, it can cause irregular bleeding patterns and has possible side effects such as headaches, weight gain, and mood changes.",
        "output": "The contraceptive implant is a highly effective form of birth control that requires minimal maintenance over a 3-year period. However, it can cause irregular bleeding and has potential side effects such as headaches, weight gain, and mood changes.",
        "instruction": "Create a summary of the pros and cons of the contraceptive implant.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "None",
        "output": "A typical vaccination schedule for a newborn baby includes:\n- Birth: Hepatitis B vaccine (HepB)\n- 1-2 months: Hepatitis B vaccine (HepB) - 2nd dose\n- 2 months: Diphtheria, tetanus, and pertussis vaccine (DTaP), Haemophilus influenzae type b vaccine (Hib), Polio vaccine (IPV), Pneumococcal vaccine (PCV), Rotavirus vaccine (RV)\n- 4 months: DTaP, Hib, IPV, PCV, RV\n- 6 months: DTaP, Hib, PCV, RV\n- 6-18 months: HepB, IPV\n- 12-15 months: Hib, PCV, Measles, mumps, and rubella vaccine (MMR), Varicella vaccine (VAR)\n- 15-18 months: DTaP\n- 4-6 years: DTaP, IPV, MMR, VAR\n\nPlease consult your pediatrician for a personalized vaccination schedule for your baby.",
        "instruction": "Recommend a vaccination schedule for a newborn baby.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient's most recent lab results showed a white blood cell count of 11,000/uL, elevated liver enzymes, and a low platelet count.",
        "output": "The patient's recent laboratory results indicated a slight elevated white blood cell count, elevated liver enzymes, and a low platelet count, which may suggest an underlying hepatic or hematologic condition.",
        "instruction": "Summarize the results of a patient's recent laboratory tests.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical Condition: Osteoporosis",
        "output": "To reduce the risk of developing osteoporosis, it is important to make lifestyle changes that promote bone health, such as engaging in weight-bearing exercises, eating a diet rich in calcium and vitamin D, avoiding smoking and excessive alcohol consumption, and taking calcium and vitamin D supplements as needed. Additionally, it is important to schedule regular checkups with your doctor to monitor bone health and evaluate any potential risks.",
        "instruction": "Given a medical condition or symptom, provide information on how to prevent or reduce the risk.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical condition: Heart attack",
        "output": "Diagnostic tests or procedures to confirm or rule out a heart attack include an electrocardiogram (ECG), blood tests for cardiac enzymes, and a coronary angiogram.",
        "instruction": "Given a medical condition, list the possible diagnostic tests or procedures used to confirm or rule out the condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "None",
        "output": "Alternative treatment options for depression include cognitive-behavioral therapy (CBT), mindfulness-based therapies, interpersonal therapy (IPT), and light therapy. Exercise, relaxation techniques, and dietary changes are also known to be helpful in managing depression.",
        "instruction": "Generate a list of alternative treatment options for depression other than medication.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient X is currently taking Lisinopril and Metformin. What are possible interactions between these medications?",
        "output": "There may be a risk of hyperkalemia when taking Lisinopril and Metformin together. Alternative medication options or adjustments to the dosages may be necessary to avoid harmful interactions.",
        "instruction": "Given a medical report, summarize the patient's current medications and possible interactions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical History: Asthma, hypertension, osteoarthritis\nCurrent Medications: Albuterol inhaler, Lisinopril, Advil\nCurrent Condition: Sudden onset of chest pain and shortness of breath",
        "output": "Potential Medication Interactions/Worsening of Condition: Advil can exacerbate asthma symptoms and should be used with caution in patients with hypertension. Albuterol inhaler can increase heart rate and may worsen chest pain and shortness of breath in patients with hypertension or heart disease. Lisinopril can also interact with Advil and increase the risk of kidney damage. It is important to consult with a medical professional before taking any new medications or continuing to use current medications in case of worsening symptoms.",
        "instruction": "Given a patient's medical history and current condition, provide a list of medications that may interact with their current medications and/or exacerbate their condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Acute Myeloid Leukemia (AML).",
        "output": "AML is a type of cancer that affects the bone marrow and blood cells. It can cause low blood counts, bleeding, and infections. Treatment usually involves chemotherapy and sometimes bone marrow transplantation. The disease can be life-threatening, but early detection and treatment can improve outcomes.",
        "instruction": "Given a medical diagnosis, explain the condition and its potential effects on the patient's health and life.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient: 35-year-old female, prediabetes, sedentary lifestyle, BMI: 28, dislikes intense exercises",
        "output": "Nutrition:\n1. Eat a balanced diet with plenty of whole grains, lean proteins, vegetables, and fruits.\n2. Focus on low-glycemic foods that help maintain stable blood sugar levels, such as legumes, nuts, and non-starchy vegetables.\n3. Limit added sugars, refined carbs, and saturated fats.\n4. Practice portion control and eat smaller, frequent meals throughout the day.\n5. Stay hydrated by drinking plenty of water and avoiding sugary and caffeinated beverages.\n\nExercise:\n1. Engage in moderate-intensity aerobic activities for at least 150 minutes per week. Examples: walking, swimming, cycling, or dancing.\n2. Include strength training exercises targeting major muscle groups at least two days per week. Examples: bodyweight exercises, resistance bands, or light dumbbell workouts.\n3. Participate in flexibility and balance exercises, such as yoga or tai chi, to improve overall body strength and stability.\n4. Break up prolonged periods of sitting by taking short breaks to stand, stretch, or walk around.\n5. Gradually increase the intensity and duration of exercises as the patient's fitness level improves.\n6. Consult with a healthcare professional before starting any new exercise program.",
        "instruction": "Devise a personalized nutrition and exercise plan for a patient with a specific medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient is a 65-year-old male with a history of smoking and alcohol consumption. He presents with a persistent cough, shortness of breath, unexplained weight loss, and chest pain.",
        "output": "A potential diagnosis for the patient is lung cancer. Further investigation, such as a chest X-ray, CT scan, or biopsy, should be conducted to confirm the diagnosis.",
        "instruction": "Based on the following patient history, provide a suggestion for a potential diagnosis and further investigation needed.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical research studies and clinical trials comparing different surgical approaches for the specific condition.",
        "output": "Based on the available medical research, different surgical approaches for the specific condition may have varying effectiveness and safety outcomes. Factors to consider may include patient age, overall health, disease severity, and preference. A healthcare professional should be consulted to evaluate and discuss the best treatment options based on individual patient factors.",
        "instruction": "Identify and compare the effectiveness and safety of different surgical approaches for a specific medical condition, such as prostate cancer or hip replacement.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The reported side effects of the drug include mild headaches, dizziness, and nausea in a small percentage of patients.",
        "output": "The new drug has a relatively safe profile, with mild side effects in a limited number of patients.",
        "instruction": "Assess the safety profile of the new drug based on the reported side effects.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Condition: Hypertension",
        "output": "Treatment options for hypertension may include lifestyle changes such as diet, exercise, and stress management, as well as medications like diuretics, ACE inhibitors, or beta-blockers.",
        "instruction": "Identify the treatment options available for a specific condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Multiple sclerosis",
        "output": "The diagnostic criteria for multiple sclerosis include clinical history, physical examination, and diagnostic testing such as MRI. Treatment options include disease-modifying therapies, symptom management, and rehabilitation. The choice of treatment depends on the severity and progression of the disease as well as individual patient factors and preferences.",
        "instruction": "Given a medical condition, describe the diagnostic criteria and available treatment options.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "How can a patient properly monitor their blood pressure at home?",
        "output": "To properly monitor blood pressure at home, the patient should first purchase an accurate blood pressure monitor. They should then sit down and place the cuff around their upper arm, following the instructions provided with the monitor. They should then press the start button, and record their blood pressure reading. This should be done at the same time each day, and the readings should be recorded and shared with their healthcare provider.",
        "instruction": "Explain how to properly monitor a patient's blood pressure at home.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "",
        "output": "Tamoxifen is a standard drug used for the treatment of early-stage hormone-receptor-positive breast cancer.",
        "instruction": "Identify the standard drug used for the treatment of early-stage breast cancer.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "In vitro experiments with isolated chondrocyte cultures show that the multifunctional cytokine transforming growth factor-beta (TGF-\u03b2) stimulates chondrocyte proliferation through a programmed process of cellular activities called autophagy, indicating a potential application for regenerating cartilage in degenerative joint diseases like osteoarthritis.",
        "output": "Laboratory tests on cartilage cells show that a special protein called TGF-\u03b2 helps the cells grow by using a natural process called autophagy. This finding could help develop treatments to rebuild cartilage in conditions like osteoarthritis, which cause joint damage.",
        "instruction": "Given a summary of a biomedical research article, simplify the text further to make it easily understandable for non-expert readers.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "No specific input required.",
        "output": "1. Maintain a healthy diet, including whole foods and limited sugar intake.\n2. Engage in regular physical activity.\n3. Manage body weight and aim for a healthy weight range.",
        "instruction": "List three preventive measures for reducing the risk of type 2 diabetes.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "45-year-old male with persistent cough, weight loss, and shortness of breath",
        "output": "The patient's symptoms of persistent cough, weight loss, and shortness of breath might suggest conditions such as lung infection, tuberculosis, or lung cancer. Further diagnostic tests and a consultation with a healthcare professional are necessary to determine the exact cause and initiate appropriate treatment.",
        "instruction": "Provide an assessment of the given patient's symptoms and suggest possible medical conditions.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient is experiencing severe headache and sensitivity to light.",
        "output": "Based on the symptoms presented, I recommend acetaminophen to treat the headache. If the headache persists or worsens, please seek medical attention for further evaluation and treatment.",
        "instruction": "Given a patient's symptoms, recommend a medication that can be used to treat the condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient has a history of kidney disease and is currently taking Aspirin for arthritis pain.",
        "output": "Based on your medical history and current medications, we recommend avoiding non-steroidal anti-inflammatory drugs (NSAIDs) such as Aspirin, which can be harmful to patients with kidney disease. Instead, we recommend alternative pain management options such as acetaminophen or prescription pain relievers. Speak to a doctor for further guidance.",
        "instruction": "Given a patient's medical history and current medications, recommend a suitable pain management plan in light of any potential drug interactions or contraindications.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The oxygen concentrator is not producing enough oxygen. The patient's oxygen saturation level is dropping.",
        "output": "Possible causes of the problem include a clogged filter, a faulty oxygen sensor, or a low oxygen flow rate setting. Solutions may include cleaning or replacing the filter, replacing the oxygen sensor, and adjusting the flow rate as necessary.",
        "instruction": "Given a medical equipment malfunction, troubleshoot the issue and provide a solution.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Lab results: Hemoglobin A1c of 9.2%, blood glucose level of 300 mg/dL.",
        "output": "These lab results indicate uncontrolled Type 2 Diabetes Mellitus. Additional testing may include checking for other complications such as high blood pressure or kidney damage. Treatment options may include adjusting medication dosages, lifestyle changes, or insulin therapy.",
        "instruction": "Given a patient's lab results, determine if they fall within normal ranges and, if not, suggest additional testing or treatment options.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "Angioplasty is a minimally invasive procedure used to treat coronary artery disease by widening narrowed or blocked arteries, improving blood flow to the heart. A catheter with a tiny balloon at the tip is inserted into the affected artery, and the balloon is inflated, pushing the plaque against the artery walls. Often, a small mesh tube (stent) is placed to keep the artery open and maintain blood flow.",
        "instruction": "Write a brief explanation of angioplasty as a treatment for coronary artery disease.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Hypertension",
        "output": "To reduce the risk of hypertension, it is essential to maintain a healthy diet low in sodium, exercise regularly, manage stress, maintain a healthy weight, and avoid excessive alcohol consumption.",
        "instruction": "Describe a preventive measure or lifestyle modification that can help reduce the risk of a particular health condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "Acupuncture is a form of alternative medicine that originated in China. It involves the insertion of thin, sterile needles into specific points on the body, known as acupuncture points. These points are believed to be connected to the body's energy pathways, called meridians. The theory behind acupuncture is that imbalances or blockages in the flow of energy (Qi) along these meridians lead to illness and discomfort. Acupuncture aims to restore the balance and flow of energy, promoting overall health and alleviating various symptoms.",
        "instruction": "Provide an explanation of acupuncture as a form of alternative medicine.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient, 55 y.o., male, with a history of high blood pressure, obesity, and sedentary lifestyle. Current symptoms: shortness of breath and fatigue.",
        "output": "1. Increasing physical activity: Aim for at least 150 minutes of moderate-intensity aerobic exercise per week, such as brisk walking, swimming, or biking.\n2. Adopting a healthier diet: Eat more fruits, vegetables, whole grains, lean proteins, and low-fat dairy products. Limit sodium, added sugars, saturated fats, and alcohol.\n3. Losing weight: Aim for a gradual and sustainable weight loss through a combination of a healthy diet and regular exercise.\n4. Practicing stress management: Incorporate stress-reduction techniques like yoga, meditation, or deep breathing exercises into your daily routine.\n5. Monitoring blood pressure: Regularly check blood pressure and consult with a healthcare professional for proper management.",
        "instruction": "Given a patient's symptoms and medical history, suggest potential lifestyle changes to improve their health.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Treatment options for moderate to severe acne:\n- Topical retinoids (such as tretinoin or adapalene)\n- Oral antibiotics (such as doxycycline or minocycline)\n- Hormonal therapy (such as spironolactone or oral contraceptives)\n- Accutane (isotretinoin) therapy",
        "output": "Each of these treatment options has potential benefits and drawbacks, and the most appropriate option depends on the patient's individual needs and medical history. Topical retinoids may be effective, but can also cause skin irritation or dryness. Oral antibiotics may lead to antibiotic resistance or other adverse effects. Hormonal therapy may be appropriate for women with hormonal acne, but can have side effects and may not be effective for all patients. Accutane therapy is highly effective for severe acne, but requires close monitoring and can have potential serious adverse effects. The appropriate course of action may include a combination of these treatments, close monitoring of symptoms and side effects, and regular follow-up care with a healthcare provider.",
        "instruction": "Given a set of medication or treatment options for a medical condition, evaluate the potential benefits and drawbacks of each and recommend an appropriate course of action.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Interaction between warfarin and aspirin.",
        "output": "Taking aspirin while on warfarin can increase the risk of bleeding due to the blood-thinning effect of both medications. Patients taking warfarin should discuss with their healthcare provider before taking any over-the-counter medications or supplements, including aspirin.",
        "instruction": "Explain how a certain medication interacts with other medications or substances.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "45-year-old male with chest pain, shortness of breath, and nausea",
        "output": "1. Myocardial Infarction (Heart attack)\n2. Angina (Chest pain related to heart disease)\n3. Pulmonary Embolism (Blood clot in the lungs)\n4. Pneumonia (Lung infection)\n5. Anxiety/Panic attack",
        "instruction": "Given the patient symptoms, suggest potential differential diagnoses that the healthcare provider should consider.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient's family history includes a history of breast cancer in multiple family members.",
        "output": "Potential risks for genetic diseases associated with the family history may include an increased risk of breast cancer due to genetic mutations such as BRCA1 or BRCA2. Recommendations for genetic counseling or testing may be appropriate to further evaluate the patient's risk of developing breast cancer or other genetic diseases.",
        "instruction": "Given a patient's family history, identify any potential risks for genetic diseases and provide recommendations for genetic counseling or testing if necessary.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Healthcare professional: physiotherapist",
        "output": "A physiotherapist, also known as a physical therapist, specializes in diagnosing, treating, and preventing a wide range of musculoskeletal conditions and movement disorders. They help patients regain mobility, reduce pain, and improve overall physical function. This is generally achieved through custom-tailored exercise programs, manual therapy techniques, and patient education on proper body mechanics and self-care strategies. Physiotherapists work with patients of all ages and various medical conditions, including sports injuries, orthopedic surgeries, arthritis, stroke, spinal cord injuries, and neurological diseases like Parkinson's or multiple sclerosis. Additionally, they play a significant role in promoting overall health, fitness, and injury prevention through exercise guidance and lifestyle modifications.",
        "instruction": "Explain the role of a specific type of healthcare professional in the medical field and the services they provide.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "1000 mg daily",
        "output": "0.035 oz daily",
        "instruction": "Convert the dosage recommendation of the given drug from the metric system to the imperial system units.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What is hypertension and why is it important to monitor blood pressure regularly?",
        "output": "Hypertension, also known as high blood pressure, occurs when the force of blood against the walls of your arteries is consistently too high. It is important to monitor blood pressure regularly because high blood pressure can lead to serious health problems such as heart disease, stroke, and kidney failure. Regular monitoring can help catch high blood pressure early and allow for earlier treatment to prevent these complications.",
        "instruction": "Provide a brief definition of the term \"hypertension\" and explain why it is important to monitor blood pressure regularly.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 75-year-old female patient is taking multiple medications for hypertension, hyperlipidemia, and osteoporosis. She reports difficulty remembering to take her medications on schedule.",
        "output": "Consolidation of medications, use of combination pills, and enrollment in a medication management program may help reduce the risk of medication errors and improve compliance with her medication regimen.",
        "instruction": "Evaluate a patient's medication regimen and provide recommendations for optimizing their medication therapy.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "Myocardial infarction: Heart attack\nTachycardia: Rapid heartbeat\nHypertension: High blood pressure\nDyspnea: Shortness of breath\nEdema: Swelling caused by fluid retention",
        "instruction": "Translate the following medical terms into layman terms: 'myocardial infarction', 'tachycardia', 'hypertension', 'dyspnea', 'edema'.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient presents with persistent headaches, dizziness, and nausea.",
        "output": "Based on the patient's symptoms, possible underlying conditions could include migraines, vertigo, or an inner ear infection. Further evaluation with imaging studies such as an MRI or CT scan may be necessary to rule out more serious conditions such as a brain tumor or aneurysm.",
        "instruction": "Given a patient's symptoms and medical history, recommend further testing or evaluation to identify a potential underlying condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What are the risk factors for developing type 2 diabetes, and how can they be addressed?",
        "output": "Risk factors for type 2 diabetes may include obesity, physical inactivity, poor diet, and family history. Prevention strategies may include lifestyle modifications, such as increased physical activity and dietary changes, as well as regular screening and management of associated comorbidities.",
        "instruction": "Given a set of epidemiological data, identify risk factors for a particular disease and suggest potential prevention strategies.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient information: 56-year-old female, weight 140 pounds, diagnosed with type 2 diabetes\nMedical condition: high blood sugar (> 200 mg/dL)",
        "output": "For high blood sugar, the recommended medication is insulin. The dosage will depend on the patient's individual needs and may vary based on factors such as weight and blood sugar levels. It is typically recommended to start with a low dose, such as 0.2-0.4 units per kilogram of body weight, and adjust as needed based on blood sugar levels and response to treatment.",
        "instruction": "Given a set of patient information, select the appropriate medication and dosage for a specific medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Lab Results: TSH (thyroid-stimulating hormone) = 0.7 mIU/L, T4 (thyroxine) = 7.5 ug/dL",
        "output": "Thyroid function: TSH and T4 levels are within the normal range, indicating normal thyroid function. No further testing or treatment is necessary at this time.",
        "instruction": "Based on the given laboratory values, evaluate a patient's thyroid function and determine if further testing or treatment is necessary.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient with severe anxiety is considering taking benzodiazepines for symptom relief.",
        "output": "Benzodiazepines can be effective at treating anxiety in the short-term, but their long-term use can be habit-forming and increase the risk of dependence and cognitive decline. Non-pharmacological interventions such as cognitive-behavioral therapy should be considered as a first-line treatment, with medication as a last resort.",
        "instruction": "Given a patient's medical history and treatment options, weigh the potential benefits and risks and recommend the appropriate course of action.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "Several risk factors can increase a person's likelihood of developing cardiovascular disease, such as smoking, obesity, high cholesterol, high blood pressure, inactivity, and poor nutrition. These risk factors can be reduced by improving one's diet, increasing exercise, quitting smoking, managing stress, and monitoring blood pressure and cholesterol levels.",
        "instruction": "Identify potential risk factors for developing a cardiovascular disease and provide steps that can be taken to reduce these risk factors.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A patient presents with severe symptoms of Parkinson's disease. What would be an appropriate referral or consult for specialized care?",
        "output": "An appropriate referral or consult for specialized care would be a neurologist who specializes in movement disorders, or a Parkinson's disease specialist.",
        "instruction": "Given a medical scenario and a question, provide an appropriate referral or consult for specialized care.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "\"Subcutaneous administration of the medication is required every four hours.\"",
        "output": "\"The medicine needs to be given as an injection under the skin every four hours.\"",
        "instruction": "Translate medical jargon or technical terminology into everyday language.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient presents with a history of type 2 diabetes and high blood pressure. Blood glucose is currently high and uncontrolled.",
        "output": "Recommended treatment plan based on best practices and clinical guidelines, including medication and lifestyle modifications.",
        "instruction": "Given a specific medical scenario, provide a recommended treatment plan based on best practices and clinical guidelines.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Surgical Procedure: Appendectomy.",
        "output": "An appendectomy is a surgical procedure to remove the appendix, a small pouch attached to the large intestine. It's most commonly performed to treat acute appendicitis, which is the inflammation and infection of the appendix. The surgery can be done either through traditional open surgery or laparoscopically (minimally invasive), and it usually takes around 1-2 hours to complete. Recovery time can vary from a few days to a few weeks, depending on the approach and the patient's overall health.",
        "instruction": "Provide a general overview of a specific surgical procedure.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "To care for a wound and prevent infection, wash your hands thoroughly before and after touching the wound. Clean the wound with soap and water and apply an antibiotic ointment as directed. Cover the wound with a sterile bandage and change it daily or as needed. Avoid touching the wound or picking at any scabs or crusts. If you notice signs of infection, such as redness, swelling, or pus, seek medical attention immediately.",
        "output": "To care for a wound and prevent infection, wash your hands thoroughly before and after touching the wound. Clean the wound with soap and water and apply an antibiotic ointment as directed. Cover the wound with a sterile bandage and change it daily or as needed. Avoid touching the wound or picking at any scabs or crusts. If you notice signs of infection, such as redness, swelling, or pus, seek medical attention immediately.",
        "instruction": "Provide recommendations for how to properly care for a wound and prevent infection.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient is scheduled for an elective surgical procedure. Provide recommendations for perioperative care.",
        "output": "Recommendations: Preoperatively, ensure adequate pain relief medication and consider the use of prophylactic antibiotics to prevent infection. Monitor fluid and electrolyte levels and administer intravenous fluids as necessary. During the procedure, maintain appropriate anesthesia and monitor vital signs closely. Postoperatively, monitor the patient for signs of pain, infection, or complications related to fluid and electrolyte imbalances. Administer appropriate pain relief medication and manage fluid and electrolyte imbalances as necessary. Encourage early ambulation and mobility as appropriate to prevent postoperative complications.",
        "instruction": "Given a medical case scenario, provide recommendations for appropriate management of perioperative care, including pain relief, infection prevention, and fluid management.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Condition: Hypertension",
        "output": "Lifestyle modifications include reducing salt intake, exercising regularly, maintaining a healthy weight, limiting alcohol consumption, following a balanced diet rich in fruits and vegetables, managing stress, and avoiding tobacco products.",
        "instruction": "Generate a list of recommended lifestyle modifications for someone with this chronic medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient has been diagnosed with acute myocardial infarction and requires angioplasty with stent placement. How can you explain this to the patient in simpler terms?",
        "output": "The patient has a serious heart attack, and a procedure is needed to open up the blocked blood vessel and place a small metal tube inside to keep it open. This will improve blood flow and prevent future heart attacks.",
        "instruction": "Convert a medical diagnosis or treatment plan into layman's terms for the patient to understand.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical procedure: colonoscopy",
        "output": "A colonoscopy is a procedure where a doctor examines the inside of your large intestine (colon) using a long, flexible tube with a small camera at the end. This helps them look for any abnormalities like polyps, inflammation, or cancer. To prepare for a colonoscopy, you'll need to follow a specific diet and take a bowel-cleansing solution to empty your colon. On the day of the procedure, you'll be given light sedation to help you relax. The flexible tube, called a colonoscope, will be gently inserted and navigated through your colon to check for any issues. The procedure usually takes about 30-60 minutes, and you might feel some pressure or discomfort. Afterward, you can return to your normal diet and activities, but you may need someone to drive you home due to the sedation.",
        "instruction": "Explain a specific medical procedure in a clear and concise manner to help patients prepare for it.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A patient with a history of type 2 diabetes and elevated fasting blood glucose levels.",
        "output": "- Oral antihyperglycemics, such as metformin or sulfonylureas, to lower blood glucose levels.\n- Insulin therapy may also be considered if glucose control remains difficult after oral medications and lifestyle modifications.",
        "instruction": "Given a patient's medical history and lab results, suggest appropriate medications for treating a specific chronic condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Myocardial infarction",
        "output": "Heart attack",
        "instruction": "Simplify the following medical term to a layman term.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Hepatitis B vaccine",
        "output": "The Hepatitis B vaccine protects against the Hepatitis B virus, which can cause serious liver infections and liver damage. The vaccine works by introducing an inactive form of the virus into the body, prompting the immune system to produce antibodies that will recognize and fight off the real virus if exposed to it in the future.",
        "instruction": "Explain what the given vaccine protects against and how it works.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Organ transplantation",
        "output": "Organ transplantation is a complex medical procedure that can significantly improve quality of life for patients with chronic organ dysfunction or failure. The benefits include a better quality of life and longer life expectancy in many cases. However, transplantation does carry risks, such as infection and rejection of the transplanted organ, which can require lifelong medical care and the use of immunosuppressive drugs.",
        "instruction": "Given a medical condition or treatment, provide a summary of potential benefits and drawbacks.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Statistical result: Hazard Ratio (HR) = 2.0 (95% CI: 1.5\u20132.7), p = 0.001",
        "output": "The specified group has a two-fold increased risk of the event in question compared to the reference group, and this result is statistically significant (p=0.001).",
        "instruction": "Interpret a specified statistical result from a biomedical study.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "During a cholecystectomy, the surgeon makes an incision in the abdomen and inserts a device known as a laparoscope, which aids in visualizing the gallbladder. The gallbladder, found below the liver, is then detached from the bile ducts and blood vessels before being removed from the body.",
        "output": "In a gallbladder removal surgery, the surgeon makes a cut in the belly, uses a special tool to see the gallbladder, and then disconnects it from tubes and blood vessels before taking it out of the body.",
        "instruction": "Convert the provided text about a surgical procedure into a more straightforward, layman's explanation.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Common medications for hypertension",
        "output": "1. Lisinopril\n2. Amlodipine\n3. Hydrochlorothiazide\n4. Metoprolol\n5. Losartan",
        "instruction": "List five common medications used to treat the given medical condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The patient has been diagnosed with osteoporosis.",
        "output": "Osteoporosis is a condition where bones become weakened and more prone to fractures. Risk factors include age, sex (more common in women), menopause, low calcium and vitamin D intake, and certain medications such as steroids. Treatment includes lifestyle changes and medication if necessary.",
        "instruction": "Explain the cause and specific risk factors for a patient's diagnosed condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Assess the potential harms and benefits of bariatric surgery for obesity.",
        "output": "Benefits: Significant and sustained weight loss, improved obesity-related comorbidities (e.g., diabetes, hypertension), and better quality of life.\n\nHarms: Potential risks include surgical complications (e.g., infection, hemorrhage), nutrient deficiencies, gastrointestinal symptoms, and psychological issues (e.g., body image concerns, mood changes).\n\nThe decision to undergo bariatric surgery should be made after considering individual risk factors, patient expectations, and available alternatives for weight management.",
        "instruction": "Assess the potential harms and benefits of a specific medical procedure or intervention.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Wound healing",
        "output": "The four stages of wound healing are as follows:\n1) Hemostasis - the blood vessels around the wound contract to minimize bleeding, and platelets form a clot to seal the wound.\n2) Inflammatory phase - the wound becomes swollen, red, and warm as immune cells migrate to the site to defend against infection and remove debris.\n3) Proliferative phase - new tissue and blood vessels begin to form as cells divide and migrate to the wound site.\n4) Remodeling phase - the new tissue matures and becomes stronger, while excess scar tissue is broken down and removed. The end result is a scar, which may fade over time.",
        "instruction": "List the four stages of wound healing and briefly describe what happens in each stage.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "What are the differences between mRNA, vector, and inactivated virus vaccines, and what are common side effects associated with vaccination?",
        "output": "mRNA vaccines work by instructing cells to produce a piece of viral protein that triggers an immune response. Vector vaccines use a harmless virus to deliver a piece of viral protein to cells. Inactivated virus vaccines contain the virus but have been deactivated, so it cannot cause an infection. Common side effects of vaccination can include soreness at the injection site, fatigue, headache, and fever. Serious side effects such as allergic reactions are rare but can occur. It is important to report any serious side effects to a healthcare provider immediately.",
        "instruction": "Provide an explanation of the different types of vaccines, their efficacy, and potential side effects.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 30-year-old female presents with fatigue, joint pain, and anemia. She has a family history of lupus.",
        "output": "Based on the patient's symptoms and medical history, lupus is a possible diagnosis. Lupus is an autoimmune disorder that can cause joint pain, fatigue, and anemia, among other symptoms. The patient's family history also increases the likelihood of this diagnosis. However, there are a number of other differential diagnoses that should also be considered, including other autoimmune disorders (such as rheumatoid arthritis or Sjogren's syndrome), infectious diseases (such as Lyme disease), or even certain medications (such as chemotherapy drugs). Factors that support a diagnosis of lupus include the presence of joint pain, anemia, and a family history of the condition. Factors that may refute this diagnosis (at least in the absence of other diagnostics) include the absence of certain specific lupus symptoms (such as a butterfly rash) or the presence of other symptoms more suggestive of a different condition. Ultimately, the best course of action will depend on further diagnostic testing and consultation with a healthcare provider.",
        "instruction": "Given a patient's medical history and current symptoms, explain the differential diagnoses that should be considered and factors that support or refute those diagnoses.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "None required.",
        "output": "CRISPR gene editing technology is a technique that allows scientists to edit or modify genetic material. It works by using a protein called Cas9 which can cut DNA at specific locations and then add or remove genetic material as desired. This technology has potential for many applications in medicine, including treatments for genetic diseases and cancers. Researchers are also exploring the possibility of using CRISPR technology for creating better crops and other advancements in agriculture.",
        "instruction": "Explain the basic principles and clinical use of CRISPR gene editing technology.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A patient is a 60-year-old female with a history of hypertension and is currently receiving cancer treatment.",
        "output": "Preventive measures might include regular hand hygiene, wearing a face mask in public settings, avoiding crowds, and practicing social distancing when possible. Vaccinations may also be recommended for high-risk patients such as those receiving cancer treatment or with other underlying health conditions.",
        "instruction": "Given a patient's medical history and current status, recommend appropriate preventive measures to reduce the risk of infectious diseases such as COVID-19.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Patient D has been monitoring their blood sugar levels over the past month. The following data represents their blood glucose levels before and after meals. \nDay 1: Before meal - 120 mg/dL, After meal - 210 mg/dL. \nDay 7: Before meal - 140 mg/dL, After meal - 230 mg/dL.\nDay 14: Before meal - 130 mg/dL, After meal - 215 mg/dL.\nDay 21: Before meal - 160 mg/dL, After meal - 240 mg/dL.\nDay 30: Before meal - 180 mg/dL, After meal - 260 mg/dL.",
        "output": "Patient D's blood sugar levels have been increasing over the past month, with higher levels after meals than before meals. This trend indicates poor glycemic control, which may put the patient at risk for complications like kidney damage, nerve damage, and heart disease. Further testing and treatment may be necessary to manage the patient's condition.",
        "instruction": "Given a medical report, analyze and summarize the data trends over a period of time to evaluate the patient's health.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "N/A",
        "output": "A double-blind study design is a type of clinical trial where neither the participants nor the researchers know which group receives the experimental treatment and which group receives the placebo or standard treatment. This design helps eliminate bias and ensures that findings are more accurate and reliable.",
        "instruction": "Describe what is meant by a \"double-blind\" study design in clinical trials.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Medical History: History of hypothyroidism, no other significant medical history\nLab Results: TSH levels elevated at 12.5 mIU/L, T3 and T4 levels within normal range.",
        "output": "Elevated TSH levels may indicate hypothyroidism or other thyroid disorders, and may require further testing or referral to an endocrinologist for management.",
        "instruction": "Given a patient's medical history and laboratory results, identify any potential abnormalities and suggest appropriate follow-up testing or referral to a specialist.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "A 35-year-old man with obesity and a family history of type 2 diabetes wants to reduce his risk of developing the disease.",
        "output": "To reduce the risk of developing type 2 diabetes, it is recommended to adopt a healthy lifestyle with regular physical activity, a balanced diet rich in fruits, vegetables, and whole grains, and weight loss if overweight or obese. Managing stress and quitting smoking can also help. Regular check-ups with a healthcare provider to monitor health markers such as blood glucose levels and blood pressure can further contribute to risk reduction.",
        "instruction": "Recommend a proper course of action for a specific health concern.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Symptoms: Cough, congestion, sore throat, and fatigue\nMedical History: No history of chronic respiratory illnesses",
        "output": "Diagnosis: Likely a common cold. Recommend self-care measures such as rest, hydrating fluids, over-the-counter medication for symptom management, and staying home to avoid spreading the illness.",
        "instruction": "Given a patient's symptoms and medical history, diagnose and recommend treatment for a common respiratory illness.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Diabetes",
        "output": "Patients with diabetes are at increased risk for a range of complications including heart disease, neuropathy, and kidney disease. To prevent these complications, it is important to closely manage blood sugar levels through a combination of diet, medication, and exercise. Regular visits with a healthcare provider and monitoring of blood pressure and cholesterol levels is also recommended to catch potential issues early.",
        "instruction": "Identify and explain potential complications and recommended preventative measures for patients with a specific chronic condition.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "The immune system is an intricate network of cells, tissues, and organs that defends the body against harmful pathogens, such as bacteria, viruses, and other foreign invaders. It includes physical barriers like the skin, cells like white blood cells that engulf and destroy harmful substances, and specialized immune cells that produce antibodies to neutralize pathogens.",
        "output": "The immune system is a collection of parts in your body that work together to protect you from harmful germs. It includes things like your skin, which helps keep germs out, and cells that find and destroy harmful substances in your body. Some immune cells also create special proteins called antibodies to make harmful germs harmless.",
        "instruction": "Simplify a description of how the body's immune system works.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "Elevated levels of thyroid-stimulating hormone (TSH).",
        "output": "Elevated TSH levels can be associated with several potential diagnoses, including hypothyroidism, thyroiditis, or iodine deficiency. Further evaluation may be needed to confirm the diagnosis and determine appropriate treatment.",
        "instruction": "Given a medical test result, suggest potential diagnoses that the results could indicate.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "In this study, we investigated the therapeutic potential of stem cell-derived extracellular vesicles (EVs) in a murine model of acute kidney injury (AKI). The experimental rats were subjected to unilateral ischemia-reperfusion injury (IRI), and then administered with 200 \u00b5g of EVs per animal 24 hours post-injury. The treatment group demonstrated significantly improved renal function, reduced tubular cell necrosis, and decreased inflammation. We also observed enhanced angiogenesis and reduced levels of fibrosis in the treated animals. The findings suggest that stem cell-derived EVs may have significant therapeutic potential in the treatment of acute kidney injury.",
        "output": "The study demonstrates that stem cell-derived extracellular vesicles (EVs) hold promising therapeutic potential in treating acute kidney injury in a murine model, with improved renal function, decreased inflammation, and enhanced angiogenesis observed in the treated animals.",
        "instruction": "Summarize a given biomedical or healthcare-related research article or abstract.",
        "domain": "med",
        "task": "tg"
    },
    {
        "input": "News article on a new diabetes treatment.",
        "output": "The credible sources include reputable medical journals, academic institutions, and government agencies. The accuracy of the information must be critically evaluated, considering the study design, sample size, and funding sources. The potential benefits and risks of the new diabetes treatment should be carefully assessed before coming to conclusions.",
        "instruction": "Given a medical news article, identify the credible sources and assess the accuracy of the information.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Is vaping safer than smoking?",
        "output": "Vaping or e-cigarettes are not safe alternatives to traditional smoking. E-cigarettes still contain nicotine, which can be addictive and may lead to lung and cardiovascular problems. Additionally, some e-cigarette devices may also contain toxic chemicals harmful to health.",
        "instruction": "Given a medical question, provide a concise and accurate answer based on the latest medical research.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Chest X-ray image",
        "output": "This chest X-ray appears abnormal due to the presence of infiltrates in the lower lobe of the right lung, which may indicate pneumonia or other respiratory infection.",
        "instruction": "Classify the given chest X-ray as normal or abnormal and provide reasoning.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient history: A 56-year-old male with a history of chronic hepatitis C infection presents with abdominal pain, nausea, and vomiting. Laboratory results show elevated levels of serum bilirubin and alkaline phosphatase.\nDiagnostic test: Ultrasound of the abdomen and liver",
        "output": "The ultrasound shows evidence of biliary obstruction, which may indicate a blockage in the bile ducts due to gallstones or liver damage caused by the hepatitis C infection.",
        "instruction": "Given a patient history and laboratory results, interpret a specific diagnostic test result.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient presents with low levels of TSH, high levels of T3/T4, and a rapidly beating heart. What is the likely diagnosis?",
        "output": "The likely diagnosis is hyperthyroidism, which is caused by an overactive thyroid gland. The lab report indicates low levels of TSH and high levels of T3/T4, and the symptoms of a rapidly beating heart are consistent with hyperthyroidism.",
        "instruction": "Given a patient's lab reports, interpret the data and diagnose the disease.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Chest pain, headache, fever, broken wrist. What is the most urgent medical condition?",
        "output": "The most urgent medical condition is chest pain because it can be a sign of a serious heart problem that requires immediate attention.",
        "instruction": "Given a list of symptoms, determine the most urgent medical condition to address and provide a brief rationale.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Tom is a 35-year-old man who smokes a pack of cigarettes every day, drinks alcohol frequently, and avoids physical activity. His diet primarily consists of fast food and sugary snacks.",
        "output": "Not following a healthy lifestyle",
        "instruction": "Based on the given information, infer whether the person is following a healthy lifestyle or not.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient's weight: 75 kg\nDosage: 10 mg/kg/day",
        "output": "750 mg/day",
        "instruction": "Calculate a patient's daily dose of medication, given their weight and the prescribed dosage.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "patient's age: 60, medical history: history of smoking, occasional moderate alcohol consumption, high blood pressure",
        "output": "Test to consider: Cardiac stress test",
        "instruction": "Given a patient's age and medical history, assess the need for a specific medical test.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Drinking eight glasses of water per day can cure chronic headaches.",
        "output": "This statement is an oversimplification and can be misleading. While proper hydration can help prevent headaches caused by dehydration, there are many other factors that can contribute to chronic headaches. It cannot be solely addressed or cured by drinking eight glasses of water daily.",
        "instruction": "Assess the quality of a given health-related statement or claim.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 45-year-old male patient presents with persistent non-productive cough, wheezing, and shortness of breath, particularly upon exercising. He was a smoker for 20 years but has recently quit. His symptoms have worsened over the past couple weeks.",
        "output": "ICD-10 Code: J44 - Other chronic obstructive pulmonary disease",
        "instruction": "Given the description of a medical condition, classify it into the appropriate International Classification of Diseases (ICD-10) category.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient underwent a laparoscopic cholecystectomy to remove the gallbladder due to gallstones.",
        "output": "Surgical procedure",
        "instruction": "Identify the type of medical procedure described in the following sentence: \"The patient underwent a laparoscopic cholecystectomy to remove the gallbladder due to gallstones.\"",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient is advised to take ibuprofen to alleviate the pain.",
        "output": "Treatment",
        "instruction": "Classify the following sentence as either describing a cause, treatment, or symptom of a disease.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Colonoscopy",
        "output": "Invasive",
        "instruction": "Identify if a given medical procedure is invasive or non-invasive.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Severe chest pain, shortness of breath, and sweating.",
        "output": "Emergency",
        "instruction": "Classify patient cases as either \"emergency\" or \"non-emergency\" based on the given symptoms.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Fever, chills, cough, chest pain, shortness of breath",
        "output": "Pneumonia",
        "instruction": "Given a list of symptoms, determine the most likely health condition or specify 'unknown' if there is not enough information to determine a condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient weighs 80 kg, and the medication prescription states to administer 0.3 mg per kg of body weight per day.",
        "output": "24 mg per day",
        "instruction": "Analyze the given information and calculate the dosage of medication per day for the patient.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Automated External Defibrillator (AED)",
        "output": "Class III",
        "instruction": "Classify the following medical device into one of the classes (Class I, Class II, or Class III) according to the risk level it poses.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 55-year-old patient presents with chest pain, shortness of breath, and fatigue. The patient has a history of smoking and hypertension.",
        "output": "The patient's symptoms and medical history suggest a number of potential diagnoses, including myocardial infarction, pulmonary embolism, and congestive heart failure. Based on the available information, the most likely diagnosis is myocardial infarction, followed by pulmonary embolism and congestive heart failure.",
        "instruction": "Given a patient's symptoms and medical history, determine a list of potential diagnoses and rank them based on probability.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 45, BMI: 35, family history of diabetes: Yes, physically active: No.",
        "output": "High",
        "instruction": "Using the information provided, assess if the patient's risk for developing type 2 diabetes is low, moderate, or high.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Height: 1.80 meters, Weight: 80 kg",
        "output": "Your BMI is 24.7, which falls within the normal weight category.",
        "instruction": "Based on provided user information, calculate BMI and indicate if the user is underweight, normal weight, overweight or obese.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Height: 5 feet 9 inches, Weight: 210 pounds",
        "output": "BMI: 31, Interpretation: Obesity",
        "instruction": "Using the given patient information, calculate the body mass index (BMI) and provide a general interpretation.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "",
        "output": "Wearing a mask during the COVID-19 pandemic helps reduce the spread of the virus by blocking respiratory droplets that may contain the virus, protecting both the individual wearing the mask and those around them.",
        "instruction": "State the importance of wearing a mask during the COVID-19 pandemic.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "False",
        "instruction": "Determine if the following statement is true or false: Immunizations only protect the individual who receives them.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient presents with fever, chills, and cough. They also report recent travel to a tropical region.",
        "output": "The likely diagnosis is malaria, which is common in many tropical regions and presents with symptoms including fever and chills.",
        "instruction": "Answer the following question based on the provided clinical scenario: what is the likely diagnosis for a patient presenting with fever, chills, and cough?",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "1. Have you been feeling down or hopeless lately? \n2. Do you find that you are disinterested in things that you used to enjoy? \n3. Have you experienced a significant loss or change in your life recently? \n4. Have you had difficulty sleeping or sleeping too much? \n5. Have you thought about harming yourself lately? \n6. Have you had physical symptoms like fatigue, weight changes, or headaches?",
        "output": "Questions 1, 2, 4, and 5 are appropriate for screening for depression.",
        "instruction": "Given a list of patient interview questions, select the appropriate ones to ask when screening for depression.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Blood type O negative is considered the universal donor.",
        "output": "True",
        "instruction": "Evaluate the given statement and state whether it is true or false.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient: 35-year-old female with suspected vitamin D deficiency. \\nDiagnostic Test: Serum 25-hydroxyvitamin D (25(OH)D) test \\nInterpretation:",
        "output": "Serum 25(OH)D test result: 30 ng/mL \\nInterpretation: Vitamin D insufficiency (deficient <20 ng/mL; insufficient 20-29 ng/mL; sufficient >30 ng/mL)",
        "instruction": "Given a clinical scenario, identify the appropriate diagnostic test and interpret the test results.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Complex term: Myocardial infarction",
        "output": "Heart attack",
        "instruction": "Simplify a complex medical term or jargon into layman's terms.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Aspirin is an anticoagulant drug.",
        "output": "False",
        "instruction": "Determine if a given medical statement is true or false based on available medical knowledge.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The doctor prescribes amoxicillin 20 mg/kg/day divided into 3 doses for a child weighing 22 kg. Calculate the dosage to be taken with each dose.",
        "output": "The child should take 146.67 mg of amoxicillin with each dose.",
        "instruction": "Calculate the dosage of the mentioned drug based on the provided information.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Shortness of breath",
        "output": "Severe form of COVID-19",
        "instruction": "Classify the given symptom as typically associated with a mild form of COVID-19, severe form, or not related to COVID-19.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 35-year-old man complains of sudden severe headache, vomiting, neck stiffness, and sensitivity to light.",
        "output": "The most likely diagnosis based on the presented symptoms is meningitis.",
        "instruction": "Given a short medical scenario, identify the most likely diagnosis based on the presented symptoms.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Research question: What is the impact of obesity on the development of type 2 diabetes?\nArticles:\nA) The role of inflammation and oxidative stress in obesity-induced insulin resistance.\nB) Gut microbiota, intestinal permeability, and obesity-associated insulin resistance.\nC) Adipocyte dysfunction in obesity and insulin resistance: molecular mechanisms and clinical implications.",
        "output": "C) Adipocyte dysfunction in obesity and insulin resistance: molecular mechanisms and clinical implications.",
        "instruction": "Given a list of biomedical research articles, select the most relevant one based on a provided research question.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Aspirin, Zoloft, Prozac, Tylenol, prednisone, ibuprofen, Xanax",
        "output": "- Pain relievers: Aspirin, Tylenol, Ibuprofen\n- Antidepressants: Zoloft, Prozac\n- Anti-anxiety: Xanax\n- Steroid: Prednisone",
        "instruction": "Given a list of treatments or medications, organize the list by categorizing them into proper categories.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Number of beats: 22, Time period: 15 seconds",
        "output": "Heart rate = 88 beats per minute",
        "instruction": "Calculate the heart rate in beats per minute, given the following information.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Hemoglobin A1c: 7.4%",
        "output": "Abnormal; a Hemoglobin A1c level of 7.4% is indicative of poor blood sugar control and diabetes.",
        "instruction": "Interpret the given laboratory result and determine if it is normal or abnormal.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "ECG results: Sinus rhythm, heart rate 88 bpm, PR interval 180 ms, QRS duration 100 ms, QTc 450 ms, no significant ST changes.",
        "output": "No significant abnormalities detected in the given ECG results.",
        "instruction": "Interpret the given electrocardiogram (ECG) results to identify any abnormalities.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Guidelines for diagnosing and treating osteoporosis in postmenopausal women",
        "output": "Effectiveness: Guidelines prioritize preventive measures and early intervention, leading to improved health outcomes and quality of life for postmenopausal women.\\nLimitations: Guidelines may not adequately consider individual patient factors and may be limited by access to resources and expertise.",
        "instruction": "Given a set of medical guidelines or recommendations, evaluate their effectiveness and potential limitations in a real-world clinical setting.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Mild headache",
        "output": "Ibuprofen or acetaminophen",
        "instruction": "Recommend an over-the-counter medication for a common ailment.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "High fever, difficulty breathing, severe headache, chest pain",
        "output": "Yes, these symptoms require immediate medical attention as they could indicate a serious condition. Seek emergency care.",
        "instruction": "Determine whether the given symptoms require an immediate medical attention.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Gram-negative rods, history of urinary catheterization",
        "output": "The most likely infection site is the urinary tract.",
        "instruction": "Given a pathogen and host characteristics, identify the most likely infection site.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Test Result: Hemoglobin level is 9.5 g/dL",
        "output": "Yes",
        "instruction": "Based on the following blood test result, determine if the individual has anemia.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "A bronchoscopy is a procedure used to examine the inside of the airways and lungs, diagnose lung conditions, or collect samples for testing, and, in some cases, to treat certain lung problems.",
        "instruction": "What is the main purpose of a bronchoscopy?",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "List of current medications and medical history for the patient.",
        "output": "Based on the patient's medical history and current medication regimen, there are potential drug interactions and contraindications that suggest a need for adjustment of medication dosages or discontinuation of certain medications.",
        "instruction": "Evaluate the appropriateness of a patient's current medication regimen based on their medical history and any potential drug interactions or contraindications.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient presents with abdominal pain, bloating, diarrhea, and a history of lactose intolerance. What might be a possible root cause?",
        "output": "The symptoms suggest that the patient may be suffering from lactose intolerance.",
        "instruction": "Given a list of symptoms and a medical history, suggest a possible root cause.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient is a 32-year-old female experiencing ongoing fatigue, excessive thirst, and frequent urination for the past three weeks. She has also noted a rapid, unexplained weight loss despite an increased appetite.",
        "output": "The patient's symptoms are suggestive of type 1 diabetes. Further diagnostic tests, such as blood glucose level measurements and HbA1c testing, should be performed to confirm the diagnosis.",
        "instruction": "Given a description of a medical case or scenario, analyze the situation and provide a potential diagnosis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Blood pressure: 130/80 mm Hg, Heart rate: 90 bpm, Temperature: 98.6 \u00b0F, Respiratory rate: 16 breaths/min.",
        "output": "Condition: Normal",
        "instruction": "Given a patient's health data, classify their condition as normal or abnormal.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Scenario: A nurse discusses a patient's medical condition with their spouse without the patient's consent.",
        "output": "This scenario is a HIPAA violation, as the healthcare provider is sharing patient information without the consent of the patient.",
        "instruction": "Given a medical scenario, identify if it is a HIPAA violation or not.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Data for chronic obstructive pulmonary disease (COPD) classification: FEV1/FVC < 70%, bronchodilator response < 12%.",
        "output": "Classification: Severe COPD.",
        "instruction": "Given a set of patient data, classify their health status according to a specific medical condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient agrees to undergo a surgical procedure after the doctor explains the risks, benefits, and alternatives to them.",
        "output": "Yes, this is an example of informed consent.",
        "instruction": "Determine whether the given scenario is an example of informed consent in a healthcare setting.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "False",
        "instruction": "Decide if the following statement about vaccines is true or false: \"Vaccines can cause an infection in healthy individuals.\"",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Classify medical images into normal or abnormal.",
        "output": "An example of a classification task in the biomedical domain is categorizing chest X-ray images as either normal or displaying signs of pneumonia.",
        "instruction": "Give an example of a classification task in the biomedical domain.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 35, Weight: 70 kg, Height: 1.75 m",
        "output": "BMI: 22.86",
        "instruction": "Given a patient's age, weight, and height, calculate their Body Mass Index (BMI) using the formula: BMI = weight (kg) / height (m)^2",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Throat infection lasting 1 week, sore throat, fever, malaise, and enlarged lymph nodes.",
        "output": "Acute",
        "instruction": "Given the medical description, categorize the condition as acute or chronic.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "Common cold, influenza, heart attack, stroke",
        "instruction": "Rank the severity of the following medical conditions from least severe to most severe: common cold, influenza, stroke, heart attack.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 45\nBMI: 29\nExercise habits: Sedentary\nDiet: High-calorie",
        "output": "Both increase physical activity and reduce calorie intake.",
        "instruction": "Given a patient's information, determine which of the following choices that the patient should consider: \"Increase physical activity\", \"Reduce calorie intake\", \"Both increase physical activity and reduce calorie intake\".",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Grocery shopping, attending an indoor concert, jogging outdoors, dining in a restaurant",
        "output": "Grocery shopping: 2, attending an indoor concert: 5, jogging outdoors: 1, dining in a restaurant: 4",
        "instruction": "Given a list of daily activities, rate the risk of spreading COVID-19 for each activity on a scale of 1 to 5 (1 = low risk, 5 = high risk).",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Description: 55-year-old hypertensive female with fluid retention.\\nPrescribed medication: Furosemide.",
        "output": "Yes, Furosemide is an appropriate medication for fluid retention in hypertensive patients.",
        "instruction": "Given a patient's case description, evaluate if the prescribed medication for the issue is appropriate.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: fever, cough, shortness of breath, fatigue \\n Possible diagnoses: pneumonia, bronchitis, asthma, common cold, COVID-19",
        "output": "Based on the symptoms provided, the most appropriate diagnosis is COVID-19. It is important to seek medical attention and follow proper quarantine procedures.",
        "instruction": "Given a patient's symptoms, select the most appropriate diagnosis from a list of possible options.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A retrospective cohort study evaluated the effectiveness of a new medication for treatment of multiple sclerosis. Patients were identified from electronic health records and followed for two years. The study found that patients who received the new medication had a significantly lower risk of relapse compared to those on standard therapy.",
        "output": "\"Validity\": The use of electronic health records may have introduced selection bias if patients who had better access to care or were more likely to receive the new medication were overrepresented in the study population. \"Limitations\": Retrospective cohort studies are subject to confounding and other sources of bias, and may not provide strong evidence of causality.",
        "instruction": "Given a description of a medical study's methodology, evaluate the study's validity and potential limitations.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Convert 180 pounds to kilograms.",
        "output": "81.6 kilograms",
        "instruction": "Convert between different measurement units in a medical context.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 45-year-old man experiences sudden chest pain, shortness of breath, and pain radiating down the left arm while exercising at the gym.",
        "output": "Yes, this situation requires immediate medical attention. The symptoms described such as sudden chest pain, shortness of breath, and pain radiating down the left arm are indicative of a potential heart attack. In this case, seeking emergency care is crucial to minimize damage and increase the chances of survival.",
        "instruction": "Given a healthcare scenario, determine if the situation described requires immediate medical attention. Provide a short explanation for your decision.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "DNA",
        "output": "The field of study associated with the analysis of DNA is genetics.",
        "instruction": "Name the field of study associated with the analysis of the given biomolecule.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The wait time was quite long, but overall, the staff was friendly, and the doctor was thorough in discussing my concerns.",
        "output": "Positive",
        "instruction": "Perform sentiment analysis on a patient's feedback and classify it as positive, negative, or neutral.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Sudden severe headache, difficulty speaking, loss of balance, sudden vision changes, and one-sided facial drooping.",
        "output": "Yes, the patient should seek immediate medical attention, as these symptoms could indicate a stroke.",
        "instruction": "Given a list of symptoms, determine if the patient should seek immediate medical attention.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient reported experiencing slight dizziness, occasional muscle pain, and persistent fatigue.",
        "output": "Mild: Slight dizziness, Occasional muscle pain; Moderate: None; Severe: Persistent fatigue",
        "instruction": "Evaluate the severity of mentioned symptoms provided in the snippet and classify them into mild, moderate, or severe.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "1. Patient privacy and data security: AI systems often require large amounts of sensitive patient information to function effectively, raising concerns about data misuse or unauthorized access, which could compromise patient privacy.\n2. Bias in AI decision-making: AI algorithms may inadvertently reinforce existing biases or disparities in healthcare due to biased training data, leading to unfair or unequal treatment of patients based on factors like race, gender, or socioeconomic status.",
        "instruction": "Identify two potential ethical concerns in the use of artificial intelligence in healthcare settings and briefly explain why they might be problematic.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Fever, cough, shortness of breath, loss of taste or smell.",
        "output": "The patient exhibits symptoms consistent with COVID-19 infection according to established diagnostic guidelines.",
        "instruction": "Given a set of symptoms or medical conditions, classify the patient into the appropriate diagnostic category according to established diagnostic guidelines or criteria.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient lab results: Age: 68 years, Serum creatinine: 2.4 mg/dL, Estimated glomerular filtration rate (eGFR): 35 mL/min/1.73m\u00b2",
        "output": "Stage 3 CKD (Moderate decrease in kidney function)",
        "instruction": "Based on the given lab results, classify the patient's kidney function using the estimated glomerular filtration rate (eGFR) and appropriate stages of chronic kidney disease (CKD).",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "High-density lipoprotein (HDL)",
        "output": "Good cholesterol",
        "instruction": "Classify the following example as either good cholesterol or bad cholesterol.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Drinking alcohol daily",
        "output": "Harmful",
        "instruction": "Classify the given lifestyle choice as either beneficial or harmful to one's health.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Blood Pressure: 138/86 mm Hg",
        "output": "The patient's blood pressure reading of 138/86 mm Hg is classified as stage 1 hypertension according to standard guidelines.",
        "instruction": "Given a patient's blood pressure readings, classify their blood pressure status according to standard guidelines.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient complains of dizziness and nausea after starting a new medication prescribed for high blood pressure.",
        "output": "Possible side effect",
        "instruction": "Based on the information provided, categorize the patient's complaint as a possible side effect, drug interaction, or adverse reaction.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Drinking cold water after a meal can cause cancer.",
        "output": "Myth",
        "instruction": "Identify if the following statement is a fact or a myth: Drinking cold water after a meal can cause cancer.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Weight of animal 1: 10 kg, dosage: 5 mg/kg; weight of animal 2: 70 kg, dosage: 1 mg/kg; weight of animal 3: 30 kg.",
        "output": "Dosage for animal 3: 2.4 mg/kg.",
        "instruction": "Given the weights and dosages of two animals, calculate the dose for a third animal with a specified weight using allometric scaling.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Fever, productive cough, fatigue, shortness of breath",
        "output": "The underlying medical condition could be a respiratory infection such as pneumonia.",
        "instruction": "Given a description of a patient's symptoms, diagnose the underlying medical condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 200 lb patient needs to take 500 mg of a medication.",
        "output": "The patient should take 250 mg of the medication.",
        "instruction": "Identify the correct medication dosage based on the patient's weight.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient complains of fatigue, muscle weakness, and weight loss. The laboratory results show low levels of potassium and high levels of cortisol.",
        "output": "The most likely disorder is Cushing Syndrome.",
        "instruction": "Given a set of symptoms and laboratory results, identify the most likely disorder.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A dataset of patients with diabetes, including their age, sex, HbA1c levels, and BMI.",
        "output": "Patients can be classified into different categories based on their disease severity, such as uncontrolled diabetes (HbA1c>7), controlled diabetes (HbA1c<7), or pre-diabetes. Patients can also be classified based on their age range and BMI.",
        "instruction": "Given a clinical dataset, classify patients into different categories based on common characteristics, such as disease severity, age range, or gender.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient has a history of penicillin allergy and is currently taking lisinopril for hypertension. A new medication, amoxicillin, is being considered for treatment of an infection.",
        "output": "No, amoxicillin should not be used as it is in the same drug class as penicillin and may cause an allergic reaction.",
        "instruction": "Given a patient's allergies and medication history, determine if a new medication being considered is safe for use.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Fatigue, pale skin, occasional dizziness. Lab results: Hemoglobin 11.1 g/dL",
        "output": "Mild anemia",
        "instruction": "Given patient symptoms and lab results, classify the severity of their anemia.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: fever, sore throat, difficulty swallowing, swollen lymph nodes. Condition: Tonsillitis",
        "output": "Yes, the symptoms (fever, sore throat, difficulty swallowing, swollen lymph nodes) are consistent with tonsillitis.",
        "instruction": "Given a list of symptoms and a possible condition, assess if the symptoms are consistent with the condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient presents with fatigue, pallor, and dyspnea upon exertion. Laboratory values show low hemoglobin and hematocrit levels and an elevated mean corpuscular volume (MCV). What type of anemia is the patient likely experiencing?",
        "output": "The patient is likely experiencing megaloblastic anemia, which is characterized by low hemoglobin and hematocrit levels and an elevated MCV due to impaired DNA synthesis in red blood cells.",
        "instruction": "Given a set of clinical and laboratory values, diagnose the patient with a type of anemia.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient presented with a fever of 101.2\u00b0F, cough, and shortness of breath.",
        "output": "Infectious",
        "instruction": "Given a patient's symptoms, classify their condition as either infectious or non-infectious.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient reports persistent muscle pain after starting a new statin medication. Is it likely that the statin is causing the muscle pain?",
        "output": "Muscle pain is a known adverse effect of statin medications, and the timing of the onset of the symptom shortly after starting the medication suggests a possible association. Further investigation, such as discontinuing the medication or performing additional diagnostic tests, may be necessary to confirm the relationship.",
        "instruction": "Given a medication and an adverse effect reported by the patient, evaluate the likelihood of the medication causing the adverse effect.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medication side effects: dizziness, headache, dry mouth, increased heart rate. Patient medical conditions: hypertension, diabetes, and a history of heart attack.",
        "output": "The medication may not be safe for the patient due to the increased heart rate side effect, considering their history of heart attack and hypertension.",
        "instruction": "Given the side effects of a medication, determine if the medication is safe for the patient with specific medical conditions.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical Device: Glucometer",
        "output": "Diagnostic",
        "instruction": "Classify the medical device into one of the following categories: diagnostic, therapeutic or assistive.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Blood pressure: 150/90 mmHg, Heart rate: 120 bpm, Respiratory rate: 20 breaths/min, Temperature: 38.5\u00b0C",
        "output": "Medical emergency",
        "instruction": "Given a set of vital signs (blood pressure, heart rate, respiratory rate, temperature), determine if they indicate a medical emergency or not.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient is a 35-year-old male who experiences frequent urination, increased thirst, extreme hunger, sudden weight loss, tiredness, and blurred vision. He was previously healthy, with no family history of diabetes.",
        "output": "Type 1 diabetes",
        "instruction": "Based on an individual patient's symptoms, classify them into either Type 1 or Type 2 diabetes.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Dosing instructions: 10 mg/kg. Patient weight: 60 kg.",
        "output": "Appropriate dose: 600 mg",
        "instruction": "Given a medication's dosing instructions and a patient's weight, calculate the appropriate dose for the patient in milligrams.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "We compared baseline characteristics, 30-day readmission rate, length of hospital stay, and in-hospital mortality between patients who underwent transradial percutaneous coronary intervention (TR-PCI) and those who underwent transfemoral percutaneous coronary intervention (TF-PCI).",
        "output": "1. baseline characteristics\n2. 30-day readmission rate\n3. length of hospital stay\n4. in-hospital mortality",
        "instruction": "Read the given paragraph from a biomedical manuscript and list the variables compared in the study.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Cholesterol is always harmful to the human body.",
        "output": "False",
        "instruction": "Determine if the provided statement is true or false based on current medical knowledge.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Fever, cough, chest pain, difficulty breathing, fatigue. Medical records reveal a history of smoking and a recent respiratory infection. Chest X-ray shows fluid in the lungs.",
        "output": "Pneumonia",
        "instruction": "Given a patient's medical records and symptoms, classify the condition as pneumonia or bronchitis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Antibiotics effectively treat all types of infections, including those caused by viruses.",
        "output": "The statement is not valid. Antibiotics have no effect on viral infections and are only used to treat bacterial infections.",
        "instruction": "Evaluate the validity of this statement about antibiotics.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Vitals: blood pressure of 130/85 mmHg, heart rate of 90 bpm, respiratory rate of 18 breaths per minute.",
        "output": "The patient's blood pressure is elevated, but not concerning. The heart rate and respiratory rate are within normal ranges. To manage the elevated blood pressure, the patient may need to make lifestyle changes (e.g. exercise, healthy diet) or start medication.",
        "instruction": "Given a set of patient vitals (e.g. blood pressure, heart rate, respiratory rate), categorize the patient's condition as normal, elevated, or concerning and suggest appropriate actions.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Type 1 diabetes is often diagnosed in children and young adults. Type 2 diabetes is more common and occurs when the body doesn't use insulin properly. People with diabetes can never eat sweets or candies.",
        "output": "People with diabetes can never eat sweets or candies. (False statement)",
        "instruction": "Identify the false statement within the given set of facts about diabetes.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical condition: Suspected pulmonary embolism",
        "output": "Imaging modality: CT pulmonary angiography.",
        "instruction": "Select the appropriate imaging modality for the given medical condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Laboratory results:\nElevated white blood cell count and C-reactive protein level. Negative results for influenza, strep, and respiratory syncytial virus.",
        "output": "These laboratory results may be indicative of a bacterial infection. Further testing and evaluation may be necessary to determine the specific type of infection.",
        "instruction": "Given a set of laboratory results, diagnose the medical condition that the patient may be experiencing.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Fever, fatigue, shortness of breath, and coughing up phlegm.",
        "output": "Disease/Condition: Pneumonia.",
        "instruction": "Given a set of patient symptoms, classify the disease or condition that is most likely responsible for these symptoms.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical database containing patient demographic data, medical history, and results from relevant tests and screenings.",
        "output": "A model that predicts which patients are at high risk for developing a certain disease based on factors such as age, family history, blood glucose levels, and cholesterol levels.",
        "instruction": "Given a medical database, develop a predictive model to identify patients at high risk for developing a certain disease (e.g. diabetes, heart disease, etc.).",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Fever, cough, shortness of breath, body aches, headache, loss of taste or smell",
        "output": "COVID-19",
        "instruction": "Given a list of recent symptoms, determine if they are indicative of a common cold, the flu, or COVID-19.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Lab results show a serum creatinine level of 1.2 mg/dL.",
        "output": "A serum creatinine level of 1.2 mg/dL is within the normal range for an adult.",
        "instruction": "Determine if a diagnostic test result is within normal range.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "People who drink coffee are not at risk of developing Alzheimer's disease because I've never seen anyone in my family, who are all coffee drinkers, develop Alzheimer's.",
        "output": "[\"Anecdotal evidence\", \"Confirmation bias\", \"Hasty generalization\"]",
        "instruction": "Evaluate the given text and identify any possible cognitive biases or logical fallacies.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Regular physical activity can contribute to a reduced risk of developing type 2 diabetes.",
        "output": "Accurate",
        "instruction": "Evaluate the following statement for its accuracy based on current knowledge in the medical field.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Adult dose: 500mg; Child's weight: 40kg; Adult weight: 70kg",
        "output": "286mg",
        "instruction": "Convert the given adult dose of a medication into a child's dose based on weight.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "",
        "output": "Thyroid-stimulating hormone (TSH) is a hormone produced by the pituitary gland. Its primary role is to regulate the production and release of thyroid hormones, specifically triiodothyronine (T3) and thyroxine (T4), from the thyroid gland. TSH helps maintain proper thyroid function, which is essential for regulating the body's metabolism, growth, development, and energy levels.",
        "instruction": "Explain the role of thyroid-stimulating hormone (TSH) in the body.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Vaccine 1: MMR - measles, mumps, rubella; Vaccine 2: HPV - human papillomavirus; Vaccine 3: yellow fever - yellow fever",
        "output": "UNKNOWN",
        "instruction": "Given a list of vaccines and their target infections, identify the vaccine(s) that would be appropriate for a specific patient based on their age, health status, and travel plans.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Weight: 75 kg, Height: 1.75 m",
        "output": "BMI: 24.49; Status: Normal weight",
        "instruction": "Calculate the BMI given a person's weight and height and determine whether the person is underweight, normal weight, overweight, or obese.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Statement: Type 1 diabetes is caused by lifestyle factors such as poor diet and inactivity.",
        "output": "Incorrect. Type 1 diabetes is caused by an autoimmune response where the body's immune system destroys insulin-producing cells in the pancreas.",
        "instruction": "Evaluate the correctness of the given medical statement, and if it is incorrect, provide the correct information.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Chest pain, shortness of breath, headache, ankle pain",
        "output": "1. Chest pain\n2. Shortness of breath\n3. Headache\n4. Ankle pain",
        "instruction": "Given a list of medical conditions or concerns, prioritize them in order of urgency for follow-up care.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: fever, cough, shortness of breath; Lab test results: positive for COVID-19; Diagnosis: COVID-19 infection",
        "output": "Classification: COVID-19 infection",
        "instruction": "Classify the given medical report based on the provided symptoms, lab test results, and diagnosis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient: 65-year-old male with a history of hypertension and diabetes. Currently taking Lisinopril and Metformin. Blood pressure and blood sugar levels remain elevated despite treatment. \\nRecommended adjustments to the treatment plan:",
        "output": "Adjustments: Increase the dosage of Lisinopril or switch to a different medication to better manage hypertension, and add a second-line agent (e.g., Sulfonylurea) to the regimen to improve glycemic control.",
        "instruction": "Given a patient's medical history and treatment plan, evaluate the effectiveness of the current treatment and recommend any necessary adjustments.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "38.5 \u00b0C",
        "output": "101.3 \u00b0F",
        "instruction": "Convert the following temperature from Celsius (\u00b0C) to Fahrenheit (\u00b0F): \"38.5 \u00b0C.\"",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical Condition: Migraine\nMedication: Sumatriptan",
        "output": "Yes, Sumatriptan is commonly prescribed as a treatment for migraines.",
        "instruction": "Given a medical condition and a medication, indicate whether the medication is commonly prescribed as a treatment for the condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Hypertension",
        "output": "High blood pressure",
        "instruction": "Translate the given medical term into plain English, explaining its meaning in a way that is clear and understandable to non-medical individuals.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "This single-arm, open-label study aims to evaluate the safety and efficacy of a new treatment for lung cancer in 20 patients.",
        "output": "Not a randomized controlled trial (RCT)",
        "instruction": "Given a clinical trial description, determine if it is a randomized controlled trial (RCT) or not.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Over-the-counter pain reliever acetaminophen is an anti-inflammatory drug commonly used to treat arthritis pain.",
        "output": "Inaccurate",
        "instruction": "Determine if the given information about a medication is accurate or inaccurate.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Amino acids can travel through the bloodstream and stimulate the pancreas to release insulin, a hormone that lowers blood sugar levels.",
        "output": "Amino acids can travel through the bloodstream and stimulate the pancreas to release insulin; however, insulin is a hormone that lowers blood glucose levels, not sugar levels.",
        "instruction": "Evaluate the accuracy of the below medical statement and correct it if needed.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient medical history: 57-year-old male with a history of chronic kidney disease, hypertension, and gout. Blood test results: Hemoglobin 7.8 g/dL, mean corpuscular volume (MCV) 84 fL, ferritin 30 ng/mL, and iron 60 mcg/dL.",
        "output": "Classification: Anemia of chronic kidney disease. Further diagnostic testing may be necessary to evaluate for other potential causes of anemia.",
        "instruction": "Given a patient's medical history and blood test results, classify the type of anemia.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Topic: The impact of exercise on mental health\nTitles:\na) The relationship between diet and mental health\nb) The role of physical activity in preventing obesity\nc) The influence of exercise on anxiety and depression",
        "output": "Most relevant article: The influence of exercise on anxiety and depression (c)",
        "instruction": "Identify the most relevant research article from a list of titles based on a given topic.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Diagnosis: Pharyngitis",
        "output": "Mild condition",
        "instruction": "Given the diagnosis, classify the severity of the condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "We conducted a study with 120 participants divided into two groups. One group received drug A, while the other group received a placebo. The researchers analyzed the participants' outcomes after six months of treatment.",
        "output": "Randomized controlled trial",
        "instruction": "Classify a given text into a specific type of biomedical research study.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "10 mL",
        "output": "2 teaspoons",
        "instruction": "Convert the following prescription dosage to teaspoon measurements: 10 mL",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical History: asthma, occasional bout of bronchitis\nSymptoms: shortness of breath, persistent cough, chest tightness",
        "output": "Pulmonologist",
        "instruction": "Given a patient's medical history and list of symptoms, determine the appropriate type of specialist for a referral.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "150/95 mmHg",
        "output": "The blood pressure reading 150/95 mmHg indicates stage 1 hypertension, as the normal range is typically below 120/80 mmHg.",
        "instruction": "Analyze the given blood pressure reading and determine whether it is normal or indicates hypertension.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient visits a healthcare facility complaining of a persistent cough and shortness of breath, later diagnosed with pneumonia.",
        "output": "ICD-10 Classification: J18.9 (Pneumonia, unspecified organism)",
        "instruction": "Classify the given medical scenario into ICD-10 categories.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Mary, a 35-year-old female with a history of heavy alcohol use and obesity, has elevated levels of ALT (127 U/L, normal range is 7-56 U/L) and AST (82 U/L, normal range is 5-40 U/L) on her routine blood test.",
        "output": "The elevated levels of ALT and AST are likely caused by hepatic damage, most probably due to Mary's alcohol abuse history and obesity.",
        "instruction": "Identify the most likely cause of a patient's elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient query: What are the side effects of taking metformin for diabetes?",
        "output": "Common side effects of metformin include diarrhea, nausea, stomach upset, and headache. More serious side effects may include lactic acidosis or low blood sugar, but these are less common.",
        "instruction": "Answer the patient's query regarding side effects of a medication.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The primary objective of this trial is to test the vaccine's safety and tolerability, determine the appropriate dosage, and identify potential side effects in a small group of healthy volunteers.",
        "output": "Phase 1",
        "instruction": "Given a description of a treatment's clinical trial, classify it as a Phase 1, Phase 2, or Phase 3 trial.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient is experiencing painful, red, and swollen eyelids.",
        "output": "Ophthalmologist",
        "instruction": "Given a patient's primary complaint, determine whether they should see a dermatologist or an ophthalmologist.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "I have been taking Lisinopril for two weeks and lately, I've been experiencing dizziness, dry cough, and headaches. Are these side effects of the medication or something else?",
        "output": "Dizziness, dry cough, and headaches could be side effects of Lisinopril. However, it's essential to consult with your healthcare professional to determine if these symptoms are related to the medication or another issue.",
        "instruction": "Given a list of symptoms, identify if the symptoms are likely a side effect of a specific medication or an unrelated issue. Base your response on general knowledge and encourage the user to consult with their healthcare professional.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Shortness of breath, chest pain, dizziness, and confusion.",
        "output": "These symptoms indicate a potentially life-threatening condition and require immediate medical attention. Emergency services should be activated and the patient should receive urgent care.",
        "instruction": "Given a set of patient symptoms, classify the severity of the condition and recommend appropriate care.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Systematic review and meta-analysis of randomized controlled trials comparing the efficacy and safety of statins and fibrates in patients with hyperlipidemia.",
        "output": "Secondary source",
        "instruction": "Determine whether the given biomedical research is likely to be a primary source or secondary source.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Fever, cough, chest pain, shortness of breath\nPathological findings: Ground-glass opacities in lung imaging, decreased oxygen saturation levels",
        "output": "The disease associated with these symptoms and findings is COVID-19.",
        "instruction": "Classify the given disease based on its symptoms and pathological findings.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: fever, fatigue, cough, shortness of breath, chest pain, loss of taste/smell, body aches \\nMedical History: No chronic conditions or allergies \\nClassify the patient's illness:",
        "output": "COVID-19",
        "instruction": "Given a list of symptoms and medical history of the patient, classify the patient into the appropriate disease category.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Lab result: Hemoglobin 16.2 g/dL, Reference range: 12.0-15.5 g/dL",
        "output": "Abnormal (High)",
        "instruction": "Given a laboratory test result, describe the result as normal or abnormal based on the reference range provided. If abnormal, specify if it is high or low.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Scenario: A physician treats a patient without disclosing all possible treatment options and potential side effects due to the assumption that the patient would not understand the medical jargon.",
        "output": "The ethical concerns in this scenario include lack of informed consent, patient autonomy, and the physician's paternalistic attitude.",
        "instruction": "Identify the ethical concerns in this medical scenario.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient complaints: Chest pain, shortness of breath, fatigue.",
        "output": "Further evaluation recommended: Yes, evaluation by a cardiologist or pulmonologist is recommended.",
        "instruction": "Given a set of patient complaints, determine if they require further evaluation by a specialist.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical condition: Hypertension\nMedication options: \n- Propranolol\n- Losartan\n- Metoprolol",
        "output": "Losartan is the most appropriate medication for treating hypertension.",
        "instruction": "Given a medical condition and a list of medications, determine which medication is the most appropriate for treating the condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient weighing 80 kg requires 5 mg of medication per kilogram of body weight.",
        "output": "The total dose required would be 400 mg.",
        "instruction": "Given the information, calculate the total dose of a medication needed.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Atrial fibrillation, hypertension, history of stroke",
        "output": "Anticoagulation therapy: Warfarin or direct oral anticoagulants like dabigatran, apixaban, or rivaroxaban",
        "instruction": "Given a set of symptoms, recommend the appropriate anticoagulation therapy for a patient with atrial fibrillation.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 35-year-old female patient presents with a headache, blurred vision, and fatigue. She has a past medical history of hypertension and is currently taking medication for it.",
        "output": "Based on the patient's symptoms and medical history, she may have hypertensive retinopathy, a complication of high blood pressure that affects the retina in the eyes.",
        "instruction": "Given the medical history and symptoms, suggest a diagnosis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A news article claims that a new drug has been discovered that can cure cancer in its early stages.",
        "output": "The claim made in the news article is currently an unproven hypothesis and not a proven fact. Though the article may raise awareness about new research, it may be misleading and cause unnecessary optimism. It is recommended to wait for further clinical testing and peer-reviewed research before making such claims.",
        "instruction": "Given a medical article or news report, assess the reliability and credibility of the source and provide reasoning for the assessment.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Ibuprofen",
        "output": "Anti-inflammatory",
        "instruction": "Classify the following drug as an analgesic, antibiotic, antiviral, or anti-inflammatory.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medication orders:\n- digoxin 0.25 mg daily\n- furosemide 40 mg twice daily\n- lisinopril 10 mg daily",
        "output": "Check for any potential drug interactions on a drug interaction database. Consider adjusting doses or changing medications to avoid interactions.",
        "instruction": "Given a set of medication orders, check for any potential drug interactions and suggest a plan of action.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Listening to music at high volumes can decrease the likelihood of developing osteoporosis.",
        "output": "The hypothesis is not meaningful. There is no scientifically known connection between listening to music at high volumes and a decrease in osteoporosis development.",
        "instruction": "Evaluate the meaningfulness of the given hypothesis and explain your reasoning.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Feeling excessively thirsty, frequent urination, increased hunger, unexplained weight loss, and persistent fatigue.",
        "output": "Yes, these symptoms might correspond to a diagnosis of diabetes.",
        "instruction": "Identify whether the provided symptoms might correspond to a diagnosis of diabetes, based on the evidence given.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient weight: 70 kg\nDosage: 10 mg/kg",
        "output": "The total medication dosage required for the patient is 700 mg.",
        "instruction": "Given a patient's weight and dosage information, calculate the total medication dosage required.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient presents with shortness of breath, chest pain, and coughing with green sputum. They have a history of smoking. A chest X-ray revealed pneumonia.",
        "output": "ICD-10 Category: J18 - Pneumonia, unspecified",
        "instruction": "Classify the given medical scenario into an appropriate ICD-10 category based on the information provided.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "",
        "output": "Acupuncture relieves pain by stimulating specific points on the body, which release endorphins and other natural pain-relieving chemicals, reducing inflammation and promoting relaxation of muscles to improve overall well-being.",
        "instruction": "How does acupuncture relieve pain?",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The individual is experiencing sudden episodes of intense fear, rapid heart rate, shortness of breath, dizziness, and a sense of impending doom.",
        "output": "The individual may be experiencing panic attacks or panic disorder.",
        "instruction": "Given a description of symptoms experienced by a person, provide a possible medical condition or disease that the person may have.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient vital signs: Blood pressure: 180/110 mmHg, Heart rate: 140 bpm, Respiratory rate: 24 breaths per minute, Oxygen saturation: 90%",
        "output": "Immediate medical attention is required.",
        "instruction": "Given a patient's vital signs, assess whether their condition is stable or requires immediate medical attention.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "What is an electrocardiogram (ECG) used for?",
        "output": "An ECG is a diagnostic test used to monitor and record the electrical activity of the heart and identify any abnormalities.",
        "instruction": "Answer a question about medical equipment:",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient history: A 35-year-old female with a history of heavy menstrual bleeding.\nLab results: Low hemoglobin, low mean corpuscular volume (MCV), low serum ferritin, normal total iron-binding capacity (TIBC), and normal vitamin B12 and folate levels.",
        "output": "The patient's anemia is likely due to iron deficiency, as evidenced by the low hemoglobin, low MCV, low serum ferritin, and normal B12 and folate levels, combined with a history of heavy menstrual bleeding.",
        "instruction": "Given the provided patient history and lab results, determine if the patient's anemia is likely due to iron deficiency or another cause.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Chemotherapy for terminal cancer",
        "output": "Palliative",
        "instruction": "Classify a given treatment or therapy based on whether it is preventive, curative, or palliative in nature.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient is taking amoxicillin and amlodipine.",
        "output": "No significant drug-drug interactions are expected between amoxicillin and amlodipine.",
        "instruction": "Given a patient's current medications, assess whether any drug-drug interactions could occur and make recommendations if necessary.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient with a family history of breast cancer and a genetic marker associated with increased cancer risk.",
        "output": "This patient has a higher likelihood of developing breast cancer due to their family history and genetic factors.",
        "instruction": "Predict the likelihood of a patient developing a certain disease based on their medical history and genetic factors.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "45-year-old female, no family history of colorectal cancer, recent onset of abdominal discomfort. Otherwise healthy, non-smoker, physically active, and maintains a balanced diet.",
        "output": "Low risk",
        "instruction": "Given a patient's history, determine if the patient has a high or low risk of colon cancer.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Current Medication: Warfarin\nMedication to Prescribe: Ibuprofen",
        "output": "Drug Interactions:\nIbuprofen may increase the risk of bleeding when taken with Warfarin. Caution should be taken when these medications are used together.",
        "instruction": "Identify the potential drug interactions when prescribing a medication for a patient who is currently taking another medication.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Dataset: Electronic Medical Records from patients with diabetes\nSpecific Condition: Uncontrolled High Blood Sugar",
        "output": "Likelihood of readmission: 70%",
        "instruction": "Given a healthcare dataset, predict the likelihood of readmission for a patient with a specific condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "What is the appropriate diagnostic tool for diagnosing osteoporosis, and why?",
        "output": "The appropriate diagnostic tool for diagnosing osteoporosis is dual-energy X-ray absorptiometry (DXA) scan. DXA scan measures bone density and can detect bone loss before fractures occur.",
        "instruction": "Identify the appropriate diagnostic tool for a given medical condition and explain the reasoning behind the selection.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient has fever, cough, and shortness of breath.",
        "output": "The patient is likely suffering from COVID-19.",
        "instruction": "Given a set of patient symptoms, classify which disease the patient is likely suffering from.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "What are the primary symptoms of COVID-19?",
        "output": "Fever, cough, shortness of breath or difficulty breathing, fatigue, and loss of taste or smell.",
        "instruction": "Given a question, provide a brief and accurate answer.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Question: What is the most effective treatment for Type 2 Diabetes?",
        "output": "The most effective treatments for Type 2 Diabetes are lifestyle changes, such as healthy eating and regular exercise, and medication, such as oral glucose-lowering drugs and insulin therapy.",
        "instruction": "Answer a specific question related to a medical condition or treatment.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Severe abdominal pain and bloating",
        "output": "Gastroenterologist",
        "instruction": "Determine what kind of specialist the patient should see based on their symptoms.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Methods: Participants were randomly assigned to one of two groups: a 10-minute aerobic exercise group (n=12) or a 10-minute rest period group (n=12). Results: The aerobic exercise group performed significantly better on cognitive tasks after the exercise compared to the rest period group. Conclusion: The study proves that participating in 10 minutes of aerobic exercise is an effective way to improve cognitive performance and should be implemented in workplace environments.",
        "output": "The conclusion appears to be reasonable, but more studies with larger sample sizes and taking other factors into account (such as the type of cognitive tasks, long-term effects, and individual variations) are needed to strengthen the validity of the study's claims.",
        "instruction": "Given a summary of a research study's methods and results, assess the validity of the conclusions made in the study.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A blog post by someone who claims to have cured their cancer with an all-natural diet.",
        "output": "Credibility: Low, as it is a personal experience post without scientific evidence. Potential biases: Confirmation bias, survivorship bias, and commercial interests if promoting a specific product or service.",
        "instruction": "Assess the reliability of the given health information source by stating its credibility and potential biases.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Context: A young woman presents with fever, sore throat, and swollen glands. \\nMedical Term: Menopause",
        "output": "Not relevant",
        "instruction": "Assess the relevance of the given medical term to the provided context.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Diagnosis: Fibromyalgia \nSymptoms: Widespread pain, fatigue, headaches, sleep disturbances, cognitive difficulties, irritable bowel syndrome, painful menstrual periods",
        "output": "LIKELY",
        "instruction": "Given a medical diagnosis and a list of symptoms, classify the diagnosis into either 'likely' or 'unlikely'.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Given a patient presenting with nausea and abdominal pain, predict the likelihood of cholecystitis.",
        "output": "The patient may be experiencing symptoms of cholecystitis, although further testing and evaluation are necessary for a confirmed diagnosis.",
        "instruction": "Given a certain medical symptom presentation, predict the likelihood of an underlying medical condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "What does MRI stand for?",
        "output": "Magnetic Resonance Imaging",
        "instruction": "Given an acronym frequently used in healthcare, provide the full term it represents.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Height: 5 feet 8 inches, Weight: 200 pounds",
        "output": "BMI: 30.4, Category: \"Obese\"",
        "instruction": "Calculate the body mass index (BMI) using the given height and weight, and determine the corresponding category (underweight, normal, overweight, or obese) based on BMI.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Blood glucose levels of 200 mg/dL, HbA1c levels of 8%, and sugar in the urine.",
        "output": "These biomarker measurements suggest a diagnosis of diabetes mellitus.",
        "instruction": "Given a set of clinical biomarker measurements, predict the corresponding diagnosis or disease state.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptom: \"I have a sudden, severe pain in the lower right side of my abdomen.\"",
        "output": "Recommended medical specialist: Gastroenterologist or General Surgeon (for possible acute appendicitis evaluation)",
        "instruction": "Given a symptom description, recommend the most appropriate medical specialist for further evaluation.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Height: 5'6\" (1.68 m), Weight: 180 lbs (81.65 kg)",
        "output": "BMI: 29.07, classified as overweight.",
        "instruction": "Calculate the body mass index (BMI) using the provided height and weight, and classify the individual's weight status.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Anti-A: agglutination\nAnti-B: no agglutination\nAnti-D: agglutination",
        "output": "Blood type: A positive (A+)",
        "instruction": "Given a patient's lab results, determine their blood type based on the ABO blood group system.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "Aspirin: acidic, Bleach: basic, Pure Water: neutral",
        "instruction": "Classify the following chemicals as acidic, basic, or neutral. Aspirin, bleach, pure water.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "None",
        "output": "No",
        "instruction": "Determine if the following symptom is commonly associated with an allergic reaction: excessive sweating.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Fever, cough, fatigue, shortness of breath",
        "output": "Possible infection: respiratory infection",
        "instruction": "Given a set of key symptoms, identify which type of infection is likely present.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Consuming apple cider vinegar every day can help you lose weight without any exercise or dietary changes.",
        "output": "Debunked",
        "instruction": "Assess the provided health claim and determine if it is scientifically supported or debunked.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient 1: Stage 3 colon cancer\nPatient 2: Mild asthma, occasional wheezing \nPatient 3: Severe case of psoriasis",
        "output": "Patient 1: Stage 3 colon cancer \nPatient 2: Mild asthma \nPatient 3: Severe psoriasis",
        "instruction": "Given a set of patient data, classify each case into the appropriate category based on their medical condition, such as cancer stage or disease severity.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Weight: 85 kg, Height: 1.75 m",
        "output": "BMI = 27.8 kg/m^2 (calculated as weight (kg) / height (m)^2)",
        "instruction": "Based on the given information, calculate the patient's body mass index (BMI).",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Article title: \"Effects of exercise on cognitive function in older adults with mild cognitive impairment\"\nQuery: \"How does physical activity affect Alzheimer's disease progression?\"",
        "output": "Relevant",
        "instruction": "Determine the relevance of the given biomedical research article to the provided query.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 38, BMI: 31.3, family history of type 2 diabetes, sedentary lifestyle, recent blood sugar test: normal",
        "output": "At risk. The individual has several risk factors for type 2 diabetes, including BMI in the obese range, a family history of the disease, and a sedentary lifestyle.",
        "instruction": "Given the provided medical information, assess if the individual is at risk for type 2 diabetes.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical history: the patient has a family history of heart disease. Symptoms include chest pain, shortness of breath, and fatigue.",
        "output": "The patient's condition is classified as heart disease, which can be caused by both genetic and environmental factors.",
        "instruction": "Given a patient's medical history and symptoms, classify the patient's condition into one of the following categories: infectious, autoimmune, genetic, or environmental.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Protein sequences of MYO5A from human, mouse, rat, and zebrafish.",
        "output": "The MYO5A protein is highly conserved across all four species, suggesting that it has an important role in cellular function. Phylogenetic analysis based on sequence alignment shows that the human and mouse sequences are more closely related to each other than to the rat and zebrafish sequences.",
        "instruction": "Given a set of protein sequences from different species, identify the homologous proteins and construct a phylogenetic tree based on sequence similarity.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: Fever, shaking chills, productive cough with yellow or green sputum, shortness of breath, chest pain",
        "output": "Pneumonia",
        "instruction": "Given a patient's signs and symptoms, classify their most likely diagnosis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "When taken together, the blood pressure medication lisinopril and the potassium supplement potassium chloride may increase the levels of potassium in your blood, causing a condition called hyperkalemia.",
        "output": "Moderate",
        "instruction": "Classify the severity of a drug interaction as mild, moderate, or severe based on the provided information.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Myocardial infarction",
        "output": "Heart attack",
        "instruction": "Simplify the given medical term using a layperson-friendly synonym or explanation.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient medical history: Frequent headaches, seizures, memory loss, CT scan shows a mass in the brain.",
        "output": "Brain tumor present",
        "instruction": "Given a patient's medical history and imaging results, determine if they have a brain tumor.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Presence of ketones in the urine",
        "output": "Lab result",
        "instruction": "Determine if the given statement is part of the patient's medical history, a physical exam finding, or a lab result.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: fatigue, fever, joint swelling and pain, rashes, loss of appetite, nausea, vomiting. Laboratory results: Erythrocyte sedimentation rate- 32mm/hr (normal range <20), C-reactive protein- 18mg/L (normal range <3), Rheumatoid factor- positive",
        "output": "The patient's disease can be classified as Rheumatoid Arthritis (ICD code- M05.9).",
        "instruction": "Given a patient's symptoms and laboratory results, classify their disease based on the International Classification of Diseases (ICD) codes.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Aspirin and ibuprofen",
        "output": "Moderate interaction.",
        "instruction": "Analyze and classify the given drug interaction as minor, moderate, or severe.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient is experiencing chest pain and difficulty breathing, and they suspect they might be having a heart attack.",
        "output": "Emergency physician",
        "instruction": "Given a scenario in the healthcare setting, identify the type of healthcare professional best suited to handle the situation.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient presents with chronic cough, copious sputum production, and shortness of breath. Chest X-ray reveals infiltrates in both lung fields.",
        "output": "Based on the symptoms and imaging findings, the patient likely has severe chronic obstructive pulmonary disease (COPD) or pneumonia. Additional tests such as pulmonary function tests or blood gasses may be used to confirm the diagnosis and determine the severity of the disease.",
        "instruction": "Given a set of medical symptoms or test results, determine the stage or severity of a disease or condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The symptoms typically last for a few weeks and can be effectively managed with appropriate treatment.",
        "output": "The disease is classified as acute.",
        "instruction": "Using the information provided, classify the disease as acute, chronic, or an acute exacerbation of a chronic disease.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Case study: Patient presenting with abdominal pain, diarrhea, and fever.",
        "output": "Possible diagnoses: Gastroenteritis, inflammatory bowel disease, or appendicitis.",
        "instruction": "Given a medical case study, classify the patient's condition into one of several possible diagnoses based on symptoms and medical history.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 72, Gender: Male, Medical conditions: Atrial fibrillation, hypertension",
        "output": "high risk",
        "instruction": "You are given the age, gender, and medical condition of a patient. Based on this information, predict whether the patient is at high, moderate, or low risk for stroke.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medication: Aspirin; Age: 45; Reported side effect: Stomach pain",
        "output": "Possible, as stomach pain is a known side effect of Aspirin.",
        "instruction": "Evaluate the likelihood of experiencing a given side effect based on the information provided.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "45%",
        "output": "0.45",
        "instruction": "Convert the following percentage into a proportion.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Systolic blood pressure of 135 mmHg and diastolic blood pressure of 90 mmHg.",
        "output": "Stage 1 hypertension",
        "instruction": "Given a patient's blood pressure reading, classify it into a particular stage of hypertension.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Test result: Hemoglobin - 14.5 g/dL (normal range: 12-16 g/dL)",
        "output": "Normal",
        "instruction": "Given a laboratory test result and the normal range of values for that test, determine if the result is normal, high or low.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "",
        "output": "Aerobic exercise can improve mental well-being by triggering the release of endorphins, which create feelings of happiness and reduce stress. Exercise also increases blood flow to the brain, promoting the growth of new brain cells, improving cognitive function, and helping to alleviate symptoms of depression and anxiety.",
        "instruction": "Explain how aerobic exercise can improve mental well-being.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "No, the statement is factually inaccurate. Numerous studies have shown no link between vaccines and autism.",
        "instruction": "State whether the following statement is factually accurate: \"Vaccines cause autism.\"",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Given a set of clinical data on a patient, including age, sex, blood pressure, blood glucose, and cholesterol levels, classify whether they are at risk for developing type 2 diabetes.",
        "output": "The patient may be classified as at risk for developing type 2 diabetes based on their clinical data.",
        "instruction": "Given patient demographic and clinical data, classify the patient into one of several conditions using machine learning algorithms.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Fever, dry cough, loss of taste and smell, difficulty breathing",
        "output": "COVID-19",
        "instruction": "Classify the given set of symptoms as most likely indicative of either a cold, flu, or COVID-19.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "See attached EKG reading. Which cardiac arrhythmia does this reading indicate? Options: A) Atrial fibrillation B) Supraventricular tachycardia C) Ventricular tachycardia D) Sinus bradycardia",
        "output": "A) Atrial fibrillation",
        "instruction": "Given an EKG reading and a set of multiple choice options, diagnose the cardiac arrhythmia.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: headache, fever, muscle aches, fatigue",
        "output": "The symptoms are more indicative of the flu, as fever and muscle aches are typically more severe in flu cases than in common colds.",
        "instruction": "Determine whether the given symptoms are more indicative of a common cold or the flu.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient has a temperature of 39.5\u00b0C, pulse rate of 120 bpm, respiratory rate of 24 breaths per minute, and blood pressure of 90/60 mmHg.",
        "output": "The patient's condition is severe based on their high temperature, elevated pulse rate, low blood pressure, and rapid breathing rate. Immediate medical attention is required.",
        "instruction": "Given patient data, classify the patient based on the severity of their condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "List of medical conditions: pneumonia, bronchitis, tuberculosis, asthma, lung cancer",
        "output": "Etiology classification:\n- Infection-related: pneumonia, bronchitis, tuberculosis\n- Chronic respiratory condition: asthma\n- Cancer-related: lung cancer",
        "instruction": "Classify a set of medical conditions based on their etiology.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "This observational study aims to assess the effectiveness of vitamin D supplementation in reducing the severity and duration of acute respiratory infections in children under five years of age. Researchers will collect data on the incidence of acute respiratory infections and measure serum vitamin D levels in the participants.",
        "output": "Does vitamin D supplementation reduce the severity and duration of acute respiratory infections in children under five years old?",
        "instruction": "For the given medical abstract, identify the research question.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient with the following symptoms: fever, cough, and shortness of breath. Laboratory tests confirmed COVID-19.",
        "output": "ICD code: U07.1. COVID-19, virus identified.",
        "instruction": "Given a set of medical data, assign a diagnosis code according to the International Statistical Classification of Diseases and Related Health Problems (ICD).",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "N/A",
        "output": "Myth",
        "instruction": "Determine if the following claim is fact or myth: \"Vaccines cause autism.\"",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A) 42-year-old pregnant woman in her second trimester\nB) 6-month-old infant\nC) 65-year-old man with a history of heart disease\nD) 54-year-old woman with an egg allergy",
        "output": "A) Suitable: Pregnancy increases the risk of severe flu complications; vaccination helps protect both the mother and the baby.\nB) Not suitable: Infants younger than 6 months cannot receive the vaccine.\nC) Suitable: Age and heart disease increase the risk of severe flu-related complications; vaccination is recommended.\nD) Not suitable: Egg allergy may cause severe allergic reactions to some flu vaccines.",
        "instruction": "Select patients for the Influenza vaccine and briefly explain the rationale.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Summary: A study published in the Journal of the American Medical Association found that a Mediterranean diet with an additional daily serving of walnuts was associated with increased endothelial function in patients with type 2 diabetes.",
        "output": "What is the title of this article?",
        "instruction": "Given a summary of a medical article, provide the title of the article.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 50-year-old male diabetic patient has shown a reduction in blood sugar levels and improved control over his diet; however, he still experiences frequent episodes of low blood sugar (hypoglycemia).",
        "output": "Improving",
        "instruction": "Given a case study, determine if a patient's condition is improving, worsening, or stable.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 22, Symptoms: Frequent urination, constant thirst, unexplained weight loss, rapid onset of symptoms, Lab results: Fasting blood glucose level: 245 mg/dL, oral glucose tolerance test: 320 mg/dL",
        "output": "Type 1 diabetes",
        "instruction": "Based on the patient's symptoms and test results below, classify the most likely diagnosis: Type 1 diabetes, Type 2 diabetes, or prediabetes.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A psychiatrist prescribes the antipsychotic drug Seroquel to a patient with only symptoms of insomnia, instead of its approved use for bipolar disorder and schizophrenia.",
        "output": "Off-label",
        "instruction": "Classify whether a medication use is off-label or approved based on the given information.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Can I take omeprazole as an injection?",
        "output": "No, omeprazole is typically administered as an oral tablet or capsule.",
        "instruction": "Determine if a proposed method of administration is appropriate for a specific medication.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Fever, cough, shortness of breath, loss of taste or smell.",
        "output": "COVID-19",
        "instruction": "Given a list of symptoms, classify the potential underlying condition or disease.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Research article: A randomized controlled trial of a new anticoagulant drug in patients with atrial fibrillation. \\nKeywords: anticoagulant therapy, stroke prevention, atrial fibrillation. \\nQuestion: What are the strengths and limitations of this study, and what are the implications for clinical practice and future research in this area?",
        "output": "The study design is strong, with a large sample size and rigorous methodology. However, the results may be limited by the short follow-up period and possible selection bias. The implications for clinical practice include the potential for a new and more effective anticoagulant therapy for patients with atrial fibrillation, but further research is necessary to confirm the long-term safety and efficacy of this new drug. Future research in this area may also focus on identifying biomarkers or clinical predictors of stroke risk in this population.",
        "instruction": "Given a medical research article and a set of relevant keywords, critically analyze the study design, results, and implications in the context of current knowledge and practice in the biomedical domain.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A patient reports dark, tarry stools and abdominal pain. They have a history of alcohol abuse and previous episodes of gastritis. What is the most likely cause of their gastrointestinal bleed?",
        "output": "The most likely cause of the patient's gastrointestinal bleed is a peptic ulcer secondary to their history of alcohol abuse and previous episodes of gastritis. Additional diagnostic workup, such as endoscopy, is necessary to confirm.",
        "instruction": "Given a patient's history and clinical presentation, identify the most likely cause of a gastrointestinal bleed.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient A: \"I barely noticed the scratchy throat and slight cough.\"\nPatient B: \"I have a high fever and chills, but I can still get out of bed and move around with some discomfort.\"\nPatient C: \"My body aches so intensely that I can't move at all.\"",
        "output": "Patient A: 1, Patient B: 3, Patient C: 5",
        "instruction": "Classify the severity of the following symptoms of the flu from 1-5, where 1 is mild and 5 is severe, based on the patient's description.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "What is the most likely diagnosis for a patient who presents with a butterfly rash on their face, joint pain, and fatigue?",
        "output": "The most likely diagnosis is lupus, as it is characterized by the presence of a butterfly rash, joint pain, and fatigue. Other autoimmune disorders such as rheumatoid arthritis and Sjogren's syndrome can also present with similar symptoms, but the butterfly rash is specific to lupus.",
        "instruction": "Given a medical scenario and a question about a specific aspect of the case, provide a brief answer and explain your reasoning.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Description: A 35-year-old male presents with sudden severe head pain, blurry vision, and dizziness after hitting his head on a cupboard.",
        "output": "Yes, this is a potential medical emergency. The sudden severe head pain, blurry vision, and dizziness could indicate a serious issue such as a concussion, brain injury, or internal bleeding. The patient should be evaluated by a healthcare professional immediately.",
        "instruction": "Given a description of a medical case, determine if the scenario constitutes a medical emergency and justify the decision.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "MAAGKTVEARLLANFLYRAYLLSAAVAATTVAFSLLVLPSGGMAGAVGGALAGLVSLLLAFLGGAHLVVYRYSRKKRM",
        "output": "Yes, it contains a transmembrane domain (a continuous stretch of hydrophobic amino acids that span the membrane, as seen in the middle of the sequence).",
        "instruction": "Based on the given protein sequence, determine if it contains a transmembrane domain.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The administration of an agent to treat bacterial infections by inhibiting the growth of bacteria or killing them.",
        "output": "Treatment",
        "instruction": "Classify the given text as a symptom, diagnosis, or treatment based on its description.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Vital signs: blood pressure 160/100 mmHg, heart rate 120 bpm, respiratory rate 25 breaths/min. Symptoms: chest pain, shortness of breath, sweating.",
        "output": "The patient is in distress and requires immediate medical attention, as these vital signs along with the symptoms indicate a possible heart attack or other serious heart condition.",
        "instruction": "Given a set of vital signs and symptoms, determine if the patient is in distress and requires immediate medical attention.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Dataset shows people with high sugar consumption also have an increased number of dental caries.",
        "output": "There is a positive correlation between sugar consumption and the number of dental caries.",
        "instruction": "Determine if there's a positive or negative correlation between two variables in a given dataset.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: fever, headache, muscle aches, and fatigue. Potential diagnoses: Influenza, Lyme disease, and Malaria.",
        "output": "Most likely diagnosis: Influenza, based on the presence of fever, headache, muscle aches, and fatigue.",
        "instruction": "Given a list of symptoms and potential diagnoses, match the symptoms with the most likely diagnosis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Carbohydrates: 250 grams, Protein: 120 grams, Fat: 55 grams",
        "output": "2085 calories (Carbohydrates: 250g x 4kcal/g = 1000kcal, Protein: 120g x 4kcal/g = 480kcal, Fat: 55g x 9kcal/g = 495kcal)",
        "instruction": "Calculate the number of calories consumed in a day based on the given macronutrient breakdown.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "- Drug A: Common side effects include dizziness, dry mouth, and constipation\n- Drug B: Common side effects include kidney damage, irregular heartbeat, and anemia\n- Drug C: Common side effects include headache, insomnia, and fatigue",
        "output": "1. Drug B (kidney damage, irregular heartbeat, anemia)\n2. Drug A (dizziness, dry mouth, constipation)\n3. Drug C (headache, insomnia, fatigue)",
        "instruction": "Given a list of drugs and their side effects, rank them in order of severity based on their side effects.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient is a 60-year-old female who lives in a northern climate, has a sedentary indoor job, wears sunscreen regularly, is overweight, and follows a vegan diet.",
        "output": "High likelihood of Vitamin D deficiency",
        "instruction": "Evaluate this patient's likelihood of having a Vitamin D deficiency based on the provided description.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Temperature: 101.5\u00b0F, Heart rate: 120 bpm, Respiratory rate: 22 bpm",
        "output": "Based on the patient's vitals, there is a potential risk of sepsis.",
        "instruction": "Given a set of patient vitals, identify if the patient is at risk of sepsis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: headache, fever, sore throat, body aches",
        "output": "Primary care physician",
        "instruction": "Given a list of symptoms, determine if the patient should see a specialist or a primary care physician.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Case study: A patient complains of sudden onset shortness of breath and chest pain after a long flight. Physical examination reveals unilateral leg swelling.\nHypothesis: The patient might have a pulmonary embolism.",
        "output": "Validate",
        "instruction": "Based on the given case study, validate or refute a hypothesis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Chest X-ray shows dense consolidation in the right lung.",
        "output": "Possible diagnosis: Pneumonia",
        "instruction": "Given a patient's medical imaging results, diagnose their condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: severe chest pain, shortness of breath, dizziness, and profuse sweating.",
        "output": "The patient needs to seek medical attention urgently, as they may be experiencing a heart attack.",
        "instruction": "Given a set of symptoms, determine if the patient needs to see a doctor urgently or if the symptoms can be managed at home.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 52, Gender: Female, Family history of breast cancer: Yes, History of smoking: No, History of alcohol use: No",
        "output": "Likelihood of developing breast cancer: High/Intermediate/Low",
        "instruction": "Given a set of patient demographics, predict the likelihood of a disease based on historical data.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The article discusses a new drug for treating a rare genetic disease. What are the potential benefits and drawbacks of this new treatment based on the presented data?",
        "output": "Based on the presented data, the new drug shows promise in improving symptoms and quality of life for individuals with the rare genetic disease. However, potential drawbacks may include side effects or accessibility and affordability issues. Further research and evaluation may be needed to fully assess the effectiveness and feasibility of the new treatment.",
        "instruction": "Given a medical journal article on a new treatment, evaluate the potential benefits and drawbacks of the treatment based on the presented data.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "(None)",
        "output": "False",
        "instruction": "Determine the accuracy of this statement: \"Antibiotics are effective in treating viral infections.\"",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient is 45 years old, has a BMI of 28, a family history of diabetes, and inconsistent physical activity.",
        "output": "High",
        "instruction": "Evaluate the risk level (high, medium, or low) of the given patient for developing diabetes.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Medical History: Obesity, high cholesterol, high blood pressure, family history of heart disease",
        "output": "Likelihood of developing heart disease: High, due to the risk factors present in the patient's medical history.",
        "instruction": "Given a patient's medical history and other relevant data, predict the likelihood of them developing a specific disease or condition.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The side effects of Drug X include gastrointestinal upset, diarrhea, and vomiting. These side effects become more severe and frequent as the dose increases.",
        "output": "Dose-dependent",
        "instruction": "Given a drug's side effects, determine if the pattern is dose-dependent or dose-independent.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient data: \n1) Hemoglobin: 12.5 g/dL\n2) Creatinine: 1.1 mg/dL\n3) INR: 2.1",
        "output": "1) Low (normal range: 13.5-17.5 g/dL for men, 11.5-15.5 g/dL for women)\n2) Normal (normal range: 0.6-1.3 mg/dL)\n3) Elevated (normal range: 0.8-1.2)",
        "instruction": "Given a set of patient data, calculate the relevant clinical measurement and determine if it falls within normal limits or not.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age-related macular degeneration",
        "output": "Age-related macular degeneration is the most common cause of blindness in adults over the age of 60.",
        "instruction": "Answer the following question based on the provided information. What is the most common cause of blindness in adults over the age of 60?",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Age: 55\nGender: Female\nSymptoms: Chest pain, shortness of breath, nausea, dizziness, and sweating",
        "output": "Severity: High risk\nSuggested course of action: Call emergency services immediately and go to the nearest hospital. This could be a sign of a heart attack.",
        "instruction": "Determine the severity of a patient's condition based on the provided details, and suggest an appropriate course of action.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "MRI",
        "output": "Is it safe to undergo an MRI if I have a metal implant in my body?",
        "instruction": "Ask a question to a healthcare professional that addresses a concern regarding a given medical procedure.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms: fever, cough, difficulty breathing, loss of taste or smell",
        "output": "COVID-19",
        "instruction": "Given a set of symptoms, identify which medical condition is most likely causing them.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "A 54-year-old man with a 40-pack-year smoking history presents with an unintentional 10-pound weight loss, productive cough, blood-streaked sputum, and shortness of breath over the past 6 months. He denies any fever or night sweats.",
        "output": "A chest CT scan is an appropriate medical test to investigate the patient's symptoms. Given the patient's smoking history, symptoms of weight loss, and blood-streaked sputum, it's important to assess the possibility of lung cancer. A chest CT scan can help identify any lung abnormalities or masses potentially related to cancer.",
        "instruction": "Given a description of the patient's symptoms and medical history, suggest an appropriate medical test to confirm the suspected diagnosis.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "What does a lumbar puncture involve?",
        "output": "A lumbar puncture involves the insertion of a needle into the lower back (lumbar region) to collect cerebrospinal fluid for diagnostic or therapeutic purposes.",
        "instruction": "Provide a concise and accurate answer to the given question about a specific medical procedure.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "What is the maximum recommended daily dose for acetaminophen?",
        "output": "According to the latest guidelines, the maximum recommended daily dose for acetaminophen is generally 3-4 grams per day. However, this may vary based on a patient's age, weight, and other medical conditions, so it's important to consult with a healthcare provider to determine appropriate dosages based on individual needs.",
        "instruction": "Given a specific question about medication dosages, provide a concise and accurate answer mentioning the appropriate guidelines or drug information.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Report:\nPatient presents with recurrent respiratory infections, chronic cough, and wheezing. Examination reveals a diminished breath sound and narrowed airway. Laboratory tests show elevated levels of eosinophil and IgE.",
        "output": "Classification: Chronic disease (asthma)",
        "instruction": "Given a medical report, classify the diagnosis into one of the four categories: infectious disease, chronic disease, genetic disorder, or developmental disorder.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Symptoms include hives, itching, difficulty breathing, swelling of the face and throat, and nausea.",
        "output": "These symptoms may be indicative of an allergic reaction.",
        "instruction": "Given a set of symptoms, determine whether they match the profile of a possible allergic reaction or an adverse drug reaction.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Nausea, vomiting, dizziness, headache, minor stomach discomfort.",
        "output": "Safe (with caution, as side effects might be tolerable and not severe)",
        "instruction": "Given the list of side effects, classify the medication as safe or potentially harmful.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Procedure: Colonoscopy\nComplications: Perforation of the colon, bleeding",
        "output": "Instructions for prevention: Follow bowel prep instructions, avoid taking blood-thinning medications before the procedure, and report any abdominal pain or bleeding after the procedure.",
        "instruction": "Given a medical procedure and its potential complications, provide instructions for preventing these complications.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Weight: 80 kg, Height: 1.75 m",
        "output": "BMI: 26.12, Category: Overweight",
        "instruction": "Calculate the body mass index (BMI) based on a person's weight and height, and label it with the appropriate category: 'Underweight', 'Normal weight', 'Overweight', or 'Obese'.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Regular consumption of aspirin can lead to liver failure.",
        "output": "False",
        "instruction": "Evaluate the given statement to see if it's true or false based on medical knowledge.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Height: 1.70 meters \nWeight: 75 kg",
        "output": "Calculated BMI: 25.95 (75 kg / (1.70 m^2))\nInterpretation: Overweight",
        "instruction": "Calculate the body mass index (BMI) given the height and weight of a patient. Provide the interpretation of the calculated BMI.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "In our newer research on Ehrlichia risticii infection, horse infected serologically by E. risticii. In broader environments, showed prevalence is high. Our brand-new findings would pave a way for future study on Ehrlichia risticii in horses relating to disease control.",
        "output": "Low quality",
        "instruction": "Assess the overall quality of a given research paper abstract.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Patient vital signs: Blood Pressure: 140/90 mmHg, Heart Rate: 80 bpm, Respiratory Rate: 18 breaths per minute, Temperature: 98.6\u00b0F",
        "output": "The patient has high blood pressure, as the measurement is above the normal range of 120/80 mmHg.",
        "instruction": "Given a patient's vital signs, determine whether the patient's blood pressure is within the normal range or not.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Carpal tunnel syndrome",
        "output": "Neurological",
        "instruction": "Classify the given condition as a neurological or orthopedic issue.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "The patient is experiencing shortness of breath, a mild fever, and a dry cough. They have no difficulty breathing while at rest and can carry out daily activities with minimal discomfort.",
        "output": "Mild case.",
        "instruction": "Classify the following patient report as a mild, moderate, or severe case.",
        "domain": "med",
        "task": "ot"
    },
    {
        "input": "Physiological parameters: mean arterial pressure (MAP) <70 mmHg, levels of serum lactate > 4 mmol/L, and urine output <0.5 mL/kg/hour.",
        "output": "Based on the given physiological parameters, the patient may be at high risk of developing septic shock within the next 24 hours and should be closely monitored.",
        "instruction": "Given a set of physiological parameters, predict the likelihood of an intensive care unit patient developing septic shock within the next 24 hours.",
        "domain": "med",
        "task": "ot"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 10. Plaintiff Laborers\u2019 Local #231 Pension Fund owned 4,170 shares of Lionbridge common stock before the Merger closed, and was entitled to vote at the Special Meeting on the Merger.  Plaintiff is a citizen of Illinois. 11. Before the Merger, defendant Lionbridge was a citizen of Massachusetts as it was incorporated in Delaware and headquartered in Waltham, Massachusetts.  Lionbridge\u2019s common stock was listed on the NASDAQ under the ticker \u201cLIOX.\u201d  Lionbridge considers itself the world\u2019s leading globalization company, providing translation and localization, digital marketing, global content management, and application testing services to the world\u2019s top brands. 12. Defendant Rory J. Cowan (\u201cCowan\u201d) was Chairman of the Board, Chief Executive Officer, and President of the Company.  Cowan founded Lionbridge in September 1996, and continued to own over 18% of the equity at the time of the Company\u2019s 1999 initial Case 1:17-cv-00478-UNA   Document 1   Filed 04/27/17   Page 5 of 28 PageID #: 5 \n- 5 -  public offering (\u201cIPO\u201d).  Cowan is identified in the Proxy Statement as a participant in the solicitation of proxies and had direct participation in and oversight of the wrongdoing alleged herein. 13. Defendant Edward A. Blechschmidt (\u201cBlechschmidt\u201d) was a director of Lionbridge from February 2003 at least until closing of the Merger.  Blechschmidt is Chair of the Audit Committee.  Blechschmidt is identified in the Proxy Statement as a participant in the solicitation of proxies and had direct participation in and oversight of the wrongdoing alleged herein. 14. Defendant Michael G. Dallas (\u201cDallas\u201d) was a director of Lionbridge from October 2014 at least until closing of the Merger.  Dallas is identified in the Proxy Statement as a participant in the solicitation of proxies and had direct participation in and oversight of the wrongdoing alleged herein. 15. Defendant Guy L. de Chazal (\u201cde Chazal\u201d) was a director of Lionbridge from February 1998, before the Company\u2019s IPO, at leas\nOnly answer with the company defendants names.",
        "output": "Lionbridge Technologies, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has  been continuously throughout all times relevant hereto, the \nowner of  Barnes & Noble  common stock. Case 1:19-cv-01320-UNA   Document 1   Filed 07/16/19   Page 2 of 17 PageID #: 2 \n 3 9. Defendant Barnes & Noble  is a Delaware corporation and maintains it s principal \nexecuti ve offices at 122 Fifth Avenue, New York, New York 10011.  Barnes & Noble \u2019s common \nstock is traded on the New York Stock Exchange  under the ticker symbol \u201c BKS .\u201d \n10. Defendant  Leonard Riggio is  Chairman of the Board of the C ompany. \n11. Defendant George Campbell Jr. is a director of the C ompany. \n12. Defendant Mark D. Carleton is a director  of the C ompany.  \n13. Defendant Scott S. Cowen is a director of the C ompany. \n14. Defendant William T. Dillard II is a director of the C ompany. \n15. Defendant Al Ferrara is a director of the C ompany. \n16. Defendant Paul B. Guenther is a director of the C ompany. \n17. Defendant Patr icia L. Higgins is a director of the C ompany.  \n18. Defendant Irwin D. Simon is a director of the C ompany. \n19. Defendant Kimberly A. Van Der Zon is a director of the C ompany. \n20. The defendants identified in paragraphs 10 through 19 are collectively referred to \nherein a s the \u201c Individual Defendants.\u201d    \n21. Defendant Parent is a Delaware  corporation  and a party to the Merger Agreement.  \n22. Defendant  Merger Sub is a De laware corporation , a wholly- owned subsidiary of \nParent, and a party to the Merger Agreement . \nCLASS ACTION ALLEGATIONS  \n23. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Barnes & Noble  (the \u201cClass\u201d ).  Excluded from the Class are defendants herein and \nany person, firm, trust, corporation, or other entity rela ted to or affiliated with any defendant.  \n24. This action is properly maintainable as a class action.  Case 1:19-cv-01320-UNA   Document 1   Filed 07/16/19   Page 3 of 17 PageID #: 3 \n 4 25. The Class is so numerous that joinder of all\nOnly answer with the company defendants names.",
        "output": "Barnes & Noble, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n16. Plaintiff, as set forth in the attached Certification, acquired Boston Scientific  \nsecurities  at artificially inflated prices during the Class Period and was damaged upon the \nrevelation of the alleged corrective disclo sures.  \n17. Defendant Boston Scientific  is a Delaware  corporation with its princip al \nexecutive offices located at 300 Boston Scientific Way , Marlborough, Massachusetts 01752 -\n1234 .  Boston Scientific \u2019s common stock  trades in an efficient market on  the New York Stock \nExchange  (\u201cNYSE \u201d) under the ticker symbol \u201cBSX .\u201d \n18. Defendant Michael F. Mahoney  (\u201cMahoney \u201d) was the Chief Executive Officer \n(\u201cCEO\u201d ) of Boston Scientific  at all relevant times . Case 1:19-cv-03642   Document 1   Filed 04/24/19   Page 5 of 33 \n  \n6 \n \n \n 19. Defendant Daniel J. Brennan  (\u201cBrennan \u201d) was the  Executive Vice President and  \nChief Financial Officer  (\u201cCFO\u201d) of Boston Scientific  at all relevant times . \n20. Defendants Mahoney  and Brennan  are sometimes referred to herein  collectively  \nas the \u201cIndividual Defendants. \u201d \n21. The Individual Defendants possessed the power and authority to control the \ncontents of the Company \u2019s SEC filings, press releases, and other market communications.  The \nIndividual Defendants were provided with copies of the Company \u2019s SEC filings and press \nreleases alleged herein to be misleading prior to or shortly after their issuance and had the ability \nand opportunity to prevent their issuance or to cause them to be corrected.  Because of their \npositions with the Company , and their access to material info rmation available to them but not to \nthe public, the Individual Defendants knew that the adverse facts specified herein had not been \ndisclosed to and were being concealed from the public, and that the positive representations \nbeing made were then materiall y false and misleading.  The Individual Defendants are liable for \nthe false statements and omissions pleaded herein.  \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 11. Plaintiff Piotr Jaszczyszyn, as set forth in the accompanying certification, incorporated by reference herein, purchased SunPower securities during the Class Period, and suffered damages as a result of the federal securities law violations and false and/or misleading statements and/or material omissions alleged herein.  12. Defendant SunPower is incorporated under the laws of Delaware with its principal executive offices located in San Jose, California. SunPower\u2019s common stock trades on the NASDAQ exchange under the symbol \u201cSPWR.\u201d  13. Defendant Peter Faricy (\u201cFaricy\u201d) was the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) at all relevant times. 14. Defendant Manavendra S. Sial (\u201cSial\u201d) was the Company\u2019s Chief Financial Officer (\u201cCFO\u201d) at all relevant times.  15. Defendants Faricy and Sial (collectively the \u201cIndividual Defendants\u201d), because of their positions with the Company, possessed the power and authority to control the contents of the Company\u2019s reports to the SEC, press releases and presentations to securities analysts, money and portfolio managers and institutional investors, i.e., the market.  The Individual Defendants were provided with copies of the Company\u2019s reports and press releases alleged herein to be misleading prior to, or shortly after, their issuance and had the ability and opportunity to prevent their issuance or cause them to be corrected.  Because of their positions and access to material non-public information available to them, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to, and were being concealed from, the public, and that the positive representations which were being made were then materially false and/or misleading.  The Individual Defendants are liable for the false statements pleaded herein.  \nOnly answer with the company defendants names.",
        "output": "SunPower Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n \n19. Plaintiff purchased or otherwis e acquired LendingClub common st ock as described in \nthe attached certification a nd was damaged by the revelation of  the alleged correc tive disclosures. \n20. Defendant LendingClub is incorporated in Delaware, and its stoc k trades on the NYSE \nunder the ticker symbol \u201cLC.\u201d  The Company's corporate headquar ters are located at 71 Stevenson \nStreet, Suite 300, San Franc isco, California 94105. \n21. Defendant Laplanche served at all relevant times as CEO and Cha irman of LendingClub \nuntil his resignation on May 6, 2016. Case 3:16-cv-02627   Document 1   Filed 05/16/16   Page 5 of 29 \n{00202475;1 }  6  \n 1 \n2 3 4 5 6 \n7 \n8 9 \n10 11 12 \n13 \n14 15 16 17 18 \n19 \n20 21 22 23 24 \n25 \n26 27 28 22. Defendant Carrie L. Dolan (\u201cDolan\u201d) has served at all relevant times as Chief Financial \nOfficer of LendingClub. \n23. The Defendants named in \u00b6\u00b6 21-22 are sometimes referred to here in as the \u201cIndividual \nDefendants.\u201d \n\nOnly answer with the company defendants names.",
        "output": "LendingClub Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n \n12. Plaintiff, as set forth in the acc ompanying Certification, purchased Crypto  \nsecurities  at artificially inflated pri ces during the Class Period and was damaged upon \nthe revelation of the alleged corrective disclosure.  \n13. Defendant Crypto  is incorporated in Nevada , and the C ompany\u2019s principal \nexecutive offices are located at 23805 Stuart Ranch Road, Suite 235, Malibu, California \n90265 .  Crypto \u2019s securities  trades on the Other OTC  under the ticker symbol \u201c CRCW .\u201d \n14. Defendant Michael Alcide Poutre II (\u201cPoutre\u201d)  has served at all relevant \ntimes as the Company\u2019s  Chief Executive Officer (\u201c CEO \u201d) and Chai rman. \n15. Defendant Ivan Ivankovich (\u201cIvankovich\u201d) has served at all relevant times \nas the Company\u2019s Chief Financial Officer (\u201cCFO\u201d) . \n16. The Defendants referenced above in \u00b6\u00b6 14-15 are sometimes referred to - \nherein as the \u201cIndividual Defendants.\u201d  \n\nOnly answer with the company defendants names.",
        "output": "The Crypto Company",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n10. Plaintiff  is, and has been at all relevant times, the owner of WildHorse  common \nstock and held such stock since prior to the wrongs complained of herein.   \n11. Defendant WildHorse  is a Delaware corporation with its principal executive offices \nlocated at 920 Memorial City Way, Suite 1400, Houston, Texas 77024. WildHorse  is an \nindependent oil and natural gas company focused on the acquisition, exploitation, development \nand production of oil, natural gas and NGL properties primarily in the Eagle Ford Shale and Austin \nChalk in East Texas . WildHorse \u2019s common stock trades on the NYSE  under the symbol \u201c WRD .\u201d \n12. Individual Defen dant Jay C. Graham  is a director of WildHorse , the Chief \nExecutive Officer of the Company,  and the  Chairman of the Board.   \n13. Individual Defendant Anthony Bahr is a director of WildHorse  and the President  of \nthe Company .   \n14. Individual Defendant Brian A. Bernasek  is, and has been at all relevant times, a \ndirector of WildHorse . \n15. Individual Defendant Jonathan M. Clarkson is, and has been at all relevant times, a \ndirector of WildHorse . \n16. Individual Defendant Scott  A. Gieselman  is, and has been at all relevant times, a \ndirector of WildHorse . \n17. Individual Defendant David W. Hayes  is, and has been at all relevant times, a \ndirector of WildHorse . Case 1:19-cv-00036-PAE   Document 3   Filed 01/03/19   Page 4 of 195 \n 18. Individual Defendant Stephanie C. Hildebrandt  is, and has been at all relevant \ntimes, a director of WildHorse . \n19. Individual Defendant Grant E. Sims  is, and has been at all relevant times, a director \nof WildHorse . \n20. Individual Defendant Martin W. Sumner is, and has been at all relevant times, a \ndirector of WildHorse . \n21. Individual Defenda nt Tony R. Weber is, and has been at all relevant times, a \ndirector of WildHorse . \n22. The parties  identified in \u00b6\u00b6 11- 21 are collectively referred to as the \u201cDefendants .\u201d \nSUBSTANTIVE ALLEGATI ONS  \nI. Background and the Propos",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n10. Plaintiff is a citizen of Texas  and, at all times relevant hereto, ha s been a J. Alexander\u2019s  \nstockholder . \n11. Defendant J. Alexander\u2019s,  through its subsidiaries, owns and operates complementary \nupscale dining restaurants in the United States .  J. Alexander\u2019s  is incorporated in Tennessee  and has \nits principal place of business at 3401 West End Avenue, Suite 260 , Nashville, TN 37202 .  Shares of \nJ. Alexander\u2019s  common stock are traded on the NYSE  under the symbol \u201c JAX.\u201d  \n12. Defendant Lonnie J. Stout II (\"Stout \") has been a Director of th e Company at all \nrelevant times.  In addition, Stout  serves as the  Executive Chairman of the Company Board.  \n13. Defendant Douglas K. Ammerman (\u201cAmmerman \") has been a director of the \nCompany at all relevant times.   \n14. Defendant Carl J. Grassi (\"Grassi \") has been a director of the Company at all relevant \ntimes .   \n15. Defendant Timothy T. Janszen (\u201cJanszen \u201d) has been a director of the Company at all \nrelevant times .   \n16. Defendant Ronald B. Maggard, Sr. (\u201cMaggard \u201d) has been a director of the Company at \nall relevant times .  \n17. Defendant Frank R. Martire (\u201cMartire \u201d) has been a director of the Company at all \nrelevant times.  In addition, Martire serves as the Lead Independent Director of the Company.  Case 1:21-cv-06925   Document 1   Filed 08/17/21   Page 4 of 27 \n \n \n- 5 - \n \nCOMPLAINT  \n 18. Defendant Raymond R. Quirk (\u201cQuirk \u201d) has been a director of the Company at all \nrelevant times.   \n19. The defendants  identified  in paragraphs  12 through  18 are collectively  referred  to \nherein as the  \u201cDirector Defendants\u201d or the  \u201cIndividual Defendants.\u201d  \n20. Non-Defendant SPB Hospitality  is a leading operator and franchisor of full -service \ndining restaurants, spanning a national footprint of hundreds of restaurants and breweries in 38 states \nand the District of Columbia . SPB Hospitality  is a Delaware limited liability company  and has its \nheadquarters in Houston, TX .  \n21. Non-Defen\nOnly answer with the company defendants names.",
        "output": "J. Alexander's Holdings, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of U.S. Concrete common stock and has held such stock since prior to the wrongs complained of herein. 10. Individual Defendant Michael D. Lundin has served as a member of the Board since 2010 and is the Chairman of the Board.  11. Individual Defendant Susan M. Ball has served as a member of the Board since 2018.  12. Individual Defendant Kurt M. Cellar has served as a member of the Board since 2010.  Case 1:21-cv-05752   Document 1   Filed 07/02/21   Page 3 of 154 13. Individual Defendant Rajan C. Penkar has served as a member of the Board since 2020.  14. Individual Defendant Ronnie Pruitt has served as a member of the Board since 2020 and is the Company\u2019s President and Chief Executive Officer.  15. Individual Defendant Theodore P. Rossi has served as a member of the Board since 2011. 16. Individual Defendant Colin M. Sutherland has served as a member of the Board since 2010. 17. Defendant U.S. Concrete is incorporated in Delaware and maintains its principal offices at 331 N. Main Street, Euless, Texas 76039.  The Company\u2019s common stock trades on the NASDAQ Stock Exchange under the symbol \u201cUSCR.\u201d 18. The defendants identified in paragraphs 10-16 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 19. The defendants identified in paragraphs 10-17 are collectively referred to as the \u201cDefendants.\u201d \nOnly answer with the company defendants names.",
        "output": "U.S. Concrete, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all time s releva nt hereto, the \nowner  of Apptio common stock.  \n9. Defendant Apptio is a Delaware corporation and maintains its principal executive \noffices at 11100 NE 8th Street, Suite 600, Bellevue, Washington 98004.  Apptio\u2019 s common stock Case 1:18-cv-01938-UNA   Document 1   Filed 12/06/18   Page 2 of 10 PageID #: 2 3 is traded on the NasdaqGM under the ticker symbol \u201cAP TI.\u201d  Apptio is a party to the Merger \nAgreement.  \n10. Defendant  Sunny Gupta is Chief Executive Officer and a director  of the company. \n11. Defendant Tom Bogan is Chairman of the Board of the company. \n12. Defendant Peter Klein is a director of the company. \n13. Defendant John McAdam is a director of the company. \n14. Defendant Matt McIlwain is a director of the company.  \n15. Defendant Rebecca Jacoby is a director of the company.  \n16. Defendant Rajeev Singh is a director of the company. \n17. Defendant Kathleen Philips is a d irector of the company.  \n18. The defendants identified in para graphs 10 through 17 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \nCLASS ACTION ALLEGATIONS  \n19. Plaintiff brings this action as a class action on behalf of himself  and t he other public \nstockholders  of Apptio (the \u201cClass\u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defendant. \n20. This action is properly maintainable as a class action.  \n21. The Cl ass is so numerous that joinder of all members is impracticable.  As of \nNovember 6, 2018, there were approximately 45,110,117 shares of Apptio common stock \noutstanding, held by hundreds, if not thousands, of individuals and entities scattered throughout \nthe country.  \n22. Questions of law and fact are common to the Class, including, among others, \nwhether defendants violated the 1934 Act and whether defendants will irreparably harm plaintiff Case 1:18-cv-01938-UNA   Documen",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n11. Plaintiff is a citizen of California and , at all times relevant hereto, ha s been an \nAcacia stockholder.   \n12. Defendant Acacia d evelops, manufactures, and sells high -speed coherent optical \ninterconnect products in the United States, China, Germany, T hailand, and internationally. The \nCompany offers embedded and pluggable module products consisting of optical interconnect \nmodules with transmission speeds ranging from 100 to 1,200 gigabits per second for use in long -\nhaul, metro, and inter -data center mar kets. It also provides semiconductor products, such as low -\npower coherent digital signal processor application -specific integrated circuits and silicon \nphotonic integrated circuits that are integrated into embedded and pluggable modules. The \nCompany sells its products through a direct sales force to network equipment manufacturers, \nnetwork operators, and cloud service providers. Acacia is organized under the laws of the State of \nDelaware and has its principal place of business at Three Mill Place, Suite 400 , Maynard, \nMassachusetts.  Acacia common shares are traded on the NASDAQ under the symbol \u201c ACIA. \u201d \n13. Defendant Murugesan Shanmugaraj (\u201cShanmugaraj \u201d) has been a director at all \nrelevant times.  In addition, he serves as Chief Executive Officer ( \u201cCEO\u201d ) of the C ompany. \n14. Defendant Benny P. Mikkelsen (\u201cMikkelsen \u201d) has been a director at all relevant \ntimes.  In addition, he serves as Chief Technology Officer ( \u201cCTO\u201d ) of the Company.  \n15. Defendant Vincent Roche ( \u201cRoche \u201d) has been a d irector at all relevant times.  In \naddition, Roche serves as the Chair of the Board. Case 1:19-cv-01463   Document 1   Filed 08/05/19   Page 4 of 29 PageID #: 45 \n 16. Defendant David J. Aldrich  (\u201cAldrich \u201d) has been a director at all relevant times.  \nIn addition, he serves as a member of the Board\u2019 s Audit and Compensation Committees.  \n17. Defendant Peter Y. Chung (\u201cChung\u201d ) has been a director at all relevant times.  In \naddition, he serves \nOnly answer with the company defendants names.",
        "output": "Acacia Communications, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n26. Plaintiff City of St. Clair Shores Police and Fire Retirement System purchased the \ncommon stock of Allstate during the Class Period as set forth in the certification attached hereto and \nwas damaged as the result of Defendants\u2019 wrongdoing as alleged in  this complaint. \n27. Defendant Allstate operates as  a property-liability insurer in the United States and \nCanada.  Allstate maintains its headquarters at 2775 Sanders Road, Northbrook, Illinois 60062.  \nIncorporated in 1992 as a holding company for Alls tate Insurance Company, Allstate has grown to \nbe the third largest personal passenger auto insurer and the largest publicly held personal lines insurer in the United States.  Throughout the Cla ss Period Allstate stock traded on the New York \nStock Exchange (\u201cNYSE\u201d) unde r the ticker symbol \u201cALL.\u201d Case: 1:16-cv-10510 Document #: 1 Filed: 11/10/16 Page 10 of 48 PageID #:10 \n- 10 - 28. Defendant Wilson was at all relevant time s the CEO and Chairman of the Board of \nAllstate, and he has held those roles since 2007 and 2008, respectively.  Wilson was also President \nof Allstate from 2005 to 2015 and ha s worked at Allstate for over 20 years. Wilson\u2019s director profile \nemphasizes his \u201cin-depth understanding of Alls tate\u2019s business,\u201d including its products and \ncustomers, and states that Wilson \u201c[c]reated and im plemented Allstate\u2019s risk and return optimization \nprogram.\u201d \n29. Defendant Winter joined Allstate as the CEO and President of Allstate Financial in \n2009.  Winter served as President of Allstate Protection Lines (\u201cAP L\u201d) (which includes Allstate \nbrand auto insurance) from 2012 to December 2014, at  which time he was promoted to President of \nAllstate.  Winter was at all re levant times \u201cresponsible for all business operations and distribution \nwithin APL.\u201d \n30. Defendant Macellaro was at all relevant times the Vice President of Investor \nRelations at Allstate. \n31. Wilson, Winter and Macellaro (the \u201cIndivi dual Defendants\u201d), because of their \npositions w\nOnly answer with the company defendants names.",
        "output": "The Allstate Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n10. Plaintiff is, and has been continuously throughout all times relevant hereto, the owner \nof Delphi common stock. \n11. Defendant Delphi is a public company incorporated under the laws of New Jersey \nwith principal executive offices located at One Angel Court, London, UK. Delphi\u2019s common stock \nis traded on the NYSE under the ticker symbol \u201cDLPH.\u201d  \n12. Defendant Timothy M. Manganello is, and has been at all relevant times, a director \nof the Company and Chairman of the Board. \n13. Defendant Richard F. Dauch is, and has been at all relevant times, a director of the \nCompany and Chief Executive Officer.   \n14. Defendant Robin J. Adams is, and has been at all relevant times, a director of the \nCompany.   \n15. Defendant Joseph S. Cantie is, and has been at all relevant times, a director of the \nCompany. \n16. Defendant Nelda J. Connors is, and has been at all relevant times, a director of the \nCompany. \n17. Defendant Gary L. Cowger is, and has been at all relevant times, a director of the \nCompany. \n18. Defendant David S. Haffner is, and has been at all relevant times, a director of the \nCompany. \n19. Defendant Dr. Helmut Leube is, and has been at all relevant times, a director of the \nCompany. \n20. Defendant Hari N. Nair is, and has been at all relevant times, a director of the \nCompany. Case 1:20-cv-02363   Document 1   Filed 03/17/20   Page 4 of 165  \n 21. Defendant MaryAnn Wright is, and has been at all relevant times, a director of the \nCompany. \n22. The Defendants identified in paragraphs 12 through 21 are collectively referred to \nherein as the \u201cBoard\u201d or the \u201cIndividual Defendants,\u201d and together with Delphi, the \u201cDefendants.\u201d  \n\nOnly answer with the company defendants names.",
        "output": "Delphi Technologies PLC",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " named in (i)-(xviii ) collectively, \u201cDefendants\u201d) t o recover damages \nfor losses Plaintiff has suffered as a result of purchasing Cam ping World Class A common \nstock in a secondary offering of such securities in October 201 7 (the \u201cOffering\u201d) pursuant to a \nregistration statement and prospectus that contained materially  false statements.  These false \nstatements allowed CWGS Holding, CVRV Acquisition LLC, CVRV Acq uisition II LLC and \nCrestview Advisors (collectively , the \u201cSelling Stockholders\u201d) t o sell their stock in the Offering \nat inflated prices, and Plaintiff has thereby been damaged.  \n2. Except for allegations specifically about Plaintiff, all allega tions herei n are based \nupon the investigation undertaken by Plaintiff\u2019s counsel, which  included, but was not limited \nto, review and analysis of (i) Ca mping World\u2019s filings with the  U.S. Securities and Exchange \nCommission (\u201cSEC\u201d); (ii) securi ties analysts\u2019 reports about Cam ping World ; (iii) transcripts of \nCamping World earnings and/or inv estor conference calls; (iv) C amping World press releases; (v) FILED: NEW YORK COUNTY CLERK 12/18/2018 06:17 PMINDEX NO. 656308/2018\nNYSCEF DOC. NO. 1 RECEIVED NYSCEF: 12/19/2018\n6 of 342 \n media reports concerning Camping World, including online news s ources; and (vi) other publicly \navailable information. Counsel\u2019s investigation is continuing, and many of  the relevant facts are \nknown only by the Defendants, or are exclusively within their c ustody or control.  Plaintiff believes \nthat additional evidence  exists to support the allegations set forth herein, which it wi ll ascertain \nduring discovery . \nI. INTRODUCTION \n3. This case arises from material misstatements made in connection  with the Offering.  \nCamping World, which provides a comprehensive range of products  and services to recreational \nvehicle (\u201cRV\u201d) enthusiasts, misle d investors about its historic al economic performance and the \nquality and adequacy of its internal controls. \n4. Plaintiff bo",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all time s relevant  hereto, the \nowner of Ellie Mae common stock. \n9. Defendant Ellie Mae  is a Delaware  corporation and maintains its principal \nexecutive offices at 4420 Rosewood Drive, Suite 500, Pleasanton, California 94588.  Ellie Mae \u2019s Case 1:19-cv-00473-UNA   Document 1   Filed 03/06/19   Page 2 of 10 PageID #: 2 3 common stock is traded on the New York Stock Exchange  under the ticker symbol \u201c ELLI .\u201d  Ellie \nMae is a party to the Merger Agreement.  \n10. Defendant Sigmund Anderman is the E xecutive C hairman of the B oard and a \ndirector of the Company. \n11. Defendant Jonathan Corr  is Chief Executive Officer , President,  and a director of \nthe Company.  \n12. Defendant  Karen Blasing  is a director of the Company.   \n13. Defendant  Carl Buccellato  is a directo r of the Company.   \n14. Defendant Craig Davis is a director of the Company.  \n15. Defendant  A. Barr Dolan  is a director of the Company.  \n16.  Defendant  Robert J. Levin is a director of the Company .  \n17. Defendant  Marina Levinson  is a director of the Company.  \n18. Defendant Jeb  S. Spencer  is a director of the Company. \n19. Defe ndant Rajat Taneja is a director of the Company. \n20. The defendants identified in para graphs 10 through 19 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \nCLASS ACTION ALLEGATIONS  \n21. Plaintiff brings this action as a class action on behalf of himself  and t he other public \nstockholders of Ellie Mae  (the \u201cClass\u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affilia ted with any defendant. \n22. This action is properly maintainable as a class action.  \n23. The Class is so numerous that joinder of all members is impracticable.  As of \nFebruary 7,  2019, there were approximately 34,936,218 shares of Ellie Mae  common stock Case 1:19-cv-00473-UNA   Document 1   Filed 03/06/19   Page 3 of 10 PageID #: 3 4 outs",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 11. Plaintiff is, and has been continuously throughout all times relevant hereto, the owner of Asta Funding common stock. 12. Defendant Asta Funding is engaged in several business segments in the financial services industry including funding of personal injury claims, through our wholly owned subsidiaries Sylvave, LLC, Simia Capital, LLC and Arthur Funding LLC, social security disability advocacy through our wholly owned subsidiaries GAR Disability Advocates, LLC (\u201cGAR\u201d) and Five Star Veterans Disability, LLC and the business of purchasing, managing for their own account and servicing distressed consumer receivables, including charged off receivables, and semi-performing receivables.  Asta Funding\u2019s common stock is traded on the NasdaqGS under the ticker symbol \u201cASFI.\u201d 13. Individual Defendant Gary Stern is, and has been at all relevant times, a director of the Company, Chairman of the board, and Chief Executive Officer.  He is also the controller of the Stern Group. 14. Individual Defendant Louis A. Piccolo is, and has been at all relevant times, a director of the Company.   15. Individual Defendant David Slackman is, and has been at all relevant times, a director of the Company. 16. Individual Defendant Timothy Bishop is, and has been at all relevant times, a director of the Company. Case 1:20-cv-07323   Document 1   Filed 09/09/20   Page 4 of 1917. Individual Defendant Mike Monteleone is, and has been at all relevant times, a director of the Company. 18. The Defendants identified in paragraphs 13 through 17 are collectively referred to herein as the \u201cBoard\u201d or the \u201cIndividual Defendants,\u201d and together with Asta Funding, the \u201cDefendants.\u201d  ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n \n23. Plaintiff is a  former employee of Terran who held shares of  Terran \u2019s Legacy \ncommon stock which by terms of the Merger Agreement was to have been converted on the \nEffective Date into freely tradeable New TOC common stock  issued from the materially false \nand misleading S -4, and available for Plaintiff to sell. \n24. Defendant Terran Orbital , Inc. is a Delaware corporation with its principal place \nof business at 6800 Broken Sound Pkwy NW Suite 200, Boca Raton, FL 33487. Terran has \napproximately 350 employees. The current post-merger entity known as Terran Orbital , Inc. \n(\u201cNew TOC\u201d) was formed by the merger o f Defendant Tailwind Two Acquisitions Corp., \n(\u201cTTAC \u201d) and the original Terran Orbital , Inc.  (\u201cLegacy TOC\u201d) , also a Delaware corporation.  \nCase 1:23-cv-01394   Document 1   Filed 02/17/23   Page 9 of 38 \n \n10 25. Defendant  Marc Bell  (\u201cBell\u201d)  is the Chairman, CEO, and Co- Founder of Legacy \nTOC  since March 2021.  \n26. Defendant James LaChance (\u201cLaChance\u201d)  was a member of Legacy TOC\u2019s board \nof directors through March 2022. \n27. Defendant Stratton Sclavos  (\u201cSclavos\u201d)  was a member of Legacy TOC\u2019s board \nfrom January 2016 through March 2022.  \n28. Defendant  Daniel  Staton  (\u201cStaton\u201d)  was a director of Legacy TOC from July 2014 \nthrough March 2022 and is a current director of New TOC. He is the founder, Chairman and \nManaging Director of Staton Capital LLC since 2003. \n29. Defendants Bell, Hobart, Sclavos, LaChance and Staton were the directors of \nLegacy TOC and are hereinafter sometimes referred to as the \u201cLegacy TOC Director Defendants.\u201d  \n30. Defendant  Gary Hobart  (\u201cHobart\u201d)  has been the Chief Financial Officer of \nLegacy TOC .  On information and belief, Hobart was tasked with overseeing financial aspects of \nthe transaction.   Since January  2009, Hobart was a Managing Director of Beach Point Capital \nManagement LP, an investment firm with over $15 billion in assets under management , \nwhich ultimately became a PIPE investor in \nIndividual defendants:",
        "output": "Marc Bell,James LaChance,Stratton Sclavos,Daniel C. Staton,Gary Hobart,Tommy Stadlen,Philip Krim,Matthew Eby,Chris Hollod,Wisdom Lu,Boris Revsin,Michael Kim",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n11. Plaintiff, a citizen of Orange County, Ca lifornia, as set forth in the attached \nCertification, acquired Scynexis securities at ar tificially inflated prices during the Class Period \nand was damaged upon the revelation of the alleged corrective disclosures.  \n12. Defendant Scynexis is located in New Je rsey. The Company\u2019s principal executive \noffices are located at 101 Hudson Street, Suite 3610, Jersey City, New Jersey 07302.  Scynexis\u2019s Case 2:17-cv-01565   Document 1   Filed 03/08/17   Page 4 of 27 PageID: 45 \n shares trade on the NASDAQ under the ticker symbol \u201cSCYX.\u201d \n13. Defendant Marco Taglietti (\u201cTaglietti\u201d)  has served as the Company\u2019s Chief \nExecutive Officer (\u201cCEO\u201d) since April 1, 2015, and as President since September 24, 2015.  \n14. Defendant Eric Francois (\u201cFrancois\u201d)  has served as the Company\u2019s Chief \nFinancial Officer (\u201cCFO\u201d) since November 2, 2015. \n15. Defendant Yves J. Ribeill (\u201cRibeill\u201d) f ounded and served as the Company\u2019s CEO \nfrom November 1999 to April 1, 2015, and as President from November 1999 to July 2015.  \n16. Defendant Jonathan Sears Woodall (\u201cWooda ll\u201d) served as the Company\u2019s interim \nCFO from July 22, 2015 until November 2, 2015.  \n17. Defendant Charles F. Osborne Jr. (\u201cOs borne\u201d) served as the Company\u2019s CFO \nfrom November 2003 until his resignation on June 30, 2015.  \n18. The defendants referenced above in \u00b6\u00b6 13- 17 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \nA. Plaintiff \n18. Plaintiff City of Miami General Employees\u2019 & Sanitation Employees\u2019 Retirement \nTrust is a single-employer defined benefit pension plan covering all City of Miami general and \nsanitation employees.  As indicated on the certification submitted herewith, Plaintiff purchased \nordinary shares of Venator at artificially inflated prices during the Class Period and suffered \ndamages as a result of the violations of the federal securities laws alleged herein. Case 1:19-cv-07182   Document 1   Filed 07/31/19   Page 6 of 507B. Corporate Defendant \n19. Defendant Venator Materials PLC is a United Kingdom corporation with its \ncorporate headquarters located at Titanium House, Hanzard Drive, Wynyard Park, Stockton-On-\nTees, TS22 5FD United Kingdom.  The Company is the issuer of the ordinary shares sold in the \nIPO and the SPO.  The Company\u2019s shares trade on The New York Stock Exchange (\u201cNYSE\u201d) \nunder ticker symbol \u201cVNTR.\u201d  As of May 2, 2019, Venator had over 106 million ordinary shares \noutstanding. \nC. Officer Defendants \n20. Defendant Simon Turner (\u201cTurner\u201d) is, and was at all relevant times, Venator\u2019s \nPresident and CEO and a Director of the Company.  Defendant Turner signed the IPO Registration \nStatement (defined below) and the SPO Registration Statement (defined below) and is therefore \nliable under the Securities Act for the untrue and misleading statements and omissions in the \nOffering Materials for the Offerings. \n21. Defendant Kurt D. Ogden (\u201cOgden\u201d) is, and was at all relevant times, Senior Vice \nPresident and Chief Financial Officer (\u201cCFO\u201d) of Venator.  Defendant Ogden signed the IPO \nRegistration Statement and the SPO Registration Statement and is therefore liable under the \nSecurities Act for the untrue and misleading statements and omissions in the Offering Materials \nfor the Offerings. \n22. Defendant Stephen Ibbotson (\u201cIbbotson\u201d) is, and was at all relevant times, Vice \nPresident and Corporate Controller of Venator.  Defendant Ibbotson signed th\nIndividual defendants:",
        "output": "Simon Turner,Kurt D Ogden,Stephen Ibbotson,Russ R Stolle,Peter R Huntsman,Robert J Margetts,Douglas Anderson,Daniele Ferrari,Kathy D Patrick",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n14. Plaintiff purchased Twitter  common stock as detailed in the certification attached \nhereto and was damaged thereby.  Case 3:19-cv-07149   Document 1   Filed 10/29/19   Page 5 of 17 \n \n5 \n COMPLAINT  \nCase No. 19-cv-07149  \n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 15. Defendant Twitter  is incorporated in Delaware and its princ ipal executiv e offices \nare at 1355 Market Stre et, Suite 900, San F rancisco, CA 94103.  Twitter \u2019s common stock trades on \nthe NYSE under the symbol \u201c TWTR .\u201d \n16. Defendant Do rsey was the Chief Executive Officer of Twitter  at all relevant times.  \n17. Defendant Ned Segal  (\u201cSegal\u201d) was  the Chie f Financial Officer of Twit ter at all \nrelevant times.  \n18. Defendants Twitter , Dorsey and S egal are collectively referred to as \u201cDefendants\u201d.  \n19. Defend ants Dorsey and Segal are also referred to herein  as the \u201cIndividual \nDefendant s.\u201d  The Indiv idual Defen dants, because of their positions  with the Company, possessed \nthe power and authority to control  the contents of Twitter \u2019s press releases , tweets, SEC fi lings  and \npresentations to securities analysts, m oney and portfolio managers and instituti onal i nvestor s, i.e., \nthe market.  The Individual Defendant s were provided with copies of the Company\u2019s press  releases  \nand statement s alleged herein to be misleading  prior to or shortly after their issuance and had the \nability and opportunity to prevent thei r issuance or cause them to be corrected.  Becau se of their \npositions  and access to material non -public information availabl e to them but not to the public, the \nIndividual Defendant s knew , or ignored with deli berate reckless,  that the adverse facts speci fied \nherein h ad not been disclosed to and were bei ng concealed  from the public and that the positive \nrepresentations which were being made were then materially false and misleading.  \nIV. CLASS ACTION ALLEGATIONS  \n20. Plaintif f brings \nOnly answer with the company defendants names.",
        "output": "Twitter, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been at all times relevant hereto, a continuous stockholder of \nKeane.   \n9. Defendant Keane is a Delaware corporation, with its principal executive offices \nlocated at 1800 Post Oak Boulevard, Suite 450, Houston, TX 77056.  Keane\u2019s  common stock \ntrades on the New York Stock Exchange  under the ticker symbol \u201c FRAC .\u201d Case 4:19-cv-02924   Document 1   Filed on 08/07/19 in TXSD   Page 3 of 22- 4 - \n 10. Defendant Robert W. Drummond (\u201cDrummond\u201d)  has been Chief Executive Officer \n(\u201cCEO\u201d) and a director of the Company since August 2018. \n11. Defendant  James C. Stewart (\u201c Stewart \u201d) has been  a director of the C ompany since \nMarch  2011 and Executive Chairman since August 2018.  Defendant Stewart previously served as \nthe Company\u2019s CEO  and Chairman  from March 2011 to August 2018.  \n12. Defendant Marc G. R. Edwards (\u201c Edwards \u201d) is the Company\u2019s Lead Independent \nDirector and has been  a director of the Company since September 2016.  \n13. Defend ant Lucas N. Batzer (\u201c Batzer \u201d) has been a director of the Company since \nMarch 2016 and is a Managing Director of Private Equity at Cerberus Capital Management, L.P. \n(together with  its affiliate s, \u201cCerberus \u201d). \n14. Defendant Dale M. Dusterhoft (\u201c Dusterhoft \u201d) has been a director of the Company \nsince March 2016.  \n15. Defendant Christian A. Garcia (\u201cGarcia\u201d) has been a director of the Company since \nMay 2017.  \n16. Defendant Lisa A. Gray (\u201cGray\u201d) has been a director of the Company since March \n2011 and is Vice Chairman of Cer berus Operations and Advisory Company, LLC . \n17. Defendant Gary M. Halverson (\u201cHalverson\u201d) has been a director of the Company \nsince September 2016.  \n18. Defendant Shawn Keane (\u201cKeane\u201d) has been a director of the Company since \nMarch 2011.  Defendant Keane previously  served as the Company\u2019s President from 2008 to 2011 \nand Vice President from 2000 to 2008. \n19. Defendant Elmer D. Reed (\u201cReed\u201d) has been a director of the Company since April \n2011.  Case 4:19-cv-02924 ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n10. Plaintiff  is, and has been at all relevant times, the owner of Rowan  common stock \nand held such stock since prior to the wrongs complained of herein.   \n11. Defendant Rowan  is a UK public limited company  with its registered office and \nprincipal executive offices are located at 2800 Post Oak Boulevard, Suite  5450 Houston, Texas \n77056.  The Company is a global provider of offshore contract drilling services to the oil and gas \nindustry in the ultra -deepwater and shallow water market, with a focus on high- specification an d \nharsh -environment jack- up rigs and ultra -deepwater drillships . Rowan \u2019s common stock trades on \nthe NYSE  under the symbol \u201c RDC .\u201d \n12. Individual Defendant William E. Albrecht is director of Rowan  and Chairman of \nthe Board.   \n13. Individual Defendant Thomas P. Burke  is a director of Rowan  and the President \nand Chief Executive Officer of the Company . \n14. Individual Defendant Thomas R. Hix is, and has been at all relevant times, a \ndirector of Rowan . \n15. Individual Defendant Jack B. Moore  is, and has been at all relevant times,  Lead  \nDirector of Rowan . \n16. Individual Defendant Suzanne P. Nimocks  is, and has been at all relevant times, a \ndirector of Rowan . \n17. Individual Defendant Thierry Pilenko is, and has been at all relevant times, a \ndirector of Rowan . \n18. Individual Defendant John J. Quicke  is, and has been at all relevant times, a director \nof Rowan . Case 1:18-cv-10423   Document 1   Filed 11/09/18   Page 4 of 195 \n 19. Individual Defendant Tore I. Sandvold is, and has been at all relevant times, a \ndirector of Rowan . \n20. Individual Defendant Charles L. Szews  is, and has been at all relevant times, a \ndirector of Rowan . \n21. The parties  identified in \u00b6\u00b6 11- 20 are collectively referred to as the \u201cDefendants\u201d.  \nCLASS ACTION ALLEGAT IONS  \n22. Plaintiff brings this action on  his own behalf and as a class action pursuant to Rule \n23 of the Federal Rules of Civil Procedure on behalf of all holders",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Choice common stock. Case 1:19-cv-01669-UNA   Document 1   Filed 09/06/19   Page 2 of 13 PageID #: 2 \n \n 3 9. Defendant Choice  is a Wisconsin corporation and a party to the Merger Agreement .  \nChoice \u2019s common stock is traded OTC  under the ticker symbol \u201c CBKW .\u201d   \n10. Defendant Rodney R. Oilschlager is Chairman of the Board of the Company . \n11. Defendant Arend A. S tam is a director of the Company . \n12. Defendant Gerald A. Thi ele is a director of the Company . \n13. Defendant Mark D. Trou dt is a director of the Company.  \n14. Defendant Kenneth J. Balda  is a director of the Company.  \n15. Defendant Stephen W. Ford is a director of the Company . \n16. Defendant Paul R. Getchel is a director of the Company . \n17. Defendant Michael L. Hannem an is a director of the Company.  \n18. Defendant David A. Jans sen is a director of the Compa ny. \n19. Defendant Thomas L. M uza is a director of the Company . \n20. Defendant James G. Poes chl is a director of the Company . \n21. Defendant Jeffrey S. Ro gge is a director of the Company .  \n22. Defendant Thomas N. Rusch is a director of the Company . \n23. Defendant John F. Supple III is a director of the Company .  \n24. The defendants identified in paragraphs 10 through 23 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d    \n25. Defendant  Nicolet  is a party to the Merger Agreement .   \nCLASS ACTION ALLEGATIONS  \n26. Plaintiff brings  this action as a class action on behalf of him self and the other public \nstockholders of Choice  (the \u201cClass \u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defend ant. Case 1:19-cv-01669-UNA   Document 1   Filed 09/06/19   Page 3 of 13 PageID #: 3 \n \n 4 27. This action is properly maintainable as a class action.  \n28. The Class is so numerous that joinder of all members is impracticab",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n6.\n \nPlaintiff, as set forth in the accompanying Certification, purchased\n \nand/or \nacquired\n \nVince\n \nsecurities\n \nat artificially inflated\n \nprices during the Class Period and was damaged \nupon the revelation of th\ne alleged corrective disclosures.\n \n7.\n \nDefendant \nVince\n \nengages in the design, merchandise, and sale of various luxury \nbrand products in the United States and internationally\n.\n \nThe Company i\ns incorporated in \nDelaware\n \nand its principal executive offices are located at \n500 5th Avenue\n\u2014\n20th Floor, New \nYork, New York 10110\n.\n \nThe Company\u2019s\n \ncommon stock is traded on \nthe New York Stock \nExchange (\u201cNYSE\u201d)\n \nunder the ticker symbol \n\u201c\nVNCE\n.\n\u201d\n \n8.\n \nDefendant \nBrenda\nn L. Hoffman\n \n(\n\u201c\nHoffman\n\u201d\n) \nhas been Chief Executive Officer \n(\u201cCEO\u201d) of Vince since October 2015.\n \n9.\n \nDefendant \nDavid Stefko\n \n(\n\u201c\nStefko\n\u201d\n) \nhas been the Chief Financial Officer (\u201cCFO\u201d) \nof Vince Holding since January 14, 2016 and its Executive Vice President since \nSeptember 20, \n2016\n.\n \n10.\n \nDefendants\n \nHoffman\n \nand \nStefko\n \nare sometimes referred to herein as the \n\u201c\nIndividual Defendants.\n\u201d\n \n11.\n \nEach of the Individual Defendants:\n \n(a)\n \ndirectly participated in the management of the Company;\n \n(b)\n \nwas directly involved in the day\n-\nto\n-\nday op\nerations of the Company at the highest \nlevels;\n Case 1:17-cv-02757   Document 1   Filed 05/05/17   Page 3 of 19 PageID #: 34\n \n(c)\n \nwas privy to confidential proprietary information concerning the Company and its \nbusiness and operations;\n \n(d)\n \nwas directly or indirectly involved in drafting, producing, reviewing and/or \ndisseminating the \nfalse and misleading statements and information alleged herein;\n \n(e)\n \nwas directly or indirectly involved in the oversight or implementation of the \nCompany\n\u2019\ns internal controls;\n \n(f)\n \nwas aware of or recklessly disregarded the fact that the false and misleading\n \nstatements were being issued concerning the Company; and/or \n \n(g)\n \napproved or ratified these statements ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " .......................................................................................................................... 11  \nA. Plaintiff ................................................................................................................. 11  \nB. The Corporate Defendant ...................................................................................... 11  \nC. The Management Defendants ............................................................................... 11  \nD. Relevant Non-Parties ............................................................................................ 13  \nIV. FACTUAL BACKGROUND ........................................................................................... 15  \nA. Valeant\u2019s Acquisition-Centric Business Model .................................................... 15  \nB. Valeant\u2019s Extraordinary Price Hikes .................................................................... 17  \nC. Valeant\u2019s Use of a Secret Pharmacy Network ...................................................... 21  \n1. Philidor ...................................................................................................... 22  \n2. Valeant\u2019s Other Secret Pharmacies ........................................................... 25  \n3. Valeant Used its Secret Pharmacy Network to Insulate its Branded \nDrugs from Generic Competition, Inflate Prices and Book \nFictitious Sales .......................................................................................... 28  \n4. Valeant Exploits \u201cPatient Assistance Programs\u201d To Raise Prices............ 40  \n5. The R&O Lawsuit and the Initial Disclosure of Valeant and \nPhilidor\u2019s Fraudulent Arrangement .......................................................... 43  \nV. DEFENDANTS MISLED INVESTORS REGARDING VALEANT\u2019S \nBUSINESS MODEL AND MANIPULATED THE COMPANY\u2019S FINANCIAL \nRESULTS ........................................................................................................................\nIndividual defendants:",
        "output": "J. Michael Pearson,Howard B Schiller,Robert L Rosiello,Deborah Jorn,Tanya Carro,Ari S Kellen",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 12. Plaintiff Jerry Peacock, as set forth in the accompanying certification, incorporated by reference herein, purchased Dutch Bros securities during the Class Period, and suffered damages as a result of the federal securities law violations and false and/or misleading statements and/or material omissions alleged herein.  Case 1:23-cv-01794   Document 1   Filed 03/01/23   Page 4 of 26 \n4  13. Defendant Dutch Bros is incorporated under the laws of Delaware with its principal executive offices located in Grants Pass, Oregon. Dutch Bros\u2019 class A common stock trades on the New York Stock Exchange (\u201cNYSE\u201d) under the symbol \u201cBROS.\u201d  14. Defendant Jonathan Ricci was the Company\u2019s President and Chief Executive Officer at all relevant times. 15. Defendant Charles L. Jemley was the Company\u2019s Chief Financial Officer at all relevant times.  16. Defendants Ricci and Jemley (collectively the \u201cIndividual Defendants\u201d), because of their positions with the Company, possessed the power and authority to control the contents of the Company\u2019s reports to the SEC, press releases and presentations to securities analysts, money and portfolio managers and institutional investors, i.e., the market. The Individual Defendants were provided with copies of the Company\u2019s reports and press releases alleged herein to be misleading prior to, or shortly after, their issuance and had the ability and opportunity to prevent their issuance or cause them to be corrected. Because of their positions and access to material non-public information available to them, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to, and were being concealed from, the public, and that the positive representations which were being made were then materially false and/or misleading. The Individual Defendants are liable for the false statements pleaded herein.  Case 1:23-cv-01794   Document 1   Filed 03/01/23   Page 5 of 26 \n5  \nOnly answer with the company defendants names.",
        "output": "Dutch Bros, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n10. Plaintiff Miramar Firefighters\u2019 Pension Fund provides retirement benefits to \nfirefighters employed by the City of Miramar, Florida.  As indicated on the certification submitted \nherewith, Plaintiff purchased shares of iRobot stock during the Class Period and suffered damages \nas a result of the violations of the federal securities laws alleged herein. Case 1:19-cv-09837   Document 1   Filed 10/24/19   Page 3 of 20411. Defendant iRobot Corporation, a Delaware corporation headquartered at 8 Crosby \nDrive, Bedford, Massachusetts 01730, is a global consumer robot company with a portfolio of \nproducts focused on indoor and outdoor cleaning applications.  The Company\u2019s common stock \ntrades on the NASDAQ, which is an efficient market, under ticker symbol \u201cIRBT.\u201d  iRobot \ncurrently has over 28 million shares of common stock outstanding, owned by at least hundreds or \nthousands of investors. \n12. Defendant Colin M. Angle is a co-founder of iRobot and has served as Chief \nExecutive Officer of the Company since June 1997 and Chairman of the Board of Directors since \nOctober 2008.  \n13. Defendant Alison Dean has served as Executive Vice President, Chief Financial \nOfficer, Treasurer, and Principal Accounting Officer of iRobot since April 2013. \n14. Defendants Angle and Dean are collectively referred to hereinafter as the \n\u201cIndividual Defendants.\u201d  The Individual Defendants, because of their positions with iRobot, \npossessed the power and authority to control the contents of iRobot\u2019s reports to the SEC, press \nreleases, and presentations to securities analysts, money and portfolio managers, and institutional \ninvestors.  Each of the Individual Defendants was provided with copies of the Company\u2019s reports \nand press releases alleged herein to be misleading prior to, or shortly after, their issuance and had \nthe ability and opportunity to prevent their issuance or cause them to be corrected.  Because of \ntheir positions and access to material non-public information, each of t\nIndividual defendants:",
        "output": "Colin M Angle,Alison Dean",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has been continuously  throughout all times relevant hereto, the \nowner of  Wright Medical  common stock. Case 1:20-cv-00061-UNA   Document 1   Filed 01/15/20   Page 2 of 12 PageID #: 2 \n 3 9. Defendant Wright Medical is a public limited liability company organized under \nthe laws of the Netherlands and a party to the Merger Agreement.   Wright Medical \u2019s common \nstock is traded on the NASDAQ Global Select Market  under the ticker symbol \u201c WMG I.\u201d \n10. Defendant Gary D. Blackford is a director  of the C ompany.  \n11. Defendant John C. Miclot  is a director of the C ompany.  \n12. Defendant Robert J. Palmisano is President, Chief Executive Officer, and  a director  \nof the C ompany.  \n13. Defendant David D. Stevens is Chairman of the Board of the C ompany.  \n14. Defendant Elizabeth H. Weatherman  is a director of the C ompany.  \n15. Defendant J. Patrick Mackin  is a director of the C ompany. \n16. Defendant Kevin C. O Boyle  is a director of the C ompany.  \n17. Defendant Amy S. Paul is a director of the Company.  \n18. Defendant Richard F. Wallman is a director of the Company.  \n19. The defendants identified in paragraphs 10 through 18 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d    \n20. Defendant Parent is a Michigan corporation and a party to the Merger Agreement.  \n21. Defendant  Buyer  is a private company organized under the l aws of the Netherlands , \na wholly -owned subsidiary of Parent , and a party to the Merger A greement . \nCLASS ACTION ALLEGATIONS  \n22. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Wright Medical  (the \u201cClass \u201d).  Excluded from the Class are defendants herein and \nany person, firm, trust, corporation, or other entity related to or affiliated with any defendant. \n23. This action is properly maintainable as a class action.  Case 1:20-cv-00061-UNA   Document 1   Filed 01/15/20   Page 3 of 12 PageID #: 3 \n 4 24. The Class is so numerous\nOnly answer with the company defendants names.",
        "output": "Wright Medical Group N.V.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n13. Plaintiff Laura Ciccarello, as s et forth in the accompanying ce rtification, \nincorporated by reference here in, purchased Alibaba securities during the Class Period, and \nsuffered damages as a result of the federal securities law viol ations and false and/or misleading \nstatements and/or material omissions alleged herein.  \n14. Defendant Alibaba is incorporated under the laws of Cayman Isla nds with its \nprincipal executive offices locat ed in Hong Kong. Alibaba\u2019s Ame rican Depositary Shares \n(\u201cADSs\u201d or \u201cshares\u201d) trades on the New York Stock Exchange (\u201cNY SE\u201d) under the symbol \n\u201cBABA.\u201d  Case 1:20-cv-09568   Document 1   Filed 11/13/20   Page 4 of 22 \nCLASS ACTION COMPLAINT \n4 15. Defendant Daniel Zhang (\u201cZhang\u201d) was the Company\u2019s Chief Execut ive Officer \n(\u201cCEO\u201d) at all relevant times. \n16. Defendant Maggie Wu (\u201cWu\u201d) was the Company\u2019s Chief Financial Of ficer \n(\u201cCFO\u201d) at all relevant times. \n17. Defendants Zhang and Wu (collectively the \u201cIndividual Defendant s\u201d), because of \ntheir positions with the Compa ny, possessed the power and autho rity to control the contents of \nthe Company\u2019s reports to the SEC, press releases and presentati ons to securities analysts, money \nand portfolio managers and institutional investors, i.e., the m arket.  The Individual Defendants \nwere provided with copies of the Company\u2019s reports and press re leases alleged herein to be \nmisleading prior to, or shortly a fter, their issuance and had t he ability and opportunity to prevent \ntheir issuance or cause them to be corrected.  Because of their  positions and access to material \nnon-public information available to them, the Individual Defend ants knew that the adverse facts \nspecified herein had not been disclosed to, and were being conc ealed from, the public, and that \nthe positive representations which were being made were then ma terially false and/or \nmisleading.  The Individual Defenda nts are liable for the false  statements pleaded herein.  \n\nIndividual defendants:",
        "output": "Daniel Zhang,Maggie Wu",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n9.  Plaintiff, as set forth in the accompanyi ng certification incorporated by reference \nherein, purchased Sunlands AD Ss pursuant and/or traceable to  the IPO and was damaged \nthereby.  \n10. Defendant Sunlands is an online post-secondary and professional education \ncompany in the PRC.  Sunlands is a Cayman Islands corporation with principal executive offices located at Building 4-6, Chaolai Science Park, No. 36, Chuangyuan Road, Chaoyang District, \nBeijing, 100012, PRC. Sunlands ADSs are listed on the New York Stock Exchange ( \u201cNYSE \u201d) \nunder the tic ker symbol \u201c STG .\u201d Sunlands was formally known as Sunlands Online Education \nGroup until August 2018. \n11. Defendant Tongbo Liu ( \u201cLiu\u201d) was, at all relevant times, Sunland \u2019s Chief \nExecutive Officer and a Director. Defendant Li u reviewed, contributed to, and signed the \nRegistration Statement. Case 1:19-cv-03744   Document 1   Filed 06/27/19   Page 3 of 16 PageID #: 3 - 4 - 12. Defendant Yipeng Li ( \u201cLi\u201d) was, at all relevant time s, Sunland \u2019s Chief Financial \nOfficer. Defendant Li reviewed, contributed  to, and signed the Registration Statement. \n13. Defendant Jianhong Yin ( \u201cYin\u201d), also known as Peng Ou, was, at all relevant \ntimes, Sunlands \u2019s Chairman of the Board of Directors. De fendant Yin reviewed, contributed to, \nand signed the Registration Statement. \n14. Defendant Lu Lu ( \u201cLu\u201d) was, at all relevant times, a Director of Sunlands. \nDefendant Lu reviewed, contributed to, and signed the Registration Statement. \n15. Defendant Michael Minhong Yu ( \u201cYu\u201d) was, at all relevant times, a Director of \nSunlands. Defendant Yu reviewed, contributed  to, and signed the Registration Statement. \n16. Defendant Yang Wang (\u201cWang \u201d) was, at all relevant times, a Director of \nSunlands. Defendant Wang reviewed, contributed  to, and signed the Registration Statement. \n17. The Defendants named in \u00b6\u00b611-16 are referred to herein as the \u201cIndividual \nDefendants.\u201d The In dividual Defendants each signed the Registration Statement, \nIndividual defendants:",
        "output": "Tongbo Liu,Yipeng Li,Jianhong Yin (aka Peng Ou),Lu Lu,Michael Minhong Yu,Yang Wang",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n11. Plaintiff James Celeste, as set forth in th e accompanying certifi cation, incorporated \nby reference herein, purchased Intrusion securiti es during the Class Period, and suffered damages \nas a result of the federal securities law violatio ns and false and/or misle ading statements and/or \nmaterial omissions alleged herein.  \n12. Defendant Intrusion is incorporated under th e laws of Delaware with its principal \nexecutive offices located in 101 East Park Blvd., Suite 13 00, Plano, Texas 75074. Intrusion\u2019s \ncommon stock trades on the NASDAQ ex change under the symbol \u201cINTZ.\u201d  Case 4:21-cv-00307   Document 1   Filed 04/16/21   Page 4 of 24 PageID #:  4 \n4 13. Defendant Jack B. Blount (\u201cBlount\u201d) wa s the Company\u2019s Chie f Executive Officer \n(\u201cCEO\u201d) at all relevant times. \n14. Defendant B. Franklin Byrd (\u201cByrd\u201d) was the Company\u2019s Chief Financial Officer \n(\u201cCFO\u201d) at all relevant times. \n15. Defendants Blount and Byrd (collectively the \u201cIndividual Defendants\u201d), because of \ntheir positions with the Company, possessed the power  and authority to control the contents of the \nCompany\u2019s reports to the SEC, press releases an d presentations to securi ties analysts, money and \nportfolio managers and institutional investors, i. e., the market.  The Individual Defendants were \nprovided with copies of the Company\u2019s reports and press releases alleged herein to be misleading \nprior to, or shortly after, their issuance and had the ability and oppor tunity to prevent their issuance \nor cause them to be corrected.  Because of their positions and access to material non-public \ninformation available to them, the Individual Defendants knew th at the adverse facts specified \nherein had not been disclosed to, and were being concealed from, the public,  and that the positive \nrepresentations which were being made were th en materially false and/or misleading.  The \nIndividual Defendants are liable for th e false statements pleaded herein.  \n\nOnly answer with the company defendants names.",
        "output": "Intrusion, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n5. Plaintiff Daryl P. Duffy, as set forth in the accompanying certification, \nwhich is incorporated by reference herein, purchased and acquired Vertex sec urities \nduring the Class Period and was damaged thereby.  \n6. Defendant Vertex is an energy company focused on the production and \ndistribution of conventional and alternative fuels.  Vertex\u2019s primary operations are located in Mobile, Alabama, where it owns and operates a 91,000 barrel-per -day \nrefinery, and engages in the supply, marketing, and trading of feedstocks and \nproducts to support the Company\u2019s operations.  Vertex common stock trades in New Case 1:23-cv-00076   Document 1   Filed 03/03/23   Page 3 of 26    PageID #: 3 \n- 3 - York City on The NASDAQ Stock Market LLC (\u201cNasdaq\u201d) under ticker  symbol \n\u201cVTNR.\u201d  \n7. Defendant Benjamin P. Cowart (\u201cCowart\u201d) served as Chief Executive \nOfficer (\u201cCEO\u201d) and Chairman of the Board of Directors of Vertex (the \u201cBoard\u201d) \nthroughout the Class Period.  \n8. Defendant Chris Carlson (\u201cCarlson\u201d) served as Chief Financial Officer \n(\u201cCFO\u201d) of Vertex throughout the Class Period.  \n9. Defendants Cowart and Carlson are collectively referred to herein as \nthe \u201cIndividual Defendants.\u201d  Vertex and the Individual Defendants are collectively \nreferred to herein as \u201cdefendants.\u201d  \n10. Each of the Individual Defendants was directly involved in the \nmanagement and day -to-day operations of the Company at the highest levels and \nwas privy to confidential proprietary information concerning the Company and its \nbusiness, operations, services, competition, sales, and present and future business prospects.  In addition, the Individual Defendants were involved in drafting, \nproducing, reviewing, and disseminating the false and misleading statements and \ninformation alleged herein, were aware of, or recklessly disrega rded, the false and \nmisleading statements being issued regarding the Company, and approved or ratified \nthese statements, in violation of the federal securities laws.  Case 1:\nOnly answer with the company defendants names.",
        "output": "Vertex Energy, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \nINTRODUCTION \n1. This is a securities class action on behalf of all persons who purchased Twitter \ncommon stock in and/or traceable to Twitter\u2019s November 7, 2013 initial stock offering (the \u201cIPO\u201d), \nseeking to pursue remedies under the Securities Act of 1933 (the \u201cSecurities Act\u201d). \n2. On or about October 3, 2013, Twitter \ufb01led with the SEC a registration statement on \nForm 8-1, which was followed by several amendments, the last of which was \ufb01led with the SEC on \nNovember 4, 2013 (Registration No. 333-191552), which became effective on November 6, 2013, \nand which was later issued to the public in connection with the IPO (the \u201cRegistration Statement\u201d). \nOn or about November 6, 2013, Twitter and the Underwriter Defendants priced the IPO at $26 per \nshare. On or about November 7, 2013, the Company \ufb01led with the SEC the \ufb01nal prospectus for the \n[PO (the \u201cProspectus\u201d), dated November 6, 2013, which forms part of the Registration Statement \n(the Prospectus and Registration Statement are collectively referred to herein as the \u201cRegistration \nStatement\u201d).' \n3. The Registration Statement described the Company\u2019s business and registered an \naggregate of 80,5 00,000 share of its common stock, including 10,500,000 shares registered to cover \nCOMPLAINT 1Ut-hWN \n\\OOO\\]O\\ \n10 \nll \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n26 \n27 \n28 an option to purchase additional shares that the Company granted to its IPO underwriters. On or \nabout November 13, 2013, the Company closed its IPO and sold 80,500,000 shares of its common \nstock ordinary shares to the public. In all, the Company raised approximately $2.09 billion-in the \nIPO, incurred approximately $5.2 million in expenses and paid the underwriters approximately $68 \nmillion, resulting in net offering proceeds of approximately $2.02 billion. \n4. Unbeknownst to investors who purchased shares in the Company\u2019s IPO, however, the \nCompany\u2019s Registration Statement contained untrue statements of material facts, omitted to state \no\nOnly answer with the company defendants names.",
        "output": "Twitter, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n6. Plaintiff purchased iAnthus common stock at  artificially inflated prices during the \nClass Period, as indicated in the Certification filed herewith, and has been damaged thereby. \n7. Defendant  iAnthus is incorporated in Canada, w ith its registered office located at \nSuite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Canada, V6E 4N7, and its \nprincipal executive offices at 505 Fifth Avenue, 23rd Floor, New York, NY 10017.  The Company\u2019s \ncommon shares are listed on the Canadian Stoc k Exchange under the trading symbol \u201cIAN,\u201d and \ntrade in the United States over- the-counter on the OTCQX, part  of the OTC Markets Group, under \nthe trading symbol \u201cITHUF.\u201d   Case 1:20-cv-03044   Document 1   Filed 04/15/20   Page 2 of 233 \n\u00a08. Gotham Green Partners (\u201cGGP\u201d) is a privat e equity firm that focuses on deploying \ncapital into cannabis and cannabis-related enterp rises. GGP manages a diversified portfolio of \ninvestments, investing across the cannabis value chain.  GGP maintains its primary offices at 1437 \n4th Street, Suite 200, Santa Monica, CA 90401.  GGP  entered into a Secured Debenture Purchase \nAgreement (the \u201c2018 Debenture Agreement\u201d) with iAnthus on May 24, 2018, which provided for \n$40 million in secured debenture financing and a c oncurrent $10 million equity financing agreement \nwith GGP (the \u201c2018 Debenture\u201d).  On Septem ber 30, 2019, GGP entere d into a non-brokered \nprivate placement offering of US $20.0 million 13% secured notes (the \u201c2019 Debenture\u201d) under an \nAmended and Restated Secured Debenture Purc hase Agreement between the Company and GGP \n(the \u201cAmended Debenture Agreement\u201d). \n9. Defendant Hadley C. Ford (\u201cFord\u201d) is the co-founder of the Company who is, and \nat all times relevant hereto has been, the Chief Executive Officer and a dir ector of the iAnthus.  \nDefendant Ford signed the 2018 Debenture Agreem ent and the Amended Debenture Agreement on \nbehalf of iAnthus.  \n10. Defendant Julius John Kalcevich (\u201cKalcevich\u201d ) is, and at\nOnly answer with the company defendants names.",
        "output": "iAnthus Capital Holdings, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n9. Plaintiff  is, and has been at all relevant times, the owner of Cincinnati Bell  \ncommon stock  and has held such stock  since prior to the wrongs complained of herein.  \n10. Individual Defendant Lynn A. Wentworth has served as a  member of the Board \nsince 2008 and is the Company\u2019s Chair of the Board.  \n11. Individual Defendant Meredith J. Ching  has served as a member of the Board  \nsince 2018.  \n12. Individual Defendant Walter A. Dods, Jr. has served as a member  of the Board \nsince 2018.  \n13. Individual Defendant John W. Eck has served as a member of the Board since \n2014.  \n14. Individual Defendant Leigh R. Fox  has served a s a member of the Board since \n2018, and is the Company\u2019s President and Chief Executive Officer.  \n15. Individual Defendant Jakki L. Haussler  has served as a member of the Board \nsince 2008.  Case 1:20-cv-01282   Document 1   Filed 02/13/20   Page 4 of 165 16. Individual Defendant Craig F. Maier  has served as a member of the Board since \n2008. \n17. Individual Defendant Russel P. Mayer  has served as a member of the Board since \n2013. \n18. Individual Defendant Theodore H. Torbeck has served as a member of the Board \nsince 2013.  \n19. Individual Defendant Martin J. Yudkovitz has served as a member of the  Board \nsince 2015.  \n20. Defendant Cincinnati Bell is incorporated in Delaware  and maintains its principal \noffices at 221 East Fourth Street , Cincinnati, OH 45202.  The Company \u2019s common s tock trades  \non the New York  Stock Exchange  under the symbol \u201c CBB.\u201d  \n21. The defe ndant s identified in paragraphs 10- 19 are collectively r eferred to as the \n\u201cIndividual Defendants\u201d or the \u201cBoard.\u201d  \n22. The defendant s identified in paragraphs 10- 20 are collectively r eferred to as the \n\u201cDefendants.\u201d  \nSUBSTANTIVE ALLEGATI ONS  \nA. The Proposed Transacti on \n23. Cincinnati Bell, together with its subsidiaries, provides diversified \ntelecommunications and technology services to residential and business customers in the United \nStates. It",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n16. Plaintiff is a pension fund established for the benefit of the current and retired \npublic employees of the State of Mississippi.  Plaintiff is responsible for the retirement income of \nemployees of the State, including current and retired employees of the State\u2019s public-school \ndistricts, municipalities, counties, community colleges, state universities, libraries and water \ndistricts.  Plaintiff provides benefits to over 75,000 retirees, manages over $28 billion in assets for \nits beneficiaries, and is responsible for providing retirement benefits to more than 250,000 current Case 2:20-cv-00955-NR   Document 1   Filed 06/26/20   Page 5 of 286 public employees.  As indicated on the certification submitted herewith, Plaintiff purchased Mylan \ncommon stock at artificially inflated prices during the Class Period and suffered damages as a \nresult of the violations of the securities laws alleged herein. \n17. Defendant Mylan is a Netherlands corporation, headquartered at 1000 Mylan \nBoulevard, Canonsburg, Pennsylvania, that claims to be one of the largest pharmaceutical \ncompanies in the world. \n18. Defendant Bresch joined Mylan in 1992 and has been Mylan\u2019s CEO since January \n1, 2012.  Bresch has been a member of Mylan\u2019s Board of Directors (the \u201cBoard\u201d) since 2011. \n19. Defendant Malik joined Mylan in July 2005 and has been Mylan\u2019s President since \nJanuary 1, 2012.  Malik has been a member of the Board since 2013. \n20. Defendant Anthony \u201cTony\u201d Mauro (\u201cMauro\u201d) joined Mylan in 1996.  Mauro \nserved as Mylan\u2019s President of North America from January 1, 2012 to January 2016.  Mauro was \nappointed as Mylan\u2019s Chief Commercial Officer in February 2016, and continues to occupy that \nrole.   \n21. Defendant Kenneth \u201cKen\u201d Parks (\u201cParks\u201d) joined Mylan in June 2016 as the \nCompany\u2019s Chief Financial Officer (\u201cCFO\u201d).   \n22. Defendants Bresch, Malik, Mauro, and Parks are collectively referred to in this \ncomplaint as the \u201cOfficer Defendants.\u201d  The Officer Defendants, because of their\nOnly answer with the company defendants names.",
        "output": "Mylan, NV",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff s, as set forth in the  certification s previously provided to the Court , \npurchased Kitov  ADSs  during the Class Period  and were  economically damaged thereby.  \n12. Defendant Kitov , through its subsidiary,  is a clinical stage biopharmaceutical \ncompany that develops combination drugs for  the simultaneous treatment of pain caused by \nosteoarthritis and hypertension . The Company \u2019s lead drug candidate is KIT-302. The Company \nis incorporated in Israel  and its principal executive offices in Tel Aviv, Israel . Kitov \u2019s common \nstock is traded on the NASDAQ Capital Market  (\u201cNASDAQ\u201d)  under the ticker symbol \n\u201cKTOV .\u201d \n13. Defendant Isaac Israel  (\u201cIsrael \u201d) has been  Kitov \u2019s Chief Executive Officer \n(\u201cCEO\u201d) throughout the Class Period . Defendant Israel  signed the Registration Statement.   \n14. Defendant Simcha Rock  (\u201cRock \u201d) has been Kitov \u2019s Chief Financial Officer \n(\u201cCFO\u201d) throughout the Class Period . Defendant Rock  signed the Registration S tatement.  \n15. Defendan ts Israel  and Rock  are collectively referred to herein as the \u201cIndividual \nDefendants. \u201d \n16. Each of the Individual Def endants:  \n(a) directly participated in the management of the Company;  \n(b) was directly involved in the day -to-day operations of the Company at the \nhighest levels;  \n(c) was privy to confidential proprietary information concerning the Company \nand its business and operations;  Case 1:17-cv-00917-LGS   Document 28   Filed 06/19/17   Page 4 of 38 \n5 (d) was directly or indirectly involved in drafting, producing, reviewing \nand/or disseminating the false and misleading statements and information alleged \nherein;  \n(e) was directly or indirectly involved in the oversight or implementation of  \nthe Company \u2019s internal controls;  \n(f) was aware of or recklessly disregarded the fact that the false and \nmisleading statements were being issued concerning the Company; and/or  \n(g) approved  or ratified these statements in violation of the federal securities \nl",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, \nthe owner of LifeLock common stock.  \n9. Defendant LifeLock is a Delaware corporation and maintains  its principal \nexecutive office  at 60 East Rio Salado Parkway, Suite 400, Tempe, Arizona 85281.  \nLifeLock \u2019s common stock is traded on the NYSE  under the ticker symb ol \u201cLOCK .\u201d \n10. Defendant Roy A. Guthrie (\u201cGuthrie\u201d) is a director and Chairman of the \nBoard of LifeLock .  According to the Company\u2019s Form DEF 14A filed with the SEC on \nMarch 24, 2016 (the \u201c2016 Proxy\u201d), Guthrie is Chair of the Audit Committee, a member \nof the Compensation Committee, and a member of the Nominating & Corporate \nGovernance Committee.  \n11. Defendant Hilary A. Schneider (\u201cSchneider\u201d) is a director and President of \nLifeLock  and was named Chief Executive Officer (\u201cCEO\u201d) in March 2016.   Case 2:16-cv-04434-DKD   Document 1   Filed 12/16/16   Page 3 of 19 \n  4 \n  \n \n \n1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 12. Defendant Todd Davis  (\u201cDavis\u201d) is a director of  LifeLock  and has served \nas Vice Chairman since March 2016 .   \n13. Defendant Gary Briggs (\u201cBriggs\u201d) is a director of  LifeLock .  According to \nthe Company\u2019s 2016 Proxy, Briggs is a member of the Compensation Committee and the \nNominating  & Corporate Governance Committee.  \n14. Defendant David Cowan (\u201cCowan\u201d) is a director of  LifeLock .   \n15. Defendant Albert Pimentel (\u201cPimentel\u201d) is a director of  LifeLock .  \nAccording to the Company\u2019s 2016 Proxy, Pimentel is a member of the Audit Committee.  \n16. Defendant  Thomas J. Ridge (\u201cRidge\u201d) is a director of  LifeLock .  According \nto the Company\u2019s 2016 Proxy, Ridge is Chair of the Nominating & Corporate \nGovernance Committee.  \n17. Defendant Jaynie Miller Studenmund (\u201cStudenmund\u201d) is a director of  \nLifeLock .  According to the Company\u2019s 2016 Proxy, Studenmund is Chair of the \nCompensation Committee and a member of the Audit Committee.",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " entering into \nthe Merger  Agreement, the Merger Consideration  represented approximately $10.31  in value for \neach share of  Gilat common stock.  By compari son, based on the closing price of Comtech  \ncommon stock on the NAS DAQ on March 2, 2020, the Merger Consideration represented \napproximately $9.56 in value for each  share of  Gilat common stock.  \n3. On March  2, 2020, in order to convince Gil at\u2019s stockholders to vote in favor of the \nProposed Transaction, Defendants filed a materially incomplete and misleading preliminary S-4 \nRegistration Statement (the \u201cRegistration Statement\u201d) w ith the United States Securities and \nExchange Commission (\u201cS EC\u201d) and sent same to stockholders  of Gil at. \n4. The Registration  Statement omits  material information  with respect  to the Proposed \nTransaction, which  renders  the Regi stration  Statement  false  and misleading.  Accordingly, plaintiff \nalleges herein  that defendan ts violated Sections  14(a)  and 20(a)  of the Securities  Exchange  Act of \n1934 (the \u201c1934 Act\u201d) in connection with the Regis tration  Statement.  \n5. In addition, a special m eeting of Gil at\u2019s stockholders will be held to vote on the \nProposed Transaction (the \u201cStockh older Vote\u201d).  It is therefore imperative that the material \ninformation that has been omitted from the Registration Statement is disclosed prior to the \nStockholder Vote so Gilat stockholders can prop erly exercise their corpora te voting rights and \nmake an i nformed decision on whether to vote in favor of the merger.  \nJURISDICTION & VENUE  \n6. This Court has jurisdiction over the claims asserted herein pursuant to Section 27 \nof the 1934 Act and 28 U.S.C. \u00a71331 because the claims asserted  herein  arise  under  Sections  14(a)  \nand 20(a)  of the 1934 Act and Rule  14a-9. Case 1:20-cv-01944   Document 1   Filed 03/04/20   Page 2 of 143 \n 7. This Court has jurisdiction over D efendants because each defendant is either a \ncorporation that conducts business in this District, or",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 17. Plaintiff, as set forth in the attached Certification, acquired National Beverage\u2019s securities at artificially inflated prices during the Class Period and was damaged upon the revelation of the alleged corrective disclosures.  18. Defendant National Beverage is headquartered in Fort Lauderdale, Florida, with principal executive offices located at 8100 SW Tenth Street, Suite 4000, Fort Lauderdale, Florida 33324.  National Beverage\u2019s securities trade on the NASDAQ under the ticker symbol \u201cFIZZ.\u201d 19. Defendant Caporella has served at all relevant times as the Company\u2019s CEO and Chairman.  20. Defendant George R. Bracken (\u201cBracken\u201d) has served at all relevant times as the Company\u2019s Executive Vice President of Finance. 21. The Defendants referenced above in \u00b6\u00b6 19-20 are sometimes referred to herein as the \u201cIndividual Defendants.\u201d 22. The Individual Defendants possessed the power and authority to control the contents of National Beverage\u2019s SEC filings, press releases, and other market communications. The Individual Defendants were provided with copies of the Company\u2019s SEC filings and press releases alleged herein to be misleading prior to or shortly after their issuance and had the ability and opportunity to prevent their issuance or to cause them to be corrected. Because of their positions with the Company, and their access to material information available to them but not to the public, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to and were being concealed from the public, and that the positive representations being Case 0:18-cv-61631-KMM   Document 1   Entered on FLSD Docket 07/17/2018   Page 5 of 256  made were then materially false and misleading. The Individual Defendants are liable for the false statements and omissions pleaded herein. \nOnly answer with the company defendants names.",
        "output": "National Beverage Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Landauer  common stock.  \n9. Defendant  Landauer  is a Delaware  corporation and maintains its principal \nexecutive offices at  2 Sciences Road, Glenwood, Illinois 60425 .  Landauer \u2019s common stock is \ntraded on the NYSE  under the ticker symbol \u201c LDR .\u201d \n10. Defendant Michael P. Kaminski  (\u201cKaminski \u201d) is a director, President, and Chief \nExecutive Officer (\u201cCEO\u201d) of Landauer .  \n11. Defendant William G. Dempsey  (\u201cDempsey \u201d) is a director of Landauer . \n12. Defendant David E. Meador  (\u201cMeador \u201d) is a director of Landauer . \n13. Defendant Thomas M. White  (\u201cWhite \u201d) is a director of Landauer.  \n14. Defendant Stephen C. Mitchell  (\u201cMitchell \u201d) is a director of Landauer.  \n15. Defendant Jeffrey A. Strong  (\u201cStrong \u201d) is a director of Landauer.  \n16. Defendant Michael T. Leatherman  (\u201cLeatherman \u201d) is a director of Landauer.  \n17. Defendant Jeffrey Allen Bailey (\u201cBailey\u201d) is a director of Landauer.  \n18. Defendant Teri G. Fontenot  (\u201cFonte not\u201d) is a director of Landauer.  \n19. Defendant Frank B. Modruson  (\u201cModruson \u201d) is a director of Landauer.  \n20. The defendants identi fied in paragraphs 10 through  19 are collectively  referred to \nherein as the \u201cIndividual Defendants.\u201d   \n21. Defendant Parent is a  Delaware  corporation  and a party to the Merger Agreement . \n22. Defendant Merg er Sub is a Delaware corporation , an indirect,  wholly -owned \nsubsidiary of Parent, and a party to the Merger Agreement.  \n Case 1:17-cv-01349-UNA   Document 1   Filed 09/25/17   Page 3 of 12 PageID #: 3 4 CLASS ACTION ALLEGATIONS  \n23. Plaintiff brings this action as  a class action o n behalf of himself  and the other \npublic stockholders of Landauer  (the \u201cClass\u201d).  Excluded from the Class are defendants herein \nand any person, firm, trust, corporation, or other entity related to or affiliated with any defendant.  \n24. This action is properly m aintainable as a class action.  \n25. The Cl\nIndividual defendants:",
        "output": "Michael P. Kaminski,William G Dempsey,David E Meador,Thomas M White,Stephen C Mitchell,Jeffrey A Strong,Michael T Leatherman,Jeffrey Allen Bailey,Teri G Fontenot,Frank B Modruson",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n18. As set forth in the attached Certification, Plaintiff Jeffrey Crass acquired Yalla \nADSs at artificially inflated prices during the Class Period and was damaged due to the federal \nsecurities violations and related misstatements alleged herein. \n19. Defendant Yalla is incorporated in the Cayman Islands, with headquarters in the \nUnited Arab Emerites.  Yalla ADSs trade on the NYSE under the ticker symbol \u201cYALA.\u201d \n20. Yalla (formerly known as \u201cFYXTech Corporation\u201d), through its wholly-owned \nsubsidiaries, operates a voice-centric social networking and entertainment platform, mainly in the \nMENA region.  The platform allows individual users free access to the basic functions on the \nplatform.  It also provides enhanced experiences for individual users by sales of virtual items and \nprovision of upgrade services on the platform.  One of Yalla\u2019s offerings is Yalla Ludo, a chatroom \nfeature in a board game app. \n21. Defendant Yang has served at all relevant times as the Company\u2019s Chairman and \nChief Executive Officer (\u201cCEO\u201d).  Yang had the power and authority to control the contents of \nYalla\u2019s SEC filings, press releases, and other market communications.\n",
        "output": "['Jeffrey Crass']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n13. Plaintiff Marisa Marder , as set forth in the accompanying \ncertification, incorporated by reference herein, purchased Campbell  common stock \nat artif icially inflated prices during the Class Period and has been damaged \nthereby.  \n14. Defendant Campbell  is a New Jersey  corporation with its principal \nexecutive offices located at One Campbell Place, Camden, New Jersey 08103 .    \n15. Defendant Denise M. Morrison  (\u201cMorrison \u201d) was the President and \nChief Executive Officer of Campbell  from the beginning of the Class Period \nthrough May 18, 2018 .   \n16. Defendant Anthony P. DiSilvestro  (\u201cDiSilvestro \u201d) is and, throughout \nthe Class Period, was  the Senior Vice President and Chie f Financial Officer of \nCampbell.  \n17. Defendants Morrison and DiSilvestro  are collectively  referred to \nherein  as the \u201cIndividual Defendants.\u201d  The Individual Defendants, because of their \npositions with the Company, possessed the power and authority to control the \ncontents of Campbell \u2019s reports to the SEC, press releases, and presentations to \nsecurities analysts, money portfolio managers , and inst itutional investors, i.e., the \nmarket.  Each Individual Defendant was provided with copies of the Company\u2019s Case 1:18-cv-14385   Document 1   Filed 09/28/18   Page 6 of 25 PageID: 67 \n reports and press releases alleged herein to be misleading prior to, or shortly after, \ntheir issuance and had the ability and opportunity to prevent  their issuance or cause \nthem to be corrected.  Because of their positions and access to material non -public \ninformation available to them, each of these Individual Defendants knew that the \nadverse facts specified herein had not been disclosed to, and were  being concealed \nfrom, the public, and that the positive representations which were being made were \nthen materially false and /or misleading .  \n",
        "output": "['Marisa Marder']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff is, and has been at all relevant times, the owner of shares of common \nstock of Outerwall.  \n12. Outerwall, a  Delaware corporation, delivers retail product and services to \nconsumers via self -service interactive kiosks.  The Company\u2019s corporate headquarters are \nlocated at 1800 114th Avenue SE, Bellevue, Washington 98004.  Its common stock is traded on \nthe NASDAQ u nder the ticker symbol \u201cOUTR.\u201d   \n13. Defendant Jeffrey J. Brown (\u201cBrown\u201d) has been a director of the Company since \nApril 2016.  Defendant Brown was appointed to the Board by Engaged Capital, LLC \n(\u201cEngaged Capital\u201d) in connection with the Cooperation Agreement (defined herein).  \n14. Defendant Nelson C. Chan (\u201cChan\u201d) has been Chairman of the Board since June \n2013 and a director of the Company since July 2011.  Defendant Chan is Chair of the \nNominating and Governance Committee, and is a member of the Compensation Commi ttee. Case 2:16-cv-01275   Document 1   Filed 08/12/16   Page 4 of 33 \nCLASS  ACTION  COMPLAINT  - 5  \n(NO. 2:16-cv-1275 ) \n  \n \n1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 15. Defendant Nora M. Denzel (\u201cDenzel\u201d) has been a director of the Company since \n2013, and served as Interim Chief Executive Officer (\u201cCEO\u201d) from January 2015 to July 2015.  \nDefendant Denzel is a member of the Nominating and Governance Committee.  \n16. Defenda nt David M. Eskenazy (\u201cEskenazy\u201d) has been a director of the \nCompany since August 2000.  Defendant Eskenazy is a member of the Audit Committee and \nthe Compensation Committee.  \n17. Defendant Ross G. Landsbaum (\u201cLandsbaum\u201d) has been a director of the \nCompany sinc e July 2014.  Defendant Landsbaum is Chair of the Audit Committee, and is a \nmember of the Nominating and Governance Committee.  \n18. Defendant Erik E. Prusch (\u201cPrusch\u201d) has been CEO and a director of the \nCompany since July 2015.   \n19. Defendant Robert D. Sznewajs ( \u201cSznewajs\u201d) has been a director of the \nCompany since August",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n23. Plaintiff Yellowdog  is a limited partnership organized under the laws of Del aware, \nwith its place of business in Seal Beach, California.  \n24. Yellowdog  purchased  CURO  securities  during the Class Period , as set forth in its \naccompanying PSLRA certification,  and was damaged thereby.   \n25. Defendant CURO  is a Delaware  corporation maintaining its principal place of \nbusiness at 3527 North Ridge Road, Wichita, Kansas .  CURO  shares  trade on  the New York Stock \nExchange (\u201cNYSE\u201d) under the ticker symbol \u201c CURO .\u201d \n26. Defendant  Gayhardt  serves as President, Chief Executive Officer, and a director  of \nCURO . \n27. Defendant Baker serves as the Executive Vice President and Chief Operating Officer  \nof CURO.  \n28. Defendant Roger W. Dean (\u201cDean\u201d) serves as Executive Vice President and Chief \nFinancial Officer of Curo.  \n29. Defendants Gayhardt, Baker and Dean  are referred to herein as the \u201cIndividual \nDefendants.\u201d  \nPRE -CLASS PERIOD STATEMENTS  \n30. Prior to and d uring the Class Period, Defendants  consistently touted the on -going \nsuccess of the transition, reaffirmed the  Company\u2019s 2018 full -year financial  guidance, and down -\nplayed  the adverse financial effects from the conversion of the Company\u2019s Canadian Single -Pay \nproducts to Open -Ended and Installment Loans.  Among other things, Defendants assured the Case 2:18-cv-02662   Document 1   Filed 12/05/18   Page 8 of 32  9 Company\u2019s investors that the upfront loan -provisioning would not have a material affect on \nCURO\u2019s business , financial results and projections during th e transition.  \n31. For example, prior  to the start of the Class Period, during  the April 2 7, 2018, CURO \n2018 first quarter earnings conference call, Defendant  Gayhardt  sought to assure the market that \nCURO had fully accounted for the transition and loss provisioning in it s modeling and guidance for \nfiscal full-year 2018 : \nDonald F. Gayhardt : Yeah. Maybe you \u2013 so, you do today have the \nmix shift then obviou\nOnly answer with the company defendants names.",
        "output": "Curo Group Holdings Corp.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n14. Plaintiff Daniel Yannes, as set fort h in the accompanying certification, \nincorporated by reference herein, purchased SC Worx securities during the Class Period, and \nsuffered damages as a result of the federal securi ties law violations and false and/or misleading \nstatements and/or material omissions alleged herein.  \n15. Defendant SCWorx is incorporated under the laws of Delaware with its principal \nexecutive offices located in New York, New York. SCWorx\u2019s  common stock trades on the \nNASDAQ exchange under the symbol \u201cWORX.\u201d \n16. Defendant Marc S. Schessel (\u201cSchessel\u201d) was the Company\u2019s Chief Executive \nOfficer (\u201cCEO\u201d) and interim Chief Financial Offi cer (\u201cCFO\u201d) at all relevant times. Defendant \nSchessel, also referred to as the \u201cIndividual De fendant\u201d, because of his positions with the \nCompany, possessed the power and authority to cont rol the contents  of the Compa ny\u2019s reports to \nthe SEC, press releases and presentations to se curities analysts, money and portfolio managers \nand institutional investors, i.e., the market.  The Individual Defe ndant was provided with copies \nof the Company\u2019s reports and press releases allege d herein to be misleadi ng prior to, or shortly \nafter, their issuance and had the ability and opportun ity to prevent their issu ance or cause them to Case 1:20-cv-03349   Document 1   Filed 04/29/20   Page 4 of 19 \nCLASS ACTION COMPLAINT \n4 be corrected.  Because of his positions and access to material non-public information available to \nthem, the Individual Defendant knew that the a dverse facts specified herein had not been \ndisclosed to, and were being concealed from, the public, and that the positive representations which were being made were then materially fa lse and/or misleading.  The Individual Defendant \nis liable for the false st atements pleaded herein.  \n",
        "output": "['Daniel Yannes']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \nA. Plaintiff \n16. Plaintiff Fern Helms (\u201cPlaintiff\u201d) is a U.S. citizen currently residing in \nCalifornia.  Plaintiff, as set forth in the accompanying Certification, purchased 100 \ncommon shares of Facebook on or around July 6, 2018 and was damaged by the news \nthat Facebook had missed many of its key financial metrics on or around July 25, 2018.   \nB. Defendants \n17. Defendant Facebook, Inc. is incorporated in Delaware and has its principal \nexecutive offices at 1601 Willow Road, Menlo Park, California 94025.  Facebook\u2019s \nsecurities trade on the NASDAQ under the ticker symbol \u201cFB.\u201d \n18. Defendant Mark E. Zuckerberg is Facebook\u2019s founder, has served at all relevant \ntimes as its CEO, and is a resident of California. \n19. Defendant David M. Wehner has served at all relevant times as Facebook\u2019s \nCFO and is a resident of California. \n20. Defendant Sheryl K. Sandberg has served at all relevant times as Facebook\u2019s \nCOO and is a resident of California. \nIV. FACTUAL BACKGROUND \nA. Facebook \n21. Facebook is the world\u2019s largest social networking platform with over 1.4 billion \nusers accessing the Platform per day, with users in at least 60 countries. \n22. Facebook operates a social networking platform that allows people to \ncommunicate with their family, friends, and coworkers, and develops technologies that \nfacilitate the sharing of information, photographs, website links, and videos.  Users can Case 1:18-cv-06774   Document 1   Filed 07/27/18   Page 6 of 24 \n7  access and utilize the Platform for \u201cfree,\u201d in the sense that no sign-up fee, access fee, or \nmonthly user fee is collected by Facebook from its users.  However, users are subject to \nviewing advertisements on Facebook\u2019s social network. \n23. Facebook collects data about its users to help advertisers and developers better \ntarget potential customers, for which it earns almost the entirety of its billions in \nrevenues. As Zuckerberg described in April 2018 when testifying before Congress, \nFacebook \u201crun[s] ads\u201d to s\nIndividual defendants:",
        "output": "Mark Zuckerberg,David M. Wehner,Sheryl Kara Sandberg",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n9. Plaintiff is, and has been at all relevant times, the owner of Tableau  common \nstock  and has held such stock  since prior to the wrongs complained of herein. \n10. Individual Defendant Adam Selipsky (\u201cSelipsky\u201d ) is the Company\u2019s President, \nand Chief Executive  Officer  (\u201cCEO\u201d). Selipsky  has been a member of the Board since \nSeptember 2016. \n11. Individual Defendant Billy Bosworth  has served as a member of the Board since \nMay 2015. Case 1:19-cv-01289-UNA   Document 1   Filed 07/10/19   Page 3 of 16 PageID #: 34 12. Individual Defendant Brooke Seawell  has served as a member of the Board since \nNovember 2011. \n13. Individual Defendant Christian Chabot  is one of the Company\u2019s co- founders and \nhas served as Chairman of the Board since the Company\u2019s inception in 2003, and was the \nCompany\u2019s President and CEO from 2003 until September 2016.  \n14. Individual Defendant Christopher Stolte  is one of the Company\u2019s co- founders and \nhas served as a member of the Board since the Company\u2019s inception in 2003. \n15. Individual Defendant Elliott Jurgensen,  Jr. has served as a member of the Boar d \nsince September 2012. \n16. Individual Defendant Gerri Martin -Flickinger  has served as a member of the \nBoard since January 2018. \n17. Individual Defendant Hilarie Koplow -McAdams has served as a member of the \nBoard since December 2016 . \n18.  Individual Defendant John McA dam has served as a member of the Board since \nDecember 2012 . \n19. Individual Defendant Patrick Hanrahan  is one of the Company\u2019s co- founders and \nhas served as a member of the Board since the Company\u2019s inception in 2003. \n20. Defendant Tableau  is incorporated in Delaw are and maintains its principal offices \nat 1621 North 34th Street, Seattle, Washington 98103.  The Company\u2019s  common s tock trade s on \nthe New York Stock Exchange  under the symbol \u201c DATA.\u201d  \n21. The defendant s identified in paragraphs 10- 19 are collectively referred to as the \n\u201cIndividual Defendants\u201d or the \u201cBoard.\u201d  Case 1:19-cv-01",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n10. Plaintiff is, and at all relevant times has been, a shareholder  of CRH . \n11. Defendant CRH  provides services and products for the treatment of gastrointestinal  \ndiseases . The Company\u2019s common stock  trades  on the NYSE American  under the ticker symbol \n\u201cCRHM \u201d. \n12. Individual Defendant Tushar Ramani is, and has been at all relevant times, the \nCompany\u2019s Chief Executive Officer and Chairman  of the CRH  Board . \n13. Individual Defendant Ian Webb is, and has been at all relevant times, a director of \nCRH . Case 1:21-cv-02597   Document 1   Filed 03/25/21   Page 3 of 17 \n4 \n 14. Individual Defendant David A. Johnson is, and has been at all relevant times,  a \ndirector of CRH .  \n15. Individual Defendant Todd Patrick  is, and has been at all relevant times, a director \nof CRH .  \n16. Individual Defendant Brian Griffin  is, and has been at all relevant times, a director \nof CRH .  \n17. The Individual Defendants referred to in \u00b6\u00b612- 16 are collectively referred to herein \nas the \u201cIndividual Defendants\u201d  or the \u201cBoard\u201d  and together with CRH  as the \u201cDefendants .\u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n9.  Plaintiff, as set forth in the accompanyi ng certification incorporated by reference \nherein, purchased Sunlands AD Ss pursuant and/or traceable to  the IPO and was damaged \nthereby.  \n10. Defendant Sunlands is an online post-secondary and professional education \ncompany in the PRC.  Sunlands is a Cayman Islands corporation with principal executive offices located at Building 4-6, Chaolai Science Park, No. 36, Chuangyuan Road, Chaoyang District, \nBeijing, 100012, PRC. Sunlands ADSs are listed on the New York Stock Exchange ( \u201cNYSE \u201d) \nunder the tic ker symbol \u201c STG .\u201d Sunlands was formally known as Sunlands Online Education \nGroup until August 2018. \n11. Defendant Tongbo Liu ( \u201cLiu\u201d) was, at all relevant times, Sunland \u2019s Chief \nExecutive Officer and a Director. Defendant Li u reviewed, contributed to, and signed the \nRegistration Statement. Case 1:19-cv-03744   Document 1   Filed 06/27/19   Page 3 of 16 PageID #: 3 - 4 - 12. Defendant Yipeng Li ( \u201cLi\u201d) was, at all relevant time s, Sunland \u2019s Chief Financial \nOfficer. Defendant Li reviewed, contributed  to, and signed the Registration Statement. \n13. Defendant Jianhong Yin ( \u201cYin\u201d), also known as Peng Ou, was, at all relevant \ntimes, Sunlands \u2019s Chairman of the Board of Directors. De fendant Yin reviewed, contributed to, \nand signed the Registration Statement. \n14. Defendant Lu Lu ( \u201cLu\u201d) was, at all relevant times, a Director of Sunlands. \nDefendant Lu reviewed, contributed to, and signed the Registration Statement. \n15. Defendant Michael Minhong Yu ( \u201cYu\u201d) was, at all relevant times, a Director of \nSunlands. Defendant Yu reviewed, contributed  to, and signed the Registration Statement. \n16. Defendant Yang Wang (\u201cWang \u201d) was, at all relevant times, a Director of \nSunlands. Defendant Wang reviewed, contributed  to, and signed the Registration Statement. \n17. The Defendants named in \u00b6\u00b611-16 are referred to herein as the \u201cIndividual \nDefendants.\u201d The In dividual Defendants each signed the Registration Statement, \nOnly answer with the company defendants names.",
        "output": "Sunlands Technology Group",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n26. Plaintiff, as set forth in th e attached Certification, acquired Goldman Sachs shares \nat artificially inflated prices  during the Class Peri od and was damaged upon the revelation of the \nalleged corrective disclosures.  Case 1:18-cv-12084   Document 1   Filed 12/20/18   Page 6 of 27 \n{00306076;3 }   \n7 \n \n \n 27. Defendant Goldman Sachs is a Delaware co rporation with its principal executive \noffices located at 200 West Street, New York, Ne w York.  Goldman Sachs\u2019s shares trade in an \nefficient market on the New York Stock Exch ange (\u201cNYSE\u201d) under the ticker symbol \u201cGS.\u201d \n28. Defendant Blankfein served as the CEO of Goldman Sachs between June 2006 and \nSeptember 2018. \n29. Defendant Harvey M. Schwartz served as  the Chief Financial Officer (\u201cCFO\u201d) of \nGoldman Sachs between January 2013 and May 2017. \n30. Defendant R. Martin Chavez served as the CFO of Goldman Sachs between May \n2017 and November 2018. \n31. The Defendants referenced above in \u00b6\u00b6 28 -30 are sometimes referred to herein \ncollectively as the \u201cIndividual Defendants.\u201d \n32. The Individual Defendants possessed th e power and authority to control the \ncontents of the Company\u2019s SEC filings, press releases, and other market communications. The \nIndividual Defendants were provid ed with copies of the Company\u2019 s SEC filings and press releases \nalleged herein to be misleading prior to or shortly after their issuance and had the ability and opportunity to prevent thei r issuance or to cause them to be corrected. Because of their positions \nwith the Company, and thei r access to material information ava ilable to them but not to the public, \nthe Individual Defendants knew that the adverse f acts specified herein had not been disclosed to \nand were being concealed from the public, and th at the positive representations being made were \nthen materially false and mislead ing. The Individual De fendants are liable for the false statements \nand omissions pleaded herein. \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n6. Plaintiff , as set forth in the accompanying certification, incorporated by reference \nherein, purchased the Company\u2019s  securities  at artificially inflated prices  during the Class Period  and \nwas econ omically damaged thereby.  \n7. Defendant  Synchronoss is incorporated in Delaware and headquartered in \nBridgewater, New Jersey . The Company  provides cloud solutions and software -based activation for \nconnected devices worldwide.  On or about January 19, 2017, the Company completed its acquisition \nof Intralinks Holdings, Inc. (\u201cIntralinks\u201d). The Company\u2019s  securities  trade on NASDAQ under the \nticker \u201c SNCR .\u201d \n8. Defendant Stephen G. Waldis  (\u201cWaldis \u201d) is the founder of the Company . Defendant \nWaldis  previously served as the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) prior to the Class \nPeriod and has been the Company\u2019s CEO since  April 27, 2017. During the Class Period, Defendant \nWaldis  was the Company\u2019s Executive Chairman , Principal Executi ve Officer and director.  \n9. Defendant  Karen L. Rosenberger ( \u201cRosenberger \u201d) was the Company\u2019s Chief \nFinancial Officer (\u201cCFO\u201d), Executive Vice President, and Treasurer during the Class Period  until her \nresignation on April 1, 2017.  \n10. Defendant  Ronald W. Hovsepia n (\u201cHovsepian\u201d) was the CEO of Intralinks prior to its \nmerger with the Company . Defendant Hovsepian was the Company\u2019s CEO from January 19, 2017 \nuntil r esignation on April 27, 2017. \n11. Defendant John Frederick (\u201cFrederick \u201d) was the Company\u2019s CFO from February 27, \n2017 until his resignation on April 27, 2017. \n12. Defendan ts Waldis , Rosenberger , Hovsepian, and Frederick  are collectively referred \nto herein as the \u201c Individual Defendants.\u201d  Case 3:17-cv-02978-FLW-LHG   Document 1   Filed 05/01/17   Page 3 of 18 PageID: 34 13. Each of the Individual Defendants:  \n(a) directly participated in the management of  the Company;  \n(b) was directly involved in the day -to-day operations of the Company at the highest \nlevels;  \n(c) was privy t\nIndividual defendants:",
        "output": "Stephen Waldis,Karen L Rosenberger,Ronald Hovsepian,John Frederick",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  (c ) review of news articles,  shareholder communications, \nconference call transcripts, and pos tings on F45\u2019s website concerning the \nCompany\u2019s public statements; and (d) review  of other publicly available information \nconcerning F45 and the de fendants named herein. \nI. NATURE AND SUMMARY  OF THE ACTION \n1. F45 is a fitness franchisor with a business model base d on rapid growth \nthrough the franchising of low-overhea d fitness facilities. The Company was \nfounded in Sydney, Australia  in 2013 and, by the time of the Company\u2019s July 16, \n2021 initial public offering more fully de scribed below, mainta ined 2,801 franchises \nin 68 countries. \n2. Plaintiff brings this class action on be half of all persons and entities that \npurchased or otherwise acquired the comm on stock (\"stock\" or \"shares\") of F45 Case 1:22-cv-01291   Document 1   Filed 12/08/22   Page 2 of 33 \nCLASS ACTION COMPLAINT  2 pursuant and/or traceable to the Compan y's false and/or misleading Form S-1 \nRegistration Statement and accompanying Prospectus and Supplemental Prospectus \n(collectively, the \"Registrat ion Statement\") issued in c onnection with the Company's \nJuly 16, 2021 initial pu blic offering of 18.75 million shar es of common stock, priced at \n$16 per share (the \"July 2021 IPO\" or the \"Offering\"), to pursue remedies under \nSections 11 and 15 of th e Securities Act of  1933 (the \"Secu rities Act\").  \n3. As set forth in the Prospect us issued in support of the July 2021 IPO, the \nCompany asserted that th e proceeds would be used, inter alia , to repay indebtedness, \nto complete the purchase of Flywheel indoor cycling studio, to pay bonuses to certain \nemployees, to pay expenses related to the offering, and for working capital and general \ncorporate purposes. \n4. In support of the July  2021 IPO F45\u2019s Registra tion Statement professed \nand represented its advantage over traditi onal owner-operated fitness facilities both \nbecause the franc hise model \u201c has enabled us to open new studios \nOnly answer with the company defendants names.",
        "output": "F45 Training Holdings, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n9. Plaintiff is, and has been continuously throughout all times relevant hereto, a  \nFirst Bancorp shareholder .  \n10. Defendant First Bancorp is a Delaware corporation and a party to the Merger \nAgreement.  First Bancorp shares are  traded on the NASDAQ under the ticker symbol \u201c FBNC.\u201d  \n11. Defendant Richard H. Moore is the Company\u2019s Chief Executive Officer and a \ndirector of the Company. \n12. Defendant James C. Crawford, III is Chairman of the Board and a director of the \nCompany. \n13. Defendant  Daniel T. Blue, Jr. is a director of the Company. \n14. Defendant Mary Clara Capel is a director of the Company. \n15. Defendant Suzanne DeFerie is a director of the Company.  \n16. Defendant Abby J. Donnelly is a director of the Company. \n17. Defendant John B. Gould is a director of the Company.  \n18. Defendant G. Mayer is a director of the Company. \n19. Defendant O. Temple Sloan, III is a director of the Company  \n20. Defendant Frederick L. Taylor II is a director of the Company. \n21. Defendant Virginia C. Thomasson is a director of the Company. Case 1:21-cv-06278   Document 1   Filed 07/23/21   Page 3 of 144 \n 22. Defendant Dennis A. Wicker is a director of the Company.  \nFACTS  \n23. First Bancorp  is a bank holding company headquartered in North Car olina. On \nMarch 31, 2021, First Bancorp had total consolidated assets of approximately $7.7 billion, total \nloans of approximately $4.6 billion, total deposits of approximately $6.7 billion, and shareholders\u2019 \nequity of approximate $0.9 billion. First Bancorp\u2019s princ ipal activity is the ownership and \noperation of First Bank, a state -chartered bank with its main office in Southern Pines, North \nCarolina.  \n24. Select is a  bank holding company headquartered in North Carolina. On \nMarch  31, 2021, Select had total  consolidated assets of approximately $1.8  billion, total loans \nof approximately $1.3  billion, total deposits of approximately $1.6  billion, and shareholders\u2019 \nequity of approximate $212 million.  Select\u2019s \nOnly answer with the company defendants names.",
        "output": "First Bancorp",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " 14. Plaintiff Jigneshkumar B. Patel, as set forth in his Certification filed contemporaneously herewith, acquired shares of eHealth common stock at artificially inflated prices, and has been damaged. 15. Defendant eHealth, Inc. is incorporated under the laws of Delaware, with its principal place of business at 2625 Augustine Drive, Second Floor, Santa Clara, CA 95054.  Its common stock trades on the Nasdaq stock exchange under the symbol EHTH. 16. Defendant Scott N. Flanders is the Chief Executive Officer of eHealth, Inc., and has served in that capacity since May 2016.  Mr. Flanders is also a director of eHealth, Inc., and has served in that capacity since February 2008. Case 5:20-cv-02395   Document 1   Filed 04/08/20   Page 4 of 27 \n5  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  17. Defendant Derek N. Yung is the Chief Financial Officer of eHealth, Inc., and has served in that capacity since June 2018. 18. Defendant David K. Francis is the current Chief Operating Officer, and former Chief Financial Officer, of eHealth, Inc. 19. Defendants Flanders, Yung, and Francis are named as Defendants for violations of all counts asserted herein, and are referred to as the \u201cIndividual Defendants.\u201d  The Individual Defendants, because of their positions with the Company, possessed the power and authority to control the contents of the Company\u2019s reports to the SEC, press releases and presentations to securities analysts, money and portfolio managers, and the investing public, i.e., the market.  The Individual Defendants were provided with copies of the Company\u2019s reports and press releases alleged herein to be misleading prior to, or shortly after, their issuance and had the ability and opportunity to prevent their issuance or cause them to be corrected.  Because of their positions and access to material, non-public information available to them, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to, and \nIndividual defendants:",
        "output": "Scott N Flanders,Derek N Yung,David K Francis",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n9. Plaintiff  is, and has been at all relevant times, the owner of Vereit  common stock \nand has held such stock since prior to the wrongs complained of herein.  \n10. Individual Defendant Susan Skerritt  has served as a director of the Company since \nFebruary 2021 . \n11. Individual Defen dant Priscilla Almodovar  has served as a director of the Company \nsince February  2011.  \n12. Individual Defendant Julie G. Richardson  has served as a director of the Company \nsince 2015 . \n13. Individual Defendant Mary Hogan Preusse  has served as a director of the Company \nsince 2017 .  \n14. Individual Defendant Eugene A. Pinover  has served as a director of the Company \nsince 2015 . \n15. Individual Defendant Richard Lieb  has served as President since 2017 . \n16. Individual Defendant David B. Henry  has served as a director of the Company since \n2015 . Case 1:21-cv-01409-SAG   Document 1   Filed 06/07/21   Page 4 of 185 17. Individual Defendant Hugh R. Frater  has served as a director of the Company since \n2015 and is the Non -Executive Chairman of the Board .  \n18. Individual Defendant Glenn Rufrano  has served as a director of the C ompany since \n2015 and is the Company\u2019s Chief Executive Officer . \n19. Defendant Vereit  is incorporated in Maryland and maintains its principal offices at \n2325 E. Camelback Road, 9th Floor, Phoenix, Arizona 85016 .  The Company\u2019s common stock \ntrades on the New Yor k Stock Exchange under the symbol \u201c VER .\u201d \n20. The defendants identified in paragraphs 10 -18 are collectively referred to as the \n\u201cIndividual Defendants\u201d or the \u201cBoard.\u201d  \n21. The defendants identified in paragraphs 10 -19 are collectively referred to as the \n\u201cDefendants .\u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n12. Plaintiff, as set forth in the attached Certification, acquired Unisys securities at \nartificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosures. \n13. Defendant Unisys is a Delaware corporation with principal executive offices \nlocated at 801 Lakeview Drive, Suite 100, Blue Bell, Pennsylvania 19422.  The Company\u2019s \ncommon stock trades in an efficient market on the New York Stock Exchange (\u201cNYSE\u201d) under \nthe ticker symbol \u201cUIS\u201d. \n14. Defendant Peter A. Altabef (\u201cAltabef\u201d) served as Unisys\u2019s Chairman, President, \nand Chief Executive Officer at all relevant times. \n15. Defendant Debra Winkler McCann (\u201cMcCann\u201d) has served as Unisys\u2019s Chief \nFinancial Officer at all relevant times. \n16. Defendants Altabef and McCann are sometimes referred to herein as the \n\u201cIndividual Defendants.\u201d  \n17. The Individual Defendants possessed the power and authority to control the \ncontents of Unisys\u2019s SEC filings, press releases, and other market communications.  The \nIndividual Defendants were provided with copies of Unisys\u2019s SEC filings and press releases \nalleged herein to be misleading prior to or shortly after their issuance and had the ability and \nopportunity to prevent their issuance or to cause them to be corrected.  Because of their positions Case 2:22-cv-04529   Document 1   Filed 11/11/22   Page 4 of 17 \n5 \n with Unisys, and their access to material information available to them but not to the public, the \nIndividual Defendants knew that the adverse facts specified herein had not been disclosed to and \nwere being concealed from the public, and that the positive representations being made were then \nmaterially false and misleading.  The Individual Defendants are liable for the false statements and \nomissions pleaded herein. \n18. Unisys and the Individual Defendants are collectively referred to herein as \n\u201cDefendants.\u201d \n\nIndividual defendants:",
        "output": "Peter A Altabef,Debra Winkler McCann",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n9. Plaintiff is a citizen of the State of New Jersey  and, at all times relevant hereto , has \nbeen a Finish Line  stockholder .   \n10. Defendant Finish Line operates as a retailer of athletic shoes, apparel, and \naccessories for men, women, and kids in the United States .  Finish Line  is an Indiana corporation \nwith its principal executive  offices located at 3308 N. Mitthoeffer Rd., Indi anapolis, Indiana 46235.  \n11. Defendant Glenn S. Lyon  (\u201cLyon \u201d) has been a Director of the Company at all \nrelevant times .  In addition, Lyon serves as the Chairman of the Company Board, and previously \nserved as the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) .   \n12. Defendant Torrence Boone  (\u201cBoone \u201d) has been a director of the Company at all \nrelevant times .  In addition, Boone serves as a member on the Board\u2019s Governance & Nominating \nCommittee . \n13. Defendant William P. Carmichael  (\u201cCarmichael \u201d) has been a director of the \nCompany at all relevant times .  In addition, Carmichael  serves as the Chair of the Board\u2019s Audit \nCommittee and is designated by the Company as a \u201cFinancial Expert\u201d and as the \u201cLead Director .\u201d \n14. Defendant Scott McNeill  (\u201cMcNeill \u201d) has been a director of the Company at all \nrelevant times .  In addition, McNeill has served as the Company\u2019s Chief Financial Officer (\u201cCFO\u201d) \nsince its inception.  Case 1:18-cv-01342-TWP-TAB   Document 1   Filed 05/02/18   Page 4 of 39 PageID #: 4 \n5 \n 15. Defendant Richard P. Crystal  (\u201cCrystal \u201d) has been a director of the Company at \nall relevant times.   In addition, Crystal  serves as a member on the Board\u2019s Compensation \nCommittee.    \n16. Defendant Faisal Masud  (\u201cMasud \u201d) has been a director of the Company at all \nrelevant times .  In addition, Masud serves as a member on the Board\u2019s Compensation Committee.    \n17. Defendant Stephen Goldsmith  (\u201cGoldsmith \u201d) has been a director of the Company \nat all relevant times .  In addition, Goldsmith serves as the Chair of the  Board\u2019s Governance & \nNominating Com",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Mackinac Financial stocks and has held such stocks since prior to the wrongs complained of herein. 10. Individual Defendant Paul D. Tobias has served as a member of the Board since 2004 and is the Company\u2019s Chairman and Chief Executive Officer.  11. Individual Defendant Walter J. Aspatore has served as a member of the Board since 2004 and is the Lead Director of the Board. 12. Individual Defendant Dennis B. Bittner has served as a member of the Board since 2004. Case 1:21-cv-04717   Document 1   Filed 05/26/21   Page 3 of 154 13. Individual Defendant Joseph D. Garea has served as a member of the Board since 2007. 14. Individual Defendant Kelly W. George has served as a member of the Board since 2006 and is the President of the Company. 15. Individual Defendant Robert Edward Mahaney II has served as a member of the Board since 2008. 16. Individual Defendant Robert H. Orley has served as a member of the Board since 2004. 17. Individual Defendant Randolph C. Paschke has served as a member of the Board since 2004. 18. Individual Defendant David R. Steinhardt has served as a member of the Board since 2012. 19. Individual Defendant Martin A. Thomson has served as a member of the Board since 2018. 20. Defendant Mackinac Financial a Michigan corporation and maintains its principal offices at 130 South Cedar Street, Manistique, Michigan 49854.  The Company\u2019s stock trades on the NASDAQ Stock Exchange under the symbol \u201cMGNC.\u201d 21. The defendants identified in paragraphs 10-19 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 22. The defendants identified in paragraphs 10-20 are collectively referred to as the \u201cDefendants.\u201d Case 1:21-cv-04717   Document 1   Filed 05/26/21   Page 4 of 155 \nOnly answer with the company defendants names.",
        "output": "Mackinac Financial Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Tribune common stock and has held such stock since prior to the wrongs complained of herein. 10. Individual Defendant Philip G. Franklin has served as a member of the Board since August 2014 and is the Chairman of the Board.  11. Individual Defendant Richard Reck has served as a member of the Board since April 2016.  12. Individual Defendant Carol Crenshaw has served as a member of the Board since April 2016. Case 1:21-cv-03779   Document 1   Filed 04/28/21   Page 3 of 134 13. Individual Defendant Christopher Minnetian has served as a member of the Board since December 2019.  14. Individual Defendant Dana Goldsmith Needleman has served as a member of the Board since December 2019.  15. Individual Defendant Terry Jimenez has served as a member of the Board, and as the Company\u2019s Chief Executive Officer and President since April 2016. 16. Individual Defendant Randall D. Smith has served as a member of the Board since 2020 and is also Alden\u2019s co-founder. 17. Defendant Tribune is incorporated in Delaware and maintains its principal offices at 560 W. Grand Avenue, Chicago, IL 60654. The Company\u2019s common stock trades on the New York Stock Exchange under the symbol \u201cTPCO.\u201d 18. The defendants identified in paragraphs 10-16 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 19. The defendants identified in paragraphs 10-17 are collectively referred to as the \u201cDefendants.\u201d \nOnly answer with the company defendants names.",
        "output": "Tribune Publishing Company",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n Case 3:17-cv-02537   Document 1   Filed 05/03/17   Page 4 of 20 \n5 \n 1 \n2 3 4 5 6 \n7 \n8 9 \n10 11 12 \n13 \n14 15 16 17 18 \n19 \n20 21 22 23 24 \n25 \n26 27 28 11. Plaintiff, as set forth in the accompanying Ce rtification, purchased Sunrun securities at \nartificially inflated prices duri ng the Class Period and was damaged upon the revelation of the alleged \ncorrective disclosure. \n12. Defendant Sunrun is incorporat ed in Delaware and its principal executive offices are \nlocated at 595 Market Street, 29th Floor, San Francisco, Californi a 94105.  Sunrun\u2019s securities are \ntraded on the NASDAQ under the ticker symbol \u201cRUN.\u201d \n13. Defendant Lynn Michelle Jurich (\u201cJurich\u201d) has served at all relevant times as the \nCompany\u2019s Chief Executive Offi cer (\u201cCEO\u201d) and Director.  \n14. Defendant Robert Patrick Komin Jr. (\u201cKomin\u201d) has served at all relevant times as the \nCompany\u2019s Chief Financia l Officer (\u201cCFO\u201d).  \n15. The Defendants referenced above in \u00b6\u00b6 13- 15 are sometimes collec tively referred to \nherein as the \u201cIndividual Defendants.\u201d \n\nOnly answer with the company defendants names.",
        "output": "Sunrun, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n6. Plaintiff, as set forth in the accompanying certification, incorporated \nby reference herein, purchased 500.com securities during the Class Period and was \neconomically damaged thereby.  \n7. Defendant 500.com , through  its subsidiaries, purports to  provide \nonline gaming services primarily in the People's Republic of China and Europe . \nThe Company  is incorporated  in the Cayman Islands  and its principal executive  \noffice  is located  at 12F, West Side, Block B, Building No. 7, Shenzhen 518115, \nThe People\u2019s Republic of China . 500.com  securities  trade on the New York Stock \nExchange (\u201cNYSE\u201d)  under the ticker symbol \u201c WBAI .\u201d \n8. Defendant Zhengming Pan (\u201cPan\u201d) has served as the Company \u2019s \nPresident, Chief Executive Officer (\u201cCEO\u201d) , and as a Director  throughout  the \nClass Period . Case 2:20-cv-00485   Document 1   Filed 01/15/20   Page 3 of 21 PageID: 3 \n \n4 9. Defendant Qiang Yuan (\u201cYuan \u201d) has served as the Company\u2019s Chief \nFinancial Officer (\u201cCFO\u201d) throughout  the Class Period .  \n10. Defendants Pan and Yuan  are collectively referred to herein as  the \n\u201cIndividual Defendants.\u201d  \n11. Each of the Individual Defendants:  \n(a) directly participated in the management of the Company;  \n(b) was directly involved in the day -to-day operations of the \nCompany at the highest levels;  \n(c) was privy to confidential propriet ary information concerning \nthe Company and its business and operations;  \n(d) was directly or indirectly involved in drafting, producing, \nreviewing and/or disseminating the false and misleading \nstatements and information alleged herein;  \n(e) was directly or i ndirectly involved in the oversight or \nimplementation of the Company \u2019s internal controls;  \n(f) was aware of or recklessly disregarded the fact that the false \nand misleading statements were being issued concerning the \nCompany; and/or  \n(g) approved or ratified these statements in violation of the federal \nsecurities laws.  Case 2:20-cv-00485   Document 1   Filed 01/15/20   \nOnly answer with the company defendants names.",
        "output": "500.com Ltd.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has been at all times  relevant hereto, a continuous stockholder of \nTGR .   \n9. Defendant TGR  is a Florida corporation, with its principal executive offices located \nat 3560 Kraft Road, Naples, Florida 34105.  TGR  is the parent company for First Florida Integrity \nBank  (the \u201cBank\u201d) .  TGR \u2019s shares trade on t he OTCQX Market  under the ticker symbol \u201c TGRF .\u201d \n10. Defendant Adam D. Compton (\u201cCompton\u201d ) has been a director of the Company \nsince 2012. \n11. Defendant Dulce V. Dudley (\u201cDudley\u201d ) has been a director of the Company since \nMay 2016.   \n12. Defendant Robert M. Feerick (\u201c Feerick \u201d) has been a director of the Company since \n2012. Case 1:21-cv-07325   Document 1   Filed 08/31/21   Page 3 of 15- 4 - 13. Defendant J. Michael Gibbons (\u201cGibbons\u201d ) has been a director of the Company \nsince October 2014. \n14. Defendant John J. Guinee (\u201c Guinee\u201d ) has been a director of the Company since \n2012. \n15. Defendant Michael J. Kerschner (\u201cKerschner \u201d) has been a director of the Company \nsince 2012. \n16. Defendant Bradford B. Kopp (\u201cKopp\u201d ) has been a director of the Company since \nJanuary 2014. \n17. Defendant James S. Lindsay (\u201cLindsay\u201d) has been a director of the Company since \n2012. \n18. Defendant Edward J. Mace (\u201c Mace\u201d ) has been a director of the Company since  \n2012. \n19. Defendant Donald W. Major (\u201c Major \u201d) has been a director of the Company since \nAugust 2014. \n20. Defendant Garrett S. Richter (\u201c Richter \u201d) is President  and Chief Executive Officer \n(\u201cCEO \u201d) of the Bank, President  of the Company, and has been a director of the Company at all \nrelevant times .   \n21. Defendant Gary L. Tice (\u201c Tice\u201d) has been  Chairman of the Board, CEO , and a \ndirector of the Company since 2012. \n22. Defendant Robert T. Zellers (\u201c Zellers \u201d) has been a director of the Company since \nMay 2014. \n23. Defendants identified in paragraphs 10-22 are referred to herein as the \u201cBoard \u201d or \nthe \u201cIndividual Defendants.\u201d  Case 1:21-cv-07325   Document 1   Filed 08/\nOnly answer with the company defendants names.",
        "output": "TGR Financial, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " 13. Plaintiff Joseph Fazio, as set forth in the accompanying certification, incorporated by reference herein, purchased Eargo securities during the Class Period, and suffered damages as a result of the federal securities law violations and false and/or misleading statements and/or material omissions alleged herein.  14. Defendant Eargo is incorporated under the laws of Delaware with its principal executive offices located in San Jose, California. Eargo\u2019s common stock trades on the NASDAQ exchange under the symbol \u201cEAR.\u201d  15. Defendant Christian Gormsen (\u201cGormsen\u201d) was the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) at all relevant times. 16. Defendant Adam Laponis (\u201cLaponis\u201d) was the Company\u2019s Chief Financial Officer (\u201cCFO\u201d) at all relevant times.  17. Defendants Gormsen and Laponis (collectively the \u201cIndividual Defendants\u201d), because of their positions with the Company, possessed the power and authority to control the contents of the Company\u2019s reports to the SEC, press releases and presentations to securities analysts, money and portfolio managers and institutional investors, i.e., the market.  The Individual Defendants were provided with copies of the Company\u2019s reports and press releases alleged herein to be misleading prior to, or shortly after, their issuance and had the ability and opportunity to prevent their issuance or cause them to be corrected.  Because of their positions and access to material non-public information available to them, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to, and were being concealed from, the public, and that the positive representations which were being made were then materially false and/or misleading.  The Individual Defendants are liable for the false statements pleaded herein.  Case 3:21-cv-07848   Document 1   Filed 10/06/21   Page 4 of 221 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28   \n CLASS ACTION COMPLAINT  4  \nIndividual defendants:",
        "output": "Christian Gormsen,Adam Laponis",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has  been continuously throughout all times relevant hereto, the \nowner of  Continental Building  Products  common stock. \n9. Defendant Continental Building  Products is a Delaware corporation and maintains \nits principal executi ve offices at 12950 Worldgate Drive, Suite 700, Herndon, Virginia 20170.  Case 1:19-cv-02303-UNA   Document 1   Filed 12/19/19   Page 2 of 10 PageID #: 2 \n 3 Continental Building Products \u2019 common stock is traded on the New York Stock Exchange  under \nthe ticker symbol \u201c CBPX .\u201d \n10. Defendant  Edward Bosowski  is Chairman of the Board of the C ompany.  \n11. Defendant James Bachmann  is Chief Executive Officer, President, and a director \nof the C ompany.  \n12. Defendant Michael Keough  is a director of the C ompany.  \n13. Defendant Michael O. Moore is a director of the C ompany.  \n14. Defendant Ira S. Strassberg is  a director of the C ompany. \n15. Defendant Jack Sweeny  is a director of the C ompany.  \n16. Defendant Chantal Veevaete  is a director of the C ompany.  \n17. The defendants identified in paragraphs 10 through 16 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d    \nCLASS ACTION ALLEGATIONS  \n18. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Continental Building Products  (the \u201cClass \u201d).  Excluded from the Class are \ndefendants herein and any person, firm, trust, corporation, or other entity related to or affiliated \nwith any defendant.  \n19. This action is properly maintainable as a class action.  \n20. The Class is so numerous that joinder of all members is impr acticable.  As of \nNovember 8, 2019, there were approximately 44,533,125 shares of Continental Building Products \ncommon stock outstanding , held by hundreds, if not thousands, of individuals and entities scattered \nthroughout the country.  Case 1:19-cv-02303-UNA   Document 1   Filed 12/19/19   Page 3 of 10 PageID #: 3 \n 4 21. Questions of law and  fact are common to",
        "output": "['Michael Kent']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n9. Plaintiff  is, and has been at all relevant times, the owner of Rosetta Stone \ncommon stock and has held such stock since prior to the wrongs complained of herein.  \n10. Individual Defendant Laurence Franklin has served as a member of the Board \nsince 2006.  Case 1:20-cv-01237-UNA   Document 1   Filed 09/16/20   Page 3 of 17 PageID #: 34 11. Individual Defendant A. John Hass III has served as a member of the Board since \n2014 and is the Company\u2019s Chief Executive Officer and the Chairman of the Board.  \n12. Individual Defendant Aedhmar  Hynes has served as a member of the Board since \n2019. \n13. Individual Defendant Patrick Gross has served as a member of the Board since  \n2006. \n14. Individual Defendant George Logue has served as a member of the Board since  \n2018. \n15. Individual Defendant David Nierenber g has served as a member of the Board \nsince 2015.  \n16. Individual Defendant Kathryn Eberle Walker has served as a member of the \nBoard since  2019.  \n17. Individual Defendant Jessie Woolley -Wilson has served as a member of the \nBoard since  2017.  \n18. Individual Defendant Ste ven Yankovich has served as a member of the Board \nsince 2014 and is the Company\u2019s Lead Independent Director.  \n19. Defendant Rosetta Stone is incorporated in Delaware and maintains its principal \noffices at 1621 North Kent St., Suite 1200, Arlington, Virginia 22209.  The Company\u2019s common \nstock trades on the New York  Exchange under the symbol \u201c RST.\u201d \n20. The defendants identified in paragraphs 10- 18 are collectively referred to as the \n\u201cIndividual Defendants\u201d or the \u201cBoard.\u201d  \n21. The defendants identified in paragraphs 10- 19 are collectively referred to as the \n\u201cDefendants.\u201d  Case 1:20-cv-01237-UNA   Document 1   Filed 09/16/20   Page 4 of 17 PageID #: 45 \nOnly answer with the company defendants names.",
        "output": "Rosetta Stone, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n11. Plaintiff Anthony Pauwels, as set fort h in the accompa nying certification, \nincorporated by reference herei n, purchased Bit Digita l securities during the Class Period, and \nsuffered damages as a result of the federal securi ties law violations and false and/or misleading \nstatements and/or material omissions alleged herein.  \n12. Defendant Bit Digital is incorporated unde r the laws of Cayman  Islands with its \nprincipal executive offices locate d in Flushing, New York. Bit Digital\u2019s shares trade on the \nNASDAQ exchange under the symbol \u201cBTBT.\u201d  \n13. Defendant Min Hu (\u201cHu\u201d) was the Comp any\u2019s Chief Executive Officer (\u201cCEO\u201d) \nat all relevant times. \n14. Defendant Erke Huang (\u201cHuang\u201d) was th e Company\u2019s Chief Financial Officer \n(\u201cCFO\u201d) at all relevant times. \n15. Defendants Hu and Huang (collectively th e \u201cIndividual Defendants\u201d), because of \ntheir positions with the Company, possessed the power  and authority to control the contents of the \nCompany\u2019s reports to the SEC, press releases an d presentations to securi ties analysts, money and \nportfolio managers and institutional investors, i. e., the market.  The Individual Defendants were \nprovided with copies of the Company\u2019s reports and press releases alleged herein to be misleading \nprior to, or shortly after, their issuance and had the ability and oppor tunity to prevent their issuance \nor cause them to be corrected.  Because of their positions and access to material non-public \ninformation available to them, the Individual Defendants knew th at the adverse facts specified \nherein had not been disclosed to, and were being concealed from, the public,  and that the positive Case 1:21-cv-00515   Document 1   Filed 01/20/21   Page 4 of 22 \nCLASS ACTION COMPLAINT \n4 representations which were being made were th en materially false and/or misleading.  The \nIndividual Defendants are liable for th e false statements pleaded herein.  \n\nIndividual defendants:",
        "output": "Min Hu,Erke Huang",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \nA. Plaintiff \n13. Plaintiff purchased CytoDyn shares at arti ficially inflated prices during the Class \nPeriod and was damaged upon the revelation of  the alleged corrective disclosures. \nB. Defendants \n14. Defendant CytoDyn is a biotech compa ny based in Vancouver, Washington.  \nCytoDyn\u2019s business is primarily focused on the development and commercialization of a drug \nnamed Leronlimab.  CytoDyn\u2019s stock trades in the United States under the symbol CYDY. \n15. The Company is liable for the acts of th e Individual Defendants  (defined below) \nand its employees under the doctrine of respondeat superior  and common law principles of agency \nbecause all of the wrongful acts complained of he rein were carried out w ithin the scope of their \nemployment. \n16. Defendant Pourhassan is CytoDyn\u2019s Ch ief Executive Officer (\u201cCEO\u201d) and a \ndirector of the Company. Case 3:21-cv-05190-BHS   Document 1   Filed 03/17/21   Page 4 of 23 \nCLASS ACTION COMPLAINT - 5   TOUSLEY BRAIN STEPHENS PLLC \n1700 Seventh Avenue, Suite 2200 \nSeattle, Washington  98101 \nTEL. 206.682.5600 \uf0b7 FAX 206.682.2992 \n \n 1 \n2 3 4 5 6 7 8 9 \n10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 \n 17. Defendant Mullholland is CytoDyn\u2019s Chief Financial Officer (\u201cCFO\u201d). \n18. Defendants Pourhassan and Mullholland are co llectively referred to herein as the \n\u201cIndividual Defendants.\u201d  \n19. CytoDyn and the Individual Defendants are collectively referred to herein as \n\u201cDefendants.\u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n9. Plaintiff is, and has been at all relevant times hereto, an owne r of Assertio common \nstock.  \n10. Defendant Assertio is a specialty pharm aceutical company that provides medicines \nin neurology, orphan, and specialt y areas in the United States. Th e Company is incorporated in \nDelaware. The Company\u2019s common stock trades  on the Nasdaq market (\u201cNASDAQ\u201d) under the \nticker symbol, \u201cASRT.\u201d \n11. Defendant James P. Fogarty (\u201cFogarty\u201d) is the Chairman of the Board of the \nCompany. Case 1:20-cv-00616-UNA   Document 1   Filed 05/06/20   Page 3 of 17 PageID #: 34 12. Defendant Arthur J. Higgins (\u201cHiggins\u201d) is the President, Chief Executive Officer, \nand a director of the Company. \n13. Defendant William T. McKee (\u201cMcKee\u201d)  is a director of the Company. \n14. Defendant James L. Tyree (\u201cTyree\u201d) is a director of the Company. \n15. Defendant Karen A. Dawes (\u201cDawes\u201d ) is a director of the Company. \n16. Defendant Peter D. Staple (\u201cStaple \u201d) is a director  of the Company. \n17. Defendant Heather L. Mason (\u201cMason\u201d ) is a director of the Company. \n18. Defendant Jay Galeota (\u201cGaleota\u201d) is a director of the Company. \n19. Defendant David Wheadon (\u201cWheadon\u201d) is  a director of the Company. \n20. Defendants Fogarty, Higgins, McKee, Tyree,  Dawes, Staple, Mason, Galeota, and \nWheadon are collectively referred to he rein as the \u201cIndividual Defendants.\u201d \n21. Defendants Assertio and the Individual Defendants are collectively referred to \nherein as the \u201cDefendants.\u201d  \nOTHER RELEVANT ENTITIES \n22. Zyla is a commercial-stage life sciences company that focuses on the development \nand marketing of various treatments for patients and healthcare providers. Zyla is incorporated in \nDelaware with principal executive offices loca ted in Wayne, Pennsylvania. Zyla\u2019s common stock \ntrades on the OTCQX Bulletin Board under the ticker symbol, \u201cZCOR.\u201d  \n\nOnly answer with the company defendants names.",
        "output": "Assertio Therapeutics, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n6. Plaintiff, as set forth in the accomp anying certification, incorporated by \nreference herein, purchased BMW  securities during the Class Period and was \neconomically damaged thereby.  \n7. Defendant BMW, together with its subsidiaries,  purports to develop, \nmanufacture, and sell automobiles and motorcycles, and spare parts and accessories \nworldwide . BMW  is incorporated in Germany  and with headquarters in Munich, \nGermany . The Company \u2019s American Deposit ary Receipts (\u201cADRs\u201d)  trade over-the-\ncounter on the OTC  under the ticker symbol s \u201cBMWYY \u201d and \u201cBAMXF.\u201d  \n8. BMW (US) Holding Corp. (\u201cBMW US\u201d), BMW\u2019s wholly -owned U.S. \nsubsidiary, is a corporation doing business in all 50 states and the District of Case 2:20-cv-15081-CCC-MF   Document 1   Filed 10/27/20   Page 3 of 27 PageID: 34 Colu mbia and is organize d under th e laws of th e State of N ew Jersey, with its \nprincipal place of bu siness l ocated in 30 0 Chestnut Ridg e Rd, Woodclif f Lake , NJ \n07677 .  \n9. Defendant Oliver Zipse ( \u201cZipse \u201d) has served as the Company\u2019s Chairm an of \nthe Board of Management and Chief Executiv e Office r (\u201cCE O\u201d) since Augus t 16, \n2019.  \n10. Defendant Harald Kr\u00fc ger (\u201c Kr\u00fcger \u201d) serv ed as the Company\u2019s CEO from \nMay 13, 2015 u ntil August 16, 2019 . \n11. Defendant Norb ert Reithof er (\u201cReithofer \u201d) has served as the Company\u2019s \nChairman of the Supervisory Board at all relevant times. \n12. Defendant Nicolas Peter (\u201cPeter\u201d) has served as the Company\u2019s Chief \nFinancial Office r (\u201cCFO \u201d) and Member of th e Boar d of Management since January \n1, 2017.  \n13. Defendant Bernhard Kuhnt (\u201cKuhnt \u201d) has served as BMW US\u2019s CE O since \nMarch 1, 2017. \n14. Defendant Ludwig Will isch ( \u201cWillis ch\u201d) has serv ed as BMW US \u2019s CEO \nfrom 2012 to February 28, 2017. \n15. Defendant s Zipse, Kr\u00fcg er, Reithof er, Peter , Kuhnt, and Willisch are \ncollectively referred to herein as the \u201c Individual Defendants. \u201d \n16. Each of the Individual Defendants:Case 2:20-cv-15081-CCC-MF   Document 1   F\nOnly answer with the company defendants names.",
        "output": "Bayerische Motoren Werke AG (BMW)\nBMW (US) Holding Corp.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n \n12. Plaintiff purchased or otherwise a cquired Evoqua  common stock as described in the \nattached certification and was damaged by the  revelation of the alleged corrective disclosure.  \n13. Defendant Evoqua  is incorporated in Delaware, and it s stock  trades on the  NYSE  under \nthe ticker symbol \u201cAQUA .\u201d  The Company \u2019s corporate headquarters are located at 210 Sixth Avenue, \nPittsburgh, Pennsylvania 15222.  \n14. Defendant Ronald C. Keating  (\u201cKeating \u201d) has served at all relevant times as Chief \nExecutive Of ficer of Evoqua . Case 1:18-cv-10320   Document 1   Filed 11/06/18   Page 3 of 23 \n 4 \n 15. Defendant Benedict J. Stas  (\u201cStas\u201d) has served at all relevant times as Chief Financial \nOfficer  of Evoqua . \n16. The Defendants named in \u00b6\u00b6  14-15 are sometimes referred to herein collectively as the \n\u201cIndividual  Defendants. \u201d \n17. The Individual Defend ants possessed the power and authority to control the contents of \nthe Company \u2019s SEC filings, press releases, and other market communications. The Individual Defendants \nwere provided with copies of the Company \u2019s SEC filings and press releases alleged herein  to be \nmisleading prior to or shortly after their issuance and had the ability and opportunity to prevent their \nissuance or to cause them to be corrected. Because of their positions with the Company, and their access \nto material information available to th em but not to the public, the Individual Defendants knew that the \nadverse facts specified herein had not been disclosed to and were being concealed from the public, and \nthat the positive representations being made were then materially false and misleading.  The Individual \nDefendants are liable for the false statements and omissions pleaded herein.  \n\nOnly answer with the company defendants names.",
        "output": "Evoqua Water Technologies Corp.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n13. Plaintiff is a pension fund based in Bost on, Massachusetts that provides retirement \nbenefits to active and retired Boston electrical wo rkers.  As indicated on the certification submitted \nherewith, Plaintiff purchased HP common stock at  artificially inflated prices during the Class \nPeriod and suffered damages as a result of the viol ations of the federal securities laws alleged \nherein. \n14. Defendant HP is a global provider of personal computer s, printers and related \nsupplies, solutions, and services.  Incorporated in Delaware, the Company maintains its corporate \nheadquarters at 1501 Page Mill Ro ad, Palo Alto, California.  The Company\u2019s common stock trades \non the New York Stock Exchange (\u201cNYSE\u201d) under ti cker symbol \u201cHPQ.\u201d  As of November 30, \n2019, HP had over 1.4 billion shares of co mmon stock outstanding, owned by hundreds or \nthousands of investors. \n15. Defendant Dion J. Weisler (\u201cWeisler\u201d) se rved as President and Chief Executive \nOfficer of HP from November 2015 until November 1, 2019. \n16. Defendant Catherine A. Lesjak (\u201cLesjak\u201d) served as HP\u2019s Chief Financial Officer \nfrom November 2015 until July 1, 2018 and served as  HP\u2019s interim Chief Op erating Officer from \nJuly 1, 2018 until February 2019. \n17. Defendant Steven J. Fieler (\u201cFieler\u201d) has served as HP\u2019s Chief Financial Officer \nsince July 1, 2018.  Previously, De fendant Fieler served as HP\u2019s Head of Global Treasury since \nJanuary 2017. \n18. Defendants Weisler, Lesjak, and Fieler ar e collectively referred to hereinafter as Case 3:20-cv-01260   Document 1   Filed 02/19/20   Page 6 of 20 \nCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS       \nCASE NO. 3:20-cv-01260  6 \n 1\n23456789\n10111213141516171819202122232425262728the \u201cIndividual Defendants.\u201d  The Individual Defe ndants, because of their positions with HP, \npossessed the power and authority to  control the contents of the Company\u2019s reports to the SEC, \npress releases, and presentations to securities  analysts, mo\nIndividual defendants:",
        "output": "Dion J Weisler,Catherine Lesjak,Steven J Fieler",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n15. Plaintiff purchased Romeo \u2019s public ly traded common stock as detailed in the \nattache d Certification and was damaged thereb y.  \n16. Defendant Romeo  is incorporated in Delaware and its current principal executive \noffice s are located at 4380 Ayers Avenue, Vernon, California 90058 .  Case 1:21-cv-03362   Document 12   Filed 04/16/21   Page 6 of 23 \n 7 17. Defendant  Lionel  E. Selwood , Jr., (\u201cSelwood , Jr.\u201d) is the Company\u2019s President \nand Chief Executive Offi cer, and a member of t he Company \u2019s board o f director s. \n18. Defendan t Lauren Webb  (\u201cWebb \u201d) is the Company \u2019s Chief Fi nancial Officer  and \na member of the Company \u2019s board of dire ctors . \n19. Defendan ts Selwood , Jr. and Webb are referred  to her ein as the \u201cIndividual \nRomeo Defendants.\u201d The Ind ividual Romeo Defend ants, beca use o f their positions with the  \nComp any, possessed the power and authority to control the contents of Romeo \u2019s press re leases \nand investor presentations to securi ties anal ysts and investor s, money and portfolio managers and \ninstitutional investors , i.e., the market.   They were provided with copies of the Compan y\u2019s \nreports and press releases alleged herein to be misleading prior to or shortly after their issuance \nand had the abilit y and oppo rtuni ty to prevent their issuance or ca use them to be corre cted. \nBeca use of their positions an d acc ess to material non -publi c information available to them but \nnot to the public, each of them knew or had reason to know that the adverse fac ts spec ified \nherein had not been  disclosed to and were b eing concealed from the public  and that t he positive \nrepresentati ons w hich were being made were  then materially false and misleading.  The \nIndividua l Romeo Defendants  are liable for the false statemen ts plea ded he rein, as those \nstatements  were each \u201cgroup -published\u201d informati on, the re sult of the colle ctive actions of the \nIndividual Romeo Defendants . \n20. Romeo  and the Individual Romeo Defe",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n6. Plaintiff Don L. Gross,  as set forth in the accompanying certification and incorporated \nby reference herein, purchased the common stock of KCS during the Cla ss Period and has been \ndamaged thereby. \n7. Defendant KCS, headquartered in Kansas C ity, Missouri, operates railroads in the \nMidwest and Mexico that run north to south, unlike most other U.S. ra ilroads that run east to west.  \nThe Company\u2019s stock traded on the NYSE, an ef ficient market, during th e Class Period under the \nticker symbol \u201cKSU.\u201d  As of October 11, 2013, there were more than 110 million shares issued and \noutstanding.   \n8. Defendant David L. Starling (\u201cStarling\u201d), at  all relevant times, served as KCS\u2019s \nPresident and Chief Executive Officer (\u201cCEO\u201d). \nCase 4:14-cv-00345-BCW   Document 1   Filed 04/15/14   Page 2 of 293 9. Defendant David R. Ebbrecht (\u201cEbbrecht\u201d), at  all relevant times, served as KCS\u2019s \nExecutive Vice President and Chief Operating Officer (\u201cCOO\u201d). \n10. Defendant Patrick J. Ottensmeyer (\u201cOttensmeye r\u201d), at all relevant times, served as \nKCS\u2019s Executive Vice President Sales & Marketing.   \n11. Defendant Michael W. Upchurch (\u201cUpchurch \u201d), at all relevant times, served as \nKCS\u2019s Executive Vice President and Chief Financial Officer (\u201cCFO\u201d). \n12. Defendants Starling, Ebbrecht, Ottensmeyer an d Upchurch are collec tively referred to \nherein as the \u201cIndividual Defendants.\u201d \n13. During the Class Period, the Individual Defe ndants, as senior executive officers \nand/or directors of KCS,  were privy to confidential and proprie tary information concerning KCS, its \noperations, finances, financial cond ition and present and future business prospects.  The Individual \nDefendants also had access to material adverse non-public information concerning KCS, as \ndiscussed in detail below.  Because of their positions with KCS, the Individual Defendants had \naccess to non-public information about its busine ss, finances, products, markets and present and \nfuture business prospects via interna\nIndividual defendants:",
        "output": "David L Starling ,David R Ebbrecht,Patrick J.  Ottensmeyer,Michael W. Upchurch",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  AND RELEVANT ENTITIES  \n8. Plaintiff is, and has been continuou sly throughout all times relevant hereto, the \nowner of Hardinge  common stock.1 \n9. Defendant Hardinge  is a New York corporation and maintains its headquarters at  \nOne Hardinge Drive, Elmira,  New York 14903.  Hardinge \u2019s common stock is traded on the \n                                                 \n1 On May 16, 1995, the Company announced that it  approved changing its name from \u201cHardinge \nBrothers, Inc.\u201d to \u201cHardinge, Inc.\u201d   Case 1:18-cv-00416   Document 1   Filed 04/04/18   Page 2 of 11 \n 3 NasdaqGM under the ticker symbol \u201c HDNG.\u201d  \n10. Defendant Richard R. Burkhart is a director of Hardinge.   \n11. Defendant B. Christopher DiSantis is the Chairman of the Hardinge  Board . \n12. Defendant Charles P. Dougherty is a director , and the President and Chief \nExecutive Officer s (\u201cCEO\u201d)  of Hardinge. \n13. Defendant Ryan Levenson is a director of Hardinge. \n14. Defendant Mitchell I. Quain is a director of Hardinge.  \n15. Defendant Benjamin Rosenzweig is a director of Hardinge.  \n16. Defendant James Silver is a director of Hardinge. \n17. Defendant Tony Tripeny  is a director of Hardinge. \n18. The defendants identified in paragraphs 10 through 17 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \n19. Non-party  Privet Fund Management  LLC is a Delaware limited liability company \nand a private investment firm focused on investing in and partnering with small capitalization \ncompanies.  Privet Fund Management  LLC is controlled by Ryan Levenson, and beneficially \nowns approximately 10.6% of the Company\u2019 s outstanding s hares.  \n20. Non-party Privet Fund  LP is a Delaware limited partnership that principally \ninvests in securities of small capitalization companies for its own account.  Privet Fund LP is \ncontrolled by Privet Fund Management  LLC, as general partner.  \n21. Non-party Hardinge Holdings, LLC is a Delaware limited liability company that \nis owned by Privet Fund  LP and Pri\nOnly answer with the company defendants names.",
        "output": "Hardinge Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n14. Plaintiff Lincolnshire Police Pension Fund is a former stockholder of Bloom Energy \n16 II who acquired Bloom Energy common stock pursuant to the Registration Statement and was damaged \n17 II thereby. \n18 15. Defendant Bloom Energy is a Delaware corporation with principal executive offices \n19 II located at 4353 North First Street, San Jose, California. Bloom Energy designs, manufactures, and \n20 II sells solid-oxide fuel cell systems for on-site power generation. The fuel cell systems, or Energy \n21 II Servers, convert fuel into electricity without combustion, providing efficient energy generation with \n22 II reduced operating costs and lower greenhouse gas emissions. \n23 16. Defendant KR Sridhar (\"Sridhar\") is Bloom Energy's Founder and a director and has \n24 II been since January 2001; Chief Executive Officer and Chairman of the Board of Directors and has \n25 II been since April 2002; and President since at least July 2011. Defendant Sridhar reviewed and signed \n26 II the Registration Statement. \n27 17. Defendant Randy Furr (\"Furr\") is Bloom Energy's Chief Financial Officer and has \n28 II been since April 2015, and Executive Vice President and has been since at least March 2016. \n- 3 - \nCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE SECURITIES ACT OF 1933 \n1 11 Defendant Furr reviewed and signed the Registration Statement. \n2 18. Defendant L. John Doerr (\"Doerr\") is Bloom Energy's Lead Independent Director and \n3 II has been since July 2018 and a director and has been since May 2002. Defendant Doerr reviewed and \n4 11 signed the Registration Statement. \n5 19. Defendant Scott Sandell (\"Sandell\") is a Bloom Energy director and has been since \n6 11 August 2003. Defendant Sandell reviewed and signed the Registration Statement. \n7 20. Defendant Eddy Zervigon (\"Zervigon\") is a Bloom Energy director and has been since \n8 II October 2007. Defendant Zervigon reviewed and signed the Registration Statement. \n9 21. Defendant Colin L. Powell (\"Powell\") is a Bloom Energy dir\nIndividual defendants:",
        "output": "KR Sridhar,Randy Furr,John Doerr,Scott Sandell,Eddy Zervigon,Colin L Powell,Peter Teti,Mary K Bush,Kelly A Ayotte",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has been at all times relevant hereto, a continuous stockholder of \nAvenue .   \n9. Defendant Avenue  is a Delaware corporation, with its principal executive offices \nlocated at 2 Gansevoort Street, 9th Floor, New York, New York 10014.   The Company is a \nspecialty pharmaceutical company that  acquires, licenses, develops, and commercializes \nproducts primarily for use in the acute/intensive care hospital setting .  Avenue \u2019s common stock \ntrades on the NASDAQ Capital Market  under the ticker symbol \u201c ATXI .\u201d \n10. Defendant Lindsay A. Rosenwald (\u201c Rosenwald \u201d) has been Executive Chairman \nof the Board since the Company\u2019s inception on February 9, 2015.  Defendant Rosenwald has \nbeen Chairman and Chief Executive Officer (\u201cCEO\u201d)  of Fortress Biotech, Inc. (\u201cFortress\u201d) since \nDecember 2013.  \n11. Defendant Lucy Lu  (\u201cLu\u201d) has been President, CEO and a director of the \nCompany since its inception on February 9, 2015.   From February 2012 to June 2017, defendant \nLu previously served as the Exe cutive Vice President and Chief Financial Officer of Fortress.  \n12. Defendant Neil Herskowitz (\u201cHerskowitz\u201d) has been a director of the Company \nsince August 2015. \n13. Defendant Jay Kranzler (\u201cKranzler \u201d) has been a director of the Company since \nFebruary 2017.  \n14. Defend ant Jeffrey Paley  (\u201cPaley \u201d) has been  a director of the Company  since \nDecember  2015.  \n15. Defendant Akhtar Samad  (\u201cSamad \u201d) has been  a director of the Company  since \nDecember 2015 . Case 1:19-cv-00085-UNA   Document 1   Filed 01/15/19   Page 4 of 21 PageID #: 4- 5 - \n \n  16. Defendant Michael S. Weiss  (\u201cWeiss \u201d) has been  a director of the Company  since \nFebru ary 2015.   Defendant Weiss also serves in several capacities at Fortress, most recently as \nExecutive Vice Chairman since February 2014.  \n17. Defendants identified in paragraphs 10- 16 are referred to herein as the \u201cBoard\u201d or \nthe \u201cIndividual Defendants .\u201d  \nOTHER RELEVANT ENTITIES  \n18. InvaGen is a New York corporatio\nOnly answer with the company defendants names.",
        "output": "Avenue Therapeutics, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 16. Plaintiff Crystal Garrett-Evans, as set forth in the accompanying certification, incorporated by reference herein, purchased Coty common stock during the Class Period, and suffered damages as a result of the federal securities law violations and false and/or misleading statements and material omissions alleged herein.  Case 1:20-cv-07277   Document 1   Filed 09/04/20   Page 7 of 33 - 7 - 17. Defendant Coty is incorporated in Maryland and headquartered in Amsterdam, Netherlands. Coty\u2019s common stock trades on the New York Stock Exchange (\u201cNYSE\u201d) under the symbol \u201cCOTY.\u201d  18. Defendant Becht served as the Chairman of Coty\u2019s Board from October 2011 to November 2018 and continued as a member of the Board until January 2019. From September 2014 to September 2016, he also served as Interim CEO overseeing Coty\u2019s operations and mergers and acquisitions agenda, including the acquisition of the P&G Specialty Beauty Business. Mr. Becht holds a Bachelor of Arts degree in economics from the University of Groningen and an MBA from the University of Chicago, Booth School of Business. 19. Defendant Pane served as Coty\u2019s CEO and a member of its Board from September 2016 to November 2018. He had joined Coty\u2019s Executive Committee in July 2015 as the Executive Vice President, Category Development. Prior to joining Coty, he spent nearly 20 years at Reckitt Benckiser in various roles, including Senior Vice President, Global Category Officer Consumer Health. Mr. Pane holds a degree in business administration from Bocconi University. 20. Defendant Laubies served as Coty\u2019s CEO, a member of the Board, and a member of the Executive Committee from November of 2018 to May 2020. In January 2019, he also assumed the leadership for formulating and implementing the strategic vision for Consumer Beauty as its President. Prior to joining Coty, he served as the CEO of Jacobs Douwe Egberts BV from September 2013 to March 2018. Mr. Laubies holds a Master\u2019s degree in Economics from Sciences Politiques",
        "output": "['Crystal Garrett-Evans']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n12.  Plaintiff, as set forth in the attached Certification, acquired Tivity  secur ities at \nartificially inflated prices during the Class Period and was  damaged upon the revelation of the \nalleged cor rective disclosures.  \n13.  Defendant Tivity  is incorporated in Delaware ,  with  principal executive offices \nlocated at 701 Cool Springs Boulevard, Franklin, Tennessee 37067 .  Tivity \u2019 s common stock  \ntrade s  on the NASDAQ  under the ticker symbol \u201c TVTY . \u201d    \nCase 3:20-cv-00165   Document 1   Filed 02/25/20   Page 4 of 20 PageID #: 45  \n 14.  Defendant Tramuto served at all relevant times as Tivity \u2019 s CEO until his \nresignation on February 19, 2020 .  \n15.  Defendant Adam C. Holland ( \u201c Holland \u201d ) has se rved  at all relevant times  as \nTivity \u2019 s Chief Financial Officer .  \n16.  Defendant s Tramuto  and Holland  are sometimes referred to herein collectively as \nthe \u201c Individual Defendants. \u201d  \n17.  The Individual Defendants possessed the power and authority to control the \ncontents  of Tivity \u2019 s  SEC filings, press releases, and other market communications.  The \nIndividual Defendants were provided with copies of Tivity \u2019 s SEC filings and press releases \nalleged herein to be misleading prior to or sh ortly after their issuance and had the ability and \nopportunity to prevent their issuance or to cause them to be corrected.  Because of their positions \nwith Tivity , and their access to material information available to them but not to the public, the \nIndividual Defendants knew that the adverse f acts specified herein had not been disclosed to and \nwere being concealed from the public, and that the positive representations being made were \nthen materially false and misleading.  The Individual Defendants are liable for the false \nstatements and omissio ns pleaded herein.  \n18.  Tivity  and the Individual Defendants are collectively referred to herein as \n\u201c Defendants. \u201d  \nSUBSTANTIVE ALLEGATI ONS  \nBackground  \n19.  Tivity  provides fitness and health im",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n15. Plaintiff Mohammed Usman Ali, as set forth in the accompanying \ncertification, incorporated by re ference herein, purchased Fran klin securities during \nthe Class Period, and suffered damages as a result of the feder al securities law \nviolations and false and/or misleading statements and/or materi al omissions alleged \nherein.  \n16. Defendant Franklin is incorporat ed under the laws of Nevada wit h its \nprincipal executive offices locat ed in San Diego, California. F ranklin\u2019s common \nstock trades on the NASDAQ exc hange under the symbol \u201cFKWL.\u201d  \n17. Defendant OC Kim (\u201cKim\u201d) was the Company\u2019s President at all \nrelevant times. \n18. Defendant David Brown (\u201cBrown\u201d)  was the Company\u2019s Acting Chief \nFinancial Officer (\u201cCFO\u201d) a t all relevant times.  Case 3:21-cv-00687-AJB-MSB   Document 1   Filed 04/16/21   PageID.4   Page 4 of 211\n23456789\n10111213141516171819202122232425262728 \n 4  19. Defendants Kim and Brown (collec tively the \u201cIndividual Defendan ts\u201d), \nbecause of their positions with the Company, possessed the powe r and authority to \ncontrol the contents of the Company\u2019s reports to the SEC, press  releases and \npresentations to securities analysts, money and portfolio manag ers and institutional \ninvestors, i.e., the market.  The Individual Defendants were pr ovided with copies of \nthe Company\u2019s reports and press releases alleged herein to be m isleading prior to, or \nshortly after, their issuance and had the ability and opportuni ty to prevent their \nissuance or cause them to be corr ected.  Because of their posit ions and access to \nmaterial non-public information available to them, the Individu al Defendants knew \nthat the adverse facts specified herein had not been disclosed to, and were being \nconcealed from, the public, and that the positive representatio ns which were being \nmade were then materially false  and/or misleading.  The Individ ual Defendants are \nliable for the false statements pleaded herein.  \n\nOnly answer with the company defendants names.",
        "output": "Franklin Wireless Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n14. Plaintiff is a citizen of Quebec, Canada and, at all times relevant hereto , has been a \nGener8  stockholder .   \n15. Defendant Gener8  engages in the transportation of international seaborne crude oil \nand petroleum products.  As of March 13, 2017, it owned a fleet of 41 vessels, including 25 very \nlarge crude carriers  (\u201cVLCCs\u201d) , 10 suezmax vessels, 4 aframax vessels, an d 2 panamax vessels, \nwith an aggregate carrying capacity of 9.7 million deadweight tons .  Gener8 is organized under \nthe laws of the Republic of the Marshall Islands and has its principal place of business at 299 Park \nAvenue, New York, NY 10171.  Shares of Gener8  common stock a re traded on the New York \nStock Exchange (\u201cNYSE\u201d)  under the symbol \u201c GNRT \u201d \n16. Defendant Peter C. Georgiopoulos  (\"Georgiopoulos \") has been a Director of the \nCompany at all relevant times .  In addition, Georgiopoulos  serves as the Company\u2019s Chief \nExecutive Officer (\u201cCEO\u201d) and as Chairman of the Company Board . Case 1:18-cv-02097   Document 1   Filed 03/08/18   Page 4 of 40 \n- 5 - \nCLASS ACTION COMPLAINT  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 17. Defendant Ethan Auerbach  (\"Auerbach \") has been a director of the Company at \nall relevant times .  In addition, Auerbach  serves on the Board\u2019s Compensation  Committee .  \nDefendant Auerbach i s a former manager and partner at, and is associated with the private equity \nfund BlueMountain Capital Management, LLC (\u201cBlueMountain\u201d) a private equity fund that, along \nwith its related entities , own 9.4% of outstanding Gener8 stock .  Defendant Auerbach w as \nappointed to the Transaction Committee of the Board to manage the sales process that lead to the \nProposed Transaction.   \n18. Defendant Nicolas Busch  (\"Busch \") has been a director of the Company at all \nrelevant times .  In addition,  Busch serves as a voting me mber of the Strategic Management \nCommittee.  \n19. Defendant Dan Ilany  (\"Ilany \") ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 8. Plaintiff is, and has been at all times relevant hereto, the owner of Willbros common stock. 9. Defendant Willbros is a Delaware corporation, with its principal executive offices located in Houston, Texas.  Willbros common stock is listed on the Over-The-Counter (\u201cOTC\u201d) under the symbol \u201cWGRP.\u201d 10. Defendant S. Miller Williams (\u201cWilliams\u201d) has served as a member of the Company\u2019s Board since May 2004, and was appointed non-executive Chairman effective December 1, 2015.   11. Defendant Michael J. Fournier (\u201cFournier\u201d) was elected President and Chief Executive Officer and appointed to serve on the Board in December 2015.  12. Defendant Daniel E. Lonergan (\u201cLonergan\u201d) has served as a Board member since July 2010.  13. Defendant Michael C. Lebens (\u201cLebens\u201d) has served as a Board member since May 2011. 14. Defendant Phil D. Wedemeyer (\u201cWedemeyer\u201d) has served as a Board member since April 2015. 15. Defendant W. Gary Gates (\u201cGates\u201d) has served as a Board member since February 2017. 16. The defendants listed in \u00b6\u00b6 10-15 are collectively referred to herein as the \u201cIndividual Defendants.\u201d Case 4:18-cv-01286   Document 1   Filed in TXSD on 04/24/18   Page 3 of 18 4 17. The Individual Defendants and Willbros are referred to herein as \u201cDefendants.\u201d \nOnly answer with the company defendants names.",
        "output": "Willbros Group, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " for their misconduct and self -dealing in \nconnection with a  prior  unfair, wrongfully accomplished reverse merger transaction ( the \n\u201cTransaction\u201d).  \n5. The Derivative Action  sought to recover damages and other relief  for claims for \nstate law  breach es of fiduciary duty, aiding and abetting breach es of fiduciary duty, constructive \nfraud, civil conspiracy, unjust enrichment, imposition of  a constructive trust and statutory \nattorneys\u2019 fees and expenses against Xuelian , Wei, Song Qiang Chen (\u201cSong\u201d), Ling Li Case 0:16-cv-62506-FAM   Document 1   Entered on FLSD Docket 10/24/2016   Page 2 of 963 \n (\u201cLing\u201d), Metamining, Inc. (\u201cMetamining\u201d), Metamining Nevada, Inc. (\u201cMetamining Nevada\u201d), \nCD International Enterprises, Inc. (\u201cCD Int\u2019l \u201d), China Direct Investments, Inc. (\u201cChina Direct\u201d), \nCapital Resource Management Co., Ltd., f/k/a Capital One Resource Co., Ltd. (\u201cCapital \nResource \u201d) and Ecolab Inc. (\u201cEcolab\u201d) . \n6. The Transaction  was designed to conceal its principals\u2019 self -dealing with resp ect \nto the Company\u2019s assets and operations, to the detriment and expense of Lin kwell.  Pursuant to \nthe publicly disclosed terms of the Transaction, Linkwell issued 94% of its equity to Metamining \nand China Direct to acquire 100% of the equity of Metamining  Nevada , a wholly owned \nsubsidiary of Metamining with no assets, operations or employees .  Linkwell\u2019s public filings \nwith the SEC , however,  did not disclose that the Transaction also involved the spin -off of the \nCompany\u2019s disinfectant business.  Discovery obtained in the Derivative Action revealed that as \npart of the agreement to transfer control of Linkwell to Song and Ling , Linkwell would spin off \nits 90% equity ownership interest in Linkwell Tech Group, Inc. (\u201cLinkwell Tech\u201d)  (and Linkwell \nTech\u2019s 100% eq uity ownership interest in Shanghai Likang Disinfectant High -Tech Co., Ltd. \n(\u201cLikang Disinfectant\u201d) and Shanghai Likang Biological High -Tech Co., Ltd. (\u201cLikang \nBiological\u201d) ) to Xuelian and We\nOnly answer with the company defendants names.",
        "output": "nan",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "   \n \nCBL denies all allegations of wrongdoing and asserts th at its actions have at all \ntimes been lawful and proper. However, given the class certification, the \naccelerated trial schedule, the inherent risk of any trial, and the potential cost of an \nadverse resolution of the litigation, the Company believes that me diation was the \nprudent path. Furthermore, it maintains that the proposed settlement is in CBL\u2019s \nbest interest and in the best interests of its shareholders.  \n \nProposed Settlement Structure  \n \nDetails of the proposed settlement structure and anticipated accounting impact are \navailable on CBL\u2019s Form 8 - K filed with the SEC today.  \n \nAs part of the proposed settlement, CBL will suspend payment of its common \ndividend for two quarters: the quarter ended June 30, 2019 (payable in third quarter \n2019), and the quarter ended September 30, 2019 (payable in fourth quarter 2019). \nThe suspension of the dividend for two quarters will preserve approximately $26.0 \nmillion in cash at the current quarterly dividend rate. Based on the current \nprojection of taxable income for 2019, which includes the impact of the settlement, \nCBL believes it will satisfy all required REIT distributions for the 2019 taxable \nyear. The proposed settlement does not restrict CBL\u2019s payment of common \ndividends thereafter. CBL anticipates re suming a quarterly distribution with its \nCase 1:19-cv-00149   Document 1   Filed 05/17/19   Page 6 of 23   PageID #: 67  \n dividend payable in January 2020 (subject to Board approval) in an amount to be \ndetermined at that time based on updated taxable income projections for 2020. \nCBL\u2019s common dividend previously declared on February 25,  2019, and payable \non April 16, 2019, will be paid as declared.  \n \n19.  To learn of the shocking size of the settlement, investors had to seek out SEC \nForm 8 - K filed that same day which revealed  in pertinent part :    \nUnder the terms of the proposed settlement, we are to set aside a common fund \nwit\nOnly answer with the company defendants names.",
        "output": "CBL & Associates Properties, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n6.\n \nPlaintiff, as set forth in the accompanying Certification, purchased \nDr. Reddy\u2019s \nsecurities\n \nat artificially inflated prices during the Class\n \nPeriod and was damaged upon the \nrevelation of the alleged corrective disclosure.\n \n7.\n \nDefendant Dr. Reddy\u2019s \nis an integrated pharmaceutical company\n \nwhich operates \nin three segments: global genetics, pharmaceutical services and active ingredients\n \n(\u201cAPI\n\u201d)\n; and \np\nroprietary products.\n \nThe Company is \nincorporated and headquartered\n \nin Telangana, India and \nmaintains an office\n \nat 107 College Road East, Princeton, New Jersey.\n \nThe Company\u2019s securities \nwere traded on the New York Stock \nExchange\n \n(\u201cNYSE\u201d) under the ticker \u201cR\nDY.\u201d\n \n \n8.\n \nDefendant \nG.V. Prasad\n \n(\u201c\nPrasad\n\u201d) \nwas \nthe Chief Executive Officer (\u201cCEO\u201d) \nand \nand Co\n-\nChairman of the Company throughout the Class Period.\n \n9.\n \nDefendant \nSaumen Chakraborty\n \n(\u201c\nChakraborty\n\u201d) \nwas \nthe Chief Financial Officer \n(\u201cCFO\u201d) \nand President \nthroughout the\n \nClass Period\n.\n \n10.\n \nDefendants \nPrasad\n \nand\n \nChakraborty\n \na\nre sometimes referred to herein as the\n \n\u201cIndividual Defendants.\u201d\n \n11.\n \nEach of the Individual Defendants:\n \n(a)\n \ndirectly participated in the management of the Company;\n \n(b)\n \nwas\n \ndirectly involved in the day\n-\nto\n-\nday operations of the Company at the highest \nlevels;\n \n(c)\n \nwas privy to confidential proprietary information concerning the Company and its \nbusiness and operations;\n \n(d)\n \nwas directly or indirectly involved in drafting, produci\nng, reviewing and/or \ndisseminating the false and misleading statements and information alleged herein;\n Case 3:17-cv-06436   Document 1   Filed 08/25/17   Page 3 of 17 PageID: 3 \n4\n \n(e)\n \nwas directly or indirectly involved in the oversight or implementation of the \nCompany\u2019s internal controls;\n \n(f)\n \nwas aware of or recklessly disregarded\n \nthe fact that the false and misleading \nstatements were being issued concerning the Company; and/or \n \n(g)\n \napproved or ratified these s\nOnly answer with the company defendants names.",
        "output": "Dr. Reddy\u2019s Laboratories Limited",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \nPlaintiff  Paul  Beisel  purchased  La Quinta  common  stock,  as set forth  in the 6. \ncertification  attached  hereto  and incorporated  herein  by reference,  and was damaged  thereby. \nDefendant  La Quinta,  a Delaware  company  that  was  incorporated  in 2013,  is an \nowner,  operator  and franchisor  of select-service  hotels. \nDefendant  Wayne  B. Goldberg  (\"Goldberg\")  served,  at all relevant  times,  as g \nPresident,  Chief  Executive  Officer  and a Director  of La Quinta. \nDefendant  Keith  A. Cline  (\"Cline\")  served,  at all relevant  times,  as Executive  Vice 9 \nPresident  and Chief  Financial  Officer  of La Quinta. \n10. Defendant  James  H. Forson  (\"Forson\")  served,  at all relevant  times,  as Senior  Vice \nPresident,  Chief  Accounting  Officer  and Treasurer  of La Quinta. \n11. Defendants  Glenn  Alba  (\"Alba\"),  Alan  J. Bowers  (\"Bowers\"),  Henry  G. Cisneros \n(\"Cisneros\"),  Giovanni  Cutaia  (\"Cutaia\"),  Brian  Kim  (\"Kim\"),  Michael  Nash  (\"Nash\"),  Mitesh  B. \nShah  (\"Shah\")  and Gary  M. Sumers  (\"Sumers\")  each  served,  at all relevant  times,  as a members  of \nLa Quinta's  Board  of Directors. \nCase 1:16-cv-03068   Document 1   Filed 04/25/16   Page 3 of 51Defendants  Goldberg,  Cline,  Forson,  Alba,  Bowers,  Cisneros,  Cutaia,  Kim,  Nash, 12. \nShah,  and Sumers  are collectively  referred  to herein  as the \"Individual  Defendants.\"  Each  of the \nIndividual  Defendants  signed  the Registration  Statement  (defined  herein)  issued  in connection  with \nthe SPO. \n13. Defendant  The Blackstone  Group  L.P.  (\"Blackstone\")  is an American  multinational \nprivate  equity,  investment  banking,  alternative  asset  management  and financial  services  corporation \nbased  in New  York  City.  Defendant  Blackstone  was  the largest  beneficial  owner  of La Quinta \ncommon  stock  at the time  of the SPO.  Defendant  Blackstone  sold  a total  of 23,862,500,00  shares  of \nLa Quinta  common  stock  in the SPO  to the public  for t\nIndividual defendants:",
        "output": "Wayne B Goldberg,Keith A Cline,James H Forson,Glenn Alba,Alan J Bowers,Henry G Cisneros,Giovanni Cutaia,Brian Kim,Michael Nash,Mitesh B Shah,Gary M Sumers",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Idera  common stock.  \n9. Defendant Idera  is a Delaware corporation and maintains its principal executive Case 1:18-cv-10485   Document 1   Filed 03/14/18   Page 2 of 14 \n 3 offices at  167 Sidney Street, Cambridge, Massachusetts 02139 .  Idera\u2019s  common stock is traded \non the NasdaqCM  under the ticker symbol \u201c IDRA .\u201d \n10. Defendant James Geraghty  (\u201cGeraghty \u201d) has served as Chairman of the Board of \nIdera  since July 2013 .  \n11. Defendant  Vincent Milano  (\u201cMilano \u201d) has served as  a director and Chief Executive \nOfficer (\u201cCE O\u201d) of Idera since December 2014 . \n12. Defendant Julian C. Baker  (\u201cBaker \u201d) has served as a director Idera  since March \n2014 . \n13. Defendant Mark Goldberg  (\u201cGoldberg \u201d) has served as a director  of Idera since \nJanuary 2014 . \n14. Defendant Maxine Gowen  (\u201cGowen \u201d) has served as a director of Idera  since \nJanuary 2016 . \n15. Defendant Kelvin M. Neu  (\u201cNeu\u201d) has served as a director of Idera  since March \n2014 . \n16. Defendant William S. Reardon  (\u201cReardon \u201d) has served as a director of Idera  since \n2002. \n17. The defendants identified in paragraphs 10 through 16 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \n18. Defendant Parent is a Delaware  limited liability company and a party to the Merger \nAgreement.  \n19. Defendant Holdco is a Delaware corporation, a wholly -owned subsidiary of the \nParent, and a party to the Merger Agreement.  \n20. Defendant  Merger Sub  A is a Delaware  corporation, a wholly -owned  subsidiary of Case 1:18-cv-10485   Document 1   Filed 03/14/18   Page 3 of 14 \n 4 the Parent, and a party to the Merger Agreem ent. \n21. Defendant Merger Sub B is a Delaware  corporation, a wholly -owned subsidiary of \nthe Parent, and a party to the Merger Agreement.  \nCLASS ACTION ALLEGATIONS  \n22. Plaintiff  brings  this action as a class action on behalf of herself  and the other public \nstockhold ers of\nIndividual defendants:",
        "output": "James Geraghty,Vincent Milano,Julian Baker,Mark Goldberg,Maxine Gowen,Kelvin M Neu,William S Reardon",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n12. Plaintiff Gary H. Ragan, as set forth in the accompanying certi fication, \nincorporated by reference herei n, purchased AppHarvest securiti es during the Class Period, and \nsuffered damages as a result of the federal securities law viol ations and false and/or misleading \nstatements and/or material omissions alleged herein.  \n13. Defendant AppHarvest is incorporated under the laws of Delaware  with its \nprincipal executive offices locat ed in Morehead, Kentucky. AppH arvest\u2019s common stock trades \non the NASDAQ exchange under the symbol \u201cAPPH.\u201d  \n14. Defendant Jonathan Webb (\u201cWebb\u201d) was the Chief Executive Office r (\u201cCEO\u201d) of \nAppHarvest at all relevant times. \n15. Defendant Loren Eggleton (\u201cEggleton\u201d) was the Chief Financial O fficer (\u201cCFO\u201d) \nof AppHarvest at al l relevant times. \n16. Defendants Webb and Eggleton (collectively the \u201cIndividual Defe ndants\u201d), \nbecause of their positions with the Company, possessed the powe r and authority to control the \ncontents of the Company\u2019s report s  t o  t h e  S E C ,  p r e s s  r e l e a s e s  a n d presentations to securities \nanalysts, money and portfolio man agers and institutional invest ors, i.e., the market.  The \nIndividual Defendants were provi ded with copies of the Company\u2019 s reports and press releases \nalleged herein to be misleading prior to, or shortly after, the ir issuance and had the ability and Case 1:21-cv-07985   Document 1   Filed 09/24/21   Page 4 of 23 \n4 opportunity to prevent their issuance or cause them to be corre cted.  Because of their positions \nand access to material non-public information available to them , the Individual Defendants knew \nthat the adverse facts specified herein had not been disclosed to, and were being concealed from, \nthe public, and that the positive representations which were be ing made were then materially \nfalse and/or misleading.  The I ndividual Defendants are liable for the false statements pleaded \nherein.  \n\nIndividual defendants:",
        "output": "Jonathan Webb,Loren Eggleton",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " Plaintiff  Kevin  D. Mahar  purchased  or acquired  GE securities  pursuant  and/or 34.\ntraceable  to the Registration  Documents  issued  in connection  with  the Company \u2019s GE Stock  Direct\nPlan and has been  damaged  thereby.\nDefendant  GE is incorporated  under  the laws of the State of New  York  and its 35.\nprincipal  executive  offices  located  in Boston,  Massachusetts.  GE also maintained  an important\nservice  center  in Schenectady,  New  York  at all relevant  times.\nDefendant  Jeffrey  R. Immelt  (\u201cImmelt\u201d ) was the Chief  Executive  Officer 36.\n(\u201cCEO\u201d ) of GE until August  1, 2017, and Chairman  of the Board  of GE until January  1, 2018.\nImmelt  signed  or authorized  the signing  of certain  of the Company \u2019s Registration  Documents  filed\nwith the SEC, and was a Director  during  the publication  and filing  of certain  of the Registration\nDocuments.\nDefendant  Jeffrey  S. Bornstein  (\u201cBornstein \u201d) was the Senior  Vice  President  and 37.\nChief  Financial  Officer  (\u201cCFO \u201d) of GE until November  1, 2017, and was GE\u2019s Vice Chairman\nuntil December  31, 2017.  Bornstein  signed  or authorized  the signing  of certain  of the Company \u2019s\nRegistration  Documents  filed  with  the SEC.\nDefendant  Jan R. Hauser  (\u201cHauser \u201d) was the Vice President,  Controller,  and 38.\nChief\nAccounting  Officer  (\u201cCAO\u201d ) of GE. Hauser  signed  or authorized  the signing  of certain  of the\nCompany \u2019s Registration  Documents  filed  with  the SEC.\nDefendant  John L. Flannery  (\u201cFlannery \u201d) was CEO and a Director  of GE 39.\nbeginning  August  1, 2017,  and GE\u2019s Charmin  of the Board  beginning  January  1, 2018.  Flannery\nwas a Director  during  the publication  and filing  of certain  of the Registration  Documents.\nDefendant  Douglas  A. Warner  III (\u201cWarner \u201d) was a Director  and the Chair  of the 40.\nGE\u2019s Audit  Committee  when  the Committee  recommended  to the Board  that the audited  financial\n9\n12 of 42\nINDEX NO. 653648/2018  \nRECEIVED  NYSCEF:  07/20/2018FILED:  NE",
        "output": "['Kevin D Mahar']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Ecology  common stock. \n9. Defendant Ecology is a New York  corporation with offices located at 90 Broad \nStreet, Suite 1906, New York, NY 10004.  Ecology \u2019s common stock is traded on the N ASDAQ \nGlobal Select Market  under the ticker symbol \u201c EEI.\u201d Case 1:19-cv-09317   Document 1   Filed 10/08/19   Page 2 of 10 3 10. Defendant  Marshall A. Heinberg  is Chairman of the Board of the Company.  \n11. Defendant Frank B. Silvestro is  a founder and director of the Company.  \n12. Defendant Ronald L. Frank is a founder and director of the Company.  \n13. Defendant Michael C. Gross  is a director of the Company.  \n14. Defendant Justin C. Jacobs  is a director of the Company.  \n15. Defendant Michael El -Hillow  is a director of the Company.  \n16. The defendants identified in paragraphs 10 through 15 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \nCLASS ACTION ALLEGATIONS  \n17. Plaintiff brings this action as a class action on behalf of himself  and the other public \nstockholders of Ecology  (the \u201cClass \u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defendant.  \n18. This action is properly maintainable as a class action.  \n19. The Class is so numerous that joinder of all members is impracticable.  As of  \nAugust 26, 2019, there were approximately 3,128,823 shares of Ecology Class A Common Stock \nand 1,200,735 shares of Ecology Class B  Common St ock outstanding , held by hundreds, if not \nthousands, of individuals and entities scattered throughout the country.  \n20. Questions of law and fact are common to the Class, i ncluding, among others, \nwhether defendants violated the 1934 Act and whether defendants will irreparably harm plaintiff \nand the other members of the Class if defendants \u2019 conduct  complained of herein continues . \n21. Plaintiff is committed to pro\nIndividual defendants:",
        "output": "Marshall A Heinberg,Frank B Silvestro,Ronald L Frank,Michael C Gross,Justin C Jacobs,Michael El-Hillow",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n12. Plaintiff, as set forth in the attached Certificatio n, acquired NRx  securities at \nartificially inflated prices during the Class Period and was  damaged upon the revelation of the \nalleged cor rective disclosures.  \n13. Defendant NRx  is incorporated in Delaware with principal executive offices \nlocated at  1201 Orange Street, Suite 600, Wilmington, Delaware 19801.  NRx \u2019s common stock \nand warrants trade in an efficient market on the Nasdaq Stock Market ( \u201cNASDAQ\u201d ) under the \ntrading symbol s \u201cNRX P\u201d and \u201cNRX PW\u201d, respectively . \n14. Defendant  Jonathan C. Javitt ( \u201cJavitt\u201d ) has served as  NRx \u2019s Chief Executive \nOfficer at all relevant times . \n15. Defendant William Fricker ( \u201cFricker \u201d) has served as NRx \u2019s Chief Financial Officer \nat all relevant times . \n16. Defendant s Javitt and Fricker  are sometimes referred to herein as the \u201c Individual \nDefendants. \u201d \n17. The Individual Defendants possessed the power and authority to control the \ncontents of NRx \u2019s SEC filings, press releases, and other market communications.  The Individual \nDefendants were prov ided with copies of NRx \u2019s SEC filings and press releases alleged herein to \nbe misleading prior to or shortly after their issuance and had the ability and opportunity to prevent \ntheir issuance or to cause them to be corrected.  Because of their positions wi th NRx , and their \naccess to material information available to them but not to the public, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to and were being concealed Case 1:22-cv-00066-UNA   Document 1   Filed 01/18/22   Page 4 of 18 PageID #: 45 \n from the public, and that the positive repre sentations being made were then materially false and \nmisleading.  The Individual Defendants are liable for the false statements and omissions pleaded \nherein.  \n18. NRx  and the Individual Defendants are collectively referred to herein as \n\u201cDefendants. \u201d \nSUBSTANTIVE ALLEG ATIONS  \nBackground  \n19. NRx  is a cli\nOnly answer with the company defendants names.",
        "output": "NRx Pharmaceuticals, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Universal American  common stock.  \n9. Defendant Universal American is a Delaware corporation and maintains  its \nprincipal executive office  at 44 South Broadway, White Plains, New York 10601.  Universal \nAmerican \u2019s common stock is tra ded on the N YSE  under the ticker symbol \u201c UAM .\u201d Case 1:17-cv-00077-UNA   Document 1   Filed 01/27/17   Page 2 of 15 PageID #: 2 \n 3 10. Defendant Richard A. Barasch (\u201c Barasch \u201d) is a director, Chairman, and Chief \nExecutive Officer (\u201cCEO\u201d) of Universal American .   \n11. Defendant Sally W. Crawford (\u201c Crawford \u201d) is a director of Universal American .  \nAccording to the Company\u2019s website, Crawford is a member of the Audit Committee, a member \nof the Compensation Committee, Chair of the Compliance Committee, and Chair of the \nNominating Committee .   \n12. Defendant Matthew W. Etheridge (\u201c Etheridge \u201d) is a director of Universal \nAmerican .  According to the Company\u2019s website, Etheridge is Chair of the Compensation \nCommittee, a member of the Investment Committee, and a member of the Compliance Committee . \n13. Defendant Mark K. Gormley (\u201c Gormley \u201d) is a director of  Universal Amer ican.  \nAccording to the Company\u2019s website,  Gormley is a member of the Audit Committee, the \nInvestment Committee, the Compliance Committee, and the Nominating Committee . \n14. Defendant Mohit Kaushal (\u201c Kaushal \u201d) is a director of  Universal American .   \n15. Defendant  Patrick J. McLaughlin (\u201cMcLaughlin \u201d) is a director of  Universal \nAmerican .  According to the Company\u2019s website, McLaughlin is Chair of the Audit Committee \nand Chair of the Investment Committee . \n16. The defendants identified in paragraphs 10 through 15 are collect ively referred to \nherein as the \u201cIndividual Defendants.\u201d   \n17. Defendant Parent is a Delaware corporation and a party to the Merger Agreement .  \n18. Defendant Merger Sub  is a Delaware corporation , an indirect wholly- owne",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n9. Plaintiff is, and has been at all releva nt times, the owner of Front Yard common \nstock and has held such stock since prio r to the wrongs complained of herein. \n10. Individual Defendant Rochelle R. Dobbs ha s served as a member of the Board since \nDecember 2016 and has been the Chair of the Board since May 2018. \n11. Individual Defendant Leland Abrams has se rved as a member of the Board since \nJune 2019.  \n12. Individual Defendant George G. Ellison (\u201cEl lison\u201d) has served as a member of the \nBoard and the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) since June 2015. Ellison is also the Case 1:20-cv-00356-UNA   Document 1   Filed 03/12/20   Page 3 of 14 PageID #: 34 co-CEO of Altisource Asset Management Corpor ation (\u201cAAMC\u201d), a company with which Front \nYard has an existing asset management agreement. \n13. Individual Defendant Michae l A. Eruzione has served as a member of the Board \nsince December 2012.  \n14. Individual Defendant Leslie Fox has serv ed as a member of the Board since 2019.  \n15. Individual Defendant Wade J. Henderson has served as a member of the Board \nsince April 2017. \n16. Individual Defendant Lazar Nikolic has se rved as a member of the Board since \nFebruary 2017. \n17. Individual Defendant George Whitfield Mc Dowell has served as a member of the \nBoard since March 2018. \n18. Defendant Front Yard is incorporated in Maryland and maintains its principal \noffices at 5100 Tamarind Reef, Christiansted, Unit ed States Virgin Islands 00820.  The Company\u2019s \ncommon stock trades on the New York St ock Exchange under the symbol \u201cRESI.\u201d \n19. The defendants identified in paragraphs 10- 17 are collectively referred to as the \n\u201cIndividual Defendants\u201d or the \u201cBoard.\u201d \n20. The defendants identified in paragraphs 10- 18 are collectively referred to as the \n\u201cDefendants.\u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  ............................................................................................................................. 5 \nIV. \nOnly answer with the company defendants names.",
        "output": "TransDigm Group, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Proofpoint common stock and has held such stock since prior to the wrongs complained of herein. 10. Individual Defendant Gary Steele has served as a member of the Board since 2002 and is the Company\u2019s Chief Executive Officer and Chairman of the Board.  11. Individual Defendant Dana Evan has served as a member of the Board since June 2008. 12. Individual Defendant Elizabeth Rafael has served as a member of the Board since February 2021.  Case 1:21-cv-04925   Document 1   Filed 06/03/21   Page 3 of 164 13. Individual Defendant Jonathan Feiber has served as a member of the Board since July 2002.  14. Individual Defendant Kevin Harvey has served as a member of the Board since December 2002.  15. Individual Defendant Kristen Gil has served as a member of the Board since October 2017. 16. Individual Defendant Leyla Seka has served as a member of the Board since September 2019. 17. Individual Defendant Michael Johnson has served as a member of the Board since July 2017. 18. Individual Defendant Richard Wallace has served as a member of the Board since May 2017. 19. Defendant Proofpoint is incorporated in Delaware and maintains its principal offices at 925 West Maude Avenue, Sunnyvale, California 94085.  The Company\u2019s common stock trades on the NASDAQ Stock Exchange under the symbol \u201cPFPT.\u201d 20. The defendants identified in paragraphs 10-18 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 21. The defendants identified in paragraphs 10-19 are collectively referred to as the \u201cDefendants.\u201d ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n15. Plaintiff David Smith was a shareholder of CVSI during the Class Period, as set \nforth in the accompanying certification, which is incorporated by reference herein. Plaintiff has been damaged by the revelation of Defendants\u2019 material misrepresentations and material omissions.  \n16. Defendant CV Sciences, Inc., is a Delaware Corporation with its principal place of \nbusiness in Las Vegas, Nevada. CVSI trades on the over -the-counter market under the ticker \nsymbol \u201cCVSI.\u201d  \n17. Defendant Michael Mona, Jr., the Co mpany\u2019s founder, served as President, Chief \nExecutive Officer, and a Director of the Company from January 2013 until May 2018. Since May 2018, Mr. Mona has served as Founder Emeritus. Case 2:18-cv-01602-JAD-PAL   Document 1   Filed 08/24/18   Page 3 of 13 \n 4  \n  \n \n1 \n2 \n3 4 5 6 7 8 9 \n10 \n11 \n12 13 14 15 \n16 17 18 19 20 21 22 23 24 25 26 27 28 18. Defendant Joseph D. Dowling has served as the Company\u2019s Chief Executive \nOfficer since May 2018. He has also served as Chief Financial Officer since June 2014. \n19. Defendant Michael Mona, III, has served as the Company\u2019s Chief Operating \nOfficer since March 2017 and a Director since May 2016.  \n20. The Defendants listed in Paragraphs 17 -19 are collectively referred to herein as the \n\u201cIndividual Defendants.\u201d  \nALLEGATIONS  \nCV Sciences, Inc. Receives Notice of Both Non -Final and Final Rejection of its Patent.  \n21. In 2016, CVSI submitted an application to the U.S. Patent Trademark Office to \npatent i ts principal pharmaceutical product, CVSI -007, titled \u201cPharmaceutical Formulations \nContaining Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction.\u201d On February 7, 2017, CVSI filed a continuing patent application under the same title, Patent #15/426,617. \n22. CVSI -007 is a chewing gum containing nicotine and synthetic cannabidiol  to \nsupport cessation of smokeless tobacco use and addiction. The Company described CVSI -007 to \nthe public as its \u201clead drug candidate\u201d in its pharmaceutical divi",
        "output": "['David Smith']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n7. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Boxwood common stock. \n8. Defendant Boxwood is a Delaware  corporation and maintains its principal \nexecutive offices at  8801 Calera Drive, Austin, Texas 78735.  Boxwood\u2019s common stock is traded \non the NASDAQ Global Select Market  under the ticker symbol \u201c BMWC .\u201d \n9. Defendant Steve M. Kadenacy  is Chief Executive Officer and  Chairman of the \nBoard of Boxwood.  \n10. Defendant Daniel E. Esters  is Chief Financial Officer and  a director of Boxwood. Case 1:19-cv-02184-UNA   Document 1   Filed 11/22/19   Page 2 of 11 PageID #: 2 \n 3 11. Defendant Joseph E. Reece is a director of Boxwood.  \n12. Defendant Richard A. Gadbois  is a di rector of Boxwood. \n13. Defendant Alan P. Krusi is a director of Boxwood. \n14. The defendants identified in paragraphs 9 through 13 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d    \nCLASS ACTION ALLEGATIONS  \n15. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Boxwoo d (the \u201cClass \u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defendant.  \n16. This action is properly maintainable as a class action.  \n17. The Class is so numerous that joinder of all members is impracticable.  T here are \napproximately 25,250,000 shares of Boxwood common stock outs tanding, of which 20,000,000 \nare outstanding public shares , held by hundreds, if not thousands, of individuals and entities \nscattered throughout the country.  \n18. Questions of law and fact are common to the Class, i ncluding, among others, \nwhether defendants violated the Exchange Act and whether defendants will irreparably harm \nplaintiff and the other members of the Class if defendants \u2019 conduct  complained of herein continues . \n19. Plaintiff is committed to prosecuting this action and has  retained competent counse",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n5. Plaintiff Victor J. Ng, as set forth in the accompanying Certification, which is \nincorporated by reference  herein, purchased Berkeley Lights common stock during the Class Period \nand has been damaged thereby.  \n6. Defendant Berkeley Lights is a biotechnology company headquartered in Emeryville, \nCalifornia.  The Company\u2019s common stock is listed on the Nasdaq Global S elect Market (\u201cNasdaq\u201d) \nunder the ticker symbol \u201cBLI.\u201d  \n7. Defendant Eric D. Hobbs (\u201cHobbs\u201d) served as the Chief Executive Officer (\u201cCEO\u201d) \nof Berkeley Lights and a member of the Company\u2019s Board of Directors (the \u201cBoard\u201d) at all relevant \ntimes.  \n8. Defendant Shaun M. Holt (\u201cHolt\u201d) served as the Chief Financial Officer (\u201cCFO\u201d) of \nBerkeley Lights at all relevant times until his unexpected transition, effective March 15, 2021, to an \nadvisory role and subsequent departure from the Company on April 30, 2021. \n9. Defendant Kurt Wood (\u201cWood\u201d) has served as the CFO of Berkeley Lights since \nMarch 15, 2021.  Prior to this position, defendant Wood served as the Company\u2019s Vice President of \nBusiness Development. \n10. Defendants referenced above in \u00b6\u00b67 -9 are referred to herein as the \u201cIndi vidual \nDefendants.\u201d  During the Class Period, the Individual Defendants ran the Company as hands -on \nmanagers, overseeing Berkeley Lights\u2019 operations, business practices and finances, and made the \nmaterially false and misleading statements described herein.   The Individual Defendants had intimate \nknowledge about core aspects of Berkeley Lights\u2019 financial and business operations, including the \nCompany\u2019s proprietary technologies and business relationships.  They were also intimately involved \nin deciding which disclosures would be made by the Company. Case 3:21-cv-09497   Document 1   Filed 12/08/21   Page 3 of 24 \n COMPLAINT FOR VIOLAT IONS OF THE FEDERAL SECURITIES LAWS  - 3 - \n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n BACKGROUND  \n11. Berkeley Lig\nIndividual defendants:",
        "output": "Eric D Hobbs,Shaun M Holt,Kurt Wood",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n9. Plaintiffs RWDSU Local 338 Retirement Fund, RWDSU Local 338 Health & \nWelfare Fund, RWDSU Local 338 General Fund, and RWDSU Local 338 Benefits Trust Fund are \nmulti-employer pension and benefits funds that provide retirement benefits to retirees in a variety \nof industries, including retail supermarkets, pharmacies, healthcare facilities, maintenance \nfacilities, and school monitors and bus drivers.  As reflected in the certification submitted herewith, \nPlaintiffs purchased shares of Stitch Fix Class A common stock during the Class Period and \nsuffered damages as a result of the violations of the federal securities laws alleged herein. \n10. Defendant Stitch Fix sells a range of apparel, shoes, and accessories through its \nwebsite and mobile application.  The Company maintains its corporate headquarters at 1 \nMontgomery Street, Suite 1500, San Francisco, California.  Stitch Fix stock trades on the \nNASDAQ, which is an efficient market, under ticker symbol \u201cSFIX.\u201d  As of June 9, 2022, there \nwere over 82.7 million shares of Stitch Fix Class A common stock outstanding, owned by at least \nhundreds or thousands of investors. \n11. Defendant Katrina Lake (\u201cLake\u201d) is the founder of Stitch Fix and has served as the \nExecutive Chairperson of the Company\u2019s Board of Directors since August 1, 2021.  Defendant \nLake previously served as the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) from its founding in \n2017 until August 1, 2021.  Case 3:22-cv-04893   Document 1   Filed 08/26/22   Page 4 of 21CLASS ACTION COMPLAINT FOR VIOLATION SOF THE FEDERAL SECURITIES LAWS 4\nCase No. 3:22-cv-4893 1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n2812. Defendant Elizabeth Spaulding (\u201cSpaulding\u201d) is the current President and CEO of \nStitch Fix and is a member of the Company\u2019s Board of the Directors.  She has served as Stitch \nFix\u2019s President since January 2020, and CEO since August 1, 2021.  \n13. Defendants Lake and Spaulding are collectively referred to hereinafter a\nOnly answer with the company defendants names.",
        "output": "Stitch Fix, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 16. Plaintiff Ryan Bibb, as set forth in the accompanying certification, incorporated by reference herein, purchased Sesen Bio securities during the Class Period, and suffered damages as a result of the federal securities law violations and false and/or misleading statements and/or material omissions alleged herein.  17. Defendant Sesen Bio is incorporated under the laws of Delaware with its principal executive offices located in Cambridge, Massachusetts. Sesen Bio\u2019s common stock trades on the NASDAQ under the symbol \u201cSESN.\u201d  18. Defendant Thomas R. Cannell (\u201cCannell\u201d) was the Chief Executive Officer (\u201cCEO\u201d) of Sesen Bio at all relevant times. 19. Defendant Monica Forbes (\u201cForbes\u201d) was the Chief Financial Officer (\u201cCFO\u201d) of Sesen Bio at all relevant times. 20. Defendants Cannell and Forbes (collectively the \u201cIndividual Defendants\u201d), because of their positions with the Company, possessed the power and authority to control the contents of the Company\u2019s reports to the SEC, press releases and presentations to securities analysts, money and portfolio managers and institutional investors, i.e., the market.  The Individual Defendants were provided with copies of the Company\u2019s reports and press releases alleged herein to be misleading prior to, or shortly after, their issuance and had the ability and opportunity to prevent Case 1:21-cv-07025   Document 1   Filed 08/19/21   Page 5 of 42 \n5 their issuance or cause them to be corrected.  Because of their positions and access to material non-public information available to them, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to, and were being concealed from, the public, and that the positive representations which were being made were then materially false and/or misleading.  The Individual Defendants are liable for the false statements pleaded herein.  ",
        "output": "['Ryan Bibb']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n11. Plaintiff John P. Ward, as set forth in the accompanying certif ication, incorporated \nby reference herein, purchased Upstart securities during the Cl ass Period, and suffered damages as \na result of the federal securities law violations and false and /or misleading statements and/or \nmaterial omissions alleged herein.  \n12. Defendant Upstart is incorporated  under the laws of Delaware wi th its principal \nexecutive offices located in San Mateo, California. Upstart\u2019s c ommon stock trades on the \nNASDAQ exchange under the symbol \u201cUPST.\u201d  \n13. Defendant Dave Girouard (\u201cGirouard\u201d) was the Chief Executive Of ficer (\u201cCEO\u201d) \nof the Company at all relevant times. \n14. Defendant Sanjay Datta (\u201cDatta\u201d) was the Company\u2019s Chief Financ ial Officer \n(\u201cCFO\u201d) at all relevant times.  \n15. Defendants Girouard and Datta (collectively the \u201cIndividual Def endants\u201d), because \nof their positions with the Comp any, possessed the power and au thority to control the contents of \nthe Company\u2019s reports to the SEC, press releases and presentati ons to securities analysts, money \nand portfolio managers and institutional investors, i.e., the m arket.  The Individual Defendants \nwere provided with copies of the  Company\u2019s reports and press re leases alleged herein to be \nmisleading prior to, or shortly after, their issuance and had t he ability and opportu nity to prevent \ntheir issuance or cause them to  be corrected.  Because of their  positions and access to material \nnon-public information available to them, the Individual Defend ants knew that the adverse facts \nspecified herein had not been disclosed to, and were being conc ealed from, the public, and that the \npositive representations which were being made were then materi ally false and/or misleading.  The \nIndividual Defendants are liable for the false statements plead ed herein.  \n\nIndividual defendants:",
        "output": "Dave Girouard,Sanjay Datta",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \nPlaintiff  Monroe  County  Employees'  Retirement  System  purchased  Advisory  Board 6. \ncommon  stock  as set forth  in the certification  attached  hereto  and incorporated  herein  by reference \nand was  damaged  thereby. \nDefendant  Advisory  Board  is a publicly  traded  consulting  company  that  provides \nperformance-improvement  software  and solutions  to the healthcare  and education  industries.  The \nCompany's  stock  is listed  and trades  on the NASDAQ  under  the ticker  symbol  \"ABCO.\"  As of May \n1, 2017,  the Company  had more  than  40.5  million  shares  of common  stock  outstanding. \nDefendant  Robert  W. Musslewhite  (\"Musslewhite\")  is, and was throughout  the Class 8 \nPeriod,  Chief  Executive  Officer  (\"CEO\")  and Chairman  of the Board  of Directors  of Advisory \nBoard. \nDefendant  Michael  T. Kirshbaum  (\"Kirshbaum\")  is, and was  throughout  the Class 9 \nPeriod,  Chief  Financial  Officer  (\"CFO\")  and Treasurer  of Advisory  Board. \n10. Musslewhite  and Kirshbaum  are sometimes  referred  to herein,  collectively,  as the \n\"Individual  Defendants.\"  The  Individual  Defendants,  together  with  Advisory  Board,  are sometimes \nreferred  to herein,  collectively,  as \"Defendants.\" \n11. Because  of the Individual  Defendants'  positions  with  the Company,  they  had access \nto the adverse  undisclosed  information  about  the Company's  business,  operations,  operational \nCase 1:17-cv-05886   Document 1   Filed 08/03/17   Page 3 of 32trends,  financial  statements,  markets  and present  and future  business  prospects  via access  to internal \ncorporate  documents  (including  the Company's  operating  plans,  budgets  and forecasts  and reports  of \nactual  operations  compared  thereto),  conversations  and connections  with  other  corporate  officers  and \nemployees,  attendance  at management  and Board  of Directors  meetings  and committees  thereof  and \nvia reports  and other  information  provided  to them  in connection  \nOnly answer with the company defendants names.",
        "output": "The Advisory Board Company",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n11. Plaintiff Reginald T. Allison, as set forth in the accompanying certification, \nincorporated by reference herein, purchased Oak Street securities during the Class Period, and \nsuffered damages as a result of the federal securi ties law violations and false and/or misleading \nstatements and/or material omissions alleged herein.  \n12. Defendant Oak Street is incorporated under the laws of Delaware with its principal \nexecutive offices located in Chicago, Illinois. Oa k Street\u2019s common stock trades on the New York \nStock Exchange (\u201cNYSE\u201d) under the symbol \u201cOSH.\u201d \n13. Defendant Michael Pykosz (\u201cPykosz\u201d) wa s the Company\u2019s Chie f Executive Officer \n(\u201cCEO\u201d) at all relevant times. \n14. Defendant Timothy Cook (\u201cCook\u201d) was th e Company\u2019s Chief Financial Officer \n(\u201cCFO\u201d) at all relevant times. Case: 1:22-cv-00149 Document #: 1 Filed: 01/10/22 Page 4 of 30 PageID #:4 \n 15. Defendants Pykosz and Cook (collectively the \u201cIndividual Defendants\u201d), because \nof their positions with the Company, possessed the power and auth ority to control the contents of \nthe Company\u2019s reports to the SEC, press releases  and presentations to se curities analysts, money \nand portfolio managers and institu tional investors, i.e., the mark et.  The Individual Defendants \nwere provided with copies of th e Company\u2019s reports and press re leases alleged herein to be \nmisleading prior to, or shortly af ter, their issuance a nd had the ability and opportunity to prevent \ntheir issuance or cause them to be corrected.  Because of their positions and access to material non-\npublic information available to them, the Indi vidual Defendants knew that the adverse facts \nspecified herein had not been disclosed to, and we re being concealed from, the public, and that the \npositive representations which were being made were then materially false and/or misleading.  The \nIndividual Defendants are liable for th e false statements pleaded herein.  \n\nOnly answer with the company defendants names.",
        "output": "Oak Street Health, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n4. Plaintiff Sidney Sandoz purchased Waterdrop ADSs in or traceable to the IPO and \nhas been damaged thereby.  \n5. Defendant Waterdrop operates an insurance techno logy platform and is based in \nBeijing, China.  The Company\u2019s ADSs trade in New York on the New York Stock Exchange \n(\u201cNYSE\u201d) under ticker symbol \u201cWDH.\u201d  Each Waterdrop ADS represents ten Class A ordinary \nshares of the Company.  The Company maintains a dual -class share structure designed to concentrate \ncontrol over the Company in the hands of Waterdrop insiders out of proportion with their economic \nstake.  Holders of Class A shares (the shares owned by public investors) are entitled to one vote per \nshare.  By  contrast, holders of Class B shares (the shares owned by Company insiders) are entitled to \nnine votes per share.   \n6. Defendant Peng Shen (\u201cShen\u201d) founded Waterdrop and served as Waterdrop\u2019s Chief \nExecutive Officer (\u201cCEO\u201d) and Chairman at the time of the IPO .  Defendant Shen beneficially \nowned and controlled approximately 70% of Waterdrop\u2019s voting shares through his ownership of \nClass A and Class B shares at the time of the IPO.  The Registration Statement stated that Waterdrop \nwas a \u201ccontrolled company\u201d cont rolled by defendant Shen.  \n7. Defendant Kangping Shi served as Waterdrop\u2019s Chief Financial Officer (\u201cCFO\u201d) at \nthe time of the IPO.  \n8. Defendant Nina Zhou served as a Waterdrop director at the time of the IPO. \n9. Defendant Kai Huang served as a Waterdrop director at  the time of the IPO.  \n10. Defendant Haiyang Yu served as a Waterdrop director at the time of the IPO.  \n11. Defendant Yao Hu served as a Waterdrop director at the time of the IPO.  \n12. Defendant Guang Yang served as a Waterdrop director at the time of the IPO.  Case 1:21-cv-07683   Document 1   Filed 09/14/21   Page 3 of 21 \n- 3 - 13. The defend ants identified in \u00b6\u00b66 -12 are referred to herein as the \u201cIndividual \nDefendants.\u201d  Each of the Individual Defendants signed the Registration Statement.  In addition, th",
        "output": "['Sidney Sandoz']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all time s releva nt hereto, the \nowner of Navigators  common stock. Case 1:18-cv-01580-UNA   Document 1   Filed 10/15/18   Page 2 of 11 PageID #: 2 3 9. Defendant Navigators  is a Delaware corporation and maintains its principal \nexecutive offices at 400 Atlantic Street, 8th  Floor, Stamford, Connecticut 06091.  Navigators \u2019 \ncommon stock is traded on the NasdaqGS  under the ticker symbol \u201c NAVG.\u201d   Navigators  is a party \nto the Merger Agreement.  \n10. Defendant Saul L. Basch  is a director  of Navigators .  \n11. Defendant Terence N. Deeks is  a director of Navigators .  \n12. Defendant  Stanley A. Galanski is President, Chief Executive Officer (\u201cCEO\u201d), and \na director of Navigators .   \n13. Defendant  Meryl D. Hartzband is a director of Navigators .   \n14. Defendant  Geoffrey E. Johnson is a director of Navigators . \n15. Defendant Robert V. Mendelson is a director of Navigators.  \n16. Defendant David M. Platter is a director of Navigators.  \n17. Defendant Patricia H. Roberts is a director of Navigators.  \n18. Defendant Janice C. Tomlinson is a director of Navigators.  \n19. Defendant Marc M. Tract is a director of Navigators.     \n20. The defendants identified in para graphs 10 through 19 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \nCLASS ACTION ALLEGATIONS  \n21. Plaintiff brings this action as a class action on behalf of himself  and the other public \nstockholders of Navigators  (the \u201cClass\u201d).  Excluded from the Cl ass are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defendant. \n22. This action is properly maintainable as a class action.  Case 1:18-cv-01580-UNA   Document 1   Filed 10/15/18   Page 3 of 11 PageID #: 3 4 23. The Class is so numerous that joinder of all members is impracticable.  As of \nAugust 14, 2018, there were 29,766,719 shares of Navigators common stock outstanding, held by \nhundreds, if not thousan\nIndividual defendants:",
        "output": "Saul L Basch,Terence N Deeks,Stanley A Galanski,Meryl D Hartzband,Geoffrey E Johnson,Robert V Mendelson,David M Platter,Patricia H Roberts,Janice C Tomlinson,Marc M Tract",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n15. Plaintiff Nawaf Alwazzan, as set forth in his Certification filed \ncontemporaneously herewith, acquired shares of STAAR common stock at \nartificially inflated prices, and has been damaged. \n16. Defendant STAAR Surgical Company is incorporated under the laws \nof the State of Delaware, with its principal place of business at 25651 Atlantic \nOcean Drive, Lake Forest, CA 92630.  Its common stock trades on the NASDAQ \nstock exchange under the symbol STAA. \n17. Defendant Caren L. Mason is the President and Chief Executive \nOfficer of STAAR. She has served on STAAR\u2019s Board of Directors since her Case 8:20-cv-01533   Document 1   Filed 08/19/20   Page 5 of 27   Page ID #:5 \n6\n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 election at the Company\u2019s 2014 Annual Meeting, and has served as STAAR\u2019s \nCEO since March 1, 2015. \n18. Defendant Deborah Andrews was formerly STAAR\u2019s Chief Financial \nOfficer, having served in that role from October 2, 2017 until her retirement in \n2020. STAAR has indicated that Ms. Andrews remains in an advisory role with the \nCompany at present. \n19. Defendant Patrick F. Williams was appointed as the CFO of STAAR \nin July 2020. \n20. Defendants Mason, Andrews, and Williams are named as Defendants \nfor violations of all counts asserted herein, and are referred to as the \u201cIndividual \nDefendants.\u201d The Individual Defendants, because of their positions with the \nCompany, possessed the power and authority to control the contents of the \nCompany\u2019s reports to the SEC, press releases and presentations to securities \nanalysts, money and portfolio managers, and the investing public, i.e., the market.  \nThe Individual Defendants were provided with copies of the Company\u2019s reports \nand press releases alleged herein to be misleading prior to, or shortly after, their \nissuance and had the ability and opportunity to prevent their issuance or cause \nthem to be corrected.  Because of their positions and access to\nIndividual defendants:",
        "output": "Caren L Mason,Deborah Andrews,Patrick F Williams",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n15. Plaintiff, as set forth in the attached Certification, acquired Sanderson Farms  \nsecuri ties at artificially inflated prices during the Class Period and was damaged upon the \nrevelation of the alleged corrective disclosures.  \n16. Defendant Sanderson Farms  is incorporated under the laws of Mississippi .  The \nCompany\u2019s  principal executive offices are located at 127 Flynt Road, Laurel, Mississippi 39443 .  \nSanderson Farms\u2019  common stock trades on the NASDAQ  under the ticker symbol \u201c SAFM .\u201d \n17. Defendant Joe F.  Sanderson Jr.   (\u201cSanderson \u201d) has served at all relevant times as \nthe Company\u2019s Chief Executive Officer and Chairman . \n18. Defendant Michael Cockrell  (\u201cCockrell \u201d) has served at all relevant times as the  \nCompany\u2019s Chief Financial Officer , Treasurer, and Director . \n19. The Defendant s referenced above in \u00b6\u00b6 17-18 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \nSUBSTANTIVE ALLEGATI ONS  \nBackground  \n20. Sanderson Farms , an integrated poultry processing company, produces, processes, \nmarkets, and distributes fresh, frozen, and prepared chicken products in th e United States.   The \nCompany sells ice pack, chill pack, bulk pack, and frozen chicken in whole, cut -up, and boneless \nform primarily under the Sanderson Farms brand name to retailers, distributors, and casual dining \noperators in the United States, as well  as to customers who resell frozen chicken in the export \nmarkets.   Sanderson Farms\u2019  prepared chicken product line includes institutional and consumer Case 1:16-cv-08420   Document 1   Filed 10/28/16   Page 5 of 28 \n6 \n packaged partially cooked or marinated chicken items for distributors and food service \nestablishments.  \nMaterially False and Misleading Statements Issued During the Class Period  \n21. The Class Period begins on December 17, 2013, when Sanderson Farms filed an \nAnnual Report on Form 10 -K with the SEC, announcing the Company\u2019s financial and operating \nresults for the qu arter and fiscal year\nIndividual defendants:",
        "output": "Joe F Sanderson Jr.,Michael Cockrell",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n12. Plaintiff, as set forth in the attached Certification, acquired 360 DigiTech  secur ities \nat artificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosures.  \n13. Defendant 360 DigiTech  is a Cayman Islands corporation  with principal executive \noffices located at 7/F Lujiazui Finance Plaza , No. 1217 , Dongfang Road , Pudong New Area, \nShanghai 200122 , PRC .  The Company \u2019s common  shares  trade in an efficient market on the \nNASDAQ  under the  ticker  symbol \u201cQFIN\u201d. \n14. Defendant  Haisheng Wu (\u201cH. Wu\u201d) has served as 360 DigiTech \u2019s Chief Executive \nOfficer  and as a Director at all relevant times . \n15. Defendant Jiang Wu ( \u201cJ. Wu\u201d) served as 360 DigiTech \u2019s Chief Financial Officer \nfrom prior to the start of the Class Period until Se ptember 2020, and has served as 360 DigiTech \u2019s \nChief Strategy Officer since September 2020.  \n16. Defendant  Zuoli Xu  (\u201cXu\u201d) has served as 360 DigiTech \u2019s Chief Financial Officer \nsince September 2020 . \n17. Defendant s H. Wu, J. Wu,  and Xu are sometimes referred to herein as the \n\u201cIndividual Defendants. \u201d \n18. The Individual Defendants possessed the power and authority to control the \ncontents of 360 DigiTech \u2019s SEC filings, press releases, and other market communications.  The \nIndividual Defendants were provided with copies of 360 DigiTech \u2019s SEC filings and press releases \nalleged herein to be misleading prior to or shortly after their issuance and had the ability and Case 1:21-cv-06013   Document 1   Filed 07/13/21   Page 4 of 29 \n5 opportunity to prevent their issuance or to cause them to be corrected.  Because of their positions \nwith 360 DigiTech , and thei r access to material information available to them but not to the public, \nthe Individual Defendants knew that the adverse facts specified herein had not been disclosed to \nand were being concealed from the public, and that the positive representations being  made were \nthen materially false and \nIndividual defendants:",
        "output": "Haisheng Wu,Jiang Wu,Zuoli Xu",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  or that \u201cValeant is conspiring with other persons or entities to Case 3:15-cv-07658   Document 1   Filed 10/22/15   Page 13 of 41 PageID: 13 \n- 13 - perpetuate a massive fraud against R&O and others.\u201d  Commenting on t he lawsuit, \nCitron stated it was evidence that Valeant is creating invoices \u201cto deceive the auditors \nand book revenue\u201d and that \u201cValeant/Philidor have created an entire network of \nphantom captive pharmacies\u201d to create fake sales of drugs or to avoid scruti ny from \nauditors.   \n26. The market reacted swiftly to the disclosures in the Citron report.  On \nOctober 21, 2015, trading in Valeant shares was halted on a circuit breaker because \nof the rapid price decline after Citron published its report on its website.  Wh en \ntrading resumed, Valeant shares fell nearly 40%, at which point trading was again \nsuspended.  After swooning down nearly $60 a share in intra -day trading, Valeant \nshares closed down approximately 19%, or $28.42 per share, on highly abnormal \ntrading volu me of more than 88 million shares, paring losses as the Company issued \na denial of the charges in the Citron report.1  \n27. The following day, the price of Valeant shares dropped again after an \nanalyst who had advised buying the stock for more than two years do wngraded the \nshares, citing questions about Valeant\u2019s close ties to specialty pharmacies that \n                                           \n1 After the market closed on October 21, 2015, Philidor issued a press release \ndisclosing that it did indeed have a co ntractual relationship with \u201caffiliated \npharmacies,\u201d including R&O, and stating that Philidor \u201cdoes not currently have a \ndirect equity ownership in R&O Pharmacy or the affiliated pharmacies, but does have \na contractual right to acquire the pharmacies now o r in the future subject to regulatory \napproval.\u201d  Case 3:15-cv-07658   Document 1   Filed 10/22/15   Page 14 of 41 PageID: 14 \n- 14 - distribute its drugs.  BMO Capital Markets (\u201cBMO\u201d) stated it \u201ccannot defend",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n14. Plaintiff, as set forth in the attached Certification, acquired RYB  securities  at \nartificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosures.  \n15. Defen dant RYB  is headquartered  in China , with principal executive offices \nlocated at 4/F, N\u00ba29 Building, Fangguyuan Section 1 , Fangzhuang, Fengtai District , Beijing \n100078 , People\u2019s Republic of China. RYB \u2019s ADRs  trade  on the NYSE  under the ticker symbol \n\u201cRYB .\u201d \n16. Defendant Yanlai Shi (\u201cShi\u201d) co -founded  RYB  and has served at all relevant \ntimes as the Company\u2019s Chief Executi ve Officer (\u201cCEO\u201d)  and Executive Director .  \n17. Defendant Wei Ping (\u201cPing\u201d) has  served  at all relevant times  as the Company\u2019s \nChief Financial Officer  (\u201cCFO\u201d) . Case 1:17-cv-09261   Document 1   Filed 11/27/17   Page 4 of 21 \n5 \n 18. The def endants referenced above in \u00b6\u00b6 16-17 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \n19. The Individual Defendants possessed the power and authority to control the \ncontents of RYB \u2019s SEC filings, press releases, and other market communications. The Individual \nDefendants were provided with copies of the  Company\u2019s SEC filings and press releases alleged \nherein to be misleading prior to or shortly after their issuance and had the ability and opportunity \nto prevent their issuance or to cause them to be corrected. Because of their positions with the \nCompany, and their access to material information available to them but not to the public, the \nIndividual Defendants knew that the adverse facts  specified herein had not been disclosed to and \nwere being concealed from the public, and that the positive representations being made were \nthen materially false and misleading. The Individual Defendants are liable for the false \nstatements and omissions pl eaded herein.  \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " in the development and management of \nSix Flags-branded parks outside of North America.  As compensation for exclusivity, brand \nlicensing rights, and design, development and management services, the Company receives fees \nduring the planning, design and development phase of each park and then would receive royalties \nand management fees once the park is operational. \n3. On June 23, 2014, Six Flags announced the signing of an agreement to build \nmultiple Six Flags-branded theme parks in China.  Six Flags partnered exclusively with Riverside \nInvestment Group Co. Ltd. (\u201cRiverside\u201d), a Chinese real estate developer, that would provide the \ncapital investment for future developments in China.  The Company emphasized expansion of its \ninternational licensing agreements as one of its key strategies to achieve revenue growth, and Six \nFlags\u2019 agreements with Riverside to develop parks in China were of particular importance to \ninvestors because they represented the largest potential driver of growth in this strategic initiative. \n4. By May 29, 2018, Six Flags had announced plans with Riverside to develop 11 \nparks across three locations in China. \n5. Throughout the Class Period, Defendants made materially false and misleading \nstatements, as well as failed to disclose material adverse facts, regarding the Company\u2019s business, Case 3:20-cv-00346-K   Document 1   Filed 02/12/20    Page 2 of 21   PageID 2Case 3:20-cv-00346-K   Document 1   Filed 02/12/20    Page 2 of 21   PageID 23 operations, and growth prospects.  Specifically, Defendants touted its business relationship with \nRiverside as an \u201cincredible partnership\u201d that \u201cshould supercharge revenue growth.\u201d  The Company \nalso stated that Riverside would \u201cwork[] through\u201d the macroeconomic issues that it faced in China \nand represented that delays in the development of its Six Flags-branded parks in China were \u201cshort-\nterm\u201d and the resulting weakened revenue patterns were \u201cnot material in the context of the long-\nterm opportu",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff Branden Hayes, as set fort h in the accompanying certification, \nincorporated by reference herein, purchas ed Huazhu securities during the Class \nPeriod, and suffered damages as  a result of the federal securities law violations and \nfalse and/or misleading statements and/or  material omissions alleged herein.  \n12. Defendant Huazhu is incorporated in the Cayman Islands and its \nprincipal executive offices are in Shanghai, China.  Huazhu\u2019s ADSs trade on the \nNASDAQ exchange under the symbol \u201cHTHT.\u201d \n13. Defendant Min (Jenny) Zhang (\u201c Zhang\u201d) was the Chief Executive \nOfficer of the Company at all relevant times. \n14. Defendant Zhang is also  referred to hereinaf ter as the \u201cIndividual \nDefendant.\u201d Defendant Zhang because of her position with the Company, possessed \nthe power and authority to control the c ontents of the Company\u2019s reports to the \nSEC, press releases and presentations to  securities analysts, money and portfolio \nmanagers and instit utional investors, i.e., the market.  The I ndividual Defendant was \nprovided with copies of the Company\u2019s repor ts and press releases alleged herein to \nbe misleading prior to, or shortly afte r, their issuance and had the ability and \nopportunity to prevent their issuance or caus e them to be corrected.  Because of her \nposition and access to material non-public  information available to her, the \nIndividual Defendant knew that the advers e facts specified herein had not been \ndisclosed to, and were be ing concealed from, the public, and that the positive \nrepresentations which were being made were then materia lly false and/or \nmisleading.  The Individual Defendant is liable for the false statements pleaded Case 2:18-cv-08633   Document 1   Filed 10/08/18   Page 4 of 21   Page ID #:41\n23456789\n10111213141516171819202122232425262728 \nCLASS ACTION COMPLAINT \n4 herein.  \n",
        "output": "['Branden Hayes']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n6.\n \nPlaintiff, as set forth in the accompanying Certification, purchased \nWeibo\n \nsecurities\n \nat artificially inflate\nd prices during the Class Period and was damaged upon the \nrevelation of the alleged corrective disclosure.\n \n7.\n \nDefendant\n \nWeibo\n \noperates as a social media platform for people to create, \ndistribute, and discover Chinese\n-\nlanguage content\n.\n \nThe Company \nis incorpora\nted in the Cayman \nIslands and its principal executive offices are located at \n \n8/F, QIHAO Plaza, No. 8 Xinyuan S. \nRoad, Chaoyang District, Beijing 100027, People\u2019s Republic of China\n.\n \nWeibo\n\u2019s\n \nsecurities are\n \ntraded on \nthe \nNASDAQ Global Select Market\n \n(\u201cNASDAQ\u201d\n) \nunder the ticker symbol \u201c\nWB\n.\n\u201d\n \n8.\n \nDefendant \nGaofei Wang\n \n(\u201c\nWang\n\u201d) \nhas been the Chief Executive Officer (\u201cCEO\u201d) \nof Weibo since February 2014\n. \n \n9.\n \nDefendant \nHerman Yu\n \n(\u201c\nYu\n\u201d) \nha\ns\n \nbeen the Chief Financial Officer (\u201cCFO\u201d) of \nWeibo since March 2015\n.\n \n \n10.\n \nDefendants \nWang and Yu \na\nre sometimes referred to herein as the \u201cIndividual \nDefendants.\u201d\n \n11.\n \nEach of the Individual Defendants:\n \n(a)\n \ndirectly participated in the management of the Company;\n \n(b)\n \nwas directly involved in the day\n-\nto\n-\nday operations of the Company at the highest\n \nlevels;\n \n(c)\n \nwas privy to confidential proprietary information concerning the Company and its \nbusiness and operations;\n \n(d)\n \nwas directly or indirectly involved in drafting, producing, reviewing and/or \ndisseminating the false and misleading statements and in\nformation alleged herein;\n Case 2:17-cv-04728   Document 1   Filed 06/27/17   Page 3 of 15 PageID: 3 \n4\n \n(e)\n \nwas directly or indirectly involved in the oversight or implementation of the \nCompany\u2019s internal controls;\n \n(f)\n \nwas aware of or recklessly disregarded the fact that the false and misleading \nstatements were being issued concerni\nng the Company; and/or \n \n(g)\n \napproved or ratified these statements in violation of the federal securities laws.\n \n12.\n \nThe Company \nis \nOnly answer with the company defendants names.",
        "output": "Weibo Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n19. Plaintiff, as set forth in  the attached Certificati on, acquired Rio Tinto ADRs at \nartificially inflated prices during the Class Period and was da maged upon the revelation of the \nalleged corrective disclosures.  \n20. Defendant Rio Tinto is incorporated in  England and Wales, and the Company\u2019s \nprincipal executive offices are located at 6 St. James\u2019s Square, London, SW1Y 4AD, United \nKingdom.  Rio Tinto\u2019s ADRs trade on th e NYSE under the ticker symbol \u201cRIO.\u201d \n21. Defendant Sam Walsh (\u201cWalsh\u201d) served as  CEO of Rio Tinto from January 2013 \nuntil July 2016. \n22. Defendant Tom Albanese (\u201cAlbanese\u201d) se rved as CEO of Rio Tinto from May 2007 \nuntil January 2013. \n23. Defendant Christopher James Lynch (\u201cLync h\u201d) has served as Chief Financial \nOfficer (\u201cCFO\u201d) of Rio Tinto since April 2013. \n24. Defendant Guy Robert Elliott (\u201cElliott\u201d) served as CFO of Rio Tinto from 2002 \nuntil April 2013. \n25. The Defendants referenced above in \u00b6\u00b6 22-24 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d \n\nOnly answer with the company defendants names.",
        "output": "Rio Tinto plc",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n14. Plaintiff, as set forth in the attached Certification, acquired  Halyard  securities at \nartificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosures.  Case 1:16-cv-05093   Document 1   Filed 06/28/16   Page 4 of 325 \n 15. Defendant  Halyard  is incorporated in  Delaware , and the Company \u2019s principal \nexecutive offices are located at 5405 Windward Parkway, Alpharetta, Georgia 30004 .   \n16. Defendant  Robert E. Abernathy  (\u201cAbernathy \u201d) has served at all relevant times as \nHalyard\u2019s  Chief Executive Officer  (\u201cCEO\u201d).  \n17. Defendant  Steven E. Voskuil (\u201cVoskuil \u201d) has served at all relevant times as \nHalyard\u2019s Chief Financial Officer (\u201cCFO\u201d).  \n18. Defendant Kimberly -Clark is incorporated in Delaware, a nd the Company\u2019s \nprincipal executive offices are located at P.O. Box 619100, Dallas, Texas 75261.  \n19. Defendant Thomas J. Falk (\u201cFalk\u201d) has served at all relevant times as Kimberly -\nClark\u2019s Executive Chairman and CEO.  \n20. Defendant Mark A. Buthman (\u201cButhman\u201d) serve d as Kimberly -Clark\u2019s CFO from \n2003 to 2015.  \n21. The Defendant s described in \u00b6\u00b6 16-17 and 19-20 are sometimes hereinafter referred \nto as the \u201cIndividual Defendant s.\u201d \nSUBSTANTIVE ALLEGATI ONS  \nBackground  \n22. Halyard provides health and healthcare supplies and solutions worldwide. The \nCompany operates through two segments, Surgical and Infection Prevention ( \u201cS&IP \u201d), and \nMedical Devices.   Halyard  markets its products directly to hospitals and other healthcare pr oviders, \nas well as through third -party distribution channels .  Prior to October 2014, Halyard was the Health \nCare operating segment of Kimberly -Clark, a manufacturer of personal care, consumer tissue, and \nprofessional products.  \n Case 1:16-cv-05093   Document 1   Filed 06/28/16   Page 5 of 326 \n Materially False and Mislea ding Statements Issued During the Class Period  \n23. The Class Period begins on February 25, 2013, the first trading day after\nOnly answer with the company defendants names.",
        "output": "Halyard Health, Inc.\nKimberly-Clark Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n9. Plaintiff  is, and has been at all relevant times, the owner of AMAG common stock \nand has held such stock since prior to the wrongs complained of herein.  \n10. Individual Defendant John A. Fallon has served as a member of the Board since \nSeptember  2014. Case 1:20-cv-01403-UNA   Document 1   Filed 10/19/20   Page 3 of 16 PageID #: 34 11. Individual Defendant Paul Fonteyne  has served as a member of the Board since  \nOctober 2019. \n12. Individual Defendant David Johnson has served as a member of the Board since \nOctober  2019. \n13. Individual Defendant Scott Myers has served as a member of the Board , President, \nand Chief Executive Officer  since  April 2020.  \n14. Individual Defendant Kathrine O\u2019Brien  has served as a member of the Board and \nsince April  2019. \n15. Individual Defendant Anne M. Phillips  has served as a member of the Board since \nApril 2019.  \n16. Individual Defendant Gino Santini has served as a member of the Board since  \nFebruary 2012 and as Chairman of the Board since April 2014. \n17. Individual Defendant Davey S. Scoon has served as a member of the Board since  \nDecember  2006. \n18. Defendant AMAG is incorporated in Delaware and maintains its principal offices \nat 1100 Winter Street, Waltham, Massachusetts 02451 .  The Company\u2019s common stock trades on \nthe NASDAQ Exchange under the symbol \u201c AMAG.\u201d  \n19. The defendants identified in paragraphs 10- 17 are collectively referred to as the \n\u201cIndividual Defendants\u201d or the \u201cBoard.\u201d  \n20. The defendants identified in paragraphs 10- 18 are collectively referred to as the \n\u201cDefendants.\u201d  Case 1:20-cv-01403-UNA   Document 1   Filed 10/19/20   Page 4 of 16 PageID #: 45 \nOnly answer with the company defendants names.",
        "output": "AMAG Pharmaceuticals, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n9. Plaintiff is, and has been at all relevant times, the owner of CenterState  common  \nstock  and has held such stock  since prior to the wrongs complained of herein. Case 1:20-cv-00379-UNA   Document 1   Filed 03/17/20   Page 3 of 16 PageID #: 34 10. Individual Defendant Ernest S. Pinner  has served as a me mber of the Board since \n2002 and is currently the Chairman of the Board . \n11. Individual Defendant Charles W. McPherson  has served as a member of the Board  \nsince 2012 and is the Company\u2019s lead independent director and Vice Chairman of the Board.  \n12. Individual Defendant James H. Bingham  has served as a member of the Board since \n1999. \n13. Individual Defendant Michael J Brown, Sr. has served as a member of the Board \nsince 2018.  \n14. Individual Defendant C. Dennis Carlton has served as a member of the Board since \n2008. \n15. Individual Defendant Michael F. Ciferri  has served as a member of the Board since \n2014. \n16. Individual Defendant John C. Corbett  has served as a member of the Board sinc e \nMay 2011 and is currently the Company\u2019s President and C hief Executive Officer . \n17. Individual Defendant Jody Jean Dreyer  has served as a member  of the Board since \n2018.  \n18. Individual Defendant Griffin A. Greene  has served as a member of the Board since \n2012. \n19. Individual Defendant John H. Holcomb, III  has served as a member of the Board \nsince 2019.  \n20. Individual Defendant Richard Murray, IV has served as a member of the Board \nsince 2019.  Case 1:20-cv-00379-UNA   Document 1   Filed 03/17/20   Page 4 of 16 PageID #: 45 21. Individual Defendant G eorge  Tierso Nunez, II has served as a member of the Board \nsince 2004.  \n22. Individual Defendant Thoma s E. Oakley has served as a member of the Board since \n2002. \n23. Individual Defendant G. Ruffner Page, Jr. has served as a member of the Board \nsince 2019.  \n24. Individual Defendant William Knox Pou, Jr. has served as a member of the Board \nsince 2012.  \n25. Individual Defe ndant Daniel R. \nIndividual defendants:",
        "output": "Ernest S Pinner,Charles W McPherson,James H Bingham,Michael J Brown Sr.,C Dennis Carlton,Michael F Ciferri,John C Corbett,Jody Jean Dreyer,Griffin A Greene,John H Holcomb III,Richard Murray IV,George Tierso Nunez II,Thomas E Oakley,G Ruffner Page Jr.,William Knox Pou Jr.,Daniel R Richey,David G Salyers,Joshua A Snively Sr.,Mark Thompson",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n15. Plaintiff is a citizen of Florida  and, at all times relevant hereto , has been a Pandora  \nstockholder .   \n16. Defendant Pandora  provides music discovery platform services in the United States \nand internationally .  Pandora  is incorporated under the laws of the State of Delaware  and has its \nprincipal place of business at 2100 Franklin Street, Suite 700, Oakland, CA 94612 .  Shares of  \nPandora  common stock a re traded on the New York Stock Exchange (\u201cNYSE\u201d) under the symbol \n\u201cP.\u201d \n17. Defendant Gregory B. Maffei  (\"Maffei \") has been a Director of the Company since \nSeptember 2017 .  In addition, Maffei  serves as the Company\u2019s Chairman of the Boar d and as a \nmember on the Board\u2019s Nominating and Corporate Governance Committee .  Notably, Maffei has \nalso served as a director on Sirius\u2019 Board of Directors since 2009, and as the Parent\u2019s Chairman \nof the Board since 2013.  Case 4:18-cv-06847   Document 1   Filed 11/12/18   Page 5 of 36 \n- 6 - \nCLASS ACTION COMPLAINT  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 18. Defendant Roger Conant Faxon  (\"Faxon\") has been a director of the Company at \nall relevant times .  In addition, Faxon  serves  as the Chair of the Board\u2019s Audit Committee ad as a \nmember  on the Board\u2019s Compensation  Committee . \n19. Defendant David J. Frear  (\"Frear \") has been a director of the Company since \nSeptember 2017 .  Notably, Frear has served as a Senior Executive Vice President and Chief \nFinancial Officer (\u201cCFO\u201d) of Sirius since 2015, and has held other executive positions at Parent \nsince 2003 . \n20. Defendant Jason Hirschhorn  (\"Hirschhorn \") has been a director of the Company \nat all relevant times.   In addition , Hirschhorn  serves as member on the  Board\u2019s Audit  Committee . \n21. Defendant Timothy Leiweke  (\"Leiweke \") has been a director of the Company at all \nrelevant times .  In addition, Leiweke  serves as the Chair of the Board\u2019s Compensation  Committee \nand\nOnly answer with the company defendants names.",
        "output": "Pandora Media, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 17. Plaintiff SidneyLazatdownedHortonworks sharesatthetimeofLheMerger, and,viathe\nMerger, received newCloudera commonstockinexchange pursuant totheRegistration Statement and\nwasdamaged thereby.\n18. Defendant Cloudera isanenterprise clouddatacompany, incorporated underthelawsof\nDelaware, andheadquartered inPaloAlto,California. Cloudera\u2019s commonstocktradesontheNYSE\nunderthedcketsymbol\u201cCLDR.\u201d\n.3-\nCOMPLAINT FORVIOLATIONS OFTHESECURITIES ACTOF1933\\DOOVQUIAMNn\u2014n\nNNNNNNNN.\u2014-.\u20144H-.\u2014-.\u2014.\u2014-H.\u2014.\u2014\ngNQMAWNHOOWQQMLWN\u2014\u2018O19. Defendant Intelisasemiconductor technology company headquartered inSantaClara,\nCalifornia. AtthetimeoftheMerger(andafter), Intelwasthelargest outside controlling shareholder of\nCloudera. Asadmitted inCloudera\u2019s public SEC\ufb01lings, Intel\u2019s controlling position afforded it\n\u201cconsiderable in\ufb02uence\u201d overCloudera. Intelexercised itscontrol overCloudera toplaceanIntel\nemployee representative, Rosemary Schooler, ontheCloudera BoardofDirectors, whoinhercapacity\nasemployee andrepresentative ofIntel,reviewed, contributed to,andsignedtheRegistradon Statement.\n20. Defendant ThomasJ.Reillyserved, atthetimeoftheMerger, astheCompany\u2019s Chief\nExecudve Of\ufb01cer(\u201cCEO\u201d). Hereviewed, contributed to,andsignedtheRegistration Statement.\n21. Defendant JimFrankola served, atthe\ufb01me0ftheMerger, astheCompany\u2019s Chief\nFinancial Of\ufb01cer(\u201cCFO\u201d). Hereviewed, contributed to,andsignedtheRegistration Statement.\n22. Defendant PriyaJainserved, atthetimeoftheMerger, astheCompany\u2019s VicePresident,\nCorporate Controller, andPrincipal Accounting Of\ufb01cer. Shereviewed, contributed to,andsignedthe\nRegistration Statement.\n23. Defendant Michael A.Olsonserved, atthetimeoftheMerger, asChairman andDirector\nontheCompany\u2019s BoardandservedastheCompany\u2019s ChiefStrategy Of\ufb01cer. Hereviewed, contributed\nto,andsignedtheRegistration Statement.\n24. Defendant MartinI.Coleserved, atthetimeoftheMerger, asaDirector onthe\nCompany\u2019s Board. Hereviewed, contributed to,andsignedtheRegistration Statement.\n25. Defendant Kimberly Hammonds serv",
        "output": "['Sidney Lazard']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \nPlaintiff  FirstFire  Global  Opportunities  Fund  LLC  purchased  Ability  common  stock, 6. \nas set forth  in the certification  attached  hereto  and  incorporated  herein  by reference,  and was \ndamaged  thereby. \nDefendant  Ability  provides  tactical  communications  intelligence  solutions  for \ngovernment  agencies,  military  forces,  and  law  enforcement  and  homeland  security  agencies \nworldwide.  It offers  interception,  surveillance,  decryption,  cyber,  and geolocation  solutions. \nDefendant  Anatoly  Hurgin  (\"Hurgin\")  is a co-founder  of the Company  and served,  at 8 \nall relevant  times,  as Chairman  and Chief  Executive  Officer  of Ability. \nDefendant  Avi Levin  (\"Levin\")  served,  at all relevant  times,  as Chief  Financial 9 \nOfficer  of Ability. \n10. Defendants  Hurgin  and Levin  are referred  to herein  as the \"Individual  Defendants.\" \nAbility  and the Individual  Defendants  are referred  to herein,  collectively,  as \"Defendants.\" \nDuring  the Class  Period,  Defendants  were  privy  to confidential  and proprietary 11. \ninformation  concerning  Ability,  its operations,  finances,  financial  condition  and present  and future \nbusiness  prospects.  Because  of their  positions  with  Ability,  Defendants  had access  to non-public \ninformation  about  its business,  finances,  products,  markets  and present  and future  business  prospects \nvia internal  corporate  documents,  conversations  and connections  with  other  corporate  officers  and \nemployees,  attendance  at management  and/or  board  of directors  meetings  and committees  thereof \nand via reports  and other  information  provided  to them  in connection  therewith.  Because  of their \npossession  of such  information,  Defendants  knew  or recklessly  disregarded  that the adverse  facts \nspecified  herein  had not been  disclosed  to, and were  being  concealed  from,  the investing  public. \nCase 1:16-cv-03893   Document 1   Filed 05/25/16   Page 3 of 23D",
        "output": "['FirstFire Global Opportunities Fund LLC']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n4. Plaintiff Philip G. Thomas purchased Riskified Class A ordinary shares in or \ntraceable to the IPO and has been damaged thereby.  \n5. Defendant Riskified is an eCommerce risk management platform that uses machine \nlearning to identify fraud.  The Company is incorpora ted and headquartered in Israel.  Riskified \nClass A ordinary shares were issued and trade in New York on the New York Stock Exchange \n(\u201cNYSE\u201d) under ticker symbol \u201cRSKD.\u201d  \n6. Defendant Eido Gal (\u201cGal\u201d) co -founded Riskified and served as Riskified\u2019s Chief \nExecut ive Officer (\u201cCEO\u201d) and a director at the time of the IPO.  \n7. Defendant Assaf Feldman (\u201cFeldman\u201d) co -founded Riskified and served as \nRiskified\u2019s Chief Technology Officer and a director at the time of the IPO.  \n8. Defendant Aglika Dotcheva (\u201cDotcheva\u201d) served as Riskified\u2019s Chief Financial \nOfficer (\u201cCFO\u201d) at the time of the IPO.  \n9. Defendant Erez Shachar served as a Riskified director at the time of the IPO.  \n10. Defendant Eyal Kishon served as a Riskified director at the time of the IPO.  \n11. Defendant Aaron Mankovski served as a Riskified director at the time of the IPO.  \n12. Defendant Tanzeen Syed served as a Riskified director at the time of the IPO.  \n13. Defendant Jennifer Ceran served as a Riskified director at the time of the IPO.  \n14. The defendants identified in \u00b6\u00b66- 13 are referred t o herein as the \u201cIndividual \nDefendants.\u201d  Each of the Individual Defendants signed the Registration Statement.  In addition, the \nIndividual Defendants each participated in the solicitation and sale of Riskified Class A ordinary \nshares to investors in the I PO for their own benefit and the benefit of Riskified as directors, \nexecutive officers and/or major shareholders of the Company.  Case 1:22-cv-03545   Document 1   Filed 05/02/22   Page 3 of 20 \n- 3 - 15. Defendants Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Credit Suisse \nSecurities (USA) LLC, Barclays Capital Inc., KeyB anc Capital Markets Inc., Piper Sandler & Co., \nT\nIndividual defendants:",
        "output": "Eido Gal,Assaf Feldman,Aglika Dotcheva,Erez Shachar,Eyal Kishon,Aaron Mankovski,Tanzeen Syed,Jennifer Ceran",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant \nhereto, the owner of  Onvia  common stock.  \n9. Defendant Onvia  is a Delaware corporation and maintains its principal \nexecutive offices at  509 Oliva  Way, Suite 400, Seattle, Washington 98101 .  Onvia\u2019s \ncommon stock is traded on the Nasdaq CM under the ticker symbol \u201c ONVI .\u201d \n10. Defendant D. Van Skilling (\u201cSkilling \u201d) has served as a director of Onvia \nsince November 2004, and as Chairman of the Board since November 2010 .  \n11. Defendant Jeffrey C. Ballowe (\u201cBallowe \u201d) has served as a director of \nOnvia since December 1999.  \n12. Defendant James L. Brill (\u201cBrill\u201d) has served as a dir ector of Onvia since \nMarch 2004 . \n13. Defendant Roger L. Feldman (\u201cFeldman \u201d) has served as a director of \nOnvia since March 2004 . \n14. Defendant Russ Mann (\u201cMann \u201d) has served as a director, President, and \nChief Executive Officer (\u201cCEO\u201d) of Onvia since January 2017 . \n15. Defendan t George I. Stoeckert (\u201cStoeckert \u201d) has served as a director of \nOnvia since June 2015 . \n16. The defendants identi fied in paragraphs 10 through  15 are collectively \nreferred to herein as the \u201cIndividual Defendants.\u201d   \n17. Defendant Guarantor is a Delaware corp oration, an affiliate of Parent \nand Merger Sub, and has guaranteed all of Parent \u2019s and Merger Sub\u2019s obligations \nunder the Merger Agreement.  \n18. Defendant Parent is a  Delaware  corporation , the sole stockholder of \nGuarantor, and  a party to the Merger Agreement . Case 2:17-cv-01601   Document 1   Filed 10/27/17   Page 3 of 14 \n CLASS ACTION COMPLAINT - 4      \n1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 19. Defendant Merger Sub is a Delaware corporation, a wholly -owned \nsubsidiary of Parent, and a party to the Merger Agreement.  \nCLASS ACTION ALLEGATIONS  \n20. Plaintiff brings this action as  a class action on behalf of himself  and the \nother public stockholders of Onvia (the \u201cClass\u201d).  Excluded from the Class are \ndefendants ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n6. Plaintiff, as set forth in the accompanying certification, incorporated by reference \nherein, purchased Infosys  securities during the Class Period an d was economically damaged \nthereby.  Case 1:19-cv-05959   Document 1   Filed 10/23/19   Page 2 of 18 PageID #: 2 \n \n3 7. Defendant Infosys, with its subsidiaries,  purports to provide consulting, technology, and \noutsourcing services in North America, Europe, India, and internationally.  Infosys  is incorporated \nin India  and its principal executive offices are located at  Electronics City, Hosur Road, Bengaluru, \nKarnataka, India 560 100 . The Company \u2019s American Depository Shares  (\u201cADSs\u201d)  trade  on the  \nNew York Stock Exchange  (\u201cNYSE \u201d) under the ticker symbol \u201cINFY. \u201d \n8. Defendant Salil Parekh  (\u201cParekh \u201d) was the Company\u2019s  Chief Executive Officer \n(\u201cCEO\u201d) throughout the Class Period .   \n9. Defendant M. D. Ranganath  (\u201cRanganath \u201d) was the Company\u2019s Chief Financial \nOfficer throughout the Class Period.   \n10. Defendants  Parekh and Ranganath  are collectively referred to herein as the \n\u201cIndividual Defendants. \u201d \n11. Each of the Individual Defendants:  \n(a) directly participated in the management of the Company;  \n(b) was directly involved in the day -to-day operations of the Company at  the \nhighest levels;  \n(c) was privy to confidential proprietary information concerning the Company \nand its business and operations;  \n(d) was directly or indirectly involved in drafting, producing, reviewing and/or \ndisseminating the false and misleading state ments and information alleged \nherein;  \n(e) was directly or indirectly involved in the oversight or implementation of \nthe Company \u2019s internal controls;  \n(f) was aware of or recklessly disregarded the fact that the false and \nmisleading statements were being issued concerning the Company; and/or  Case 1:19-cv-05959   Document 1   Filed 10/23/19   Page 3 of 18 PageID #: 3 \n \n4 (g) approved or ratified these statements in violation of the federal securities \nla\nIndividual defendants:",
        "output": "Salil Parekh,M D Ranganath",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n9. Plaintiff City of Roseville Employees\u2019 Retirement System purcha sed Align common \nstock during the Class Period, as  reflected in the attached Cer tification, which is incorporated herein \nby reference, and was damaged thereby. \n10. Defendant Align Technology, Inc. is a medical device company.  Align common \nstock trades on the NASDAQ exchange in New York City under the ticker symbol \u201cALGN.\u201d  Align \nis liable for the fraud alleg ed herein under \u00a710(b) of the 1934  Act. \n11. Defendant Joseph M. Hogan (\u201cHoga n\u201d) is the President and CEO of  Align as well as \na member of the Company\u2019s Board of Directors.  Hogan has held t hese positions at all relevant times \nthroughout the Class Period. \n12. Defendant John F. Morici (\u201cMorici \u201d) is the Chief Financial Offi cer of Align and Vice \nPresident of Global Finance.  Morici held these positions at al l relevant times throughout the Class \nPeriod. \n13. Defendants Hogan and Morici are also referred to herein collect ively as the \n\u201cIndividual Defendants.\u201d \n14. Because of the Individual Defendants\u2019 positions with the Compan y, they had access \nto the adverse undisclosed information about the Company\u2019s busi ness, operations, operational \ntrends, financial statements, markets, and present and future b usiness prospects via access to internal \ncorporate documents (including th e Company\u2019s operating plans, b udgets and forecasts, and reports \nof actual operations compared th ereto), conversations and conne ctions with other corporate officers \nand employees, attendance at management and Board of Directors meetings and committees thereof, \nand via reports and other infor mation provided to them in conne ction therewith. \n15. It is appropriate to treat the Individual Defendants as a group  for pleading purposes \nand to presume that the false, misleading, and incomplete infor mation conveyed in the Company\u2019s Case 1:20-cv-01822   Document 1   Filed 03/02/20   Page 4 of 29 \n- 4 - public filings, press releases, and other publications as",
        "output": "['City of Roseville General Employees Retirement System']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \nPlaintiffs \n9. Plaintiffs, as set forth in the attached Certifications, acquired HUMBL \nsecurities, including HUMBL common stock and ETX products, at artificially \ninflated prices during the Class Period and were damaged upon the revelation of \nthe alleged corrective disclosures. Case 3:22-cv-00723-AJB-BLM   Document 1   Filed 05/19/22   PageID.3   Page 3 of 403 \nCLASS ACTION COMPLAINT 1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n2810. Plaintiff Matt Pasquinelli is a resident and citizen of Pennsylvania, \nliving in Canonsburg, Pennsylvania.  Plaintiff Pasquinelli purchased HUMBL \ncommon stock as well as unregistered BLOCK ETX securities and suffered \ninvestment losses as a result of Defendants\u2019 conduct. \n11. Plaintiff Bryan Paysen is a resident and citizen of Texas, living in \nRound Rock, Texas.  Plaintiff Paysen purchased HUMBL common stock and \nsuffered investment losses as a result of Defendants\u2019 conduct. \nDefendants \n12. Defendant HUMBL LLC is a Delaware corporation with its principal \nexecutive offices located at 600 B Street, Suite 300, San Diego, CA 92101.  The \nCompany\u2019s common stock trades in OTC under the ticker symbol \u201cHMBL.\u201d  The \ncompany\u2019s unregistered securities, the BLOCK Exchange Traded Index products, \nare known as \u201cBLOCK ETXs.\u201d \n13. Defendant Bryan Foote (\u201cFoote\u201d) is a resident and citizen of \nCalifornia, living in San Diego, California.  Foote has served as HUMBL\u2019s CEO at \nall relevant times. \n14. Defendant Jeffrey Hinshaw (\u201cHinshaw\u201d) is a resident and citizen of \nCalifornia, living in San Diego, California.  Hinshaw has served as HUMBL\u2019s \nChief Financial Officer at all relevant times. \n15. Defendant George Sharp (\u201cSharp\u201d) is a resident and citizen of \nArizona, living in Scottsdale, Arizona.  Sharp previously served as an advisor to \nHUMBL and currently serves as Capital Markets Advisor. \n16. Defendants Foote, Hinshaw, and Sharp are sometimes referred to \nherein as \u201cIndividual Defendants.\u201d \n17. The Individual Defendants",
        "output": "['Matt Pasquinelli', 'Bryan Paysen']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 13. Plaintiff, as set forth in the attached Certification, acquired Bellicum securities at artificially inflated prices during the Class Period and was damaged upon the revelation of the alleged corrective disclosures.  14. Defendant Bellicum is headquartered in Texas, with its principal executive offices located at 2130 West Holcombre Boulevard, Suite 800, Houston, Texas 77030.  Bellicum\u2019s shares trade on the NASDAQ under the ticker symbol \u201cBLCM.\u201d 15. Defendant Richard A. Fair (\u201cFair\u201d) has served as the Company\u2019s Chief Executive Officer (\u201cCEO\u201d), President and Director since January 2017. 16. Defendant Alan A. Musso (\u201cMusso\u201d) has served as the Company\u2019s Chief Financial Officer (\u201cCFO\u201d) and Treasurer since November 2014.  17. The Defendants referenced above in \u00b6\u00b6 15-16 are sometimes referred to herein as the \u201cIndividual Defendants.\u201d   18. The Individual Defendants possessed the power and authority to control the contents of Bellicum\u2019s SEC filings, press releases, and other market communications. The Individual Defendants were provided with copies of the Company\u2019s SEC filings and press releases alleged herein to be misleading prior to or shortly after their issuance and had the ability and opportunity to prevent their issuance or to cause them to be corrected. Because of their positions with the Company, and their access to material information available to them but not to the public, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to and were being concealed from the public, and that the positive representations being made were then materially false and misleading. The Individual Defendants are liable for the false statements and omissions pleaded herein.  Case 4:18-cv-00338   Document 1   Filed in TXSD on 02/06/18   Page 4 of 18 \n5  \nOnly answer with the company defendants names.",
        "output": "Bellicum Pharmaceuticals, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is a citizen of Canada and, at all times r elevant hereto, ha s been an \nAimmune stockholder .   \n9. Defendant Aimmune a clinical -stage biopharmaceutical company  that develops and \ncommercializes product candidates for the treatment of peanut and other food allergies . Aimmune \nis incorporated under the laws of the State of Delaware and has its principal place of business at \n8000 Marina Blvd.,  Suite 300, Brisbane,  California  94005 .  Shares of Aimmune common stock \nare traded on the NasdaqGS under the symbol \u201cAIMT .\u201d \n10. Jayson Dallas (\"Dallas \") has been a Director of the Company at all relevant times.  \nIn addition, Dallas serves as the Company\u2019s President and Chief Executive Officer (\u201cCEO\u201d) . \n11. Defendant Greg Behar (\"Behar \") has been a director of the Company at all \nrelevant  times .  Case 5:20-cv-06609   Document 1   Filed 09/21/20   Page 3 of 26 \n- 4 - \nCLASS ACTION COMPLAINT  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 12. Defendant Patrick Enright (\"Enright \") has been a director of the Company at all \nrelevant times .   \n13. Defendant Kate Falberg  (\"Falberg \") has been a director of the Company at all \nrelevant times.  In addition, Falberg serves as the Chair of the Audit Committee of the Company .   \n14. Defendant Brett Haumann (\"Haumann \") has been a director of the Company at all \nrelevant times . \n15. Defendant Mark Iwicki (\u201cIwicki\u201d) has been a director of the Company at all \nrelevant times .   \n16. Defendant Mark McDade (\u201cMcDade\u201d) has been  a director of the Company at all \nrelevant times. In addition, McDade serves as the Company\u2019s Chairman of the Board .   \n17. Defendant Stacey D. Seltzer (\u201cSeltzer\u201d) has been a director of the Company at all \nrelevant times.  \n18. Defendants identified  in \u00b6\u00b6  10 - 17 are collectively referred to as the \u201cIndividual \nDefendants.\u201d   \n19. Non-Defendant Nestl\u00e9  together with its subsidiaries, operates as a food and \nbeverage company . \nOnly answer with the company defendants names.",
        "output": "Aimmune Therapeutics, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n5. Plaintiff Jeffry Brown purchased Acutus common stock during the \nClass Period, as set forth in the Certification attached hereto and incorporated herein \nby reference, and suffered damages.  \n6. Defendant Acutus is an arrhythmia management company focused on \nimproving the diagnosis and treatment of cardiac arrhythmias.  Defendant Acutus is \nbased in Carlsbad, California and its common stock trades on NASDAQ under the \nticker symbol \u201cAFIB.\u201d  \n7. Defendant Vince Burgess (\u201cBurgess\u201d) served,  at all relevant times, as \nAcutus\u2019 President, Chief Executive Officer (\u201cCEO\u201d) and Director.  \n8. Defendant David H. Roman (\u201cRoman\u201d) served, at all relevant times, as \nAcutus\u2019 Chief Financial Officer (\u201cCFO\u201d).  \n9. Defendants Burgess and Roman are referred to herein as the \u201cIndividual \nDefendants.\u201d  During the Class Period, the Individual Defendants ran the Company \nas hands- on managers overseeing Acutus\u2019 operations and finances and made the \nmaterially false and misleading statements described herein.  The Individual \nDefe ndants had intimate knowledge about core aspects of Acutus\u2019 financial and \nbusiness operations.  They were also intimately involved in deciding which \ndisclosures would be made to investors by Acutus.  \nSUBSTANTIVE ALLEGATI ONS  \nBackground  \n10. Acutus designs and manufactures a range of tools for catheter -based \nablation procedures and markets and sells its products to hospitals and \nelectrophysiologists that treat patients with arrhythmias.  \n11. The Company\u2019s primary product is its AcQMap imaging and mapping \nsystem, which c onsists of a console, workstation, proprietary software algorithms, Case 3:22-cv-00206-JO-KSC   Document 1   Filed 02/15/22   PageID.3   Page 3 of 33 \n  - 3 -  \n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n and a single -use catheter that contains ultrasound transducers and electrodes which \ncollect the data required to create a comprehensive map of a patient\u2019s cardiac \nana\nOnly answer with the company defendants names.",
        "output": "Acutus Medical, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff was, and was  continuously at all relevan t times , the owner of Boston Private  \ncommon stock . \n12. Defendant Boston Private Financial Holdings, Inc. was a Massachusetts corporation \nheadquartered in Boston, Massachusetts. Boston Private \u2019s common stock traded  on the N asdaq  under  the \nticker symbol \u201c BPFH .\u201d \n13. Defendant Anthony DeChellis (\u201c DeChellis\u201d) was, and was at all relevant times, the \nCompany\u2019s Chief Executive Office r and a director of the Company.  \n14. Defendant Stephen M. Waters  (\u201cWaters \u201d) was, and was  at all relevant times, the Cha irman \nof the Board of Directors of the Company.  \n15. Defendant Mark F. Furlong (\u201cFurlong\u201d)  was, and was  at all relevant times , a director of the \nCompany. \n16. Defendant  Joseph C. Guyaux (\u201cGuyaux\u201d) was , and was  at all relevant times , a director of \nthe Company . \n17. Defendant  Deborah F. Kuenstner (\u201cKuenstner\u201d) was , and was  at all relevant times , a \ndirector of the Company.  \n18. Defendant Gloria C. Larson (\u201cLarson\u201d) was, and was  at all relevant times , a director of the \nCompany. \n19. Defendant Kimberly S. Stevenson (\u201cStevenson\u201d) was, and was  at all relevant times , a \ndirector of the Company.  \n20. Defendant Luis A. Ubinas (\u201cUbinas\u201d) was, and was  at all relevant times , a director of the \nCompany. \n21. Defendant Lizabeth H. Zlatkus (\u201cZlatkus\u201d) , was, and was at all relevant times , a director of \nthe Company. Case 1:21-cv-11537-PBS   Document 1   Filed 09/20/21   Page 5 of 296  22. The Defendants identif ied in paragraphs 1 2 through 21 are collectively  referred to herein \nas the \u201cDefendants. \u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n12. Plaintiff, as set forth in the attached Certification, acquired GW Pharmaceuticals \nsecurities at artificially inflated prices during the Class Period and was damaged upon the \nrevelation of the alleged corrective disclosures.  \n13. Defendant GW Pharmaceuticals is an Ire land corporation with its principal \nexecutive offices located at Sovereign Hous e, Vision Park, Cambridge, CB24 9BZ, United \nKingdom.  GW Pharmaceutical\u2019s shares trade on the NASDAQ under the ticker symbol \u201cGWPH.\u201d \n14. Defendant Justin D. Gover (\u201cGover\u201d) has served at all relevant times as the \nCompany\u2019s Chief Executive Officer  and Executive Director.  \n15. Defendant Adam David George (\u201cGeorge\u201d) has served at all relevant times as the \nCompany\u2019s Chief Financial Officer, Company Secretar y, and Executive Director. \n16. The defendants referenced above in \u00b6\u00b6 14- 15 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d \n\nIndividual defendants:",
        "output": "Justin D Gover,Adam David George",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n5. Plaintiff Dagan Investments LLC, as set forth in the certification attached hereto and \nincorporated by reference herein, purchased FHS ADSs directly in and traceable to the IPO and has \nbeen damaged thereby.  \n6. Defendant FHS, incorporated in the Cayman Islands and headquartered in Yunnan \nProvince, operates private high schools in Western China and provides for -profit tutoring services.  \nThe Company\u2019s ADSs trade in New York on t he New York Stock Exchange (\u201cNYSE\u201d) under the \nticker symbol \u201cFHS.\u201d  Each FHS ADS represents three Class A ordinary shares of the Company.  \nThe Company maintains a dual -class voting structure designed to concentrate control over the \nCompany in the hands of insiders out of proportion with their economic stake in FHS.  The \nCompany has Class A and Class B ordinary shares, which have the same rights except that Class A \nshares are not convertible and entitle holders to one vote per share, while Class B shares are  \nconvertible into Class A shares and entitle holders to 20 votes per share.  \n7. Defendant Shaowei Zhang (\u201cZhang\u201d) founded FHS and has served as FHS\u2019s Chief \nExecutive Officer (\u201cCEO\u201d) and Chairman since September 2018.  Defendant Zhang, his spouse Yu \nWu, and Lon gwater Topco B.V. beneficially owned all of FHS\u2019s issued Class B ordinary shares at \nthe time of the IPO.  Either directly or through affiliated investment vehicles, Zhang beneficially \nowned 47% of FHS ordinary shares prior to the IPO, and, after the IPO, c ontinued to own 38% of all Case 1:22-cv-03831   Document 1   Filed 05/11/22   Page 3 of 25 \n- 3 - FHS ordinary shares (both Class A and Class B) entitling him to over 65% voting power over the \nCompany (assuming no exercise of the underwriters\u2019 overallotment option). \n8. Defendant Lidong Zhu served as FHS\u2019s Chief Financial Officer  (\u201cCFO\u201d) from \nAugust 2019 until his resignation in October 2021.  He was also an FHS director from the time of \nthe IPO until December 31, 2021. \n9. Defendant Guangzhou Zhao served\nOnly answer with the company defendants names.",
        "output": "First High-School Education Group Co. Ltd.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff  is, and has been at all relevant times  hereto , an owner of Builders  common \nstock .  \n12. Defendant Builders manufactures and supplies building materials, manufactured \ncomponents, and construction services to professional homebuilders, sub -contractors, remodelers, Case 2:20-cv-15553   Document 1   Filed 11/04/20   Page 3 of 15 PageID: 34 and consumers in the United States. The Company serves the New Jersey market in several \nlocations throughout  the State .1 The Company is incorporated in Delaware . The Company \u2019s \ncommon stock  trade s on the NASDAQ  under the ticker symbol , \u201cBLDR .\u201d \n13. Defendant Paul S. Levy  (\u201cLevy \u201d) is Chairman of the Board of the Company . \n14. Defendant Daniel Agroskin (\u201cAgroskin\u201d) is a director of the Company.  \n15. Defendant David A. Barr (\u201cBarr\u201d) is a director of the Company.  \n16. Defendant Cleveland A. Christophe (\u201cChristophe\u201d) is a director of the Company.  \n17. Defendant Chad Crow (\u201cCrow\u201d) is Chief Executive Officer and a director of the \nCompany.  \n18. Defendant Janice Davis (\u201cDavis\u201d) is a director of the Company.  \n19. Defendant William Bradley Hayes (\u201cHayes\u201d) is a director of the Company.  \n20. Defendant Brett N. Milgrim  (\u201cMilgrim \u201d) is a director of the Company.  \n21. Defendant Floyd F. Sherman  (\u201cSherman \u201d) is a director of the Company.  \n22. Defendant Craig Steinke  (\u201cSteinke \u201d) is a director of the Company.  \n23. Defendants Levy , Agroskin , Barr, Christophe, Crow, Davis, Hayes, Milgrim, \nSherman , and Steinke are collectively referred to herein as the \u201cIndividual Defendants. \u201d \n24. Defendants Builders  and the Individual Defendants are collectively referred to \nherein as the \u201cDefendants. \u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n5. Plaintiff Zoya Qaiyum, as set forth in the certification attached hereto and \nincorporated by reference herein, purchased Rocket Class A common stock during the \nClass Period and has been damaged thereby.  \n6. Defendant Rocket is an onlin e mortgage lender.  Rocket Class A \ncommon stock trades on the New York Stock Exchange (\u201cNYSE\u201d) under the ticker \nsymbol \u201cRKT.\u201d  \n7. Defendant Jay D. Farner (\u201cFarner\u201d) was at all relevant times the Chief \nExecutive Officer (\u201cCEO\u201d) and Vice Chairman of Rocket.  \n8. Defendant Julie R. Booth (\u201cBooth\u201d) was at all relevant times the Chief \nFinancial Officer (\u201cCFO\u201d) and Treasurer of Rocket.  Case 2:21-cv-11528-PDB-APP   ECF No. 1, PageID.3   Filed 06/29/21   Page 3 of 31 \n- 3 - 9. Defendant Robert Dean Walters (\u201cWalters\u201d) was at all relevant times the \nPresident and Chief Operating Officer (\u201cCOO\u201d) of Rocket.  \n10. Defendant Daniel Gilbert (\u201cGilbert\u201d) is the founder and former CEO of \nRocket.  During the Class Period, defendant Gilbert served as the Chairman of the \nBoard of Directors of Rocket.  \n11. The defendants referenced above in \u00b6\u00b67- 10 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d  \n12. Each of the Individual Defendants was directly involved in the \nmanagement and day- to-day operations of the Company at the highest levels and was \nprivy to confidential proprietary information concerning the Company and it s \nbusiness, operations, services, competition, acquisition plans, and present and future \nbusiness prospects, as alleged herein.  In addition, the Individual Defendants were \ninvolved in drafting, producing, reviewing and/or disseminating the false and misle ading statements and information alleged herein, were aware of, or recklessly \ndisregarded, the false and misleading statements being issued regarding the Company, \nand approved or ratified these statements, in violation of the federal securities laws.  \n13. As of ficers and controlling persons of a publicly held company whose \nsecurities are reg",
        "output": "['Zoya Qaiyum']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Ribbon common stock.  Case 1:20-cv-00069-UNA   Document 1   Filed 01/16/20   Page 2 of 11 PageID #: 2 \n 3 9. Defendant Ribbon is a Delaware  corporation and maintains its principal executive \noffices at  4 Tec hnology Park Drive, Westford, Massachusetts 01886.  Ribbon\u2019s common stock is \ntraded on the NASDAQ Global Select Market  under the ticker symbol \u201c RBBN.\u201d  \n10. Defendant Kim S. Fennebresque is a director of Ribbon. \n11. Defendant Bruns H. Grayon is  a director of Ribbon. \n12. Defendant Beatriz V. Infante is a director of Ribbon.  \n13. Defendant Richard J. Lynch is Chairman of the Board of Ribbon. \n14. Defendant Kent J. Mathy  is a director of Ribbon. \n15. Defendant Scott E. Schubert is a director of Ribbon. \n16. Defendant Rick  W. Smith is director of Ribbon.  \n17. The defendants identified in paragraphs 10 through 16 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d    \nCLASS ACTION ALLEGATIONS  \n18. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Ribbon (the \u201cClass \u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other enti ty related to or affiliated with any defendant. \n19. This action is properly maintainable as a class action.  \n20. The Class is so numerous that joinder of all members is impracticable.  As of \nJanuary 8, 2020, there were approximately 110,959,971 shares of Ribbon common  stock \noutstanding, held by hundreds, if not thousands, of individuals and entities scattered throughout \nthe country.  \n21. Questions of law and fact are common to the Class, i ncluding, among others, \nwhether defendants violated the 1934  Act and whe ther defendants will irreparably harm plaintiff Case 1:20-cv-00069-UNA   Document 1   Filed 01/16/20   Page 3 of 11 PageID #: 3 \n 4 and the other members of the Class if defendants \u2019 conduct  complain\nOnly answer with the company defendants names.",
        "output": "Ribbon Communications Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Knoll stocks and has held such stocks since prior to the wrongs complained of herein. 10. Individual Defendant Andrew B. Cogan has served as a member of the Board since February 1996 and is the Chairman of the Board and the Chief Executive Officer of the Company.  11. Individual Defendant Roberto Ardagna has served as a member of the Board since August 2020. 12. Individual Defendant Daniel W. Dienst has served as a member of the Board since August 2017. 13. Individual Defendant Stephen F. Fisher has served as a member of the Board since December 2005.  Case 1:21-cv-04759   Document 1   Filed 05/27/21   Page 3 of 19 \n4 14. Individual Defendant Jeffrey A. Harris has served as a member of the Board since February 1996. 15. Individual Defendant Jeffrey Henderson has served as a member of the Board since October 2020. 16. Individual Defendant Ron Kass has served as a member of the Board since July 2018. 17. Individual Defendant Christopher G. Kennedy has served as a member of the Board since November 2014. 18. Individual Defendant John F. Maypole has served as a member of the Board since December 2004. 19. Individual Defendant Sarah E. Nash has served as a member of the Board since September 2006. 20. Individual Defendant Stephanie Stahl has served as a member of the Board since August 2013. 21. Defendant Knoll a Delaware corporation and maintains its principal offices at 1235 Water Street, East Greenville, Pennsylvania 18041.  The Company\u2019s stock trades on the New York Stock Exchange under the symbol \u201cKNL.\u201d 22. The defendants identified in paragraphs 10-20 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 23. The defendants identified in paragraphs 10-21 are collectively referred to as the \u201cDefendants.\u201d Case 1:21-cv-04759   Document 1   Filed 05/27/21   Page 4 of 19 \n5 \nOnly answer with the company defendants names.",
        "output": "Knoll Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n9. Plaintiff is, and has been at all relevant times, the owner of Innophos common \nstock and has held such stock sin ce prior to the wrongs complai ned of herein. \n10. Individual Defendant Gary Cappeline has served as a member of t he Board since \n2007. \n11. Individual Defendant Jane Hilk ha s served as a member of the Bo ard since 2018.  Case 2:19-cv-20474   Document 1   Filed 11/19/19   Page 3 of 15 PageID: 34 12. Individual Defendant Kim Ann Mi nk has been the Company\u2019s Chief Executive \nOfficer and President since De cember 2015, a director of Innoph os since January 2016, and \nChairman of the Board since February 2017.  \n13. Individual Defendant Linda Myrick has served as a member of the  Board since \n2006.  \n14. Individual Defendant Karen Osar has served as a member of the B oard since \n2007. \n15. Individual Defendant John M. Steitz has served as a member of t he Board since \n2009. \n16. Individual Defendant Peter T. Thomas has served as a member of the Board since \n2016. \n17. Individual Defendant Robert J. Za tta has served as a member of the Board since \n2016. \n18. Defendant Innophos is incorporated in Delaware and maintains it s principal \noffices at 259 Prospect Plains Road, Building A, Cranbury, NJ 0 8512.  The Company\u2019s common \nstock trades on the NASDAQ Stock E xchange under the symbol \u201cIPH S.\u201d \n19. The defendants identified in par agraphs 10-17 are collectively referred to as the \n\u201cIndividual Defendant s\u201d or the \u201cBoard.\u201d \n20. The defendants identified in par agraphs 10-18 are collectively referred to as the \n\u201cDefendants.\u201d \n\nIndividual defendants:",
        "output": "Gary Cappeline,Jane Hilk,Kim Ann Mink,Linda Myrick,Karen Osar,John M Steitz,Peter T Thomas,Robert J Zatta",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \nPlaintiff  \n29. Plaintiff WALTER WELCH , as set forth in the accompanying cert ification, \nincorporated by reference herein, acquired the common stock of Waitr  in connection with the \nGoing Public Transaction and the Secondary Offering  at artificially inflated prices during the \nClass Period and has been damaged thereby.  Case 2:19-cv-01260   Document 1   Filed 09/26/19   Page 12 of 114 PageID #:  1213 \n Defendant s \n30. Defendant  CHRISTOPH ER MEAUX was CEO, Chairman of the Board of \nDirectors and co -Founder of the Company during the Class Period.  On August 8, 2019, \nDefendant  Meaux was removed from his position as CEO  of the Company.  During the Class \nPeriod, Defendant  Meau x was instrumental in the preparation  of, and/or signed and certified the \nCompany\u2019s SEC filings, including but not limited to Waitr\u2019s Form(s) 10- Q and Form 10- K \nand/or the materially false and misleading Secondary Offering Filings , and the materially false \nand misleading Goi ng Public Transaction Proxy/Prospectus Filings . \n31. Defendant  DAVID PRINGLE  (\u201cPringle \u201d) was  Chief Financial Officer  (\u201cCFO\u201d) \nand Principal Financial Officer  of the Company during the Class Period , until his departure  in \nApril  2019.  During the Cl ass Period, Def endant  Pringle was instrumental in the preparation of, \nand/or signed and certified the Company\u2019s SEC filings, includi ng but not limited to Waitr\u2019s \nForm 10- K and the materially false and misleading Going Public Transaction Proxy/Prospectus \nFilings .  \n32. Defendant  JEFF YURECKO  (\u201cYurecko \u201d) was CFO  and Principal Financial \nOfficer of the Company, beginning on April 2019 during the Class Period, after replac ing \nDefendant  Pringle .  During the  Class Period, Defendant  Yurecko was instrumental in the \nprepa ration of, and/ or signed and certified the Company\u2019s SEC filings, including but not limited \nto Waitr\u2019s Form(s) 10 -Q and/or the materially false and misleading Secondary Offering Filings .  \n33. Defendant  TILMAN J. FERTITT\nOnly answer with the company defendants names.",
        "output": "Waitr Holdings, Inc. f/k/a Landcadia Holdings Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n14. Plaintiff is a citizen of Brunswick Count y, North Carolina.  As set forth in the \nattached Certification, he acquired Antares secu rities at artificially inflated prices during the \nClass Period and was damaged upon the revelati on of the alleged corrective disclosures.  \n15. Defendant Antares is incor porated in Delaware, with principal executive offices \nlocated at 100 Princeton Sout h, Suite 300, Ewing, New Jersey 08628.  Antares\u2019s shares trade on \nthe NASDAQ under the ticker symbol \u201cATRS.\u201d \n16. Defendant Robert F. Apple (\u201cApple\u201d) has served at all relevant times as the \nCompany\u2019s Chief Executive Officer (\u201c CEO\u201d), President and Director. \n17. Defendant Fred M. Powell (\u201cPowell\u201d) has served at all relevant times as the \nCompany\u2019s Chief Financial Officer (\u201c CFO\u201d) and Senior Vice President. \n18. The defendants referenced above in \u00b6\u00b6 16- 17 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d \n Case 3:17-cv-08945   Document 1   Filed 10/23/17   Page 4 of 21 PageID: 4 \n5 \n ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \nA. Plaintiffs \n21. Plaintiffs Oakland County Employees\u2019 Retirement System and Oakland County \nVoluntary Employees\u2019 Beneficiary Association are governmental employee benefit plans for \nemployees and retirees of Oakland County, Michigan.  As indicated in the certification submitted \nherewith, Plaintiffs purchased Sotera common stock at artificially inflated prices during the Class \nPeriod and suffered damages as a result of the violations of the federal securities laws alleged \nherein. \nB. Corporate Defendant \n22. Defendant Sotera is incorporated in Delaware and maintains its corporate \nheadquarters at 9100 South Hills Blvd, Suite 300, Broadview Heights, Ohio.  The Company\u2019s Case: 1:23-cv-00143  Doc #: 1  Filed:  01/24/23  7 of 47.  PageID #: 77 common stock trades on NASDAQ under the ticker symbol \u201cSHC.\u201d  As of October 25, 2022, \nSotera had over 282 million shares of common stock outstanding, owned by hundreds or thousands \nof investors. \nC. Officer Defendants  \n23. Defendant Michael B. Petras, Jr. (\u201cPetras\u201d) is, and was at all relevant times, \nSotera\u2019s Chairman and Chief Executive Officer (\u201cCEO\u201d).  Defendant Petras signed the IPO \nRegistration Statement (defined below) and the SPO Registration Statement (defined below) and \nis therefore liable under the Securities Act for the untrue and misleading statements and omissions \nin the Offering Materials for the Offerings. \n24. Defendant Scott J. Leffler (\u201cLeffler\u201d) served as Sotera\u2019s Chief Financial Officer \nand Treasurer from April 2017 until July 20, 2022.  Defendant Leffler signed the IPO Registration \nStatement and the SPO Registration Statement and is therefore liable under the Securities Act for \nthe untrue and misleading statements and omissions in the Offering Materials for the Offerings.  \n25. Defendant Michael F. Biehl (\u201cBiehl\u201d) has served as Sotera\u2019s Interim Chief \nFinancial Officer since July 20, 2022.  \n26. Defendant Michael P. Rutz (\u201cRutz\u201d) has served as President of Sterigenics since \nOctober 2020.  Prior\nIndividual defendants:",
        "output": "Michael B Petras Jr.,Scott J Leffler,Michael F Biehl,Michael P Rutz,Kathleen A Hoffman,Ruoxi Chen,Sean L Cunningham,David Donnini,Stephanie M Geveda,Ann R Klee,Constantine S Mihas,James C Neary,Vincent K Petrella",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n11. Plaintiff purchased Cloopen ADS pursuant or traceable to the IPO and was \ndamaged thereby. \n12. Defendant Cloopen is a leading multi-capability cloud-based communications \nsolution provider in China that offers a full suite of cloud-based communications solutions, \nCloopen conducted the IPO in New York, and its ADS are listed on the NYSE under the ticker \nsymbol \u201cRAAS.\u201d FILED: NEW YORK COUNTY CLERK 04/19/2021 05:52 PMINDEX NO. 652617/2021\nNYSCEF DOC. NO. 2 RECEIVED NYSCEF: 04/19/2021\n4 of 19 \n5 \n 13. Defendant Cogency Global Inc. (\u201cCogency Global\u201d) was Cloopen\u2019s authorized \nU.S. representative for purposes of the IPO.  Defendant Colleen A. DeVries (\u201cDeVries\u201d), who \nsigned the Registration Statement, is an employee of Defendant Cogency Global.  As a result, \nDefendant Cogency Global is liable for the securities law violations committed by Defendant \nDeVries, in its capacity as employer and as a control person under the Securities Act. \n14. Defendant Changxun Sun (\u201cSun\u201d) founded Cloopen and was, at the time of the \nIPO, Cloopen\u2019s Chief Executive Officer (\u201cCEO\u201d) and Chairman of Cloopen\u2019s Board of Directors \n(the \u201cBoard\u201d).  Defendant Sun reviewed, contributed to, and signed the Registration Statement.  \n15. Defendant Yipeng Li (\u201cLi\u201d) was, at the time of the IPO, Cloopen\u2019s Chief Financial \nOfficer (\u201cCFO\u201d) and a Director on Cloopen\u2019s Board.  Defendant Li reviewed, contributed to, and \nsigned the Registration Statement.  \n16. Defendant Kui Zhou (\u201cZhou\u201d) was, at the time of the IPO, a Director on Cloopen\u2019s \nBoard.  Defendant Zhou reviewed, contributed to, and signed the Registration Statement.   \n17. Defendant Qingsheng Zheng (\u201cZheng\u201d) was, at the time of the IPO, a Director on \nCloopen\u2019s Board.  Defendant Zheng reviewed, contributed to, and signed the Registration \nStatement.   \n18. Defendant Xiaodong Liang (\u201cLiang\u201d) was, at the time of the IPO, a Director on \nCloopen\u2019s Board.  Defendant Liang reviewed, contributed to, and signed the Registration \nStatement.   \n19. De\nIndividual defendants:",
        "output": "Changxun Sun,Yipeng Li,Kui Zhou,Qingsheng Zheng,Xiaodong Liang,Zi Yang,Ming Liao,Feng Zhu,Lok Yan Hui,Jianhong Zhou,Ching Chiu",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n5. Plaintiff City of Sterling Heights, as set forth in the accompanying certification \nincorporated by reference herein, purchased the ADS of Anheuser -Busch during the Class Period \nand has been damaged thereby.  \n6. Defendant Anheuser -Busc h is engaged in the production, distribution, and sale of \nbeer, alcoholic beverages, and soft drinks worldwide.  The Company maintains its headquarters in \nLeuven, Belgium and its ADS trade on the NYSE under the ticker symbol \u201cBUD.\u201d  \n7. Defendant Carlos Brito ( \u201cBrito\u201d) is, and was at all relevant times, Anheuser -Busch\u2019s \nChief Executive Officer.  \n8. Defendant Felipe Dutra (\u201cDutra\u201d) is, and was at all relevant times, Anheuser -Busch\u2019s \nChief Financial and Solutions Officer.  \n9. Defendant John Blood (\u201cBlood\u201d) is, and was at all relevant times, Anheuser -Busch\u2019s \nGeneral Counsel and Company Secretary.  \n10. Defendants Brito, Dutra and Blood are collectively referred to hereinafter as the \n\u201cIndividual Defendants.\u201d  Anheuser -Busch and the Individual Defendants are collectively referred t o \nherein as \u201cDefendants.\u201d  \n11. Because of the Individual Defendants\u2019 executive positions, they each had access to \nthe undisclosed adverse information about Anheuser -Busch\u2019s business, operations, liquidity, \noperational trends, deleveraging efforts, controls, mar kets, and present and future business prospects Case 1:19-cv-05854   Document 1   Filed 06/21/19   Page 3 of 33 \n- 3 - via internal corporate documents, conversations and connections with other corporate officers and \nemployees, attendance at management and Board of Directors meetings and committees thereof.  \n12. It is appropriate to treat Defendants as a group for pleading purposes and to presume \nthat the false, misleading and incomplete information conveyed in the Company\u2019s public filings, \npress releases and other publications, as alleged herein, are the collective actions of the narrowly \ndefined group of Defendants identified above.  Each of the Individual Defendants was \nOnly answer with the company defendants names.",
        "output": "Anheuser-Busch InBev SA/NV",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n13. Plaintiff Cambridge Retirement System is a contribut ory retirement system for \nactive and retired employees of the City of Cambridge, Massachusetts, the Cambridge Housing \nAuthority, the Cambridge Public Health Commission, and the Cambridge Redevelopment \nAuthority. As of December 31, 2018, Plaintiff manages a pproximately $1.3 billion in assets on \nbehalf of approximately six thousand participants. As shown in the attached certification, Plaintiff \npurchased shares of EQT stock during the Class Period; held shares of EQT stock on September \n25, 2017, the record da te for EQT shareholders to vote on the Acquisition; held Rice stock on \nNovember 13, 2017, the closing date of the Acquisition, and acquired EQT stock in exchange for \nits Rice stock in the Acquisition; and suffered damages as a result of the violations of t he federal Case 2:19-cv-00754-MPK   Document 1   Filed 06/25/19   Page 5 of 40 \n6 securities laws alleged in this Action.  Plaintiff also  held shares of Rice stock on September 21, \n2017, the record date for Rice shareholders to vote on the Acquisition.  \n14. Defendant EQT is a Pennsylvania  corporation he adquartered at 25 Liberty Ave nue, \nSuite 1700,  Pittsburgh, Pennsylvania, that calls itself the largest natural -gas producer in the United \nStates.  \n15. Defendant Steven T. Schlotterbeck joined EQT in 2010 and was EQT\u2019s President \nand CEO from March 1, 2017, until March 15, 2018, when his resi gnation from all of his positions \nas an officer and director of the Company, effective the day before, was publicly announced. \nSchlotterbeck signed the Registration Statement (defined below) for the Acquisition, as well as \nEQT\u2019s annual report on Form 10 -K for the year ended December 31, 2017.  \n16. Defendant Robert J. McNally (\u201cMcNally\u201d) was EQT\u2019s Senior Vice President and \nChief Financial Officer from March 2016 to November 2018. McNally signed the Registration \nStatement for the Acquisition, as well as EQT\u2019s annu al report on Form 10 -K for th\nIndividual defendants:",
        "output": "Steven T Schlotterbeck,Robert J McNally,David L Porges,Jimmi Sue Smith,James Rohr,Vicky A Bailey,Philip G Behrman,Kenneth M Burke,A Bray Cary Jr.,Margaret K Dorman,Stephen A Thorington,Lee T Todd Jr.,Christine J Toretti,Daniel J Rice IV,Robert F. Vagt",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n11. Plaintiff Frank Miller, as se t forth in the accompanying certification, incorporated \nby reference herein, purchased Cadence securities  during the Class Period, and suffered damages \nas a result of the federal securities law violatio ns and false and/or misl eading statements and/or \nmaterial omissions alleged herein.  Case 4:19-cv-03492   Document 1   Filed on 09/16/19 in TXSD   Page 3 of 20 \nCLASS ACTION COMPLAINT \n3 12. Defendant Cadence is incorporated under th e laws of Delaware with its principal \nexecutive offices located in Houston, Texas.  Cadence\u2019s Class A comm on stock trades on the \nNew York Stock Exchange (\u201cNYSE\u201d) under the symbol \u201cCADE.\u201d \n13. Defendant Paul B. Murphy (\u201cMurphy\u201d) was the Chief Executive Officer of the \nCompany at all relevant times. \n14. Defendant Valerie C. Toalson (\u201cToals on\u201d) was the Chief Financial Officer \n(\u201cCFO\u201d) of the Company at all relevant times. \n15. Defendants Murphy and Toalson (collect ively the \u201cIndividual Defendants\u201d), \nbecause of their positions with the Company, po ssessed the power and authority to control the \ncontents of the Company\u2019s report s to the SEC, press releases a nd presentations to securities \nanalysts, money and portfolio manage rs and institutional investors, i.e., the market.  The \nIndividual Defendants were provi ded with copies of the Company\u2019s reports and press releases \nalleged herein to be misleading prior to, or shor tly after, their issuance and had the ability and \nopportunity to prevent their issuance or cause them  to be corrected.  Because of their positions \nand access to material non-public information av ailable to them, the Individual Defendants knew \nthat the adverse facts specified herein had not b een disclosed to, and were being concealed from, \nthe public, and that the positive representations wh ich were being made were then materially \nfalse and/or misleading.  The I ndividual Defendants are liable for the false statements pleaded \nherein.  \n\nIndividual defendants:",
        "output": "Paul B Murphy,Valerie Toalson",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n \n11. Plaintiff, as set forth in the accompany ing certification, incorporated by reference herein, \npurchased the common stock of Omnicell during the Class Period and has been damaged upon the \nrevelation of the alleged corrective di sclosure . \n12. Defendant Omnicell  provides automation solutions for medication and supply \nmanagement in healthcare worldwide. The company operates in two segments, Acute Care and Non -\nAcute Care.   The Company maintains principal executive offices at 590 East Middlefield Road, Case 4:15-cv-01280-HSG   Document 1   Filed 03/19/15   Page 3 of 16 \n4 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n29 \n30 \n31 \n32 Mountain View, California 94043.  The Company\u2019s common stock is traded on the NASDAQ Global \nSelect Market ( \u201cNASDAQ \u201d) under the ticker symbol \u201c OMCL .\u201d \n13. Defendant Randall A. Lipp s (\u201cLipps \u201d) has served as the Company\u2019s President and Chief \nExecutive  Officer (\u201cCEO\u201d) at all relevant times . \n14. Defendant Robin G. Seim (\u201cSeim \u201d) has served as the Company\u2019s Executive Vice \nPresident  Finance  and Chief  Financial Officer (\u201cCFO\u201d) at all relevant t imes . \n15. Defendants Lipps and Seim are collectively referred to herein as the \u201cIndividual  \nDefendants.\u201d  Defendant Omnicell and the Individual Defendants are collectively referred to  herein as \nthe \u201cDefendants.\u201d  \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n9. Plaintiff is , and has been continuously since January 2010 , a holder of National \nOilwell Varco  common stock .     \n10. National Oilwell Varco  is a corporation organized under the laws of the State of \nDelaware .  The Company\u2019s last fiscal year ended December 31 , 201 5.  As of April 1 , 2016 , it \nhad 377,066,012  shares of  common stock issued and outstanding .  The Company\u2019s common  \nstock is traded on the New York Stock Exchange  under the symbol \u201c NOV .\u201d  National Oilwell  Case 2:16-cv-01859-JS   Document 1   Filed 04/19/16   Page 2 of 53 \n Varco  is a provider in the design, manufacture and sale of equipment and components used in oil \nand gas drilling, completion and production operations, and the provision of oilfield services to \nthe upstream oil and gas industry . \nWRONGFUL ACTS AND OMISSION S \n11. National Oilwell Varco  has scheduled an annual shareholder meeting for May 18 , \n2016 .  It furnished the proxy statement  for this annual meeting (\u201cProxy Statement\u201d) to \nstockholders on or about  April 11 , 2016  to solicit their proxies for four proposals .  \n12. SEC regulation 17 C.F.R. \u00a7 240.14a -3(a), requires that public companies may not \nsolicit stockholder votes without furnishing a proxy statement \u201c conta ining the information  \nspecified in Schedule 14A.\u201d   \n13. Item 10(a)(1)  of Schedule 14A  require s that \u201c [i]f actio n is to be taken with respect \nto any plan pursuant to which cash or noncash compensa tion may be paid or distributed,\u201d the \nproxy statement soliciting this vote must \u201c[d] escribe briefly the material features of the plan \nbeing acted upon, identify each class of persons who will be eligible to participate therein, \nindicate the approximate number of persons in each such class, and state the basis of such \nparticipation. \u201d  \n14. Proposal 4  of the Proxy Statement at issue  here, concerning amendments to the \nPlan, failed t o disclose the classes of  eligible participants, their approximate number, and the \nbases of their par\nOnly answer with the company defendants names.",
        "output": "National Oilwell Varco, Inc",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of CoLucid  common stock. Case 1:17-cv-10197   Document 1   Filed 02/03/17   Page 2 of 20 3 9. Defendant CoLucid  is a Dela ware corporation and maintains its principal \nexecutive offices at  222 Third Street , Cambridge, Massachusetts 02142.  CoLucid \u2019s common \nstock is traded on the NasdaqGM  under the ticker symbol \u201c CLCD .\u201d \n10. Defendant Thomas P. Mathers (\u201c Mathers \u201d) has served as  a director  and Chief \nExecutive Officer (\u201cCEO\u201d)  of CoLucid  since 2011 .  \n11. Defendant  Art Pappas  (\u201cPappas \u201d) is a director and Chairman of the Board of \nCoLucid .  According to the  Company\u2019s website, Pappas is Chair of the Nominating & Corporate \nGovernance Committee  and a member of the Compensation Committee .  Eli Lilly owns a non-\ncontrolling limited liability company membership interest, which represents approximately 29% \nof the economic interest, in a fund of funds that owns non- controlling limited partnership \nintere sts in investment funds that own Company s hares, including a non- controlling limited \npartnership interest, which represents approximately 12% of the economic interest, in A.M. Pappas Lif e Science Ventures III, L.P. (\u201cPappas Life Science Ventures\u201d) .  Pappas  is the \nManaging Partner of Pappas Capital, LLC ( \u201cPappas Capital\u201d) , which manages a series of venture \ncapital funds, including Pappas Life Science Ventures, and Pappas has an ownership interest in such fund.  Pappas Life Science Ventures  and Pappas Capital  have entered into tender and \nsupport agreements, pursuant to which they have agreed to tender their Company shares in the \nTender O ffer.   \n12. Defendant  Martin Edwards (\u201c Edwards \u201d) is a director of CoLucid .  According to \nthe Company\u2019s website,  Edwards is a memb er of the Audit Committee and the Nominating & \nCorporate Governance Committee.  \n13. Defendant Alison Lawton (\u201cLawton \u201d) is a director of CoLucid .  According to the \nCompany\u2019s w\nIndividual defendants:",
        "output": "Thomas P Mathers,Art Pappas,Martin Edwards,Alison Lawton,Mark Corrigan,Luc Marengere,Marvin White",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n9. Plaintiff  is, and has been at all relevant times, the owner of Telaria common  stock  \nand has held such stock  since prior to the wrongs complained of herein.  \n10. Individual Defendant Paul Caine has served as a director of the Company since \n2014 and the Company\u2019s Executive  Chairman since 2017.  \n11. Individual Defendant Doug Knopper has served as a member  of the Board  since \n2018.  Case 1:20-cv-01010   Document 1   Filed 02/05/20   Page 3 of 154 12. Individual Defendant Warren Lee  has served as a member of the Board since  \n2006. \n13. Individual Defendant Rachel Lam  has served as a member of the Board since \n2018.  \n14. Individual Defendant James Rossman  has served as a member of the Board since  \n2018. \n15. Individual Defendant Robert Schechter  has served as a  member of the Board since \n2013. \n16. Individual Defendant Kevin Thompson has served as a member of the Board \nsince 2017.  \n17. Individual Defendant Mark Zagorski  has served as a member of the Board since  \n2017 and is the Company\u2019s Chief Executive Officer . \n18. Defendant Telaria  is incorporated in Delaware and maintains its principal offices \nat 222 Broadway, New York, New York 10038.   The Company \u2019s common s tock trades  on the  \nNew York  Stock Exchange under the symbol \u201c TLRA .\u201d \n19. The defendant s identified in paragraphs 10- 17 are collectively r eferred to as the \n\u201cIndividual Defendants \u201d or the \u201c Board. \u201d \n20. The defendant s identified in paragraphs  10-18 are collectively r eferred to as the \n\u201cDefendants. \u201d \nSUBSTANTIVE ALLEGATI ONS  \nA. The Proposed Transaction   \n21. Telaria provides a software platform for publishers to manage and monetize video \nadvertising in the United States. The company offers publishers with real-time analytics, data, \nand decisioning tools to control their video advertising business, as well as a monetization Case 1:20-cv-01010   Document 1   Filed 02/05/20   Page 4 of 155 solution to optimize yield across a publisher's supply of digital video inven\nOnly answer with the company defendants names.",
        "output": "Telaria, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " on the summons. \n-t If this attachment is used, insert the following statement in the plaintiff or defendant box on the summons: \"Additional Parties \nAttachment form is attached.\" \nList additional parties (Check only one box. Use a separate page for each type of party.): \nD Plaintiff IZI Defendant 0 Cross-Complainant D Cross-Defendant \nMICHAEL S. DELL; ZANE ROWE; EGON DURBAN; WILLIAM D. GREEN; MARCY S. KLEVORN; \nKHOZEMA Z. SHIPCHANDLER; MORGAN STANLEY & CO. LLC; GOLDMAN SACHS & CO. LLC; \nCITIGROUP GLOBAL MARKETS INC.; MERRILL LYNCH, PIERCE, FENNER & SMITH INC.; \nBARCLAYS CAPITAL INC.; CREDIT SUISSE SECURITIES (USA) LLC; RBC CAPITAL MARKETS, \nLLC; UBS SECURITIES LLC; WELLS FARGO SECURITIES, LLC; KEYBANC CAPITAL MARKETS \nINC.; WILLIAM BLAIR & CO., LLC; MISCHLER FINANCIAL GROUP, INC.; SAMUEL A. RAMIREZ \n& CO., INC.; SIEBERT CISNEROS SHANK & CO., LLC; WILLIAMS CAPITAL GROUP, L.P. \nForm Adopted for Mandalory Ue:s \nJudiciaJ Council of California \nSUIJ\"200(A) [Re>. January 1, 2007] ADDITIONAL PARTIES ATTACHMENT \nAttachment to Summons Page 2 of 2 \nPage 1 o11. 1 JOHN T. JASNOCH (CA 281605) \nSCOTT +SCOTT ATTORNEYS AT LAW LLP \n2 600 W. Broadway, Suite 3300 \n3 San Diego, CA 92101 \nTelephone: 619-233-4565 \n4 Facsimile: 619-233-0508 \njj asnoch@scott -scott. com \n5 \nCounsel for Plaintiff Jason Hill \n6 \n[Additional counsel listed on signature page.] \n7 \n8 FILED \nSan Francisco COunty Superior Coutt \nJUN L4 2019 \n9 SUPERIOR COURT OF THE STATE OF CALIFORNIA \nCOUNTY OF SAN FRANCISCO \n10 \nJASON HILL, Individually and on Behalf of All Case No. c G c WI' , 9 .... 5 r. 6 r 5 0 \n11 Others Similarly Situated, \n12 Plaintiff, \n13 vs. \n14 PIVOTAL SOFTWARE, INC.; ROBERT l\\1EE; \nCYNTHIA GAYLOR; PAUL MARITZ; CLASS ACTION \nCOMPLAINT FOR VIOLATIONS OF \nTHE SECURITIES ACT OF 1933 \n15 MICHAELS. DELL; ZANE ROWE; EGON DEMAND FOR JURY TRIAL \nDURBAN; WILLIAM D. GREEN; MARCY S. \n16 KLEVORN; KHOZEMA Z. \nSHIPCHANDLER; MORGAN STANLEY & \n17 CO. LLC; GOLDMAN SACHS & CO. LLC; \nCITIGROUP GLOBAL MARKETS INC.; \n18 \nIndividual defendants:",
        "output": "Robert Mee,Cynthia Gaylor,Paul Maritz,Michael Dell,Zane Rowe,Egon Durban,William D Green,Marcy S Klevorn,Khozema Z Shipchandler",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n11. Plaintiff Eric Ollila purcha sed B&W stock as described in the attached certification \nand suffered damages as a result of the securities fraud alleged herein. \nCase 3:17-cv-00109   Document 1   Filed 03/03/17   Page 4 of 29 \n- 4 - 12. Defendant Babcock & Wilcox Ente rprises, Inc. is incorporated in Delaware and has \nits headquarters in this District .  Shares of B&W stock trade on the NYSE under the ticker symbol \n\u201cBW.\u201d \n13. Defendant E. James Ferland (\u201cFerland\u201d) is the Company\u2019s Chairman of the Board of \nDirectors (the \u201cBoard\u201d) and Chief Executive Officer. \n14. Defendant Jenny L. Apker (\u201cApker\u201d) is the Company\u2019s Senior Vice President and \nChief Financial Officer. \n15. Defendants Ferland and Apker (collectively, the \u201cIndividual Defendants\u201d), because of \ntheir positions with the Compa ny, possessed the power and authority  to control the contents of \nB&W\u2019s quarterly reports, press re leases, and presentations to securities analysts, money and \nportfolio managers, and investors, i.e., the market.  They were provided with copies of the \nCompany\u2019s reports and press releases  alleged herein to be misleading prior to or shortly after their \nissuance and had the ability and opportunity to preven t their issuance or cause them to be corrected.  \nBecause of their positions with the Company and th eir access to material information available to \nthem but not to the public, the Individual Defenda nts knew that the adverse facts specified herein \nhad not been disclosed to and were being co ncealed from the public and that the positive \nrepresentations being made were then materially false and mislead ing.  The Individual Defendants \nare liable for the false statements pleaded herein. \nFRAUDULENT SCHEME AND COURSE OF BUSINESS \n16. Defendants are liable for: (a) making false statements; or (b) failing to disclose \nadverse facts known to them about B&W.  Defendan ts\u2019 fraudulent scheme and course of business \nthat operated as a fraud or deceit  on purchasers of B&W stock was \nOnly answer with the company defendants names.",
        "output": "Babcock & Wilcox Enterprises, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  ................................ ................................ ................................ ................................ ........  4 \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n9. Plaintiff is an individual  citizen of the State of Massachusetts .  He is , and at all \ntimes relevant hereto, ha s been a MRVC stockholder . \n10. Defendant MRVC  is a Delaware corporation and m aintains its principal executive \noffices at 20520 Nordhoff Street, Chatsworth, CA 91311 .  MRVC \u2019s common stock is traded on \nthe Nasdaq under the ticker symbol \u201c MRVC. \u201d  \n11. Defendant  Ken Traub (\u201cTraub\u201d)  has been a director at all relevant times \nand is Chairman o f the Board .   \n12. Defendant  Robert Pons (\u201cPons\u201d)  has been a director at all relevant times and \nis Vice -Chairman of the Board.  \n13. Defendant  Mark J. Bonney  has been a director at all relevant times.  He is \nalso President and Chief Executive Officer  (\u201cCEO\u201d) of the Company . \n14. Defendant  Jeannie H. Diefenderfer  (\u201cDiefenderfer \u201d) has been a director at all \nrelevant times.   \n15. Defendant  Brian Bellinger  (\u201cBellinger \u201d) has been a director at all relevant times .   \n16. Defendant  Jeffrey Tuder  (\u201cTuder \u201d) has been a director at all relev ant times . \n17. The defendants  identified  in paragraphs  12 through  17 are collectively  referred  to \nherein as the \u201cDirector Defendants\u201d or the \u201cIndividual Defendants.\u201d  \n18. Defendant  Parent  is a Delaware  corporation  and a party to the Merger  Agree ment.   \n19. Defendant  Merger Sub is a Delaware  corporation,  a wholly -owned  subsidi ary of \nParent, and a party to the Merger Agree ment.   \nJURISDICTION AND VENUE  \n20. This Court has subject matter jurisdiction pursuant to Section 27 of the Exchange \nAct (15 U.S.C. \u00a7 78aa) and 28 U.S.C. \u00a7 1331 (federal question jurisdiction) as Plaintiff alleges Case 2:17-cv-05434   Document 1   Filed 07/24/17   Page 4 of 27   Page ID #:4 \n- 5 - \nCLASS ACTION COMPLAINT  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n violations of Sections 14(e) and Section 20(a) of the Exchange Act.  This action is not a collusive \none to confer jurisdiction on a court",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n19. Plaintiff Mark Habelt, as set forth in his Certification filed contemporaneously \nherewith, acquired shares of iRhythm common stock at artifi cially inflated prices, and has been \ndamaged.  \n20. Defendant iRhythm Technologies, Inc. is incorporated under the laws of the State \nof Delaware, with its principal place of business at 699 8th Street, Suite 600, San Francisco, CA \n94103. Its common stock trades on the NASDAQ stock exchange under the symbol IRTC. \n21. Defendant Kevin M. King was, from July 2012 until approximately January 12, \n2021, iRhythm\u2019s President, Chief Executive Officer, and a member of the Company\u2019s Board of Directors. Mr. King remains a member of the Company\u2019s Board of Directors. \n22. Defendants King is named as a Defendant for violations of all counts asserted \nherein, and is sometimes referred to as the \u201cIndividual Defendant.\u201d The Individual Defendant, because of his positions with the Company, poss essed the power and authority to control the \ncontents of the Company\u2019s reports to the SEC, press releases and presentations to securities analysts, money and portfolio managers, and the investing public, i.e. , the market. The Individual \nDefendant was provi ded with copies of the Company\u2019s reports and press releases alleged herein \nto be misleading prior to, or shortly after, their issuance and had the ability and opportunity to prevent their issuance or cause them to be corrected. Because of his positions and  access to \nmaterial, non -public information available to him, the Individual Defendant knew that the adverse \nfacts specified herein had not been disclosed to, and were being concealed from, the public, and that the positive representations that were being made were then materially false and/or misleading. The Individual Defendant is therefore liable for the misstatements and omissions plead \nherein.  \n\nIndividual defendants:",
        "output": "Kevin M King",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " Case 2:16-cv-02683   Document 1   Filed 11/22/16   Page 5 of 27 \n 6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  26. Plaintiffs purchased or held Facebook stock during the Class Period, and suffered damages as a result of the federal securities law violations and false and/or misleading statements and/or material omissions alleged herein. 27. Defendant Facebook, Inc. (\u201cFacebook\u201d) is a publicly traded U.S. company incorporated in Delaware, with its principal place of business at 1 Hacker Way, Menlo Park, CA 94025. 28. Defendant Mark Zuckerberg is the founder and Chief Executive Officer of Facebook, and during the Class Period sold millions of shares of the Company, while in possession of adverse undisclosed information about the Company. 29. Defendant David Wehner is the Chief Financial Officer of the Company and sold tens of thousands of shares of Facebook stock during the Class Period, while in possession of adverse undisclosed information about the Company. 30. Defendant Sharon Sandburg is the Chief Operating Officer of the Company and sold hundreds of thousands of shares of Facebook stock during the Class Period, while in possession of adverse undisclosed information about the Company.  31. Defendant Christopher Cox is the Chief Product Officer of the Company and sold tens of thousands of shares of Facebook stock during the Class Period, while in possession of adverse undisclosed information about the Company. 32. Defendant Michael Todd Schroepfer is the Chief Technology Officer and sold tens of thousands of shares of Facebook stock during the Class Period, while in possession of adverse undisclosed information about the Company.  33. Defendant Jas Athwal is the Chief Accounting Officer of the Company and sold thousands of shares of Facebook stock during the Class Period, while in possession of adverse undisclosed information about the Company.  Case 2:16-cv-02683   Document 1   Filed 11/22/16   Page 6 of 27 \n 7 1 2 3 4 5 6 7 8 9 10\nIndividual defendants:",
        "output": "Mark Zuckerberg,David M. Wehner,Sheryl Kara Sandberg,Christopher Cox,Michael Todd Schroepfer,Jas Athwal",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n22. Plaintiff, as  set forth in the attached Certification, acquired Chipotle  securities at \nartificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosures.  \n23. Defendant Chipotle  is incorporated in  Delaware , and the Company \u2019s principal \nexecutive offices are located at 1401 Wynkoop Street, Suite 500, Denver, Colorado 80202 .  \nChipotle \u2019s common stock trades on the NYSE  under the ticker symbol \u201c CMG.\u201d \n24. Defendant  M. Steven Ells (\u201cElls\u201d)  served as  the Company \u2019s Co-Chief Ex ecutive \nOfficer  (\u201cCEO\u201d)  with Defendant Montgomery F. Moran (\u201cMoran\u201d) from 2009 until December \n2016, and as sole CEO since December 2016.   Case 1:17-cv-01760   Document 1   Filed 07/20/17   USDC Colorado   Page 6 of 24 \n7 \n 25. Defendant Moran  served as the Company\u2019s Co -CEO  with Defendant Ells from \n2009 until December 12, 2016 .  \n26. Defendant John R. Hartung (\u201cHartung\u201d)  has served at all relevant times as the \nCompany\u2019s Chief Financial Officer  and Principal Accounting Officer.  \n27. The Defendant s referenced above in \u00b6\u00b6 24-26 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \n\nOnly answer with the company defendants names.",
        "output": "Chipotle Mexican Grill, Inc",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Misonix stocks and has held such stocks since prior to the wrongs complained of herein. 10. Individual Defendant Patrick J. Beyer has served as a member of the Board since 2021.  11. Individual Defendant Michael Koby has served as a member of the Board since 2019. 12. Individual Defendant Paul LaViolette has served as a member of the Board since 2019. 13. Individual Defendant Thomas M. Patton has served as a member of the Board since 2015.  14. Individual Defendant Stravros Vizirgianakis has served as a member of the Board since 2013 and is the Company\u2019s President and Chief Executive Officer. Case 2:21-cv-05127   Document 1   Filed 09/15/21   Page 3 of 16 PageID #: 3 \n4 15. Defendant Misonix a Delaware corporation and maintains its principal offices at 1938 New Highway, Farmingdale, New York 11735.  The Company\u2019s stock trades on the NASDAQ Stock Exchange under the symbol \u201cMSON.\u201d 16. The defendants identified in paragraphs 10-14 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 17. The defendants identified in paragraphs 10-15 are collectively referred to as the \u201cDefendants.\u201d ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n7. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Accelerize common stock. \n8. Defendant Accelerize is a Delaware corporation and maintains its principal \nexecutive offices at  20411 SW Birch Street, Suite 250, Newport Beach, California 92660.  \nAccelerize \u2019s common stock is traded on the OTCQB Market  under the ticker symbol \u201c ACLZ .\u201d \n9. Defendant Brian Ross (\u201cRoss\u201d)  is Chief Executive Officer and a director of the \nCompany.  \n10. Defendant Gre g Akselrud (\u201cAkselrud\u201d) is a director of the Company . \n11. Defendant Mario Marsillo (\u201cMarsillo\u201d)  is a director of the Company.     Case 1:19-cv-01086-UNA   Document 1   Filed 06/12/19   Page 2 of 10 PageID #: 2 \n 3 12. The defendants identified in paragraphs 9 through 11 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \nCLASS ACTION ALLEGATIONS  \n13. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Accelerize (the \u201cClass \u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity r elated to or affiliated with any defendant. \n14. This action is properly maintainable as a class action.  \n15. The Class is so numerous that joinder of all members is impracticable.  As of May \n20, 2019, there were approximately 66,179,709 shares of Accelerize common stock outstanding, \nheld by hundreds, if not thousands, of individuals and entities scattered throughout the country.  \n16. Questions of law and fact are common to the Class, i ncluding, among others, \nwhether defendants violated the 1934 Act and whether defendants  will irreparably harm plaintiff \nand the other members of the Class if defendants \u2019 conduct  complained of herein continues . \n17. Plaintiff is committed to prosecuting this action and has retained competent counsel \nexperienced in litigation of this nature.  Plain tiff\u2019s  claims are typical of the claims of the other \nmembers of the Class an\nOnly answer with the company defendants names.",
        "output": "Accelerize Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff is, and has been at all times relevant hereto, a stockholder of MuleSoft.   \n12. MuleSoft is a corporation organized and existing under the laws of the State of \nDelaware.  It maintains its principal executive offices at 77 Geary Street , Suite 400, San Francisco, Case 4:18-cv-02071-DMR   Document 1   Filed 04/05/18   Page 3 of 141 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n30 \n31 \n32  \n 4 Case No. 3:18 -cv-02071  \nCOMPLAINT FOR VIOLAT ION OF THE FEDERAL S ECURITIES LAWS  California, 94108.  MuleSoft common stock is listed for public trading on the New York Stock \nExchange under the ticker symbol \u201cMULE.\u201d  MuleSoft is named as a defendant herein solely for the \npurpose of providing full and complete  relief.  \n13. Defendant Mark Burton has served as a director of the Company since January 2009.  \n14. Defendant Michael Capellas has served as a director of the Company since June 2015.  \n15. Defendant Steve n Collins has served as a director of the Company since July 2014 . \n16. Defendant Gary Little has served as a director of the Company since August 2006.  \n17. Defendant Ravi Mhatre has served as a director of the Company since May 2007.  \n18. Defendant Marcus Ryu has served as a director of the Company since December 2017.  \n19. Defendant Gre g Schott has served as Chief Executive Officer of the Company since \nFebruary 2009 and as Chairman and a director of the Company since March 2009.  \n20. Defendant Yvonne Wassenaar has served as a director of the Company since \nDecember 2017.  \n21. Defendant Ann Winblad has served as a director of the Company since September \n2006.  \n22. The Defendants referred to in paragraphs  13-21 are collectively referred to herein as \nthe \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d  \n23. Defendants MuleSoft and the Individual Defendants are collectively referred to as the \n\u201cDefendants.\u201d  \n24. Salesforce, a non -party, provides the number one customer relationship managem",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n6. Plaintiff, as set forth in the accompanying Certification, purchased Northern Dyn asty\u2019s \nsecurities at artificially inflated prices during the Class Period and was damaged upon the \nrevelation of the alleged corrective disclosure.  Case 1:20-cv-05917   Document 1   Filed 12/04/20   Page 2 of 22 PageID #: 2 \n \n3 7. Defendant Northern Dynasty engages in the exploration of mineral properties in the \nUnited States. Its princi pal mineral property is the Pebble copper -gold-molybdenum project \ncomprising 2,402 mineral claims that covers an area of approximately 417 square miles located \nin southwest Alaska (the \u201cPebble Project\u201d). Northern Dynasty is incorporated in British \nColumbia , Canada with its principal executive offices located at 15th Floor, 1040 West Georgia \nStreet, Vancouver, British Columbia, Canada V6E 4H1. The Company\u2019s securities are traded on \nNew York Stock Exchange (\u201cNYSE\u201d) under the ticker symbol \u201cNAK.\u201d  \n8. Defendant Ronald William Thiessen (\u201cThiessen\u201d) has served as Northern Dynasty\u2019s \nChief Executive Officer (\u201cCEO\u201d), President, and Director throughout the Class Period.  \n9. Defendant Mark C. Peters (\u201cPeters\u201d) has served as Northern Dynasty\u2019s Chief Financial \nOfficer (\u201cCFO\u201d) since April 2019.  \n10. Defendant Marchand Snyman (\u201cSnyman\u201d) served as Northern Dynasty\u2019s Chief Financial \nOfficer (\u201cCFO\u201d) from August 2008 until April 2019.  \n11. Defendant Tom Collier (\u201cCollier\u201d) served as CEO of Pebble Partnership Limited, a \nsubsidiary o f the Company, until September 23, 2020.  \n12. Defendants Thiessen, Peters , Synman,  and Collier are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \n13. Each of the Individual Defendants:  \n(a) directly participated in the management of the Company;  \n(b) was directly involved in the day -to-day operations of the Company at the \nhighest levels;  \n(c) was privy to confidential proprietary information concerning the \nCompany and its business and operations;  Case 1:20-cv-05917   Document 1   Filed 12/04/",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  at any point in the process.   Moreover, the Board did not \neven require a go -shop period, accepting, instead, a w eak \u201cwindow shop\u201d period of thirty days.  \n7. Instead , the Board has entered into the Proposed Transaction  to procure for \nthemselves and senior management of the Company significant and immediate benefits with no Case 3:18-cv-00535-MPS   Document 1   Filed 03/29/18   Page 2 of 33 \n- 3 - thought to the  Company\u2019s public stockholders .  For instance, pursuant to the terms of the Merger \nAgreement, upon the consummation of the Proposed Transaction , Company Board Members and \nexecutive officers will be able to exchange all Company equity awards for the merger \nconsideration .  Moreover, certain Directors and other insiders will also be the recipients of \nlucrative change -in-control agreements, triggered upon the termination of their employment as a \nconsequence of the consummation of the Proposed Transaction . \n8. In fact , Defendant Billy Bishop , CEO of  Blue Buffalo, negotiated not only retention \nof employment with the surviving entity, but a substantial pay raise as well, all while negotiations \nto achieve the best possible deal for the stockholders of the Company should have been happening.   \n9. Defendants breached their fiduciary duties to the Company\u2019s stockholder s by \nagreeing to t he Proposed Transaction  which undervalues Blue Buffalo  and is the resul t of a flawed \nsales process.   \n10. As part of such a process, the Board and Company agreed to an onerous and \npreclusive no solicitation clause , that , after a short 30 -day \u201c window shop period \u201d, the Company \ncannot terminate the Proposed Transaction should a third party offer a deal that the Board considers \nto be a superior offer.   This is particularly prejudicial give n the lack of any actual market check \nprior to the Merger Agreement being signed.  \n11. In violation of sections 14(a) and 20(a) of the Securities and Exchange Act of 1934 \n(the \u201cExchange Act \u201d), and in violation of",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n9. Plaintiff is, and has been at all times relevant hereto, a continuous stockholder of \nGeneral.  \n10. Defendant General is a Delaware corporation with its principal executive offices \nlocated at 39 East Union Street, Pasadena, California 91103.  General is a leading specialty rental services company.  General\u2019s common stock is traded on the NASDAQ Global Sele ct Market \nunder the ticker symbol \u201cGFN.\u201d   \n11. Defendant Ronald F. Valenta (\u201cValenta\u201d) has been Chairman of the Board since Case 1:21-cv-00677-UNA   Document 1   Filed 05/10/21   Page 3 of 17 PageID #: 34 June 2014, Executive Chairman of the Board since January 2018, and a director of the Company \nsince its inception.  Defendant Valenta was previously Chief Executive Officer (\u201cCEO\u201d) of the \nCompany since its inception through December 2017. \n12. Defendant James B. Roszak (\u201cRoszak\u201d) has been Lead Independent Director since \nJune 5, 2014, and a director of the Company since November 2005.   \n13. Defendant Susan L. Harris (\u201cHarris \u201d) has been a director of the Company since \nDecember 2008.    \n14. Defendant Larry D. Tashjian (\u201cTashjian\u201d) has been a director of the Company since \nFebruary 2014.   \n15. Defendant William H. Baribault (\u201cBaribault\u201d) has been a dir ector of the Company \nsince December 2015.  \n16. Defendant Manuel Marrero (\u201cMarrero\u201d) has been a director of the Company since \nNovember 2005.  \n17. Defendant Douglas B. Trussler (\u201cTrussler\u201d) has been a director of the Company \nsince December 2017.  \n18. Defendant Jody E. Mill er (\u201cMiller\u201d) has been President of the Company since \nJanuary 2017, CEO since January 2018, and a director of the Company since December 2017.  \nDefendant Miller was also Executive Vice President (\u201cEVP\u201d) of the Company from June 2015 to \nJanuary 2017.  \n19. Defend ants identified in paragraphs 11 to 18  are collectively referred to herein as \nthe \u201cBoard\u201d or the \u201cIndividual Defendants.\u201d  \n \nThe Proposed Transaction  \n20. On April 15, 2021, General issued a press release announcing\nOnly answer with the company defendants names.",
        "output": "General Finance Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n11. Plaintiff Mohammad Uddin, as set forth in the accompanying cert ification, \nincorporated by reference here in, purchased Conn\u2019s securities d uring the Class Period, and \nsuffered damages as a result of t he federal securities law viol ations and false and/or misleading \nstatements and/or material  omissions alleged herein.  \n12. Defendant Conn\u2019s is incorporated under the laws of Delaware wit h its principal \nexecutive offices located in The Woodlands, Texas. Conn\u2019s commo n stock trades on the \nNASDAQ exchange under the symbol \u201cCONN.\u201d \n13. Defendant Norman L. Miller (\u201cMill er\u201d) was the Company\u2019s Chief E xecutive \nOfficer (\u201cCEO\u201d) and Chairman of t he Board at all relevant times . \n14. Defendant George L. Bchara (\u201cBchara\u201d) was the Company\u2019s Chief F inancial \nOfficer (\u201cCFO\u201d) at a ll relevant times. \n15. Defendants Miller and Bchara (collectively the \u201cIndividual Defe ndants\u201d), because \nof their positions with the Co mpany, possessed the power and au thority to control the contents of \nthe Company\u2019s reports to the SEC, press releases and presentati ons to securities analysts, money \nand portfolio managers and institutional investors, i.e., the market.  The Individual Defendants \nwere provided with copies of the Company\u2019s reports and press re leases alleged herein to be \nmisleading prior to, or shortly after, their issuance and had t he ability and opportunity to prevent \ntheir issuance or cause them to be corrected.  Because of their  positions and access to material \nnon-public information available to them, the Individual Defend ants knew that the adverse facts \nspecified herein had not been disclosed to, and were being conc ealed from, the public, and that \nthe positive representations which were being made were then ma terially false and/or \nmisleading.  The Individual Defe ndants are liable for the false  statements pleaded herein.  \n\nOnly answer with the company defendants names.",
        "output": "Conn's, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n5. Plaintiff Dagan Investments LLC, as set forth in the certification attached hereto and \nincorporated by reference herein, purchased FHS ADSs directly in and traceable to the IPO and has \nbeen damaged thereby.  \n6. Defendant FHS, incorporated in the Cayman Islands and headquartered in Yunnan \nProvince, operates private high schools in Western China and provides for -profit tutoring services.  \nThe Company\u2019s ADSs trade in New York on t he New York Stock Exchange (\u201cNYSE\u201d) under the \nticker symbol \u201cFHS.\u201d  Each FHS ADS represents three Class A ordinary shares of the Company.  \nThe Company maintains a dual -class voting structure designed to concentrate control over the \nCompany in the hands of insiders out of proportion with their economic stake in FHS.  The \nCompany has Class A and Class B ordinary shares, which have the same rights except that Class A \nshares are not convertible and entitle holders to one vote per share, while Class B shares are  \nconvertible into Class A shares and entitle holders to 20 votes per share.  \n7. Defendant Shaowei Zhang (\u201cZhang\u201d) founded FHS and has served as FHS\u2019s Chief \nExecutive Officer (\u201cCEO\u201d) and Chairman since September 2018.  Defendant Zhang, his spouse Yu \nWu, and Lon gwater Topco B.V. beneficially owned all of FHS\u2019s issued Class B ordinary shares at \nthe time of the IPO.  Either directly or through affiliated investment vehicles, Zhang beneficially \nowned 47% of FHS ordinary shares prior to the IPO, and, after the IPO, c ontinued to own 38% of all Case 1:22-cv-03831   Document 1   Filed 05/11/22   Page 3 of 25 \n- 3 - FHS ordinary shares (both Class A and Class B) entitling him to over 65% voting power over the \nCompany (assuming no exercise of the underwriters\u2019 overallotment option). \n8. Defendant Lidong Zhu served as FHS\u2019s Chief Financial Officer  (\u201cCFO\u201d) from \nAugust 2019 until his resignation in October 2021.  He was also an FHS director from the time of \nthe IPO until December 31, 2021. \n9. Defendant Guangzhou Zhao served",
        "output": "['Dagan Investments LLC']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n17. Plaintiff Roei Azar, as set for th in the accompanying Certifica tion incorporated herein \nby reference, purchased Grubhub common stock during the Class P eriod and has been damaged \nthereby. \n18. Defendant Grubhub, headquartered i n Chicago, Illinois, is one o f the nation\u2019s leading \nonline and mobile platforms for restaurant pick-up and delivery  orders.  The Company\u2019s common \nstock is listed on the NYSE under the ticker symbol \u201cGRUB.\u201d \n19. Defendant Matthew Maloney (\u201cMa loney\u201d) is a founder of Grubhub a nd served as its \nCEO throughout the Class Period. \n20. Defendant Adam DeWitt (\u201cDeWitt\u201d) served as Grubhub\u2019s President and Chief \nFinancial Officer (\u201cCFO\u201d) t hroughout the Class Period. \n21. The defendants referenced above i n \u00b6\u00b619-20 are referred to here in as the \u201cIndividual \nDefendants.\u201d  The Individual Defe ndants, because of their posit ions with the Company, possessed \nthe power and authority to control the contents of Grubhub\u2019s qu arterly reports, shareholder letters, \npress releases, and presentations to securities analysts, money  and portfolio managers, and \ninstitutional investors, i.e., the market.  They were provided with copies of the Company\u2019s reports \nand press releases alleged herein to be misleading prior to or shortly after their issuance and had the \nability and opportunity to prevent their issuance or cause them  to be corrected.  Because of their \npositions with the Company, and their access to material non-pu blic information available to them \nbut not to the public, the Individual Defendants knew that the adverse facts specified herein had not \nbeen disclosed to and were being concealed from the public and that the positive representations \nbeing made were then materially false and misleading.  The Indi vidual Defendants are liable for the \nfalse and misleading statements pleaded herein. Case: 1:19-cv-07665 Document #: 1 Filed: 11/20/19 Page 7 of 30 PageID #:1 \n- 7 - 22. Defendants are liable for: (i) ma king false statements; or (ii) \nOnly answer with the company defendants names.",
        "output": "Grubhub, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n11. Plaintiff  Chris Masilionis , as set forth in the attached Certification, \nacquired SLW  securities at artificially inflated prices during the Class Period and was \ndamaged upon the revelation of the alleged corrective disclosures.  \n12. Defendant SLW  provides precious metal streaming service s. SLW  is \nheadquartered in Vancouver , British Columbia, Canada  and trades on the NYSE  \nunder the ticker symbol \u201c SLW .\u201d \n13. Defendant Randy V. J. Smallwood (\u201cSmallwood\u201d) has served as the \nCompany\u2019 s President  since January 2010  and as Chief Executive Officer  (\u201cCEO \u201d) \nfrom April  11, 2011  to the present.  Case 2:15-cv-05146   Document 1   Filed 07/08/15   Page 3 of 15   Page ID #:3 \n- 4 - \nClass Action Complaint for Violation of the Federal Securities Laws  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 14. Defendant Peter Barnes (\u201c Barnes \u201d) served as the C ompany\u2019s CEO from \nthe beginning of the Class Period until his resignation effective April  11, 2011 . \n15. Defendant Gary Brown  (\u201cBrown \u201d) served as the Company\u2019s Chief \nFinanc ial Officer  (\u201cCFO \u201d) throughout the entire Class Period.  \n16.  The defendants referenced above in \u00b6\u00b6 1 3 \u2013 15 are sometimes referred \nto herein as the \u201cIndividual Defendants. \u201d \n17. Defendant SLW  and the Individual Defendants are referred to herein, \ncollectively, as the \u201c Defendants. \u201d \n\nIndividual defendants:",
        "output": "Randy V.J. Smallwood,Peter Barnes,Gary Brown",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n10. Plaintiff is, and has been continuously throughout all times rel evant hereto, the owner \nof WES  common units . \n11. Defendant WES  is a Delaware MLP managed by its general partner, Western Gas \nHoldings, LLC  (\u201cWES GP\u201d) , a Delaware limited liability company that is owned and controlled by Case 1:19-cv-00832   Document 1   Filed 01/28/19   Page 3 of 164  WGP .  WES\u2019s c ommon units trade on the NYSE under the ticker symbol \u201cWES.\u201d  \n12. Defendant Benjamin M. Fink is, and has been at all relevant times, a director of the \nCompany.  Defendant Fink also currently serves as Chairman of the Board.  \n13. Defendant Robin H. Fielder is, and has been at all relevant times, a director of the \nCompany.  Defendant Fielder is also the  President and Chief Executive Officer of the Company .   \n14. Defendant Robert G. Gwin is, and has been at all relevant times, a director of the \nCompany.   \n15. Defendant Steven D. Arnold is, and has been at all relevant times, a director of the \nCompany.  \n16. Defendant Daniel E. Brown is, and has been at all relevant times, a director of the \nCompany.  \n17. Defendant Milton Carroll is, and has been at all relevant times, a director of the \nCom pany.  \n18. Defendant James R. Crane is, and has been at all relevant times, a director of the \nCompany.  \n19. Defendant David J. Tudor is, and has been at all relevant times, a director of the \nCompany.  \n20. Defendant Mitchell W. Ingram is, and has been at all relevant times, a director of the \nCompany.  \n21. The defendants identified in paragraphs 12 through 20 are collectively referred to \nherein as the \u201cBoard\u201d or the \u201cIndividual Defendants,\u201d and together with WES , the \u201cDefendants.\u201d  \n\nOnly answer with the company defendants names.",
        "output": "Western Gas Partners, LP",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n11. Plaintiff Marc Jansen, as set forth in the accompanying certification, incorporated \nby reference herein, purchased IFF securities dur ing the Class Period, and suffered damages as a \nresult of the federal securities law violations and false and/or mislea ding statements and/or \nmaterial omissions alleged herein.  \n12. Defendant IFF is incorporated under the laws of New York with its principal \nexecutive offices located in New York, New York.  IFF\u2019s shares trades on the New York Stock \nExchange (\u201cNYSE\u201d) exchange under the symbol \u201cIFF.\u201d \n13. Defendant Andreas Fibig (\u201c Fibig\u201d) was the President and Chief Executive Officer \nof the Company at all relevant times. \n14. Defendant Richard A. O\u2019L eary (\u201cO\u2019Leary\u201d) was the Ch ief Financial Officer of \nthe Company at all relevant times. \n15. Defendants Fibig and O\u2019Leary, (collect ively the \u201cIndividual Defendants\u201d), \nbecause of their positions with the Company, po ssessed the power and authority to control the \ncontents of the Company\u2019s report s to the SEC, press releases a nd presentations to securities \nanalysts, money and portfolio manage rs and institutional investors, i.e., the market.  The \nIndividual Defendants were provi ded with copies of the Company\u2019s reports and press releases \nalleged herein to be misleading prior to, or shor tly after, their issuance and had the ability and \nopportunity to prevent their issuance or cause them  to be corrected.  Because of their positions \nand access to material non-public information av ailable to them, the Individual Defendants knew \nthat the adverse facts specified herein had not b een disclosed to, and were being concealed from, \nthe public, and that the positive representations wh ich were being made were then materially \nfalse and/or misleading.  The I ndividual Defendants are liable for the false statements pleaded \nherein.  Case 1:19-cv-07536   Document 1   Filed 08/12/19   Page 4 of 23CLASS ACTION COMPLAINT \n4 \nOnly answer with the company defendants names.",
        "output": "International Flavors & Fragrances Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 7. Plaintiff  is, and  has  been  at times  relevant  hereto,  an owner  and  holder  of  common  \nshares  of  Gas  Natural.\n8. Nominal  Defendant  Gas  Natural  is an Ohio  corporation,  with its headquarters  \nlocated  at 1375  East  Ninth  Street,  Suite  3100,  Cleveland,  Ohio  44114.\n9. Defendant  Gregory  J. Osborne  (\u201cDefendant  Osborne \u201d) is the  President  and  Chief  \nExecutive  Officer  of  the  Company  and  has  served  as a Director  of  the  Company  since  September  \n2009.  Defendant  Osborne  was  promoted  to the  position  of  Chief  Executive  Officer  on  May  14,  \n2014  after  his  father,  Richard  M.  Osborne,  was  ousted  as the  Company \u2019s Chief  Executive  Officer  \nand  Chairman.  Upon  information  and  belief,  Defendant  Osborne  is a citizen  of  the  State  of  Ohio.\n10.  Defendant  Michael  B. Bender  (\u201cDefendant  Bender \u201d) has  been a director  since  \nFebruary  2015  and  is the  Chairman  of  the  Governance  and  Nominating  Committee.  Defendant  \nBender  is also  the Corporate  Secretary,  Corporate  Counsel,  and  a Director  of the InterTech  \nGroup,  Inc.  Upon  information  and  belief,  Defendant  Bender  is a citizen  of  the  State  of South  \nCarolina.\n5\nElectronically  Filed  11/03/2016  16:17  / / CV  16 871400  / Confirmation  Nbr.  900876  / CLAHJ\nCase: 1:16-cv-02880-PAG  Doc #: 1-1  Filed:  11/28/16  7 of 71.  PageID #: 1411.  Defendant  James  P. Carney  (\u201cDefendant  Carney \u201d) has  served  as a Director  of  the  \nCompany  since  June  2015  and  is a member  of  the  Audit  Committee  and  the  Governance  and  \nNominating  Committee.  Upon  information  and  belief,  Defendant  Carney  is a citizen  of  the  State  \nof  Ohio.\n12.  Defendant  Richard  K. Greaves  (\u201cDefendant  Greaves \u201d) has  served  as a Director  of  \nthe  Company  since  July  2013.  Defendant  Greaves  serves  on  the  Compensation  Committee  and  as \nthe  Chairman  of  the  Audit  Committee.  Upon  information  and  belief,  Defendant  \nOnly answer with the company defendants names.",
        "output": "Gas Natural, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n10. Plaintiff has owned the common stock of Ge nomic since prior to the announcement of \nthe Proposed Transaction herein complained  of and continues to own this stock. \n11. Genomic is a corporation duly organized a nd existing under the laws of Delaware and \nmaintains its principal offices in Redwood City, Calif ornia.  Genomic is, and at all relevant times \nhereto was, listed and traded on the NAS DAQ Stock Exchange under the symbol \u201cGHDX.\u201d \n12. Defendant Julian Baker has been a memb er of the Board since January 2001. \n13. Defendant Felix Baker, Ph.D. has been  a member of the Board since 2012.  \n14. Defendant Fred Cohen, M.D., D.Phil. has b een a member of the Board since April \n2002. \n15. Defendant Barry P. Flannelly, Pharm.D. has been a member of the Board since April \n2019. \n16. Defendant Henry J. Fuchs, M.D. has been  a member of the Board since September \n2013.  \n17. Defendant Ginger L. Graham has been a member of the Board since 2008. \n18. Defendant Geoffrey M. Parker has been  a member of the Board since June 2016. \n19. Defendant Kimberly Popovits has been the Company\u2019s Chairman, Chief Executive \nOfficer, and President since 2009. \n20. The Defendants referred to in paragraphs 12- 19 are collectively referred to herein as the \n\u201cIndividual Defendants\u201d and/or the \u201cBoard.\u201d \n21. The Defendants referred to in paragraphs 11- 20 are collectively referred to herein as the \n\u201cDefendants.\u201d Case 3:19-cv-05556   Document 1   Filed 09/04/19   Page 4 of 161 \n2 \n3 4 5 6 7 \n8 \n9 \n10 11 12 13 \n14 \n15 16 17 18 19 \n20 \n21 22 23 24 25 \n26 \n27 28 \n  \nCOMPLAINT FOR VIOLATIONS OF SECTIONS 14(a) \nAND 20(a) OF THE SECURITIES EXCHANGE ACT OF 1934 \n- 4 - \nIndividual defendants:",
        "output": "Julian Baker,Felix Baker,Fred Cohen,Barry P Flannelly,Henry J Fuchs,Ginger L Graham,Geoffrey M Parker,Kimberly Popovits",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  including the material terms and conditions of the proposal and the identity of the party \nmakin g the proposal; (iii) \u201cmatching rights\u201d that allow Jazz four (4) days to match any superior \noffer , plus an additional three (3) day period following a material amendment to the terms and \nconditions of a superior offer or the submission of a new offer ; and (iv) a provision requiring Case 3:16-cv-03814   Document 1   Filed 06/27/16   Page 2 of 29 PageID: 2 3 Celator  to pay a termination fee of $ 45.8 million if the Company decides to pursue a competing \noffer.  The collective effect of these provisions is to chill any potential post -deal market check.  \n5. Finally , compounding the unfairness of the  Proposed Transaction, on June 10 , \n2016 , Celator  filed a Recommendation Statement  on Schedule 14D -9 Solicitation/ \nRecommendation Statement  (the \u201cRecommendation Statement \u201d) with the U.S. Securities and \nExchange Commission (\u201c SEC\u201d).  The Reco mmendation Statement , which recommends that \nCelator  stockholders  vote in favor of the Proposed Transaction, omits or misrepresents material \ninformation concerning, among other things: (i) the background of the Proposed Transaction ; (ii) \nthe data and inputs  underlying the financial valuation exercises that purportedly support the so -\ncalled \u201cfairness opinion\u201d provided by Celator\u2019s financial advisor, MTS Securities , LLC (\u201c MTS \nSecurities \u201d); and  (iii) Celator\u2019s financial projections, relied upon by MTS Securitie s.  The failure \nto adequately disclose such material information constitutes a violation of sections 14(a) and \n20(a) of the U.S. Securities and Exchange Act of 1934 (the \u201cExchange Act \u201d) as stockholders  \nneed such information in order to cast a fully -informe d vote in connection with the Proposed \nTransaction.   \n6. In short, the Proposed Transaction is designed to unlawfully divest Celator \u2019s \npublic stockholders  of the Company\u2019s valuable assets without fully disclosing all material \ninformation conce\nIndividual defendants:",
        "output": "Michael R Dougherty,Scott Jackson,Joseph A Mollica,Jean-Pierre Bizzari,RIchard S Kollender,Joseph M Lobacki,Scott Morenstein,Nicole Vitullo",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n15. Plaintiff, as set forth in the attached Certification, acquired Papa John\u2019s  securities \nat artificially inflated prices during the Class Period and was damaged  upon the revelation of the \nalleged corrective disclosures.  \n16. Defendant Papa John\u2019s  is incorporated in Delaware , with principal executive \noffices located at 2002 Papa John\u2019s Boulevard, Louisville, Kentucky 40299 .  Papa John\u2019s \ncommon stock  trade s on the NASDAQ  under the ticker symbol \u201c PZZA \u201d. \n17. Defendant Schnatter  served as Papa John\u2019s  CEO  from April 2011 to December \n2017.  \n18. Defendant  Steve M. Ritchie (\u201cRitchie\u201d) has served as Papa John\u2019s  CEO since \nJanuary 2018  and as its President since July 2015.  \n19. Defendant Lance F. Tucker (\u201cTucker\u201d) has served at all relevant times as Papa \nJohn\u2019s  Chief Financial Officer . \n20. The Defendant s referenced above in \u00b6\u00b6  17-19 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  Case 1:18-cv-07927   Document 1   Filed 08/30/18   Page 4 of 26 \n5 \n 21. The Individual Defendants possessed the power and authority to control the \ncontents of Papa John\u2019s  SEC filings, press releases, and other market communications. The \nIndividual Defendants were provided with copies of Papa John\u2019s  SEC filings and press releas es \nalleged herein to be misleading prior to or shortly after their issuance and had the ability and \nopportunity to prevent their issuance or to cause them to be corrected. Because of their positions \nwith Papa John\u2019s , and their access to material informatio n available to them but not to the public, \nthe Individual Defendants knew that the adverse facts specified herein had not been disclosed to \nand were being concealed from the public, and that the positive representations being made were \nthen materially fals e and misleading. The Individual Defendants are liable for the false \nstatements and omissions pleaded herein.  \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of CEB common stock.  Case 1:17-cv-00220-AJT-MSN   Document 1   Filed 02/24/17   Page 2 of 17 PageID# 2 \n 3 9. Defenda nt CEB is a Delaware corporation and maintains  its principal executive \noffice  at 1919 North Lynn Street, Arlington, Virginia 22209 .  CEB\u2019s common stock is traded on \nthe NYSE  under the ticker symbol \u201cCEB.\u201d \n10. Defendant Thomas  L. Monahan , III (\u201cMonahan \u201d) is a d irector, Chairman of the \nBoard, and Chief Executive Officer (\u201cCEO\u201d) of CEB .   \n11. Defendant Gregor  S. Bailar  (\u201cBailar \u201d) is a director of CEB.  According to the \nCompany\u2019s website, B ailar is Chair of the Audit Committee .   \n12. Defendant Stephen  M. Carter  (\u201cCarter \u201d) is a director  of CEB.  According to the \nCompany\u2019s website,  Carter is a member of the Audit Committee and Chair of the Compensation \nCommittee . \n13. Defendant Gordon  J. Coburn  (\u201cCoburn \u201d) is a director of  CEB .  According to the \nCompany\u2019s website,  Coburn is a membe r of the Audit Committee and Chair of the Nominating \nand Corporate Governance Committee.  \n14. Defendant Kathleen  A. Corbet  (\u201cCorbet \u201d) is a director of  CEB .  According to the \nCompany\u2019s website, Corbet is a member of the Audit Committee .   \n15. Defendant  L. Kevin  Cox (\u201cCox\u201d) is a director of  CEB.  According to the \nCompany\u2019s website,  Cox is a member of the Compensation Committee and a member of the \nNominating and Corporate Governance Committee . \n16. Defendant Daniel  O. Leemon  (\u201cLeemon\u201d ) is a director of  CEB .  According to th e \nCompany\u2019s website,  Leemon is a member of the Compensation Committee and a member of the \nNominating and Corporate Governance Committee . \n17. Defendant  Stacey S.  Rauch  (\u201cRauch \u201d) is a director of  CEB.  According to the \nCompany\u2019s website,  Rauch is a member of the  Audit Committee . Case 1:17-cv-00220-AJT-MSN   Document 1   Filed 02/24/17   Page 3 of 17 PageID# 3 \n 4 18. Defendant Jeffrey  R. Tarr (\u201cTarr\u201d",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " will reach an agreement on any terms, or at all and neither the Offer nor the Merger is conditioned \nupon any executive officer or director of the Compa ny entering into any such \nagreement, arrangement or understanding.  \n  \nId. at 10.  The Recommendation Statement fails, however, to disclose the specific details of all \nemployment and retention -related discussions and negotiations that occurred between Gilead  and \nForty Seven  executive officers and directors, including who participated in all such communications, \nwhen they occurred and their content.  The Recommendation  Statement further fails to disclose \nwhether any of Gilead \u2019s proposals or indications of inte rest mentioned management retention, \nconsulting arrangements, cash, stock and co -investment opportunities, or equity participation in the \ncombined company.  \n44. Communications regarding post -transaction employment and merger -related benefits \nduring the negotiat ion of the underlying transaction must be disclosed to stockholders.  This \ninformation is necessary for stockholders to understand potential conflicts of interest of management Case 3:20-cv-01853-LB   Document 1   Filed 03/16/20   Page 14 of 18 \n- 15 - \nCOMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n \n and the Board, as that information provides illumination concerning motivations  that would prevent \nfiduciaries from acting solely in the best interests of the Company\u2019s stockholders . \n45. The omission of this information renders the statements in the \u201cBackground of the \nOffer and Merger\u201d and \u201c Future Arrangements \u201d sections of the Recommendation Statement false \nand/or materially misleading in contravention of the Exchange Act.  \n46. The Individual Defendants were aware of their duty to disclose the above-referenced \nomitted information and acted negligently (if not deliberately) in failing  to include this information \nin ",
        "output": "['Stephen Bushansky']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has  been continuously throughout all times relevant hereto, the \nowner of  Barnes & Noble  common stock. Case 1:19-cv-01320-UNA   Document 1   Filed 07/16/19   Page 2 of 17 PageID #: 2 \n 3 9. Defendant Barnes & Noble  is a Delaware corporation and maintains it s principal \nexecuti ve offices at 122 Fifth Avenue, New York, New York 10011.  Barnes & Noble \u2019s common \nstock is traded on the New York Stock Exchange  under the ticker symbol \u201c BKS .\u201d \n10. Defendant  Leonard Riggio is  Chairman of the Board of the C ompany. \n11. Defendant George Campbell Jr. is a director of the C ompany. \n12. Defendant Mark D. Carleton is a director  of the C ompany.  \n13. Defendant Scott S. Cowen is a director of the C ompany. \n14. Defendant William T. Dillard II is a director of the C ompany. \n15. Defendant Al Ferrara is a director of the C ompany. \n16. Defendant Paul B. Guenther is a director of the C ompany. \n17. Defendant Patr icia L. Higgins is a director of the C ompany.  \n18. Defendant Irwin D. Simon is a director of the C ompany. \n19. Defendant Kimberly A. Van Der Zon is a director of the C ompany. \n20. The defendants identified in paragraphs 10 through 19 are collectively referred to \nherein a s the \u201c Individual Defendants.\u201d    \n21. Defendant Parent is a Delaware  corporation  and a party to the Merger Agreement.  \n22. Defendant  Merger Sub is a De laware corporation , a wholly- owned subsidiary of \nParent, and a party to the Merger Agreement . \nCLASS ACTION ALLEGATIONS  \n23. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Barnes & Noble  (the \u201cClass\u201d ).  Excluded from the Class are defendants herein and \nany person, firm, trust, corporation, or other entity rela ted to or affiliated with any defendant.  \n24. This action is properly maintainable as a class action.  Case 1:19-cv-01320-UNA   Document 1   Filed 07/16/19   Page 3 of 17 PageID #: 3 \n 4 25. The Class is so numerous that joinder of all",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n6. Plaintiff, as set forth in the accompanying Certification, purchased Northern Dyn asty\u2019s \nsecurities at artificially inflated prices during the Class Period and was damaged upon the \nrevelation of the alleged corrective disclosure.  Case 1:20-cv-05917   Document 1   Filed 12/04/20   Page 2 of 22 PageID #: 2 \n \n3 7. Defendant Northern Dynasty engages in the exploration of mineral properties in the \nUnited States. Its princi pal mineral property is the Pebble copper -gold-molybdenum project \ncomprising 2,402 mineral claims that covers an area of approximately 417 square miles located \nin southwest Alaska (the \u201cPebble Project\u201d). Northern Dynasty is incorporated in British \nColumbia , Canada with its principal executive offices located at 15th Floor, 1040 West Georgia \nStreet, Vancouver, British Columbia, Canada V6E 4H1. The Company\u2019s securities are traded on \nNew York Stock Exchange (\u201cNYSE\u201d) under the ticker symbol \u201cNAK.\u201d  \n8. Defendant Ronald William Thiessen (\u201cThiessen\u201d) has served as Northern Dynasty\u2019s \nChief Executive Officer (\u201cCEO\u201d), President, and Director throughout the Class Period.  \n9. Defendant Mark C. Peters (\u201cPeters\u201d) has served as Northern Dynasty\u2019s Chief Financial \nOfficer (\u201cCFO\u201d) since April 2019.  \n10. Defendant Marchand Snyman (\u201cSnyman\u201d) served as Northern Dynasty\u2019s Chief Financial \nOfficer (\u201cCFO\u201d) from August 2008 until April 2019.  \n11. Defendant Tom Collier (\u201cCollier\u201d) served as CEO of Pebble Partnership Limited, a \nsubsidiary o f the Company, until September 23, 2020.  \n12. Defendants Thiessen, Peters , Synman,  and Collier are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \n13. Each of the Individual Defendants:  \n(a) directly participated in the management of the Company;  \n(b) was directly involved in the day -to-day operations of the Company at the \nhighest levels;  \n(c) was privy to confidential proprietary information concerning the \nCompany and its business and operations;  Case 1:20-cv-05917   Document 1   Filed 12/04/\nOnly answer with the company defendants names.",
        "output": "Northern Dynasty Minerals Ltd",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n10. Plaintiff City of Birmi ngham Firemen\u2019s and Policemen\u2019s Supplemental Pension \nSystem purchased Ryanair ADSs, as set forth in the accompanying certification incorporated herein \nby reference, and has been damaged thereby. \n11. Defendant Ryanair is an airline operator based in Dublin, Ireland.  Its ordinary shares \ntrade on the Dublin Stock Exchange  under the ticker symbol \u201cRYA.\u201d  Its ADSs trade on the Nasdaq \nunder the ticker symbol \u201cRYAAY.\u201d  Each ADS  represents five ordinary shares. \n12. Defendant Michael O\u2019Leary (\u201cO\u2019Leary\u201d) has served as a director of Ryanair since \n1988 and as the Company\u2019s Chief Ex ecutive Officer (\u201cCEO\u201d) since 1994. \n13. Defendant O\u2019Leary made, or caused to be ma de, false and misleading statements that \nartificially inflated the price of Ryanair ADSs.  Defendant O\u2019Leary, because of his positions with the \nCompany, possessed the power and authority to contro l the contents of Ryanai r\u2019s quarterly reports, Case 1:18-cv-10330   Document 1   Filed 11/06/18   Page 4 of 41 \n- 4 - press releases and presentations to securities  analysts, money and portfolio managers and \ninstitutional investors, i.e., the market.  He was provided with copies of the Company\u2019s reports and \npress releases alleged herein to be misleading prior to or shortly after their issuance and had the \nability and opportunity to prevent their issuance or cause them to  be corrected.  Because of his \npositions with the Company, personal participation in  the fraud as detailed herein, and his access to \nmaterial non-public information available to him bu t not to the public, defendant O\u2019Leary knew that \nthe adverse facts specifie d herein had not been disclosed to and were being concealed from the \npublic and that the positive represen tations being made were then ma terially false and misleading.  \nDefendant O\u2019Leary is liable for the false and misleading statements pleaded herein. \nBACKGROUND \n14. Ryanair is an airline operator headquarte red in Dublin, Ireland.  The Company wa\nIndividual defendants:",
        "output": "Michael O'Leary",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n12. Plaintiff is, and has been continuously throughout all times relevant hereto, the owner \nof Meet Group common stock. \n13. Defendant Meet Group is a public company incorporated under the laws of Delaware \nwith principal executive offices located at 100 Union Square Drive, New Hope, PA.  Meet Group\u2019s \ncommon stock is traded on the NasdaqGS under the ticker symbol \u201cMEET.\u201d \n14. Defendant Spencer Rhodes is, and has been at all relevant times, a director of the \nCompany and Chairman of the Board. \n15. Defendant Geoffrey Cook is, and has been at all relevant times, a director of the \nCompany and Chief Executive Officer.   \n16. Defendant Jean Clifton is, and has been at all relevant times, a director of the \nCompany.   \n17. Defendant Christopher Fralic is, and has been at all relevant times, a director of the \nCompany. \n18. Defendant Keith Richman is, and has been at all relevant times, a director of the \nCompany. \n19. Defendant Bedi Singh is, and has been at all relevant times, a director of the Company. Case 1:20-cv-02855   Document 1   Filed 04/06/20   Page 4 of 155  \n 20. Defendant Jason Whitt is, and has been at all relevant times, a director of the \nCompany. \n21. The Defendants identified in paragraphs 14 through 20 are collectively referred to \nherein as the \u201cBoard\u201d or the \u201cIndividual Defendants,\u201d and together with Meet Group, the \n\u201cDefendants.\u201d  \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n12. Plaintiff Paul Ansfield (\u201cPlaintiff\u201d or \u201cAnsfield\u201d) purchased shares of Infoblox \ncommon stock during the Class Period as reflected in his certification and suffered losses as a result of the conduct complained of herein.   Case3:14-cv-02500-VC   Document1   Filed05/30/14   Page4 of 26 \n \n-4- \nCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS  \n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 13. Defendant Infoblox is a global technology company, incorporated in \nDelaware.  Infoblox was founded in Illinois in 1999.  In May 2003, the Company was \nreincorporated in Delaware.  Infobl ox maintain s its headquarters and principal  place of \nbusiness in Santa Clara, California.  Infoblox sells products that manage and protect networks.  Infoblox represents that it provides a broad family of enterprise and service provider -class solutions to over 7,000 enterprises and service providers with a goal of making \ncustomer networks more available, secure, and automated.  Throughout the Class Period, Infoblox traded in an efficient market on the New York Stock Exchange (\u201cNYSE\u201d) under the ticker symbol \u201cBLOX.\u201d  As of February 28, 2014, the Company had over 53.87 million \nshares outstanding. \n14. Defendant Robert Thomas (\u201cThomas\u201d) is and was, at all relevant times, the \nCompany\u2019s Chief Executive Officer (\u201cCEO\u201d), as well as a Infoblox\u2019s President.  Thomas is described as being responsible for \u201cbuilding Infoblox into a highly profitable and valued \nbusiness.\u201d  During the Class Period, Thomas certified the Company\u2019s SEC filings pursuant to Sections 302 and 906 of the Sarbanes -Oxley Act of 2002 (\u201cSOX\u201d).  The document s certified \nby Thomas contain materially false statements and critical omissions that, along with other materially false statements and critical omissions made during the Class P eriod, provided \nshareholders with a highly inaccurate representation of Infobl ox\u2019s financial status.  Thomas \n\nOnly answer with the company defendants names.",
        "output": "Infoblox, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n13. Plaintiff Marisa Marder , as set forth in the accompanying \ncertification, incorporated by reference herein, purchased Campbell  common stock \nat artif icially inflated prices during the Class Period and has been damaged \nthereby.  \n14. Defendant Campbell  is a New Jersey  corporation with its principal \nexecutive offices located at One Campbell Place, Camden, New Jersey 08103 .    \n15. Defendant Denise M. Morrison  (\u201cMorrison \u201d) was the President and \nChief Executive Officer of Campbell  from the beginning of the Class Period \nthrough May 18, 2018 .   \n16. Defendant Anthony P. DiSilvestro  (\u201cDiSilvestro \u201d) is and, throughout \nthe Class Period, was  the Senior Vice President and Chie f Financial Officer of \nCampbell.  \n17. Defendants Morrison and DiSilvestro  are collectively  referred to \nherein  as the \u201cIndividual Defendants.\u201d  The Individual Defendants, because of their \npositions with the Company, possessed the power and authority to control the \ncontents of Campbell \u2019s reports to the SEC, press releases, and presentations to \nsecurities analysts, money portfolio managers , and inst itutional investors, i.e., the \nmarket.  Each Individual Defendant was provided with copies of the Company\u2019s Case 1:18-cv-14385   Document 1   Filed 09/28/18   Page 6 of 25 PageID: 67 \n reports and press releases alleged herein to be misleading prior to, or shortly after, \ntheir issuance and had the ability and opportunity to prevent  their issuance or cause \nthem to be corrected.  Because of their positions and access to material non -public \ninformation available to them, each of these Individual Defendants knew that the \nadverse facts specified herein had not been disclosed to, and were  being concealed \nfrom, the public, and that the positive representations which were being made were \nthen materially false and /or misleading .  \n\nIndividual defendants:",
        "output": "Denise M Morrison,Anthony P DiSilvestro",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  ........................................................................................................................................ 2 \n V. INTRODUCTION AND SUMMARY OF THE ACTIO N ............................................................ 2 \n VI. EVENTS LEADING UP TO THE BEGINNING OF THE CLASS PERIOD ............................ 10 \n \nA. Musk Fails to Timely Disclose His 9+% Stake in Twitter  ................................................12 \n \nB. Musk Fails to Disclose He Had Been Invited to Join the Twitter Board ...........................14 \n \nC. After Unexpectedly Announcing He Would Not Join Its Board, Musk Discloses an Intent \nto Buy Twitter, and Threatens to Go Hostile Through a Tender Offer if Twitter\u2019s Board Does Not Acquiesce  ...........................................................................................................18 \n \nD. Musk Finances the Proposed Buyout in Part by Pledging Billions of Dollars of His Tesla \nStock as Collateral for a L oan From Morgan Stanley, But the Proxy Fails to Disclose the \nFull Risks of Such Loans ...................................................................................................22 \n \nVII. FALSE STATEMENTS DURING THE CLASS PERIOD  ......................................................... 27 \n \nA. Musk\u2019s May 13, 2022 Tweet .............................................................................................28 \n \nB. Musk\u2019s May 14, 2022 Tweet .............................................................................................30 \n \nC. Musk\u2019s May 16, 2022 St atement  .......................................................................................32 \n \nD. Musk\u2019s May 17, 2022 Tweet .............................................................................................33 \n \nE. Musk\u2019s May 21, 2022 Tweets ............................................................................................34 \n \nVIII.  MUSK\u2019S SCIENTER AND MOTIVE AND OPPORTUNITY TO COMMIT FRAUD  ..",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n15. Plaintiff, as set forth in the attached Certification, acquired  Coinbase \nsecurities at artificially inflated prices during the Class Per iod and was damaged \nupon the revelation of the allege d corrective disclosures. \n16. Defendant Coinbase is a Delaware  corporation.  According to its  SEC \nfilings, Coinbase is a \u201cremote -first\u201d company and, accordingly,  does not maintain a \nheadquarters. Coinbase\u2019s Class A common stock trades in an effi cient market on the \nNASDAQ under the trading symbol \u201cCOIN\u201d. \n17. Defendant Armstrong has served as Coinbase\u2019s CEO and a Director  of \nthe Company at all relevant times.  \n18. Defendant Alesia J. Haas (\u201cHaas\u201d)  has served as Coinbase\u2019s Chie f \nFinancial Officer at all relevant times. \n19. Defendants Armstrong and Haas are  sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \n20. The Individual Defendants possessed the power and authority to control \nthe contents of Coinbase\u2019s SEC filings, press releases, and oth er market Case 1:22-cv-04915   Document 1   Filed 08/04/22   Page 6 of 37 PageID: 67 communications.  The Individual De fendants were provided with c opies of \nCoinbase\u2019s SEC filings and press releases alleged herein to be misleading prior to or \nshortly after their issuance and had the ability and opportunit y to prevent their \nissuance or to cause them to be corrected.  Because of their po sitions with Coinbase, \nand their access to material information available to them but not to the public, the \nIndividual Defendants knew that the adverse facts specified her ein had not been \ndisclosed to and were being conc ealed from the public, and that  the positive \nrepresentations being made were then materially false and misle ading.  The \nIndividual Defendants are liable for the false statements and o missions pleaded \nherein. \n21. Coinbase and the Individual Defendants are collectively referre d to \nherein as \u201cDefendants.\u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the  \nowner of Akorn common stock.  \n9. Defendant Akorn is a Louisiana corporation and maintains its principal executive \noffices at 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045.  Akorn \u2019s common stock is Case 3:17-cv-00350-BAJ-RLB   Document 1    06/02/17   Page 2 of 18 3 traded on the NasdaqGS  under the ticker symbol \u201cAKRX .\u201d \n10. Defendant John N. Kapoor (\u201cKapoor \u201d) is a director of Akorn and has served as \nChairman of the Board since October 1990 .  \n11.   Defendant  Kenneth S. Abramowitz (\u201cAbramowitz \u201d) is a director of Akorn .   \n12.  Defendant Adrienne L. Graves (\u201cGraves \u201d) is a director of Akorn.  \n13.  Defendant Ronald M. Johnson (\u201cJohnson \u201d) has served as a director of Akorn since \nMay 2003 . \n14. Defendant Steven J. Meyer (\u201cMeyer\u201d) has served as a director of Akorn since June \n2009 .   \n15. Defendant Terry A. Rappuhn (\u201cRappuhn\u201d) has served as a director of  Akorn since \nApril 2015.  \n16. Defendant Brian Tambi (\u201cTambi\u201d) has served as a director of Akorn since June \n2009.  \n17. Defendant Alan Weinstein (\u201cWeinstein\u201d) has served as a director of Akorn since \nJuly 2009.  \n18. Defendant Raj Rai (\u201cRai\u201d) was appointed Interim Chief Exec utive Officer (\u201cCEO\u201d) \nof the Company in June 2009, and was appointed CEO in May 2010 . \n19. The defendants identified in paragraphs 10 through 18 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \n20. Defendant Parent  is a German stock corporation  and a party to the Merger \nAgreement .   \n21. Defendant Merger  Sub is a Louisiana corporation , a wholly -owned subsidiary of \nParent , and a Party to the Merger Agreement . Case 3:17-cv-00350-BAJ-RLB   Document 1    06/02/17   Page 3 of 18 4 CLASS ACTION ALLEGATIONS  \n22. Plaintiff brings  this action as a class action o n behalf of h imself and the other public \nstockholders of Akorn  (the \u201cClass\u201d).  Excluded from the Class are defendants herein and any \nperson, f\nIndividual defendants:",
        "output": "John N Kapoor,Kenneth S Abramowitz,Adrienne L Graves,Ronald M Johnson,Steven J Meyer,Terry Allison Rappuhn,Brian Tambi,Alan Weinstein,Rajat Rai",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has  been continuously throughout all times relevant hereto, the \nowner of  Senomyx common stock. \n9. Defendant Senomyx is a Delaware corporation and maintains its principal \nexecutive offices at  4767 Nexus Centre Drive, San Diego, California 92121.  Senomyx \u2019s common Case 1:18-cv-01547-UNA   Document 1   Filed 10/08/18   Page 2 of 15 PageID #: 2 \n 3 stock is traded on the NasdaqGM  under the ticker symbol \u201c SNMX.\u201d  \n10. Defendant  Kent Snyder i s Chairman of the Board of Senom yx. \n11. Defendant Stephen A. Block i s a director of Senomyx.  \n12. Defendant Tom Erdmann i s a director of Senomyx. \n13. Defendant Mary Ann Gray i s a director of Senomyx.  \n14. Defendant John W. Poyhonen (\u201cPoyhonen\u201d ) is President, Chief Executive Officer \n(\u201cCEO\u201d), and a director of Senomyx.  \n15. Defen dant Dan Stebbins i s a director of Senomyx. \n16. Defendant Christopher Twomey i s a director of Senomyx.  \n17. The defendants identified in paragraphs 10 through 16 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d   \n18. Defendant Parent is a Delaware corporation and a party to the Merger Agreement.  \n19. Defendant  Merger Sub is a Delaware c orporation, a wholly- owned subsidiary of \nthe Parent, and a party to the Merger Agreement . \nCLASS ACTION ALLEGATIONS  \n20. Plaintiff  brings  this action as a class action on behalf of herself  and the other public \nstockholders of Senomyx  (the \u201cClass\u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defendant. \n21. This action  is properly maintainable as a class action.  \n22. The Class is so numerous that joinder of all members is impracticable.  As of  \nSeptember 16, 2018, there were approximately 48,980,204 shares of Senomyx common stock \noutstanding, held by hundreds, if not thousands, of individuals and entities scattered throughout \nthe country.  Case 1:18-cv-01547-UNA   Document 1   Filed 10/08/18   Page 3\nIndividual defendants:",
        "output": "Kent Snyder,Stephen A Block,Tom Erdmann,Mary Ann Gray,John W Poyhonen,Dan Stebbins,Christopher Twomey",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n11. Plaintiff Olivier Trembl ay, as set forth in the accompanying certification, \nincorporated by reference herein, purchased L oop securities during the Class Period, and suffered \ndamages as a result of the federal securities law violations and false and/ or misleading statements \nand/or material omissi ons alleged herein.  \n12. Defendant Loop is incorporated under th e laws of Nevada with its principal \nexecutive offices located in Quebec, Cana da. Loop\u2019s common stock trades on the NASDAQ \nexchange under the symbol \u201cLOOP.\u201d  \n13. Defendant Daniel Solomita (\u201cSolomita\u201d)  was the Company\u2019s Chief Executive \nOfficer (\u201cCEO\u201d) at all relevant times. \n14. Defendant Nelson Gentiletti (\u201cGentiletti \u201d) was the Company\u2019s Chief Financial \nOfficer (\u201cCFO\u201d) since January 1, 2019. \n15. Defendants Solomita and Gentiletti (col lectively the \u201cIndividual Defendants\u201d), \nbecause of their positions with the Company, po ssessed the power and authority to control the \ncontents of the Company\u2019s report s to the SEC, press releases a nd presentations to securities \nanalysts, money and portfolio managers and institu tional investors, i.e., the market.  The Individual \nDefendants were provided with copies of the Comp any\u2019s reports and press re leases alleged herein \nto be misleading prior to, or shortly after, thei r issuance and had the abili ty and opportunity to Case 1:20-cv-08538   Document 1   Filed 10/13/20   Page 4 of 31 \nCLASS ACTION COMPLAINT \n4 prevent their issuance or cause them to be co rrected.  Because of their positions and access to \nmaterial non-public information available to them, the Individual Defenda nts knew that the \nadverse facts specified herein had not been disclo sed to, and were being concealed from, the public, \nand that the positive representations which were be ing made were then materially false and/or \nmisleading.  The Individual Defendants are liable  for the false statemen ts pleaded herein.  \n",
        "output": "['Olivier Tremblay']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n6. Plaintiff is, and has been at all relevant times hereto , an owner of RumbleON \ncommon stock.  \n7. Defendan t RumbleON operates an e- commerce platform th at aggregates and \ndistributes pre -owned vehicles to and from consumers and dealers in North America . The Case 1:21-cv-04057   Document 1   Filed 07/19/21   Page 2 of 15 PageID #: 23 Company is  incorporated in  Nevada . The Company\u2019 s common stock trade s on the \nNASDAQ under the ticker symbol, \u201c RMBL .\u201d \n8. Defendant Adam Alexander  (\u201cAlexander \u201d) is a director of the Company. \n9. Defendant Denmar J. Dixon ( \u201cDixon \u201d) is a director  of the Company.  \n10. Defendant  Richard A. Gray Jr. ( \u201cGray \u201d) is a director of the Company.  \n11. Defendant Peter Levy  (\u201cLevy \u201d) is a director of the Company . \n12. Defendant  Michael Marchlik  (\u201cMarchlik \u201d) is a director of the Company . \n13. Defendant Kevin Westfall  (\u201cWestfall\u201d ) is a director of the Company.  \n14. Defendants Alexander , Dixon, Gray , Levy , Marchlik , and Westfall are collectively \nreferred to herein as the \u201c Individual Defendants. \u201d \n15. Defendants RumbleOn  and the Individual Defendants are collectively referred to \nherein as the \u201c Defendants. \u201d \n\nOnly answer with the company defendants names.",
        "output": "RumbleON, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Aegion common stock and has held such stock since prior to the wrongs complained of herein. 10. Individual Defendant Stephen P. Cortinovis has served as a member of the Board since 1997.  11. Individual Defendant Stephanie A. Cuskley has served as a member of the Board since 2005 and is the Chairwoman of the Board.  12. Individual Defendant Walter J. Galvin has served as a member of the Board since 2014.  13. Individual Defendant Rhonda Germany Ballintyn has served as a member of the Board since 2017.  Case 1:21-cv-02247   Document 1   Filed 03/15/21   Page 3 of 164 14. Individual Defendant Charles R. Gordon has served as a member of the Board since 2009 and is currently the Company\u2019s President and Chief Executive Officer.  15. Individual Defendant M. Richard Smith has served as a member of the Board since 2009. 16. Individual Defendant Phillip D. Wright has served as a member of the Board since 2011. 17. Defendant Aegion is incorporated in Delaware and maintains its principal offices at 17988 Edison Avenue, Chesterfield, Missouri 63005.  The Company\u2019s common stock trades on the NASDAQ Stock Exchange under the symbol \u201cAEGN.\u201d 18. The defendants identified in paragraphs 10-16 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 19. The defendants identified in paragraphs 10-17 are collectively referred to as the \u201cDefendants.\u201d \nOnly answer with the company defendants names.",
        "output": "Aegion Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " 10. Plaintiff Geor gianna H anrahan, IRA, (\u201cPlaintiff\u201d), is the IR A account  of\nGeor gianna H anrahan, a nat ural person who resides in Norwalk, Connec ticut.  As\ndetai led in the  Certification of the P laintiff, attached her eto (and i ncorporated herein by\nreferenc e), the Pl aintiff sold 255 s hares of Hew lett-Pack ard common st ock, during the\nClass Period.  The Pl aintiff did not  purchas e any  Hewlett-Pack ard common st ock during\nthe C lass Period.\n11. Defendant  Hewlett-Pack ard is a Delaware corporation, w ith its- 4 -headq uarters in Pal o Alto, California.  It is located and does business  throughout the\nUnited S tates  and internationally, including in this judicial district. \n12. Defendant Carleton Fiorina  (\u201cFiorina\u201d) is, and at all relevant time s was,\nChairman of the B oard of Di rectors and Chief Ex ecutive Officer  of Hew lett-Pack ard.\n13. The De fendants Hewlett-Pack ard and Fiorina are collectively referred to\nherein as the \u201cDefendants. \u201d\nSUBSTA NTIVE A LLEGA TIONS\nThe Defendants\u2019 Public Statemen ts and Filings Regarding the Merger On\nSeptembe r 3, 20 01 and Throug hout the Class  Period\n14. On Se ptember 3, 20 01, HP and Com paq issued  a press release\nannounc ing that HP and Compaq  had agreed to  merge.  That pr ess release, a copy of\nwhich is atta ched  hereto  as Ex hibit A (here inafter the  \u201cSepte mber 3, 20 01 Pre ss\nRelease\u201d ) stated, inter alia , that the merger agreeme nt ha d been \u201c...u nanimously\napproved by  both  Boar ds of Directors....\u201d\n15. On S eptember  4, 2001, commenc ing at 9:00 a.m., the D efendants,  along\nwith Com paq and  Michael Cape llas, Comp aq\u2019s C hairm an and Chie f Executive Officer,\nand ot hers speaki ng on b ehalf of HP, held a meet ing for the investment c ommunit y, at\nwhich Defendants and ot hers discussed numer ous aspec ts of the M erger and\nansw ered questions from member s of the i nvestment c ommunit y regarding the Merger. \nThis me eting w as acce ssible to th e investing public by  telep hone call\nIndividual defendants:",
        "output": "Carleton Fiorina",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n16. Plaintiff, as set forth in the attached Certification, acquired Colony \nsecurities at artificially inflated prices during the Class Period and was damaged \nupon the revelation of the alleged corrective disclosures.  \n17. Colony is a Maryland corporation with its principal executive offices \nlocated at 515 South Flower Street,  44th Floor, Los Angeles,  California  90071 .  \nColony\u2019s securities trade in an efficient market on the New York Stock Exchange \n(\u201cNYSE\u201d) under the ticker symbol \u201cCLNY.\u201d  \n18. Defendant Thomas J. Barrack, Jr.  (\u201cBarrack \u201d) has served as Colony\u2019s \nChief Executive Officer at all relevant times.  \n19. Defendant Mark M. Hedstrom (\u201cHedstrom\u201d) has served as Colony\u2019s \nChief Financial Officer at all relevant times.  \n20. Defendant Darren J. Tangen (\u201cTangen\u201d) served as Col ony\u2019s President \nat all relevant times.  \n21. Defendants Barrack , Hedstrom, and Tangen are sometimes referred to \nherein as the \u201cIndividual Defendants.\u201d  \n22. The Individual Defendants possessed the power and authority to control \nthe contents of Colony\u2019s SEC filings, pr ess releases, and other market \ncommunications.  The Individual Defendants were provided with copies of Colony\u2019s \nSEC filings and press releases alleged herein to be misleading prior to or shortly \nafter their issuance and had the ability and opportunity to p revent their issuance or Case 2:20-cv-04673   Document 1   Filed 05/26/20   Page 6 of 32   Page ID #:6 \n7 \nCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n to cause them to be corrected.  Because of their positions with Colony, and their \naccess to material information available to them but not to the public, the Individual \nDefendants knew that the adverse facts specified herein had no t been disclosed to \nand were being concealed from the public, and that the positive representations being \nmade were then materially false and misl\nOnly answer with the company defendants names.",
        "output": "Colony Capital, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n14. Plaintiff Pierre Brazeau, as set forth in  the accompanying certification which is \nincorporated herein by reference, purchased Ca ssava common stock during the Class Period and \nwas damaged thereby. \n15. Defendant Cassava was inco rporated in 1998 as Pain  Therapeutics, Inc. and \nchanged its name to Cassava Sciences, Inc. in  March 2019.  The Company is headquartered in \nAustin, Texas.  Cassava common stock trades in an efficient market on the NASDAQ under the ticker symbol \u201cSAVA.\u201d  As of A ugust 2, 2021, there were more than  40 million shares of Cassava \ncommon stock issued and outstanding. \n16. Defendant Remi Barbier (\u201cBarbier\u201d) founded Cassava and served as its President \nand Chief Executive Officer (\u201cCEO\u201d) and the Chairman  of its Board of Dire ctors at all relevant \ntimes. \n17. Defendant Eric J. Schoen (\u201cSchoen\u201d) served  as the Chief Financial Officer (\u201cCFO\u201d) \nof Cassava at all relevant times. \n18. Defendant James W. Kupiec (\u201cKupiec\u201d) serv ed as the Chief Clinical Development \nOfficer of Cassava at all relevant times. \n19. Defendant Nadav Friedmann (\u201cFriedmann\u201d) se rved as the Chief Medical Officer of \nCassava and a member of its Board of  Directors at all relevant times. \n20. Defendant Michael Marsman (\u201cMarsman\u201d) se rved as the Senior Vice President of \nRegulatory Affairs at Cassava  at all relevant times. Case 1:21-cv-00751   Document 1   Filed 08/27/21   Page 5 of 27 \n- 6 - 21. Defendants Barbier, Schoen, Kupiec, Fr iedmann and Marsman are sometimes \nreferred to herein as the \u201cIndivi dual Defendants.\u201d  The Individual Defendants made, or caused to \nbe made, false statements that artificially infl ated the prices of Cassa va common stock during the \nClass Period.  The Individual Defendants, because of their positions with the Company, possessed the power and authority to contro l the contents of Cassava\u2019s press releases, interim financial \nreports and presentations to secu rities analysts, money and portfo lio managers, and institutional \ninvestors, i.e",
        "output": "['Pierre Brazeau']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n \n14. Plaintiff, as set forth in the accompanying Certification, purchased common shares of \nGoPro at artificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosure. \n15. Defendant GoPro, Inc.  is incorporated in Delaware, and the Company\u2019s principal \nexecutive offices are located at Pier 1, Bay 3, San Francisco, Calif ornia 94111.  GoPro\u2019s common stock \ntrades on the NASDAQ under the ticker symbol \u201cGPRO.\u201d \n16. Defendant Nicholas D. Woodma n (\u201cWoodman\u201d) has served at all relevant times as the \nCompany\u2019s Chief Executive Officer and Chairman. \n \n\nOnly answer with the company defendants names.",
        "output": "GoPro, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Brocade  common stock.  \n9. Defendant Brocade  is a Delaware corporation and maintains its principal executive \noffices at  130 Holger Way, San Jose , California 95 134.  Brocade \u2019s common stock is traded on the \nNasdaq GS under the ticker symbol \u201cBRCD .\u201d \n10. Defendant  Judy Bruner (\u201cBruner \u201d) has served as a director  of Brocade since \nJanuary 2009 .  According to the Company\u2019s website, Bruner is Chair of the Audit Committee.  \n11. Defendant  Lloyd A. Carney (\u201cCarney \u201d) has served as a director of Brocade  since \nFebruary 2013 and as Chief Executive Officer (\u201cCEO\u201d) since  January 2013 .   \n12. Defendant  Renato A. DiPentima (\u201cDiPentima \u201d) has served as a director of Brocade  \nsince  January 2007 .  According to the Company\u2019s website, DiPentima is a member of the \nCompensation Committee and the Nominating and Governance Committee.  \n13. Defendant  Alan L. Earhart (\u201cEarhart \u201d) has served as a director of Brocade  since  \nFebruary 2009.   According to the Company\u2019s website, E arhart is a member of the Audit \nCommittee.    \n14. Defendant  John W. Gerdelman (\u201cGerdelman \u201d) has served as a director of Brocade  \nsince  January 2007 .  According to the Company\u2019s website, Gerdelman is a member of the Audit \nCommittee and the Corporate Development Committee.  \n15. Defendant  Kim C. Goodman (\u201cGoodman \u201d) has served as a director of Brocade  \nsince  February 2016 .   \n16. Defendant  David L. House (\u201cHouse \u201d) has served as a director of Brocade  since  \nFebruary 2004 and as Chairman of the Board since December 2005 .  Accordi ng to the Company\u2019s Case 3:16-cv-07081-EMC   Document 1   Filed 12/12/16   Page 3 of 171 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n  \n \n 4  \nCOMPLAINT FOR VIOLAT ION OF THE SECURITIES EXCHANGE ACT OF 1934  \n \n \n website, House is a member of the Compensation Committee, the Nominating and Governance \nComm\nOnly answer with the company defendants names.",
        "output": "Brocade Communication Systems, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 8. Plaintiff, at all relevant times, is the owner of shares of Nanometrics common stock.    9. Defendant Nanometrics is a leading provider of advanced, high-performance process control metrology and inspection solutions used primarily in the semiconductor manufacturing industry, as well as in the fabrication of other solid-state devices and components in the optoelectronic, LED and storage industries, and more recently in the industrial, aerospace and Case 5:19-cv-05625   Document 1   Filed 09/06/19   Page 3 of 161 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 30 31 32  \n 3 Case No. _______________ COMPLAINT FOR VIOLATION OF THE SECURITIES EXCHANGE ACT OF 1934 scientific research markets. Nanometrics\u2019 principal executive offices are located at 1550 Buckeye Drive, Milpitas, California 95035.  Nanometrics\u2019 common stock is traded on the NASDAQ under the symbol \u201cNANO.\u201d 10. Defendant Bruce C. Rhine (\u201cRhine\u201d) has served as Nanometrics\u2019 Chairman of the Board of Directors since July 2007 and as a director since July 2006. 11. Defendant Pierre-Yves Lesaicherre (\u201cLesaicherre\u201d) has served as Nanometrics as President, Chief Executive Officer and Director since November 2017. 12. Defendant Edward J. Brown, Jr. (\u201cBrown\u201d) has served as a director since February 2013. 13. Defendant Christopher A. Seams (\u201cSeams\u201d) has served as a director since August 2015. 14. Defendant Timothy J. Stultz, Ph.D. (\u201cStultz\u201d) has served as a director of Nanometrics since August 2007. 15. Defendant Christine A. Tsingos (\u201cTsingos\u201d) has served as a director since May 2014. 16. Defendants Rhine, Lesaicherre, Brown, Seams, Stultz, and Tsingos are collectively referred to herein as the \u201cBoard\u201d or the \u201cIndividual Defendants.\u201d FURTHER \nOnly answer with the company defendants names.",
        "output": "Nanometrics, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n13. Plaintiff City of Riviera Beach G eneral Employees Retirement Sy stem provides \nretirement benefits to eligible general employees of the City o f Riviera Beach, Florida.  Plaintiff \npurchased shares of Macquarie\u2019s common stock on the New York St ock Exchange (\u201cNYSE\u201d) \nduring the Class Period and suffered damages as a result of the  violations of the federal securities \nlaws alleged herein. \n14. Defendant Macquarie Infrastructu re Corporation, a Delaware corp oration \nheadquartered at 125 West 55th Street, New York, New York 10019 , owns and operates a portfolio \nof infrastructure and infrastru cture-like businesses.  The Comp any\u2019s common stock trades on the \nNYSE, which is an efficient market, under ticker symbol \u201cMIC.\u201d  Macquarie currently has over \n84 million shares of common stock outstanding, owned by at leas t hundreds or thousands of \ninvestors. \n15. Defendant James Hooke served as Chief Executive Officer of Macq uarie from July \n2014 to December 31, 2017.  Case 1:18-cv-03608   Document 1   Filed 04/23/18   Page 5 of 276 16. D e f e n d a n t  J a y  D a v i s  h a s  s e r v e d  a s  t h e  H e a d  o f  I n v e s t o r  R e l a t i o n s and Vice \nPresident of Macquarie since March 2008. \n17. Defendant Liam Stewart (\u201cStewart\u201d) has served as the Chief Fina ncial Officer of \nMacquarie since June 2015. \n18. Defendant Richard D. Courtney (\u201cCourtney\u201d) has served as the Ch ief Executive \nOfficer of IMTT since February 2015. \n19. Defendants Hooke, Davis, Stewart, and Courtney are collectively  referred to \nhereinafter as the \u201cIndividual Defendants.\u201d  The Individual Def endants, because of their positions \nwith Macquarie, possessed the power and authorit y to control th e contents of Macquarie\u2019s reports \nto the SEC, press releases, and presentations to securities ana lysts, money and portfolio managers, \nand institutional investors.  Each  of the Individual Defendants  was provided with copies of the \nCompany\u2019s reports and press releases alleged herein to be \nOnly answer with the company defendants names.",
        "output": "Macquarie Infrastructure Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n10. Plaintiff has owned the common stock of C ypress since prior to the announcement of \nthe Proposed Transaction herein complained  of and continues to own this stock. \n11. Cypress is a corporation dul y organized and existing under the laws of Delaware and \nmaintains its principal offices in San Jose, California.  Cypress is, and at all relevant times hereto was, listed and traded on the NASDAQ Stock Exchange under the symbol \u201cCY.\u201d \n12. Defendant W. Steve Albrecht has been the Ch airman of the Board since June 2017 and  \nhas been a member of the Board since 2003.  \n13. Defendant Hassane El-Khoury has been the Company\u2019s President and Chief Executive \nOfficer, and a member of the Board since August 2016. \n14. Defendant Oh Chul Kwon has been a member of the Board since 2015, \n15. Defendant Catherine P. Lego has been  a member of the Board since 2017. \n16. Defendant Camillo Martino has been a member of the Board since 2017. \n17. Defendant Jeffrey J. Owens has been a member of the Board since 2017. \n18. Defendant Jeannine P. Sargent has b een a member of the Board since 2017. \n19. Defendant Michael S. Wishart has been a member of the Board since 2015. \n20. The Defendants referred to in paragraphs 12- 19 are collectively referred to herein as the \n\u201cIndividual Defendants\u201d and/or the \u201cBoard.\u201d \n21. The Defendants referred to in paragraphs 11- 19 are collectively referred to herein as the \n\u201cDefendants.\u201d \n\nOnly answer with the company defendants names.",
        "output": "Cypress Semiconductor Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n12. Plaintiff, as set forth in the attached Certification, acquired Aquestive  \nsecurities at artificially inflated prices during the Class Period and was damaged \nupon the revelation of the alleged corrective disclosures.  \n13. Defendant Aquestive  is a Delaware corporation with principal \nexecutive offices located at 30 Technology Drive, Warren, New Jersey 07059 .  \nAquestive  securities trade in an efficient market  on the Nasdaq Global Market \n(\u201cNASDAQ\u201d)  under the symbol \u201cAQST .\u201d \n14. Defendant Keith J. Kendall  (\u201cKendall \u201d) has served as Aquestive \u2019s \nChief Executive  Officer  at all relevant times . \n15. Defendant  John T. Maxwell (\u201cMaxwell \u201d) has served as Aquestive \u2019s \nChief Financial Officer at all relevant times . \n16. Defendant s Kendall and Maxwell are sometimes referred to herein as \nthe \u201cIndividual Defendants. \u201d \n17. The Individual Defendants possessed the power and authority to control \nthe contents of Aquestive \u2019s SEC filings, press releases, and other market Case 1:21-cv-03751   Document 1   Filed 03/01/21   Page 5 of 34 PageID: 5 \n6 \n communications.  The Individual Defend ants were provided with copies of \nAquestive \u2019s SEC filings and press releases alleged herein to be misleading prior to \nor shortly after their issuance and had the ability and opportunity to prevent their \nissuance or to cause them to be corrected.  Because o f their positions with Aquestive , \nand their access to material information available to them but not to the public, the \nIndividual Defendants knew that the adverse facts specified herein had not been \ndisclosed to and were being concealed from the public, a nd that the positive \nrepresentations being made were then materially false and misleading.  The \nIndividual Defendants are liable for the false statements and omissions pleaded \nherein.  \n18. Aquestive  and the Individual Defendants are collectively referred to \nherein as \u201cDefendants. \u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n11. Plaintiff Bhupendra V. Shah, as set fo rth in the accompa nying certification, \nincorporated by reference herei n, purchased Chegg securities dur ing the Class Period, and suffered \ndamages as a result of the federa l securities law violations and fa lse and/or misleading statements \nand/or material omissi ons alleged herein.  \n12. Defendant Chegg is incorporated under the laws of Delaware with its principal \nexecutive offices located at 3990 Freedom Ci rcle, Santa Clara, California 95054.  Chegg\u2019s \ncommon stock trades on the New York Stock Exchange (\u201cNYSE\u201d) under the symbol \u201cCHGG.\u201d \n13. Defendant Daniel Rosensweig (\u201cRosensweig \u201d) was the Chief Executive Officer of \nthe Company at all relevant times. Case 3:18-cv-05956   Document 1   Filed 09/27/18   Page 3 of 171\n23456789\n10111213141516171819202122232425262728 \nCLASS ACTION COMPLAINT \n3 14. Defendant Rosensweig is also referred to  hereinafter as the \u201cIndividual Defendant.\u201d \nDefendant Rosensweig because of his position with the Company, possessed the power and authority to control the contents of the Comp any\u2019s reports to the SEC, press releases and \npresentations to securities analysts, money and portfolio managers and institutional investors, i.e., \nthe market.  The Individual Defendant was provid ed with copies of the Company\u2019s reports and \npress releases alleged herein to be misleading prior to, or shortly after, their issuance and had the \nability and opportunity to prevent their issuance or cause them to be corrected.  Because of his \nposition and access to material non-public information available to her, the Individual Defendant \nknew that the adverse facts specified herein had not been disclosed to, a nd were being concealed \nfrom, the public, and that the posi tive representations which were be ing made were then materially \nfalse and/or misleading.  The Individual Defendant  is liable for the false statements pleaded \nherein.  \n\nIndividual defendants:",
        "output": "Daniel Rosensweig",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been at  all times relevant hereto, an  owner of Birner common \nstock. \n9. Defendant Birner  is a Colorado corporation, with its  principal executive offices \nlocated in Denver, Colorado.  Birner  common stock is listed on the over -the-counter  under the \nsymbol \u201c BDMS .\u201d \n10. Defendant Frederic W.J. Birner (\u201cF. Birner\u201d) is the Company\u2019s Chief Executive \nOfficer and a director of the Company . \n11. Defendant  Joshua S. Horowitz  (\u201cHorowitz \u201d) is the Interim Chairman of the Board \nand a director of the Company .   \n12. Defendant Burton J. Rubin ( \u201cRubin\u201d ) is a director of the Company . \n13. Defendant  Bradley Tirpak  (Tirpak \u201d) is a director of the Company .  \n14. Defendant Gregory Gale Fulton  (\u201cFulton\u201d ) is a director of the Company . \n15. Defendant John M. Climaco ( \u201cClimaco \u201d) is a director of the Company . \n16. Defendant  Thomas D. Wolf  (\u201cWolf \u201d) is a director of the Company . Case 1:18-cv-02757   Document 1   Filed 10/29/18   USDC Colorado   Page 3 of 18 4 17. The defendants listed in \u00b6\u00b6 10- 16 are collectively referred to herein as the \n\u201cIndividual Defendants.\u201d  \n18. The Individual Defendants and Birner  are referred to herein as \u201c Defendants. \u201d \nSUBSTANTIVE ALLEGATI ONS  \n19. According to the Company \u2019s Form 10- K for the  year ended December 31, 2017, \nBirner  \u201cis a dental service organization devoted to servicing geographically dense dental practice \nnetworks in select markets,\u201d including Colorado, New Mexico and Arizona.  T he \u201cCompany \nprovides a solution to the needs of dentists, patients and third -party payors by allowing the \nCompany\u2019s affiliated dentists to provide high -quality, efficient dental care in patient -friendly, \nfamily practice settings.\u201d     \n20. On October 3 , 2018, Birner  and Mid-Atlantic  Dental issued a press release  \nannouncing t hat they had  entered into a definitive agreement where Birner  will be  acquired by \nMid-Atlantic  Dental .  According to the press release, Mid -Atlantic  Dental  \u201cwill pur",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " 17. Plaintiff JasonMcLees acquired newDXCshares ViatheMerger, inexchange forCSC\nshares, pursuant totheOffering Materials andwasdamaged asaresult.\n18. Defendant HPEisatechnology company incorporated underthelaws0fDelaware and\nheadquartered inPaloAlto,California. Inconnection WiththeMerger, HPEspunoffitsEnterprise\nServices business segment, merging itwithCSCt0formDXC.HPEorchestrated, negotiated, and\ncontrolled theMerger. Before theMerger, HPEwasthesolecontrolling shareholder 0fDXC.After\ntheMerger, HPEshareholders heldacontrolling majority (approximately 50.1%) 0ftheoutstanding\ncommon shares ofDXC.HPEexercised itscontrol overDXCandtheMerger bydesignating HPE\nemployee representatives asof\ufb01cers anddirectors 0fDXC,who,Within thescope oftheir\nemployment withHPE,reviewed, contributed t0,signed, 0ragreed t0benamedasincoming of\ufb01cer\nanddirector designees intheRegistration Statement.\n19. Defendant DXCisatechnology company formed fromthemerger ofHPE\u2019SEnterprise\nServices business withCSC.DXCisincorporated underthelaws0fDelaware, and,atthetime0f\ntheMerger, washeadquartered inPaloAlto,California. DXC\u2019scommon stocktrades ontheNYSE\nStockExchange undertheticker symbol \u201cDXC.\u201d\n20. Defendant RishiVarnais,andatallrelevant timeshasbeen,anemployee andGeneral\nCounsel t0HPE.Atthetime0ftheMerger, inhiscapacity asanemployee representative 0fHPE,\nheserved asDXC\u2019sPresident, Secretary, andPrincipal Executive Of\ufb01cer, andasaDirector 0nthe\nDXCBoard. Inhiscapacity asanemployee representative ofHPE,hereviewed, contributed t0,and\nsigned theRegistration Statement.\n21. Defendant Timothy C.Stonesifer was,atallrelevant times, theChiefFinancial Of\ufb01cer\n(\u201cCFO\u201d) 0fHPE.AtthetimeoftheMerger, inhiscapacity asanemployee representative ofHPE,\nheserved asDXC\u2019sCFOandasaDirector ontheDXCBoard. Inhiscapacity asanemployee\nrepresentative ofHPE,hereviewed, contributed t0,andsigned theRegistration Statement.\n22. Defendant Jeremy K.COXserved, atthetimeoftheMerger, asaDirector ontheDXC\nBoard. Hereviewed, contributed t0,andsig\nIndividual defendants:",
        "output": "Rishi Varna,Timothy C Stonesifer,Jeremy K Cox,Mukesh Aghi,Amy E Alving,David Herzog,Sachin Lawande,J Michael Lawrie,Julio A Portalatin,Peter Rutland,Manoj P Singh,Margaret C Whitman,Robert F Woods",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has  been continuously throughout all times relevant hereto, the \nowner of  Anixter  common stock. \n9. Defendant Anixter  is a Delaware corporation and maintains its principal executi ve \noffices at 2301 Patriot Boulevard, Glenview, Illinois 60026.  A nixter \u2019s common stock is traded on Case 1:99-mc-09999   Document 1894   Filed 12/09/19   Page 2 of 12 PageID #: 181900Case 1:19-cv-02239-UNA   Document 1   Filed 12/09/19   Page 2 of 12 PageID #: 2 \n 3 the New York Stock Exchange  under the ticker symbol \u201c AXE .\u201d \n10. Defendant  Samuel Zell  is Chairman of the Board of the C ompany.  \n11. Defendant Lord  James Blyth  is a director of the C ompany.  \n12. Defendant Frederic F. Brace is a director of the C ompany.  \n13. Defendant Linda Walker Bynoe  is a director of the C ompany.  \n14. Defendant Robert J. Eck is a director of the Company.  \n15. Defendant William A. Galvin  is President, Chief Executive Officer, and a director \nof the C ompany.  \n16. Defendant F. Philip Handy  is a director of the C ompany.  \n17. Defendant Melvyn N. Klein  is a director of the C ompany.  \n18. Defendant Jamie Moffitt is a director of the C ompany.  \n19. Defendant George Mu\u00f1oz is a director of the Company.  \n20. Defendant Scott R. Peppet is a director of the Company.  \n21. Defendant Valarie L. Sheppard is a director of the Company.  \n22. Defendant William S. Simon is a director of the Company.  \n23. Defendant Charles M. Swoboda is a director of the Company.  \n24. The defendants identified in paragraphs 10 through 23 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d    \nCLASS ACTION ALLEGATIONS  \n25. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Anixter  (the \u201cClass \u201d).  Excluded from the Class are defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defendant.  \n26. This action is properly maintainable as a class action.  Case 1:\nIndividual defendants:",
        "output": "Samuel Zell,Lord James Blyth,Frederic F Brace,Linda Walker Bynoe,Robert Eck,William A Galvin,F Philip Handy,Melvyn N Klein,Jamie Moffitt,George Munoz,Scott R Peppet,Valarie L Sheppard,William S Simon,Charles Swoboda",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n12. Plaintiff Paul Ansfield (\u201cPlaintiff\u201d or \u201cAnsfield\u201d) purchased shares of Infoblox \ncommon stock during the Class Period as reflected in his certification and suffered losses as a result of the conduct complained of herein.   Case3:14-cv-02500-VC   Document1   Filed05/30/14   Page4 of 26 \n \n-4- \nCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS  \n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 13. Defendant Infoblox is a global technology company, incorporated in \nDelaware.  Infoblox was founded in Illinois in 1999.  In May 2003, the Company was \nreincorporated in Delaware.  Infobl ox maintain s its headquarters and principal  place of \nbusiness in Santa Clara, California.  Infoblox sells products that manage and protect networks.  Infoblox represents that it provides a broad family of enterprise and service provider -class solutions to over 7,000 enterprises and service providers with a goal of making \ncustomer networks more available, secure, and automated.  Throughout the Class Period, Infoblox traded in an efficient market on the New York Stock Exchange (\u201cNYSE\u201d) under the ticker symbol \u201cBLOX.\u201d  As of February 28, 2014, the Company had over 53.87 million \nshares outstanding. \n14. Defendant Robert Thomas (\u201cThomas\u201d) is and was, at all relevant times, the \nCompany\u2019s Chief Executive Officer (\u201cCEO\u201d), as well as a Infoblox\u2019s President.  Thomas is described as being responsible for \u201cbuilding Infoblox into a highly profitable and valued \nbusiness.\u201d  During the Class Period, Thomas certified the Company\u2019s SEC filings pursuant to Sections 302 and 906 of the Sarbanes -Oxley Act of 2002 (\u201cSOX\u201d).  The document s certified \nby Thomas contain materially false statements and critical omissions that, along with other materially false statements and critical omissions made during the Class P eriod, provided \nshareholders with a highly inaccurate representation of Infobl ox\u2019s financial status.  Thomas \n\nIndividual defendants:",
        "output": "Robert Thomas,Remo Canessa",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has  been continuously throughout all times relevant hereto, the \nowner of  Tetraphase common stock. Case 1:20-cv-00826-UNA   Document 1   Filed 06/17/20   Page 2 of 13 PageID #: 2 \n 3 9. Defendant Tetraphase  is a Delaware corporation and maintains it s principal \nexecutive offices at 480 Arsenal Way, Watertown, Massachusetts 02472.  Tetraphase \u2019s common \nstock is traded on the NASDAQ Global Select Market under the ticker symbol \u201c TTPH .\u201d \n10. Defendant L. Patrick Gage is a director  of the Company. \n11. Defendant Larry Edwards  is Chief Executive Officer and  President  of the \nCompany.  \n12. Defendant Garen Bohlin  is a director of the Company.  \n13. Defendant Steven Boyd  is a director of the Company.  \n14. Defendant Jeffrey A. Chodakewitz  is a director of the Company.  \n15. Defendant John G. Freund  is a director of the Company.  \n16. Defendant Gerri Henwood is a director of the Company.  \n17. Defendant Guy Macdonald is a director of the Company.  \n18. Defendant Keith Maher is a director of the Company.  \n19. Defendant Nancy Wysenski is a director of the Company.    \n20. The defendants identified in paragraphs 10 through 19 are collectively referred to \nherein as the \u201cIndividual Defendants.\u201d    \n21. Defendant Parent  is a Delaware corporation  and a party to the Merger Agreement.  \n22. Defendant  Merger Sub is a Delaware corporation , a wholly -owned  subsidiary of \nParent , and a party to the Merger A greement . \nCLASS ACTION ALLEGATIONS  \n23. Plaintiff  brings  this action as a class action on behalf of himself  and t he other public \nstockholders of Tetraphase (the \u201c Class \u201d).  Excluded from the Class are  defendants herein and any \nperson, firm, trust, corporation, or other entity related to or affiliated with any defendant.  Case 1:20-cv-00826-UNA   Document 1   Filed 06/17/20   Page 3 of 13 PageID #: 3 \n 4 24. This action is properly maintainable as a class action.  \n25. The Class is so numerous that joinder of all members is impra\nOnly answer with the company defendants names.",
        "output": "Tetraphase Pharmaceuticals Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n14. Plaintiff, Iron Workers Local  Union No. 405 Annuity Fund, as se t forth in the \naccompanying certification attached as Exhibit A, incorporated by reference herein, purchased \nDollar General common stock at artificially inf lated prices dur ing the Class Period and has been \ndamaged thereby. \n15. Defendant Dollar General is a T ennessee corporation headquarter ed in \nGoodlettsville, Tennessee, and i s a discount retailer with over  12,000 stores nationwide.     \n16. Defendant Todd Vasos (\u201cVasos\u201d) is and throughout the Class Peri o d  w a s  t h e  \nCompany\u2019s CEO. \n17. Vasos, because of his position in the Company, possessed the po wer and authority \nto control the contents of the Co mpany\u2019s reports to the SEC, pr ess releases, and presentations to \nsecurities analysts, money and portfolio managers, and institut ional investors, i.e., the market.  \nVasos was provided with copies of the Company\u2019s reports and pre ss releases alleged herein to be \nmisleading prior to or shortly after their issuance, and had th e ability and opportunity to prevent \ntheir issuance or cause them to be corrected.  Because of his p osition and access to material non-\npublic information available to him, Vasos knew that the advers e facts specified herein had not \nbeen disclosed to, and were being concealed from, the public, a nd that the positive \nrepresentations which were being made were then materially fals e and misleading.  Vasos is \nliable for the false statements p leaded herein because he made,  or caused to be made, all the false \nstatements pleaded herein. \n   \nCase 3:17-cv-00063   Document 1   Filed 01/18/17   Page 5 of 17 PageID #: 5 \n6 ",
        "output": "['Iron Workers, Local 405']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Landmark common units and has held such units since prior to the wrongs complained of herein. 10. Individual Defendant Arthur P. Brazy, Jr. (\u201cBrazy\u201d) is the Chief Executive Officer (\u201cCEO\u201d) and a member of the Board of the Partnership. Brazy is also the CEO of Landmark Dividend. 11. Individual Defendant Steven M. Sonnenstein is a member of the Board of the Partnership and is affiliated with Landmark Dividend.  12. Individual Defendant Sadiq Malik is a member of the Board of the Partnership and is affiliated with Landmark Dividend. 13. Individual Defendant Thomas Carey White III is a member of the Board of the Partnership.  14. Individual Defendant Gerald Tywoniuk is a member of the Board of the Partnership.  15. Individual Defendant Keith Benson is a member of the Board of the Partnership. 16. Defendant Landmark is a Delaware limited partnership and maintains its principal offices at 400 Continental Blvd., Suite 500, El Segundo, CA 90245.  The Company\u2019s common units trades on the NASDAQ Stock Exchange under the symbol \u201cLMRK.\u201d 17. The defendants identified in paragraphs 10-15 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 18. The defendants identified in paragraphs 10-16 are collectively referred to as the \u201cDefendants.\u201d Case 1:21-cv-07635   Document 1   Filed 09/13/21   Page 4 of 145 ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n9. Plaintiff is, and has been at all relevant times, the owner of Innophos common \nstock and has held such stock sin ce prior to the wrongs complai ned of herein. \n10. Individual Defendant Gary Cappeline has served as a member of t he Board since \n2007. \n11. Individual Defendant Jane Hilk ha s served as a member of the Bo ard since 2018.  Case 2:19-cv-20474   Document 1   Filed 11/19/19   Page 3 of 15 PageID: 34 12. Individual Defendant Kim Ann Mi nk has been the Company\u2019s Chief Executive \nOfficer and President since De cember 2015, a director of Innoph os since January 2016, and \nChairman of the Board since February 2017.  \n13. Individual Defendant Linda Myrick has served as a member of the  Board since \n2006.  \n14. Individual Defendant Karen Osar has served as a member of the B oard since \n2007. \n15. Individual Defendant John M. Steitz has served as a member of t he Board since \n2009. \n16. Individual Defendant Peter T. Thomas has served as a member of the Board since \n2016. \n17. Individual Defendant Robert J. Za tta has served as a member of the Board since \n2016. \n18. Defendant Innophos is incorporated in Delaware and maintains it s principal \noffices at 259 Prospect Plains Road, Building A, Cranbury, NJ 0 8512.  The Company\u2019s common \nstock trades on the NASDAQ Stock E xchange under the symbol \u201cIPH S.\u201d \n19. The defendants identified in par agraphs 10-17 are collectively referred to as the \n\u201cIndividual Defendant s\u201d or the \u201cBoard.\u201d \n20. The defendants identified in par agraphs 10-18 are collectively referred to as the \n\u201cDefendants.\u201d \n\nOnly answer with the company defendants names.",
        "output": "Innophos Holdings, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  ................................ ................................ ................................ ............................  5 \nA. Plaintiff  ................................ ................................ ................................ ...................  5 \nB. Defendants  ................................ ................................ ................................ ..............  5 \n1. Corporate Defendant  ................................ ................................ ...................  5 \n2. Selling Stockholder Defendants  ................................ ................................ .. 6 \n3. Individual Defendants  ................................ ................................ .................  7 \n4. Underwriter Defendants  ................................ ................................ ..............  9 \nIV. \nOnly answer with the company defendants names.",
        "output": "Ping Identity Holding Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of  Nielsen  common stock.  \n9. Defendant Nielsen  is a public limited company formed under the laws of England \nand Wales and a party to the Agreement.  Nielsen \u2019s common stock is traded on the New Yor k Case 1:20-cv-10893   Document 1   Filed 12/23/20   Page 2 of 10 \n 3 Stock Exchange , which is headquartered in New York, New York, under the ticker symbol \n\u201cNLSN .\u201d \n10. Defendant James A. Attwood Jr. is  Chairman of the Board  of the Company. \n11. Defendant David Kenny is Chief Executive Officer and  a director of the Company.  \n12. Defendant Guerrino De Luca is  a director of the Company. \n13. Defendant Karen M. Hoguet  is a director of the Company. \n14. Defendant Janice Marinelli  Mazza is a director of the Company.  \n15. Defendant Jonathan Miller is a director of the Compa ny. \n16. Defendant David Rawlinson is a director of the Company. \n17. Defendant Nancy Tellem is a director of the Company.  \n18. Defendant Lauren Zalaznick is a director of the Company.  \n19. Defendant Thomas H. Castro is a director of the Company.  \n20. Defendant Harish Manwani i s a director of the Company. \n21. Defendant Robert C. Pozen is a director of the Company.  \n22. Defendant Javier G. Tereul is a director of the Company.  \n23. The defendants identified in paragraphs 10 through 22 are collectively referred to \nherein as the \u201cIndividual Defendants. \u201d   \n\nOnly answer with the company defendants names.",
        "output": "Nielsen Holdings plc",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n11. Plaintiff Casey Roberts, as set forth in  the accompanying certification, incorporated \nby reference herein, purchased Zuora securities during the Class Period, and suffered damages as a \nresult of the federal securities law violations and false and/or mislea ding statements and/or \nmaterial omissions alleged herein.  \n12. Defendant Zuora is incorporated under the laws of Delaware with its principal \nexecutive offices located in San Mateo, Califor nia.  Zuora\u2019s common stock trades on the New \nYork Stock Exchange (\u201cNYSE\u201d) under the symbol \u201cZUO.\u201d \n13. Defendant Tien Tzuo (\u201cTzuo\u201d) was the Ch ief Executive Officer of the Company at \nall relevant times. \n14. Defendant Tyler Sloat (\u201cSloa t\u201d) was the Chief Financial Officer of the Company at \nall relevant times. \n15. Defendants Tzuo and Sloat (collectively th e \u201cIndividual Defendants\u201d), because of \ntheir positions with the Company, possessed the power  and authority to contro l the contents of the \nCompany\u2019s reports to the SEC, press releases and presentations to securiti es analysts, money and \nportfolio managers and institutional investors, i.e., the market.  The Individual Defendants were \nprovided with copies of the Comp any\u2019s reports and press releases alleged herein to be misleading \nprior to, or shortly after, their issuance and ha d the ability and opportunity to prevent their \nissuance or cause them to be corrected.  Becaus e of their positions and access to material non-\npublic information available to them, the Indi vidual Defendants knew that the adverse facts \nspecified herein had not been disclosed to, and we re being concealed from, the public, and that the \npositive representations which were being made were  then materially false and/or misleading.  The \nIndividual Defendants are liable for th e false statements pleaded herein.  \n\nIndividual defendants:",
        "output": "Tien Tzuo,Tyler Sloat",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " .  The failure to adequately \ndisclose such material information constitutes  a violation of the above -referenced \nsections of the Exchange Act , as Numerex  stockholders need such informati on to \ncast a fully -informed vote in connection with the Proposed Transaction . \n4. In short, unless remedied, Numerex \u2019s public stockholders will be \nforced to make a voting decision on the Proposed Transaction without full \ndisclosure of all material information concerning the Proposed Transaction being \nprovided to them.  Plaintiff seeks to enjoin the stockholder vote on the Proposed \nTransaction unless and until such Exchange Act violations are cured . \nJURISDICTION AND VENUE  \n5. This Court has jurisdiction over the cla ims asserted herein for \nviolations of Sections 14( a) and 20(a) of the Exchange Act and SEC Rule 14 a-9 Case 1:17-cv-03893-CAP   Document 1   Filed 10/04/17   Page 3 of 25- 4 - promulgated thereunder pursuant to Section 27 of the Exchange Act, 15 U.S.C. \u00a7 \n78aa, and 28 U.S.C. \u00a7 1331 (federal question jurisdiction).  \n6. This Court has jurisdiction over the defendants because each \ndefendant is either a corporation that conducts business in and maintains operations \nwithin this District, or is an individual with sufficient minimum contacts with this \nDistrict so as to make th e exercise of jurisdiction by this Court permissible under \ntraditional notions of fair play and substantial justice.  \n7. Venue is proper in this District pursuant to 28 U.S.C. \u00a7 1391 as well \nas under Section 27 of the Exchange Act, 15 U.S.C. \u00a7 78aa, because a substantial \nportion of the actionable conduct took place in this District.  \nTHE PARTIES  \n8. Plaintiff is, and has been at all times relevant hereto, a continuous \nstockholder of Numerex . \n9. Defendant  Numerex  is a Pennsylvania  corporation with its principal \nexecuti ve offices located at 400 Interstate North Parkway SE, Suite 1350, Atlanta, \nGeorgia 30339.   Numerex  is a provider of managed enterprise solutions enablin",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n20. Plaintiff, as set forth in the attached Certification, acquir ed the Company \u2019s \nsecurities at artificially inflated prices during the Class Period and was damaged upon the \nrevelation of the alleged cor rective disclosures.  \n21. Defendant Enservco  is a Delaware  corporation  with principal executive offices \nlocated at 14133 Co unty Road 9\u00bd, Longmont, Colorado 80504 .  Enservco \u2019s common stock  trade s \nin an efficient market  on the NYSE American (\u201cNYSE \u201d) under the  trading  symbol \u201c ENSV \u201d. \n22. Defendant  Murphy  has served as  Enservco\u2019s CEO  at all relevant times.   Murphy  \nalso serves as Enservco\u2019s Executive Chairman  and as managing member of Cross River Capital \nManagement, LLC, the general partner of Cross River Partners.  \n23. Defendant  Hargrave  served as Enservco\u2019s CFO  at all relevant times .  Hargrave  also \nserved as Enservco\u2019s Presi dent during the Class Period . \n24. Defendant s Murphy and Hargrave are sometimes referred to herein as the \n\u201cIndividual Defendants. \u201d \n25. The Individual Defendants possessed the power and authority to control the \ncontents of Enservco \u2019s SEC filings, press releases, and other market communications.  The \nIndividual Defendants were provided with copies of Enservco \u2019s SEC filings and press release s \nalleged herein to be misleading prior to or sh ortly after their issuance and had the ability and \nopportunity to prevent their issuance or to cause them to be corrected.  Because of their positions \nwith Enservco , and their access to material information a vailable to them but not to the public, the \nIndividual Defendants knew that the adverse facts specified herein had not been disclosed to and \nwere being concealed from the public, and that the positive representations being made were then Case 1:22-cv-01267   Document 1   Filed 05/20/22   USDC Colorado   Page 6 of 30 \n7 \n materially false a nd misleading.  The Individual Defendants are liable for the false statements and \nomissions pleaded herein.  \n26. Enser\nOnly answer with the company defendants names.",
        "output": "Enservco Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 21. Plaintiff was, and at all relevant times, a shareholder of Maxwell.  22. Defendant Maxwell is a Delaware corporation and maintains its principal executive office at 3888 Calle Fortunada, San Diego, California 92123. Maxwell develops, manufactures, and markets energy storage and power delivery products for transportation, industrial, and other applications. Prior to the consummation of the Merger, the Company\u2019s common stock traded on the Nasdaq under the ticker symbol \u201cMXWL\u201d. Maxwell survived the Merger as a wholly owned subsidiary of Tesla. 23. Individual Defendant Steve Bilodeau was, at all relevant times, a director of Maxwell and the Chairman of the Board.   24. Individual Defendant Dr. Franz J. Fink was, at all relevant times, a director of Maxwell and the President and Chief Executive Officer of the Company. 25. Individual Defendant Richard Bergman was, at all relevant times, a director of the Company. 26. Individual Defendant J\u00f6rg Buchheim was, at all relevant times, a Case 3:19-cv-01094-BEN-BLM   Document 1   Filed 06/11/19   PageID.9   Page 9 of 35  \n11 CLASS ACTION COMPLAINT  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  director of the Company.  27. Individual Defendant Burkhard Goeschel was, at all relevant times, a director of the Company. 28. Individual Defendant Ilya Golubovich was, at all relevant times, a director of the Company. 29. Individual Defendant John Mutch was, at all relevant times, a director of the Company. 30. The defendants identified in paragraphs 22-29 are collectively referred to as the \u201cDefendants\u201d. ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  reside  in this County,  the parties  transact\nbusiness  in this County,  certain  of the defendants  have  submitted  to venue  in this County  by written\nagreement,  the transactions  underlying  the Complaint  took  place  in substantial  part in this County,\nand the causes  of action  arose  in this County.\nDATED:  Melville,  New  York  \nSeptember  18, 2019ROBBINS  GELLER  RUDMAN  \n& DOWD  LLP  \nSAMUEL  H. RUDMAN\ns/ Samuel  H. Rudman\nSAMUEL  H. RUDMAN\n58 South  Service  Road,  Suite  200 \nMelville,  NY 11747  \nTelephone:  631/367-7100  \n631/367-1173  (fax)  \nsrudman@rgrdlaw.com\nROBBINS  GELLER  RUDMAN  \n& DOWD  LLP  \nBRIAN  E. COCHRAN  \n200 South  Wacker  Drive,  31st Floor  \nChicago,  IL 60606  \nTelephone:  312/674-4674  \n312/674-4676  (fax)  \nbcochran@rgrdlaw.com\n3 of 23\nINDEX NO. 655420/2019  \nRECEIVED  NYSCEF:  09/18/2019FILED:  NEW YORK COUNTY  CLERK  09/18/2019  01:32  PM\nNYSCEF  DOC. NO. 1\nROBBINS  GELLER  RUDMAN  \n& DOWD  LLP  \nKENNETH  J. BLACK  \nPost  Montgomery  Center  \nOne Montgomery  Street,  Suite 1800  \nSan Francisco,  CA 94104  \nTelephone:  415/288-4545  \n415/288-4534  (fax)  \nkblack@rgrdlaw.com\nJOHNSON  FISTEL,  LLP  \nMICHAEL  I. FISTEL,  JR. \n40 Powder  Springs  Street  \nMarietta,  GA 30064  \nTelephone:  470/632-6000  \n770/200-3101  (fax)  \nmichaelf@johnsonfistel.com\nAttorneys  for Plaintiff\n4 of 23\nINDEX NO. 655420/2019  \nRECEIVED  NYSCEF:  09/18/2019FILED:  NEW YORK COUNTY  CLERK  09/18/2019  01:32  PM\nNYSCEF  DOC. NO. 1\nSUPREME  COURT  OF THE STATE  OF NEW  YORK  \nCOUNTY  OF NEW  YORK\nX\nJIANMING  LYU,  Individually  and on Behalf  \nof All Others  Similarly  Situated,Index  No.\nCLASS  ACTION\nPlaintiff,\nCOMPLAINT  FOR  VIOLATIONS  OF THE  \nSECURITIES  ACT  OF 1933 vs.\nRUHNN  HOLDING  LIMITED,  MIN  FENG,  \nLEI SUN,  CHAO  SHEN,  ZHENBO  CHI,  KE \nCHENG,  SHEK  YUEN  TING,  FENGCHUN  \nJIN, SHANGZHEN  LI, ZHENXING  SHAO,  \nPEN  HUNG  TUNG,  JUNHONG  QI, \nXIAOCAO  XU, CITIGROUP  GLOBAL  \nMARKETS  INC.,  UBS SECURITIES  LLC  \nand TOP CAPITAL  PA\nIndividual defendants:",
        "output": "Min Feng,Lei Ray Sun,Chao Eric Shen,Zhenbo Nick Chi,Ke Cheng,Shek Yuen Ting,Fengchun Jin,Shangzhen Li,Zhenxing Shao,Pen Hung Tung,Junhong Qi,Xiaocao Cecilia Xu",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n9. Plaintiff  is, and has been at all relevant times, the owner of Alder  common stock  \nand has held such stock  since prior to the wrongs complained of herein.  \n10. Individual Defendant Robert W. Azelby  is the Company\u2019s President and Chief \nExecutive Officer and has served as a member of the Board since June 2018. Case 1:19-cv-01797-UNA   Document 1   Filed 09/24/19   Page 3 of 15 PageID #: 34 11. Individual Defendant Paul R. Carter  has served  as a member of the Board since \nSeptember 2015.  \n12. Individual Defendant Paul B. Cleveland has served as a member of the Board \nsince August 2015 and as Chairman of the Board s ince November 2018.  \n13. Individual Defendant A. Bruce Montgomer y has served as a member of the Board \nsince October 2010.  \n14. Individual Defendant Heather Preston,  has been  a member of the Board since \nDecember 2007 .  \n15. Individual Defendant Clay B. Siegall has served as a member of the Board since \nNovember 2005.  \n16. Individual Defendant Wendy L. Yarno  has served as a member of the Board since \nMarch 2017.  \n17. Defendant Alder  is incorporated in Delaware and maintains its principal offices at \n11804 North Creek Parkway South Bothell, Washington 98011.  The Company\u2019s  common s tock \ntrades  on the NASDAQ Stock Exchange  under the symbol \u201c ALDR .\u201d \n18. The defendant s identified in paragraphs 10- 16 are collectively referred to as the \n\u201cIndividual Defendants \u201d or the \u201c Board .\u201d \n19. The defendant s identified in paragraphs 10- 17 are collectively r eferred to as the \n\u201cDefendants. \u201d \nSUBSTANTIVE ALLEGATI ONS  \nA. The Proposed Transaction   \n20. Alder BioPharmaceuticals , Inc. operates as a clinical -stage biopharmaceutical \ncompany. It discovers, develops, and commercializes therapeutic antibodies to transform the \ntreatment paradigm for patients with migraine in the United States, Australia, and Ireland. The Case 1:19-cv-01797-UNA   Document 1   Filed 09/24/19   Page 4 of 15 PageID #: 45 Company \u2019s lead  product candidate is epti\nIndividual defendants:",
        "output": "Robert W Azelby,Paul R Carter,Paul B Cleveland,A Bruce Montgomery,Heather Preston,Clay B Siegall,wendy Yarno",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n14. Plaintiff, as set forth in the attached Certification, acquired BT Group  ADRs  at \nartificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosures.  \n15. Defendant BT Group  is incorporated under the laws of England . The Company\u2019s  \nprincipal executive offices are located at 81 Newgate Street London England  X0 EC1A  7AJ.  BT \nGroup \u2019s shares trade  on the NYSE  under the ticker symbol  \u201cBT.\u201d \n16. Defendant Gavin E. Patterson (\u201cPatterson \u201d) has served as the Company\u2019s Chie f \nExecutive Officer  (\u201cCEO\u201d) since September 2013.   \n17. Defendant Ian Livingston (\u201cLivingston\u201d) served as the Company\u2019s CEO from June \n2008 to September 2013.  \n18. Defendant Tony Chanmugam (\u201cChanmugam\u201d) served as the Company\u2019s F inance \nDirector  from 2008 to July 2016.  \n19. The Defendant s referenced above in \u00b6\u00b6 16-18 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  Case 1:17-cv-00558   Document 1   Filed 01/25/17   Page 5 of 32 \n6 \n  \nSUBSTANTIVE ALLEGATI ONS  \nBackground  \n20. BT Group  is a multinat ional telecommunications services company that offers \nfixed -line services, broadband, mobile and TV products and services, and networked IT services \nin the United Kingdom and across the world. The Company also sells wholesale products and \nservices to commu nications providers around the world. Globally, BT  Group  supplies managed \nnetworked IT services to multinational corporations, domestic businesses, and national and local \ngovernment organizations.  \nMaterially False and Misleading Statements Issued During t he Class Period  \n21. The Class Period begins on May 23, 2013 , when BT Group filed an annual report \non Form 20-F with the SEC, announcing the Company\u2019s financial and operating results for the \nquarter and fiscal year ended March 31 , 2013 (the \u201c201 3 20-F\u201d).  For the quarter, BT Group \nreported net income of \u00a3555 m illion, or \u00a30.07 per diluted share, on revenue of \u00a34.81 billion, \ncompared t\nIndividual defendants:",
        "output": "Gavin E Patterson,Ian Livingston,Tony Chanmugam",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " A.\nPlaintiff\n24.\nPlaintiff\npurchased\nLoma\nNegra\nADSs\npursuant\nor\ntraceable\nto\nthe\nOffering\nMaterials\nissued\nin\nconnection\nwith\nthe\nCompany's\nIPO\non\nthe\ndate\nof\nthe\nOffering\nand\nhas\nbeen\ndamaged\nthereby.\nB.\nLoma\nNegra\n25.\nDefendant\nLoma\nNegra\nis\nincorporated\nunder\nthe\nlaws\nof\nArgentina\nwith\ncorporate\nheadquarters\nlocated\nat\nReconquista\n1088,\n7th\nFloor,\nCiuidad\nAutonoma\nde\nBuenos\nAires,\nArgentina,\nC1003ABQ.\nAccording\nto\nthe\nRegistration\nStatement,\nLoma\nNegra\nhas\nengaged\nC\nT\nCorporation\nSystem,\n111\nEighth\nAvenue,\nNew\nYork,\nNew\nYork\n10011\nas\nits\nagent\nfor\nservice.\nTo\nthis\nend,\nJames\nM.\nHalpin,\nassistant\nsecretary\nof\nC\nT\nCorporation\nSystem,\nsigned\nthe\nRegistration\nStatement\nas\nLoma\nNegra's\n\"Authorized\nRepresentative\nin\nthe\nUnited\nStates.\"\n26.\nIn\nthe\nOffering,\nthe\nCompany\nsold\n1,800,000\nADSs\nfor\ngross\nproceeds\nof\n$34.2\nmillion\nand\nnet\nproceeds\nof\n$31.8\nmillion.\n27.\nLoma\nNegra's\nADSs\nare\ntraded\non\nthe\nNew\nYork\nStock\nExchange\nunder\nthe\nticker\nsymbol\n\"LOMA.\"\n28.\nDefendant\nLoma\nNegra\nis\nstrictly\nliable\nfor\nthe\nmaterially\nuntrue\nand\nmisleading\nstatements\nincorporated\ninto\nthe\nOffering\nMaterials.\nC.\nThe\nIndividual\nDefendants\n29.\nDefendant\nSergio\nFaifman\nwas\nat\nthe\ntime\nof\nthe\nIPO\nthe\nCompany's\nChief\nFILED: NEW YORK COUNTY CLERK 06/21/2018 04:37 PMINDEX NO. 653114/2018\nNYSCEF DOC. NO. 2 RECEIVED NYSCEF: 06/21/2018\n7 of 30Executive\nOfficer\n(\"CEO\"),\nVice\nPresident\nof\nthe\nBoard,\nand\nsigned\nor\nauthorized\nthe\nsigning\nof\nthe\nCompany's\nRegistration\nStatement.\nAt\nthe\ntime\nof\nthe\nIPO,\nDefendant\nFaifman\nwas\nalso\nthe\nVice-president\nof\nInterCement\nParticipa\u00e7\u00f5es\nS.A.\n(\"InterCement\")\n(the\nCompany's\ncontrolling\nshareholder)\nfor\nLoma\nNegra\nand\nYguaz\u00fa\nCementos.\n30.\nDefendant\nMarcos\nGradin\nwas\nat\nthe\ntime\nof\nthe\nIPO\nthe\nCompany's\nChief\nFinancial\nOfficer\n(\"CFO\")\nand\nsigned\nor\nauthorized\nthe\nsigning\nof\nthe\nCompany's\nRegistration\nStatement.\n31.\nDefendant\nRicardo\nFonseca\nde\nMendon\u00e7a\nLima\nwas\nat\nthe\ntime\nof\nthe\nIPO\nthe\nPresident\nof\nthe\nCompany's\nBoard\nand\nsigned\nor\nauthorized\nthe\nsigning\nof\nthe\nCompan\nOnly answer with the company defendants names.",
        "output": "Loma Negra Compa\u00f1\u00eda Industrial Argentina Sociedad An\u00f3nima",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n10. Plaintiff Plumbers & Steamfitters Local  773 Pension Fund purchased Danske Bank \nADRs as set forth in the accompanying certification, in corporated herein by re ference, and has been \ndamaged thereby. \n11. Defendant Danske Bank, headquartered in  Copenhagen, Denmark, provides various \npersonal banking, business banking, corporate and in stitutional, and wealth management products \nand services, along with mortgage  finance, real-estate brokerage , foreign exchange and equity \nservices, and also trades in fixed income produc ts.  The Company operates 280 branches in eight \ncountries, with operations in Denmark, Finland, Sweden, Norway, Ireland, the United Kingdom, and \ninternationally.  Danske Bank ADRs traded in an efficient market throughout  the Class Period, with \nits ordinary shares trading on the OMX in Cope nhagen under the ticker symbol \u201cDANSKE.CO\u201d and \nits ADRs trading largely in tandem on the U.S. over-the-counter (\u201cOTC\u201d) market under various \nticker symbols such as \u201cDNKEY.\u201d  An estimat ed 245 million Danske Bank ADRs are issued, \noutstanding and trading in the Unite d States.  According to the inve stor relations portion of Danske \nBank\u2019s website (visited December 12, 2018), th e Company has \u201ca sponsored level 1 ADR \nprogramme with J.P. Morgan as depositary ba nk,\u201d through which \u201c[t] wo ADRs represent one \nordinary Danske Bank share and are publicly traded  over-the-counter (OTC) in the US.\u201d  In its Case 1:19-cv-00235   Document 1   Filed 01/09/19   Page 4 of 53 \n- 4 - February 6, 2014 annual financial re port (detailed below), Danske Ba nk noted that its shares then \ntraded both on the OTC in the United States an d on the OTX in Denmark, stating that it then \n\u201cestimate[d] that shareholders outside Denmark, main ly in the UK and the US, [held] almost 48% of \nits share capital.\u201d \n12. Defendant Thomas F. Borgen (\u201cBorgen\u201d) was, until he tendere d his resignation on \nSeptember 19, 2018, Danske Bank\u2019s Chief Executive Officer (\u201cCEO\u201d) and a member of its Exe",
        "output": "['Plumbers & Steamfitters, Local 773']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n13. Plaintiff, as set forth in the attached Certification, acquired GEO  securities at \nartificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged corrective disclosures.  \n14. Defendant GEO  is incorporated in  Florida , and the Company\u2019s  principal executive \noffices are located at 621 Northwest 53rd Street, Suite 700,  Boca Raton, Florida 33487 .  GEO \u2019s \ncommon stock trades on the NYSE  under the ticker symbol \u201c GEO .\u201d Case 9:16-cv-81494-DMM   Document 1   Entered on FLSD Docket 08/25/2016   Page 4 of 32 \n5 \n 15. Defendant  George C. Zoley  (\u201cZoley \u201d) has served at all relevant times as  the \nCompany\u2019s Chairman and Chief Executive Officer . \n16. Defendant Brian R. Evans  (\u201cEvans \u201d) has served at all relevant times as the \nCompany\u2019s Chief  Financial Officer  and Senior Vice President . \n17. The defendants referenced above in \u00b6\u00b6 15-16 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \nSUBSTANTIVE ALLEGATI ONS  \nBackground  \n18. GEO  provides government -outsourced services specializing in the management of \ncorrectional, detention, and re -entry facilities, and the provision of community based services and \nyouth services in the United States, Australia, South Africa, the United Kingdom, and Canada.  \nThe Company  operates through four segments: U.S. Corrections & Detention, GEO Community \nServices, International Services, and Facility Construction & Design.  \nMaterially False and Misleading Statements Issued During the Class Period  \n19. The Class P eriod begins on March 1 , 2012, when GEO  filed an Annual Report on \nForm 10 -K with the SEC, announcing the Company\u2019s financial and operating results for the quarter \nand year ended December 31, 2011 (the \u201c2011 10 -K\u201d).  For the quarter, GEO  reported net income  \nof $18.63  million, or $0.3 0 per diluted share, on revenue of $ 406.85  million, compared to net \nincome of $ 23.05 million, or $0.3 6 per diluted share, on revenue of $374 .4 million for the\nOnly answer with the company defendants names.",
        "output": "The GEO Group, Inc",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n Case 3:17-cv-02537   Document 1   Filed 05/03/17   Page 4 of 20 \n5 \n 1 \n2 3 4 5 6 \n7 \n8 9 \n10 11 12 \n13 \n14 15 16 17 18 \n19 \n20 21 22 23 24 \n25 \n26 27 28 11. Plaintiff, as set forth in the accompanying Ce rtification, purchased Sunrun securities at \nartificially inflated prices duri ng the Class Period and was damaged upon the revelation of the alleged \ncorrective disclosure. \n12. Defendant Sunrun is incorporat ed in Delaware and its principal executive offices are \nlocated at 595 Market Street, 29th Floor, San Francisco, Californi a 94105.  Sunrun\u2019s securities are \ntraded on the NASDAQ under the ticker symbol \u201cRUN.\u201d \n13. Defendant Lynn Michelle Jurich (\u201cJurich\u201d) has served at all relevant times as the \nCompany\u2019s Chief Executive Offi cer (\u201cCEO\u201d) and Director.  \n14. Defendant Robert Patrick Komin Jr. (\u201cKomin\u201d) has served at all relevant times as the \nCompany\u2019s Chief Financia l Officer (\u201cCFO\u201d).  \n15. The Defendants referenced above in \u00b6\u00b6 13- 15 are sometimes collec tively referred to \nherein as the \u201cIndividual Defendants.\u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff  Chris Masilionis , as set forth in the attached Certification, \nacquired SLW  securities at artificially inflated prices during the Class Period and was \ndamaged upon the revelation of the alleged corrective disclosures.  \n12. Defendant SLW  provides precious metal streaming service s. SLW  is \nheadquartered in Vancouver , British Columbia, Canada  and trades on the NYSE  \nunder the ticker symbol \u201c SLW .\u201d \n13. Defendant Randy V. J. Smallwood (\u201cSmallwood\u201d) has served as the \nCompany\u2019 s President  since January 2010  and as Chief Executive Officer  (\u201cCEO \u201d) \nfrom April  11, 2011  to the present.  Case 2:15-cv-05146   Document 1   Filed 07/08/15   Page 3 of 15   Page ID #:3 \n- 4 - \nClass Action Complaint for Violation of the Federal Securities Laws  1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 14. Defendant Peter Barnes (\u201c Barnes \u201d) served as the C ompany\u2019s CEO from \nthe beginning of the Class Period until his resignation effective April  11, 2011 . \n15. Defendant Gary Brown  (\u201cBrown \u201d) served as the Company\u2019s Chief \nFinanc ial Officer  (\u201cCFO \u201d) throughout the entire Class Period.  \n16.  The defendants referenced above in \u00b6\u00b6 1 3 \u2013 15 are sometimes referred \nto herein as the \u201cIndividual Defendants. \u201d \n17. Defendant SLW  and the Individual Defendants are referred to herein, \ncollectively, as the \u201c Defendants. \u201d \n",
        "output": "['Chris Masilionis']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff is, and at all relevant times has been, a holder of Thunder Bridge  common \nstock.  \n12. Defendant Thunder Bridge  is a blank check company formed in order to effect a \nmerger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar \nbusiness combination with one or more businesses or entities.  The Company \u2019s principal executive \noffice is located at 9912 Georgetown Pike Suite D203 Great Falls, Virginia 22066 . Thunder \nBridge\u2019s securities are quoted on the Nasdaq stock exchange under the ticker symbols THBRU, \nTHBR and THBRW.  \n13. Individual Defendant Gary Simanson  has served as the  Chief Executive Officer and \nas a director  at all relevant times .  \n14. Individual Defendant David E. Mangum  has served as a director at all relevant \ntimes.  \n15. Individual Defendant Mary Ann Gillespie  has served as director of the Company at \nall relevant times.  \n16. Individual Defendant Robert Hartheimer  has served as director of the Company at \nall relevant times.  \n17. Individual Defendant Stewart Paperin  has served as director of the Company at all \nrelevant times.  \n18. Individual Defendant Allerd Derk Stikker  has served as a director of the Company \nat all relevant times.  \n19. The Individual Defendants referred  to in \u00b6\u00b6 13-18 are collectively referred to herein \nas the \u201cIndividual Defendants \u201d and/or the \u201cBoard \u201d, and together with Thunder Bridge  they are Case 1:21-cv-01768   Document 1   Filed 03/01/21   Page 4 of 14 \n \n5 \n referred  to herein as the \u201cDefendants .\u201d \n \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n11. Plaintiff Michael Guttentag, as set fo rth in the accompanying certification, \nincorporated by reference herein, purchased Ji anpu shares during the Class Period, and suffered \ndamages as a result of the federal securities law violations and false and/ or misleading statements \nand/or material omissi ons alleged herein.  \n12. Defendant Jianpu is incorporated under the laws of the Cayman Islands with its \nprincipal executive offices locate d in Beijing, China. Jianpu\u2019s ADSs trade on the New York Stock \nExchange (\u201cNYSE\u201d) under the symbol \u201cJT.\u201d  Case 1:21-cv-01419   Document 1   Filed 02/17/21   Page 4 of 31 \n4 13. Defendant David Ye (\u201cYe\u201d) was the Comp any\u2019s Chief Executive Officer (\u201cCEO\u201d) \nat all relevant times. \n14. Defendant Yil\u00fc (Oscar) Chen (\u201cChen\u201d) wa s the Company\u2019s Chief Financial Officer \n(\u201cCFO\u201d) at all relevant times. \n15. Defendants Ye and Chen (collectively th e \u201cIndividual Defendants\u201d), because of \ntheir positions with the Company, possessed the power  and authority to control the contents of the \nCompany\u2019s reports to the SEC, press releases an d presentations to securi ties analysts, money and \nportfolio managers and institutional investors, i. e., the market.  The Individual Defendants were \nprovided with copies of the Company\u2019s reports and press releases alleged herein to be misleading \nprior to, or shortly after, their issuance and had the ability and oppor tunity to prevent their issuance \nor cause them to be corrected.  Because of their positions and access to material non-public \ninformation available to them, the Individual Defendants knew th at the adverse facts specified \nherein had not been disclosed to, and were being concealed from, the public,  and that the positive \nrepresentations which were being made were th en materially false and/or misleading.  The \nIndividual Defendants are liable for th e false statements pleaded herein.  \n",
        "output": "['Michael Guttentag']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n6. Plaintiff is, and has been at all relevant times hereto , an owner of Garrison\u2019s  \ncommon stock.  \n7. Defenda nt Garrison  is a business development company specializing in \ninvestments primarily in the debt and equity of middle market companies. The Company is Case 1:20-cv-04512   Document 1   Filed 09/23/20   Page 2 of 16 PageID #: 23 incorporated in Delaware and headquartered in New York City . The Company\u2019 s common stock  \ntrade s on the Nasdaq Global Select  Market  under the ticker symbol , \u201cGARS .\u201d \n8. Defendant Joseph Tansey ( \u201cTansey \u201d) is Chief Executive Officer  and Chairman of \nthe Board of the Company. \n9. Defendant Brian Chase (\u201cChase\u201d) is a director of the Company . \n10. Defendant Cecil Martin  (\u201cMartin \u201d) is a director of the Company.  \n11. Defendant Joe Morea (\u201cMorea\u201d) is a director of the Company.  \n12. Defendant Matthew Westwood  (\u201cWestwood \u201d) is a director of the Company. \n13. Defendants Tansey , Chase , Martin , Morea, and Westwood are collectively referred \nto herein as the \u201c Individual Defendants.\u201d  \n14. Defendants Garrison  and the Individual Defendants are collectively referred to \nherein as the \u201c Defendants. \u201d \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n10. Plaintiff Charlene Jones  is, and has been continuously throughout all \ntimes relevant hereto, the owner of Accuride  common stock.  Charlene Jones  is a \ncitizen of Tennessee . \n11. Defendant Accuride is a Delaware corporation and maintains its \nprincipal executive offices at 7140 Office Circle, Evansville, Indiana.  The Company \nis a leading supplier of components to the North American and European commercial \nvehicle industries.  Accuride\u2019s common stock is traded on the New York Stock \nExchange under the ticker symbol \u201cACW.\u201d  \n12. Defendant Richard F. Dauch  (\u201cDauch \u201d) has served as President and \nChief Executive Officer (\u201cCEO\u201d) and a director of Accuride  since February 1, 2011.  \n13. Defendant John W. Risner  (\u201cRisner \u201d) has served as Chairman and a \ndirector of Accuride since 2010.  Risner is also a member of the Audit Committee  and \nNominating and Corporate Governance Committee.  \n14. Defendant Robert E. Davis  (\u201cDavis \u201d) has served as a director of Accuride Case 3:16-cv-00210-RLY-MPB   Document 1   Filed 10/20/16   Page 4 of 45 PageID #: 45 \n since 2013.  Davis serves as the representative of Accur ide\u2019s largest stockholder, \nCetus Capital, LLC, and was appointed to the Accuride Board pursuant to that \ncertain Investors Agreement, dated De cember 19, 2012.  Da vis is also the Chairman \nof the Compensation  and Human Resources Committee.  \n15. Defendant Lewis Kling  (\u201cKling \u201d) has served as a director of Accuride \nsince 201 2.  Kling is also the Chairman of the Nominating and Corporate Governance \nCommittee . \n16. Defendant Robert J. Adams  (\u201cAdams \u201d) has served as a director of \nAccuride since 2013.  Adams is also the Chairman  of the Audit Committee.  \n17. Defendant Keith E. Busse  (\u201cBusse \u201d) has served as a director of Accuride \nsince 2010.  Busse is also a member of the  Compensation and Human Resources \nCommittee  and the Nominating and Corporate Governance Committee . \n18. Defendant James R. Rulseh  (\u201cRulseh \u201d) has served as a director of \nAccuri\nIndividual defendants:",
        "output": "Richard F Dauch,John W Risner,Robert E Davis,Lewis Kling,Robert J Adams,Keith Busse,James R Rulseh",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n13. Plaintiff, as set forth in the attached Certification, acquired Acacia  securities at \nartificially inflated prices during the Class Period and was damaged upon the revelation of th e \nalleged corrective disclosures.  \n14. Defendant Acacia  is incorporated in Delaware , with  principal executive offices \nlocated at Three Mill and Main Place, Suite 400, Maynard, Massachusetts 01754.   Acacia \u2019s \nshares trade  on the NASDAQ  under the ticker symbol \u201c ACIA.\u201d \n15. Defendant Murugesan Shanmugaraj  (\u201cShanmugaraj \u201d) has served at all relevant \ntimes as the Company\u2019s Chie f Executive Officer  (\u201cCEO\u201d), President and Director.   \n16. Defendant John F. Gavin (\u201cGavin\u201d)  has served at all relevant times as the \nCompan y\u2019s Chief Fina ncial Officer (\u201cCFO\u201d) . \n17. The def endants referenced above in \u00b6\u00b6 15-16 are sometimes referred to herein as \nthe \u201cIndividual Defendants.\u201d  \n\nOnly answer with the company defendants names.",
        "output": "Acacia Communications, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n5. Plaintiff Shanice Christie  purchased Cloudera common stock on the public market \nduring the Class Period as described in the Certification attached hereto and incorporated herein by \nreference and suffered damages  as a result of the violations of the federal securities laws alleged \nherein.  \n6. Defendant Cloudera is a data management and software company  incorporated under \nthe laws of Delaware with its principal executive offices located at 395 Page Mill Road, Palo Alto, \nCalifornia.  The Company\u2019s common stock trades on the New York Stock Exchange (\u201cNYSE\u201d) under \nthe symbol \u201cCLDR.\u201d  As of May 31, 2019, there w ere 274,207,493 shares of the Company\u2019s common \nstock outstanding.  \n7. Defendant Thomas J. Reilly (\u201cReilly\u201d) was Cloudera\u2019s Chief Executive Officer \n(\u201cCEO\u201d) and a director throughout the Class Period.  He announced his sudden retirement on the last \nday of the Class Period.  \n8. Defendant Jim Frankola (\u201cFrankola\u201d) was Cloudera\u2019s Ch ief Financial Officer \n(\u201cCFO\u201d) throughout the Class Period.  Case 5:19-cv-03221   Document 1   Filed 06/07/19   Page 3 of 29 \n3 \nCLASS ACTION COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS  \n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 9. Defendant Michael A. Olson (\u201cOlson\u201d) founded Cloudera and served as its Chief \nStrategy Officer (\u201cCSO\u201d) and Chairman of its board of directors (the \u201cBoard\u201d) during the Class Period  \nuntil January 3, 2019 .  \n10. Defendants Reilly, Frankola , and Olson are collectively referred to herein as the \n\u201cIndividual Defendants.\u201d  During the Class Period, the Individual Defendants ran the Company as \nhands -on managers overseeing Cloudera\u2019s operations and finances and mad e the materially false and \nmisleading statements described herein.  The Individual Defendants had intimate knowledge about \ncore aspects of Cloudera\u2019s financial and business operations.  They were also intimately involved in \ndeciding which disclosures would  b\nOnly answer with the company defendants names.",
        "output": "Cloudera, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8.  Plaintiff , as set forth in the accompanying cert ification incorporated by refere nce \nherein,  purchased Sundial  shares  pursuant and/or traceable to the IPO and was damaged thereby . \n9. Defendant Sundial is incorporated in the Province of Alberta, Canada and \nmaintains its principal executive offices in Calgary in Albert a, Canada . Sundial purports to \nproduc e and ma rket craft pioneering cannabis brands to \u201cHeal, He lp and Play.\u201d Sundial operates \nfive facilities, including two facilities in Alberta, Canada and three in  the United Kingdom, and \nas of August 2019, was building a third Canadian facility in British Columbia . Sundial \u2019s shares  \nare listed on NASDAQ under the t icker symbol \u201c SNDL .\u201d The Company\u2019s registered agent for \nservice of process in the U.S. is Corporation Service Company, 1180 Avenue of the Americas, \nSuite 210, New York, NY 10036 - 8401. The transfer  agent a nd registrar for Sundial\u2019s common \nstock in the U.S. is Equity Stock Transfer, LLC at its principa l office in New York, New  York.  \n10. Defendant Torsten Kuenzlen (\u201cKuenzlen\u201d) is, and was at t he time of the IPO, a \nmember of Sundial\u2019s Board of Directors (the \u201cBoar d\u201d) and the Company\u2019s Chief Executive \nOfficer (\u201cCEO\u201d). At the time of the IPO, Kuenzlen owned approximately 3.7  million Sundial \nshares, or 4.94% of the Company\u2019s common stock.  Defendant  Kuenzlen  signed or authorized the \nsigning and issuance of the Registra tion Statement.   Case 1:19-cv-08913   Document 1   Filed 09/25/19   Page 3 of 174 \n 11. Defendant James Keough (\u201cKeough\u201d) is, and was at the time of the IPO, the Chief \nFinancial Officer  (\u201cCFO \u201d) of Sundial.  Defendant Keough  reviewed, contributed to, and signed \nthe Registration S tatement. Defendant Keough  signed or auth orized t he signing and issuance of \nthe Registration Statement.  \n12. Defendant Edward Hellard (\u201cHellard\u201d), is, and was at the time of the IPO, \nSundial \u2019s Executive Chairman of the Company\u2019s Board . At the time of the IPO, Hel\nIndividual defendants:",
        "output": "Torsten Kuenzlen,James Keough,Edward Hellard,Greg Mills,Gregory Turnbull,Lee Tamkee,Elizabeth Cannon",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n Plaintiff Michael Tollen  purchased Geron common stock on the public market  \nduring the Class Period as described in the Certification attached hereto and incorporated herein \nby reference and suffered damages as a result of the violations of the federal securities laws \nalleged herein.  \n Defendant Geron is a biopharmaceutical company with its headquarters located \nin Menlo Park, California.  Geron\u2019s common stock is traded under the symbol GERN on the \nNASDAQ, which is an efficient market.  As of November 1, 2019 , there were \n199,777, 619 shares of the Company\u2019s common stock outstanding.  \n Defendant John A. Scarlett was, at all relevant times, Presi dent and CEO of the \nCompany throughout the Class Period.  \n During the Class Period, Defendant Scarlett ran the Company as a hands -on \nmanager overseeing Geron\u2019s operations and finances and made the materially false and \nmisleading statements described herein.  Defendant Scarlett had intimate knowledge about core \naspects of Geron\u2019s financial and business operations.  He was also intimately involved in Case 3:20-cv-00547   Document 1   Filed 01/23/20   Page 5 of 24 \n 5  \n CLASS ACTION COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS  \n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 deciding which disclosures would be made by Geron.  Because of his position and access to \nmaterial non -public in formation available to him, Defendant Scarlett knew that the adverse facts \nspecified herein had not been disclosed to, and were being concealed from, the public, and that \nthe positive representations which were being made were then materially false and/or \nmisleading.  Defendant Scarlett, because of his position with Geron, possessed the power and \nauthority to control the contents of the Company\u2019s reports to the SEC, press releases, and \npresentations to securities analysts, money and portfolio managers, and institutional investors.  \nDefendant Scarlett was p\nOnly answer with the company defendants names.",
        "output": "Geron Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n15. Plainti ff, as set forth in the attached Certification, acquired Humanigen  \nsecurities at artificially inflated prices during the Class Period and was damaged \nupon the revelation of the alleged corrective disclosures.  Case 1:22-cv-05258   Document 1   Filed 08/26/22   Page 5 of 37 PageID: 5 \n6 \n 16. Defendant Humanigen  is a Delaware corporation  with principal \nexecutive offices located at 830 Morris Turnpike, 4th Floor, Short Hills, New Jersey \n07078 .  Humanigen \u2019s common stock  trade s in an efficient market on the Nasdaq \nStock Market (\u201cNASDAQ \u201d) under the trading symbol \u201cHGEN \u201d. \n17. Defendant Cameron Durr ant (\u201cDurrant \u201d) has served as Humanigen\u2019s \nChairman and Chief Executive Officer at all relevant times.  \n18. Defendant Timothy Morris (\u201cMorris \u201d) has served as Humanigen\u2019s \nChief Operating Officer and Chief Financial Officer at all relevant times.  \n19. Defendant s Durrant and Morris are sometimes referred to herein as the \n\u201cIndividual Defendants. \u201d \n20. The Individual Defendants possessed the power and authority to control \nthe contents of Humanigen \u2019s SEC filings, press releases, and other market \ncommunications.  The Indivi dual Defendants were provided with copies of \nHumanigen \u2019s SEC filings and press releases alleged herein to be misleading prior to \nor shortly after their issuance and had the ability and opportunity to prevent their \nissuance or to cause them to be corrected.   Because of their positions with \nHumanigen , and their access to material information available to them but not to the \npublic, the Individual Defendants knew that the adverse facts specified herein had \nnot been disclosed to and were being concealed from th e public, and that the positive \nrepresentations being made were then materially false and misleading.  The Case 1:22-cv-05258   Document 1   Filed 08/26/22   Page 6 of 37 PageID: 6 \n7 \n Individual Defendants are liable for the false statements and omissions pleaded \nherein.  \n21. Humanigen  and the Individual Def\nIndividual defendants:",
        "output": "Cameron Durrant,Timothy Morris",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n10. Plaintiff  is, and has been at all relevant times, the owner of Jaguar common stock \nand held such stock since prior to the wrongs complained of herein.   \n11. Defendant Jaguar is a Delaware Corporation with its principle executive offices \nlocated at 201 Mission Street, Suite  2375 San Francisco, CA 94105.  Jaguar is an animal health \ncompany focused on developing and commercializing first- in-class gastrointestinal products for \ncompanion and production animals, foals, and high value horses .  Jaguar\u2019s common stock trades \non the NASDAQ under the symbol \u201cJAGX\u201d.  \n12. Individual Defendant James J. Bochnowski is a director of Jagu ar and is the \nChairman of the Board.   \n13. Individual Defendant Lisa Conte is a director of Jaguar and is the founder and \nChief Executive Officer of the Company.  \n14. Individual Defendant Bernard M. Goldsmith is, and has been at all relevant times, \na director of th e Company.  Case 3:17-cv-04102   Document 1   Filed 07/20/17   Page 4 of 17 \n \n5 \nCLASS ACTION COMPLAINT   1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 15. Individual Defendant Jiahao Qiu is, and has been at all relevant times, a director \nof the Company.  \n16. Individual Defendant Zhi Yang is, and has been at all relevant times, a director of \nthe Company.  \n17. Individual Defendant Folkert Kamphuis is, and has  been at all relevant times, a \ndirector of the Company.  \n18. Individual Defendant John Micek III is, and has been at all relevant times, a \ndirector of the Company.  \n19. Individual Defendant Ari Azhir is, and has been at all relevant times, a director of \nthe Company . \n20. The defendants identified in paragraphs 11- 19 are collectively referred to as the \n\u201cDefendants\u201d.  \nCLASS ACTION ALLEGAT IONS  \n21. Plaintiff brings this action on his own behalf and as a class action pursuant to \nRule 23 of the Federal Rules of Civil Procedure on behalf of all holders of Jaguar common stock \nwho are being and wi\nIndividual defendants:",
        "output": "James J Bochnowski,Lisa Conte,Bernard M Goldsmith,Jiahao Qiu,Zhi Yang,Folkert Kamphuis,John Micek III,Ari Azhir",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n15. Plaintiff Mohammed Usman Ali, as set forth in the accompanying \ncertification, incorporated by re ference herein, purchased Fran klin securities during \nthe Class Period, and suffered damages as a result of the feder al securities law \nviolations and false and/or misleading statements and/or materi al omissions alleged \nherein.  \n16. Defendant Franklin is incorporat ed under the laws of Nevada wit h its \nprincipal executive offices locat ed in San Diego, California. F ranklin\u2019s common \nstock trades on the NASDAQ exc hange under the symbol \u201cFKWL.\u201d  \n17. Defendant OC Kim (\u201cKim\u201d) was the Company\u2019s President at all \nrelevant times. \n18. Defendant David Brown (\u201cBrown\u201d)  was the Company\u2019s Acting Chief \nFinancial Officer (\u201cCFO\u201d) a t all relevant times.  Case 3:21-cv-00687-AJB-MSB   Document 1   Filed 04/16/21   PageID.4   Page 4 of 211\n23456789\n10111213141516171819202122232425262728 \n 4  19. Defendants Kim and Brown (collec tively the \u201cIndividual Defendan ts\u201d), \nbecause of their positions with the Company, possessed the powe r and authority to \ncontrol the contents of the Company\u2019s reports to the SEC, press  releases and \npresentations to securities analysts, money and portfolio manag ers and institutional \ninvestors, i.e., the market.  The Individual Defendants were pr ovided with copies of \nthe Company\u2019s reports and press releases alleged herein to be m isleading prior to, or \nshortly after, their issuance and had the ability and opportuni ty to prevent their \nissuance or cause them to be corr ected.  Because of their posit ions and access to \nmaterial non-public information available to them, the Individu al Defendants knew \nthat the adverse facts specified herein had not been disclosed to, and were being \nconcealed from, the public, and that the positive representatio ns which were being \nmade were then materially false  and/or misleading.  The Individ ual Defendants are \nliable for the false statements pleaded herein.  \n",
        "output": "['Mohammed Usman Ali']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 8. Plaintiff Louisiana Sheriffs is a multi-employer, defined benefit, governmental \nretirement plan providing retirement, disability and death benefits to approximately 25,000 active \nand retired employees of the sheriff\u2019s offices in all 64 Louisiana parishes.  As of June 30, 2016, \nPlaintiff managed roughly $3 billion in assets.  As indicated on the certification submitted \nherewith, Plaintiff purchased shares of Cardinal stock during the Class Period at artificially inflated \nprices and suffered damages as a result of the violations of the federal securities laws alleged \nherein. Case: 2:19-cv-03347-EAS-EPD Doc #: 1 Filed: 08/01/19 Page: 4 of 32  PAGEID #: 44 9. Defendant Cardinal is a global, integrated healthcare services and products \ncompany.  Incorporated in Ohio, the Company maintains its headquarters at 7000 Cardinal Place, \nDublin, Ohio 43017.  The Company\u2019s common stock trades on the NASDAQ, which is an efficient \nmarket, under ticker symbol \u201cCAH.\u201d  As of January 31, 2019, Cardinal had over 298 million shares \nof stock outstanding, owned by at least hundreds or thousands of investors. \n10. Defendant George S. Barrett (\u201cBarrett\u201d) was Cardinal\u2019s Chief Executive Officer \n(\u201cCEO\u201d) from August 31, 2009 to January 1, 2018.  Barrett also served as the Executive Chairman \nof the Board of Cardinal from August 31, 2009 to November 7, 2018. \n11. Defendant Donald M. Casey, Jr. (\u201cCasey\u201d) was the CEO of the Medical Segment \nat Cardinal from April 2012 until February 2018, where he had full management responsibility for \nthe Company\u2019s Medical Segment including medical-surgical products and services for hospitals, \nphysician offices, clinical laboratories, ambulatory surgery centers, long-term care facilities and \nother health care providers.  The Cordis business reported to Casey, and Casey was responsible for \nmanaging Cordis\u2019s integration into Cardinal\u2019s operations. \n12. Defendant Michael C. Kaufmann (\u201cKaufmann) has been CEO and a member of the \nCompany\u2019s Board of Dire\nOnly answer with the company defendants names.",
        "output": "Cardinal Health, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n16. Plaintiff NECA -IBEW Pension Trust Fund (The Decatur Plan) was at all times \nrelevant hereto a sharehold er of PCC.  \n17. Plaintiff Angela Lohmann, as Trustee for the Angela Lohmann Revocable Trust was \nat all times relevant hereto a shareholder of PCC.  \n18. Defendant PCC was an Oregon corporation headquartered in Portland, Oregon.  PCC, \nas a result of the Acquisition, is now 100% owned by Berkshire.  Case 3:16-cv-01756-YY    Document 1    Filed 09/02/16    Page 5 of 29 \n{SSBLS Main Documents/8636/001/0060 3605 -1 } \nPAGE 5 \u2013 CLASS ACTION ALLEGATION COMPLAINT   \n \nSTOLL STOLL BERNE LOKTING & SHLACHTER P.C.  \n209 S.W. OAK STREET, SUITE 500  \nPORTLAND, OREGON 97204  \nTEL. (503) 227- 1600   FAX (503) 227- 6840 19. Defendant Mark Donegan was the CEO and Chairman of the Board of PCC and was \nat all relevant times a director and Chairman of the Board, and is now an employee of Berkshire.  \n20. Defendant Don R. Graber was at all relevant times a director of PCC.  \n21. Defendant Lester L. Lyles was at all relevant times a director of PCC.  \n22. Defendant Daniel J. Murphy was at all relevant times a director of PCC.  \n23. Defendant Vernon E. Oechsle was at all relevant times a director of PCC.  \n24. Defendant Ulrich Schmi dt was at all relevant times a director of PCC.  \n25. Defendant Richard L. Wambold was at all relevant times a director of PCC.  \n26. Defendant Timothy A. Wicks was at all relevant times a director of PCC.  \n27. The defendants named above in \u00b6\u00b6  19-26 are sometimes collectiv ely referred to \nherein as the \u201cIndividual Defendants.\u201d  \nCLASS ACTION ALLEGAT IONS  \n28. Plaintiffs\u2019 claims are brought as a class action pursuant to Federal Rule of Civil \nProcedure 23 on behalf of all public holders of PCC stock who were harmed by defendants\u2019 acti ons \ndescribed below (the \u201cClass\u201d).  Excluded from the Class are defendants herein and any person, firm, \ntrust, corporation, or other entity related to or affiliated with any defendants.  \n29. Plaintiffs\u2019 claims ar\nOnly answer with the company defendants names.",
        "output": "Precision Castparts Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 12. Plaintiff, as set forth in the attached Certification, acquired TechnipFMC securities at artificially inflated prices during the Class Period and was damaged upon the revelation of the alleged corrective disclosures.  Case 4:17-cv-02368   Document 1   Filed in TXSD on 08/03/17   Page 4 of 20 \n5  13. Defendant TechnipFMC is headquartered in London, the United Kingdom, with principal executive offices located at One St. Paul\u2019s Churchyard, London EC4M 8AP, the United Kingdom, and its U.S. headquarters are located at 11740 Katy Freeway, Energy Tower 3, Houston, Texas 77079. TechnipFMC\u2019s shares trade on the NYSE under the ticker symbol \u201cFTI.\u201d 14. Defendant Douglas J. Pferdehirt (\u201cPferdehirt\u201d) has served at all relevant times as the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) and Director.  15. Defendant Maryann T. Mannen (\u201cMannen\u201d) has served at all relevant times as the Company\u2019s Chief Financial Officer (\u201cCFO\u201d) and Executive Vice President. 16. The defendants referenced above in \u00b6\u00b6 14-15 are sometimes referred to herein as the \u201cIndividual Defendants.\u201d ",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n24. Plaintiff, as set forth in the attached Certification, acquired Altria  securities at \nartificially inflated prices during the Class Period and was damaged upon the revelation of the \nalleged cor rective disclosures.  \n25. Altria  is a Virginia -registered  corporation with principal executive offices located \nat 6601 West Broad Street , Richmond, Virginia 23230 .  The Company \u2019s stock trades in an efficient \nmarket  on the New York Stock Exchange  (\u201cNYSE \u201d) under the ticker symbol \u201c MO.\u201d \n26. Defendant Howard A. Willard III  (\u201cWillard \u201d) has served as Altria \u2019s Chairman and \nCEO  at all relevant times.  \n27. Defendant William F. Gifford, Jr.  (\u201cGifford \u201d) has served as Altria \u2019s Vice Chairman \nand Chief Financial Officer at all relevant times.  \n28. Defendant s Willard  and Gifford  are sometimes referred to herein  collectively  as the \n\u201cIndividual Defendants.\u201d  \n29. The Individual Defendants possessed the power and authority to control the \ncontents of Altria \u2019s SEC filings, press releases, and other market communications.  The Individual \nDefendants were provided with copies of Altria \u2019s SEC filings and press releases alleged herein to Case 1:19-cv-05579   Document 1   Filed 10/02/19   Page 6 of 29 PageID #: 6 \n7 \n be misleading prior to or sh ortly after their issuance and had the ability and opportunity to prevent \ntheir issuance or to cause them to be co rrected.  Because of their positions with Altria , and their \naccess to material information available to them but not to the public, the Individual Defendants \nknew that the adverse facts specified herein had not been disclosed to and were being concealed \nfrom the public, and that the positive representations being made were then materially false and \nmisleading.  The Individual Defendants are liable for the false statements and omissions pleaded \nherein.  \n\nOnly answer with the company defendants names.",
        "output": "Altria Group, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n14. Plaintiff General Retirement System of the City of Detroit purchased Sea Notes  \ndirectly in the Offering  and has been damaged thereby.  \n15. Defendant Sea is an online gaming and e -commerce company. It is headquartered \nin Singapore and incorporated in the Cayman Islands.   \n16. Defendant Li co -founded Sea and has served as its Chairman of the Board of \nDirectors (the \u201cBoard\u201d) and Chief Executive Officer (\u201cCEO\u201d) since May 2009. Li revie wed, FILED: NEW YORK COUNTY CLERK 06/17/2022 05:52 PMINDEX NO. 155162/2022\nNYSCEF DOC. NO. 1 RECEIVED NYSCEF: 06/17/2022\n9 of 41 \n   \n5  contributed to, and signed the Offering  Materials. Pursuant to a Power of Attorney, Li was \nauthorized to sign the Offering  Materials as attorney -in-fact for Defendants Tony Tianyu Hou \n(\u201cHou\u201d), Khoon Hua Kuok (\u201cKuok\u201d), David Heng Chen Seng (\u201cSeng\u201d), Re n, and Gang Ye (\u201cYe\u201d), \neach of whom personally signed the September 8, 2021 Form F -3. \n17. Defendant Ye co -founded Sea and has served as a Board member since March \n2010.  Ye has served as Sea\u2019s COO since January 2017 and as its Group Chief Technology Officer, \nfrom March 2010 to December 2016. Ye reviewed, contributed to, and signed the Offering  \nMaterials.  \n18. Defendant Hou has served as a Board member since February 2018. Hou joined \nSea in September 2010 and has served as its Chief Financial Officer since January 20 13. Hou \nreviewed, contributed to, and signed the Offering  Materials.  \n19. Defendant Tencent is a technology conglomerate headquartered in Shenzhen, \nChina, and a principal shareholder of Sea . As described below, Tencent has consistently held a \ncontrolling intere st in Sea and was involved in developing the Company\u2019s most valuable game, \nFree Fire.  \n20. Defendant Ren has served as a Board member since September 2013 and thus \nserved in that capacity when Sea completed its 2017 initial public Offering  (\u201cIPO\u201d). Since May \n2012, he has been COO of Tencent, and leads the development of Tencent\u2019s Platform & Content",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " 10. Plaintiff Donna Esposito, as set forth in the accompanying certification, incorporated by reference herein, purchased Block securities during the Class Period, and suffered damages as a result of the federal securities law violations and false and/or misleading statements and/or material omissions alleged herein.  11. Defendant Block is incorporated under the laws of Delaware. The Company \u201cdo[es] not designate a headquarters location as [it has] adopted a distributed work model.\u201d Block\u2019s Class A common stock trades on the New York Stock Exchange (\u201cNYSE\u201d) under the symbol \u201cSQ.\u201d  12. Defendant Jack Dorsey (\u201cDorsey\u201d) was the Company\u2019s Chief Executive Officer (\u201cCEO\u201d) at all relevant times. 13. Defendant Amrita Ahuja (\u201cAhuja\u201d) was the Company\u2019s Chief Financial Officer (\u201cCFO\u201d) at all relevant times.  14. Defendants Dorsey and Ahuja (collectively the \u201cIndividual Defendants\u201d), because of their positions with the Company, possessed the power and authority to control the contents of the Company\u2019s reports to the SEC, press releases and presentations to securities analysts, money and portfolio managers and institutional investors, i.e., the market.  The Individual Defendants were provided with copies of the Company\u2019s reports and press releases alleged herein to be misleading prior to, or shortly after, their issuance and had the ability and opportunity to prevent their issuance or cause them to be corrected.  Because of their positions and access to material non-public information available to them, the Individual Defendants knew that the adverse facts specified herein had not been disclosed to, and were being concealed from, the public, and that the Case 1:22-cv-08636   Document 1   Filed 10/11/22   Page 4 of 204  positive representations which were being made were then materially false and/or misleading.  The Individual Defendants are liable for the false statements pleaded herein.  ",
        "output": "['Donna Esposito']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n12. Plaintiff has maintained shares of Loral Space common stock at all relevant times.  \n13. Defendant Loral Space & Communications, Inc. is incorporated under the laws of \nDelaware  with its  principal executive offices l ocated at  600 Fifth Ave, 16th Floor, New York, \nNY, 10020. The Company\u2019 s common stock trades on the N asdaq  under the ticker symbol \n\u201cLORL \u201d. \n14. Individual Defendant Mark H. Rachesky  is, and has been at all relevant times,  the \nformer Chief Executive Officer  and Non -Executive Chairman of the Board. \n15. Individual Defendant Michael B. Targoff  is, and has been at all relevant times, a \ndirector of Loral Space.  \n16. Individual Defendant John D. Harkey Jr. is, and has been at all relevant times,  a \ndirector of  Loral Space.  \n17. Individual Defendant Arthur L. Simon is, and has been at all relevant times,  a \ndirector of  Loral Space.  \n18. Individual Defendant John P. Stenbit  is, and has been at all relevant times,  a director \nof Loral Space.  \n19. Individual Defendant Janet T. Yeung  is, and has been at all relevant times,  a director \nof Loral Space.  \n20. The defendants identified in paragraphs 14 through 19 are collectively referred to Case 1:21-cv-04007   Document 1   Filed 05/05/21   Page 4 of 185  herein as the \u201c Board \u201d or the \u201c Individual Defendants,\u201d  and together wit h Loral Space, the \n\u201cDefendants. \u201d  \n\nOnly answer with the company defendants names.",
        "output": "Loral Space & Communications, Ltd.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n11. Plaintiff  is, and has been at all relevant times  hereto , an owner of Builders  common \nstock .  \n12. Defendant Builders manufactures and supplies building materials, manufactured \ncomponents, and construction services to professional homebuilders, sub -contractors, remodelers, Case 2:20-cv-15553   Document 1   Filed 11/04/20   Page 3 of 15 PageID: 34 and consumers in the United States. The Company serves the New Jersey market in several \nlocations throughout  the State .1 The Company is incorporated in Delaware . The Company \u2019s \ncommon stock  trade s on the NASDAQ  under the ticker symbol , \u201cBLDR .\u201d \n13. Defendant Paul S. Levy  (\u201cLevy \u201d) is Chairman of the Board of the Company . \n14. Defendant Daniel Agroskin (\u201cAgroskin\u201d) is a director of the Company.  \n15. Defendant David A. Barr (\u201cBarr\u201d) is a director of the Company.  \n16. Defendant Cleveland A. Christophe (\u201cChristophe\u201d) is a director of the Company.  \n17. Defendant Chad Crow (\u201cCrow\u201d) is Chief Executive Officer and a director of the \nCompany.  \n18. Defendant Janice Davis (\u201cDavis\u201d) is a director of the Company.  \n19. Defendant William Bradley Hayes (\u201cHayes\u201d) is a director of the Company.  \n20. Defendant Brett N. Milgrim  (\u201cMilgrim \u201d) is a director of the Company.  \n21. Defendant Floyd F. Sherman  (\u201cSherman \u201d) is a director of the Company.  \n22. Defendant Craig Steinke  (\u201cSteinke \u201d) is a director of the Company.  \n23. Defendants Levy , Agroskin , Barr, Christophe, Crow, Davis, Hayes, Milgrim, \nSherman , and Steinke are collectively referred to herein as the \u201cIndividual Defendants. \u201d \n24. Defendants Builders  and the Individual Defendants are collectively referred to \nherein as the \u201cDefendants. \u201d \n\nOnly answer with the company defendants names.",
        "output": "Builders FirstSource, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and  has been continuously throughout all times relevant hereto, the \nowner of LogMeIn common stock.  \n9. Defendant LogMeIn is a Delaware corporation and a party to the Merger \nAgreement.   LogMeIn common stock is  traded on the NASDAQ under the ticker symbol  \n\u201cLOGM. \u201d \n10. Defendant Robert M. Calderoni is Ch airman of the Board of the  Company.  \n11. Defend ant Sara C. Andrews is  a director of the Company \n12. Defendant Steven J. Benson is a director of the  Company. \n13. Defendant Ita Brennan  is a director of the  Company. \n14. Defend ant Michael J. Christenson is a director of t he Company \n15. Defendant Edwin J. Gillis  is a director of the  Company. \n16. Defendant David J. Henshall  is a director of the  Company. \n17. Defendant Peter J. Sacripanti is  a director of the Company. \n18. Defendant William R. Wagne r is President & Chief Executive Officer and a \ndirector of the Company.  \n19. The defendants ident ified in paragraphs 11 through 19 are collectively referred \nto herein as the \u201cIndividual  Defendants.\u201d  \nFACTS  \n20. LogMeIn is a leading provider of unified communications and collaboration, identity \nand access management, and customer engagement and support solutions.   LogMeIn simplif ies how Case 1:20-cv-00582   Document 1   Filed 01/22/20   Page 3 of 11people connect with each other and the world around them to drive meaningful interactions, deepen \nrelationships, and create better out comes for individuals and businesses. LogMeIn has millions of \ncustomers spanning virtually every country across the globe. LogMeIn is headquartered in Boston, \nMassachusetts with additional locations in North America, South America, Europe, Asia and Austral ia. \n21. On December 17 , 2019, LogMeIn\u2019s Board caused the Company to enter into the \nMerger Agreement . \n22. Pursuant  to the terms  of the Merger Agreement,  LogMeIn\u2019s  stockholders  will receive \n$86.05 in cash  for each share of LogMeIn common stock they own in an all -cash merger .  \n23. T",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n9. Plaintiff is, and has been continuously throughout all times relevant hereto, a \nTengasco shareholder.  \n10. Defendant Tengasco is a Delaware corporation and a party to the Merger \nAgreement.  Tengasco  shares are traded on the N YSE  under the ticker symbol \u201c TGC .\u201d  \n11. Peter  E. Salas is Chairman of the Board of the Company.  \n12. Matthew K. Behren is a director of the Company.  \n13. Richard M. Thon is a director of the Company. \nFACTS  \n14. Tengasco  is an independent oil and gas company that utilizes technologi es to \nexplore for, develop and produce domestic oil and natural gas reserves, and engage in well drilling activities.  \n15. REP operates as an oil and gas company. REP focuses on acquisition, \ndevelopment and production of oil, natural gas, and natural gas liquid. REP operates in West Texas \nand Southeastern New Mexico.  \n16. On October 21, 2020, Tengasco\u2019s Board caused the Company to ente r into the \nMerger Agreement .   \n17. The Merger Agreement provides that Tengasco has agreed with REP , a Delaware \ncorporation,  and Antman Sub, LLC, a newly-formed Delaware limited liability company and Case 1:20-cv-10111   Document 1   Filed 12/02/20   Page 3 of 114 \n wholly-owned subsidiary of Tengasco (\u201cMerger Sub\u201d). Under the Merger Agreement, among \nother things and subject to terms and conditions set forth therein, Merger Sub will be merged w ith \nand into REP  with REP surviving as a subsidiary of Tengasco (the \u201cMerger\u201d).   \n18. At the Effective Time (as defined in the Merger Agreement), and as a result of the \nMerger:  \neach REP common unit outstanding immediately prior to the effective time \n(excluding any REP common units held as treasury stock or held by any \nsubsidiary of REP) will be converted solely into the right to receive: (i) a number \nof shares of TGC common stock equal to the Exchange Ratio (together with any \ncash to be paid in lieu o f fractional shares of TGC common stock payable \npursuant to the merger agreement) and (ii) any dividends \nOnly answer with the company defendants names.",
        "output": "Tengasco, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " 9. Plaintiff is, and has been at all relevant times, the owner of Sykes common stock and has held such stock since prior to the wrongs complained of herein. 10. Individual Defendant Mark Bozek has served as a member of the Board since May 2019. 11. Individual Defendant James S. Macleod has served as a member of the Board since May 2005 and Non-Executive Chairman of the Board since May 2016.  12. Individual Defendant Chuck Sykes has served as a member of the Board since August 2004 and is the President and Chief Executive Officer.  13. Individual Defendant William D. Muir, Jr. has served as a member of the Board since 2014.  Case 1:21-cv-06043   Document 1   Filed 07/14/21   Page 3 of 154 14. Individual Defendant Lorraine Leigh Lutton has served as a member of the Board since 2014. 15. Individual Defendant Vanessa C.L. Chang has served as a member of the Board since 2016.  16. Individual Defendant Carlos E. Evans has served as a member of the Board since May 2016. 17. Individual Defendant W. Mark Watson has served as a member of the Board since May 2018. 18. Individual Defendant Jeanne Beliveau-Dunn has served as a member of the Board since 2021. 19. Defendant Sykes is incorporated in Florida and maintains its principal offices at 400 North Ashley Drive, Suite 2800, Tampa, FL 33602.  The Company\u2019s common stock trades on the NASDAQ Stock Exchange under the symbol \u201cSYKE.\u201d 20. The defendants identified in paragraphs 10-18 are collectively referred to as the \u201cIndividual Defendants\u201d or the \u201cBoard.\u201d 21. The defendants identified in paragraphs 10-19 are collectively referred to as the \u201cDefendants.\u201d \nOnly answer with the company defendants names.",
        "output": "Sykes Enterprises, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n12. Plaintiff purchased Abengoa\u2019s ADS  as set forth herein and in his  certification \nfiled herewith.  \n13. Abengoa is a corporation organized and existing under the laws of S pain.  It \nmaintains its principal corporate offices at Campus Palmas Altas, No. 1, Calle Energ\u00eda Solar , \nSeville, 41014, Spain .  \n14. Defendant Santiago Seage (\u201cSeage\u201d) has served as First Vice -Chairman and Chief \nExecutive Officer  (\u201cCEO\u201d)  of Abengoa  since May 20 15.  He was CEO of Abengoa Yield plc \n(\u201cAB Y\u201d or \u201cAbengoa Yield\u201d ) from its formation in December 2013 through May 2015.  \nDefendant Seage held other senior management positions at Abengoa since joining the Company in 2005. \n15. Defendant  Manuel Sanchez Ortega (\u201cSanchez Ortega\u201d) was the CEO  of Abengoa  \nfrom March 2010 through May 2015 and its First Vice -Chairman from February 2015 through \nJuly 2015.  He is currently a member of Abengoa\u2019s International Advisory Board.  \n16. Defendant Ignacio G arc\u00eda Alvear (\u201cGarcia Alvear\u201d) has served as Co -Chief \nFinancial Officer (\u201cCFO\u201d)  for Investor Relations and Capital Markets of Abengoa  since \nFebruary 1, 2015.  Defendant Garcia Alvear joined Abengoa in 1995 and served as the CFO of Abengoa Bioenergy from January 2004 through February 1, 2015.  \n17. Defendant Barbara Zubiria (\u201cZubiria\u201d) was Executive Vice President, Capital \nMarkets and Investor Relations of Abengoa  from January 2011 through January 2015.  \n 4 Case 1:15-cv-06279   Document 1   Filed 08/10/15   Page 4 of 2218. Seage, Sanchez Ortega, Garcia Alvear, and Zubiria are collectively referred to \nherein as th e \u201cIndividual Defendants.\u201d  \n19. Abengoa and the Individual Defendants  are collectively referred to herein as \n\u201cDefendants.\u201d  \nCONTROL PERSON ALLEGATIONS  \n20. By reason of the Individual Defendants \u2019 positions  with the Company as executive \nofficers (and in Seage\u2019s and Sa nchez Ortega\u2019s cases , as a director as well)  the Individual \nDefendants possessed the power and authority to control the contents of Abengoa\u2019\nIndividual defendants:",
        "output": "Santiago Seage,Manuel Sanchez Ortega,Ignacio Garcia Alvear,Barbara Zubiria",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n11. Plaintiff is, and  has been at all relevant times, the owner of shares of Threshold  common \nstock .  \n12. Defendant Harold E. Selick (\u201cSelick \u201d) joined Threshold  as Chief Executive Officer in \nJune 2002 and has served as a member of the Company\u2019s  board of directors since his appointment .  On \nMarch 16, 2017, Selick resigned as the Company\u2019 s Chief Executive Officer, effective March 31, 2017.  \nFollowing his resignatio n, Selick continue s to serve as a member of and Chairman of the Company Board.  \n13. Defendant Wilfred E. Jaeger  (\u201cJaeger \u201d) has served as a member of the Company Board \nsince 2001 .  On March 16, 2017, the  Company\u2019s  board of directors appointed Jaeger  to serve as interim \nChief Executive Officer of the Company, effective April 1, 2017.  \n14. Defendant George G.C. Parker  (\u201cParker \u201d) has served as a member of the Company\u2019s  \nboard of directors since October 2004.  \n15. Defendant Jeffrey W. Bird  (\u201cBird\u201d) has served as a member of the Company\u2019s  board of \ndirectors since November 2008.   \n16. Defendant David R. Hoffmann (\u201cHoffman\u201d) has served as a member of the Company\u2019s \nboard of directors since April 2007.  \n17. Defendant David R. Parkinson  (\u201cParkinson\u201d)  has served as a member of the Company\u2019s \nboard of directors  since 2010 . \n18. Defendant Bruce C. Cozadd  (\u201cCozadd\u201d)  has served as a member of the Company\u2019s board \nof directors since December 2005 . \n19. Defendants Cozadd , Parkinson , Hoffman , Bird, Parker , Jaeger , and Se lick are collectively \nreferred to herein as the \u201cBoard\u201d or the \u201cIndividual Defendants.\u201d   \n20. Defendant Threshold  is a clinical -stage  biopharmaceutical company that has historically \nused its expertise in the tumor  microenvironment to discover and develop thera peutic and diagnostic \nagents that selectively target tumor cells for the treatment  of patients living with cancer . The Company \nis a Delaware corporation and maintains its principal offices at 3705 Haven Ave., Suite 120, Menlo Park, Case 3:17-cv-\nIndividual defendants:",
        "output": "Harold E Selick,Wilfred E Jaeger,George G C Parker,Jeffrey W Bird,David R Hoffmann,David R Parkinson,Bruce C Cozadd",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n14. Plaintiff, as set forth in the attached Certification, acquired Fennec  securities at \nartificially inflated prices during the Class Period and was  damaged upon the revelation of the \nalleged cor rective disclosures.  \n15. Defendant Fennec  is organized under the laws of British Columbia, Canada , with \nprincipal executive offices located at PO Box 13628, 68 TW Alexander Drive, Research Triangle \nPark, North Carolina 27709.  Fennec \u2019s common shares  trade in an efficient market on the  Nasdaq  \nCapital  Market  (\u201cNASDAQ\u201d) under the trading symbol  \u201cFENC \u201d. \n16. Defendant  Rostislav Raykov (\u201c Raykov \u201d) has served as  Fennec \u2019s Chief Executive \nOfficer at all relevant times .   \n17. Defendant  Robert Andrade  (\u201cAndrade \u201d) has served  as Fennec \u2019s Chief Financial \nOfficer at all relevant times . \n18. Defendant s Raykov and Andrade are sometimes referred to herein as the \n\u201cIndividual Defendants.\u201d  \nCase 1:22-cv-00115   Document 1   Filed 02/09/22   Page 4 of 185 \n 19. The Individual Defendants possessed the power and authority to control the \ncontents of Fennec \u2019s SEC filings, press releases, and other market communications.  The \nIndividual Defendants were provided with copies of Fennec \u2019s SEC filings and press releases \nalleged herein to be misleading prior to or shortly after their issuance and had the ability and \nopportunity to prevent their issuance or to cause them to be corrected.  Because of their positi ons \nwith Fennec, and their access to material information available to them but not to the public, the \nIndividual Defendants knew that the adverse facts specified herein had not been disclosed to and were being concealed from the public, and that the posit ive representations being made were then \nmaterially false and misleading.  The Individual Defendants are liable for the false statements and \nomissions pleaded herein. \n20. Fennec  and the Individual Defendants are collectively referred to herein as \n\u201cDefendants. \u201d \nSUBSTANTIVE ALLEG ATIONS  \nBackgr\nOnly answer with the company defendants names.",
        "output": "Fennec Pharmaceuticals, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n11. Plaintiff is, and has been continuously throughout all times relevant hereto, the owner \nof SRAC common stock. \n12. Defendant SRAC is a public company incorporated under the laws of Delaware with \nprincipal executive offices located at  1345 Abbot Kinney Blvd., Venice, CA 90291.  SRAC\u2019s \ncommon stock is traded on the N asdaqGS  under the ticker symbol \u201c SRAC.\u201d  \n13. Defendant Brian Kabot is, and has been at all relevant times, a director of the \nCompany, Chairman of the Board, and Chief Executive Officer.  \n14. Defendant James Norris  is, and has been at all relevant times, a director of the \nCompany.   \n15. Defendant Marc Elliot Lehmann is, and has been at all relevant times, a director of the \nCompany.  \n16. Defendant Ann Kono is, and has been at all relevant times , a director of the Company. \n17. Defendant Kellen O\u2019Keefe is, and has been at all relevant times, a director of the \nCompany. \n18. Defendant  James Hofmockel is, and has been at all relevant times, a director of the \nCompany. \n19. The defendants identified in paragraphs 13 through 18 are collectively referred to \nherein as the \u201cBoard\u201d or the \u201cIndividual Defendants,\u201d and together with SR AC, the \u201cDefendants.\u201d  \n \n \n \n Case 1:20-cv-10193   Document 1   Filed 12/03/20   Page 4 of 155  \nOnly answer with the company defendants names.",
        "output": "Stable Road Acquisition Corp. n/k/a Momentus, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n13. Plaintiff, as set forth in the accompanyi ng certification, incorporated by reference \nherein, purchased Shiloh common  stock during the Class Peri od, and suffered damages as a \nresult of the federal securities law violations and false and/or mislea ding statements and/or \nmaterial omissions alleged herein.  \n14. Defendant Shiloh is a Delaware corporati on with its principal executive offices \nlocated at 880 Steel Drive, Valley City, Ohio 44280.  \n15. Defendant Ramzi Hermiz (\u201cHermiz\u201d) was,  at all relevant times, President and \nCEO of Shiloh.   \n16. Defendant Thomas M. Dugan (\u201cDugan\u201d) wa s at all relevant times Vice President \nof Finance and Treasurer of Shiloh. \n17. Defendants Hermiz and Dugan are collectiv ely referred to hereinafter as the \n\u201cIndividual Defendants.\u201d  The Individual Defenda nts, because of their positions with the \nCompany, possessed the power and au thority to control the contents  of Shiloh\u2019s reports to the \nSEC, press releases and presentations to secur ities analysts, money and portfolio managers and Case 1:15-cv-07449-KMW   Document 1   Filed 09/21/15   Page 5 of 31\u00a0\nCLASS ACTION COMPLAINT \n5 institutional investors, i.e., the market.  Each defendant wa s provided with copies of the \nCompany\u2019s reports and press releas es alleged herein to be mislea ding prior to, or shortly after, \ntheir issuance and had the ability and opportunity to  prevent their issuance or cause them to be \ncorrected.  Because of their positions and access to material non-public information available to \nthem, each of these defendants knew that the a dverse facts specified herein had not been \ndisclosed to, and were being concealed from, the public, and that the positive representations which were being made were then material ly false and/or misleading.  The Individual \nDefendants are liable for the false statements pleaded herein, as those statements were each \n\u201cgroup-published\u201d information, the result of the co llective actions of the Individual Defendants.  \n\nOnly answer with the company defendants names.",
        "output": "Shiloh Industries, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been continuously throughout all times relevant hereto, the \nowner of Brocade  common stock.  \n9. Defendant Brocade  is a Delaware corporation and maintains its principal executive \noffices at  130 Holger Way, San Jose , California 95 134.  Brocade \u2019s common stock is traded on the \nNasdaq GS under the ticker symbol \u201cBRCD .\u201d \n10. Defendant  Judy Bruner (\u201cBruner \u201d) has served as a director  of Brocade since \nJanuary 2009 .  According to the Company\u2019s website, Bruner is Chair of the Audit Committee.  \n11. Defendant  Lloyd A. Carney (\u201cCarney \u201d) has served as a director of Brocade  since \nFebruary 2013 and as Chief Executive Officer (\u201cCEO\u201d) since  January 2013 .   \n12. Defendant  Renato A. DiPentima (\u201cDiPentima \u201d) has served as a director of Brocade  \nsince  January 2007 .  According to the Company\u2019s website, DiPentima is a member of the \nCompensation Committee and the Nominating and Governance Committee.  \n13. Defendant  Alan L. Earhart (\u201cEarhart \u201d) has served as a director of Brocade  since  \nFebruary 2009.   According to the Company\u2019s website, E arhart is a member of the Audit \nCommittee.    \n14. Defendant  John W. Gerdelman (\u201cGerdelman \u201d) has served as a director of Brocade  \nsince  January 2007 .  According to the Company\u2019s website, Gerdelman is a member of the Audit \nCommittee and the Corporate Development Committee.  \n15. Defendant  Kim C. Goodman (\u201cGoodman \u201d) has served as a director of Brocade  \nsince  February 2016 .   \n16. Defendant  David L. House (\u201cHouse \u201d) has served as a director of Brocade  since  \nFebruary 2004 and as Chairman of the Board since December 2005 .  Accordi ng to the Company\u2019s Case 3:16-cv-07081-EMC   Document 1   Filed 12/12/16   Page 3 of 171 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n  \n \n 4  \nCOMPLAINT FOR VIOLAT ION OF THE SECURITIES EXCHANGE ACT OF 1934  \n \n \n website, House is a member of the Compensation Committee, the Nominating and Governance \nComm\nIndividual defendants:",
        "output": "Judy Bruner,Lloyd Carney,Renato A DiPentima,Alan L Earhart,John W Gerdelman,Kim C Goodman,David L House,L William Krause,David E Roberson,Sanjay Vaswani",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n12. Plaintiff is an individual  citizen of the State of Florida .  She is, and at all times \nrelevant hereto ha s been , a Churchill stockholder . \n13. Defendant Churchill  is a Delaware corporation and maintains its principal \nexecutive offices at 640 Fifth Avenue, 12th Floor, New York, NY 10019 . Churchill\u2019s  common \nstock is traded on the N YSE  under the ticker symbol \u201c CCXX .\u201d  \n14. Defendant  Jeremy Paul Abson  (\u201cAbson \u201d) has served as  direct or of the Company \nat all relevant times.   \n15. Defendant  Michael Klein  (\u201cKlein \u201d) has served as  direct or of the Company at all \nrelevant times. Klein  also serves as the Company\u2019s Chairman of the Board  and Chief Executive  Case 1:20-cv-06318   Document 1   Filed 08/11/20   Page 4 of 26 \n 5 Officer (\u201cC EO\u201d).  Defendant Klein is also the owner of M. Klein and Company, which owns the \nKlein Group, the financial advisor engaged by the Company, as a wholly owned subsidiary.  \n16. Defendant  Glenn August  (\u201cAugust \u201d) has served as  direct or of the Company at all \nrelevant tim es. \n17. Defendant  Mike Eck  (\u201cEck\u201d) has served as  direct or of the Company at all relevant \ntimes.  He is a Managing Director at M. Klein and Company  \n18. Defendant  Bonnie Jonas  (\u201cJonas \u201d) has served as  direct or of the Company at all \nrelevant times.  \n19. Defendant  Mark Klein  (\u201cKlein\u201d)  has served as  direct or of the Company at all \nrelevant times.  \n20. Defendant  Malcolm S. McDermid  (\u201cMcDermid\u201d)  has served as  direct or of the \nCompany at all relevant times.  \n21. Defendant  Karen Mills  (\u201cMills\u201d)  has served as  direct or of the Company at all \nrelevant times.  \n22. The defendants  identified  in paragraphs  14 through  21 are collectively  referred  to \nherein as the \u201cDirector Defendants\u201d or the \u201cIndividual Defendants.\u201d  \n23. Non-Party  Multiplan is a private company that uses technology -enabled provider \nnetwork, negotiation, claim pricing and payment accuracy services as building blocks for \nmedical and dental payers to cust\nIndividual defendants:",
        "output": "Jeremy Paul Abson,Michael Klein,Glenn R August,Michael Eck,Mark S Klein,Malcolm S McDermid,Karen G Mills",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n16. Plaintiff, Prakash Mohanty , purchased Avid common stock during the Class Period as \ndescribed in the Certification attached hereto and incorpora ted herein by reference and suffered \ndamages thereon.  \n17. Defendant Avid is headquartered in Burlington, Massachusetts.  During the Class \nPeriod, Avid had more than 40 million shares of common stock outstanding, which shares traded in \nan efficient market on th e NASDAQ under the ticker symbol \u201cAVID.\u201d  Avid was followed by scores \nof stock analysts and stock rating agencies and was constantly in communication with the markets \nand investors in quarterly conference calls and frequent presentations to investor and an alyst \nconferences.  Avid also filed periodic public reports with the SEC, and regularly issued press \nreleases to the financial press.  \n18. Defendant Louis Hernandez, Jr. (\u201cHernandez\u201d) is, and was at all relevant times, \nAvid\u2019s President, CEO , and Chairman of its  Board of Directors.   \n19. Defendant Ilan Sidi  (\u201cSidi\u201d)  is, and has been at all relevant times, Avid\u2019s Interim \nCFO and Vice President of Human Resources.   \n20. Defendants Hernandez  and Sidi are sometimes referred to herein as the \u201cIndividual \nDefendants.\u201d  \n21. During t he Class Period, the Individual Defendants ran Avid as \u201chands -on\u201d managers \noverseeing Avid\u2019s operations and finances and made the material false and misleading statements \ndescribed herein.  The Individual Defendants were intimately knowledgeable about all aspects of \nAvid\u2019s financial and business operations, as they received daily reports and had access to Case 1:16-cv-12336   Document 1   Filed 11/21/16   Page 6 of 24 \n- 6 - computerized information regarding sales, costs and expenses, product demand, inventory \nmanagement , and the conditions surrounding the NEXIS  launch.  They  were also intimately involved \nin deciding which disclosures would be made by Avid.  Indeed , the Individual Defendants made \nvarious public statements for Avid during the Class Period, a\nOnly answer with the company defendants names.",
        "output": "Avid Technology, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n17. Plaintiff Roei Azar, as set for th in the accompanying Certifica tion incorporated herein \nby reference, purchased Grubhub common stock during the Class P eriod and has been damaged \nthereby. \n18. Defendant Grubhub, headquartered i n Chicago, Illinois, is one o f the nation\u2019s leading \nonline and mobile platforms for restaurant pick-up and delivery  orders.  The Company\u2019s common \nstock is listed on the NYSE under the ticker symbol \u201cGRUB.\u201d \n19. Defendant Matthew Maloney (\u201cMa loney\u201d) is a founder of Grubhub a nd served as its \nCEO throughout the Class Period. \n20. Defendant Adam DeWitt (\u201cDeWitt\u201d) served as Grubhub\u2019s President and Chief \nFinancial Officer (\u201cCFO\u201d) t hroughout the Class Period. \n21. The defendants referenced above i n \u00b6\u00b619-20 are referred to here in as the \u201cIndividual \nDefendants.\u201d  The Individual Defe ndants, because of their posit ions with the Company, possessed \nthe power and authority to control the contents of Grubhub\u2019s qu arterly reports, shareholder letters, \npress releases, and presentations to securities analysts, money  and portfolio managers, and \ninstitutional investors, i.e., the market.  They were provided with copies of the Company\u2019s reports \nand press releases alleged herein to be misleading prior to or shortly after their issuance and had the \nability and opportunity to prevent their issuance or cause them  to be corrected.  Because of their \npositions with the Company, and their access to material non-pu blic information available to them \nbut not to the public, the Individual Defendants knew that the adverse facts specified herein had not \nbeen disclosed to and were being concealed from the public and that the positive representations \nbeing made were then materially false and misleading.  The Indi vidual Defendants are liable for the \nfalse and misleading statements pleaded herein. Case: 1:19-cv-07665 Document #: 1 Filed: 11/20/19 Page 7 of 30 PageID #:1 \n- 7 - 22. Defendants are liable for: (i) ma king false statements; or (ii) \nIndividual defendants:",
        "output": "Matthew Maloney,Adam DeWitt",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  ................................ ................................ ................................ ............................. 5 \nIV. SUBSTANTIVE ALLEGATI ONS  ................................ ................................ ..................... 5 \nA. Background  ................................ ................................ ................................ .............. 5 \nB. Defendants\u2019 False and Misleading Statements During the Class Period  ............... 10 \nC. The Truth Begins to Emerge  ................................ ................................ .................. 18 \nV. CLASS ACTION ALLEGAT IONS  ................................ ................................ .................. 21 \nVI. LOSS CAUSATION  ................................ ................................ ................................ .......... 22 \nVII.  APPLICABILITY OF PRE SUMPTION OF RELIANCE : FRAUD ON THE \nMARKET DOCTRINE  ................................ ................................ ................................ .....23 \nVIII.  NO SAFE HARBOR  ................................ ................................ ................................ ......... 23 \nIX. ADDITIONAL SCIENTER ALLEGATIONS  ................................ ................................ ..24 \nX. CAUSES OF ACTION  ................................ ................................ ................................ ......25 \nCOUNT I  VIOLATION O F SECTION 10(B) OF T HE EXCHANGE ACT AND RULE \n10B-5 PROMULGATED TH EREUNDER (AGAINST AL L DEFENDANTS)  ............. 25 \nCOUNT II  VIOLATION OF SECTION 20(A) OF THE EXCHANGE ACT (AG AINST \nMUILENBURG AND SMITH ) ................................ ................................ ........................ 26 \nPRAYER FOR RELIEF  ................................ ................................ ................................ ................ 26 \n Case: 1:19-cv-02394 Document #: 1 Filed: 04/09/19 Page 2 of 31 PageID #:2 \n- 1 - \n010815 -11 1115270  V1 Plaintiff, \nIndividual defendants:",
        "output": "Dennis A Muilenburg,Gregory D Smith",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n21. Plaintiff  is a pension fund created for the benefit of current and former Collinsville, \nIllinois police offic ers.  As of the record date of the Mer ger, Plaintiff owned shares of Discovery \nSeries C common stock.  Plaintiff exchanged those shares of Discovery  Series C common stock \nfor WBD common stock pursuant to the Registration Statement and Prospectus as part of the \nMerger, and purchased additional WBD shares on the open market  after the completion of the \nMerger , and was damaged thereby.   Plaintiff\u2019s certification attesting to its exchange of and trading \nin WBD common stock is annexed hereto.  \n22. Defendant WBD is a global media and entertainment company that creates and \ndistributes  a portfolio of content and brands across television, film and streaming.  WBD \u2019s \ncommon shares  trade on the NASDAQ under the symbol \u201c WBD .\u201d  WBD is incorporated in the \nState of Delaware and has its principal  place of business in New York, New York.  \n23. Defendant David Zaslav  (\u201cZaslav\u201d)  served as Discovery\u2019s Chief Executive Officer  \nand President from 2007  until the effective date of the Merger .  He was a member of Discovery\u2019s \nBoard of Directors from September 2008  until the effective date of the Merger .  From the effective \ndate of the M erger to the date of the filing of this Complaint, Zaslav has ser ved as WBD\u2019s CEO \nand President , and as a member of the WBD Board . \n24. Defendant Gunnar Wiedenfels  served as Discovery\u2019s C hief Financial Officer from \nMarch 31, 2017 until  the effective date of the Merger, and has served as WBD\u2019s CFO from the \neffective date of the M erger to the date of the filing of this Complaint . \n25. Defendants Zaslav and Wiedenfels each signed the Registration Statement or \nauthorized the signing of the Registration Statement on their behalf.  Case 1:22-cv-08171   Document 1   Filed 09/23/22   Page 6 of 337 26.  Defendants Zaslav and Wiedenfels are herein collectively referred to as the \n\u201cIndividual Defendants.\u201d  \nFACTUAL \nIndividual defendants:",
        "output": "David Zaslav,Gunnar Wiedenfels",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n21. Plaintiff City of Taylor General Employees Retirement System purc hased Astec stock \nas described in the attached certification, which is incorporated herein by reference, and suffered \ndamages as a result of the conduct alleged herein.  \n22. Defendant Astec is incorporated in Tennessee and has its headquarters in this District.   \nShares of Astec stock trade on the NASDAQ under the ticker symbol \u201cASTE.\u201d   \n23. Defendant Benjamin G. Brock was the Company\u2019s CEO and President, a member of \nthe Company\u2019s Board, and a member of the Board\u2019s executive committee.  Brock resigned from \nthese posi tions on January 21, 2019.  \nCase 1:19-cv-00024   Document 1   Filed 02/01/19   Page 6 of 50   PageID #: 6 \n- 6 - 24. Defendant David C. Silvious (\u201cSilvious\u201d) is the Company\u2019s Chief Financial Officer \n(\u201cCFO\u201d), Treasurer and Vice President.  \n25. Defendants Brock and Silvious are collectively referred to as the \u201cIndividual \nDefendants.\u201d  Each of the Indi vidual Defendants acted and/or made the statements detailed herein in \nhis capacity as an officer and/or director of Astec.  The Individual Defendants, because of their \npositions with the Company, possessed the power and authority to control the contents of  Astec\u2019s \nquarterly reports, press releases, and presentations to securities analysts, money and portfolio \nmanagers, and institutional investors, i.e., the market.  They were provided with copies of the \nCompany\u2019s reports and press releases alleged herein to  be misleading prior to or shortly after their \nissuance and had the ability and opportunity to prevent their issuance or cause them to be corrected.  \nBecause of their positions with the Company and their access to material information available to \nthem but  not to the public, the Individual Defendants knew that the adverse facts specified herein \nhad not been disclosed to and were being concealed from the public and that the positive \nrepresentations being made were then materially false and misleading.  The I ndiv\nIndividual defendants:",
        "output": "Benjamin G Brock,David C Silvious",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n9. Plaintiff Robert Lowinger  (\u201cPlaintiff\u201d) purchased and acquired Funko securities \npursuant to the Registration Statement and Prospectus issued in connection with the Company\u2019s \nIPO and has incurred statutory damages.  \n10. Defendant Funko, Inc. is a Delaware corporation with its principal executive \noffices located at 2802 Wetmore Avenue, Everett, Washington 98201. Funko\u2019s common stock \ntrades on the NASDAQ under the ticker symbol \u201cFNKO.\u201d \n1 Section 16(c) of the Securities Act refers to \u201ccovered class actions,\u201d which are defined as lawsuits brought as class \nactions or brought on behalf of more than 50 persons asserting claims under state or common law. Case 2:18-cv-00201   Document 1-1   Filed 02/07/18   Page 4 of 1812\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\nCOMPLAINT FOR VIOLATIONS  \nOF SECTIONS 11, 12 AND 15 OF  \nTHE SECURITIES ACT OF 1933- 4KELLER ROHRBACK L .L.P. \n1201 Third Avenue, Suite 3200 \nSeattle, WA 98101-3052 \nTELEPHONE: (206) 623-1900 \nFACSIMILE: (206) 623-3384 11. Defendant Brian Mariotti  (\u201cMariotti\u201d) has served, at all relevant times, as the \nCompany\u2019s Chief Executive Officer and Director. Mariotti signed the Company\u2019s registration \nstatement, filed on Form S-1 with the SEC on October 6, 2017, as amended, and declared effective \nby the SEC on November 1, 2017 (the \u201cRegistration Statement\u201d). \n12. Defendant Russell Nickel (\u201cNickel\u201d) has served, at all relevant times, as the \nCompany\u2019s Chief Financial Officer (Principal Financial Officer and Principal Accounting \nOfficer). Nickel signed the Company\u2019s Registration Statement filed with the SEC. \n13. Defendant Ken Brotman (\u201cBrotman\u201d) was a director of Funko at the time of the \nfiling of the part of the Registration Statement with respect to which his liability is asserted. \nBrotman signed the Registration Statement. \n14. Defendant Gino Dellomo (\u201cDellomo\u201d) was a director of Funko at the time of the \nfiling of the part of the Registration Statement with respect to which his liab\nOnly answer with the company defendants names.",
        "output": "Funko, Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n8. Plaintiff is, and has been continuously th roughout all times relevant hereto, the \nowner of Wolverine  common stock.  \n9. Defendant Wolverine is a Maryland corporation and maintains its principal \nexecutive offices at 5710 Eastman Avenue, Midland, Michigan 48640.  The Company is the bank \nholding company for Wolverine Bank.  Wolverine\u2019s common stock is traded on the NASDAQCM \nunder the ticker symbol \u201cWBKC.\u201d  \n10. Defendant Richard M . Reynolds  (\u201cReynolds \u201d) is a director of Wolverine  and \nChairman of the Board.   According to the Company\u2019s website, Reynolds is a member of the Case 1:17-cv-02565-RDB   Document 1   Filed 09/06/17   Page 3 of 19 4 Company\u2019s Audit Committee, the Compensation Committee, and the Nominating and Corporate \nGovernance Committee.  \n11. Defendant Roberta N. Arnold (\u201c Arnold\u201d)  is a director of Wolverine .  According to \nthe Company\u2019s website, Arnold is a member of the Company\u2019s Compensation Committee and the \nNominating and Corporate Governance Committee .   \n12. Defendant Eric P. Blackhurst  (\u201cBlackhurst \u201d) is a director of Wolverine . According \nto the Company\u2019s websi te, Blackhurst is C hair of the Nominating  and Corporate Governance \nCommittee and a member of the Audit Committee.  \n13. Defendant David  H. Dunn  (\u201cDunn\u201d) is a director , President,  and Chief Executive \nOfficer (\u201cCEO\u201d) of Wolverine .  \n14. Defendant James W . Fisher  (\u201cFisher\u201d) is a director of Wolverine .  According to the \nCompany\u2019s website, Fisher is a member of the Company\u2019s Audit Committee and the \nCompensation Committee.  \n15. Defendant Howard  I. Ungerleider  (\u201cUngerleider \u201d) is a director of Wolverine . \nAccording to the Company\u2019s website, Ungerleider is a member of the Company\u2019s Audit \nCommittee and the Nominating and Corporate  Governance Committee.  \n16. Defendant Joseph Donald Sheets  (\u201cSheets \u201d) is a director of Wolverine .  According \nto the Company\u2019s website , Sheets is Chair of the  Audit Committee and a member of the \nCompensation Committee.  \n17. D",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n11. Plaintiff, as set forth in the a ttached Certification, acquired  Organogenesis \nsecurities at artificially inflated prices during the Class Per iod and was damaged upon the \nrevelation of the alleged corrective disclosures. \n12. Defendant Organogenesis is a Delaw are corporation with principa l executive \noffices located at 85 Dan Roa d, Canton, Massachusetts 02021.  O rganogenesis\u2019 Class A common \nstock trades in an efficient mar ket on the NASDAQ under the tic ker symbol \u201cORGO\u201d. \n13. Defendant Gary S. Gillheeney, Sr. (\u201cGillheeney\u201d) has served as Organogenesis\u2019 \nPresident, Chief Ex ecutive Officer, and a D irector of the Compa ny at all relevant times. \n14. Defendant David C. Francisco (\u201cFrancisco\u201d) has served as Organo genesis\u2019 Chief \nFinancial Officer at all relevant times. \n15. Defendants Gillheeney and Francisco are sometimes referred to h erein as the \n\u201cIndividual Defendants.\u201d \n16. The Individual Defendants possess ed the power and authority to control the \ncontents of Organogenesis\u2019 SEC fi lings, press releases, and oth er market communications.  The \nIndividual Defendants were pro vided with copies of Organogenesi s\u2019 SEC filings and press releases \nalleged herein to be misleading prior to or shortly after their  issuance and had the ability and \nopportunity to prevent their issuance or to cause them to be co rrected.  Because of their positions \nwith Organogenesis, and their access to material information av ailable to them but not to the \npublic, the Individual Defendant s knew that the adverse facts s pecified herein had not been \ndisclosed to and were being concealed from the public, and that  the positive representations being Case 1:21-cv-06845   Document 1   Filed 12/10/21   Page 4 of 26 PageID #: 45 made were then materially false and misleading.  The Individual  Defendants are liable for the false \nstatements and omission s pleaded herein. \n17. Organogenesis and the Individual Defendants are collectively re ferred to herein as \n\u201cDefendants.\u201d \n\nOnly answer with the company defendants names.",
        "output": "Organogenesis Holdings Inc.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": "  \n8. Plaintiff is, and has been at all times relevant hereto, a common s tockholder of \nCafePress . \n9. Defendant CafePress  is a Delawar e corporation and maintains its principal \nexecutive offices at  11909 Shelbyville Road, Louisville, Kentucky 40243.   Founded in \n1999, CafePress  is the recognized pione er of customizable products.  Its global online platform \nenables people to express themselves through engaging community generated designs and licensed and personalized one -of-a-kind products .  CafePress \u2019 common stock is traded on the \nNASDAQ Global Market  under the ticker symbol \u201cPRSS .\u201d \n10. Defendant Fred E. Durham , III (\u201cDurham \u201d) is a Co -Founder, Chairman of the Case 1:18-cv-01607-UNA   Document 1   Filed 10/17/18   Page 3 of 18 PageID #: 3 4 Board  and Chief Executive Officer (\u201cCEO\u201d) of the Company and has been a director of the \nCompany since August 1999.  Defendant Durham previously served as  CEO  and Chief Product \nOfficer of the Company from 1999 to 2011 and  returned to his leadership role as CEO in August \n2014. \n11. Defendant Anthony C. Allen (\u201cAllen \u201d) has been  a director of CafePress  since \nMay 2015.  \n12. Defendant Mary Ann Arico ( \u201cArico \u201d) has been  a director of CafePress  since July \n2016. \n13. Defendant Kenneth T. McBride (\u201cMcBride\u201d) has been  a director of CafePress  \nsince May 2015.  \n14. Defendant Alan B. Howe (\u201cHowe \u201d) has been a director of CafePress since \nFebruary 2018.  \n15. Defendants Durham, Allen, Arico, McBride and Howe are collecti vely referred to \nherein as the \u201cBoard\u201d or the \u201cIndividual Defendants.\u201d  \nOTHER RELEVANT ENTITIES  \n16. Snapfish is a California limited liability company  headquartered  in San Francisco, \nCalifornia.  Founded in 1999, Snapfish is the leader in online photo printing services providing \nhigh-quality photo products to consumers looking for great value and selection.  The company \noperates in multiple countries around the world and supports blue -chip companies\u2019 photo efforts . \n17. Merger Sub\nIndividual defendants:",
        "output": "Fred E. Durham, III,Anthony C Allen,Mary Ann Arico,Kenneth T McBride,Alan Howe",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n10. Plaintiff is, and has been continuously throughout all times rel evant hereto, the owner \nof WES  common units . \n11. Defendant WES  is a Delaware MLP managed by its general partner, Western Gas \nHoldings, LLC  (\u201cWES GP\u201d) , a Delaware limited liability company that is owned and controlled by Case 1:19-cv-00832   Document 1   Filed 01/28/19   Page 3 of 164  WGP .  WES\u2019s c ommon units trade on the NYSE under the ticker symbol \u201cWES.\u201d  \n12. Defendant Benjamin M. Fink is, and has been at all relevant times, a director of the \nCompany.  Defendant Fink also currently serves as Chairman of the Board.  \n13. Defendant Robin H. Fielder is, and has been at all relevant times, a director of the \nCompany.  Defendant Fielder is also the  President and Chief Executive Officer of the Company .   \n14. Defendant Robert G. Gwin is, and has been at all relevant times, a director of the \nCompany.   \n15. Defendant Steven D. Arnold is, and has been at all relevant times, a director of the \nCompany.  \n16. Defendant Daniel E. Brown is, and has been at all relevant times, a director of the \nCompany.  \n17. Defendant Milton Carroll is, and has been at all relevant times, a director of the \nCom pany.  \n18. Defendant James R. Crane is, and has been at all relevant times, a director of the \nCompany.  \n19. Defendant David J. Tudor is, and has been at all relevant times, a director of the \nCompany.  \n20. Defendant Mitchell W. Ingram is, and has been at all relevant times, a director of the \nCompany.  \n21. The defendants identified in paragraphs 12 through 20 are collectively referred to \nherein as the \u201cBoard\u201d or the \u201cIndividual Defendants,\u201d and together with WES , the \u201cDefendants.\u201d  \n",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n19. Plaintiff City of Roseville Employees\u2019 Retirement System purchased Apple common \nstock during the Class Period, as set forth in the accompanying certification incorporated by reference herein, and has been damaged thereby. \n20. Defendant Apple is a Cupertino, Califor nia-based tech company.  Apple common \nstock is listed and trades on the NASDAQ, an effi cient market, under the ticker symbol \u201cAAPL.\u201d  \nAs of October 26, 2018, the Company had 4.75 b illion shares issued and outstanding. \n21. Defendant Timothy D. Cook (\u201c Cook\u201d) is, and was at all relevant times, CEO of Apple \nand a member of its Board of Directors. \n22. Defendant Luca Maestri (\u201cMaestri\u201d) is, and wa s at all relevant ti mes, Senior Vice \nPresident and Chief Financial Officer (\u201cCFO\u201d) of Apple. \n23. Defendants Cook and Maestri are sometimes referred to herein as the \u201cIndividual \nDefendants.\u201d  Apple and the Individual Defenda nts are referred to he rein, collectively, as \n\u201cdefendants.\u201d \nDEFENDANTS\u2019 MATERIALLY FALSE AND MISLEADING \nCLASS PERIOD STATEMENTS \n24. The Class Period starts on November 2, 2018.  On November 1,  2018, after the close \nof trading, Apple issued a release reporting its f ourth quarter 2018 (\u201c4Q18\u201d) and FY18 results for the \nperiod that had ended September 29, 2018 \u2013 more than  one month earlier.  A pple\u2019s release issued \nthat day emphasized that \u201c\u2018[o]ver the past two months, [Apple had] delivered huge advancements for \n[its] customers through new versions of iPhone, A pple Watch, iPad and Mac as well as [its] four \noperating systems, and [that it was]  enter[ing] the holiday season w ith [its] strongest lineup of Case 4:19-cv-02033-YGR   Document 1   Filed 04/16/19   Page 8 of 23 \n COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS  - 8 -\n 1\n23456789\n10111213141516171819202122232425262728products and services ever.\u2019\u201d  Accordingly, based on that lineup, among other factors, Apple \u2013 then \nalready more than one-third of the way into 1Q19 \u2013 set public 1Q19 revenue e xpectations ",
        "output": "['City of Roseville General Employees Retirement System']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " \n27. Plaintiff Salvador Verdin purchased Genius shares at artificially inflated \nprices during the Class Period and was damaged upon the revelation of the alleged \ncorrective disclosures. \n28. Defendant Genius Brands International, Inc., is a multimedia company \nbased in Beverly Hills, California.  The Company\u2019s securities are traded in the \nUnited States under the ticker symbol \u201cGNUS.\u201d  The securities trade on the \nNASDAQ national securities market. Case 2:20-cv-07457   Document 1   Filed 08/18/20   Page 7 of 21   Page ID #:77 \nCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n2829. Defendant Andy Heyward is the founder and was CEO of Genius at all \nrelevant times. \n30. The Company is liable for the acts of its employees under the doctrine \nof respondeat superior and common law principles of agency because all of the \nwrongful acts complained of herein were carried out within the scope of their \nemployment. \n31. The scienter of the other employees and agents of the Company is \nsimilarly imputed to the Company under respondeat superior and agency \nprinciples. \n32. Genius and Heyward are collectively referred to herein as \u201cDefendants.\u201d \n",
        "output": "['Salvador Verdin']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": " Plaintiff  Plymouth  County purchased  Impinj common  stock pursuant  and 28.\ntraceable  to both  the SPO and the IPO and was damaged  thereby.\nDefendant  Impinj  is a manufacturer  and provider  of \u201cRAIN  RFID \u201d hardware  and 29.\nsoftware  solutions  used by commercial  and industrial  clients  to track and identify  products.\nIncorporated  in Delaware  and headquartered  in Seattle,  Impinj common  stock trades  in this\nCounty  on the NASDAQ  stock  exchange  under  the ticker  symbol  \u201cPI.\u201d\nDefendant  Diorio  was, at the time of the IPO and SPO, Impinj \u2019s Chief  Executive 30.\nOfficer  (\u201cCEO\u201d ) and a director  on Impinj \u2019s board  of directors  (the \u201cBoard\u201d ). Defendant  Diorio\nreviewed,  contributed  to, and signed  the IPO and SPO  Registration  Statements.\nDefendant  Fein was, at the time of the IPO and SPO, Impinj \u2019s CFO. Defendant 31.\nFein  reviewed,  contributed  to, and signed  the IPO and SPO Registration  Statements.\nDefendant  Peter  van Oppen  (\u201cvan Oppen\u201d ) was, at the time of the IPO and SPO, 32.\nChairman  of Impinj \u2019s Board. Defendant  van Oppen  reviewed,  contributed  to, and signed  the\nIPO and SPO Registration  Statements.\nDefendant  Tom A. Alberg  (\u201cAlberg\u201d ) was, at the time of the IPO and SPO, a 33.\ndirector  on Impinj \u2019s Board. Defendant  Alberg  reviewed,  contributed  to, and signed  the IPO and\nSPO Registration  Statements.\nDefendant  Clinton  Bybee  (\u201cBybee \u201d) was, at the time of the IPO and SPO, a 34.\ndirector  on Impinj \u2019s Board. Defendant  Bybee  reviewed,  contributed  to, and signed  the IPO and\nSPO Registration  Statements.\n10\n11 of 29\nINDEX NO. 650629/2019  \nRECEIVED  NYSCEF:  01/31/2019FILED:  NEW YORK COUNTY  CLERK  01/31/2019  03:19  PM\nNYSCEF  DOC. NO. 2\nDefendant  Gregory  Sessler  (\u201cSessler \u201d) was, at the time of the IPO and SPO, a 35.\ndirector  on Impinj \u2019s Board. Defendant  Sessler  reviewed,  contributed  to, and signed  the IPO and\nSPO  Registration  Statements.\nDefendant  Theresa  Wise  (\u201cWise \u201d) was, at the time of the I",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n15. Plaintiff Nawaf Alwazzan, as set forth in his Certification filed \ncontemporaneously herewith, acquired shares of STAAR common stock at \nartificially inflated prices, and has been damaged. \n16. Defendant STAAR Surgical Company is incorporated under the laws \nof the State of Delaware, with its principal place of business at 25651 Atlantic \nOcean Drive, Lake Forest, CA 92630.  Its common stock trades on the NASDAQ \nstock exchange under the symbol STAA. \n17. Defendant Caren L. Mason is the President and Chief Executive \nOfficer of STAAR. She has served on STAAR\u2019s Board of Directors since her Case 8:20-cv-01533   Document 1   Filed 08/19/20   Page 5 of 27   Page ID #:5 \n6\n 1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 election at the Company\u2019s 2014 Annual Meeting, and has served as STAAR\u2019s \nCEO since March 1, 2015. \n18. Defendant Deborah Andrews was formerly STAAR\u2019s Chief Financial \nOfficer, having served in that role from October 2, 2017 until her retirement in \n2020. STAAR has indicated that Ms. Andrews remains in an advisory role with the \nCompany at present. \n19. Defendant Patrick F. Williams was appointed as the CFO of STAAR \nin July 2020. \n20. Defendants Mason, Andrews, and Williams are named as Defendants \nfor violations of all counts asserted herein, and are referred to as the \u201cIndividual \nDefendants.\u201d The Individual Defendants, because of their positions with the \nCompany, possessed the power and authority to control the contents of the \nCompany\u2019s reports to the SEC, press releases and presentations to securities \nanalysts, money and portfolio managers, and the investing public, i.e., the market.  \nThe Individual Defendants were provided with copies of the Company\u2019s reports \nand press releases alleged herein to be misleading prior to, or shortly after, their \nissuance and had the ability and opportunity to prevent their issuance or cause \nthem to be corrected.  Because of their positions and access to\nOnly answer with the company defendants names.",
        "output": "STAAR Surgical Company",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " \n12. Plaintiff Guolian Zhou, as set forth in the accompanying certif ication, \nincorporated by reference herei n, purchased Annovis securities during the Class Period, and \nsuffered damages as a result of the federal securities law viol ations and false and/or misleading \nstatements and/or material omissions alleged herein.  \n13. Defendant Annovis is incorporated under the laws of Delaware wi th its principal \nexecutive offices located in Berwyn, Pennsylvania. Annovis\u2019s co mmon stock trades on the New \nYork Stock Exchange (\u201cNYSE\u201d) under the symbol \u201cANVS.\u201d  \n14. Defendant Maria Maccecchini (\u201cMaccecchini\u201d) was the Company\u2019s C hief \nExecutive Officer (\u201cCEO\u201d) at all relevant times. \n15. Defendant Jeffrey McGroarty (\u201cMcGroarty\u201d) was the Company\u2019s Chi ef Financial \nOfficer (\u201cCFO\u201d) at all relevant times. Case 2:21-cv-03668   Document 1   Filed 08/17/21   Page 4 of 26 \n4 16. Defendants Maccecchini and McGroar ty (collectively the \u201cIndivid ual \nDefendants\u201d), because of their positions with the Company, poss essed the power and authority to \ncontrol the contents of the Company\u2019s reports to the SEC, press  releases and presentations to \nsecurities analysts, money and portfolio managers and instituti onal investors, i.e., the market.  \nThe Individual Defendants were provided with copies of the Comp any\u2019s reports and press \nreleases alleged herein to be misleading prior to, or shortly a fter, their issuance and had the \nability and opportunity to prevent their issuance or cause them  to be corrected.  Because of their \npositions and access to material non-public information availab le to them, the Individual \nDefendants knew that the adverse facts specified herein had not  been disclosed to, and were \nbeing concealed from, the public, and that the positive represe ntations which were being made \nwere then materially false and/ or misleading.  The Individual D efendants are liable for the false \nstatements pleaded herein.  \n\nIndividual defendants:",
        "output": "Maria Maccecchini,Jeffrey McGroarty",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are individuals.",
        "input": " reside in th is County, the parties transact \nbusiness in this County, certain of the defendants have submitt ed to venue in this County by written \nagreement, the transactions underlying the complaint took place  in substantial part in this County, \nand the causes of acti on arose in this County. \nDATED:  Melville, New York \n      September 23, 2020 ROBBINS GELLER RUDMAN \n &  D O W D  L L P  \nSAMUEL H. RUDMAN \n \ns/ Samuel H. Rudman \n SAMUEL H. RUDMAN \n \n58 South Service Road, Suite 200 \nMelville, NY  11747 \nTelephone:  631/367-7100 \n631/367-1173 (fax) \nsrudman@rgrdlaw.com \n \nROBBINS GELLER RUDMAN \n &  D O W D  L L P  \nBRIAN E. COCHRAN  \n200 South Wacker Drive, 31st Floor \nChicago, IL  60606 \nTelephone:  312/674-4674 \n312/674-4676 (fax) \nbcochran@rgrdlaw.com FILED: NEW YORK COUNTY CLERK 09/23/2020 02:59 PMINDEX NO. 654654/2020\nNYSCEF DOC. NO. 1 RECEIVED NYSCEF: 09/23/2020\n4 of 34 \n- 4 -  \nJOHNSON FISTEL, LLP \nRALPH M. STONE \n1700 Broadway, 41st Floor \nNew York, NY  10019 \nTelephone:  212/292-5690 \n212/292-5680 (fax) \nralphs@johnsonfistel.com \n \nJOHNSON FISTEL, LLP \nMICHAEL I. FISTEL, JR. \n40 Powder Springs Street \nMarietta, GA  30064 \nTelephone:  470/632-6000 \n770/200-3101 (fax) \nmichaelf@johnsonfistel.com \n \nAttorneys for Plaintiff \n \n FILED: NEW YORK COUNTY CLERK 09/23/2020 02:59 PMINDEX NO. 654654/2020\nNYSCEF DOC. NO. 1 RECEIVED NYSCEF: 09/23/2020\n5 of 34 \n SUPREME COURT OF THE STATE OF NEW YORK \nCOUNTY OF NEW YORK \n X  \nHANDY HO, Individually and on Behalf of \nAll Others Similarly Situated, \nPlaintiff, \nvs. \n9F INC., LEI SUN, YANJUN LIN, YIFAN \nREN, CHANGXING XIAO, FLYNN \nXUXIAN HUANG, IVAN XU, JUNSHENG \nZHANG, WING HON CHEUNG, SIU FUNG \nMING, FANGXIONG GONG, DAVID CUI, \nLEI LIU, CREDIT SUISSE SECURITIES \n(USA) LLC, HAITONG INTERNATIONAL \nSECURITIES COMPANY LIMITED, CLSA \nLIMITED, CHINA INVESTMENT \nSECURITIES INTERNATIONAL \nBROKERAGE LIMITED and 9F PRIMASIA \nSECURITIES LIMITED, \nDefendants. \n \n : \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \n: \nX \nIndividual defendants:",
        "output": "Lei Sun,Yanjun Lin,Yifan Ren,Changxing Xiao,Flynn Xuxian Huang,Ivan Xu,Junsheng Zhang,Wing Hon Cheung,Fangxiong Gong,David Cui,Lei Liu,Siu Fung Ming",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "Extract the name(s) of the plaintiff from the excerpt. If the plaintiff is not named, return \"Not named\"",
        "input": "  \n11. Plaintiff, as set forth in the attached Certification, acquired Enviva  securities at \nartificially inflated prices during the Class Period and was  damaged upon the revelation of the \nalleged cor rective disclosures.  \n12. Defendant Enviva  is a Delaware corporation  with principal executive offices \nlocated at 7272 Wisconsin Avenue, Suite 1800, Bethesda, Maryland 20814.  Enviva \u2019s common \nstock  trades  in an efficient market on the New York Stock Exchange (\u201cNYSE \u201d) under the trading \nsymbol \u201c EVA\u201d . \n13. Defendant John K. Keppler ( \u201cKeppler \u201d) has served as Enviva \u2019s Chairman and \nChief Executive Officer at all relevant times . \n14. Defendant Shai S. Even (\u201cEven \u201d) has served as Enviva \u2019s Executive Vice President \nand Chief Financial Officer  at all relevant times . \n15. Defendant s Keppler  and Even  are sometimes referred to herein as the \u201c Individual \nDefendants. \u201d Case 8:22-cv-02844-DKC   Document 1   Filed 11/03/22   Page 4 of 375 \n 16. The Individual Defendants possessed the power and authority to control the \ncontents of Enviva \u2019s SEC filings, press releases, and other market communications.  The \nIndividual Defendants were p rovided with copies of Enviva \u2019s SEC filings and press releases \nalleged herein to be misleading prior to or shortly after their issuance and had the ability and \nopportunity to prevent their issuance or to cause them to be corrected.  Because of their positi ons \nwith Enviva , and their access to material information available to them but not to the public, the \nIndividual Defendants knew that the adverse facts specified herein had not been disclosed and were being concealed from the public, and that the positive  representations being made were then \nmaterially false and misleading.  The Individual Defendants are liable for the false statements and \nomissions pleaded herein. \n17. Enviva  and the Individual Defendants are collectively referred to herein as \n\u201cDefendants. \u201d \nSUBSTANTIVE ALLEG ATIONS  \nBackground  \n18. Enviva , fo",
        "output": "['Not named']",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": " \n8. Plaintiff Iron Workers Local 580 Joint Funds provides, among ot her things, pension \nand health benefits to both active and retired participants in the iron working industry, as well as \ntheir dependents and beneficiarie s.  Plaintiff purchased shares  of NVIDIA stock on the public Case 5:18-cv-07669   Document 1   Filed 12/21/18   Page 3 of 20 \nCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES  LAWS 3 \nCase No.  1\n23456789\n10111213141516171819202122232425262728market during the Class Period and suffered damages as a result  of the violations of the federal \nsecurities laws alleged herein. \n9. Defendant NVIDIA is a multinational technology company.  Incorp orated in \nDelaware, the Company maintains its corporate headquarters at 2 788 San Tomas Expressway, \nSanta Clara, California.  NVIDI A stock trades on the NASDAQ, wh ich is an efficient market, \nunder ticker symbol \u201cNVDA.\u201d  As of November 9, 2018, there were  610 million shares of NVIDIA \nstock outstanding, owned by at leas t hundreds or thousands of i nvestors. \n10. Defendant Jensen Huang (\u201cHuang\u201d) is, and was at all relevant ti mes, President and \nChief Executive Officer of NVIDIA,  as well as a member of the C ompany\u2019s Board of Directors.   \n11. Defendant Collette Kress (\u201cKress\u201d ) is, and was at all relevant times, Executive Vice \nPresident and Chief Financial Officer of NVIDIA. \n12. Defendants Huang and Kress are collectively referred to hereina fter as the \n\u201cIndividual Defendants.\u201d  The Individual Defendants, because of  their positions with NVIDIA, \npossessed the power and authority  to control the contents of NV IDIA\u2019s reports to the SEC, press \nreleases, and presentations to s ecurities analysts, money and p ortfolio managers, and institutional \ninvestors.  Each of the Indivi dual Defendants wa s provided with  copies of the Company\u2019s reports \nand press releases alleged herei n to be misleading prior to, or  shortly after, thei r issuance and had \nthe ability and opportunity to pr event \nOnly answer with the company defendants names.",
        "output": "NVIDIA Corporation",
        "domain": "legal",
        "task": "ie"
    },
    {
        "instruction": "From each excerpt, extract the names of the defendants that are companies.",
        "input": "  \n10. Plaintiff is a citizen of Florida  and, at all times relevant hereto , has been a \nKlondex  stockholder .   \n11. Defendant Klondex  together with its subsidiaries, acquires, explores, develops, \nand produces mineral properties in t he United States and Canada.  It primarily explores for gold \nand silver deposits .  Klondex  is organized under the  laws of the Canadian Province of British \nColumbia and has its  United States\u2019  principal place of business at 6110 Plumas Street Suite A, \nReno, Nevada 89519.  Shares of Klondex  common stock a re traded on the New York Stock \nExchange (\u201cNYSE\u201d)  under the symbol \u201c KLDX .\u201d \n12. Defendant Richard J. Hall  (\"Hall\") has been a Director of the Company at all \nrelevant times .  In addition, Hall  serves as the Chairman  of the Company Board.  \n13. Defend ant Blair Schultz  (\"Schultz \") has been a director of the Compa ny at all \nrelevant times .  \n14. Defend ant Rodney Cooper (\" Cooper \") has been a director  of the Compa ny at \nall relevant times . \n15. Defend ant Mark Daniel  (\"Daniel \") has been a director  of the Compa ny at all \nrelevant times . \n16. Defend ant Jamie Haggarty  (\"Haggarty \") has been a director of the Compa ny at \nall relevant times.    \n17. Defend ant Paul Andre Huet  (\"Huet \") has been a director  of the Company at all \nrelevant times .  In addition, Huet  serves the Company\u2019s Chief Executive Officer . \n18. Defendant William Matlack  (\u201cMatlack \u201d) has been a director of the Company at all \nrelevant times . \n19. Defendant Charles Oliver (\u201cOliver\u201d) has been a director of the Company at all \nrelevant times.    Case 3:18-cv-00256-LRH-VPC   Document 1   Filed 05/31/18   Page 4 of 35 \n- 5 - \nCLASS ACTION COMPLAINT  \n1 \n2 \n3 \n4 \n5 \n6 \n7 \n8 \n9 \n10 \n11 \n12 \n13 \n14 \n15 \n16 \n17 \n18 \n19 \n20 \n21 \n22 \n23 \n24 \n25 \n26 \n27 \n28 \n 20. Defendants Hall, Schultz, Cooper, Daniel, Haggarty, Huet, Matlack, and Oliver  \nidentified  in \u00b6\u00b6 12 -  19 are collectively referred to as the \u201cIndividual Defendants.\u201d   \n21. Parent  is a\nOnly answer with the company defendants names.",
        "output": "Klondex Mines Ltd.",
        "domain": "legal",
        "task": "ie"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: the Company shall not, and shall cause each of its Subsidiaries not to, directly or indirectly, do any of the following without the prior written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed): (Page 17)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in law that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, with respect to the BancShares Parties, CIT or the Surviving Bank, as the case may be, any effect, change, event, circumstance, condition, occurrence or development (including such effect, change, event circumstance, condition, occurrence or development with respect to any matter whether or not pending as of the date of this Agreement that causes such matter (even if not a Material Adverse Effect previously) to constitute a Material Adverse Effect thereafter) that, either individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (i) the business, properties, assets, liabilities, results of operations or financial condition of such party and its Subsidiaries taken as a whole (provided, however, that, with respect to this clause (i), Material Adverse Effect shall not be deemed to include the impact of (A) changes, after the date hereof, in U.S. generally accepted accounting principles (\u201cGAAP\u201d) or applicable regulatory accounting requirements, (B) changes, after the date hereof, in laws, rules or regulations (including the Pandemic Measures) of general applicability to companies in the industries in which such party and its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities, (C) changes, after the date hereof, in global,     8      national or regional political conditions (including the outbreak of war or acts of terrorism) or in economic or market (including equity, credit and debt markets, as well as changes in interest rates) conditions affecting the financial services industry generally and not specifically relating to such party or its Subsidiaries (including any such changes arising out of the Pandemic), (D) changes, after the date hereof, resulting from hurricanes, earthquakes, tornados, floods or other natural disasters or from any outbreak of any disease or other public health event (including the Pandemic), (E) public disclosure of the transactions contemplated hereby or actions expressly required by this Agreement or that are taken with the prior written consent of the other party in contemplation of the transactions contemplated hereby, or (F) a decline in the trading price of a party\u2019s common stock or the failure, in and of itself, to meet earnings projections or internal financial forecasts, but not, in either case, including any underlying causes thereof; except, with respect to subclause (A), (B), (C) or (D), to the extent that the effects of such change are materially disproportionately adverse to the business, results of operations or financial condition of such party and its Subsidiaries, taken as a whole, as compared to similar companies in the banking industry) or (ii) the ability of such party to timely consummate the transactions contemplated hereby. (Pages 16-17)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: SECTION 5.01. Conduct of Business of the Company.  (a) Except for matters set forth in Section 5.01(a) of the Company Disclosure Letter or as otherwise expressly contemplated by this Agreement or required by applicable Law (including any COVID-19 Response) except or with the prior written consent of Parent (such consent not to be unreasonably withheld, delayed or conditioned), from the date of this Agreement to the earlier of the termination of this Agreement and the Effective Time, the Company shall, and shall cause its Subsidiaries to, conduct its business in the ordinary course of business consistent with past practice in all material   39   respects and use commercially reasonable efforts to preserve as substantially intact its organizations, assets, employees, Authorizations, business and its existing relations with key customers, suppliers and other Persons with whom the Company or its Subsidiaries have significant business relationships and use commercially reasonable efforts to keep available the services of its employees (subject to Section 5.01(a)(viii)), in each case, consistent with past practice. (Pages 47-48)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: except as <omitted> with the prior written approval of Parent or Merger Sub (which shall not be unreasonably withheld, delayed or conditioned), the Company shall, and shall cause each Company Subsidiary to, (i) conduct its business in the ordinary course consistent with past practice (Page 27)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cKnowledge\u201d means, with respect to Peoples, the Knowledge of any officer of Peoples with the title of Chief Executive Officer, President, Executive Vice President of Operations, or Chief Financial Officer, and, with respect to Premier Financial, the Knowledge of any officer of Premier Financial, Citizens Bank or Premier Bank with the title of Chairman, Chief Executive Officer, President, Chief Financial Officer, Chief Operating Officer, Chief Credit Officer, Chief Lending Officer, President of Citizens Bank, Compliance officer for Citizens Bank, the President of Premier Bank, or the Compliance Officer for Premier Bank. An officer of Peoples or Premier Financial shall be deemed to have \u201cKnowledge\u201d of a particular fact or matter if such officer is actually aware of such fact or matter or a prudent individual would be reasonably expected to discover or otherwise become aware of such fact or matter in the course of conducting a reasonably comprehensive investigation concerning the existence of such fact or matter. (Page 7)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "When are representations and warranties required to be made according to the bring down provision?\nOption A: At Closing Only\nOption B: At Signing & At Closing\n\nMerger Agreement: Section 8.02       Conditions to the Obligations of Parent and Merger Sub. The obligations of Parent and Merger Sub to consummate the Merger are subject to the satisfaction (or waiver by each of Parent and Merger Sub, if permissible under Applicable Law), at or prior to the Closing, of the following further conditions: (a) Representations and Warranties. <omitted>  (ii)              Each of the representations and warranties made by the Company in this Agreement other than the Company Fundamental Representations (without giving effect to any references to any \u201cCompany Material Adverse Effect\u201d or other \u201cmateriality\u201d qualifications) shall be true and correct in all respects as of the date hereof and as of the Closing Date as if made as and on the Closing Date, in each case, (A) except for representations and warranties that speak as of a particular date, which shall be true and correct in all respects as of such date, and (B) except where the failure to be so true and correct has not had and would not reasonably be expected to have a Company Material Adverse Effect. (Page 35)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 5.4 No Solicitation by the Company; Other Offers. <omitted> (d) <omitted> Notwithstanding the foregoing, the Company Board may, at any time prior to the Acceptance Time, take any of the actions set forth in Sections 5.4(d)(i)-(iii) below (provided, however, that prior to taking any such action, the Company complies with Section 5.4(e) of this Agreement): (i) if there is an Intervening Event, effect a Change in Company Board Recommendation if the Company Board concludes in good faith, after consultation with outside counsel, that the failure to take such action would be reasonably likely to be inconsistent with the Company Board\u2019s fiduciary duties under applicable Law; (ii) effect a Change in Company Board Recommendation in response to an Acquisition Proposal that did not result from a material breach of the Company\u2019s obligations under this Section 5.4 if the Company Board concludes in good faith, after consultation with outside counsel, that the failure to take such action would be reasonably likely to be inconsistent with the Company Board\u2019s fiduciary duties under applicable Law and the Company Board concludes in good faith, after consultation with the Company\u2019s financial advisor, that the Acquisition Proposal constitutes a Superior Proposal (Page 45)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 4.4 No Solicitation of Transactions. <omitted> (f)                 <omitted> if (i) the Company receives a Qualifying Acquisition Proposal that the Company Board determines <omitted> is a Superior Proposal <omitted> the Company Board may not effect a Change of Board Recommendation pursuant to the foregoing clause <omitted> unless: <omitted>   (ii)               the Company shall have provided <omitted> notice to Parent, at least four (4) Business Days in advance (the \u201cSuperior Proposal Notice Period\u201d) <omitted> (iv)              following the Company\u2019s <omitted> negotiation <omitted> with Parent <omitted> during the Superior Proposal Notice Period and after considering the results of such negotiations and giving effect to any proposals, amendments or modifications made or agreed to by Parent, if any, the Company Board (after consultation with one or more of its financial advisors and outside legal counsel) shall have determined <omitted> that such Superior Proposal still constitutes a Superior Proposal (it being understood and agreed that any change to the financial or other material terms of an Acquisition Proposal that was previously the subject of a notice hereunder shall require a new notice to Parent as provided above, but with respect to any such subsequent notices the Superior Proposal Notice Period shall be deemed to be three (3) Business Days rather than four (4) Business Days); and (Pages 22-23)\n\nAnswer by outputting a singled letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Under what circumstances could the Board take actions on a different acquisition proposal notwithstanding the no-shop provision?\nOption A: If failure to take actions would lead to \"breach\" of fiduciary duties\nOption B: If failure to take actions would be \"inconsistent\" with fiduciary duties\nOption C: If failure to take actions would lead to \"reasonably likely/expected breach\" of fiduciary duties\nOption D: If failure to take actions would lead to \"reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: If failure to take actions would lead to \"reasonably likely/expected violation\" of fiduciary duties\nOption F: If taking such actions is \"required to comply\" with fiduciary duties\nOption G: If failure to take actions would lead to \"violation\" of fiduciary duties\nOption H: Under no circumstances could the Board do so.\nOption I: Other circumstances\n\nMerger Agreement: 6.13 Acquisition Proposals.  <omitted>  provided, that, <omitted> in the event TCF receives an <omitted> TCF Acquisition Proposal, it may, and may permit its Subsidiaries and its and its Subsidiaries\u2019 Representatives to, furnish or cause to be furnished nonpublic information or data and participate in such negotiations or discussions to the extent that its Board of Directors concludes in good faith <omitted> that failure to take such actions would be more likely than not to result in a violation of its fiduciary duties under applicable law; (Page 70)\n\nAnswer by only outputting the letter (i.e. A, B, C, D, E, F, G, H, or I) of the relevant option.",
        "output": "I",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: Section 5.4 No Company Solicitation. <omitted> (e) Notwithstanding anything in this Section 5.4to the contrary, at any time before the Company Stockholder Approval is obtained, the Company Board may make a Company Change of Recommendation or authorize the Company to terminate this Agreement under Section 7.1(d)(i) if: <omitted> (v) at the end of such five (5) Business Day period and taking into account any changes to the terms hereof proposed by Parent in a written definitive agreement duly executed and delivered by Parent (provided, that if Parent has proposed any changes to the terms hereof or the transactions contemplated hereby and there is any subsequent amendment to any material term of such Alternative Acquisition Proposal, the Company Board shall provide a new Company Recommendation Change Notice (including all required information and documents) and an additional three (3) Business Day period from the date of such notice shall apply), the Company Board determines in good faith (after consultation with outside legal counsel and a nationally recognized financial advisor) that such Alternative Acquisition Proposal continues to be a Superior Acquisition Proposal and that the failure to make such a Company Change of Recommendation in response to such Alternative Acquisition Proposal or authorize the Company to terminate this Agreement under Section 7.1(d)(i) would be inconsistent with the Company Board\u2019s fiduciary duties under applicable Law. (Page 61)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (ii) Conversion of Company Securities. Each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other than Canceled Shares) shall be converted into the right to receive, in accordance with the terms of this Agreement, $24.00 per share in cash (the \u201cMerger Consideration\u201d). (Page 8)\n\nAnswer and only output A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cAcquisition Proposal\u201d means any offer or proposal (other than an offer or proposal by the Buyer Parties) to engage in an Acquisition Transaction.  <omitted>   \u201cAcquisition Transaction\u201d means any transaction or series of related transactions (other than the transactions contemplated hereby) involving: <omitted> (ii) any direct or indirect purchase, license or other acquisition <omitted> of assets constituting or accounting for more than 15% of the consolidated assets, revenue or net income of the Company Group  <omitted>  \u201cSuperior Proposal\u201d means any <omitted> Acquisition Proposal for an Acquisition Transaction <omitted> . For purposes of the reference to an \u201cAcquisition Proposal\u201d in this definition, all references to (i) \u201c15%\u201d in the definition of \u201cAcquisition Transaction\u201d will be deemed to be references to \u201c50%\u201d (Pages 17-18)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: provided, however, that with respect to clause (i) only, no Effect to the extent resulting or arising from any of the following, shall, to such extent, be deemed to constitute, or be taken into account in determining the occurrence of, a Company Material Adverse Effect: (A) general economic, political, business, financial or market conditions affecting the industry in which the Company and its Subsidiaries operate; (B) geopolitical conditions, including trade and national security policies and export controls and executive orders relating thereto, any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); (C) any pandemic (including the SARS-CoV-2 virus and COVID-19 disease), epidemic, plague, or other outbreak of illness or public health event, hurricane, flood, tornado, earthquake or other natural disaster or act of God or changes resulting from weather conditions; (D) any failure by the Company or any of its Subsidiaries to meet any internal or external projections or forecasts or any decline in the price of Company Common Stock (but excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves constitute or be taken into account in determining whether there has been, or would be, a Company Material Adverse Effect); (E) the public announcement or pendency of the Merger and the other transactions contemplated hereby, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, business partners or employees (provided that this clause (E) shall not apply to (x) any representation or warranty in Section 2.6 to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Merger or (y) any action or omission by the Company, any Company Subsidiary or their respective Representatives in order to comply with the Company\u2019s obligations under Section 4.1(a)); (F) changes in applicable Legal Requirements or the interpretation thereof; (G) changes in GAAP or any other applicable accounting standards or the interpretation thereof; or (H) any action expressly required to be taken by the Company pursuant to the terms of this Agreement or at the express written direction or consent of Parent or Acquisition Sub; provided, further, that any Effect relating to or arising out of or resulting from any change or event referred to in clause (A), (C), (F) or (G) above may constitute, and be taken into account in determining the occurrence of, a Company Material Adverse Effect if and only to the extent that such change or event has a disproportionate impact on the Company and its Subsidiaries as compared to other participants that operate in the industry in which the Company and its Subsidiaries operate. (Page 102)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (a) At the Effective Time, each share of Common Stock issued and outstanding immediately prior to the Effective Time (other than (i) Cancelled Shares, and (ii) Dissenting Shares) shall, by virtue of the Merger and without any action on the part of the holder thereof or the Company or the Purchaser Parties, be converted into the right to receive $4.80 in cash, without any interest thereon (the \u201cMerger Consideration\u201d). (Page 19)\n\nAnswer and only output A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: (f) Exception to Change in Recommendation Provision (Superior Proposal). <omitted> following receipt of a written Acquisition Proposal by the Company <omitted> the Company\u2019s board of directors may <omitted> make a Change in Recommendation <omitted>  (it being understood and agreed that any amendment to the financial terms or any other material term or condition of such Superior Proposal shall require a new notice and an additional three (3) Business Day period) (Pages 55-56)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: (d)               The Company Board shall not be entitled to effect an Adverse Recommendation Change or terminate this Agreement pursuant to Section 9.01(h) unless, prior to adoption of this Agreement by the Required Company Stockholder Approval:   (i)              (A) an Acquisition Proposal that did not result from a breach of Section 6.01(a) (other than a breach that is immaterial and unintentional) is made to the Company by a Third Party following the date hereof; (B) the Company Board determines in good faith, after consultation with its financial and outside legal advisors, that such Acquisition Proposal constitutes, or could reasonably be expected to lead to, a Superior Proposal, (C) the Company has provided, at least seventy-two (72) hours in advance (or, if such seventy-two (72)-hour period does not include at least one (1) Business Day, ending on the first (1st) Business Day commencing after the passage of such seventy-two (72)-hour period), written notice (a \u201cNotice of Adverse Recommendation Change\u201d) to Parent that the Company intends to take such action (it being understood that the delivery of a Notice of Adverse Recommendation Change and any amendment or update thereto and the determination to so deliver such notice, amendment or update will not, by itself, constitute an Adverse Recommendation Change), which notice includes, as applicable, (1) written notice of the material terms and conditions of such Acquisition Proposal, (2) an unredacted copy of the Alternative Acquisition Agreement in respect of such Acquisition Proposal, (3) an unredacted copy of   any other Contracts to be entered into in connection with such Acquisition Proposal that the Company Board determined was material to its decision that the Acquisition Proposal constitutes a Superior Proposal; (D) during such seventy-two (72)-hour period following the time of Parent\u2019s receipt of the Notice of Adverse Recommendation Change, the Company shall have, and shall have caused its directors, officers and employees to, and shall have used reasonable best efforts to cause its other Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement, the Commitment Letters and Guaranty so that such Acquisition Proposal ceases to constitute a Superior Proposal; and (E) following the end of such seventy-two (72)-hour period described in the preceding clause (D), the Company Board shall have determined in good faith, after consultation with its financial and outside legal advisors, taking into account any changes to this Agreement, the Commitment Letters and Guaranty irrevocably offered in writing by Parent in response to the Notice of Adverse Recommendation Change or otherwise, that the Superior Proposal giving rise to the Notice of Adverse Recommendation Change continues to constitute a Superior Proposal and that the failure to make such Adverse Recommendation Change would still be inconsistent with its fiduciary duties under Applicable Law; provided, however, that, in the event of any material amendment of such Superior Proposal or any material change to the facts and circumstances relating to the Adverse Recommendation Change, the Company shall be required to issue a new Notice of Adverse Recommendation Change or otherwise comply again with the requirements of this Section 6.02(d) (provided, however, that for purposes of this sentence, references to the seventy-two (72)-hour period above shall be deemed to be references to a forty-eight (48)-hour period (or, if such forty-eight (48)-hour period does not include at least one (1) Business Day, ending on the first (1st) Business Day commencing after the passage of such forty-eight (48)-hour period) from the time of Parent\u2019s receipt of the Notice of Adverse Recommendation Change); or (Pages 27-28)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the capitalization representations and warranties be according to the bring down provision?\nOption A: Accurate in all material respects\nOption B: Accurate in all respects\nOption C: Accurate in all respects with below-threshold carveout\nOption D: Accurate in all respects with de minimis exception\n\nMerger Agreement: 7.2           Conditions to Obligations of the Tyler Entities .   The obligations of the Tyler Entities to consummate the Merger shall  further be subject to the satisfaction on or prior to the  Closing Date of each of the following conditions, any and all of  which may be waived in writing in whole or in part by Tyler, to the extent permitted by applicable Law: (a)          Representations and Warranties. <omitted> (iii)          the other representations and warranties of NIC set forth in ARTICLE IV that are not listed in the immediately preceding subsections (i) and (ii) (without giving effect to any qualification as to materiality or NIC Material Adverse Effect contained therein) shall be true and correct as of the date hereof and shall be true and correct as of the Closing as though made as of the Closing (except representations and warranties that by their terms speak specifically as of another date, in which case as of such date), except, with respect to this subsection (iii), where any failures of any such representations and warranties to be true and correct (without giving effect to any qualification as to materiality or NIC Material Adverse Effect contained therein) have not had and would not reasonably be expected to have, individually or in the aggregate, a NIC Material Adverse Effect. (Page 47)\n\nAnswer by only outputting the option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is there specific reference to pandemic-related governmental responses or measures in the clause that qualifies pandemics or other public health events for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d shall mean any state of fact, event, change, effect, circumstance, occurrence or development that is materially adverse to the business, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole, excluding any event, change, effect, circumstance, occurrence or development that results from or arises out of: (a) changes after the date of this Agreement in GAAP or the authoritative interpretation thereof; (b) changes after the date of the Agreement in applicable Legal Requirements; (c) general economic, business, financial, capital market or political conditions; (d) changes generally affecting the industry in which the Company and its Subsidiaries participates; (e) the outbreak or escalation of hostilities, any acts of war, sabotage, terrorism or military actions (or any escalation or worsening of any such hostilities, acts of war, sabotage, terrorism or military actions), or the continuation or worsening of the COVID-19 pandemic; (f) the negotiation, announcement or pendency of this Agreement, the Merger or the other transactions contemplated by this Agreement (provided that this clause \u201c(f)\u201d shall not apply to any representation or warranty in Section 2.19 to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Merger); (g) the Company\u2019s failure to meet public estimates or forecasts of revenues, earnings or other financial metrics, in and of itself, or the failure to meet internal projections, forecasts or budgets of revenues, earnings or other financial metrics, in and of itself, provided that in each case the underlying cause or causes may be taken into account in determining whether there has been or would reasonably be expected to be a Company Material Adverse Effect, to the extent otherwise permitted by this definition; (h) any decline in the Company\u2019s stock price or any decline in the market price or trading volume of the Company Common Stock on Nasdaq, in and of itself, or the suspension of trading in or delisting of the Company Common Stock on Nasdaq, provided, that in each case the underlying cause or causes may be taken into account in determining whether there has been or would reasonably be   A-3   expected to be a Company Material Adverse Effect, to the extent otherwise permitted by this definition; (i) any action taken or omitted to be taken at the written request of Parent or the taking of any action required by this Agreement; (j) any lawsuit commenced by a stockholder of the Company (in his, her or its capacity as a stockholder) alleging breach of fiduciary duty in connection with the execution of the Agreement or the consummation of the transactions contemplated by the Agreement, except, in the case of each of clauses \u201c(a),\u201d \u201c(b),\u201d \u201c(c),\u201d \u201c(d),\u201d and \u201c(e)\u201d of this proviso, to the extent that such changes have a disproportionate adverse impact on the Company and its Subsidiaries relative to other participants in the industries in which the Company and its Subsidiaries operate, in which case the incremental disproportionate impact or impacts may be taken into account in determining whether there has been or would reasonably be expected to be a Company Material Adverse Effect. (Pages 81-82)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: Without limiting the foregoing, and as an extension thereof, except as set forth in Section 6.1 of the Company Disclosure Schedule, as expressly permitted by any other provision of this Agreement or as required by Law, the Company shall not, and shall cause each Company Subsidiary not to, between the date of this Agreement and the earlier of the Effective Time and valid termination of this Agreement in accordance with Section 8.1, directly or indirectly, do, or agree to do, any of the following without the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned): (Page 35)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the Forward Looking Standard (FLS) with respect to Material Adverse Effect (MAE)?\nOption A: \"Could\" (reasonably) be expected to\nOption B: \"Would\"\nOption C: \"Would\" (reasonably) be expected to\nOption D: No\nOption E: Other forward-looking standard\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means, with respect to the Company and its Subsidiaries, any change, event, occurrence, development, circumstance or condition that, individually or in the aggregate (x) has or would reasonably be expected to prevent or materially impair or delay the ability of the Company and its Subsidiaries, to consummate the transactions contemplated hereby or (y) has had or would reasonably be expected to have a material adverse effect on the financial condition, properties, assets, business or results of operations of the Company and its Subsidiaries, taken as a whole, excluding for the purposes of clause (y), any such effect resulting from or arising in connection with: (1) changes in, or events generally affecting, the financial, securities or capital markets, (2) general economic or political conditions in the United States or any foreign jurisdiction in which the Company or any of its Subsidiaries operate, including any changes in currency exchange rates, interest rates, monetary policy or inflation, (3) changes in, or events generally affecting, the industries in which the Company or any of its Subsidiaries operate, (4) any acts of war, disease outbreak, epidemic, pandemic (in the case of pandemic, including SARS-CoV-2 or COVID-19 pandemic, including any evolutions or mutations of the SARS-CoV-2 virus (the \u201cCOVID-19 Pandemic\u201d)), sabotage, civil disobedience or terrorism or natural disasters (including hurricanes, tornadoes, floods or earthquakes), (5) any COVID-19 Measures, (6) any failure by the Company or any of its Subsidiaries to meet any internal or published budgets, projections, forecasts or predictions in respect of financial performance for any period, (7) a decline in the price of the Shares, or a change in the trading volume of the Shares, on the New York Stock Exchange (\u201cNYSE\u201d), provided, that the exceptions in clauses (6) and (7) shall not prevent or otherwise affect a determination that any change, event, occurrence, development, circumstance or condition underlying such failure or decline or change (if not otherwise falling within any of the exclusions pursuant to the other clauses of this definition) has resulted in, or contributed to, a Company Material Adverse Effect, (8) changes in applicable Law, (9) changes in U.S. generally accepted accounting principles (\u201cGAAP\u201d) (or authoritative interpretation thereof), (10) the taking of any specific action expressly required by this Agreement or taken with Parent\u2019s written consent (other than pursuant to Section 6.1 of this Agreement), (11) the announcement or pendency (but, for the avoidance of doubt, not the consummation) of this Agreement and the Merger, including the impact thereof on the relationships with customers, suppliers, distributors, partners and other third parties with whom the Company has a relationship or (12) any litigation brought by stockholders of the Company or Parent alleging breach of duty or inadequate disclosure in connection with this Agreement or any of the transactions contemplated hereby (it being understood and agreed that the exception in this clause (12) shall apply to the effects arising out of or relating to the bringing of such litigation and not those arising out of or resulting from an actual breach (or other claim) that is the subject thereof); provided, that the changes, events,   9   occurrences, developments, circumstances or conditions set forth in the foregoing clauses (1), (2), (3), (4), (5), (8) and (9) shall be taken into account in determining whether a \u201cCompany Material Adverse Effect\u201d has occurred to the extent such changes, events, occurrences, developments, circumstances or conditions have a disproportionate adverse effect on the Company and its Subsidiaries, taken as a whole, relative to other participants in the industries in which the Company and its Subsidiaries operate (but only the incremental disproportionate effect on the Company and its Subsidiaries, taken as a whole), (Pages 16-17)\n\nAnswer by outputting a singled letter A, B, C, D or E.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is there specific reference to pandemic-related governmental responses or measures in the clause that qualifies pandemics or other public health events for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means any Effect which, individually or in the aggregate, has had, or would reasonably be expected to have, a material adverse effect on the business, assets, financial condition or results of operations of the Company; provided, that none of the following shall be deemed in and of themselves, either alone or in combination, to constitute, and none of the following shall be taken into account in determining whether there is, or would reasonably likely to be, a Material Adverse Effect: (i) any Effect generally affecting the U.S. or foreign economies, financial or securities markets, or political, legislative, or regulatory conditions, or the industries in which the Company operates;   (ii) any Effect arising out of or otherwise relating to fluctuations in the value of any currency exchange, interest or inflation rates or tariffs;   (iii) any Effect arising out of or otherwise relating to any change (or proposed change) in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP);   (iv) any Effect arising out of or otherwise relating to any act of terrorism, cyberterrorism (whether or not or sponsored by a Governmental Body), outbreak of hostilities, acts of war, trade war, national or international calamity or any other similar event (or the escalation of any of the foregoing);   (v) any acts of God, natural disasters, force majeure events, weather or environmental events or health emergencies, including pandemics (including COVID-19) or epidemics (or the escalation of any of the foregoing) and any governmental or industry responses thereto, including any COVID-19 Measures;   (vi) any change in the market price or trading volume of the Company\u2019s stock or change in the Company\u2019s credit ratings;   (vii) the failure of the Company to meet internal or analysts\u2019 expectations, projections, forecasts, guidance or estimates, including the results of operations of the Company;   (viii) any Effect or other matter resulting from the negotiation, execution, announcement, pendency or performance of this Agreement and the Transactions, including any Effect related to the identity of Parent, or facts and circumstances relating thereto, any loss or threatened loss of, or adverse change or threatened adverse change in, the relationship of the Company with any of its current or prospective suppliers, customers, wholesalers, service providers, distributors, licensors, licensees, regulators, employees, creditors, stockholders or other third parties (other than for purposes of any representation or warranty contained in Section 4.5 (Non-Contravention) but subject to disclosures in Section 4.5 of the Company Disclosure Schedule); and   (ix) any Effect arising out of or otherwise directly relating to any action taken by the Company at the written direction or approval of Parent or any action specifically required to be taken by the Company, or the failure of the Company to take any action that the Company is specifically prohibited from taking by the terms of this Agreement;   provided, however, that in the cases of clauses (i) through (iv), such exclusion shall only be applicable to the extent such matter does not have a materially disproportionate Effect on the Company relative to other companies in the industries in which the Company operates that are of a similar size to the Company, in which case such Effect shall be taken into account only to the extent of such materially disproportionate Effect on the   -8-   Company; provided, further, that in the cases of clauses (vi) and (vii), the underlying causes of any such Effect may be considered in determining whether a Material Adverse Effect occurred to the extent not otherwise excluded by another exception in this definition. (Pages 12-13)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is there specific reference to pandemic-related governmental responses or measures in the clause that qualifies pandemics or other public health events for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d with respect to a Person means an effect that: (a) is materially adverse to the business, financial condition or results of operations of the Person and its Subsidiaries taken as a whole; or (b) materially and adversely affects the ability of the Person to consummate the Merger on or by the Termination Date or to perform its material obligations under this Agreement; provided, however, that a Material Adverse Effect shall not be deemed to include the impact of or be deemed to occur as a result of, either alone or in combination, any effects to the extent attributable to: (i) any changes in Laws or other changes affecting depository institutions generally; (ii) any changes to GAAP or regulatory accounting requirements; (iii) any changes in general economic conditions; (iv) any changes in prevailing interest and deposit rates, or changes in financial, securities or credit markets; (v) any changes in national or international political or social conditions, including any outbreak or escalation of major hostilities or acts of terrorism which involves the United States, declarations of any national or global epidemic, pandemic or disease outbreak (including the Covid-19 virus), or the material worsening of such conditions threatened or existing as of the date of this Agreement; (vi) any modifications or changes to valuation policies and practices in connection with the Transactions or restructuring charges taken in connection with the Transactions, in each case in accordance with GAAP; (vii) (A) any actions taken or not taken or (B) modifications or changes made, or failure to make modifications or changes, by AB or the Bank to AB\u2019s or the Bank\u2019s general business, practices or policies, in each case, at the request of GBCI; (viii) the impact of the public announcement of, pendency of or completion of the Transactions on relationships with customers and employees; (ix) any failure, in and of itself, to meet internal projections or forecasts (except that the facts or circumstances giving rise or contributing to such failure may nonetheless constitute, or be taken into account in determining whether there has been, a Material Adverse Effect); (x) any actions or omissions of a party taken with the prior consent of the other, or which have been waived in writing by the other party, or in contemplation of the Transactions as required or permitted hereunder, or as required under any regulatory approval received in connection with the Transactions; or (xi) any changes in the trading price or trading volume of securities of such Person on the NASDAQ Global Select Market or NASDAQ Capital Market (except that the facts or circumstances giving rise or contributing to such failure may nonetheless constitute, or be taken into account in determining whether there has been, a Material Adverse Effect), as applicable, or any other securities trading market, except, in the case of clauses (i), (ii), (iii), (iv), and (v), to the extent such event does not have a materially more adverse effect on such party than experienced by similarly situated depository institutions. (Page 10)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cCompany Superior Proposal\u201d means a bona fide written Company Takeover Proposal with respect to the Company or its Subsidiaries (except that, for purposes of this definition, each reference in the definition of \u201cCompany Takeover Proposal\u201d to \u201c15%\u201d shall be \u201c50%\u201d), that the Company\u2019s board determines in good faith (after consultation with outside legal counsel and a financial advisor of national reputation) (a) is reasonably likely to be consummated in accordance with its terms, taking into account all financial, legal, regulatory, timing and other aspects of such proposal and (b) would, if consummated, result in a transaction that is more favorable from a financial point of view to the holders of the Company\u2019s common stock than the transactions contemplated by this Agreement, taking into account:  (i) all financial considerations; (ii) the identity of the Third Party making such Company Takeover Proposal; (iii) the anticipated timing, conditions (including any financing condition or the reliability of any debt or equity funding commitments) and prospects for completion of such Company Takeover Proposal; (iv) the other terms and conditions of such Company Takeover Proposal and the implications thereof on the Company, including relevant legal, regulatory, and other aspects of such Company Takeover Proposal deemed relevant by the Company (including any conditions relating to financing, stockholder approval, regulatory approvals, or other events or circumstances beyond the control of the Company); and (v) any revisions to the terms of this Agreement and the transaction contemplated by this Agreement proposed by Parent during the Company Superior Proposal Notice Period set forth in Section 6.02(d). <omitted> \u201cCompany Takeover Proposal\u201d means an inquiry, proposal, or offer from or on behalf of, or indication of interest in making a proposal or offer (including any amendment or modification to any existing indication of interest, inquiry, offer or proposal) by or on behalf of, any Person or group relating to any transaction or series of related transactions (other than any such inquiry, proposal, offer or indication of interest made by or on behalf of Parent, US Holdco, Merger Sub or one or more of their Subsidiaries as contemplated by this Agreement), relating to, or that would reasonably be expected to lead to, in one transaction or a series of related transactions, any:  (a) direct or indirect acquisition of assets of the Company or its Subsidiaries (including any voting equity interests of Subsidiaries, but excluding sales of assets in the ordinary course of business consistent with past practice) equal to 15% or more of the fair market value of the Company\u2019s and its Subsidiaries\u2019 consolidated assets, taken as a whole, or to which 15% or more of the Company\u2019s and its Subsidiaries\u2019 revenues, income or EBITDA on a consolidated basis, taken as a whole, are attributable; (b) direct or indirect acquisition of 15% or more of the voting equity interests of the Company or any of its Subsidiaries whose business constitutes 15% or more of the consolidated revenues, income, EBITDA or assets of the Company and its Subsidiaries, taken as a whole; (c) tender offer or exchange offer that if consummated would result in any Person or group (as defined in Section 13(d) of the Exchange Act) beneficially owning (within the meaning of Section 13(d) of the Exchange Act) 15% or more of the voting power of the Company; (d) merger, consolidation, joint venture, partnership, consolidation, dissolution, liquidation, tender offer, recapitalization, reorganization, spin-off, share exchange, acquisition, license agreement, other business combination, or similar transaction involving the Company or any of its Subsidiaries, pursuant to which such Person or group (as defined in Section 13(d) of the Exchange Act) would own 15% or more of the consolidated net revenues, net income, or assets of the Company and its Subsidiaries, taken as a whole; (e) liquidation, dissolution (or the adoption of a plan of liquidation or dissolution), or recapitalization or other significant corporate reorganization of the Company or one or more of its Subsidiaries which, individually or in the aggregate, generate or constitute 15% or more of the consolidated net revenues, net income, or assets of the Company and its Subsidiaries, taken as a whole; or (f) any combination of the foregoing. (Page 11)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any effect, event,  development or change that, individually or in the aggregate with all other effects, events, developments or changes, is, or would reasonably be expected to be, materially adverse to (i) the business, results of operations or financial condition, assets of the Company and its Subsidiaries, taken as a whole or (ii) the ability of the Company or Hospitality to consummate the Mergers before the End Date; provided, however, that in the case of clause (i), no effect, event, development or change resulting from, arising out of, attributable to or relating to any of the following shall be deemed to be or constitute a \u201cCompany Material Adverse Effect,\u201d and no effect, event, development or change (by itself or when aggregated or taken together with any and all other such effects, events, developments or changes) to the extent resulting from, arising out of, attributable to, or related to any of the following shall be taken into account when determining whether a \u201cCompany Material Adverse Effect\u201d has occurred or would reasonably be likely to occur: (a) general economic conditions (or changes in such conditions) in the United States or any region thereof or any other country or region in the world, or conditions in the global economy generally; (b) conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets in the United States or any region thereof or any other country or region in the world, including (i) changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and (ii) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any region thereof or any other country or region in the world; (c) conditions (or changes in such conditions) in any of the industries in which the Company and or its Subsidiaries conduct business; (d) political conditions (or changes in such conditions) in the United States or any region thereof or any other country or region in the world or acts of war, sabotage or terrorism (including any escalation or general worsening of any such acts of war, sabotage or terrorism) in the United States or any region thereof or any other country or region in the world; (e) any Force Majeure event; (f) the announcement of this Agreement or the pendency or consummation of the transactions contemplated hereby, including (i) the identity of Parent and its affiliates and (ii) the impact thereof on relationships, contractual or otherwise, with customers, suppliers, licensors, distributors, partners or employees (provided that this clause (f) shall not apply to any representation or warranty in Section 5.5 and, solely to the extent related thereto, the condition set forth in Section 8.2(a)); (g) the taking of any action expressly required by this Agreement or with the consent of Parent in writing ; (h) changes in law or other legal or regulatory conditions (or the interpretation thereof), or changes in GAAP or other accounting standards (or the interpretation thereof), in each case, after the date hereof; (i) changes in the stock price of the Paired Common Shares or the trading volume of the Paired Common Shares, or any failure by the Company or Hospitality to meet any public estimates or expectations of the revenue, earnings or other financial performance or results of operations of the Company or Hospitality for any period, or any failure by any Paired Entity or Paired Entities Subsidiary to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (but not, in each case, the underlying cause of such changes or failures, unless such changes or failures would otherwise be excepted from this definition); or (j) any litigation by the stockholders of the Paired Entities related to this Agreement, the Mergers or other transactions contemplated hereby; except to the extent such effects, events,  developments or changes to the extent resulting from, arising out of, attributable to or related to the matters described in the foregoing clauses (a) through (e) and (h) disproportionately adversely affect the Company and its Subsidiaries, taken as a whole, as compared to other companies that conduct business in the United States and in the industries in which the Company and its Subsidiaries conduct business (in which case, such adverse effects (if any) shall be taken into account when determining whether a \u201cCompany Material Adverse Effect\u201d has occurred or would reasonably be likely to occur solely to the extent they are disproportionate). (Page 86)\nAnswer and only output Yes or No.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: SECTION 7.1. Conduct of the Company.   (a) During the Pre-Closing Period, except (i) as set forth in Section 7.1 of the Company Disclosure Letter, (ii) as required by the express terms of this Agreement, (iii) with the prior written consent of Parent (which consent shall not be unreasonably withheld, conditioned, or delayed), or (iv) as required by applicable Law (including COVID-19 Measures), the Company shall, and shall cause the Company Subsidiaries to, (x) conduct their respective business only in the ordinary and usual course of business and consistent with past practice, (Page 63)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the wording of the Specific Performance clause regarding the parties\u2019 entitlement in the event of a contractual breach?\nOption A: \"entitled to seek\" specific performance\nOption B: \"entitled to\" specific performance\n\nMerger Agreement: Section 10.12 Enforcement; Exclusive Jurisdiction. (a) The rights and remedies of the Parties shall be cumulative with and not exclusive of any other remedy conferred hereby. The Parties agree that irreparable damage would occur and that the Parties would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches or threatened breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, including the obligations to consummate the Merger and obligations under Section 7.11, in the Court of Chancery of the State of Delaware or, if under applicable Law exclusive jurisdiction over such matter is vested in the federal courts, any federal court located in the State of Delaware without proof of actual damages or otherwise (and each Party hereby waives any requirement for the securing or posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are entitled at law or in equity. (Page 91)\n\nAnswer and only output A or B!",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: Except <omitted> (ii) as approved by Parent (which approval will not be unreasonably withheld, conditioned or delayed); <omitted> at all times during the period commencing with the execution and delivery of this Agreement and continuing until the earlier to occur of the termination of this Agreement <omitted> and the Effective Time, the Company will not, and will not permit any of its Subsidiaries, to: (Page 62)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 7.2 Company Acquisition Proposals. <omitted> (e) <omitted> the Company Board may effect a Company Adverse Recommendation Change <omitted> if: (i) (A) a bona fide written Company Acquisition Proposal is made to the Company after the date of this Agreement <omitted> and such Company Acquisition Proposal is not withdrawn prior to such Company Adverse Recommendation Change or (B) there has been an Intervening Event; (ii) in the case of a Company Acquisition Proposal, the Company Board concludes in good faith, after consultation with the Company\u2019s outside financial advisors and outside legal counsel, that (x) such Company Acquisition Proposal constitutes a Superior Proposal and (y) failure to take such action would reasonably be expected to be inconsistent with the directors\u2019 fiduciary duties under applicable Laws; and (iii) in the case of an Intervening Event, the Company Board concludes in good faith, after consultation with the Company\u2019s outside legal counsel, that failure to take such action would reasonably be expected to be inconsistent with the directors\u2019 fiduciary duties under applicable Laws. (Page 75)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Under what circumstances could the Board take actions on a different acquisition proposal notwithstanding the no-shop provision?\nOption A: If failure to take actions would lead to \"breach\" of fiduciary duties\nOption B: If failure to take actions would be \"inconsistent\" with fiduciary duties\nOption C: If failure to take actions would lead to \"reasonably likely/expected breach\" of fiduciary duties\nOption D: If failure to take actions would lead to \"reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: If failure to take actions would lead to \"reasonably likely/expected violation\" of fiduciary duties\nOption F: If taking such actions is \"required to comply\" with fiduciary duties\nOption G: If failure to take actions would lead to \"violation\" of fiduciary duties\nOption H: Under no circumstances could the Board do so.\nOption I: Other circumstances\n\nMerger Agreement: Section 6.02          No Solicitation by the Company. <omitted> (b) <omitted> if <omitted> the Board of Directors of the Company receives a <omitted> Company Acquisition Proposal <omitted> the Board of Directors of the Company, directly or indirectly through its Representatives, may (i) contact the Third Party that has made such Company Acquisition Proposal in order to ascertain facts or clarify terms for the sole purpose of the Board of Directors of the Company informing itself about such Company Acquisition Proposal and such Third Party and (ii) if the Board of Directors of the Company determines in good faith, after consultation with its financial advisor and outside legal counsel, that such Company Acquisition Proposal is or could reasonably be expected to lead to a Company Superior Proposal, (A) subject to compliance with this Section 6.02, engage in negotiations or discussions with such Third Party and (B) furnish to such Third Party and its Representatives and financing sources non-public information relating to the Company or any of its Subsidiaries pursuant to a confidentiality agreement that (1) does not contain any provision that would prevent the Company from complying with its obligation to provide disclosure to Parent pursuant to this Section 6.02 and (2) contains confidentiality and use provisions that, in each case, are no less favorable in the aggregate to the Company than those contained in the Confidentiality Agreement; (Page 75)\n\nAnswer by only outputting the letter (i.e. A, B, C, D, E, F, G, H, or I) of the relevant option.",
        "output": "H",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: Section 5.5 No Solicitation by the Company. <omitted>    (d) If, at any time after the date of this Agreement and prior to the receipt of the Company Stockholder Approval, the Company Board receives a Company Acquisition Proposal that the Company Board determines in good faith, after consultation with its outside financial advisors and outside legal counsel, constitutes a Company Superior Proposal that was not initiated, sought, solicited, knowingly facilitated, knowingly encouraged, knowingly induced or otherwise procured in breach of this Agreement, the Company Board may effect a Company Adverse Recommendation Change or terminate this Agreement pursuant to Section 7.1(c)(ii) in order to enter into a definitive agreement with respect to such Company Superior Proposal if (A) the Company Board determines in good faith, after consultation with its outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (B) the Company provides Parent with five (5) Business Days\u2019 prior written notice of the Company Board\u2019s intention to effect such a Company Adverse Recommendation Change or terminate this Agreement pursuant to Section 7.1(c)(ii), which notice shall include the identity of the party (or parties) making such Company Superior Proposal, the material terms of such Company Superior Proposal (including the price) and copies of the current drafts of material agreements providing for such Company Superior Proposal; (C) for a period of five (5) Business Days following the notice delivered pursuant to clause (B) of this Section 5.5(d), the Company shall have discussed and negotiated in good faith and made the Company\u2019s Representatives available to discuss and negotiate in good faith (in each case to the extent Parent desires to negotiate) with Parent\u2019s Representatives any proposed modifications to the terms and conditions of this Agreement so that the failure to take such action would no longer reasonably be expected to be inconsistent with the fiduciary duties of the Company Board under applicable Law (it being understood and agreed that any amendment to any material term or condition of any Company Superior Proposal shall require a new notice and a new three (3)-Business Day negotiation period); and (D) no earlier than the end of such negotiation period, the Company Board shall have determined in good faith, after consultation with its outside legal counsel and after considering the terms of any proposed amendment or modification to this Agreement, that (x) the Company Acquisition Proposal that is the subject of the notice described in clause (B) above still constitutes a Company Superior Proposal and (y) the failure to take such action would still be (Pages 28-29)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "F",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in response to an intervening event?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: Other specified standard\n\nMerger Agreement: SECTION 5.3 No Solicitation by the Company; Company Recommendation. <omitted> (d) <omitted> the Company Board or the Company Special   41   Committee may make a Company Adverse Recommendation Change if either (x) in the case of a Company Adverse Recommendation Change made in response to a Company Acquisition Proposal, the Company Board or the Company Special Committee has determined in good faith, after consultation with its outside financial advisors and outside legal counsel, that such Company Acquisition Proposal constitutes a Company Superior Proposal and that failure to take such action would reasonably be expected to be inconsistent with the directors\u2019 fiduciary duties under applicable Law or (y) in the case of a Company Adverse Recommendation Change made in response to a Company Intervening Event, the Company Board or the Company Special Committee has determined in good faith, after consultation with its outside financial advisors and outside legal counsel, that, as a result of a Company Intervening Event, the failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (Pages 46-47)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, or I.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: Section 5.1      Conduct of Business by the Company and Parent.   (a)           From and after the date hereof and prior to the Effective Time or the date, if any, on which this Agreement is earlier terminated pursuant to Section 7.1 (the \u201cTermination Date\u201d), except (i) as may be required by applicable Law or any Governmental Entity of competent jurisdiction, (ii) for any actions taken reasonably and in good faith to respond to COVID-19 Measures (provided that prior to taking any material actions that the Company intends to take, to the extent the Company intends to take such actions in reliance on this clause (ii), the Company will use commercially reasonable efforts to provide advance notice to and consult with Parent (if reasonably practicable) prior to taking such actions), (iii) as may be consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned); provided that Parent shall be deemed to have consented in writing if it provides no response within five (5) business days after a request by the Company for such consent, (iv) as may be required or expressly contemplated by this Agreement, or (v) as otherwise set forth in Section 5.1 of the Company Disclosure Schedule, the Company covenants and agrees with Parent to use commercially reasonable efforts to, and to cause each of its Subsidiaries to use its commercially reasonable efforts to, conduct the business of the Company and its Subsidiaries in all material respects in the ordinary course of business and, to the extent consistent therewith, use commercially reasonable efforts to preserve its assets and business organization intact in all material respects; (Page 38)\n\nAnswer and only output A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 5.3 Company Acquisition Proposals. <omitted>  (e) <omitted> the Company may make a Company Adverse Recommendation Change <omitted> and concurrently enter into a binding definitive agreement to effect such Company Superior Proposal.   (f) The Company Board shall not take any action set forth in Section 5.3(e) unless the Company has (i) provided <omitted> notice to Parent (a \u201cNotice of Company Superior Proposal\u201d) <omitted> provided, however, that if during the Company Superior Proposal Notice Period any revisions are made to a Company Acquisition Proposal and such revisions are material (it being understood and agreed that any change to consideration with respect to such proposal is material), the Company shall deliver a new Notice of Company Superior Proposal to Parent <omitted> (except that the \u201cfour (4) Business Day\u201d period referred to in clause (ii) of this proviso shall instead be a two (2) Business Day period). (Page 59)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: \u201cordinary course of business\u201d means an action taken, or omitted to be taken, in the ordinary course of such business in all respects that is materially consistent with past practice <omitted> Without prior written consent of GBCI (which consent shall not be unreasonably withheld, conditioned or delayed under subparagraphs (d), (e), (k), and (o) below) <omitted> AB and the Bank will use commercially reasonable efforts to conduct their respective businesses only in the ordinary course of business in all material respects (Page 35)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the capitalization representations and warranties be according to the bring down provision?\nOption A: Accurate in all material respects\nOption B: Accurate in all respects\nOption C: Accurate in all respects with below-threshold carveout\nOption D: Accurate in all respects with de minimis exception\n\nMerger Agreement: Section 6.3    Conditions to the Obligations of Parent and Merger Sub. <omitted> (iii)    the other representations and warranties of the Company set forth in Article III shall be true and correct as of the date of this Agreement and as of the Closing Date as though made as of the Closing (Page 61)\n\nAnswer by only outputting the option letter A, B, C or D.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: provided, however, that an effect, change, development, event or circumstance shall not be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company if such effect, change, development, event or circumstance results or arises from: (a) any adverse change in economic, financial, capital market, political or social conditions in the United States or in other locations in which the Inphi Entities have material operations that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such adverse change may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (b) any adverse change in conditions generally affecting the semiconductor industry that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such adverse change may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (c) changes in the stock price or trading volume of the Company Common Stock (it being understood that the facts or circumstances giving rise to any such change in stock price or trading volume may be taken into account in determining whether a Material Adverse Effect on the Company has occurred or would reasonably be expected to occur, if such facts or circumstances are not otherwise excluded from such determination pursuant to this proviso); (d) the failure of the Company to meet securities analysts\u2019 published projections of earnings, revenues or other financial metrics or the failure of the Company to meet internal projections, forecasts or budgets of revenues, earnings or other financial metrics (it being understood, however, that the facts or circumstances giving rise to any such failure may be taken into account in determining whether a Material Adverse Effect on the Company has occurred or would reasonably be expected to occur, if such facts or circumstances are not otherwise excluded from such determination pursuant to this proviso); (e) any adverse change that is effected after the date of the Agreement in Legal Requirements or other legal or regulatory conditions, or in GAAP or other accounting standards (or the interpretation thereof), that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such adverse change may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (f) any act of war, sabotage or terrorism that occurs, worsens or changes after the date of the Agreement in the U.S. or in other locations in which the Inphi Entities have material operations and that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such act of war, sabotage or terrorism may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (g) any act of God, earthquake, hurricane, tsunami, tornado, flood, mudslide, wild fire or other natural disaster, weather conditions, epidemic, pandemic or disease outbreak (including the COVID-19 virus or the continuation or worsening thereof) or other force majeure event (including actions taken by Governmental Bodies in connection with such events) that occurs, worsens or changes after the date of the Agreement and that in each case does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such event may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (h) the public announcement of the Agreement or the Contemplated Transactions (including the public announcement and identification of Marvell as a Principal Party or any public communication by Marvell or any of its Affiliates regarding its plans or intentions with respect to the business of the Company or any other Inphi Entity) or any loss of customers, suppliers, distributors or other business partners or employees suffered by the Company as a result of such public announcement; or (i) any stockholder class action or derivative litigation arising from or relating to the Agreement or the Contemplated Transactions commenced against the Company after the date of the Agreement and alleging a breach of fiduciary duty of the Company\u2019s directors relating to their approval of the Agreement or false or misleading public disclosure by the Company with respect to the Agreement. (Page 129)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the fundamental representations and warranties be according to the bring down provision?\nOption A: Accurate at another materiality standard (e.g., hybrid standard)\nOption B: Accurate in all material respects\nOption C: Accurate in all respects\n\nMerger Agreement: 7.2          Conditions to Obligation of Parent and Merger Sub. The obligations of Parent and Merger Sub to effect the Merger shall be subject to the satisfaction or waiver, at or prior to the Effective Time, of the following conditions:     (a)          (A) each representation or warranty of the Company set forth in this Agreement, other than Sections 3.3, 3.4(a), 3.4(b), and 3.19, shall be true and correct (without giving effect to any qualification as to \u201cmateriality\u201d or \u201cMaterial Adverse Effect\u201d set forth therein) as of the Closing Date as though made on or as of such date (other than those representations and warranties that address matters only as of a particular date or only with respect to a specified period of time, which need only be true and correct as of such date or with respect to such period), except, in each case, where the failure of such representations and warranties to be true and correct, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect that is continuing, (Pages 39-40)\n\nAnswer by only outputting the letter of the option A, B or C.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is the \u201cability to consummate\u201d concept subject to Material Adverse Effect (MAE) carveouts?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any change, event, effect, development or occurrence that (a) has or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, assets, condition (financial or otherwise), prospects or results of operations of the Company and the Subsidiaries of the Company, taken as a whole, excluding any effect to the extent it results from or arises out of (i) general conditions in the industries in which the Company operates, (ii) general economic or regulatory, legislative or political conditions or securities, credit, financial or other capital markets conditions (including changes generally in prevailing interest rates, currency exchange rates, credit market conditions and capital markets price levels or trading volumes), in each case in the United States or elsewhere in the world, (iii) any change or prospective change in applicable Law or GAAP (or interpretation or enforcement thereof), (iv) geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or terrorism, (v) any hurricane, tornado, flood, volcano, earthquake, epidemic, disease outbreak, public health event, pandemic (including COVID-19 and any worsening thereof (including any COVID-19 Response)) or other natural or man-made disaster, (vi) the failure of the Company to meet any internal or external projections, forecasts, estimates or predictions in respect of revenues, earnings or other financial or operating metrics before, on or after the date of this Agreement, or changes or prospective changes in the market price or trading volume of the Company Common Stock or the credit rating of the Company and/or its Subsidiaries (it being understood that the underlying facts or occurrences giving rise or contributing to such failure or change may be taken into account in determining whether there has been a Company Material Adverse Effect if such facts or occurrences are not otherwise excluded from being taken into account pursuant to this definition in determining whether the has been a Company Material Adverse Effect), (vii) the execution, announcement, performance or consummation of any of the Transactions, including the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, partners, employees of Governmental Entities, or any Proceeding brought by any Company stockholder (direct or derivative) in respect of this Agreement or any of the Transactions, in each case to the extent resulting from or arising in connection with such announcement or consummation (it being understood that this clause (vii) shall not apply with respect to (a) any representation or warranty contained in this Agreement to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Transactions or the performance of obligations under this Agreement, including the Transactions or (b) any closing condition related to the foregoing clause (a)), (viii) any action taken by the Company or its Subsidiaries that is expressly required by this Agreement (other than 5.01(a)) or with Parent\u2019s written consent or at Parent\u2019s written request, or the failure to take any action by the Company or its Subsidiaries if that action is expressly prohibited by this Agreement (only to the extent that Parent unreasonably withholds, conditions or delays consent to the taking of such action after receipt of the written request therefor from the Company), and (ix) changes resulting or arising from the identity of, or any facts or circumstances relating to, Parent,   76   Merger Sub or any of their respective Affiliates, including the financing obtained or to be obtained by Parent, Merger Sub or any of their respective Affiliates, except, in the case of clause (i), (ii), (iii), (iv) or (v), to the extent that the Company is disproportionately affected thereby as compared with other participants in the industries in which the Company operates (in which case the incremental disproportionate impact or impacts may be taken into account in determining whether there has been a Company Material Adverse Effect) or (b) prevents or materially impairs or delays the consummation of the Merger and the other Transactions or the ability of the Company to perform its obligations under this Agreement. (Pages 84-85)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: except <omitted> as Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, conditioned or delayed), <omitted> (b) without limiting the foregoing, the Company shall not and shall cause each of its subsidiaries not to and, with respect to subclauses (xi)(A) and (xix) below, shall not cause or authorize any Company Joint Venture to: (Page 51)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cKnowledge\u201d, whether or not capitalized, or any similar expression: (i) with respect to the Company, means the actual knowledge of the individuals named on Section 1.1(a) of the Company Disclosure Schedule, in each case, after reasonable inquiry of those employees directly reporting to such Person; (Page 6)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means any event, change, occurrence or effect that would have a material adverse effect on the business, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, occurrence or effect arising out of, attributable to or resulting from, alone or in combination, (1) changes in general economic or business conditions or in the financial, debt, banking, capital, credit or securities markets, or in interest or exchange rates, in each case, in the United States or elsewhere in the world; (2) general changes or developments in any of the industries in which the Company or its Subsidiaries operate; (3) actions required under this Agreement and approved by Parent in accordance with Section 5.7 to obtain any approval or authorization under applicable antitrust or competition Laws for the consummation of the Merger or any other transaction contemplated hereby; (4) (x) changes after the date of this Agreement in any applicable Laws (including any COVID-19 Measures) or (y) changes after the date of this Agreement in GAAP or in applicable accounting regulations or principles or interpretations thereof; (5) any change in the price or trading volume of the Company\u2019s stock, in and of itself (provided, that the facts or occurrences giving rise to or contributing to such change in price or trading volume that are not otherwise excluded from the definition of \u201cMaterial Adverse Effect\u201d may be taken into account in determining whether there has been a Material Adverse Effect); (6) any failure by the Company to meet internal or published projections, forecasts or revenue or earnings predictions, in and of itself (provided, that the facts or occurrences giving rise to or contributing to such failure that are not otherwise excluded from the definition of \u201cMaterial Adverse Effect\u201d may be taken into account in determining whether there has been a Material Adverse Effect); (7) geopolitical conditions or any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); (8) natural or manmade disasters, hurricanes, floods, tornados, tsunamis, earthquakes or other weather conditions or other acts of God; (9) any epidemic, pandemic or disease outbreak (including COVID-19), or any Law issued by a Governmental Entity, the Centers for Disease Control and Prevention, the World Health Organization or industry group providing for COVID-19 Measures, business closures, \u201csheltering-in-place,\u201d curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease outbreak (including COVID-19) or any change in such Law or interpretation thereof following the date of this Agreement or any worsening of such conditions threatened or existing as of the date of this Agreement; (10) any national or international political or social conditions, including the engagement in, or escalation, outbreak or worsening of, hostilities in or by any country or the occurrence of any act of war or any similar act of terrorism, civil unrest, protests, public demonstrations or the response of any       9   Governmental Entity thereto; (11) the announcement of this Agreement and the transactions contemplated hereby, including the initiation of litigation by any stockholder of the Company with respect to this Agreement, and including any termination of, reduction in or similar negative impact on relationships, contractual or otherwise, with any customers, suppliers, distributors, partners or employees of the Company and its Subsidiaries due to the announcement and performance of this Agreement or the identity of the parties to this Agreement, or the performance of this Agreement and the transactions contemplated hereby, including compliance with the covenants set forth herein; provided, that in no event shall this clause (11) impact the Company\u2019s representations in Section 3.4; or (12) any actions taken (or omitted to be taken) at the express written direction of Parent (except to the extent the Company was prohibited from taking such action pursuant to Section 5.1 and requested the consent of Parent to take such action); provided, in the case of clauses (1), (2), (4), (7), (8) and (10), to the extent the impact of such event, change, occurrence or effect is not disproportionately adverse to the Company and its Subsidiaries, taken as a whole, relative to other companies operating in the industries in which the Company and its Subsidiaries operate; provided, further, that in such event, only the incremental disproportionate impact shall be taken into account when determining whether there has been a \u201cMaterial Adverse Effect\u201d. (Pages 16-17)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (a) Outstanding Company Common Stock. Each share of Company Common Stock and Company Non-Voting Common Stock (each, a \u201cShare\u201d and, collectively, \u201cShares\u201d), excluding Excluded Shares, issued and outstanding immediately prior to the Effective Time, shall become and be converted into the right to receive 0.50 of a share (the \u201cExchange Ratio\u201d) of Parent Common Stock (the \u201cMerger Consideration\u201d), without interest thereon. At the Effective Time, all Shares (other than Excluded Shares) shall no longer be outstanding and shall <omitted> automatically be cancelled and retired and shall cease to exist, and each holder of a certificate that immediately prior to the Effective Time represented any Shares (a \u201cCertificate\u201d) and each holder of a Share not represented by a Certificate (a \u201cBook-Entry Share\u201d), other than any Excluded Shares, shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration plus any dividends or distributions to which the holder thereof has the right to receive pursuant to Section 3.03(c) as well as any cash in lieu of fractional shares which such holder has the right to receive pursuant to Section 3.03(d). (Pages 16-17)\n\nAnswer and only output A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.3 Company Acquisition Proposals. <omitted>  (e) <omitted> the Company may make a Company Adverse Recommendation Change <omitted> and concurrently enter into a binding definitive agreement to effect such Company Superior Proposal.   (f) The Company Board shall not take any action set forth in Section 5.3(e) unless the Company has (i) provided written notice to Parent (a \u201cNotice of Company Superior Proposal\u201d) informing Parent that the Company has determined that a Company Acquisition Proposal constitutes a Company Superior Proposal, identifying the Person making such Company Superior Proposal and providing a copy of the draft agreement intended to effect such Company Superior Proposal, (ii) for the four (4) Business Day period following Parent\u2019s receipt of the Notice of Company Superior Proposal (the \u201cCompany Superior Proposal Notice Period\u201d), permitted Parent to make counteroffers or proposals, including to amend the terms and conditions of this Agreement (to the extent Parent wishes to do so), and (iii) after complying with clauses (i) and (ii), determined in good faith (after consultation with the Company\u2019s outside legal counsel and financial advisors and taking into account any such counteroffer or proposed amendment to the terms and conditions of this Agreement) that such Company Acquisition Proposal remains a Company Superior Proposal; provided, however, that if during the Company Superior Proposal Notice Period any revisions are made to a Company Acquisition Proposal and such revisions are material (it being understood and agreed that any change to consideration with respect to such proposal is material), the Company shall deliver a new Notice of Company Superior Proposal to Parent and shall comply with the requirements of this Section 5.3(f) with respect to such new Notice of Company Superior Proposal (except that the \u201cfour (4) Business Day\u201d period referred to in clause (ii) of this proviso shall instead be a two (2) Business Day period). (Page 59)\n\nAnswer by outputting a singled letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do pandemics or other public health events have to have disproportionate impact to qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d shall mean, with respect to Bridge Bancorp or DCB, respectively, any effect that (i) is material and adverse to the financial condition, results of operations or business of Bridge Bancorp and the Bridge Bancorp Subsidiaries taken as a whole, or of DCB and the DCB Subsidiaries, taken as a whole, or (ii) does or would materially impair the ability of either DCB, on the one hand, or Bridge Bancorp, on the other hand, to perform its obligations under this Agreement or otherwise materially threaten or materially impede the consummation of the transactions contemplated by this Agreement; provided that \u201cMaterial Adverse Effect\u201d shall not be deemed to include the impact of (a) changes in laws and regulations affecting financial institutions or their holding companies generally, or interpretations thereof by Governmental Entities, (b) changes in GAAP or regulatory accounting principles generally applicable to financial institutions and their holding companies, (c) actions and omissions of a party hereto (or any of its Subsidiaries) taken with the prior written consent of the other party, (d) the announcement of this Agreement and the transactions contemplated hereby, and compliance with this Agreement on the business, financial condition or results of operations of the parties and their respective subsidiaries, including the expenses incurred by the parties hereto in consummating the transactions contemplated by this Agreement, (e) changes in national or international political or social conditions including the engagement by the United States in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon or within the United States, or any of its territories, possessions or diplomatic or consular offices or upon any military installation, equipment or personnel of the United States, declarations of any national or global epidemic, pandemic or disease outbreak (including the COVID-19 virus), or the material worsening of such conditions threatened or existing as of the date of this Agreement, (f) a decline in the trading price of a party\u2019s common stock or the failure, in and of itself, to meet earnings projections or internal financial forecasts (it being understood that the underlying cause of such decline or failure may be taken into account in determining whether a Material Adverse Effect has occurred), (g) the expenses incurred by either party in negotiating, documenting, effecting and consummating the transactions contemplated by this Agreement, or (h) changes caused by the impact of the execution or announcement of this Agreement and the consummation of the transactions contemplated hereby on relationships with customers or employees (including the loss of personnel or customers subsequent to the date of this Agreement); except, with respect to subclauses (a), (b) and (e), to the extent that the effects of such change are materially disproportionately adverse to the business, properties, assets, liabilities, results of operations or financial condition of DCB and the DCB Subsidiaries, taken as a whole, or Bridge Bancorp and the Bridge Bancorp Subsidiaries, taken as a whole, as the case may be, as compared to other companies in the financial services industry. (Page 11)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cKnowledge\u201d means the actual knowledge of (a) for Parent, the individuals listed in Section 9.14(a) of the Parent Disclosure Schedule under the heading \u201cKnowledge\u201d (the \u201cParent Knowledge Persons\u201d) and (b) for the Company, the individuals listed in Section 9.14(a) of the Company Disclosure Schedule under the heading \u201cKnowledge\u201d (the \u201cCompany Knowledge Persons\u201d), in each case, after due inquiry; (Page 102)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: 6.3 Shareholders\u2019 Approval and Stockholder Approval <omitted> (c) Subject to Section 8.1 and Section 8.2, if the Board of Directors of NYCB or Flagstar, after receiving the advice of its outside counsel and, with respect to financial matters, its outside financial advisors, determines in good faith that it would be more likely than not to result in a violation of its fiduciary duties under applicable law to make or continue to make the NYCB Board Recommendation or Flagstar Board Recommendation, as applicable, such Board of Directors may, in the case of NYCB, prior to the receipt of the Requisite NYCB Vote, and in the case of Flagstar, prior to the receipt of the Requisite Flagstar Vote, submit this Agreement to its stockholders or shareholders, respectively, without recommendation (which, for the avoidance of doubt, shall constitute a Recommendation Change) (although the resolutions approving this Agreement as of the date hereof may not be rescinded or amended), in which event such Board of Directors may communicate the basis for its lack of a recommendation to its stockholders or shareholders, as applicable, in the Joint Proxy Statement or an appropriate amendment or supplement thereto to the extent required by law; provided, that such Board of Directors may not take any actions under this sentence unless it (i) gives the other party at least three (3) business days\u2019 prior written notice of its intention to take such action and a reasonable description of the event or circumstances giving rise to its determination to take such action (including in the event such action is taken in response to an Acquisition Proposal, the latest material terms and conditions and the identity of the third party in any such Acquisition Proposal, or any amendment or modification thereof, or describe in reasonable detail such other event or circumstances); and (ii) at the end of such notice period, takes into account any amendment or modification to this Agreement proposed by the other party and, after receiving the advice of its outside counsel and, with respect to financial matters, its outside financial advisors, determines in good faith that it would nevertheless be more likely than not to result in a violation of its fiduciary duties under applicable law to make or -50-      continue to make the NYCB Board Recommendation or Flagstar Board Recommendation, as the case may be. Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of this Section 6.3(c) and will require a new notice period as referred to in this Section 6.3(c). (Pages 58-59)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the Tail Period?\nOption A: 12 months or longer\nOption B: Other\nOption C: within 12 months\nOption D: within 6 months\nOption E: within 9 months\n\nMerger Agreement: 8.3 Expenses and Other Payments. <omitted> (d) If (i) (A) Parent or the Company terminates this Agreement <omitted> (ii) within twelve (12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Competing Proposal (or publicly approves or recommends to the stockholders of the Company or otherwise does not oppose, in the case of a tender or exchange offer, a Competing Proposal) or consummates a Competing Proposal, then the Company shall pay Parent the Company Termination Fee less any amount previously paid by the Company pursuant to Section 8.3(c). (Page 84)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: provided, however, that, with respect to this clause (i), Material Adverse Effect shall not be deemed to include the impact of (A) changes, after the date hereof, in U.S. generally accepted accounting principles (\u201cGAAP\u201d) or applicable regulatory accounting requirements, (B) changes, after the date hereof, in laws, rules or regulations of general applicability (including the Pandemic Measures) to companies in the industries in which such party and its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities, (C) changes, after the date hereof, in global, national or regional political conditions (including the outbreak of war or acts of terrorism) or in economic or market (including equity, credit and debt markets, as well as changes in interest rates) conditions affecting the financial services industry generally and not specifically relating to such party or its Subsidiaries (including any such changes arising out of the Pandemic or any Pandemic Measures), (D) changes, after the date hereof, resulting from hurricanes, earthquakes, tornados, floods or other natural disasters or from any epidemic, pandemic, outbreak of any disease or other public health event (including the Pandemic), (E) public disclosure of the execution of this Agreement, public disclosure or consummation of the transactions contemplated hereby (including any effect on a party\u2019s relationships with its customers or employees) (it being understood that the foregoing shall not apply for purposes of the representations and warranties in Sections 3.3(b), 3.4, 4.3(b) or 4.4) or actions expressly required by this Agreement or that are taken with the prior written consent of the other party in contemplation of the transactions contemplated hereby, or (F) a decline in the trading price of a party\u2019s common stock or the failure, in and of itself, to meet earnings projections or internal financial forecasts (it being understood that the underlying causes of such decline or failure may be taken into account in determining whether a Material Adverse Effect has occurred); except, with respect to subclauses (A), (B), (C) or (D), to the extent that the effects of such change are materially disproportionately adverse to the business, properties, assets, liabilities, results of operations or financial condition of such party and its Subsidiaries, taken as a whole, as -9-      compared to other companies in the industry in which such party and its Subsidiaries operat (Pages 17-18)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in law that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, when used with respect to any Party, any fact, circumstance, effect, change, event or development (\u201cEffect\u201d) that (a) would prevent, materially delay or materially impair the ability of such Party or its Subsidiaries to consummate the Transactions or (b) has, or would have, a material adverse effect on the financial condition, business, assets or results of operations of such Party and its Subsidiaries, taken as a whole; provided, however, that with respect to this clause (b) only, no Effect (by itself or when aggregated or taken together with any and all other Effects) to the extent directly or indirectly resulting from, arising out of, or attributable to any of the following shall be deemed to be or constitute a \u201cMaterial Adverse Effect\u201d or shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur:   A-6   (i) general economic conditions (or changes in such conditions) or conditions in the global economy generally; (ii) conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets, including (A) changes in interest rates and changes in exchange rates for the currencies of any countries and (B) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market; (iii) conditions (or changes in such conditions) in the oil and gas exploration, development or production industry (including changes in commodity prices, general market prices and regulatory changes affecting the industry); (iv) political conditions (or changes in such conditions, including any changes or developments arising from or in connection with the November 3, 2020 United States federal elections) or acts of war (whether or not declared), armed hostility (by recognized governmental forces or otherwise), sabotage or terrorism or cyber attack (including any escalation or general worsening of any such acts of war, sabotage or terrorism); (v) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, pandemics (including the existence and impact of the COVID-19 pandemic), or weather conditions; (vi) effects resulting from the negotiation, execution and announcement of this Agreement or the pendency or consummation of the Transactions, including the impact thereof on the relationships of the Company and its Subsidiaries with customers, suppliers, partners, employees or governmental bodies, agencies, officials or authorities (other than with respect to any representation or warranty that is intended to address the consequences of the execution or delivery of this Agreement or the announcement or consummation of the Transactions); (vii) compliance with the terms of, or the taking of any action expressly permitted or required by, this Agreement (except for any obligation under this Agreement to operate in the Ordinary Course (or similar obligation) pursuant to Sections 6.1 or 6.2, as applicable); (viii) changes in Law or other legal or regulatory conditions, or the interpretation thereof, or changes in GAAP or other accounting standards (or the interpretation thereof), or that result from any action taken for the purpose of complying with any of the foregoing; (ix) any changes in such Party\u2019s stock price or the trading volume of such Party\u2019s stock, or any failure by such Party to meet any analysts\u2019 estimates or expectations of such Party\u2019s revenue, earnings or other financial performance or results of operations for any period, or any failure by such Party or any of its Subsidiaries to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (it being understood that the facts or occurrences giving rise to or contributing to such changes or failures may constitute, or be taken into account in determining whether there has been or will be, a Material Adverse Effect); or (x) changes in GAAP or the interpretations thereof after the date of this Agreement.;   A-7   provided, however, except to the extent such Effects directly or indirectly resulting from, arising out of, attributable to or related to the matters described in the foregoing clauses (i) \u2013 (v) (excluding any Effect arising from, resulting from or related to COVID-19 or COVID-19 Measures, to the extent any COVID-19 Actions are taken in accordance with this Agreement) disproportionately adversely affect such Party and its Subsidiaries, taken as a whole, as compared to other similarly situated industry participants, in which case only the incremental disproportionate impact shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur. (Pages 99-101)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: SECTION 5.02. No Solicitation.  <omitted> (b) <omitted> Notwithstanding the foregoing, and only at a time prior to the receipt of the Company Stockholder Approval, the Company may (x) make an Adverse Recommendation Change <omitted> in response to an Intervening Event, (y) make an Adverse Recommendation Change <omitted> in response to a Superior Proposal <omitted> , but in each case only if: <omitted> in light of such Superior Proposal <omitted> the Company Board shall have determined in good faith, after consultation with outside legal counsel and consultation with a financial advisor of nationally recognized reputation, that failure to make an Adverse Recommendation Change <omitted> or to make an Adverse Recommendation Change <omitted> would reasonably be expected to be inconsistent with its fiduciary duties (Page 53)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.1         Conduct of Business by the Company Pending the Closing. The Company agrees that between the date of this Agreement and the First Effective Time or the date, if any, on which this Agreement is terminated pursuant to Section 8.1, except (a) as set forth in Section 5.1 of the Company Disclosure Letter, (b) as required or specifically permitted pursuant to this Agreement, (c) as required by Law, (d) for any actions taken or omitted to be taken reasonably and in good faith to respond to COVID-19 or any COVID-19 Measures (\u201cCOVID-19 Response\u201d); provided that (x) if such COVID-19 Response would (in the absence of this clause (d)) otherwise require Parent\u2019s consent pursuant to this Section 5.1 and could reasonably be expected to have an adverse financial impact on the Company or any Company Subsidiary (including the Canyon Newco Entities) of at least $5,000,000 or could reasonably be expected to otherwise materially and adversely impact the Company and the Company Subsidiaries (including the Canyon Newco Entities), taken as a whole, the Company shall, prior to making any such action, (A) provide prior written notice to Parent describing the material facts regarding the situation and the proposed course of action and (B) reasonably consult with Parent and consider in good faith Parent\u2019s suggestions and/or feedback, and (y) in the case of any other COVID-19 Response that would (in the absence of this clause (d)) otherwise require Parent\u2019s consent pursuant to this Section 5.1, the Company shall, prior to making any such COVID-19 Response, notify Parent in writing, or (e) as consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned), the Company (i) shall, and shall cause the Company Subsidiaries to, use reasonable best efforts to conduct their business in all material respects in the ordinary course of business consistent with past practice and to keep available the services of their present key employees and maintain their existing relations and goodwill with material customers, members, suppliers, licensors, licensees and other third parties with whom it has material business relations; provided, however, that no action with respect to subject matters specifically addressed by subclauses (ii)(a) through (r) shall be deemed a breach of this clause (i)  (Page 23)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the fundamental representations and warranties be according to the bring down provision?\nOption A: Accurate at another materiality standard (e.g., hybrid standard)\nOption B: Accurate in all material respects\nOption C: Accurate in all respects\n\nMerger Agreement: Section 9.02. Conditions to the Obligations of Parent and Merger Sub 1 and Merger Sub 2. <omitted> (iv) the other representations and warranties of the Company contained in this Agreement <omitted> shall be true and correct at and as of the date of this Agreement and at and as of the Closing as if made at and as of the Closing (Page 115)\n\nAnswer by only outputting the letter of the option A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: WHEREAS, pursuant to this Agreement, Purchaser has agreed to commence a tender offer <omitted> to purchase all of the issued and outstanding shares of Company Common Stock <omitted> at a price per Share of $24.05 (<omitted> the \u201cOffer Price\u201d); <omitted> (iii) except as provided in clauses (i) and (ii) above and subject to Section 2.5(b) and Section 2.10, each share of Company Common Stock outstanding immediately prior to the Effective Time shall be converted into the right to receive the Offer Price, without interest (the \u201cMerger Consideration\u201d); (Page 12)\n\nAnswer and only output A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: provided, however, that in no event shall any of the following, alone or in combination, be deemed to constitute, nor be taken into account in determining whether there has been or will be, a Company Material Adverse Effect: <omitted> (e) change <omitted> arising out of <omitted> (m) any effect, change, event, occurrence or circumstance arising out of, resulting from or related to (Page 10)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do pandemics or other public health events have to have disproportionate impact to qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any event, effect, occurrence, fact, circumstance, condition or change that, individually or in the aggregate, has had or would be reasonably likely to have a material adverse effect on (a) the business, operations, condition (financial or otherwise) or results of operations of the Company and the Company Subsidiaries, taken as a whole, or (b) the ability of the Company to consummate the Transactions; provided, however, that with respect to clause (a) only, none of the following shall be deemed in and of themselves, either alone or in combination, to constitute, and except as provided below, none of the following shall be taken into account in determining whether there is, or would reasonably be likely to be, a Company Material Adverse Effect:   (i)    general economic or political conditions (or changes or disruptions in such conditions) in the United States or any other country or region in the world, or conditions in the global economy generally;   (ii)    conditions (or changes or disruptions in such conditions) generally affecting the industries in which the Company and Company Subsidiaries operate;   (iii)    conditions (or changes or disruptions in such conditions) in the securities markets, capital markets, credit markets, currency markets or other financial markets in the United States or any other country or region in the world, including (A) changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and (B) any suspension of trading in equity, debt, derivative or hybrid securities, securities generally (including Company Common Stock) on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world;   (iv)    political conditions (or changes or disruptions in such conditions) in the United States or any other country or region in the world or acts of war (whether or not declared), armed or unarmed hostilities or attacks, acts of terrorism, sabotage, or the escalation or worsening thereof in the United States or any other country or region in the world;   (v)    (A) any actions taken by Parent or any of its controlled Affiliates, (B) the failure of Parent or Merger Subsidiary to comply with their respective obligations under this Agreement, (C) any   actions taken by the Company or the Company Subsidiaries to which Parent has expressly consented or requested in writing or (D) the Company taking any action expressly required by this Agreement (other than by Section 5.2);   (vi)    any changes in applicable Law (including COVID-19 Measures), accounting rules (including GAAP) or other legal or regulatory conditions or the enforcement, implementation or interpretation thereof;   (vii)    other than for purposes of Section 3.3(c), Section 3.3(d), Section 4.3 and the conditions to Closing related thereto, the announcement, pendency or completion of this Agreement, including, to the extent resulting therefrom, (A) the loss or departure of officers or other employees of the Company or any of the Company Subsidiaries, or (B) the termination or potential termination of (or the failure or potential failure to renew or enter into) any Contracts with customers, suppliers, distributors or other business partners;   (viii)    any natural or man-made hurricane, earthquake, flood, disaster, acts of God, pandemic (including COVID-19) or other force majeure events in the United States or any other country or region in the world;   (ix)    changes in the Company\u2019s stock price or the trading volume of the Company\u2019s stock, in and of itself, or any failure by the Company to meet any internal or published forecasts, estimates, projections or expectations of the Company\u2019s revenue, earnings or other financial performance or results of operations for any period (provided that the underlying causes of such changes or failures (subject to the other provisions of this definition) shall not be excluded); and   (x)    the availability or cost of equity, debt or other financing to Parent or Merger Subsidiary;   (xi)    any litigation, claim, action or other proceeding threatened, made or brought based upon, arising out of or with respect to allegations of a breach of fiduciary duty or violation of securities laws, in each case relating to this Agreement or any of the Transactions; or   except, in the case of clause (i), (ii), (iii), (iv), (vi) or (viii), to the extent the Company or the Company Subsidiaries are disproportionately affected thereby as compared with other participants in the industries in which the Company and the Company Subsidiaries operate (in which case the disproportionate impact or impacts may be taken into account in determining whether there is, or would reasonably be likely to be, a Company Material Adverse Effect). (Pages 66-67)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: 7.5          Acquisition Proposals. <omitted> (b )          No Change in Recommendation or Alternative Acquisition Agreement .  Except as permitted in this Section 7.5(b), neither the Company Board, the Hospitality Board nor any of their committees shall:   (i)          (A) withhold, withdraw, qualify or modify (or publicly propose or resolve to withhold, withdraw, qualify or modify), in a manner adverse to Parent, the Company Board Recommendation or the Hospitality Board Recommendation, (B) authorize, approve, adopt or recommend or otherwise declare advisable (or publicly propose or resolve to authorize, approve, adopt or recommend or otherwise declare advisable) any Acquisition Proposal or (C) fail to include the Company Board Recommendation and the Hospitality Board Recommendation in the Joint Proxy Statement (either of the foregoing, a \u201cChange of Recommendation\u201d); or   ( i i )         except as expressly permitted by, and after compliance with this Section 7.5, authorize, approve, adopt or recommend or otherwise declare advisable (or publicly propose or resolve to authorize, approve, adopt or recommend or otherwise declare advisable), or cause or permit any Paired Entity or any Paired Entities Subsidiary to enter into, any Alternative Acquisition Agreement (other than an Acceptable Confidentiality Agreement entered into in compliance with Section 7.5(a)).   Notwithstanding anything to the contrary set forth in this Agreement, the Company Board or the Hospitality Board may, prior to but not after the time the Requisite Vote is obtained, (A) make a Change of Recommendation if an Intervening Event has occurred and if, after consulting with its financial advisor and outside legal counsel, the Company Board or the Hospitality Board determines in good faith that the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law or (B) if the Paired Entities have not breached this Section 7.5(c) and have not breached the other subsections of this Section 7.5 in any material respect, make a Change of Recommendation and/or terminate this Agreement pursuant to Section 9.1(c)(i) if the Paired Entities receive an Acquisition Proposal (not resulting from a breach of this Section 7.5) that the Company Board and the Hospitality Board have determined in good faith, after consulting with their financial advisor and outside legal counsel, (x) constitutes a Superior Proposal after having complied with, and giving effect to all of the adjustments which may be offered by Parent pursuant to, this Section 7.5(b) and such Acquisition Proposal is not withdrawn and (y) the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law; provided that neither the Company Board nor the Hospitality Board may take any such action unless prior to making such Change of Recommendation or authorizing such termination to enter into a definitive written agreement providing for the implementation of such Superior Proposal pursuant to Section 9.1(c)(i), (I) the Paired Entities provide prior written notice (\u201cNotice Period Commencement Notice\u201d) to Parent at least four (4) Business Days in advance (the \u201cNotice Period\u201d) of their intention to take such action, which notice shall include, in the case of a Superior Proposal, the name of the person or group making the Superior Proposal and substantial final draft of the definitive agreement reflecting such Superior Proposal and, in the case of an Intervening Event, a reasonably detailed description of such Intervening Event, (II) if requested by Parent, during the Notice Period the Paired Entities shall, and shall direct their Representatives to, negotiate with Parent in good faith should Parent propose to make amendments or other revisions to the terms and conditions of this Agreement such that, in the case of a Superior Proposal, such Acquisition Proposal no longer constitutes a Superior Proposal and, in the case of an Intervening Event, the failure to take such action is no longer reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law as determined in the good faith judgment of the Company Board or the Hospitality Board after consulting with their financial advisor and outside legal counsel and (III) the Company Board and the Hospitality Board has taken into account any amendments or other revisions to the terms and conditions of this Agreement agreed to by Parent in writing prior to the end of the Notice Period and (1)  the Company Board and the Hospitality Board determined in good faith that, after consulting with its financial advisor and outside legal counsel, in the case of an Intervening Event, a failure to make such Change of Recommendation continues to be reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law and (2) the Company Board and the Hospitality Board determined in good faith that, after consulting with their financial advisor and outside legal counsel, in the case of an Acquisition Proposal, the Acquisition Proposal giving rise to such Change of Recommendation continues to constitute a Superior Proposal and the failure to make such Change of Recommendation continues to be inconsistent with the directors\u2019 fiduciary duties under applicable Law; it being understood that any change to the financial terms or any other material amendments or other material revisions to any Acquisition Proposal will be deemed to be a new Acquisition Proposal, including for purposes of the Notice Period; provided, however, that, subsequent to the initial Notice Period, the Notice Period shall be reduced to two (2) Business Days following receipt by Parent of any such new Notice Period Commencement Notice. (Page 59)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of asset deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: 4.4 Meeting of the Company\u2019s Stockholders; Company Change in Recommendation. <omitted> (c) <omitted> the Company Board may make a 52 Company Change in Recommendation related to a Company Acquisition Proposal if <omitted> (iii) <omitted> provided that if there is any material development with respect to such Company Acquisition Proposal, the Company shall, in each case, be required to deliver to Parent an additional notice <omitted> and a new negotiation period under clause \u201c(A)\u201d above shall commence (except that the original four (4) Business Day notice period referred to in clause \u201c(A)\u201d above shall instead be equal to the longer of (1) three (3) Business Days and (2) the period remaining under the original four (4) Business Day noticed period of clause \u201c(A)\u201d above, during which time the Company shall be required to comply with the requirements of Section 4.4(c)(iii) anew with respect to such additional notice (but substituting the time periods therein with the foregoing three (3) Business Day period); (Page 57)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do pandemics or other public health events have to have disproportionate impact to qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means any event, change, circumstance, occurrence or effect that has had or would reasonably be expected to have a material adverse effect on the business, assets, properties, liabilities, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, other than any event, change, occurrence or effect arising out of, attributable to or resulting from, alone or in combination, (1) changes in general economic or business conditions or in the financial, debt, banking, capital, credit or securities markets, or in interest or exchange rates, in each case, in the United States or elsewhere in the world; (2) general changes or developments in any of the primary industries in which the Company or its Subsidiaries operate; (3) actions required under this Agreement in accordance with Section 5.7 to obtain any approval or authorization under applicable antitrust or competition Laws for the consummation of the Merger or any other transaction contemplated hereby; (4) (x) changes after the date of this Agreement in any applicable Laws (other than any COVID-19 Measures, which shall be subject to clause (9) below) or (y) changes after the date of this Agreement in GAAP or in applicable accounting regulations or principles or interpretations thereof; (5) any change in the price or trading volume of the Company\u2019s stock, in and of itself (provided, that the facts or occurrences giving rise to or contributing to such change in price or trading volume that are not otherwise excluded from the definition of \u201cMaterial Adverse Effect\u201d may be taken into account in determining whether there has been a Material Adverse Effect); (6) any failure by the Company to meet internal or published projections, forecasts or revenue or earnings predictions, in and of 9      itself (provided, that the facts or occurrences giving rise to or contributing to such failure that are not otherwise excluded from the definition of \u201cMaterial Adverse Effect\u201d may be taken into account in determining whether there has been a Material Adverse Effect); (7) geopolitical conditions or any outbreak, continuation or escalation of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); (8) natural or manmade disasters, hurricanes, floods, tornados, tsunamis, earthquakes or other weather conditions or other acts of God; (9) any epidemic, pandemic or disease outbreak (including COVID-19), or any Law issued by a Governmental Entity (as defined below), the Centers for Disease Control and Prevention, the World Health Organization or industry group providing for COVID-19 Measures, quarantines, \u201cshelter-in-place\u201d or \u201cstay at home\u201d orders, workforce reductions, social distancing, shut downs, closures, sequesters or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease outbreak (including COVID-19) or any change in such Law or interpretation thereof following the date of this Agreement or any worsening of such conditions threatened or existing as of the date of this Agreement; (10) any national or international political or social conditions, including the engagement in, or escalation, outbreak or worsening of, hostilities in or by any country or the occurrence of any act of war or any similar act of terrorism, civil unrest, protests, public demonstrations or the response of any Governmental Entity thereto; (11) the announcement of this Agreement and the transactions contemplated hereby, including the initiation of litigation by any stockholder of the Company with respect to this Agreement, and including any termination of, reduction in or similar negative impact on relationships, contractual or otherwise, with any customers, suppliers, distributors, partners or employees of the Company or any of its Subsidiaries due to the announcement of this Agreement or the identity of the parties to this Agreement, or the performance of this Agreement and the transactions contemplated hereby, including compliance with the covenants set forth herein; provided, that in no event shall this clause (11) impact the Company\u2019s representations in Section 3.4; (12) any actions, determinations, terms or conditions taken, not taken, made, set or imposed by any lessor in accordance with the terms of the Sale Leaseback Agreements in response to any actions taken by the Company or any of its Subsidiaries solely to comply with the Company\u2019s obligations under Section 5.7 and to the extent such actions are expressly required by Section 5.7; or (13) any actions taken (or omitted to be taken) at the express written direction of Parent (except to the extent the Company was prohibited from taking such action pursuant to Section 5.1 and requested the consent of Parent to take such action); except, in the case of clauses (1), (2), (4), (7), (8) and (10), to the extent that the impact of such event, change, occurrence or effect is disproportionately adverse to the Company and its Subsidiaries, taken as a whole, relative to other companies operating in the industries in which the Company and its Subsidiaries operate; provided, that in such event, only the incremental disproportionate impact shall be taken into account when determining whether there has been a \u201cMaterial Adverse Effect\u201d. (Pages 16-17)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: except <omitted> with the prior written consent of Parent (such shall not be unreasonably withheld, conditioned or delayed), the Company shall not, and shall not permit any of its Subsidiaries to <omitted> : (Page 25)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: (d)               The Company Board shall not be entitled to effect an Adverse Recommendation Change <omitted> unless <omitted> :   (i)              (A) an Acquisition Proposal <omitted> is made <omitted> ; <omitted> (C) the Company has provided <omitted> notice <omitted> to Parent that the Company intends to take such action <omitted> provided, however, that, in the event of any material amendment of such Superior Proposal or any material change to the facts and circumstances relating to the Adverse Recommendation Change, the Company shall be required to issue a new Notice of Adverse Recommendation Change or otherwise comply again with the requirements of this Section 6.02(d) (provided, however, that for purposes of this sentence, references to the seventy-two (72)-hour period above shall be deemed to be references to a forty-eight (48)-hour period (or, if such forty-eight (48)-hour period does not include at least one (1) Business Day, ending on the first (1st) Business Day commencing after the passage of such forty-eight (48)-hour period) from the time of Parent\u2019s receipt of the Notice of Adverse Recommendation Change); (Pages 27-28)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is the \u201cability to consummate\u201d concept subject to Material Adverse Effect (MAE) carveouts?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any event, occurrence, state of facts, condition, effect, circumstance, development, action, omission or change (each, an \u201cEffect\u201d) that has, or would reasonably be expected to have, individually or in the aggregate with one or more Effects, a material adverse effect on the business, results of operations, or financial condition of the Company and its Subsidiaries, taken as a whole; provided, however, that no Effect to the extent, directly or indirectly, resulting or arising from or related to any of the following shall be deemed to constitute a Company Material  Adverse Effect, or be taken into account, in whole or in part, in determining whether, a Company Material Adverse Effect has occurred or may, would or could occur:  (i) changes generally affecting the economy, financial or securities markets, or political conditions; (ii) the announcement, or pendency or consummation of the transactions contemplated by this Agreement, including the impact thereof on relationships, contractual or otherwise, of the Company and its Subsidiaries with employees, suppliers, customers, Governmental Entities, or other third Persons (it being understood and agreed that this clause shall not apply with respect to Section 4.03(b) or Section 4.03(c)); (iii) any changes in applicable Law (including COVID-19 Measures) or GAAP or other applicable accounting standards, including interpretations thereof, (iv) acts of war, sabotage, or terrorism, or military actions, or the escalation thereof; (v) natural disasters, weather conditions, epidemics, pandemics, or disease outbreaks (including COVID-19) or public health emergencies (as declared by the World Health Organization or the Health and Human Services Secretary of the United States); (vi) general conditions in the industry in which the Company and its Subsidiaries operate; (vii) any failure, in and of itself, by the Company to meet any internal or published projections, forecasts, estimates, or predictions in respect of revenues, earnings, or other financial or operating metrics for any period (it being understood that the facts or occurrences giving rise to or contributing to such failure may be deemed to constitute, or be taken into account in determining whether there has been or would reasonably be expected to become, a Company Material Adverse Effect, to the extent permitted by this definition and not otherwise excepted by another clause of this proviso); (viii) any change, in and of itself, in the market price or trading volume of the Company\u2019s securities or in its credit ratings (it being understood that the facts or occurrences giving rise to or contributing to such change may be deemed to constitute, or be taken into account in determining whether there has been or would reasonably be expected to become, a Company Material Adverse Effect, to the extent permitted by this definition and not otherwise excepted by another clause of this proviso); or (ix) actions taken as required by the Agreement or actions or omissions taken with Parent\u2019s consent; provided further, however, that any Effect resulting from any event, change, and effect referred to in clauses (i), (iii), (iv), (v), or (vi) immediately above (excluding any Effect arising from, resulting from or related to COVID-19 or any COVID-19 Measure) shall be taken into account in determining whether a Company Material Adverse Effect has occurred or would reasonably be expected to occur to the extent that such event, change, or effect has a disproportionate effect on the Company and its Subsidiaries, taken as a whole, compared to other participants in the industries in which the Company and its Subsidiaries conduct their businesses. (Page 10)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: Section 5.4 Company No Solicitation. <omitted>     prior to <omitted> terminating this Agreement <omitted> (D) in the event of any change to any material terms of such Company Superior Proposal, the Company shall, in each case, have delivered to Parent an additional notice consistent with that described in clause (A) above of this proviso and a new notice period under clause (A) of this proviso shall commence (except that the four Business Day notice period referred to in clause (A) above of this proviso shall instead be equal to the longer of (i) three Business Days and (ii) the period remaining under the notice period under clause (A) of this proviso immediately prior to the delivery of such additional notice under this clause (D)) (Page 65)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cAcquisition Proposal\u201d means (other than the Transactions) any indication of interest, inquiry, request for non-public information, proposal or offer from any Person or Group, other than Parent and its Subsidiaries, in each case relating to any (a) direct or indirect acquisition (whether in a single transaction or a series of related transactions) of assets of the Company or the Company Subsidiaries (including securities of the Company Subsidiaries) equal to 20% or more of  the  consolidated  assets  of  the  Company,  or  to  which  20%  or  more  of  the  revenues  or  earnings  of  the  Company  on  a consolidated  basis  are  attributable;(b) direct or indirect acquisition or issuance (whether in a single transaction or a series of related transactions) of (i) 20% or more of the outstanding shares ofCompany Common Stock or (ii) any equity or voting securities of the Company or any of the Company Subsidiaries representing, directly or indirectly, 20% or more of the consolidated assets of the Company or 20% or more of the revenues or earnings of the Company and the Company Subsidiaries on a consolidated basis; (c) tender offer or exchange offer that, if consummated, would result in such Person or Group beneficially owning (i) 20% or more of the outstanding shares of Company Common Stock or (ii) any equity or voting securities of the Company or any of the Company Subsidiaries representing, directly or indirectly, 20% or more of the consolidated assets of the Company and the Company Subsidiaries or 20% or more of the revenues or earnings of the Company and the CompanySubsidiaries  on  a consolidated  basis;  or  (d)  merger,  consolidation,  share  exchange,  business  combination,  joint  venture,  reorganization, recapitalization, liquidation,  dissolution  or  similar  transaction  involving  the  Company  or  any  of  the  Company  Subsidiaries,  under  which such  Person  or  Group  would  acquire, directly  or  indirectly,  (i)  assets  (including  securities  of  the  Company  Subsidiaries)  equal  to 20%  or  more  of  the  consolidated  assets  of  the  Company  and  the Company  Subsidiaries,  or  to  which  20%  or  more  of  the  revenues  or earnings of the Company and its Subsidiaries on a consolidated basis are attributable, or (ii) beneficial ownership of (A) 20% or more of the outstanding shares of Company Common Stock or (B) any equity or voting securities of the Company or any of the Company Subsidiaries representing, directly or indirectly, 20% or more of the consolidated assets of the Company and the Company Subsidiaries or 20% or more of the revenues or earnings of the Company and Company Subsidiaries on a consolidated basis <omitted> ( i )            \u201cSuperior Proposal\u201d means any unsolicited, bona fide written Acquisition Proposal (that has not been withdrawn and that did not result from a breach or violation (other than an isolated, inadvertent and immaterial breach or violation) of the provisions of Section 6.3), (with all references to \u201c20%\u201d in the definition of Acquisition Proposal being deemed to be references to \u201c50%\u201d), that (A) if a cash transaction (whether in whole or in part), is not subject to a financing condition (and if financing is required, such financing is then fully committed and reasonably determined to be available by the Company Board); (B) is reasonably likely to be consummated on the terms and conditions contemplated thereby; and (C) the Company Board shall have determined in good faith After Consultation is more favorable to the stockholders of the Company (in their capacity as such) from a financial point of view than the Merger, in each case taking into account such factors as are determined by the Company Board in good faith to be relevant, including (I) the identity of the Person(s) making such Acquisition Proposal and the prior history of such Person(s) with the consummation or failure to consummate similar transactions, (II) the anticipated timing, conditions and prospects for completion of the transaction contemplated by such offer or proposal, including any governmental or other approval requirements (including divestitures and entry into other commitments and limitations) and (III) any proposal to amend this agreement made by Parent in connection therewith or in response thereto; (Pages 39-40)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: (a) The Company shall, and shall cause each of its Subsidiaries to, from and after the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement <omitted> except (1) as Parent shall otherwise approve in writing (such approval not to be unreasonably withheld, conditioned or delayed), <omitted> conduct its business in the Ordinary Course of Business <omitted> \u201cOrdinary Course of Business\u201d means, with respect to any Person, the conduct of such Person\u2019s business that is consistent in all material respects in nature, scope and magnitude with the past practices of such Person prior to the date of this Agreement (Pages 35-36)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: 6.2 Solicitation of Transactions. <omitted> (c)  <omitted>  (iii)            Notwithstanding anything to the contrary contained in this Agreement, at any time prior to the time the Requisite Company Vote is obtained, the Company Board may in response to an Acquisition Proposal that the Company Board determines in good faith (after consultation with outside legal counsel and its financial advisor) constitutes a Superior Proposal and that was made after the date of this Agreement and did not result from a breach of Section 6.2(b)(i), (A) make a Change in Recommendation (other than the type in clause (F) of Change in Recommendation) if the Company Board has concluded in good faith (after consultation with its outside legal counsel) that, in light of the receipt of such Superior Proposal, that failure to make such Change in Recommendation would be inconsistent with its fiduciary duties under applicable Law, or (B) cause the Company to terminate this Agreement pursuant to Section 8.1(f) and concurrently with such termination enter into an Acquisition Agreement if the Company Board has concluded in good faith, after consultation with its outside legal counsel, that, in light of the receipt of such Superior Proposal, that failure to so terminate this Agreement would be inconsistent with its fiduciary duties under applicable Law; provided, however, that the Company Board may not effect a Change in Recommendation or terminate this Agreement unless the Company shall have provided prior written notice to Parent at least five (5) business days in advance of its intention to take such action (a \u201cNotice of Designated Superior Proposal\u201d), and prior to effecting such Change in Recommendation or termination of this Agreement, the Company shall, and shall cause its Representatives to, during such five (5) business day period, negotiate with Parent in good faith (to the extent that Parent desires to negotiate) to make such adjustments to the terms and conditions of this Agreement so that the Change in Recommendation is no longer necessary and such Superior Proposal no longer constitutes a Superior Proposal (and in the event of any material change to any of the terms (including the form, amount and timing of payment of consideration) of such Superior Proposal the Company, the Company shall, in each case, deliver to Parent an additional notice consistent with that described in this proviso and a renewed negotiation period under this proviso shall commence (except that the five (5) business day period shall instead be equal to three (3) business days; provided that if such additional notice is delivered during the initial five (5) business day negotiation period, the initial negotiation period shall not be reduced by such notice)); provided further, that the Company shall not be entitled to terminate this Agreement pursuant to the foregoing clause (B), and any purported termination pursuant to the foregoing clause (B) shall be void and of no force or effect, unless concurrently with such termination the Company pays by wire transfer of immediately available funds the Company Termination Fee in accordance with Section 8.1(f). (Page 31)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "F",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the capitalization representations and warranties be according to the bring down provision?\nOption A: Accurate in all material respects\nOption B: Accurate in all respects\nOption C: Accurate in all respects with below-threshold carveout\nOption D: Accurate in all respects with de minimis exception\n\nMerger Agreement: CONDITIONS TO THE OFFER <omitted> 2. Additionally, Purchaser is not required to accept for payment or <omitted> to pay for any Shares validly tendered and not validly withdrawn in connection with the Offer if, immediately prior to the then applicable Expiration Date, any of the following conditions exist: <omitted>  (b) <omitted> (ii) the representations and warranties of the Company contained in the Agreement <omitted> and that (x) are not made as of a specific date are not true and correct as of the Expiration Date, as though made on and as of the Expiration Date (Page 81)\n\nAnswer by only outputting the option letter A, B, C or D.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: 6.3 Boston Private Shareholder Approval. (a) <omitted> However, subject to Section 8.1 and Section 8.2, if the Board of Directors of Boston Private, after receiving the advice of its outside counsel and, with respect to financial matters, its financial advisors, determines in good faith that it would more likely than not result in a violation of its fiduciary duties under applicable law to continue to recommend this Agreement, then in submitting this Agreement to its shareholders, the Board of Directors of Boston Private may submit this Agreement to its shareholders without recommendation (although the resolutions approving this Agreement as of the date hereof may not be rescinded or amended), in which event the Board of Directors of Boston Private may communicate the basis for its lack of a recommendation to its shareholders in the Proxy Statement or an appropriate amendment or supplement thereto to the extent required by law; provided, that the Board of Directors of Boston Private may not take any actions under this sentence unless (i) Boston Private shall have complied in all material respects with Section 6.9; (ii) if such actions are taken in response to an unsolicited bona fide Acquisition Proposal, the Boston Private Board of Directors shall have concluded in good faith, after giving effect to all the adjustments which may be offered by SVB Financial pursuant to clause (iv) below, that such Acquisition Proposal constitutes a Superior Proposal; (iii) Boston Private shall notify SVB Financial, at least four (4) business days in advance, of the intention of the Boston Private Board of Directors to change its recommendation (including, in the event such change in recommendation is in response to an Acquisition Proposal, the identity of the party making such Acquisition Proposal and furnish to SVB Financial all the material terms and conditions of such proposal to the extent not previously provided pursuant to Section 6.9, or describe in reasonable detail such other event or circumstances if such change in recommendation is not in response to an Acquisition Proposal); and (iv) prior to effecting a change in the recommendation of the Boston Private Board of Directors, Boston Private shall, and shall cause its financial and legal advisors to, during the period following Boston Private\u2019s delivery of the notice referred to in clause (iii) above, negotiate with SVB Financial in good faith for a period of up to four (4) business days (to the extent SVB Financial desires to negotiate) to allow SVB Financial to propose such adjustments in the terms and conditions of this Agreement so that an Acquisition Proposal referred to in clause (ii) above ceases to constitute a Superior Proposal or so that it would no longer more likely than not result in a violation of the Boston Private Board of Directors\u2019 fiduciary duties under applicable law to continue to recommend this Agreement.  Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of this Section 6.3 and will require a new notice period as referred to in this Section 6.3. (Page 64)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "H",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: except <omitted> (iv) as Parent shall otherwise consent in writing (e-mail by an officer of Parent being sufficient) (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts to conduct its business in the ordinary course of business consistent with past practice (Page 39)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: 7.2. Acquisition Proposals; Change of Recommendation. <omitted> (d) No Change of Recommendation <omitted> ; Exceptions. <omitted> the Company Board may (1) effect a Change of Recommendation <omitted> (any action described in clause (1) <omitted> being a \u201cFundamental Action\u201d) if (A) an <omitted> Acquisition Proposal <omitted> is received by the Company or an Intervening Event has occurred, and (B) the Company Board determines <omitted> that <omitted> in the case of an Acquisition Proposal, such Acquisition Proposal constitutes a Superior Proposal and <omitted> the Company has given Parent <omitted> notice at least four Business Days in advance (such notice period, the \u201cNotice Period\u201d and such notice, the \u201cNotice\u201d) <omitted> that the Company Board intends to consider whether to take such Fundamental Action <omitted> (it being understood that any amendment or modification to the economic or other material terms of any such Acquisition Proposal <omitted> shall require a new Notice and a new Notice Period (which, subsequent to the initial Notice Period, shall be reduced to two Business Days <omitted> )). (Page 42)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in GAAP or other accounting principles that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any condition, fact, occurrence, development, change, circumstance, event or effect (each an \u201cEffect\u201d) that (1) has or would reasonably be expected to have, individually or in the aggregate together with all other Effects, a material adverse effect on the business, assets, liabilities, condition (financial or otherwise) or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided, however, that none of the following, and no Effect arising out of or resulting from the following shall constitute or be taken into account in determining whether there has been, a \u201cCompany Material Adverse Effect\u201d: (a) the entry into this Agreement, the announcement or pendency of this Agreement or the Transactions, the performance of this Agreement or the pendency or consummation of the Transactions, in each case, including (i) by reason of the identity of, or any facts or circumstances relating to, Parent, Sub or any of their respective affiliates and (ii) the impact of any of the foregoing on any of the Company\u2019s or any of the Company Subsidiaries\u2019 relationships (contractual or otherwise) with respect to customers, suppliers, vendors, business partners or employees (it being understood and agreed that this clause (a) shall not apply with respect to any representation or warranty the purpose of which is to address the consequences of the execution and delivery o f this Agreement or the consummation of the transactions contemplated hereby, or the performance of obligations hereunder or thereunder); (b) any Effect affecting the economy or the financial, credit or securities markets in the United States or elsewhere in the world (including interest rates and exchange rates or any changes therein), or any Effect affecting any business or industries in which the Company or any of the Company Subsidiaries operates; (c) the suspension of trading in securities generally on Nasdaq (but not the underlying cause of such suspension, unless such underlying cause would otherwise be excepted from this definition); (d) any development or change in applicable Law (after the date of this Agreement), including COVID-19 Measures, or GAAP or other applicable accounting standards or the interpretation of any of the foregoing (it being understood and agreed that this clause (d) shall not apply with respect to any representation or warranty the purpose of which is to address compliance with applicable Laws or GAAP); (e) any action taken by the Company or any of the Company Subsidiaries at the written request of Parent that is not expressly required to be taken by the terms of this Agreement, the taking of any action expressly required by the terms of this Agreement (other than pursuant to clause (1) or (2) of Section 5.01), or the failure of the Company to take any action that the Company is expressly prohibited by the terms of the Agreement from taking; (f) the commencement, occurrence, continuation or escalation of any armed hostilities, sabotage or acts of war (whether or not declared) or terrorism, or any escalation or worsening of acts of terrorism, armed hostilities or war; (g) any actions or claims made or brought by any of the current or former shareholders of the Company (or on their behalf or on behalf of the Company, but in any event only in their capacities as current or former shareholders) arising out of this Agreement or any of the Transactions; (h) the existence, occurrence, continuation or escalation of any acts of God, force majeure events, any earthquakes, floods, hurricanes, tropical storms, fires or other natural disasters or weather-related events or any national, international or regional calamity or any civil unrest or any disease outbreak, pandemic or epidemic, including COVID-19; (i) any public comments or other public communications by Parent or Sub of its express intentions with respect to the Company or any Company Subsidiary, including any public communications to any employees of the Company or any Company Subsidiary; or (j) any changes in the market price or trading volume of the Shares, in and of itself, or any changes in the ratings or the ratings outlook for the Company or any of the Company Subsidiaries by any applicable rating agency or changes in any analyst\u2019s recommendations or ratings with respect to the Company or any of the Company Subsidiaries, or any failure of the Company or any Company Subsidiary to meet any internal or external projections, budgets, guidance, forecasts or estimates of revenues, earnings or other financial results or metrics for any period, in and of itself (but not, in each case of this clause (j), the underlying cause of any such change or failure, unless such underlying cause would otherwise be excepted from this definition) (provided, that this clause (j) shall not be construed as implying that the Company is making any representation or warranty with respect to any internal or external projections, budgets, guidance, forecasts or estimates of revenues, earnings or other financial results or metrics for any period); provided, further, that with respect to the foregoing clauses (b), (c), (d), (f) and (h), any such Effect shall not be prohibited from being taken into account in determining whether a Company Material Adverse Effect has occurred if it disproportionately adversely affects the Company and the Company Subsidiaries, taken as a whole, compared to other companies operating primarily in the same industries in which the Company and the Company Subsidiaries operate, or (2) prevents or materially delays the consummation by the Company of the Merger on or before the Outside Date, provided that in no event shall the failure of the condition in \u200bSection 6.01(c) to have occurred, in and of itself, be considered in determining whether an Effect has prevented or materially delayed the consummation by the Company of the Merger for purposes of this clause (2) (but not, for the avoidance of doubt, the underlying cause of any such failure). (Page 30)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 5.04 Company Recommendation. <omitted>  (b) Superior Proposal. <omitted> the Company Board (or any duly authorized committee thereof) may, in response to the receipt of a <omitted> Competing Proposal <omitted> make a Change of Company Recommendation <omitted> only if:   (i) the Company Board <omitted> determines <omitted> (B) such Competing Proposal constitutes a Superior Proposal;   <omitted> provided, that any change to the financial terms (including any change to the amount or form of consideration payable) or other material amendment to the terms of such Competing Proposal (whether or not in response to any changes proposed by Parent pursuant to clause (iii)) shall require a new Notice of Change of Recommendation and an additional two (2) Business Day period from the date of such notice during which the terms of clause (i) through (iv) shall apply mutatis mutandis (other than the number of days). (Page 19)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: From the date hereof until the Effective Time, <omitted> without the prior written consent of Peoples, Premier Financial shall not, and shall cause its Subsidiaries not to:   15   (a) Ordinary Course. Conduct the business of Premier Financial and its Subsidiaries other than in the ordinary and usual course (Pages 18-19)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in response to an intervening event?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: Other specified standard\n\nMerger Agreement: Section 6.02.      Acquisition Proposals; Change of Recommendation.  <omitted>  (d)           No Change of Recommendation or Alternative Acquisition Agreement.  <omitted>  (iii)                Notwithstanding anything to the contrary set forth in this Agreement, prior to the Offer Acceptance Time, the Company Board may:   (x) effect a Change of Recommendation if: (A)  a bona fide written Acquisition Proposal that did not result from a violation of this Section 6.02 is received by the Company and has not been withdrawn, and  the Company Board determines in good faith, after consultation with outside legal counsel, that a failure to effect a Change of Recommendation would be inconsistent with the directors\u2019 fiduciary duties under applicable Law and, after consultation with its financial advisor, that such Acquisition Proposal constitutes a Superior Proposal; or (B) the Company Board determines in good faith that an Intervening Event has occurred and, after consultation with outside legal counsel, that a failure to effect a Change of Recommendation would be inconsistent with   the directors\u2019 fiduciary duties under applicable Law, and/or (Pages 32-33)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, or I.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "When are representations and warranties required to be made according to the bring down provision?\nOption A: At Closing Only\nOption B: At Signing & At Closing\n\nMerger Agreement: Section 6.3    Conditions to the Obligations of Parent and Merger Sub. The obligation of Parent and Merger Sub to effect the Merger is also subject to the satisfaction, or waiver by Parent, at or prior to the Effective Time of the following conditions: (a)    Representations and Warranties. <omitted> (iii)    the other representations and warranties of the Company set forth in Article III shall be true and correct as of the date of this Agreement and as of the Closing Date as though made as of the Closing (except to the extent that any such representation and warranty speaks as of a particular date, in which case as of such earlier date), except for inaccuracies of representations and warranties the circumstances giving rise to which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect (it being understood that, for purposes of determining the accuracy of such representations and warranties, all materiality, \u201cMaterial Adverse Effect\u201d and similar qualifiers set forth in such representations and warranties shall be disregarded). (Page 61)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of offer could the Board take actions on notwithstanding the no-shop provision?\nOption A: Acquisition Proposal only\nOption B: Superior Offer, or Acquisition Proposal reasonably likely/expected to result in a Superior Offer\n\nMerger Agreement: Section 6.4           No Solicitation by the Company and Company Change in Recommendation. <omitted>  (b)          Notwithstanding anything to the contrary contained in this Agreement, if, prior to obtaining the Company Stockholder Approval, the Company receives a bona fide written Company Acquisition Proposal (which Company Acquisition Proposal was made after the date of this Agreement and did not result from a material breach of this Section 6.4), and the Company Board determines in good faith, after consultation with its financial advisors and outside counsel, that such Company Acquisition Proposal constitutes, or could reasonably be expected to lead to, a Company Superior Proposal, then the Company and its Representatives may, subject to compliance with this Section 6.4, do any or all of the following: (i) furnish any information (including non-public information) or access thereto to any third party making such Company Acquisition Proposal; provided that (A) prior to furnishing any such information or access, the Company has received from such third party an executed Company Acceptable Confidentiality Agreement and (B) any such non-public information so furnished has been previously provided or made available to Parent or is provided or made available to Parent promptly (and in any event no later than 24 hours) after it is so furnished to such third party or (ii) participate or engage in negotiations or discussions with the Person or group making such Company Acquisition Proposal and its Representatives regarding such Company Acquisition Proposal. (Page 65)\n\nAnswer by only outputting a letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: \u201cordinary course of business\u201d means an action taken, or omitted to be taken, in the ordinary course of such business in all respects that is materially consistent with past practice, without taking into account the transactions contemplated hereby including the Transactions; provided that \u201cordinary course of business\u201d shall be deemed to include all Covid-19 Actions. <omitted> 4.1.2 Ordinary and Usual Course. Without prior written consent of GBCI (which consent shall not be unreasonably withheld, conditioned or delayed under subparagraphs (d), (e), (k), and (o) below), subject to applicable Law and except (y) as set forth on Schedule 4.1.2 and (z) for Permitted Actions, from the date of this Agreement until the earlier of the Effective Time or an earlier Termination Date, AB and the Bank will use commercially reasonable efforts to conduct their respective businesses only in the ordinary course of business in all material respects and will not do, and AB will not permit any other AB Subsidiary to do, any of the following: (Page 35)\n\nAnswer and only output A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the wording of the Specific Performance clause regarding the parties\u2019 entitlement in the event of a contractual breach?\nOption A: \"entitled to seek\" specific performance\nOption B: \"entitled to\" specific performance\n\nMerger Agreement: 9.5 Notice of Termination; Effect of Termination and Abandonment <omitted> 10.7. Specific Performance. <omitted> each Party agrees that <omitted> each Party shall be entitled to enforce specifically the terms and provisions of this Agreement and to an injunction restraining any breach or violation or threatened breach or violation of the provisions of this Agreement, consistent with the provisions of Section 10.6(b), in the Chosen Courts without necessity of posting a bond or other form of security. (Page 99)\n\nAnswer and only output A or B!",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What carveouts pertaining to Material Adverse Effect (MAE) does the relational language apply to?\nOption A: All MAE carveouts\nOption B: No\nOption C: Some MAE carveouts\n\nMerger Agreement: \u201cMaterial Adverse Effect on the Company\u201d means any effect, change, development, event or circumstance that, considered individually or together with all other effects, changes, developments, events and circumstances, has had or resulted in, or would reasonably be expected to have or result in, a material adverse effect on the business, operations, financial condition or results of operations of the Inphi Entities, taken as a whole; provided, however, that an effect, change, development, event or circumstance shall not be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company if such effect, change, development, event or circumstance results or arises from: (a) any adverse change in economic, financial, capital market, political or social conditions in the United States or in other locations in which the Inphi Entities have material operations that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such adverse change may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (b) any adverse change in conditions generally affecting the semiconductor industry that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such adverse change may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (c) changes in the stock price or trading volume of the Company Common Stock (it being understood that the facts or circumstances giving rise to any such change in stock price or trading volume may be taken into account in determining whether a Material Adverse Effect on the Company has occurred or would reasonably be expected to occur, if such facts or circumstances are not otherwise excluded from such determination pursuant to this proviso); (d) the failure of the Company to meet securities analysts\u2019 published projections of earnings, revenues or other financial metrics or the failure of the Company to meet internal projections, forecasts or budgets of revenues, earnings or other financial metrics (it being understood, however, that the facts or circumstances giving rise to any such failure may be taken into account in determining whether a Material Adverse Effect on the Company has occurred or would reasonably be expected to occur, if such facts or circumstances are not otherwise excluded from such determination pursuant to this proviso); (e) any adverse change that is effected after the date of the Agreement in Legal Requirements or other legal or regulatory conditions, or in GAAP or other accounting standards (or the interpretation thereof), that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such adverse change may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (f) any act of war, sabotage or terrorism that occurs, worsens or changes after the date of the Agreement in the U.S. or in other locations in which the Inphi Entities have material operations and that does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such act of war, sabotage or terrorism may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (g) any act of God, earthquake, hurricane, tsunami, tornado, flood, mudslide, wild fire or other natural disaster, weather conditions, epidemic, pandemic or disease outbreak (including the COVID-19 virus or the continuation or worsening thereof) or other force majeure event (including actions taken by Governmental Bodies in connection with such events) that occurs, worsens or changes after the date of the Agreement and that in each case does not have a disproportionate adverse impact on the Inphi Entities relative to other participants in the semiconductor industry (it being understood that the incremental disproportionate adverse impact or impacts of such event may be taken into account in determining whether there has been or would reasonably be expected to be a Material Adverse Effect on the Company); (h) the public announcement of the Agreement or the Contemplated Transactions (including the public announcement and identification of Marvell as a Principal Party or any public communication by Marvell or any of its Affiliates regarding its plans or intentions with respect to the business of the Company or any other Inphi Entity) or any loss of customers, suppliers, distributors or other business partners or employees suffered by the Company as a result of such public announcement; or (i) any stockholder class action or derivative litigation arising from or relating to the Agreement or the Contemplated Transactions commenced against the Company after the date of the Agreement and alleging a breach of fiduciary duty of the Company\u2019s directors relating to their approval of the Agreement or false or misleading public disclosure by the Company with respect to the Agreement. (Page 129)\n\nAnswer and only output A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: Section 5.1         Conduct of Business by the Company Pending the Closing. The Company agrees that between the date of this Agreement and the First Effective Time or the date, if any, on which this Agreement is terminated pursuant to Section 8.1, except (a) as set forth in Section 5.1 of the Company Disclosure Letter, (b) as required or specifically permitted pursuant to this Agreement, (c) as required by Law, (d) for any actions taken or omitted to be taken reasonably and in good faith to respond to COVID-19 or any COVID-19 Measures (\u201cCOVID-19 Response\u201d); provided that (x) if such COVID-19 Response would (in the absence of this clause (d)) otherwise require Parent\u2019s consent pursuant to this Section 5.1 and could reasonably be expected to have an adverse financial impact on the Company or any Company Subsidiary (including the Canyon Newco Entities) of at least $5,000,000 or could reasonably be expected to otherwise materially and adversely impact the Company and the Company Subsidiaries (including the Canyon Newco Entities), taken as a whole, the Company shall, prior to making any such action, (A) provide prior written notice to Parent describing the material facts regarding the situation and the proposed course of action and (B) reasonably consult with Parent and consider in good faith Parent\u2019s suggestions and/or feedback, and (y) in the case of any other COVID-19 Response that would (in the absence of this clause (d)) otherwise require Parent\u2019s consent pursuant to this Section 5.1, the Company shall, prior to making any such COVID-19 Response, notify Parent in writing, or (e) as consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned), the Company (i) shall, and shall cause the Company Subsidiaries to, use reasonable best efforts to conduct their business in all material respects in the ordinary course of business consistent with past practice and to keep available the services of their present key employees and maintain their existing relations and goodwill with material customers, members, suppliers, licensors, licensees and other third parties with whom it has material business relations; provided, however, that no action with respect to subject matters specifically addressed by subclauses (ii)(a) through (r) shall be deemed a breach of this clause (i)  (Page 23)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cCompany Superior Proposal\u201d means a <omitted> Company Takeover Proposal <omitted> that if consummated would result in a third party (or in the case of a direct merger between such third party and the Company, the stockholders of such third party) acquiring, directly or indirectly, <omitted> more than 50.1% of the assets or revenues of the Company and its Subsidiaries, taken as a whole (Page 108)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of asset deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 5.11    No Solicitation by First Choice; Superior Proposals. <omitted> ( e )    Notwithstanding Section 5.11(d) or any other provision of this Agreement, prior to obtaining the Requisite First Choice Shareholder Approval, the First Choice Board (or any committee thereof) may make a First Choice Subsequent Determination after the fifth (5 ) Business Day following Enterprise\u2019s receipt of a notice (the \u201cNotice of Determination\u201d) from First Choice informing Enterprise that the First Choice Board (or such committee) has determined in good faith, after consultation with outside legal counsel and its financial advisor, that an Acquisition Proposal constitutes a Superior Proposal and the failure to make a First Choice Subsequent Determination with respect to such Superior Proposal would breach or reasonably be expected to result in a breach of its fiduciary duties under applicable Law (it being understood that the initial determination under this clause will not be considered a First Choice Subsequent Determination), but only if: (i) the Notice of Determination includes or is accompanied by the material terms and conditions of such Superior Proposal and the identity of the Person making such Superior Proposal, including copies of any proposed material agreements providing for such Superior Proposal; (ii) during the five (5) Business Day period after receipt of the Notice of Determination (the \u201cNotice Period\u201d), First Choice and the First Choice Board shall have negotiated in good faith with Enterprise, to the extent Enterprise desires to negotiate, to make such adjustments, modifications or amendments to the terms and conditions of this Agreement as would enable First Choice to proceed with the First Choice Recommendation without a First Choice Subsequent Determination; provided, however, that Enterprise shall not have any obligation to propose any adjustments, modifications or amendments to the terms and conditions of this Agreement, and (iii) at the end of the Notice Period, after taking into account any such adjusted, modified or amended terms, if any, as may have been proposed by Enterprise in writing before expiration of the Notice Period, the First Choice Board has again in good faith, after consultation with outside legal counsel and its financial advisor, made the determination that such Acquisition Proposal constitutes a Superior Proposal and the failure to make a First Choice Subsequent Determination with respect to such Superior Proposal would breach or reasonably be expected to result in a breach of its fiduciary duties under applicable Law. In the event of any material revisions to an Acquisition Proposal that is the subject of a Notice of Determination and that occur prior to a First Choice Subsequent Determination, First Choice shall be required to deliver a new Notice of Determination to Enterprise and again comply with the requirements of this Section 5.11(e), except that the Notice Period shall be reduced to three (3) Business Days. (Pages 73-74)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: (b) The Company agrees with Parent, on behalf of itself and its Subsidiaries, that, from the date hereof and prior to the earlier of the Effective Time and the Termination Date, except (i) as may be required by applicable Law or the regulations or requirements of any stock exchange or regulatory organization applicable to the Company or any of its Subsidiaries or Company Benefit Plan, (ii) with the prior written consent of Parent (such consent not to be unreasonably conditioned, withheld or delayed), (iii) as may be expressly contemplated or required by this Agreement, (iv) in connection with a Company COVID Action or (v) as set forth in Section 5.1 of the Company Disclosure Letter, the Company: (Page 55)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: excluding any effect, change, condition, state of fact, development, occurrence or event to the extent resulting from or arising out of (i) general economic or political conditions in the United States or any foreign jurisdiction in which RemainCo or any of its RemainCo Subsidiaries or Minority Investment Entities conduct business or in securities, credit or financial markets, including changes in interest rates and changes in exchange rates, (ii) changes or conditions generally affecting the industries, markets or geographical areas in which the Company or any of its Subsidiaries or Minority Investment Entities operates, (iii) any rulemakings or Proceedings before the FCC that generally affect the broadcast television industry, (iv) outbreak or escalation of hostilities, acts of war (whether or not declared), terrorism or sabotage, or other changes in geopolitical conditions, including any material worsening of such conditions threatened or existing as of the date hereof, (v) any epidemics, pandemics (including the COVID-19 or any COVID-19 Measures), natural disasters (including hurricanes, tornadoes, floods or earthquakes) or other force majeure events or any escalation or worsening of any of the foregoing, (vi) any failure by RemainCo or its RemainCo Subsidiaries or Minority Investment Entities to meet any internal or published (including analyst) projections, expectations, forecasts or predictions in respect of the Company\u2019s revenue, earnings or other financial performance or results of operations, or any failure by the Company to meet its internal budgets, plans or forecasts of its revenue, earnings or other financial performance or results of operations   4   (provided that the underlying effect, change, condition, state of fact, development, occurrence or event giving rise to or contributing to such failure shall be included and considered), (vii) changes after the date hereof in GAAP or the interpretation thereof or the adoption, implementation, promulgation, repeal, modification, amendment, reinterpretation, change or proposal of any Law applicable to the operation of the business of the Company or any of its Subsidiaries or Minority Investment Entities, (viii) the taking of any action by the Company expressly required by, or the Company\u2019s failure to take any action expressly prohibited by, this Agreement, (ix) any change in the market price or trading volume of the Company\u2019s securities (provided that the underlying effect, change, condition, state of fact, development, occurrence or event giving rise to or contributing to such change shall be considered), and (x) other than, in each case, with respect to any representation, warranty, or covenant set forth in this Agreement that is intended to address the consequences of the execution or delivery of this Agreement or the announcement or consummation of the transactions contemplated hereby, including, but not limited to, the representations and warranties set forth in Section 3.3, Section 3.4, and the conditions set forth in Section 8.2(a) to the extent relating to such representations and warranties, the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby, or the public announcement or pendency of this Agreement or the Merger, including any resulting loss or departure of officers or other employees of RemainCo or any of its RemainCo Subsidiaries or Minority Investment Entities, or the termination or reduction (or potential reduction) or any other resulting negative development in RemainCo\u2019s or any of its RemainCo Subsidiaries\u2019 or Minority Investment Entities\u2019 relationships, contractual or otherwise, with any of its advertisers, customers, suppliers, distributors, licensees, licensors, lenders, business partners, employees or regulators, including the FCC (in each case excluding any breach of this Agreement by the Company or its Affiliates); provided that in the cases of clauses (i), (ii), (iii), (iv), (v) and (vii), any effect, change, condition, development, or event may be considered to the extent it disproportionately affects the Company and the RemainCo Subsidiaries and the Minority Investment Entities relative to the other participants in the television broadcast industry. (Pages 8-9)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: Section 6.4           No Solicitation by the Company and Company Change in Recommendation.  <omitted>  (f)           Notwithstanding anything to the contrary contained in this Agreement, the Company shall not be entitled to make a Company Change in Recommendation pursuant to Section 6.4(e) or terminate this Agreement pursuant to Section 8.1(h) or Section 8.1(i) unless:   (i)          the Company shall have provided to Parent three Business Days\u2019 prior written notice (the \u201cCompany Superior Proposal Notice\u201d), which notice (A) shall not constitute a Company Change in Recommendation, advising Parent that the Company intends to take such action, and (B) shall include (1) the material terms and conditions of any such Company Superior Proposal, (2) an unredacted copy of the Company Alternative Acquisition Agreement in respect of such Company Acquisition Proposal, and (3) an unredacted copy of any other Contracts to be entered into in connection with such Company Acquisition Proposal that the Company Board determined were material to its decision that such Company Acquisition Proposal constitutes a Company Superior Proposal;   (ii)         during such three-Business Day period, if requested in writing by Parent in good faith, the Company and its Representatives shall have engaged in good faith negotiations with Parent regarding changes to the terms of this Agreement intended by Parent to cause such Company Acquisition Proposal to no longer constitute a Company Superior Proposal; and   62    (iii)       the Company Board shall have considered any adjustments to this Agreement that may be proposed in writing by Parent (the \u201cParent Proposed Changed Terms\u201d) no later than 11:59 p.m., New York City time, on the third Business Day of such three-Business Day period and shall have determined in good faith (after consultation with its financial advisors and outside counsel) that the Company Superior Proposal would continue to constitute a Company Superior Proposal if such Parent Proposed Changed Terms were to be given effect, and that the failure to make the Company Change in Recommendation or terminate this Agreement pursuant to Section 8.1(i) would reasonably be expected to be inconsistent with the fiduciary obligations of the Company Board under applicable Law; provided, however, that any (1) material revisions to the terms of a Company Superior Proposal or (2) material revisions to a Company Acquisition Proposal that the Company Board had determined no longer constitutes a Company Superior Proposal, shall constitute a new Company Acquisition Proposal and shall in each case require the Company to deliver to Parent a new Company Superior Proposal Notice, except that the references to three Business Days in this Section 6.4(f) shall be deemed to be two Business Days. (Pages 66-67)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: except <omitted> (v) with the prior written consent of Parent (which consent will not be unreasonably withheld, conditioned or delayed), the Company will not, and will cause each Company Subsidiary not to:   (a)          (i) conduct its business and the business of the Company Subsidiaries other than in the ordinary course, in any material respect (Page 58)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Under what circumstances could the Board take actions on a different acquisition proposal notwithstanding the no-shop provision?\nOption A: If failure to take actions would lead to \"breach\" of fiduciary duties\nOption B: If failure to take actions would be \"inconsistent\" with fiduciary duties\nOption C: If failure to take actions would lead to \"reasonably likely/expected breach\" of fiduciary duties\nOption D: If failure to take actions would lead to \"reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: If failure to take actions would lead to \"reasonably likely/expected violation\" of fiduciary duties\nOption F: If taking such actions is \"required to comply\" with fiduciary duties\nOption G: If failure to take actions would lead to \"violation\" of fiduciary duties\nOption H: Under no circumstances could the Board do so.\nOption I: Other circumstances\n\nMerger Agreement: Section 7.3 No Solicitation by the Company. <omitted> (b) <omitted> if <omitted> the Company receives an unsolicited Company Acquisition Proposal <omitted> that the Company Board reasonably determines in good faith, after consultation with the Company\u2019s outside financial advisors and outside legal counsel, (i) is or could reasonably be expected to lead to a Superior Company Proposal and (ii) failure to take such action would be reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law, then the Company may <omitted> furnish nonpublic information relating to the Company and its Subsidiaries to the Person or group (or any of their Representatives or potential financing sources) making such Company Acquisition Proposal and engage in discussions or negotiations with such Person or group and their Representatives regarding such Company Acquisition Proposal (Page 68)\n\nAnswer by only outputting the letter (i.e. A, B, C, D, E, F, G, H, or I) of the relevant option.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in law that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, when used with respect to any Party, any fact, circumstance, effect, change, event, occurrence or development (\u201cEffect\u201d) that has had, or would reasonably be expected to have, a material adverse effect on the financial condition, business, or operations of such Party and its Subsidiaries, taken as a whole; provided, however, that no Effect (by itself or when aggregated or taken together with any and all other Effects) to the extent directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be deemed to be or constitute a \u201cMaterial Adverse Effect\u201d or shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur: (a) general economic conditions (or changes in such conditions) or conditions in the global economy generally; (b) conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets, including (i) changes in interest rates and changes in exchange rates for the currencies of any countries and (ii) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market; (c) conditions (or changes in such conditions) in the industries or geographical areas in which such Party and its Subsidiaries operate; (d) political conditions (or changes in such conditions) or acts of war (whether or not declared), sabotage, civil disobedience, cyberattacks or terrorism (including any escalation or general worsening of any such acts of war, sabotage, civil disobedience, cyberattacks or terrorism); (e) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, pandemics (including the COVID-19 pandemic), weather conditions or other force majeure events; (f) the announcement, negotiation, execution and delivery of this Agreement or the pendency or consummation of the Transactions, including any Effect on the relationship of any Party or its Subsidiaries, contractual or otherwise, with customers, employees, unions, suppliers, distributors, financing sources, partners, Governmental Entities or similar relationship relating to the execution and delivery of this Agreement or the pendency or consummation of the Transactions (other than with respect to any representation or warranty to the extent the express purpose of such representation or warranty is to address the consequences of the execution or delivery of this Agreement or the announcement or consummation of the Transactions); (g) the taking of any action expressly required by this Agreement (except for any obligation under this Agreement to operate in the ordinary course of business consistent with past practice (or similar obligation) pursuant to Sections 6.1 or 6.2, as applicable); (h) changes in Law or other legal or regulatory conditions, or any COVID-19 Measures or the interpretation of any such Laws, conditions or COVID-19 Measures, or changes in GAAP or other accounting standards; (i) any changes in such Party\u2019s stock price or the trading volume of such Party\u2019s stock, or any failure by such Party to meet any analysts\u2019 estimates or expectations of such Party\u2019s revenue, earnings or other financial performance or results of operations for any period, or any failure by such Party or any of its Subsidiaries to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (it being understood that the facts or occurrences giving rise to or contributing to such changes or failures may constitute, or be taken into account in determining whether there has been or will be, a Material Adverse Effect, to the extent not otherwise excluded from this definition); (j) any Transaction Litigation; or (k) with respect to a Company Material Adverse Effect or a Parent Material Adverse Effect, the identity of Parent or any of its Affiliates or the Company or any of its Affiliates, respectively; provided, that with respect to the exceptions set forth in clauses (a) through (e), if such Effect has had a disproportionate adverse effect on such Party and its Subsidiaries, taken as a whole, as compared to other companies operating in the office furniture and residential furnishing industries, then only the incremental disproportionate adverse effect of such Effect shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d exists or has occurred. (Page 83)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 6.04. No Solicitation; Other Offers. <omitted> ( b )   Exceptions.  Notwithstanding  anything  contained  in  this Agreement  to  the  contrary <omitted> (ii) the Board of Directors may <omitted> make an Adverse Recommendation Change <omitted>  (d)   Last Look. Neither the Board of Directors nor the Company shall take any of the actions referred to in Section 6.04(b)(ii) unless (i) the Company shall have notified Parent <omitted> of its intention to take such action <omitted> provided, however, that in the event of any amendment to the financial terms or any other material terms of an Acquisition Proposal, the Company will be required to deliver a new written notice to Parent and to comply with the requirements of this Section 6.04(d) with respect to such new written notice (it being understood that the \u201cNotice Period\u201d in respect of such new written notice will be two Business Days). (Page 24)\n\nAnswer by outputting a singled letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.2. Go-Shop; Acquisition Proposals. <omitted> (c) Except as set forth in this Section 5.2(c) or in Section 5.2(d), neither the Company Board nor any committee thereof shall (1) withhold, withdraw, qualify or modify (or publicly propose to withhold, withdraw, qualify or modify), in each case in a manner adverse to Parent, the Company Recommendation, (2) fail to include the Company Recommendation in the Proxy Statement, (3) adopt, approve or recommend or endorse or otherwise declare advisable, or publicly propose to adopt, approve or recommend, any Acquisition Proposal, (4) fail to publicly reaffirm the Company Recommendation in connection with the public disclosure by the Company of an Acquisition Proposal (other than of the type referred to in the following clause (5)) by any Person other than Parent and Merger Sub; provided that the Company shall not be required to make such reaffirmation more than once in respect of such public disclosure of an Acquisition Proposal except in connection with any material amendment of such Acquisition Proposal (and no more than once in connection with each such amendment); or (5) fail to recommend, in a Solicitation/Recommendation Statement on Schedule 14D-9 under the Exchange Act, against any Acquisition Proposal that is a tender offer or exchange offer subject to Regulation 14D promulgated under the Exchange Act within ten (10) Business Days after the commencement (within the meaning of Rule 14d-2 under the Exchange Act) of such tender offer or exchange offer (any of the foregoing, a \u201cChange of Recommendation\u201d). Notwithstanding the foregoing or anything to the contrary set forth in this Agreement, prior to the time the Stockholder Approval is obtained, the Company Board may (x) effect a Change of Recommendation contemplated by clauses (1) or (2) of the definition thereof if, upon the occurrence of an Intervening Event, the Company Board determines in good faith, after consultation with its outside legal counsel, that failure to do so would be reasonably likely to be inconsistent with its fiduciary obligations under applicable Law or (y) if the Company receives, directly or indirectly through one or more of its Representatives, a written, bona fide Acquisition Proposal that the Company Board concludes in good faith, after consultation with its financial advisor and outside legal counsel, constitutes a Superior Proposal and such Acquisition Proposal did not result from a breach of this Section 5.2, effect a Change of Recommendation and/or terminate this Agreement pursuant to Section 7.3(a) in order to enter into an Alternative Acquisition Agreement providing for such Superior Proposal, and, in the case of either clause (x) or (y): (Pages 47-48)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, when used with respect to any Party, any fact, circumstance, effect, change, event or development (\u201cEffect\u201d) that (a) would prevent, materially delay or materially impair the ability of such Party or its Subsidiaries to consummate the Transactions or (b) has, or would have, a material adverse effect on the financial condition, business, or results of operations of such Party and its Subsidiaries, taken as a whole; provided, however, that with respect to this clause (b) only, no Effect (by itself or when aggregated or taken together with any and all other Effects) to the extent directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be deemed to be or constitute a \u201cMaterial Adverse Effect\u201d or shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur:   (i)       general economic conditions (or changes in such conditions) or conditions in the global economy generally;   (ii)      conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets, including (A) changes in interest rates and changes in exchange rates for the currencies of any countries and (B) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market;     A-5        (iii)     conditions (or changes in such conditions) in the oil and gas exploration, development or production industry (including changes in commodity prices, general market prices and regulatory changes affecting the industry);   (iv)     political conditions (or changes in such conditions, including any changes or developments arising from or in connection with the November 3, 2020 United States federal elections) or acts of war, sabotage or terrorism (including any escalation or general worsening of any such acts of war, sabotage or terrorism);   (v)      earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, pandemics (including the existence and impact of the COVID-19 pandemic) or weather conditions;   (vi)     the announcement of this Agreement or the pendency or consummation of the Transactions (other than with respect to any representation or warranty that is intended to address the consequences of the execution or delivery of this Agreement or the announcement or consummation of the Transactions);   (vii)    compliance with the terms of, or the taking of any action expressly permitted or required by, this Agreement (except for any obligation under this Agreement to operate in the Ordinary Course (or similar obligation) pursuant to Sections 6.1 or 6.2, as applicable);   (viii)   changes in Law or other legal or regulatory conditions, or the interpretation thereof, or changes in GAAP or other accounting standards (or the interpretation thereof), or that result from any action taken for the purpose of complying with any of the foregoing; or   (ix)     any changes in such Party\u2019s stock price or the trading volume of such Party\u2019s stock, or any failure by such Party to meet any analysts\u2019 estimates or expectations of such Party\u2019s revenue, earnings or other financial performance or results of operations for any period, or any failure by such Party or any of its Subsidiaries to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (it being understood that the facts or occurrences giving rise to or contributing to such changes or failures may constitute, or be taken into account in determining whether there has been or will be, a Material Adverse Effect);   provided, however, except to the extent such Effects directly or indirectly resulting from, arising out of, attributable to or related to the matters described in the foregoing clauses (i) \u2013 (v) (excluding any Effect arising from, resulting from or related to COVID-19, COVID-19 Measures or the November 3, 2020 United States federal elections) disproportionately adversely affect such Party and its Subsidiaries, taken as a whole, as compared to other similarly situated industry participants (it being understood and agreed that, for the purposes of determining whether a Party has been disproportionately adversely affected compared to other similarly situated industry participants, the Company shall be compared to independent exploration and production companies primarily focused in the Permian Basin and Parent shall be compared to independent diversified exploration and production companies), in which case only the incremental disproportionate impact shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur. (Pages 100-101)\nAnswer and only output Yes or No.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: 7.2.    Company Acquisition Proposals. <omitted> (b) No Change in Company Recommendation or Alternative Acquisition Agreement. <omitted> Notwithstanding anything to the contrary set forth in this Section 7.2(b), the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee may, prior to but not after the time the Requisite Company Stockholder Approvals are obtained, make a Change of Company Recommendation if, and only if, (A) an Intervening Event has occurred and the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee has determined in good faith, after consulting with its financial advisor and outside legal counsel, that failure to take such action would be inconsistent with such directors\u2019 fiduciary duties under applicable Law, or (B) the Company receives a Company Acquisition Proposal and the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee has determined in good faith, after consulting with its financial advisor and outside legal counsel, that such Company Acquisition Proposal constitutes a Company Superior Proposal and that failure to take such action would be inconsistent with such directors\u2019 fiduciary duties under applicable Law; provided that neither the Company Board nor the Special Committee may take any such action (and the Special Committee may not recommend to the Company Board to take such action) unless (I) prior to making such Change of Company Recommendation, the Company provides prior written notice to Parent at least four (4) Business Days in advance (the \u201cNotice Period\u201d) of its intention to take such action and the basis thereof, which notice shall include, in the case of a Company Superior Proposal, the information required under Section 7.2(e) and, in the case of an Intervening   -38-   Event, a reasonably detailed description of such Intervening Event, (II) during the Notice Period, the Company shall, and shall cause its employees, financial advisor and outside legal counsel to, be reasonably available to negotiate with Parent in good faith should Parent propose to make amendments or other revisions to the terms and conditions of this Agreement such that, in the case of a Company Superior Proposal, such Company Acquisition Proposal no longer constitutes a Company Superior Proposal or, in the case of an Intervening Event, the failure to take such action would no longer be inconsistent with the directors\u2019 fiduciary duties under applicable Law as determined in the good faith judgment of the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee, after consulting with its financial advisor and outside legal counsel, and (III) the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee, as the case may be, has taken into account any amendments or other revisions to the terms and conditions of this Agreement agreed to by Parent in writing prior to the end of the Notice Period and has determined in good faith, after consulting with its financial advisor and outside legal counsel, that a failure to make such Change of Company Recommendation would still be inconsistent with the directors\u2019 fiduciary duties under applicable Law; it being understood that any amendments or other revisions to any Company Acquisition Proposal will be deemed to be a new Company Acquisition Proposal, including for purposes of the Notice Period; provided, however, subsequent to the initial Notice Period, the Notice Period shall be reduced to two (2) Business Days. (Pages 43-44)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (a) Capital Stock. <omitted> (i) each share of common stock, par value $0.01 per share, of Merger Sub that is issued and outstanding as of immediately prior to the Effective Time will be converted into one validly issued, fully paid and nonassessable share of common stock of the Surviving Corporation, and thereupon each certificate representing ownership of such shares of common stock of Merger Sub will thereafter represent ownership of shares of common stock of the Surviving Corporation; (Page 27)\n\nAnswer and only output A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: except <omitted> (w) with the prior written consent of Parent (which consent shall not be unreasonably conditioned, withheld or delayed), <omitted> the Company shall <omitted> ensure that the business and operations of the Acquired Companies are conducted in the ordinary course of business in accordance with past practices and in compliance with all then- applicable Law. (Page 48)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the Forward Looking Standard (FLS) with respect to Material Adverse Effect (MAE)?\nOption A: \"Could\" (reasonably) be expected to\nOption B: \"Would\"\nOption C: \"Would\" (reasonably) be expected to\nOption D: No\nOption E: Other forward-looking standard\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, when used with respect to any Party, any fact, circumstance, effect, change, event or development (\u201cEffect\u201d) that (a) would prevent, materially delay or materially impair the ability of such Party or its Subsidiaries to consummate the Transactions or (b) has, or would have, a material adverse effect on the financial condition, business, assets or results of operations of such Party and its Subsidiaries, taken as a whole; provided, however, that with respect to this clause (b) only, no Effect (by itself or when aggregated or taken together with any and all other Effects) to the extent directly or indirectly resulting from, arising out of, or attributable to any of the following shall be deemed to be or constitute a \u201cMaterial Adverse Effect\u201d or shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur:   A-6   (i) general economic conditions (or changes in such conditions) or conditions in the global economy generally; (ii) conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets, including (A) changes in interest rates and changes in exchange rates for the currencies of any countries and (B) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market; (iii) conditions (or changes in such conditions) in the oil and gas exploration, development or production industry (including changes in commodity prices, general market prices and regulatory changes affecting the industry); (iv) political conditions (or changes in such conditions, including any changes or developments arising from or in connection with the November 3, 2020 United States federal elections) or acts of war (whether or not declared), armed hostility (by recognized governmental forces or otherwise), sabotage or terrorism or cyber attack (including any escalation or general worsening of any such acts of war, sabotage or terrorism); (v) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, pandemics (including the existence and impact of the COVID-19 pandemic), or weather conditions; (vi) effects resulting from the negotiation, execution and announcement of this Agreement or the pendency or consummation of the Transactions, including the impact thereof on the relationships of the Company and its Subsidiaries with customers, suppliers, partners, employees or governmental bodies, agencies, officials or authorities (other than with respect to any representation or warranty that is intended to address the consequences of the execution or delivery of this Agreement or the announcement or consummation of the Transactions); (vii) compliance with the terms of, or the taking of any action expressly permitted or required by, this Agreement (except for any obligation under this Agreement to operate in the Ordinary Course (or similar obligation) pursuant to Sections 6.1 or 6.2, as applicable); (viii) changes in Law or other legal or regulatory conditions, or the interpretation thereof, or changes in GAAP or other accounting standards (or the interpretation thereof), or that result from any action taken for the purpose of complying with any of the foregoing; (ix) any changes in such Party\u2019s stock price or the trading volume of such Party\u2019s stock, or any failure by such Party to meet any analysts\u2019 estimates or expectations of such Party\u2019s revenue, earnings or other financial performance or results of operations for any period, or any failure by such Party or any of its Subsidiaries to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations (it being understood that the facts or occurrences giving rise to or contributing to such changes or failures may constitute, or be taken into account in determining whether there has been or will be, a Material Adverse Effect); or (x) changes in GAAP or the interpretations thereof after the date of this Agreement.;   A-7   provided, however, except to the extent such Effects directly or indirectly resulting from, arising out of, attributable to or related to the matters described in the foregoing clauses (i) \u2013 (v) (excluding any Effect arising from, resulting from or related to COVID-19 or COVID-19 Measures, to the extent any COVID-19 Actions are taken in accordance with this Agreement) disproportionately adversely affect such Party and its Subsidiaries, taken as a whole, as compared to other similarly situated industry participants, in which case only the incremental disproportionate impact shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur. (Pages 99-101)\n\nAnswer by outputting a singled letter A, B, C, D or E.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, with respect to any Party, any Effect that (x) is materially adverse to the assets, financial condition, business or continuing results of operations of such Party and its Subsidiaries, taken as a whole, or (y) prevents or materially impairs or delays the ability of such Party to consummate the Merger or the other transactions contemplated hereby on or prior to the Outside Date; provided, however, a Material Adverse Effect shall not include any Effect to the extent arising out of or resulting from:  (a) changes after the date hereof in general United States or global economic conditions, in financial, debt, securities, capital or credit markets, including changes in interest rates, general business, labor or regulatory conditions or social or political conditions; (b) changes after the date hereof generally affecting the industry or industries in which such Party or any of its Subsidiaries operates or any of the markets or geographical areas in which such Party or any of its Subsidiaries operate; (c) changes or proposed changes after the date hereof in Law or the interpretation thereof or in GAAP or the interpretation thereof; (d) acts of war, armed hostility, terrorism (including cyber-terrorism or cyber-attacks), riots, demonstrations, public disorders, civil disobedience or any escalation or worsening thereof; (e) force majeure events, including storms, fires, floods, earthquakes, hurricanes, tornados or other acts of God, natural disasters or calamities; (f) any epidemic, pandemic or disease outbreak (including COVID-19) or worsening thereof, including commercially reasonable responses thereto (including the COVID-19 Measures); (g) any Effect to the extent attributable to the negotiation, execution, announcement, pendency or performance of this Agreement or the consummation of transactions contemplated hereby, including the impact thereof on relationships, contractual or otherwise, of such Party or any of its Subsidiaries with customers, suppliers, lenders, partners, employees or regulators (provided that this clause (g) shall not apply to any representation or warranty to the extent the purpose of such representation or warranty is to address the consequences resulting from this Agreement or the consummation of the transactions contemplated hereby); (h) any failure, in and of itself, by such Party to meet any internal or published projections (whether published by such Party or any analysts) or forecasts or estimates of revenues or earnings or results of operations for any period (it being understood and agreed that the facts and circumstances giving rise to any such failure that are not otherwise excluded from the definition of a Material Adverse Effect may be taken into account in determining whether there has been a Material Adverse Effect); (i) any change in the price or trading volume of any publicly traded securities of such Party (it being understood and agreed that the facts and circumstances giving rise to such change that are not otherwise excluded from the definition of a Material Adverse Effect may be taken into account in determining whether there has been a Material Adverse Effect); (j) any reduction in the credit rating of such Party or its Subsidiaries (it being understood and agreed that the facts and circumstances giving rise to such change that are not otherwise excluded from the definition of a Material Adverse Effect may be taken into account in determining whether there has been a Material Adverse Effect), (k) any bankruptcy, insolvency or reorganization of any tenant under any lease between such Party and such tenant, (l) acts required to be taken or not taken by such Party or any of its Subsidiaries under the terms of this Agreement or taken or not taken at the written request of the other Party, (m) with respect to the Company, any Company Transaction Litigation (except if it has resulted in a non-appealable judicial determination definitively finding a breach of duty by the Board of Trust Managers of the Company) or, with respect to either Party, any litigation alleging that the disclosure contained in the Proxy Statement (whether filed in preliminary or definitive form) violates the federal securities Laws (except if it has resulted in a non-appealable judicial determination definitively finding such a violation), and (n) with respect to the Company, the identity of Parent or any of its Affiliates or any communication by Parent or any of its Affiliates regarding plans, proposals, intentions or projections with respect to the Company, any of its Subsidiaries, or their employees or business; and provided, further, that if any Effect described in any of clauses (a), (b), (d), (e) or (f) has had a disproportionate adverse impact on such Party and its Subsidiaries, taken as a whole, relative to other companies operating in the industry in which such Party operates, then the incremental impact of such Effect may be taken into account for the purpose of determining whether a Material Adverse Effect has occurred. (Page 96)\nAnswer and only output Yes or No.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cAcquisition Proposal\u201d means any proposal or offer from any Person or group of Persons (other than Parent, Merger Sub or their respective Affiliates) relating to (A) any direct or indirect acquisition or purchase, in a single transaction or series of related transaction, by any Person or group (as defined under Section 13 of the Exchange Act) of a business that constitutes 20% or more of the net revenues, net income or fair market value (as determined in good faith by the Board of Directors of the Company) of the consolidated total assets (it being understood that total assets include equity securities of subsidiaries of the Company) of the Company and its subsidiaries, taken as a whole  <omitted>    \u201cSuperior Proposal\u201d means a bona fide and written Acquisition Proposal (except that the references in the definition thereof to \u201c20% or more\u201d shall be deemed to be references to \u201c50.1% or more\u201d) (Page 53)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of asset deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 5.3 Company Acquisition Proposals. <omitted>  (e) <omitted> the Company may make a Company Adverse Recommendation Change <omitted> and concurrently enter into a binding definitive agreement to effect such Company Superior Proposal.   (f) The Company Board shall not take any action set forth in Section 5.3(e) unless the Company has (i) provided written notice to Parent (a \u201cNotice of Company Superior Proposal\u201d) informing Parent that the Company has determined that a Company Acquisition Proposal constitutes a Company Superior Proposal, identifying the Person making such Company Superior Proposal and providing a copy of the draft agreement intended to effect such Company Superior Proposal, (ii) for the four (4) Business Day period following Parent\u2019s receipt of the Notice of Company Superior Proposal (the \u201cCompany Superior Proposal Notice Period\u201d), permitted Parent to make counteroffers or proposals, including to amend the terms and conditions of this Agreement (to the extent Parent wishes to do so), and (iii) after complying with clauses (i) and (ii), determined in good faith (after consultation with the Company\u2019s outside legal counsel and financial advisors and taking into account any such counteroffer or proposed amendment to the terms and conditions of this Agreement) that such Company Acquisition Proposal remains a Company Superior Proposal; provided, however, that if during the Company Superior Proposal Notice Period any revisions are made to a Company Acquisition Proposal and such revisions are material (it being understood and agreed that any change to consideration with respect to such proposal is material), the Company shall deliver a new Notice of Company Superior Proposal to Parent and shall comply with the requirements of this Section 5.3(f) with respect to such new Notice of Company Superior Proposal (except that the \u201cfour (4) Business Day\u201d period referred to in clause (ii) of this proviso shall instead be a two (2) Business Day period). (Page 59)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: 4.3.2 Submission to Shareholders. AB will promptly take the actions necessary in accordance with applicable Law and its articles of incorporation and bylaws to convene a shareholders\u2019 meeting to consider the approval of this Agreement and to authorize the transactions contemplated by this Agreement (such meeting and any adjournment or postponement thereof, the \u201cAB Meeting\u201d). The AB Meeting will be held on the earliest practical date after the date the Prospectus/Proxy Statement may first be sent to AB\u2019s shareholders without objection by applicable Governmental Authorities. The board of directors of AB has adopted a resolution recommending approval of this Agreement and the Merger by AB\u2019s shareholders, and it shall not withdraw, modify, or qualify its recommendation unless, subsequent to the Execution Date, AB receives a Superior Proposal and the board of directors of AB determines, in good faith and upon the written advice of independent legal counsel, that it would be inconsistent with its fiduciary duties under applicable Law not to withdraw, modify, or qualify such recommendation. AB shall use its commercially reasonable efforts to obtain from the shareholders of AB approval of this Agreement in accordance with Utah Law, including (except as provided in the preceding sentence) by communicating to its shareholders its recommendation (and including such recommendation in the Prospectus/Proxy Statement) that they approve this Agreement and the Merger. Subject to applicable Law, AB shall adjourn or postpone the AB Meeting if, as of the time for which such meeting is originally scheduled, there are insufficient shares of AB Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of such meeting, or if, on the date of such AB Meeting, (a) AB has not received proxies representing a sufficient number of shares necessary to obtain the required approval by AB\u2019s shareholders and such approval remains possible to obtain and (b) the shareholders of AB have authorized by the requisite vote under Utah Law the adjournment pursuant to the Prospectus/Proxy Statement; provided that AB shall only be required to adjourn the AB Meeting two times pursuant to this Section 4.3.2. (Page 41)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the Tail Period?\nOption A: 12 months or longer\nOption B: Other\nOption C: within 12 months\nOption D: within 6 months\nOption E: within 9 months\n\nMerger Agreement: 8.2       Effect of Termination. <omitted> (b) (i) In the event that <omitted>  this Agreement is terminated <omitted> (B) <omitted> Cadence enters into a definitive agreement or consummates a transaction with respect to an Acquisition Proposal (whether or not the same Acquisition Proposal as that referred to above) (Page 82)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cSuperior Proposal\u201d means an <omitted> Acquisition Proposal that if consummated would result in a Person or group <omitted> acquiring beneficial ownership of or becoming the beneficial owner of, directly or indirectly, more than 50% of the: <omitted> (b) consolidated net revenues, net income or total assets (it being understood that total assets include equity securities of Subsidiaries of the Company) (Pages 80-81)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: Section 6.02          No Solicitation by the Company.  <omitted> (d)          <omitted> the Board of Directors of the Company may <omitted> (ii) terminate this Agreement in accordance with Section 10.01(d)(iii); provided, that (A) the Company shall first notify Parent in writing at least four Business Days before taking such action that the Company intends to take such action, <omitted> (D) in the event of any change, from time to time, to any of the financial terms or any other material terms of such Company Superior Proposal, the Company shall, in each case, have delivered to Parent an additional notice consistent with that described in clause (A) of this proviso and a new notice period under clause (A) of this proviso shall commence each time, except each such notice period shall be three Business Days (instead of four Business Days), during which time the Company shall be required to comply with the requirements of this Section 6.02(d) anew with respect to each such additional notice, including clauses (A) through (D) above of this proviso. (Page 76)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: each share of Common Stock, par value $1.00 per share, of the Company (\u201cCommon Stock\u201d) and Class B Common Stock, par value $1.00 per share, of the Company (\u201cClass B Stock\u201d, and together with the Common Stock, the \u201cCompany Stock\u201d) shall be converted into the right to receive $14.51 in cash (such amount, the \u201cMerger Consideration\u201d <omitted>  Section 2.6 Effect of the Merger on Capital Stock of the Company and Merger Sub. At the Effective Time, by virtue of the Merger <omitted> : <omitted> (b) Each share of Company Stock issued and outstanding immediately prior to the Effective Time <omitted> shall at the Effective Time automatically be converted into the right to receive the Merger Consideration (Page 22)\n\nAnswer and only output A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the fundamental representations and warranties be according to the bring down provision?\nOption A: Accurate at another materiality standard (e.g., hybrid standard)\nOption B: Accurate in all material respects\nOption C: Accurate in all respects\n\nMerger Agreement: Section 6.2    Additional Parent and Merger Subsidiary Conditions. <omitted> (iii)    The representations and warranties of the Company set forth in this Agreement <omitted> shall be true and correct as of the Agreement Date and as of the Closing Date (Page 51)\n\nAnswer by only outputting the letter of the option A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: except with the prior written consent of Enterprise (which consent will not be unreasonably withheld or delayed), First Choice shall, and shall cause each First Choice Subsidiary to (a) carry on its business only in the Ordinary Course of Business <omitted>   \u201cOrdinary  Course  of  Business\u201d means  the  ordinary  course  of  business  of  First  Choice  and  First  Choice Subsidiaries  (including  First Choice  Bank)  or  Enterprise  and  Enterprise Subsidiaries  (including  EB&T),  as  applicable,  consistent  with  past practice, including with respect to frequency and amount in all material respects. (Page 59)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What carveouts pertaining to Material Adverse Effect (MAE) does the relational language apply to?\nOption A: All MAE carveouts\nOption B: No\nOption C: Some MAE carveouts\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any condition, fact, occurrence, development, change, circumstance, event or effect (each an \u201cEffect\u201d) that (1) has or would reasonably be expected to have, individually or in the aggregate together with all other Effects, a material adverse effect on the business, assets, liabilities, condition (financial or otherwise) or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided, however, that none of the following, and no Effect arising out of or resulting from the following shall constitute or be taken into account in determining whether there has been, a \u201cCompany Material Adverse Effect\u201d: (a) the entry into this Agreement, the announcement or pendency of this Agreement or the Transactions, the performance of this Agreement or the pendency or consummation of the Transactions, in each case, including (i) by reason of the identity of, or any facts or circumstances relating to, Parent, Sub or any of their respective affiliates and (ii) the impact of any of the foregoing on any of the Company\u2019s or any of the Company Subsidiaries\u2019 relationships (contractual or otherwise) with respect to customers, suppliers, vendors, business partners or employees (it being understood and agreed that this clause (a) shall not apply with respect to any representation or warranty the purpose of which is to address the consequences of the execution and delivery o f this Agreement or the consummation of the transactions contemplated hereby, or the performance of obligations hereunder or thereunder); (b) any Effect affecting the economy or the financial, credit or securities markets in the United States or elsewhere in the world (including interest rates and exchange rates or any changes therein), or any Effect affecting any business or industries in which the Company or any of the Company Subsidiaries operates; (c) the suspension of trading in securities generally on Nasdaq (but not the underlying cause of such suspension, unless such underlying cause would otherwise be excepted from this definition); (d) any development or change in applicable Law (after the date of this Agreement), including COVID-19 Measures, or GAAP or other applicable accounting standards or the interpretation of any of the foregoing (it being understood and agreed that this clause (d) shall not apply with respect to any representation or warranty the purpose of which is to address compliance with applicable Laws or GAAP); (e) any action taken by the Company or any of the Company Subsidiaries at the written request of Parent that is not expressly required to be taken by the terms of this Agreement, the taking of any action expressly required by the terms of this Agreement (other than pursuant to clause (1) or (2) of Section 5.01), or the failure of the Company to take any action that the Company is expressly prohibited by the terms of the Agreement from taking; (f) the commencement, occurrence, continuation or escalation of any armed hostilities, sabotage or acts of war (whether or not declared) or terrorism, or any escalation or worsening of acts of terrorism, armed hostilities or war; (g) any actions or claims made or brought by any of the current or former shareholders of the Company (or on their behalf or on behalf of the Company, but in any event only in their capacities as current or former shareholders) arising out of this Agreement or any of the Transactions; (h) the existence, occurrence, continuation or escalation of any acts of God, force majeure events, any earthquakes, floods, hurricanes, tropical storms, fires or other natural disasters or weather-related events or any national, international or regional calamity or any civil unrest or any disease outbreak, pandemic or epidemic, including COVID-19; (i) any public comments or other public communications by Parent or Sub of its express intentions with respect to the Company or any Company Subsidiary, including any public communications to any employees of the Company or any Company Subsidiary; or (j) any changes in the market price or trading volume of the Shares, in and of itself, or any changes in the ratings or the ratings outlook for the Company or any of the Company Subsidiaries by any applicable rating agency or changes in any analyst\u2019s recommendations or ratings with respect to the Company or any of the Company Subsidiaries, or any failure of the Company or any Company Subsidiary to meet any internal or external projections, budgets, guidance, forecasts or estimates of revenues, earnings or other financial results or metrics for any period, in and of itself (but not, in each case of this clause (j), the underlying cause of any such change or failure, unless such underlying cause would otherwise be excepted from this definition) (provided, that this clause (j) shall not be construed as implying that the Company is making any representation or warranty with respect to any internal or external projections, budgets, guidance, forecasts or estimates of revenues, earnings or other financial results or metrics for any period); provided, further, that with respect to the foregoing clauses (b), (c), (d), (f) and (h), any such Effect shall not be prohibited from being taken into account in determining whether a Company Material Adverse Effect has occurred if it disproportionately adversely affects the Company and the Company Subsidiaries, taken as a whole, compared to other companies operating primarily in the same industries in which the Company and the Company Subsidiaries operate, or (2) prevents or materially delays the consummation by the Company of the Merger on or before the Outside Date, provided that in no event shall the failure of the condition in \u200bSection 6.01(c) to have occurred, in and of itself, be considered in determining whether an Effect has prevented or materially delayed the consummation by the Company of the Merger for purposes of this clause (2) (but not, for the avoidance of doubt, the underlying cause of any such failure). (Page 30)\n\nAnswer and only output A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any event, change, effect, development, or occurrence that has a material adverse effect on the business, assets, condition (financial or   96   otherwise), or results of operations of the Company Entities, taken as a whole; provided, however, that any event, change, effect, development, or occurrence arising out of any of the following shall not be such a Company Material Adverse Effect or be taken into account in determining whether a Company Material Adverse Effect has occurred or would reasonably be expected to occur:   (i) any change in general U.S. or global economic conditions;   (ii) any change in the general conditions of the industry or industries in which the Company or the Company Subsidiaries operate;   (iii) any change in general regulatory, legislative or political conditions or in securities, credit, financial, debt or other capital markets in the United States or elsewhere in the world;   (iv) any change in applicable Law or GAAP (or authoritative interpretations or enforcement thereof) after the date hereof;   (v) any change in geopolitical conditions, the outbreak or escalation of hostilities, any acts of war (whether or not declared), sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage, or terrorism;   (vi) any hurricane, earthquake, flood, or other natural disaster;   (vii) any pandemic or epidemic (including, without limitation, COVID-19) or any national declaration of emergency by the United States government;   (viii) the public announcement, pendency, or anticipated consummation of the transactions contemplated by this Agreement, or the Company\u2019s performance of its obligations hereunder pursuant to the express requirements hereof, including any impact thereon on the relationships, contractual or otherwise, with customer, suppliers, lessors, vendors, investors, lenders, partners, contractors, or employees of the Company Entities, and the performance of this Agreement and the transactions contemplated hereby, including compliance with the covenants set forth herein;   (ix) any Transaction-Related Litigation with respect to the Company; or   (x) any decline, in and of itself, in the trading price or trading volume of the Company Common Stock, any failure by the Company to meet any internal or published projections, forecasts, estimates, or predictions of revenues, earnings or other financial or operating metrics for any period or any reduction in the credit rating of the Company or any of the Company Subsidiaries (provided that any event, change, effect, development, or occurrence giving rise to or contributing to such decline, failure, or reduction that is not otherwise excluded from the definition of Company Material Adverse Effect may be a Company Material Adverse Effect and may be taken into account in determining whether a Company Material Adverse Effect has occurred or whether a Company Material Adverse Effect would reasonably be expected to occur);   97   provided, however, that any event, change, effect, development, or occurrence referred to in clauses (i)\u2013(iv) may be a Company Material Adverse Effect and may be taken into account in determining whether a Company Material Adverse Effect has occurred or whether a Company Material Adverse Effect would reasonably be expected to occur, in each case, to the extent that such event, change, effect, development, or occurrence has a disproportionate adverse effect on the Company Entities, taken as a whole, relative to the adverse effects thereof on other companies operating in the industries in which the Company Entities operate (in which case, only the incremental disproportionate adverse effect may be taken into account when determining whether a Company Material Adverse Effect has occurred or whether a Company Material Adverse Effect would reasonably be expected to occur). (Pages 97-99)\nAnswer and only output Yes or No.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: Except <omitted> as consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned), prior to the Effective Time, the Company shall, and shall cause each Company Subsidiary to, use reasonable best efforts to conduct its business in the Ordinary Course of Business in all material respects    <omitted>    \u201cOrdinary Course of Business\u201d means the ordinary and usual course of day-to-day operations of the businesses of the Company Entities, consistent with past custom and practice (Page 19)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.1 Conduct of the Company. From the date of this Agreement until the earlier to occur of the Effective Time and the termination of this Agreement in accordance with Article IX, except as otherwise expressly permitted or expressly contemplated by this Agreement or the Spin-Off Agreements or actions undertaken to effect the Separation and Distribution and other provisions of the Spin-Off Agreements, as set forth in Section 5.1 of the Company Disclosure Letter, as consented to in writing by Parent (such consent not to be unreasonably withheld, conditioned or delayed) or as required by applicable Law, the Company shall, and shall cause each of its RemainCo Subsidiaries to, (i) conduct its business in all material respects in the ordinary course of business consistent with past practices, (Page 55)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the Tail Period?\nOption A: 12 months or longer\nOption B: Other\nOption C: within 12 months\nOption D: within 6 months\nOption E: within 9 months\n\nMerger Agreement: Section 10.3    Fees and Expenses. <omitted>  (c)    If <omitted>  this Agreement is terminated <omitted> (iii) prior to the date that is twelve (12) months after the date of such termination, the Company enters into a definitive written agreement with any Person with respect to such Acquisition Proposal, then the Company shall pay to Nicolet, within two (2) Business Days after execution of such definitive written agreement, the Termination Fee by wire transfer of immediately available funds to such account as Nicolet shall designate. (Page 52)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 4.1 Interim Operations. (a) <omitted> except (1) to the extent Parent shall otherwise give its prior consent in writing (which consent shall not be unreasonably withheld, conditioned or delayed), <omitted> the Company shall, and shall cause the Company Subsidiaries to, conduct its business in the ordinary course consistent with past practice in all material respects (Page 51)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: 4.1 Interim Operations.  (a) <omitted> the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except (1) to the extent Parent shall otherwise give its prior consent in writing (which consent shall not be unreasonably withheld, conditioned or delayed), <omitted> the Company shall, and shall cause the Company Subsidiaries to, use reasonable best efforts to conduct its business in the ordinary course consistent in all material respects with past practice (Page 46)\n\nAnswer and only output A, B or C.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of asset deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: 7.5          Acquisition Proposals. <omitted> (b )          No Change in Recommendation or Alternative Acquisition Agreement .  Except as permitted in this Section 7.5(b), neither the Company Board, the Hospitality Board nor any of their committees shall:   (i)          (A) withhold, withdraw, qualify or modify (or publicly propose or resolve to withhold, withdraw, qualify or modify), in a manner adverse to Parent, the Company Board Recommendation or the Hospitality Board Recommendation, (B) authorize, approve, adopt or recommend or otherwise declare advisable (or publicly propose or resolve to authorize, approve, adopt or recommend or otherwise declare advisable) any Acquisition Proposal or (C) fail to include the Company Board Recommendation and the Hospitality Board Recommendation in the Joint Proxy Statement (either of the foregoing, a \u201cChange of Recommendation\u201d); or   ( i i )         except as expressly permitted by, and after compliance with this Section 7.5, authorize, approve, adopt or recommend or otherwise declare advisable (or publicly propose or resolve to authorize, approve, adopt or recommend or otherwise declare advisable), or cause or permit any Paired Entity or any Paired Entities Subsidiary to enter into, any Alternative Acquisition Agreement (other than an Acceptable Confidentiality Agreement entered into in compliance with Section 7.5(a)).   Notwithstanding anything to the contrary set forth in this Agreement, the Company Board or the Hospitality Board may, prior to but not after the time the Requisite Vote is obtained, (A) make a Change of Recommendation if an Intervening Event has occurred and if, after consulting with its financial advisor and outside legal counsel, the Company Board or the Hospitality Board determines in good faith that the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law or (B) if the Paired Entities have not breached this Section 7.5(c) and have not breached the other subsections of this Section 7.5 in any material respect, make a Change of Recommendation and/or terminate this Agreement pursuant to Section 9.1(c)(i) if the Paired Entities receive an Acquisition Proposal (not resulting from a breach of this Section 7.5) that the Company Board and the Hospitality Board have determined in good faith, after consulting with their financial advisor and outside legal counsel, (x) constitutes a Superior Proposal after having complied with, and giving effect to all of the adjustments which may be offered by Parent pursuant to, this Section 7.5(b) and such Acquisition Proposal is not withdrawn and (y) the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law; provided that neither the Company Board nor the Hospitality Board may take any such action unless prior to making such Change of Recommendation or authorizing such termination to enter into a definitive written agreement providing for the implementation of such Superior Proposal pursuant to Section 9.1(c)(i), (I) the Paired Entities provide prior written notice (\u201cNotice Period Commencement Notice\u201d) to Parent at least four (4) Business Days in advance (the \u201cNotice Period\u201d) of their intention to take such action, which notice shall include, in the case of a Superior Proposal, the name of the person or group making the Superior Proposal and substantial final draft of the definitive agreement reflecting such Superior Proposal and, in the case of an Intervening Event, a reasonably detailed description of such Intervening Event, (II) if requested by Parent, during the Notice Period the Paired Entities shall, and shall direct their Representatives to, negotiate with Parent in good faith should Parent propose to make amendments or other revisions to the terms and conditions of this Agreement such that, in the case of a Superior Proposal, such Acquisition Proposal no longer constitutes a Superior Proposal and, in the case of an Intervening Event, the failure to take such action is no longer reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law as determined in the good faith judgment of the Company Board or the Hospitality Board after consulting with their financial advisor and outside legal counsel and (III) the Company Board and the Hospitality Board has taken into account any amendments or other revisions to the terms and conditions of this Agreement agreed to by Parent in writing prior to the end of the Notice Period and (1)  the Company Board and the Hospitality Board determined in good faith that, after consulting with its financial advisor and outside legal counsel, in the case of an Intervening Event, a failure to make such Change of Recommendation continues to be reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law and (2) the Company Board and the Hospitality Board determined in good faith that, after consulting with their financial advisor and outside legal counsel, in the case of an Acquisition Proposal, the Acquisition Proposal giving rise to such Change of Recommendation continues to constitute a Superior Proposal and the failure to make such Change of Recommendation continues to be inconsistent with the directors\u2019 fiduciary duties under applicable Law; it being understood that any change to the financial terms or any other material amendments or other material revisions to any Acquisition Proposal will be deemed to be a new Acquisition Proposal, including for purposes of the Notice Period; provided, however, that, subsequent to the initial Notice Period, the Notice Period shall be reduced to two (2) Business Days following receipt by Parent of any such new Notice Period Commencement Notice. (Page 59)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is the \u201cability to consummate\u201d concept subject to Material Adverse Effect (MAE) carveouts?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any Effect that, individually or in the aggregate, has a material adverse effect on the financial condition, business or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided, however, that no Effects resulting or arising from or relating to any of the following shall be deemed to constitute a Company Material Adverse Effect or shall be taken into account when determining whether a Company Material Adverse Effect exists or has occurred or is reasonably likely to exist or occur: (a) any changes in general United States or global economic conditions to the extent that such Effects do not disproportionately impact the Company relative to other peer companies operating in the industry or industries in which the Company operates, (b) conditions (or changes therein) in any industry or industries in which the Company operates to the extent that such Effects do not disproportionately impact the Company relative to other peer companies operating in such industry or industries, (c) general legal, tax, economic, political and/or regulatory conditions (or changes therein), including any changes affecting financial, credit or capital market conditions, to the extent that such Effects do not disproportionately impact the Company relative to other companies operating in the industry or industries in which the Company operates, (d) any change in GAAP or interpretation thereof to the extent that such Effects do not disproportionately impact the Company relative to other peer companies operating in the industry or industries in which the Company operates, (e) any adoption, implementation, promulgation, repeal, modification, amendment, reinterpretation, change or proposal of any applicable Law of or by any Governmental Entity to the extent that such Effects do not disproportionately impact the Company relative to other peer companies operating in the industry or industries in which the Company operates, (f) the execution and delivery of this Agreement or the consummation of the Transactions, or the public announcement thereof, or any action or failure to take any action that is required or prohibited (other than, to the extent not excluded by another clause of this definition, the Company\u2019s compliance with its obligations pursuant to Section 5.1, except to the extent that Parent has unreasonably withheld a consent under Section 5.1), respectively, under the terms of this Agreement or that is consented to or requested by Parent in writing, or which the Company did not take on account of withheld consent from Parent (provided, that this clause (f) shall not apply with respect to any representation or warranty that is expressly intended to address the consequences of the execution, delivery or performance of this Agreement or the consummation of the Transactions (including Section 3.3(c)) or with respect to the condition to Closing contained in Section 7.2(a), to the extent it relates to such representations and warranties), (g) changes in the Company Common Stock price in and of itself (it being understood that the facts or occurrences giving rise or contributing to such changes that are not otherwise excluded from the definition of a \u201cCompany Material Adverse Effect\u201d may be taken into account), (h) any failure by the Company to meet any internal or published projections, estimates or expectations of the Company\u2019s revenue, earnings or other financial performance or results of operations for any period, in and of itself, or any failure by the Company to meet its internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations, in and of itself (it being understood that the facts or occurrences giving rise or contributing to such failure that are not otherwise excluded from the definition of a \u201cCompany Material Adverse Effect\u201d may be taken into account), (i) Effects arising out of changes in geopolitical conditions, acts of terrorism or sabotage, war (whether or not declared), the commencement, continuation or escalation of a war, acts of armed hostility, weather conditions or any other force majeure events, including any material worsening of such conditions threatened or existing as of the date of this Agreement, to the extent that such Effects do not disproportionately impact the Company relative to other companies operating in the industry or industries in which the Company operates, (j) any litigation, claims, actions, suits or proceedings arising from allegations of a breach of fiduciary duty or violation of applicable Law relating to this Agreement or the Transactions, (k) as disclosed (including as deemed disclosed pursuant to the preamble to Article III) with respect to the representations and warranties in Section 3.10, or (l) Effects arising from or relating to any epidemic, pandemic or disease outbreak (including COVID-19) or any COVID-19 Measures or other restrictions that relate to, or arise out of, any epidemic, pandemic or disease outbreak (including COVID-19) or material worsening of such conditions threatened or existing as of the date of this Agreement. (Page 39)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (c) Conversion of Company Common Stock.   (i) Each share of Company Common Stock issued and outstanding immediately prior to the First Effective Time (other than the Excluded Shares) (collectively, the \u201cShares\u201d) shall be converted into and become one (1) share of Initial Surviving Company Stock, and each such share of Initial Surviving Company Stock shall immediately thereafter be automatically exchanged for (A) 0.6710 (the \u201cExchange Ratio\u201d) Parent ADSs duly and validly issued against the deposit of the requisite number of underlying Parent Ordinary Shares in accordance with the Deposit Agreement (the \u201cMerger Consideration\u201d) in accordance with Section 2.3(a) (Page 9)\n\nAnswer and only output A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 5.4 Non-Solicitation. <omitted>  (b) <omitted> in response to a Superior Proposal with respect to East that was not initiated, solicited, knowingly encouraged or knowingly facilitated by East or any of the East Subsidiaries or any of their respective Representatives, the East Board may make an East Adverse Recommendation Change; provided, however, that East shall not be entitled to exercise its right to make an East Adverse Recommendation Change in response to a Superior Proposal with respect to East (x) until three (3) Business Days after East provides written notice to Central <omitted> (it being understood that any change in the financial or other material terms of a Superior Proposal shall require a new East Notice and a new two (2) Business Day period under this Section 5.4(b)) (Page 76)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.4 No Company Solicitation. <omitted> the Company Board may make a Company Change of Recommendation <omitted> if: <omitted> (v) <omitted> Parent has proposed any changes to the terms hereof <omitted> and there is any subsequent amendment to any material term of such Alternative Acquisition Proposal, the Company Board shall provide <omitted> an additional three (3) Business Day period from the date of such notice shall apply (Page 61)\n\nAnswer by outputting a singled letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the Forward Looking Standard (FLS) with respect to Material Adverse Effect (MAE)?\nOption A: \"Could\" (reasonably) be expected to\nOption B: \"Would\"\nOption C: \"Would\" (reasonably) be expected to\nOption D: No\nOption E: Other forward-looking standard\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any condition, fact, occurrence, development, change, circumstance, event or effect (each an \u201cEffect\u201d) that (1) has or would reasonably be expected to have, individually or in the aggregate together with all other Effects, a material adverse effect on the business, assets, liabilities, condition (financial or otherwise) or results of operations of the Company and the Company Subsidiaries, taken as a whole; provided, however, that none of the following, and no Effect arising out of or resulting from the following shall constitute or be taken into account in determining whether there has been, a \u201cCompany Material Adverse Effect\u201d: (a) the entry into this Agreement, the announcement or pendency of this Agreement or the Transactions, the performance of this Agreement or the pendency or consummation of the Transactions, in each case, including (i) by reason of the identity of, or any facts or circumstances relating to, Parent, Sub or any of their respective affiliates and (ii) the impact of any of the foregoing on any of the Company\u2019s or any of the Company Subsidiaries\u2019 relationships (contractual or otherwise) with respect to customers, suppliers, vendors, business partners or employees (it being understood and agreed that this clause (a) shall not apply with respect to any representation or warranty the purpose of which is to address the consequences of the execution and delivery o f this Agreement or the consummation of the transactions contemplated hereby, or the performance of obligations hereunder or thereunder); (b) any Effect affecting the economy or the financial, credit or securities markets in the United States or elsewhere in the world (including interest rates and exchange rates or any changes therein), or any Effect affecting any business or industries in which the Company or any of the Company Subsidiaries operates; (c) the suspension of trading in securities generally on Nasdaq (but not the underlying cause of such suspension, unless such underlying cause would otherwise be excepted from this definition); (d) any development or change in applicable Law (after the date of this Agreement), including COVID-19 Measures, or GAAP or other applicable accounting standards or the interpretation of any of the foregoing (it being understood and agreed that this clause (d) shall not apply with respect to any representation or warranty the purpose of which is to address compliance with applicable Laws or GAAP); (e) any action taken by the Company or any of the Company Subsidiaries at the written request of Parent that is not expressly required to be taken by the terms of this Agreement, the taking of any action expressly required by the terms of this Agreement (other than pursuant to clause (1) or (2) of Section 5.01), or the failure of the Company to take any action that the Company is expressly prohibited by the terms of the Agreement from taking; (f) the commencement, occurrence, continuation or escalation of any armed hostilities, sabotage or acts of war (whether or not declared) or terrorism, or any escalation or worsening of acts of terrorism, armed hostilities or war; (g) any actions or claims made or brought by any of the current or former shareholders of the Company (or on their behalf or on behalf of the Company, but in any event only in their capacities as current or former shareholders) arising out of this Agreement or any of the Transactions; (h) the existence, occurrence, continuation or escalation of any acts of God, force majeure events, any earthquakes, floods, hurricanes, tropical storms, fires or other natural disasters or weather-related events or any national, international or regional calamity or any civil unrest or any disease outbreak, pandemic or epidemic, including COVID-19; (i) any public comments or other public communications by Parent or Sub of its express intentions with respect to the Company or any Company Subsidiary, including any public communications to any employees of the Company or any Company Subsidiary; or (j) any changes in the market price or trading volume of the Shares, in and of itself, or any changes in the ratings or the ratings outlook for the Company or any of the Company Subsidiaries by any applicable rating agency or changes in any analyst\u2019s recommendations or ratings with respect to the Company or any of the Company Subsidiaries, or any failure of the Company or any Company Subsidiary to meet any internal or external projections, budgets, guidance, forecasts or estimates of revenues, earnings or other financial results or metrics for any period, in and of itself (but not, in each case of this clause (j), the underlying cause of any such change or failure, unless such underlying cause would otherwise be excepted from this definition) (provided, that this clause (j) shall not be construed as implying that the Company is making any representation or warranty with respect to any internal or external projections, budgets, guidance, forecasts or estimates of revenues, earnings or other financial results or metrics for any period); provided, further, that with respect to the foregoing clauses (b), (c), (d), (f) and (h), any such Effect shall not be prohibited from being taken into account in determining whether a Company Material Adverse Effect has occurred if it disproportionately adversely affects the Company and the Company Subsidiaries, taken as a whole, compared to other companies operating primarily in the same industries in which the Company and the Company Subsidiaries operate, or (2) prevents or materially delays the consummation by the Company of the Merger on or before the Outside Date, provided that in no event shall the failure of the condition in \u200bSection 6.01(c) to have occurred, in and of itself, be considered in determining whether an Effect has prevented or materially delayed the consummation by the Company of the Merger for purposes of this clause (2) (but not, for the avoidance of doubt, the underlying cause of any such failure). (Page 30)\n\nAnswer by outputting a singled letter A, B, C, D or E.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is there specific reference to pandemic-related governmental responses or measures in the clause that qualifies pandemics or other public health events for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any change, event, effect, development or occurrence that (a) has or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, assets, condition (financial or otherwise), prospects or results of operations of the Company and the Subsidiaries of the Company, taken as a whole, excluding any effect to the extent it results from or arises out of (i) general conditions in the industries in which the Company operates, (ii) general economic or regulatory, legislative or political conditions or securities, credit, financial or other capital markets conditions (including changes generally in prevailing interest rates, currency exchange rates, credit market conditions and capital markets price levels or trading volumes), in each case in the United States or elsewhere in the world, (iii) any change or prospective change in applicable Law or GAAP (or interpretation or enforcement thereof), (iv) geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or terrorism, (v) any hurricane, tornado, flood, volcano, earthquake, epidemic, disease outbreak, public health event, pandemic (including COVID-19 and any worsening thereof (including any COVID-19 Response)) or other natural or man-made disaster, (vi) the failure of the Company to meet any internal or external projections, forecasts, estimates or predictions in respect of revenues, earnings or other financial or operating metrics before, on or after the date of this Agreement, or changes or prospective changes in the market price or trading volume of the Company Common Stock or the credit rating of the Company and/or its Subsidiaries (it being understood that the underlying facts or occurrences giving rise or contributing to such failure or change may be taken into account in determining whether there has been a Company Material Adverse Effect if such facts or occurrences are not otherwise excluded from being taken into account pursuant to this definition in determining whether the has been a Company Material Adverse Effect), (vii) the execution, announcement, performance or consummation of any of the Transactions, including the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, partners, employees of Governmental Entities, or any Proceeding brought by any Company stockholder (direct or derivative) in respect of this Agreement or any of the Transactions, in each case to the extent resulting from or arising in connection with such announcement or consummation (it being understood that this clause (vii) shall not apply with respect to (a) any representation or warranty contained in this Agreement to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Transactions or the performance of obligations under this Agreement, including the Transactions or (b) any closing condition related to the foregoing clause (a)), (viii) any action taken by the Company or its Subsidiaries that is expressly required by this Agreement (other than 5.01(a)) or with Parent\u2019s written consent or at Parent\u2019s written request, or the failure to take any action by the Company or its Subsidiaries if that action is expressly prohibited by this Agreement (only to the extent that Parent unreasonably withholds, conditions or delays consent to the taking of such action after receipt of the written request therefor from the Company), and (ix) changes resulting or arising from the identity of, or any facts or circumstances relating to, Parent,   76   Merger Sub or any of their respective Affiliates, including the financing obtained or to be obtained by Parent, Merger Sub or any of their respective Affiliates, except, in the case of clause (i), (ii), (iii), (iv) or (v), to the extent that the Company is disproportionately affected thereby as compared with other participants in the industries in which the Company operates (in which case the incremental disproportionate impact or impacts may be taken into account in determining whether there has been a Company Material Adverse Effect) or (b) prevents or materially impairs or delays the consummation of the Merger and the other Transactions or the ability of the Company to perform its obligations under this Agreement. (Pages 84-85)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: 5.06 Registration Statement; Joint Proxy Statement; Change of Recommendation. <omitted> (ii) Notwithstanding anything to the contrary set forth in this Agreement, prior to the time, but not after, the Company Shareholder Approval contemplated by this Agreement is obtained, the Company Board may withhold, withdraw or adversely modify the Company Board Recommendation or approve, recommend or otherwise declare advisable any Superior Proposal made to the Company after the date hereof that was not solicited, initiated, encouraged or facilitated in breach of this Agreement, if (A) an unsolicited bona fide written offer is made to the Company and is not withdrawn and the Company Board determines in good faith (after consultation with its financial advisor and outside counsel) that such Acquisition Proposal is a Superior Proposal, and (B) the Company Board determines in good faith, after consultation with outside counsel, that the failure to take such action would result in a violation of the directors\u2019 fiduciary duties under applicable Law; provided, however, that no such Company Change of Recommendation may be made until after (I) at least five (5) Business Days following Parent\u2019s receipt of notice from the Company advising that the Company Board intends to take such action and the basis therefor, including all necessary   -52-   information under Section 5.08 and (II) the Company has negotiated in good faith to permit Parent to modify this Agreement during such five (5) Business Day period. In determining whether to make a Company Change of Recommendation, the Company Board shall take into account any changes to the terms of this Agreement proposed by Parent and any other information provided by Parent in response to such notice. Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of this Section 5.05, including with respect to the notice period referred to in this Section 5.05. (Pages 55-56)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "F",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: Section 6.03    Company Recommendation.  <omitted>  (b)  (i) <omitted> if the Company receives an Acquisition Proposal <omitted> and <omitted> (i) such Acquisition Proposal constitutes a Superior Proposal and (ii) <omitted> the Company Board may (A) make an Adverse Recommendation Change <omitted> subject to compliance with the terms of paragraph (ii) below.   (ii)    No Adverse Recommendation Change pursuant to Section 6.03(b)(i) may be made <omitted> :   <omitted>      (A)    until after <omitted> following <omitted> notice from the Company <omitted> advising Parent that the Company Board intends to make an Adverse Recommendation Change in connection with a Superior Proposal <omitted> (it being understood and agreed that any amendment to the financial terms or any other material term of such Superior Proposal shall require a new Notice of Superior Proposal and the Superior Proposal Notice Period shall be deemed to have recommenced on the date of such new Notice of Superior Proposal); (Pages 65-66)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Except <omitted> (iv) with the prior written consent of Central (which consent shall not be unreasonably delayed, withheld or conditioned), <omitted>  from the date hereof until the earlier of the Effective Time or the date this Agreement shall be terminated in accordance with Article VII (the \u201cPre-Closing Period\u201d), East (which for purposes of this Section 4.1 shall include the East Subsidiaries) shall, (A) conduct the business and operations of East and the East Subsidiaries, taken as a whole, in all material respects in the ordinary course consistent with past practice (Page 62)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: Section 5.1 Conduct of Company Business Prior to the First Effective Time. (a) Except (i) as required hereby or by applicable Law (including any COVID-19 Measure), (ii) as disclosed in Section 5.1(a) of the Company Disclosure Schedule or (iii) as consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned), prior to the First Effective Time, the Company shall, and shall cause each Company Subsidiary to, use commercially reasonable efforts to conduct its business in the Ordinary Course of Business in all material respects and, to the extent consistent therewith, use commercially reasonable efforts <omitted> \u201cOrdinary Course of Business\u201d means the ordinary and usual course of day-to-day operations of the businesses of the Company Entities or Parent Entities, as applicable, consistent with past custom and practice; provided, that no action or omission that would constitute a breach of Contract, violation of Law or any tort (including negligence) shall be an action or omission in the Ordinary Course of Business. (Page 52)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cAcquisition Proposal\u201d shall mean, with respect to BancShares or CIT, as applicable, other than the transactions contemplated by this Agreement, any offer, proposal, solicitation or inquiry relating to, or any third-party indication of interest in, or the filing of any regulatory application or notice, from or by any person relating to, (i) any acquisition or purchase, direct or indirect, of twenty-five percent (25%) or more of the consolidated assets of a party and its Subsidiaries or twenty-five percent (25%) or more of any class of equity or voting securities of a party or its Subsidiaries whose assets, individually or in the aggregate, constitute twenty-five percent (25%) or more of the consolidated assets of the party, (ii) any tender offer (including a self-tender offer) or exchange offer that, if consummated, would result in such third party beneficially owning twenty-five percent (25%) or more of any class of equity or voting securities of a party or its Subsidiaries whose assets, individually or in the aggregate, constitute twenty-five percent (25%) or more of the consolidated assets of the party, or (iii) any merger, consolidation, share exchange, business combination, reorganization, recapitalization, liquidation, dissolution or other similar transaction involving a party or its Subsidiaries whose assets, individually or in the aggregate, constitute twenty-five percent (25%) or more of the consolidated assets of the party.  <omitted>    \u201cSuperior Proposal\u201d shall mean any bona fide written Acquisition Proposal which the board of directors of BancShares or CIT, as applicable, determines, in good faith, after taking into account all legal, financial, regulatory, and other aspects of such proposal (including the amount, form, and timing of payment of consideration, the financing thereof, any associated break-up or termination fees, including those provided for in this Agreement, expense reimbursement provisions, and all conditions to consummation) and the person making the proposal, and after consulting with its financial advisor (which shall be a nationally recognized investment     55      banking firm) and outside legal counsel, is (i) more favorable from a financial point of view to BancShares\u2019 or CIT\u2019s, as applicable, stockholders than the transactions contemplated by this Agreement and (ii) reasonably likely to be timely consummated on the terms set forth; provided, however, that for purposes of this definition of Superior Proposal, references to \u201ctwenty-five percent (25%) or more\u201d in the definition of Acquisition Proposal shall be deemed to be references to \u201cseventy-five percent (75%) or more.\u201d (Pages 63-64)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: Section 6.01          Conduct of the Company.   (a)          From the date of this Agreement until the earlier of the First Effective Time and the termination of this Agreement, except (x) as prohibited or required by Applicable Law, (y) as set forth in Section 6.01 of the Company Disclosure Schedule, or (z) as otherwise required or expressly contemplated by this Agreement, unless Parent shall have given its prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts to conduct its business in all material respects in the ordinary course of business and to preserve intact its business organization, keep available the services of its present key employees and maintain its existing relations and goodwill with material customers, members, suppliers, licensors, licensees and other Third Parties with whom it has material business relations; (Page 69)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Under what circumstances could the Board take actions on a different acquisition proposal notwithstanding the no-shop provision?\nOption A: If failure to take actions would lead to \"breach\" of fiduciary duties\nOption B: If failure to take actions would be \"inconsistent\" with fiduciary duties\nOption C: If failure to take actions would lead to \"reasonably likely/expected breach\" of fiduciary duties\nOption D: If failure to take actions would lead to \"reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: If failure to take actions would lead to \"reasonably likely/expected violation\" of fiduciary duties\nOption F: If taking such actions is \"required to comply\" with fiduciary duties\nOption G: If failure to take actions would lead to \"violation\" of fiduciary duties\nOption H: Under no circumstances could the Board do so.\nOption I: Other circumstances\n\nMerger Agreement: Section 5.10    Acquisition Proposals. <omitted>  provided that, in the event the Company receives an unsolicited bona fide Acquisition Proposal, from a Person other than Nicolet, after the execution of this Agreement and prior to the receipt of the Company Shareholder Approval, and the Company Board concludes in good faith, after consultation with its financial advisor and outside counsel, that such Acquisition Proposal constitutes a Superior Proposal or could reasonably be likely to result in a Superior Proposal and, after considering the advice of outside counsel, that failure to take such actions could be reasonably likely to result in a violation of the directors\u2019 fiduciary duties under applicable law, the Company may: (i) furnish information with respect to it to such Person making such Acquisition Proposal pursuant to a customary confidentiality agreement (subject to the requirement that any such information not previously provided to Nicolet shall be promptly furnished to Nicolet); (ii) participate in discussions or negotiations regarding such Acquisition Proposal; and (iii) terminate this Agreement in order to concurrently enter into an agreement with respect to such Acquisition Proposal; provided, however, that the Company may not terminate this Agreement pursuant to this Section 5.10 unless and until (x) five (5) Business Days have elapsed following the delivery to Nicolet of a written notice of such determination by the Company Board and, during such five (5) Business-Day period, the parties cooperate with one another with the intent of enabling the parties to engage in good faith negotiations so that the Contemplated Transactions may be effected, and (y) at the end of such five (5) Business-Day period, the Company Board continues, in good faith and after consultation with outside legal counsel and financial advisors, to believe that a Superior Proposal continues to exist. (Page 41)\n\nAnswer by only outputting the letter (i.e. A, B, C, D, E, F, G, H, or I) of the relevant option.",
        "output": "E",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: Section 5.3 No Solicitation. <omitted> (d) <omitted> Notwithstanding anything in this Agreement to the contrary, at any time prior to receipt of the Company Stockholder Approval, in response to an Alternative Proposal that did not result from a material breach of this Section 5.3, if the Board of Directors of the Company determines in good faith, after consultation with its financial advisors and outside legal counsel, that (1) such Alternative Proposal constitutes a Superior Proposal and (2) the failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, then (x) the Board of Directors of the Company may effect a Change of Recommendation and/or authorize or cause the Company to take the actions in the following clause (y), and/or (y) the Company may, notwithstanding anything in this Agreement to the contrary, terminate this Agreement and concurrently with such termination enter into a Company Acquisition Agreement with respect to such Superior Proposal, provided that prior to taking any such action: (A) the Company provides Parent four (4) business days\u2019 prior written notice of its intention to take such action, which notice shall include the information with respect to such Superior Proposal that is specified in Section 5.3(b) (it being understood that each time any material revision or amendment to the terms of the Alternative Proposal determined to be a Superior Proposal is made, the four (4) business day period shall be extended for an additional three (3) business days after notification of such change in accordance with Section 5.3(b) and this Section 5.3(d) to Parent); (B) during the applicable period described in clause (A) (the \u201cTakeover Notice Period\u201d), the Company considers and discusses with Parent in good faith any adjustments or modifications to the terms of this Agreement proposed by Parent; and (C) at the end of the Takeover Notice Period, the Board of Directors of the Company again makes the determination in good faith, after consultation with its outside legal counsel and financial advisors (and after taking into account any adjustments or modifications proposed by Parent during the Takeover Notice Period), that the Alternative Proposal continues to be a Superior Proposal (Page 46)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "When are representations and warranties required to be made according to the bring down provision?\nOption A: At Closing Only\nOption B: At Signing & At Closing\n\nMerger Agreement: CONDITIONS TO THE OFFER   The obligation of Merger Sub to accept for purchase, and pay for, Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to the satisfaction of the conditions set forth in clauses (a) through (h) below. Accordingly, notwithstanding any other provision of the Offer or the Agreement to the contrary, Merger Sub shall not be required to accept for purchase or (subject to any applicable rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act) pay for, and may delay the acceptance for payment of, or (subject to any such rules and regulations) the payment for, any tendered Shares, and, to the extent permitted by the Agreement, may terminate the Offer: (i) upon termination of the Agreement; and (ii) at any scheduled Expiration Date (subject to any extensions of the Offer pursuant to Section 1.1(c)), if: (A) the Minimum Condition, the Termination Condition and conditions set forth in clause (e) shall not be satisfied by one minute after 11:59 p.m. Eastern Time on the Expiration Date; or (B) any of the additional conditions set forth below shall not be satisfied or waived in writing by Parent: <omitted> (b) <omitted> (iii)     the remaining sections of ARTICLE IV shall be true and correct in all respects (without giving effect to any \u201cmateriality,\u201d \u201cMaterial Adverse Effect\u201d or similar qualifiers contained in any such representations and warranties) as of the date of the Agreement and as of the Offer Acceptance Time as if made of the Offer Acceptance Time (except to the extent any such representation or warranty speaks as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except where the failures of any such representations and warranties to be so true and correct, individually or in the aggregate, would not be reasonably expected to have a Material Adverse Effect; (Page 110)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: 5.2 Operation of the Company\u2019s Business. (a) Except (i) as expressly required by this Agreement, (ii) as required by applicable Law, (iii) as set forth in Section 5.2(a) or Section 5.2(b) of the Company Disclosure Letter, (iv) in connection with any action taken, or omitted to be taken, pursuant to any COVID-19 Measures or which is otherwise taken, or omitted to be taken, in response to COVID-19 or any other pandemic, epidemic or disease outbreak, in each case in this clause (iv) as determined by the Company in its reasonable discretion to be reasonably necessary in light of then-current conditions and developments; provided, in the case of this clause (iv), that the Company shall, to the extent reasonably practicable under the circumstances, provide reasonable advance notice to and consult with Parent and keep Parent reasonably informed on a reasonably current basis with respect to any such action or inaction that would reasonably be expected to have a material impact on the Company\u2019s day-to-day business operations, or (v) as consented to in writing by Parent (which consent will not be unreasonably withheld, conditioned or delayed), during the Interim Period, the Company shall and shall cause the Company Subsidiaries to: (A) conduct its business (x) in the ordinary course (Page 40)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cSuperior Proposal\u201d means a bona fide written Takeover Proposal <omitted> ; provided that for the purposes of this definition of \u201cSuperior Proposal,\u201d all references in the term Takeover Proposal to \u201c10% or more\u201d shall be deemed to be references to \u201cmore than 50%,\u201d <omitted> \u201cTakeover Proposal\u201d means any inquiry, indication of interest, proposal or offer from any Third Party relating to (a) any direct or indirect acquisition or purchase, in a single transaction or a series of transactions, of <omitted> (ii) 10% or more (based on the fair market value thereof, as determined by the Company Board of Directors) of the assets (including capital stock of the Subsidiaries of the Company) of the Company and its Subsidiaries, taken as a whole (Page 15)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of offer could the Board take actions on notwithstanding the no-shop provision?\nOption A: Acquisition Proposal only\nOption B: Superior Offer, or Acquisition Proposal reasonably likely/expected to result in a Superior Offer\n\nMerger Agreement: Section 5.03 Solicitation; Change of Company Recommendation. <omitted> (b)            Notwithstanding anything to the contrary contained in this Agreement but subject to the last sentence of this Section 5.03(b), if, at any time following the execution of this Agreement and prior to the earlier of the Company obtaining the Company Stockholder Approval or the termination of this Agreement (and in no event after the Company obtains the Company Stockholder Approval), (i) the Company has received a bona fide written Competing Proposal from a person after the date of this Agreement that did not result from a breach of Section 5.03(a) (other than an immaterial and unintentional breach), and (ii) the Company Board (or any committee thereof) determines in good faith, after consultation with its outside financial advisors and outside legal counsel, that such Competing Proposal constitutes or would reasonably be expected to lead to a Superior Proposal and the failure to take any of the following actions would be reasonably likely to be inconsistent with the Company Board\u2019s fiduciary duties under applicable Law, then the Company, the Company Subsidiaries and the Company\u2019s Representatives may, subject to compliance with the applicable provisions of this Section 5.03 with respect to such Competing Proposal (other than immaterial or unintentional failures to comply), (A) furnish information, including with respect to the Company and the Company Subsidiaries, to the person making such Competing Proposal and its Representatives and (B) participate in discussions or negotiations with the person making such Competing Proposal and its Representatives in connection with such Competing Proposal; provided, however, that the Company shall not disclose any material non-public information regarding the Company or the Company Subsidiaries pursuant to the foregoing without first entering into an Acceptable Confidentiality Agreement with such person if such person is not already party to an Acceptable Confidentiality Agreement with the Company. The Company shall provide Parent and Sub any non- public information that is provided to any such person in connection with such Competing Proposal that was not previously made available (whether prior to or after the execution of this Agreement) to Parent or Sub reasonably promptly following the time it is provided to such person or, with respect to such information conveyed verbally, promptly (and, in any event, within forty-eight (48) hours thereafter). (Page 24)\n\nAnswer by only outputting a letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: from the date of this Agreement to the Effective Time, the Company shall not, and shall not permit any Company Subsidiary to <omitted> do any of the following, except (A) with the prior written consent of Parent <omitted> : (Page 47)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 5.1           Conduct of the Business Pending the Merger. The Company covenants and agrees that from the date of this Agreement until the earlier of (1) the Effective Time or (2) termination of this Agreement in accordance with Section 8.1, except as contemplated or permitted by this Agreement or required by applicable Laws or any Governmental Authority or with the prior written approval of Parent or Merger Sub (which shall not be unreasonably withheld, delayed or conditioned), the Company shall, and shall cause each Company Subsidiary to, (i) conduct its business in the ordinary course consistent with past practice and (Page 27)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in GAAP or other accounting principles that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any effect, circumstance, occurrence or change that is material and adverse to the business, assets or deposit liabilities, properties, operations, results of operations or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole, or that materially impairs the ability of the Company to consummate the Merger and the transactions contemplated hereby on a timely basis; provided, however, that none of the following effects, circumstances, occurrences or changes shall be considered when determining if a Company Material Adverse Effect has occurred: (A) any change in Law or GAAP or interpretations thereof (except to the extent that, with respect to this clause (A), such effect, circumstance, occurrence or change disproportionately adversely affects the Company and its Subsidiaries compared to other companies of similar size operating in the commercial banking industry in which the Company operates, in which case only the disproportionate effect will be taken into account); (B) effects resulting from worsening of geopolitical conditions in the United States or acts of war, sabotage or terrorism (including any escalation or general worsening of any such acts of war, sabotage or terrorism) in the United States or any other country in which the Company and any of its Subsidiaries conduct material operations; (C) any change in market price or trading volume of Company Common Stock (except to the extent that, with respect to this clause (C), the facts or circumstances giving rise or contributing to such change may be deemed to constitute, or be taken into account in determining whether there has been, a Company Material Adverse Effect, except to the extent such facts or circumstances are themselves excepted from the definition of Company Material Adverse Effect pursuant to any other clause of this definition); (D) any action taken by the Company with Parent\u2019s express written consent or any action taken by the Company that the Company was expressly required to take pursuant to the terms of this Agreement; (E) any failure, in and of itself, by the Company to meet internal or other estimates, predictions, projections or forecasts of revenue, net income or any other measure of financial performance (except to the   -4-   extent that, with respect to this clause (E), the facts or circumstances giving rise or contributing to failure to meet estimates or projections may be deemed to constitute, or be taken into account in determining whether there has been, a Company Material Adverse Effect, except to the extent such facts or circumstances are themselves excepted from the definition of Company Material Adverse Effect pursuant to any other clause of this definition); (F) changes in economic conditions affecting commercial banks generally (except to the extent that with respect to this clause (F), such change in economic condition disproportionately adversely affects the Company and its Subsidiaries, compared to other companies in California of similar size operating in the commercial banking industry in which the Company operates, in which case only the disproportionate effect will be taken into account); (G) for purposes of the condition set forth in Section 6.03(e), those matters disclosed in the Company Disclosure Schedule consistent with the standard set forth in Section 4.01(a) and based on the information on those matters provided on or prior to the date hereof (for the avoidance of doubt, except to the extent of any adverse developments with respect to such matters that arise after the date hereof); or (H) changes in relationships with customers or employees of the Company and its Subsidiaries that were primarily the result of the announcement or public disclosure of this Agreement and the transactions contemplated hereby. (Pages 7-8)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: SECTION 5.2 Conduct of Business by the Company. Except for matters set forth in Section 5.2 of the Company Disclosure Schedule or otherwise expressly permitted or expressly contemplated by this Agreement or required by applicable Law (including COVID-19 Measures) or with the prior written consent of Parent (which shall not be unreasonably withheld, conditioned or delayed), from the date of this Agreement until the Effective Time, or, if earlier, the termination of this Agreement in accordance with its terms, the Company shall, and shall cause each Company Subsidiary to, (i) conduct its business in the ordinary course of business in all material respects (Page 42)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cCompany Superior Proposal\u201d means a Company Takeover Proposal (i) that if consummated would result in a third party <omitted> acquiring, directly or indirectly, <omitted> all or substantially all the assets of the Company and its Subsidiaries, taken as a whole, for consideration consisting of cash and/or securities (Page 78)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: Section 5.4 No Company Solicitation. <omitted> the Company Board may make a Company Change of Recommendation <omitted> if: <omitted> (v) <omitted> Parent has proposed any changes to the terms hereof <omitted> and there is any subsequent amendment to any material term of such Alternative Acquisition Proposal, the Company Board shall provide <omitted> an additional three (3) Business Day period from the date of such notice shall apply (Page 61)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the fundamental representations and warranties be according to the bring down provision?\nOption A: Accurate at another materiality standard (e.g., hybrid standard)\nOption B: Accurate in all material respects\nOption C: Accurate in all respects\n\nMerger Agreement: Section 7.2 Additional Conditions to Obligations of Parent and Merger Sub. The obligations of Parent and Merger Sub to consummate the Merger are subject to the satisfaction at or prior to the Effective Time of the following conditions, any or all of which may be waived exclusively by Parent, in whole or in part, to the extent permitted by applicable Law: (a)            Representations and Warranties of the Company. <omitted>  (iii) all other representations and warranties of the Company set forth in Article IV shall have been true and correct as of the date of this Agreement   and shall be true and correct as of the Closing Date, as though made on and as of the Closing Date (except that representations and warranties that speak as of a specified date or period of time shall have been true and correct only as of such date or period of time), except, in the case of this clause (iii), where the failure of such representations and warranties to be so true and correct (without regard to qualification or exceptions contained therein as to \u201cmateriality\u201d, \u201cin all material respects\u201d or \u201cCompany Material Adverse Effect\u201d) would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. (Pages 43-44)\n\nAnswer by only outputting the letter of the option A, B or C.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of asset deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 6.4           No Solicitation by the Company and Company Change in Recommendation. <omitted>  (f)           <omitted> the Company shall not be entitled to make a Company Change in Recommendation <omitted> unless:   (i)          the Company shall have provided to Parent <omitted> notice (the \u201cCompany Superior Proposal Notice\u201d), <omitted> advising Parent that the Company intends to take such action, <omitted>   (iii)      <omitted> provided, however, that any (1) material revisions to the terms of a Company Superior Proposal or (2) material revisions to a Company Acquisition Proposal that the Company Board had determined no longer constitutes a Company Superior Proposal, shall constitute a new Company Acquisition Proposal and shall in each case require the Company to deliver to Parent a new Company Superior Proposal Notice, except that the references to three Business Days in this Section in this Section 6.4(f) shall be deemed to be two Business Days. (Pages 66-67)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means an event, state of facts, circumstance, change, effect, development, occurrence or combination of the foregoing (an \u201cEffect\u201d) that individually or in the aggregate has had, or would reasonably be expected to have, a material adverse effect on the business, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole; provided that the term Company Material Adverse Effect will not include any Effect to the extent resulting from or arising out of: 102      (A) changes after the date of this Agreement in general business, economic or market conditions in the United States or elsewhere in the world (including changes generally in prevailing interest rates, credit availability and liquidity, currency exchange rates and price levels or trading volumes in the United States or foreign securities or credit markets), changes in political or social conditions, including civil unrest, protests and public demonstrations or any other law, directive, pronouncement or guideline issued by a Governmental Entity, or any outbreak or escalation of hostilities, declared or undeclared acts of war or terrorism, in each case generally affecting the industries in which the Company and its Subsidiaries operate; (B) any changes or developments generally in the industries in which the Company or any of its Subsidiaries are expected to conduct their business from and after the Closing; (C) the announcement or the existence of, compliance with or performance under, this Agreement or the transactions contemplated hereby (provided, however, that the exceptions in this clause (C) shall not apply to any representation or warranty contained in Section 3.3(a) or Section 3.3(c)(i) to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the performance of obligations or satisfaction of conditions under this Agreement); (D) any taking of any action or failure to take an action at the request of Parent or its Affiliates or which is required by the terms of this Agreement; (E) changes in applicable Law, GAAP or accounting standards; (F) floods, hurricanes, tornados, earthquakes, fires or other natural disasters; (G) national or international disasters, acts of God, sabotage, calamities, emergencies, or any escalation or worsening thereof, whether or not occurring or commenced before the date of this Agreement; (H) any epidemic, pandemic or disease outbreak (including COVID-19) and any political or social conditions, including civil unrest, protests and public demonstrations or any other law, directive, pronouncement or guideline issued by a Governmental Entity, the Centers for Disease Control and Prevention or the World Health Organization, \u201csheltering in place,\u201d curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease outbreak (including COVID-19) or any change in such law (including COVID-19 Measures), directive, pronouncement or guideline or interpretation thereof, or the action of any third party arising out of or relating to any of the foregoing, in each case, following the date of this Agreement or any material worsening of such conditions threatened or existing as of the date of this Agreement; 103      (I) any Actions arising from allegations of breach of fiduciary duty or otherwise relating to this Agreement or the transactions contemplated hereby; or (J) failure by the Company to meet any financial projections or forecasts or estimates of revenues, earnings or other financial metrics for any period (provided that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect); except, in each case with respect to clauses (A), (B), (E), (F), (G) and (H), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries are expected to operate from and after the Closing. (Pages 106-108)\nAnswer and only output Yes or No.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: Section 6.03.No Solicitation by the Company. <omitted> the Board of Directors of the Company may <omitted> (iii) following receipt of a Company Superior Proposal after the date of this Agreement and prior to the Company Approval Time (and in no event on or after the Company Approval Time), (A) make a Company Adverse  Recommendation Change <omitted> but in each case referred to in the foregoing clauses (i) through (iii) only if the Board of Directors of the Company determines in good faith by majority vote, after consultation with the Company\u2019s outside legal counsel and a financial advisor of nationally recognized reputation, that the failure to take such action would be reasonably likely to be inconsistent with its duties under Applicable Law. <omitted> (d) <omitted> the Board of Directors of the Company may effect a Company Adverse Recommendation Change involving or relating to the occurrence of a Company Intervening Event if the Board of Directors of the Company determines in good faith, after consultation with the Company\u2019s outside legal counsel and financial advisor, that the failure to take such action would be reasonably likely to be inconsistent with its duties under Applicable Law (Pages 88-89)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Under what circumstances could the Board take actions on a different acquisition proposal notwithstanding the no-shop provision?\nOption A: If failure to take actions would lead to \"breach\" of fiduciary duties\nOption B: If failure to take actions would be \"inconsistent\" with fiduciary duties\nOption C: If failure to take actions would lead to \"reasonably likely/expected breach\" of fiduciary duties\nOption D: If failure to take actions would lead to \"reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: If failure to take actions would lead to \"reasonably likely/expected violation\" of fiduciary duties\nOption F: If taking such actions is \"required to comply\" with fiduciary duties\nOption G: If failure to take actions would lead to \"violation\" of fiduciary duties\nOption H: Under no circumstances could the Board do so.\nOption I: Other circumstances\n\nMerger Agreement: 6.3 No Solicitation by Golden. <omitted> (e)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fNotwithstanding anything in this Agreement to the contrary: \u202f <omitted>\u202f (ii)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fprior to, but not after, the receipt of the Golden Stockholder Approval, Golden and its Representatives may engage in the activities prohibited by Sections 6.3(b)(ii)or 6.3(b)(iii)(and, only with respect to a Golden Competing Proposal that satisfies the requirements in this Section6.3(e)(ii), may solicit, propose, knowingly encourage, or knowingly facilitate any inquiry or the making of any proposal or offer with respect to such Golden Competing Proposal or any modification thereto) with any Person if Golden receives a bona fide written Golden Competing Proposal from such Person that was not solicited at any time following the execution of this Agreement in breach of the obligations set forth in this Section\u202f6.3; provided, however, that (A)no information that is prohibited from being furnished pursuant to Section\u202f6.3(b)may be furnished until Golden receives an executed confidentiality agreement from such Person containing limitations on the use and disclosure of non-public information furnished to such Person by or on behalf of Golden that are no less favorable to Golden in the aggregate than the terms of the Confidentiality Agreement (including standstill restrictions), as determined by the Golden Board in good faith after consultation with its legal counsel; (provided, further, that such confidentiality agreement does not contain provisions that prohibit Golden from providing any information to Labrador in accordance with this Section\u202f6.3 or that otherwise prohibits Golden from complying with the provisions of this Section\u202f6.3), (B)that any such non-public information has previously been made available to, or is made available to, Labrador prior to or concurrently with (or in the case of oral non-public information only, promptly (and in any event within the shorter of one Business Day and 48 hours) after) the time such information is made available to such Person, and (C)prior to taking any such actions, the Golden Board or any committee thereof determines in good faith, after consultation with its financial advisors and outside legal counsel, that such Golden Competing Proposal is, or would reasonably be expected to lead to, a Golden Superior Proposal; (Pages 33-34)\n\nAnswer by only outputting the letter (i.e. A, B, C, D, E, F, G, H, or I) of the relevant option.",
        "output": "H",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of offer could the Board take actions on notwithstanding the no-shop provision?\nOption A: Acquisition Proposal only\nOption B: Superior Offer, or Acquisition Proposal reasonably likely/expected to result in a Superior Offer\n\nMerger Agreement: Section 6.3          No Solicitation of Transactions. <omitted> (b)         Notwithstanding Section 6.3(a), at any time following the date of this Agreement and prior to the time when the Company Stockholder Approval is obtained (and in no event after the Company Stockholder Approval is obtained), in response to a bona fide written Acquisition Proposal received after the date hereof that the Company Board determines in good faith After Consultation constitutes or would reasonably be expected to result in a Superior Proposal, and with respect to which the Company Board determines in good faith After Consultation, that the failure to take such action would be inconsistent with the Company Board\u2019s fiduciary duties to the Company\u2019s stockholders under applicable Law, then the Company and the Representatives of the Company may, subject to compliance with this Section 6.3, (i) engage or participate in discussions or negotiations with, and only with, the Person (or such Person\u2019s representatives) that has made such Acquisition Proposal, and (ii) furnish to the Person (or such Person\u2019s representatives) that has made the Acquisition Proposal information relating to the Company and the Company Subsidiaries or afford access to the business, properties, assets, books, records or the personnel of the Company and the Company Subsidiaries, in each case pursuant to an Acceptable Confidentiality Agreement; provided that the Company did not receive such Acquisition Proposal in connection with or as a result of breaching or violating the terms of this Section 6.3 (other than an isolated, inadvertent and immaterial breach or violation). (Page 38)\n\nAnswer by only outputting a letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: 7.2. Acquisition Proposals. <omitted>   (iv) <omitted> Any material amendment to any Superior Proposal, will be deemed to be a new Superior Proposal for purposes of this Section 7.2(d) and will require a new determination and notice period as referred to in this Section 7.2(d). (Page 53)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: Section 5.3. No Solicitation by the Company.  <omitted>  (e) Prior to the Company taking any action permitted (i) under Section 5.3(d)(i), the Company shall provide Parent with <omitted> notice advising Parent that the Company Board of Directors intends to effect a Change of Recommendation <omitted> With respect to Section 5.3(e)(ii), if there are any material amendments, revisions or changes to the terms of any such Superior Proposal (including any revision to the amount, form or mix of consideration the Company Stockholders would receive as a result of the Superior Proposal), the Company shall notify Parent of each such amendment, revision or change in compliance with Section 5.3(c) and the applicable four (4) Business Day period shall be extended until at least three (3) Business Days after the time that Parent receives notification from the Company of each such revision, and the Company Board of Directors shall not take any such action permitted under Section 5.3(d)(ii) prior to the end of any such period (which period shall expire at 11:59 p.m., Pacific Time, on the applicable day) as so extended in accordance with the terms of this Section 5.3(e). (Page 63)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 7.2 Acquisition Proposals; Change of Recommendation <omitted> the Company Board may: (A) effect a Change of Recommendation (1) if (x) an <omitted> Acquisition Proposal is received by the Company <omitted> or (y) an Intervening Event has occurred,<omitted> (2) the Company Board determines in good faith, after consultation with outside legal counsel, that based on the information then available and after consultation with an independent financial advisor of nationally recognized reputation, that a failure to effect a Change of Recommendation would be inconsistent with the directors\u2019 fiduciary duties under applicable Law and, in the case of an Acquisition Proposal contemplated by clause (A)(1)(x) of this Section 7.2(d)(iii), that such Acquisition Proposal constitutes a Superior Proposal; and/or (B) cause or permit the Company or any of the Company\u2019s Subsidiaries to enter into an Alternative Acquisition Agreement with respect to a Superior Proposal (Pages 73-74)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cSuperior Proposal\u201d means an unsolicited and bona fide written Acquisition Proposal made after the date of this Agreement, that if the transactions or series of related transactions contemplated thereby were consummated would result in a Person or Group (other than Guarantor or any of its Subsidiaries or any Group of which Guarantor or any of its Subsidiaries is a member) becoming the beneficial owner of, directly or indirectly, at least 80 percent of the: (a) total voting power of the equity securities of the Company and its Subsidiaries (or of the surviving entity in a merger involving the Company or the resulting, direct or indirect, parent of the Company or such surviving entity); or (b) consolidated net revenues, net income or total assets of the Company, in each case of the foregoing clauses (a) and (b) of this definition, as of the date of such Acquisition Proposal that the Company Board has determined in good faith, after consultation with outside legal counsel and its financial advisor that (i) if consummated, would result in a transaction more favorable to the Company\u2019s stockholders from a financial point of view than the transactions contemplated by this Agreement (after taking into account any revisions to the terms and conditions of this Agreement proposed by Parent pursuant to Section 6.02(d)(iii)) and (ii) is reasonably likely to be consummated, taking into account any legal, financial, regulatory and financing aspects (including the existence of a financing contingency), and the likelihood and timing of consummation thereof. (Page 22)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.2. Acquisition Proposals. <omitted> Notwithstanding the foregoing or anything to the contrary set forth in this Agreement, prior to the Expiration Date, (x) if an Intervening Event occurs and the Special Committee determines in good faith, after consultation with its outside legal counsel, that failure to effect a Change of Recommendation in light of such Intervening Event would be reasonably likely to be inconsistent with their fiduciary obligations under applicable Law, the Company Board (acting upon the recommendation and direction of the Special Committee) may effect a Change of Recommendation contemplated by clauses (1) or (2) of the definition thereof or (y) if the Company receives, directly or indirectly through one or more of its Representatives, an unsolicited, written, bona fide Acquisition Proposal that the Company Board (acting upon the recommendation of the Special Committee) and the Special Committee concludes in good faith, after consultation with their financial advisor and outside legal counsel, constitutes a Superior Proposal and such Acquisition Proposal did not result from a material breach by the Company of this Section 5.2, the Company Board (acting upon the recommendation of the Special Committee) and the Special Committee may effect a Change of Recommendation and/or terminate this Agreement pursuant to Section 7.3(a) in order to enter into an Alternative Acquisition Agreement providing for such Superior Proposal, and, in the case of either clause (x) or (y): (i) the Company shall have provided prior written notice to Parent, at least three (3) Business Days in advance, that it intends to effect a   Change of Recommendation (a \u201cNotice of Change of Recommendation\u201d) and/or terminate this Agreement pursuant to Section 7.3(a), which notice shall specify in reasonable detail the basis for the Change of Recommendation and/or termination and (A) in the case of a Superior Proposal, the identity of the Person or group of Persons making such Superior Proposal and the material terms thereof, along with a copy of any proposed agreement in respect of such Superior Proposal (or, if there is no such proposed agreement, a written summary of the material terms and conditions of such Superior Proposal); or (B) in the case of an Intervening Event, reasonable detail regarding the Intervening Event;   41   (ii) after providing such notice and prior to effecting such Change of Recommendation and/or terminating this Agreement pursuant to Section 7.3(a), the Company shall have negotiated, and shall have caused its Representatives to be available to negotiate, with Parent and Merger Sub in good faith (to the extent Parent and Merger Sub desire to negotiate) during such three (3) Business Day period (the \u201cNotice Period\u201d) to make such adjustments to the terms and conditions of this Agreement as would obviate the need for the Company to effect a Change of Recommendation and/or terminate this Agreement pursuant to Section 7.3(a); and (iii) following the end of the Notice Period, the Company Board (acting upon the recommendation of the Special Committee) and the Special Committee shall have determined in good faith, after consultation with their outside legal counsel and, with respect to clause (A) below, their financial advisor, taking into account any changes to this Agreement proposed in writing by Parent in response to the Notice of Change of Recommendation, that (A) the Superior Proposal giving rise to the Notice of Change of Recommendation continues to be a Superior Proposal or (B) in the case of an Intervening Event, the failure of the Company Board and the Special Committee to effect a Change of Recommendation would continue to be reasonably likely to be inconsistent with its fiduciary obligations under applicable Law. Any amendment to the financial terms or any other material change to the terms of a Superior Proposal shall require the Company to deliver a new Notice of Change of Recommendation and the Company shall be required to comply again with the requirements of clauses (i) - (iii) above; provided, however, that subsequent to the initial Notice Period, the Notice Period shall be reduced to two (2) Business Days following receipt by Parent of any such new Notice of Change of Recommendation. (Pages 22-23)\n\nAnswer by outputting a singled letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do pandemics or other public health events have to have disproportionate impact to qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, with respect to the BancShares Parties, CIT or the Surviving Bank, as the case may be, any effect, change, event, circumstance, condition, occurrence or development (including such effect, change, event circumstance, condition, occurrence or development with respect to any matter whether or not pending as of the date of this Agreement that causes such matter (even if not a Material Adverse Effect previously) to constitute a Material Adverse Effect thereafter) that, either individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (i) the business, properties, assets, liabilities, results of operations or financial condition of such party and its Subsidiaries taken as a whole (provided, however, that, with respect to this clause (i), Material Adverse Effect shall not be deemed to include the impact of (A) changes, after the date hereof, in U.S. generally accepted accounting principles (\u201cGAAP\u201d) or applicable regulatory accounting requirements, (B) changes, after the date hereof, in laws, rules or regulations (including the Pandemic Measures) of general applicability to companies in the industries in which such party and its Subsidiaries operate, or interpretations thereof by courts or Governmental Entities, (C) changes, after the date hereof, in global,     8      national or regional political conditions (including the outbreak of war or acts of terrorism) or in economic or market (including equity, credit and debt markets, as well as changes in interest rates) conditions affecting the financial services industry generally and not specifically relating to such party or its Subsidiaries (including any such changes arising out of the Pandemic), (D) changes, after the date hereof, resulting from hurricanes, earthquakes, tornados, floods or other natural disasters or from any outbreak of any disease or other public health event (including the Pandemic), (E) public disclosure of the transactions contemplated hereby or actions expressly required by this Agreement or that are taken with the prior written consent of the other party in contemplation of the transactions contemplated hereby, or (F) a decline in the trading price of a party\u2019s common stock or the failure, in and of itself, to meet earnings projections or internal financial forecasts, but not, in either case, including any underlying causes thereof; except, with respect to subclause (A), (B), (C) or (D), to the extent that the effects of such change are materially disproportionately adverse to the business, results of operations or financial condition of such party and its Subsidiaries, taken as a whole, as compared to similar companies in the banking industry) or (ii) the ability of such party to timely consummate the transactions contemplated hereby. (Pages 16-17)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: except <omitted> (iii) as may be consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned); provided that Parent shall be deemed to have consented in writing if it provides no response within five (5) business days after a request by the Company for such consent, <omitted> the Company covenants and agrees with Parent to use commercially reasonable efforts to, and to cause each of its Subsidiaries to use its commercially reasonable efforts to, conduct the business of the Company and its Subsidiaries in all material respects in the ordinary course of business (Page 38)\n\nAnswer and only output A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "When are representations and warranties required to be made according to the bring down provision?\nOption A: At Closing Only\nOption B: At Signing & At Closing\n\nMerger Agreement: Section 6.     Conditions Precedent to Obligations of Marvell, HoldCo, Bermuda Merger Sub and Delaware Merger Sub The obligations  of  Marvell,  HoldCo,  Bermuda  Merger  Sub  and  Delaware  Merger Sub  to  effect  the  Mergers  and  otherwise  consummate  the Contemplated Transactions are subject to the satisfaction (or waiver by Marvell, on behalf of itself, HoldCo, Bermuda Merger Sub and Delaware Merger Sub), at or prior to the Closing, of each of the following conditions:6.1     Accuracy of Representations. (a)     Each of the representations and warranties of the Company contained in this Agreement, other than the Specified Representations, shall have been accurate in all respects as of the date of this Agreement and shall be accurate in all respects as of the Closing Date as if made on and as of the Closing Date (in each case, other than any such representation or warranty made as of a specific earlier date, which shall have been accurate in all respects as of such earlier date), except that any inaccuracies in such representations and warranties will be disregarded if the circumstances giving rise to all such inaccuracies (considered collectively) do not constitute, and would not reasonably be expected to have or result in, a Material Adverse Effect on the Company; provided, however, that, for purposes of determining the accuracy of such representations and warranties as of the foregoing dates: (i) all \u201cMaterial Adverse Effect\u201d and other materiality and similar qualifications limiting the scope of such representations and warranties shall be disregarded; and (ii) any update of or modification to the Company Disclosure Schedule made or purported to have been made on or after the date of this Agreement shall be disregarded. (Page 90)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: provided that, for purposes of the foregoing clause (ii), in no event shall any of the following arising after the date of this Agreement, alone or in combination, or any Effect to the extent any of the foregoing results from any of the following arising after the date of this Agreement, be taken into account in determining whether there shall have occurred a Company Material Adverse Effect: (A) changes in the Company\u2019s stock price or trading volume, in and of themselves (but not, in each case, the underlying cause of such change, unless such underlying cause would otherwise be excepted from this definition); (B) any failure by the Company to meet, or changes to, published revenue, earnings or other financial projections, or any failure by the Company to meet any internal budgets, plans or forecasts of revenue, earnings or other financial projections, in each case in and of itself (but not, in each case, the underlying cause of such failure, unless such underlying cause would otherwise be excepted from this definition); (C) general business, economic or political conditions in the United States or any other country or region in the world, or changes therein; (D) conditions in the financial, credit, banking, capital or currency markets in the United States or any other country or region in the world, or changes therein, including (1) changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries and (2) any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world; (E) changes in general conditions in an industry in which the Acquired Companies operate; (F) acts of hostilities, war, sabotage or terrorism (including any outbreak, escalation or general worsening of any such acts of hostilities, war, sabotage or terrorism) in the United States or any other country or region in the world; (G) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or other natural or man-made disasters or acts of God or weather conditions in the United States or any other country or region in the world, or any escalation of the foregoing; (H) any epidemic, pandemic or other similar outbreak (including continuation or escalation of the COVID-19 pandemic) in the United States or any country or region in the world where the Acquired Companies have material operations, or any escalation of the foregoing; (I) the execution or announcement of this Agreement or the pendency or consummation of the Transactions, including the impact thereof on the relationships, contractual or otherwise, of the Acquired Companies with employees, customers, contractors, lenders, suppliers, vendors or partners, or the identity of Parent or any of its Affiliates as the acquirer of the Company (it being understood and agreed that this clause (I) shall not apply with respect to any representation or warranty the purpose of which is to address the consequences of the execution and delivery of this Agreement or the consummation of the Transactions, or the performance of obligations hereunder or thereunder); (J) (1) any action taken by the Company at the written request of Parent that is not expressly required to be taken by the terms of this Agreement or (2) any action expressly required to be taken by the Company by the terms of this Agreement and that are necessary for purposes of consummating the Merger; (K) changes in Law; (L) changes or proposed changes in GAAP or other accounting standards (or the enforcement or interpretation thereof); and (M) any Transaction Litigation; provided that, in each of the foregoing clauses (C), (D), (E), (F), (G), (H), (K) and (L), such Effects referred to therein may be taken into account to the extent that the Acquired Companies are disproportionally affected relative to other similarly situated companies in the industry in which the Acquired Companies operate, in each case only to the extent of any such incremental disproportionate impact or impacts. (Page 4)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: Section 6.2 Operation of the Company\u2019s Business.   (a) During the Pre-Closing Period: (i) except <omitted> (C) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed) <omitted> the Company shall use its commercially reasonable efforts to (i) conduct in all material respects its business and operations in the ordinary course (Pages 40-41)\n\nAnswer and only output A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: SECTION 5.02.No Solicitation.  <omitted> (b) <omitted> Notwithstanding the foregoing, and only at a time prior to the receipt of the Company Stockholder Approval, the Company may (x) make an Adverse Recommendation Change under clause (A) of the definition thereof in response to an Intervening Event, (y) make an Adverse Recommendation Change under clause (A) of the definition thereof in response to a Superior Proposal or (z) terminate this Agreement pursuant to Section 8.01(f) in response to a Superior Proposal in order to enter into a definitive agreement providing for such Superior Proposal, but in each case only if: (1) the Company Board has received a Superior Proposal that did not result, directly or indirectly, from a breach of Section 5.02 (in the case of the preceding clause (y) or clause (z)), or an Intervening Event has occurred (in the case of the preceding clause (x)); (2) in light of such Superior Proposal (in the case of the preceding clause (y) or clause (z)) or such Intervening Event (in the case of the preceding clause (x)), as the case may be, the Company Board shall have determined in good faith, after consultation with outside legal counsel and consultation with a financial advisor of nationally recognized reputation, that failure to make an Adverse Recommendation Change under clause (A) of the definition thereof (in the case of the preceding clause (y)) or to terminate this Agreement (in the case of the preceding clause (z)) or to make an Adverse Recommendation Change under clause (A) of the definition thereof (in the case of the preceding clause (x)) would reasonably be expected to be inconsistent with its fiduciary duties to the stockholders of the Company under Delaware Law (any such determination, a \u201cWithdrawal Determination\u201d); (3) the Company has notified Parent in writing that it has made a Withdrawal Determination (any such notice, a \u201cTriggering Notice\u201d) and provided Parent unredacted copies of the documents and/or agreements providing for the Superior Proposal (including any other documents or agreements referred to in or to be entered into in connection with the Superior Proposal) or described the Intervening Event in writing in reasonable detail, as the case may be; (4) during the five (5) business days commencing on the date of receipt by Parent of the Triggering Notice (such time period, the \u201cNotice Period\u201d), if requested by Parent, the Company shall have negotiated in good faith with Parent to permit Parent to make a proposal to amend the terms of the Transactions or the Transaction Agreements; (5) at the end of the Notice Period, and taking into account any irrevocable written proposals (including any proposal to amend the terms of the Transactions or the Transaction Agreements) made by Parent since receipt of the Triggering Notice (a \u201cParent Proposal\u201d), such Superior Proposal remains a Superior Proposal and the Company Board has again made a Withdrawal Determination in response to such Superior Proposal or such Intervening Event is continuing and the Company Board has again made a Withdrawal Determination in response to such Intervening Event (it being understood and agreed that if, in light of any Parent Proposal, the Company Board is no longer able to make a Withdrawal Determination with respect to such Superior Proposal or Intervening Event, then the Company shall immediately enter into amendments to the Transaction Agreements with Parent and Sub that embodies the terms of such Parent Proposal); (6) the Company is in compliance in all material respects with Section 5.02 and Parent is not at such time entitled to terminate this Agreement pursuant to Section 8.01(c) or Section 8.01(d)(ii); and (7) the Company (i) has paid prior to or concurrently pays the Termination Fee to Parent pursuant to Section 8.02 and immediately after such termination enters into a definitive agreement providing for such Superior Proposal, in the case of a termination of this Agreement pursuant to the preceding clause (z) or (ii) has set aside for immediate payment, the funds for the fee due under Section 8.02 in the case of an Adverse Recommendation Change pursuant to the preceding clause (x) or (y). The Company acknowledges and agrees that each successive modification to the financial terms or other material terms of an Acquisition Proposal that is determined to be a Superior Proposal, and any material change to the Intervening Event, shall require a new Triggering Notice and a new Notice Period (except that the five (5) business day notice period referred to in the Notice Period shall instead be equal to the longer of (I) three (3) business days and (II) the period remaining under the Notice Period immediately prior to the delivery of such additional notice under this sentence). (Page 53)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "F",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 5.4 Acquisition Proposals.   <omitted>   (d) <omitted> following receipt of a <omitted> Acquisition Proposal <omitted> that the Company Board determines <omitted> constitutes a Superior Proposal, the Company Board may <omitted> make an Adverse Recommendation Change <omitted> if <omitted> (i) (A) the Company shall have provided to Parent <omitted> notice, <omitted> (it being understood and agreed that any amendment to the financial terms or any other material term or condition of such Superior Proposal shall require a new notice and an additional three Business Day period) (Pages 44-45)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in response to an intervening event?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: Other specified standard\n\nMerger Agreement: Section 6.1 Company No Solicitation.  <omitted>    (d) <omitted> (i) the Company Board of Directors may effect a Company Change of Recommendation in response to an Intervening Event or (ii) if the Company Board of Directors determines in good faith, after consultation with its financial advisor and outside legal counsel, in response to an Acquisition Proposal <omitted> that such proposal constitutes a Superior Proposal, and such Acquisition Proposal is not withdrawn, the Company or the Company Board of Directors may (A) make a Company Change of Recommendation <omitted> if (and only if) <omitted> (2) after consultation with its financial advisor and outside legal counsel, the Company Board of Directors determines that the failure to make a Company Change of Recommendation, <omitted> would be reasonably expected to result in a breach of its fiduciary duties under applicable Laws (Pages 54-55)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, or I.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 7.5          Acquisition Proposals. <omitted>  the Company Board or the Hospitality Board may, <omitted> (A) make a Change of Recommendation if an Intervening Event has occurred and if, after consulting with its financial advisor and outside legal counsel, the Company Board or the Hospitality Board determines in good faith that the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law <omitted> make a Change of Recommendation and/or terminate this Agreement pursuant to Section 9.1(c)(i) if the Paired Entities receive an Acquisition Proposal (not resulting from a breach of this Section 7.5) that the Company Board and the Hospitality Board have determined in good faith, after consulting with their financial advisor and outside legal counsel, (x) constitutes a Superior Proposal after having complied with, and giving effect to all of the adjustments which may be offered by Parent pursuant to, this Section 7.5(b) and such Acquisition Proposal is not withdrawn and (y) the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law; (Page 59)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any Effect that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on the financial condition, business or operations of the Company and the Company Subsidiaries, taken as a whole; provided, however, that no Effects to the extent resulting or arising from the following shall be deemed to constitute a Company Material Adverse Effect or shall be taken into account when determining whether a Company Material Adverse Effect exists or has occurred: (a) any changes in United States, regional, global or international economic conditions, including any changes affecting financial, credit, foreign exchange or capital market conditions; (b) any changes in conditions in the business collaboration technology industry; (c) any changes in political, geopolitical, regulatory or legislative conditions in the United States or any other country or region of the world; (d) any changes after the date hereof in GAAP or the interpretation thereof; (e) any changes after the date hereof in applicable Law or the interpretation thereof; (f) any failure by the Company to meet any internal or published projections, estimates or expectations of the Company\u2019s revenue, earnings or other financial performance or results of operations for any period, in and of itself, or any failure by the Company to meet its internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations, in and of itself (it being understood that the facts or occurrences giving rise or contributing to such failure that are not otherwise excluded from this definition of a \u201cCompany Material Adverse Effect\u201d may be taken into account); (g) any acts of terrorism or sabotage, war (whether or not declared), the commencement, continuation or escalation of a war, acts of armed hostility, weather conditions, natural disasters, epidemics or pandemics (including the COVID-19 pandemic) or other force majeure events, including any material worsening of such conditions threatened or existing as of the date hereof; (h) the execution and delivery of this Agreement, the identity of Parent or any Parent Subsidiary, the pendency or consummation of this Agreement, the Mergers and the other Transactions, including the effect thereof on the relationships with current or prospective customers, suppliers, distributors, partners, financing sources, employees or sales representatives, or the public announcement of this Agreement or the Transactions, including any litigation arising out of or relating to this Agreement or the Transactions, in each case only to the extent resulting from the execution and delivery of this Agreement, the identity of Parent or any Parent Subsidiary, the pendency or consummation of this Agreement, the Mergers and the other Transactions, or the   A-5   public announcement of this Agreement and the Transactions, as applicable (provided that this clause (h) shall not apply to any representation or warranty to the extent the purpose of such representation or warranty is to address, as applicable, the consequences resulting from the execution and delivery of this Agreement, the pendency or consummation of this Agreement, the Mergers and the other Transactions); and (i) any action or failure to take any action which action or failure to act is requested in writing by Parent or otherwise expressly required by this Agreement (other than pursuant to Section 5.1(a)); provided that with respect to the exceptions set forth in clauses (a), (b), (c), (d), (e) and (g), if such Effect has had a disproportionate adverse effect on the Company or any Company Subsidiary relative to other companies operating in the business collaboration technology industry, then only the incremental disproportionate adverse effect of such Effect shall be taken into account for the purpose of determining whether a Company Material Adverse Effect exists or has occurred. (Pages 98-99)\nAnswer and only output Yes or No.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: Non-Solicitation; Acquisition Proposals; Change of Recommendation  <omitted>    (c) Change of Recommendation.    (i) <omitted> if a written Acquisition Proposal <omitted> is received by the Company, and the Board of Directors of the Company determines <omitted> that such Acquisition Proposal would, if consummated, constitute a Superior Proposal, the Board of Directors of the Company may <omitted> (x) effect a Change of Recommendation <omitted> ; provided further, that <omitted> Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of Section 6.1(d) and this Section 6.1(c)(i) and require a new Company Notice, except that references in this Section 6.1(c)(i) to \u201cfour (4) Business Days\u201d shall be deemed to be references to \u201cthree (3) Business Days\u201d (Pages 49-50)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: Section 5.3            Solicitation by the Company. <omitted>   the Company Board of Directors may (i) make a Change of Recommendation in response to an Intervening Event, or (ii) following receipt of a bona fide written Competing Proposal, which the Company Board of Directors determines in good faith after consultation with the Company\u2019s outside legal and financial advisors is a Superior Proposal, (A) make a Change of Recommendation <omitted> if and only if the Company Board of Directors has determined in good faith after consultation with the Company\u2019s outside legal counsel that the failure to take such action would be inconsistent with the duties of the members of the Company Board of Directors under applicable Law (Page 27)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cSuperior Proposal\u201d means any bona fide written Acquisition Proposal made by a Third Party that, if consummated, would result in such Third Party\u2019s (or its stockholders\u2019) owning, directly or indirectly, greater than 50% of the equity securities of the Company (or of the shares of the surviving entity in a merger or the direct or indirect parent of the surviving entity in a merger) or greater than 50% of the assets of the Company and Company Subsidiaries, taken as a whole (based on the fair market value thereof, as determined by the Company Board) and that the Company Board determines in good faith after consultation with its financial advisor and its outside legal counsel (x) if consummated, to be more favorable from a financial point of view to the Company\u2019s stockholders (in their capacities as stockholders) than the Merger, taking into account any changes to the terms of this Agreement proposed by Parent in response to such offer or otherwise and (y) after taking into account all financial, legal, financing, regulatory and other terms and conditions of such proposal and of this Agreement, is reasonably likely to be completed on the terms proposed. (Page 30)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: (a) The Company shall, and shall cause each of its Subsidiaries to, from and after the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement <omitted> except (1) as Parent shall otherwise approve in writing (such approval not to be unreasonably withheld, conditioned or delayed), <omitted> conduct its business in the Ordinary Course of Business <omitted> \u201cOrdinary Course of Business\u201d means, with respect to any Person, the conduct of such Person\u2019s business that is consistent in all material respects in nature, scope and magnitude with the past practices of such Person prior to the date of this Agreement (Pages 35-36)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: except <omitted> (iii) as may be consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned); provided that Parent shall be deemed to have consented in writing if it provides no response within five (5) business days after a request by the Company for such consent, <omitted> the Company covenants and agrees with Parent to use commercially reasonable efforts to, and to cause each of its Subsidiaries to use its commercially reasonable efforts to, conduct the business of the Company and its Subsidiaries in all material respects in the ordinary course of business (Page 38)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Under what circumstances could the Board take actions on a different acquisition proposal notwithstanding the no-shop provision?\nOption A: If failure to take actions would lead to \"breach\" of fiduciary duties\nOption B: If failure to take actions would be \"inconsistent\" with fiduciary duties\nOption C: If failure to take actions would lead to \"reasonably likely/expected breach\" of fiduciary duties\nOption D: If failure to take actions would lead to \"reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: If failure to take actions would lead to \"reasonably likely/expected violation\" of fiduciary duties\nOption F: If taking such actions is \"required to comply\" with fiduciary duties\nOption G: If failure to take actions would lead to \"violation\" of fiduciary duties\nOption H: Under no circumstances could the Board do so.\nOption I: Other circumstances\n\nMerger Agreement: SECTION 5.02. Acquisition Proposals. <omitted> (c) Information Exchange; Discussions or Negotiation. Notwithstanding anything to the contrary contained in Section 5.02(a), prior to obtaining the Company Requisite Vote, in the event that the Company, any of its Subsidiaries or its or their Representatives receive from any Person, after the date of this Agreement, an unsolicited, bona fide written Acquisition Proposal that did not result from a breach of this Section 5.02, and that the Company Board determines in good faith, after consultation with its financial advisors and outside legal counsel, is, or is reasonably likely to lead to, a Superior Proposal, the Company may (i) furnish or provide information to the Person making such Acquisition Proposal and its Representatives pursuant to an Acceptable Confidentiality Agreement; provided, however, that the Company shall as promptly as is reasonably practicable (and in any event within one (1) Business Day) make available to Parent and Merger Sub any written material non-public information concerning the Company or its Subsidiaries that is provided to any Person pursuant to this Section 5.02(c)(i), to the extent such information was not previously made available to Parent, Merger Sub or their Representatives, and (ii) engage in discussions and negotiations with such Person and its Representatives with respect to such Acquisition Proposal. (Page 35)\n\nAnswer by only outputting the letter (i.e. A, B, C, D, E, F, G, H, or I) of the relevant option.",
        "output": "H",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: Any amendment to the financial terms or any other material change to the terms of a Superior Proposal shall require the Company to deliver a new Notice of Change of Recommendation <omitted> and the Company shall be required to comply again with the requirements of clauses (i)-(iii) above; provided, however, that references to the four (4) Business Day period above shall then be deemed to be references to a two (2) Business Day period following receipt by Parent of any such new Notice of Change of Recommendation (Page 49)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of offer could the Board take actions on notwithstanding the no-shop provision?\nOption A: Acquisition Proposal only\nOption B: Superior Offer, or Acquisition Proposal reasonably likely/expected to result in a Superior Offer\n\nMerger Agreement: Section 6.03.No Solicitation by the Company. <omitted> (b)     Notwithstanding \u200bSection 6.03(a), if at any time prior to the receipt of the Company Stockholder Approval (the \u201cCompany Approval Time\u201d; it being understood and agreed that the Company Approval Time shall be deemed to have occurred upon delivery of the Written Consent) (and in no event on or after the Company Approval Time), the Board of Directors of the Company receives a bona fide written Company Acquisition Proposal made after the date hereof which has not resulted from a violation of this \u200bSection 6.03, the Board of Directors of the Company may prior to the Company Approval Time (and in no event on or after the Company Approval Time) and, subject to compliance with this \u200bSection 6.03(b), \u200bSection 6.03(c) and \u200bSection 6.03(e), (i) engage in negotiations or discussions with any Third Party that, subject to the Company\u2019s compliance with Section 6.03(a), has made after the date of this Agreement an unsolicited bona fide written Company Acquisition Proposal that the Board of Directors of the Company determines in good faith, after consultation with a financial advisor of nationally recognized reputation and outside legal counsel to the Company, constitutes or is reasonably likely to lead to a Company Superior Proposal, (ii) thereafter furnish to such Third Party and its Representatives and financing sources nonpublic information relating to the Company or any of its Subsidiaries pursuant to a confidentiality agreement with terms (including \u201cstandstill\u201d or similar terms) no less favorable to the Company than those contained in the Company Confidentiality Agreement, a copy of which shall be provided, promptly after its execution, to Parent for informational purposes; <omitted> but in each case referred to in the foregoing clauses (i) through (iii) only if the Board of Directors of the Company determines in good faith by majority vote, after consultation with the Company\u2019s outside legal counsel and a financial advisor of nationally recognized reputation, that the failure to take such action would be reasonably likely to be inconsistent with its duties under Applicable Law. (Page 88)\n\nAnswer by only outputting a letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: Section 5.3 No Solicitation. <omitted> Notwithstanding anything in this Agreement to the contrary, at any time prior to receipt of the Company Stockholder Approval, in response to an Alternative Proposal that did not result from a material breach of this Section 5.3, if the Board of Directors of the Company determines in good faith, after consultation with its financial advisors and outside legal counsel, that (1) such Alternative Proposal constitutes a Superior Proposal and (2) the failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, then (x) the Board of Directors of the Company may effect a Change of Recommendation and/or authorize or cause the Company to take the actions in the following clause (y), and/or (y) the Company may, notwithstanding anything in this Agreement to the contrary, terminate this Agreement and concurrently with such termination enter into a Company Acquisition Agreement with respect to such Superior Proposal, provided that prior to taking any such action: (A) the Company provides Parent four (4) business days\u2019 prior written notice of its intention to take such action, which notice shall include the information with respect to such Superior Proposal that is specified in Section 5.3(b) (it being understood that each time any material revision or amendment to the terms of the Alternative Proposal determined to be a Superior Proposal is made, the four (4) business day period shall be extended for an additional three (3) business days after notification of such change in accordance with Section 5.3(b) and this Section 5.3(d) to Parent); (B) during the applicable period described in clause (A) (the \u201cTakeover Notice Period\u201d), the Company considers and discusses with Parent in good faith any adjustments or modifications to the terms of this Agreement proposed by Parent; and (C) at the end of the Takeover Notice Period, the Board of Directors of the Company again makes the determination in good faith, after consultation with its outside legal counsel and financial advisors (and after taking into account any adjustments or modifications proposed by Parent during the Takeover Notice Period), that the Alternative Proposal continues to be a Superior Proposal (Page 46)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the capitalization representations and warranties be according to the bring down provision?\nOption A: Accurate in all material respects\nOption B: Accurate in all respects\nOption C: Accurate in all respects with below-threshold carveout\nOption D: Accurate in all respects with de minimis exception\n\nMerger Agreement: Section 6.3     Conditions to Obligations of Parent and Merger Sub to Effect the Merger. <omitted> (a)            (i) the representations and warranties of the Company (other than Sections 3.2(a), 3.2(b), 3.2(c), 3.2(d) and 3.2(f)(ii)) set forth in Article III that are qualified by a \u201cCompany Material Adverse Effect\u201d shall be true and correct as so qualified at and as of the Closing Date as if made at and as of such time <omitted> (ii) the representations and warranties of the Company (other than Sections 3.2(a), 3.2(b), 3.2(c), 3.2(d) and 3.2(f)(ii)) set forth in Article III that are not qualified by a \u201cCompany Material Adverse Effect\u201d <omitted> shall be true and correct at and as of the Closing Date as if made at and as of such time (Page 64)\n\nAnswer by only outputting the option letter A, B, C or D.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: provided that the term Company Material Adverse Effect will not include any Effect to the extent resulting from or arising out of: 102      (A) changes after the date of this Agreement in general business, economic or market conditions in the United States or elsewhere in the world (including changes generally in prevailing interest rates, credit availability and liquidity, currency exchange rates and price levels or trading volumes in the United States or foreign securities or credit markets), changes in political or social conditions, including civil unrest, protests and public demonstrations or any other law, directive, pronouncement or guideline issued by a Governmental Entity, or any outbreak or escalation of hostilities, declared or undeclared acts of war or terrorism, in each case generally affecting the industries in which the Company and its Subsidiaries operate; (B) any changes or developments generally in the industries in which the Company or any of its Subsidiaries are expected to conduct their business from and after the Closing; (C) the announcement or the existence of, compliance with or performance under, this Agreement or the transactions contemplated hereby (provided, however, that the exceptions in this clause (C) shall not apply to any representation or warranty contained in Section 3.3(a) or Section 3.3(c)(i) to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the performance of obligations or satisfaction of conditions under this Agreement); (D) any taking of any action or failure to take an action at the request of Parent or its Affiliates or which is required by the terms of this Agreement; (E) changes in applicable Law, GAAP or accounting standards; (F) floods, hurricanes, tornados, earthquakes, fires or other natural disasters; (G) national or international disasters, acts of God, sabotage, calamities, emergencies, or any escalation or worsening thereof, whether or not occurring or commenced before the date of this Agreement; (H) any epidemic, pandemic or disease outbreak (including COVID-19) and any political or social conditions, including civil unrest, protests and public demonstrations or any other law, directive, pronouncement or guideline issued by a Governmental Entity, the Centers for Disease Control and Prevention or the World Health Organization, \u201csheltering in place,\u201d curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease outbreak (including COVID-19) or any change in such law (including COVID-19 Measures), directive, pronouncement or guideline or interpretation thereof, or the action of any third party arising out of or relating to any of the foregoing, in each case, following the date of this Agreement or any material worsening of such conditions threatened or existing as of the date of this Agreement; 103      (I) any Actions arising from allegations of breach of fiduciary duty or otherwise relating to this Agreement or the transactions contemplated hereby; or (J) failure by the Company to meet any financial projections or forecasts or estimates of revenues, earnings or other financial metrics for any period (provided that the exception in this clause (J) shall not prevent or otherwise affect a determination that any event, change, effect, development or occurrence underlying such failure has resulted in, or contributed to, a Company Material Adverse Effect); except, in each case with respect to clauses (A), (B), (E), (F), (G) and (H), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries are expected to operate from and after the Closing. (Pages 106-108)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cCompany Superior Proposal\u201d means a Company Takeover Proposal (i) that if consummated would result in a third party (or in the case of a direct merger between such third party and the Company, the shareholders of such third party) acquiring, directly or indirectly, more than 50% of the voting power of the Company Common Stock or all or substantially all the assets of the Company and its Subsidiaries, taken as a whole, for consideration consisting of cash and/or securities, (ii) that is reasonably capable of being completed, taking into account all financial, legal, regulatory and other aspects of such proposal, including all conditions contained therein, and (iii) that the Company Board determines in good faith, after consultation with legal counsel and its financial advisor (taking into account any changes to this Agreement proposed by Parent as contemplated by Section 5.2), is more favorable to the stockholders of the Company than the consideration to be received by the stockholders of the Company in the Merger. (Page 78)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Except <omitted> as otherwise consented to by Parent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), the Company covenants and agrees that, until the earlier of the Effective Time and the termination of this Agreement pursuant to Article VIII, it shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts to conduct its businesses in the Ordinary Course in all material respects <omitted> \u201cOrdinary Course\u201d means, with respect to an action taken by any Person, that such action is consistent with the ordinary course of business and past practices of such Person (Page 51)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: 6.3 TCF Shareholder Approval.  <omitted> if the Board of Directors of TCF, after receiving the advice of its outside counsel and, with respect to financial matters, its financial advisors, determines in good faith that it would more likely than not result in a violation of its fiduciary duties under applicable law to continue to recommend this Agreement and the Merger, then, prior to the receipt of the Requisite TCF Vote, in submitting this Agreement and the Merger to its shareholders, the Board of Directors of TCF may withhold or withdraw or modify or qualify in a manner adverse to Huntington the TCF Board Recommendation or may submit this Agreement and the Merger to its shareholders without recommendation (each, a \u201cTCF Adverse Recommendation Change\u201d) (Pages 62-63)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "H",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: 7.2. Acquisition Proposals. <omitted>   (iv) <omitted> Any material amendment to any Superior Proposal, will be deemed to be a new Superior Proposal for purposes of this Section 7.2(d) and will require a new determination and notice period as referred to in this Section 7.2(d). (Page 53)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "E",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cKnowledge\u201d <omitted> means <omitted> the actual knowledge of the individuals set forth in Section 1.01 of the Company Disclosure Schedule, (Page 15)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: (d)          Notwithstanding anything in this Section 6.3 to the contrary, but subject to Section 6.3(e), at any time prior to the NIC Stockholder Approval being obtained, the NIC Board of Directors may (i) make a Change of Recommendation (only of the type contemplated by Section 6.3(a)(iv) or Section 6.3(a)(v)) in response to an Intervening Event if the NIC Board of Directors has determined in good faith after consultation with NIC\u2019s outside legal counsel, that the failure to take such action would be reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law or (ii) make a Change of Recommendation (of the type contemplated by Section 6.3(a)(iv) or Section 6.3(a)(v)) and cause NIC to terminate this Agreement pursuant to and in accordance with Section 8.1(h) in order to enter into a definitive agreement providing for an unsolicited Acquisition Proposal received after the date of this Agreement (which, for the avoidance of doubt, did not result from a breach of Section 6.3(a)(i) or (ii) and such Acquisition Proposal is not withdrawn) if the NIC Board of Directors determines in good faith after consultation with NIC\u2019s outside legal counsel and financial advisors that such Acquisition Proposal constitutes a Superior Proposal; provided that notwithstanding anything to the contrary herein, neither NIC nor any NIC Subsidiary shall enter into any NIC Acquisition Agreement unless this Agreement has been terminated in accordance with Section 8.1. (Page 36)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "I",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 6.03.No Solicitation by the Company. <omitted> (b)     Notwithstanding \u200bSection 6.03(a), if at any time prior to the receipt of the Company Stockholder Approval (the \u201cCompany Approval Time\u201d; it being understood and agreed that the Company Approval Time shall be deemed to have occurred upon delivery of the Written Consent) (and in no event on or after the Company Approval Time), the Board of Directors of the Company receives a bona fide written Company Acquisition Proposal made after the date hereof which has not resulted from a violation of this \u200bSection 6.03, the Board of Directors of the Company may prior to the Company Approval Time (and in no event on or after the Company Approval Time) and, subject to compliance with this \u200bSection 6.03(b), \u200bSection 6.03(c) and \u200bSection 6.03(e), <omitted> (iii) following receipt of a Company Superior Proposal after the date of this Agreement and prior to the Company Approval Time (and in no event on or after the Company Approval Time), (A) make a Company Adverse Recommendation Change and/or (B) terminate this Agreement in accordance with \u200bSection 10.01(d)(i) in order to cause the Company to enter into an Alternate Company Acquisition Agreement with respect to a Company Superior Proposal (a \u201cCompany Superior Proposal Termination\u201d), but in each case referred to in the foregoing clauses (i) through (iii) only if the Board of Directors of the Company determines in good faith by majority vote, after consultation with the Company\u2019s outside legal counsel and a financial advisor of nationally recognized reputation, that the failure to take such action would be reasonably likely to be inconsistent with its duties under Applicable Law. Nothing contained herein shall prevent the Board of Directors of the Company from (A) complying with Rule 14e-2(a) under the Securities Exchange Act with regard to a Company Acquisition Proposal, so long as any action taken or statement made to so comply is consistent with this \u200bSection 6.03 or (B) making any required disclosure to the stockholders of the Company if the Board of Directors of the Company determines in good faith, after consultation with its outside legal counsel, that failure to take such action would be reasonably likely to be inconsistent with Applicable Law; provided that any Company Adverse Recommendation Change involving or relating to a Company Acquisition Proposal and/or Company Superior Proposal Termination may only be made in accordance with the provisions of this \u200bSection 6.03(b), \u200bSection 6.03(c) and \u200bSection 6.03(e) and, even if permitted by this sentence, shall have the consequences set forth in this Agreement. For the avoidance of doubt, issuing a \u201cstop, look and listen\u201d disclosure or similar communication of the type contemplated by Rule 14d-9(f) under the Securities Exchange Act shall not be a Company Adverse Recommendation Change. <omitted> (d) Notwithstanding anything in this Agreement to the contrary, at any time prior to the Company Approval Time (and in no event on or after the Company Approval Time), the Board of Directors of the Company may effect a Company Adverse Recommendation Change involving or relating to the occurrence of a Company Intervening Event if the Board of Directors of the Company determines in good faith, after consultation with the Company\u2019s outside legal counsel and financial advisor, that the failure to take such action would be reasonably likely to be inconsistent with its duties under Applicable Law; provided that (i) the Company shall (A) promptly notify Parent in writing of its intention to take such action (which notice shall set forth in reasonable detail a description of the Company Intervening Event and the rationale for the Company Adverse Recommendation Change) and (B) negotiate in good faith with Parent (to the extent Parent wishes to so negotiate) for five (5) Business Days following such notice regarding revisions to the terms of this Agreement proposed by Parent, and(ii) the Board of Directors of the Company shall not effect any Company Adverse Recommendation Change involving or relating to a Company Intervening Event unless, after the five (5) Business Day period described in the foregoing clause (B), the Board of Directors of the Company determines in good faith by majority vote, after consultation with the Company\u2019s outside legal counsel and financial advisor, that the failure to take such action would be reasonably likely to be inconsistent with its duties under Applicable Law. (Pages 88-89)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section  5.4    Shareholders Meeting. <omitted>  the Company Board, after consultation with its financial advisor and outside counsel, determines in good faith that (a) an Acquisition Proposal constitutes a Superior Proposal and (b) it is reasonably likely that to continue to recommend this Agreement to its shareholders in light of such Acquisition Proposal would result in a violation of its fiduciary duties under the MBCA, then, in submitting this Agreement at the Company Shareholders Meeting, the Company Board may make an Adverse Recommendation or publicly propose or resolve to make an Adverse Recommendation. (Page 40)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: WHEREAS, the Parties intend that <omitted> Merger Sub shall commence a cash tender offer to acquire any and all of the outstanding Shares (as defined below) of the Company for $72.00 per share (such amount, or any other amount per share paid in such offer in accordance with this Agreement, the \u201cOffer Price\u201d), net to the seller in cash <omitted> Each Share issued and outstanding immediately prior to the Effective Time <omitted> shall be converted automatically into and shall thereafter represent only the right to receive the Offer Price, net to the seller in cash, without interest (the \u201cMerger Consideration\u201d) (Page 30)\n\nAnswer and only output A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cknowledge\u201d <omitted> means the actual knowledge of any of the individuals listed in Section 10.5(p) of the Company Disclosure Letter (Page 83)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.3            Solicitation by the Company. <omitted> (d)           Notwithstanding anything in this Section 5.3 or Section 5.4 to the contrary, at any time prior to the receipt of the Company Stockholder Approval, the Company Board of Directors may (i) make a Change of Recommendation in response to an Intervening Event, or (ii) following receipt of a bona fide written Competing Proposal, which the Company Board of Directors determines in good faith after consultation with the Company\u2019s outside legal and financial advisors is a Superior Proposal, (A) make a Change of Recommendation or (B) if such Competing Proposal did not result from a breach of Section 5.3(a), terminate this Agreement pursuant to Section 8.1(g) in order to enter into a definitive agreement providing for such Superior Proposal, in each case with respect to clauses (i) and (ii), if and only if the Company Board of Directors has determined in good faith after consultation with the Company\u2019s outside legal counsel that the failure to take such action would be inconsistent with the duties of the members of the Company Board of Directors under applicable Law and the Company complies with Section 5.3(e). (Page 27)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: Section 5.1      Conduct of Business by the Company and Parent.   (a)           From and after the date hereof and prior to the Effective Time or the date, if any, on which this Agreement is earlier terminated pursuant to Section 7.1 (the \u201cTermination Date\u201d), except (i) as may be required by applicable Law or any Governmental Entity of competent jurisdiction, (ii) for any actions taken reasonably and in good faith to respond to COVID-19 Measures (provided that prior to taking any material actions that the Company intends to take, to the extent the Company intends to take such actions in reliance on this clause (ii), the Company will use commercially reasonable efforts to provide advance notice to and consult with Parent (if reasonably practicable) prior to taking such actions), (iii) as may be consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned); provided that Parent shall be deemed to have consented in writing if it provides no response within five (5) business days after a request by the Company for such consent, (iv) as may be required or expressly contemplated by this Agreement, or (v) as otherwise set forth in Section 5.1 of the Company Disclosure Schedule, the Company covenants and agrees with Parent to use commercially reasonable efforts to, and to cause each of its Subsidiaries to use its commercially reasonable efforts to, conduct the business of the Company and its Subsidiaries in all material respects in the ordinary course of business and, to the extent consistent therewith, use commercially reasonable efforts to preserve its assets and business organization intact in all material respects; (Page 38)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cKnowledge\u201d means (i) with respect to the Company, the actual knowledge, after reasonable inquiry, of each individual listed in Section 1.1(a) of the Company Disclosure Letter, (Page 16)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the fundamental representations and warranties be according to the bring down provision?\nOption A: Accurate at another materiality standard (e.g., hybrid standard)\nOption B: Accurate in all material respects\nOption C: Accurate in all respects\n\nMerger Agreement: CONDITIONS TO THE OFFER <omitted>  (c) (i) other than the representations and warranties listed in clauses (d)(ii) and (d)(iii) in this ANNEX I, the representations and warranties of the Company Parties set forth in the Agreement will be true and correct (without giving effect to any materiality or Company Material Adverse Effect qualifications set forth therein) as of the Expiration Time as if made at and as of the Expiration Time (except to the extent that any such representation and warranty expressly speaks as of an earlier date, in which case such representation and warranty will be true and correct as of such earlier date), except for such failures to be true and correct that would not have a Company Material Adverse Effect; (Page 104)\n\nAnswer by only outputting the letter of the option A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 6.3 No Solicitation by Golden. <omitted> the Golden Board may effect a Golden Change of Recommendation; provided, however, that such a Golden Change of Recommendation may not be made unless and until: \u202f (A)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fthe Golden Board determines in good faith after consultation with its financial advisors and outside legal counsel that such Golden Competing Proposal is a Golden Superior Proposal; \u202f (B)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fthe Golden Board determines in good faith, after consultation with its outside legal counsel, that failure to effect a Golden Change of Recommendation in response to such Golden Superior Proposal would be inconsistent with the fiduciary duties owed by the Golden Board to the stockholders of Golden under applicable Law; \u202f<omitted>  in response to a Golden Intervening Event <omitted> Golden may <omitted> effect a Golden Change of Recommendation; provided, however, that such a Golden Change of Recommendation may not be made unless and until: \u202f<omitted>\u202fthe Golden Board determines in good faith, after consultation with its outside legal counsel, that failure to effect a Golden Change of Recommendation in response to such Golden Intervening Event would be inconsistent with the fiduciary duties owed by the Golden Board to the stockholders of Golden under applicable Law; (Pages 34-35)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: 6.3 Stockholders' Approvals.  <omitted>    (b) <omitted> each of the Boards of Directors of BancShares and CIT may submit this Agreement to its stockholders without recommendation (which, for the avoidance of doubt, shall constitute a Recommendation Change) <omitted> if, but only if, <omitted> (2) BancShares or CIT, as applicable, delivers to the other party at least four (4) business days\u2019 prior written notice of its intention to take such action, <omitted> in the event that, following delivery of the notice referred to in sub-clause (2) above, there is any material revision to the terms of such Acquisition Proposal, including, any revision in price, the four (4) business day period during which the parties agree to negotiate in good faith shall be extended, if applicable, to ensure that at least two (2) business days remain to negotiate subsequent to the time BancShares or CIT, as applicable, notifies the other party of any such material revision (it being understood that there may be multiple extensions)). (Page 58)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 6.3          No Solicitation by NIC. <omitted>  With respect to Section 6.3(e)(ii), i f there are any material amendments, revisions, or changes to the material terms of any such Superior Proposal (including any revision to the amount, form, or mix of consideration NIC Stockholders would receive as a result of the Superior Proposal), NIC shall notify Tyler of each such amendment, revision, or change in compliance with Section 6.3(c) and the applicable four-Business Day period shall be extended until at least two Business Days after the time that Tyler receives notification from NIC of each such revision, and the NIC Board of Directors shall not take any such action permitted under Section 6.3(d)(ii) prior to the end of any such period (which period shall expire at 11:59 p.m., Central Time, on the applicable day) as so extended in accordance with the terms of this Section 6.3(e). (Page 37)\n\nAnswer by outputting a singled letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: Section 5.3 Company Acquisition Proposals. <omitted>  (e) <omitted> the Company may make a Company Adverse Recommendation Change <omitted> and concurrently enter into a binding definitive agreement to effect such Company Superior Proposal.   (f) The Company Board shall not take any action set forth in Section 5.3(e) unless the Company has (i) provided <omitted> notice to Parent (a \u201cNotice of Company Superior Proposal\u201d) <omitted> provided, however, that if during the Company Superior Proposal Notice Period any revisions are made to a Company Acquisition Proposal and such revisions are material (it being understood and agreed that any change to consideration with respect to such proposal is material), the Company shall deliver a new Notice of Company Superior Proposal to Parent <omitted> (except that the \u201cfour (4) Business Day\u201d period referred to in clause (ii) of this proviso shall instead be a two (2) Business Day period). (Page 59)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cknowledge\u201d of any Party means <omitted>  the actual knowledge of Matt Gallagher, Ryan Dalton, David Dell\u2019Osso, Stephanie Reed and Colin Roberts. (Page 109)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: Section 5.3 No Solicitation. <omitted> the Board of Directors of the Company may effect a Change of Recommendation <omitted> provided that prior to taking any such action: (A) the Company provides Parent <omitted> prior written notice of its intention to take such action <omitted> (it being understood that each time any material revision or amendment to the terms of the Alternative Proposal determined to be a Superior Proposal is made, the four (4) business day period shall be extended for an additional three (3) business days after notification of such change in accordance with Section 5.3(b) and this Section 5.3(d) to Parent) (Page 46)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the capitalization representations and warranties be according to the bring down provision?\nOption A: Accurate in all material respects\nOption B: Accurate in all respects\nOption C: Accurate in all respects with below-threshold carveout\nOption D: Accurate in all respects with de minimis exception\n\nMerger Agreement: 7.2           Conditions to Obligations of SVB Financial.  <omitted>  All other representations and warranties of Boston Private set forth in this Agreement <omitted> shall be true and correct in all respects as of the date of this Agreement and <omitted> as of the Closing Date as though made on and as of the Closing Date (Page 77)\n\nAnswer by only outputting the option letter A, B, C or D.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the Tail Period?\nOption A: 12 months or longer\nOption B: Other\nOption C: within 12 months\nOption D: within 6 months\nOption E: within 9 months\n\nMerger Agreement: Section 6.2               Effect of Termination; Termination Fees. <omitted> (b)                In the event that: <omitted> (ii)               this Agreement is validly terminated <omitted> (B) <omitted> the Company enters into a definitive Contract with respect to an Acquisition Proposal or consummates an Acquisition Proposal (which need not be the same Acquisition Proposal that was made, announced or publicly known prior to the termination of this Agreement) (Page 29)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: except <omitted> (w) with the prior written consent of Parent (which consent shall not be unreasonably conditioned, withheld or delayed), <omitted> the Company shall <omitted> ensure that the business and operations of the Acquired Companies are conducted in the ordinary course of business in accordance with past practices and in compliance with all then- applicable Law. (Page 48)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: 7.5          Acquisition Proposals. <omitted> (b )          No Change in Recommendation or Alternative Acquisition Agreement .  Except as permitted in this Section 7.5(b), neither the Company Board, the Hospitality Board nor any of their committees shall:   (i)          (A) withhold, withdraw, qualify or modify (or publicly propose or resolve to withhold, withdraw, qualify or modify), in a manner adverse to Parent, the Company Board Recommendation or the Hospitality Board Recommendation, (B) authorize, approve, adopt or recommend or otherwise declare advisable (or publicly propose or resolve to authorize, approve, adopt or recommend or otherwise declare advisable) any Acquisition Proposal or (C) fail to include the Company Board Recommendation and the Hospitality Board Recommendation in the Joint Proxy Statement (either of the foregoing, a \u201cChange of Recommendation\u201d); or   ( i i )         except as expressly permitted by, and after compliance with this Section 7.5, authorize, approve, adopt or recommend or otherwise declare advisable (or publicly propose or resolve to authorize, approve, adopt or recommend or otherwise declare advisable), or cause or permit any Paired Entity or any Paired Entities Subsidiary to enter into, any Alternative Acquisition Agreement (other than an Acceptable Confidentiality Agreement entered into in compliance with Section 7.5(a)).   Notwithstanding anything to the contrary set forth in this Agreement, the Company Board or the Hospitality Board may, prior to but not after the time the Requisite Vote is obtained, (A) make a Change of Recommendation if an Intervening Event has occurred and if, after consulting with its financial advisor and outside legal counsel, the Company Board or the Hospitality Board determines in good faith that the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law or (B) if the Paired Entities have not breached this Section 7.5(c) and have not breached the other subsections of this Section 7.5 in any material respect, make a Change of Recommendation and/or terminate this Agreement pursuant to Section 9.1(c)(i) if the Paired Entities receive an Acquisition Proposal (not resulting from a breach of this Section 7.5) that the Company Board and the Hospitality Board have determined in good faith, after consulting with their financial advisor and outside legal counsel, (x) constitutes a Superior Proposal after having complied with, and giving effect to all of the adjustments which may be offered by Parent pursuant to, this Section 7.5(b) and such Acquisition Proposal is not withdrawn and (y) the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law; provided that neither the Company Board nor the Hospitality Board may take any such action unless prior to making such Change of Recommendation or authorizing such termination to enter into a definitive written agreement providing for the implementation of such Superior Proposal pursuant to Section 9.1(c)(i), (I) the Paired Entities provide prior written notice (\u201cNotice Period Commencement Notice\u201d) to Parent at least four (4) Business Days in advance (the \u201cNotice Period\u201d) of their intention to take such action, which notice shall include, in the case of a Superior Proposal, the name of the person or group making the Superior Proposal and substantial final draft of the definitive agreement reflecting such Superior Proposal and, in the case of an Intervening Event, a reasonably detailed description of such Intervening Event, (II) if requested by Parent, during the Notice Period the Paired Entities shall, and shall direct their Representatives to, negotiate with Parent in good faith should Parent propose to make amendments or other revisions to the terms and conditions of this Agreement such that, in the case of a Superior Proposal, such Acquisition Proposal no longer constitutes a Superior Proposal and, in the case of an Intervening Event, the failure to take such action is no longer reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law as determined in the good faith judgment of the Company Board or the Hospitality Board after consulting with their financial advisor and outside legal counsel and (III) the Company Board and the Hospitality Board has taken into account any amendments or other revisions to the terms and conditions of this Agreement agreed to by Parent in writing prior to the end of the Notice Period and (1)  the Company Board and the Hospitality Board determined in good faith that, after consulting with its financial advisor and outside legal counsel, in the case of an Intervening Event, a failure to make such Change of Recommendation continues to be reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law and (2) the Company Board and the Hospitality Board determined in good faith that, after consulting with their financial advisor and outside legal counsel, in the case of an Acquisition Proposal, the Acquisition Proposal giving rise to such Change of Recommendation continues to constitute a Superior Proposal and the failure to make such Change of Recommendation continues to be inconsistent with the directors\u2019 fiduciary duties under applicable Law; it being understood that any change to the financial terms or any other material amendments or other material revisions to any Acquisition Proposal will be deemed to be a new Acquisition Proposal, including for purposes of the Notice Period; provided, however, that, subsequent to the initial Notice Period, the Notice Period shall be reduced to two (2) Business Days following receipt by Parent of any such new Notice Period Commencement Notice. (Page 59)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the capitalization representations and warranties be according to the bring down provision?\nOption A: Accurate in all material respects\nOption B: Accurate in all respects\nOption C: Accurate in all respects with below-threshold carveout\nOption D: Accurate in all respects with de minimis exception\n\nMerger Agreement: Section 7.2. Conditions to Obligations of Parent. The obligations of Parent, Merger Sub I and Merger Sub II to consummate the Mergers shall be subject to the satisfaction on or prior to the Closing Date of each of the following conditions, any and all of which may be waived in whole or in part by Parent, Merger Sub I and Merger Sub II, as the case may be, to the extent permitted by applicable Law: <omitted> (D) the other representations and warranties of the Company set forth in this Agreement (without giving effect to any qualification as to materiality or Company Material Adverse Effect contained therein) shall be true and correct as of the date hereof and shall be true and correct as of the Closing as though made as of the Closing (except representations and warranties that by their terms speak specifically as of another date, in which case as of such date), except, with respect to this clause (D), where any failures of any such representations and warranties to be true and correct (without giving effect to any qualification as to materiality or Company Material Adverse Effect contained therein) have not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. (Page 82)\n\nAnswer by only outputting the option letter A, B, C or D.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cAcquisition Proposal\u201d shall mean any bona fide written offer, indication of interest or proposal relating to an Acquisition Transaction (other than an offer or proposal by Parent or one of the Company Subsidiaries) contemplating or otherwise relating to any Acquisition Transaction.   A-2   \u201cAcquisition Transaction\u201d shall mean any transaction or series of related transactions (other than the Transactions) involving: (a) any merger, consolidation, share exchange, business combination, issuance of securities, direct or indirect acquisition of securities, recapitalization, tender offer, exchange offer or other similar transaction in which (i) a Person or \u201cgroup\u201d (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires, or if consummated in accordance with its terms would acquire, beneficial or record ownership of securities representing more than 20% of the outstanding shares of any class of voting securities of the Company; or (ii) the Company issues securities representing more than 20% of the outstanding shares of any class of voting securities of the Company; (b) any direct or indirect sale, lease, exclusive license, exchange, transfer, acquisition or disposition of any assets of the Company and the Company Subsidiaries that constitute or account for (i) 20% or more of the consolidated net revenues of the Company, consolidated net income of the Company or consolidated book value of the Company; or (ii) 20% or more of the fair market value of the assets of the Company; or (c) any liquidation or dissolution of the Company  <omitted>  \u201cSuperior Proposal\u201d shall mean a bona fide written Acquisition Proposal that if consummated would result in a Person or group (or the shareholders of any Person) owning, directly or indirectly, (a) more than 50% of the outstanding Shares of the Company Common Stock or (b) more than 50% of the assets of the Company and the Company Subsidiaries, taken as a whole, in either case, which the Company Board determines in good faith (after consultation with its financial advisor and outside counsel): (i) to be reasonably likely to be consummated if accepted; and (ii) if consummated, would result in a transaction more favorable to the Company\u2019s stockholders from a financial point of view than the Offer and the Merger, in each case, taking into account at the time of determination all relevant circumstances, including the various legal, financial and regulatory aspects of the proposal, all the terms and conditions of such proposal and this Agreement, any changes to the terms of this Agreement offered by Parent in response to such Acquisition Proposal, the identity of the Person making the Acquisition Proposal, and the anticipated timing, conditions and the ability of the Person making such Acquisition Proposal to consummate the transactions contemplated by such Acquisition Proposal (based upon, among other things, expectation of obtaining required approvals or any necessary financing). (Page 77)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means with respect to any Person, any effect, circumstance, occurrence or change that is material and adverse to the financial position, results of operations or business of such Person and its Subsidiaries, taken as a whole, or which would materially impair the ability of such Person to perform its obligations under this Agreement or otherwise materially impairs the ability of such Person to consummate the transactions contemplated hereby; provided, however, that Material Adverse Effect shall not be deemed to include the impact of (a) changes in banking and similar Laws of general applicability or interpretations thereof by Governmental Authorities, (b) changes in GAAP or regulatory accounting requirements applicable to banks or bank holding companies generally, (c) changes after the date of this Agreement in general economic or capital market conditions affecting financial institutions or their market prices generally, including, but not limited to, changes in levels of interest rates generally and any change in the value of deposits, borrowings or loan service rights associated therewith, (d) the effects of any action or omission taken by First Choice or any First Choice Subsidiary with the prior consent of Enterprise, and vice versa, or as otherwise expressly permitted or contemplated by this Agreement; (e) the impact of the Agreement and the transactions contemplated hereby, including the impact of any public announcement thereof, on relationships with customers or employees (including the loss of personnel subsequent to the date of this Agreement); (f) changes in national or international political or social conditions including the engagement by the United States in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon or within the United States, and any national or global epidemic, pandemic or disease outbreak (including COVID-19), or the worsening of such conditions threatened or existing as of the date of this Agreement; (g) the failure, in and of itself, to meet earnings projections or internal financial forecasts, but not including the underlying causes thereof (unless otherwise excluded hereunder); (h) any actual or threatened Legal Proceeding against First Choice and/or the members of the First Choice Board related to this Agreement and the disposition, adjudication or settlement thereof; and (i) natural disaster or other force majeure event; provided, further, that any effect, circumstance, occurrence or change referred to in clauses (a), (b), (c), and (f)  above shall be taken into account in determining whether a Material Adverse Effect has occurred to the extent such effect, circumstance, occurrence or change has disproportionally affected First Choice and First Choice Subsidiaries or Enterprise and Enterprise Subsidiaries, as applicable, as compared to similarly situated participants in the banking industry. For the avoidance of doubt, any changes in any program administered by or related to the SBA under which First Choice participates, including, without limitation, any changes in any Laws   96   applicable or relating thereto (or any interpretations of any such Laws), that would (A) eliminate or materially limit or impair the ability of First Choice or any First Choice Subsidiary to originate or service Loans under any such program, or (B) eliminate or materially limit or impair Loan guarantees under such program, whether on a prospective or retroactive basis, in each case shall be deemed a \u201cMaterial Adverse Effect\u201d with respect to First Choice and its Subsidiaries, taken as a whole. (Pages 101-102)\nAnswer and only output Yes or No.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: except or with the prior written consent of Parent (such consent not to be unreasonably withheld, delayed or conditioned), from the date of this Agreement to the earlier of the termination of this Agreement and the Effective Time, the Company shall, and shall cause its Subsidiaries to, conduct its business in the ordinary course of business consistent with past practice in all material <omitted> respects (Pages 47-48)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 7.2 Company Acquisition Proposals. <omitted> (f) Prior to making any Company Adverse Recommendation Change <omitted> : (i) the Company Board shall provide Parent at least four Business Days\u2019 prior written notice of its intention to take such action <omitted> (it being understood and agreed that any material amendments or other material revisions to any Company Acquisition Proposal that was previously the subject of a notice hereunder will be deemed to be a new Company Acquisition Proposal, and shall require a new notice to Parent as provided above, but, with respect to any subsequent notice, references herein to \u201cfour Business Days\u201d shall be deemed references to \u201ctwo Business Days\u201d). (Page 76)\n\nAnswer by outputting a singled letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the Tail Period?\nOption A: 12 months or longer\nOption B: Other\nOption C: within 12 months\nOption D: within 6 months\nOption E: within 9 months\n\nMerger Agreement: 8.3           Expenses and Other Payments.  <omitted>  (e)               If (i) (A) Parent or the Company terminates this Agreement  <omitted>  (ii) <omitted>  the Company enters into a definitive agreement with respect to a Company Competing Proposal (or publicly approves or recommends to the stockholders of the Company or otherwise does not oppose, in the case of a tender or exchange offer, a Company Competing Proposal) or consummates a Company Competing Proposal (Page 85)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: Section 6.02. Acquisition Proposals; Change of Recommendation. <omitted> (d) No Change of Recommendation or Alternative Acquisition Agreement.  <omitted>  (iii) Notwithstanding anything to the contrary set forth in this Section 6.02(d), prior to the Offer Acceptance Time, if there has not been a breach of the Company\u2019s obligations set forth in this Section 6.02, the Company Board may: (A) effect a Change of Recommendation (1) if an (x) unsolicited, bona fide written Acquisition Proposal is received by the Company and has not been withdrawn or (y) Intervening Event has occurred, and (2) the Company Board determines in good faith, after consultation with outside legal counsel,   -68-   that a failure to effect a Change of Recommendation would be inconsistent with the directors\u2019 fiduciary duties under applicable Law and, in the case of an Acquisition Proposal contemplated by clause (A)(1)(x) of this Section 6.02(d)(iii), after consultation with its financial advisor, that such Acquisition Proposal constitutes a Superior Proposal; and/or (B) cause or permit the Company or any of the Company\u2019s Subsidiaries to enter into an Alternative Acquisition Agreement with respect to a Superior Proposal (and the Company may enter into or cause one of its Subsidiaries to enter into such an Alternative Acquisition Agreement) or agree, authorize or commit to do so; provided, however, that no such actions may be taken unless and until: (I) the Company has given Parent written notice at least four Business Days in advance (the \u201cNotice Period\u201d), which notice shall set forth in writing that the Company Board intends to consider whether to take such action and a reasonably detailed description of the basis therefor, and shall also include, (y) in the case of such an Acquisition Proposal, all information required by Section 6.02(c), mutatis mutandis, and (z) in the case of an Intervening Event, a reasonably detailed description of such Intervening Event; (II) during the Notice Period, to the extent requested by Parent, the Company shall, and shall cause its Representatives to, negotiate in good faith with Parent to revise this Agreement so that the conditions set forth in clauses (A)(2) of this Section 6.02(d)(iii) would not be satisfied or such Alternative Acquisition Agreement contemplated by clause (B) of this Section 6.02(d)(iii) would no longer be with respect to a Superior Proposal, as applicable; and (III) at the end of the Notice Period, the Company Board shall have taken into account any revisions to this Agreement proposed by Parent in writing in response to such notice contemplated by clause (I) of this 6.02(d)(iii) prior to the end of the Notice Period, and shall have thereafter determined in good faith, after consultation with outside legal counsel, that a failure to effect a Change of Recommendation would continue to be inconsistent with the directors\u2019 fiduciary duties under applicable Law, or that such Alternative Acquisition Agreement contemplated by clause (B) of this Section 6.02(d)(iii), after consultation with its financial advisor, continues to be an Alternative Acquisition Agreement with respect to a Superior Proposal, as the case may be (it being understood that (y) any revisions to any Acquisition Proposal shall be deemed to be a new Acquisition Proposal for purposes of Section 6.02(c) and this Section 6.02(d)(iii), including for purposes of the Notice Period, except that subsequent to the initial Notice Period, the Notice Period shall be reduced to two Business Days and (z) prior to the Company or any of its Subsidiaries entering into an Alternative Acquisition Agreement contemplated by clause (B) of this Section 6.02(d)(iii), the Company shall have terminated this Agreement and abandoned the transactions contemplated by this Agreement pursuant to Section 8.03(b)). (Pages 73-74)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 6. 4          Shareholders\u2019 Approvals. Each of BancorpSouth and Cadence shall call, give notice of, convene and hold a meeting of its shareholders <omitted> for the purpose of obtaining <omitted> (b) if so desired and mutually agreed, a vote upon other matters of the type customarily brought before a meeting of shareholders in connection with the approval of a merger agreement or the transactions contemplated thereby, and each of Cadence and BancorpSouth shall use its reasonable best efforts to cause such meetings to occur as soon as reasonably practicable and on the same date and at the same time, and to set the same record date for each such meeting. Each of BancorpSouth and Cadence and their respective Boards of Directors shall use its reasonable best efforts to obtain from the shareholders of BancorpSouth and Cadence, respectively, the Requisite BancorpSouth Vote and the Requisite Cadence Vote, respectively, including by communicating to the respective shareholders of BancorpSouth and Cadence its recommendation (and including such recommendation in the Joint Proxy Statement) that, in the case of BancorpSouth, the shareholders of BancorpSouth approve this Agreement (the \u201cBancorpSouth Board Recommendation\u201d), and in the case of Cadence, that the shareholders of Cadence approve this Agreement (the \u201cCadence Board Recommendation\u201d), BancorpSouth and each of BancorpSouth and Cadence and their respective Boards of Directors shall not (i) withhold, withdraw, modify or qualify in a manner adverse to the other party the BancorpSouth Board Recommendation, in the case of BancorpSouth, or the Cadence Board Recommendation, in the case of Cadence, (ii) fail to make the BancorpSouth Board Recommendation, in the case of BancorpSouth, or the Cadence Board Recommendation, in the case of Cadence, in the Joint Proxy Statement, (iii) adopt, approve, recommend or endorse an Acquisition Proposal or publicly announce an intention to adopt, approve, recommend or endorse an Acquisition Proposal, (iv) fail to publicly and without qualification (A) recommend against any Acquisition Proposal, or (B) reaffirm the BancorpSouth Board Recommendation, in the case of BancorpSouth, or the Cadence Board Recommendation, in the case of Cadence, in each case, within ten (10) business days (or such fewer number of days as remains prior to the BancorpSouth Meeting or the Cadence Meeting, as applicable) after an Acquisition Proposal is made public or any request by the other party to do so, or (v) publicly propose to do any of the foregoing (any of the foregoing a \u201cRecommendation Change\u201d). However, subject to Section 8.1 and Section 8.2, if the Board of Directors of BancorpSouth or Cadence, after receiving the advice of its outside counsel and, with respect to financial matters, its financial advisors, determines in good faith that it would more likely than not result in a violation of its fiduciary duties under applicable law to make or continue to make the BancorpSouth Board Recommendation or the Cadence Board Recommendation, as applicable, such Board of Directors may, in the case of BancorpSouth, prior to the receipt of the Requisite BancorpSouth Vote, and in the case of Cadence, prior to the receipt of the Requisite Cadence Vote, submit this Agreement to its shareholders without recommendation (although the resolutions approving this Agreement as of the date hereof may not be rescinded or amended), in which event such Board of Directors may communicate the basis for its lack of a recommendation to its shareholders in the Joint Proxy Statement or an appropriate amendment or supplement thereto to the extent required by law; provided, that such Board of Directors may not take any actions under this sentence unless it (A) gives the other party at least three (3) business days\u2019 prior written notice of its intention to take such action and a reasonable description of the event or circumstances giving rise to its determination to take such action (including, in the event such action is taken in response to a n Acquisition Proposal, the latest material terms and conditions and the identity of the third party in any such Acquisition Proposal, or any amendment or modification thereof, or describe in reasonable detail such other event or circumstances), and (B) at the end of such notice period, takes into account any amendment or modification to this Agreement proposed by the other party and, after receiving the advice of its outside counsel and, with respect to financial matters, its financial advisors, determines in good faith that it would nevertheless more likely than not result in a violation of its fiduciary duties under applicable law to make or continue to make the BancorpSouth Board Recommendation or Cadence Board Recommendation, as the case may be. Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of this Section 6.4 and will require a new notice period as referred to in this Section 6.4. BancorpSouth or Cadence shall adjourn or postpone the BancorpSouth Meeting or the Cadence Meeting, as the case may be, if, as of the time for which such meeting is originally scheduled there are insufficient shares of BancorpSouth Common Stock or Cadence Common Stock, as the case may be, represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of such meeting, or if on the date of such meeting Cadence or BancorpSouth, as applicable, has not received proxies representing a sufficient number of shares necessary to obtain the Requisite Cadence Vote or the Requisite BancorpSouth Vote, and subject to the terms and conditions of this Agreement, Cadence or BancorpSouth, as applicable, shall continue to use reasonable best efforts to solicit proxies from its shareholders in order to obtain the Requisite Cadence Vote or Requisite BancorpSouth Vote, respectively. Notwithstanding anything to the contrary in this Agreement, but subject to the obligation to adjourn or postpone such meeting as set forth in the immediately preceding sentence, unless this Agreement has been terminated in accordance with its terms, (x) the BancorpSouth Meeting shall be convened and this Agreement shall be submitted to the shareholders of BancorpSouth at the BancorpSouth Meeting, and (y) the Cadence Meeting shall be convened and this Agreement shall be submitted to the shareholders of Cadence at the Cadence Meeting, and nothing contained in this Agreement shall be deemed to relieve either BancorpSouth or Cadence of such obligation. (Page 68)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in law that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any fact, circumstance, change, event, occurrence or effect that (x) has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the financial condition, business or results of operations of the Company and its Subsidiaries, taken as a whole or (y) materially impairs, materially delays or prevents, or would reasonably be expected to materially impair, materially delay or prevent, the Company from consummating the Transactions; provided, that for purposes of clause (x), none of the following, and no effect arising out of, relating to or resulting from the following, shall constitute or be taken into account in determining whether there has been, or would reasonably be expected to be, a \u201cCompany Material Adverse Effect\u201d: (i) any facts, circumstances, changes, events, occurrences or effects generally affecting (A) the industries in which the Company and its Subsidiaries operate or (B) the economy, credit, debt, securities or financial or capital markets in the United States or elsewhere in the world, including changes in interest or exchange rates or deterioration in the credit markets generally; (ii) any facts, circumstances, changes, events, occurrences or effects to the extent arising out of, resulting from or attributable to (A) changes or prospective changes in Law, in GAAP or in accounting standards, or any changes or prospective changes in the interpretation or enforcement of any of the foregoing, (B) entry into and consummation and performance of this Agreement and the transactions contemplated hereby and the public announcement thereof, including the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, partners, employees, regulators or other third parties (except that this clause (B) shall not apply to the representations and warranties made in Section 3.5 (and to the extent related to Section 3.5, the condition in Section (c) of Annex I)), (C) acts of war (whether or not declared) or any   outbreak of hostilities, sabotage or terrorism, or any escalation or worsening of any such acts of war (whether or not declared), outbreak of hostilities, sabotage or terrorism, (D) weather, earthquakes, hurricanes, tornados, natural disasters, climatic conditions, epidemics, pandemics or outbreaks of illness (including COVID-19) or other public health event or other force majeure events, whether or not weather-related, (E) any civil unrest, regulatory and political conditions or developments, or any response of any Governmental Entity thereto, (F) any change resulting or arising from the identity of, or any facts or circumstances relating to, Parent, Merger Sub or their respective Affiliates, (G) any legal proceedings made or brought by any of the current or former stockholders of the Company (on their own behalf or on behalf of the Company), but in any event only in their capacities as current or former stockholders, or otherwise under the DGCL or other applicable Law, or other litigation (except that clause (G), solely with respect to such other litigation, shall not apply to the representations and warranties made in Section 3.5 (and to the extent related to Section 3.5, the condition in Section (c) of Annex I)), arising out of or related to this Agreement or any of the transactions contemplated hereby, (H) actions or omissions of the Company or any of its Subsidiaries requested or consented to in writing by Parent or expressly required by this Agreement, (I) any decline in the market price, or change in trading volume, of the Shares (or the volatility thereof), or (J) any failure to meet any internal or public projections, forecasts or estimates of revenue, earnings, cash flow or cash position, or other metrics; or   69   (iii) any item or matter disclosed in the Company Disclosure Schedule; provided, that (x) facts, circumstances, changes, events, occurrences or effects set forth in clauses (i), (ii)(A), (ii)(C), (ii)(D) and (ii)(E) above may be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect to the extent such facts, circumstances, changes, events, occurrences or effects have a disproportionate adverse effect on the Company and its Subsidiaries, taken as a whole, in relation to others in the industries of the Company and its Subsidiaries (provided, that only the incremental disproportionate adverse effects of such facts, circumstances, changes, events, occurrences or effects may be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect), and (y) that the underlying cause of any decline, change or failure referred to in clause (ii)(I) or (ii)(J) may be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect unless such underlying cause is otherwise excluded hereby. (Pages 35-36)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in law that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any Effect that, individually or in the aggregate with any one or more other Effects, (i) has had or would reasonably be expected to have a material adverse effect on the business, financial condition or results of operations of the Company and the Company Subsidiaries, taken as a whole, or (ii) would reasonably be expected to prevent or delay beyond the Outside Date the closing of the Merger; provided, however, that no Effect, to the extent resulting or arising from the following, individually or in the aggregate with any one or more other Effects, shall constitute or shall be considered in determining whether there has occurred a Company Material Adverse Effect:  (A) changes in general economic, regulatory, political, business, financial, congressional appropriation or market conditions in the United States or elsewhere in the world; (B) changes in the credit, debt, financial or capital markets or in interest or exchange rates, in each case, in the United States or elsewhere in the world; (C) changes in conditions generally affecting the industry in which the Company and the Company Subsidiaries operate, including changes in Governmental Entity funding level or program changes; (D) any outbreak of any military conflict, declared or undeclared war, armed hostilities, or acts of foreign or domestic terrorism (including cyber-terrorism); (E) any epidemic, plague, pandemic or other outbreak of illness or public health event (including COVID-19), hurricane, flood, tornado, earthquake or other natural disaster or act of God (or any worsening of any of the foregoing), including, in each case, the response of governmental and non-governmental entities (including COVID-19 Measures); (F) any failure by the Company or any of the Company Subsidiaries to meet any internal or external projections or forecasts, any change in the market price or trading volume of Company Common Stock or any change in the Company\u2019s credit rating (but excluding, in each case, the underlying causes of such failure or decline, as applicable, unless such underlying causes would otherwise be excepted from this definition); (G) the public announcement, pendency or performance of the Transactions or the identity of, or any facts or circumstances relating to Parent, Merger Sub or their respective Affiliates, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, vendors, lenders, investors, licensors, licensees, venture partners or employees (other than, in each case, for purposes of any representation or warranty set forth in Section 4.4, Section 4.5 or Section 4.11(i)); (H) changes in, including any actions taken to comply with any change in, applicable Laws or the interpretation thereof; (I) changes in, including any actions taken to comply with any change in, GAAP or any other applicable accounting standards or the interpretation thereof; (J) any action required or specifically permitted to be taken by the Company pursuant to the terms of this Agreement or taken at the prior written direction of Parent or Merger Sub; (K) any breach of this Agreement by Parent or Merger Sub; or (L) any litigation or other Proceeding brought by any stockholder of the Company (or a derivative or similar claim) in connection with this Agreement or any of the Transactions to the extent asserting breach of fiduciary duty, inadequate disclosure or violations of applicable securities Law claims; provided, further, that any Effect arising out of or resulting from any change or event referred to in clause (A), (B), (C), (D), (E), (H) or (I) above may constitute, and be taken into account in determining the occurrence of, a Company Material Adverse Effect if and only to the extent that such change or event has a disproportionate adverse impact on the Company and the Company Subsidiaries as compared to any other participants that operate in the industries in which the Company and the Company Subsidiaries operate. (Page 9)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 6.03. Go-Shop; No Solicitation. <omitted> (e)                Notwithstanding anything contained in this Agreement to the contrary, at any time prior to the Acceptance Time, if the Company Board determines, after consultation with outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties, the Company Board may make an Adverse Recommendation Change; provided, that, if the Company is making an Adverse Recommendation Change in response to any fact, event, change, development or set of circumstances other than an Acquisition Proposal (which shall be governed by Section 6.03(h)), then the Company Board shall not make such Adverse Recommendation Change unless the Company has (i) provided to Parent at least three (3) calendar days\u2019 prior written notice that it intends to take such action and specifying in reasonable detail the facts underlying the decision by the Company Board to take such action and (ii) during such three (3) calendar day period, if requested by Parent, engaged in negotiations with Parent to amend this Agreement in such a manner that obviates the need for such Adverse Recommendation Change.  <omitted>   (h) Further, the Company Board shall not make an Adverse Recommendation Change in response to an Acquisition Proposal (or terminate this Agreement pursuant to Section 10.01(d)(i)), unless (i) the Company Board has determined, after consultation with its financial advisor and outside legal counsel, that such Acquisition Proposal constitutes a Superior Proposal, (Page 30)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the additional matching rights period for modifications in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 days\nOption D: 4 business days\nOption E: 5 business days\nOption F: > 5 business days\nOption G: None\n\nMerger Agreement: 7.2.    Company Acquisition Proposals. <omitted> (b) No Change in Company Recommendation or Alternative Acquisition Agreement. <omitted> Notwithstanding anything to the contrary set forth in this Section 7.2(b), the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee may, prior to but not after the time the Requisite Company Stockholder Approvals are obtained, make a Change of Company Recommendation if, and only if, (A) an Intervening Event has occurred and the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee has determined in good faith, after consulting with its financial advisor and outside legal counsel, that failure to take such action would be inconsistent with such directors\u2019 fiduciary duties under applicable Law, or (B) the Company receives a Company Acquisition Proposal and the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee has determined in good faith, after consulting with its financial advisor and outside legal counsel, that such Company Acquisition Proposal constitutes a Company Superior Proposal and that failure to take such action would be inconsistent with such directors\u2019 fiduciary duties under applicable Law; provided that neither the Company Board nor the Special Committee may take any such action (and the Special Committee may not recommend to the Company Board to take such action) unless (I) prior to making such Change of Company Recommendation, the Company provides prior written notice to Parent at least four (4) Business Days in advance (the \u201cNotice Period\u201d) of its intention to take such action and the basis thereof, which notice shall include, in the case of a Company Superior Proposal, the information required under Section 7.2(e) and, in the case of an Intervening   -38-   Event, a reasonably detailed description of such Intervening Event, (II) during the Notice Period, the Company shall, and shall cause its employees, financial advisor and outside legal counsel to, be reasonably available to negotiate with Parent in good faith should Parent propose to make amendments or other revisions to the terms and conditions of this Agreement such that, in the case of a Company Superior Proposal, such Company Acquisition Proposal no longer constitutes a Company Superior Proposal or, in the case of an Intervening Event, the failure to take such action would no longer be inconsistent with the directors\u2019 fiduciary duties under applicable Law as determined in the good faith judgment of the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee, after consulting with its financial advisor and outside legal counsel, and (III) the Company Board (acting upon the recommendation of the Special Committee) or the Special Committee, as the case may be, has taken into account any amendments or other revisions to the terms and conditions of this Agreement agreed to by Parent in writing prior to the end of the Notice Period and has determined in good faith, after consulting with its financial advisor and outside legal counsel, that a failure to make such Change of Company Recommendation would still be inconsistent with the directors\u2019 fiduciary duties under applicable Law; it being understood that any amendments or other revisions to any Company Acquisition Proposal will be deemed to be a new Company Acquisition Proposal, including for purposes of the Notice Period; provided, however, subsequent to the initial Notice Period, the Notice Period shall be reduced to two (2) Business Days. (Pages 43-44)\n\nAnswer by only outputting the option letter A, B, C, D, E, F or G.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cAcquisition Proposal\u201d means any offer or proposal from a Person <omitted> relating to any transaction or series of related transactions <omitted> involving: <omitted> (c) any sale, lease, exchange, transfer or other disposition to a person of more than 15% of the consolidated assets of NIC and the NIC Subsidiaries, taken as a whole (measured by the fair market value thereof). <omitted> \u201cSuperior Proposal\u201d means a bona fide, written Acquisition Proposal (with references in the definition thereof to 15% and 85% being deemed to be replaced with references to 80% and 20%, respectively) (Page 66)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: 6.1    No Solicitation. <omitted>  <omitted> the Company Board may effect a Company Board Recommendation Change in response to a Superior Proposal or an Intervening Event if: (i) the Company Board shall have determined in good faith (after consultation with outside counsel and outside financial advisor) that the failure to effect a Company Board Recommendation Change would be reasonably likely to be inconsistent with its fiduciary obligations under applicable law; <omitted> (iii) the Company has notified the Parent <omitted> that it intends to effect a Company Board Recommendation Change <omitted>  provided, however, that in the event of any material revisions to an Acquisition Proposal underlying a potential Company Board Recommendation Change, the Company will be required to notify Parent of such revisions and the applicable three (3) Business Day period described above shall be extended until two (2) Business Days after the time Parent receives notification from the Company of such revisions. (Page 34)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: the Company Board of Directors may <omitted> terminate this Agreement pursuant to Section 8.1(g) in order to enter into a definitive agreement providing for such Superior Proposal,  if and only if <omitted> the Company complies with Section 5.3(e).    <omitted>          Prior to the Company taking any action permitted <omitted> (ii) under Section 5.3(d)(ii), <omitted> (D) in the event of any change, from time to time, to any of the financial terms or any material change to any of the other material terms of such Superior Proposal, the Company shall, in each case, have delivered to Parent an additional notice consistent with that described in clause (ii)(A) and a new notice period under clause (ii)(A) during which time the Company shall be required to comply with the requirements of this Section 5.3(e)(ii) anew with respect to each such additional notice, including clauses (ii)(A) through (ii)(D) above, except that such new notice period shall be two (2) business days. (Page 27)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: Section 5.1 Conduct of the Company. From the date of this Agreement until the earlier to occur of the Effective Time and the termination of this Agreement in accordance with Article IX, except as otherwise expressly permitted or expressly contemplated by this Agreement or the Spin-Off Agreements or actions undertaken to effect the Separation and Distribution and other provisions of the Spin-Off Agreements, as set forth in Section 5.1 of the Company Disclosure Letter, as consented to in writing by Parent (such consent not to be unreasonably withheld, conditioned or delayed) or as required by applicable Law, the Company shall, and shall cause each of its RemainCo Subsidiaries to, (i) conduct its business in all material respects in the ordinary course of business consistent with past practices, (Page 55)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Does the wording of the Efforts Covenant clause include \u201cconsistent with past practice\u201d?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 5.1 Interim Operations of the Company and Parent.   (a) From the date of this Agreement and until the Effective Time or the earlier termination of this Agreement in accordance with its terms, except as (v) otherwise expressly contemplated by this Agreement, (w) set forth in the applicable subsection of Section 5.1 of the Company Disclosure Letter (it being agreed that disclosure of any item in any subsection of Section 5.1 of the Company Disclosure Letter shall be deemed   36   disclosure with respect to any other subsection of Section 5.1 of the Company Disclosure Letter only to the extent that the relevance of such item to such subsection is reasonably apparent on its face), (x) required by applicable Law, (y)(A) required to comply with COVID-19 Measures or otherwise taken (or not taken) by the Company or any of its Subsidiaries reasonably and in good faith to respond to COVID-19 or COVID-19 Measures or (B) taken (or not taken) by the Company or any of its Subsidiaries reasonably and in good faith to respond to any other extraordinary event that was not reasonably foreseeable as of the date of this Agreement and occurring after the date of this Agreement that is outside of the control of the Company or its Affiliates and is outside of the ordinary course of business of the Company and its Subsidiaries and Joint Ventures (and is not related to a Company Takeover Proposal); provided that prior to taking any actions in reliance on this clause (y), which would otherwise be prohibited by any provision of this Agreement, the Company will use commercially reasonable efforts to provide advance notice to and consult with Parent (if reasonably practicable) with respect thereto or (z) consented to in writing by Parent (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each of its Subsidiaries to, use its commercially reasonable efforts to conduct its business in all material respects in the ordinary course of business consistent with past practice and in compliance in all material respects with all material applicable Laws, and shall, and shall cause each of its Subsidiaries to, use its commercially reasonable efforts to preserve intact its present business organization, keep available the services of its directors, officers and employees and maintain existing relations and goodwill with customers, distributors, lenders, partners (including Joint Venture partners and others with similar relationships), suppliers and others having material business associations with it or its Subsidiaries; (Pages 40-41)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the Tail Period?\nOption A: 12 months or longer\nOption B: Other\nOption C: within 12 months\nOption D: within 6 months\nOption E: within 9 months\n\nMerger Agreement: Section 7.3 Termination Fee; Expenses.   (a) If this Agreement is terminated:    <omitted>    (C) <omitted> the Company or any of its Subsidiaries enters into a definitive agreement with a third party with respect to or consummates a transaction that is a Company Takeover Proposal with a third party; (Page 96)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the Tail Period?\nOption A: 12 months or longer\nOption B: Other\nOption C: within 12 months\nOption D: within 6 months\nOption E: within 9 months\n\nMerger Agreement: Section 11.04. Expenses. <omitted> (b)    Termination Fee. <omitted> (ii)    If (A) this Agreement is terminated <omitted> (C) <omitted> the Company shall have consummated a transaction for an Acquisition Proposal (Page 79)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: (b) Except <omitted> (y) as consented to in writing by Parent (which consent will not be unreasonably withheld, conditioned or delayed), during the Interim Period, the Company shall not and shall cause the Company Subsidiaries not to: (Page 40)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is the \u201cability to consummate\u201d concept subject to Material Adverse Effect (MAE) carveouts?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, with respect to any Person, any event, change, circumstance, occurrence or effect that (i) has, or would have, a material adverse effect on the business, financial condition or results of operations of such Person and its Subsidiaries, taken as a whole, or (ii) would reasonably be expected to prevent, materially delay or materially impair the ability of such Person to consummate the Transactions; provided, however, in the case of clause (i) only, no event, change, circumstance, occurrence or effect to the extent directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be deemed to be or constitute a \u201cMaterial Adverse Effect\u201d or shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or would occur: (A) changes in conditions or developments generally applicable to the oil and gas exploration, development or production industry in the United States or any area or areas where the assets of such Person or any of its Subsidiaries are located, including any increase in operating costs or capital expenses or any reduction in drilling activity or production, or changes in Law or regulation affecting such industry; (B) general economic or political conditions or securities, credit, financial or other capital markets conditions (or changes in such conditions), including changes generally in supply, demand, price levels, interest rates, changes in the price of any commodity (including Hydrocarbons) or general market prices, changes in the cost of fuel, sand or proppants and changes in exchange rates, in each case in the United States or any foreign jurisdiction; (C) any failure, in and of itself, by such Person to meet any internal or published projections, forecasts, estimates or predictions in respect of revenues, earnings, production or other financial or operating metrics for any period (it being understood that the events, changes, circumstances, occurrences or effects giving rise to or contributing to such failure may be deemed to constitute or be taken into account in determining whether there has occurred or would occur a Material Adverse Effect); (D) the execution and delivery of this Agreement; (E) the public announcement of the Transactions, including the impact thereof on the relationships, contractual or otherwise, of such Person or any of its Subsidiaries with employees, labor unions, customers, suppliers or partners; (F) any change, in and of itself, in the market price or trading volume of such Person\u2019s securities (it being understood that the events, changes, circumstances, occurrences or effects giving rise to or contributing to such change may be deemed to constitute, or be taken into account in determining whether there has been or will be, a Material Adverse Effect); (G) any change in applicable Law, COPAS or GAAP (or authoritative interpretation thereof); (H) geopolitical conditions (or changes in such conditions), the outbreak or escalation of hostilities, any acts of war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or terrorism; (I) any epidemic, pandemic, disease outbreak (including the COVID-19 virus) or other public health crisis or public health event, or the worsening of any of the   99   foregoing; (J) any disruption in the purchase or transportation of crude oil or natural gas produced or otherwise sold by such Person or its Subsidiaries as a result of any shutdown, interruption or declaration of force majeure by any pipeline operator or other purchaser of such products; (K) natural declines in well performance or reclassification or recalculation of reserves in the ordinary course of business; (L) seasonal reductions in revenues and/or earnings of such Person or any of its Subsidiaries in the ordinary course of their respective businesses; (M) any actions taken or omitted to be taken by a Party at the written direction of the other Parties (for the avoidance of doubt any action by, or omission of, a Party for which such Party sought or requested, and the other Parties provided, consent shall not be deemed to be \u201cat the written direction of\u201d such Party); or (N) compliance with the terms of, or the taking of any action expressly required by, this Agreement (except for any obligation under this Agreement to operate in the ordinary course of business (or similar obligation) pursuant to Section 5.1), except to the extent any such event, change, circumstance, occurrence or effect directly or indirectly resulting from, arising out of, attributable to or related to any of the matters described in clauses (A), (B), (G), (H) and (I), has a disproportionate effect on such Person and its Subsidiaries, taken as a whole, relative to other similarly situated Persons in the oil and gas exploration, development and production industry in the geographic areas in which such Person and any of its Subsidiaries operate (in which case, such event, change, circumstance, occurrence or effect (if any) shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or would occur solely to the extent it is disproportionate). (Pages 109-110)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in response to an intervening event?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: Other specified standard\n\nMerger Agreement: Section 5.3 No Solicitation. <omitted> (d) <omitted> Notwithstanding anything in this Agreement to the contrary, at any time prior to receipt of the Company Stockholder Approval, in response to an Alternative Proposal that did not result from a material breach of this Section 5.3, if the Board of Directors of the Company determines in good faith, after consultation with its financial advisors and outside legal counsel, that (1) such Alternative Proposal constitutes a Superior Proposal and (2) the failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, then (x) the Board of Directors of the Company may effect a Change of Recommendation and/or authorize or cause the Company to take the actions in the following clause (y), and/or (y) the Company may, notwithstanding anything in this Agreement to the contrary, terminate this Agreement and concurrently with such termination enter into a Company Acquisition Agreement with respect to such Superior Proposal, provided that prior to taking any such action: (A) the Company provides Parent four (4) business days\u2019 prior written notice of its intention to take such action, which notice shall include the information with respect to such Superior Proposal that is specified in Section 5.3(b) (it being understood that each time any material revision or amendment to the terms of the Alternative Proposal determined to be a Superior Proposal is made, the four (4) business day period shall be extended for an additional three (3) business days after notification of such change in accordance with Section 5.3(b) and this Section 5.3(d) to Parent); (B) during the applicable period described in clause (A) (the \u201cTakeover Notice Period\u201d), the Company considers and discusses with Parent in good faith any adjustments or modifications to the terms of this Agreement proposed by Parent; and (C) at the end of the Takeover Notice Period, the Board of Directors of the Company again makes the determination in good faith, after consultation with its outside legal counsel and financial advisors (and after taking into account any adjustments or modifications proposed by Parent during the Takeover Notice Period), that the Alternative Proposal continues to be a Superior Proposal. Notwithstanding anything in this Agreement to the contrary, the Board of Directors of the Company may, at any time prior to the receipt of the Company Stockholder Approval, effect a Change of Recommendation in response to an Intervening Event if: (i) the Company provides Parent four (4) business days\u2019 prior written notice of its intention to take such action, which notice shall include all material information with respect to any such Intervening Event and a description of the Board of Directors of the Company\u2019s rationale for such action; (ii) during such four (4) business day period described in clause (x), the Company considers and discusses in good faith with Parent and its Representatives any adjustments or modifications to the terms of this Agreement; and (z) at the end of the four (4) business day period described in clause (x), the Board of Directors of the Company determines in good faith after consultation with its financial advisors and outside legal counsel (after taking into account any adjustments or modifications to the terms of this Agreement proposed by Parent during the period described in clause (x)) that the failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law. (Page 46)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, or I.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cSuperior Proposal\u201d means an <omitted> Acquisition Proposal made after the date of this Agreement, that if the transactions or series of related transactions contemplated thereby were consummated would result in a Person or Group <omitted> becoming the beneficial owner of, directly or indirectly, at least 80 percent of the <omitted> (b) consolidated net revenues, net income or total assets of the Company (Page 22)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: Section 5.04 Company Recommendation. <omitted>  (b) Superior Proposal. <omitted> the Company Board (or any duly authorized committee thereof) may, in response to the receipt of a <omitted> Competing Proposal <omitted> that did not result from a breach of \u200bSection 5.03(a) <omitted> terminate this Agreement in accordance with Section 7.01(d) in order to cause the Company to enter into a binding and definitive written Alternative Acquisition Agreement with respect to a Competing Proposal), only if: <omitted>  <omitted> provided, that any change to the financial terms (including any change to the amount or form of consideration payable) or other material amendment to the terms of such Competing Proposal (whether or not in response to any changes proposed by Parent pursuant to clause (iii)) shall require a new Notice of Change of Recommendation and an additional two (2) Business Day period from the date of such notice during which the terms of clause (i) through (iv) shall apply mutatis mutandis (other than the number of days). (Page 19)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 5.3. No Solicitation.   <omitted>   (d) Company Board Recommendation Change <omitted> . <omitted> : (i) <omitted> the Company Board may effect a Company Board Recommendation Change in response to an Intervening Event if the Company Board determines in good faith (after consultation with its financial advisor and outside legal counsel) that the failure to do so would be inconsistent with its fiduciary duties pursuant to applicable Law   <omitted>   (ii) if the Company has received a <omitted> Acquisition Proposal <omitted> , then the Company Board may (A) effect a Company Board Recommendation Change with respect to such Superior Proposal <omitted> if and only if: (1) the Company Board determines in good faith (after consultation with its financial advisor and outside legal counsel) that the failure to do so would be inconsistent with its fiduciary duties pursuant to applicable Law; (Pages 67-69)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cCompany Acquisition Proposal\u201d means any offer <omitted> relating to a Company Acquisition Transaction.     \u201cCompany Acquisition Transaction\u201d means, other than the Transactions, any transaction (including any single- or multi-step transaction) or series of related transactions with a Person or \u201cgroup\u201d (as defined in the Exchange Act) relating to <omitted> (b) the acquisition by such Person or \u201cgroup\u201d of any business or assets of the Company and the Company Subsidiaries representing at least 20% of (i) the consolidated assets of the Company (including indirectly through ownership of equity in Company Subsidiaries) and the Company Subsidiaries, taken as a whole  <omitted>  \u201cCompany Superior Proposal\u201d means a bona fide written Company Acquisition Proposal (provided, that for this purpose the references to \u201c20%\u201d in the definition of Company Acquisition Transaction shall be deemed to be references to \u201c50%\u201d) made by a third party, that did not result from a material breach of Section 6.4, that the Company Board determines in its good faith judgment (after consultation with its financial advisors and outside counsel), taking into account all of the terms and conditions of such Company Acquisition Proposal and this Agreement (including any offer by Parent to amend the terms of this Agreement, termination or break-up fee, expense reimbursement provisions and conditions to consummation) and taking into account all financial, legal, regulatory and other aspects of such Company Acquisition Proposal that the Company Board considers in good faith to be appropriate (including the conditionality and the timing and likelihood of consummation of such proposal) is reasonably likely to be consummated in accordance with its terms and would, if consummated, result in a transaction that is more favorable to the Company\u2019s stockholders (solely in their capacity as such) from a financial point of view than the Transactions. (Page 11)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the capitalization representations and warranties be according to the bring down provision?\nOption A: Accurate in all material respects\nOption B: Accurate in all respects\nOption C: Accurate in all respects with below-threshold carveout\nOption D: Accurate in all respects with de minimis exception\n\nMerger Agreement: 7.3     Conditions to the Obligations of the Parent and the Merger Sub  <omitted> (iv) all other representations and warranties of the Company contained in this Agreement shall be true and correct as of the Closing Date, as though made on and as of the Closing Date (Pages 48-49)\n\nAnswer by only outputting the option letter A, B, C or D.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 4.4 No Solicitation of Transactions. <omitted> (f)                 <omitted> if (i) the Company receives a Qualifying Acquisition Proposal that the Company Board determines <omitted> is a Superior Proposal <omitted> the Company Board may not effect a Change of Board Recommendation pursuant to the foregoing clause <omitted> unless: <omitted>   (ii)               the Company shall have provided <omitted> notice to Parent, at least four (4) Business Days in advance (the \u201cSuperior Proposal Notice Period\u201d) <omitted> (iv)              following the Company\u2019s <omitted> negotiation <omitted> with Parent <omitted> during the Superior Proposal Notice Period and after considering the results of such negotiations and giving effect to any proposals, amendments or modifications made or agreed to by Parent, if any, the Company Board (after consultation with one or more of its financial advisors and outside legal counsel) shall have determined <omitted> that such Superior Proposal still constitutes a Superior Proposal (it being understood and agreed that any change to the financial or other material terms of an Acquisition Proposal that was previously the subject of a notice hereunder shall require a new notice to Parent as provided above, but with respect to any such subsequent notices the Superior Proposal Notice Period shall be deemed to be three (3) Business Days rather than four (4) Business Days); and (Pages 22-23)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: except <omitted> (w) with the prior written consent of Parent (which consent shall not be unreasonably conditioned, withheld or delayed) <omitted> none of the Acquired Companies will: (Page 48)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What negative covenants does the requirement of Buyer consent apply to?\nOption A: Applies only to specified negative covenants\nOption B: Applies to all negative covenants\n\nMerger Agreement: Without limiting the foregoing, during the period from the date of this Agreement through the earlier of the Closing or the termination of this Agreement, except (1) to the extent Parent shall otherwise give its prior consent in writing (which consent shall not be unreasonably withheld, conditioned or delayed), (2) as set forth in Part 4.1(a) of the Company Disclosure Schedule, (3) as may be required by applicable Legal Requirements or (4) as expressly permitted or required by this Agreement, the Company shall not (and shall not permit any Company Subsidiary to), in each case by merger, consolidation, division, operation of law, or otherwise: (Page 46)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in GAAP or other accounting principles that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d shall mean any change, event, circumstance, occurrence, effect, development or state of facts (collectively, \u201cEffects\u201d) that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on the business, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole; provided that no Effect shall be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect to the extent arising out of, resulting from or relating to any of the following: (i) any Effect generally affecting any of the industries or markets in which the Company or its Subsidiaries operates; (ii) any promulgation or enactment of, implementation of, enforcement of, change in interpretation of, change in implementation of, or change in enforcement of, any Law or GAAP or governmental   75   policy; (iii) general economic, regulatory or political conditions (or changes therein), including any governmental shutdown or slowdown, or conditions (or changes therein) in the financial, credit or securities markets (including changes in interest rates, currency exchange rates, monetary policy or fiscal policy), in any country or region in which the Company or any of its Subsidiaries conducts business; (iv) any acts of God, natural disasters, terrorism, armed hostilities, sabotage, war, curfews, riots, demonstrations or public disorders or any escalation or worsening of acts of terrorism, armed hostilities, war, riots, demonstrations or public disorders; (v) any epidemic, pandemic or disease outbreak (including COVID-19) or any COVID-19 Measures or any change in such COVID-19 Measures or interpretations thereof following the date of this Agreement; (vi) the announcement, pendency of or performance of the Transaction, including by reason of the identity of Parent and including the impact of any of the foregoing on any relationships, contractual or otherwise, with customers, suppliers, distributors, collaboration partners, employees or regulators (provided that the exception set forth in this clause (vi) shall not apply with respect to the representation and warranty in Section 3.3(b) to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution, delivery or performance of this Agreement or the consummation of any of the Transactions and, to the extent related to such representation and warranty, the condition set forth in Section 6.2(a)); (vii) the taking of any action expressly required by the terms of this Agreement or taken at the written request of, or with the prior written consent of, Parent or Merger Subs; (viii) any change in the market price, or change in trading volume, of the capital stock of the Company (it being understood that the Effects giving rise or contributing to such change may be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect to the extent that they are not otherwise excluded by clauses (i) through (x) hereof); (ix) any failure by the Company or its Subsidiaries to meet internal, analysts\u2019 or other earnings estimates or financial projections or forecasts for any period, or any changes in credit ratings and any changes in any analysts recommendations or ratings with respect to the Company or any of its Subsidiaries (it being understood that the Effects giving rise or contributing to such failure or change may be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse Effect to the extent that they are not otherwise excluded by clauses (i) through (x) hereof); and (x) any Transaction Litigation; except, in each of clauses (i) through (v), such Effect shall be taken into account in the determination of whether a Company Material Adverse Effect has occurred solely to the extent (and only to the extent) that such Effect materially and disproportionately affected the Company and its Subsidiaries relative to other participants in the industries in the same geographies in which the Company and its Subsidiaries operate. (Pages 79-80)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What counts as Knowledge?\nOption A: Actual knowledge\nOption B: Constructive knowledge\n\nMerger Agreement: provided, however, that Material Adverse Effect shall not be deemed to include the impact of (a) changes, after the date hereof, in GAAP or applicable bank regulatory accounting requirements; (b) changes, after the date hereof, in laws, rules or regulations (including the Pandemic Measures) of general applicability to companies in the industries in which the party and its Subsidiaries operate, or interpretations thereof by courts or Governmental Authorities; (c) changes, after the date hereof, in global, national or regional political conditions (including the outbreak of war or acts of terrorism) or in economic or market (including equity, credit and debt markets, as well as changes in interest rates) conditions affecting the financial services industry generally and not specifically relating to the party or its Subsidiaries (including any such changes arising out of the Pandemic or any Pandemic Measures); (d) changes, after the date hereof, resulting from hurricanes, earthquakes, tornados, floods or other natural disasters or from any outbreak of any disease or other public health event (including the Pandemic); (e) public disclosure of the execution of this Agreement, or (except in the case of the representations contained in Sections 5.01(c)(ii), 5.01(d), 5.02(d)(ii) and 5.02(e)) consummation of the transactions contemplated hereby (including any effect on a party\u2019s relationships with its customers or employees) or actions expressly required by this Agreement in contemplation of the transactions contemplated hereby; (f) a decline in the trading price of a party\u2019s common stock, in and of itself, or the failure, in and of itself, to meet earnings projections or internal financial forecasts (it being understood that the underlying cause of such decline or failure may be taken into account in determining whether a Material Adverse Effect has occurred), and (g) the occurrence of any natural or man-made disaster; except, with respect to subclauses (a), (b), (c), (d) and (g), to the extent that the effects of the change are materially disproportionately adverse to the business, properties, assets, liabilities, results of operations or financial condition of the party and its Subsidiaries, taken as a whole, as compared to other companies in the industry in which the party and its Subsidiaries operate). (Page 8)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Non-Solicitation; Acquisition Proposals; Change of Recommendation  <omitted>    (c) Change of Recommendation.    (i) <omitted> if a written Acquisition Proposal <omitted> is received by the Company, and the Board of Directors of the Company determines <omitted> that such Acquisition Proposal would, if consummated, constitute a Superior Proposal, the Board of Directors of the Company may <omitted> (x) effect a Change of Recommendation <omitted> ; provided further, that <omitted> Any material amendment to any Acquisition Proposal will be deemed to be a new Acquisition Proposal for purposes of Section 6.1(d) and this Section 6.1(c)(i) and require a new Company Notice, except that references in this Section 6.1(c)(i) to \u201cfour (4) Business Days\u201d shall be deemed to be references to \u201cthree (3) Business Days\u201d (Pages 49-50)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: (d) If, at any time prior to obtaining the Company Stockholder Approval, the Company Board (or any duly authorized committee thereof) receives a Company Takeover Proposal that it determines in good faith (after consultation with its outside counsel and financial advisor) constitutes a Company Superior Proposal, the Company Board (or any duly authorized committee thereof) may (i) effect a Company Adverse Recommendation Change or (ii) authorize the Company to terminate this Agreement pursuant to Section 7.1(d)(iii) in order to enter into a definitive written agreement providing for a Company Superior Proposal (any such agreement, a \u201cCompany Alternative Acquisition Agreement\u201d), in the case of each of clauses (i) and (ii) if (A) the Company Board (or any duly authorized committee thereof) determines in good faith (after consultation with its outside counsel and financial advisor) that the failure to take such action would be inconsistent with the Company\u2019s directors\u2019 fiduciary duties under applicable Law; (B) the Company has notified Parent in writing that it intends to effect a Company Adverse Recommendation Change or terminate this Agreement (which notice shall not constitute a Company Adverse Recommendation Change), including if applicable a copy of the proposed Company Alternative Acquisition Agreement between the Company and the Person making such Company Superior Proposal; (C) for a period of four (4) Business Days following the notice delivered pursuant to clause (B) of this Section 5.3(d), the Company shall have made Company Representatives available to discuss and negotiate in good faith (in each case, to the extent Parent desires to negotiate) with Parent Representatives any proposed modifications to the terms and conditions of this Agreement so that the Company Takeover Proposal that is the subject of the notice described in clause (B) above no longer constitutes a Company Superior Proposal or the failure to take such action would no longer be inconsistent with the Company\u2019s directors\u2019 fiduciary duties under applicable Law (it being understood and agreed that any amendment to any material term or condition of any Company Superior Proposal shall require a new notice and a new negotiation period (except that such new negotiation period shall be for two (2) Business Days)); and (D) no earlier than the end of such negotiation period, the Company Board (or any duly authorized committee thereof) shall have determined in good faith (after consultation with its outside counsel and financial advisor), after considering the terms of any proposed amendment or modification to this Agreement, that (x) the Company Takeover Proposal that is the subject of the notice described in clause (B) above would still constitute a Company Superior Proposal and (y) the failure to take such action would still be inconsistent with the Company\u2019s directors\u2019 fiduciary duties under applicable Law.   (e) Other than in connection with a Company Superior Proposal (which shall be subject to Section 5.3(d) and shall not be subject to this Section 5.3(e)), prior to obtaining the Company Stockholder Approval the Company Board (or any duly authorized committee thereof) may effect a Company Adverse Recommendation Change, but only in response to a Company Intervening Event and only if (i) the Company Board (or any duly authorized committee thereof) determines in good faith (after consultation with its outside counsel and financial advisor) that the failure to take such action would be inconsistent with the Company\u2019s directors\u2019 fiduciary duties under applicable Law; (ii) the Company has notified Parent in writing that it intends to effect a Company Adverse Recommendation Change due to the occurrence of a Company Intervening Event (which notice shall specify and describe the Company Intervening Event in reasonable detail and which notice shall not constitute a Company Adverse Recommendation Change); (iii) for a period of four (4) Business Days following the notice delivered pursuant to clause (ii) of this Section 5.3(e), the Company shall have made Company Representatives available to discuss and negotiate in good faith (in each case to the extent Parent desires to negotiate), with Parent Representatives any proposed modifications to the terms and conditions of this Agreement so that the failure to take such action would no longer be inconsistent with the Company\u2019s directors\u2019 fiduciary duties under applicable Law (it being understood and agreed that any material change to the facts and circumstances relating to the Company Intervening Event shall require a new notice and a new negotiation period (except that such new negotiation period shall be for two (2) Business Days)); and (iv) no earlier than the end of the negotiation period, the Company Board (or any duly authorized committee thereof) shall have determined in good faith (after consultation with its outside counsel and financial advisor), after considering the terms of any proposed amendment or modification to this Agreement, that the failure to take such action would still be inconsistent with the Company\u2019s directors\u2019 fiduciary duties under applicable Law. (Page 50)\n\nAnswer by outputting a singled letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: except as <omitted> (z) consented to in writing by Parent (which consent shall not be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each of its Subsidiaries to, use its commercially reasonable efforts to conduct its business in all material respects in the ordinary course of business consistent with past practice and in compliance in all material respects with all material applicable Laws (Pages 40-41)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: each share of Company Common Stock, issued and outstanding immediately prior to the Effective Time ( <omitted> including Company Stock Awards and shares of Company Common Stock underlying Company RSU Awards, the \u201cEligible Shares\u201d) shall be converted into the right to receive from Parent that number of fully paid and nonassessable shares of Parent Common Stock equal to the Exchange Ratio ( <omitted> the \u201cMerger Consideration\u201d). As used in this Agreement, \u201cExchange Ratio\u201d means a number (rounded to five decimal places) obtained by dividing the Existing Company Stockholder Equity Recovery by Eligible Shares. <omitted>  (b) Each outstanding award of restricted stock units issued pursuant to the Company Equity Plan that is outstanding or payable immediately prior to the Effective Time (each, a \u201cCompany RSU Award\u201d) <omitted>  \u201cExisting Company Stockholder Equity Recovery\u201d means 490,221 shares of Parent Common Stock. (Page 13)\n\nAnswer and only output A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (a) Each share of common stock <omitted> shall thereupon be converted <omitted> into <omitted> the right to receive $24.00 in cash (Page 10)\n\nAnswer and only output A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means with respect to any Party and its Subsidiaries, any fact, circumstance, event, change, effect, development or occurrence that, individually or in the aggregate together with all other facts, circumstances, events, changes, effects, developments or occurrences, directly or indirectly, (i) has had or would reasonably be expected to result in a material adverse effect on the condition (financial or otherwise), results of operations, Assets, liabilities or business of such Party and its Subsidiaries taken as a whole; provided, that a \u201cMaterial Adverse Effect\u201d shall not be deemed to include effects to the extent resulting from (A) changes after the date of this Agreement in GAAP or regulatory accounting requirements, (B) changes after the date of this Agreement in Laws of general applicability to companies in the financial services industry, (C) changes after the date of this Agreement in global, national or regional political conditions or general economic or market conditions in the United States (and with respect to Bryn Mawr, the Commonwealth of Pennsylvania, and with respect to WSFS, the State of Delaware), including changes in prevailing interest rates, credit availability and liquidity, currency exchange rates, and price levels or trading volumes in the United States or foreign securities markets, affecting other companies in the financial services industry, (D) after the date of this Agreement, general changes in the credit markets or general downgrades in the credit markets, (E) failure, in and of itself, to meet earnings projections or internal financial forecasts, but not including any underlying causes thereof unless separately excluded hereunder, or changes in the trading price of a Party\u2019s common stock, in and of itself, but not including any underlying causes unless separately excluded hereunder, (F) the public disclosure of this Agreement and the impact thereof on relationships with customers or employees, (G) any outbreak or escalation of hostilities, declared or undeclared acts of war or terrorism, (H) changes, after the date hereof, resulting from hurricanes, earthquakes, tornados, floods or other natural disasters or from any epidemic, pandemic, or outbreak of any disease or other public health event (including the Pandemic and the implementation of the Pandemic Measures) in the jurisdictions in which Bryn Mawr or WSFS operate or (I) actions or omissions taken with the prior written consent of the other Party or expressly required by this Agreement; except, with respect to clauses (A), (B), (C), (D), (G), and (H) to the extent that the effects of such change disproportionately affect such Party and its Subsidiaries, taken as a whole, as compared to other companies in the industry in which such Party and its Subsidiaries operate or (ii) prevents or materially impairs the ability of such Party to timely consummate the transactions contemplated hereby. (Page 73)\nAnswer and only output Yes or No.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 5.4 No Solicitation by the Company; Other Offers. <omitted> (d) <omitted> Notwithstanding the foregoing, the Company Board may, at any time prior to the Acceptance Time, take any of the actions set forth in Sections 5.4(d)(i)-(iii) below (provided, however, that prior to taking any such action, the Company complies with Section 5.4(e) of this Agreement): (i) if there is an Intervening Event, effect a Change in Company Board Recommendation if the Company Board concludes in good faith, after consultation with outside counsel, that the failure to take such action would be reasonably likely to be inconsistent with the Company Board\u2019s fiduciary duties under applicable Law; (ii) effect a Change in Company Board Recommendation in response to an Acquisition Proposal that did not result from a material breach of the Company\u2019s obligations under this Section 5.4 if the Company Board concludes in good faith, after consultation with outside counsel, that the failure to take such action would be reasonably likely to be inconsistent with the Company Board\u2019s fiduciary duties under applicable Law and the Company Board concludes in good faith, after consultation with the Company\u2019s financial advisor, that the Acquisition Proposal constitutes a Superior Proposal (Page 45)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What carveouts pertaining to Material Adverse Effect (MAE) does the relational language apply to?\nOption A: All MAE carveouts\nOption B: No\nOption C: Some MAE carveouts\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any change, event, effect, development or occurrence that (a) has or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, assets, condition (financial or otherwise), prospects or results of operations of the Company and the Subsidiaries of the Company, taken as a whole, excluding any effect to the extent it results from or arises out of (i) general conditions in the industries in which the Company operates, (ii) general economic or regulatory, legislative or political conditions or securities, credit, financial or other capital markets conditions (including changes generally in prevailing interest rates, currency exchange rates, credit market conditions and capital markets price levels or trading volumes), in each case in the United States or elsewhere in the world, (iii) any change or prospective change in applicable Law or GAAP (or interpretation or enforcement thereof), (iv) geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or terrorism, (v) any hurricane, tornado, flood, volcano, earthquake, epidemic, disease outbreak, public health event, pandemic (including COVID-19 and any worsening thereof (including any COVID-19 Response)) or other natural or man-made disaster, (vi) the failure of the Company to meet any internal or external projections, forecasts, estimates or predictions in respect of revenues, earnings or other financial or operating metrics before, on or after the date of this Agreement, or changes or prospective changes in the market price or trading volume of the Company Common Stock or the credit rating of the Company and/or its Subsidiaries (it being understood that the underlying facts or occurrences giving rise or contributing to such failure or change may be taken into account in determining whether there has been a Company Material Adverse Effect if such facts or occurrences are not otherwise excluded from being taken into account pursuant to this definition in determining whether the has been a Company Material Adverse Effect), (vii) the execution, announcement, performance or consummation of any of the Transactions, including the impact thereof on relationships, contractual or otherwise, with customers, suppliers, distributors, partners, employees of Governmental Entities, or any Proceeding brought by any Company stockholder (direct or derivative) in respect of this Agreement or any of the Transactions, in each case to the extent resulting from or arising in connection with such announcement or consummation (it being understood that this clause (vii) shall not apply with respect to (a) any representation or warranty contained in this Agreement to the extent that the purpose of such representation or warranty is to address the consequences resulting from the execution and delivery of this Agreement or the consummation of the Transactions or the performance of obligations under this Agreement, including the Transactions or (b) any closing condition related to the foregoing clause (a)), (viii) any action taken by the Company or its Subsidiaries that is expressly required by this Agreement (other than 5.01(a)) or with Parent\u2019s written consent or at Parent\u2019s written request, or the failure to take any action by the Company or its Subsidiaries if that action is expressly prohibited by this Agreement (only to the extent that Parent unreasonably withholds, conditions or delays consent to the taking of such action after receipt of the written request therefor from the Company), and (ix) changes resulting or arising from the identity of, or any facts or circumstances relating to, Parent,   76   Merger Sub or any of their respective Affiliates, including the financing obtained or to be obtained by Parent, Merger Sub or any of their respective Affiliates, except, in the case of clause (i), (ii), (iii), (iv) or (v), to the extent that the Company is disproportionately affected thereby as compared with other participants in the industries in which the Company operates (in which case the incremental disproportionate impact or impacts may be taken into account in determining whether there has been a Company Material Adverse Effect) or (b) prevents or materially impairs or delays the consummation of the Merger and the other Transactions or the ability of the Company to perform its obligations under this Agreement. (Pages 84-85)\n\nAnswer and only output A, B or C.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the fundamental representations and warranties be according to the bring down provision?\nOption A: Accurate at another materiality standard (e.g., hybrid standard)\nOption B: Accurate in all material respects\nOption C: Accurate in all respects\n\nMerger Agreement: SECTION 7.02. Additional Conditions to Obligations of Parent and Merger Sub. <omitted> Each of the representations and warranties of the Company set forth in <omitted> (iii) Article III <omitted> shall be true and correct in all respects <omitted> as of the date of this Agreement and as of the Closing Date (Page 54)\n\nAnswer by only outputting the letter of the option A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How accurate must the fundamental representations and warranties be according to the bring down provision?\nOption A: Accurate at another materiality standard (e.g., hybrid standard)\nOption B: Accurate in all material respects\nOption C: Accurate in all respects\n\nMerger Agreement: 7.2 Additional Conditions to Obligations of Parent and Merger Sub. <omitted> all other representations and warranties of the Company set forth in Article IV shall have been true and correct as of the date of this Agreement and shall be true and correct as of the Closing Date, as though made on and as of the Closing Date (Pages 80-81)\n\nAnswer by only outputting the letter of the option A, B or C.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cknowledge\u201d of CIT means the actual knowledge of any of the officers of CIT listed on Section 9.6 of the CIT Disclosure Schedule (Page 72)\n\nAnswer and only output A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted in response to an intervening event?\nOption A: No\nOption B: Yes\n\nMerger Agreement: SECTION 7.8. No Solicitation. <omitted> (d) <omitted> the Company Board may effect a Company Adverse Recommendation Change <omitted> if, and only if, (i) in the case of a termination of this Agreement to enter into a Specified Agreement <omitted> in connection with the Superior Proposal <omitted> , (ii) the Company Board determines in good faith, after consultation with the Company\u2019s outside legal counsel, that the failure to make the Company Adverse Recommendation Change <omitted> to enter into a Specified Agreement would be inconsistent with the fiduciary duties of the Company Board under applicable Law <omitted>  (e) <omitted> the Company Board may make a Company Adverse Recommendation Change with respect to an Intervening Event, if and only if: (i) the Company Board determines in good faith, after consultation with the Company\u2019s outside legal counsel, that the failure to make the Company Adverse Recommendation Change would be inconsistent with the fiduciary duties of the Company Board under applicable Law; (Pages 76-77)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: Except <omitted> (v) as consented to in writing by Parent (which consent will not be unreasonably withheld, conditioned or delayed), during the Interim Period, the Company shall and shall cause the Company Subsidiaries to: (A) conduct its business (x) in the ordinary course (Page 40)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cAcquisition Proposal\u201d means (other than the Transactions) any indication of interest, inquiry, request for non-public information, proposal or offer from any Person or Group, other than Parent and its Subsidiaries, in each case relating to any (a) direct or indirect acquisition (whether in a single transaction or a series of related transactions) of assets of the Company or the Company Subsidiaries (including securities of the Company Subsidiaries) equal to 20% or more of  the  consolidated  assets  of  the  Company,  or  to  which  20%  or  more  of  the  revenues  or  earnings  of  the  Company  on  a consolidated  basis  are  attributable;(b) direct or indirect acquisition or issuance (whether in a single transaction or a series of related transactions) of (i) 20% or more of the outstanding shares ofCompany Common Stock or (ii) any equity or voting securities of the Company or any of the Company Subsidiaries representing, directly or indirectly, 20% or more of the consolidated assets of the Company or 20% or more of the revenues or earnings of the Company and the Company Subsidiaries on a consolidated basis; (c) tender offer or exchange offer that, if consummated, would result in such Person or Group beneficially owning (i) 20% or more of the outstanding shares of Company Common Stock or (ii) any equity or voting securities of the Company or any of the Company Subsidiaries representing, directly or indirectly, 20% or more of the consolidated assets of the Company and the Company Subsidiaries or 20% or more of the revenues or earnings of the Company and the CompanySubsidiaries  on  a consolidated  basis;  or  (d)  merger,  consolidation,  share  exchange,  business  combination,  joint  venture,  reorganization, recapitalization, liquidation,  dissolution  or  similar  transaction  involving  the  Company  or  any  of  the  Company  Subsidiaries,  under  which such  Person  or  Group  would  acquire, directly  or  indirectly,  (i)  assets  (including  securities  of  the  Company  Subsidiaries)  equal  to 20%  or  more  of  the  consolidated  assets  of  the  Company  and  the Company  Subsidiaries,  or  to  which  20%  or  more  of  the  revenues  or earnings of the Company and its Subsidiaries on a consolidated basis are attributable, or (ii) beneficial ownership of (A) 20% or more of the outstanding shares of Company Common Stock or (B) any equity or voting securities of the Company or any of the Company Subsidiaries representing, directly or indirectly, 20% or more of the consolidated assets of the Company and the Company Subsidiaries or 20% or more of the revenues or earnings of the Company and Company Subsidiaries on a consolidated basis <omitted> ( i )            \u201cSuperior Proposal\u201d means any unsolicited, bona fide written Acquisition Proposal (that has not been withdrawn and that did not result from a breach or violation (other than an isolated, inadvertent and immaterial breach or violation) of the provisions of Section 6.3), (with all references to \u201c20%\u201d in the definition of Acquisition Proposal being deemed to be references to \u201c50%\u201d), that (A) if a cash transaction (whether in whole or in part), is not subject to a financing condition (and if financing is required, such financing is then fully committed and reasonably determined to be available by the Company Board); (B) is reasonably likely to be consummated on the terms and conditions contemplated thereby; and (C) the Company Board shall have determined in good faith After Consultation is more favorable to the stockholders of the Company (in their capacity as such) from a financial point of view than the Merger, in each case taking into account such factors as are determined by the Company Board in good faith to be relevant, including (I) the identity of the Person(s) making such Acquisition Proposal and the prior history of such Person(s) with the consummation or failure to consummate similar transactions, (II) the anticipated timing, conditions and prospects for completion of the transaction contemplated by such offer or proposal, including any governmental or other approval requirements (including divestitures and entry into other commitments and limitations) and (III) any proposal to amend this agreement made by Parent in connection therewith or in response thereto; (Pages 39-40)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cCompany Superior Proposal\u201d means any <omitted> Company Acquisition Proposal <omitted> to acquire, directly or indirectly, pursuant to a tender offer, exchange offer, merger, consolidation or other business combination or similar acquisition transaction, (i) all or substantially all of the non-\u201ccash or cash equivalent\u201d assets of the Company (Page 10)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes caused by general economic and financial conditions that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any event, change, effect, development or occurrence (each, an \u201cEffect\u201d) that (i) would prevent the ability of the Company Entities, taken as a whole, to consummate the Merger or any of the other transactions contemplated hereby prior to the Outside Date (as it may be extended under Section 7.1(b)(i)) or (ii) has a material adverse effect on the business, assets, Liabilities, financial condition or results of operations of the Company Entities, taken as a whole; provided, however, that, solely for purposes of a Company Material Adverse Effect under this clause (ii), any Effect (by itself or when aggregated and taken together with any and all other Effects) to the extent directly or indirectly arising out, resulting from, attributable to or related to any of the following shall not be deemed to be or constitute a Company Material Adverse Effect or be taken into account in determining whether such a Company Material Adverse Effect has occurred or would reasonably be expected to occur (except as otherwise provided herein): (1) any change in general U.S. or global economic conditions, or conditions in the global economy generally;     80      (2) any change in the general conditions of the health care, health insurance or managed care industries or any other industry in which any Company Entity operates; (3) any change in general legal, regulatory, legislative or political conditions or in securities, credit, financial, debt or other capital markets, in each case, in the United States or any foreign jurisdiction, including any change in currency exchange rate, interest rates, monetary policy or inflation; (4) any change in applicable Law, GAAP or Applicable SAP (or authoritative interpretations of any of the foregoing) after the date hereof, or any change to the extent resulting from any action taken for the purpose of complying with any of the foregoing; (5) any change in geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage, civil disobedience or terrorism, or any escalation or worsening of any such acts of war, sabotage, civil disobedience or terrorism; (6) any hurricane, earthquake, flood or other natural disasters, acts of God, any change resulting from weather conditions or pandemics (including the existence and impact of the COVID-19 pandemic); (7) (A) the execution and delivery hereof, the public announcement, pendency or anticipated consummation hereof, the Merger or any other transaction contemplated hereby, including the impact thereof on the relationships with (which, for the avoidance of doubt, shall include the termination of any Contracts with) customers, suppliers, vendors, distributors, partners and other third parties with whom the Company has a business or contractual relationship, (B) the Company having performed or complied with its covenants and agreements hereunder (except for performance or compliance with Section 5.1(a)), including the failure to take any action specifically prohibited hereunder (and for which Parent has declined to consent) or (C) the taking of any action at the written request of or with the prior written consent of Parent; (8) any decline, in and of itself, in the trading price or trading volume of the Company Common Stock or any failure by the Company to meet any internal or published projections, forecasts, estimates or predictions of revenues, earnings or other financial or operating metrics for any period or any reduction in the credit rating of the Company or any Company Subsidiary (provided that any Effect giving rise to or contributing to such decline, failure or reduction that is not otherwise excluded by the foregoing clauses (1)\u2013(7) may be a Company Material Adverse Effect and may be taken into account in determining whether a Company Material Adverse Effect has occurred or whether a Company Material Adverse Effect would reasonably be expected to occur); or      81             (9) any Company Stockholder Litigation; provided, however, that any Effect directly or indirectly arising from, resulting from or related to the matters referred to in the foregoing clauses (1)\u2013(6) may be taken into account in determining whether a Company Material Adverse Effect has occurred or whether a Company Material Adverse Effect would reasonably be expected to occur, in each case, to the extent that such Effect has a disproportionate adverse effect on the Company Entities, taken as a whole, relative to the adverse effects thereof on other similarly situated companies operating in the industries in which the Company Entities operate. (Pages 38-39)\nAnswer and only output Yes or No.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the efforts standard?\nOption A: Commercially reasonable efforts\nOption B: Flat covenant (no efforts standard)\nOption C: Reasonable best efforts\n\nMerger Agreement: \u201cOrdinary Course of Business\u201d means, with respect to any Person, the conduct that is consistent in nature and scope with the past practices of such Person prior to the date of this Agreement and taken in the ordinary course of normal, day-to-day operations of such Person. <omitted> (a) The Company shall, and shall cause each of its Subsidiaries to, from and after the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement pursuant to Article VIII, unless Parent shall otherwise approve in writing, <omitted> conduct its business in the Ordinary Course of Business, in all material respects (Page 67)\n\nAnswer and only output A, B or C.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of offer could the Board take actions on notwithstanding the no-shop provision?\nOption A: Acquisition Proposal only\nOption B: Superior Offer, or Acquisition Proposal reasonably likely/expected to result in a Superior Offer\n\nMerger Agreement: Section 5.10    Acquisition Proposals. <omitted>  provided that, in the event the Company receives an <omitted> Acquisition Proposal, from a Person other than Nicolet, <omitted> and the Company Board concludes in good faith, after consultation with its financial advisor and outside counsel, that such Acquisition Proposal constitutes a Superior Proposal or could reasonably be likely to result in a Superior Proposal and, after considering the advice of outside counsel, that failure to take such actions could be reasonably likely to result in a violation of the directors\u2019 fiduciary duties under applicable law, the Company may: (i) furnish information with respect to it to such Person making such Acquisition Proposal pursuant to a customary confidentiality agreement (subject to the requirement that any such information not previously provided to Nicolet shall be promptly furnished to Nicolet); (ii) participate in discussions or negotiations regarding such Acquisition Proposal; and (iii) terminate this Agreement in order to concurrently enter into an agreement with respect to such Acquisition Proposal; (Page 41)\n\nAnswer by only outputting a letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "When are representations and warranties required to be made according to the bring down provision?\nOption A: At Closing Only\nOption B: At Signing & At Closing\n\nMerger Agreement: 7.2 Additional Conditions to Obligations of Labrador and Merger Sub. <omitted> (iii)all other representations and warranties of Golden set forth in Article\u202fIV <omitted> shall have been true and correct as of the date of this Agreement and shall be true and correct as of the Closing Date, as though made on and as of the Closing Date (Page 44)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (a)   Except as otherwise provided in Section 2.02(b), Section 2.02(c) or Section 2.04, each share of Company Common Stock outstanding immediately prior to the Effective Time shall be converted into the right to receive $17.25 in cash, without interest (the \u201cMerger Consideration\u201d). As of the Effective Time, all such shares of Company Common Stock shall no longer be outstanding and shall automatically be canceled and retired and shall cease to exist, and shall thereafter represent only the right to receive the Merger Consideration to be paid in accordance with Section 2.03, without interest. (Page 9)\n\nAnswer and only output A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "When are representations and warranties required to be made according to the bring down provision?\nOption A: At Closing Only\nOption B: At Signing & At Closing\n\nMerger Agreement: 7.03 Conditions to Obligation of Peoples. The obligation of Peoples to consummate the Merger is also subject to the fulfillment or written waiver by Peoples prior to the Effective Time of each of the following conditions: (a) Representations and Warranties . The representations and warranties of Premier Financial set forth in this Agreement shall be true and correct, subject to Section 5.01, as of the date of this Agreement and as of the Effective Time as though made on and as of the Effective Time (except that representations and warranties that by their terms speak as of the date of this Agreement or some other date shall be true and correct as of such date) and Peoples shall have received a certificate, dated the Effective Date, signed on behalf of Premier Financial, by the Chief Executive Officer of Premier Financial to such effect. (Page 65)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is an \u201cIntervening Event\u201d required to occur after signing?\nOption A: No. It may occur or arise prior to signing.\nOption B: Yes. It must occur or arise after signing.\n\nMerger Agreement: \u201cAcquisition Proposal\u201d means any inquiry, offer, proposal or indication of interest (in writing or otherwise) from any Third Party relating to any transaction or series of related transactions involving (i) any acquisition or purchase by any Third Party, directly or indirectly, of 15% or more of any class of outstanding voting or equity securities of the Company, or any tender offer or exchange offer that, if consummated, would result in any Third Party beneficially owning 15% or more of any class of outstanding voting or equity securities of theCompany, (ii) any merger, amalgamation, consolidation, share exchange, business combination, asset acquisition, sale, joint venture, license, collaboration, research and development or other similar transaction involving assets or businesses that constitute or represent 15% or more of the consolidated revenue, net income or assets of the Company and the Company Subsidiaries, taken as a whole, (iii) any sale or license of (other than any non-exclusive license and non-material license granted by the Company in the ordinary course of business consistent with past practice), or joint venture, partnership or collaboration with respect to the Company Platform or any Company Product or (iv) any liquidation, dissolution, recapitalization, extraordinary dividend or other significant corporate reorganization of the Company, the business of which constitutes 15% or more of the consolidated revenue, net income or assets of the Company and the Company Subsidiaries, taken as a whole. <omitted> \u201cSuperior Proposal\u201d means a bona fide written Acquisition Proposal made by any Third Party after the date hereof that is on terms that the Company Board determines in good faith (after consultation with outside legal counsel and a financial advisor of nationally recognized reputation), taking into account all legal, financial, regulatory, and other aspects of the Acquisition Proposal and the Third Party making the Acquisition Proposal (including any conditions to closing and certainty of closing, timing, any applicable break-up fees and expense reimbursement provisions, and ability of such Third Party to consummate the Acquisition Proposal), (i) would, if consummated, result in a transaction that is more favorable to the holders of Company Common Stock (solely in their capacity as such) from a financial point of view than the Transactions (including any revisions to the terms of this Agreement proposed by Parent   10   pursuant to Section 7.8(d)) and (ii) is reasonably likely to be consummated on the terms proposed without undue delay; provided, however, that, for purposes of this definition of \u201cSuperior Proposal,\u201d references in the term \u201cAcquisition Proposal\u201d to \u201c15% or more\u201d shall be deemed to be references to \u201cmore than 50%\u201d; and further provided that in no event shall an Acquisition Proposal be deemed to be a Superior Proposal if consummation of the transaction contemplated thereby is subject to any financing condition or otherwise requires financing that is not fully committed (Pages 14-15)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cSuperior Proposal\u201d means a bona fide written Takeover Proposal that did not result from a breach of Section 6.06 and that the Company Board of Directors determines in good faith (after consultation with its financial advisor and outside counsel), considering all financial, legal, regulatory and other factors as the Company Board of Directors considers to be appropriate, is reasonably expected to be consummated and, if consummated, would be more favorable to the shareholders of the Company than the Merger; provided that for the purposes of this definition of \u201cSuperior Proposal,\u201d all references in the term Takeover Proposal to \u201c10% or more\u201d shall be deemed to be references to \u201cmore than 50%,\u201d all references to \u201cCompany Class A Shares, Company Class B Shares or Company Common Shares\u201d shall be deemed references to \u201cCompany Class A Shares, Company Class B Shares and Company Common Shares\u201d and all references to \u201cany class of equity securities\u201d shall be deemed to be references to \u201ceach class of equity securities.\u201d <omitted> \u201cTakeover Proposal\u201d means any inquiry, indication of interest, proposal or offer from any Third Party relating to (a) any direct or indirect acquisition or purchase, in a single transaction or a series of transactions, of (i) 10% or more of the outstanding (A) Company Class A Shares, (B) Company Class B Shares or (C) Company Common Shares or (ii) 10% or more (based on the fair market value thereof, as determined by the Company Board of Directors) of the assets (including capital stock of the Subsidiaries of the Company) of the Company and its Subsidiaries, taken as a whole, (b) any tender offer or exchange offer that, if consummated, would result in any Third-Party owning, directly or indirectly, 10% or more of the outstanding (i) Company Class A Shares, (ii) Company Class B Shares or (iii) Company Common Shares or (c) any merger, consolidation, business combination, recapitalization, liquidation, dissolution, binding share exchange or similar transaction involving the Company pursuant to which any Third Party (or the shareholders of any Third Party) would own, directly or indirectly, 10% or more of any class of equity securities of the Company or of the surviving entity in a merger or the resulting direct or indirect parent of the Company or such surviving entity, other than, in each case, the transactions contemplated hereby, (d) any issuance, sale or disposition, directly or indirectly, to any Person or group of any securities (or options, rights, warrants to purchase, or securities convertible into or exchangeable for, such securities) representing 10% or more of the voting power of the Company, or (e) any combination of the foregoing (in each case, other than the Merger and the transactions contemplated by this Agreement). (Page 15)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What type of consideration is specified in this agreement?\nOption A: All Cash\nOption B: All Stock\nOption C: Mixed Cash/Stock\nOption D: Mixed Cash/Stock: Election\n\nMerger Agreement: (b) Capital Stock of the Company. <omitted>   (i)          <omitted> each share of common stock <omitted> of the Company (\u201cCompany Common Stock\u201d), issued and outstanding immediately prior to the Effective Time <omitted> shall be converted into the right to receive <omitted> (A) $11.00 per share in cash, without interest, from Parent (such amount of cash, the \u201cCash Consideration\u201d) and (B) a number of validly issued, fully paid and nonassessable shares of Parent Common Stock equal to the Exchange Ratio from Parent (such shares of Parent Common Stock, together with the Cash Consideration, the \u201cMerger Consideration\u201d). <omitted>   (iv)          Each share of Company Preferred Stock shall remain outstanding as a share of Company Preferred Stock immediately following the Effective Time, and no consideration shall be delivered in exchange therefor. (Page 10)\n\nAnswer and only output A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 6.02   Company No Solicitation.  <omitted> (d)    Company Superior Proposal or Company Acquisition Agreement.  Except as expressly permitted by this Section 6.02, the Company Board shall not effect a Company Adverse Recommendation Change or enter into (or permit any of its Subsidiaries to enter into) a Company Acquisition Agreement.  Notwithstanding the foregoing, at any time prior to the receipt of the Requisite Company Vote, the Company Board may effect a Company Adverse Recommendation Change or enter into (or permit any Subsidiary to enter into) a Company Acquisition Agreement only if (i) the Company Board determines in good faith after consultation with its outside legal counsel and financial advisor of national reputation that a given Company Takeover Proposal constitutes or would reasonably be expected to lead to a Superior Proposal and that failure to effect a Company Adverse Recommendation Change in response to such actual or potential Company Superior Proposal would be inconsistent with the fiduciary duties owed by the Company Board to the stockholders of the Company under applicable Law, (ii) the Company promptly notifies Parent, in writing, at least three (3) Business Days (the \u201cCompany Superior Proposal Notice Period\u201d) before making a Company Adverse Recommendation Change with respect to a Company Superior Proposal or entering into (or causing one of its Subsidiaries to enter into) a Company Acquisition Agreement, of its intention to take such action with respect to a Company Superior Proposal, which notice shall state expressly that the Company has received a Company Takeover Proposal that the Company Board (or a committee thereof) intends to declare a Company Superior Proposal and that it intends to effect a Company Adverse Recommendation Change and/or the Company intends to enter into a Company Acquisition Agreement in connection with such Company Superior Proposal (it being understood that the delivery and receipt of any such notice shall not, in and of itself, be a Company Adverse Recommendation Change), (iii) the Company specifies the identity of the party making the Company Superior Proposal and the material terms and conditions thereof in such notice and includes an unredacted copy of the Company Takeover Proposal and attaches to such notice the most current version of any proposed agreement (which version shall be updated on a prompt basis) and any related documents, including financing documents, to the extent provided by the relevant party in connection with, and containing material terms of, the Company Superior Proposal, (iv) the Company shall, and shall cause its Representatives to, during the Company Superior Proposal Notice Period, negotiate with Parent in good faith to make such adjustments in the terms and conditions of this Agreement so that such Company Takeover Proposal ceases to constitute a Company Superior Proposal, if Parent, in its discretion, proposes to make such adjustments (it being understood and agreed that in the event that, after commencement of the Company Superior Proposal Notice Period, there is any material revision to the terms of a Company Superior Proposal, including, any revision in price or financing, the Company Superior Proposal Notice Period shall be extended, if applicable, to ensure that at least two (2) Business Days remains in the Company Superior Proposal Notice Period subsequent to the time the Company notifies Parent of any such material revision (it being understood that there may be multiple extensions)), and (v) at the conclusion of the Company Superior Proposal Notice Period, the Company Board (or a committee thereof) determines in good faith, after consulting with outside legal counsel and its financial advisor, that such Company Takeover Proposal continues to constitute a Company Superior Proposal after taking into account any adjustments made by Parent during the Company Superior Proposal Notice Period in the terms and conditions of this Agreement or otherwise and that the failure to make a Company Adverse Recommendation Change would be inconsistent with the Company directors\u2019 fiduciary duties under applicable Law. (Page 79)\n\nAnswer by outputting a singled letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: Section 7.2 Company Acquisition Proposals. <omitted> (e) <omitted> the Company Board may effect a Company Adverse Recommendation Change <omitted> if: (i) (A) a bona fide written Company Acquisition Proposal is made to the Company after the date of this Agreement <omitted> and such Company Acquisition Proposal is not withdrawn prior to such Company Adverse Recommendation Change or (B) there has been an Intervening Event; (ii) in the case of a Company Acquisition Proposal, the Company Board concludes in good faith, after consultation with the Company\u2019s outside financial advisors and outside legal counsel, that (x) such Company Acquisition Proposal constitutes a Superior Proposal and (y) failure to take such action would reasonably be expected to be inconsistent with the directors\u2019 fiduciary duties under applicable Laws; and (iii) in the case of an Intervening Event, the Company Board concludes in good faith, after consultation with the Company\u2019s outside legal counsel, that failure to take such action would reasonably be expected to be inconsistent with the directors\u2019 fiduciary duties under applicable Laws. (Page 75)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "In case the Buyer\u2019s consent for the acquired company\u2019s ordinary business operations is required, are there any limitations on the Buyer\u2019s right to condition, withhold, or delay their consent?\nOption A: Yes. Consent may not be unreasonably withheld, conditioned or delayed.\nOption B: No.\n\nMerger Agreement: 7.1.    Interim Operations.   (a)    The Company covenants and agrees that, from the execution of this Agreement until the Effective Time (unless Parent shall otherwise consent in writing (such consent not to be unreasonably withheld, conditioned or delayed)), and except (x) as otherwise expressly required, contemplated or permitted by this Agreement, (y) as set forth in Section 7.1(a) of the Company Disclosure Letter or (z) as required by applicable Laws (including any Law issued in response to the COVID-19 (or SARS-CoV-2) virus), the Company shall use its reasonable best efforts to conduct its business in the ordinary course of business consistent with past practice in all material respects and, to the extent consistent therewith, it shall use its reasonable best efforts to preserve its business organizations substantially intact and maintain existing relations and goodwill with Governmental Entities, customers, suppliers, production companies, distributors, licensees, licensors, creditors, lessors, employees and business associates and others having material business dealings with it and keep available the services of its present employees and agents. (Page 38)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of stock deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 6.02          No Solicitation by the Company.  <omitted> (d)          <omitted> the Board of Directors of the Company may <omitted> (i) make a Company Adverse Recommendation Change <omitted> provided, that (A) the Company shall first notify Parent in writing at least four Business Days before taking such action that the Company intends to take such action, <omitted> (D) in the event of any change, from time to time, to any of the financial terms or any other material terms of such Company Superior Proposal, the Company shall, in each case, have delivered to Parent an additional notice consistent with that described in clause (A) of this proviso and a new notice period under clause (A) of this proviso shall commence each time, except each such notice period shall be three Business Days (instead of four Business Days), during which time the Company shall be required to comply with the requirements of this Section 6.02(d) anew with respect to each such additional notice, including clauses (A) through (D) above of this proviso. (Page 76)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in GAAP or other accounting principles that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means, when used with respect to either Golden or Labrador, any fact, circumstance, effect, change, event or development (\u201cEffect\u201d) that has had, or would have, a material adverse effect on the financial condition, business or operations of such Party and its Subsidiaries, taken as a whole; provided, however, that no Effect (by itself or when aggregated or taken together with any and all other Effects) to the extent directly or indirectly resulting from, arising out of, attributable to, or related to any of the following shall be deemed to be or constitute a \u201cMaterial Adverse Effect\u201d or shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur: \u202f A-7 \u202f \u202f (i)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fgeneral economic conditions (or changes in such conditions) or changes in global or national economic conditions generally; \u202f (ii)conditions (or changes in such conditions) in the securities markets, credit markets, currency markets or other financial markets, including (A)changes in interest rates and changes in exchange rates for the currencies of any countries and (B)any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market; \u202f (iii)conditions (or changes in such conditions) in the oil and gas exploration, development or production industry (including changes in commodity prices, general market prices and regulatory changes affecting the industry); \u202f   (iv)political conditions (or changes in such conditions) or acts of war, sabotage or terrorism (including any escalation or general worsening of any such acts of war, sabotage or terrorism); \u202f (v)acts of god or force majeure events, including earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, pandemics (including the existence and impact of the COVID-19 pandemic) or weather conditions; \u202f (vi)the announcement of this Agreement or the pendency or consummation of the Transactions (other than with respect to any representation or warranty that is intended to address the consequences of the execution or delivery of this Agreement or the announcement or consummation of the Transactions); \u202f (vii)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fcompliance with the terms of, or the taking of any action expressly required by, this Agreement (except for any obligation under this Agreement to operate in the Ordinary Course (or similar obligation) pursuant to Sections 6.1 or 6.1(a), as applicable); \u202f (viii)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fchanges in Law or other legal or regulatory conditions, or the interpretation or enforcement thereof, or changes in GAAP or other accounting standards (or the interpretation or enforcement thereof), or that result from any action taken for the purpose of complying with any of the foregoing; or \u202f (ix)\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202fany changes in such Party\u2019s stock price or the trading volume of such Party\u2019s stock, or any failure by such Party to meet any analysts\u2019 estimates or expectations of such Party\u2019s revenue, earnings or other financial performance or results of operations for any period, or any failure by such Party or any of its Subsidiaries to meet any internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations for any period (it being understood that the facts or occurrences giving rise to or contributing to such changes or failures may constitute, or be taken into account in determining whether there has been or will be, a Material Adverse Effect); \u202f A-8 \u202f \u202f provided, however, except to the extent such Effects directly or indirectly resulting from, arising out of, attributable to or related to the matters described in the foregoing clauses (i)through (v)(excluding any Effect arising out of, resulting from or related to COVID-19 or COVID-19 Measures) disproportionately adversely affect such Party and its Subsidiaries, taken as a whole, as compared to other similarly situated industry participants (it being understood and agreed that, for the purposes of determining whether a Party has been disproportionately adversely affected compared to other similarly situated industry participants, Golden shall be compared to independent exploration and production companies primarily focused in the Permian Basin and Labrador shall be compared to independent exploration and production companies primarily focused in the Marcellus natural gas trend), in which case only the incremental disproportionate impact shall be taken into account when determining whether a \u201cMaterial Adverse Effect\u201d has occurred or may, would or could occur. (Pages 53-54)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in connection with the Fiduciary Termination Right (FTR)?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: 5 calendar days\nOption H: Greater than 5 business days\n\nMerger Agreement: Section 5.3. No Solicitation by the Company. <omitted>  (d) Notwithstanding anything in this Section 5.3 to the contrary, but subject to Section 5.3(e), at any time prior to the Company Stockholder Approval being obtained, the Company Board of Directors may (i) make a Change of Recommendation (only of the type contemplated by Section 5.3(a)(iv) or Section 5.3(a)(vi)) in response to an Intervening Event if the Company Board of Directors has determined in good faith after consultation with the Company\u2019s outside legal counsel and financial advisors, that the failure to take such action would be reasonably likely to violate the directors\u2019 fiduciary duties under applicable Law or (ii) make a Change of Recommendation and cause the Company to terminate this Agreement pursuant to and in accordance with Section 8.1(h) in order to enter into a definitive agreement providing for an unsolicited Acquisition Proposal received after the date of this Agreement (which, for the avoidance of doubt, did not result from a breach of this Section 5.3 and such Acquisition Proposal is not withdrawn) if the Company Board of Directors determines in good faith after consultation with the Company\u2019s outside legal counsel and financial advisors that such Acquisition Proposal constitutes a Superior Proposal, but only if the Company Board of Directors has determined in good faith after consultation with the Company\u2019s outside legal counsel and financial advisors, that failure to take such action would be reasonably likely to violate the directors\u2019 fiduciary duties under applicable Law; provided that notwithstanding anything to the contrary herein, neither the Company nor any Company Subsidiary shall enter into any Company Acquisition Agreement unless this Agreement has been validly terminated in accordance with Section 8.1. \u201cIntervening Event\u201d means any Effect that is material to the Company and the Company Subsidiaries (taken as a whole) and was not known by or reasonably foreseeable to the Company or the Company Board of Directors as of or prior to the date hereof; provided, however, that in no event shall the following events, changes or developments constitute an Intervening Event: (A) the receipt, existence or terms of an Acquisition Proposal or any inquiry or communications relating thereto or any matter relating thereto or consequence thereof, (B) changes in the market price or trading volume of the Class A Common Stock, the   -58-   Parent Common Stock or any other securities of the Company, Parent or their respective Subsidiaries, or any change in credit rating or the fact that the Company meets or exceeds (or that Parent fails to meet or exceed) internal or published estimates, projections, forecasts or predictions for any period, (C) changes in general economic, political or financial conditions or markets (including changes in interest rates, exchange rates, stock, bond and/or debt prices), (D) changes in GAAP, other applicable accounting rules or applicable Law or, in any such case, changes in the interpretation thereof or (E) natural disasters, epidemics or pandemics (including the existence and impact of the COVID-19 pandemic).  (e) Prior to the Company taking any action permitted (i) under Section 5.3(d)(i), the Company shall provide Parent with four (4)- Business Days\u2019 prior written notice advising Parent that the Company Board of Directors intends to effect a Change of Recommendation and specifying, in reasonable detail, the reasons therefor, and during such four (4) Business Day period (which period shall expire at 11:59 p.m., Pacific Time, on the fourth (4th) Business Day), the Company shall cause its Representatives (including its executive officers) to negotiate in good faith (to the extent Parent desires to negotiate) any proposal by Parent to amend the terms and conditions of this Agreement in a manner that would obviate the need to effect a Change of Recommendation and at the end of such four (4) Business Day period (which period shall expire at 11:59 p.m., Pacific Time, on the fourth (4th) Business Day) the Company Board of Directors again makes the determination under Section 5.3(d)(i) (after in good faith taking into account any amendments proposed by Parent) or (ii) under Section 5.3(d)(ii), the Company shall provide Parent with four (4) Business Days\u2019 prior written notice advising Parent that the Company Board of Directors intends to take such action and specifying the material terms and conditions of the Acquisition Proposal, including a copy of any proposed definitive documentation, and during such four (4) Business Day period (which period shall expire at 11:59 p.m., Pacific Time, on the fourth (4th) Business Day), the Company shall cause its Representatives (including its executive officers) to negotiate in good faith (to the extent Parent desires to negotiate) any proposal by Parent to amend the terms and conditions of this Agreement such that such Acquisition Proposal would no longer constitute a Superior Proposal and at the end of such four (4) Business Day period (which period shall expire at 11:59 p.m., Pacific Time, on the fourth (4th) Business Day) the Company Board of Directors again makes the determination under Section 5.3(d)(ii) (after in good faith taking into account the amendments proposed by Parent). With respect to Section 5.3(e)(ii), if there are any material amendments, revisions or changes to the terms of any such Superior Proposal (including any revision to the amount, form or mix of consideration the Company Stockholders would receive as a result of the Superior Proposal), the Company shall notify Parent of each such amendment, revision or change in compliance with Section 5.3(c) and the applicable four (4) Business Day period shall be extended until at least three (3) Business Days after the time that Parent receives notification from the Company of each such revision, and the Company Board of Directors shall not take any such action permitted under Section 5.3(d)(ii) prior to the end of any such period (which period shall expire at 11:59 p.m., Pacific Time, on the applicable day) as so extended in accordance with the terms of this Section 5.3(e). (Page 63)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is Change of Recommendation permitted as long as the board determines that such change is required to fulfill its fiduciary obligations?\nOption A: No\nOption B: Yes\n\nMerger Agreement: Section 7.3 No Solicitation by the Company. <omitted> the Company Board may effect a Company Adverse Recommendation Change <omitted> if: (i)(A) a Company Acquisition Proposal is made to the Company after the date of this Agreement and such Company Acquisition Proposal is not withdrawn prior to such Company Adverse Recommendation Change or (B) there has been an Intervening Event; (ii) in the case of a Company Acquisition Proposal, the Company Board concludes in good faith, after consultation with the Company\u2019s outside financial advisors and outside legal counsel, that such Company Acquisition Proposal constitutes a Superior Company Proposal; and (iii) the Company Board concludes in good faith, after consultation with the Company\u2019s outside legal counsel, that failure to take such action would be reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Laws (Page 69)\n\nAnswer by only outputting the option letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in response to an intervening event?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: Other specified standard\n\nMerger Agreement: Section 5.3    Acquisition Proposals. <omitted> (e)    Change of Recommendation / Superior Proposal Termination. Notwithstanding anything to the contrary in this Agreement, at any time prior to the time the Company Stockholder Approval is obtained, (x) the Company Board may make a Change of Recommendation (1) if the Company receives a bona fide unsolicited Acquisition Proposal following the Agreement Date that did not result from a violation of Section 5.3(a) and the Company Board determines in good faith (after consultation with the Company\u2019s outside legal and financial advisors) based on the information then available that such Acquisition Proposal constitutes a Superior Proposal or (2) other than in connection with an Acquisition Proposal, in response to an event, occurrence, development or state of facts or circumstances occurring after the Agreement Date that was not known by the Company Board prior to the Agreement Date, in either case of (1) or (2), only if the Company Board determines in good faith that the failure to take such action would be inconsistent with the directors\u2019 fiduciary duties under applicable Law and (y) if the Company Board is permitted to make a Change of Recommendation pursuant to clause (x)(1), the Company may also terminate this Agreement pursuant to Section 7.1 to enter into an Alternative Acquisition Agreement with respect to the applicable Superior Proposal; (Page 35)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, or I.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the knowledge requirement in the definition of \u201cIntervening Event\u201d?\nOption A: Known, but consequences unknown or not reasonably foreseeable, at signing\nOption B: Known, but consequences unknown, at signing\nOption C: Not known and not reasonably foreseeable at signing\nOption D: Not known at signing\n\nMerger Agreement: \u201cSuperior Proposal\u201d shall mean, with respect to a party hereto, any bona fide written Acquisition Proposal with respect to such party made by a third party to acquire, directly or indirectly, pursuant to a tender offer, exchange offer, merger, share exchange, consolidation or other business combination, (A) all or substantially all of the assets of such party and its Subsidiaries, taken as a whole, or (B) all or substantially all of the common equity securities of such party, in each case on terms which a majority of the board of directors of such party determines in good faith (after consultation with its financial advisors and outside legal counsel, and taking into account all financial, legal and regulatory terms and conditions of the Acquisition Proposal and this Agreement, including any alternative transaction (including any modifications to the terms of this Agreement) proposed by the other party hereto pursuant to Section 5.4, including any conditions to and expected timing of consummation, and any risks of non-consummation, of such Acquisition Proposal) to be more favorable to such party and its stockholders (in their capacity as stockholders) as compared to the transactions contemplated hereby and to any alternative transaction (including any modifications to the terms of this Agreement) proposed by any other party hereto pursuant to Section 5.4. (Page 120)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Under what circumstances could the Board take actions on a different acquisition proposal notwithstanding the no-shop provision?\nOption A: If failure to take actions would lead to \"breach\" of fiduciary duties\nOption B: If failure to take actions would be \"inconsistent\" with fiduciary duties\nOption C: If failure to take actions would lead to \"reasonably likely/expected breach\" of fiduciary duties\nOption D: If failure to take actions would lead to \"reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: If failure to take actions would lead to \"reasonably likely/expected violation\" of fiduciary duties\nOption F: If taking such actions is \"required to comply\" with fiduciary duties\nOption G: If failure to take actions would lead to \"violation\" of fiduciary duties\nOption H: Under no circumstances could the Board do so.\nOption I: Other circumstances\n\nMerger Agreement: 6.3          No Solicitation by NIC. <omitted> (b)          Notwithstanding the limitations set forth in this Agreement, if NIC or any of its Representatives receives, <omitted> an <omitted> Acquisition Proposal <omitted> which the NIC Board of Directors determines in good faith after consultation with NIC\u2019s outside legal counsel and financial advisors (i) constitutes a Superior Proposal or (ii) would reasonably be expected to result in a Superior Proposal, then in either event NIC may take the following actions: (A) furnish information with respect to NIC and the NIC Subsidiaries to the person making such Acquisition Proposal and its Representatives, if, and only if, prior to so furnishing such information, NIC receives from such person an executed Acceptable Confidentiality Agreement and NIC also provides Tyler, prior to or substantially concurrently with (and in any event within 24 hours after) the time such information is provided or made available to such person, any nonpublic information furnished to such other person that was n o t previously furnished to Tyler, and (B) engage in discussions or negotiations with such person and its Representatives with respect to such Acquisition Proposal.  NIC shall promptly (and in any event within 24 hours after such determination) inform Tyler in writing if NIC determines to begin providing information or to engage in discussions or negotiations concerning an Acquisition Proposal pursuant to this Section 6.3(b). (Page 36)\n\nAnswer by only outputting the letter (i.e. A, B, C, D, E, F, G, H, or I) of the relevant option.",
        "output": "H",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What standard should the board follow when determining whether to change its recommendation in connection with a superior offer?\nOption A: \"Breach\" of fiduciary duties\nOption B: \"Inconsistent\" with fiduciary duties\nOption C: \"Reasonably likely/expected breach\" of fiduciary duties\nOption D: \"Reasonably likely/expected to be inconsistent\" with fiduciary duties\nOption E: \"Reasonably likely/expected violation\" of fiduciary duties\nOption F: \"Required to comply\" with fiduciary duties\nOption G: \"Violation\" of fiduciary duties\nOption H: More likely than not violate fiduciary duties\nOption I: None\nOption J: Other specified standard\n\nMerger Agreement: 7.5          Acquisition Proposals. <omitted> (b)          No Change in Recommendation or Alternative Acquisition Agreement. <omitted> Notwithstanding anything to the contrary set forth in this Agreement, the Company Board or the Hospitality Board may, prior to but not after the time the Requisite Vote is obtained, (A) make a Change of Recommendation if an Intervening Event has occurred and if, after consulting with its financial advisor and outside legal counsel, the Company Board or the Hospitality Board determines in good faith that the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law or (B) if the Paired Entities have not breached this Section 7.5(c) and have not breached the other subsections of this Section 7.5 in any material respect, make a Change of Recommendation and/or terminate this Agreement pursuant to Section 9.1(c)(i) if the Paired Entities receive an Acquisition Proposal (not resulting from a breach of this Section 7.5) that the Company Board and the Hospitality Board have determined in good faith, after consulting with their financial advisor and outside legal counsel, (x) constitutes a Superior Proposal after having complied with, and giving effect to all of the adjustments which may be offered by Parent pursuant to, this Section 7.5(b) and such Acquisition Proposal is not withdrawn and (y) the failure to take such action would be reasonably likely to be inconsistent with such directors\u2019 fiduciary duties under applicable Law; provided that neither the Company Board nor the Hospitality Board may take any such action unless prior to making such Change of Recommendation or authorizing such termination to enter into a definitive written agreement providing for the implementation of such Superior Proposal pursuant to Section 9.1(c)(i), (I) the Paired Entities provide prior written notice (\u201cNotice Period Commencement Notice\u201d) to Parent at least four (4) Business Days in advance (the \u201cNotice Period\u201d) of their intention to take such action, which notice shall include, in the case of a Superior Proposal, the name of the person or group making the Superior Proposal and substantial final draft of the definitive agreement reflecting such Superior Proposal and, in the case of an Intervening Event, a reasonably detailed description of such Intervening Event, (II) if requested by Parent, during the Notice Period the Paired Entities shall, and shall direct their Representatives to, negotiate with Parent in good faith should Parent propose to make amendments or other revisions to the terms and conditions of this Agreement such that, in the case of a Superior Proposal, such Acquisition Proposal no longer constitutes a Superior Proposal and, in the case of an Intervening Event, the failure to take such action is no longer reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law as determined in the good faith judgment of the Company Board or the Hospitality Board after consulting with their financial advisor and outside legal counsel and (III) the Company Board and the Hospitality Board has taken into account any amendments or other revisions to the terms and conditions of this Agreement agreed to by Parent in writing prior to the end of the Notice Period and (1)  the Company Board and the Hospitality Board determined in good faith that, after consulting with its financial advisor and outside legal counsel, in the case of an Intervening Event, a failure to make such Change of Recommendation continues to be reasonably likely to be inconsistent with the directors\u2019 fiduciary duties under applicable Law and (2) the Company Board and the Hospitality Board determined in good faith that, after consulting with their financial advisor and outside legal counsel, in the case of an Acquisition Proposal, the Acquisition Proposal giving rise to such Change of Recommendation continues to constitute a Superior Proposal and the failure to make such Change of Recommendation continues to be inconsistent with the directors\u2019 fiduciary duties under applicable Law; it being understood that any change to the financial terms or any other material amendments or other material revisions to any Acquisition Proposal will be deemed to be a new Acquisition Proposal, including for purposes of the Notice Period; provided, however, that, subsequent to the initial Notice Period, the Notice Period shall be reduced to two (2) Business Days following receipt by Parent of any such new Notice Period Commencement Notice. (Page 59)\n\nAnswer by only outputting the letter option letter A, B, C, D, E, F, G, H, I or J.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "How long is the initial matching rights period in case the board changes its recommendation?\nOption A: 2 business days or less\nOption B: 3 business days\nOption C: 3 calendar days\nOption D: 4 business days\nOption E: 4 calendar days\nOption F: 5 business days\nOption G: Greater than 5 business days\n\nMerger Agreement: Section 6.04. No Solicitation; Other Offers. <omitted> ( b )   Exceptions.  Notwithstanding  anything  contained  in  this Agreement  to  the  contrary,  at  any  time  prior  to  receipt  of  the  Company  Stockholder Approval: <omitted> (ii) the Board of Directors may <omitted> make an Adverse Recommendation Change <omitted>  (d)   Last Look. Neither the Board of Directors nor the Company shall take any of the actions referred to in Section 6.04(b)(ii) unless (i) the Company shall have notified Parent, in writing and at least four Business Days prior to taking such action (the \u201cNotice Period\u201d), of its intention to take such action, specifying, in reasonable detail, the reasons for the Adverse Recommendation Change and attaching a copy of any proposed agreements for the Superior Proposal, if applicable, (ii) during the Notice Period, the Company negotiated with Parent and its Representatives in good faith (to the extent that Parent desires to so negotiate) to make such adjustments to the terms and conditions of this Agreement as would enable the Board of Directors to maintain the Company Recommendation and not make an Adverse Recommendation Change or, in the case of a Superior Proposal, terminate this Agreement; and (iii) following the expiration of the Notice Period, the Board of Directors determines in good faith, taking into account any amendments to the terms hereof proposed by Parent, that the failure to effect an Adverse Recommendation Change would be reasonably likely to be inconsistent with its fiduciary duties; provided, however, that in the event of any amendment to the financial terms or any other material terms of an Acquisition Proposal, the Company will be required to deliver a new written notice to Parent and to comply with the requirements of this Section 6.04(d) with respect to such new written notice (it being understood that the \u201cNotice Period\u201d in respect of such new written notice will be two Business Days). (Page 24)\n\nAnswer and only output A, B, C, D, E, F, G or H.",
        "output": "D",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What qualifies as a superior offer in terms of asset deals?\nOption A: \"All or substantially all\"\nOption B: 50%\nOption C: Greater than 50% but not \"all or substantially all\"\nOption D: Less than 50%\n\nMerger Agreement: Section 6.3          No Solicitation of Transactions. <omitted> the Company Board may not effect a Change of Board Recommendation unless: (i) the Company shall have provided prior <omitted> notice to Parent <omitted> of its intention to effect such a Change of Board Recommendation <omitted> In the event of any amendment to the financial terms or any other material revisions to the Superior Proposal, the Company shall be required to deliver a new written notice to Parent pursuant to Section 6.3(d)(i) and to comply with the requirements of this Section 6.3(d) with respect to such new written notice (including a new Superior Proposal Notice Period), except that the Superior Proposal Notice Period shall be at least two Business Days (rather than the four Business Days contemplated by Section 6.3(d)(i) above). (Page 39)\n\nAnswer by only outputting the letter option letter A, B, C or D.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the Forward Looking Standard (FLS) with respect to Material Adverse Effect (MAE)?\nOption A: \"Could\" (reasonably) be expected to\nOption B: \"Would\"\nOption C: \"Would\" (reasonably) be expected to\nOption D: No\nOption E: Other forward-looking standard\n\nMerger Agreement: \u201cCompany Material Adverse Effect\u201d means any Effect that, individually or in the aggregate with all other Effects, is or would reasonably be expected to (A) be materially adverse to the business, financial condition, assets, Liabilities or results of operations of the Company and its Subsidiaries, taken as a whole or (B) prevent or materially delay the consummation of the Transactions past the Outside Date; provided that, solely with respect to the foregoing clause (A), none of the following Effects (and no Effect that directly results from or arises in connection with the following) shall constitute or shall be taken into account in determining whether there is a Company Material Adverse Effect to the extent resulting from or arising out of: (a) changes in or affecting the economies or general business, economic, regulatory or legislative conditions or securities, financial, credit or capital market conditions (including changes generally in prevailing interest rates, currency exchange rates, credit markets or equity price levels, trading volumes or the imposition of new or increased tariffs) anywhere in the world in which the Company and its Subsidiaries operate, (b) changes in the trading volume or trading price of Shares (provided that the facts and circumstances giving rise to such changes in such volume or price may be deemed to constitute, and may be taken into account in determining whether there is, a Company Material Adverse Effect), (c) changes in the industry in which the Company and its Subsidiaries operate, (d) national or international political conditions, acts of war (whether or not declared), the threat, commencement, continuation or escalation of a war, acts of armed hostility, sabotage, terrorism or cyber intrusion, government shutdown or other international or national calamity or any material worsening of such conditions threatened, or existing as of the Agreement Date, (e) changes (or prospective changes) in Law or GAAP (or in the interpretation thereof), (f) any failure by the Company to meet its guidance or any published analyst projections, estimates or expectations of the Company\u2019s past or projected revenue, earnings or other financial performance or results of operations for any period, in and of itself, and any resulting analyst downgrade of the Company\u2019s securities, or any failure by the Company to meet its internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations, in and of itself (provided that the facts and circumstances giving rise to such failures may be deemed to constitute, and may be taken into account in determining whether there is a Company Material Adverse Effect if such facts and circumstances are not otherwise excluded under this definition), (g) any legal or related Proceedings made or brought by any of the current or former Company Stockholders (on their own behalf or on behalf of the Company) against the Company or the Company Board, relating to, in connection with, or arising out of the Merger or the other Transactions, including the Proxy Statement, (h) any Effects directly or indirectly attributable to the execution, announcement or pendency of this Agreement or the anticipated consummation of the Merger (including the identity of, or any facts or circumstances relating to, Parent as the acquirer of the Company), including the impact thereof on relationships, contractual or otherwise, with officers, employees, customers, suppliers, distributors, vendors, licensors, licensees, lenders, investors, Governmental Authorities, subcontractors or partners (including the exercise, or prospective exercise, by any party of rights that arise upon a change of control) (provided, that this clause (h) shall not apply to any representations and warranties set forth in Section 2.4 or the condition set forth in Section 5.2(a) to the extent related thereto), (i) fires, pandemics, epidemics, disease outbreaks, quarantine restrictions, earthquakes, hurricanes, tornadoes or other natural or man-made disaster or any other national or international calamity, crisis or disaster, or any escalation or worsening of any of the foregoing and including any COVID-19 Responses taken in compliance with Section 4.1 and (j) except for the obligations of the Company and its Subsidiaries set forth in the first sentence of Section 4.1, any Effects resulting from or arising out of (i) the failure by the Company or any of its Subsidiaries to take any action expressly prohibited by this Agreement or (ii) any actions taken by the Company or any of its Subsidiaries as expressly required by this Agreement or with the prior written consent, or at the prior written request, of Parent or Merger Sub after disclosure to Parent of all material facts and information; provided that, with respect to clauses (a), (c), (d), (e) and (i), only to the extent such Effect does not adversely affect the Company and its Subsidiaries, taken as a whole, in a disproportionate manner relative to other similarly situated participants in the industry in which the Company and its Subsidiaries operate (in which case only the incremental disproportionate impact or impacts may be taken into account in determining whether there has been a Company Material Adverse Effect). (Page 34)\n\nAnswer by outputting a singled letter A, B, C, D or E.",
        "output": "C",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Is \u201cfinancial point of view\u201d the sole consideration when determining whether an offer is superior?\nOption A: No\nOption B: Yes\n\nMerger Agreement: 6.3 No Solicitation by the Company. <omitted>  (e) Notwithstanding anything in this Agreement to the contrary: <omitted>  (iii) prior to, but not after, the receipt of the Company Stockholder Approval, in response to a bona fide written Competing Proposal from a third party that did not arise from a breach of the obligations set forth in this Section 6.3, if the Company Board so chooses, the Company Board may effect a Company Change of Recommendation; provided, however, that such a Company Change of Recommendation may not be made unless and until: (A) the Company Board determines in good faith after consultation with its financial advisors and outside legal counsel that such Competing Proposal is a Superior Proposal;   -56-   (B) the Company Board determines in good faith, after consultation with its outside legal counsel, that failure to effect a Company Change of Recommendation in response to such Superior Proposal would be inconsistent with the fiduciary duties owed by the Company Board to the stockholders of the Company under applicable Law; (C) the Company provides Parent written notice of such proposed action and the basis thereof four (4) Business Days in advance, which notice shall set forth in writing that the Company Board intends to take such action and the reasons therefor (including the financial analyses conducted by or on behalf of the Company Board); (D) after giving such notice and prior to effecting such Company Change of Recommendation, the Company negotiates (and causes its Representatives to negotiate) in good faith with Parent (to the extent Parent wishes to negotiate) to make such adjustments or revisions to the terms of this Agreement as would permit the Company Board not to effect a Company Change of Recommendation in response thereto; and (E) at the end of the four (4) Business Day period, prior to taking action to effect a Company Change of Recommendation, the Company Board takes into account any adjustments or revisions to the terms of this Agreement proposed by Parent in writing and any other information offered by Parent in response to the notice, and determines in good faith after consultation with its financial advisors of nationally recognized reputation and outside legal counsel, that the Competing Proposal remains a Superior Proposal and that the failure to effect a Company Change of Recommendation in response to such Superior Proposal would be inconsistent with the fiduciary duties owed by the Company Board to the stockholders of the Company under applicable Law; provided, that in the event of any material amendment or material modification to any Superior Proposal (it being understood that any amendment or modification to the economic terms of any such Superior Proposal shall be deemed material), the Company shall be required to deliver a new written notice to Parent and to comply with the requirements of this Section 6.3(e)(iii)(E) with respect to such new written notice, except that the advance written notice obligation set forth in this Section 6.3(e)(iii)(E) shall be reduced to two (2) Business Days; provided, further, that any such new written notice shall in no event shorten the original four (4) Business Day notice period; and (Pages 60-61)\n\nAnswer by outputting a singled letter A or B.",
        "output": "A",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "What is the liability standard for no-shop breach by Target Non-D&O Representatives?\nOption A: Reasonable standard\nOption B: Strict liability\n\nMerger Agreement: \u201cKnowledge\u201d means with <omitted>  that any of Harry H. Herington, Stephen M. Kovzan, Jayne Friedland Holland, or William A. Van Asselt is actually aware of the particular fact or matter (Page 61)\n\nAnswer and only output A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Do changes in GAAP or other accounting principles that have disproportionate impact qualify for Material Adverse Effect (MAE)?\nOption A: No\nOption B: Yes\n\nMerger Agreement: \u201cMaterial Adverse Effect\u201d means any event, change, development, circumstance, fact or effect that, individually or taken together with any other events, changes, developments, circumstances, facts or effects that have occurred prior to the date of determination of the occurrence of a Material Adverse Effect, (x) is, or would reasonably be expected to be, materially adverse to the condition (financial or otherwise), properties, assets, liabilities (fixed, contingent or otherwise), business operations or results of operations of the Company and its Subsidiaries (taken as a whole) or (y) would prevent, materially delay, or materially impair the ability of the Company to consummate the Offer and/or Merger; provided, however, that, with respect to clause (x), no such event, change, development, circumstance, fact or effect to the extent resulting from any of the following, either individually or in the aggregate, shall be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur:   (a)           events, changes, developments, circumstances, facts or effects that are the result of factors generally affecting the economy, credit, capital, securities or financial markets or political, regulatory or business conditions in the geographic markets in which the Company or any of its Subsidiaries operate or their products or services are sold;   (b)           events, changes, developments, circumstances, facts or effects that are the result of factors generally affecting the industries in which the Company or any of its Subsidiaries operate in the geographic markets in which they operate or where their products or services are sold;   (c)           events, changes, developments, circumstances, facts or effects arising from the announcement of this Agreement, the consummation of the transactions contemplated by this Agreement or the identity of Parent, Merger Sub or their Affiliates as the acquiror of the Company, including (i) in or with respect to, the relationship of the Company or any of its Subsidiaries, contractual or otherwise, with customers, Governmental Entities, employees, labor unions, labor organizations, works councils or similar organizations, suppliers, distributors, financing sources, partners or similar relationship; or (ii) any Transaction Litigation (but not any finally adjudicated breach of fiduciary duty or violation of Law itself);   (d)           changes in GAAP or in any applicable Law, including changes in COVID-19 Measures;   (e)           any failure by the Company to meet any internal or public projections or forecasts or estimates of revenues or earnings; provided that any event, change, development, circumstance, fact or effect underlying such failure may be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur;   (f)            any event, change, development or effect resulting from acts of war (whether or not declared), civil disobedience or unrest, sabotage, terrorism, military or para-military actions or the escalation of any of the foregoing, any natural disaster or calamity or any outbreak of illness or other public health event (including COVID-19 and variants thereof and other pandemics) in each case to the extent not caused by the Company or any of its Subsidiaries or its or their respective Representatives;   (g)           a decline in the market price of the Shares on the NASDAQ; provided that any event, change, development or effect underlying such decline in market price may be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur;     -10-       (h)           any action taken (or failure to take any action) by the Company that is expressly required or prohibited (as applicable) by the terms of this Agreement; provided further that, with respect to clauses (a), (b), (d) and (f) of this definition, such events, changes, developments, circumstances, facts or effects (as the case may be) shall be taken into account in determining whether a \u201cMaterial Adverse Effect\u201d has occurred or would reasonably be expected to occur to the extent (but only to such extent) they disproportionately adversely affect the Company and its Subsidiaries (taken as a whole) relative to other companies operating in the industries in which the Company and its Subsidiaries operate. (Page 8)\n\nAnswer by only outputting the option letter A or B.",
        "output": "B",
        "instruction": "Read the segment of a merger agreement and answer the multiple-choice question by choosing the option that best characterizes the agreement.",
        "domain": "legal",
        "task": "mc"
    },
    {
        "input": "Clause:   If you have any questions (or comments) concerning this Policy, please email us at privacy@fiverr.com, and we will make an effort to reply within a reasonable timeframe.\nQuestion: can other people see my financial information\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Potential situations when you may make personal data available to Lima Sky include, but are not limited to: (i) registration for Services, including leaderboards; (ii) subscribing to newsletters; (iii) requesting technical support; and (iv) otherwise through use of Services where personal data is required for use and/or participation.\nQuestion: hwere is it saved\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: (a)Make our service available: We use your Registration and Account information to (i) register you for the App and create your User Account for Viber; (ii) create your profile and make it visible; (iii) process your payments; (iv) create your Viber ID; (v) provide customer service, give you information about your account, and respond to your requests; (vi) personalize your experience by providing content (such as games) on the Service, including targeted advertising of Viber services and other 3rd party services that we believe may be of most interest to you; personalization may include automated decisions about what you will view and when, but be assure that it will not have legal effects on you (vii) indicate which of your contacts is already a Viber member and notify you when your contacts become active on the Service (viii) display the name of the contact as it appears in your address book when a call is received on the Service, and (ix) sync your contacts with Viber running on Windows, MacOS, Linux, Android tablets, iPads and Windows Tablets.\nQuestion: does this send information to a third party?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please check their policies before submitting any of your personal data.\nQuestion: will the application make money off of the info i enter in the app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We do not use or collect your precise geographic location.\nQuestion: does it share my location to anyone?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may use, record and store archives of these communications on PeopleFuns servers to protect the safety and well being of our users and PeopleFuns rights and property in connection with the Services.\nQuestion: does it read my contacts?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Service providers are third parties (other companies or individuals) that help us to provide, analyze and improve our Services.\nQuestion: do you ever sell my personal information to other companies for marketing purposes?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: What happens if you do NOT consent to 23andMe Research?\nQuestion: will my password be stored securely?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: The Site may be accessible through or contain connections to areas where you may be able to publicly post information, communicate with others such as discussion boards or blogs, review products and merchants, and submit media content.\nQuestion: can other users see any of my personal info if i use groupon?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you have completed the Individual Level Data Sharing Consent, or additional consent agreement, in addition to the uses above under the Main Consent Document, 23andMe may share De-identified Individual-level Genetic Information and Self-Reported Information with select third party research collaborators for 23andMe partners for Research purposes.\nQuestion: will you sell my information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For individuals located in the Designated Countries: Our legal basis for processing your Sensitive Information for the purpose described above is based on your consent.\nQuestion: will the information be shared with a 3rd party\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will receive interaction information from your use of our Services.\nQuestion: does the app protect my account details from being accessed by other people?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may share your information (in some cases personal information) with third parties in the following circumstances:\nQuestion: does the app contain third party ads?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you are a California resident and want such a list, please contact us atCaliforniaRequest@viber.com.\nQuestion: are my message encrypted on viber?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may disclose aggregated and anonymous information to describe the Services to prospective partners, advertisers, and other third parties, and for other lawful purposes.\nQuestion: does this app sell customer information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Here is a link to the Privacy Policies for all our advertising partners:\nQuestion: is my information secure\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We maintain server around the world and your information may be processed on servers located outside of the country where you live.\nQuestion: does this app get access to my other apps like twitter and instagram?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: to analyze traffic and other end user activity to improve your experience).\nQuestion: does the app contain third party ads?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: This can include information about sellers and their Gigs, User's location, sharing of portfolio, ratings and feedbacks by buyers and anything you choose to add to your user profile.\nQuestion: what information does the company store about me?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Games may use location-based tracking, which relies upon a mobile devices GPS coordinates.\nQuestion: any malware (virus) function worked in this app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Where we or our affiliate companies process your payments as a payment service provider, or where we fulfill any purchases you have made on Keep, we may collect, use and store your Personal Information in order to fulfill such purchases.\nQuestion: what information is shared when i share something with friends?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you have provided your e-mail address to PeopleFun, we may use it to respond to (i) customer support inquiries, and (ii) keep you informed of your in-Game activity, including comments from friends and notifications about in-Game status.\nQuestion: does this app ask for permission if it's going to use data elsewhere on my phone?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If your account has been blocked you can contact our support.\nQuestion: how is my data stored?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You should not disclose your authentication information to any third party and should immediately notify 23andMe of any unauthorized use of your password.\nQuestion: do you keep my data forever\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You can control what data you share through privacy settings available on some social media sites.\nQuestion: has viber had any privacy breaches in the past?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If we are aware that a child under 13 has provided us with personal identifiable Information, we will delete such information from our files.\nQuestion: are my goals shared with third parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Google Analytics is used to perform many of the tasks listed above.\nQuestion: will the information be shared with a 3rd party\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Any information included in your publicly visible Keep profile, which may include your profile ID, name and photo;\nQuestion: who has access to my workout plans?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Because Viber is global, the recipients above may be located outside the country in which you are located.\nQuestion: what information can the other party see about me?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you choose not to complete a Consent Document or any additional agreement with 23andMe, your Personal Information will not be used for 23andMe Research.\nQuestion: can other members view my real name?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will share personal information if we have a good-faith belief that access, use, preservation, or disclosure of the information is reasonably necessary to a) meet any applicable law, regulation, legal process, or enforceable governmental request, or b) detect, prevent, or otherwise address fraud, security, or technical issues, or c) protect against harm to the rights, property or safety of Keep, our users, or the public as required or permitted by law.\nQuestion: what information will this app have access to of mine?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may receive reports based on the use of these technologies from third party service providers as de-identified, Individual-level Information or as Aggregate Information (as described in section 4.c).\nQuestion: how does the app make sure my genetic data stays secure?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please note that we will not accept requests via the telephone, mail, or by facsimile, and we are not responsible for notices that are not labeled or sent properly, or that do not have complete information.\nQuestion: do you keep a record of our text ?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We do not sharePersonal InformationwithThird-Party Ad-Servers; however,Third-Party Ad-Serversmay automatically collectNon-Identifying Informationabout your visit to the Site and other websites, your device address, your Internet Service Provider and the browser you use to visit the Site.\nQuestion: what does groupon do with collected data? (eg, does it sell it to third parties?)                  \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: to provide our services or information you request, and to process and complete any transactions; to respond to your emails, submissions, questions, comments, requests, and complaints and provide customer service; to analyze usage and trends with anonymous user data, and to improve the quality of our service and user experience; to send you confirmations, updates, security alerts, and support and administrative messages and otherwise facilitate your use of, and our administration and operation of, our services; You are welcome to ask for our confirmation whenever you feel concerned about how your personal information is being processed, where and for what purpose.\nQuestion: will the application make money off of the info i enter in the app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Information you provide through your communications with our customer support team.\nQuestion: are you storing any of my information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Once you confirm your request to delete your account and data, your account will no longer be accessible while we process your request.\nQuestion: how long do you store my medical information for?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Aggregate information We may share Aggregate Information, which is information that has been stripped of your name and contact information and combined with information of others so that you cannot reasonably be identified as an individual, with third parties.\nQuestion: is my information shared with any third parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: With adequate data support, we will create and update more popular training classes for you to take.\nQuestion: can the app access my location?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: References in this Privacy Statement to Groupon, we, or us also apply to Affiliates.\nQuestion: does it share my purchase information with others?                                        \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We do not share personal information with third parties for their direct marketing purposes unless you affirmatively agree to such disclosure, typically by opting in to receive information from a third party that is participating in a sweepstakes or other promotion through our Services.\nQuestion: does it collect any of my contact's information\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You may also discontinue your participation in 23andMe Research by deleting your 23andMe account (as described in section 5.d).\nQuestion: who has access to my test results?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Your information collected through the Service may be stored and processed in the United States or any other country in which 23andMe or its subsidiaries, affiliates or service providers maintain facilities and, therefore, your information may be subject to the laws of those other jurisdictions which may be different from the laws of your country of residence.\nQuestion: what will you do with my dna?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Receiving personnel do not perform testing, and testing personnel handle saliva samples that are only identified by a unique barcode.\nQuestion: do you keep my information and build a database for selling me products with it?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: However, we cannot guarantee the confidentiality and security of your information due to the inherent risks associated with storing and transmitting data electronically.\nQuestion: do you publish my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: This Privacy Policy does not apply to any third-party websites, services or applications, even if they are accessible through our Services.\nQuestion: what type of access does it have on my device?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We (or ourVendorson our behalf), use information collected as described in this Privacy Statement to:\nQuestion: can groupon see what i'm shopping for on the internet?       \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   The Site uses cookies to collect statistical data about its use, to tailor the Site's functionality to suit personal preferences and to assist with various aspects of Site operation.\nQuestion: are you certified to be secure?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: This Privacy Statement does not apply to the collection of information in any way other than as listed above.\nQuestion: does it have access to my camera?                            \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: The information collected may be used to offer you targeted ad-selection and delivery in order to personalize your user experience by ensuring that advertisements for products and services you see will appeal to you, a practice\nQuestion: does the app contain third party ads?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Our Services may contain advertisements from companies other than PeopleFun that may link to their own websites.\nQuestion: does the app contain third party ads?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Global Privacy Officer, 23andMe, Inc., 899 West Evelyn Avenue, Mountain View, CA 94041 1.800.239.5230, privacy@23andme.com\nQuestion: what steps do you take to protect my data from hackers?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you have questions about this Privacy Statement, or wish to submit a complaint, please email 23andMe's Privacy Administrator at privacy@23andme.com, or send a letter to:\nQuestion: do you use my date to modify the app\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please note that once we receive your request, it may take an additional period of time for your opt-out to become effective.\nQuestion: does the wordscapes app have access to my location?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   Once you have given us your agreement to the use of cookies, we shall store a cookie on your computer or device to remember this for next time, so that we can store your preferences and save you time on subsequent visits by eliminating the need to repeatedly enter the same data.\nQuestion: can other people see your real name?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You may withdraw your consent at any time within your Account Settings or by emailing privacy@23andme.com We will only contact you by electronic means (email, push notification, SMS, etc) with information about our Services that are similar to those which were the subject of a previous sale or negotiations of a sale to you.\nQuestion: do you ever sell my personal information to other companies for marketing purposes?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you sign into the Site or Games with Facebook Connect we will collect information that is visible via your Facebook account such as: (1) your first and last name, (2) Facebook ID, (3) Profile Picture/URL, and (4) list of Facebook friends.\nQuestion: does this app use data on my phone not within the app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:  When you use our Services, we may collect and store information about your location by converting your IP address into a rough geo-location or by accessing your mobile devices GPS coordinates or coarse location if you enable location services on your device.\nQuestion: does it collect any of my contact's information\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe and our third party genotyping laboratory will retain your Genetic Information, date of birth, and sex as required for compliance with applicable legal obligations, including the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) and CA Business and Professional Code Section 1265 and CAP accreditation requirements.\nQuestion: will you sell my information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Your unique advertising identifier is created by your mobile devices operating system and you can change it or choose not to share it at any time.\nQuestion: does the app protect my account details from being accessed by other people?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may use location information to improve and personalize our Services for you.\nQuestion: does the app contain third party ads?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Contact Information: your name, postal addresses, email addresses, social networking website user account names, telephone numbers, or other addresses at which you are able to receive communications.\nQuestion: do i need to enter any personal information to use it?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:    to obtain a copy of your personal information together with information about how and on what basis that personal information is processed;\nQuestion: do you sell my information to third parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you believe we might have any information from or about a child under 13, please contact us at legal@fiverr.com.\nQuestion: will my performance ratings be available for everyone to see?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe will ask for your consent to share Individual-level Genetic Information or Self-Reported Information with any third party, other than our service providers as necessary for us to provide the Services to you.\nQuestion: do you sell my genetic data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you want to deactivate your Groupon account or have other questions or requests, please contact us.\nQuestion: will my information be saved after i use groupon once?              \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For individuals located in the Designated Countries: Our legal basis for processing your Personal Information for the purpose described above depends on the nature of the customer support request.\nQuestion: is it possible for health insurance companies to get ahold of my data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Lima Sky reserves the right to modify this Privacy Policy at reasonable times, so please review it frequently.\nQuestion: does it connect to the internet?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When you make purchases through Keep, you may need to provide certain Personal Information to complete the purchase, such as your credit card information, bank account information.\nQuestion: do you keep and upload my activity to your database\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Lima Sky reserves the right to use and disclose the collected non-personal data for purposes of advertisement by Lima Sky or Lima Skys partners and contractors.\nQuestion: is my account information being shared?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Our Services may contain links to websites and services that are owned or operated by third parties (each, a Third-party Service).\nQuestion: does the app connect to the internet at any point during its use?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: To provide you with a better experience through improving our products, services, content, and advertising or otherwise where you have consented, we may share the personal information with our affiliate companies and with joint venture partners and third-party service providers, contractors and agents, and use it consistent with this Privacy Policy.\nQuestion: will they share my information with anyone?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Note that chats with bots and Public Accounts, and communities are not end-to-end encrypted, but we do encrypt such messages when sent to the Viber servers and when sent from the Viber servers to the third party (the Public Account owner and/or additional third party tool (eg CRM solution) integrated by such owner).\nQuestion: do you record what our cameras see?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You can access, update and delete yourPersonal Informationyou provided to us, as described below, by managing this information through your online account or sending us an email atprivacy@groupon.com.\nQuestion: how will my data be stored                                          \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please contact us if you have any questions or comments about our privacy practices or this Privacy Statement.\nQuestion: where is the privacy statement                                                            \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you experience difficulties changing your consent status, contact the Human Protections Administrator at hpa@23andMe.com.\nQuestion: do you keep my data forever\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Right of access to and rectification of your Personal Information.\nQuestion: are you obtaining information about my family?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We use your information to ensure our services are working as intended, such as troubleshooting issues reported from you.\nQuestion: will my information be shared with other companies for marketing?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Non-Identifiable Informationmeans information that alone cannot identify you, including data fromCookies,Pixel Tags and Web Beacons, andDevice Data.\nQuestion: what happen if my account get compromise?                                                 \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Privacy Administrator 23andMe, Inc. 899 West Evelyn Avenue Mountain View, CA 94041 1.800.239.5230\nQuestion: do you publish my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When the laboratory has completed their analysis, they securely send the resulting Genetic Information to us identified by your unique barcode.\nQuestion: does 23andme use my test results for marketing purposes?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Send you reminders, technical notices, updates, security alerts, support and administrative messages, service bulletins, marketing messages, and requested information, including on behalf ofBusiness Partners;\nQuestion: what are all the features are available in this app?                                      \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Some third-party services providers that we engage (including third-party advertisers) may also place their own Cookies on your device.\nQuestion: does the app show targeted advertisements?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We contractually ensure that any third party processing your personal information equally provide for confidentiality and integrity of your data in a secure way.\nQuestion: has fiverr been hacked before\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: (b) Social Media Information:If you sign in to your Viber account through third-party social media sites like Facebook, Twitter or VK, you agree to give us on-going access to your personal information on such sites (eg, your public profile, friend list, accounts you follow or who follow you, your email address, birthday, work history, education history, interests, current city, and video viewing).\nQuestion: when do you delete stored data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Accounts created with PeopleFun are considered active until we receive a user request to delete them or deactivate them.\nQuestion: is my privacy secured?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For more information about our marketing practices, please review our Cookie Policy.\nQuestion: will you sell my information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you have any questions about how these other websites use your information, you should review their policies and contact them directly.\nQuestion: what information of mine does it access\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe may use individual-level Genetic Information and Self-Reported Information internally at 23andMe for research purposes.\nQuestion: will my test results be shared with any third party entities?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you use any features on the Site to send information about a product or service to another person (eg, a friend, a colleague, a professional associate, etc), we will also collect thePersonal Informationof that other person to the extent disclosed by you and may contact them using the information you provided us.\nQuestion: can groupon see what i'm shopping for on the internet?       \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Consistent with applicable legal requirements, we take commercially reasonable steps to require third parties to adequately safeguard your personal information and only process it in accordance with our instructions;\nQuestion: do you sell my information to third parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: This Privacy Policy informs you of your choices and our practices regarding any information you provide to us.\nQuestion: do you access any of my contact's information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You also have a right to lodge a complaint with a competent supervisory authority situated in a Member State of your habitual residence, place of work, or place of alleged infringement.\nQuestion: what will you do with my dna?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you consent, you can always choose to opt-out at a later date by using the settings on your phone or tablet.\nQuestion: is a facebook account necessary to play the game?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: To prevent unauthorized on-line access to data, Lima Sky maintains data behind a firewall-protected server.\nQuestion: hwere is it saved\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may also offer you the ability to import your contacts or manually enter e-mail addresses so that you can locate your contacts on PeopleFun and invite your contacts to join you in the Games.\nQuestion: does it have access to other apps like credit card app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe incorporates explicit security reviews in the software development lifecycle, quality assurance testing and operational deployment.\nQuestion: how secure is your website from hackers?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Non-Identifiable Informationmeans information that alone cannot identify you, including data fromCookies,Pixel Tags and Web Beacons, andDevice Data.\nQuestion: does it need location services while not using it?           \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You have the option to share directly with individuals with 23andMe accounts through (i) our Forums, (ii) relative finding features (eg, \"DNA Relatives\"), (iii) other sharing features and tools.\nQuestion: do you sell my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Evaluate your eligibility for certain types of offers, products or services that may be of interest to you, and analyze advertising effectiveness;\nQuestion: what are all the features are available in this app?                                      \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: The information helps us improve our services to you and customize your browsing experience.\nQuestion: how much is it?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Users with multi-profile accounts (i.e., where multiple family members register their kits to one account) should use caution in setting profile-level privacy settings.\nQuestion: can i delete my personally identifying information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: The types of personal data may vary depending on the type of activity you are engaged in.\nQuestion: is my account information being shared?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For purposes of this Privacy Policy, non-personal data means information that does not directly identify you.\nQuestion: what information does this app collect from my phone\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You are solely responsible for compliance with any data protection or privacy obligations in your jurisdiction when you use the Site or provide us withPersonal Information.\nQuestion: does it listen in on audio via the mic?                                                            \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may do this through in-Game dialog boxes, which you may choose to skip.\nQuestion: does it sell data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: *This Privacy Statement was last updated on July 17, 2018.\nQuestion: will you sell my information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   Where relevant under applicable laws, all processing of your personal information will be justified by a \"condition\" for processing.\nQuestion: what applications does this app have access to?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: to facilitate a direct relationship with you, including in connection with any program we administer on behalf of theBusiness Partner;\nQuestion: do i need to enter any personal information to use it?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You can opt out of the collection and use of your information for ad targeting by going to http://www.aboutads.info/choices or http://www.youronlinechoices.eu/ to limit collection through the Site or by configuring the settings on your mobile device to limit ad tracking through the App.\nQuestion: will this app sell my information to any 3rd parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Some sharing features, including receiving sharing invitations, may require that you opt-out, however you will always be required to take a positive action, such as opting in, to share sensitive data.\nQuestion: do you publish my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Some of the safeguards we use include firewalls, data encryption, physical access controls to our data centers and information access authorization controls.\nQuestion: the photos and videos shared will be kept confidential?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We also may use information collected as described in this Privacy Statement with your consent or as otherwise required or permitted by law.\nQuestion: does it share my personal information with others?           \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Unless you consent to sample storage (Biobanking) and additional analyses, your saliva sample and DNA are destroyed after the laboratory completes its work, subject to the laboratory's legal and regulatory requirements.\nQuestion: do you publish my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you post information on a public feature of our Services or through social media sites, plug-ins or other applications, do not forget this information is public on our Services and, depending upon your privacy settings, may also become public on the Internet.\nQuestion: will viber comply to government information request?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe complies with the Privacy Shield Principles for all onward transfers of Personal Information from the EU, EEA and Switzerland, including the onward transfer liability provisions.\nQuestion: will you sell my information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: These Features may collect your IP address, which page you are visiting on our site, and may set a cookie to enable the Feature to function properly.\nQuestion: what information is collected from me?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: to provide our services or information you request, and to process and complete any transactions; to respond to your emails, submissions, questions, comments, requests, and complaints and provide customer service; to analyze usage and trends with anonymous user data, and to improve the quality of our service and user experience; to send you confirmations, updates, security alerts, and support and administrative messages and otherwise facilitate your use of, and our administration and operation of, our services; You are welcome to ask for our confirmation whenever you feel concerned about how your personal information is being processed, where and for what purpose.\nQuestion: is there a way to opt out of data sharing\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you do not want us to collect location information, you may disable that feature on your mobile device.\nQuestion: does it have access to my contacts?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: with any GrouponAffiliatewho may only use thePersonal Informationfor the purposes described in this Privacy Statement;\nQuestion: does groupon sell my personal information?                                                         \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   Under applicable EU regulation, as of May 25, 2018 you may have some or all of the following rights in respect of your personal information:\nQuestion: what information can other people see?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Some sharing features, including receiving sharing invitations, may require that you opt-out, however you will always be required to take a positive action, such as opting in, to share sensitive data.\nQuestion: is it possible for health insurance companies to get ahold of my data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please recognize that protecting your Personal Information is also your responsibility.\nQuestion: is any information recorded\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:  When you use our Services, we may collect and store information about your location by converting your IP address into a rough geo-location or by accessing your mobile devices GPS coordinates or coarse location if you enable location services on your device.\nQuestion: what data does it collect\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may also offer you the ability to import your contacts or manually enter e-mail addresses so that you can locate your contacts on PeopleFun and invite your contacts to join you in the Games.\nQuestion: does the wordscapes app collect any personally identifiable information like my name or email?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: The person you referred may contact us at privacy@23andme.com to request that we remove this information from our database.\nQuestion: does the app require any special permissions for access on my phone?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe will also retain limited information related to your account and data deletion request, including but not limited to, your email address, account deletion request identifier, and record of legal agreements for a limited period of time as required by contractual obligations, and/or as necessary for the establishment, exercise or defense of legal claims and for audit and compliance purposes.\nQuestion: will you destroy my dna sample when you are finished?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: As part of the Rakuten Group, Viber relies on the Rakuten Group Binding Corporate Rules to legitimize international data transfers within the Group.\nQuestion: is the messages sent through it are safe?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you do not wish to receive these requests, you can manage them in your Account Settings.\nQuestion: are you obtaining information about my family?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Lima Sky does not knowingly collect Personal Information from persons under the age of 13 without parental consent.\nQuestion: does this app record audio?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please include all the relevant details, so your ticket can be handled correctly.\nQuestion: how is my info protected from hackers?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: De-identified Information: information that has been stripped of your Registration Information (eg, your name and contact information) and other identifying data such that you cannot reasonably be identified as an individual, also known as pseudonymized information.\nQuestion: can other customers i connect with access my personal information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You can also control your privacy settings within the App to change the visibility of your online status or prevent other users from knowing which Viberapps and games you are using.\nQuestion: can any 3rd party see my conversations?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may also send notifications about offerings by Viber or third-parties, that we think may be of interest to you.\nQuestion: are my message encrypted on viber?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: The information provided in your registration, if you link your email to the Viber account, will be shared with Rakuten group to create the Rakuten account and/or to link your Rakuten account with your Viber account.\nQuestion: what information can the other party see about me?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When calling through Viber Out, just like regular phone calls you make, details of the call are available to the phone operator of the person you called (and possibly other facilitating phone operators  but this is the same as any regular phone call you make).\nQuestion: do you keep a record of our text ?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: (a) Registration and Account Information:When you use our various Services you voluntarily give us personal information (eg, name, email, birth date, age, phone number and, when necessary, billing information) and you are not anonymous to us.\nQuestion: do you require me to submit identifying information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Web-Behavior Information collected through tracking technology (eg from cookies and similar technologies) We and our third party service providers use cookies and similar technologies (such as web beacons, tags, scripts and device identifiers) to:\nQuestion: is it possible for health insurance companies to get ahold of my data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Receiving personnel do not perform testing, and testing personnel handle saliva samples that are only identified by a unique barcode.\nQuestion: do you sell my genetic data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: No one under age 13 should provide any personal information to or on the Site.\nQuestion: will my location be constantly tracked?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may share with our service providers unique identifiers to determine the best way to tell potential new users about our services.\nQuestion: what data do you keep and for how long?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:              sending private messages or invitations to other users, either directly through the Games or to their e-mail accounts;\nQuestion: does it read my contacts?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Users who contact us via email, the email addresses and information you submitted voluntarily will also be collected.\nQuestion: what information do you take from me.\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Your information collected through the Service may be stored and processed in the United States or any other country in which 23andMe or its subsidiaries, affiliates or service providers maintain facilities and, therefore, your information may be subject to the laws of those other jurisdictions which may be different from the laws of your country of residence.\nQuestion: how long do you store my medical information for?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: to report or collect on debts owed to us or ourBusiness Partners;\nQuestion: does it share my personal information with others?           \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: provide information to ourVendors.This Privacy Statement does not apply to the collection of information in any way other than as listed above.\nQuestion: does it share my personal information with others?           \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: At this stage, whatever you share publicly is available to the entire Viber community.\nQuestion: can anyone view my account?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: (a) Registration and Account Information:When you use our various Services you voluntarily give us personal information (eg, name, email, birth date, age, phone number and, when necessary, billing information) and you are not anonymous to us.\nQuestion: do you record what our cameras see?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When you ask for assistance from our Customer Support team, we will collect and store the contact information you provide (generally your name and e-mail address), information about your game play or activity on the Games, and your user name or ID number.\nQuestion: does it collect payment information\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Any research involving your data that has already been performed or published prior to your withdrawal from 23andMe Research will not be reversed, undone, or withdrawn.\nQuestion: is my data anonymized?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Individual-level Information: information about a single individual's genotypes, diseases or other traits/characteristics, but which is not necessarily tied to Registration Information.\nQuestion: how secure is your website from hackers?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will collect information, includingPersonal InformationandNon-Identifying Information, when you interact with us and the Site, for example when you:\nQuestion: does it have access to my contacts?                                 \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Data, including Registration Information, Genetic Information, and Self-Reported Information are segmented across logical database systems to further prevent re-identifiability.\nQuestion: do you keep my information and build a database for selling me products with it?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For more information about their privacy policy, you may find it at https://www.mopub.com/legal/privacy/.\nQuestion: does it try to connect to any social media accounts?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you provide us with Personal Information about others, or if others give us your information, for the purpose of ordering the Service as a gift, we will only use that information for the specific reason for which it was provided to us.\nQuestion: do you ever sell my personal information to other companies for marketing purposes?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You may manage how your mobile device and mobile browser share certainDevice Datawith Groupon, as well as how your mobile browser handlesCookiesby adjusting the privacy and security settings on your mobile device.\nQuestion: have there been any security breach in the last few years?  \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We ask you to be responsible for safeguarding your password, secret questions and answers, and other authentication information you use to access our Services.\nQuestion: how secure is your website from hackers?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you upload content, including your personal information, to a social network and then tag the Site, your submission will be subject to that social network's terms of use and privacy policy, even where you post on an official Fiver page on the social network.\nQuestion: who is allowed to use it?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: To process, analyze and deliver your genetic testing results As described above, to receive results through the Personal Genetic Service, you must create a 23andMe account, register your kit, and submit your saliva sample to our contracted genotyping laboratory, which processes and analyzes your sample to provide us with your raw Genetic Information.\nQuestion: are my health records accessed in this process at all?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You can control what data you share through privacy settings available on some social media sites.\nQuestion: is it keep my phone numbers undisclosed?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will help you export the information based on applicable law and your specific request.\nQuestion: why do you need so many unrelated permissions?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:  When you use our Services, we may collect and store information about your location by converting your IP address into a rough geo-location or by accessing your mobile devices GPS coordinates or coarse location if you enable location services on your device.\nQuestion: does this app need access to any of my social media accounts?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Privacy Shield 23andMe participates in and has certified its compliance with both the EU-U.S. and Swiss-U.S. Privacy Shield Frameworks as set forth by the U.S. Department of Commerce regarding the collection, use, and retention of Personal Information transferred from the European Union (EU), European Economic Area (EEA), and Switzerland to the United States, respectively.\nQuestion: is it possible for health insurance companies to get ahold of my data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You may manage how your mobile device and mobile browser share certainDevice Datawith Groupon, as well as how your mobile browser handlesCookiesby adjusting the privacy and security settings on your mobile device.\nQuestion: does it need my location at all times, or can i just type in it whenever i'm looking for a coupon?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When you make purchases through Keep, you may need to provide certain Personal Information to complete the purchase, such as your credit card information, bank account information.\nQuestion: does the app access my contact list?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For more information about our marketing practices, please review our Cookie Policy.\nQuestion: can other customers i connect with access my personal information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You agree and consent to our collection, transfer, and processing of yourPersonal InformationandNon-Identifiable Informationin accordance with this Privacy Statement.\nQuestion: does it save all info on me if i delete my acct?                         \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   Fiverr (including Fiverr Inc., Fiver International Ltd. and its affiliates) respects your privacy and is committed to protect the personal information of its users - buyers, sellers, and visitors browsing the Site (Users).\nQuestion: how is my info protected from hackers?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Google Analytics for Firebase: If you wish to find out more information on Google Analytics for Firebase, please follow this link: https://www.firebase.com/terms/privacy-policy.html\nQuestion: do i need to use my real name?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: To use our genetic testing services, you must purchase, or receive as a gift, a 23andMe Personal Genetic Service testing kit, create an online account and register your kit, and ship your saliva sample to our third party laboratory.\nQuestion: is any information recorded\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:    to maintain appropriate business records, to comply with lawful requests by public authorities and to comply with applicable laws and regulations or as otherwise required by law.\nQuestion: what information do you collect?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:  Non-Personal Information: It includes but is not limited to your devices configuration, the package ID and version of the application that you use.\nQuestion: why do you need access to my phone calls?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:  Personal Information: When registering for TickTick, we collect personal information such as your name.\nQuestion: does the app continuously track my location?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: to combat fraud or criminal activity, and to protect our rights or those of ourAffiliates, users, andBusiness Partners, or as part of legal proceedings affecting Groupon;\nQuestion: does groupon sell my personal information?                                                         \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: This data is then assigned a randomly generated ID so an individual cannot reasonably be identified.\nQuestion: are you obtaining information about my family?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will ask for your explicit consent to share any sensitive personal information such as race, religion, sexual orientation, or health.\nQuestion: do you access any of my contact's information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   When you register to the Site we ask you to provide certain personal information, including a valid email address, location, facebook or google account log in details and username.\nQuestion: what are the app's permissions\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may collect information about you in any one or more of the following ways:\nQuestion: is it monitoring my location?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Whether to third parties or internally, any transfers of personal information from the European Economic Area (EEA) to countries not deemed to provide an adequate level of data protection are governed by European Union (EU) standard contractual clauses, or in the case of the United States, the EU - US Privacy Shield, and/or equivalent data transfer regulations to protect the security and confidentiality of personal information.\nQuestion: how am i sure no one will steal my identity?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Information we collect in the course of you using Keep  such as certain location data and log data; and\nQuestion: do you keep track of my physical measurements like height and weight?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: In some instances, we may be required to process one customers Personal Information to resolve another customers dispute or request.\nQuestion: do you sell my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:    to respond to a subpoena or court order, judicial process or to regulatory authorities, if we believe we are required to do so by law, or that doing so is reasonably necessary to comply with legal processes; when we believe it necessary or appropriate to disclose personal information to law enforcement authorities, such as to investigate actual or suspected fraud or violations of law, breaches of security, or breaches of this Policy; to respond to claims against us; and to protect the rights, property, or personal safety of Fiverr, our customers, or the public;\nQuestion: do you use a secure payment service?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You should be aware that any information you provide or post in these areas may be read, collected, and used by others who access them.\nQuestion: is my information shared with any third parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Once delivered, receiving personnel at the laboratory remove and discard kit packaging, which in some cases may contain \"sender information\" (eg, name, address), before testing personnel receive the samples for processing.\nQuestion: do you publish my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If for some reason, the message, wasnt delivered to its destination within up to 2 weeks, it will be deleted from our servers.\nQuestion: are my video calls recorded?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If it comes to Lima Skys attention that Personal Information has been collected from a person under the age of 13, Lima Sky will delete this information as quickly as possible.\nQuestion: does it save anything locally?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may also use this information to establish and set up your account, verify or re-issue a password, log your activity and contact you from time to time.\nQuestion: how does fiverr ensure payments from customers are secure?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We use them to collect visitors preferences and thus to better optimize the user experience.\nQuestion: does having this on my device create a privacy concern?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Administer rewards, surveys, sweepstakes, contests, or other promotional activities or events sponsored by us or ourBusiness Partners;\nQuestion: does it share my personal information with others?           \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We do not condition participation in our Services on you providing more personal information than is reasonably necessary for that activity.\nQuestion: is it monitoring my location?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For individuals located in the Designated Countries: Our legal basis for processing your Sensitive Information for the purpose described above is based on your consent.\nQuestion: will my test results be shared with any third party entities?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   Further information about our data security practices can be provided on request.\nQuestion: how does fiverr ensure payments from customers are secure?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For more information about our marketing practices, please review our Cookie Policy.\nQuestion: is my information shared with any third parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Groupon will use such information in accordance with applicable laws.\nQuestion: does it have access to my contacts?                                 \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please contact us if you have any questions or comments about our privacy practices or this Privacy Statement.\nQuestion: this app ask any kind personal details like credit card details?    \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will never share with or sell the information gained through the use of Apple HealthKit, such as age, weight and heart rate data, to advertisers or other agencies without your authorization.\nQuestion: what information is shared when i share something with friends?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may also offer you the ability to import your contacts or manually enter e-mail addresses so that you can locate your contacts on PeopleFun and invite your contacts to join you in the Games.\nQuestion: does it read my contacts?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: The Rakuten Group Binding Corporate Rules can be found at https://corp.rakuten.co.jp/privacy/en/bcr.html.\nQuestion: is any data collected by the app has any connection with the third party sites?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You have the option to share directly with individuals with 23andMe accounts through (i) our Forums, (ii) relative finding features (eg, \"DNA Relatives\"), (iii) other sharing features and tools.\nQuestion: do you publish my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We use your personal information to pursue our legitimate interests where your rights and freedoms do not outweigh these interests.\nQuestion: does the app sell any personal information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: This Privacy Statement does not cover the collection methods or use of the information collected byThird-Party Ad-Servers, and Groupon is not responsible forCookiesor clear gifs in third party ads.\nQuestion: who will have access to my information?                                                            \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For example, Aggregate Information may include a statement that \"30% of our female users share a particular genetic trait,\" without providing any data or testing results specific to any individual user.\nQuestion: will the information be shared with a 3rd party\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: (e)Prevent Fraud & Spam; enforcement of law: We really want Viber to be free of spam and fraudulent content so that you feel safe and free.\nQuestion: if i send a message that is considered dirty, will the controllers of the app see it?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We need your help too: it is your responsibility to make sure that your personal information is accurate and that your password(s) and account registration information are secure and not shared with third-parties.\nQuestion: how is my data stored?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will never share with or sell the information gained through the use of Apple HealthKit, such as age, weight and heart rate data, to advertisers or other agencies without your authorization.\nQuestion: are my goals shared with third parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Some of our Services allow you to share information with others on a public basis.\nQuestion: does the app hide the content  of the messages i send from other people on my contact list?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe implements physical, technical, and administrative measures to prevent unauthorized access to or disclosure of your information, to maintain data accuracy, to ensure the appropriate use of information, and otherwise safeguard your Personal Information.\nQuestion: where is the information saved\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Genetic Information includes the 23andMe results reported to you as part of our Services, and may be used for other purposes, as outlined in Section 3 below.\nQuestion: who has access to my test results?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Your interactions with these Features are governed by the privacy statements of the third party companies providing them.\nQuestion: do you use my date to modify the app\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: As part of this mission, we use your information for the following purposes:\nQuestion: who will be able to see my information and/or the messages that i send?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Regardless of where we transfer your information, we still protect your information in the manner described in this Privacy Statement.\nQuestion: have there been any security breach in the last few years?  \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will also keep your Viber Out call detail records for billing and legal records, and to make you relevant offers.\nQuestion: if it's free, does viber profit off its users in some way?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Third-Party Ad-ServersmeansVendorsand other third parties that provide the technology to place ads on websites and track ad performance.\nQuestion: does it sell my data to anyone?                                                           \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:  We collect and hold only the information absolutely necessary for using our services, as well as limiting the internal access to your personal information for the purposes stated in Information Usage below.\nQuestion: does this app capture my ip address?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: To process, analyze and deliver your genetic testing results As described above, to receive results through the Personal Genetic Service, you must create a 23andMe account, register your kit, and submit your saliva sample to our contracted genotyping laboratory, which processes and analyzes your sample to provide us with your raw Genetic Information.\nQuestion: do you ever sell my personal information to other companies for marketing purposes?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: What happens if you do NOT consent to 23andMe Research?\nQuestion: what information is collected from me?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We recognize a special obligation to protect personal information obtained from young children.\nQuestion: does this app use data on my phone not within the app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You can also remove or delete content from your account or entirely delete your whole Keep account.\nQuestion: will any photos i take be accessed by outside parties?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Our payment processing service provider may also retain this information to enable you to purchase additional items through our Game without having to re-enter it each time.\nQuestion: when i installation time any personal details ask in this app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: \"23andMe Research\" refers to research aimed at publication in peer-reviewed journals and other research funded by the federal government (such as the National Institutes of Health - NIH) conducted by 23andMe.\nQuestion: do you keep my data forever\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please note, however, that if you dont accept Cookies, you may not be able to access all portions or features of the Services.\nQuestion: what permissions does the app require in order to work?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will respond to your request within thirty (30) days.\nQuestion: what information are they collecting?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When you refer a person to 23andMe or choose to share your 23andMe results with another person, we will ask for that person's email address.\nQuestion: is any information recorded\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: This includes partners managing our advertising placements and also advertisers themselves and their agencies or third parties managing their advertising demands.\nQuestion: does viber have any affiliation with the advertisement industry?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Some sharing features, including receiving sharing invitations, may require that you opt-out, however you will always be required to take a positive action, such as opting in, to share sensitive data.\nQuestion: will you sell my information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Business Partnersmeans, collectively, third parties with whom we conduct business, such as merchants, co-marketers, distributors, resellers, and other companies or organizations with whom Groupon enters into agreements to support its business and operations.\nQuestion: what kind of data does groupon collect?                             \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Flurry Analytics: If you wish to find out more information on Flurry analytics, please follow this link: http://www.flurry.com/legal-privacy/privacy-policy\nQuestion: why does the app need to collect that information to function?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We cannot prevent or control further use of this information so please make sure you only post information that youre happy to be seen publicly.\nQuestion: is there any sort of encryption for communications?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We encourage you to read more about the information we collect, how we use it, understand the meaning of cookie (no, you cant eat it) and more in the long version of our Policy below.\nQuestion: can other people see my financial information\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: You may also discontinue your participation in 23andMe Research by deleting your 23andMe account (as described in section 5.d).\nQuestion: who will have access to my medical information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: A controller is a natural or legal person, public authority, agency or other body which, alone or jointly with others, determines the purposes and means of the processing of your Personal Information.\nQuestion: who will have access to my dna?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please note that certain records, for example those pertaining to payments or customer service matters, will be retained for legal and accounting purposes.\nQuestion: what areas of my phone/computer does this gain access to?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When using our products and services, you can always manage, review and update information in your account, for instance, you can manage your personal information at any time, such as your Keep ID and photo.\nQuestion: are my statistics kept private?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Your Account may be used to publicly identify you as part of social features of the Services, which may include user-to-user interaction, chat or messaging functionality, public leaderboards, head-to-head competition, and other similar features.\nQuestion: does it read my contacts?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Analytics companies may access anonymous data (such as your IP address, device vendor ID, and/or device advertising ID) to help us understand how Services are used.\nQuestion: can i control my privacy settings?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Once delivered, receiving personnel at the laboratory remove and discard kit packaging, which in some cases may contain \"sender information\" (eg, name, address), before testing personnel receive the samples for processing.\nQuestion: does the app save the address that my kit is shipped to?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Some third-party services providers that we engage (including third-party advertisers) may also place their own Cookies on your device.\nQuestion: is my information sold\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We use that information to enhance user experience, personalize your browsing experience as well as monitor the Site for preventing fraud and inappropriate content or behaviour.\nQuestion: are there specific privacy settings in the app that would allow me to adjust my privacy preferences as i see fit?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: to deliver and target behavioral or personalized ads; and to inform users about new products or promotional offers.\nQuestion: what permissions does the app require in order to work?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We may keep activity data on a non-identifiable basis to improve our services.\nQuestion: how is my data used?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you have any questions about security on our Web site, you can contact us at privacy@groupon.com.\nQuestion: what does groupon do with collected data? (eg, does it sell it to third parties?)                  \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We have implemented controls to balance our interests with your rights.\nQuestion: what permissions does the app request?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Where the payment is processed by a third-party payment service provider, we do not collect or store such Personal Information, though we may receive summary information about transactions.\nQuestion: does it have access to my gps information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: (e)Prevent Fraud & Spam; enforcement of law: We really want Viber to be free of spam and fraudulent content so that you feel safe and free.\nQuestion: does the app hide the content  of the messages i send from other people on my contact list?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: All credit card information you supply is transmitted via Secure Socket Layer (SSL) technology and then encrypted within our databases.\nQuestion: does this app access any of my data behind the scenes?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   Users who have registered to the Site agree to keep their password in strict confidence and not disclose such password to any third party.\nQuestion: how does fiverr protect freelancers' personal information?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We implement procedures and maintain contractual terms with each service provider to protect the confidentiality and security of your information.\nQuestion: do you have any association with google?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Should you wish to update your sample storage preference to discard a stored sample, you can do so within your Account Settings once your sample has completed processing.\nQuestion: do you sell my genetic data?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Note that chats with bots and Public Accounts, and communities are not end-to-end encrypted, but we do encrypt such messages when sent to the Viber servers and when sent from the Viber servers to the third party (the Public Account owner and/or additional third party tool (eg CRM solution) integrated by such owner).\nQuestion: how is my data used?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: (d) Process Your Payments: We may use your Information like your name and phone number to process your payments for our Services through a secured third-party service provider and, on an aggregate basis to determine charges for our phone carriers and other service providers.\nQuestion: how is my data used?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Please check back periodically to keep informed of updates or changes to this Privacy Policy.\nQuestion: do you track my location in real time.\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: However we will not share Individual-level Genetic Information or Self-Reported Information with any third party without your consent.\nQuestion: do you publish my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If you create an Account, you may be required to provide your name, e-mail address, a password and other information that helps us confirm that it is you accessing your account.\nQuestion: what permissions does the app require in order to work?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Starting with Viber 6.0, all of Vibers core features are secured with end-to-end encryption: Viber calls, one-on-one messages, group messages, private media sharing and secondary devices.\nQuestion: will my personal details be shared with third party  companies?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: We will also store the correspondence and any information contained within.\nQuestion: does it collect payment information\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Users with multi-profile accounts (i.e., where multiple family members register their kits to one account) should use caution in setting profile-level privacy settings.\nQuestion: is the information encrypted\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:              sending private messages or invitations to other users, either directly through the Games or to their e-mail accounts;\nQuestion: what permissions does the app require in order to work?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:   We do not sell or rent your personal information to third parties for their marketing purposes without your explicit consent.\nQuestion: who can see which tasks i hire workers for?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: When you install the Viber App, youll also be asked to allow us access to your mobile devices address book.\nQuestion: will my personal details be shared with third party  companies?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: Other Programsmeans special programs, features and functionality on our Site or other co-branded websites withBusiness Partnersthat we reasonably control and that have special use terms applicable to such special programs, features and functionality.\nQuestion: will you ever sell my information?                                                        \n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:    as long as it is necessary and relevant for our operations, e.g.\nQuestion: how constantly is the app being updated\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: If we are aware that a child under 13 has provided us with personal identifiable Information, we will delete such information from our files.\nQuestion: do you sell my data\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: For purposes of this Privacy Policy, non-personal data means information that does not directly identify you.\nQuestion: what data does this game collect?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause:  Non-Personal Information: It includes but is not limited to your devices configuration, the package ID and version of the application that you use.\nQuestion: will the application make money off of the info i enter in the app?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Irrelevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: 23andMe collects and stores the following types of Personal Information: Registration Information: information you provide about yourself when registering for and/or purchasing our Services (eg name, email, address, user ID and password, and payment information).\nQuestion: is my data anonymized?\n\nAnswer and only output Irrelevant or Relevant.",
        "output": "Relevant",
        "instruction": "Classify if the clause is relevant to answering the question",
        "domain": "legal",
        "task": "jri"
    },
    {
        "input": "Clause: - We collect loyalty program information. As part of our services you can track your loyalty rewards with many popular retailers. To do this, we permit you to provide us with your loyalty account information with those retailers. For example, we may collect your phone number or email address if you provide them as your loyalty program account numbers or IDs.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Although some of this information (such as IDFA, IDFV, Advertising ID, Android ID, IP address) may uniquely identify your device, this information does not identify you personally. Some legislation (such as US) may treat information that uniquely identifies your device as personal information.\nDescription: The policy describes collection of the user's ad ID (such as the Google Ad ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Connect with Facebook: If you use one of our applications and connect to your Facebook account within such application, you will be providing us with basic account information i.e., user ID, name, email, gender, birthday, current city, profile picture URL and the user IDs of your friends who have also connected with our applications. In addition, we will cache data we receive from the Facebook APIs to improve our user experience. If you want us to delete the data we receive from Facebook about you, please contact us at contact@doodlemobile.com.\nDescription: The policy describes collection of the user's gender by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We may occasionally ask you to complete optional online surveys. These surveys may ask you for contact information and demographic information (like zip code, age, gender, etc.). We use this data to customize your experience at Paytm, providing you with content that we think you might be interested in and to display content according to your preferences.\nDescription: The policy describes collection of the user's ZIP code by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 5.2. We may also use other technologies, including but not limited to, web bugs, tracking pixels and cookies. Web bugs allow Us to know if a certain page was visited or whether an email was opened, while tracking pixels allow Us to advertise more efficiently by excluding current users from certain promotional messages, identifying the source of a new installation or delivering ads to You on other websites. Cookies allow Us to improve the quality of the Services, make recommendations, and make the Services easier to use for You. A cookie is a small text file recorded on Your hard drive that identifies You as a unique user and contains certain information about Your particular login session and/or Your use of the Services. Please note that companies delivering advertisements within the Services may also use cookies or other technologies, and those practices are subject to their own policies.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: People who store or post information about you on the community features of the Pandora Service, or by your enabling connectivity with another website, application, or service where friends or other listeners store such information. For instance, your friends may store information about you in places such as their friend lists, address books, or photos on our Service or other websites, applications, or services such as social media applications with which the Pandora Service interacts.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: What Information You Can Access If you are a registered user, you can access most information associated with your Account by logging into the Services and checking your Account Settings page. Registered and unregistered users can access and delete cookies through their web browser settings.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Automatic Data Collection and Advertising We may use tools or third party analytical software to collect and use certain non-personal data that does not enable us to identify you. The types of non-personal data we may collect and use include, but are not limited to: (i) mobile device identifiers, such as the resettable advertising identifier assigned to your device; (ii) mobile device type and device properties; (iii) mobile device software platform and firmware; (iv) mobile phone carrier; (v) geographical data; and (vi) other non-personal data as reasonably required by us to enhance our services.\nDescription: The policy describes collection of the user's unspecified location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: II. Information We Collect In providing our services, we collect, store and use the following Information relating to you: \"Information\" is Personal Information and Non-Personal Information; \"Personal Information\" is any information or combination of information that relates to you, and can be used to identify you. Personal Information may include the following: information you make available to us when you open an account or use our services, such as your name, telephone number and email address; information which you make available to our services as you use them, including Shared Information you make available to others through our services and information you store using our services; Shared Information that others using our services make available about you, such as information contained in posts they make and communications they make to you and others using our services; and information we collect as you use our services, such as certain Location Data and Log Data.\nDescription: The policy describes collection of the user's WiFi location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Location Information We request permission for our app's collection of precise location from your device per the permission system used by your mobile operating system. If you initially permit the collection of this information, you can later disable it by changing the location settings on your mobile device. However, this will limit your ability to use certain features of our Services. Additionally, disabling our app's collection of precise location from your device will not limit our ability to collect your trip location information from a Driver's device nor our ability to derive approximate location from your IP address.\nDescription: The policy describes collection of the user's Bluetooth location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Rovio and its partners do collect non-personally identifiable data from children. This includes, for example, collection of IP-based geolocation data to ensure that the product, service or features served comply with applicable laws of that nation.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information We Get from Your Use of Our Services Device Information When you use any of Meitu applications on a mobile platform, we may collect and record certain information such as your unique device ID (persistent /non-persistent), hardware type, media access control (\"MAC\") address, international mobile equipment identity (\"IMEI\"), the version of your operating system (\"OS\"), your device name, and your location (based on your Internet Protocol (\"IP\") address, country code of SIM and GPS). This information is useful to us for troubleshooting and helps us understand usage trends among all users.\nDescription: The policy describes collection of the user's MAC address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Technical information is based on cookies, web beacons and log files (as explained in more detail in the \"Cookies, Web Beacons and Log Files\" section below) or otherwise, including: technical information such as mobile carrier, your IP address and your device's version and identification number. We do not collect technical information.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: No part of the services offered by Psafe collctes your personal information, including name, home address, email address and contact telephone number.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Using applications cookies On this site device identifiers are used to personalize content and ads, in order to provide social media features and to analyze traffic. We also share these identifiers and other information on your device with our social media partners, advertising and web analytics. Cookies applications are used by Google Admob and Google Analitycs. These cookies or tracking are used to direct more advertising depending on the behaviors and habits of users. Thus, a more effective advertising is achieved. Our applications store an identification number, searches, websites visited, number of visits to the store application, location, time, date, time of the session in the application and number of sessions in the application.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 9. SOCIAL LOGINS Some of the Apalon Apps may offer you the ability to register and login using your third party social media account details (like your Facebook or Twitter logins). Where you choose to do this, we will receive certain profile Information about you from your social media provider. The profile Information we receive may very depending on the Apalon App you are using, and on the social media provider concerned, but will often include your name, e-mail address and friends list. We will use the Information we receive only for the purposes that are described in this Privacy Policy or that are otherwise made clear to you in the Apalon App you are using. Please note that we do not control, and are not responsible for, other uses of your personal information by your third party social media provider. We recommend that you see their privacy policy to understand how they collect, use and share your Information, and how you can set your privacy preferences on their sites and apps.\nDescription: The policy describes receiving data from the Facebook single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: \"Cookies\" are small text files that are placed on your hard drive by a Web server when you access our Services. We may use both session Cookies and persistent Cookies to identify that you've logged in to the Services and to tell us how and when you interact with our Services. We may also use Cookies to monitor aggregate usage and web traffic routing on our Services and to customize and improve our Services. Unlike persistent Cookies, session Cookies are deleted when you log off from the Services and close your browser. Although most browsers automatically accept Cookies, you can change your browser options to stop automatically accepting Cookies or to prompt you before accepting Cookies. Please note, however, that if you don't accept Cookies, you may not be able to access all portions or features of the Services. Some third-party services providers that we engage (including third-party advertisers) may also place their own Cookies on your hard drive. Note that this Privacy Policy covers only our use of Cookies and does not include use of Cookies by such third parties.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information we collect about you United collects and maintains information, including personal information, about you directly from you (both online and offline), automatically when you use our sites and third party sites. We collect information from you when you make travel arrangements, contact us, complete a survey, register for the MileagePlus program, participate in a promotion, or otherwise interact with us. The type of information we collect about you depends on your particular interaction with us, and may include, but not limited to, the following information: Name; Contact information; MileagePlus number and security information; Gender and date of birth; Payment information (e.g., credit card information); Passport information and photograph; Government ID or redress number; Images; Travel preferences and special requests; Purchase information (including both travel and non-travel purchases); User and activity data from our sites and applications; Survey responses; and Tax identification number of promotion or survey winner, depending on the value of the prize.\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Any use of Cookies - or of other tracking tools - by this Application or by the owners of third party services used by this Application, unless stated otherwise, serves to identify Users and remember their preferences, for the sole purpose of providing the service required by the User.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 2.9 We only collect email addresses that were provided to us directly by you. Your email address will only be used for the following purposes: (i) the promotion of (new) games; (ii) service emails (on updates, new design, new features, etc.);\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information Collected by Cookies and Other Technologies. Like most online services and mobile applications, we may use cookies and other technologies, such as web beacons, web storage, and unique advertising identifiers, to collect information about your activity, browser, and device. We may also use these technologies to collect information when you interact with services we offer through one of our partners, such as commerce features. Most web browsers are set to accept cookies by default. If you prefer, you can usually remove or reject browser cookies through the settings on your browser or device. Keep in mind, though, that removing or rejecting cookies could affect the availability and functionality of our services. To learn more about how we use cookies and your choices, please check out our Cookie Statement. To learn more about how third parties use these technologies on our services, be sure to read the Analytics and Advertising Services Provided by Others section of our Privacy Policy.\nDescription: The policy describes collection of the user's ad ID (such as the Google Ad ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: E-mails and Telephone Calls. We require an e-mail address from you when you register for our services. We use your e-mail for both transactional (e.g., order confirmation, refund and renewal processing, notifying of matches for our Singles service) and promotional (e.g., newsletters, new product offerings, special discounts, event notifications, special third-party offers) purposes. E-mail messages we send you may contain code that enables our database to track your usage of the e-mails, including whether the e-mail was opened and what links (if any) were clicked. If you would rather not receive promotional e-mails from us, please see the section below labeled \"Choice/Opt-Out\". We reserve the right to send you certain communications relating to the eHarmony services, such as service announcements and administrative messages, without offering you the opportunity to opt out of receiving them. We may also contact you by telephone or text message (including to any wireless number you may provide to us) solely in connection with eHarmony's services. If you would rather not receive telephone calls or text messages from us, you may change or delete your number from your account preferences page(s), or ask to be removed from our contact list if you receive a call or text message from us. We fully comply with the requirements of the U.S. CAN-SPAM Act.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: For your convenience, information relating to our use of cookies and similar technologies is set out in a separate Cookies Policy. The Cookies Policy forms part of the Privacy Policy, and whenever we refer to the Privacy Policy, we are referring to the Privacy Policy incorporating the Cookies Policy.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We do not receive your email address and password.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Read More When you are shopping at an Under Armour store we collect any contact and purchase information that is necessary to process your transaction. For example, we collect payment information, email (to provide e-receipts when preferred), and physical address (for shipping). In addition, if you consent and where permissible, we may collect your email and phone numbers in order to send you information about products and promotions.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: COLLECTED INFORMATION What do we collect? We or our TPPs, may require Customers who register to purchase products (including, but not limited to, end-user licenses to use our intellectual property) from our Website or within our Apps, to be on our e-mail list, or generally to use our products, including, but not limited to, our Website and Apps (collectively, the \"Service\" or \"Services\") to give Us or our TPPs contact and other information, which may include but is not limited to Your name, company name, address, phone number, email address, cookies, IP address (collectively \"Personal Information\"). You can opt out of providing said information by not entering it when asked or not visiting the Website or using the Apps, although not providing it may hinder Your ability to use the Services. You can opt out of any correspondence from Us by following the applicable opt out procedures listed on any correspondence, but You should be aware that archival or back-up copies of said Personal Information will not cease to exist and your Personal Information may still be included in the aggregate and in the Hottrix history files. Further, We are under no obligation to remove said information or make any edits to your Personal Information and shall not be held liable for failing to do so nor for any of our TPPs failure to do so.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 7. subject to obtaining your consent in such form as may be required under the applicable law, we (including our affiliated companies and their designated Service Providers (as defined in C.1 below)) may use your name, phone number, residential address, email address, fax number and other data (\"Marketing Data\") to provide notices, surveys, product alerts, communications and other marketing materials to you relating to goods and services offered by us on the Sites including but not limited to Gold Suppliers membership, Verified Members membership, Free Members membership (each of Gold Suppliers membership, Verified Members membership, and Free Members membership, a \"Membership\" and collectively, the \"Memberships\") the value added services ancillary to the Memberships, and other products and services offered by us and/or our affiliated companies and their designated Service Providers from time to time to members of the Sites;\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information Automatically Collected We use a third-party Service Provider (defined below) to automatically log information about you and your computer or mobile device, and how you use and interact with the Service. For example, when you access the Service, we may log\u200e your operating system type,\u200e browser type and\u200e language,\u200e the pages you viewed,\u200e how long you spent on a page,\u200e access times,\u200e Internet protocol (IP) address, your mobile device ID, mobile device serial number, unique user ID, wireless carrier, and information about your use of and actions on the Service. We may also use third party advertisements to support our Service. Some of these advertisers may use technology such as cookies, web beacons, pixel tags, or log files when they advertise on our Service, which may send these advertisers information, including your non-personal information.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 3. SHARING OF INFORMATION We may share non-Personal Information, such as aggregate data and Usage Information such as Device Identifiers and general geographic data with third parties. We may also share your information as disclosed at the time you provide your information, as set forth in this Privacy Notice and in the following circumstances: Third Parties. We may share your Personal Information with third parties that perform functions on our behalf (or on behalf of our partners) such as service providers that host or operate our Platforms, analyze data, process transactions and payments, fulfill orders or provide customer service; sponsors or other third parties that participate in or administer our promotions, contests, sweepstakes, surveys or provide marketing or promotional assistance and \"powered by\" partners or partners in co-branded sites. Your Personal Information and location data may also be used by us or shared with our subsidiaries, affiliates, sponsors, partners, advertisers, advertising networks, advertising servers, and analytics companies or other third parties in connection with marketing, promotional, and other offers, as well as product information, and for providing such third party with advertising, analytics and market research. These advertisers, advertising networks, advertising servers, and analytics companies use various technologies to collect data in order to send (or serve) relevant ads to users on our Platforms, or on platforms or websites operated by third parties. These technologies may include the placement of cookies or web beacons, the use of unique or non-unique non-personal identifiers, or the use of other technologies on our Platforms, which may be used to track user behavior, to track how our Platforms are being used, to link various devices you may use, build consumer profiles and possibly to serve you more relevant ads. This Privacy Policy does not cover the use of various technologies by advertisers, advertising networks, advertising servers, and analytics companies outside of our properties.\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information we receive from social networking sites. When you interact with our site through various social media, such as when you login and share through Facebook, Instagram and others, we may receive information from the social network including your profile information, profile picture, gender, user name, user ID associated with your social media account, age range, language, country, friends list, and any other information you permit the social network to share with third parties. The data we receive is dependent upon your privacy settings with the social network. You should always review, and if necessary, adjust your privacy settings on third-party websites and services before linking or connecting them to our website or Service.\nDescription: The policy describes collection of the user's gender by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information We Get from Your Use of Our Services Device Information When you use any of Meitu applications on a mobile platform, we may collect and record certain information such as your unique device ID (persistent /non-persistent), hardware type, media access control (\"MAC\") address, international mobile equipment identity (\"IMEI\"), the version of your operating system (\"OS\"), your device name, and your location (based on your Internet Protocol (\"IP\") address, country code of SIM and GPS). This information is useful to us for troubleshooting and helps us understand usage trends among all users.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: In general, Peel may use your Registration Data and/or other information or data we receive or collect, as well as data we derive or infer from combinations of the foregoing, for a variety of purposes, such as: *To facilitate the creation of and secure your account on the Service.\nDescription: The policy describes collection of the user's gender by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Yes. We may share your information with third parties generally in the ways that are described in this privacy statement. We may disclose User Provided and Automatically Collected Information: as required by law, such as to comply with a subpoena, or similar legal process; when we believe in good faith that disclosure is necessary to protect our rights, protect your safety or the safety of others, investigate fraud, or respond to a government request; with our trusted services providers who work on our behalf, do not have an independent use of the information we disclose to them, and have agreed to adhere to the rules set forth in this privacy statement. with third party advertising networks and analytics companies as described below under the Section entitled Automatic Data Collection and Advertising. with affiliated companies.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: In the case of live television programs, we determine what content is available to you based in part on your zip code. In addition, the SmartTV helps make the searchable guides and other SmartTV content more relevant to you by highlighting programming and content that is likely to interest you, such as episodes of programs that you may have missed and new programs, applications and other content that we believe you will find of interest. We base these recommendations on: Information about content that you have watched, purchased, downloaded, or streamed through Samsung applications on your SmartTV or other devices; Information about applications you have accessed through the SmartTV panels; Information about your clicks on the \"Like,\" \"Dislike,\" \"Watch Now,\" and other buttons on your SmartTV; The query terms you enter into SmartTV search features, including when you search for particular video content; and Other SmartTV usage and device information, including, but not limited to, IP address, information stored in cookies and similar technologies, information that identifies your hardware or software configuration, browser information, and the page(s) you request.\nDescription: The policy describes collection of the user's MAC address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Facebook: When you access the Game through Facebook, we may receive your basic account information (user ID, name, email, gender, birthday, current city, profile picture URL, and the user IDs of the user's friends who have also connected with your application) from Facebook.\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information we collect In addition to the information listed in the Google Privacy Policy we may also collect the following: Registration information - When you sign up for Google Payments, you are creating a Google Payments Account that is associated with your Google Account. Depending on the Google Payments services you use, in addition to the information listed in the Google Privacy Policy, you may be asked to provide the following information: Credit or debit card number and card expiration date, bank account number and expiration date, address, phone number, date of birth, social security number or taxpayer identification number (or some other government-issued identification number), and for sellers or businesses specifically, your business category and certain information about your sales or transaction volume. In some cases, we may also ask you to send us additional information or to answer additional questions to help verify your information. Finally, if you register a Carrier or Operator Billing Account, we will ask you to provide us with certain information about your Carrier or Operator account.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: All Permissions are used in Products to provide best user experience. All personal and non-personal information obtained by the use of above Permissions are used only by the Products itself and are not stored, used, disclosed outside of the Products. Changes to our Privacy Policy\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: General Location. If you turn on the General Location feature, apps that cannot use your precise location will have access to your general location, such as your city, postal code, or region.\nDescription: The policy describes collection of the user's ZIP code by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information Collected by Third Parties Third Parties' Services Our Services may contain third party tracking tools from third party service providers. Such third parties may use cookies, APIs, and SDKs in our Services to enable them to collect and analyze your information on our behalf. The third parties may have access to information such as your device identifier, MAC address, IMEI, locale (specific location where a given language is spoken), geo-location information, and IP address for the purpose of providing their services under their respective privacy policies. The Policy does not cover the use of tracking tools from third parties. We do not have access or control over these third parties. If you would like to know the information of the corresponding third parties, please contact us at support@meitu.com or legal@meitu.com\nDescription: The policy describes collection of the user's unspecified location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The Information You Provide Us When using our Services, we might recommend you sign up for a Meitu account to take full advantage of our Services and their features. When you do, we will collect the information you provide to identify you for the purpose of the register of your Meitu account, including your account name, mobile phone number and so on\uff0cwhich are necessary to sign up for a Meitu account.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We, and our third party service providers, don't collect and analyse cookies, IP addresses, device type, device identifiers, browser types, browser language, URLs, domain names, landing pages, game state, the date and time of usage of the Service, and other similar information.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: On first launch, the Licensed Application will request permission to use location data.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We do not communicate your personal information to any third party sponsor. Personal Information means and includes all information that can be linked to a specific individual or to identify any individual, such as name, address, mailing address, telephone number, email ID, credit card number, cardholder name, card expiration date, information about your mobile phone, DTH service, data card, electricity connection, Smart Tags and any details that may have been voluntarily provide by the user in connection with availing any of the services on Paytm\nDescription: The policy describes collection of the user's phone number by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: To create an account on LinkedIn, you must provide us with at least your name, email address and/or mobile number, and a password and agree to our User Agreement and this Privacy Policy, which governs how we treat your information. You may provide additional information during the registration flow (for example, your postal code, job title, and company) to help you build your profile and to provide you more customized services (for example: language-specific profile pages, updates, content, more relevant ads and career opportunities). You understand that, by creating an account, we and others will be able to identify you by your LinkedIn profile. We may also ask for your credit card details if you purchase certain additional services.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: You may remove any information concerning AccessPoint that you provided to us during your use of Our Service. To this effect, you shall send a formal application to us via email at our designated email address. The Title of the email for the formal application shall be \"apply to unsharedAccessPoint\". You shall also provide us with the following information so that we can be sure you are the legal owner or has obtained the proper authorization to the Accesspoint: (a) SSIDs;\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Contact Information If you have any questions or concerns or complaints about our Privacy Policy or our data collection or processing practices, or if you want to report any security violations to us, please contact us at the following address or phone number: PSafe Tecnologia S.A.\nDescription: The policy describes collection of the user's postal address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: When you use the Apalon App(s), we may use the App Identifiers to facilitate access to the Apalon Apps, help us recognize you across different Apalon Apps, to enable you to use the Apalon Apps, to personalize your experience, to increase security, measure the use and effectiveness of our Apalon Apps and serve advertising. You can block certain App Identifiers by changing the settings of your device.\nDescription: The policy describes collection of the user's unspecified identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: You are ultimately responsible for the security of your email address and password. Please take care when using and storing them. We recommend that you do not divulge your password to anyone. You should log out of your browser at the end of each session to ensure that others cannot access your Personal Information and correspondence, especially if several people have access to your personal computer or you are using a computer in a public place, such as a library or Internet caf\u00e9.\nDescription: The policy describes collection of the user's password by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Cookies and other technologies Cookies are small data text files and can be stored on your computer's hard drive (if your Web browser permits). This website uses cookies for the following general purposes: To help us recognize your browser as a previous visitor and save and remember any preferences that may have been set while your browser was visiting our site. For example, if you register on our site, we may use cookies to remember your registration information, so you do not need to log into our site each time you visit. We also may record your password in a cookie, if you checked the box entitled \"Sign me in automatically next time.\" Please note that member IDs, passwords, and any other account-related data included in such cookies are encrypted for security purposes. Unless you register with us, these cookies will not contain any personal information.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 1. Information Collection You generally are not required to provide information about yourself when you visit the Services. However, we may ask you for some or all of the following types of information when you register with our Services, sign up for contests or sweepstakes, participate in surveys, access various content or features, submit comments or content, use a send-to-a-friend feature, or directly contact us with questions or feedback: Contact information, such as name, e-mail address, postal address, and telephone number; Unique identifiers, such as a user name or password; Demographic information, such as gender; Financial information, such as credit card or other payment information; Real-time Geolocation information; Communications preferences; Search queries; Comments and other information posted in our interactive online forums; Correspondence and other information that you send to us; and Additional information as otherwise described to you at the point of collection or pursuant to your consent.\nDescription: The policy describes collection of the user's unspecified demographic data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We do not use or collect your precise geographic location.\nDescription: The policy describes collection of the user's Bluetooth location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Rovio or third parties operating the ad serving technology may use demographic and geo-location information (for more information regarding use of Location Data see below Section 3) as well as information logged from your hardware or device to ensure that relevant advertising is presented within the Service. Rovio or third parties may collect and use data, for such purposes, including but not limited to, data such as IP address, Device ID, MAC address, installed software, application usage data, hardware type, Operating System information, browser information, unique identifiers in browser cookies, Flash cookies, and HTML5 local storage, Internet and on-line usage information and in-game information.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information from third party social network accounts If you sign into the Site with a third party social network, such as Facebook Connect, we will collect any information that you have agreed to make available to Smule through such account, which may include: (1) your first and last name, (2) your user ID/URL, (3) your profile picture, (4) your list of friends, (5) your email address and/or phone number, and/or (6) your birthday. This information will be primarily used for user registration and to enhance your social experience on the Site, which may include friend-to-friend interaction and notifications, chat, or messaging functionality, public leaderboards, head-to-head competition and other similar features. If you sign into Smule with a third party social network and agree to make your list of friends on such network available to Smule, your friends on such network will automatically follow you on the Site and your Smule account will be automatically configured to follow your friends. You can, however, unfollow any other user on Smule at any time.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Using Our Services: We receive information when you interact with our Services, even if you have not created an account (\"Log Data\"). For example, when you visit our websites, sign into our Services, interact with our email notifications, use your account to authenticate to a third-party website, application, or service, or visit a third-party website, application, or service that includes a Twitter button or widget, we may receive information about you. This Log Data may include your IP address, browser type, operating system, the referring web page, pages visited, location, your mobile carrier, device information (including device and application IDs), search terms, or cookie information. We also receive Log Data when you click on, view or interact with links on our Services, including links to third-party applications, such as when you choose to install another application through Twitter. We use Log Data to make inferences, like what topics you may be interested in, and to customize the content we show you, including ads. We keep Log Data as needed for the purposes described in this Privacy Policy. We will either delete Log Data or remove any common account identifiers, such as your username, full IP address, email address, or phone number, after a maximum of 18 months, if not sooner as provided below for Widget Data.\nDescription: The policy describes collection of the user's mobile carrier name or other mobile carrier identifier by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Location Information. We may collect or infer information about the general location of your Device when you access or use the Platform; or if you choose to turn on your Bluetooth, Wi-Fi or other geolocation functionality when you use the App, subject to your consent, the App may collect, infer, and use more precise geolocation information. We may use and share your location with certain third-parties for analytics, attribution and advertising purposes (currently advertising use is restricted to iHeartMedia properties only).\nDescription: The policy describes collection of the user's Bluetooth location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Analytics and Advertising Services Provided by Others We may let other companies use cookies, web beacons, and similar tracking technologies on our services. These companies may collect information about how you use our services and other websites and online services over time and across different services. This information may be used to, among other things, analyze and track data, determine the popularity of certain content, and better understand your online activity.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We also may collect certain information automatically when you visit the Services, including: Your Internet Protocol (IP) address, which is the number automatically assigned to your computer whenever you access the Internet and that can sometimes be used to derive your general geographic area; Your device type or mobile carrier; Other unique identifiers, including mobile device identification numbers; Your browser type and operating system; Sites you visited before and after visiting the Services; Pages you view and links you click on within the Services; Information collected through cookies, web beacons, Local Shared Objects, and other technologies; Information about your interactions with e-mail messages, such as the links clicked on and whether the messages were received, opened, or forwarded; and Standard Server Log Information\nDescription: The policy describes collection of the user's unspecified identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Facebook: When you access the Game through Facebook, we may receive your basic account information (user ID, name, email, gender, birthday, current city, profile picture URL, and the user IDs of the user's friends who have also connected with your application) from Facebook.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: However, if you: Purchase a product from DataViz Register a new product Download a trial version of our software Sign up for a mailing list or enter a contest Fill out a survey, or sign onto a page that requires authorization Or enter into any other transaction with us, You may be asked to provide us your name, e-mail address, phone number, fax number, postal address, credit card number (for purchases), and possibly other personal information. Additional demographic information may be optionally requested in order to improve our service to our customers. We may use the information you provide to: Keep you informed of new releases of our products.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Effective as of October 1, 2012. Updated to (1) include section on Group Plans, (2) clarify use of cookies, and (3) permit use by children with parent's consent as part of Group Plan.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 4.10. You may be offered the option of importing Your contact list or address book contacts, either automatically or manually, into the Services in order to enable You to (i) locate any of Your contacts who are also users of the Services; and/or (ii) invite Your contacts to become users of the Services. Should You opt to import Your contact list or address book contacts, You are authorising Us to store Your contact details on Our databases for these purposes, unless You expressly revoke this authorisation. For the avoidance of doubt, any passwords which You provide to Us to facilitate this import shall not be stored by Us.\nDescription: The policy describes collection of the user's password by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: send you communications, including by email. For example, we may use email to respond to support inquiries or to share information about our products, services, and promotional offers that we think may interest you. monitor and analyze trends and usage. personalize the services by, among other things, suggesting friends or profile information, or customizing the content we show you, including ads. contextualize your experience by, among other things, tagging your Memories content using your precise location data (if, of course, you've consented to us collecting that data) and applying other labels based on the content.\nDescription: The policy describes collection of the user's WiFi location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Advertising We may collect and use information about you, such as your device identifier, MAC address, IMEI, geo-location information and IP address for the purpose of the tracking of the advertising. This information is used together to create a unique user number to help us to better count and track advertising based on language, geographic location and other relevant details. This information is NOT SOLD to outside parties.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: It is not possible to link, create, or log in to your Uber account with a payment provider (e.g., Google Wallet) or social media service (e.g., Facebook).\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: July 2014 - Collecting gender information.\nDescription: The policy describes collection of the user's gender by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: To join the Badoo network you don't have to complete our online registration form. We do not ask you to provide us with information about you such as your name, your email address, your gender, your date of birth, your location details.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 6. COOKIES, IDENTIFIERS AND DATA ANALYSIS We may collect certain device data and electronic identifiers such as the mobile device identifier provided by your mobile device operating system, your mobile operating system details and the name of your mobile carrier. For example, if you use the iOS platform then Advertiser IDs (also known as \"IDFAs\" if you have an Apple device or \"Android Ad IDs\" if you have an Android device) may be collected. Other identifiers collected may include IP addresses, OpenUDID, Session ID, ODIn1, iOS Vendor IDs, MAC addresses, IMEI, Android ID for Android platform, and ODIN1 for OS X (together with the IDFAs, the \"App Identifiers\").\nDescription: The policy describes collection of the user's IMEI (International Mobile Equipment Identity) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: \"Log Data\" is technical information that is automatically collected by us when you use our services, whether through the use of cookies, web beacons and log files (as explained in more detail in the \"Cookies, Web Beacons and Log Files\" section below) or otherwise, including: technical information such as your mobile carrier, configuration information made available by your web browser or other programs you use to access our services, your IP address and your device's version and identification number, information about what you have searched for and looked at while using our services, such as web search terms used, social media profiles visited and details of other information and content accessed or requested by you in using our services; information about communications you have made using our services, such as the people you've communicated with and the time, data and duration of your communications; and metadata, which means information related to items you have made available through our services, such as the date, time or location that a shared photograph or video was taken or posted.\nDescription: The policy describes collection of the user's mobile carrier name or other mobile carrier identifier by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 1 Effective date and update Effective date of this privacy policy: 2013/05/01 2 Information we will collect and trace 2.1 NQ Mobile's official websites may be accessed anonymously. However, the use of our products and services as well as certain activities such as payment transactions, surveys, and forum communications will require customer information input and customer consent. This information may include: name, address, telephone number, as well as the brand name and model of the user's mobile phone. When using our NQ Family Guardian mobile application we will collect a parent's email address, password and a child's name or display name as well as their age range and a parents mobile number. Some examples may include: 2.1.1 If you submit an order online or use our products and services, the required information will be collected, including but not limited to yours or your child's NQ Mobile UID, the number, brand and model of yours or your child's mobile phone as well as your credit card number.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Email Address: We may work with data partners and advertising platforms to help increase the relevancy of ads we provide to our listeners. In doing so, we may use information representing an encrypted or hashed value derived from information we have received, such as your email address, in connection with these partners and platforms.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: \"Device Information\": When using some of BANDAI NAMCO's mobile applications, BANDAI NAMCO and/or certain third party service providers may collect certain Device Information from the mobile device on which you are using that mobile application, including: (i) the mobile device type, manufacturer, and model; (ii) the device's unique device identifier (UDID), Google Advertising ID (GAID), Android ID, ID for Advertisers (IDFA), ID for Vendors (IDFV), MAC address, International Mobile Equipment Identity (IMEI), or other unique device identifiers; (iii) device operating system (e.g., Android, iOS) and version, mobile browser type (e.g. Safari, Chrome, etc.) and version; (iv) network connection type (such as WiFi) and status, network provider ID, carrier user ID (a number uniquely allocated to you by your network provider); (v) the title and version of the mobile application in use by you, and any associated API keys; (vi) and a list of other applications installed or running on the mobile device; and (vii) other similar device and performance information.\nDescription: The policy describes collection of the user's ad ID (such as the Google Ad ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: \"Personal Data\" is information that can be used, directly or indirectly, alone or together with other information, to identify you as an individual Athlete. This may include your precise Location Data and your Performance Data.\nDescription: The policy describes collection of the user's WiFi location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information Sent by Your Mobile Device. We are not collecting information that your mobile device sends when you use our Services, like a device identifier, user settings and the operating system of your device.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information We Collect From You Information about you. We may collect information from you during your use of the Services, including your name, username, password, email address, postal address, phone number, mobile phone number, payment information, gender, birth year, and other information you provide or post on our Services or allow us to access when you do certain things, such as: Sign up and complete our registration form; Create or edit your user profile; Login to the Services; Submit questions or answer questions; Contact our customer support team or use our reporting mechanisms; Enter a sweepstakes or contest or register for a promotion; Participate in voting or polling activities; Request certain features (e.g., newsletters, updates, or other products); Connect with the Services or otherwise allow us to access certain information about you via a social media service; or Post user-generated content to or on our Services.\nDescription: The policy describes collection of the user's gender by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Personal Information You Provide to Us: We receive and store any information you enter on our Services or provide to us in any other way, including via any third party site or service through which you authorize us to access your information (e.g., Facebook). The types of Personal Information collected in this fashion may include but not limited to, an individual's name, phone number, credit card or other billing information, email address and home address. This Privacy Policy in no way limits or restricts our collection of aggregate or anonymous information. In this Privacy Policy, we refer to all information collected from or about you, including personal information and non-personal information, as \"Your Information.\" Use of Applications: When you launch any of our applications, we collect information regarding your device type, operating system and version, carrier provider, IP address, Media Access Control (MAC) address, International Equipment Mobile ID (IMEI), whether you are using a point package, the game version, the device's geo-location, language settings, and unique device ID. In addition, we create a unique user ID to track your use of our Service. This unique user ID is stored in connection with your Account profile information to enable us to move Your Information to a new device at your request. In addition, it may be used to link a character with which you play our games to your username on the Forums. When you play our games, we also collect information about your play and interaction with other users and the Service.\nDescription: The policy describes collection of the user's MAC address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: At any time, you may enable or disable location based tracking by accessing the Settings pane and toggling the checkmark for the option labeled \"Use location data\".\nDescription: The policy describes collection of the user's WiFi location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 9.1.2 Cookies are used to personalize webpages and / or recognize you when you are accessing our websites, in order to conveniently browse and access our websites after having registered for our products, services and/or other support services.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: What Information do we gather and track? We record IP addresses (the Internet address of a computer) to track sessions on our site. Tracking gives us an idea of which parts and pages of our site users are visiting, how often they visit them, and how long they spend there. We do not link IP addresses to anything personally identifiable. This means that even if your session is tracked, you still remain anonymous.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: KAKAO will collect the following information: When you sign up for the Services or in the course of your use of the Services, KAKAO will collect your telephone number, contact information saved on your smartphone or other device (telephone numbers and names of third parties), username (nickname), Kakao Account email address, For information about sending e-mail and password through the official website of KAKAO, individual applications or programs. You may choose to provide us with your birthday, gender, user ID, photos (including meta-information), and location information. Device-specific information (such as your operating system, screen size and unique device identifiers), IP address, cookies, date of visit, record of illegitimate use, service use records, etc. can be created automatically and collected in the course of service use or business process.\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: ONEX SOFTECH APPS does not save or upload your contacts. Permission to access contact information is used when you search contacts in ONEX SOFTECH APPS search bar. Read calendar events plus confidential information\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 4. INFORMATION WE RECEIVE FROM THIRD PARTIES We may receive information about you from third parties. For example, if you are on another website and you opt-in to receive information from iHeartMedia, that website will submit to us your email address and other information about you so that we may contact you as requested. You may also choose to participate in a third party application or feature (such as one of our Facebook or Twitter applications or a similar application or feature on a third party website) through which you allow us to collect (or the third party to share) information about you, including Usage Information, Device Identifiers, and Personal Information such as lists of your friends, \"likes\", comments you have shared, groups and location. Services like Facebook Connect give you the option to post information about your activities on our Platform to your profile page to share with others within your network. In addition, we may receive information about you if other users of a third party website give us access to their profiles and you are one of their \"connections\" or information about you is otherwise accessible through your \"connections'\" web page, profile page, or similar page on a social networking or other third party website or interactive service. We may also receive information about you from third party data providers. We may supplement the information we collect about you through the Platforms with such information from third parties in order to enhance our ability to serve you, to tailor our content to you and/or to offer you opportunities to purchase products or services that we believe may be of interest to you.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Interest-based Ads. We use cookies, Javascript, pixel tags, Device ID tracking and other technology to collect information about (i) your visit to our sites, your engagement with our apps and other third party partner websites and apps that we do not own or operate but with whom we have agreements and (ii) your interaction with emails we deliver (\"Online Data\"). We analyze what pages you visit on our sites and the third party sites, what products or services you view, and whether you view or click on ads that are shown to you. We use this information to send you interest-based ads. All such data is also collected anonymously, and is aggregated with other data we collect and/or similar data collected by partners to create segments, groups of users and certain general-interest categories or segments that we have inferred based on (a) demographic or interest data, and a general geographic location derived from your IP Address or mobile device, (b) the pages you view and links you click when viewing an email or using our sites and services and those of our partners, and/or (c) the search terms you enter when using certain search services. We use this information to get a more accurate picture of audience interests in order to serve ads we believe are more relevant to your interests.\nDescription: The policy describes collection of the user's IP location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Each Mobile App will also send us error-reporting information in the event that it crashes or hangs. This enables us to investigate the error and to improve the stability of the Mobile App for future releases. As part of these error reports, the Mobile App sends us information about the mobile device type and version, the UID, the time the error occurred, the feature being used and the state of the application when the error occurred. We do not use this information for any purpose other than investigating and remedying the error.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 3. Uses of Collected Information (a) If you submit personally identifiable information to us (in particular in completing our registration form to set up an Account or by accessing our Services through your Account with a third party service), you agree to us using your personal information in connection with the operation, maintenance, improvement and/or advertisement of the Servicesand will enable us to identify the Services that are most relevant to your needs. For Users who are not in Singapore and in countries where we work with third party agent partners, we may share your information with our agent partners in order to provide local customer service.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: II. Information We Collect In providing our services, we collect, store and use the following Information relating to you: \"Information\" is Personal Information and Non-Personal Information; \"Personal Information\" is any information or combination of information that relates to you, and can be used to identify you. Personal Information may include the following: information you make available to us when you open an account or use our services, such as your name, telephone number and email address; information which you make available to our services as you use them, including Shared Information you make available to others through our services and information you store using our services; Shared Information that others using our services make available about you, such as information contained in posts they make and communications they make to you and others using our services; and information we collect as you use our services, such as certain Location Data and Log Data.\nDescription: The policy describes collection of the user's IP address by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We automatically collect some information from your computer or Device when you visit TripAdvisor. For example, we will collect session data, including your IP address, Web browser software, and referring website. We also may collect information about your online activity, such as content viewed, pages visited, and searches and/or reservations facilitated or made. One of our goals in collecting this automatic information is to help us understand the interests and preferences of our users and customize your user experience.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Location Information: By downloading our App or using the Platform, you consent to our collection and use of your Device location information and sharing of location information with third parties for analytics and advertising purposes (currently advertising use is exclusively within iHeartMedia properties). If you initially consent to our collection of precise location information, you can subsequently stop the collection of precise location information at any time by going to the setting feature on your Device and changing your preferences. If you do so, certain features of our App may no longer function. You also may stop our collection of location information by following the standard uninstall process to remove our App from your device.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: HealthVault Account and Health Records. To create a new HealthVault account, you must provide personal data such as name, date of birth, e-mail address, postal code and country/region. Depending on which features you use, you may be asked for additional information. A HealthVault account allows you to manage one or more health records, such as the ones you create for yourself and your family members. You can add or remove data to a health record you manage at any time.\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 2.2 In addition, we store certain information from your browser, using \"cookies.\" A cookie is a piece of data stored on the user's computer and is tied to information about the user. 6677g may use cookies, web beacons (web bugs), or similar technologies to enhance and personalize your experience on our products, including the following: (a) to operate and improve offerings on our products; (b) to help authenticate you when you are on our products;\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Some of the Applications use third parties' services such as Google Play Games Services Sign-In, Apple's Game Center Sign In, Facebook, YouTube, Twitter or Vkontakte Log In. You may also share the content you created within the Application on Google Play Games Services, Game Center, Facebook or Vkontakte (\"Third Party Social Network\"). By logging in to the Application using Third Party Social Network or by using the Application to share content on such Third Party Social Network, you are authorizing us to collect, store, and use any and all information, in accordance with this Privacy Policy, that you agreed that such third parties could provide to us through the Application Programming Interfaces (\"API\"). Your agreement takes place when you \"accept\" or \"allow\" (or similar terms) one of our applications on such Third Party Social Networks. The information you allow us to access varies by Application, and it is affected by the privacy settings you and your friends establish on those Third Party Social Networks. You can control and find out more about these settings at Facebook, Vkontakte, Google Play Games Services and Game Center. These third party sites are governed by their own privacy policies and end user agreements and we are not responsible for, and have no control over, the sharing practices or policies of the third parties that operate those sites. For additional questions you can contact us at privacy@outfit7.com.\nDescription: The policy describes receiving data from the Facebook single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Please note that when you watch a video or access applications or content provided by a third-party, that provider does not collect or receive information about your SmartTV (e.g., its IP address and device identifiers), the requested transaction (e.g., your request to buy or rent the video), or your use of the application or service.\nDescription: The policy describes collection of the user's IP address by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Although we and our advertising partners use ad identifiers, cookies and similar technologies to enable us and third parties to provide more relevant advertising to you, these technologies also: allow us to recognise you and your device; allow our Services to interact with a third party social network or platform (where you have chosen to allow such interaction); allow our payment processors to process your payment instructions; and enable us and third parties to provide you with more customized services, for example to provide our services in the correct language.\nDescription: The policy describes collection of the user's ad ID (such as the Google Ad ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Examples of the information we do not collect include the Internet protocol (IP) address used to connect your computer to the Internet; login; e-mail address; password; computer and connection information such as browser type, version, and time zone setting, browser plug-in types and versions, operating system, and platform; purchase history, which we sometimes aggregate with similar information from other customers to create features like\u00a0Top Sellers; the full Uniform Resource Locator (URL) clickstream to, through, and from our Web site, including date and time; cookie number; products you viewed or searched for; and the phone number you used to call our 800 number.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: If you click on any advertisements through Our game, the advertisers may use cookies and other web-tracking technologies to collect data. Some of this may be personal information, and some of it non-personal information. We recommend that you review the terms of use and privacy policy for any advertiser with whom you are interacting before doing so.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Users can add or may have Metadata added to their User Content including a hashtag (e.g., to mark keywords when you post a photo), geotag (e.g., to mark your location to a photo), comments or other data. This makes your User Content more searchable by others and more interactive. If you geotag your photo or tag your photo using other's APIs then, your latitude and longitude will be stored with the photo and searchable (e.g., through a location or map feature) if your photo is made public by you in accordance with your privacy settings.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Read More We may sponsor contests, challenges, sweepstakes and other promotions (\"Promotions\") and we may request that you provide Personal Data, such as name, address, email address, telephone number and age and other information that may be appropriate in order to participate. If you win, we also may need to collect certain tax information, waivers and releases, depending on the prize.\nDescription: The policy describes collection of the user's Bluetooth location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The data we process on you may include, but is not limited to: email address, device ID, IP-address, user names and passwords.\nDescription: The policy describes collection of the user's password by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 1. INFORMATION WE COLLECT We collect the following types of information.\nDescription: The policy describes collection of the user's password by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Create and manage customer database(s) of its users including basic account information (such as your name, date of birth, address, contact details), applicable device ID(s) (relating to the devices you are using to access and receive particular applications and services), related product or service usage information and customer preference information as provided by you from time to time. As part of our ongoing customer relationship management activities, we may consolidate several databases into one or otherwise link separate databases to more effectively manage your accounts.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: To provide location-based services, AccuWeather and its partners and licensees utilize certain geographic tracking technologies that may collect, use, and/or share precise location data (such as GPS signals sent by a mobile device) or information that can be used to approximate a location (such as a cell ID), including the real-time geographic location of your computer or mobile device. This location data is collected anonymously in a form that does not personally identify you and is used by AccuWeather and its partners and licensees to provide and improve location-based products and services. By accepting AccuWeather's Privacy Statement and/or by using AccuWeather's products and/or services, you consent to use by AccuWeather and its Providers, partners and licensees of such geographic tracking technologies.\nDescription: The policy describes collection of the user's Bluetooth location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: User Provided Information - The Application obtains the information you provide when you download and use the Application. We may ask that you provide: (a) your name, email address, age, user name, password and other registration information; (b) transaction-related information, such as when you make purchases, respond to any offers, or download or use applications from us; (c) information you provide us when you contact us for help; and (d) information you enter into our system when using the Application, such as contact information and project management information. We may also use the information you provided us to contact your from time to time to provide you with important information, required notices and marketing promotions.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 8.2 Personal Information which you provide TabTale directly and/or through Third Parties via your installation and/or use of the Crazy Labs Apps or behavior with respect to advertisements thereof (such as your advertising identifier, persistent identifier and/or your geo location data), inter alia, through such Third Parties' SDK embedded in our Crazy Labs Apps. In addition, local Personal Information may also be stored on your device via generally accepted industry technologies used within the Crazy Labs Apps, such as \"cookies\" and local storage (see Section 19 below for further details with respect to Cookies and Local Storage).\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We don't collect your precise geolocation data (which includes the device's cellular, Wi-Fi, Global Positioning System (GPS) networks and/or Bluetooth information).\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Specific Accounts - Viber Out Account, Viber ID Viber Out Account Registration: Our Viber Out service allows you to call a number outside of the Viber registered community at low cost local rates. If you want to use Viber Out, you'll need to create a \"Viber Account\" by selecting a password, and providing certain personal information (e.g., name, email and billing information).\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: In order to fully function, the Licensed Application requires precise information about the location of your mobile device. For example, this location information is used to provide a map in the Licensed Application detailing your geographic location when you scanned an item.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: - We collect location information. We may collect information about the location from which you are using our services. This might include stores you visit. We may also collect your ZIP code. We may collect location information using different technologies. These technologies may include the location services of your operating system and browser as well as sensor data from your device. We may also collect and use Wi-Fi and GPS information and information on nearby Wi-Fi access points and cell towers. We might collect location information in the background, including when you are not directly interacting with our app. We may also collect location information from third party providers. Third party providers may also collect location information on our platforms.\nDescription: The policy describes collection of the user's unspecified location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Additional profile information You may also choose to provide Smule with additional Personal Data for your profile, which we will make public (your \"Public Profile\"), such as a picture, your location and an additional blurb about yourself. The information that you provide in your Public Profile will be visible to others, including anonymous visitors to the Site.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Location Information: When using some of BANDAI NAMCO's mobile applications BANDAI NAMCO and/or certain third party service providers, may collect location information from your device for the purpose of determining where you are playing the mobile application. BANDAI NAMCO will only share this information for the sole purpose of providing you with services relating to the mobile application on your device, such as directing your device to a server hosting online features for that mobile application. You may opt-out of location-based services at any time by changing certain settings on your mobile device as described in Section A9, below.\nDescription: The policy describes collection of the user's unspecified location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Use of Personal Information by PSafe We use the Personal Information we collect to offer services and features that can be tailored to users' needs, and even allows us to customize our services to make the users' experiences with PSafe as comfortable as possible. We use the Personal Information we request as follows: To develop internal studies about the interests, behaviors and demographics of users in order to better understand their needs and interests and therefore offer better services or provide related information.\nDescription: The policy describes collection of the user's unspecified demographic data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The only personal information we collect from you for the purposes of offering our services are persistent identifiers (such as device ID, IDFA, IDFV, advertising ID, IP address). Such persistent identifiers are used and shared with third parties solely for providing support for the internal operations meaning to place contextual advertisement (including frequency capping), to authenticate users of or personalize the content on Applications, to maintain or analyze the functioning of the Applications, personalize the content of the Application (such as sending push notifications), to perform network communications to protect the security or integrity of the user or the Application, to ensure legal or regulatory compliance.\nDescription: The policy describes collection of the user's ad ID (such as the Google Ad ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information We Collect from Third Parties We may collect information that other users provide about you when they use our services. For example, if another user allows us to collect information from their device phonebook-and you're one of that user's contacts-we may combine the information we collect from that user's phonebook with other information we have collected about you. We may also obtain information from other companies that are owned or operated by us, or any other third-party sources, and combine that with the information we collect through our services.\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: These technologies collect and use information so we can serve appropriate advertising to you and help track results and measure effectiveness. In addition to identifiers, this information includes: Advertisements served and the location of the ad; Length of time an advertisement was visible; Domain type, IP address, size of the advertisement; and Advertisement response.\nDescription: The policy describes collection of the user's unspecified identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Manage and improve the Apalon App(s). For this purpose, we may use and combine your Information which we collect across different Apalon Apps used by you; When we collect your precise geolocation data (subject to your consent) (which may be via the device's cellular, Wi-Fi, Global Positioning System (GPS) networks and/or Bluetooth information), we do so to provide you with our location-related products and services, for example to provide you with forecast and weather alerts for your location, and also to facilitate, measure, or otherwise support advertising by third parties (through our apps or third parties' apps) that may be related to your location over time. When you share your Information with us via a social network provider like Facebook, we use this to show Information on your social network profile (subject to your privacy setting and preferences for such social network) and to allow you to share Information about our services with your connections or on your social network profile.\nDescription: The policy describes collection of the user's cell tower location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Registration Related Information. Information you provide when you register for the Software & Services (if applicable), such as name, home or work addresses, e-mail address, telephone and fax numbers, birth date and gender;\nDescription: The policy describes collection of the user's postal address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 3.6. We receive and store the information that You provide, including Your telephone number, when You sign up to and consent to having text messages sent directly to Your mobile phone. These text messages notify You of in-game activity within the Services and may allow You to access the Services from Your mobile device.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Some of the Apalon Apps do not offer you the ability to register and login using your third party social media account details (like your Facebook or Twitter logins). We will not receive profile Information about you from your social media provider (e.g., your name, e-mail address or friends list).\nDescription: The policy describes receiving data from the Facebook single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Use of Applications When you launch any of our applications, we collect information regarding your device type, operating system and version, carrier provider, IP address, Media Access Control (MAC) address, International Equipment Mobile ID (IMEI), whether you are using a point package, the game version, the device's geo-location, language settings, and unique device ID. In addition, we create a unique user ID to track your use of our Service. This unique user ID is stored in connection with your Account profile information to enable us to move Your Information to a new device at your request. In addition, it may be used to link a character with which you play our games to your username on the Forums. When you play our games, we also collect information about your play and interaction with other users and the Service.\nDescription: The policy describes collection of the user's mobile carrier name or other mobile carrier identifier by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Third party ad network providers, advertisers, sponsors and/or traffic measurement services may use cookies, JavaScript, web beacons (including clear GIFs), Flash LSOs and other technologies to measure the effectiveness of their ads and to personalize advertising content to you. These third-party cookies and other technologies are governed by each third party's specific privacy policy, and not this Privacy Policy.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We may use third parties to serve ads on the site, products and services. Certain third parties may automatically collect information about your visits to our site and other websites, your IP address, your ISP, the browser you use to visit the site (but not your name, address, e-mail address or telephone number). They do this by using cookies or other technologies. Information collected may be used, among other things, to deliver advertising targeted to your interests and to better understand the usage and visitation of our site and the other sites tracked by these third parties. This policy does not apply to, and we are not responsible for, cookies or pixel tags in third party ads, and we encourage you to check the privacy policies of advertisers and/or ad services to learn about their use of cookies and other technologies. If you would like more information about this practice and to know your choices about not having this information used by these companies, click here: http://www.aboutads.info/choices.\nDescription: The policy describes collection of the user's phone number by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 3. Online Use There are three types of data and information which may be collected from Users of our Kids Apps: 3.1 Non-personal Information: TabTale allows Third Parties to collect non-identifiable and anonymous information as detailed below (\"Kids Non-personal Information\"). To put it simply, with respect to such Kids Non-personal Information TabTale and the Third Parties are not aware of the identity of the User from whom Third Parties have collected the Kids Non-personal Information. Kids Non-personal Information collected by Third Parties may include the following technical information: type of operation system (e.g. Android, iOS, etc.), type of browser (e.g. Explorer, Firefox, Chrome, Safari, etc.), screen resolution (e.g. 800\u00d7600, 1024\u00d7768, etc.), language (e.g. English), device type (e.g. Galaxy, HTC, iPhone, etc.), geo-location - only general location may be collected. No street name or city/town name is collected.\nDescription: The policy describes collection of the user's unspecified location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information We Collect Through Your Use of Our Services When you use our Services, we collect information about you in the following general categories: Location Information: When you use the Services for transportation or delivery, we collect precise location data about the trip from the Uber app used by the Driver. If you permit the Uber app to access location services through the permission system used by your mobile operating system (\"platform\"), we may also collect the precise location of your device when the app is running in the foreground or background. We may also derive your approximate location from your IP address.\nDescription: The policy describes collection of the user's IP location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Message Data. We automatically record it and store it in your phone without transmitting to our server.\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Social Networks. If you connect your Shazam account to any social network or music streaming service, including, but not limited to, Facebook, Google+ or Spotify, your name, birthdate, email address, gender, friend list, profile picture and playlists, along with other elements of your social network profile that you have made available may be shared with other Shazam users. Further, your Facebook friends/contacts may be able to use the Shazam apps to search for or view your Shazam profile and the data contained therein, such as your tags and other activity, including date/time. Please refer to the privacy settings in your social network or music streaming account for information about what data is shared with Shazam and other connected applications and to manage the data that is shared through your account, including information about your activities using our sites or apps. Go to the \"preferences\" screen to see your options to adjust the access levels to the data in your Shazam profile but, again, if you don't want a social network or music streaming service to gain access to your data, do not connect to that network via Shazam. If you would like to disconnect a social media or music streaming account from Shazam, refer to the settings of that social media or music streaming account and its provider.\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The data we collect depends on the products and features you use, and can include the following: Name and contact data. We collect your first and last name, email address, postal address, phone number, and other similar contact data.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Please note that we do not have access to or control over cookies or other technologies these third parties may use to collect information about your interests, and the information practices of these third parties are not covered by this Privacy Policy. Some of these companies are members of the Network Advertising Initiative, which offers a single location to opt out of ad targeting from member companies. To learn more, please click here.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The products and services we provide do not read private information concerning your phone and your using of the phone, such as SMS, MMS, Email, Contacts, call log, call conversation, location information, the phone number, the IMSI, the IMEI, the ICCID, or the ESN.\nDescription: The policy describes collection of the user's IMSI (International Mobile Subscriber Identity) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information we collect through our mobile application(s) We may collect information from you when you use our mobile application(s), including, but not limited to: name, email address, MileagePlus account information, government ID or passenger redress number, passport information and/or photograph, date of birth, payment information (e.g., credit card number, expiration date and billing name and address), if not already provided.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: To show you ads on behalf of advertisers, we use information that you make available to us when you interact with the Platform (e.g. by listening, liking or creating playlists), including location data, together with information you provide to us through the Platform, e.g. demographic information, you choose to make available to us (such as your age or gender) directly or through third party services as well as information your browser sends us when using the Platform (e.g. referral URLs, device type or location data). This allows us to show you ads that are more relevant and interesting to you. Please note that we do not share personal data with advertisers. Instead, advertisers pre-define a specific audience by certain generic criteria (e.g. the city of residence, the age range, or the number of followers of an unidentified user) for a specific ad campaign. If your profile matches these generic criteria, we may choose to display a suitable ad to you. We may also display ads based on the content that you have recently viewed or searched. Before we may use location data from the app for the first time, your mobile device will generally ask you for permission first. In case you gave permission to do so, location based services in your device will collect location data for a couple of seconds. These will then be shared with us or a respective service provider. When we engage third party services such as ad-networks that enable us showing you interest based ads, we may also allow them to collect certain information such as cookie data from you. This information would allow these third-parties to deliver targeted advertisements that they believe will be of most interest to you. If you allow third party websites to collect and share data when you interact with their platform, ad-networks may use that information together with the information we allow them to collect on the Platform. Please see the privacy policy of such third party websites to understand what data may be collected and how to opt-out.\nDescription: The policy describes collection of the user's gender by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: In some cases, an Apalon App may provide you with the option to register using social media account details, like your Facebook, Twitter or other social media account. If you choose to register in this way, we will collect the Information described in the section called \"Social Logins\" [LINK] below. We will also collect your Information when you use Apalon Apps such as when you post or share material, upload data, request further services or make selections using the Apalon Apps, if such functionality is available in the Apalon App.\nDescription: The policy describes receiving data from the Facebook single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 3.2. We will also collect: Your screen name (user ID); Technical or other details about any device which you use to access the Services: Internet and/or network connection (including your IP address, Media Access Control (MAC), operating system, browser type or other software); hardware (including computer hardware or mobile model); mobile device details (including your mobile device type and number; mobile carrier details; and unique device identifier) or other technical details. Details of your use of the Services including, but not limited to: traffic data, location/geographical data, the Service resources that you access, the time you spend on the Services, crash reports and reasons for connection drops. Data that you provide to Us via any third party website, application or service (including Facebook or Google) which You use to access the Services or which you make publicly available on such third party website or service, or which you give Us via any forms on the website www.topeleven.com (or any other Nordeus or Top Eleven website), by text message, via player forums, data stored in Services log files or by contacting Us. Information provided when you report a problem with any of the Services. We may also ask you to complete surveys that We use for research purposes, although you do not have to respond to them.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Rovio or third parties operating the ad serving technology may use demographic and geo-location information (for more information regarding use of Location Data see below Section 3) as well as information logged from your hardware or device to ensure that relevant advertising is presented within the Service. Rovio or third parties may collect and use data, for such purposes, including but not limited to, data such as IP address, Device ID, MAC address, installed software, application usage data, hardware type, Operating System information, browser information, unique identifiers in browser cookies, Flash cookies, and HTML5 local storage, Internet and on-line usage information and in-game information.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Does Badoo collect any other personal information about me? If you contact our Customer Support team via Feedback page, we will receive your email address, and may track your IP address as well as the information you send to us to help resolve your query. We will keep records of our communications with you, including any complaints that we receive from you about other users (and from other users about you).\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Last Updated: March 31, 2017 TABLE OF CONTENTS: 1. Introduction 2. Data We Collect 3. How We Use The Information We Collect 4. Cross-App Advertising and Other Interest-Based Advertising Technologies 5. Sharing Your Information 6. No Cookies, identifiers and data analysis 7. How We Protect Your Information 8. Information Relating to Children 9. Social Logins 10. Where We Store Your Information 11. How Long We Store Your Information 12. Data Deletion 13. Access To and Choices Regarding Your Information 14. How To Contact Us 1. INTRODUCTION This \"Apalon Apps\" branded mobile application and any services provided through this application (the \"Apalon App\" and collectively, the \"Apalon Apps\") a list of which is available at www.apalon.com are provided to you by IAC Search and Media Europe, Ltd., an Irish registered company, with company number 373923 and its registered office at Unit 1, Digiweb Building, College Business and Technology Park, Blanchardstown North Road, Dublin 15, Ireland (referred to as \"IAC\", \"we\", \"us\" or \"our\"). Our Privacy Policy applies when you use any of the Apalon Apps and should be read together with the End User License Agreement EULA. By using an Apalon App, you are consenting to our processing of your information in ways set out in this Privacy Policy.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We also obtain data from third parties. For example, we supplement the data we collect by purchasing demographic data from other companies. We also use services from other companies to help us determine a location based on your IP address in order to customize certain products to your location.\nDescription: The policy describes collection of the user's unspecified demographic data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: In Settings, you can also view which applications have access to the location service or your device's location history, turn off or on access to the location service for particular applications, or turn off the location service. You can also set a default location, which will be used when the location service can't detect a more exact location for your device.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Automatic Data Collection and Advertising We may work with analytics companies to help us understand how the Applications is being used, such as the frequency and duration of usage. We work with advertisers and third party advertising networks, who need to know how you interact with advertising provided in the Applications which helps us keep the cost of the Applications free. Advertisers and advertising networks use some of the information collected by the Applications, including, but not limited to, the unique identification ID of your mobile device and mobile operating system. To protect the anonymity of this information, we use an encryption technology to help ensure that these third parties can't identify you personally. These third parties may also obtain anonymous information about other applications you've downloaded to your mobile device, the mobile websites you visit, your non-precise location information (e.g., your zip code), and other non- precise location information in order to help analyze and serve anonymous targeted advertising on the Applications and elsewhere. We may also share encrypted versions of information you have provided in order to enable our partners to append other available information about you for analysis or advertising related use.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: By using a First Touch Games application in conjunction with an SNS, you are authorizing First Touch Games to collect, store, and use in accordance with this Privacy Policy any and all information that you agreed the SNS could provide to First Touch Games through the SNS Application Programming Interface (\"API\"). Your agreement takes place when you \"accept\" or \"allow\" (or similar terms) one of our applications on an SNS.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: When you use an Application on a Device, we will collect and use information about you in generally similar ways and for similar purposes as when you use the TripAdvisor website. In addition, we may collect information about your location if you have instructed your Device to send such information to the Application via the privacy settings on that Device, or if you have uploaded photos tagged with location information. We may use the location information collected from your Device or photos to enhance your use of the Application by providing you with relevant content and contextual advertising. For example, we may use your location to show you reviews of hotels or restaurants near you when you are traveling. You can change the privacy settings of your Device at any time, in order to turn off the functionality to share location information with the Application and/or the functionality to tag your photos with location information. Please note that turning off location sharing may affect certain features of our App. If you have any queries about the privacy settings of your Device, we suggest you contact the manufacturer of your Device or your mobile service provider for help.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Samsung Privacy Policy 1. WHAT INFORMATION DO WE COLLECT ABOUT YOU? Information you provide directly Some Services enable you to give us information directly. For example: A number of our Services enable users to create accounts or profiles. In connection with these Services, we may ask you to provide certain information about yourself to set up the account or profile. For example, you can submit certain information about yourself, such as your name and email address, when you create a Samsung Account. If you order a product or paid service from us, we may ask for your name, contact information, shipping and billing address(es), and credit card information in order to process your order.\nDescription: The policy describes collection of the user's postal address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: It is understood that this policy covers the use of cookies by this website and not the use of cookies by advertisers. PSafe does not control the use of cookies by third parties.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Mobile Device Information When you access the Services via a mobile device, we will collect information related to the mobile device such as the serial number or MAC address and the open UDID of the device. We may use this information to improve and personalize our Services for you.\nDescription: The policy describes collection of the user's SIM serial number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: i. Location Information Some features we offer work better if we know what area you are in. Lookout may collect location information in two ways. We may receive it directly from your mobile device, or, in some situations, we may receive location data from cell tower or Wi-Fi hotspot information. We may use third-party service providers to translate that information into usable location information.\nDescription: The policy describes collection of the user's cell tower location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: g) Location information: When you use BlackBerry Offerings, enable data services, use the browser or location-based functionality on your device, location information associated to your device (e.g. Global Positioning System (GPS) or similar satellite triangulation information, carrier or tower ID, the BSSID (Broadcast Service Set Identifier) and MAC address (Media Access Control address) of Wi-Fi access points, and signal strength of visible Wi-Fi hotspots or wireless towers) may be communicated to BlackBerry or our service providers. If BlackBerry collects and subsequently stores such information, it will be in a form that does not personally identify you (e.g. BlackBerry does not maintain a system that would link specific individuals to a BSSID). BlackBerry may process such information to provide you with or facilitate the provision of information and location-based services (e.g. mapping services, measuring traffic congestion, location-sensitive promotions or coupons). If you choose to use location-based services, you agree that such geographic location information may be processed to provide you with such services. You may manage through the settings on your device either the overall settings for your device's GPS or location functionality or individual settings for each application. If you choose to use location-based services or other applications to disclose your location to other persons or entities, you assume responsibility for the risks involved in doing so, and it is your responsibility to use them appropriately and according to applicable law. If you use Third Party Offerings which provide location-based services, please review the third party's terms and conditions and privacy policy regarding how your location and personal information will be processed, and how to opt-out of any location-based services and advertising provided by the third party.\nDescription: The policy describes collection of the user's SSID or BSSID by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: You are responsible for maintaining the secrecy of your password at all times. We recommend a strong password that you do not use with other services. If you believe your password has been compromised, please change your password immediately via the Lookout website, or contact us at support@lookout.com for assistance. You are responsible for ensuring that the email address associated with your account is accurate. We use that email to contact you about service updates, changes to our policies, and account activities such as requests for your information or locate attempts on your device. Lookout is not responsible for personal data transmitted to a third party as a result of a user's providing an incorrect email address.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Cookies and Other Web Technologies.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We harvest these data from Facebook, from You and from third parties.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: COLLECTED INFORMATION What do we collect? We or our TPPs, may require Customers who register to purchase products (including, but not limited to, end-user licenses to use our intellectual property) from our Website or within our Apps, to be on our e-mail list, or generally to use our products, including, but not limited to, our Website and Apps (collectively, the \"Service\" or \"Services\") to give Us or our TPPs contact and other information, which may include but is not limited to Your name, company name, address, phone number, email address, cookies, IP address (collectively \"Personal Information\"). You can opt out of providing said information by not entering it when asked or not visiting the Website or using the Apps, although not providing it may hinder Your ability to use the Services. You can opt out of any correspondence from Us by following the applicable opt out procedures listed on any correspondence, but You should be aware that archival or back-up copies of said Personal Information will not cease to exist and your Personal Information may still be included in the aggregate and in the Hottrix history files. Further, We are under no obligation to remove said information or make any edits to your Personal Information and shall not be held liable for failing to do so nor for any of our TPPs failure to do so.\nDescription: The policy describes collection of the user's postal address by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Personal Information and Non-Personal Information Candy Mobile may collect personal and non-personal information from you when you use the Service. Personal information is information that specifically identifies an individual, including, but not limited to, an individual's name, phone number, credit card or other billing information, email address and home address. This Privacy Policy in no way limits or restricts our collection of aggregate or anonymous information. In this Privacy Policy, we refer to all information collected from or about you, including personal information and non-personal information, as \"Your Information.\" Use of Applications When you launch any of our applications, we collect information regarding your device type, operating system and version, carrier provider, IP address, Media Access Control (MAC) address, International Equipment Mobile ID (IMEI), whether you are using a point package, the game version, the device's geo-location, language settings, and unique device ID. In addition, we create a unique user ID to track your use of our Service. This unique user ID is stored in connection with your Account profile information to enable us to move Your Information to a new device at your request. In addition, it may be used to link a character with which you play our games to your username on the Forums. When you play our games, we also collect information about your play and interaction with other users and the Service.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Third-Parties and Affiliates: We may receive information about you from third parties, such as other Twitter users, partners (including ad partners), or our corporate affiliates. For example, other users may share or disclose information about you, such as when they mention you, share a photo of you, or tag you in a photo. Your privacy settings control who can tag you in a photo. Our ad partners and affiliates may share information with us such as a browser cookie ID, mobile device ID, or cryptographic hash of a common account identifier (such as an email address), as well as demographic or interest data and content viewed or actions taken on a website or app. Our ad partners, particularly our advertisers, may enable us to collect similar information directly from their website or app by integrating our advertising technology.\nDescription: The policy describes collection of the user's unspecified demographic data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We target (and measure the performance of) ads to Members, Visitors and others both on and off of our Services through a variety of ad networks and ad exchanges, using the following, whether separately or combined: Advertising technologies on and off of our Services, like web beacons, pixels, ad tags, cookies, and mobile identifiers as permitted by mobile platforms; Member-provided profile and contact information and categories (for example, \"product managers in Texas\"); Information inferred from a Member's profile (for example, using job titles to infer age, industry, seniority, and compensation bracket; or names to infer gender);\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: It is understood that this policy covers the use of cookies by this website and not the use of cookies by advertisers. PSafe does not control the use of cookies by third parties.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Cooxies applications: On this site device identifiers are used to personalize content and ads, in order to Provide social media features and to analyze traffic. We Also share These identifiers and other information on your device with our social media partners, advertising and web analytics.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Mail and Calendar app. The Mail and Calendar app allows you to connect all your email, calendars, and files in one place, including those from third-party email and file storage providers. The app provides location-based services, such as weather information in your calendar, but you can disable the app's use of your location. When you add an account to the Mail and Calendar app your email, calendar items, files, contacts, and other settings from your account will automatically sync to your device and to Microsoft's servers. At any time, you can remove an account or make changes to the data that's synced from your account. To configure an account, you must provide the app with the account credentials (such as user name and password), which will be sent over the Internet to the third-party provider's server. The app will first attempt to use a secure (SSL) connection to configure your account but will send this information unencrypted if your email provider does not support SSL. If you add an account provided by an organization (such as a company email address), the owner of the organizational domain can implement certain policies and controls (for example, multi-factor authentication or the ability to remotely wipe data from your device) that may affect your use of the app.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Web Beacons. Web beacons may also be found on the AccuWeather Sites Web beacons are used to monitor user navigation to tailor the AccuWeather Sites to our subscribers or users' preferences and enhance the site's offerings. For a thorough description of web beacons and their uses, please click here.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: While it is not our intention to collect any personally identifiable information (\"PII\") (except for registration and user support purposes as set forth in this Privacy Policy), the data collected may include PII. As part of our privacy measures, we implement certain rules designed to avoid the unintentional collection of PII such as email addresses, social security numbers, credit card numbers, login information etc. Such rules are based on known field types, parameters, values and algorithms but they are not foolproof and hence the Software & Services may sometimes, unintentionally, collect unwanted information. We regularly examine and update these rules.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Personal Information is not received by us when you open an account or use our services, such as your name, telephone number and email address;\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information about your friends. You can choose to invite your friends to join ASKfm so that you can stay in touch with them on the Services. To allow you to use this feature, we will ask your permission to access your personal contact list, which we will only access to store for your own use, to assist you with inviting friends to join you on the Services, and to notify you when someone you know joins the Services. To make it easier to search and find friends and people you know on ASKfm, users may search for other members using first and last name, email address, and location.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Personal Information and Non-Personal Information Doodle Mobile may collect personal and non-personal information from you when you use the Service. Personal information is information that specifically identifies an individual, including, but not limited to, an individual's name, phone number, credit card or other billing information, email address and home address. This Privacy Policy in no way limits or restricts our collection of aggregate or anonymous information. In this Privacy Policy, we refer to all information collected from or about you, including personal information and non-personal information, as \"Your Information.\" Use of Applications When you launch any of our applications, we collect information regarding your device type, operating system and version, carrier provider, IP address, Media Access Control (MAC) address, International Equipment Mobile ID (IMEI), whether you are using a point package, the game version, the device's geo-location, language settings, and unique device ID. In addition, we create a unique user ID to track your use of our Service. This unique user ID is stored in connection with your Account profile information to enable us to move Your Information to a new device at your request. In addition, it may be used to link a character with which you play our games to your username on the Forums. When you play our games, we also collect information about your play and interaction with other users and the Service.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We use third parties such as Foursquare to provide data on which the location information on Badoo is based. When doing so, we receive and use data of Foursquare's users, and we share data with Foursquare for use by Foursquare for its own purposes. For more information on how Foursquare treat data, please see https://foursquare.com/legal/privacy/\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Social Networks. If you connect your Shazam account to any social network or music streaming service, including, but not limited to, Facebook, Google+ or Spotify, your name, birthdate, email address, gender, friend list, profile picture and playlists, along with other elements of your social network profile that you have made available may be shared with other Shazam users. Further, your Facebook friends/contacts may be able to use the Shazam apps to search for or view your Shazam profile and the data contained therein, such as your tags and other activity, including date/time. Please refer to the privacy settings in your social network or music streaming account for information about what data is shared with Shazam and other connected applications and to manage the data that is shared through your account, including information about your activities using our sites or apps. Go to the \"preferences\" screen to see your options to adjust the access levels to the data in your Shazam profile but, again, if you don't want a social network or music streaming service to gain access to your data, do not connect to that network via Shazam. If you would like to disconnect a social media or music streaming account from Shazam, refer to the settings of that social media or music streaming account and its provider.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: For example, if you use the iOS platform then Advertiser IDs (also known as \"IDFAs\" if you have an Apple device or \"Android Ad IDs\" if you have an Android device) may are not collected. Other identifiers not collected include IP addresses, OpenUDID, Session ID, ODIn1, iOS Vendor IDs, MAC addresses, IMEI, Android ID for Android platform, and ODIN1 for OS X (together with the IDFAs, the \"App Identifiers\"). ... Apalon doesn't use the Google Analytics tool Firebase. App Identifiers and other Information which Apalon does not gather are neither provided to Google.\nDescription: The policy describes collection of the user's MAC address by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Cookies are small text files containing a string of alphanumeric characters. myTuner may use both session cookies (disappear after you close your browser) and persistent cookies (used by your browser on subsequent visits).\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We may use technical means to collect information about You when You use our Services. This information may include your Internet Protocol address, time of your requests or actions in the service, mobile device ID, hardware type and operating system version, operating system, access times, browser type and language, location based on Internet Protocol (\"IP\") address or Global Positioning System (GPS), advertising ID, media access control (\"MAC\") address, international mobile equipment identity (\"IMEI\"), your device name, your email address (if You have connected e.g. to Facebook or Google+), and referring website addresses.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Correcting/updating your personal information If your personally identifiable information changes (such as your zip code), or if you no longer desire our service, we will endeavor to provide a way to correct, update or remove your personal data provided to us. This can be accomplished by contacting DataViz via e-mail, fax, phone or mail communication. Registered users can update their information here or by contacting DataViz directly.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 3. SHARING OF INFORMATION We may share non-Personal Information, such as aggregate data and Usage Information such as Device Identifiers and general geographic data with third parties. We may also share your information as disclosed at the time you provide your information, as set forth in this Privacy Notice and in the following circumstances: Third Parties. We may share your Personal Information with third parties that perform functions on our behalf (or on behalf of our partners) such as service providers that host or operate our Platforms, analyze data, process transactions and payments, fulfill orders or provide customer service; sponsors or other third parties that participate in or administer our promotions, contests, sweepstakes, surveys or provide marketing or promotional assistance and \"powered by\" partners or partners in co-branded sites. Your Personal Information and location data may also be used by us or shared with our subsidiaries, affiliates, sponsors, partners, advertisers, advertising networks, advertising servers, and analytics companies or other third parties in connection with marketing, promotional, and other offers, as well as product information, and for providing such third party with advertising, analytics and market research. These advertisers, advertising networks, advertising servers, and analytics companies use various technologies to collect data in order to send (or serve) relevant ads to users on our Platforms, or on platforms or websites operated by third parties. These technologies may include the placement of cookies or web beacons, the use of unique or non-unique non-personal identifiers, or the use of other technologies on our Platforms, which may be used to track user behavior, to track how our Platforms are being used, to link various devices you may use, build consumer profiles and possibly to serve you more relevant ads. This Privacy Policy does not cover the use of various technologies by advertisers, advertising networks, advertising servers, and analytics companies outside of our properties.\nDescription: The policy describes collection of the user's e-mail by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Cookies We automatically collect certain information through the use of \"cookies\". Cookies are small data files that are stored on your hard drive by a Web site. We use cookies to collect information about your device, including where available your IP address, operating system and browser type, for system administration and to report information to our branded partners.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Social Platform Registrations and Social Media Plugins Some of the ZeroFour Sites permit or require you to register or log into your account via a third party social networking platform or permit you to use social media plugins.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We are not collecting information from you during your use of the Services, particularly, your name, username, password, email address, postal address, phone number, mobile phone number, payment information, gender, birth year ...\nDescription: The policy describes collection of the user's password by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information AdHub Collects Device Information When you use a Samsung service that includes ads provided by AdHub, AdHub receives certain information about your device. This information may include the device's hardware model, IMEI number and other unique device identifiers, MAC address, IP address, operating system version, and settings.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We DO NOT collect your name, location or phone number.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: To show you ads on behalf of advertisers, we use information that you make available to us when you interact with the Platform (e.g. by listening, liking or creating playlists), including location data, together with information you provide to us through the Platform, e.g. demographic information, you choose to make available to us (such as your age or gender) directly or through third party services as well as information your browser sends us when using the Platform (e.g. referral URLs, device type or location data). This allows us to show you ads that are more relevant and interesting to you. Please note that we do not share personal data with advertisers. Instead, advertisers pre-define a specific audience by certain generic criteria (e.g. the city of residence, the age range, or the number of followers of an unidentified user) for a specific ad campaign. If your profile matches these generic criteria, we may choose to display a suitable ad to you. We may also display ads based on the content that you have recently viewed or searched. Before we may use location data from the app for the first time, your mobile device will generally ask you for permission first. In case you gave permission to do so, location based services in your device will collect location data for a couple of seconds. These will then be shared with us or a respective service provider. When we engage third party services such as ad-networks that enable us showing you interest based ads, we may also allow them to collect certain information such as cookie data from you. This information would allow these third-parties to deliver targeted advertisements that they believe will be of most interest to you. If you allow third party websites to collect and share data when you interact with their platform, ad-networks may use that information together with the information we allow them to collect on the Platform. Please see the privacy policy of such third party websites to understand what data may be collected and how to opt-out.\nDescription: The policy describes collection of the user's age (including birth date and age range) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 4. CROSS-APP ADVERTISING AND OTHER INTEREST-BASED ADVERTISING TECHNOLOGIES As described in Sections 3 and 5 of this Privacy Policy, we sometimes work with third parties to deliver ads, content or offers. Sometimes we or these third parties do so through a mobile \"SDK.\" The SDK is a bit of computer code that app developers can include in their apps to enable ads to be shown, data to be collected, and related services to be implemented. We may use this and similar technology to deliver certain advertising through mobile applications and browsers based on data associated with your mobile device, and we may work with third parties who likewise embed their SDKs into Apalon Apps, for third party advertising. If you'd like to opt-out from having ads tailored to you in this way on your mobile device, please follow the instructions below.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Pixel Tags. You can disable pixel tags by changing your browser settings to omit images and disable Javascript, or there may be commercially available software packages that can assist with dealing with pixel tags.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Email Communications. We will use the email address you provide when you create your HealthVault account to send you an email requesting that you validate your email address, to include in sharing invitations you send through HealthVault, and to send you service notifications, such as email notifications that information is available to add to your HealthVault records.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 2. Ad Serving Technology Rovio reserves the right to use and disclose the collected, non-personal data for purposes of advertising by Rovio or Rovio's partners and contractors.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information Related to Use of the Services. Our servers automatically record certain information about how a person uses our Services (we refer to this information as \"Log Data\"), including both Account holders and non-Account holders (either, a \"User\"). Log Data may include information such as a User's Internet Protocol (IP) address, browser type, operating system, the web page that a User was visiting before accessing our Services, the pages or features of our Services to which a User browsed and the time spent on those pages or features, search terms, the links on our Services that a User clicked on and other statistics. We use Log Data to administer the Services and we analyze (and may engage third parties to analyze) Log Data to improve, customize and enhance our Services by expanding their features and functionality and tailoring them to our Users' needs and preferences. We may use a person's IP address to generate aggregate, non-identifying information about how our Services are used.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Greenhouse - These cookies are used to provide you with a personalized user experience when you apply for a job with us. You can read the Greenhouse Privacy Policy here.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Part 2- Other Information That is Collected: Cookies. Ziff Davis and its partners use cookies or similar technologies to analyze trends, administer the websites, track users' movements around the website, and to gather demographic information about our user base as a whole. You can control the use of cookies at the individual browser level but if you choose to disable cookies, it may limit your use of certain features or functions on our website or service. To manage Flash cookies, please click here. Please see our Cookie Policy for more information, including a more in-depth explanation of what cookies are, the different types of cookies used on Ziff Davis sites, and how to change or delete them.\nDescription: The policy describes collection of the user's unspecified demographic data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 4.2.1. additional data received while accessing the Site, including information regarding technical devices, technical interaction with the Site (as for a host IP-address, user's operating system, type of a browser, geographic position, the Internet provider, contacts, data obtained accessing the camera, microphone and similar devices) and further Users' actions on the Site. Information containing the Site activity history is available for User in \"Settings / Security\"; 4.2.2. information that is automatically received at the time of access to the Site with the use of cookies; 4.2.3. information that is created by the users on the Site outside the page edit section http://vk.com/edit (including statuses, entries in the microblog (\"Wall\"), pictures, audio recordings, video recordings, comments, entries in the group discussions);\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: c. Device Information When you use Lookout Services, our servers automatically record certain information about your mobile device. This information may include an equipment identifier (e.g., IMEI, UDID), subscriber identifier (e.g., IMSI), device name, mobile phone number, device type and manufacturer, operating system type and version, wireless carrier/operator, network type, country of origin, Internet Protocol (\"IP\") address, and the dates and times of your requests. We use this information to provide our services, and support if needed, and to create de-identified or aggregate information about our users. For example, collecting your device's phone number allows the service to contact your phone via SMS when you locate your phone from the Lookout web application.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Our Interest-Based Advertisement Practices Advertising Service Providers Some of our third-party service providers or business partners are advertising networks, marketing partners, publishers and other entities who perform analytics and advertise our products and services on websites not affiliated with us (\"Advertising Service Providers\"). In connection with these advertising services, we or our Advertising Service Providers, like Google Analytics (more on this below) may use cookies, web beacons, and similar technologies to collect behavioral information about how you use our site or other websites in order to perform tracking and marketing analytics or serve advertisements that are more likely to be of interest to you (\"Interest-Based Advertisements\"). Our Advertising Service Providers may permit you to opt out of all or some Interest-Based Advertisements on designated websites. For example, many of our Advertising Service Providers participate in the Network Advertising Initiative opt-out program or the Digital Advertising Alliance opt-out program.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The data that you transfer and share through Xender may be intercepted, collected, used and disclosed by third parties. We are not responsible for any interception, collection, use and disclosure of your information by any third party.\nDescription: The policy describes collection of unspecified contact data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Any of your Information you provide or permit to be provided to us via a social network or public forum provider like Facebook, including when you link an Apalon App to your social network or public forum account (e.g. for registration or social sharing purposes). This data may include your use of the Apalon App on such public forums and/or social networks, including with whom you share the Apalon App. For further information as to how and for what purpose the social network or public forum provider collects, uses and shares your data, as well as how you can set your privacy preferences on their site or apps, please see their privacy policy. We automatically collect certain Information from your device when you use the Apalon App including Information about your device, carrier and other technical data.\nDescription: The policy describes collection of the user's mobile carrier name or other mobile carrier identifier by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 5. Third-Party Sites and Services Xender websites, products and services may contain links to third-party websites, products, and services. Our products and services may also use or offer products or services from third parties (such as Facebook, etc.). Data collected by third party parties, which may include such things as location data or contact details, is governed by their privacy practices. We encourage you to learn about the privacy practices of those third parties. We are not responsible for, the privacy practices of Websites operated by third parties, whether they are linked to or otherwise accessible from Xender. The inclusion of a link or accessibility of third party Websites does not imply endorsement of such third party Website by us.\nDescription: The policy describes collection of unspecified contact data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We use third-party advertising companies and advertising networks to serve ads to you on our behalf when you visit our Web site. These companies may use information (not including personal information such as your name, address email address or telephone number) about your visits to this and other web sites in order to provide advertisements about goods and services of interest to you.\nDescription: The policy describes collection of the user's postal address by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: b. Non- Personal Information. We may use Non-Personal Information for any purpose as below: 1 To personalize user experience- We may use your Non- Personal Information to understand demographics, customer interest, and other trends among our Users; 2 To help develop our service- We may use Non- Personal Information to provide, maintain, improve and modify the Applications, Services and the Site and develop new services; 3 To further develop J2 Interactive business. We may use Non- Personal Information for promotion and marketing purposes.\nDescription: The policy describes collection of the user's unspecified demographic data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: General Location. If you turn on the General Location feature, apps that cannot use your precise location will have access to your general location, such as your city, postal code, or region.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: How the information that Theft Alerts collects is used: When Theft Alerts is activated and a photo is taken, the picture and location data are stored briefly on our servers so we can send you an email with the picture and a map of your device's location. The picture is then deleted from our server. We send the email to the address associated with your account (or for Group Plans, to the address associated with the device that took the photo), so remember to keep your email address up to date in your account settings. We use technical information about Theft Alert's activities on your device to study, optimize, and troubleshoot our products.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Device Identifier. We or our service providers automatically collect your IP address or other unique identifier (\"Device Identifier\") for the Device (computer, mobile phone, tablet or other device) you use to access the Platforms. A Device Identifier is a number such as a mobile advertising identifier (Android AAID or Apple IDFA) that is assigned to your Device when you access a website or its servers, and our computers identify your Device by its Device Identifier. We may use a Device Identifier to, among other things, administer the Platforms, help diagnose problems with our servers, analyze trends, provide attribution metrics to our advertisers and partners, track users' web page movements, help identify you and your shopping cart, and gather broad demographic information for aggregate use.\nDescription: The policy describes collection of the user's IP address by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Scan is not collecting, using and sharing location data with ad providers, including the precise geographic location of your mobile device.\nDescription: The policy describes collection of the user's GPS location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Social Platform Registrations and Social Media Plugins Some of the ZeroFour Sites permit or require you to register or log into your account via a third party social networking platform or permit you to use social media plugins.\nDescription: The policy describes collection of the user's unspecified identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: These third parties may also obtain anonymous information about other applications you've downloaded to your mobile device, the mobile websites you visit, your non-precise location information (e.g., your zipcode), and other non- precise location information in order to help analyze and serve anonymous targeted advertising on the Application and elsewhere. We may also share encrypted versions of information you have provided in order to enable our partners to append other available information about you for analysis or advertising related use.\nDescription: The policy describes collection of the user's cell tower location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Device identifiers: When you use a mobile device like a tablet or phone to access our Service, we may access, collect, monitor, store on your device, and/or remotely store one or more \"device identifiers.\" Device identifiers are small data files or similar data structures stored on or associated with your mobile device, which uniquely identify your mobile device. A device identifier may be data stored in connection with the device hardware, data stored in connection with the device's operating system or other software, or data sent to the device by Instagram.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Rovio or third parties operating the ad serving technology may use demographic and geo-location information (for more information regarding use of Location Data see below Section 3) as well as information logged from your hardware or device to ensure that relevant advertising is presented within the Service. Rovio or third parties may collect and use data, for such purposes, including but not limited to, data such as IP address, Device ID, MAC address, installed software, application usage data, hardware type, Operating System information, browser information, unique identifiers in browser cookies, Flash cookies, and HTML5 local storage, Internet and on-line usage information and in-game information.\nDescription: The policy describes collection of the user's unspecified demographic data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: (b) Improve our Services: We use call log information and usage information (as described above) to better understand network behavior and trends (numbers of messages and calls made by users, typical destinations, call lengths, network type, etc.), detect potential outages and technical issues (this helps us notice things like a drop in call volume in a certain geography, a shift in call length, a change in typical networks, etc.) to improve our Services. We may look into a specific call log in response to a customer support request. We maintain call log information for only as long as is needed for business and/or legal purposes. We use aggregate information about our users and non-personal information to analyze our Services and user behavior and prepare aggregated reports.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information You Give Us We may collect information you choose to provide to us, such as your\u200e name, email address, mobile phone number,\u200e your photo, your friends' contact information as stored on your phone, and the content that you create, such as your texts, photos, and videos. If, as part of your use of the Service, you connect your Service account with an account from a supported social network account, such as Facebook (a \"Social Media Account\"), we may receive personal information from the corresponding social network that relates to your Social Media Account. Such personal information may be about you and/or your Social Media Account contacts. Please check the policies of the applicable social network in order to understand what information we receive. Even if you later disconnect your Service account from your Social Media Account, we still keep a copy of the personal information (such as your Social Media Account profile photo and your contact list) that we received from the connection of the two accounts, so that we may more easily connect you with your Social Media Account contacts who register with the Service in the future.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Our Use of Web Beacons and Analytics Services Microsoft web pages may contain electronic images known as web beacons (also called single-pixel gifs) that we use to help deliver cookies on our websites, count users who have visited those websites and deliver co-branded products. We also include web beacons in our promotional email messages or newsletters to determine whether you open and act on them.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: \"Received Information\" means a user's private, personal or personally identifying or identifiable data or information, including content and contact information such as name, email address, or social network identifier.\nDescription: The policy describes collection of the user's IP address by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Third Party Advertising: BANDAI NAMCO's mobile applications may also include third party advertising such as interstitial, static, and video advertisements, as well as \"offer walls.\" Certain third party advertisers listed in Section A9, below, may collect certain Device Information (such as your device's unique device identifier (UDID), Google Advertising ID (GAID), Android ID, ID for Advertisers (IDFA), ID for Vendors (IDFV), MAC address, International Mobile Equipment Identity (IMEI) or your IP address) to analyze your interest in advertisements displayed to you and to serve other advertisements more likely to appeal to your interests. If you have previously interacted with advertisements displayed by the same third party advertisers through other applications or websites, they may link your Device Information to other Non-PII they've previously collected from or been provided with by you. BANDAI NAMCO is unable to make any promises or guarantees regarding such third party's use or the security of any Device Information collected or used by a third party advertiser in this manner, but prohibits such third parties from using Device Information collected through your interactions with a BANDAI NAMCO mobile application for the benefit of any third party. Please refer to the instructions provided in Section A9, below, if you would prefer to \"opt out\" from having these third party advertisers use your Device Information to serve interest-based advertisements to you, or if you would like to reset your certain Device Information they may have collected from you for that purpose. Advertisements displayed in BANDAI NAMCO's mobile applications may also contain links to third party websites and applications and your interaction with such advertisements may take you outside of BANDAI NAMCO's mobile applications and may result in information being collected about you by BANDAI NAMCO, by the third party serving such advertisements, by the advertiser, or by the distributor of any advertised applications. Once you interact with an advertisement, whether or not you interacting with features outside of BANDAI NAMCO's mobile application, this Privacy Policy will no longer apply to any information collected by or provided to such the third party advertiser through such interactions. Information shared with or collected by BANDAI NAMCO through such interactions will be treated in accordance with this Privacy Policy, but any third party's collection or use of that information may be subject to its own privacy policy, which may contain restrictions and allow uses that differ from those described in this Privacy Policy. BANDAI NAMCO is unable to make any promises or guarantees regarding the use or security of any information shared with or collected by a third party through your interaction with any advertisements in BANDAI NAMCO's mobile applications and recommends reviewing all applicable policies of such third parties before interacting with any advertisements they display.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: You can't share your Information with us via a social network provider like Facebook.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The information we collect includes\uff1a Any names, email addresses, mailing addresses, telephone numbers, uploaded profile photos or bank cards, etc. entered or filled in when you register for an account. Bank card or credit card information is used to pay for Pinguo Technology services or products. The information collected When using \"Share Photo Stream\" or \"Share\" services.\nDescription: The policy describes collection of the user's postal address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: To use your email address or other contact information to send you articles, news, updates, newsletters, marketing materials, or any other information related to the Service. You can opt out from receiving certain notifications by following the instructions in each email or communication from imo to \"unsubscribe.\"\nDescription: The policy describes collection of unspecified contact data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: IV. IS PERSONAL INFORMATION ABOUT ME SECURE? Your account is protected by a password for your privacy and security. If you access your account via a third party site or service, you may have additional or different sign-on protections via that third party site or service. You must prevent unauthorized access to your account and Personal Information by selecting and protecting your password and/or other sign-on mechanism appropriately and limiting access to your computer or device and browser by signing off after you have finished accessing your account.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Who We Are We are Under Armour, Inc. and Under Armour Europe B.V., as well as our family of affiliated companies (\"Under Armour\"). We provide internet and mobile application based services including the apps linked to below: Under Armour Record MapMyFitness MyFitnessPal Endomondo Information We Collect Under Armour collects information to operate our business and provide you with innovative fitness and wellness solutions. We collect both Personal Data and Other Information in support of these efforts.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information Collected Automatically Usage Information. Whenever you visit or interact with the Platforms, we, as well as any third-party advertisers and/or service providers, may use a variety of technologies that automatically or passively collect information about how the Platforms are accessed and used (\"Usage Information\"). Usage Information may include Device Identifiers (as defined below), browser type, device type, operating system, application version, the page served, the time, the preceding page views, and your use of features or applications on the Platforms, such as song history, interaction with friends and group activities. This information helps us keep our Platforms fresh and interesting to our visitors and allows us to tailor content to a visitor's interests.\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We use cookies for two purposes. First, we utilize persistent cookies to save your registration ID and login password for future logins. Second, we utilize session ID cookies to enable certain features of the Services in order to better understand how you interact with the Services and to monitor aggregate usage by Maple Media Website Users and web traffic routing. Unlike persistent cookies, session cookies are deleted from your computer when you log off from the Services and then close your browser.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Data collected by business partners and ad networks to serve you with relevant advertising. The advertisements you see on this website are served by us or by our service providers. But we also allow third parties to collect information about your online activities through cookies and other technologies. These third parties include (1) business partners, who collect information when you view or interact with one of their advertisements on our sites; and (2) advertising networks, which collect information about your interests when you view or interact with one of the advertisements they place on many different websites on the Internet. The information gathered by these third parties is used to make predictions about your characteristics, interests or preferences and to display advertisements on our sites and across the Internet tailored to your apparent interests. We do not permit these third parties to collect personal information about you (such as email address) on our site, nor do we share with them any personal information about you.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Provide you with software updates, (your device will send its device ID to us). These updates may contain critical security and functionality patches that make your phone more secure (protecting all the personal data on your phone) and improve its performance. For staff training and quality assurance purposes, particularly in relation to our customer relations staff at our call, email and other customer support centres Ask for your opinions on Sony Mobile products and services and conduct product surveys Facilitate and process your searches and requests for information when you contact us about Sony Mobile and its products and services Hold prize draws, contests and other promotional offers Consider employing you if contact us via one of Sony Mobile's job application websites Checkout assistance service\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information you provide us directly: Your username, password and e-mail address when you register for an Instagram account.\nDescription: The policy describes collection of the user's password by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We and our third party service providers may combine this information with information that we (or they) already have collected about you. For more information, refer to the \"Use of cookies, web beacons and other similar technologies\" section below.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Note on In-Store Tracking: We may collect Location Data in our stores in order to better understand Athlete preferences and provide product recommendations. If you allow push notifications, Location Data and push notifications may be leveraged to reach out to you if we detect you are in our stores. For example, we may use in-store beacons to communicate with you via our Services (your consent is obtained before recommendations and offers are sent to your device).\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: In all circumstances, we may perform these functions directly or use a third party vendor to perform these functions on our behalf who will be obligated to use your personal information only to perform services for us. Also, if you access our Service from a third party social platform, such as Facebook, we may share non-personal information with that platform to the extent permitted by your agreement with it and its privacy settings.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Log information When you use our services or view content provided by Google, we automatically collect and store certain information in server logs. This includes: details of how you used our service, such as your search queries. telephony log information like your phone number, calling-party number, forwarding numbers, time and date of calls, duration of calls, SMS routing information and types of calls. Internet protocol address. device event information such as crashes, system activity, hardware settings, browser type, browser language, the date and time of your request and referral URL. cookies that may uniquely identify your browser or your Google Account.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Yes. We may share your information with third parties generally in the ways that are described in this privacy statement. We may disclose User Provided and Automatically Collected Information: as required by law, such as to comply with a subpoena, or similar legal process; when we believe in good faith that disclosure is necessary to protect our rights, protect your safety or the safety of others, investigate fraud, or respond to a government request; with our trusted services providers who work on our behalf, do not have an independent use of the information we disclose to them, and have agreed to adhere to the rules set forth in this privacy statement. with third party advertising networks and analytics companies as described below under the Section entitled Automatic Data Collection and Advertising. with affiliated companies.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Other Information: Ad Serving and Ziff Davis. At times we display ads both on our network of owned and operated websites and apps and on non-Ziff Davis websites and apps. When you visit one of our websites, use one of our apps or view ads that we serve off of our network elsewhere, you may see multiple kinds of ads, such as text ads next to search results and graphical ads shown on web pages and apps. Sometimes these ads are based on the content of the page on which they appear. Other times these ads are generated by matching the ad to your interests as inferred from your browsing activities collected online; or the ads may be based on your location using your IP address and/or browser- see Interest-based Ads below. Either way, Ziff Davis tries to show you relevant ads, and to do so, we may use information we know or receive about you, such as your browsing habits, gender, location or interests.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Enable Location Feature: This is Non-Personal Information. This feature remains inoperative until you visit a website that requests your location and you choose to opt in to the feature. If you elect not to use the feature, the Application will not send information about your location to such website. Each time you visit such website, the Application will ask you if you want it to provide the site with your current location. Additionally, you may elect to have the Application remember your choice to allow or not allow the feature for each site. You are able to opt out at any time of having the Application remember your choice, just like any other preference setting. Except as otherwise stated in this Agreement or the applicable third party service provider's policies, we only permit our third party providers that are acting on our behalf (as opposed to search results providers) to use this information in connection with the service(s) they are providing to us. They are required to ensure that any information collected on our behalf is anonymized and aggregated before they are permitted to use such information to develop new features or products and services, or to improve the overall quality of their products and services. This means that they are required to ensure that your IP address and unique identifier of your Application will be stripped out before being used by any of our third party provider's other products or features. For more information on how our geolocation services providers use information sent by the Application, please see the privacy policy links in our list of third party service providers. Please carefully consider any website or service provider's privacy practices before agreeing to share your location.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Cookie Functions Cookie Purposes Analytics and research Badoo uses Google Analytics to collect information about how visitors use the Badoo site. We use the information to compile reports and to help us improve the site. The cookies collect information in an anonymous form, including the number of visitors to the site, where visitors have come to the site from and the pages they visited. For more information about Google's privacy policy, please visit http://www.google.com/intl/en/policies/\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Camera and Photo apps. If you allow the Camera app to use your location, location data is embedded in the photos you take with your device. Other descriptive data, such as camera model and the date that the picture was taken, is also embedded in photos and videos. If you choose to share a photo or video, any embedded data will be accessible to the people and services you share with. You can disable the Camera app's access to your location by turning off all access to the location service in your device's Settings menu or turning off the Camera app's access to the location service.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: II. Information We Collect In providing our services, we collect, store and use the following Information relating to you: \"Information\" is Personal Information and Non-Personal Information; \"Personal Information\" is any information or combination of information that relates to you, and can be used to identify you. Personal Information may include the following: information you make available to us when you open an account or use our services, such as your name, telephone number and email address; information which you make available to our services as you use them, including Shared Information you make available to others through our services and information you store using our services; Shared Information that others using our services make available about you, such as information contained in posts they make and communications they make to you and others using our services; and information we collect as you use our services, such as certain Location Data and Log Data.\nDescription: The policy describes collection of the user's phone number by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We may contact you based on Your personal information, for instance, sending Our product updates information or service information to Your email address or mobile phone number You submitted for registration. You may opt not to receive such information. Notwithstanding Your foregoing option, we will still send special service emails in connection with You (e.g. notices about changes in service terms and conditions).\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Received Information shared with third parties may be provided in hashed or encrypted form, consistent with market practices, and may be used to identify users across devices and channels for the purpose of serving targeted advertising. We may be compensated for information, including Received Information, shared with third parties. Users will not receive compensation in connection with such sharing or other use. Third Party Partners\nDescription: The policy describes collection of the user's unspecified identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Further, if you explicitly agree to share your information with such third-party advertising companies who advertise on Flipkart, we shall share your name, contact or such other information with third parties.\nDescription: The policy describes collection of unspecified contact data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: You may use our address book or \"contacts\" importer (or other similar features) to upload your address book into our Services. We store this information (including phone numbers) and use it to help you manage and leverage your contacts in connection with our Services. We also use this information to enhance your experience with our Services by helping you to grow your network by: identifying your contacts that are already Members of our Services; providing a template to send invitations on your behalf to your contacts that are not Members; and suggesting people you may know (even if not in your contacts) but are not yet connected with you on our Services (as we may infer from your shared connections or shared managers, employers, educational institutions and other such factors). We may also use this information to show you and other Members that you share the same uploaded contacts who may or may not be Members.\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Advertising IDAdvertising IDmainadvertisingidmodule Summary Windows generates a unique advertising ID for each user on a device. When the advertising ID is enabled, apps can access and use the advertising ID in much the same way that websites can access and use a unique identifier stored in a cookie. Thus, your advertising ID can be used by app developers (and the advertising networks they work with) to provide more relevant advertising and other personalized experiences across their apps. You can turn off access to this identifier at any time in the device Settings. If you choose to turn it on again, the advertising ID will be reset and a new identifier will be generated. When a third-party app accesses the advertising ID, its use of the advertising ID will be subject to its own privacy policy. For more information on Microsoft's use of data for advertising, see the How We Use Data section of this statement.\nDescription: The policy describes collection of the user's ad ID (such as the Google Ad ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 4. User information 4.1. Users' personal data The Users' personal data include: 4.1.1. data that are provided by the Users and are minimally necessary for registering on the Site: name, surname, sex, mobile phone number and/or e-mail; 4.1.2. data that are provided by the Users using the edit section for their Site pages http://vk.com/edit (including family status, date of birth, native city, family relations, home address, education details);\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Parental Review Parents, if you would like to review your child's information, ask to have it deleted, and/or refuse to allow any further collection or use of the child's information, then please send a letter to our Privacy Manager at Miniclip S.A., Rue des Beaux-Arts 8, 2000, Neuch\u00e2tel, Switzerland. Please be sure to include your email address and a telephone number where we can reach you. Our phone number is +41 327 235902. To protect your child's privacy and security, we will take reasonable steps to help verify your identity before granting you access to the information that we collect and maintain about your child.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Data Collected by Other Advertising Companies. Advertisers sometimes include their own web beacons (or those of their other advertising partners) within their advertisements that we display, enabling them to set and read their own cookie. Additionally, Microsoft partners with third-party ad companies to help provide some of our advertising services, and we also allow other third-party ad companies to display advertisements on our sites. These third parties may place cookies on your computer and collect data about your online activities across websites or online services. These companies currently include, but are not limited to: A9, AOL Advertising, AppNexus, Criteo, Facebook, MediaMath, nugg.adAG, Rocket Fuel, Yahoo!. You may find more information on each company's practices, including the choices it offers, by clicking on the company names above. Many of them are also members of the NAI or DAA, which each provide a simple way to opt out of ad targeting from participating companies.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We store personal information as long as it is needed for the provision of our services. Traffic information is erased or made anonymous when it is no longer needed for the purpose of the transmission or, in the case of payable services, up to the end of the period during which the bill may lawfully be challenged or payment pursued. Location information is stored to the extent and for the duration necessary for the provision of a value-added service. Cookies, direct marketing and provision of value-added services information (including traffic information used for these purposes) is stored as long as the same is necessary for the provision of these activities, or up to the time when a user opts out from such use in accordance with this Privacy Policy and the \"Access to Personal Information\" section herein. Other information is stored for as long as we consider it to be necessary for the provision of our services. This section shall not prevent any technical storage or access to information for the sole purpose of carrying out the transmission of a communication or as strictly necessary in order for us to provide the service you requested. For US\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: You cannot connect with a social networking service.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Device Information: If you access and use the Service from a computer, mobile phone, tablet, automobile, or other electronic device, we may collect information about those devices. For example, our servers receive and store information about your computer and browser, including your Internet Protocol (IP) address, browser type, and other related software or hardware information. If you access the Service from a mobile phone, tablet, automobile, or other electronic device, we may collect and store information such as device type, operating system version and type, unique identifiers (such as Android Advertising ID, VIN, MAC address, and IDFA), carrier, and other related information for that device.\nDescription: The policy describes collection of the user's mobile carrier name or other mobile carrier identifier by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Log information When you use our services or view content provided by AtomicAdd, we automatically collect and store certain information in server logs. This includes: details of how you used our service, such as your search queries.\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: IDs are pieces of information (mainly advertising IDs) that an app transfers to an individual's storage for record-keeping purposes. IDs make app-use easier by saving use patterns while you are at the App. IDs may be used to analyze the App usage, improve content, customize the App's content and layout and for other customer service purposes. An ID may enable us to relate your use of our App to other information about you, including your Personal Information. All of these purposes serve to improve and personalize your experience on our App.\nDescription: The policy describes collection of the user's unspecified identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We make other tools available to sync information with our Services, and may also develop additional features that allow Members to use their account in conjunction with other third-party services. For example, our mobile applications allow you to sync your device's calendar, email and/or contacts apps with our Services to show you the LinkedIn profiles of meeting attendees, email correspondents and/or your contacts.\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The way in which we collect Location Data is different depending on whether you are accessing the Services through a website or a mobile application. The collection of your Location Data may occur even when our Services are not actively open and running. To learn more about how to control geolocation collection within the Services, please visit here.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: What types of information do the Identity Protection Services collect: Contact information (such as name, address, phone number, and e-mail address); private information (such as driver's license number, social security number, passport number, or other identification number); financial information (such as bank account, debit and credit card numbers); medical insurance number; and other personal information about you (or other people you enroll in the service) that you provide to us in connection with your enrollment in our identity protection products.\nDescription: The policy describes collection of the user's phone number by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Contacts Information: If you permit the Uber app to access the address book on your device through the permission system used by your mobile platform, we may access and store names and contact information from your address book to facilitate social interactions through our Services and for other purposes described in this Statement or at the time of consent or collection.\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Back to top Other useful privacy and security related materials Further useful privacy and security related materials can be found through Google's policies and principles pages, including: Information about our technologies and principles, which includes, among other things, more information on how Google uses cookies. technologies we use for advertising. how we recognize patterns like faces. A page that explains what data is shared with Google when you visit websites that use our advertising, analytics and social products. The Privacy Checkup tool, which makes it easy to review your key privacy settings. Google's safety center, which provides information on how to stay safe and secure online.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 1. Collection of Personally Identifiable Information and other Information When you register and use our App, you provide us your name, email address, age, user name, password and other registration information ('Personal Information').We collect and store the Personal Information which is provided by you from time to time. Our primary goal in doing so is to provide you a safe, efficient, smooth and customized experience and to help resolve disputes and troubleshoot problems. This also allows us to provide services and features that most likely meet your needs, and to improve our App to make your experience safer and easier. We also use such Personal Information to inform you about updates on products, services; customize user experience; detect and protect us against error, fraud and other criminal activity; enforce our terms and conditions; and as otherwise described to you at the time of collection.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: A. WHAT KIND OF INFORMATION WE COLLECT a. Personal Information. When you download TopBuzz, to make the content personal for you, our equipment will automatically record information as follows.\nDescription: The policy describes collection of the user's IMEI (International Mobile Equipment Identity) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Some of BANDAI NAMCO's mobile applications may not be accessible to you unless you provide certain requested information, such as your age or date of birth. In some cases, particular features of some BANDAI NAMCO mobile applications may not be accessible or may not function properly unless permitted to access various features, other applications, or information stored on your mobile device, such as your device's GPS, camera, phone, stored images files, microphone or WiFi connection. If you prefer not to provide information or access requested by a BANDAI NAMCO mobile application, you may not be able to enjoy certain features of that mobile application, or to access that mobile application at all.\nDescription: The policy describes collection of the user's GPS location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Communicate with you by e-mail, postal mail, telephone and/or mobile devices (including through in-application advertising) about products or services that may be of interest to you either from us, our parent or subsidiary companies or other third parties. If you do not wish to receive in-application advertising, in some cases you can upgrade to the paid version of the app;\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We may allow You to connect the Service to your social media account(s) such as through Facebook Connect, Apple's Game Center or any other third party service to obtain information about You when You consent to allow your social networking site to make that information available to Ovilex Soft and, consequently Ovilex Soft may be able to collect certain information from your social networking profile when your social networking site permits to make that information available. In such case we may collect Personal Information, such as your user ID, name, e-mail address, and profile picture that are available in your public profile with such third party, and content such as posts, comments, media, and applications. You may be able to control the types of personal data available in the profile of such third party services by adjusting the privacy settings available therein.\nDescription: The policy describes receiving data from the Facebook single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Connect with Facebook: If you use one of our applications and connect to your Facebook account within such application, you will be providing us with basic account information i.e., user ID, name, email, gender, birthday, current city, profile picture URL and the user IDs of your friends who have also connected with our applications. In addition, we will cache data we receive from the Facebook APIs to improve our user experience. If you want us to delete the data we receive from Facebook about you, please contact us at contact@doodlemobile.com.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: What information we collect from you In General. We receive and store any information you enter on our website or give us in any other way. This includes information that can identify you (\"personal information\"), including your first and last name, telephone number, postal and email addresses, and billing information (such as credit card number, cardholder name, and expiration date). We may also request information about your hotel room preferences and frequent flyer and car rental program information. You can choose not to provide information to us, but in general some information about you is required in order for you to register as a member; book travel; complete a traveler profile; participate in a survey, contest, or sweepstakes; ask us a question; or initiate other transactions on our site.\nDescription: The policy describes collection of the user's postal address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information We Automatically Collect In addition to information you provide to us, we automatically collect certain information about how you access and interact with our Services (\"Usage Information\"). This Usage Information is a key part of how we improve your Credit Karma experience and provide more personalized insights and recommendations. We and our business partners may use various technologies to collect and store Usage Information in connection with our Services. These may include things like cookies, browser web storage (e.g., HTML5), web beacons and similar technologies. There are three types of Usage Information we may collect: Device Information. This is information about how you access our Services, such as the operating system, hardware model, application or browser type and version, and unique identifiers associated with your device. We may also integrate with built-in device features (e.g., when you turn on fingerprint access for your Credit Karma account).\nDescription: The policy describes collection of the user's WiFi location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: PSafe may also collect and store information, including Personal Information, when provided by the user or a third-party that the user has authorized, including (without limitation) name, sex, and user ID on a third-party service (for example, if the user agrees to connect their Facebook and/or Google account with the PSafe service and/or product).\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We may collect your location based information for the purpose of providing you with a correct version of the application and our better Services. Except otherwise provided in the Policy, we will not share this information with any third party. If you no longer wish to allow us to track or use such information, you may turn the internet access and/or GPS off at the device level or disable the relevant permission to our application.\nDescription: The policy describes collection of the user's MAC address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Pixel Tags, also known as clear GIFs, beacons, spotlight tags or web bugs, are a method for passing information from the user's computer to a third party website. Used in conjunction with cookies, Ziff Davis may use pixel tags to improve our understanding of site traffic, visitor behavior, and response to promotional campaigns. Pixel tags are also used as a supplement to our server logs and other methods of traffic and response measurement, and they are sometimes used in conjunction with small Javascript-based applications. We may also implement pixel tags provided by other companies for the same purpose. We may use clear GIFs in our HTML-based emails to let us know which emails have been opened by recipients.\nDescription: The policy describes collection of the user's HTTP cookies, flash cookies, pixel tags, or similar identifiers by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: What information does Badoo collect about my friends and contacts?\nDescription: The policy describes collection of contact data from a user's address book on the phone by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: The information we collect does not include (where available) the type and model of the device you use, the device's unique device identifier, operating system, language options and mobile network information to allow you to use our services.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: You consent to the third party use, sharing and transfer of your Personal Information (both inside and outside of your jurisdiction) as described in this section. These third parties will use Personal Information to provide services to us and for their own internal use, including analytics use. We allow third parties such as analytics providers and advertising partners to collect your Personal Information over time and across different websites or online services when you use our services.\nDescription: The policy describes collection of the user's GPS location data by by ad networks, analytics services, or other third parties.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: For advertising that appears in apps on Windows, you may use the opt-out linked to your personal Microsoft account, or opt out of interest-based advertising by turning off the advertising ID in Windows Settings.\nDescription: The policy describes collection of the user's ad ID (such as the Google Ad ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 4. Third Party 4.1 In general, the Applications, the Services and the Site access third party information (such as your Facebook account information) through application interfaces. We may provide links to third-party Web sites, such as Facebook, as a service to our users. The Site may also carry advertisements from other companies. When you click on links of third parties in an Application, the Services or the Site, you may leave the Application, the Services or the Site. We do not collect your information on and through and This Policy does not address, and we are not responsible for, the privacy practices of Web sites operated by third parties, whether they are linked to or otherwise accessible from an Application, the Services or the Site. The inclusion of a link or accessibility of third party Websites does not imply endorsement of such third party Website by us. 4.2 The information that you transfer and share through the Application, the Services and/or the Site may be intercepted, collected, used and disclosed by third parties. We are not responsible for any interception, collection, use and disclosure of your information by any third party. Please choose other ways to transfer and share if you have higher security requirements.\nDescription: The policy describes receiving data from an unspecified single sign on service\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Cookies; Pixel Tags. The technologies used on the Platforms to collect Usage Information, including Device Identifiers, include but are not limited to: cookies (data files placed on a Device when it is used to visit the Platforms), mobile analytics software and pixel tags (transparent graphic image, sometimes called a web beacon or tracking beacon, placed on a web page or in an email, which indicates that a page or email has been viewed). Cookies may also be used to associate you with social networking sites like Facebook and Twitter and, if you so choose, enable interaction between your activities on the Platforms and your activities on such social networking sites. We, or our vendors and third party partners, may place cookies or similar files on your Device for security purposes, to facilitate site navigation and to personalize your experience while visiting our Platforms (such as to select which ads or offers are most likely to appeal to you, based on your interests, preferences, location, or demographic information), as well as for market research related purposes. A pixel tag may tell your browser to get content from another server.\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: 3.2 Non-Personal Information We may disclose Non-Personal Information to our trusted partners who shall comply with this privacy policy and the relevant privacy laws. We do not combine Non-Personal Information with Personal Information (such as combining your name with your unique User Device number).\nDescription: The policy describes collection of the user's device ID (such as the Android ID) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Facebook, Google+, Game Center, Game Circle and Google Play Logins: We use these services to connect players to their friends for co-operative and competitive play, and to compare scores and progress. We use the respective platform standard versions of these services and only reference the username/email associated to associate with your saved data, scores, and game progress.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Information You Can Access Examples of information you can access easily at Amazon.com include up-to-date information regarding recent orders; personally identifiable information (including name, e-mail, password, communications and personalized advertising preferences, address book, and 1-Click settings); payment settings (including credit card information and promotional certificate and gift card balances); e-mail notification settings (including Product Availability Alerts, Delivers, and newsletters); Recommendations (including Recommended for You and Improve Your Recommendations); shopping lists and gift registries (including Wish Lists and Baby and Wedding Registries); Seller accounts; and Your Profile (including your product Reviews, Recommendations, Listmania lists, Reminders, personal profile, and Wish List).\nDescription: The policy describes collection of the user's password by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: For the Talking Angela App we might ask you for your age, provided that this data shall be visible to us only on an aggregated level. This means that the age you provide shall not be seen in your data log, but it will be hashed in the app; we will not be able to connect it with your specific device ID. The age information provided shall be used only for making the Application more appealing to users. For more information on the processing of the data that you provide to us via the chatterbot functionality, please see the \"Collection of Data Log Files\" section. (Please note that this functionality was removed in version 2.6 of the Talking Angela App.)\nDescription: The policy describes collection of the user's age (including birth date and age range) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Examples of Information Collected Information You Give Us You provide most such information when you search, buy, post, participate in a contest or questionnaire, or communicate with customer service. For example, you provide information when you search for a product; place an order through Amazon.com or one of our third-party sellers; provide information in Your Account (and you might have more than one if you have used more than one e-mail address when shopping with us) or Your Profile ; communicate with us by phone, e-mail, or otherwise; complete a questionnaire or a contest entry form; use our services such as Amazon Instant Video; compile Wish Lists or other gift registries; participate in Discussion Boards or other community features; provide and rate Reviews; and employ Product Availability Alerts, such as Available to Order Notifications. As a result of those actions, you might supply us with such information as your name, address, and phone numbers; credit card information; people to whom purchases have been shipped, including addresses and phone number; people (with addresses and phone numbers) listed in 1-Click settings; e-mail addresses of your friends and other people; content of reviews and e-mails to us; personal description and photograph in Your Profile ; and financial information, including Social Security and driver's license numbers.\nDescription: The policy describes collection of the user's postal address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: For example, you cannot submit certain information about yourself, such as your name and email address, when you create a Samsung Account.\nDescription: The policy describes collection of the user's e-mail by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We also collect non-Personal Information. By non-Personal Information, we mean data that cannot identify you. Non-Personal Information can be linked to the game (score, length of playing, activities) or to the general use ( Internet Protocol Addresses, Browser type, Browser Language, referring and exit URLs, number of clicks).\nDescription: The policy describes collection of the user's IP address by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: c. Device Information When you use Lookout Services, our servers automatically record certain information about your mobile device. This information may include an equipment identifier (e.g., IMEI, UDID), subscriber identifier (e.g., IMSI), device name, mobile phone number, device type and manufacturer, operating system type and version, wireless carrier/operator, network type, country of origin, Internet Protocol (\"IP\") address, and the dates and times of your requests. We use this information to provide our services, and support if needed, and to create de-identified or aggregate information about our users. For example, collecting your device's phone number allows the service to contact your phone via SMS when you locate your phone from the Lookout web application.\nDescription: The policy describes collection of the user's IMSI (International Mobile Subscriber Identity) by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: When you access our App by or through a mobile device, we may receive or collect and store a unique identification numbers associated with your device (\"Device ID\"), mobile carrier, device type and manufacturer, phone number, and, depending on your mobile device settings, your geographical location data, including GPS coordinates (e.g. latitude and/or longitude) or similar information regarding the location of your mobile device.\nDescription: The policy describes collection of the user's unspecified location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: We don't collect your precise geolocation data (which includes the device's cellular, Wi-Fi, Global Positioning System (GPS) networks and/or Bluetooth information).\nDescription: The policy describes collection of the user's GPS location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Incorrect",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "Clause: Users can add or may have Metadata added to their User Content including a hashtag (e.g., to mark keywords when you post a photo), geotag (e.g., to mark your location to a photo), comments or other data. This makes your User Content more searchable by others and more interactive. If you geotag your photo or tag your photo using other's APIs then, your latitude and longitude will be stored with the photo and searchable (e.g., through a location or map feature) if your photo is made public by you in accordance with your privacy settings.\nDescription: The policy describes collection of the user's GPS location data by a party to the contract.\n\nAnswer and only output \"Correct\" or \"Incorrect\".",
        "output": "Correct",
        "instruction": "Classify if the description of each clause is correct.",
        "domain": "legal",
        "task": "jrw"
    },
    {
        "input": "ETAuto | 12 October 2015, 2:49 PM IST Share NEW DELHI: Volvo Financial Services, the captive financing arm of Volvo Group, has started its new innings in India by launching its standalone operations in India.Volvo Financial Services has been present in India in association with SREI PNB Paribas since 2011 but has now re launched the services alone.Volvo Financial services will offer financial solutions to customers to buy its products that include Volvo construction equipment, Volvo trucks and buses, and Volvo Eicher Commercial Vehicle.Volvo Financial Services is a global enterprise, and being part of the group, we have a strong understanding of the use of the products made by Volvo Group and Volvo Eicher Commercial Vehicles,\" said Scott Rafkin, EVP and Global President Volvo Financial Services.",
        "output": "owner_of",
        "instruction": "What is the relationship between Volvo and Volvo trucks in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Whilst, for instance, the fast -- the food service board that goes to fast food industry and on the go, that is weak because not all restaurants and fast food places have opened up.",
        "output": "product_or_material_produced: food industry, food; product_or_material_produced: fast food industry, fast food",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "( EXPE ) Amy Bohutinsky, COO, Zillow Group (Nasdaq:Z and ZG) Mike Cagney, CEO, Chairman and Co-founder, SoFi Jeff Lawson, Co-founder and CEO, Twilio Dalton Caldwell, Partner, Y Combinator Peter Pham, Co-founder and Partner, Science Inc. Matthew Glickman, Entrepreneur and Management Lecturer, Stanford Graduate School of Business \"Today's launch, which coincides with Nasdaq's 25th anniversary in the Bay Area, opens the doors to opportunities for entrepreneurs to connect with Nasdaq's network of innovative listed companies and their leaders,\" said Bruce Aust, Vice Chairman, Nasdaq, and President, Nasdaq Entrepreneurial Center.",
        "output": "stock_exchange: Zillow, Nasdaq",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Fiat Chrysler CEO Sergio Marchionne has said the public offer will be made in the fourth quarter.",
        "output": "employer",
        "instruction": "What is the relationship between Sergio Marchionne and Fiat in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "AN APPETITE FOR CHIPS Analog's rivals, such as National Semiconductor Corp., Texas Instruments Inc. and Linear Technology Corp., also advanced.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between National Semiconductor and Texas Instruments from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Market Movers techMARK 3,171.08 -0.51% FTSE 100 6,732.92 -0.31% FTSE 250 17,582.44 -0.34% FTSE 100 - Risers Mondi (MNDI) 1,500.00p +1.15% Anglo American (AAL) 879.00p +1.09% Wolseley (WOS) 4,295.00p +0.82% Hikma Pharmaceuticals (LSE: HIK.L - news ) (HIK) 2,099.00p +0.82% Direct Line Insurance Group (DLG) 353.00p +0.77% Fresnillo (FRES) 681.50p +0.74% Legal & General Group (LGEN) 269.90p +0.67% Travis Perkins (LSE: TPK.L - news ) (TPK) 2,175.00p +0.51% RSA Insurance Group (RSA) 419.50p +0.41% United Utilities Group (UU.)",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Direct Line and Insurance from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Eurogroup President Jeroen Dijsselbloem said euro zone finance ministers may make a \u201cmajor decision\u201d when they hold an emergency session on Saturday to weigh a new Greek proposal for emergency funding.",
        "output": "chairperson: Eurogroup, Jeroen Dijsselbloem",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Vivendi now owns the largest record label Universal Music Group and French pay-TV operator Canal Plus (Paris: FR0000125460 - news ) , as well as a 19.9 percent stake in Telecom Italia (Other OTC: TIAJF - news ) and about 1 percent of Spain's Telefonica (Amsterdam: TA6.AS - news ) .",
        "output": "subsidiary",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Vivendi and Universal Music Group from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Later this month, Paypal will be spun off from eBay and operate as an independent company, giving it more heft.",
        "output": "owned_by",
        "instruction": "What is the relationship between Paypal and eBay in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Sluggish sales of Samsung Electronics Co.\u2019s Galaxy S6 smartphones helped trigger a share decline that wiped more than $10 billion from its market value in July -- almost twice the capitalization of local rival LG Electronics Inc.",
        "output": "product_or_material_produced: Samsung, Electronics",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "BorgWarner Inc. manufactures and sells engineered automotive systems and components primarily for powertrain applications worldwide.",
        "output": "product_or_material_produced: BorgWarner, powertrain",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "MUMBAI: Early stage investor 500 Startups, Smile Multimedia and angel investors like Snapdeal cofounders Kunal Bahl & Rohit Bansal and Freshdesk founder Girish Matrubootham are investing Rs 2.6 crore in software as a service ( SaaS )-based training and recruitment platform Capabiliti.",
        "output": "founded_by",
        "instruction": "What is the relationship between Snapdeal and Kunal Bahl in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "LONDON (ShareCast) - (ShareCast News) - Canaccord Genuity (Other OTC: CCORF - news ) upgraded its recommendation for Premier Oil (LSE: PMO.L - news ) to 'hold' from 'sell' and lifted its price target to 105p from 100p.",
        "output": "headquarters_location",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Premier Oil and LONDON from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In June, a California labour commissioner ruled that an Uber driver was an employee, not a contractor.",
        "output": "location_of_formation: commissioner, California",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "And we now present continuing operations being the former Coty less Wella revenues and direct costs and directly attributable costs.",
        "output": "parent_organization",
        "instruction": "What is the relationship between Wella and Coty in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "E-commerce major Flipkart on Monday launched its instant refund mechanism facility, a move that will help its customers get refunds within 24 hours of returning the product.",
        "output": "industry: Flipkart, E-commerce",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "\u201cWe suspect the performance in this category could prove lumpy, given the fierce competitive dynamics of the U.S. hair care space, and it will take a few more quarters until we can get a sense whether this improvement is sustainable.\u201d The other brands included in P&G\u2019s deal with Coty are Sebastian Professional, Clairol Professional, Sassoon Professional, Nioxin, SP (System Professional), Koleston, Soft Color, Color Charm, Wellaton, Natural Instincts, Nice & Easy, VS Salonist, VS ProSeries Color, Londa/Kadus, Miss Clairol, L\u2019image, Bellady, Blondor, Welloxon, Shockwaves, New Wave, Design, Silvikrin, Wellaflex, Forte, Wella Styling, Wella Trend, Balsam Color, Hugo Boss, Dolce & Gabbana, Gucci, Lacoste, Bruno Banani, Christina Aguilera, Escada, Gabriela Sabatini, James Bond 007, Mexx, Stella McCartney and Alexander McQueen.",
        "output": "parent_organization",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Wella and Coty from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Wednesday, September 16, 2015 12:09PM IST (6:39AM GMT) (BW)(NV-RIMINI-STREET) Rimini Street Announces Next Phase of Growth Strategy for Japan, Appoints New Country Leadership SAP veteran to lead \u201cPhase III\u201d market expansion efforts as Oracle and SAP customers increasingly consider independent maintenance Las Vegas, United States Rimini Street, Inc. , the leading independent provider of enterprise software support services for SAP SE\u2019s (NYSE:SAP) Business Suite and BusinessObjects software and Oracle Corporation\u2019s (NYSE:ORCL) Siebel , PeopleSoft , JD Edwards , E-Business Suite , Oracle Database , Oracle Middleware , Hyperion and Oracle Retail software, announced that Yorio Wakisaka has been appointed country manager of Japan, effective September 15 th .",
        "output": "subsidiary: PeopleSoft, JD Edwards",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Eurozone leaders and officials -- some of whom viewed the plebiscite as an in-out vote on Greece's membership in the euro -- scrambled to work out their response.",
        "output": "currency: Eurozone, euro",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Lloyd Blankfein Goldman Sachs Group Inc Chief Executive Officer",
        "output": "employer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Lloyd Blankfein and Goldman Sachs from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Investors will receive 1.15 shares of ComScore for each Rentrak share they own, according to a statement Tuesday from the companies.",
        "output": "owner_of",
        "instruction": "What is the relationship between ComScore and Rentrak in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Lackluster offerings this year from Samsung Electronics Co Ltd will help Apple stand out in the marketplace, analyst Patrick Moorhead of Moor Insights & Strategy wrote in an email.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Samsung and Electronics from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The price tag represents the company\u2019s strategy of more aggressively taking on General Motors Co. GM 1.40 % \u2019s struggling Cadillac brand, and competing with Toyota Motor Corp. TM 2.29 % \u2019s Lexus brand and Germany\u2019s BMW AG BMW 3.98 % or Audi AG NSU -1.22 % .",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Lexus and Toyota from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "And then last year what we were able to do that started to pay dividends and benefits is we eliminated excess capacity that existed with Ultratech having manufacturing facilities in both Singapore and San Jose and we moved that Singapore operations to San Jose.",
        "output": "headquarters_location: Ultratech, San Jose",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Thu, Jul 30, 2015, 23:31 BST - UK Markets closed Google quietly releases new Google Glass By Andrew Trotman | Telegraph \u2013 38 minutes ago 66.25 -0.30",
        "output": "developer: Google Glass, Google",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Greek Prime Minister Alexis Tsipras had urged his fellow members of parliament to vote 'yes' and survived despite up to 42 rebel votes or abstentions from his Syriza party's MPs, including a 'no' vote from former finance minister Yannis Varoufakis.",
        "output": "chairperson: Syriza, Alexis Tsipras",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Oct 21 (Reuters) - A major consolidation in the global auto industry could happen in the next 24 months, Fiat Chrysler Automobiles NV Chief Executive Sergio Marchionne told CNBC.",
        "output": "employer: Sergio Marchionne, Fiat",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Amazon looking to tap into the huge food retail market Amazon already offers its AmazonFresh service for delivering groceries in select cities in the United States.",
        "output": "industry",
        "instruction": "What is the relationship between AmazonFresh and retail in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Metal and mining stocks came in for severe selling pressure after metal behemoth, Glencore saw a 30 per cent slump in Europe.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Glencore and mining from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Elsewhere, Chilean copper giant Codelco was enjoying a rare rally amid what one trader thought was a short squeeze on its bonds.",
        "output": "product_or_material_produced: Codelco, copper",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "iiNet shareholders met in Perth on Monday to vote on a scheme of arrangement under which TPG will acquire all of the iiNet shares that it does not already own.",
        "output": "location_of_formation",
        "instruction": "What is the relationship between iiNet and Perth in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Western Digital Chief Executive Steve Milligan said in an interview that the Sandisk acquisition will ultimately dilute Unisplendor's stake and that he was highly confident it would be approved by regulators.",
        "output": "parent_organization",
        "instruction": "What is the relationship between Sandisk and Western Digital in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Reuters reported General Electric Co.'s GE Capital unit for now will remain designated as \"systemically important\" - a tag that carries greater regulatory scrutiny.",
        "output": "owned_by",
        "instruction": "What is the relationship between GE Capital and General Electric in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Neil continued, \u201cThe southern sales team has further expanded to enhance our coverage throughout the region, with three key appointments in London and a new Head of Sales.",
        "output": "headquarters_location",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between southern and London from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Presidents Jean-Claude Juncker of EC, Doland Tusk of the European Council, Jeroen Dijsselbloem of the Eurogroup and Mario Draghi of the ECB took part in the meeting, Efe news agency reported.",
        "output": "chairperson",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Eurogroup and Jean-Claude Juncker from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The move comes at a time when among major steel companies, SAIL, JSW and JSPL posted net losses in Q1 of FY16, while Essar Steel and Tata Steel saw lower net profits partly due to cheaper steel imports by user industries.",
        "output": "product_or_material_produced: Tata Steel, steel",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Prime minister Alexis Tsipras has been struggling to convince enough MPs within his Syriza party to back him, guaranteeing the judicial and banking reforms pass.",
        "output": "chairperson",
        "instruction": "What is the relationship between Syriza and Alexis Tsipras in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Dubai is the offshore territory where Food For Health sells most, through the Spinneys supermarket chain, for whose newsletter Plapp writes regular diet advice, and explains some of her more exotic ingredients like slippery elm, amaranth and teff.",
        "output": "headquarters_location",
        "instruction": "What is the relationship between Spinneys and Dubai in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "British Airways and Iberia holding company International Airlines Group (IAG) said Thursday it had ordered 31 Airbus plans, including firm orders for 11 longhaul craft for its Spanish airline.",
        "output": "owned_by: British Airways, International Airlines Group; parent_organization: British Airways, International Airlines Group",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The report titled India Sugar Market Outlook to 2019- R&D Advancements and Government Support to Propel Market provides a comprehensive analysis of the various aspects such as market size of the sugar industry by value and production volume in India.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between sugar industry and Sugar from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "I am not expecting any rate cut (by RBI),\" SBI Chairperson Arundhati Bhattacharya told PTI.\"",
        "output": "position_held",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Arundhati Bhattacharya and Chairperson from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Yum China will operate as a publicly traded company and become a franchisee of Yum Brands in mainland China, paying the parent a percentage of its sales for exclusive rights to three of the company's brands - KFC, Pizza Hut and Taco Bell.",
        "output": "brand",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Yum China and Pizza Hut from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Greek Prime Minister Alexis Tsipras on Wednesday faced down a major mutiny in his radical left Syriza party and violent protests in the streets of Athens to win parliamentary approval for the draconian reforms demanded in return for a new 86-billion-euro bailout package.",
        "output": "chairperson",
        "instruction": "What is the relationship between Syriza and Alexis Tsipras in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "At the closing of transaction, which is expected by the end of 2020, Zovio and the University of Arizona Global Campus will enter into the Strategic Services agreement.",
        "output": "subsidiary: Zovio, the University of Arizona Global Campus",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The agreement, signed at a meeting held in Tunis under the chairmanship of Minister of Transport Mahmoud Ben Romdhane, in the presence of the Director of Congo's Air Transport, the CEO of Tunisair and the Director General of Civil Aviation, also establishes a bilateral co-operation programme in the technical fields, training and exchange of expertise.",
        "output": "headquarters_location",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Tunisair and Tunis from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Health Care Industry Stratasys 3D printing Contact: Stratasys Media Contacts",
        "output": "industry",
        "instruction": "What is the relationship between Stratasys and 3D printing in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "2 COMMENTS David Gilmour spent the last 50 years making music with Pink Floyd , and in that time he has released just a handful of solo albums.",
        "output": "member_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between David Gilmour and Pink Floyd from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Citigroup Will Close Banamex USA Bank will pay regulators $140 million over unit\u2019s money-laundering controls By christina.rexrode@wsj.com Updated July 22, 2015 3:29 p.m.",
        "output": "operator: Banamex, Citigroup",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The fervour follows the high-profile launch of MYbank by Alibaba Group Holding and WeBank by Tencent Holdings, the guiding stars of the impending private bank boom.",
        "output": "owner_of: Tencent, WeBank; owned_by: WeBank, Tencent",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In addition, we announced the collaboration with Intel designed to develop an integrated software platform for virtualized RAN to accelerate the rollout of both existing LTE and future 5G networks.",
        "output": "product_or_material_produced: Intel, software",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Eni continues to pursue selling down its 43 percent stake in Saipem as part of plans to shift more than $5 billion of the oil contractor's debt off its books.",
        "output": "parent_organization: Saipem, Eni",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "I think it's more probable to be additive, right, to either move it up in the range or help -- go above that, but we're not making any determination of that at this time.",
        "output": "original_broadcaster: move it, go",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "British Airways and Iberia holding company International Airlines Group (IAG) said Thursday it had ordered 31 Airbus plans, including firm orders for 11 longhaul craft for its Spanish airline.",
        "output": "owned_by",
        "instruction": "What is the relationship between British Airways and International Airlines Group in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "We have no Fortune Global 500 manufacturer, he notes, and Scandinavia has five.",
        "output": "creator",
        "instruction": "What is the relationship between Global 500 and Fortune in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "10 Brews To Watch In The Anheuser-Busch InBev SABMiller deal 10/21/2015 - 3:19 PM EDT What's going to be the impact of beer giant Anheuser-Busch InBev 's purchase of rival SABMiller ?",
        "output": "parent_organization",
        "instruction": "What is the relationship between SABMiller and Anheuser-Busch InBev in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "So SmartBuy, HDFC's e-mall or virtual storefront that's integrated with its PayZapp app, comes with a disclaimer, \"SmartBuy is a platform only for display of offers extended by Merchants to HDFC Bank's customers, and HDFC Bank is not selling/rendering any of these products/services....",
        "output": "operator",
        "instruction": "What is the relationship between HDFC and HDFC Bank in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The bank has sought permission from the Finance Ministry in this regard, SBI Chairperson Arundhati Bhattacharya told PTI.",
        "output": "position_held: Arundhati Bhattacharya, Chairperson",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The upward trend in car premiums for the last 12 months puts Hastings Insurance's IPO in a sweet spot and gives much needed relief to car insurance companies such as RSA Insurance Group Plc, Admiral Group Plc (LSE: ADM.L - news ) , Direct Line Insurance (Other OTC: DIISY - news ) Group Plc and esure Group Plc, which have been finding the market increasingly competitive.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between esure and insurance from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "\"Instead of working with other companies and trying to create models of audiences they think might be gamers, by being able to directly target PlayStation users, we know they're actual gamers in the actual gaming environment,\" Mr Levick told Fairfax Media.",
        "output": "platform: create, PlayStation",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The black-and-white film from the year Adolf Hitler came to power purports to show future British king Edward VIII instructing his nieces, the current monarch Elizabeth, aged about six or seven at the time, and her three-year-old sister, Princess Margaret, how to perform the Nazi salute.",
        "output": "position_held",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Edward VIII and king from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "German chemicals and pharmaceuticals giant Bayer (Milan: BAY.MI - news ) said Friday that it plans to float its polymers business Covestro on the stock exchange in the fourth quarter of this year.",
        "output": "owned_by: Covestro, Bayer",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Google Inc's Chromecast and Amazon.com Inc's Fire TV were next.",
        "output": "manufacturer",
        "instruction": "What is the relationship between Chromecast and Google in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "-- Anglo-Dutch oil major Royal Dutch Shell to acquire BG Group (notified July 29/deadline Sept. 2)",
        "output": "parent_organization",
        "instruction": "What is the relationship between BG Group and Royal Dutch Shell in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Warren Buffett's Berkshire Hathaway has reported a 37 per cent drop in its second-quarter profit as the paper value of its investments fell and its insurance companies reported an underwriting loss.",
        "output": "industry",
        "instruction": "What is the relationship between Berkshire Hathaway and insurance in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In a recent Dispatches programme on Channel 4 researchers asked a number of people which savings accounts they thought paid the best interest rates.",
        "output": "original_broadcaster",
        "instruction": "What is the relationship between Dispatches and Channel in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "- Fool.co.uk 5 Potential Takeover Targets: RSA Insurance Group plc, Amlin plc, Hiscox Ltd, Lancashire Holdings Limited and Beazley plc - Fool.co.uk Follow the quotes you care about most.",
        "output": "industry: Amlin, Insurance; industry: Hiscox, Insurance",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In 2012 The Seattle Times began a report from Kentucky : \"On an average day, 51-year-old Connie Milby covered more than 10 miles in her tennis shoes, walking and climbing up and down three flights of stairs to retrieve tools, toys and a vast array of other merchandise for Amazon.com shoppers.",
        "output": "location_of_formation",
        "instruction": "What is the relationship between vast and Seattle in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Join the Nation's Conversation To find out more about Facebook commenting please read the Conversation Guidelines and FAQs Facebook showed tech IPOs are a zero-sum game (Investors always lose) John Shinal, Special for USA TODAY 4:51 p.m. EDT September 29, 2015 In this March 25, 2015 file photo, Mark Zuckerberg talks about the Messenger app during the Facebook F8 Developer Conference in San Francisco.",
        "output": "creator",
        "instruction": "What is the relationship between Facebook and Mark Zuckerberg in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Gavin Newsom and 2015 NBA Champion Golden State Warriors Center, Festus Ezeli, joined Nasdaq officials, CEO Bob Greifeld and Vice Chairman Bruce Aust, in ringing the Nasdaq Closing Bell remotely from San Francisco in celebration of the launch of the Nasdaq Entrepreneurial Center.",
        "output": "headquarters_location: Golden State Warriors, San Francisco",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Yum Brands rose 2.2 percent to $86.11, a day after the owner of the KFC and Pizza Hut chains named new leaders for its China division as activist investors lobby the company to spin off that business.",
        "output": "subsidiary",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Yum Brands and Pizza Hut from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "How does Glencore CEO Ivan Glasenberg get out of this?",
        "output": "owned_by",
        "instruction": "What is the relationship between Glencore and Ivan Glasenberg in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "But with PayPal now formally split from eBay , and with former American Express executive Schulman at the helm, the company is gearing up for a fight as it tries to maintain its dominant position in the fiercely competitive online payments sector.",
        "output": "owner_of",
        "instruction": "What is the relationship between eBay and PayPal in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "ComScore \u2014 The data analytics company bought viewership rating provider Rentrak for about $771 million in stock.",
        "output": "owner_of: ComScore, Rentrak",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "So we're not in the Walmart that's only a grocery store, but we're in every other Walmart out there.",
        "output": "operator: grocery, Walmart",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Coles accounts for about 45 per cent of the profit of the Wesfarmers conglomerate, which includes Bunnings, Officeworks and coal mines, among other things.",
        "output": "subsidiary",
        "instruction": "What is the relationship between Wesfarmers and Officeworks in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "A Kentucky Fried Chicken (KFC) sign is pictured outside its restaurant in Paramus, New Jersey July 8, \u2026 MOSCOW (Reuters) - U.S. fast-food giant Yum Brands Inc (YUM.N) said on Friday it planned to keep up the pace of expansion of its KFC chain in Russia, seeing an opportunity in a crisis that is leading consumers to seek cheaper treats over fine meals.",
        "output": "subsidiary",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Yum Brands and KFC from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "- CLSA has joined the chorus of investment banks predicting that Hong Kong will run into a bear property market as it forecast a 17 percent price drop in the next 27 months.",
        "output": "headquarters_location: CLSA, Hong Kong",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Using the new features, users can block specific email addresses in Gmail on the web and over the next week on Android, Google said in a blogpost.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Gmail and Google from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "\u201cWe already have over 85 per cent market share in the Tata Magic segment and now we plan to further consolidate it by launching Magic Mantra, which is a more powerful vehicle,\u201d Tata Motors Senior Vice President, Commercial Vehicles Business Unit, R Ramakrishnan said.",
        "output": "manufacturer: Tata Magic, Tata Motors",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Nate, I think what we've -- what we're seeing happening with the ability to reprice the CD portfolio, the $400 million that is still coming due yet this year, that's going to have a pretty good significant impact on deposit costs.",
        "output": "distribution_format",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between impact and CD from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Chief Executive Officer Indra Nooyi has worked to trim Pepsi\u2019s expenses as the strong dollar damps sales abroad and Americans grow wary of soda over concerns about obesity and artificial sweeteners .",
        "output": "position_held: Indra Nooyi, Chief Executive Officer",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Stratasys Ltd. 09/09/2015 | Press release HASCO Combines Stratasys 3D Printing with Quick-Change Mold System to Create New Price/Performance Benchmark for Low Volume Injection Molding",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Stratasys and 3D Printing from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Drew Houston , CEO and Co-Founder of Dropbox",
        "output": "creator",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Dropbox and Drew Houston from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "-- U.S. packages delivery company FedEx to acquire Dutch peer TNT (notified July /deadline extended to Dec. 8 from Aug. 3 after the European Commission opened an in-depth investigation)",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between FedEx and TNT from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Vivendi now owns the largest record label Universal Music Group and French pay-TV operator Canal Plus (Paris: FR0000125460 - news ) , as well as a 19.9 percent stake in Telecom Italia (Other OTC: TIAJF - news ) and about 1 percent of Spain's Telefonica (Amsterdam: TA6.AS - news ) .",
        "output": "parent_organization",
        "instruction": "What is the relationship between Universal Music Group and Vivendi in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The logo of U.S. conglomerate General Electric is pictured at the company's site in Belfort, June 23, \u2026 (Reuters) - General Electric Co (GE.N) on Friday posted higher-than-expected quarterly profit, as its businesses producing jet engines and power turbines offset declines in its oil and gas segment.",
        "output": "industry: General Electric, conglomerate",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Moon Studios founded in 2010 by Thomas Mahler and Gennadiy Korol is a BAFTA award winning studio, best known for developing the critically acclaimed Ori and the Blind Forest and Ori and the Will of the Wisps.",
        "output": "employer",
        "instruction": "What is the relationship between Thomas Mahler and Moon Studios in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Movers: Glencore PLC GLEN, +16.95% GLCNF, +16.45% surged 17% in London after analysts at Citigroup suggested the mining group should go private if it can\u2019t regain confidence from investors.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Glencore and mining from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Warren Buffett's Berkshire Hathaway has reported a 37 per cent drop in its second-quarter profit as the paper value of its investments fell and its insurance companies reported an underwriting loss.",
        "output": "industry: Berkshire Hathaway, insurance",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Lackluster offerings this year from Samsung Electronics Co Ltd will help Apple stand out in the marketplace, analyst Patrick Moorhead of Moor Insights & Strategy wrote in an email.",
        "output": "product_or_material_produced",
        "instruction": "What is the relationship between Samsung and Electronics in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "BlackRock Inc. and Citigroup Inc. are among the firms to have sold large bond deals backed by loans made by Prosper.",
        "output": "owned_by: Citigroup, BlackRock",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "It's a gold rush, maybe a gold mine if they're successful.",
        "output": "product_or_material_produced: gold mine, gold",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Mattel MAT, -1.09% the maker of Barbie and American Girl dolls, Fisher Price, Hot Wheels and many other iconic toys, is in the middle of a turnaround, having brought in a new chief executive earlier this year.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Mattel and Barbie from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The Chicago Tribune has reported that 200,000 visitors attended a free fan festival tied to the 2015 draft and noted that a university study pegged the draft's direct economic impact on Chicago at nearly $44 million, including hotel and restaurant revenue, sales-tax revenue and temporary jobs created.",
        "output": "headquarters_location: Chicago Tribune, Chicago",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "(Reuters) - Solera Holdings Inc, the insurance claims processing software maker that has sought to sell itself in a leveraged buyout, has so far failed to agree on an acquisition price with private equity firms, people familiar with the matter said on Friday.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Solera Holdings and software from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Now watching Up next Prime day to boost Amazon's results; eBay posts first quarter since Paypal spinoff",
        "output": "owned_by",
        "instruction": "What is the relationship between Paypal and eBay in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "\"Our results for the quarter show very balanced performance across our business lines,\" said Citigroup chief executive Michael Corbat in a statement.",
        "output": "employer: Michael Corbat, Citigroup",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "With brands such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend, Kimberly-Clark holds No.",
        "output": "manufacturer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Kotex and Kimberly-Clark from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "As used herein, the \"Company,\"\"we,\"\"us\" and \"our\" refer to Weatherford International plc (\"Weatherford Ireland\"), a public limited company organized under the laws of Ireland, and its subsidiaries on a consolidated basis, or for periods prior to June 17, 2014, to our predecessor, Weatherford International Ltd. (\"Weatherford Switzerland\"), a Swiss joint-stock corporation and its subsidiaries on a consolidated basis.",
        "output": "legal_form",
        "instruction": "What is the relationship between Weatherford International and limited company in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "His remarks came as divided eurozone ministers halted \"very difficult\" talks on the Greek bailout deal Saturday, with just a day left before a final deadline for an agreement to stop Athens crashing out of the 19-country euro area.",
        "output": "currency",
        "instruction": "What is the relationship between eurozone and euro in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Because of the impact of COVID-19, we have stopped its growth, so it is limited to 30 aircraft, and we won\u2019t be adding any further aircraft in the Lauda fleet, I think, for the foreseeable future, unless there\u2019s some significant pricing opportunities on the Airbus side.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Airbus and aircraft from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The Embraer Phenom 300 jet with four people on board was flying from Milan's Malpensa airport to Blackbushe airport in southern England when it crashed at a nearby car auction site.",
        "output": "manufacturer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Phenom 300 and Embraer from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Western Digital (WDC) has agreed to buy rival SanDisk (SNDK) for around $19 billion in cash and stock.",
        "output": "owned_by: SanDisk, Western Digital; owner_of: Western Digital, SanDisk; parent_organization: SanDisk, Western Digital; subsidiary: Western Digital, SanDisk",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Despite losing a month of shaft sinking in Q2 due to COVID, the 4 Shaft is progressing very well.",
        "output": "product_or_material_produced: shaft sinking, Shaft",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The Microsoft Lumia 535 is the latest quad-core smartphone, which allows users to enjoy Microsoft in-built experiences like Skype, Office suite, Xbox and OneDrive.",
        "output": "owned_by",
        "instruction": "What is the relationship between Xbox and Microsoft in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Shoppers Stop: Shoppers Shop shares will be in focus as the fashion retailer has entered into an exclusive strategic partnership with E-commerce major Snapdeal to create the Shoppers Stop experience in the digital marketplace through a flagship Shoppers Stop store on Snapdeal.",
        "output": "industry: Snapdeal, E-commerce",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Reuters reported General Electric Co.'s GE Capital unit for now will remain designated as \"systemically important\" - a tag that carries greater regulatory scrutiny.",
        "output": "parent_organization",
        "instruction": "What is the relationship between GE Capital and General Electric in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "He played a key role in coordinating the effort for Balfour Beatty Construction and its mission-aligned trade contractors to construct the 65,000-square-foot Ronald McDonald House of San Diego for the Ronald McDonald House Charities of San Diego at-cost \u2013 saving the charity millions of dollars.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Balfour Beatty and Construction from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Also, you've got the new sort of VR 14 server boards being developed by Intel and Intel's customer base and 40% of those 50% is what we are hearing is going to.",
        "output": "product_or_material_produced",
        "instruction": "What is the relationship between Intel and server in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "BlackRock Inc. and Citigroup Inc. are among the firms to have sold large bond deals backed by loans made by Prosper.",
        "output": "owned_by",
        "instruction": "What is the relationship between Citigroup and BlackRock in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Other Articles FM Arun Jaitley inaugurates Bandhan Bank in Kolkata Arun Jaitley to inaugurate Bandhan Bank in Kolkata today Banks seek shareholders' nod for Rs 5,934 crore capital infusion To overhaul and strengthen the urban cooperative bank (UCB) structure, an internal committee of the Reserve Bank of India ( RBI ) has recommended that UCBs with business size more than Rs 20,000 crore be allowed to convert into universal commercial banks while those with a lower size be converted to small finance banks.",
        "output": "headquarters_location",
        "instruction": "What is the relationship between Bandhan Bank and Kolkata in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Golden Gate Capital has worked on deals with Elliott before, including the $6.9 billion acquisition of business software maker BMC Software Inc in 2013.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between BMC Software and software from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Barrick will deliver silver to RGLD Gold in amounts equal to 75% of Barrick\u2019s interest in the silver produced at the Pueblo Viejo mine beginning on January 1, 2016 until 50.00 million ounces of silver have been delivered, and 37.50% of Barrick\u2019s interest in silver produced thereafter.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Pueblo Viejo mine and Gold from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "383.40p +3.43% Fallers Evraz (EVR) 113.10p -8.20% Hunting (HTG) 576.50p -5.49% Zoopla Property Group (WI) (ZPLA) 264.80p -4.75% Lonmin (LMI) 106.70p -4.65% ICAP (IAP) 505.00p -4.63% Homeserve (HSV) 425.00p -3.47% Foxtons Group (LSE: FOXT.L - news ) (FOXT) 229.60p -3.08% Acacia Mining (ACA) 292.90p -2.98% Alent (ALNT) 362.90p -2.66% Grainger (GRI (Shanghai: 600894.SS - news ) ) 223.10p -2.45%",
        "output": "industry",
        "instruction": "What is the relationship between Lonmin and Mining in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The sum to be paid to Bavaria is equivalent to 45 percent of the amount state-owned lender BayernLB was awarded by a Munich court in May, according to Schelling.",
        "output": "headquarters_location",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between BayernLB and Munich from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "We now have over 2,400 clients using our container solutions and nearly 600 IBM Services clients utilizing Red Hat technology.",
        "output": "parent_organization",
        "instruction": "What is the relationship between Red Hat and IBM in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The attachments contain a \u201dransomware\u201d program that, when opened, locks all the data on a computer and demands payment to release them.",
        "output": "platform",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between program and computer from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In December 2014, investors who had purchased American Depository Shares (ADSs) of Petrobras on the New York Stock Exchange filed a securities class action in the Southern District of New York, alleging violations of the Securities Act of 1933, the Securities Exchange Act of 1934 , and (in an amended complaint) Brazilian securities laws.",
        "output": "stock_exchange",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Petrobras and New York Stock Exchange from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Separately, I'd like to note a few words about the retail network, an important event here that the Gazprom Neft went out to introduce modern technologies for energy efficiencies, modernizing the equipment at more than 600 of its retail location, which enabled us to raise the level of energy efficiency by 50%.",
        "output": "industry",
        "instruction": "What is the relationship between Gazprom Neft and retail in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Exxon Mobil Corp Exxon Valdez oil spill",
        "output": "owned_by: Exxon Valdez, Exxon",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "** Czech energy company EPH and state oil product pipelines company Cepro plan to coordinate efforts to buy Unipetrol from Poland's PKN Orlen, a Czech newspaper reported, citing two sources.",
        "output": "product_or_material_produced: Unipetrol, oil",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "-- U.S. company Berkshire Hathaway (Sao Paolo: BERK34.SA - news ) to acquire U.S. personal care and cosmetics company Procter & Gamble's Duracell battery unit (approved July 23)",
        "output": "owned_by",
        "instruction": "What is the relationship between Duracell and Berkshire Hathaway in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Apple Inc KFC Apple Pay",
        "output": "owned_by",
        "instruction": "What is the relationship between Apple Pay and Apple Inc in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "From left, Troy Pickard from the Australian Local Government Association, NT Chief Minister Adam Giles, Queensland Premier Annastacia Palaszczuk, Western Australia Premier Colin Barnett, South Australia Premier Jay Weatherill, Prime Minister Tony Abbott, NSW Premier Mike Baird, Premier of Victoria Daniel Andrews, Premier of Tasmania Will Hodgman and ACT Chief Minister Andrew Barr at the leaders' retreat at Victoria Barracks in Sydney.",
        "output": "position_held: Will Hodgman, Premier of Tasmania",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Chief Financial Officer Amy Hood said last week that Microsoft was looking to generate additional revenue by building search and gaming capabilities into the Windows 10 interface.",
        "output": "developer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Windows 10 and Microsoft from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Mimecast has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol \u201cMIME.\u201d Goldman, Sachs & Co. is acting as lead book-running manager, and Barclays Capital Inc., Jefferies LLC and RBC Capital Markets, LLC are acting as book-running managers.",
        "output": "stock_exchange",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Mimecast and Nasdaq from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In December 2013, the CFPB and the Justice Department ordered Ally Financial Inc. and Ally Bank to pay $80 million in consumer restitution and an $18 million civil penalty for similar discrimination against 235,000 minority auto loan borrowers in a similar scheme.",
        "output": "subsidiary",
        "instruction": "What is the relationship between Ally Financial and Ally Bank in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "We continue to make progress on the Avon integration and synergies.",
        "output": "publisher: We, Avon",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Yet London wasn't always king of forex: The hegemony of the pound sterling in the British empire meant that before 1914, London played second fiddle in forex to Paris, Vienna, Berlin and New York.",
        "output": "currency",
        "instruction": "What is the relationship between British empire and pound sterling in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "442.60p +0.59% Berkeley Group Holdings (The) (BKG) 3,479.00p +0.55% Hikma Pharmaceuticals (LSE: HIK.L - news ) (HIK) 2,473.00p +0.32% Associated British Foods (LSE: ABF.L - news ) (ABF) 3,250.00p +0.28% Capita (CPI (Other OTC: CPICQ - news ) ) 1,215.00p +0.25% FTSE 100 - Fallers Glencore (Amsterdam: GX8.AS - news ) (GLEN) 73.91p -23.98% Anglo American (AAL) 567.50p -7.68% BHP Billiton (NYSE: BBL - news ) (BLT) 976.90p -4.79% Rio Tinto (RIO) 2,119.50p -4.40% Antofagasta (LSE: ANTO.L - news ) (ANTO) 484.20p -4.31% Standard Chartered (BSE: 580001.BO - news ) (STAN) 632.80p -4.15% Vodafone Group (NasdaqGS: VOD - news ) (VOD) 208.95p -4.00% Fresnillo (Amsterdam: FN6.AS - news ) (FRES) 598.50p -3.23% Aberdeen Asset Management (Other OTC: ABDNF - news ) (ADN) 297.80p -2.78% GKN (GKN (LSE: GKN.L - news ) ) 256.30p -2.62% FTSE 250 - Risers Ultra Electronics Holdings (ULE) 1,695.00p +2.17% Saga (Frankfurt: 2S8.F - news ) (SAGA (LSE: SAGA.L - news ) ) 205.00p +1.84% Indivior (Berlin: 2IV.BE - news ) (INDV) 234.60p +1.69% Ophir Energy (Other OTC: OPGYF - news ) (OPHR) 82.55p +1.60% Home Retail Group (HOME) 135.50p +1.50% Renishaw (RSW) 2,001.00p +1.47% Poundland Group (Other OTC: PDLDF - news ) (PLND) 279.30p +1.45% Caledonia Investments (CLDN) 2,180.00p +1.44% Workspace Group (LSE: WKP.L - news ) (WKP) 950.00p +1.39% Vesuvius (VSVS) 356.10p +1.31% FTSE 250 - Fallers Kaz Minerals (LSE: KAZ.L - news ) (KAZ) 81.65p -19.56% Just Retirement Group (JRG) 160.00p -8.04% Allied Minds (Other OTC: ALLWF - news ) (ALM) 355.80p -6.37% Premier Oil (LSE: PMO.L - news ) (PMO) 63.05p -6.11% Vedanta Resources (Other OTC: VDNRF - news ) (VED) 431.10p -5.34% Tullow Oil (LSE: TLW.L - news ) (TLW) 161.50p -4.72% Worldwide Healthcare Trust (WWH) 1,740.00p -4.71% Weir Group (WEIR) 1,121.00p -3.86% Hunting (Frankfurt: 0YT.F - news ) (HTG) 388.10p -3.36% IMI (IMI (LSE: IMI.L - news ) ) 932.00p -2.87% FTSE TechMARK - Risers Filtronic (FTC) 6.75p +3.85% SDL (Shenzhen: 002658.SZ - news ) (SDL (LSE: SDL.L - news ) ) 333.75p +3.33% XP Power Ltd (LSE: XPP.L - news ) .",
        "output": "industry: Poundland, Retail; owned_by: Indivior, Investments",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "But with PayPal now formally split from eBay , and with former American Express executive Schulman at the helm, the company is gearing up for a fight as it tries to maintain its dominant position in the fiercely competitive online payments sector.",
        "output": "subsidiary",
        "instruction": "What is the relationship between eBay and PayPal in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Interbrand\u2019s analysis shows that Alcantara\u2019s brand value now totals more than $100 million euros, a 15-fold increase from an Interbrand valuation of $6.5 million euros in 2006.",
        "output": "industry",
        "instruction": "What is the relationship between Interbrand and brand in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "** Anheuser-Busch InBev and SABMiller, the world's top two brewers, have agreed in principle to one of the biggest mergers in corporate history after a near month-long courtship resulted in SABMiller accepting an offer worth more than $100 billion.",
        "output": "owned_by",
        "instruction": "What is the relationship between SABMiller and Anheuser-Busch InBev in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "First Eagle is currently owned by members of the Arnhold family, private equity firm TA Associates Management and employees.",
        "output": "industry: TA Associates, private equity",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Thomson Reuters Eikon Adds Data Visualization Features for FX Analysis Thomson Reuters Eikon Adds Data Visualization Features for FX Analysis Thomson Reuters has announced the launch of a data visualization for currencies that is being made available to users of the Eikon platform Advertising Print This Post",
        "output": "business_division",
        "instruction": "What is the relationship between Thomson Reuters and Reuters in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Worldpay has floated on the London Stock Exchange (Other OTC: LDNXF - news ) in the UK's largest IPO this year , giving the payments processor a market cap of \u00a34.8bn.",
        "output": "headquarters_location",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Worldpay and London from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "\u201cA lot of work now is project-oriented and we\u2019re beginning to see the use of collaborative tools like Google Docs and Google Hangouts that let people do their work from afar,\u201d she told me.And, Ruddy added, \u201cwe\u2019ve seen a big increase in the number of organizations buying laptops and other communications devices for employees.\u201dLarge employers are more likely to let staffers telework regularly or full-time than smaller ones, according to the report; 70 percent of employers with 10,000 to 19,000 employees allow regular telework vs. 50 percent of those with under 100 employees.",
        "output": "creator",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Google Hangouts and Google from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Thu, Jul 30, 2015, 01:38 BST - UK Markets open in 6 hrs 22 mins Samsung Electronics posts 8% fall in Q2 net profit AFP \u2013 8 minutes ago View Photo",
        "output": "product_or_material_produced: Samsung, Electronics",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Britain's Merlin Entertainments rose 4.7 percent after announcing that it will take its Legoland amusement park to Shanghai as part of a deal agreed with investment firm China Media Capital during the state visit of Chinese President Xi Jinping.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Merlin Entertainments and Legoland from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Recognized as an eight-time Gartner Magic Quadrant leader, we continue to relentlessly innovate to stay ahead of the pack.",
        "output": "creator: Magic Quadrant, Gartner; owned_by: Magic Quadrant, Gartner",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Pichai quickly began to receive more responsibility, however, taking on involvement with various Google search products including Firefox, Google Toolbar, Desktop Search, Gadgets, and Google Gears and Gadgets.",
        "output": "developer: Gears, Google; creator: Gears, Google; owned_by: Google search, Google; owned_by: Gears, Google",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Wynn created its first Macau casino in 2006 with Encore at Wynn Macau opening in 2010.",
        "output": "headquarters_location",
        "instruction": "What is the relationship between Wynn Macau and Macau in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Shares in Wynn Resorts Ltd have lost over half their value since last year and those of Las Vegas Sands Corp are down nearly 40 percent from their 2014 high.",
        "output": "headquarters_location: Wynn Resorts, Las Vegas",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Bringing Xandr and WarnerMedia or Turner's advertising just makes sense in this environment where you're focused on acting efficiently and acting as one, it's really important.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Xandr and advertising from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Indeed, in the year after the digital Walkman disaster, Stringer, the British man running the Sony American operations, threw himself into the task of fighting the silos, with sometimes comical results.",
        "output": "manufacturer: Walkman, Sony",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Western Digital (WDC) has agreed to buy rival SanDisk (SNDK) for around $19 billion in cash and stock.",
        "output": "subsidiary",
        "instruction": "What is the relationship between Western Digital and SanDisk in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Cann points to some material combinations already formed or in the works, on all sides of the industry: Shell-BG Group on the supply side, Baker Hughes-Halliburton in services, and on the purchasing side, the powerful Jera combination between Tokyo Electric Power Co and Chubu Electric Power Co.",
        "output": "headquarters_location: Jera, Tokyo",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The e-commerce site made Shopify the go-to company for smaller vendors that want to sell products on Amazon.com and need to integrate their inventory and payment systems with those of the retailer's.",
        "output": "industry: Shopify, e-commerce",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "GM Retail Sales Up 14 Percent Mon, Aug 3 2015 GM's four brands post their best combined July total and retail sales since 2007 Chevrolet delivers its best total and retail sales for any July since 2006 Chevrolet and GMC sold more than 86,000 pickups - best July since 2006 GMC Sierra and Canyon earned the highest Average Transaction Prices in their segments Buick sales up 18 percent on strong crossover demand Large planned reductions in daily rental deliveries continue",
        "output": "manufacturer",
        "instruction": "What is the relationship between GMC Sierra and GMC in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Shares of FireEye and CyberArk are up 24 percent and 32 percent respectively this year, compared with a two percent gain in the Nasdaq Composite Index.",
        "output": "stock_exchange: FireEye, Nasdaq; stock_exchange: CyberArk, Nasdaq",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "EBay also plans to complete the spinoff of its PayPal payments unit.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between EBay and PayPal from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Business Council of Australia chief executive Jennifer Westacott called on the commission to go beyond its draft report into workplace relations when it delivered its final recommendations to the Abbott government later this year.",
        "output": "employer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Jennifer Westacott and Business Council of Australia from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "OCEANAGOLD Corp expects 2015 production to increase while costs fall after the gold miner takes control of Waihi Gold Mine in New Zealand later this year.",
        "output": "product_or_material_produced",
        "instruction": "What is the relationship between Gold Mine and gold in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "After a long courtship, SABMiller agreed on Tuesday to a deal that would rank among the top five mergers in history , creating a global beer behemoth that would brew one in every three beers worldwide.",
        "output": "product_or_material_produced: SABMiller, beer",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The Bengaluru-based Independent and Public Spirited Media Trust with a starting corpus of Rs 100 crore has been anchored by billionaire Wipro chairman Azim Premji and philanthropist Rohini Nilekani, the wife of Infosys co-founder Nandan Nilekani.",
        "output": "founded_by: Wipro, Azim Premji; owned_by: Wipro, Azim Premji; director_/_manager: Wipro, Azim Premji",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "I can maybe answer the question on Spotify and the stake we have in Spotify.",
        "output": "distributed_by: answer, Spotify",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Amazon has launched a music streaming service just weeks after Apple (NasdaqGS: AAPL - news ) took on industry-leader Spotify.",
        "output": "distribution_format",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between launched and music streaming from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Tuesday 13 October INTERIMS LiDCO Group (Other OTC: LDRUF - news ) INTERIM DIVIDEND PAYMENT DATE Intertek Group (Other OTC: IKTSF - news ) INTERNATIONAL ECONOMIC ANNOUNCEMENTS Trade balance (CHINA) Consumer Price Index (GER) (07:00) ZEW Survey (EU) (10:00) ZEW Survey (GER) (10:00) GMS (Taiwan OTC: 6481.TWO - news ) O'Key Group GDR (Reg S) (WI) FINALS DotDigital Group (LSE: DOTD.L - news ) , Nanoco Group (LSE: NANO.L - news ) , Proactis Holdings (LSE: PHD.L - news ) IMSS Michael Page International (Other OTC: MPGPF - news ) EGMS GCP Infrastructure Investments Ltd, UDG Healthcare Public Limited Company AGMS CSF Group (LSE: CSFG.L - news ) , FinnAust Mining (LSE: FAM.L - news ) , Leeds Group (LSE: LDSG.L - news ) , Myanmar Investments International Ltd, Premaitha Health (LSE: NIPT.L - news ) TRADING ANNOUNCEMENTS Michael Page International UK ECONOMIC ANNOUNCEMENTS BRC Sales Monitor (00:01) Consumer Price Index (09:30) Producer Price Index (09:30) Retail Price Index (09:30)",
        "output": "legal_form: Intertek, Public Limited Company",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Reuters reported General Electric Co.'s GE Capital unit for now will remain designated as \"systemically important\" - a tag that carries greater regulatory scrutiny.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between GE Capital and General Electric from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "\u201cBy continuing to profitably deliver on our large and diverse backlog, we are driving strong growth in revenue, earnings and cash flow,\u201d Boeing president and CEO Dennis Muilenburg said.",
        "output": "employer",
        "instruction": "What is the relationship between Dennis Muilenburg and Boeing in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Accra, July 2, 2015 - To consolidate its position as the leading Telecom Business brand in Ghana, Vodafone Ghana through the Vodafone Business Solutions (VBS) platform, has launched a loyalty package for its enterprise customers.",
        "output": "parent_organization",
        "instruction": "What is the relationship between Vodafone Ghana and Vodafone in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Investors have been after Google ( GOOGL ) CEO Larry Page for years to cut back on the pie-in-the-sky bets that many see as a costly distraction to the company's highly profitable core search and Internet advertising businesses.",
        "output": "employer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Larry Page and Google from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "On the London exchange, shares in Swiss-based mining giant Glencore Xstrata fell more than 30 per cent.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Glencore and mining from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "bull Experience working on projects encompassing both IT systems and business process change is a must bull Product lifecycle knowledge of credit cards, mortgages, andor personal loans is a strong plus bull Prior working experience with Citibank or Retail banking or Credit Cards or Consumer Risk is a strong plus bull Agile project experience is a strong plus bull BS or equivalent technology degree Qualifications ndash Skill bull Extremely strong listening, requirements elicitation, analysis and problem solving skills bull Extremely strong interpersonal skills ndash collaboration across multiple business and technology functions, relationship building and consensus building are a must bull Extremely strong documentation and oral communications skills bull Be a self-starter and work productively with minimal direction bull Learn quickly and produce under pressure and tight deadlines bull Demonstrate functional and business knowledge regarding prior projects bull Strong SQL data querying and analysis skills bull Strong Excel, Visio, PowerPoint, MS Word and MS Access knowled Key Skills Business Analyst, Retail Risk Business Analyst, Retail Risk",
        "output": "industry: minimal, Retail",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Similarly, the Media24 group in South Africa, - which owns papers such as the Daily Sun, City Press and all the Afrikaans language titles - is part of the giant Naspers group .",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between City Press and Naspers from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Mining stocks were mostly lower, with heavyweights BHP Billiton (NYSE: BBL - news ) , Anglo American (LSE: AAL.L - news ) , Rio Tinto (LSE: RIO.L - news ) and Glencore (Xetra: A1JAGV - news ) all trading lower, as metal prices dipped across the board and copper suffered in particular.",
        "output": "industry: Glencore, Mining",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "So we're not in the Walmart that's only a grocery store, but we're in every other Walmart out there.",
        "output": "operator",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between grocery and Walmart from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Twitter rose 4.8 per cent to $US31.15 after Bloomberg reported that former Microsoft chief executive Steve Ballmer owns a 4 per cent stake in the company.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Steve Ballmer and Microsoft from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Market Movers techMARK 3,171.08 -0.51% FTSE 100 6,732.92 -0.31% FTSE 250 17,582.44 -0.34% FTSE 100 - Risers Mondi (MNDI) 1,500.00p +1.15% Anglo American (AAL) 879.00p +1.09% Wolseley (WOS) 4,295.00p +0.82% Hikma Pharmaceuticals (LSE: HIK.L - news ) (HIK) 2,099.00p +0.82% Direct Line Insurance Group (DLG) 353.00p +0.77% Fresnillo (FRES) 681.50p +0.74% Legal & General Group (LGEN) 269.90p +0.67% Travis Perkins (LSE: TPK.L - news ) (TPK) 2,175.00p +0.51% RSA Insurance Group (RSA) 419.50p +0.41% United Utilities Group (UU.)",
        "output": "product_or_material_produced: Direct Line, Insurance",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "While Governor Elvira Nabiullina has set a course for monetary easing to match slowing inflation, policy makers last month paused their easing cycle for the first time in 2015.",
        "output": "position_held",
        "instruction": "What is the relationship between Elvira Nabiullina and Governor in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Phillips 66 was up 2.3 percent at $79.01 after Warren Buffett's Berkshire Hathaway disclosed a $4.48 billion stake in the oil refiner.",
        "output": "owned_by",
        "instruction": "What is the relationship between Phillips 66 and Berkshire Hathaway in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "So, I would forecast such transactions where we do some partnerships to strengthen the business, but not reduce the direct exposure of ArcelorMittal to the mining business.",
        "output": "industry: ArcelorMittal, mining",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "MEXICO CITY \u2014 State-owned Mexican oil company Pemex is reporting second quarter losses of $US5.2 billion ($A7.16 billion) due mainly to lower petroleum prices.",
        "output": "product_or_material_produced",
        "instruction": "What is the relationship between Pemex and petroleum in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In addition to financials/ERP software suites, NetSuite offers a broad suite of applications, including accounting, Customer Relationship Management (CRM), Professional Services Automation (PSA) and ecommerce that enables companies to manage most of their core business operations in its single integrated suite.",
        "output": "product_or_material_produced: NetSuite, software",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Sundar Pichai, now CEO of Google , epitomises these changes, following on Satya Nadella of Microsoft (not in Silicon Valley, but linked to it nonetheless), Shantanu Narayen of Adobe, and others, going back to pioneers such as Vinod Khosla, Kanwal Rekhi and Suhas Patil.",
        "output": "employer: Satya Nadella, Microsoft",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "FINALS Abcam (LSE: ABC.L - news ) , City of London Investment Group, Empiric Student Property (LSE: ESP.L - news ) , Kalibrate Technologies (LSE: KLBT.L - news ) AGMS F&C Managed Portfolio Trust Growth Shares, F&C Managed Portfolio Trust Income Shares, Infrastructure India (LSE: IIP.L - news ) FINAL DIVIDEND PAYMENT DATE Games Workshop Group, Greene King (Other OTC: GKNGY - news ) , Pets at Home Group Tuesday 15 September INTERIMS Accesso Technology Group, Bango (LSE: BGO.L - news ) , Centralnic Group (LSE: CNIC.L - news ) , HaloSource Inc (LSE: HAL.L - news ) .",
        "output": "location_of_formation: Games Workshop, London",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In the last quarter, several banks and e-commerce companies have launched mobile wallets such as Freecharge wallet from Snapdeal and Lime wallet from Axis Bank .",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Freecharge and Snapdeal from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Restaurant % of consumers who say they would consider restaurant for their next meal in August 2015 % of consumers who say they would consider restaurant for their next meal in February 2015 Change in score Chick-fil-A 21.8 12 9.8 IHOP 32.1 24.9 7.2 Taco Bell 20.1 13.8 6.3 Starbucks 26.2 21.3 5 Caribou Coffee 6.9 1.9 5 Source: YouGov BrandIndex Of course, being a breakfastarian doesn\u2019t mean eating healthier.",
        "output": "product_or_material_produced: Starbucks, Coffee",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "As Uniper is a subsidiary of the Fortum Group, we\u2019re now for the first time reporting the group financials with the Uniper consolidated income statement.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Uniper and Fortum from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Facebook CEO Mark Zuckerberg noted recently that, while gaming will likely drive the early sales of its VR technology, over the long term, the bigger potential is in day-to-day communications.",
        "output": "creator",
        "instruction": "What is the relationship between Facebook and Mark Zuckerberg in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Now CMO Today reports the deal is happening : comScore will acquire Rentrak in an all-stock deal to \u201cbuild a cross-platform currency,\u201d said comScore Chief Executive Serge Matta, who will lead the combined company.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between comScore and Rentrak from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Nestl\u00e9 advertised via social media and introduced a new brand Nescaf\u00e9 Chilled Latte in 2014.",
        "output": "manufacturer",
        "instruction": "What is the relationship between Nescaf\u00e9 and Nestl\u00e9 in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Engineering Concorde Mark 2: Airbus files plans for new supersonic jet Aerospace giant Airbus sketches out ideas for passenger jet that could fly faster and higher than Concorde in US Patent Office filing Concorde might have gone out of service, but aircraft designers have hopes for a successor to the iconic jet Photo: Dennis Stone / Rex Features By Alan Tovey , Industry Editor 12:23PM BST 04 Aug 2015",
        "output": "product_or_material_produced: Airbus, aircraft",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Western Digital (WDC) has agreed to buy rival SanDisk (SNDK) for around $19 billion in cash and stock.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Western Digital and SanDisk from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Ultra Electronics is an internationally successful energy, defense, security and transport company with a long, consistent track record of development and growth.",
        "output": "industry",
        "instruction": "What is the relationship between Ultra Electronics and transport in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Takoradi, Aug. 17, GNA - Mrs Joyce Esi Boakye, Manager, Listing, of the Ghana Stock Exchange (GAX), has encouraged Ghanaian businesses to list on the stock market as another avenue of boosting their capital base.",
        "output": "operator: stock market, Stock Exchange",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In addition, Coty Inc. offers a portfolio of color cosmetic products under the Bourjois brand.",
        "output": "parent_organization",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Bourjois and Coty from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Yahoo CEO Marissa Mayer said commercials make content better and called ad-blocking a mistake [ CMO Today ]",
        "output": "employer: Marissa Mayer, Yahoo",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Foreign Minister Timo Soini of Finland's eurosceptic Finns Party told his country's MTV television that Greece's future in the eurozone depended on European taxpayers \"willingness to pay\".",
        "output": "chairperson",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Finns Party and Timo Soini from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The 3D printing pioneers Stratasys Ltd. ( SSYS ) and 3D Systems Corp. ( DDD ) touched highs of $120.36 and $80.13 in 2014 and 2013 respectively.",
        "output": "industry",
        "instruction": "What is the relationship between Stratasys and 3D printing in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Twitter rose 4.8 per cent to $US31.15 after Bloomberg reported that former Microsoft chief executive Steve Ballmer owns a 4 per cent stake in the company.",
        "output": "employer: Steve Ballmer, Microsoft; owner_of: Steve Ballmer, Microsoft",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "According to Phil Weisberg, Global Head of FX, Thomson Reuters in a recent statement on the membership, \u201cAs a leading independent provider of FX transaction venues, Thomson Reuters actively supports cross-industry initiatives such as FXPA to ensure a sound, liquid, transparent and competitive FX market.",
        "output": "subsidiary: Thomson Reuters, Reuters; business_division: Thomson Reuters, Reuters",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The increase was particularly strong for the GMC truck line, where sales soared 23.8 percent to 47,386.",
        "output": "product_or_material_produced: GMC, truck",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "EDF agreed in July to buy between 51 percent and 75 percent of Areva's reactor arm Areva NP, a deal seen crucial for France which generates three quarters of its electricity from nuclear plants.",
        "output": "owned_by",
        "instruction": "What is the relationship between Areva and France in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Western Digital Chief Executive Steve Milligan said in an interview that the Sandisk acquisition will ultimately dilute Unisplendor's stake and that he was highly confident it would be approved by regulators.",
        "output": "subsidiary",
        "instruction": "What is the relationship between Western Digital and Sandisk in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Gigi Hadid at the office Seafolly's headquarters in Mascot, Sydney, are much more basic than the glamorous home of Louis Vuitton across town in King Street, where the deal with LVMH was nutted out.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Louis Vuitton and LVMH from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Excluding $4.4 million of costs associated with the strategic restructuring initiative recorded in the six months ended June 30, 2019, our selling, general and administrative expenses increased $6.4 million primarily due to increased selling and marketing expenses in connection with the commercial launch of ANJESO.",
        "output": "industry",
        "instruction": "What is the relationship between initiative and marketing in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Last month, the Hong Kong garment manufacturer said it had so far failed to negotiate an agreement with striking workers at the Artigas factory in Shenzhen, which is a supplier to Fast Retailing, operator of the Uniqlo casual clothing chain.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Uniqlo and clothing from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Depressed platinum prices and bearish broker notes dragged shares in Lonmin Group to its lowest level since listing on the London Stock Exchange (Other OTC: LDNXF - news ) in 1982.",
        "output": "headquarters_location",
        "instruction": "What is the relationship between Lonmin and London in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "House passage would mark a victory for food and agricultural companies that have lobbied for the bill, and a blow to opponents, which include consumer, health and environmental groups and organic food industry players.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between food industry and food from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The move could add to awareness of Uniqlo's brand as its global expansion gathers pace, with Fast Retailing expecting to have more Uniqlo outlets overseas than in Japan by this autumn.",
        "output": "subsidiary: Fast Retailing, Uniqlo; parent_organization: Uniqlo, Fast Retailing; owned_by: Uniqlo, Fast Retailing",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Comcast Corp.\u2019s NBCUniversal said Thursday it will launch a comedy-focused subscription video service for $3.99 a month featuring content from the likes of Jimmy Fallon and other talent.",
        "output": "parent_organization: NBCUniversal, Comcast; owned_by: NBCUniversal, Comcast; subsidiary: Comcast, NBCUniversal; founded_by: NBCUniversal, Comcast",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "It was the $US60 billion float of Glencore in 2011, followed by the $US29 billion takeover of coal major Xstrata that turned Glasenberg into something of a hero in London.",
        "output": "owned_by",
        "instruction": "What is the relationship between Xstrata and Glencore in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Eddy Cue, Apple's senior vice president for Internet software and services, wrote on Twitter that he felt the Gibney film was \"an inaccurate and meanspirited view of my friend.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Twitter and Internet from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Eddy Cue, Apple's senior vice president for Internet software and services, wrote on Twitter that he felt the Gibney film was \"an inaccurate and meanspirited view of my friend.",
        "output": "industry",
        "instruction": "What is the relationship between Twitter and Internet in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Now in monogenic disorders, Sanofi Genzyme pioneered this field, starting with enzyme replacement therapies to address a range of lysosomal storage diseases.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Genzyme and Sanofi from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "And of course that's even before you get to this year's announcements from iOS 14, which boasts the radical redesign to the home screen, powerful updates to messages, streamlined and effortless app clips and even greater privacy transparency and controls to major updates to Apple Pencil, Siri and calling and iPad OS 14 to much anticipated sleep tracking, new fitness and wellness features and unprecedented customization and watchOS 7 to the new macOS Big Sur boasting the biggest redesign upgrade to macOS since OS X.",
        "output": "platform: clips, iOS",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "US online marketplace giant eBay last week disclosed a plan to spinoff its PayPal online payments unit, which will trade as an independent.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between eBay and PayPal from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The new expanded joint venture will operate as National Geographic Partners and will combine the National Geographic television channels with National Geographic\u2019s other media and consumer-oriented assets, including: National Geographic magazines; National Geographic Studios; related digital and social media platforms; books; maps; children\u2019s media; and ancillary activities, including travel, location-based entertainment, archival sales, catalog, licensing and ecommerce businesses.",
        "output": "legal_form: National Geographic Partners, joint venture; subsidiary: National Geographic Partners, National Geographic",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Google Inc has a Google Authenticator app, which can provide two-factor authentication for services like Gmail, Google Apps and Google Drive.",
        "output": "manufacturer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Google Authenticator and Google from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "\u201cKaplan University is honored to welcome United States Senator Susan Collins to our campus in Augusta,\u201d said Matthew Cote, Executive Director, Kaplan University Augusta campus.",
        "output": "position_held",
        "instruction": "What is the relationship between Susan Collins and United States Senator in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Phillips 66 was up 3.5 percent at $79.97 after Warren Buffett's Berkshire Hathaway disclosed a $4.48 billion stake in the oil refiner.",
        "output": "owner_of",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Berkshire Hathaway and Phillips 66 from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Fonterra said last week that its milk collection volumes will fall by 2-3 percent this season.",
        "output": "product_or_material_produced: Fonterra, milk",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Worldwide sales for Mattel girls and boys brands fell 3 percent in constant currency to $601.8 million, with sales for the Barbie brand were down 11 percent.",
        "output": "owner_of",
        "instruction": "What is the relationship between Mattel and Barbie in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Recent examples include our long-term partnership with Danone for the Evian brand, our investment with a path to ownership in A-Shoc Smart Energy, and our licensing agreement with Peet's Coffee for ready-to-drink beverages.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Evian and Danone from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "This safety stock helps minimize shipping disruptions and also prepares us for some key Axon Body 3 shipments to major customers in Q3 and Taser orders we are expected to fulfill in the back half of the year.",
        "output": "manufacturer",
        "instruction": "What is the relationship between Taser and Axon in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "HT Correspondent, Hindustan Times , New Delhi | Updated: Aug 01, 2015 03:10 IST Vehicles queuing up near a New Delhi petrol pump.",
        "output": "headquarters_location",
        "instruction": "What is the relationship between Hindustan Times and New Delhi in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "But with PayPal now formally split from eBay , and with former American Express executive Schulman at the helm, the company is gearing up for a fight as it tries to maintain its dominant position in the fiercely competitive online payments sector.",
        "output": "subsidiary",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between eBay and PayPal from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Chinese companies picked out as success stories during a government-organised visit to the region included the wind turbine maker Goldwind and TBEA (Shanghai: 600089.SS - news ) , the Shanghai-listed power transmission firm notable for its development projects in Africa and its twice-yearly collective weddings on the campuses where most of its employees live and work.",
        "output": "product_or_material_produced: Goldwind, wind turbine",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "About 2,700 people work for P&G\u2019s Duracell battery division, which P&G has agreed to sell to Berkshire Hathaway in a deal that is to close this year.",
        "output": "parent_organization",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Duracell and Berkshire Hathaway from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "View photo Samsung Electronics CEO JK Shin announced two new phones at an event in New York City on August 13, 2015.",
        "output": "product_or_material_produced: Samsung, Electronics",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The EPRs being built in France and Finland were designed by Areva (Paris: FR0011027143 - news ) , another state-owned French firm, but EDF has now taken over Areva's reactor arm and is working on an upgraded EPR it hopes will be easier and cheaper to build.",
        "output": "parent_organization",
        "instruction": "What is the relationship between Areva and France in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "* ABI /SAB MILLER : Anheuser-Busch InBev is asking banks to underwrite up to $70 billion in debt financing to back its potential takeover of SABMiller (Xetra: BRW1.DE - news ) , banking sources said.",
        "output": "parent_organization",
        "instruction": "What is the relationship between SABMiller and Anheuser-Busch InBev in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Tencent (HKSE: 0700-OL.HK - news ) , which makes the WeChat software -- used by 500 million in China -- said it had repaired the flaw and that there had been \"no theft (or) leakage of users' information or money.\"",
        "output": "developer",
        "instruction": "What is the relationship between WeChat and Tencent in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "German chemicals and pharmaceuticals giant Bayer (Milan: BAY.MI - news ) said Friday that it plans to float its polymers business Covestro on the stock exchange in the fourth quarter of this year.",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Covestro and Bayer from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "This follows hot on the heels of the ?6.5bn acquisition of Lafarge and Holcim's cement assets, and boosts the firm's growth profile still further.",
        "output": "product_or_material_produced: Lafarge, cement",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Since Microsoft has launched Windows 10 as a \u2018service\u2019 and not a product, it is worthwhile to look at the new features and usability of this OS.",
        "output": "developer",
        "instruction": "What is the relationship between Windows 10 and Microsoft in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Viacom (NasdaqGS: VIAB - news ) fell 7.5 percent, 21st Century Fox lost 7.0 percent, CBS shed 4.6 percent and Comcast dropped 4.7 percent.",
        "output": "owned_by: Viacom, CBS; subsidiary: Viacom, CBS; parent_organization: Viacom, CBS",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "So the way we talk about TSYS and Global Payments is that on a combined basis we have 1300 FI customers around the world, I will tell you financial services, is a very big piece of AWS\u2019s footprint today, and obviously, it's a very large business.",
        "output": "subsidiary",
        "instruction": "What is the relationship between TSYS and Global Payments in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Ad Blockers Are Great for Facebook Inc and Apple Inc The rise of ad blockers makes Apple News and Facebook better choices for advertisers.",
        "output": "product_or_material_produced",
        "instruction": "What is the relationship between Facebook Inc and Facebook in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "General Motors is more competitive in passenger cars than it has been in over a decade, but the 2016 Chevrolet Cruze faces an uphill battle.",
        "output": "manufacturer",
        "instruction": "What is the relationship between Chevrolet Cruze and General Motors in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In addition, in light of the tragic events that occurred in our hometown of Minneapolis and the more recent events in our founding state of Wisconsin, I also want to thank the Jamf team for their commitment to be part of the solution as we listen, learn and take action against racial bias and justice and inequity.",
        "output": "headquarters_location",
        "instruction": "What is the relationship between Jamf and Minneapolis in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "383.40p +3.43% Fallers Evraz (EVR) 113.10p -8.20% Hunting (HTG) 576.50p -5.49% Zoopla Property Group (WI) (ZPLA) 264.80p -4.75% Lonmin (LMI) 106.70p -4.65% ICAP (IAP) 505.00p -4.63% Homeserve (HSV) 425.00p -3.47% Foxtons Group (LSE: FOXT.L - news ) (FOXT) 229.60p -3.08% Acacia Mining (ACA) 292.90p -2.98% Alent (ALNT) 362.90p -2.66% Grainger (GRI (Shanghai: 600894.SS - news ) ) 223.10p -2.45%",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Lonmin and Mining from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Washington Prime Group is a retail REIT, which has ownership, management, acquisition and development of retail properties.",
        "output": "industry",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Prime and retail from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "* EVRAZ - One of Russia's largest steelmakers said on Friday its second-quarter crude steel output fell 14 percent quarter-on-quarter to 3.4 million tonnes.",
        "output": "product_or_material_produced",
        "instruction": "What is the relationship between EVRAZ and steel in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "German chemicals and pharmaceuticals giant Bayer (Milan: BAY.MI - news ) said Friday that it plans to float its polymers business Covestro on the stock exchange in the fourth quarter of this year.",
        "output": "owned_by",
        "instruction": "What is the relationship between Covestro and Bayer in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The full line-up consists of Bank of America Merrill Lynch , BNY Mellon , BlackRock , Citadel, Citigroup , Credit Suisse , Deutsche Bank , Goldman Sachs , HSBC, Jefferies , JPMorgan , Maverick Capital, Morgan Stanley , Nomura and Wells Fargo .",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Citigroup and BlackRock from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "TheStreet's Jim Cramer said Nordstrom has a great growth division in Nordstrom Rack and the company has spent billions of dollars on developing its website.",
        "output": "parent_organization: Nordstrom Rack, Nordstrom",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Google also sells a Chromecast device for $35.",
        "output": "manufacturer: Chromecast, Google; developer: Chromecast, Google",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "On the London exchange, shares in Swiss-based mining giant Glencore Xstrata fell more than 30 per cent.",
        "output": "industry: Glencore, mining; owned_by: Xstrata, Glencore",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The likely outcome would be -- and I think you saw a Logan Green statement from Lyft last week that said that they like -- they would look to shut down in some parts of California.",
        "output": "chief_executive_officer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Lyft and Logan Green from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Mr Elliott downplayed suggestions that ANZ's $8.2 billion sale last week to Macquarie Group of its Esanda dealer finance business was motivated by a desire to boost capital levels, indicating that the business was sold because it was off strategy, given it did not involve fostering customer relationships.",
        "output": "subsidiary: Macquarie Group, Esanda",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "It currently has no CEO, so that doesn't help for a start, but even under previous incumbent Antony Jenkins Barclays seemed to be unsure of how it was going to deliver improving shareholder value.",
        "output": "employer",
        "instruction": "What is the relationship between Antony Jenkins and Barclays in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "LONDON (ShareCast) - (ShareCast News) - David Cameron's government suffered its first defeat in the House of Commons on Monday night after eurosceptic Tories joined forces with opposition MPs to defy the prime minister on the rules surrounding an EU referendum.",
        "output": "headquarters_location",
        "instruction": "What is the relationship between Tories and LONDON in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Granite is listed on the New York Stock Exchange and is part of the S&P MidCap 400 Index, the MSCI KLD 400 Social Index and the Russell 2000 Index.",
        "output": "stock_exchange: MSCI, New York Stock Exchange; stock_exchange: Russell 2000, New York Stock Exchange",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The last luxury apartment complex to spark a debate over the price of property in central London was Clarges Mayfair - built by the leading UK property group, British Land (LSE: BLND.L - news ) .",
        "output": "headquarters_location: British Land, London; location_of_formation: apartment, London",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In addition to strong results from pure play and omnichannel ecomm, Hasbro Pulse, our D2C channel had a record quarter and implemented successful campaigns, including Fan First Friday which brings fans something new and exciting each and every week about the brands they love.",
        "output": "original_broadcaster: pure, channel",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "RIO DE JANEIRO/SYDNEY, Aug 26 (Reuters) - Brazilian mining giant Vale has continued its disposal of non-core holdings, agreeing to sell a mothballed coal mine in Australia jointly to Glencore Plc and Bloomfield Group for an undisclosed sum.",
        "output": "industry: Glencore, mining",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "One of the fund\u2019s biggest bets is SABMiller (Xetra: BRW1.DE - news ) , the global beer and soft drinks business that owns Peroni and Castle lagers, among other brands.",
        "output": "product_or_material_produced",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between SABMiller and beer from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "2004 Chrysler Sebring Coupe   2004 Chrysler Sebring Coupe",
        "output": "manufacturer: Chrysler Sebring, Chrysler; brand: Chrysler Sebring, Chrysler",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Under CEO Jean-Charles Naouri everything has not always been seemless but the results are here: Casino Group are the number 1 retailer in Brazil, Colombia and Uruguay, with Argentina also being a huge market.",
        "output": "director_/_manager",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Casino Group and Jean-Charles Naouri from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In a recent Dispatches programme on Channel 4 researchers asked a number of people which savings accounts they thought paid the best interest rates.",
        "output": "original_broadcaster: Dispatches, Channel",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Zacks Investment Research Consumer Discretionary Personal Investing Ideas & Strategies iRobot Corporation vacuum cleaning Roomba",
        "output": "manufacturer",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Roomba and iRobot from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The Envision is bigger than the Buick Encore subcompact and smaller than the Buick Enclave.",
        "output": "brand: Buick Encore, Buick",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Meanwhile, the other Oshawa assembly line manufactures the current models of Chevrolet Impala, Buick Regal, Chevrolet Camaro and Cadillac XTS.In 2005, General Motors announced for the first time, the plans of closing the plant in 2008.",
        "output": "parent_organization: Buick, General Motors; manufacturer: Chevrolet Camaro, General Motors; owned_by: Buick, General Motors; brand: Chevrolet Camaro, Chevrolet",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Welcoming the investment, the Mayor of London Boris Johnson said: \"This is tremendous vote of confidence in London's thriving life sciences sector as well as the skills and talent of our amazing healthcare professionals.",
        "output": "position_held: Boris Johnson, Mayor of London",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "According to Phil Weisberg, Global Head of FX, Thomson Reuters in a recent statement on the membership, \u201cAs a leading independent provider of FX transaction venues, Thomson Reuters actively supports cross-industry initiatives such as FXPA to ensure a sound, liquid, transparent and competitive FX market.",
        "output": "subsidiary: Thomson Reuters, Reuters; business_division: Thomson Reuters, Reuters",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Nobel Prize Winning Professor Eugene Fama from The University of Chicago presented his argument in the 1960\u2019s that financial markets are, in the long run, efficient and that since all information is available for investors to act upon, securities are properly priced.",
        "output": "employer",
        "instruction": "What is the relationship between Eugene Fama and University of Chicago in the context of the input sentence. Choose an answer from: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "USJ had planned a Tokyo listing this year, but the timing of that has become uncertain due to concerns about being crowded out by the $11.5 billion initial public offerings of Japan Post group companies in November, two sources familiar with the matter have told Reuters.",
        "output": "headquarters_location: Japan Post, Tokyo",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Comcast Corp.\u2019s NBCUniversal said Thursday it will launch a comedy-focused subscription video service for $3.99 a month featuring content from the likes of Jimmy Fallon and other talent.",
        "output": "founded_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between NBCUniversal and Comcast from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "In December 2014, investors who had purchased American Depository Shares (ADSs) of Petrobras on the New York Stock Exchange filed a securities class action in the Southern District of New York, alleging violations of the Securities Act of 1933, the Securities Exchange Act of 1934 , and (in an amended complaint) Brazilian securities laws.",
        "output": "stock_exchange: Petrobras, New York Stock Exchange",
        "instruction": "Given phrases that describe the relationship between two words/phrases as options, extract the word/phrase pair and the corresponding lexical relationship between them from the input text. The output format should be \"relation1: word1, word2; relation2: word3, word4\". Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "The firm's recent acquisition of Sky Italia and Sky Deutschland could generate further growth using the formula that's been so successful in the UK.",
        "output": "parent_organization",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Sky Italia and Sky from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Harcourts is excited to have the Southern California natives as a part of the team and considers them to be brilliant assets to the company as it continues to grow further into North Orange County.",
        "output": "legal_form",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Harcourts and company from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Trade experts expect more garment business to move to Vietnam, but South Korea\u2019s Samsung Electronics Co. SSNHZ 0.00 % plans to nearly double its current $4.5 billion investment in manufacturing electronics in Vietnam.",
        "output": "product_or_material_produced: Samsung, Electronics",
        "instruction": "Given the input sentence, please extract the subject and object containing a certain relation in the sentence according to the following relation types, in the format of \"relation1: word1, word2; relation2: word3, word4\". Relations include: product/material produced; manufacturer; distributed by; industry; position held; original broadcaster; owned by; founded by; distribution format; headquarters location; stock exchange; currency; parent organization; chief executive officer; director/manager; owner of; operator; member of; employer; chairperson; platform; subsidiary; legal form; publisher; developer; brand; business division; location of formation; creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Does Xandr operate more closely with WarnerMedia or DTV even though Xandr is now under WarnerMedia?",
        "output": "owned_by",
        "instruction": "Utilize the input text as a context reference, choose the right relationship between Xandr and WarnerMedia from the options. Options: product/material produced, manufacturer, distributed by, industry, position held, original broadcaster, owned by, founded by, distribution format, headquarters location, stock exchange, currency, parent organization, chief executive officer, director/manager, owner of, operator, member of, employer, chairperson, platform, subsidiary, legal form, publisher, developer, brand, business division, location of formation, creator.",
        "domain": "fin",
        "task": "red"
    },
    {
        "input": "Aviva, Friends Life top forecasts ahead of 5.6 billion pound merger",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "These two companies have moved in opposite directions on the stock market so far this year, but now seem set to move up and to the right.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amgen Inc. on Wednesday logged better-than-expected revenue and a decline in profit in the first quarter.",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Stocks moved lower Wednesday morning after a four-day rally for the Dow and the S&P 500.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Britain's FTSE forges ahead as Shire surges",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "There may not be a better time to buy this fast-growing company than today.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "YIT Construction and the town of Riihim+\u00f1ki have signed a lease contract whereby the town will occupy the Travel Centre office facilities .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amazon has been selling surveillance cameras infected with malware $AMZN #Amazon  https://t.co/TohLEQ8FK6 https://t.co/5PR4cBtVVy",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Skyworks Solutions Inc SWKS is trading lower Friday after the company announced its fiscal first-quarter 2022 financial results.\u00a0 Skyworks reported quarterly revenue of $1.51 billion, which beat the $1.5 billion estimate.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Hedge Funds Have Never Been This Bullish On Cathay General Bancorp (CATY)",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "maybe closing all those $AAPL calls i had this morning was a bad idea, money left on the table...",
        "output": "positive",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$BXS: BancorpSouth Announces Extension of Merger Agreements with ... http://stks.co/s2PDF",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$FB bot some @78.47 breakout from the consolidation zone :D",
        "output": "positive",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$AXP Looking for continuation with volume increase http://stks.co/c8sR",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "CRISPR Therapeutics down 5% after hours on equity offering",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Cramo Group 's financial targets for 2010-2013 are sales growth higher than 10 percent per year ; return on equity above 15 percent .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Macy's -6% as hard hats come out for earnings",
        "output": "negative",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Standard Chartered's Shares Plunge 7% After Fitch Downgrade",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The situation of coated magazine printing paper will continue to be weak .",
        "output": "negative",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "@gakrum nice chart shows distinctive down channel not a dip.. where do you see the bottom? $SPY ..$150? ..$130?",
        "output": "negative",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Pepsi's parent company, household-products maker Church & Dwight, and three others have consistent earnings despite the condition of the economy.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Tullow Oil Suspends Dividend Amid Oil Price Fall",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Tesla Cybertruck debut drew ridicule online after the newly-unveiled model\u2019s armored glass windows cracked like spi\u2026 https://t.co/3h9ch5lK1r",
        "output": "negative",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "PRESS: Serco Set To Appoint Roy Gardner, Ex-Centrica, As Chairman - FT",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "FTSE falls to 3-month low on Greek debt concerns, easyJet skids",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Baird likes drug wholesalers in premarket analyst action",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "While many retail companies work to expand their online presence, e-commerce juggernaut\u00a0Amazon.com Inc (NASDAQ: AMZN) is bringing\u00a0its clothing shopping experience to the physical world.\u00a0 What Happened: Amazon on Thursday announced its\u00a0first-ever physical fashion store, Amazon Style.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Ford Recalls More Than 500,000 Pickups for Fire Risk",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$FB Dax says bye bye 2013 - finished a great yr w 28% plus!",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Having a China based operation will not only enable us to fully leverage our resources and expertise in wireless solutions , but also strengthen our capability to offer industry-leading products for our customers in China . ''",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Speaking to just-drinks today , a spokesperson for Olvi said : `` We have performed very well in all four countries we operate in - namely , Finland , Estonia , Latvia and Lithuania . ''",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Royal Dutch Shell to Buy BG Group for Nearly $70 Billion",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$NQ got hit hard lower this AM --> looks like it has found support a 18.89 http://stks.co/s052z",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Royal Dutch Shell to Buy BG Group for Nearly $70 Billion",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The main trade group representing US airlines thanked the Biden administration for helping to \u201cavert catastrophic disruption\u201d for air travel Wednesday during a limited 5G service launch.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$CNDO 21% short float, shorts likely to take profits into close",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amazon.com Inc. AMZN, -0.61% said Wednesday that it identified and dismantled three counterfeiting operations in China, with help from local Public Security Bureaus (PSB) and Amazon's Counterfeit Crimes Unit (CCU). The ecommerce giant said more than 240,000 counterfeit items were seized by law enforcement in the Guangdong and Jiangxi provinces.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Costco: A Premier Retail Dividend Play https://t.co/Fa5cnh2t0t $COST",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Tesco leads FTSE higher on Clubcard bid reports",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Google is approaching its stock split deadline. The split is going to make Google stock significantly more affordable.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "YIT Construction and the town of Riihim+\u00f1ki have signed a lease contract whereby the town will occupy the Travel Centre office facilities .",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Breaking: Tesla recalls all Model X cars  .. details on show now $TSLA",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. MU, HPE, QCOM and UMC are some such stocks.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Urban Outfitters stock down 9% after Q3 results",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "GlaxoSmithKline targets growth across units, scraps ViiV IPO",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "MSFT stock is showing signs of secular growth, meaning that it's a lucrative buy in 2022's bear market. Key metrics confirm the premise.",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "#Tesla: Model X Recall Adds To Reliability Issues $TSLA https://t.co/jVXQ4DoXnP",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Although US stocks closed higher on the first trading day of February, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Known as Post Bank , the concept would see Fidelity Bank rolling out 75 offices in Ghana Post premises , to provide financial services to the people .",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$KNDI #China #ElectricCar maker. China car sales +7.8%. Also, may feed off $TSLA momentum run lately.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Tieto was looking for an energy solution which would best support the idea of sustainable development , and we were happy to be able to provide such a solution , saysJouni Haikarainen , Vice President , Fortum .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Long $X 24.62",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Sainsbury's, Asda, Tesco and Morrisons will all cut petrol prices as oil falls ...",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Sudden optimism about iPhone sales (i.e., not as bad as expected) gives Apple $AAPL a lift.  https://t.co/oKTCw4YiB5",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The item included restructuring costs of EUR1 .6 m , while a year earlier they were EUR13 .1 m. Diluted EPS stood at EUR0 .3 versus a loss per share of EUR 0.1 .",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$AAPL AAPL finally breaking under the 49 M.A.. With no buybacks this week, look for AAPL to test the 120 support area.",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "New Morrisons duo get former boss's support to diffuse investor tension",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "A cheaper Netflix subscription with ads is coming in November. We explain how much it will cost and what to expect from the service.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The surgical robotics leader produces tremendous results, but the pandemic has been a persistent headwind over the past two years.",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Revenue grew 1 percent to euro742 .2 million US$ 964 million from euro735 million .",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Apple Inc.'s biggest event of the year kicked off Wednesday with Chief Executive Tim Cook saying that the consumer-electronics giant will focus on its iPhone, Apple Watch and AirPod lineups with updates.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Given the cheap prices of tech stocks right now, would this be the ideal time to buy?",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$GOOGL Hit With Lawsuit from Russian Search Engine $YNDX http://stks.co/b1kD8",
        "output": "negative",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Most of the permanent layoffs will be in the plywood and sawn timber sectors of the Finnish company 's operations at several domestic mills , where earlier this year it temporarily laid off some 1,200 workers to save costs .",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$WYNN big bounce",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amazon's proposal to halt certain online selling and marketing practices in a bid to avert possible hefty EU antitrust fines should be rejected because it is weak and full of loopholes, a group of 11 non-governmental bodies have told EU regulators.",
        "output": "negative",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "These stocks aren't Dividend Aristocrats today, but they could very well end up in that club.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Prospects for Aurora Cannabis Stock Look Grim",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amazon.com, Inc AMZN was trading down over 1% on Tuesday morning after sliding over 3% on Monday, breaking bearishly down from a triangle pattern that Benzinga pointed out on Friday.",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Market pullbacks can offer a treasure trove of ideas in the form of relative strength.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$GTAT Will re-enter short on bounce...",
        "output": "negative",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Some iPhone 14 Pro and Pro Max users have experienced the rear camera physically shaking, blurring photos and creating a buzzing or grinding noise.",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "An individual promotion also generated slightly higher-than-expected revenues .",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Abrupt Reversal Of Shale Oil's Fortunes Points To A Radical Reset Of Oil Prices. https://t.co/d0VIc2DVca #finance #markets #trading",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "U.S. December wholesale inventories revised lower",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Tesla Motors recalls 2,700 Model X SUVs $TSLA https://t.co/xDGrAExkKz",
        "output": "negative",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Yum Brands Q4 KFC same-store sales up 3%; FactSet consensus up 2.7%",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "`` We 're delighted with the move '' says Morna Cowie , co-owner , above , `` it 's double the size of our current shop and has a lovely feel to it . ''",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The pulp production in Finnish Kemij+\u00f1rvi will also be liquidated and about 1,100 employees loose their jobs .",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$MOS looking good here at $58.65. Calls are active in this month and weekly",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Jan. 6 -- Ford is struggling in the face of slowing truck and SUV sales and a surfeit of up-to-date , gotta-have cars .",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "In addition , the company will reduce a maximum of ten jobs .",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Operating profit excluding non-recurring items decreased to EUR 6.2 mn from EUR 16.8 mn in 2007 , representing 2.3 % of net sales .",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "`` We are happy to be working with Rapala to encourage boaters and anglers to introduce newcomers to the sport , '' said RBFF President & CEO Frank Peterson .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$NEON oversold",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Investing is very much a mental game of trying to control one's emotions. We tend to let negative emotions rob us of the opportunities presented during bear markets where valuable assets are on sale.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "All major videogame makers like Microsoft Corporation (MSFT), Sony Corporation (SONY) and Electronic Arts (EA) and Activision Blizzard (ATVI) are trying to bounce back from their recent lows.",
        "output": "negative",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "FTSE falls to 3-month low on Greek debt concerns, easyJet skids",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Orion 's net profit for the third quarter of 2007 decreased to 36.5 mln euro ( $ 52.1 mln ) from 40.3 mln euro ( $ 57.5 mln ) a year earlier .",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Novartis buys remaining rights to GSK treatment in deal up to $1 billion",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$AMRN You can many times find top and bottoms when shorts start rejoicing or bulls start rejoicing. Currently it is the shorts rejoicing",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "In the third quarter , net sales increased by 12 % year-on-year to EUR159 .5 m , or by 6 % at comparable currency rates growth .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$AAPL $131 rally mode",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "long $SDLP $CPGX $TWTR $BITA $LABU $FB $TSLA $ETE $SDRL  Autocharts @ https://t.co/nxLx1ES7nY",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Sarat Sethi, Douglas C. Lane and Associates, joins 'Halftime Report' to discuss why he bought more Qualcomm shares.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$EA points to the two Facebook games and accuses $ZNGA of copyright infringement. http://stks.co/g3A1",
        "output": "negative",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Christopher Danely of Citi joins \"Squawk on the Street\" to discuss his new note on Intel and why he's optimistic for the stock.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$CYTX looks like an ascending channel on Finfiz http://stks.co/f26r4",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Verizon and AT&T accused of hurting rivals",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$tsla bad day to short",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "2 Turnaround Buys For 2016? BHP Billiton plc And Home Retail Group Plc",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Sainsbury sells unit to LloydsPharmacy",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Shire share price under pressure after $32bn Baxalta deal",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Firms in the US are pointing to economic turbulence in the face of the upcoming earnings season, potentially preparing investors",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Google is a cash flow machine with a large economic moat. The company's diversification efforts will limit near-term margin growth but will reward investors over the long term.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "UPDATE: EasyJet Passenger Numbers, Aer Lingus Traffic Up In February",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Other carriers and handset makers spin it as a positive event that will raise interest for higher-end phones and pricier data plans .",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "FLEX LNG misses on revenue",
        "output": "negative",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Finnish lifting equipment maker Kone Oyj said on October 4 , 2007 it won an order worth 15 mln euro $ 21.2 mln to deliver a total of 53 custom designed elevators to Norwegian shipbuilder Aker Yards ASA .",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Hedge Funds Aren\u2019t Done Buying Simulations Plus, Inc. (SLP)",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$INPX new intraday high. CV angle. Covid-19 event on Wednesday.",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$IACI http://stks.co/tJU Looks good on the weekly chart.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Airline stocks are taking off on Thursday with recent Q4 earnings news behind today's rise in price for the shares today! The post Airline Stocks: What Has LUV, JBLU, UAL and AAL Heading Higher Today appeared first on InvestorPlace.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Majority of U.S. firms in China see revenue hit from coronavirus: AmCham survey",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "YouTube today announced it will for the first time stream free, ad-supported TV shows \u2014 a move that puts in into more direct competition with the growing number of free streaming services on the market, including Tubi, Pluto TV, The Roku Channel, IMDb TV, Xumo, Plex, and NBCU's Peacock. The company said it will initially [\u2026]",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "AstraZeneca diabetes drug combination faces delay after FDA rebuff",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Sainsbury sells unit to LloydsPharmacy",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "VIVUS $VVUS bear raid in effect. Stock down 12%",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "These moderate but significant changes resulted in a significant 24-32 % reduction in the estimated CVD risk .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "expecting  $SPY to close above 205.20 $AAPL",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "RECAP: $MSFT rumor this morning had them spinning off XBOX unit, stock grinds up all day to close on highs",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "CompaniesNew Aggreko CEO to reshape business, strip costs",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Hard to find new buyers of $TSLA at 250.  Shorts continue to pile in.",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The company moved to an operating profit of EUR10 .9 m versus an operating loss of EUR15 .3 m. It also turned to EPS of EUR0 .08 versus loss per share of EUR0 .04 .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Citi reels in PT on Nu Skin",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "AMZN stock is in the red today ahead of an impending stock split. The company is also dealing with backlash from a new injuries report.",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Finnish pharmaceuticals company Orion 's net sales rose to EUR 190mn in the first quarter of 2009 from EUR 180mn in the first quarter of 2008 .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Turnover rose to EUR21m from EUR17m .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "AstraZeneca to Buy ZS Pharma for $2.7 Billion",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "RT @ACInvestorBlog $AAPL still on track for $500",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "In its presentation Tuesday (March 8), Apple unveiled several new developments as part of its new product rollout, including a new Mac desktop and display, a new iPhone and a new chip. The tech giant introduced its Mac Studio and Studio Display, which are intended to give users an updated way to build their studios.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "After two years of Covid disruptions, \"prices can be really high and people are saying, 'I don't care,'\" Booking Holdings CEO Glenn Fogel told CNBC.",
        "output": "negative",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "However , the orders received during the period under review fell by 17 % quarter-on-quarter from the EUR 213 million recorded in the second quarter of 2010 .",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "NVIDIA Corporation (NASDAQ: NVDA) shares are trading higher by 8.65% to $149.67 during Thursday's session.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "GE to Sell Majority Stake in Bank BPH's Core Bank to Alior Bank",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "REFILE-Aviva Investors to move 34 bln euros in assets from AXA fund arm",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The stock rose for a second day on Wednesday bringing its two-day rise to GBX12 .0 or 2.0 % .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Shares of Standard Chartered ( STAN ) rose 1.2 % in the FTSE 100 , while Royal Bank of Scotland ( RBS ) shares rose 2 % and Barclays shares ( BARC ) ( BCS ) were up 1.7 % .",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Stacy Rasgon, Bernstein senior semis analyst, joins 'TechCheck' to discuss what's driving Nvidia's rising stock price, what industries are the ones to focus on and if Nvidia will get taken down by visionary companies like Tesla.",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Micron (MU) closed the most recent trading day at $80.52, moving +1.07% from the previous trading session.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "`` Several growth initiatives in the chosen geographic areas are already ongoing , '' it continued , noting Lindex opened its first store in the Czech Republic this autumn in Brno .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Macy's now sees full-year sales down 2.5% to down 2.0% vs. prior about flat",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Uber Loses License In London",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Long $X 24.62",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$ZSL looking very weak, could be a good short setup.",
        "output": "negative",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Ruukki signed the contract with Norwegian company Veidekke Entreprenor AS .",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Commission income rose by 25.7 % to EUR 16.1 mn from EUR 12.8 mn in 2004 .",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "AstraZeneca to Pay Inovio Up to $700 Million for Cancer Drug",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "CNBC's Lauren Thomas joins 'The Exchange' to report on big new from Peloton today, as the company will begin selling some of its equipment and apparel on Amazon.com.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Operating profit for the nine-month period increased from EUR13 .6 m , while net sales increased from EUR394 .7 m , as compared to the corresponding period in 2005 .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "L&G still paying price for dividend cut during crisis, chief says",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "@gakrum nice chart shows distinctive down channel not a dip.. where do you see the bottom? $SPY ..$150? ..$130?",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Apple Inc said on Tuesday it will host its annual developers' conference in an online format for the third year in a row, from June 6 to June 10.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "European stocks hover near 3-week low, Dialog and BHP slump",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "SABMiller revenue hit by weaker EM currencies",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Matinas Rides Amarin's Coattails as Vascepa Wins FDA Panel Vote",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$GLD http://stks.co/44ow On closer inspection.  Resistance 10 points north at 200d and downward trendline. Chart 2 of 2.",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Pretax loss totaled EUR 117mn compared to a loss of EUR 65mn in the corresponding period .",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "With the extension of the new contract for a further eight engines , the plant will now produce over 100 MW , it said .",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Results: Synaptics Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "I'm liking the price action in $SWKS, currently @21.80 ; my target: 24.00+ before year end.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Energy Up As Exxon Cuts CapEx Spending -- Energy Roundup #economy #MarketScreener https://t.co/pZc2wlKsXZ https://t.co/TX2jWQyK1m",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$SLW is down, but weekly $34 calls (-28.95%), .23 x .25 have 321 volume. Worth a chance here, jmho: http://stks.co/1Qfg",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Imperial Tobacco Adds Quarterly Dividends After Profit Rose",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Verizon and AT&T accused of hurting rivals",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "After a banner year the IPO market is cooling off. But that doesn't mean there won't be any.",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "In light of the Russia-Ukraine conflict, both the SPY and QQQ ETFs closed Friday in the green. Here's what you need to know.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "firm 28 October 2009 - Finnish lifting equipment maker Konecranes Oyj HEL : KCR1V said today it acquired US Machine Tool Solutions Unlimited in Cincinnati , Ohio , for an undisclosed sum .",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The unit raised $861 million by selling 41 million shares, valuing it at roughly $17 billion",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Publishing Sweden 's operating loss was EUR 1.1 mn in Q1 of 2009 , compared to a profit of EUR 0.6 mn a year ago .",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The U.S. Securities and Exchange Commission said Friday it had settled charges against technology company Nvidia Corporation for what it called \"inadequate disclosures\" concerning the impact of cryptomining on the company's gaming business.",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Alex Gerko\u2019s XTX Markets more than doubled profits last year https://t.co/bwn5Nld5u1",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Cristiano Amon, Qualcomm CEO, joins 'TechCheck' to discuss the company's future aspirations and work with the auto industry from the Consumer Electronics Show in Las Vegas, Nevada.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "`` We are pleased with the efforts of both negotiating teams and look forward to a productive four years ahead . ''",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Take-Two Interactive to buy Zynga Inc for $12.70 billion in cash and stock.",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "`` We continued actively to focus R&D and to position our offering away from point solutions towards dynamic end-to-end solutions , '' Ervio stated .",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The market is a bit scary now -- but these long-term tech plays are more than worth your attention.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$EFUT hod  posted buy pm at $4.40",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "You're only hearing bits and pieces of the whole story. The bigger picture is much more encouraging.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Finnish flexible packaging manufacturer Suominen Corporation reports net sales of EUR 54.5 mn in the first quarter of 2008 , compared with EUR 54.3 mn a year earlier .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Google has released new details of its performance system overhaul internally, and it shows employees will more easily fall into lower-rated categories.",
        "output": "negative",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$BXS: BancorpSouth Announces Extension of Merger Agreements with ... http://stks.co/s2PDF",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The ARKK ETF, Twitter, Qualcomm and Walmart were our top stock trades for Monday. Let's look at how the charts are setting up now.",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Intel Corporation (NASDAQ:INTC) shareholders have a chop on their shoulders about executive remuneration packages, based on a regulatory filing by the tech giant yesterday. Shareholders voted almost two to one in opposition to the compensation packages for the computer chip leviathan's top management, including a package worth US$178.6mln to chief executive officer Pat Gelsinger.",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "AstraZeneca diabetes drug combination faces delay after FDA rebuff",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Walter Investment Management Corp Receives a Sell from Compass Point $WAC http://stks.co/c1IvX",
        "output": "negative",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The software maker, which earlier said it had plans to cut positions affecting less than 1% of its total workforce, is latest tech company to show signs of concern about future demand.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Short interest increases yet again http://stks.co/e19h via @ryandetrick $SPY",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$CTRP just broke resistance, watching for a #redtogreen #breakout right out of the gate tomorrow morning. #stocks https://t.co/8VXFUUIt04",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "City spirits sink after Diageo comes up short with sales slide",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$NFLX and $TSLA making all kinds of gains \u00f0\u009f\u0093\u0088",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "It's a bad idea to make 5 min predictions based on faith: RT @dandyduct $AAPL Sell signal hit at 584, it will go down for the next 5 min",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "27 January 2011 - Finnish IT solutions provider Affecto Oyj ( HEL : AFE1V ) said today it has won a EUR1 .2 m ( USD1 .6 m ) contract from state-owned Lithuanian Social Insurance Institution ( SODRA ) .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$GOOG breakout very likely medium target $700+ http://stks.co/1Lpz http://chart.ly/lgb94rr",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "CompaniesMeggitt profits hit by weak energy and military markets",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Natural gas futures tumble 5% and are poised to close at a nearly 4-year low",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$ZM here we go..... down....",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The consensus price target hints at a 38.5% upside potential for Lululemon (LULU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$RNN staying above the open a very good sign!!!",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Kesko Agro Eesti , the retailer and wholesaler of grain , agricultural and warehousing machinery and accessories , had net sales of 81 million euros in 2007 , an increase by one-tenth over the preceding year .",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "BofA Upgrades WestRock After Containerboard Conference, London Pulp Week",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "@NASDboy I think the DNF crew can get this $NFLX short into the next 30 days heading into earnings",
        "output": "negative",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amani Gold : Secures Gold Dealers License in Tanzania #AmaniGold #Stock #MarketScreener https://t.co/fUr63A7aVB https://t.co/AHlEWGRAtq",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$FREE Ha Heeeeeere comes the pump! So glad I picked up 9K end of day! Get ready for the bull ride!",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "An EU document seen by Reuters shows tech firms could soon face fines of up to 6% of annual turnover if they fail to police \"manipulative behavior.\"",
        "output": "negative",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Qualcomm is still set to benefit from a strong shift to 5G handset despite some slowing demand in China.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$PCLN runs into the 50sma on the acquisition news",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$amzn 4 period RSI is down at 20, just read Connors book on trading strategies",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Dow futures up 73 points, or 0.3%; S&P 500 futures rise 8 points, or 0.2%",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$FB Nice buyable intraday dip right here",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "As you know, we are all doomed. Capitalism is ending, the Fed has ruined everything by being first too soft and now too tough. It's all going to zero.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Apple has no choice but to pay TSMC what it wants. Intel is aiming to be a disruptor.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "`` We are very pleased to be working with Fujitsu and NTT DoCoMo to advance the progress of LTE , '' said Juergen Walter , Head of Converged Core , Nokia Siemens Networks .",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Zynga Inc. ZNGA, +1.03% said Friday the \"go-shop\" period under its previously announced merger agreement with videogame publisher Take-Two Interactive Software TTWO, +3.52% has been completed and said it still expects the deal to close in the first quarter of Take-Two's fiscal 2023 ending June 30, 2022. \"Zynga's Board of Directors continues to believe that the transaction with Take-Two is in the best interests of Zynga and its stockholders, and recommends that Zynga's stockholders approve and adopt the Agreement,\" the company said in a statement.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Royal Dutch Shell to Buy BG Group for Nearly $70 Billion",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "A looming recession, high fuel prices, and labor pressures are \u201clegitimate\u201d risks that U.S. airlines face, but this isn't 2008.",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$XLB the weakest sector this year and possible false breakout  http://stks.co/dL1Z",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$GALE Breakout Coming Soon!",
        "output": "positive",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "have notified that as a result of the Company issuing 14,432,000 new shares in the directed offering , the joint holdings of Pequot has decreased below 1-10 to 9.63 % of total number of shares and votes in the Company .",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$TSLA lots of green on the 5 min, watch the hourly $259.33 possible resistance currently @ $257.00",
        "output": "positive",
        "instruction": "Assign a sentiment category to this tweet related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "InterContinental Hotels first-quarter global room revenue lags estimates",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Balfour Beatty plc Set To Reinstate Dividend (And Rival National Grid plc And Centrica PLC Once More?)",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Forecasts by the Commerce Department foreshadow an end to the chip shortage.",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Is it time to buy these two beaten-down growth stocks?",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The balloting will take place this week and could produce the second union at an Amazon facility in the United States.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Benefon , a wireless and GPS technology company , will supply Karputer with its TWIG navigation platform , a GPS satellite navigation and voice guidance service .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "`` BasWare 's product sales grew strongly in the financial period , by 24 percent .",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Revenue grew 12 percent to (  x20ac ) 3.6 billion ( US$ 4.5 billion ) .",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Shire to buy NPS for $5.2 billion to boost rare disease drugs",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Most of the permanent layoffs will be in the plywood and sawn timber sectors of the Finnish company 's operations at several domestic mills , where earlier this year it temporarily laid off some 1,200 workers to save costs .",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$STE - Steris EPS beats by $0.03, beats on revenue https://t.co/eLU8b642Zv",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "There is a world of opportunity in international stocks.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amazon will continue to lay off employees in the coming year, CEO Andy Jassy wrote in a memo to workers on Thursday.",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Nike Warns Coronavirus Is Presuring Sales in China",
        "output": "negative",
        "instruction": "What is the sentiment of the input tweet from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Coca-Cola Breaks Down a Record Quarter",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Both companies have generated immense gains over the last several years and have undoubtedly been a staple in many portfolios.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "S&P downgrades Barclays and RBS on government bailout fears",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Lam Research's (LRCX) fiscal second-quarter results reflect strength across systems and the customer support business. Yet, impacts of the OMICRON variant and supply chain constraints remain concerns.",
        "output": "positive",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Mike Hamilton will take over March 1 as chairman of the United Airlines ALPA chapter. He replaces Todd Insler, a tough act to follow.",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "FastJet slams EasyJet founder Stelios for going public, is 'taking legal advice' over letter about contractual ...",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Britain's FTSE falls back with Ashtead, commodities under pressure",
        "output": "negative",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Rival companies $GWR and WATCO eyeing $RA w take-over interest.  http://stks.co/o0xY",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Bitcoin's back above $7,000 after its biggest one-day gain in two weeks https://t.co/KOdr1WJXoJ",
        "output": "positive",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "With Britain suffering through its worst\u00a0cost-of-living crisis\u00a0in decades\u2014owing to high inflation and soaring energy prices\u2014hundreds of workers at an Amazon AMZN, +0.05% warehouse in Coventry, England, this month\u00a0demanded\u00a0a wage hike. If the demand is not met, they say they will go on\u00a0strike in November, just ahead of Black Friday and the holiday shopping season.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Amazon.com, Inc. (NASDAQ: AMZN) shares traded lower by 4.77% to $114.56 to close Friday's trading session, but were otherwise marginally higher by 0.73% for the week.\u00a0Amazon shares were\u00a0trading sharply lower Friday amid overall market weakness after better-than-expected US unemployment data dimmed hopes for",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Supply chain problems have led to billions of dollars of lost revenue so far -- and challenges may have worsened in fiscal Q3.",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Alphabet's Google asked a federal judge on Friday to dismiss the majority of an antitrust lawsuit filed by Texas and other states that accused the search giant of abusing its dominance of the online advertising market.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Speculation has run rampant about Intel purportedly being last in line to receive EUV tools and being unable to secure enough tools to ramp its EUV nodes. So, the bear thesis goes, even if Intel executes its leadership process roadmap flawlessly, Intel won't be able to ship these nodes.",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "There seems to be stock split fever in the air, and RH is catching it.",
        "output": "positive",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "@StockTwits: @Kbkiwi: $TSLA Tesla Model S sales exceed target, profitability guidance amended upward: http://stks.co/jQ0w\"\"",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The majority of the company 's personnel in Finland is temporarily laid off from one to six weeks in the period from February to June 2009 period .",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Six Flags raises quarterly dividend by a penny to 83 cents a share",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Google repeatedly positions itself as a staunch supporter of privacy in the public sphere, but that posturing does not always apply behind closed doors. Google employees sometimes acknowledge that the company's data-mining practices are both invasive and opaque\u2014so opaque that even they \u201cdon't understand and can't describe\u201d exactly how users are being tracked, according to internal interview excerpts found in a series of newly unsealed court records.",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$SLW is down, but weekly $34 calls (-28.95%), .23 x .25 have 321 volume. Worth a chance here, jmho: http://stks.co/1Qfg",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "UPDATE: CIB, Legal & General Sell Egyptian Life Joint Venture To AXA",
        "output": "positive",
        "instruction": "Categorize the input news's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$OCN - BTIG sees 'material improvement' to Ocwen book value https://t.co/8MMo05uiM6",
        "output": "positive",
        "instruction": "Categorize the input tweet's emotional tone into one of three groups.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "$FB Big Money Is Pouring Into Facebook From All Directions;http://stks.co/sOwG",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Prospects for Aurora Cannabis Stock Look Grim",
        "output": "negative",
        "instruction": "Determine the sentiment expressed in the tweet from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "TRLPC - CRH backs Lafarge Holcim asset buy with 6.5 bln euro bridge loan",
        "output": "positive",
        "instruction": "Determine the sentiment expressed in the news from financial perspective.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The national average for a gallon of regular gasoline reached $4.173 as of Tuesday, climbing 50 cents from a week earlier, according to AAA data.",
        "output": "negative",
        "instruction": "Characterize the news's sentiment using the following options.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "ACB, MYGN among premarket losers",
        "output": "negative",
        "instruction": "Characterize the tweet's sentiment using the following options.\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "On Wednesday, Flex drivers rallied outside of an Amazon warehouse in Southern California to ask the company to increase pay because of rising gas prices.",
        "output": "negative",
        "instruction": "Assign a sentiment category to this news related to finance.\nOptions: negative, positive",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "The disposal of Autotank will also strengthen Aspo 's capital structure , '' commented Gustav Nyberg , CEO of Aspo .",
        "output": "positive",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "Stora Enso Oyj said its second-quarter result would fall by half compared with the same period in 2007 .",
        "output": "negative",
        "instruction": "What is the sentiment of the input news from financial perspective?\nOptions: positive, negative",
        "domain": "fin",
        "task": "sa"
    },
    {
        "input": "india : bse to launch gold & silver futures from oct 1",
        "output": "No",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Dhanteras buying fails to lift gold",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold may stay range-bound next few weeks; surplus pressures silver",
        "output": "Yes",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "pilgrim's pride completes gold kist acquisition",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "april gold down $6.70, or 0.6%, to settle at $1,209.40/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "india can afford gold import of $30 billion a year: rangarajan",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold rate today: gold, silver down in morning trade",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold hits 2-week high on Ukraine tensions",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold ends higher, but suffers a weekly loss",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold down a third day on dollar strength, with inflation risk in focus",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures jump 1% ahead of russia-ukraine talks",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold prices up by rs 125 to regain rs 30,000 level",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures rise after u.s. jobs report",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures up $4.60 at $815.90 an ounce",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold edges off one-week low as Greece news knocks stocks",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "retail gold buying soars in april after sharp selloff",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices hold steady as dollar eases",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures up $5.60 at $1,737.80 an ounce",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold hub Switzerland is a net importer",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "feb. gold climbs $13.60, or 1.1%, to settle at $1,239.60/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "april gold drops $12.70, or 1%, to trade at $1,316.80/oz",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold prices post modest climb, remain under $460",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold at best in 2 weeks, regains safe-haven status",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold holds steady as investors brace for greece default on debt payments",
        "output": "Yes",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Festive demand lifts gold, silver prices",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold slips further on selling pressure",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold etf gains 8% on record trading volume",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "indian gold importers at bay, eyeing u.s. data",
        "output": "No",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "after gold, silver proves its mettle in local markets",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold, silver import norms tightened",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "polyus gold year net rose 57%",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "buy mcx gold dec; target rs 26945/27070: way2wealth",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures climbs as dollar tumbles",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures down at Rs 28,396 per 10 gm",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold prices reclaim $1,200 ahead of new u.s. tariffs on china",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold prices slip as surging u.s. treasury yields lift dollar",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "April gold settles at $1,248.50/oz, up $1.30, or 0.1%",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold, silver decline further on global cues",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "oil inches higher, gold pushes toward $1,900",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures briefly top $1,300/oz on comex",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold logs lowest finish in a month-adds to drop as fed points to rate hikes",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "comex gold settles at a nearly three-week high",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold eases on reduced jewellery offtake, silver declines",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, silver extend gains on rising global trend",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold erases loss to end in positive territory as stocks lose steam",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures edge up in electronic trade vs. settlement after FOMC minutes",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold recovers early lost ground, back around $1270 level",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold price forecast: monthly-high on radar amid string of higher-lows",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold snaps two-day losing trend, up rs 30 on seasonal demand",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, silver slip in morning trade",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures close above $460 an ounce",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec. gold down $1 at $1,712 after $1,719.90 high",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures rise, headed for seventh-straight win",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "spot gold quoted at $418, up $1.10 from new york",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures close up $2 at $596.30 an ounce",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold steady around highest in nearly 7 weeks on n.korea tensions",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "amex gold bugs index closes down 2.2% for the week",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold ends slightly higher following a recent drop to three-week lows",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Dec. gold settles at $1,351.90/oz, up $5.20, or 0.4%",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "april gold ends down $2.40 at $971.80 an ounce on nymex",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "charts : gold 7-year bear market phase is over",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold falls in electronic trade after fomc minutes",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures remain lower after durables data",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures extend losses to 4th session in a row",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold buying picks up ahead of festive season in india, china",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold prices dip in asia, but market poised for rebound on global events",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "china set to overtake india in gold imports this year: world gold council",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "hold stocks of gold loan companies: sonam udasi, idbi capital",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "india : rising gold price vindicates rbi's investment plan",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "commodity bets: trading tips for gold, crude & copper",
        "output": "Yes",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec. gold falls $6 on day to settle at $1,103.30/oz on comex",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold steady ahead of us non-farm payrolls report",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures fall; copper trades at lowest level since june",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures score a 2-week high as fed inaction fuels bulls",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, silver prices climb; copper futures at all-time high",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "polyus gold year net rose 57%",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold end at best in six weeks; silver 1.9% higher",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold ends sharply lower, loses over $26 on the week",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "spot gold quoted at $517.40 in asia trade",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold inches up to Rs 29,270; silver slips to Rs 42,400 per kg",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold ends 0.3% lower at $1,694.20 an ounce",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "MCX-Gold likely to extend its rally",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "India gold extends rise to over 2-mth high",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold turns higher on flight-to-safety buying",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "buy mcx gold dec; target rs 27245/27370 : way2wealth",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "cboe gold index up 0.9% at 111.32",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, silver soar to new record high on global surge",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold touches new high overseas, dips a tad here",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices end the first half of the year roughly 7.9% higher",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "april gold up $1.50 to close at $663/oz for the session",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec. gold falls $9, or 0.7%, to settle at $1,275.80/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold eases on low buying, silver gains",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold slides $8.10 to settle at $1,292.60/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "frank holmes : gold: to preserve and grow your money",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "December gold up 0.3% at $1,286.40/oz.",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold ends lower as expectations grow for interest-rate hike later this year",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "marshall & ilsley to pay $700m for gold banc",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold jumps to 3 week high",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold edges lower after best day since April as dollar steadies",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures up 90c at $1,102.20 an ounce",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, silver soar on global cues",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures close near one-week low",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "companhia vale do rio doce sells gold mine for $20.9m",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures climb over 2% in afternoon dealings",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "mcx gold june contract slips 1%",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold firms after three days of losses as equities drop",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "commodity bets: trading tips for gold, crude & copper",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold investment demand falls 34%, but WGC says it was still 'robust'",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "why you shouldn't be selling gold",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold ends higher, but loses 1.2% on week",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "August gold down $7.70, or 0.6%, at $1,285.60/oz.",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold closes down 3.4%; copper falls 6.5%",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices to trade lower today: Angel Commodities",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Dec. gold climbs by $5.40, or 0.4%, to $1,275.90/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold inches up as physical demand offsets stronger dollar",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "rbc : gold is ignoring its usual headwinds",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, oil extend to gains after ism services data",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold speculators cut back on their bearish bets this past week",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures finish lower ahead of Fed interest-rate decision",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold falls for third straight day, to $1,250.90",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold climbs by rs 330 per ten grams in early trade",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold up from two-month low before bernanke",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, oil steady after consumer sentiment data",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold holds losses after jobs report",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold sinks 2% as dollar rises, crude oil slumps",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures log highest settlement since Nov. 10",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold falls to Rs 30,750 on weak demand",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures rise on firm Asian cues",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "spot gold quoted at $440.40 down 30c from new york",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "sharps pixley: greater china's imports of swiss gold continue strong",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec. gold settles at $1,301.70/oz on comex, down $9.80, or 0.8%",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "IBJA wants better role for gold industry in GJEPC",
        "output": "Yes",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold sales fetch fewer bucks",
        "output": "Yes",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold climbs to six-week high as european concerns spur demand",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold, silver to trade sideways on friday; here's why",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "august gold falls $1 to close at $667.30/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold near &#36;1,500/oz as eurozone crisis simmers",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "metals focus : rising silver prices outperforming gold",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold declines as us federal reserve refrains from specific easing measures",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "feb. gold climbs 70 cents, or less than 0.1%, to settle at $1,322.30/oz",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures trade near unchanged ahead of Comex settlement",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold ends at a more than 1-week low, but notches slight monthly gain",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold prices trade at one-month high",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "etfs : gold etf flows shift course",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Dec. gold settles at $1,346.10/oz, up $2.70, or 0.2%",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices gain 0.5% for highest settlement in nearly eight weeks",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "sell mcx gold below rs 28400; target 28350:dani commodities",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "a 'death cross' is haunting gold",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold plunges to the lowest in six months but you still cannot buy",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold edges up from 1-week ow",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "April gold off $9, or 0.7%, at $1,227.80/oz.",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures mark lowest finish in more than 2 weeks",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures drop to a 1-month low as Yellen watch continues",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold, silver lower ahead of Fed speakers, FOMC minutes",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "if china slows down u.s. debt buying, will gold rally or plunge?",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "buy gold on every dip: kaushal jaini",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures tap intraday high of $1,724",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures settle higher after declining over the past two sessions",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "silver coins log biggest single day fall; gold dips rs 835",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold fails to hold gains as stocks trade higher",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold eases on dollar strength ahead of ECB, US jobs data",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold / silver / copper futures - weekly outlook: june 19 - 23",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures slip to Rs 26,948 per 10 gm",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Feb. gold gains $14.90, or 1.2%, to $1,291.50/oz",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold / Silver / Copper futures - weekly outlook: July 18 - 22",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold up from two-month low before bernanke",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Demand for gold on the rise amid uncertainty in global markets",
        "output": "Yes",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold bounces off 5-1/2-month low on physical buying",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "decline in gold demand trims growth in import bill",
        "output": "Yes",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "June gold settles at $1,255.50/oz, down $5.90, or 0.5%",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec gold drops $7.40, or 1.7%, to $434/oz in ny",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "supply tightens; gold borrowing rates hit 2009 highs",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures end higher, but below $1,800",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures settle below $1,300 on comex",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold gains on Ukraine unrest, weak Chinese output data",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures close down $16.10 at $651.90 an ounce",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold rises more than 1% to hit 3-week high as fed outlook supports",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold slumps below $1,200, risk appetite dents safe-haven demand",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Akshaya Tritiya 2018 | Gold to glitter amid uncertain times, strong trend likely for next one month",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold steady near 7-week highs ahead of us jobs data",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec. gold down 40 cents at $1,419.80/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "bourses eye brisk business in gold etfs tomorrow, waive off charges",
        "output": "No",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold fails to hold gains as stocks trade higher",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold fluctuates near 2-week high with U.S. data, Iraq violence in focus",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "crude oil down, gold futures up after jobless data",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold rises to record; gains 6.3% in week",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec. gold down 40 cents at $1,419.80/oz",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold perched at $1,200 ahead of US jobs report",
        "output": "Yes",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures rally, near 18-year high",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold inches down as dollar gains",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold price falls as dollar strengthens",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "mcx goldguinea feb contract trading lower",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "trading in gold bonds to begin by month-end: finance ministry",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold, silver futures rise with U.S. data, Ukraine talks in focus",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Dec. gold gains $2.40, or 0.2%, to settle at $1,344.10/oz",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "deutsche bank cuts gold, silver forecast for 2013",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures close down $16.10 at $651.90 an ounce",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold falls to session lows after u.s. gdp report",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "August gold climbs $9.40, or 0.8%, to settle at $1,254.90/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures close down $2.50, or 0.2%, at $1,274.30/oz.",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold spikes to 5-month highs as us launches missile strikes on syria",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "commodity bets: trading ideas for gold, crude and copper",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "December gold $4.90, or 0.4%, lower at $1,313.20/oz.",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures log lowest finish since June, down 1.8% for the week",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "neutron star mergers may create much of the universe's gold",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold ends at record high on weaker stocks, outlook",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold prices ease in asia as fed seen on track to exit easy policy",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "the curious case of clay turning to gold",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures end at a three-session high",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold rebounds from 3-month lows to finish higher",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold hits new high of Rs 30,570 per 10 gm",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "December gold down 0.5% at $1,321.70/oz.",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "april gold falls $5.90, or 0.5%, to settle at $1,311.90/oz",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold up from two-month low before bernanke",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold erases loss to end in positive territory as stocks lose steam",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Dec. gold gains $2.40, or 0.2%, to settle at $1,344.10/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures lose more than $21 in three days",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures, metals index reach fresh highs",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold ends lower as havens lose ground after French vote",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold inches up as prospects for further US rate hikes weigh on dollar",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "bloomberg intelligence : this will 'unlock the cage for well-rested gold bulls'",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "how yellen's gamble screwed up gold",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold falls to 7-week low as rate hike expectations rise",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices to trade lower today: Angel Commodities",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold fluctuates near 2-week high with U.S. data, Iraq violence in focus",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold rallies on dollar weakness, record oil prices",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dubai : vat and higher prices suck glitter out of gold",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Expect Gold to trade negative: Sushil Finance",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "stockists' buying drives up gold; silver range-bound",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold price bounce may unravel on us infrastructure plan",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec gold up $7.60, up 2%, at $383.80/oz",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures climb as much as $9 in morning trading",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures settle lower ahead of fed policy statement",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold ends at more-than-2-week low",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold, Silver may trade with positive bias:Angel Commodities",
        "output": "No",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices to trade lower Angel Commodities",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold slips as dollar steadies; n. korea headlines in focus",
        "output": "No",
        "instruction": "Does the news headline talk about price? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold mostly flat in asia as investors cautious ahead of fed policy views",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "commerzbank : gold to reclaim $1,300 an ounce by the end of 2018",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "dec gold futures up $3.70 at $493.20 an ounce",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures fall to Rs 25,275 per 10 gm",
        "output": "Yes",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold broke out and then broke down",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "will china drop gold next?",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures close lower, but gain almost 11% year to date",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold gains on Ukraine unrest, weak Chinese output data",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold near seven-and-a-half months high on safe-haven demand",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "don't read too much into gold's drop",
        "output": "No",
        "instruction": "Does the news headline talk about price in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "april gold up $4.70, or 0.4%, at $1,342.70/oz",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold futures up on higher asian cues",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold surrenders 11-month highs on stronger dollar, upbeat economic data",
        "output": "Yes",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "August gold climbs $3, or 0.2%, to $1,249.40/oz after highs above $1,253",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold demand slides to eight-year low in q3 2017 - wgc",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold weaker in Asia as Caixin PMI dips to 78-month-low",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "august gold rises 1.3% to $934.70 an ounce",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures off 0.4% at $1,313.60/oz.",
        "output": "No",
        "instruction": "Does the news headline talk about price going up? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold futures open lower at Rs 29,565",
        "output": "No",
        "instruction": "Does the news headline compare gold with any other asset? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold demand in india sluggish as price hardens",
        "output": "Yes",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices dip in Asia, few demand cues seen from India, China",
        "output": "Yes",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold drops more than 4%, falls below $1,800",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "february gold up 0.4% at $1,345.70/oz.",
        "output": "No",
        "instruction": "Does the news headline talk about price staying constant? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "oil and gold looking a little bit more 'normal' as 2017 draws to a close",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold falls as dollar firms, n.korea worries ease",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the past? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "mcx goldguinea august contract firms up",
        "output": "No",
        "instruction": "Does the news headline talk about price going down? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "gold rallies to highest finish in nearly a year",
        "output": "No",
        "instruction": "Does the news headline talk about a general event (apart from prices) in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "Gold prices dip in Asia on profit taking, easy monetary policies support",
        "output": "No",
        "instruction": "Does the news headline talk about price in the future? Please choose an answer from {Yes/No}.",
        "domain": "fin",
        "task": "ha"
    },
    {
        "input": "\u4e92\u6362\u5408\u7ea6\u662f\u6307\u4ea4\u6613\u53cc\u65b9\u4e4b\u95f4\u7ea6\u5b9a\u7684\u5728\u672a\u6765\u67d0\u4e00\u671f\u95f4\u5185\u4ea4\u6362\u4ed6\u4eec\u8ba4\u4e3a\u5177\u6709\u76f8\u7b49\u7ecf\u6d4e\u4ef7\u503c\u7684____\u7684\u5408\u7ea6\u3002\nA. \u6807\u7684\u8d44\u4ea7\nB. \u91d1\u878d\u8d44\u4ea7\nC. \u73b0\u91d1\u6d41\nD. \u8d27\u5e01\n",
        "output": "C. \u73b0\u91d1\u6d41",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5c5e\u4e8e\u7f8e\u56fd\u56fd\u9645\u6536\u652f\u7edf\u8ba1\u4e2d\u8d37\u65b9\u9879\u76ee\u7684\u662f____\u3002\nA. \u7f8e\u56fd\u5546\u54c1\u51fa\u53e3\nB. \u7f8e\u56fd\u5c45\u6c11\u5728\u4e2d\u56fd\u65c5\u6e38\u7684\u652f\u51fa\nC. \u7f8e\u56fd\u4f01\u4e1a\u5bf9\u4e2d\u56fd\u7684\u6295\u8d44\nD. \u7f8e\u56fd\u5c45\u6c11\u5bf9\u4e2d\u56fd\u7684\u6350\u6b3e\n",
        "output": "A. \u7f8e\u56fd\u5546\u54c1\u51fa\u53e3",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u8003\u8651\u4f01\u4e1a\u6240\u5f97\u7a0e\u4f46\u4e0d\u8003\u8651\u4e2a\u4eba\u6240\u5f97\u7a0e\u7684\u60c5\u51b5\u4e0b\uff0c\u4e0b\u5217\u5173\u4e8e\u8d44\u672c\u7ed3\u6784\u6709\u7a0eMM\u7406\u8bba\u7684\u8bf4\u6cd5\u4e2d\uff0c\u9519\u8bef\u7684\u662f____\u3002\nA. \u8d22\u52a1\u6760\u6746\u8d8a\u5927\uff0c\u4f01\u4e1a\u4ef7\u503c\u8d8a\u5927\nB. \u8d22\u52a1\u6760\u6746\u8d8a\u5927\uff0c\u4f01\u4e1a\u5229\u606f\u62b5\u7a0e\u73b0\u503c\u8d8a\u5927\nC. \u8d22\u52a1\u6760\u6746\u8d8a\u5927\uff0c\u4f01\u4e1a\u6743\u76ca\u8d44\u672c\u6210\u672c\u8d8a\u9ad8\nD. \u8d22\u52a1\u6760\u6746\u8d8a\u5927\uff0c\u4f01\u4e1a\u52a0\u6743\u5e73\u5747\u8d44\u672c\u6210\u672c\u8d8a\u9ad8\n",
        "output": "D. \u8d22\u52a1\u6760\u6746\u8d8a\u5927\uff0c\u4f01\u4e1a\u52a0\u6743\u5e73\u5747\u8d44\u672c\u6210\u672c\u8d8a\u9ad8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6ce8\u518c\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u4e0b\u5173\u4e8e\u7a0e\u6536\u8bf4\u6cd5\u6b63\u786e\u7684\u662f____\u3002\nA. \u7a0e\u6536\u5bf9\u52b3\u52a8\u7684\u66ff\u4ee3\u6548\u5e94\u8868\u660e\u653f\u5e9c\u5f81\u7a0e\u4f1a\u4f7f\u95f2\u6687\u4e0e\u52b3\u52a8\u7684\u76f8\u5bf9\u4ef7\u683c\u53d1\u751f\u53d8\u5316\uff0c\u95f2\u6687\u4ef7\u683c\u76f8\u5bf9\u964d\u4f4e\u4e86\uff0c\u5f15\u8d77\u4e2a\u4eba\u4ee5\u95f2\u6687\u4ee3\u66ff\u52b3\u52a8\uff0c\u5373\u52b3\u52a8\u4f9b\u7ed9\u7684\u51cf\u5c11\u3002\u56e0\u6b64\uff0c\u6211\u56fd\u53ef\u901a\u8fc7\u5f81\u7a0e\u89e3\u51b3\u52b3\u52a8\u529b\u4f9b\u5927\u4e8e\u6c42\u7684\u95ee\u9898\u3002\nB. \u6240\u5f97\u7a0e\u6307\u6570\u5316\u662f\u4e00\u9879\u6709\u52a9\u4e8e\u51cf\u8f7b\u901a\u8d27\u81a8\u80c0\u5bf9\u6240\u5f97\u7a0e\u5f71\u54cd\u7684\u63aa\u65bd\u3002\u7a0e\u6536\u5bf9\u52b3\u52a8\u4f9b\u7ed9\u7684\u6536\u5165\u6548\u5e94\u4e0e\u66ff\u4ee3\u6548\u5e94\u5448\u53cd\u65b9\u5411\u8fd0\u52a8\uff0c\u524d\u8005\u523a\u6fc0\u4eba\u4eec\u66f4\u52a0\u52aa\u529b\u5de5\u4f5c\uff0c\u540e\u8005\u4fc3\u4f7f\u4eba\u4eec\u51cf\u5c11\u52b3\u52a8\u4f9b\u7ed9\u3002\u52b3\u52a8\u4f9b\u7ed9\u7684\u589e\u51cf\u6700\u7ec8\u53d6\u51b3\u4e8e\u6536\u5165\u6548\u5e94\u4e0e\u66ff\u4ee3\u6548\u5e94\u7684\u5bf9\u6bd4\u3002\u56e0\u6b64\uff0c\u5355\u7eaf\u901a\u8fc7\u5f81\u7a0e\u5e76\u4e0d\u80fd\u89e3\u51b3\u52b3\u52a8\u529b\u4f9b\u5927\u4e8e\u6c42\u7684\u95ee\u9898\u3002\u7a0e\u6536\u5bf9\u50a8\u84c4\u7684\u6536\u5165\u6548\u5e94\u7684\u5927\u5c0f\u53d6\u51b3\u4e8e\u6240\u5f97\u7a0e\u7684\u5e73\u5747\u7a0e\u7387\u6c34\u5e73\uff0c\u800c\u66ff\u4ee3\u6548\u5e94\u7684\u5927\u5c0f\u53d6\u51b3\u4e8e\u6240\u5f97\u7a0e\u7684\u8fb9\u9645\u7a0e\u7387\u9ad8\u4f4e\u3002\u51cf\u7a0e\u653f\u7b56\u662f\u5b9e\u65bd\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u7684\u4e00\u79cd\u9009\u62e9\u3002\u4ece\u7f8e\u56fd\u7684\u5b9e\u8df5\u770b\u6765\uff0c\u51cf\u7a0e\u653f\u7b56\u53ea\u9002\u7528\u4e8e\u7ecf\u6d4e\u8870\u9000\u671f\u3002\nC. \u7a0e\u6536\u5bf9\u50a8\u84c4\u7684\u6536\u5165\u6548\u5e94\u7684\u5927\u5c0f\u53d6\u51b3\u4e8e\u6240\u5f97\u7a0e\u7684\u8fb9\u9645\u7a0e\u7387\u6c34\u5e73\uff0c\u800c\u66ff\u4ee3\u6548\u5e94\u7684\u5927\u5c0f\u53d6\u51b3\u4e8e\u6240\u5f97\u7a0e\u7684\u5e73\u5747\u7a0e\u7387\u9ad8\u4f4e\u3002\nD. \u51cf\u7a0e\u653f\u7b56\u662f\u4e00\u79cd\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\uff0c\u5728\u7ecf\u6d4e\u7e41\u8363\u671f\u4f7f\u7528\uff0c\u66f4\u6709\u9526\u4e0a\u6dfb\u82b1\u7684\u6548\u679c\u3002\n",
        "output": "B. \u6240\u5f97\u7a0e\u6307\u6570\u5316\u662f\u4e00\u9879\u6709\u52a9\u4e8e\u51cf\u8f7b\u901a\u8d27\u81a8\u80c0\u5bf9\u6240\u5f97\u7a0e\u5f71\u54cd\u7684\u63aa\u65bd\u3002\u7a0e\u6536\u5bf9\u52b3\u52a8\u4f9b\u7ed9\u7684\u6536\u5165\u6548\u5e94\u4e0e\u66ff\u4ee3\u6548\u5e94\u5448\u53cd\u65b9\u5411\u8fd0\u52a8\uff0c\u524d\u8005\u523a\u6fc0\u4eba\u4eec\u66f4\u52a0\u52aa\u529b\u5de5\u4f5c\uff0c\u540e\u8005\u4fc3\u4f7f\u4eba\u4eec\u51cf\u5c11\u52b3\u52a8\u4f9b\u7ed9\u3002\u52b3\u52a8\u4f9b\u7ed9\u7684\u589e\u51cf\u6700\u7ec8\u53d6\u51b3\u4e8e\u6536\u5165\u6548\u5e94\u4e0e\u66ff\u4ee3\u6548\u5e94\u7684\u5bf9\u6bd4\u3002\u56e0\u6b64\uff0c\u5355\u7eaf\u901a\u8fc7\u5f81\u7a0e\u5e76\u4e0d\u80fd\u89e3\u51b3\u52b3\u52a8\u529b\u4f9b\u5927\u4e8e\u6c42\u7684\u95ee\u9898\u3002\u7a0e\u6536\u5bf9\u50a8\u84c4\u7684\u6536\u5165\u6548\u5e94\u7684\u5927\u5c0f\u53d6\u51b3\u4e8e\u6240\u5f97\u7a0e\u7684\u5e73\u5747\u7a0e\u7387\u6c34\u5e73\uff0c\u800c\u66ff\u4ee3\u6548\u5e94\u7684\u5927\u5c0f\u53d6\u51b3\u4e8e\u6240\u5f97\u7a0e\u7684\u8fb9\u9645\u7a0e\u7387\u9ad8\u4f4e\u3002\u51cf\u7a0e\u653f\u7b56\u662f\u5b9e\u65bd\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u7684\u4e00\u79cd\u9009\u62e9\u3002\u4ece\u7f8e\u56fd\u7684\u5b9e\u8df5\u770b\u6765\uff0c\u51cf\u7a0e\u653f\u7b56\u53ea\u9002\u7528\u4e8e\u7ecf\u6d4e\u8870\u9000\u671f\u3002",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u653f\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u4ee5\u6210\u672c\u4f5c\u4e3a\u5185\u90e8\u7ed3\u7b97\u4ef7\u683c\u4e2d\uff0c\u4ec0\u4e48\u4f7f\u63d0\u4f9b\u4ea7\u54c1\u548c\u52b3\u52a1\u7684\u90e8\u95e8\u5c06\u5176\u5de5\u4f5c\u7684\u6210\u7ee9\u548c\u7f3a\u9677\u5168\u90e8\u4e0d\u6298\u4e0d\u6263\u8f6c\u7ed9\u4e86\u4f7f\u7528\u90e8\u95e8\uff0c\u800c\u4f7f\u7528\u90e8\u95e8\u672c\u4e0d\u5e94\u8be5\u5bf9\u8fd9\u4e9b\u6210\u7ee9\u548c\u7f3a\u9677\u627f\u62c5\u8d23\u4efb____\u3002\nA. \u5b9e\u9645\u6210\u672c\u6cd5\nB. \u6807\u51c6\u6210\u672c\u6cd5\nC. \u6807\u51c6\u6210\u672c\u52a0\u6210\u6cd5\nD. \u53d8\u52a8\u6210\u672c\u6cd5\n",
        "output": "A. \u5b9e\u9645\u6210\u672c\u6cd5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u79df\u8d41\u878d\u8d44\u7684\u4e3b\u8981\u7279\u70b9\u4e0d\u5305\u62ec____\u3002\nA. \u6240\u6709\u6743\u8f6c\u79fb\nB. \u79df\u91d1\u652f\u4ed8\nC. \u7075\u6d3b\u6027\nD. \u98ce\u9669\u627f\u62c5\n",
        "output": "A. \u6240\u6709\u6743\u8f6c\u79fb",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5546\u4e1a\u94f6\u884c\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f8(\u4e0a\u5e02\u516c\u53f8)\u662fABC\u4f1a\u8ba1\u5e08\u4e8b\u52a1\u6240\u7684\u5e38\u5e74\u5ba1\u8ba1\u5ba2\u6237\uff0c\u81ea2013\u5e74\u52302017\u5e74\uff0c\u738b\u661f\u90fd\u662f\u8be5\u5ba1\u8ba1\u9879\u76ee\u7684\u9879\u76ee\u5408\u4f19\u4eba\uff0c2018\u5e74ABC\u4f1a\u8ba1\u5e08\u4e8b\u52a1\u6240\u7ee7\u7eed\u5ba1\u8ba1\u7532\u516c\u53f8\uff0c\u5219\u4ee5\u4e0b\u6709\u5173\u8bf4\u6cd5\u4e2d\u6070\u5f53\u7684\u662f____\u3002\nA. \u738b\u661f\u4e0d\u5e94\u7ee7\u7eed\u4f5c\u4e3a\u9879\u76ee\u5408\u4f19\u4eba\nB. 2019\u5e74\u5982\u679c\u7532\u516c\u53f8\u4ecd\u59d4\u6258ABC\u4f1a\u8ba1\u5e08\u4e8b\u52a1\u6240\u5ba1\u8ba1\uff0c\u5219\u738b\u661f\u53ef\u4ee5\u7ee7\u7eed\u4f5c\u4e3a\u9879\u76ee\u5408\u4f19\u4eba\nC. \u5982\u679c\u51fa\u73b0\u7279\u6b8a\u60c5\u51b5\uff0c\u4f7f\u5f97\u4f1a\u8ba1\u5e08\u4e8b\u52a1\u6240\u4e0d\u80fd\u6309\u65f6\u8f6e\u6362\u5173\u952e\u5ba1\u8ba1\u5408\u4f19\u4eba\uff0c\u5728\u83b7\u5f97\u7532\u516c\u53f8\u6cbb\u7406\u5c42\u540c\u610f\u7684\u524d\u63d0\u4e0b\uff0c\u4e14\u80fd\u591f\u91c7\u53d6\u9632\u8303\u63aa\u65bd\u6d88\u9664\u5bf9\u72ec\u7acb\u6027\u4ea7\u751f\u7684\u4e0d\u5229\u5f71\u54cd\uff0c\u5728\u6cd5\u5f8b\u6cd5\u89c4\u5141\u8bb8\u7684\u60c5\u51b5\u4e0b\uff0c\u738b\u661f\u53ef\u4ee5\u7ee7\u7eed\u8fde\u4efb\u4e24\u5e74\u3002\nD. \u738b\u661f\u53ef\u4ee5\u4f5c\u4e3a\u5ba1\u8ba1\u9879\u76ee\u7ec4\u6210\u5458\u53c2\u4e0e\u7532\u516c\u53f82018\u5e74\u8d22\u52a1\u62a5\u8868\u7684\u5ba1\u8ba1\n",
        "output": "A. \u738b\u661f\u4e0d\u5e94\u7ee7\u7eed\u4f5c\u4e3a\u9879\u76ee\u5408\u4f19\u4eba",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5947\u5f02\u671f\u6743\u7684\u4e3b\u8981\u7c7b\u578b\u4e0d\u5305\u62ec____\u3002\nA. \u4e09\u503c\u671f\u6743\nB. \u6253\u5305\u671f\u6743\nC. \u969c\u788d\u671f\u6743\nD. \u4e9a\u5f0f\u671f\u6743\n",
        "output": "A. \u4e09\u503c\u671f\u6743",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5de5\u7a0b\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u4eba\u4ee510000\u5143\u6295\u8d44A\u80a1\u7968\uff0c\u9884\u8ba1\u6301\u6709\u534a\u5e74\u540e\u5c06\u5176\u552e\u51fa\uff0c\u9884\u8ba1\u672a\u6765\u534a\u5e74\u5185\u83b7\u5229800\u5143\uff0c\u672a\u6765\u534a\u5e74\u80a1\u7968\u5e02\u503c\u4e3a10500\u5143\u53ef\u80fd\u6027\u4e3a60$\\%$\uff0c\u5e02\u503c\u4e3a11000\u5143\u53ef\u80fd\u6027\u4e3a20$\\%$\uff0c\u5e02\u503c\u4e3a9500\u5143\u53ef\u80fd\u6027\u4e3a20$\\%$\uff0c\u6295\u8d44\u8005\u9884\u671f\u5e74\u6301\u6709\u6536\u76ca\u7387\u4e3a____\u3002\nA. 0.039\nB. 0.06\nC. 0.096\nD. 12\n",
        "output": "D. 12",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u4eba\u9000\u4f11\u65f6\u6709\u73b0\u91d110\u4e07\uff0c\u62df\u9009\u62e9\u4e00\u9879\u6c47\u62a5\u6bd4\u8f83\u7a33\u5b9a\u7684\u6295\u8d44\uff0c\u5e0c\u671b\u6bcf\u4e2a\u5b63\u5ea6\u80fd\u6536\u51652000\u5143\u8865\u8d34\uff0c\u90a3\u4e48\u8be5\u9879\u6295\u8d44\u7684\u6709\u6548\u5e74\u5229\u7387\u4e3a____\u3002\nA. 2$\\%$\nB. 8$\\%$\nC. 8.24$\\%$\nD. 10.04$\\%$\n",
        "output": "C. 8.24$\\%$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u878d\u8d44\u79df\u8d41\u4e0e\u7ecf\u8425\u79df\u8d41\u7684\u4e3b\u8981\u533a\u522b\u4e0d\u5305\u62ec____\u3002\nA. \u98ce\u9669\u4e0e\u62a5\u916c\u7684\u8f6c\u79fb\u4e0d\u540c\nB. \u671f\u9650\u5dee\u5f02\nC. \u627f\u79df\u4eba\u62e5\u6709\u7684\u6743\u5229\u4e0d\u540c\nD. \u8ba2\u91d1\u662f\u5426\u5177\u6709\u5b8c\u5168\u652f\u4ed8\u6027\n",
        "output": "D. \u8ba2\u91d1\u662f\u5426\u5177\u6709\u5b8c\u5168\u652f\u4ed8\u6027",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5546\u4e1a\u94f6\u884c\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5bf9\u4e2a\u4eba\u5546\u7528\u623f\u8d37\u6b3e\uff0c\u8d37\u6b3e\u5ba1\u6279\u4eba\u5e94\u5206\u6790\u7684\u5185\u5bb9\u4e0d\u5305\u62ec____\u3002\nA. \u8d37\u6b3e\u8d44\u6599\u662f\u5426\u5b8c\u6574\u3001\u9f50\u5168\nB. \u501f\u6b3e\u4eba\u662f\u5426\u7b26\u5408\u6761\u4ef6\u3001\u8d44\u4fe1\u662f\u5426\u826f\u597d\u3001\u8fd8\u6b3e\u6765\u6e90\u662f\u5426\u8db3\u989d\u53ef\u4fe1\nC. \u501f\u6b3e\u4eba\u6237\u7c4d\u6240\u5728\u5730\u662f\u5426\u5728\u8d37\u6b3e\u94f6\u884c\u6240\u5728\u5730\u533a\nD. \u8d37\u6b3e\u62c5\u4fdd\u662f\u5426\u7b26\u5408\u89c4\u5b9a\uff0c\u6743\u5c5e\u662f\u5426\u6e05\u6670\n",
        "output": "C. \u501f\u6b3e\u4eba\u6237\u7c4d\u6240\u5728\u5730\u662f\u5426\u5728\u8d37\u6b3e\u94f6\u884c\u6240\u5728\u5730\u533a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u7968\u636e\u6cd5\u5f8b\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u5404\u9879\u4e2d\uff0c\u5c5e\u4e8e\u7968\u636e\u7684\u76f8\u5bf9\u5fc5\u8981\u8bb0\u8f7d\u4e8b\u9879\u7684\u662f____\u3002\nA. \u7968\u636e\u91d1\u989d\nB. \u80cc\u4e66\u8bb0\u8f7d\u7684\u6761\u4ef6\nC. \u7968\u636e\u5230\u671f\u65e5\nD. \u627f\u5151\u8bb0\u8f7d\u7684\u6761\u4ef6\n",
        "output": "C. \u7968\u636e\u5230\u671f\u65e5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u300a\u6700\u9ad8\u4eba\u6c11\u68c0\u5bdf\u9662\u3001\u516c\u5b89\u90e8\u5173\u4e8e\u516c\u5b89\u673a\u5173\u7ba1\u8f96\u7684\u5211\u4e8b\u6848\u4ef6\u7acb\u6848\u8ffd\u8bc9\u6807\u51c6\u7684\u89c4\u5b9a\uff08\u4e8c\uff09\u300b\u7b2c\u56db\u5341\u56db\u6761\u7684\u89c4\u5b9a\uff0c\u4ee5\u975e\u6cd5\u5360\u6709\u4e3a\u76ee\u7684\uff0c\u4f7f\u7528\u8bc8\u9a97\u65b9\u6cd5\u975e\u6cd5\u96c6\u8d44\uff0c\u6570\u989d\u5728____\u4ee5\u4e0a\u7684\uff0c\u5e94\u4e88\u7acb\u6848\u8ffd\u8bc9\u3002\nA. 10\u4e07\u5143\nB. 20\u4e07\u5143\nC. \u0421.30\u4e07\u5143\nD. 50\u4e07\u5143\n",
        "output": "A. 10\u4e07\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8bc1\u5238\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u8d22\u653f\u653f\u7b56\u5de5\u5177\uff0c\u4e5f\u79f0\u8d22\u653f\u653f\u7b56\u624b\u6bb5\uff0c\u662f\u8d22\u653f\u653f\u7b56\u4e3b\u4f53\u6240\u9009\u62e9\u7684\u7528\u4ee5\u8fbe\u5230\u653f\u7b56\u76ee\u6807\u7684\u5404\u79cd\u8d22\u653f\u624b\u6bb5\uff0c\u5b83\u4e3b\u8981\u5305\u62ec____\u3002\nA. \u7a0e\u6536\nB. \u56fd\u503a\nC. \u4e00\u822c\u516c\u5171\u6536\u5165\nD. \u653f\u5e9c\u516c\u76ca\u6295\u8d44\n",
        "output": "A. \u7a0e\u6536",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u653f\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u6d4e\u5357\uff0c\u8354\u679d\u7684\u4ef7\u683c\u6bd4\u82f9\u679c\u7684\u4ef7\u683c\u8d355\u500d\uff0c\u800c\u5728\u5e7f\u5dde\uff0c\u8354\u679d\u7684\u4ef7\u683c\u53ea\u662f\u82f9\u679c\u76840.5\uff0c\u90a3\u4e48\u4e24\u5730\u7684\u6d88\u8d39\u8005\u90fd\u8fbe\u5230\u6548\u7528\u6700\u5927\u5316\u65f6____\u3002\nA. \u6d88\u8d39\u8005\u7684\u8354\u679d\u5bf9\u82f9\u679c\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\u76f8\u7b49\nB. \u8354\u679d\u5bf9\u82f9\u679c\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\uff0c\u6d4e\u5357\u6d88\u8d39\u8005\u8981\u5927\u4e8e\u5e7f\u4e1c\u6d88\u8d39\u8005\nC. \u82f9\u679c\u5bf9\u8354\u679d\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\uff0c\u6d4e\u5357\u6d88\u8d39\u8005\u8981\u5927\u4e8e\u5e7f\u4e1c\u6d88\u8d39\u8005\nD. \u65e0\u6cd5\u786e\u5b9a\n",
        "output": "B. \u8354\u679d\u5bf9\u82f9\u679c\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\uff0c\u6d4e\u5357\u6d88\u8d39\u8005\u8981\u5927\u4e8e\u5e7f\u4e1c\u6d88\u8d39\u8005",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u501f\u6b3e\u4eba\u5df2\u8d44\u4e0d\u62b5\u503a\u5c5e\u4e8e____\u7684\u7279\u5f81\u3002\nA. \u53ef\u7591\u7c7b\u8d37\u6b3e\nB. \u6b63\u5e38\u7c7b\u8d37\u6b3e\nC. \u5173\u6ce8\u7c7b\u8d37\u6b3e\nD. \u6b21\u7ea7\u7c7b\u8d37\u6b3e\n",
        "output": "A. \u53ef\u7591\u7c7b\u8d37\u6b3e",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u8bf4\u6cd5\u9519\u8bef\u7684\u662f____\u3002\nA. 2005\u5e7411\u6708\uff0c\u56fd\u5bb6\u53d1\u5c55\u6539\u9769\u59d4\u7b49\u5341\u90e8\u59d4\u8054\u5408\u53d1\u5e03\u300a\u521b\u4e1a\u6295\u8d44\u4f01\u4e1a\u7ba1\u7406\u6682\u884c\u529e\u6cd5\u300b\nB. 2008\u5e7410\u6708,\u56fd\u52a1\u9662\u529e\u516c\u5385\u53d1\u5e03\u300a\u56fd\u52a1\u9662\u529e\u516c\u5385\u8f6c\u53d1\u3008\u5173\u4e8e\u521b\u4e1a\u6295\u8d44\u5f15\u5bfc\u57fa\u91d1\u89c4\u8303\u8bbe\u7acb\u4e0e\u8fd0\u4f5c\u6307\u5bfc\u610f\u89c1\u3009\u7684\u901a\u77e5\u300b\nC. 2009\u5e7410\u6708\uff0c\u56fd\u5bb6\u53d1\u5c55\u6539\u9769\u59d4\u3001\u8d22\u653f\u90e8\u53d1\u5e03\u300a\u5173\u4e8e\u5b9e\u65bd\u65b0\u5174\u4ea7\u4e1a\u521b\u4e1a\u6295\u8d44\u8ba1\u5212\u3001\u5f00\u5c55\u4ea7\u4e1a\u6280\u672f\u7814\u7a76\u4e0e\u5f00\u53d1\u8d44\u91d1\u53c2\u80a1\u8bbe\u7acb\u521b\u4e1a\u6295\u8d44\u57fa\u91d1\u8bd5\u70b9T\u4f5c\u7684\u901a\u77e5\u300b\nD. 2016\u5e7411\u6708\uff0c\u8d22\u653f\u90e8\u53d1\u5e03\u300a\u653f\u5e9c\u6295\u8d44\u57fa\u91d1\u6682\u884c\u7ba1\u7406\u529e\u6cd5\u300b\uff0c\u89c4\u8303\u653f\u5e9c\u5f15\u5bfc\u57fa\u91d1\u7684\u89c4\u8303\u8fd0\u884c\uff0c\u540c\u65f6\u9f13\u52b1\u653f\u5e9c\u8d22\u653f\u8d44\u91d1\u652f\u6301\u521b\u4e1a\u6295\u8d44\u3002\n",
        "output": "D. 2016\u5e7411\u6708\uff0c\u8d22\u653f\u90e8\u53d1\u5e03\u300a\u653f\u5e9c\u6295\u8d44\u57fa\u91d1\u6682\u884c\u7ba1\u7406\u529e\u6cd5\u300b\uff0c\u89c4\u8303\u653f\u5e9c\u5f15\u5bfc\u57fa\u91d1\u7684\u89c4\u8303\u8fd0\u884c\uff0c\u540c\u65f6\u9f13\u52b1\u653f\u5e9c\u8d22\u653f\u8d44\u91d1\u652f\u6301\u521b\u4e1a\u6295\u8d44\u3002",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u9879\u76ee\u6295\u8d44\u51b3\u7b56\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u4e24\u4e2a\u4e92\u65a5\u9879\u76ee\u7684\u521d\u59cb\u6295\u8d44\u989d\u4e0d\u4e00\u6837\uff0c\u5728\u6743\u8861\u65f6\u9009\u62e9\u5185\u542b\u62a5\u916c\u7387\u9ad8\u7684\u9879\u76ee\nB. \u5bf9\u4e92\u65a5\u9879\u76ee\u4f18\u9009\u65f6\uff0c\u4f7f\u7528\u51c0\u73b0\u503c\u6cd5\u4e0e\u4f7f\u7528\u5185\u542b\u62a5\u916c\u7387\u6cd5\u7684\u7ed3\u679c\u662f\u4e00\u81f4\u7684\nC. \u4f7f\u7528\u83b7\u5229\u6307\u6570\u6cd5\u8fdb\u884c\u6295\u8d44\u51b3\u7b56\u53ef\u80fd\u4f1a\u8ba1\u7b97\u51fa\u591a\u4e2a\u83b7\u5229\u6307\u6570\nD. \u56de\u6536\u671f\u6cd5\u4e3b\u8981\u6d4b\u5b9a\u6295\u8d44\u65b9\u6848\u7684\u6d41\u52a8\u6027\u800c\u975e\u76c8\u5229\u6027\n",
        "output": "D. \u56de\u6536\u671f\u6cd5\u4e3b\u8981\u6d4b\u5b9a\u6295\u8d44\u65b9\u6848\u7684\u6d41\u52a8\u6027\u800c\u975e\u76c8\u5229\u6027",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5546\u4e1a\u4fe1\u7528\u7684\u5c40\u9650\u6027\u6ca1\u6709\u8868\u73b0\u5728____\u3002\nA. \u4fe1\u7528\u89c4\u6a21\u53d7\u5355\u4e2a\u8d44\u672c\u6570\u91cf\u7684\u9650\u5236\nB. \u4fe1\u7528\u671f\u9650\u53d7\u5355\u4e2a\u8d44\u672c\u5468\u8f6c\u72b6\u51b5\u7684\u9650\u5236\nC. \u4fe1\u7528\u8303\u56f4\u53d7\u5546\u54c1\u6d41\u901a\u6e20\u9053\u7684\u9650\u5236\nD. \u4fe1\u7528\u5bf9\u8c61\u53d7\u8d44\u672c\u5f52\u6d41\u901f\u5ea6\u7684\u9650\u5236\n",
        "output": "C. \u4fe1\u7528\u8303\u56f4\u53d7\u5546\u54c1\u6d41\u901a\u6e20\u9053\u7684\u9650\u5236",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u653f\u6cbb\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "FrasierProducts\u516c\u53f8\u4e00\u76f4\u4fdd\u6301\u6bcf\u5e7410$\\%$\u7684\u589e\u957f\u901f\u5ea6\uff0c\u5e76\u9884\u671f\u8fd9\u4e00\u589e\u957f\u7387\u4ecd\u4f1a\u5ef6\u7eed\uff0c\u516c\u53f8\u9884\u8ba1\u4e0b\u4e00\u5e74\u5ea6\u7684\u6bcf\u80a1\u6536\u76ca\u4e3a4.00\u5143\u3002\u8be5\u516c\u53f8\u7684\u80a1\u5229\u652f\u4ed8\u7387\u4e3a35$\\%$\uff0c\u8d1d\u5854\u503c\u4e3a1.25\u3002\u5982\u679c\u65e0\u98ce\u9669\u5229\u7387\u4e3a7$\\%$\uff0c\u5e02\u573a\u56de\u62a5\u7387\u4e3a15$\\%$\uff0c\u5219\u8be5\u516c\u53f8\u666e\u901a\u80a1\u7684\u671f\u671b\u73b0\u884c\u5e02\u503c\u4e3a\u591a\u5c11____\u3002\nA. 14\u5143\nB. 16\u5143\nC. 20\u5143\nD. 28\u5143\n",
        "output": "C. 20\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u6216\u6709\u4e8b\u9879\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u6216\u6709\u4e8b\u9879\u5f62\u6210\u7684\u9884\u8ba1\u8d1f\u503a\u662f\u4f01\u4e1a\u627f\u62c5\u7684\u73b0\u65f6\u4e49\u52a1\nB. \u9884\u8ba1\u8d1f\u503a\u5e94\u5f53\u4e0e\u5176\u76f8\u5173\u7684\u6216\u6709\u8d44\u4ea7\u76f8\u62b5\u540e\u5728\u8d44\u4ea7\u8d1f\u503a\u8868\u4e2d\u4ee5\u51c0\u989d\u5217\u62a5\nC. \u6216\u6709\u4e8b\u9879\u5f62\u6210\u7684\u8d44\u4ea7\u5e94\u5f53\u5728\u5f88\u53ef\u80fd\u6536\u5230\u65f6\u4e88\u4ee5\u786e\u8ba4\nD. \u9884\u8ba1\u8d1f\u503a\u8ba1\u91cf\u5e94\u8003\u8651\u4e0e\u5176\u76f8\u5173\u7684\u6216\u6709\u8d44\u4ea7\u9884\u671f\u5904\u7f6e\u4ea7\u751f\u7684\u635f\u76ca\n",
        "output": "A. \u6216\u6709\u4e8b\u9879\u5f62\u6210\u7684\u9884\u8ba1\u8d1f\u503a\u662f\u4f01\u4e1a\u627f\u62c5\u7684\u73b0\u65f6\u4e49\u52a1",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u8fdb\u884c\u6295\u8d44\u9879\u76ee\u98ce\u9669\u5206\u6790\u65f6\uff0c\u6613\u5938\u5927\u8fdc\u671f\u73b0\u91d1\u6d41\u91cf\u98ce\u9669\u7684\u65b9\u6cd5\u662f____\u3002\nA. \u8c03\u6574\u73b0\u91d1\u6d41\u91cf\u6cd5\nB. \u98ce\u9669\u8c03\u6574\u6298\u73b0\u7387\u6cd5\nC. \u51c0\u73b0\u503c\u6cd5\nD. \u5185\u542b\u62a5\u916c\u7387\u6cd5\n",
        "output": "B. \u98ce\u9669\u8c03\u6574\u6298\u73b0\u7387\u6cd5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5bf9\u4e8e\u4e00\u4e2a\u53cc\u98ce\u9669\u6a21\u578b\uff0c\u5df2\u77e5\uff1a$\\mu_{x+t}^{(1)}=\\frac{k}{50-t}$, $0\\leq{t}<50$\uff0c $\\mu_{x+t}^{(2)}=\\frac{1}{50-t}$, $0\\leq{t}<50$\uff0c $h(2|{T}={t})=0.5$,$0\\leq{t}<50$\u3002\u5219$g(20)$\u7b49\u4e8e____\u3002\nA. 0.012\nB. 0.024\nC. 0.036\nD. 0.048\n",
        "output": "B. 0.024",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u56fd\u7cbe\u7b97\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u76f4\u63a5\u6807\u4ef7\u6cd5\u4e0b\uff0c\u6839\u636e\u56fd\u9645\u6536\u652f\u6a21\u578b\u53ef\u4ee5\u5224\u65ad____\u3002\nA. \u6c47\u7387\u4e0e\u672c\u56fd\u7269\u4ef7\u6210\u540c\u65b9\u5411\u53d8\u52a8\nB. \u6c47\u7387\u4e0e\u672c\u56fd\u7269\u4ef7\u6210\u53cd\u65b9\u5411\u53d8\u52a8\nC. \u6c47\u7387\u4e0e\u5916\u56fd\u6536\u5165\u6210\u540c\u65b9\u5411\u53d8\u52a8\nD. \u6c47\u7387\u4e0e\u672c\u56fd\u5229\u7387\u6210\u6b63\u65b9\u5411\u53d8\u52a8\n",
        "output": "A. \u6c47\u7387\u4e0e\u672c\u56fd\u7269\u4ef7\u6210\u540c\u65b9\u5411\u53d8\u52a8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5df2\u77e5\u5145\u5206\u5c31\u4e1a\u7684\u56fd\u6c11\u6536\u516510000\u4ebf\u7f8e\u5143\uff0c\u5b9e\u9645\u56fd\u6c11\u6536\u51659800\u4ebf\u7f8e\u5143\uff0c\u8fb9\u9645\u6d88\u8d39\u503e\u5411\u662f80$\\%$\uff0c\u5728\u589e\u52a0100\u4ebf\u7f8e\u5143\u7684\u6295\u8d44\u4ee5\u540e\uff0c\u7ecf\u6d4e\u5c06\u53d1\u751f____\u3002\nA. \u9700\u6c42\u62c9\u52a8\u7684\u901a\u8d27\u81a8\u80c0\nB. \u6210\u672c\u63a8\u8fdb\u7684\u901a\u8d27\u81a8\u80c0\nC. \u7ed3\u6784\u6027\u901a\u8d27\u81a8\u80c0\nD. \u9700\u6c42\u4e0d\u8db3\u7684\u5931\u4e1a\n",
        "output": "A. \u9700\u6c42\u62c9\u52a8\u7684\u901a\u8d27\u81a8\u80c0",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "____\u662f\u6295\u8d44\u6700\u91cd\u8981\u7684\u73af\u8282\u4e4b\u4e00\u3002\nA. \u4f30\u503c\nB. \u80a1\u6743\nC. \u4ef7\u503c\nD. \u8c03\u67e5\n",
        "output": "A. \u4f30\u503c",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5173\u4e8e\u653f\u5e9c\u4f1a\u8ba1\uff0c\u4e0b\u5217\u9879\u76ee\u8868\u8ff0\u4e2d\u9519\u8bef\u7684\u662f____\u3002\nA. \u9884\u7b97\u4f1a\u8ba1\u5b9e\u884c\u6536\u4ed8\u5b9e\u73b0\u5236\uff08\u56fd\u52a1\u9662\u53e6\u6709\u89c4\u5b9a\u7684\uff0c\u4ece\u5176\u89c4\u5b9a\uff09\nB. \u8d22\u52a1\u4f1a\u8ba1\u5b9e\u884c\u6743\u8d23\u53d1\u751f\u5236\nC. \u653f\u5e9c\u9884\u7b97\u62a5\u544a\u7684\u7f16\u5236\u4e3b\u8981\u4ee5\u6536\u4ed8\u5b9e\u73b0\u5236\u4e3a\u57fa\u7840\uff0c\u4ee5\u9884\u7b97\u4f1a\u8ba1\u6838\u7b97\u751f\u6210\u7684\u6570\u636e\u4e3a\u51c6\nD. \u653f\u5e9c\u8d22\u52a1\u62a5\u544a\u7684\u7f16\u5236\u4e3b\u8981\u4ee5\u6743\u8d23\u53d1\u751f\u5236\u4e3a\u57fa\u7840\uff0c\u4ee5\u8d22\u52a1\u4f1a\u8ba1\u6838\u7b97\u751f\u6210\u7684\u6570\u636e\u4e3a\u51c6\n",
        "output": "C. \u653f\u5e9c\u9884\u7b97\u62a5\u544a\u7684\u7f16\u5236\u4e3b\u8981\u4ee5\u6536\u4ed8\u5b9e\u73b0\u5236\u4e3a\u57fa\u7840\uff0c\u4ee5\u9884\u7b97\u4f1a\u8ba1\u6838\u7b97\u751f\u6210\u7684\u6570\u636e\u4e3a\u51c6",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5982\u679c\u5bf9\u4e8e\u6d88\u8d39\u8005A\u6765\u8bf4\uff0c\u4ee5\u5546\u54c1x\u66ff\u4ee3\u5546\u54c1y\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\u7b49\u4e8e4\uff0c\u5bf9\u4e8e\u6d88\u8d39\u8005B\u6765\u8bf4\uff0c\u4ee5\u5546\u54c1x\u66ff\u4ee3\u5546\u54c1y\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\u7b49\u4e8e3\uff0c\u90a3\u4e48\u6709\u53ef\u80fd\u53d1\u751f\u7684\u60c5\u51b5\u4e3a____\u3002\nA. B\u7528x\u5411A\u4ea4\u6362y\nB. B\u7528y\u5411A\u4ea4\u6362x\nC. A\u548cB\u4e0d\u4f1a\u4ea4\u6362\u5546\u54c1\nD. \u65e0\u4ea4\u6362\u53d1\u751f\n",
        "output": "A. B\u7528x\u5411A\u4ea4\u6362y",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u4e2d\u56fd\u4eba\u6c11\u94f6\u884c\u53d1\u5e03\u7684\u300a\u8d27\u5e01\u653f\u7b56\u6267\u884c\u62a5\u544a\u300b2011\u5e749\u6708\u672b\uff0c\u5e7f\u4e49\u8d27\u5e01\u4f9b\u7ed9M\u4f59\u989d\u4e3a78.7\u4e07\u4ebf\u5143\u540c\u6bd4\u589e\u957f13.0$\\%$\uff0c\u4ee5\u4e0b\u4e0d\u5c5e\u4e8eM\u7684\u662f____\u3002\nA. \u73b0\u91d1\nB. \u6d3b\u671f\u5b58\u6b3e\nC. \u5b9a\u671f\u5b58\u6b3e\nD. \u94f6\u884c\u51c6\u5907\u91d1\n",
        "output": "D. \u94f6\u884c\u51c6\u5907\u91d1",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u592e\u94f6\u884c\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5916\u6c47\u50a8\u5907\u6784\u6210\u4e2d\uff0c\u98ce\u9669\u6027\u8f83\u5927\u7684\u662f____\u3002\nA. \u9ec4\u91d1\nB. \u5916\u6c47\u8d44\u4ea7\nC. \u7279\u522b\u63d0\u6b3e\u6743\nD. \u5728IMF\u7684\u5934\u5bf8\n",
        "output": "B. \u5916\u6c47\u8d44\u4ea7",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u592e\u94f6\u884c\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u4fe1\u7528\u8bc4\u5206\u6a21\u578b\u7684\u8bf4\u6cd5\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u4fe1\u7528\u8bc4\u5206\u6a21\u578b\u662f\u5efa\u7acb\u5728\u5bf9\u5f53\u524d\u5e02\u573a\u6570\u636e\u6a21\u62df\u7684\u57fa\u7840\u4e0a\nB. \u4fe1\u7528\u8bc4\u5206\u6a21\u578b\u53ef\u4ee5\u7ed9\u51fa\u5ba2\u6237\u4fe1\u7528\u98ce\u9669\u6c34\u5e73\u7684\u5206\u6570\nC. \u4fe1\u7528\u8bc4\u5206\u6a21\u578b\u53ef\u4ee5\u63d0\u4f9b\u5ba2\u6237\u8fdd\u7ea6\u6982\u7387\u7684\u51c6\u786e\u6570\u503c\nD. \u4fe1\u7528\u8bc4\u5206\u6a21\u578b\u53ef\u4ee5\u53ca\u65f6\u53cd\u6620\u4f01\u4e1a\u4fe1\u7528\u72b6\u51b5\u7684\u53d8\u5316\n",
        "output": "B. \u4fe1\u7528\u8bc4\u5206\u6a21\u578b\u53ef\u4ee5\u7ed9\u51fa\u5ba2\u6237\u4fe1\u7528\u98ce\u9669\u6c34\u5e73\u7684\u5206\u6570",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u51ef\u6069\u65af\u7684\u300a\u5c31\u4e1a\u3001\u5229\u606f\u548c\u8d27\u5e01\u901a\u8bba\u300b\u53d1\u8868\u540e\uff0c\u4eba\u4eec\u610f\u8bc6\u5230\u51ef\u6069\u65af\u7406\u8bba\u6240\u8574\u6db5\u7684\u5b9e\u9645\u5de5\u8d44\u5bf9\u603b\u9700\u6c42\u7684\u51b2\u51fb\u662f____\u3002\nA. \u53cd\u5468\u671f\u7684\nB. \u987a\u5468\u671f\u7684\nC. \u975e\u5468\u671f\u7684\nD. \u8fd1\u4f3c\u5468\u671f\u7684\n",
        "output": "A. \u53cd\u5468\u671f\u7684",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d27\u5e01\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "F\u516c\u53f8\u4ee5\u521b\u65b0\u95fb\u540d\u4e8e\u4e16\uff0c\u516c\u53f8\u4e3b\u8981\u63a8\u51fa\u667a\u80fd\u624b\u673a\u3002\u5b83\u7684\u603b\u90e8\u4f4d\u4e8e\u52a0\u5229\u798f\u5c3c\u4e9a\u5dde\uff0c\u5176\u79d1\u7814\u96c6\u4e2d\u5ea6\u5f88\u9ad8\uff0c\u51e0\u4e4e\u6240\u6709F\u516c\u53f8\u7684\u79d1\u6280\u548c\u8bbe\u8ba1\u90fd\u8bde\u751f\u4e8e\u6b64\u3002F\u516c\u53f8\u5145\u5206\u5229\u7528\u5176\u6280\u672f\u4f18\u52bf\uff0c\u53c8\u9762\u5411\u5168\u7403\u628a\u4ea7\u54c1\u5236\u9020\u96c6\u4e2d\u5728\u4e2d\u5fc3\u5730\u533a\u7684\u51e0\u4e2a\u9ad8\u6548\u7387\u3001\u6700\u5177\u751f\u4ea7\u6210\u672c\u4f18\u52bf\u7684\u5de5\u5382;\u4e14F\u516c\u53f8\u5728\u5168\u7403\u9500\u552e\u6807\u51c6\u5316\u4ea7\u54c1\uff0c\u7f3a\u4e4f\u5bf9\u4e1c\u9053\u56fd\u5f53\u5730\u9700\u6c42\u7684\u654f\u611f\u53cd\u5e94\u548c\u7075\u6d3b\u6027\u3002F\u516c\u53f8\u91c7\u7528\u7684\u56fd\u9645\u5316\u7ecf\u8425\u6218\u7565\u4e3a____\u3002\nA. \u56fd\u9645\u6218\u7565\nB. \u5168\u7403\u5316\u6218\u7565\nC. \u8de8\u56fd\u6218\u7565\nD. \u591a\u56fd\u672c\u571f\u5316\u6218\u7565\n",
        "output": "B. \u5168\u7403\u5316\u6218\u7565",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u884c\u4e3a\u4e2d\uff0c\u65e2\u4e0d\u5f81\u6536\u589e\u503c\u7a0e\u4e5f\u4e0d\u5f81\u6536\u6d88\u8d39\u7a0e\u7684\u662f____\u3002\nA. \u9ad8\u6863\u5316\u5986\u54c1\u751f\u4ea7\u4f01\u4e1a\u5c06\u751f\u4ea7\u7684\u9ad8\u6863\u5316\u5986\u54c1\u5956\u52b1\u7ed9\u6709\u7a81\u51fa\u8d21\u732e\u7684\u804c\u5de5\nB. \u9ad8\u6863\u5316\u5986\u54c1\u751f\u4ea7\u4f01\u4e1a\u5c06\u81ea\u4ea7\u7684\u9ad8\u6863\u9999\u6c34\u7cbe\u7528\u4e8e\u7ee7\u7eed\u751f\u4ea7\u9ad8\u6863\u9999\u6c34\nC. \u9ad8\u6863\u5316\u5986\u54c1\u751f\u4ea7\u4f01\u4e1a\u5c06\u81ea\u4ea7\u7684\u9ad8\u6863\u9999\u6c34\u7cbe\u7528\u4e8e\u7ee7\u7eed\u751f\u4ea7\u666e\u901a\u62a4\u80a4\u54c1\nD. \u5916\u8d38\u4f01\u4e1a\u8fdb\u53e3\u6728\u5236\u4e00\u6b21\u6027\u7b77\u5b50\n",
        "output": "B. \u9ad8\u6863\u5316\u5986\u54c1\u751f\u4ea7\u4f01\u4e1a\u5c06\u81ea\u4ea7\u7684\u9ad8\u6863\u9999\u6c34\u7cbe\u7528\u4e8e\u7ee7\u7eed\u751f\u4ea7\u9ad8\u6863\u9999\u6c34",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u4f01\u4e1a\u56fd\u6709\u8d44\u4ea7\u6cd5\u5f8b\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u8bbe\u7acb\u56fd\u6709\u72ec\u8d44\u516c\u53f8\u7684\u6cd5\u5f8b\u4f9d\u636e\u662f____\u3002\nA. \u300a\u5168\u6c11\u6240\u6709\u5236\u5de5\u4e1a\u4f01\u4e1a\u6cd5\u300b\nB. \u300a\u4f01\u4e1a\u56fd\u6709\u8d44\u4ea7\u6cd5\u300b\nC. \u300a\u4e2a\u4eba\u72ec\u8d44\u4f01\u4e1a\u6cd5\u300b\nD. \u300a\u516c\u53f8\u6cd5\u300b\n",
        "output": "D. \u300a\u516c\u53f8\u6cd5\u300b",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5229\u7528$\\chi^{2}$\u5206\u5e03\u8fdb\u884c\u72ec\u7acb\u6027\u68c0\u9a8c\uff0c\u8981\u6c42\u6837\u672c\u5bb9\u91cf\u5e94\u5145\u5206\u5927\uff0c\u7279\u522b\u662f\u6bcf\u4e2a\u5355\u5143\u4e2d\u7684\u671f\u671b\u9891\u6570$fe$\u4e0d\u80fd\u8fc7\u5c0f\u3002\u5982\u679c\u53ea\u6709\u4e24\u4e2a\u5355\u5143\uff0c\u6bcf\u4e2a\u5355\u5143\u7684\u671f\u671b\u9891\u6570\u5fc5\u987b____\u3002\nA. \u5927\u4e8e\u7b49\u4e8e1\nB. \u5927\u4e8e\u7b49\u4e8e2\nC. \u5927\u4e8e\u7b49\u4e8e5\nD. \u5927\u4e8e\u7b49\u4e8e10\n",
        "output": "C. \u5927\u4e8e\u7b49\u4e8e5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u201c\u8fd0\u7528\u8d44\u672c\u8d44\u4ea7\u5b9a\u4ef7\u6a21\u578b\u4f30\u8ba1\u6743\u76ca\u6210\u672c\u201d\u7684\u8868\u8ff0\u4e2d\uff0c\u9519\u8bef\u7684\u662f____\u3002\nA. \u901a\u8d27\u81a8\u80c0\u7387\u8f83\u4f4e\u65f6\uff0c\u53ef\u9009\u62e9\u4e0a\u5e02\u4ea4\u6613\u7684\u653f\u5e9c\u957f\u671f\u503a\u5238\u7684\u5230\u671f\u6536\u76ca\u7387\u4f5c\u4e3a\u65e0\u98ce\u9669\u62a5\u916c\u7387\nB. \u516c\u53f8\u4e09\u5e74\u524d\u53d1\u884c\u4e86\u8f83\u5927\u89c4\u6a21\u7684\u516c\u53f8\u503a\u5238\uff0c\u4f30\u8ba1$\\beta$\u7cfb\u6570\u65f6\u5e94\u4f7f\u7528\u53d1\u884c\u503a\u5238\u65e5\u4e4b\u540e\u7684\u4ea4\u6613\u6570\u636e\u8ba1\u7b97\nC. \u91d1\u878d\u5371\u673a\u5bfc\u81f4\u8fc7\u53bb\u4e24\u5e74\u8bc1\u5238\u5e02\u573a\u8427\u6761\uff0c\u4f30\u8ba1\u5e02\u573a\u98ce\u9669\u6ea2\u4ef7\u65f6\u5e94\u5254\u9664\u8fd9\u4e24\u5e74\u7684\u6570\u636e\nD. \u4e3a\u4e86\u66f4\u597d\u5730\u9884\u6d4b\u957f\u671f\u5e73\u5747\u98ce\u9669\u6ea2\u4ef7\uff0c\u4f30\u8ba1\u5e02\u573a\u98ce\u9669\u6ea2\u4ef7\u65f6\u5e94\u4f7f\u7528\u6743\u76ca\u5e02\u573a\u7684\u51e0\u4f55\u5e73\u5747\u6536\u76ca\u7387\n",
        "output": "C. \u91d1\u878d\u5371\u673a\u5bfc\u81f4\u8fc7\u53bb\u4e24\u5e74\u8bc1\u5238\u5e02\u573a\u8427\u6761\uff0c\u4f30\u8ba1\u5e02\u573a\u98ce\u9669\u6ea2\u4ef7\u65f6\u5e94\u5254\u9664\u8fd9\u4e24\u5e74\u7684\u6570\u636e",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e00\u822c\u6765\u8bf4\uff0c\u4e00\u56fd\u56fd\u9645\u6536\u652f\u51fa\u73b0\u5de8\u989d\u987a\u5dee\u4f1a\u4f7f\u5176____\u3002\nA. \u8d27\u5e01\u75b2\u8f6f\nB. \u8d27\u5e01\u575a\u633a\nC. \u901a\u8d27\u7d27\u7f29\nD. \u5229\u7387\u4e0b\u8dcc\n",
        "output": "B. \u8d27\u5e01\u575a\u633a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u5546\u4e1a\u94f6\u884c\u5168\u90e8\u5173\u8054\u65b9\u6388\u4fe1\u603b\u989d\u4e3a110\u4ebf\u5143\uff0c\u8d44\u672c\u51c0\u989d\u4e3a210\u4ebf\u5143\uff0c\u5219\u5176\u5173\u8054\u6388\u4fe1\u6bd4\u4f8b\u7ea6\u4e3a____\u3002\nA. 41$\\%$\nB. 52$\\%$\nC. 191$\\%$\nD. 200$\\%$\n",
        "output": "B. 52$\\%$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e3a\u4e86\u786e\u4fdd\u94f6\u884c\u7684\u8d22\u52a1\u62a5\u544a\u516c\u5141\u5730\u53cd\u6620\u516c\u53f8\u7684\u8d22\u52a1\u72b6\u51b5\u4ee5\u53ca\u516c\u53f8\u5728\u5404\u91cd\u8981\u65b9\u9762\u7684\u8868\u73b0\uff0c\u8463\u4e8b\u4f1a\u548c\u9ad8\u7ea7\u7ba1\u7406\u5c42\u53ef\u4f7f\u7528\u5916\u90e8\u5ba1\u8ba1\u5e08\uff0c\u4e0b\u5217\u5173\u4e8e\u5916\u90e8\u5ba1\u8ba1\u76ee\u7684\u7684\u8868\u8ff0\u9519\u8bef\u7684\u662f____\u3002\nA. \u8bc4\u4f30\u4ece\u5546\u4e1a\u94f6\u884c\u6536\u5230\u62a5\u544a\u7684\u7cbe\u786e\u6027\nB. \u8bc4\u4ef7\u5546\u4e1a\u94f6\u884c\u603b\u4f53\u7ecf\u8425\u60c5\u51b5\nC. \u8bc4\u4ef7\u5546\u4e1a\u94f6\u884c\u5404\u9879\u98ce\u9669\u7ba1\u7406\u5236\u5ea6\nD. \u8bc4\u4ef7\u94f6\u884c\u5404\u9879\u8d44\u4ea7\u7ec4\u5408\u7684\u8d28\u91cf\u548c\u98ce\u9669\u66b4\u9732\u7a0b\u5ea6\n",
        "output": "D. \u8bc4\u4ef7\u94f6\u884c\u5404\u9879\u8d44\u4ea7\u7ec4\u5408\u7684\u8d28\u91cf\u548c\u98ce\u9669\u66b4\u9732\u7a0b\u5ea6",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u6709\u7a0e\u7684MM\u7406\u8bba\uff0c\u4e0b\u5217\u5404\u9879\u4e2d\u4f1a\u5f71\u54cd\u4f01\u4e1a\u4ef7\u503c\u7684\u662f____\u3002\nA. \u503a\u52a1\u5229\u606f\u62b5\u7a0e\nB. \u503a\u52a1\u4ee3\u7406\u6210\u672c\nC. \u503a\u52a1\u4ee3\u7406\u6536\u76ca\nD. \u8d22\u52a1\u56f0\u5883\u6210\u672c\n",
        "output": "A. \u503a\u52a1\u5229\u606f\u62b5\u7a0e",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u6709\u5173\u9879\u76ee\u7ec4\u8ba8\u8bba\u7684\u8bf4\u6cd5\u4e2d\uff0c\u4e0d\u6b63\u786e\u7684\u662f____\u3002\nA. \u6240\u6709\u9879\u76ee\u7ec4\u6210\u5458\u6bcf\u6b21\u5747\u5e94\u53c2\u4e0e\u9879\u76ee\u7ec4\u8ba8\u8bba\uff0c\u4e13\u5bb6\u65e0\u9700\u53c2\u52a0\u9879\u76ee\u7ec4\u7684\u8ba8\u8bba\nB. \u9879\u76ee\u7ec4\u5e94\u5f53\u6839\u636e\u5ba1\u8ba1\u7684\u5177\u4f53\u60c5\u51b5\uff0c\u6301\u7eed\u4ea4\u6362\u6709\u5173\u88ab\u5ba1\u8ba1\u5355\u4f4d\u8d22\u52a1\u62a5\u8868\u53d1\u751f\u91cd\u5927\u9519\u62a5\u53ef\u80fd\u6027\u7684\u4fe1\u606f\nC. \u6ce8\u518c\u4f1a\u8ba1\u5e08\u5e94\u5f53\u8003\u8651\u5728\u5ba2\u6237\u63a5\u53d7\u6216\u4fdd\u6301\u8fc7\u7a0b\u4e2d\u83b7\u53d6\u7684\u4fe1\u606f\u662f\u5426\u4e0e\u8bc6\u522b\u91cd\u5927\u9519\u62a5\u76f8\u5173\uff0c\u6b64\u5916\u6ce8\u518c\u4f1a\u8ba1\u5e08\u8fd8\u5e94\u5f53\u8003\u8651\u5411\u88ab\u5ba1\u8ba1\u5355\u4f4d\u63d0\u4f9b\u5176\u4ed6\u670d\u52a1\u4ee5\u53ca\u4ee5\u524d\u671f\u95f4\u5ba1\u8ba1\u83b7\u53d6\u7684\u7ecf\u9a8c\u662f\u5426\u6709\u52a9\u4e8e\u8bc6\u522b\u91cd\u5927\u9519\u62a5\u98ce\u9669\nD. \u9879\u76ee\u7ec4\u5e94\u8ba8\u8bba\u88ab\u5ba1\u8ba1\u5355\u4f4d\u6240\u9762\u4e34\u7684\u7ecf\u8425\u98ce\u9669\u3001\u8d22\u52a1\u62a5\u8868\u5bb9\u6613\u53d1\u751f\u9519\u62a5\u7684\u9886\u57df\u4ee5\u53ca\u53d1\u751f\u9519\u62a5\u7684\u65b9\u5f0f\uff0c\u7279\u522b\u662f\u7531\u4e8e\u821e\u5f0a\u5bfc\u81f4\u91cd\u5927\u9519\u62a5\u7684\u53ef\u80fd\u6027\n",
        "output": "A. \u6240\u6709\u9879\u76ee\u7ec4\u6210\u5458\u6bcf\u6b21\u5747\u5e94\u53c2\u4e0e\u9879\u76ee\u7ec4\u8ba8\u8bba\uff0c\u4e13\u5bb6\u65e0\u9700\u53c2\u52a0\u9879\u76ee\u7ec4\u7684\u8ba8\u8bba",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5404\u9879\u4ea4\u6613\u6216\u4e8b\u9879\u4ea7\u751f\u7684\u5dee\u989d\u4e2d\uff0c\u5e94\u5f53\u8ba1\u5165\u6240\u6709\u8005\u6743\u76ca\u7684\u662f____\u3002\nA. \u4f01\u4e1a\u53d1\u884c\u53ef\u8f6c\u6362\u516c\u53f8\u503a\u5238\u7684\u53d1\u884c\u4ef7\u683c\u4e0e\u8d1f\u503a\u516c\u5141\u4ef7\u503c\u4e4b\u95f4\u7684\u5dee\u989d\nB. \u4f01\u4e1a\u5c06\u503a\u52a1\u8f6c\u4e3a\u6743\u76ca\u5de5\u5177\u65f6\u503a\u52a1\u8d26\u9762\u4ef7\u503c\u4e0e\u6743\u76ca\u5de5\u5177\u516c\u5141\u4ef7\u503c\u4e4b\u95f4\u7684\u5dee\u989d\nC. \u4f01\u4e1a\u8d2d\u5165\u53ef\u8f6c\u6362\u516c\u53f8\u503a\u5238\u5b9e\u9645\u652f\u4ed8\u7684\u4ef7\u6b3e\u4e0e\u53ef\u8f6c\u6362\u516c\u53f8\u503a\u5238\u9762\u503c\u4e4b\u95f4\u7684\u5dee\u989d\nD. \u4f01\u4e1a\u53d1\u884c\u516c\u53f8\u503a\u5238\u5b9e\u9645\u6536\u5230\u7684\u4ef7\u6b3e\u4e0e\u503a\u5238\u9762\u503c\u4e4b\u95f4\u7684\u5dee\u989d\n",
        "output": "A. \u4f01\u4e1a\u53d1\u884c\u53ef\u8f6c\u6362\u516c\u53f8\u503a\u5238\u7684\u53d1\u884c\u4ef7\u683c\u4e0e\u8d1f\u503a\u516c\u5141\u4ef7\u503c\u4e4b\u95f4\u7684\u5dee\u989d",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u201c\u6324\u51fa\u6548\u5e94\u201d\u53d1\u751f\u4e8e____\u3002\nA. \u8d27\u5e01\u4f9b\u7ed9\u51cf\u5c11\u4f7f\u5229\u7387\u63d0\u9ad8\uff0c\u6324\u51fa\u4e86\u5bf9\u5229\u7387\u654f\u611f\u7684\u79c1\u4eba\u90e8\u95e8\u652f\u51fa\nB. \u79c1\u4eba\u90e8\u95e8\u589e\u7a0e\uff0c\u51cf\u5c11\u4e86\u79c1\u4eba\u90e8\u95e8\u7684\u53ef\u652f\u914d\u6536\u5165\u548c\u652f\u51fa\nC. \u653f\u5e9c\u652f\u51fa\u589e\u52a0\uff0c\u63d0\u9ad8\u4e86\u5229\u7387\uff0c\u6324\u51fa\u4e86\u5bf9\u5229\u7387\u654f\u611f\u7684\u79c1\u4eba\u90e8\u95e8\u652f\u51fa\nD. \u653f\u5e9c\u652f\u51fa\u51cf\u5c11\uff0c\u5f15\u8d77\u6d88\u8d39\u652f\u51fa\u4e0b\u964d\n",
        "output": "C. \u653f\u5e9c\u652f\u51fa\u589e\u52a0\uff0c\u63d0\u9ad8\u4e86\u5229\u7387\uff0c\u6324\u51fa\u4e86\u5bf9\u5229\u7387\u654f\u611f\u7684\u79c1\u4eba\u90e8\u95e8\u652f\u51fa",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u8bbe\u968f\u673a\u53d8\u91cf$\\xi$\u7684\u6982\u7387\u5bc6\u5ea6\u4e3a$f(x)=\\frac{1}{2\\sqrt{\\pi}}e^{-\\frac{(x-3)^{2}}{4}}(-\\infty<x<+\\infty)$\uff0c\u5219\u4ee5\u4e0b\u54ea\u4e2a\u7edf\u8ba1\u91cf\u670d\u4ece$N(0,1)$____\u3002\nA. $\\frac{\\xi+3}{2}$\nB. $\\frac{\\xi+3}{\\sqrt{2}}$\nC. $\\frac{\\xi-3}{2}$\nD. $\\frac{\\xi-3}{\\sqrt{2}}$\n",
        "output": "D. $\\frac{\\xi-3}{\\sqrt{2}}$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "YF\uff1d\u8981\u7d20\u51c0\u6536\u5165\uff0cTR\uff1d\u51c0\u8f6c\u79fb\uff0c\u5219\u56fd\u5185\u751f\u4ea7\u603b\u503c(GDP)\u3001\u56fd\u6c11\u751f\u4ea7\u603b\u503c(GNP)\u4e4b\u95f4\u5173\u7cfb\u6b63\u786e\u7684\u662f____\u3002\nA. GNP\uff1dGDP\nB. GDP\uff1dGNP\uff0bTR\nC. GNP=GDP\uff0bTR\nD. GNP\uff1dGDP\uff0bYF\n",
        "output": "D. GNP\uff1dGDP\uff0bYF",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u592e\u94f6\u884c\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u7a0e\u79cd\u4e2d\u5c5e\u4e8e\u4e2d\u592e\u653f\u5e9c\u4e0e\u5730\u65b9\u653f\u5e9c\u5171\u4eab\u6536\u5165\u7684\u662f____\u3002\nA. \u8015\u5730\u5360\u7528\u7a0e\nB. \u4e2a\u4eba\u6240\u5f97\u7a0e\nC. \u8f66\u8f86\u8d2d\u7f6e\u7a0e\nD. \u571f\u5730\u589e\u503c\u7a0e\n",
        "output": "B. \u4e2a\u4eba\u6240\u5f97\u7a0e",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4f9d\u636e\u4f01\u4e1a\u4f1a\u8ba1\u51c6\u5219\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u6709\u5173\u6536\u5165\u548c\u5229\u5f97\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u6536\u5165\u6e90\u4e8e\u65e5\u5e38\u6d3b\u52a8\uff0c\u5229\u5f97\u4e5f\u53ef\u80fd\u6e90\u4e8e\u65e5\u5e38\u6d3b\u52a8\nB. \u6536\u5165\u4f1a\u5f71\u54cd\u5229\u6da6\uff0c\u5229\u5f97\u4e5f\u4e00\u5b9a\u4f1a\u5f71\u54cd\u5229\u6da6\u603b\u989d\nC. \u6536\u5165\u6e90\u4e8e\u65e5\u5e38\u6d3b\u52a8\uff0c\u5229\u5f97\u6e90\u4e8e\u975e\u65e5\u5e38\u6d3b\u52a8\nD. \u6536\u5165\u4f1a\u5bfc\u81f4\u6240\u6709\u8005\u6743\u76ca\u7684\u589e\u52a0\uff0c\u5229\u5f97\u4e0d\u4e00\u5b9a\u4f1a\u5bfc\u81f4\u6240\u6709\u8005\u6743\u76ca\u7684\u589e\u52a0\n",
        "output": "C. \u6536\u5165\u6e90\u4e8e\u65e5\u5e38\u6d3b\u52a8\uff0c\u5229\u5f97\u6e90\u4e8e\u975e\u65e5\u5e38\u6d3b\u52a8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5bf9\u53d1\u653e\u8d37\u6b3e\u7684\u64cd\u4f5c\u7a0b\u5e8f\u7684\u6392\u5e8f\uff0c\u6b63\u786e\u7684\u662f____\u3002(1)\u6309\u8d26\u52a1\u5904\u7406\u90e8\u95e8\u7684\u8981\u6c42\u63d0\u4ea4\u5ba1\u6279\u53ca\u76f8\u5173\u7528\u6b3e\u51ed\u8bc1\u529e\u7406\u63d0\u6b3e\u624b\u7eed\u3002(2)\u6709\u5173\u7528\u6b3e\u5ba1\u6279\u8d44\u6599\u6309\u5185\u90e8\u5ba1\u6279\u6d41\u7a0b\u7ecf\u6709\u6743\u7b7e\u5b57\u4eba\u7b7e\u5b57\u540c\u610f\u3002(3)\u94f6\u884c\u53d7\u7406\u501f\u6b3e\u4eba\u63d0\u6b3e\u7533\u8bf7\u4e66\u3002(4)\u501f\u6b3e\u4eba\u6309\u5408\u540c\u8981\u6c42\u63d0\u4ea4\u63d0\u6b3e\u7533\u8bf7\u548c\u5176\u4ed6\u6709\u5173\u8d44\u6599\u3002(5)\u8d37\u6b3e\u53d1\u653e\u5ba1\u67e5\u3002\nA. (4)(5)(3)(2)(1)\nB. (4)(3)(5)(1)(2)\nC. (4)(3)(5)(2)(1)\nD. (5)(3)(4)(2)(1)\n",
        "output": "C. (4)(3)(5)(2)(1)",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "____\u662f\u6307\u8d1f\u6709\u6e05\u7b97\u4e49\u52a1\u7684\u4e3b\u4f53\uff0c\u6309\u7167\u6cd5\u5f8b\u6cd5\u89c4\u89c4\u5b9a\u548c\u57fa\u91d1\u5408\u540c\u7ea6\u5b9a\u7684\u65b9\u5f0f\u3001\u7a0b\u5e8f\u5bf9\u57fa\u91d1\u7684\u8d44\u4ea7\u3001\u8d1f\u503a\u3001\u6743\u76ca\u7b49\u8fdb\u884c\u5168\u9762\u7684\u6e05\u7406\u548c\u5904\u7f6e\u7684\u884c\u4e3a\u3002\nA. \u57fa\u91d1\u7ec8\u6b62\nB. \u57fa\u91d1\u9000\u51fa\nC. \u57fa\u91d1\u6e05\u7b97\nD. \u57fa\u91d1\u8865\u507f\n",
        "output": "C. \u57fa\u91d1\u6e05\u7b97",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e3a\u4e86\u8d44\u4ea7\u51cf\u503c\u6d4b\u8bd5\u7684\u76ee\u7684\uff0c\u4f01\u4e1a\u9700\u8981\u5bf9\u8d44\u4ea7\u672a\u6765\u73b0\u91d1\u6d41\u91cf\u8fdb\u884c\u9884\u8ba1\uff0c\u5e76\u9009\u62e9\u6070\u5f53\u7684\u6298\u73b0\u7387\u5bf9\u5176\u8fdb\u884c\u6298\u73b0\uff0c\u4ee5\u786e\u5b9a\u8d44\u4ea7\u9884\u8ba1\u672a\u6765\u73b0\u91d1\u6d41\u91cf\u7684\u73b0\u503c\u3002\u6839\u636e\u4f01\u4e1a\u4f1a\u8ba1\u51c6\u5219\u7684\u89c4\u5b9a\uff0c\u9884\u8ba1\u8d44\u4ea7\u672a\u6765\u73b0\u91d1\u6d41\u91cf\u7684\u671f\u9650\u5e94\u5f53\u662f____\u3002\nA. 5\u5e74\nB. \u6c38\u4e45\nC. \u8d44\u4ea7\u5269\u4f59\u4f7f\u7528\u5bff\u547d\nD. \u4f01\u4e1a\u7ecf\u8425\u671f\u9650\n",
        "output": "C. \u8d44\u4ea7\u5269\u4f59\u4f7f\u7528\u5bff\u547d",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5047\u8bbe\u4f60\u8d2d\u4e70\u4e00\u4e2a4\u5e74\u671f\u7684\u96f6\u606f\u7968\u503a\u5238\uff0c\u5982\u679c\u9690\u542b\u7684\u8fdc\u671f\u5229\u7387\u4fdd\u6301\u4e0d\u53d8\uff0c\u503a\u5238\u9762\u503c=1000\u7f8e\u5143\uff0c\u4f60\u7b2c1\u5e74\u6295\u8d44\u7684\u9884\u671f\u6536\u76ca\u7387\u662f\u591a\u5c11____\u3002\nA. 5$\\%$\nB. 7$\\%$\nC. 9$\\%$\nD. 10$\\%$\n",
        "output": "A. 5$\\%$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u4e0a\u5e02\u516c\u53f8\u5305\u542b\u8d44\u672c\u516c\u79ef80\u4e07\u5143\uff0c\u76c8\u4f59\u516c\u79ef150\u4e07\u5143\uff0c\u8d1f\u503a60\u4e07\u5143\uff0c\u672a\u5206\u914d\u5229\u6da660\u4e07\u5143\uff0c\u5b9e\u6536\u8d44\u672c100\u4e07\u5143\uff0c\u5219\u8be5\u516c\u53f8\u7684\u6240\u6709\u8005\u6743\u76ca\u4e3a____\u4e07\u5143\u3002\nA. 350\u4e07\u5143\nB. 200\u4e07\u5143\nC. 390\u4e07\u5143\nD. 100\u4e07\u5143\n",
        "output": "C. 390\u4e07\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5e86\u5174\u516c\u53f8\u662f\u4e00\u5bb6\u4e13\u4e3a\u5927\u578b\u5236\u9020\u4f01\u4e1a\u63d0\u4f9b\u6a61\u80f6\u8f6e\u80ce\u7684\u751f\u4ea7\u4f01\u4e1a\uff0c\u4ea7\u54c1\u4e3b\u8981\u9500\u5f80\u5168\u7403\u516d\u5341\u591a\u4e2a\u56fd\u5bb6\u3002\u5e86\u5174\u516c\u53f8\u4f1a\u9488\u5bf9\u4e0d\u540c\u7684\u7528\u6237\u63d0\u4f9b\u6807\u51c6\u4e0d\u540c\u7684\u8f6e\u80ce\uff0c\u6bd4\u5982\u98de\u673a\u5236\u9020\u5546\u6240\u9700\u7684\u8f6e\u80ce\u5c31\u4f1a\u6bd4\u8f7f\u8f66\u5236\u9020\u5546\u6240\u9700\u7684\u8f6e\u80ce\u5b89\u5168\u6807\u51c6\u8981\u9ad8\u51fa\u8bb8\u591a\u3002\u540c\u65f6\uff0c\u8be5\u516c\u53f8\u4f1a\u7ed3\u5408\u8d2d\u4e70\u529b\u3001\u8d2d\u4e70\u9891\u7387\u3001\u8d2d\u4e70\u65b9\u5f0f\u7b49\u6307\u6807\u5c06\u7528\u6237\u5212\u5206\u4e3a\u5927\u578b\u3001\u4e2d\u578b\u548c\u5c0f\u578b\uff0c\u5e76\u5bf9\u8fd9\u4e9b\u4e0d\u540c\u89c4\u6a21\u7684\u7528\u6237\u63d0\u4f9b\u4e0d\u540c\u7684\u8425\u9500\u7b56\u7565\u3002\u4f9d\u636e\u4ea7\u4e1a\u5e02\u573a\u7ec6\u5206\u7684\u53d8\u91cf\uff0c\u5e86\u5174\u516c\u53f8\u91c7\u7528\u7684\u4e0d\u5305\u62ec____\u3002\nA. \u7528\u6237\u7684\u884c\u4e1a\u7c7b\u522b\nB. \u7528\u6237\u7684\u5730\u7406\u4f4d\u7f6e\nC. \u8d2d\u4e70\u884c\u4e3a\u56e0\u7d20\nD. \u7528\u6237\u89c4\u6a21\n",
        "output": "B. \u7528\u6237\u7684\u5730\u7406\u4f4d\u7f6e",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u4e0b\u9762\u7684\u98ce\u9669\u56e0\u7d20\u4e2d\uff0c\u5c5e\u4e8e\u6280\u672f\u98ce\u9669\u56e0\u7d20\u7684\u662f____\u3002\nA. \u6c7d\u8f66\u5239\u8f66\u7cfb\u7edf\u5931\u7075\nB. \u5efa\u7b51\u7269\u65c1\u8fb9\u7684\u52a0\u6cb9\u7ad9\nC. \u9a7e\u9a76\u5458\u7684\u7c97\u5fc3\u5927\u610f\nD. \u6076\u610f\u6b3a\u8bc8\n",
        "output": "A. \u6c7d\u8f66\u5239\u8f66\u7cfb\u7edf\u5931\u7075",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4fdd\u9669\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u8d37\u6b3e\u903e\u671f\u662f\u53cd\u6620\u5ba2\u6237\u98ce\u9669\u7684\u5ba2\u89c2\u4fe1\u53f7\uff0c\u8d37\u6b3e\u903e\u671f\u8d85\u8fc7\u4e00\u5b9a\u671f\u9650\uff08\u598290\u5929\u4ee5\u4e0a\uff09\uff0c\u81f3\u5c11\u5e94\u5212\u5206\u4e3a____\u3002\nA. \u5173\u6ce8\u7c7b\nB. \u53ef\u7591\u7c7b\nC. \u635f\u5931\u7c7b\nD. \u6b21\u7ea7\u7c7b\n",
        "output": "D. \u6b21\u7ea7\u7c7b",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u81ea\u7136\u5931\u4e1a\u7387\u7684\u63cf\u8ff0\u54ea\u4e00\u4e2a\u662f\u6b63\u786e\u7684____\u3002\nA. \u81ea\u7136\u5931\u4e1a\u7387\u662f\u5386\u53f2\u4e0a\u6700\u4f4e\u9650\u5ea6\u6c34\u5e73\u7684\u5931\u4e1a\u7387\nB. \u81ea\u7136\u5931\u4e1a\u7387\u4e0e\u4e00\u56fd\u7684\u7ecf\u6d4e\u6548\u7387\u4e4b\u95f4\u5173\u7cfb\u5bc6\u5207\nC. \u81ea\u7136\u5931\u4e1a\u7387\u6052\u5b9a\u4e0d\u53d8\nD. \u81ea\u7136\u5931\u4e1a\u7387\u5305\u542b\u6469\u64e6\u6027\u5931\u4e1a\n",
        "output": "D. \u81ea\u7136\u5931\u4e1a\u7387\u5305\u542b\u6469\u64e6\u6027\u5931\u4e1a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u73b0\u4ee3\u91d1\u878d\u884d\u751f\u8bc1\u5238\u7684\u5b9a\u4ef7\u7406\u8bba\u6ca1\u6709\u5efa\u7acb\u5728\u4ee5\u4e0b\u54ea\u4e2a\u5047\u8bbe\u57fa\u7840____\u3002\nA. \u5e02\u573a\u4e0d\u5b58\u5728\u6469\u64e6\nB. \u5e02\u573a\u53c2\u4e0e\u8005\u65e0\u5bf9\u624b\u8fdd\u7ea6\u7684\u98ce\u9669\nC. \u5e02\u573a\u5b8c\u5168\u7ade\u4e89\nD. \u5e02\u573a\u5b58\u5728\u65e0\u98ce\u9669\u5957\u5229\u673a\u4f1a\n",
        "output": "D. \u5e02\u573a\u5b58\u5728\u65e0\u98ce\u9669\u5957\u5229\u673a\u4f1a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5de5\u7a0b\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u6295\u8d44\u51b3\u7b56\u4e2d\uff0c\u73b0\u91d1\u6d41\u91cf\u5206\u6790\u7684\u4e3b\u8981\u4f5c\u7528\u662f____\u3002\nA. \u8bc4\u4f30\u6295\u8d44\u9879\u76ee\u7684\u6301\u7eed\u76c8\u5229\u80fd\u529b\nB. \u6d4b\u7b97\u6295\u8d44\u9879\u76ee\u7684\u56de\u6536\u671f\nC. \u8bc4\u4f30\u6295\u8d44\u9879\u76ee\u7684\u98ce\u9669\nD. \u4f30\u8ba1\u6295\u8d44\u9879\u76ee\u7684\u73b0\u91d1\u6d41\u91cf\n",
        "output": "D. \u4f30\u8ba1\u6295\u8d44\u9879\u76ee\u7684\u73b0\u91d1\u6d41\u91cf",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u4e0b\u5173\u4e8e\u51c0\u73b0\u503c\u7684\u63cf\u8ff0\uff0c\u9519\u8bef\u7684\u662f____\u3002\nA. \u51c0\u73b0\u503c\u8d8a\u5927\u7684\u9879\u76ee\uff0c\u5176\u5185\u90e8\u62a5\u916c\u7387\u4e00\u5b9a\u8d8a\u9ad8\nB. \u9009\u5b9a\u878d\u8d44\u6210\u672c\u7387\u4e3a\u8d34\u73b0\u7387\uff0c\u51c0\u73b0\u503c\u5927\u4e8e\u96f6\u7684\u9879\u76ee\u662f\u6709\u5229\u53ef\u56fe\u7684\nC. \u8d34\u73b0\u7387\u8d8a\u9ad8\uff0c\u51c0\u73b0\u503c\u8d8a\u5c0f\nD. \u67d0\u9879\u76ee\u7684\u51c0\u73b0\u503c\u662f\u6307\u8be5\u9879\u76ee\u4ea7\u751f\u7684\u6240\u6709\u73b0\u91d1\u6d41\u7684\u73b0\u503c\u4e4b\u548c\n",
        "output": "A. \u51c0\u73b0\u503c\u8d8a\u5927\u7684\u9879\u76ee\uff0c\u5176\u5185\u90e8\u62a5\u916c\u7387\u4e00\u5b9a\u8d8a\u9ad8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u6211\u56fd\u4f1a\u8ba1\u51c6\u5219\u7684\u6709\u5173\u89c4\u5b9a\uff0c\u786e\u5b9a\u5408\u5e76\u8303\u56f4\u7684\u4e3b\u8981\u4f9d\u636e\u662f\u6bcd\u516c\u53f8\u4e0e\u88ab\u6295\u8d44\u5355\u4f4d\u4e4b\u95f4\u7684____\u3002\nA. \u5173\u8054\u5173\u7cfb\nB. \u63a7\u5236\u5173\u7cfb\nC. \u8d2d\u4e70\u5173\u7cfb\nD. \u7ba1\u7406\u5173\u7cfb\n",
        "output": "B. \u63a7\u5236\u5173\u7cfb",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f8\u662f\u4e00\u5bb6\u56fd\u6709\u4f01\u4e1a\uff0c\u516c\u53f8\u7ecf\u8425\u7a33\u5b9a\u3002\u5728\u7f16\u52362020\u5e74\u9884\u7b97\u65f6\uff0c\u516c\u53f8\u7ba1\u7406\u5c42\u8981\u6c42\u4ee5\u5b9e\u9645\u4e1a\u7ee9\u4f5c\u4e3a\u57fa\u7840\uff0c\u589e\u52a0\u76f8\u5e94\u7684\u5185\u5bb9\u3002\u6839\u636e\u4e0a\u8ff0\u4fe1\u606f\u53ef\u4ee5\u5224\u65ad\uff0c\u8be5\u516c\u53f8\u7684\u9884\u7b97\u7c7b\u578b\u5c5e\u4e8e____\u3002\nA. \u589e\u91cf\u9884\u7b97\nB. \u96f6\u57fa\u9884\u7b97\nC. \u52a8\u6001\u9884\u7b97\nD. \u9759\u6001\u9884\u7b97\n",
        "output": "A. \u589e\u91cf\u9884\u7b97",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u8fd0\u7528\u884d\u751f\u4ea7\u54c1\u8fdb\u884c\u98ce\u9669\u7ba1\u7406\u9700\u6ee1\u8db3\u7684\u6761\u4ef6\u4e0d\u5305\u62ec____\u3002\nA. \u6ee1\u8db3\u5408\u89c4\u8981\u6c42\nB. \u5efa\u7acb\u5b8c\u5584\u7684\u5916\u90e8\u63a7\u5236\u63aa\u65bd\nC. \u5408\u683c\u7684\u64cd\u4f5c\u4eba\u5458\nD. \u4e0e\u516c\u53f8\u7684\u4e1a\u52a1\u548c\u53d1\u5c55\u6218\u7565\u4fdd\u6301\u4e00\u81f4\n",
        "output": "B. \u5efa\u7acb\u5b8c\u5584\u7684\u5916\u90e8\u63a7\u5236\u63aa\u65bd",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5e02\u573a\u4e0d\u80fd\u63d0\u4f9b\u7eaf\u7cb9\u7684\u516c\u5171\u7269\u54c1\u662f\u56e0\u4e3a____\u3002\nA. \u516c\u5171\u7269\u54c1\u4e0d\u5177\u6709\u6392\u4ed6\u6027\nB. \u516c\u5171\u7269\u54c1\u4e0d\u5177\u6709\u7ade\u4e89\u6027\nC. \u6d88\u8d39\u8005\u90fd\u60f3\u201c\u514d\u8d39\u4e58\u8f66\u201d\nD. \u4ee5\u4e0a\u4e09\u79cd\u60c5\u51b5\u90fd\u662f\n",
        "output": "D. \u4ee5\u4e0a\u4e09\u79cd\u60c5\u51b5\u90fd\u662f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u516c\u53f8\u539f\u672c\u62e5\u6709\u4e09\u4e2a\u4ea7\u54c1\u4e8b\u4e1a\u90e8\uff0c\u6bcf\u4e2a\u4e8b\u4e1a\u90e8\u53ea\u6709\u4e00\u6761\u4ea7\u54c1\u7ebf\uff0c\u4f46\u662f\u901a\u8fc7\u6536\u8d2d\u53e6\u4e24\u5bb6\u516c\u53f8\uff0c\u4f01\u4e1a\u4e0d\u65ad\u6269\u5f20\u4ea7\u54c1\u7ebf\u3002\u8be5\u516c\u53f8\u7684\u7ed3\u6784\u8c03\u6574\u4e3a\u62e5\u6709\u4e09\u4e2a\u4e8b\u4e1a\u90e8\uff0c\u6bcf\u4e2a\u4e8b\u4e1a\u90e8\u90fd\u6709\u591a\u6761\u4ea7\u54c1\u7ebf\u3002\u76ee\u524d\u8be5\u516c\u53f8\u7684\u7ec4\u7ec7\u7ed3\u6784\u7684\u4f18\u70b9\u4e0d\u5305\u62ec____\u3002\nA. \u4fbf\u4e8e\u4f01\u4e1a\u6301\u7eed\u6210\u957f\nB. \u9996\u5e2d\u6267\u884c\u5b98\u6240\u5728\u7684\u603b\u90e8\u5458\u5de5\u7684\u5de5\u4f5c\u91cf\u4f1a\u6709\u6240\u51cf\u8f7b\nC. \u80fd\u591f\u901a\u8fc7\u8bf8\u5982\u8d44\u672c\u56de\u62a5\u7387\u7b49\u65b9\u6cd5\u5bf9\u4e8b\u4e1a\u90e8\u7684\u7ee9\u6548\u8fdb\u884c\u8d22\u52a1\u8bc4\u4f30\u548c\u6bd4\u8f83\nD. \u4e0e\u4ea7\u54c1\u4e3b\u7ba1\u548c\u804c\u80fd\u4e3b\u7ba1\u4e4b\u95f4\u7684\u8054\u7cfb\u66f4\u52a0\u76f4\u63a5\uff0c\u4ece\u800c\u80fd\u591f\u505a\u51fa\u66f4\u6709\u8d28\u91cf\u7684\u51b3\u7b56\n",
        "output": "D. \u4e0e\u4ea7\u54c1\u4e3b\u7ba1\u548c\u804c\u80fd\u4e3b\u7ba1\u4e4b\u95f4\u7684\u8054\u7cfb\u66f4\u52a0\u76f4\u63a5\uff0c\u4ece\u800c\u80fd\u591f\u505a\u51fa\u66f4\u6709\u8d28\u91cf\u7684\u51b3\u7b56",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u94f6\u884c\u8d26\u7c3f\u5229\u7387\u98ce\u9669\u7ba1\u7406\u63aa\u65bd\u4e0d\u5305\u62ec____\u3002\nA. \u5b8c\u5584\u94f6\u884c\u8d26\u7c3f\u5229\u7387\u98ce\u9669\u6cbb\u7406\u7ed3\u6784\nB. \u52a0\u5f3a\u8d44\u4ea7\u8d1f\u503a\u5339\u914d\u7ba1\u7406\nC. \u5b8c\u5584\u5546\u4e1a\u94f6\u884c\u7684\u5b9a\u4ef7\u673a\u5236\nD. \u5b9e\u65bd\u4e1a\u52a1\u5355\u4e00\u5316\u7684\u53d1\u5c55\u6218\u7565\n",
        "output": "D. \u5b9e\u65bd\u4e1a\u52a1\u5355\u4e00\u5316\u7684\u53d1\u5c55\u6218\u7565",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u751f\u4ea7\u51fd\u6570\u7684\u8981\u7d20\u66ff\u4ee3\u5f39\u6027\u8868\u793a\u7684\u662f____\u3002\nA. \u4e24\u79cd\u8981\u7d20\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\u7684\u53d8\u5316\u7387\u4e0e\u6bd4\u4f8b\u7684\u53d8\u5316\u7387\u4e4b\u6bd4\nB. \u7ef4\u6301\u4ea7\u51fa\u4e0d\u53d8\uff0c\u51cf\u5c11\u4e00\u5355\u4f4d\u7684\u67d0\u4e00\u8981\u7d20\u6295\u5165\uff0c\u9700\u589e\u52a0\u53e6\u4e00\u8981\u7d20\u6295\u5165\u6570\u91cf\nC. \u8981\u7d20\u66ff\u4ee3\u5f39\u6027\u7b49\u4e8e$\\frac{\\mathrm{d}\\ln(\\frac{K}{L})}{\\mathrm{d}\\ln(\\frac{MP_{L}}{MP_{K}})}$\nD. \u8981\u7d20\u7684\u66ff\u4ee3\u5f39\u6027\u5c31\u662f\u8981\u7d20\u7684\u8fb9\u9645\u66ff\u4ee3\u7387\n",
        "output": "C. \u8981\u7d20\u66ff\u4ee3\u5f39\u6027\u7b49\u4e8e$\\frac{\\mathrm{d}\\ln(\\frac{K}{L})}{\\mathrm{d}\\ln(\\frac{MP_{L}}{MP_{K}})}$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8ba1\u91cf\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u4fe1\u6258\u4e1a\u52a1\u7684\u98ce\u9669\u8d1f\u62c5\u4e0a\uff0c\u4fe1\u6258\u5b58\u6b3e\u7684\u98ce\u9669\u5168\u90e8\u7531____\u627f\u62c5\uff0c\u800c\u59d4\u6258\u8d37\u6b3e\u4e0e\u6295\u8d44\u7684\u4e3b\u8981\u98ce\u9669\u7531____\u627f\u62c5\u3002\nA. \u53d7\u6258\u4eba\u3001\u59d4\u6258\u65b9\nB. \u59d4\u6258\u65b9\u3001\u53d7\u6258\u65b9\nC. \u4e2d\u4ecb\u4eba\u3001\u59d4\u6258\u65b9\nD. \u62c5\u4fdd\u65b9\u3001\u59d4\u6258\u65b9\n",
        "output": "A. \u53d7\u6258\u4eba\u3001\u59d4\u6258\u65b9",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u592e\u94f6\u884c\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u671f\u8d27\u4ea4\u6613\u7684\u771f\u6b63\u76ee\u7684\u662f____\u3002\nA. \u4f5c\u4e3a\u4e00\u79cd\u5546\u54c1\u4ea4\u6362\u7684\u5de5\u5177\nB. \u51cf\u5c11\u4ea4\u6613\u8005\u6240\u627f\u62c5\u7684\u98ce\u9669\nC. \u8f6c\u8ba9\u5b9e\u7269\u8d44\u4ea7\u6216\u91d1\u878d\u8d44\u4ea7\u7684\u8d22\u4ea7\u6743\nD. \u4e0a\u8ff0\u8bf4\u6cd5\u90fd\u6b63\u786e\n",
        "output": "B. \u51cf\u5c11\u4ea4\u6613\u8005\u6240\u627f\u62c5\u7684\u98ce\u9669",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u57fa\u91d1\u6258\u7ba1\u4eba\u5bf9\u57fa\u91d1\u7ba1\u7406\u4eba\u7684\u4f30\u503c\u7ed3\u679c\u5373\u57fa\u91d1\u8d44\u4ea7\u51c0\u503c\u7684\u590d\u6838\uff0c\u4e0d\u5305\u62ec\u5bf9____\u7684\u6838\u5bf9\u3002\nA. \u57fa\u91d1\u4efd\u989d\u51c0\u503c\nB. \u57fa\u91d1\u4efd\u989d\u51c0\u503c\u53d8\u5316\u7387\nC. \u57fa\u91d1\u4efd\u989d\u7d2f\u8ba1\u51c0\u503c\nD. \u671f\u521d\u57fa\u91d1\u4efd\u989d\u51c0\u503c\n",
        "output": "B. \u57fa\u91d1\u4efd\u989d\u51c0\u503c\u53d8\u5316\u7387",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u4e0b\u54ea\u4e2a\u7406\u8bba\u7528\u4e8e\u89e3\u91ca\u8d44\u672c\u8d44\u4ea7\u5b9a\u4ef7\u6a21\u578b(CAPM)\u4e2d\u7684\u98ce\u9669\u548c\u6536\u76ca\u5173\u7cfb____\u3002\nA. \u5e02\u573a\u7ec4\u5408\nB. \u8d44\u672c\u5e02\u573a\u7ebf\nC. \u8bc1\u5238\u5e02\u573a\u7ebf\nD. \u8d44\u4ea7\u5e02\u573a\u7ebf\n",
        "output": "B. \u8d44\u672c\u5e02\u573a\u7ebf",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6700\u8fd1\u53d1\u8868\u7684\u4e00\u4efd\u62a5\u544a\u79f0\uff0c\u201c\u7531150\u90e8\u65b0\u8f66\u7ec4\u6210\u7684\u4e00\u4e2a\u6837\u672c\u8868\u660e\uff0c\u5916\u56fd\u65b0\u8f66\u7684\u4ef7\u683c\u660e\u663e\u9ad8\u4e8e\u672c\u56fd\u751f\u4ea7\u7684\u65b0\u8f66\u201d\u3002\u8fd9\u4e00\u7ed3\u8bba\u5c5e\u4e8e____\u3002\nA. \u5bf9\u6837\u672c\u7684\u63cf\u8ff0\nB. \u5bf9\u6837\u672c\u7684\u63a8\u65ad\nC. \u5bf9\u603b\u4f53\u7684\u63cf\u8ff0\nD. \u5bf9\u603b\u4f53\u7684\u63a8\u65ad\n",
        "output": "D. \u5bf9\u603b\u4f53\u7684\u63a8\u65ad",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u516c\u53f8\u7ba1\u7406\u5c42\u8d1f\u8d23\u6253\u9020\u804c\u4e1a\u9053\u5fb7\u6587\u5316\uff0c\u7ba1\u7406\u5c42\u53ef\u4ee5\u91c6\u53d6\u4ee5\u4e0b\u884c\u52a8\uff0c\u9664\u4e86____\u3002\nA. \u786e\u8ba4\u5e76\u6b63\u5f0f\u8bb0\u5f55\u7ec4\u7ec7\u7684\u4ef7\u503c\u89c2\nB. \u754c\u5b9a\u884c\u4e3a\u539f\u5219\nC. \u8bbe\u7acb\u62ab\u9732\u63ed\u53d1\u6e20\u9053\nD. \u5236\u5b9a\u4ef7\u503c\u89c2\u4e0e\u804c\u4e1a\u9053\u5fb7\u6216\u884c\u4e3a\u89c4\u8303\n",
        "output": "C. \u8bbe\u7acb\u62ab\u9732\u63ed\u53d1\u6e20\u9053",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u9009\u9879\u4e2d\uff0c____\u4e0d\u80fd\u4f5c\u4e3a\u4e2a\u4eba\u4f4f\u623f\u8d37\u6b3e\u8d28\u62bc\u62c5\u4fdd\u7684\u8d28\u7269\u3002\nA. \u56fd\u5bb6\u91cd\u70b9\u5efa\u8bbe\u503a\u5238\nB. \u4e58\u8f66\u7684\u53d1\u7968\nC. \u4e2a\u4eba\u5b9a\u671f\u50a8\u84c4\u5b58\u6b3e\u5b58\u5355\nD. \u8d22\u653f\u90e8\u53d1\u884c\u7684\u51ed\u8bc1\u5f0f\u56fd\u503a\n",
        "output": "B. \u4e58\u8f66\u7684\u53d1\u7968",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u4e0b\u65b9\u6cd5\u4e0d\u80fd\u589e\u52a0\u5ba1\u8ba1\u7a0b\u5e8f\u4e0d\u53ef\u9884\u89c1\u6027\u7684\u662f____\u3002\nA. \u5b9e\u5730\u76d8\u67e5\u4e00\u4e9b\u4ef7\u503c\u8f83\u4f4e\u7684\u56fa\u5b9a\u8d44\u4ea7\nB. \u51fd\u8bc1\u786e\u8ba4\u9500\u552e\u6761\u6b3e\nC. \u5728\u4e0d\u4e8b\u5148\u901a\u77e5\u88ab\u5ba1\u8ba1\u5355\u4f4d\u7684\u60c5\u51b5\u4e0b\uff0c\u9009\u62e9\u4e00\u4e9b\u4ee5\u524d\u672a\u66fe\u8bbf\u95ee\u8fc7\u7684\u76d8\u70b9\u5730\u70b9\u8fdb\u884c\u5b58\u8d27\u76d1\u76d8\nD. \u5bf9\u603b\u6536\u5165\u8fdb\u884c\u5206\u6790\n",
        "output": "D. \u5bf9\u603b\u6536\u5165\u8fdb\u884c\u5206\u6790",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u4e1a\u52a1\u4e2d\uff0c\u5e94\u5f53\u5f81\u6536\u589e\u503c\u7a0e\u7684\u662f____\u3002\nA. \u8d37\u6b3e\u5229\u606f\nB. \u5b58\u6b3e\u5229\u606f\nC. \u878d\u8d44\u6027\u552e\u540e\u56de\u79df\u4e1a\u52a1\u4e2d\u627f\u79df\u65b9\u51fa\u552e\u8d44\u4ea7\u53d6\u5f97\u7684\u6536\u5165\nD. \u88ab\u4fdd\u9669\u4eba\u83b7\u5f97\u7684\u4fdd\u9669\u8d54\u4ed8\n",
        "output": "A. \u8d37\u6b3e\u5229\u606f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u65b0\u53e4\u5178\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u7684\u7406\u8bba\u6e0a\u6e90\u662f____\u3002\nA. \u8d27\u5e01\u4e3b\u4e49\nB. \u4ef7\u683c\u673a\u5236\nC. \u653f\u5e9c\u5e72\u9884\nD. \u5e02\u573a\u7406\u8bba\n",
        "output": "A. \u8d27\u5e01\u4e3b\u4e49",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f820\u00d73\u5e747\u67081\u65e5\u81ea\u6bcd\u516c\u53f8\uff08\u4e01\u516c\u53f8\uff09\u53d6\u5f97\u4e59\u516c\u53f860$\\%$\u80a1\u6743\uff0c\u5f53\u65e5\uff0c\u4e59\u516c\u53f8\u4e2a\u522b\u8d22\u52a1\u62a5\u8868\u4e2d\u51c0\u8d44\u4ea7\u8d26\u9762\u4ef7\u503c\u4e3a3200\u4e07\u5143\u3002\u8be5\u80a1\u6743\u7cfb\u4e01\u516c\u53f8\u4e8e20\u00d71\u5e746\u6708\u81ea\u516c\u5f00\u5e02\u573a\u8d2d\u5165\uff0c\u4e01\u516c\u53f8\u5728\u8d2d\u5165\u4e59\u516c\u53f860$\\%$\u80a1\u6743\u65f6\u786e\u8ba4\u4e86800\u4e07\u5143\u5546\u8a89\u300220\u00d73\u5e747\u67081\u65e5\uff0c\u6309\u4e01\u516c\u53f8\u53d6\u5f97\u8be5\u80a1\u6743\u65f6\u4e59\u516c\u53f8\u53ef\u8fa8\u8ba4\u51c0\u8d44\u4ea7\u516c\u5141\u4ef7\u503c\u4e3a\u57fa\u7840\u6301\u7eed\u8ba1\u7b97\u7684\u4e59\u516c\u53f8\u53ef\u8fa8\u8ba4\u51c0\u8d44\u4ea7\u4ef7\u503c\u4e3a4800\u4e07\u5143\u3002\u4e3a\u8fdb\u884c\u8be5\u9879\u4ea4\u6613\uff0c\u7532\u516c\u53f8\u652f\u4ed8\u6709\u5173\u5ba1\u8ba1\u7b49\u4e2d\u4ecb\u673a\u6784\u8d39\u7528120\u4e07\u5143\u3002\u4e0d\u8003\u8651\u5176\u4ed6\u56e0\u7d20\uff0c\u7532\u516c\u53f8\u5e94\u786e\u8ba4\u5bf9\u4e59\u516c\u53f8\u80a1\u6743\u6295\u8d44\u7684\u521d\u59cb\u6295\u8d44\u6210\u672c\u662f____\u3002\nA. 1920\u4e07\u5143\nB. 2040\u4e07\u5143\nC. 2880\u4e07\u5143\nD. 3680\u4e07\u5143\n",
        "output": "D. 3680\u4e07\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u8d44\u672c\u4e3b\u4e49\u518d\u751f\u4ea7\u7684\u7279\u70b9\u662f\u6269\u5927\u518d\u751f\u4ea7\u3002\u8d44\u672c\u5bb6\u5c06\u83b7\u5f97\u5269\u4f59\u4ef7\u503c\u7684\u4e00\u90e8\u5206\u8f6c\u5316\u4e3a\u8d44\u672c\uff0c\u4f7f\u751f\u4ea7\u5728\u6269\u5927\u7684\u89c4\u6a21\u4e0a\u91cd\u590d\u8fdb\u884c\uff0c\u8fd9\u5c31\u662f\u8d44\u672c\u4e3b\u4e49\u6269\u5927\u518d\u751f\u4ea7\u3002\u8d44\u672c\u4e3b\u4e49\u6269\u5927\u518d\u751f\u4ea7\u7684\u6e90\u6cc9\u662f____\u3002\nA. \u8d44\u672c\u96c6\u4e2d\nB. \u8d44\u672c\u79ef\u7d2f\nC. \u8d44\u672c\u5faa\u73af\nD. \u8d44\u672c\u5468\u8f6c\n",
        "output": "B. \u8d44\u672c\u79ef\u7d2f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u653f\u6cbb\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u591a\u5143\u7ebf\u6027\u56de\u5f52\u6a21\u578b\u4e2d\uff0c\u82e5\u4ec5\u5b58\u5728\u591a\u91cd\u5171\u7ebf\u6027\uff0c\u5219____\u3002\nA. \u5728\u5b8c\u5168\u5171\u7ebf\u6027\u4e0b\uff0c\u53ef\u4ee5\u5f97\u5230\u53c2\u6570\u7684\u4f30\u8ba1\u91cf\nB. \u5728\u8fd1\u4f3c\u5171\u7ebf\u6027\u4e0b\uff0c\u53c2\u6570\u4f30\u8ba1\u91cf\u7684\u65b9\u5dee\u6700\u5c0f\nC. \u5728\u8fd1\u4f3c\u5171\u7ebf\u6027\u4e0b\uff0c\u53c2\u6570\u4f30\u8ba1\u91cf\u7684\u65b9\u5dee\u589e\u5927\nD. \u9700\u8981\u53d1\u5c55\u65b0\u7684\u65b9\u6cd5\u4f30\u8ba1\u8be5\u6a21\u578b\uff0c\u8fd9\u5305\u62ec\u666e\u901a\u6700\u5c0f\u4e8c\u4e58\u6cd5\u3001\u5dee\u5206\u6cd5\u7b49\n",
        "output": "D. \u9700\u8981\u53d1\u5c55\u65b0\u7684\u65b9\u6cd5\u4f30\u8ba1\u8be5\u6a21\u578b\uff0c\u8fd9\u5305\u62ec\u666e\u901a\u6700\u5c0f\u4e8c\u4e58\u6cd5\u3001\u5dee\u5206\u6cd5\u7b49",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8ba1\u91cf\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u8bc1\u5238\u6295\u8d44\u54a8\u8be2\u4eba\u5458\u4ece\u4e1a\u7ba1\u7406\uff0c\u8bf4\u6cd5\u9519\u8bef\u7684\u662f____\u3002\nA. \u8bc1\u5238\u6295\u8d44\u54a8\u8be2\u4eba\u5458\u901a\u8fc7\u6240\u5728\u673a\u6784\u5411\u4e2d\u56fd\u8bc1\u76d1\u4f1a\u767b\u8bb0\nB. \u5411\u5ba2\u6237\u63d0\u4f9b\u8bc1\u5238\u6295\u8d44\u987e\u95ee\u670d\u52a1\u7684\u4eba\u5458\uff0c\u5e94\u5f53\u7b26\u5408\u76f8\u5173\u4ece\u4e1a\u6761\u4ef6\uff0c\u5e76\u5728\u4e2d\u56fd\u8bc1\u5238\u4e1a\u534f\u4f1a\u767b\u8bb0\u4e3a\u8bc1\u5238\u6295\u8d44\u987e\u95ee\nC. \u8bc1\u5238\u6295\u8d44\u54a8\u8be2\u4eba\u5458\u4e0d\u5f97\u540c\u65f6\u57282\u4e2a\u6216\u80052\u4e2a\u4ee5\u4e0a\u7684\u8bc1\u5238\u6295\u8d44\u54a8\u8be2\u673a\u6784\u6267\u4e1a\nD. \u540c\u4e00\u4eba\u5458\u4e0d\u5f97\u540c\u65f6\u767b\u8bb0\u4e3a\u8bc1\u5238\u5206\u6790\u5e08\u548c\u8bc1\u5238\u6295\u8d44\u987e\u95ee\n",
        "output": "A. \u8bc1\u5238\u6295\u8d44\u54a8\u8be2\u4eba\u5458\u901a\u8fc7\u6240\u5728\u673a\u6784\u5411\u4e2d\u56fd\u8bc1\u76d1\u4f1a\u767b\u8bb0",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8bc1\u5238\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6309\u7167\u300a\u8bc1\u5238\u516c\u53f8\u5185\u90e8\u63a7\u5236\u6307\u5f151\u300b\u7684\u8981\u6c42\uff0c\u4e0b\u5217\u5173\u4e8e\u8bc1\u5238\u516c\u53f8\u53d7\u6258\u6295\u8d44\u7ba1\u7406\u4e1a\u52a1\u7684\u8868\u8ff0\uff0c\u8bf4\u6cd5\u9519\u8bef\u7684\u662f____\u3002\nA. \u53d7\u6258\u6295\u8d44\u7ba1\u7406\u4e1a\u52a1\u5e94\u4e0e\u81ea\u8425\u4e1a\u52a1\u4e25\u683c\u5206\u79bb\uff0c\u72ec\u7acb\u51b3\u7b56\u3001\u72ec\u7acb\u8fd0\u4f5c\nB. \u5bf9\u59d4\u6258\u4eba\u7684\u8d44\u4fe1\u72b6\u51b5\u3001\u6536\u76ca\u9884\u671f\u3001\u98ce\u9669\u627f\u53d7\u80fd\u529b\u3001\u6295\u8d44\u504f\u597d\u7b49\u8fdb\u884c\u4e86\u89e3\uff0c\u5e76\u5173\u6ce8\u59d4\u6258\u4eba\u8d44\u91d1\u6765\u6e90\u7684\u5408\u6cd5\u6027\nC. \u4e3a\u52a0\u5f3a\u5ba2\u6237\u5bf9\u8bc1\u5238\u516c\u53f8\u8d44\u7ba1\u6c34\u5e73\u7684\u4fe1\u4efb\uff0c\u53d7\u6258\u6295\u8d44\u7ba1\u7406\u5408\u540c\u4e2d\u53ef\u4ee5\u6709\u627f\u8bfa\u6536\u76ca\u6761\u6b3e\nD. \u5c01\u95ed\u8fd0\u4f5c\u3001\u4e13\u6237\u7ba1\u7406\u53d7\u6258\u8d44\u4ea7\uff0c\u786e\u4fdd\u5ba2\u6237\u8d44\u91d1\u4e0e\u81ea\u6709\u8d44\u91d1\u7684\u5206\u6237\u7ba1\u7406\u3001\u72ec\u7acb\u8fd0\u4f5c\n",
        "output": "C. \u4e3a\u52a0\u5f3a\u5ba2\u6237\u5bf9\u8bc1\u5238\u516c\u53f8\u8d44\u7ba1\u6c34\u5e73\u7684\u4fe1\u4efb\uff0c\u53d7\u6258\u6295\u8d44\u7ba1\u7406\u5408\u540c\u4e2d\u53ef\u4ee5\u6709\u627f\u8bfa\u6536\u76ca\u6761\u6b3e",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8bc1\u5238\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e3a\u4e86\u5728\u503a\u5238\u8bc4\u7ea7\u673a\u6784\u83b7\u5f97\u8f83\u9ad8\u8bc4\u7ea7\uff0c\u516c\u53f8\u5e94\u8be5\u5177\u6709____\u3002\nA. \u8f83\u4f4e\u7684\u5229\u606f\u4fdd\u969c\u500d\u6570\nB. \u8f83\u4f4e\u7684\u8d44\u4ea7\u8d1f\u503a\u6bd4\u7387\nC. \u8f83\u9ad8\u7684\u901f\u52a8\u6bd4\u7387\nD. \u8f83\u4f4e\u7684\u8d44\u4ea7\u8d1f\u503a\u6bd4\u7387\u548c\u8f83\u9ad8\u7684\u901f\u52a8\u6bd4\u7387\n",
        "output": "D. \u8f83\u4f4e\u7684\u8d44\u4ea7\u8d1f\u503a\u6bd4\u7387\u548c\u8f83\u9ad8\u7684\u901f\u52a8\u6bd4\u7387",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u804c\u4e1a\u9053\u5fb7\u57fa\u672c\u539f\u5219\u7684\u4fdd\u5bc6\u539f\u5219\u7684\u8bf4\u6cd5\u4e2d\uff0c\u9519\u8bef\u7684\u662f____\u3002\nA. \u4f1a\u5458\u5e94\u5f53\u5bf9\u6240\u5728\u4f1a\u8ba1\u5e08\u4e8b\u52a1\u6240\u3001\u5de5\u4f5c\u5355\u4f4d\u5185\u90e8\u7684\u6d89\u5bc6\u4fe1\u606f\u4fdd\u5bc6\nB. \u5728\u6cd5\u5f8b\u6cd5\u89c4\u6216\u804c\u4e1a\u51c6\u5219\u5141\u8bb8\u65f6\uff0c\u4f1a\u5458\u53ef\u4ee5\u4e0d\u7ecf\u5ba2\u6237\u6388\u6743\uff0c\u5411\u4f1a\u8ba1\u5e08\u4e8b\u52a1\u6240\u3001\u5de5\u4f5c\u5355\u4f4d\u4ee5\u5916\u7684\u7b2c\u4e09\u65b9\u900f\u9732\u5176\u6240\u83b7\u77e5\u7684\u6d89\u5bc6\u4fe1\u606f\nC. \u4f1a\u5458\u63a5\u53d7\u6ce8\u518c\u4f1a\u8ba1\u5e08\u534f\u4f1a\u6216\u76d1\u7ba1\u673a\u6784\u7684\u6267\u4e1a\u8d28\u91cf\u68c0\u67e5\u65f6\uff0c\u5e94\u5728\u5f81\u5f97\u5ba2\u6237\u7684\u540c\u610f\u540e\uff0c\u624d\u80fd\u7b54\u590d\u534f\u4f1a\u6216\u76d1\u7ba1\u673a\u6784\u7684\u8be2\u95ee\u548c\u8c03\u67e5\nD. \u6cd5\u5f8b\u6cd5\u89c4\u5141\u8bb8\u7684\u60c5\u51b5\u4e0b\uff0c\u5728\u6cd5\u5f8b\u8bc9\u8bbc\u3001\u4ef2\u88c1\u4e2d\u7ef4\u62a4\u81ea\u5df1\u7684\u5408\u6cd5\u6743\u76ca\u65f6\uff0c\u4f1a\u5458\u53ef\u4ee5\u62ab\u9732\u6d89\u5bc6\u4fe1\u606f\n",
        "output": "C. \u4f1a\u5458\u63a5\u53d7\u6ce8\u518c\u4f1a\u8ba1\u5e08\u534f\u4f1a\u6216\u76d1\u7ba1\u673a\u6784\u7684\u6267\u4e1a\u8d28\u91cf\u68c0\u67e5\u65f6\uff0c\u5e94\u5728\u5f81\u5f97\u5ba2\u6237\u7684\u540c\u610f\u540e\uff0c\u624d\u80fd\u7b54\u590d\u534f\u4f1a\u6216\u76d1\u7ba1\u673a\u6784\u7684\u8be2\u95ee\u548c\u8c03\u67e5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u76ee\u524d\u6211\u56fd\u300a\u516c\u53f8\u6cd5\u300b\u89c4\u5b9a\uff0c\u80a1\u4efd\u6709\u9650\u516c\u53f8\u6ce8\u518c\u8d44\u672c\u7684\u6700\u4f4e\u9650\u989d\u4e3a\u4eba\u6c11\u5e01____\u3002\nA. 5000\u4e07\u5143\nB. 3000\u4e07\u5143\nC. 1000\u4e07\u5143\nD. 500\u4e07\u5143\n",
        "output": "D. 500\u4e07\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u53ef\u8f6c\u6362\u503a\u5238\u7684\u63cf\u8ff0\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u4e0e\u666e\u901a\u503a\u5238\u76f8\u540c\nB. \u662f\u666e\u901a\u503a\u5238\u4e0e\u671f\u8d27\u7684\u590d\u5408\nC. \u662f\u5426\u8f6c\u6362\u7684\u6743\u5229\u5c5e\u4e8e\u53d1\u884c\u8005\nD. \u662f\u666e\u901a\u503a\u5238\u4e0e\u671f\u6743\u7684\u590d\u5408\n",
        "output": "D. \u662f\u666e\u901a\u503a\u5238\u4e0e\u671f\u6743\u7684\u590d\u5408",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5de5\u7a0b\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u4ee3\u7406\u7684\u8bf4\u6cd5\uff0c\u4e0d\u6b63\u786e\u7684\u662f____\u3002\nA. \u4ee3\u7406\u4eba\u5728\u4ee3\u7406\u6743\u9650\u5185\uff0c\u4ee5\u88ab\u4ee3\u7406\u4eba\u7684\u540d\u4e49\u5b9e\u65bd\u6c11\u4e8b\u6cd5\u5f8b\u884c\u4e3a\nB. \u6c11\u4e8b\u4e3b\u4f53\u53ef\u4ee5\u901a\u8fc7\u4ee3\u7406\u4eba\u5b9e\u65bd\u6c11\u4e8b\u6cd5\u5f8b\u884c\u4e3a\nC. \u6cd5\u5b9a\u4ee3\u7406\u4eba\u6309\u7167\u88ab\u4ee3\u7406\u4eba\u7684\u59d4\u6258\u884c\u4f7f\u4ee3\u7406\u6743\nD. \u4f9d\u7167\u6cd5\u5f8b\u89c4\u5b9a\u3001\u5f53\u4e8b\u4eba\u7ea6\u5b9a\u6216\u8005\u6c11\u4e8b\u6cd5\u5f8b\u884c\u4e3a\u7684\u6027\u8d28\uff0c\u5e94\u5f53\u7531\u672c\u4eba\u4eb2\u81ea\u5b9e\u65bd\u7684\u6c11\u4e8b\u6cd5\u5f8b\u884c\u4e3a\uff0c\u4e0d\u5f97\u4ee3\u7406\n",
        "output": "C. \u6cd5\u5b9a\u4ee3\u7406\u4eba\u6309\u7167\u88ab\u4ee3\u7406\u4eba\u7684\u59d4\u6258\u884c\u4f7f\u4ee3\u7406\u6743",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u7406\u6027\u9884\u671f\u7684\u603b\u4f9b\u7ed9\u51fd\u6570\uff0c\u53ea\u8981\u4e2d\u592e\u94f6\u884c\u516c\u5f00\u5ba3\u5e03\u63d0\u9ad8\u8d27\u5e01\u589e\u957f\u7387\uff0c\u5219____\u3002\nA. \u5931\u4e1a\u7387\u548c\u901a\u8d27\u81a8\u80c0\u7387\u4f1a\u4e0a\u5347\nB. \u5931\u4e1a\u7387\u4e0d\u53d8\uff0c\u901a\u8d27\u81a8\u80c0\u7387\u4e0a\u5347\nC. \u5931\u4e1a\u7387\u548c\u901a\u8d27\u81a8\u80c0\u7387\u90fd\u4e0d\u53d1\u751f\u53d8\u5316\nD. \u5931\u4e1a\u7387\u4e0a\u5347\uff0c\u901a\u8d27\u81a8\u80c0\u7387\u4e0d\u4e00\u5b9a\u4e0a\u5347\n",
        "output": "B. \u5931\u4e1a\u7387\u4e0d\u53d8\uff0c\u901a\u8d27\u81a8\u80c0\u7387\u4e0a\u5347",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u56fd\u7cbe\u7b97\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "2020\u5e741\u67083\u65e5\uff0c\u7532\u516c\u53f8\u4ee5\u4e00\u9879\u56fa\u5b9a\u8d44\u4ea7\uff08\u4e0d\u52a8\u4ea7\uff09\u4f5c\u4e3a\u5bf9\u4ef7\uff0c\u53d6\u5f97\u4e59\u516c\u53f840$\\%$\u6709\u8868\u51b3\u6743\u8d44\u672c\uff0c\u80fd\u591f\u5bf9\u4e59\u516c\u53f8\u65bd\u52a0\u91cd\u5927\u5f71\u54cd\u3002\u7532\u516c\u53f8\u4ed8\u51fa\u7684\u8be5\u9879\u56fa\u5b9a\u8d44\u4ea7\u539f\u4ef7\u4e3a5600\u4e07\u5143\uff0c\u5df2\u63d0\u6298\u65e71000\u4e07\u5143\uff0c\u672a\u8ba1\u63d0\u51cf\u503c\u51c6\u5907\uff0c\u5f53\u65e5\u7684\u516c\u5141\u4ef7\u503c\u4e3a4000\u4e07\u5143\u3002\u53d6\u5f97\u8be5\u9879\u6295\u8d44\u65f6\uff0c\u4e59\u516c\u53f8\u6240\u6709\u8005\u6743\u76ca\u8d26\u9762\u4ef7\u503c\u4e3a11000\u4e07\u5143\uff0c\u53ef\u8fa8\u8ba4\u51c0\u8d44\u4ea7\u516c\u5141\u4ef7\u503c\u4e3a12000\u4e07\u5143\u3002\u53d6\u5f97\u8be5\u9879\u80a1\u6743\u6295\u8d44\u8fc7\u7a0b\u4e2d\u7532\u516c\u53f8\u53e6\u53d1\u751f\u624b\u7eed\u8d39\u7b49100\u4e07\u5143\u3002\u53cc\u65b9\u91c7\u7528\u7684\u4f1a\u8ba1\u653f\u7b56\u3001\u4f1a\u8ba1\u671f\u95f4\u76f8\u540c\u3002\u7532\u516c\u53f8\u53d6\u5f97\u8be5\u9879\u80a1\u6743\u6295\u8d44\u65f6\u5f71\u54cd2020\u5e74\u5ea6\u7684\u5229\u6da6\u603b\u989d\u4e3a____\u4e07\u5143\u3002\nA. 700\nB. -600\nC. 100\nD. 200\n",
        "output": "C. 100",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u535a\u5f08\u4e2d\uff0c\u5c40\u4e2d\u4eba\u4ece\u4e00\u4e2a\u535a\u5f08\u4e2d\u5f97\u5230\u7684\u7ed3\u679c\u88ab\u79f0\u4e3a____\u3002\nA. \u6536\u76ca\nB. \u652f\u4ed8\nC. \u51b3\u7b56\nD. \u5229\u6da6\n",
        "output": "B. \u652f\u4ed8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u542b\u6709$G$\u4e2a\u5185\u751f\u53d8\u91cf\u7684\u5b8c\u5907\u8054\u7acb\u65b9\u7a0b\u7ec4\u4e2d\uff0c\u5f53\u8bc6\u522b\u7684\u9636\u6761\u4ef6\u4e3a$M-N_{i}<G-1$\uff08$M$\u4e3a\u8054\u7acb\u65b9\u7a0b\u7ec4\u4e2d\u5185\u751f\u53d8\u91cf\u548c\u524d\u5b9a\u53d8\u91cf\u7684\u603b\u6570\uff0c$N_{i}$\u4e3a\u7b2c$i\u4e2a\u65b9\u7a0b\u4e2d\u5185\u751f\u53d8\u91cf\u548c\u524d\u5b9a\u53d8\u91cf\u7684\u603b\u6570\uff09\u65f6\uff0c\u5219\u8868\u793a____\u3002\nA. \u7b2c$i$\u4e2a\u65b9\u7a0b\u6070\u597d\u8bc6\u522b\nB. \u7b2c$i$\u4e2a\u65b9\u7a0b\u4e0d\u53ef\u8bc6\u522b\nC. \u7b2c$i$\u4e2a\u65b9\u7a0b\u8fc7\u5ea6\u8bc6\u522b\nD. \u7b2c$i$\u4e2a\u65b9\u7a0b\u5177\u6709\u552f\u4e00\u7edf\u8ba1\u5f62\u5f0f\n",
        "output": "B. \u7b2c$i$\u4e2a\u65b9\u7a0b\u4e0d\u53ef\u8bc6\u522b",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8ba1\u91cf\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6295\u8d44\u8005\u5728\u83b7\u5f97\u7ea6\u5b9a\u7684____\u6536\u76ca\u7387\u540e\uff0c\u7ba1\u7406\u4eba\u624d\u80fd\u83b7\u5f97\u4e1a\u7ee9\u62a5\u916c\u3002\nA. \u6700\u5c11\nB. \u95e8\u69db\nC. \u6700\u9ad8\nD. \u4ee5\u4e0a\u90fd\u662f\n",
        "output": "D. \u4ee5\u4e0a\u90fd\u662f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e3a\u4e86\u4f30\u8ba1\u67d0\u57ce\u5e02\u4e2d\u62e5\u6709\u7a7a\u8c03\u7684\u5bb6\u5ead\u6bd4\u4f8b\uff0c\u62bd\u53d6500\u4e2a\u5bb6\u5ead\u7684\u4e00\u4e2a\u6837\u672c\uff0c\u5f97\u5230\u62e5\u6709\u7a7a\u8c03\u7684\u5bb6\u5ead\u6bd4\u4f8b\u4e3a80$\\%$\uff0c\u8fd9\u91cc\u768480$\\%$\u662f____\u3002\nA. \u53c2\u6570\u503c\nB. \u7edf\u8ba1\u91cf\u7684\u503c\nC. \u6837\u672c\u91cf\nD. \u53d8\u91cf\n",
        "output": "B. \u7edf\u8ba1\u91cf\u7684\u503c",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "A\u516c\u53f8\u6301\u6709B\u516c\u53f820$\\%$\u7684\u80a1\u6743\uff0c\u8be5\u957f\u671f\u80a1\u6743\u6295\u8d44\u53d6\u5f97\u65f6\u786e\u8ba4\u5546\u8a8920\u4e07\u5143\uff0c\u622a\u81f32020\u5e741\u67081\u65e5\u957f\u671f\u80a1\u6743\u6295\u8d44\u8d26\u9762\u4ef7\u503c\u4e3a1500\u4e07\u5143\uff08\u660e\u7ec6\u79d1\u76ee\u4e3a\u6210\u672c1000\u4e07\u5143\uff0c\u635f\u76ca\u8c03\u6574400\u4e07\u5143\uff0c\u5176\u4ed6\u6743\u76ca\u53d8\u52a8100\u4e07\u5143\uff09\u3002\u5f53\u65e5A\u516c\u53f8\u53c8\u4ee52800\u4e07\u5143\u4e3a\u5bf9\u4ef7\u53d6\u5f97B\u516c\u53f835$\\%$\u7684\u80a1\u6743\uff0c\u6b3e\u9879\u4ee5\u94f6\u884c\u5b58\u6b3e\u652f\u4ed8\uff0c\u5f53\u65e5B\u516c\u53f8\u53ef\u8fa8\u8ba4\u51c0\u8d44\u4ea7\u516c\u5141\u4ef7\u503c\u603b\u989d\u4e3a13500\u4e07\u5143\uff0c\u53d6\u5f97\u8be5\u90e8\u5206\u80a1\u6743\u540e\uff0cA\u516c\u53f8\u80fd\u591f\u5bf9B\u516c\u53f8\u5b9e\u65bd\u63a7\u5236\uff0c\u56e0\u6b64A\u516c\u53f8\u5c06\u5bf9B\u516c\u53f8\u7684\u80a1\u6743\u6295\u8d44\u8f6c\u4e3a\u6210\u672c\u6cd5\u6838\u7b97\u3002A\u516c\u53f82020\u5e74\u521d\u65b0\u589e\u6295\u8d44\u4e1a\u52a1\u5bf9\u5176\u7559\u5b58\u6536\u76ca\u7684\u5f71\u54cd\u91d1\u989d\u4e3a____\u3002\nA. -600\u4e07\u5143\nB. -500\u4e07\u5143\nC. 0\nD. -540\u4e07\u5143\n",
        "output": "C. 0",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "M\u516c\u53f8\u6700\u521d\u662f\u4e00\u5bb6\u7535\u5b50\u5546\u52a1\u4f01\u4e1a\uff0c\u540e\u6765\u6210\u957f\u4e3a\u4e1a\u52a1\u6db5\u76d6\u7f51\u4e0a\u5546\u57ce\u3001\u9910\u996e\u3001\u9152\u5e97\u548c\u7269\u6d41\u7684\u5927\u578b\u591a\u5143\u5316\u516c\u53f8\u3002M\u516c\u53f8\u7684\u53d1\u5c55\u4f53\u73b0\u4e86\u516c\u53f8____\u3002\nA. \u7ecf\u8425\u54f2\u5b66\u7684\u53d8\u5316\nB. \u5b97\u65e8\u7684\u53d8\u5316\nC. \u516c\u53f8\u76ee\u7684\u7684\u53d8\u5316\nD. \u6218\u8def\u5c42\u6b21\u7684\u53d8\u5316\n",
        "output": "B. \u5b97\u65e8\u7684\u53d8\u5316",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "2020\u5e743\u6708\uff0c\u67d0\u8fdb\u51fa\u53e3\u516c\u53f8\u8fdb\u53e3\u540c\u724c\u53f7\u5c0f\u8f7f\u8f6620\u8f86\uff0c\u5b8c\u7a0e\u4ef7\u683c\u5408\u8ba1400\u4e07\u5143\u4eba\u6c11\u5e01\uff1b\u5173\u7a0e\u7a0e\u989d120\u4e07\u5143\uff1b\u6d88\u8d39\u7a0e51.43\u4e07\u5143\uff1b\u589e\u503c\u7a0e74.29\u4e07\u5143\uff0c\u8be5\u516c\u53f8\u5c0613\u8f86\u5c0f\u8f7f\u8f66\u552e\u51fa\uff0c2\u8f86\u5956\u52b1\u7ed9\u4f18\u79c0\u5458\u5de5\uff0c4\u8f86\u5f85\u552e\uff0c1\u8f86\u7559\u672c\u5355\u4f4d\u4f7f\u7528\u3002\u5219\u8be5\u516c\u53f8\u5e94\u7eb3\u8f66\u8f86\u8d2d\u7f6e\u7a0e\u7a0e\u989d____\u4e07\u5143\u3002\nA. 1.82\nB. 2.86\nC. 5.71\nD. 8.57\n",
        "output": "B. 2.86",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6309\u5b8c\u5de5\u4ea7\u54c1\u548c\u6708\u672b\u5728\u4ea7\u54c1\u6570\u91cf\u6bd4\u4f8b\u5206\u914d\u8ba1\u7b97\u5b8c\u5de5\u4ea7\u54c1\u548c\u6708\u672b\u5728\u4ea7\u54c1\u7684\u539f\u6750\u6599\u8d39\u7528\uff0c\u5fc5\u987b\u5177\u5907\u7684\u6761\u4ef6\u662f____\u3002\nA. \u539f\u6750\u6599\u968f\u751f\u4ea7\u8fdb\u5ea6\u9646\u7eed\u6295\u5165\nB. \u539f\u6750\u6599\u5728\u751f\u4ea7\u5f00\u59cb\u65f6\u4e00\u6b21\u6295\u5165\nC. \u539f\u6750\u6599\u6d88\u8017\u5b9a\u989d\u6bd4\u8f83\u51c6\u786e\u7a33\u5b9a\nD. \u4ea7\u54c1\u6210\u672c\u4e2d\u539f\u6750\u6599\u8d39\u7528\u6bd4\u91cd\u8f83\u5927\n",
        "output": "B. \u539f\u6750\u6599\u5728\u751f\u4ea7\u5f00\u59cb\u65f6\u4e00\u6b21\u6295\u5165",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u53d8\u52a8\u6210\u672c\u6cd5\u7684\u5c40\u9650\u6027\u5305\u62ec\u54ea\u4e9b\u65b9\u9762____\u3002\nA. \u5ffd\u7565\u56fa\u5b9a\u6210\u672c\u7684\u5f71\u54cd\nB. \u8ba1\u7b97\u590d\u6742\u5ea6\u9ad8\nC. \u4e0d\u80fd\u9002\u7528\u4e8e\u6279\u91cf\u751f\u4ea7\nD. \u65e0\u6cd5\u53cd\u6620\u4f01\u4e1a\u7684\u6210\u672c\u7ed3\u6784\n",
        "output": "A. \u5ffd\u7565\u56fa\u5b9a\u6210\u672c\u7684\u5f71\u54cd",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "Williams\u662f\u4e00\u540d\u4f1a\u8ba1\u804c\u5458\uff0c\u5176\u5e74\u6536\u5165\u4e3a35000\u3002Williams\u51b3\u5b9a\u8f9e\u53bb\u73b0\u5728\u7684\u5de5\u4f5c\u5e76\u53c2\u52a0\u4e3a\u671f\u4e00\u5e74\u7684\u5168\u65e5\u5236MBA\u9879\u76ee\u3002\u5047\u8bbeWilliams\u5728\u8fd9\u4e00\u5e74\u5185\u4e0d\u4f1a\u4ece\u4e8b\u4efb\u4f55\u5168\u804c\u5de5\u4f5c\u6216\u517c\u804c\u5de5\u4f5c\u3002\u4ed6\u5168\u5e74\u7684\u5b66\u8d39\u3001\u4e66\u672c\u8d39\u3001\u751f\u6d3b\u8d39\u548c\u5176\u4ed6\u82b1\u8d39\u5171\u8ba125000\u3002\u6839\u636e\u4ee5\u4e0a\u4fe1\u606f\uff0cWilliams\u7684MBA\u5b66\u4e60\u7684\u5e74\u5ea6\u603b\u7ecf\u6d4e\u6210\u672c\u4e3a____\u3002\nA. 10000\nB. 35000\nC. 25000\nD. 60000\n",
        "output": "D. 60000",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u4e0b\u4e0d\u5c5e\u4e8e\u8d44\u672c\u5e02\u573a\u529f\u80fd\u7684\u6709____\u3002\nA. \u8d44\u672c\u5e02\u573a\u662f\u8d44\u6e90\u5408\u7406\u914d\u7f6e\u7684\u6709\u6548\u573a\u6240\nB. \u8d44\u672c\u5e02\u573a\u662f\u7b79\u96c6\u8d44\u91d1\u7684\u91cd\u8981\u6e20\u9053\nC. \u4e3a\u4e2d\u592e\u94f6\u884c\u516c\u5f00\u5e02\u573a\u64cd\u4f5c\u63d0\u4f9b\u4e86\u573a\u6240\nD. \u8d44\u672c\u5e02\u573a\u6709\u5229\u4e8e\u4fc3\u8fdb\u4ea7\u4e1a\u7ed3\u6784\u5411\u9ad8\u7ea7\u5316\u65b9\u5411\u53d1\u5c55\n",
        "output": "C. \u4e3a\u4e2d\u592e\u94f6\u884c\u516c\u5f00\u5e02\u573a\u64cd\u4f5c\u63d0\u4f9b\u4e86\u573a\u6240",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d27\u5e01\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u4eba\u4e8e\u7b2c\u4e00\u5e74\u5e74\u521d\u5411\u94f6\u884c\u501f\u6b3e30000\u5143\uff0c\u9884\u8ba1\u5728\u672a\u6765\u6bcf\u5e74\u5e74\u672b\u507f\u8fd8\u501f\u6b3e6000\u5143\uff0c\u8fde\u7eed10\u5e74\u8fd8\u6e05\uff0c\u5219\u8be5\u9879\u8d37\u6b3e\u7684\u5e74\u5229\u7387\u4e3a____\u3002\nA. 20$\\%$\nB. 14$\\%$\nC. 16.13$\\%$\nD. 15.13$\\%$\n",
        "output": "D. 15.13$\\%$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u56fd\u9645\u6536\u652f\u7684\u7f3a\u53e3\u662f\u6307____\u3002\nA. \u9519\u8bef\u4e0e\u9057\u6f0f\nB. \u7ecf\u5e38\u9879\u76ee\u4e0e\u8d44\u672c\u9879\u76ee\u7684\u5dee\u989d\nC. \u56fd\u9645\u6536\u652f\u5dee\u989d\nD. \u57fa\u672c\u5dee\u989d\n",
        "output": "C. \u56fd\u9645\u6536\u652f\u5dee\u989d",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d27\u5e01\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e00\u53ea\u606f\u7968\u503a\u5238\u7684\u5356\u51fa\u4ef7\u5728\u300a\u534e\u5c14\u8857\u65e5\u62a5\u300b\u4e0a\u663e\u793a\u4e3a1080\uff08\u4e5f\u5c31\u662f\u9762\u503c1000\u7f8e\u5143\u7684108$\\%$\uff09\uff0c\u5982\u679c\u6700\u540e\u4e00\u6b21\u7684\u5229\u606f\u652f\u4ed8\u662f\u4e24\u4e2a\u6708\u4ee5\u524d\uff0c\u606f\u7968\u7387\u4e3a12$\\%$\uff0c\u90a3\u4e48\u8fd9\u53ea\u503a\u5238\u7684\u53d1\u7968\u4ef7\u683c\u662f____\u7f8e\u5143\u3002\nA. 1080\nB. 1100\nC. 1120\nD. 1210\n",
        "output": "B. 1100",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e00\u540d\u7814\u7a76\u4eba\u5458\u5e0c\u671b\u901a\u8fc7\u56fe\u5f62\u6765\u8bf4\u660e4\u6708\u4efd\u4ee5\u6765\u5317\u4eac\u5730\u533a\u4e8c\u624b\u623f\u79df\u91d1\u6bcf\u5929\u7684\u53d8\u5316\uff0c\u5982\u4e0b____\u6700\u5408\u9002\u3002\nA. 1\nB. \u6563\u70b9\u56fe\nC. \u6298\u7ebf\u56fe\nD. \u830e\u53f6\u56fe\n",
        "output": "C. \u6298\u7ebf\u56fe",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u94f6\u884c\u7406\u8d22\u4ea7\u54c1\u8981\u7d20\u5305\u542b\u7684\u4fe1\u606f\u4e0d\u5305\u62ec____\u3002\nA. \u4ea7\u54c1\u5f00\u53d1\u4e3b\u4f53\u4fe1\u606f\nB. \u4ea7\u54c1\u5f00\u53d1\u5ba2\u4f53\u4fe1\u606f\nC. \u4ea7\u54c1\u76ee\u6807\u5ba2\u6237\u4fe1\u606f\nD. \u4ea7\u54c1\u7279\u5f81\u4fe1\u606f\n",
        "output": "B. \u4ea7\u54c1\u5f00\u53d1\u5ba2\u4f53\u4fe1\u606f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u57ce\u9547\u571f\u5730\u4f7f\u7528\u7a0e\u5f81\u6536\u65b9\u6cd5\u7684\u8868\u8ff0\u4e2d\uff0c\u7b26\u5408\u7a0e\u6cd5\u89c4\u5b9a\u7684\u662f____\u3002\nA. \u6309\u6708\u8ba1\u7b97\u7f34\u7eb3\nB. \u6309\u5b63\u8ba1\u7b97\u7f34\u7eb3\nC. \u6309\u5e74\u8ba1\u7b97\u3001\u5206\u671f\u7f34\u7eb3\nD. \u6309\u534a\u5e74\u8ba1\u7b97\u3001\u5206\u671f\u7f34\u7eb3\n",
        "output": "C. \u6309\u5e74\u8ba1\u7b97\u3001\u5206\u671f\u7f34\u7eb3",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6ce8\u518c\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u671f\u8d27\u4ea4\u6613\u6240\u7684\u98ce\u9669\u4e2d\uff0c____\u6307\u7531\u4e8e\u4ea4\u6613\u6240\u7684\u98ce\u9669\u7ba1\u7406\u5236\u5ea6\u4e0d\u5065\u5168\u6216\u8005\u6267\u884c\u98ce\u9669\u7ba1\u7406\u5236\u5ea6\u4e0d\u4e25\u3001\u4ea4\u6613\u8005\u8fdd\u89c4\u64cd\u4f5c\u7b49\u539f\u56e0\u6240\u9020\u6210\u7684\u98ce\u9669\uff0c____\u662f\u6307\u7531\u4e8e\u8ba1\u7b97\u673a\u4ea4\u6613\u7cfb\u7edf\u6216\u901a\u4fe1\u4fe1\u606f\u7cfb\u7edf\u51fa\u73b0\u6545\u969c\u800c\u5e26\u6765\u7684\u98ce\u9669\u3002\nA. \u7ba1\u7406\u98ce\u9669;\u6280\u672f\u98ce\u9669\nB. \u7ed3\u7b97\u98ce\u9669;\u6280\u672f\u98ce\u9669\nC. \u7ba1\u7406\u98ce\u9669;\u4ea4\u6613\u98ce\u9669\nD. \u6cd5\u5f8b\u98ce\u9669;\u7cfb\u7edf\u98ce\u9669\n",
        "output": "A. \u7ba1\u7406\u98ce\u9669;\u6280\u672f\u98ce\u9669",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u671f\u8d27\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u4e0d\u5c5e\u4e8e\u516c\u53f8\u4fe1\u8d37\u7ba1\u7406\u7684\u539f\u5219\u7684\u662f____\u3002\nA. \u8bda\u4fe1\u7533\u8d37\u539f\u5219\nB. \u534f\u8bae\u627f\u8bfa\u539f\u5219\nC. \u8d37\u540e\u7ba1\u7406\u539f\u5219\nD. \u8d37\u524d\u7ba1\u7406\u539f\u5219\n",
        "output": "D. \u8d37\u524d\u7ba1\u7406\u539f\u5219",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ec0\u4e48\u662f\u884d\u751f\u5de5\u5177\u7684\u516c\u5141\u4ef7\u503c\u5957\u671f\u4fdd\u503c____\u3002\nA. \u4e00\u79cd\u7528\u4e8e\u964d\u4f4e\u884d\u751f\u5de5\u5177\u7684\u516c\u5141\u4ef7\u503c\u6ce2\u52a8\u98ce\u9669\u7684\u7b56\u7565\nB. \u4e00\u79cd\u7528\u4e8e\u63d0\u9ad8\u884d\u751f\u5de5\u5177\u7684\u516c\u5141\u4ef7\u503c\u6ce2\u52a8\u98ce\u9669\u7684\u7b56\u7565\nC. \u4e00\u79cd\u7528\u4e8e\u589e\u52a0\u884d\u751f\u5de5\u5177\u7684\u6536\u76ca\u7684\u7b56\u7565\nD. \u4e00\u79cd\u7528\u4e8e\u51cf\u5c11\u884d\u751f\u5de5\u5177\u7684\u6536\u76ca\u7684\u7b56\u7565\n",
        "output": "A. \u4e00\u79cd\u7528\u4e8e\u964d\u4f4e\u884d\u751f\u5de5\u5177\u7684\u516c\u5141\u4ef7\u503c\u6ce2\u52a8\u98ce\u9669\u7684\u7b56\u7565",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u671f\u8d27\u4ea4\u6613\u65b9\u5f0f\u4e2d\u4e92\u8054\u7f51\u4ea4\u6613\u7684\u8868\u8ff0\uff0c\u9519\u8bef\u7684\u662f____\u3002\nA. \u5ba2\u6237\u901a\u8fc7\u4e92\u8054\u7f51\u4e0b\u8fbe\u4ea4\u6613\u6307\u4ee4\u7684\uff0c\u671f\u8d27\u516c\u53f8\u5e94\u5f53\u4ee5\u9002\u5f53\u7684\u65b9\u5f0f\u4fdd\u5b58\u8be5\u4ea4\u6613\u6307\u4ee4\nB. \u671f\u8d27\u516c\u53f8\u4e3a\u5ba2\u6237\u63d0\u4f9b\u4e92\u8054\u7f51\u59d4\u6258\u670d\u52a1\u7684\uff0c\u5e94\u5f53\u5bf9\u5ba2\u6237\u8fdb\u884c\u4e92\u8054\u7f51\u4ea4\u6613\u98ce\u9669\u7684\u7279\u522b\u63d0\u793a\nC. \u5ba2\u6237\u901a\u8fc7\u4e92\u8054\u7f51\u4e0b\u8fbe\u4ea4\u6613\u6307\u4ee4\u7684\uff0c\u671f\u8d27\u516c\u53f8\u5e94\u5f53\u8fdb\u884c\u5ba2\u6237\u4ea4\u6613\u6307\u4ee4\u5ba1\u6838\nD. \u671f\u8d27\u516c\u53f8\u5fc5\u987b\u4e3a\u5ba2\u6237\u63d0\u4f9b\u4e92\u8054\u7f51\u59d4\u6258\u670d\u52a1\n",
        "output": "D. \u671f\u8d27\u516c\u53f8\u5fc5\u987b\u4e3a\u5ba2\u6237\u63d0\u4f9b\u4e92\u8054\u7f51\u59d4\u6258\u670d\u52a1",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u671f\u8d27\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e3a\u4fdd\u6301\u5236\u5ea6\u7a33\u5b9a\u6027\u548c\u8fde\u7eed\u6027\u3001\u4fdd\u62a4\u6295\u8d44\u8005\u5408\u7406\u9884\u671f\uff0c\u6839\u636e\u300a\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u5916\u5546\u6295\u8d44\u6cd5\u300b\u89c4\u5b9a\uff0c\u4f9d\u7167\u201c\u5916\u8d44\u4e09\u6cd5\u201d\u5df2\u7ecf\u8bbe\u7acb\u7684\u5916\u5546\u6295\u8d44\u4f01\u4e1a\uff0c\u5728\u8be5\u6cd5\u65bd\u884c\u540e\u4e00\u5b9a\u5e74\u9650\u5185\u53ef\u4ee5\u7ee7\u7eed\u4fdd\u7559\u539f\u4f01\u4e1a\u7ec4\u7ec7\u5f62\u5f0f\u3002\u8be5\u5e74\u9650\u662f____\u3002\nA. 1\u5e74\nB. 3\u5e74\nC. 10\u5e74\nD. 5\u5e74\n",
        "output": "D. 5\u5e74",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f8\u4e0b\u5217\u7ecf\u6d4e\u4e1a\u52a1\u4e2d\uff0c\u5e94\u4f5c\u4e3a\u4e3b\u8981\u8d23\u4efb\u4eba\u7684\u662f____\u3002\nA. \u7532\u516c\u53f8\u4eceA\u822a\u7a7a\u516c\u53f8\u8d2d\u4e70\u6298\u6263\u673a\u7968\uff0c\u5bf9\u5916\u9500\u552e\u65f6\uff0c\u53ef\u81ea\u884c\u51b3\u5b9a\u552e\u4ef7\uff0c\u4f46\u672a\u51fa\u552e\u673a\u7968\u4e0d\u80fd\u9000\u56deA\u822a\u7a7a\u516c\u53f8\nB. \u7532\u516c\u53f8\u4eceA\u822a\u7a7a\u516c\u53f8\u8d2d\u4e70\u6298\u6263\u673a\u7968\uff0c\u5bf9\u5916\u9500\u552e\u65f6\uff0cA\u822a\u7a7a\u516c\u53f8\u51b3\u5b9a\u673a\u7968\u552e\u4ef7\uff0c\u672a\u51fa\u552e\u673a\u7968\u7531A\u822a\u7a7a\u516c\u53f8\u6536\u56de\nC. \u7532\u516c\u53f8\u8fd0\u8425\u4e00\u4e2a\u8d2d\u7269\u7f51\u7ad9\uff0c\u7531\u96f6\u552e\u5546\u8d1f\u8d23\u5546\u54c1\u5b9a\u4ef7\u3001\u53d1\u8d27\u53ca\u552e\u540e\u670d\u52a1\u7b49\uff0c\u7532\u516c\u53f8\u4ec5\u6536\u53d6\u4e00\u5b9a\u624b\u7eed\u8d39\u7528\nD. \u7532\u516c\u53f8\u7ecf\u8425\u7684\u5546\u573a\u4e2d\u8bbe\u7acb\u6709B\u54c1\u724c\u670d\u88c5\u4e13\u67dc\uff0cB\u54c1\u724c\u670d\u88c5\u7ecf\u9500\u5546\u81ea\u884c\u51b3\u5b9a\u5546\u54c1\u5b9a\u4ef7\u3001\u9500\u552e\u7b49\u60c5\u51b5\uff0c\u6309\u5e74\u652f\u4ed8\u5546\u573a\u7ecf\u8425\u8d39\u7528\uff0c\u7532\u516c\u53f8\u65e0\u6743\u5e72\u9884B\u4e13\u67dc\u7684\u7ecf\u8425\u6d3b\u52a8\n",
        "output": "A. \u7532\u516c\u53f8\u4eceA\u822a\u7a7a\u516c\u53f8\u8d2d\u4e70\u6298\u6263\u673a\u7968\uff0c\u5bf9\u5916\u9500\u552e\u65f6\uff0c\u53ef\u81ea\u884c\u51b3\u5b9a\u552e\u4ef7\uff0c\u4f46\u672a\u51fa\u552e\u673a\u7968\u4e0d\u80fd\u9000\u56deA\u822a\u7a7a\u516c\u53f8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u627f\u79df\u4eba\u5bf9\u878d\u8d44\u79df\u5165\u7684\u8d44\u4ea7\u91c7\u7528\u516c\u5141\u4ef7\u503c\u4f5c\u4e3a\u5165\u8d26\u4ef7\u503c\u7684\uff0c\u5206\u644a\u672a\u786e\u8ba4\u878d\u8d44\u8d39\u7528\u6240\u91c7\u7528\u7684\u5206\u644a\u7387\u662f____\u3002\nA. \u94f6\u884c\u540c\u671f\u8d37\u6b3e\u5229\u7387\nB. \u79df\u8d41\u5408\u540c\u4e2d\u89c4\u5b9a\u7684\u5229\u7387\nC. \u51fa\u79df\u4eba\u51fa\u79df\u8d44\u4ea7\u7684\u65e0\u98ce\u9669\u5229\u7387\nD. \u4f7f\u6700\u4f4e\u79df\u8d41\u4ed8\u6b3e\u989d\u7684\u73b0\u503c\u4e0e\u79df\u8d41\u8d44\u4ea7\u516c\u5141\u4ef7\u503c\u76f8\u7b49\u7684\u6298\u73b0\u7387\n",
        "output": "D. \u4f7f\u6700\u4f4e\u79df\u8d41\u4ed8\u6b3e\u989d\u7684\u73b0\u503c\u4e0e\u79df\u8d41\u8d44\u4ea7\u516c\u5141\u4ef7\u503c\u76f8\u7b49\u7684\u6298\u73b0\u7387",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7406\u8d22\u89c4\u5212\u5e08\u6536\u96c6\u5ba2\u6237\u4fe1\u606f\u65f6\uff0c\u505a\u6cd5\u4e0d\u6b63\u786e\u7684\u662f____\u3002\nA. \u4e13\u4e1a\u7406\u8d22\u5e08\u8981\u505a\u7684\u4e0d\u662f\u7ea0\u7ed3\u4e8e\u81ea\u5df1\u662f\u5426\u4f1a\u89e6\u72af\u5ba2\u6237\u7684\u9690\u79c1\uff0c\u6216\u8005\u5ba2\u6237\u4f1a\u4e0d\u4f1a\u544a\u8bc9\u81ea\u5df1\uff0c\u800c\u662f\u628a\u91cd\u5fc3\u653e\u5728\u5f15\u5bfc\u5ba2\u6237\u3001\u4e86\u89e3\u5176\u8d22\u52a1\u95ee\u9898\u548c\u6d89\u53ca\u7684\u5176\u4ed6\u5bb6\u5ead\u8d22\u52a1\u4fe1\u606f\u4e0a\nB. \u5f15\u5bfc\u5ba2\u6237\uff0c\u544a\u8bc9\u5ba2\u6237\u4e3a\u4ec0\u4e48\u6211\u4eec\u8981\u4e86\u89e3\u8fd9\u4e9b\u4fe1\u606f\uff0c\u6211\u4eec\u80fd\u901a\u8fc7\u8fd9\u4e9b\u4fe1\u606f\uff0c\u53ef\u4ee5\u5411\u4ed6\u53cd\u9988\u54ea\u4e9b\u80fd\u591f\u5e2e\u52a9\u4ed6\u505a\u597d\u5bb6\u5ead\u8d22\u52a1\u51b3\u5b9a\u7684\u8d44\u8baf\nC. \u5728\u5177\u4f53\u63d0\u95ee\u7684\u65f6\u5019\uff0c\u5c3d\u53ef\u80fd\u5148\u56f4\u7ed5\u5ba2\u6237\u5173\u5fc3\u7684\u95ee\u9898\uff0c\u4e0d\u8981\u53bb\u95ee\u90a3\u4e9b\u4e0e\u5176\u4e0d\u76f8\u5173\u7684\u4fe1\u606f\nD. \u5bf9\u5ba2\u6237\u7684\u5404\u65b9\u9762\u4fe1\u606f\u4f5c\u5168\u9762\u4e86\u89e3\uff0c\u5305\u62ec\u9690\u79c1\n",
        "output": "D. \u5bf9\u5ba2\u6237\u7684\u5404\u65b9\u9762\u4fe1\u606f\u4f5c\u5168\u9762\u4e86\u89e3\uff0c\u5305\u62ec\u9690\u79c1",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5173\u4e8eProbit\u6a21\u578b\u548cLogit\u6a21\u578b\u7684\u53c2\u6570\u4f30\u8ba1\uff0c\u4e0b\u5217\u8868\u8ff0\u9519\u8bef\u7684\u662f____\u3002\nA. \u5728\u91cd\u590d\u89c2\u6d4b\u503c\u4e0d\u53ef\u5f97\u7684\u60c5\u5f62\u4e0b\uff0cLogit\u6a21\u578b\u53ef\u91c7\u7528\u5b8c\u5168\u4fe1\u606f\u6700\u5927\u4f3c\u7136\u6cd5\u4e2d\u6240\u91c7\u7528\u7684\u8fed\u4ee3\u65b9\u6cd5\nB. \u5728\u91cd\u590d\u89c2\u6d4b\u503c\u53ef\u5f97\u7684\u60c5\u5f62\u4e0b\uff0c\u4e24\u6a21\u578b\u53ef\u91c7\u7528\u5e7f\u4e49\u6700\u5c0f\u4e8c\u4e58\u6cd5\nC. \u5728\u91cd\u590d\u89c2\u6d4b\u503c\u4e0d\u53ef\u5f97\u7684\u60c5\u5f62\u4e0b\uff0c\u4e24\u6a21\u578b\u53ef\u91c7\u7528\u5b8c\u5168\u4fe1\u606f\u6700\u5927\u4f3c\u7136\u6cd5\nD. \u5728\u91cd\u590d\u89c2\u6d4b\u503c\u4e0d\u53ef\u5f97\u548c\u53ef\u5f97\u4e24\u79cd\u60c5\u5f62\u4e0b\uff0c\u4e24\u6a21\u578b\u90fd\u8981\u91c7\u7528\u5b8c\u5168\u4fe1\u606f\u6700\u5927\u4f3c\u7136\u4f30\u8ba1\u7684\u8fed\u4ee3\u6cd5\n",
        "output": "D. \u5728\u91cd\u590d\u89c2\u6d4b\u503c\u4e0d\u53ef\u5f97\u548c\u53ef\u5f97\u4e24\u79cd\u60c5\u5f62\u4e0b\uff0c\u4e24\u6a21\u578b\u90fd\u8981\u91c7\u7528\u5b8c\u5168\u4fe1\u606f\u6700\u5927\u4f3c\u7136\u4f30\u8ba1\u7684\u8fed\u4ee3\u6cd5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8ba1\u91cf\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u6837\u672c\u7edf\u8ba1\u91cf\u4f30\u8ba1\u603b\u4f53\u53c2\u6570\u65f6\uff0c\u8981\u6c42\u4f30\u8ba1\u91cf\u7684\u6570\u5b66\u671f\u671b\u7b49\u4e8e\u88ab\u4f30\u8ba1\u7684\u603b\u4f53\u53c2\u6570\uff0c\u8fd9\u4e00\u6570\u5b66\u6027\u8d28\u79f0\u4e3a____\u3002\nA. \u65e0\u504f\u6027\nB. \u6709\u6548\u6027\nC. \u4e00\u81f4\u6027\nD. \u671f\u671b\u6027\n",
        "output": "A. \u65e0\u504f\u6027",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u8d44\u672c\u662f\u5728\u8fd0\u52a8\u4e2d\u589e\u6b96\u7684\uff0c\u8d44\u672c\u5468\u800c\u590d\u59cb\u3001\u4e0d\u65ad\u53cd\u590d\u5faa\u73af\uff0c\u53eb\u4f5c\u8d44\u672c\u7684\u5468\u8f6c\u3002\u5982\u679c\u6bcf\u6b21\u8d44\u672c\u5468\u8f6c\u5e26\u6765\u7684\u5269\u4f59\u4ef7\u503c\u4e00\u5b9a\uff0c\u5219\u8d44\u672c\u5468\u8f6c\u8d8a\u5feb\uff0c\u5728\u4e00\u5b9a\u65f6\u671f\u5185\u5e26\u6765\u7684\u5269\u4f59\u4ef7\u503c\u5c31\u8d8a\u591a\u3002\u5f71\u54cd\u8d44\u672c\u5468\u8f6c\u5feb\u6162\u7684\u5173\u952e\u56e0\u7d20\u6709____\u3002\u2160.\u751f\u4ea7\u8d44\u672c\u4e2d\u56fa\u5b9a\u8d44\u672c\u548c\u6d41\u52a8\u8d44\u672c\u7684\u6784\u6210\u2161.\u53ef\u53d8\u8d44\u672c\u589e\u591a\u2162.\u8d44\u672c\u6709\u673a\u6784\u6210\u2163.\u8d44\u672c\u5468\u8f6c\u65f6\u95f4\nA. \u2160,\u2161,\u2162,\u2163\nB. \u2161,\u2162,\u2163\nC. \u2160,\u2161,\u2162\nD. \u2160,\u2163\n",
        "output": "D. \u2160,\u2163",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u653f\u6cbb\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u539f\u5219\u4e0a\u5e94\u91c7\u7528\u8d37\u6b3e\u4eba\u53d7\u6258\u652f\u4ed8\u65b9\u5f0f\u7684\u60c5\u5f62\u4e0d\u5305\u62ec____\u3002\nA. \u5bf9\u4e8e\u6d41\u52a8\u8d44\u91d1\u8d37\u6b3e\uff0c\u8d37\u6b3e\u4eba\u4e0e\u501f\u6b3e\u4eba\u65b0\u5efa\u7acb\u4fe1\u8d37\u4e1a\u52a1\u5173\u7cfb\u4e14\u501f\u6b3e\u4eba\u4fe1\u7528\u72b6\u51b5\u826f\u597d\nB. \u5bf9\u4e8e\u6d41\u52a8\u8d44\u91d1\u8d37\u6b3e\uff0c\u652f\u4ed8\u5bf9\u8c61\u660e\u786e\u4e14\u5355\u7b14\u652f\u4ed8\u91d1\u989d\u8f83\u5927\nC. \u5bf9\u4e8e\u56fa\u5b9a\u8d44\u4ea7\u8d37\u6b3e\uff0c\u5355\u7b14\u91d1\u989d\u8d85\u8fc7\u9879\u76ee\u603b\u6295\u8d44\u76845$\\%$\nD. \u5bf9\u4e8e\u56fa\u5b9a\u8d44\u4ea7\u8d37\u6b3e\uff0c\u5355\u7b14\u91d1\u989d\u8d85\u8fc7500\u4e07\u5143\u4eba\u6c11\u5e01\n",
        "output": "A. \u5bf9\u4e8e\u6d41\u52a8\u8d44\u91d1\u8d37\u6b3e\uff0c\u8d37\u6b3e\u4eba\u4e0e\u501f\u6b3e\u4eba\u65b0\u5efa\u7acb\u4fe1\u8d37\u4e1a\u52a1\u5173\u7cfb\u4e14\u501f\u6b3e\u4eba\u4fe1\u7528\u72b6\u51b5\u826f\u597d",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e3a\u4e86\u4e86\u89e3\u88ab\u5ba1\u8ba1\u5355\u4f4d\u53ca\u5176\u73af\u5883\uff0c\u6ce8\u518c\u4f1a\u8ba1\u5e08\u5fc5\u987b\u5b9e\u65bd\u7684\u98ce\u9669\u8bc4\u4f30\u7a0b\u5e8f\u662f____\u3002\nA. \u8be2\u95ee\u3001\u89c2\u5bdf\nB. \u8ffd\u8e2a\u4ea4\u6613\u5728\u8d22\u52a1\u62a5\u544a\u4fe1\u606f\u7cfb\u7edf\u4e2d\u7684\u5904\u7406\u8fc7\u7a0b\nC. \u5b9e\u65bd\u5206\u6790\u7a0b\u5e8f\u4ee5\u8bc6\u522b\u5f02\u5e38\u7684\u4ea4\u6613\u6216\u4e8b\u9879\uff0c\u4ee5\u53ca\u5bf9\u8d22\u52a1\u62a5\u8868\u548c\u5ba1\u8ba1\u4ea7\u751f\u5f71\u54cd\u7684\u91d1\u989d\u3001\u6bd4\u7387\u548c\u8d8b\u52bf\nD. \u51fd\u8bc1\n",
        "output": "C. \u5b9e\u65bd\u5206\u6790\u7a0b\u5e8f\u4ee5\u8bc6\u522b\u5f02\u5e38\u7684\u4ea4\u6613\u6216\u4e8b\u9879\uff0c\u4ee5\u53ca\u5bf9\u8d22\u52a1\u62a5\u8868\u548c\u5ba1\u8ba1\u4ea7\u751f\u5f71\u54cd\u7684\u91d1\u989d\u3001\u6bd4\u7387\u548c\u8d8b\u52bf",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u6b63\u5411\u5e02\u573a\u4e0a\uff0c\u5957\u5229\u4ea4\u6613\u8005\u4e70\u51655\u6708\u5927\u8c46\u671f\u8d27\u5408\u7ea6\u7684\u540c\u65f6\u5356\u51fa9\u6708\u5927\u8c46\u671f\u8d27\u5408\u7ea6\uff0c\u5219\u8be5\u4ea4\u6613\u8005\u9884\u671f____\u3002\nA. \u672a\u6765\u4ef7\u5dee\u4e0d\u786e\u5b9a\nB. \u672a\u6765\u4ef7\u5dee\u4e0d\u53d8\nC. \u672a\u6765\u4ef7\u5dee\u6269\u5927\nD. \u672a\u6765\u4ef7\u5dee\u7f29\u5c0f\n",
        "output": "D. \u672a\u6765\u4ef7\u5dee\u7f29\u5c0f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u671f\u8d27\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u4e2a\u4eba\u4f4f\u623f\u8d37\u6b3e\u7684\u8d37\u540e\u7ba1\u7406\u4e2d\uff0c\u5c31\u5408\u540c\u4e3b\u4f53\u53d8\u66f4\u4e8b\u9879\u8868\u8ff0\u9519\u8bef\u7684\u662f____\u3002\nA. \u7ecf\u5ba1\u6279\u540c\u610f\u53d8\u66f4\u501f\u6b3e\u5408\u540c\u4e3b\u4f53\u540e\uff0c\u8d37\u6b3e\u94f6\u884c\u4e0e\u53d8\u66f4\u540e\u7684\u501f\u6b3e\u4eba\u3001\u62c5\u4fdd\u4eba\u91cd\u65b0\u7b7e\u8ba2\u6709\u5173\u5408\u540c\u6587\u672c\nB. \u5728\u62b5\uff08\u8d28\uff09\u62bc\u767b\u8bb0\u53d8\u66f4\u7b49\u624b\u7eed\u529e\u59a5\u540e\uff0c\u7ecf\u529e\u4eba\u586b\u5199\u4e2a\u4eba\u4f4f\u623f\u501f\u6b3e\u5408\u540c\u4e3b\u4f53\u53d8\u66f4\u901a\u77e5\u4e66\uff0c\u8fde\u540c\u4e00\u4efd\u501f\u6b3e\u5408\u540c\u4ea4\u4f1a\u8ba1\u90e8\u95e8\u529e\u7406\u6709\u5173\u501f\u6b3e\u4e3b\u4f53\u53d8\u66f4\u4e8b\u5b9c\nC. \u65b0\u5408\u540c\u501f\u6b3e\u5229\u7387\u6309\u65b0\u5408\u540c\u5229\u7387\u7ea6\u5b9a\u6267\u884c\nD. \u65b0\u5408\u540c\u501f\u6b3e\u5229\u7387\u6309\u539f\u5408\u540c\u5229\u7387\u7ea6\u5b9a\u6267\u884c\n",
        "output": "C. \u65b0\u5408\u540c\u501f\u6b3e\u5229\u7387\u6309\u65b0\u5408\u540c\u5229\u7387\u7ea6\u5b9a\u6267\u884c",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u8bc1\u5238\u6cd5\u5f8b\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u5173\u4e8e\u533a\u57df\u6027\u80a1\u6743\u5e02\u573a\u76f8\u5173\u89c4\u5219\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u53ef\u91c7\u7528\u534f\u8bae\u8f6c\u8ba9\u7684\u65b9\u5f0f\u8fdb\u884c\u4ea4\u6613\nB. \u53ef\u5c06\u6743\u76ca\u62c6\u5206\u4e3a\u5747\u7b49\u4efd\u989d\u516c\u5f00\u53d1\u884c\nC. \u53ef\u5c06\u6743\u76ca\u6309\u7167\u6807\u51c6\u5316\u4ea4\u6613\u5355\u4f4d\u6301\u7eed\u6302\u724c\u4ea4\u6613\nD. \u6743\u76ca\u6301\u6709\u4eba\u7d2f\u79ef\u53ef\u8d85\u8fc7200\u4eba\n",
        "output": "A. \u53ef\u91c7\u7528\u534f\u8bae\u8f6c\u8ba9\u7684\u65b9\u5f0f\u8fdb\u884c\u4ea4\u6613",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u9879\u76ee\u4e0d\u5c5e\u4e8e\u8d27\u5e01\u6027\u8d44\u4ea7\u6027\u8d28\u7684\u662f____\u3002\nA. \u73b0\u91d1\nB. \u94f6\u884c\u5b58\u6b3e\nC. \u65e0\u5f62\u8d44\u4ea7\nD. \u5e94\u6536\u8d26\u6b3e\n",
        "output": "C. \u65e0\u5f62\u8d44\u4ea7",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6309\u7167\u300a\u8bc1\u5238\u6cd5\u300b\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u60c5\u5f62\uff0c\u5c5e\u4e8e\u516c\u5f00\u53d1\u884c\u8bc1\u5238\u7684\u662f____\u3002\nA. \u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u8bc1\u5238\u7d2f\u8ba1\u672a\u8d85\u8fc7200\u4eba\nB. \u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u8bc1\u5238\u7d2f\u8ba1210\u4eba\uff0c\u5176\u4e2d\u4e0d\u5305\u542b\u4f9d\u6cd5\u5b9e\u65bd\u5458\u5de5\u6301\u80a1\u8ba1\u5212\u7684\u5458\u5de5\u4eba\u6570\nC. \u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u8bc1\u5238\u7d2f\u8ba1210\u4eba\uff0c\u5176\u4e2d\u5305\u542b\u4f9d\u6cd5\u5b9e\u65bd\u5458\u5de5\u6301\u80a1\u8ba1\u5212\u7684\u5458\u5de520\u4eba\nD. \u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u8bc1\u5238\u7684\n",
        "output": "B. \u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u8bc1\u5238\u7d2f\u8ba1210\u4eba\uff0c\u5176\u4e2d\u4e0d\u5305\u542b\u4f9d\u6cd5\u5b9e\u65bd\u5458\u5de5\u6301\u80a1\u8ba1\u5212\u7684\u5458\u5de5\u4eba\u6570",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8bc1\u5238\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "20\u00d74\u5e742\u67081\u65e5\uff0c\u7532\u516c\u53f8\u4ee5\u589e\u53d11000\u4e07\u80a1\u672c\u516c\u53f8\u666e\u901a\u80a1\u80a1\u7968\u548c\u4e00\u53f0\u5927\u578b\u8bbe\u5907\u4e3a\u5bf9\u4ef7\uff0c\u53d6\u5f97\u4e59\u516c\u53f825$\\%$\u80a1\u6743\u3002\u5176\u4e2d\uff0c\u6240\u53d1\u884c\u666e\u901a\u80a1\u9762\u503c\u4e3a\u6bcf\u80a11\u5143\uff0c\u516c\u5141\u4ef7\u503c\u4e3a\u6bcf\u80a110\u5143\u3002\u4e3a\u589e\u53d1\u80a1\u4efd\uff0c\u7532\u516c\u53f8\u5411\u8bc1\u5238\u627f\u9500\u673a\u6784\u7b49\u652f\u4ed8\u4f63\u91d1\u548c\u624b\u7eed\u8d39400\u4e07\u5143\u3002\u7528\u4f5c\u5bf9\u4ef7\u7684\u8bbe\u5907\u8d26\u9762\u4ef7\u503c\u4e3a1000\u4e07\u5143\uff0c\u516c\u5141\u4ef7\u503c\u4e3a1200\u4e07\u5143\u3002\u5f53\u65e5\uff0c\u4e59\u516c\u53f8\u53ef\u8fa8\u8ba4\u51c0\u8d44\u4ea7\u516c\u5141\u4ef7\u503c\u4e3a40000\u4e07\u5143\u3002\u5047\u5b9a\u7532\u516c\u53f8\u80fd\u591f\u5bf9\u4e59\u516c\u53f8\u65bd\u52a0\u91cd\u5927\u5f71\u54cd\u3002\u4e0d\u8003\u8651\u5176\u4ed6\u56e0\u7d20\uff0c\u7532\u516c\u53f8\u8be5\u9879\u957f\u671f\u80a1\u6743\u6295\u8d44\u7684\u521d\u59cb\u6295\u8d44\u6210\u672c\u662f____\u3002\nA. 10000\u4e07\u5143\nB. 11000\u4e07\u5143\nC. 11200\u4e07\u5143\nD. 11600\u4e07\u5143\n",
        "output": "C. 11200\u4e07\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u9009\u53d6\u6d4b\u8bd5\u9879\u76ee\u7684\u65b9\u6cd5\u7684\u8bf4\u6cd5\u4e2d\uff0c\u4e0d\u6b63\u786e\u7684\u662f____\u3002\nA. \u5982\u679c\u88ab\u5ba1\u8ba1\u5355\u4f4d\u7684\u63a7\u5236\u73af\u5883\u826f\u597d\uff0c\u6ce8\u518c\u4f1a\u8ba1\u5e08\u53ef\u4ee5\u66f4\u591a\u5730\u5728\u671f\u4e2d\u5b9e\u65bd\u8fdb\u4e00\u6b65\u5ba1\u8ba1\u7a0b\u5e8f\nB. \u5b58\u5728\u7279\u5b9a\u98ce\u9669\u65f6\uff0c\u53ef\u4ee5\u9009\u53d6\u5168\u90e8\u9879\u76ee\u8fdb\u884c\u6d4b\u8bd5\nC. \u7531\u4e8e\u4fe1\u606f\u7cfb\u7edf\u81ea\u52a8\u6267\u884c\u7684\u8ba1\u7b97\uff0c\u9009\u53d6\u5168\u90e8\u9879\u76ee\u8fdb\u884c\u68c0\u67e5\u7b26\u5408\u6210\u672c\u6548\u76ca\u539f\u5219\nD. \u6ce8\u518c\u4f1a\u8ba1\u5e08\u4ece\u603b\u4f53\u4e2d\u7684\u7279\u5b9a\u9879\u76ee\u4e2d\u9009\u53d6\u4e00\u90e8\u5206\u8fdb\u884c\u9488\u5bf9\u6027\u6d4b\u8bd5\uff0c\u5373\u91c7\u7528\u5ba1\u8ba1\u62bd\u6837\n",
        "output": "D. \u6ce8\u518c\u4f1a\u8ba1\u5e08\u4ece\u603b\u4f53\u4e2d\u7684\u7279\u5b9a\u9879\u76ee\u4e2d\u9009\u53d6\u4e00\u90e8\u5206\u8fdb\u884c\u9488\u5bf9\u6027\u6d4b\u8bd5\uff0c\u5373\u91c7\u7528\u5ba1\u8ba1\u62bd\u6837",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u5047\u8bbe\u68c0\u9a8c\u4e2d\uff0c\u5982\u679c\u6211\u4eec\u76f8\u4fe1\u539f\u5047\u8bbe\u662f\u771f\u7684\uff0c\u800c\u72af\u7b2c\u2161\u7c7b\u9519\u8bef\u53c8\u4e0d\u4f1a\u9020\u6210\u592a\u5927\u7684\u5f71\u54cd\uff0c\u6b64\u65f6\uff0c\u68c0\u9a8c\u7684\u663e\u8457\u6027\u6c34\u5e73\u5e94\u8be5____\u3002\nA. \u5927\u4e9b\nB. \u5c0f\u4e9b\nC. \u65e0\u6cd5\u786e\u5b9a\nD. \u7b49\u4e8e0.05\n",
        "output": "B. \u5c0f\u4e9b",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ece\u6295\u8d44\u89d2\u5ea6\u6765\u770b\uff0c\u6295\u8d44\u57fa\u91d1\u56fd\u9645\u5316\u7684\u610f\u4e49\u4e0d\u5305\u62ec____\u3002\nA. \u81ea\u7531\u5730\u9009\u62e9\u6295\u8d44\u5730\u57df\u548c\u6295\u8d44\u6807\u7684\nB. \u8f83\u5927\u5e45\u5ea6\u5730\u51cf\u5c11\u975e\u7cfb\u7edf\u6027\u98ce\u9669\nC. \u8d44\u4ea7\u89c4\u6a21\u7684\u6269\u5927\uff0c\u80fd\u4f7f\u57fa\u91d1\u7ba1\u7406\u516c\u53f8\u4ee5\u8f83\u5c11\u7684\u5355\u4f4d\u6210\u672c\u83b7\u53d6\u8f83\u5927\u7684\u89c4\u6a21\u6548\u76ca\nD. \u628a\u63e1\u4e0d\u540c\u533a\u57df\u7684\u6295\u8d44\u673a\u4f1a\uff0c\u6700\u5927\u5316\u57fa\u91d1\u6295\u8d44\u8005\u5229\u76ca\n",
        "output": "B. \u8f83\u5927\u5e45\u5ea6\u5730\u51cf\u5c11\u975e\u7cfb\u7edf\u6027\u98ce\u9669",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u94f6\u884c\u4e1a\u6d88\u8d39\u8005\u5728\u94f6\u884c\u6d88\u8d39\u8fc7\u7a0b\u4e2d\uff0c\u9664\u8d2d\u4e70\u94f6\u884c\u5df2\u6709\u98ce\u9669\u63d0\u793a\u7c7b\u7684\u4ea7\u54c1\u800c\u9020\u6210\u7684\u635f\u5931\u5916\uff0c\u5176\u4ed6\u975e\u56e0\u81ea\u5df1\u6545\u610f\u6216\u8005\u8fc7\u5931\u800c\u906d\u53d7\u4eba\u8eab\u3001\u8d22\u4ea7\u635f\u5bb3\u65f6\uff0c\u6709\u5411\u94f6\u884c\u63d0\u51fa\u8bf7\u6c42\u8d54\u507f\u7684\u6743\u5229\uff0c\u4f53\u73b0\u4e86\u94f6\u884c\u4e1a\u6d88\u8d39\u8005\u7684____\u3002\nA. \u5b89\u5168\u6743\nB. \u4f9d\u6cd5\u6c42\u507f\u6743\nC. \u91d1\u878d\u9690\u79c1\u6743\nD. \u53d7\u5c0a\u91cd\u6743\n",
        "output": "B. \u4f9d\u6cd5\u6c42\u507f\u6743",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5206\u671f\u4ed8\u6b3e\u4e1a\u52a1\u624b\u7eed\u8d39\u4e0d\u5305\u62ec\u62ec\u4ee5\u4e0b\u54ea\u4e00\u79cd____\u3002\nA. \u5206\u671f\u4ed8\u6b3e\u624b\u7eed\u8d39\nB. \u63d0\u524d\u8fd8\u6b3e\u624b\u7eed\u8d39\nC. \u5206\u671f\u4ed8\u6b3e\u5c55\u671f\u624b\u7eed\u8d39\nD. \u63d0\u524d\u8fd8\u6b3e\u5c55\u671f\u624b\u7eed\u8d39\n",
        "output": "D. \u63d0\u524d\u8fd8\u6b3e\u5c55\u671f\u624b\u7eed\u8d39",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7533\u8bf7\u4e2a\u4eba\u6c7d\u8f66\u8d37\u6b3e\uff0c\u501f\u6b3e\u4eba\u5e94\u63d0\u4f9b\u4e00\u5b9a\u7684\u62c5\u4fdd\u63aa\u65bd\uff0c\u4e0d\u5305\u62ec____\u3002\nA. \u4ee5\u8d37\u6b3e\u6240\u8d2d\u8f66\u8f86\u4f5c\u62b5\u62bc\nB. \u623f\u5730\u4ea7\u62b5\u62bc\nC. \u7b2c\u4e09\u65b9\u4fdd\u8bc1\nD. \u4fe1\u7528\u62c5\u4fdd\n",
        "output": "D. \u4fe1\u7528\u62c5\u4fdd",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u56da\u72af\u7684\u4e24\u96be\u56f0\u5883\u6a21\u578b\u4e2d____\u3002\nA. \u53cc\u65b9\u90fd\u72ec\u7acb\u4f9d\u7167\u81ea\u8eab\u5229\u76ca\u884c\u52a8\uff0c\u7ed3\u679c\u9677\u5165\u6700\u4e0d\u5229\u7684\u5c40\u9762\nB. \u53cc\u65b9\u90fd\u72ec\u7acb\u4f9d\u7167\u81ea\u8eab\u5229\u76ca\u884c\u4e8b\uff0c\u5bfc\u81f4\u6700\u597d\u7684\u9009\u62e9\nC. \u53cc\u65b9\u8fdb\u884c\u5408\u4f5c\uff0c\u5f97\u5230\u4e86\u6700\u597d\u7684\u7ed3\u679c\nD. \u53cc\u65b9\u8fdb\u884c\u5408\u4f5c\uff0c\u5f97\u5230\u4e86\u6b21\u4f18\u7684\u7ed3\u679c\n",
        "output": "A. \u53cc\u65b9\u90fd\u72ec\u7acb\u4f9d\u7167\u81ea\u8eab\u5229\u76ca\u884c\u52a8\uff0c\u7ed3\u679c\u9677\u5165\u6700\u4e0d\u5229\u7684\u5c40\u9762",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "2014\u5e7411\u67083\u65e5\uff0c\u4eba\u6c11\u6cd5\u9662\u53d7\u7406\u4e86\u7532\u516c\u53f8\u7684\u7834\u4ea7\u7533\u8bf7\u3002\u6839\u636e\u4f01\u4e1a\u7834\u4ea7\u6cd5\u5f8b\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u5df2\u7ecf\u5f00\u59cb\u3001\u5c1a\u672a\u7ec8\u7ed3\u7684\u4e0e\u7532\u516c\u53f8\u6709\u5173\u7684\u6c11\u4e8b\u8bc9\u8bbc\u4e2d\uff0c\u5e94\u5f53\u4e2d\u6b62\uff0c\u4e14\u4e0d\u56e0\u7ba1\u7406\u4eba\u80fd\u591f\u4ee3\u8868\u503a\u52a1\u4eba\u53c2\u52a0\u8bc9\u8bbc\u800c\u7ee7\u7eed\u8fdb\u884c\u7684\u662f____\u3002\nA. \u80a1\u4e1c\u4e59\u4ee5\u7532\u516c\u53f8\u8463\u4e8b\u957f\u51b3\u7b56\u5931\u8bef\u5bfc\u81f4\u516c\u53f8\u635f\u5931\u4e3a\u7531\uff0c\u5bf9\u5176\u63d0\u8d77\u7684\u8bc9\u8bbc\nB. \u7532\u516c\u53f8\u4ee5\u62d6\u6b20\u8d27\u6b3e\u4e3a\u7531\uff0c\u5bf9\u4e19\u516c\u53f8\u63d0\u8d77\u7684\u8bc9\u8bbc\nC. \u503a\u6743\u4eba\u4e01\u516c\u53f8\u4ee5\u7532\u516c\u53f8\u80a1\u4e1c\u620a\u4e0e\u7532\u516c\u53f8\u6cd5\u4eba\u4eba\u683c\u4e25\u91cd\u6df7\u540c\u4e3a\u7531\uff0c\u4e3b\u5f20\u620a\u76f4\u63a5\u627f\u62c5\u8d23\u4efb\u7684\u8bc9\u8bbc\nD. \u7532\u516c\u53f8\u4ee5\u603b\u7ecf\u7406\u5e9a\u8fdd\u53cd\u7ade\u4e1a\u7981\u6b62\u4e3a\u7531\uff0c\u4e3b\u5f20\u5176\u8fd4\u8fd8\u4e0d\u5f53\u5229\u76ca\u7684\u8bc9\u8bbc\n",
        "output": "C. \u503a\u6743\u4eba\u4e01\u516c\u53f8\u4ee5\u7532\u516c\u53f8\u80a1\u4e1c\u620a\u4e0e\u7532\u516c\u53f8\u6cd5\u4eba\u4eba\u683c\u4e25\u91cd\u6df7\u540c\u4e3a\u7531\uff0c\u4e3b\u5f20\u620a\u76f4\u63a5\u627f\u62c5\u8d23\u4efb\u7684\u8bc9\u8bbc",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5173\u4e8e\u91d1\u672c\u4f4d\u5236\u7684\u9648\u8ff0\uff0c\u4e0b\u9762____\u9519\u8bef\u7684\u3002\nA. \u4ee5\u91d1\u5e01\u4e3a\u672c\u4f4d\u8d27\u5e01\nB. \u4e3a\u4e86\u4fdd\u8bc1\u91d1\u5e01\u7684\u542b\u91d1\u91cf\uff0c\u7531\u653f\u5e9c\u72ec\u5bb6\u94f8\u9020\u91d1\u5e01\nC. \u9ec4\u91d1\u81ea\u7531\u8f93\u51fa\u548c\u8f93\u5165\nD. \u4e24\u56fd\u8d27\u5e01\u4e4b\u95f4\u7684\u6c47\u7387\u662f\u7531\u94f8\u5e01\u5e73\u4ef7\u51b3\u5b9a\u7684\n",
        "output": "B. \u4e3a\u4e86\u4fdd\u8bc1\u91d1\u5e01\u7684\u542b\u91d1\u91cf\uff0c\u7531\u653f\u5e9c\u72ec\u5bb6\u94f8\u9020\u91d1\u5e01",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u878d\u8d44\u79df\u8d41\u4e1a\u52a1\u4e2d\uff0c\u82e5\u672a\u7eed\u79df\uff0c\u627f\u79df\u4eba\u5728\u5411\u51fa\u79df\u4eba\u652f\u4ed8\u8fdd\u7ea6\u91d1\u65f6\uff0c\u627f\u79df\u4eba\u5e94\u501f\u8bb0\u7684\u4f1a\u8ba1\u79d1\u76ee\u662f____\u3002\nA. \u7ba1\u7406\u8d39\u7528\nB. \u8d22\u52a1\u8d39\u7528\nC. \u8425\u4e1a\u5916\u652f\u51fa\nD. \u8425\u4e1a\u8d39\u7528\n",
        "output": "C. \u8425\u4e1a\u5916\u652f\u51fa",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5e02\u573a\u9700\u6c42\u66f2\u7ebf\u662f\u7531\u5404\u4e2a\u5355\u72ec\u5382\u5546\u9700\u6c42\u66f2\u7ebf\u6a2a\u5411\u52a0\u603b\u5408\u800c\u5f97\u5230\u7684\uff0c\u5f53\u6bcf\u4e2a\u5382\u5546\u8981\u7d20\u4f7f\u7528\u91cf\u90fd\u589e\u52a0\u65f6\uff0c\u8fd9\u65f6\u5e02\u573a\u9700\u6c42\u66f2\u7ebf\u5c06\u4f1a____\u3002\nA. \u5176\u4e0b\u90e8\u5411\u91cc\u504f\u8f6c\uff0c\u5373\u505a\u987a\u65f6\u9488\u8f6c\u52a8\nB. \u5176\u4e0b\u90e8\u5411\u5916\u504f\u8f6c\uff0c\u5373\u505a\u9006\u65f6\u9488\u8f6c\u52a8\nC. \u5411\u4e0b\u5e73\u884c\u79fb\u52a8\nD. \u5411\u4e0a\u5e73\u884c\u79fb\u52a8\n",
        "output": "A. \u5176\u4e0b\u90e8\u5411\u91cc\u504f\u8f6c\uff0c\u5373\u505a\u987a\u65f6\u9488\u8f6c\u52a8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e3a\u4e86\u9632\u6b62\u865a\u5047\u4ea4\u6613\u767b\u8bb0\u5165\u8d26\uff0c\u88ab\u5ba1\u8ba1\u5355\u4f4d\u4ee5\u4e0b\u5185\u90e8\u63a7\u5236\u8bbe\u8ba1\u5b58\u5728\u7f3a\u9677\u7684\u662f____\u3002\nA. \u4f9d\u636e\u9644\u6709\u6709\u6548\u88c5\u8fd0\u51ed\u8bc1\u548c\u9500\u552e\u5355\u7684\u9500\u552e\u53d1\u7968\u8bb0\u5f55\u9500\u552e\nB. \u5ba2\u6237\u7684\u8ba2\u5355\u53ea\u6709\u7b26\u5408\u7ba1\u7406\u5c42\u6388\u6743\u7684\u6807\u51c6\u65f6\u624d\u80fd\u63a5\u53d7\nC. \u72ec\u7acb\u68c0\u67e5\u5df2\u5904\u7406\u9500\u552e\u53d1\u7968\u4e0a\u7684\u9500\u552e\u91d1\u989d\u4e0e\u4f1a\u8ba1\u8bb0\u5f55\u91d1\u989d\u7684\u4e00\u81f4\u6027\nD. \u5b9a\u671f\u5411\u5ba2\u6237\u5bc4\u9001\u5bf9\u8d26\u5355\uff0c\u5e76\u8981\u6c42\u5ba2\u6237\u5c06\u4efb\u4f55\u4f8b\u5916\u60c5\u51b5\u76f4\u63a5\u5411\u6307\u5b9a\u7684\u672a\u6267\u884c\u6216\u8bb0\u5f55\u9500\u552e\u4ea4\u6613\u7684\u4f1a\u8ba1\u4e3b\u7ba1\u62a5\u544a\n",
        "output": "C. \u72ec\u7acb\u68c0\u67e5\u5df2\u5904\u7406\u9500\u552e\u53d1\u7968\u4e0a\u7684\u9500\u552e\u91d1\u989d\u4e0e\u4f1a\u8ba1\u8bb0\u5f55\u91d1\u989d\u7684\u4e00\u81f4\u6027",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "Capital\u516c\u53f8\u5df2\u51b3\u5b9a\u7ec8\u6b62\u67d0\u79cd\u4ea7\u54c1\u7684\u751f\u4ea7\uff0c\u8be5\u4ea7\u54c1\u539f\u672c\u901a\u8fc7\u56db\u5e74\u524d\u8d2d\u7f6e\u7684\u4e00\u53f0\u673a\u5668\u8fdb\u884c\u751f\u4ea7\uff0c\u8be5\u673a\u5668\u7684\u8d2d\u7f6e\u6210\u672c\u4e3a70000\u3002\u8be5\u673a\u5668\u5f53\u524d\u7684\u8d26\u9762\u4ef7\u503c\u4e3a30000\u3002\u7531\u4e8e\u5e02\u573a\u4e0a\u76ee\u524d\u53ef\u7528\u7684\u673a\u5668\u5728\u6280\u672f\u4e0a\u5df2\u5f97\u5230\u6539\u8fdb\uff0c\u56e0\u6b64Capital\u516c\u53f8\u73b0\u5b58\u7684\u8fd9\u53f0\u673a\u5668\u5df2\u6ca1\u6709\u4efb\u4f55\u6b8b\u503c\u3002\u8be5\u516c\u53f8\u6b63\u5728\u8bc4\u4f30\u4e0e\u65b0\u4ea7\u54c1\u7684\u751f\u4ea7\u76f8\u5173\u7684\u5404\u4e2a\u56e0\u7d20\u3002\u5de5\u7a0b\u4eba\u5458\u5efa\u8bae\uff0c\u73b0\u5b58\u7684\u8fd9\u53f0\u673a\u5668\u53ef\u7528\u4e8e\u751f\u4ea7\u65b0\u4ea7\u54c1\u3002\u4e0e\u751f\u4ea7\u65b0\u4ea7\u54c1\u76f8\u5173\u7684\u5176\u4ed6\u6210\u672c\u5305\u62ec\u6750\u6599\u6210\u672c20000\u4ee5\u53ca\u4eba\u5de5\u6210\u672c5000\u3002\u5ffd\u7565\u6240\u5f97\u7a0e\uff0c\u5219\u4e0e\u751f\u4ea7\u6216\u4e0d\u751f\u4ea7\u65b0\u4ea7\u54c1\u7684\u51b3\u7b56\u76f8\u5173\u7684\u6210\u672c\u4e3a____\u3002\nA. 25000\nB. 30000\nC. 55000\nD. 95000\n",
        "output": "A. 25000",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u9879\u5b58\u6b3e\u5229\u7387\u4e3a6$\\%$\uff0c\u6bcf\u534a\u5e74\u590d\u5229\u4e00\u6b21\uff0c\u5176\u5b9e\u9645\u5229\u7387\u4e3a____\u3002\nA. 0.03\nB. 0.0609\nC. 0.06\nD. 0.066\n",
        "output": "B. 0.0609",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "____\uff0c\u9996\u62793\u4e2a5\u5e74\u671f\u56fd\u503a\u671f\u8d27\u5408\u7ea6\u6b63\u5f0f\u5728\u4e2d\u56fd\u91d1\u878d\u671f\u8d27\u4ea4\u6613\u6240\u63a8\u51fa\u3002\nA. 41523\nB. 40669\nC. 35892\nD. 2000\u5e746\u67088\u65e5\n",
        "output": "A. 41523",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u53ea\u53ef\u8f6c\u6362\u503a\u5238\u7684\u9762\u503c\u662f1000\u7f8e\u5143\uff0c\u73b0\u5728\u7684\u5e02\u573a\u4ef7\u683c\u662f995\u7f8e\u5143\u3002\u53d1\u884c\u503a\u5238\u7684\u516c\u53f8\u80a1\u7968\u4ef7\u683c\u662f32\u7f8e\u5143\uff0c\u53ef\u8f6c\u6362\u7387\u662f31\u80a1\u3002\u503a\u5238\u7684\u5e02\u573a\u8f6c\u6362\u4ef7\u503c\u662f____\u7f8e\u5143\u3002\nA. 665\nB. 742\nC. 853\nD. 992\n",
        "output": "D. 992",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5982\u679c\u6548\u7387\u5e02\u573a\u5047\u8bf4\u6210\u7acb\u7684\u8bdd\uff0c\u4e0b\u5217\u54ea\u79cd\u8bf4\u6cd5\u662f\u6b63\u786e\u7684____\u3002\nA. \u53ef\u4ee5\u7cbe\u786e\u9884\u6d4b\u672a\u6765\u4e8b\u4ef6\nB. \u4ef7\u683c\u53cd\u6620\u4e86\u6240\u6709\u53ef\u83b7\u5f97\u7684\u4fe1\u606f\nC. \u8bc1\u5238\u4ef7\u683c\u53d8\u52a8\u7684\u539f\u56e0\u65e0\u6cd5\u77e5\u9053\nD. \u80a1\u4ef7\u4e0d\u4f1a\u53d8\u52a8\n",
        "output": "B. \u4ef7\u683c\u53cd\u6620\u4e86\u6240\u6709\u53ef\u83b7\u5f97\u7684\u4fe1\u606f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5e02\u573a\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5f71\u54cd\u57fa\u91d1\u7c7b\u4ea7\u54c1\u6536\u76ca\u7684\u56e0\u7d20\u4e0d\u5305\u62ec____\u3002\nA. \u57fa\u91d1\u6240\u6295\u8d44\u7684\u5bf9\u8c61\u4ea7\u54c1\nB. \u57fa\u91d1\u7ba1\u7406\u4eba\u5458\u7684\u4e1a\u52a1\u7d20\u8d28\nC. \u57fa\u91d1\u7ba1\u7406\u516c\u53f8\u7684\u6574\u4f53\u4e1a\u52a1\u8fd0\u884c\u60c5\u51b5\nD. \u57fa\u91d1\u6258\u7ba1\u4eba\u5bf9\u57fa\u91d1\u6295\u8d44\u8fd0\u4f5c\u7684\u76d1\u7763\n",
        "output": "D. \u57fa\u91d1\u6258\u7ba1\u4eba\u5bf9\u57fa\u91d1\u6295\u8d44\u8fd0\u4f5c\u7684\u76d1\u7763",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u91d1\u878d\u5e02\u573a\u4e3a\u4eba\u4eec\u521b\u9020\u4e86\u4e30\u5bcc\u7684\u91d1\u878d\u5de5\u5177\u548c\u591a\u79cd\u4ea4\u6613\u65b9\u5f0f\uff0c\u4e3a\u4e0d\u540c\u6295\u8d44\u504f\u597d\u7684\u8d44\u91d1\u4f9b\u7ed9\u8005\u53ca\u9700\u6c42\u8005\u8fdb\u884c\u591a\u79cd\u5f62\u5f0f\u7684\u91d1\u878d\u6295\u8d44\u878d\u8d44\u4ea4\u6613\u521b\u9020\u4e86\u4fbf\u6377\u7684\u6761\u4ef6\uff0c\u8fd9\u662f\u91d1\u878d\u5e02\u573a\u7684____\u3002\nA. \u8d22\u5bcc\u7ba1\u7406\u529f\u80fd\nB. \u907f\u9669\u529f\u80fd\nC. \u8d44\u91d1\u878d\u901a\u96c6\u805a\u529f\u80fd\nD. \u4ea4\u6613\u529f\u80fd\n",
        "output": "C. \u8d44\u91d1\u878d\u901a\u96c6\u805a\u529f\u80fd",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u592a\u5947\u516c\u53f8\u4e00\u5bb6\u4ece\u4e8b\u996e\u6599\u751f\u4ea7\u7684\u5916\u8d44\u4f01\u4e1a\uff0c\u8be5\u516c\u53f8\u7684\u85aa\u916c\u7ed3\u6784\u7531\u57fa\u672c\u5de5\u8d44\u3001\u5956\u91d1\u3001\u6d25\u8d34\u548c\u798f\u5229\u6784\u6210\uff0c\u5176\u85aa\u916c\u6c34\u5e73\u662f\u56fd\u5185\u996e\u6599\u884c\u4e1a\u5e73\u5747\u85aa\u916c\u76843\u500d\u5de6\u53f3\u3002\u592a\u5947\u516c\u53f8\u91c7\u53d6\u7684\u85aa\u916c\u6c34\u5e73\u7b56\u7565\u662f____\u3002\nA. \u9886\u5148\u578b\u7b56\u7565\nB. \u5339\u914d\u578b\u7b56\u7565\nC. \u62d6\u540e\u578b\u7b56\u7565\nD. \u6df7\u5408\u578b\u7b56\u7565\n",
        "output": "A. \u9886\u5148\u578b\u7b56\u7565",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6ce8\u518c\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6309\u7167\u6700\u5927\u8bda\u4fe1\u539f\u5219\uff0c\u6295\u4fdd\u4eba\u6545\u610f\u8fdd\u53cd\u544a\u77e5\u4e49\u52a1\uff0c\u4fdd\u9669\u4eba\u53ef\u4ee5\u89e3\u9664\u4fdd\u9669\u5408\u540c,\u5bf9\u5408\u540c\u89e3\u9664\u524d\u53d1\u751f\u7684\u4fdd\u9669\u4e8b\u6545\u6240\u5bfc\u81f4\u7684\u635f\u5931\uff0c\u6b63\u786e\u7684\u5904\u7406\u65b9\u5f0f\u662f____\u3002\nA. \u5168\u90e8\u627f\u62c5\u8d54\u507f\u6216\u7ed9\u4ed8\u4fdd\u9669\u91d1\u7684\u8d23\u4efb\nB. \u90e8\u5206\u7684\u627f\u62c5\u8d54\u507f\u6216\u7ed9\u4ed8\u4fdd\u9669\u91d1\u7684\u8d23\u4efb\nC. \u4e0d\u627f\u62c5\u8d54\u507f\u6216\u7ed9\u4ed8\u4fdd\u9669\u91d1\u7684\u8d23\u4efb\uff0c\u5e76\u4e0d\u9000\u8fd8\u4fdd\u9669\u8d39\nD. \u4e0d\u627f\u62c5\u8d54\u507f\u6216\u7ed9\u4ed8\u4fdd\u9669\u91d1\u7684\u8d23\u4efb\uff0c\u4f46\u53ef\u9000\u8fd8\u4fdd\u9669\u8d39\n",
        "output": "C. \u4e0d\u627f\u62c5\u8d54\u507f\u6216\u7ed9\u4ed8\u4fdd\u9669\u91d1\u7684\u8d23\u4efb\uff0c\u5e76\u4e0d\u9000\u8fd8\u4fdd\u9669\u8d39",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4fdd\u9669\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u540c\u65f6\u552e\u51fa\u7532\u80a1\u7968\u76841\u80a1\u770b\u6da8\u671f\u6743\u548c1\u80a1\u770b\u8dcc\u671f\u6743\uff0c\u6267\u884c\u4ef7\u683c\u5747\u4e3a50\u5143\uff0c\u5230\u671f\u65e5\u76f8\u540c\uff0c\u770b\u6da8\u671f\u6743\u7684\u4ef7\u683c\u4e3a5\u5143\uff0c\u770b\u8dcc\u671f\u6743\u7684\u4ef7\u683c\u4e3a4\u5143\u3002\u5982\u679c\u5230\u671f\u65e5\u7684\u80a1\u7968\u4ef7\u683c\u4e3a48\u5143\uff0c\u8be5\u6295\u8d44\u7ec4\u5408\u7684\u51c0\u6536\u76ca\u662f____\u5143\u3002\nA. 5\nB. 7\nC. 9\nD. 11\n",
        "output": "B. 7",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5173\u4e8e\u4e2a\u4eba\u5f81\u4fe1\u67e5\u8be2\u7533\u8bf7\uff0c\u4e0b\u5217\u8bf4\u6cd5\u9519\u8bef\u7684\u662f____\u3002\nA. \u5bf9\u4e8e\u5404\u5730\u67e5\u8be2\u673a\u6784\u8f6c\u4ea4\u7684\u67e5\u8be2\u7533\u8bf7\uff0c\u5f81\u4fe1\u4e2d\u5fc3\u5e94\u5728\u4e24\u4e2a\u5de5\u4f5c\u65e5\u5185\u4e88\u4ee5\u5904\u7406\nB. \u7533\u8bf7\u4eba\u53ef\u4ee5\u4e8b\u5148\u7ea6\u5b9a\u7684\u63a5\u6536\u65b9\u5f0f\uff0c\u5305\u62ec\u73b0\u573a\u9886\u53d6\u548c\u7535\u5b50\u90ae\u4ef6\u6216\u90ae\u5bc4\nC. \u63a5\u5230\u67e5\u8be2\u7533\u8bf7\u540e\uff0c\u67e5\u8be2\u673a\u6784\u5e94\u4f9d\u6cd5\u5bf9\u7533\u8bf7\u4eba(\u6307\u672c\u4eba\u3001\u4ee3\u7406\u4eba\u6216\u53f8\u6cd5\u90e8\u95e8\u7ecf\u529e\u4eba\u5458)\u63d0\u4f9b\u7684\u8d44\u6599\u5f53\u573a\u8fdb\u884c\u5ba1\u6838\nD. \u59d4\u6258\u4ed6\u4eba\u63d0\u4ea4\u67e5\u8be2\u7533\u8bf7\u7684\uff0c\u4ec5\u80fd\u7531\u59d4\u6258\u4eba\u524d\u5f80\u9886\u53d6\n",
        "output": "D. \u59d4\u6258\u4ed6\u4eba\u63d0\u4ea4\u67e5\u8be2\u7533\u8bf7\u7684\uff0c\u4ec5\u80fd\u7531\u59d4\u6258\u4eba\u524d\u5f80\u9886\u53d6",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "Mcfadden\u516c\u53f8\u5728\u8fc7\u53bb\u51e0\u5e74\u7684\u88c5\u8fd0\u8d39\u7528\u5982\u4e0b\uff1a\u56fa\u5b9a\u6210\u672c16000\u5143\uff0c\u5e73\u5747\u6bcf\u6b21\u88c5\u8f7d\u91cf15\u78c5\uff0c\u6bcf\u78c5\u6210\u672c50\u5143\uff0c\u516c\u53f8\u4e0b\u4e00\u5e74\u7684\u9884\u7b97\u6570\u636e\u5982\u4e0b\u6240\u793a\uff1a\u88c5\u8fd0\u4ef6\u65708000\uff0c\u9500\u552e\u8ba2\u5355\u6570\u91cf800\uff0c\u88c5\u8fd0\u6b21\u6570800\uff0c\u9500\u552e\u603b\u91d1\u989d1200000\u5143\uff0c\u603b\u8fd0\u91cf\uff08\u78c5\uff099600\u3002\u8bf7\u95ee\u516c\u53f8\u4e0b\u4e00\u5e74\u5ea6\u7684\u88c5\u8fd0\u6210\u672c\u7684\u9884\u7b97\u989d\u5e94\u8be5\u662f\u591a\u5c11____\u3002\nA. 20000\nB. 16000\nC. 4800\nD. 20800\n",
        "output": "D. 20800",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5982\u679c\u7532\u884c\u4e1a\u7684\u5229\u7387\u9ad8\u4e8e\u4e59\u884c\u4e1a\u7684\u5229\u7387\uff0c\u5219____\u3002\nA. \u7532\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u5e94\u8be5\u6bd4\u4e59\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u66f4\u7f3a\u4e4f\u5f39\u6027\nB. \u7532\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u5c06\u9010\u6e10\u51cf\u5c11\uff0c\u800c\u4e59\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u9010\u6e10\u589e\u52a0\uff0c\u76f4\u5230\u5229\u7387\u76f8\u7b49\u4e3a\u6b62\nC. \u7532\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u5c06\u9010\u6e10\u589e\u52a0\uff0c\u800c\u4e59\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u9010\u6e10\u51cf\u5c11\uff0c\u76f4\u5230\u5229\u7387\u76f8\u7b49\u4e3a\u6b62\nD. \u7532\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u5e94\u8be5\u6bd4\u4e59\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u66f4\u5bcc\u6709\u5f39\u6027\n",
        "output": "C. \u7532\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u5c06\u9010\u6e10\u589e\u52a0\uff0c\u800c\u4e59\u884c\u4e1a\u7684\u8d44\u672c\u4f9b\u7ed9\u9010\u6e10\u51cf\u5c11\uff0c\u76f4\u5230\u5229\u7387\u76f8\u7b49\u4e3a\u6b62",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u56fd\u7cbe\u7b97\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u9879\u76ee\u4e2d\uff0c\u5e94\u786e\u8ba4\u4e3a\u65e0\u5f62\u8d44\u4ea7\u7684\u662f____\u3002\nA. \u4f01\u4e1a\u81ea\u521b\u5546\u8a89\nB. \u4f01\u4e1a\u5185\u90e8\u4ea7\u751f\u7684\u54c1\u724c\nC. \u4f01\u4e1a\u5185\u90e8\u7814\u7a76\u5f00\u53d1\u9879\u76ee\u7814\u7a76\u9636\u6bb5\u7684\u652f\u51fa\nD. \u4e3a\u5efa\u9020\u5382\u623f\u83b7\u5f97\u571f\u5730\u4f7f\u7528\u6743\u652f\u4ed8\u7684\u571f\u5730\u51fa\u8ba9\u91d1\n",
        "output": "D. \u4e3a\u5efa\u9020\u5382\u623f\u83b7\u5f97\u571f\u5730\u4f7f\u7528\u6743\u652f\u4ed8\u7684\u571f\u5730\u51fa\u8ba9\u91d1",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u9762\u503c\u4e3a100\u5143\u7684\u6c38\u4e45\u6027\u503a\u5238\u7968\u9762\u5229\u7387\u662f10$\\%$\uff0c\u5f53\u5e02\u573a\u5229\u7387\u4e3a8$\\%$\u65f6\uff0c\u8be5\u503a\u5238\u7684\u7406\u8bba\u5e02\u573a\u4ef7\u683c\u5e94\u8be5\u662f____\u5143\u3002\nA. 100\nB. 125\nC. 110\nD. 1375\n",
        "output": "B. 125",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ece\u56fd\u9645\u8d38\u6613\u5bf9\u751f\u4ea7\u8981\u7d20\u5206\u914d\u7684\u5f71\u54cd\u6765\u770b\uff0c\u56fd\u9645\u8d38\u6613\u6709\u5229\u4e8e____\u3002\nA. \u751f\u4ea7\u8fdb\u53e3\u7ade\u4e89\u54c1\u4e2d\u5bc6\u96c6\u4f7f\u7528\u7684\u751f\u4ea7\u8981\u7d20\u6536\u5165\u7684\u589e\u52a0\nB. \u751f\u4ea7\u8fdb\u53e3\u7ade\u4e89\u54c1\u4e2d\u5bc6\u96c6\u4f7f\u7528\u7684\u5171\u540c\u751f\u4ea7\u8981\u7d20\u6536\u5165\u7684\u589e\u52a0\nC. \u751f\u4ea7\u51fa\u53e3\u54c1\u4e2d\u5bc6\u96c6\u4f7f\u7528\u7684\u5171\u540c\u751f\u4ea7\u8981\u7d20\u6536\u5165\u7684\u589e\u52a0\nD. \u751f\u4ea7\u51fa\u53e3\u54c1\u4e2d\u5bc6\u96c6\u4f7f\u7528\u7684\u751f\u4ea7\u8981\u7d20\u6536\u5165\u7684\u589e\u52a0\n",
        "output": "D. \u751f\u4ea7\u51fa\u53e3\u54c1\u4e2d\u5bc6\u96c6\u4f7f\u7528\u7684\u751f\u4ea7\u8981\u7d20\u6536\u5165\u7684\u589e\u52a0",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ece\u4e2d\u95f4\u4ea7\u54c1\u5e02\u573a\u4e0d\u5b8c\u5168\u6027\u89d2\u5ea6\u7814\u7a76\u8de8\u56fd\u516c\u53f8\u5bf9\u5916\u6295\u8d44\u7684\u7406\u8bba\u662f____\u3002\nA. \u5784\u65ad\u4f18\u52bf\u7406\u8bba\nB. \u5185\u90e8\u5316\u7406\u8bba\nC. C\u533a\u4f4d\u4f18\u52bf\u7406\u8bba\nD. \u8fb9\u9645\u4ea7\u4e1a\u8f6c\u79fb\u7406\u8bba\n",
        "output": "B. \u5185\u90e8\u5316\u7406\u8bba",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u6709\u5173\u81ea\u52a8\u63a7\u5236\u80fd\u4e3a\u4f01\u4e1a\u5e26\u6765\u7684\u597d\u5904\u7684\u8bf4\u6cd5\u4e2d\uff0c\u4e0d\u6b63\u786e\u7684\u662f____\u3002\nA. \u81ea\u52a8\u63a7\u5236\u6bd4\u8f83\u5bb9\u6613\u88ab\u7ed5\u8fc7\nB. \u81ea\u52a8\u63a7\u5236\u80fd\u591f\u6709\u6548\u5904\u7406\u5927\u6d41\u91cf\u4ea4\u6613\u53ca\u6570\u636e\nC. \u81ea\u52a8\u4fe1\u606f\u7cfb\u7edf\u53ef\u4ee5\u63d0\u9ad8\u4fe1\u606f\u7684\u53ca\u65f6\u6027\u3001\u51c6\u786e\u6027\uff0c\u5e76\u4f7f\u4fe1\u606f\u53d8\u5f97\u66f4\u6613\u83b7\u53d6\nD. \u81ea\u52a8\u4fe1\u606f\u7cfb\u7edf\u3001\u6570\u636e\u5e93\u53ca\u64cd\u4f5c\u7cfb\u7edf\u7684\u76f8\u5173\u5b89\u5168\u63a7\u5236\u53ef\u4ee5\u5b9e\u73b0\u6709\u6548\u7684\u804c\u8d23\u5206\u79bb\n",
        "output": "A. \u81ea\u52a8\u63a7\u5236\u6bd4\u8f83\u5bb9\u6613\u88ab\u7ed5\u8fc7",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5047\u8bbe\u6bcf\u4e00\u4e2a\u98ce\u9669\u5355\u4f4d\u7684\u7eaf\u4fdd\u8d39\u662f175\u5143\uff0c\u56fa\u5b9a\u8d39\u7528\u662f12.5\u5143\uff0c\u53ef\u53d8\u8d39\u7528\u7684\u6bd4\u4f8b\u662f17.5$\\%$\uff0c\u800c\u9884\u671f\u5229\u6da6\u9644\u52a0\u7387\u662f5$\\%$\uff0c\u5219\u6bcf\u4e00\u4e2a\u98ce\u9669\u5355\u4f4d\u7684\u6bdb\u4fdd\u8d39\u4e3a____\u3002\nA. 203.54\nB. 241.94\nC. 268.4\nD. 378.15\n",
        "output": "B. 241.94",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u56fd\u7cbe\u7b97\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u56fd\u5bb6\u9884\u7b97\u4f53\u7cfb\u662f\u5728____\u57fa\u7840\u4e0a\u5f62\u6210\u7684\u56fd\u5bb6\u9884\u7b97\u7ec4\u7ec7\u7ed3\u6784\u3002\nA. \u56fd\u5bb6\u653f\u6743\u7ed3\u6784\u3001\u884c\u653f\u533a\u57df\u5212\u5206\u548c\u8d22\u653f\u7ba1\u7406\u4f53\u5236\nB. \u56fd\u5bb6\u653f\u6743\u673a\u5236\u3001\u884c\u653f\u533a\u57df\u5212\u5206\u548c\u8d22\u653f\u7ba1\u7406\u4f53\u5236\nC. \u56fd\u5bb6\u653f\u6743\u7ed3\u6784\u3001\u884c\u653f\u533a\u57df\u7ba1\u7406\u548c\u8d22\u653f\u7ba1\u7406\u4f53\u5236\nD. \u56fd\u5bb6\u653f\u6743\u673a\u5236\u3001\u884c\u653f\u533a\u57df\u7ba1\u7406\u548c\u8d22\u653f\u7ba1\u7406\u4f53\u5236\n",
        "output": "A. \u56fd\u5bb6\u653f\u6743\u7ed3\u6784\u3001\u884c\u653f\u533a\u57df\u5212\u5206\u548c\u8d22\u653f\u7ba1\u7406\u4f53\u5236",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u653f\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u671f\u8d27\u6295\u8d44\u8005\u8bbe\u7f6e\u56de\u64a4\u70b9\u7684\u8bf4\u6cd5\u9519\u8bef\u7684\u662f____\u3002\nA. \u652f\u6491\u6216\u963b\u529b\u4f4d\u6b62\u635f\u6b62\u76c8\nB. \u4e70\u5165\u5efa\u4ed3\u5728\u652f\u6491\u4f4d\uff0c\u6b62\u76c8\u5e73\u4ed3\u5728\u963b\u529b\u4f4d\uff0c\u4e70\u8fdb\u4e4b\u540e\u8dcc\u7834\u652f\u6491\u4f4d\u6b62\u635f\nC. \u8fd0\u7528\u8d44\u91d1\u989d\u8fdb\u884c\u6b62\u635f\nD. \u5728\u6bcf\u6b21\u5165\u5e02\u8fdb\u884c\u4e70\u5356\u4e4b\u524d\uff0c\u8981\u660e\u786e\u5730\u8ba1\u5212\u4e8f\u635f\u591a\u5c11\u70b9\u6b62\u635f\u79bb\u573a\uff0c\u4f46\u524d\u63d0\u662f\u6295\u8d44\u8005\u8981\u62e5\u6709\u4e00\u4e2a\u80dc\u51fa\u7387\u9ad8\u4e8e60$\\%$\u7684\u6a21\u5f0f\uff0c\u540c\u65f6\u4fdd\u8bc1\u76c8\u5229\u603b\u70b9\u6570\u5c0f\u4e8e\u6b62\u635f\u603b\u70b9\u6570\n",
        "output": "D. \u5728\u6bcf\u6b21\u5165\u5e02\u8fdb\u884c\u4e70\u5356\u4e4b\u524d\uff0c\u8981\u660e\u786e\u5730\u8ba1\u5212\u4e8f\u635f\u591a\u5c11\u70b9\u6b62\u635f\u79bb\u573a\uff0c\u4f46\u524d\u63d0\u662f\u6295\u8d44\u8005\u8981\u62e5\u6709\u4e00\u4e2a\u80dc\u51fa\u7387\u9ad8\u4e8e60$\\%$\u7684\u6a21\u5f0f\uff0c\u540c\u65f6\u4fdd\u8bc1\u76c8\u5229\u603b\u70b9\u6570\u5c0f\u4e8e\u6b62\u635f\u603b\u70b9\u6570",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u671f\u8d27\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5206\u6790\u653f\u5e9c\u90e8\u95e8\u8d22\u653f\u72b6\u51b5\u7684\u65b9\u6cd5\u9664\u4e86\u603b\u5dee\u989d\uff0c\u8fd8\u6709____\u3002\nA. \u7ecf\u5e38\u6027\u6536\u652f\u5dee\u989d\nB. \u57fa\u672c\u5dee\u989d\nC. \u8d38\u6613\u5dee\u989d\nD. \u7ecf\u5e38\u9879\u76ee\u5dee\u989d\n",
        "output": "A. \u7ecf\u5e38\u6027\u6536\u652f\u5dee\u989d",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u592e\u94f6\u884c\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "____\u662f\u8d44\u6e90\u914d\u7f6e\u548c\u5229\u7528\u7684\u65b9\u5f0f\u3002\nA. \u7ecf\u6d4e\u4f53\u5236\nB. \u7ecf\u6d4e\u5236\u5ea6\nC. \u653f\u4f53\nD. \u56fd\u4f53\n",
        "output": "A. \u7ecf\u6d4e\u4f53\u5236",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5916\u5e01\u62a5\u8868\u6298\u7b97\u4e3a\u4eba\u6c11\u5e01\u62a5\u8868\u65f6\uff0c\u5916\u5e01\u8d44\u4ea7\u8d1f\u503a\u8868\u4e2d\u7684\u201c\u672a\u5206\u914d\u5229\u6da6\u201d\u9879\u76ee\u5e94\u5f53____\u3002\nA. \u6309\u5386\u53f2\u6c47\u7387\u6298\u7b97\nB. \u6309\u73b0\u884c\u6c47\u7387\u6298\u7b97\nC. \u6839\u636e\u6298\u7b97\u540e\u6240\u6709\u8005\u6743\u76ca\u53d8\u52a8\u8868\u4e2d\u5176\u4ed6\u9879\u76ee\u6570\u989d\u8ba1\u7b97\u786e\u5b9a\nD. \u6309\u5e73\u5747\u6c47\u7387\u6298\u7b97\n",
        "output": "C. \u6839\u636e\u6298\u7b97\u540e\u6240\u6709\u8005\u6743\u76ca\u53d8\u52a8\u8868\u4e2d\u5176\u4ed6\u9879\u76ee\u6570\u989d\u8ba1\u7b97\u786e\u5b9a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u6cd5\u5f8b\u4e2d\uff0c\u660e\u786e\u89c4\u5b9a\u201c\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u516c\u6c11\u6709\u4f9d\u7167\u6cd5\u5f8b\u7eb3\u7a0e\u7684\u4e49\u52a1\u201d\u7684\u662f____\u3002\nA. \u300a\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u5baa\u6cd5\u300b\nB. \u300a\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u6c11\u6cd5\u901a\u5219\u300b\nC. \u300a\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u4e2a\u4eba\u6240\u5f97\u7a0e\u6cd5\u300b\nD. \u300a\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u7a0e\u6536\u5f81\u6536\u7ba1\u7406\u6cd5\u300b\n",
        "output": "A. \u300a\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u5baa\u6cd5\u300b",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u8ff0\u54ea\u79cd\u80a1\u7968\u6307\u6570\u7684\u6743\u91cd\u914d\u7f6e\u65b9\u5f0f\u4f1a\u4f7f\u5f97\u5177\u6709\u5927\u5e02\u503c\u7684\u516c\u53f8\u80a1\u7968\u5bf9\u6307\u6570\u7684\u5f71\u54cd\u66f4\u5927____\u3002\nA. \u7b49\u6743\u91cd\nB. \u4ef7\u683c\u52a0\u6743\nC. \u5e02\u503c\u52a0\u6743\nD. \u7b49\u7ea7\u6743\u91cd\n",
        "output": "C. \u5e02\u503c\u52a0\u6743",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u91d1\u94f6\u9996\u9970\u6d88\u8d39\u7a0e\u7684\u8bf4\u6cd5\uff0c\u7b26\u5408\u73b0\u884c\u6d88\u8d39\u7a0e\u653f\u7b56\u89c4\u5b9a\u7684\u662f____\u3002\nA. \u91d1\u9996\u9970\u7684\u8fdb\u53e3\u5e94\u7eb3\u6d88\u8d39\u7a0e\nB. \u94f6\u9996\u9970\u7684\u51fa\u5382\u9500\u552e\u5e94\u7eb3\u6d88\u8d39\u7a0e\nC. \u94bb\u77f3\u9970\u54c1\u7684\u6279\u53d1\u5e94\u7eb3\u6d88\u8d39\u7a0e\nD. \u91d1\u57fa\u5408\u91d1\u9576\u5d4c\u9996\u9970\u7684\u96f6\u552e\u5e94\u7eb3\u6d88\u8d39\u7a0e\n",
        "output": "D. \u91d1\u57fa\u5408\u91d1\u9576\u5d4c\u9996\u9970\u7684\u96f6\u552e\u5e94\u7eb3\u6d88\u8d39\u7a0e",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e24\u5e74\u671f\uff0c\u7968\u9762\u5229\u738710$\\%$\uff0c\u503a\u5238\u9762\u503c=1000\u7f8e\u5143\uff0c\u6309\u5e74\u4ed8\u606f\u7684\u503a\u5238\u7684\u4ef7\u683c\u662f\u591a\u5c11____\u3002\nA. 1092\u7f8e\u5143\nB. 1054\u7f8e\u5143\nC. 1000\u7f8e\u5143\nD. 1073\u7f8e\u5143\n",
        "output": "D. 1073\u7f8e\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u80a1\u6307\u671f\u6743\u5e02\u573a\u4e0a\uff0c\u5982\u679c\u9884\u671f\u80a1\u5e02\u4f1a\u5728\u4ea4\u6613\u5b8c\u6210\u540e\u8fc5\u901f\u4e0a\u6da8\uff0c\u4ee5\u4e0b\u4ea4\u6613\u98ce\u9669\u6700\u5927\u7684\u662f____\u3002\nA. \u5356\u51fa\u770b\u6da8\u671f\u6743\nB. \u5356\u51fa\u770b\u8dcc\u671f\u6743\nC. \u4e70\u5165\u770b\u6da8\u671f\u6743\nD. \u4e70\u5165\u770b\u8dcc\u671f\u6743\n",
        "output": "A. \u5356\u51fa\u770b\u6da8\u671f\u6743",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5bf9\u4e0a\u5e02\u516c\u53f8\u800c\u8a00\uff0c\u4e0b\u5217\u5404\u7c7b\u62a5\u544a\u5fc5\u987b\u7ecf\u6ce8\u518c\u4f1a\u8ba1\u5e08\u5ba1\u8ba1\u7684\u662f____\u3002\nA. \u4e2d\u671f\u8d22\u52a1\u62a5\u544a\nB. \u5e74\u5ea6\u8d22\u52a1\u62a5\u544a\nC. \u5b63\u5ea6\u8d22\u52a1\u62a5\u544a\nD. \u6708\u5ea6\u8d22\u52a1\u62a5\u544a\n",
        "output": "B. \u5e74\u5ea6\u8d22\u52a1\u62a5\u544a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u6c11\u4e8b\u5236\u5ea6\u7684\u6cd5\u5f8b\u89c4\u5b9a\uff0c\u4e0b\u5217\u5173\u4e8e\u9644\u6761\u4ef6\u6c11\u4e8b\u6cd5\u5f8b\u884c\u4e3a\u6240\u9644\u6761\u4ef6\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u65e2\u53ef\u4ee5\u662f\u4eba\u7684\u884c\u4e3a\uff0c\u4e5f\u53ef\u4ee5\u662f\u81ea\u7136\u73b0\u8c61\nB. \u65e2\u53ef\u4ee5\u662f\u5c06\u6765\u4e8b\u5b9e\uff0c\u4e5f\u53ef\u4ee5\u662f\u8fc7\u53bb\u4e8b\u5b9e\nC. \u65e2\u5305\u62ec\u7ea6\u5b9a\u4e8b\u5b9e\uff0c\u4e5f\u5305\u62ec\u6cd5\u5b9a\u4e8b\u5b9e\nD. \u65e2\u53ef\u4ee5\u662f\u786e\u5b9a\u53d1\u751f\u7684\u4e8b\u5b9e\uff0c\u4e5f\u53ef\u4ee5\u662f\u4e0d\u786e\u5b9a\u53d1\u751f\u7684\u4e8b\u5b9e\n",
        "output": "A. \u65e2\u53ef\u4ee5\u662f\u4eba\u7684\u884c\u4e3a\uff0c\u4e5f\u53ef\u4ee5\u662f\u81ea\u7136\u73b0\u8c61",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u91c7\u7528\u95f4\u63a5\u6807\u4ef7\u6cd5\u7684\u56fd\u5bb6\u662f____\u3002\nA. \u65e5\u672c\nB. \u7f8e\u56fd\nC. \u6cd5\u56fd\nD. \u4e2d\u56fd\n",
        "output": "B. \u7f8e\u56fd",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "2015\u5e743\u670829\u65e5\uff0c\u534e\u590f\u4e0a\u8bc150ETF\u57fa\u91d1\u7684\u6536\u76d8\u4ef7\u4e3a\u00a52.649\uff0c4\u6708\u4efd\u5230\u671f\u3001\u884c\u6743\u4ef7\u683c\u4e3a\u00a52.250\u7684\u4e0a\u8bc150ETF\u8ba4\u8d2d\u671f\u6743\u7684\u6536\u76d8\u4ef7\u4e3a\u00a50.406\uff0c\u90a3\u4e48\uff0c\u8be5\u671f\u6743\u7684\u5185\u5728\u4ef7\u503c\u6216\u6267\u884c\u4ef7\u503c\u4e3a____\u3002\nA. 1.844\nB. 0.399\nC. 2.243\nD. 0.406\n",
        "output": "B. 0.399",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5de5\u7a0b\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "____\u53cd\u6620\u4e86\u516c\u53f8\u7ecf\u8425\u6d3b\u52a8\u3001\u6295\u8d44\u6d3b\u52a8\u548c\u878d\u8d44\u6d3b\u52a8\u6240\u4ea7\u751f\u7684\u73b0\u91d1\u6d41\u91cf\u3002\nA. \u8d44\u4ea7\u8d1f\u503a\u8868\nB. \u5229\u6da6\u8868\nC. \u73b0\u91d1\u6d41\u91cf\u8868\nD. \u4e0a\u8ff0\u6240\u6709\u62a5\u8868\u90fd\n",
        "output": "C. \u73b0\u91d1\u6d41\u91cf\u8868",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u4f01\u4e1a\u56e0\u4e1a\u52a1\u9700\u8981\uff0c\u7533\u8bf7\u94f6\u884c\u4e3a\u5176\u5f00\u5177\u94f6\u884c\u6c47\u7968\uff0c\u94f6\u884c\u7ecf\u5ba1\u67e5\u540e\uff0c\u540c\u610f\u4f01\u4e1a\u7684\u7533\u8bf7\uff0c\u4e3a\u5176\u5f00\u5177\u4e86\u4e00\u5f20100\u4e07\u5143\u7684\u94f6\u884c\u6c47\u7968\u3002\u94f6\u884c\u7684\u8fd9\u4e00\u4e1a\u52a1\u4f53\u73b0\u4e86\u94f6\u884c\u7684____\u3002\nA. \u4fe1\u7528\u4e2d\u4ecb\u804c\u80fd\nB. \u652f\u4ed8\u4e2d\u4ecb\u804c\u80fd\nC. \u5316\u8d27\u5e01\u6536\u5165\u4e3a\u8d44\u672c\u804c\u80fd\nD. \u521b\u9020\u4fe1\u7528\u6d41\u901a\u5de5\u5177\u804c\u80fd\n",
        "output": "D. \u521b\u9020\u4fe1\u7528\u6d41\u901a\u5de5\u5177\u804c\u80fd",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5bf9\u4e8e\u5916\u503a\u800c\u8a00\uff0c\u56fd\u9645\u4e0a\u901a\u7528\u7684\u8d1f\u503a\u7387\u6307\u6807\u662f____\u3002\nA. \u5f53\u5e74\u503a\u52a1\u4f59\u989d\u5360\u5546\u54c1\u548c\u52b3\u52a1\u51fa\u53e3\u603b\u989d\u7684\u767e\u5206\u6bd4\nB. \u5f53\u5e74\u503a\u52a1\u6536\u5165\u5360\u8d22\u653f\u652f\u51fa\u7684\u6bd4\u91cd\nC. \u5f53\u5e74\u503a\u52a1\u8fd8\u672c\u4ed8\u606f\u989d\u5360\u5546\u54c1\u548c\u52b3\u52a1\u51fa\u53e3\u603b\u989d\u7684\u767e\u5206\u6bd4\nD. \u5f53\u5e74\u503a\u52a1\u4f59\u989d\u5360GNP\u7684\u767e\u5206\u6bd4\n",
        "output": "D. \u5f53\u5e74\u503a\u52a1\u4f59\u989d\u5360GNP\u7684\u767e\u5206\u6bd4",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u653f\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "2013\u5e746\u67081\u65e5\uff0c\u4eba\u6c11\u6cd5\u9662\u53d7\u7406\u4e86\u5bf9\u7532\u516c\u53f8\u63d0\u8d77\u7684\u7834\u4ea7\u7533\u8bf7\u3002\u6839\u636e\u4f01\u4e1a\u7834\u4ea7\u6cd5\u5f8b\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u4eba\u5458\u4e2d\uff0c\u6709\u8d44\u683c\u62c5\u4efb\u7ba1\u7406\u4eba\u7684\u662f____\u3002\nA. \u66fe\u4e8e2008\u5e741\u67081\u65e5\u81f32009\u5e7412\u670831\u65e5\u62c5\u4efb\u7532\u516c\u53f8\u6cd5\u5f8b\u987e\u95ee\u7684\u4e19\u5f8b\u5e08\u4e8b\u52a1\u6240\nB. \u7532\u516c\u53f8\u8463\u4e8b\u4e01\nC. 3\u5e74\u524d\u88ab\u540a\u9500\u6267\u4e1a\u8bc1\u4e66\uff0c\u4f46\u73b0\u5df2\u91cd\u83b7\u6267\u4e1a\u8d44\u683c\u7684\u6ce8\u518c\u4f1a\u8ba1\u5e08\u4e59\nD. \u7532\u516c\u53f8\u76d1\u4e8b\u4f1a\u4e3b\u5e2d\u7684\u59bb\u5b50\u620a\n",
        "output": "A. \u66fe\u4e8e2008\u5e741\u67081\u65e5\u81f32009\u5e7412\u670831\u65e5\u62c5\u4efb\u7532\u516c\u53f8\u6cd5\u5f8b\u987e\u95ee\u7684\u4e19\u5f8b\u5e08\u4e8b\u52a1\u6240",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5173\u4e8e\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u8bf4\u6cd5\u4e0d\u6b63\u786e\u7684\u662f____\u3002\nA. \u5f53\u7ecf\u6d4e\u751f\u6d3b\u4e2d\u9700\u6c42\u4e0d\u8db3\u65f6\uff0c\u8fd0\u7528\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u53ef\u4ee5\u4f7f\u793e\u4f1a\u603b\u9700\u6c42\u4e0e\u603b\u4f9b\u7ed9\u7684\u5dee\u989d\u7f29\u5c0f\u4ee5\u4fbf\u8fbe\u5230\u5e73\u8861\nB. \u5f53\u7ecf\u6d4e\u751f\u6d3b\u4e2d\u603b\u9700\u6c42\u4e0e\u603b\u4f9b\u7ed9\u5e73\u8861\u65f6\uff0c\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u4f1a\u4f7f\u793e\u4f1a\u603b\u9700\u6c42\u8d85\u8fc7\u603b\u4f9b\u7ed9\nC. \u5f53\u7ecf\u6d4e\u751f\u6d3b\u4e2d\u793e\u4f1a\u603b\u9700\u6c42\u8d85\u8fc7\u603b\u4f9b\u7ed9\u65f6\uff0c\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u4f7f\u603b\u4f9b\u7ed9\u8d85\u8fc7\u603b\u9700\u6c42\nD. \u5f53\u7ecf\u6d4e\u751f\u6d3b\u4e2d\u793e\u4f1a\u603b\u9700\u6c42\u8d85\u8fc7\u603b\u4f9b\u7ed9\u65f6\uff0c\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u4f7f\u603b\u4f9b\u7ed9\u4e0d\u8d85\u8fc7\u603b\u9700\u6c42\n",
        "output": "D. \u5f53\u7ecf\u6d4e\u751f\u6d3b\u4e2d\u793e\u4f1a\u603b\u9700\u6c42\u8d85\u8fc7\u603b\u4f9b\u7ed9\u65f6\uff0c\u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\u4f7f\u603b\u4f9b\u7ed9\u4e0d\u8d85\u8fc7\u603b\u9700\u6c42",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u653f\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636eCAPM\uff0c\u4e00\u4e2a\u7ec4\u5408\u7684\u8d1d\u5854\u503c\u4e3a1\uff0c\u963f\u5c14\u6cd5\u503c\u4e3a\u96f6\uff0c\u90a3\u4e48\u8fd9\u4e2a\u7ec4\u5408\u7684\u9884\u671f\u6536\u76ca\u7387\u4e3a____\u3002\nA. \u65e0\u98ce\u9669\u6536\u76ca\u7387$r_f$\nB. \u4ecb\u4e8e\u5e02\u573a\u6536\u76ca\u7387$r_M$\u548c\u65e0\u98ce\u9669\u6536\u76ca\u7387$r_f$\u4e4b\u95f4\nC. $\\beta(r_M-r_f)$\nD. \u5e02\u573a\u9884\u671f\u6536\u76ca\u7387$r_M$\n",
        "output": "D. \u5e02\u573a\u9884\u671f\u6536\u76ca\u7387$r_M$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5e02\u573a\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "(1)\u5e73\u4ef7\u503a\u5238X\uff0c5\u5e74\u671f\uff0c10$\\%$\u606f\u7968\u7387\uff0c(2)\u96f6\u606f\u7968\u503a\u5238Y\uff0c5\u5e74\u671f\uff0c10$\\%$\u7684\u5230\u671f\u6536\u76ca\u7387\uff0c\u4ee5\u4e0a\u4e24\u79cd\u503a\u5238\u54ea\u4e00\u79cd\u5bf9\u5229\u7387\u7684\u6ce2\u52a8\u66f4\u4e0d\u654f\u611f____\u3002\nA. \u503a\u5238X\uff0c\u56e0\u4e3a\u4e45\u671f\u66f4\u77ed\nB. \u503a\u5238X\uff0c\u56e0\u4e3a\u5230\u671f\u65f6\u95f4\u66f4\u957f\nC. \u503a\u5238Y\uff0c\u56e0\u4e3a\u4e45\u671f\u66f4\u957f\nD. \u503a\u5238Y\uff0c\u56e0\u4e3a\u5230\u671f\u65f6\u95f4\u66f4\u77ed\n",
        "output": "A. \u503a\u5238X\uff0c\u56e0\u4e3a\u4e45\u671f\u66f4\u77ed",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "95$\\%$\u7f6e\u4fe1\u6c34\u5e73\u7684\u533a\u95f4\u4f30\u8ba1\u4e2d95$\\%$\u7684\u7f6e\u4fe1\u6c34\u5e73\u662f____\u3002\nA. \u603b\u4f53\u53c2\u6570\u843d\u5728\u4e00\u4e2a\u7279\u5b9a\u7684\u6837\u672c\u6240\u6784\u9020\u7684\u533a\u95f4\u5185\u7684\u6982\u7387\u4e3a95$\\%$\nB. \u603b\u4f53\u53c2\u6570\u843d\u5728\u4e00\u4e2a\u7279\u5b9a\u7684\u6837\u672c\u6240\u6784\u9020\u7684\u533a\u95f4\u5185\u7684\u6982\u7387\u4e3a5$\\%$\nC. \u5728\u7528\u540c\u6837\u65b9\u6cd5\u6784\u9020\u7684\u603b\u4f53\u53c2\u6570\u7684\u591a\u4e2a\u533a\u95f4\u4e2d\uff0c\u5305\u542b\u603b\u4f53\u53c2\u6570\u7684\u533a\u95f4\u6bd4\u4f8b\u4e3a95$\\%$\nD. \u5728\u7528\u540c\u6837\u65b9\u6cd5\u6784\u9020\u7684\u603b\u4f53\u53c2\u6570\u7684\u591a\u4e2a\u533a\u95f4\u4e2d\uff0c\u5305\u542b\u603b\u4f53\u53c2\u6570\u7684\u533a\u95f4\u6bd4\u4f8b\u4e3a5$\\%$\n",
        "output": "C. \u5728\u7528\u540c\u6837\u65b9\u6cd5\u6784\u9020\u7684\u603b\u4f53\u53c2\u6570\u7684\u591a\u4e2a\u533a\u95f4\u4e2d\uff0c\u5305\u542b\u603b\u4f53\u53c2\u6570\u7684\u533a\u95f4\u6bd4\u4f8b\u4e3a95$\\%$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5927\u989d\u53ef\u8f6c\u8ba9\u5b9a\u671f\u5b58\u5355\u7684\u7279\u5f81\u4e0d\u5305\u62ec____\u3002\nA. \u53ef\u4ee5\u8f6c\u8ba9\u6d41\u901a\nB. \u91d1\u989d\u8f83\u5927\nC. \u4e0d\u8bb0\u540d\nD. \u80fd\u63d0\u524d\u652f\u53d6\n",
        "output": "D. \u80fd\u63d0\u524d\u652f\u53d6",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u6211\u56fd\u589e\u503c\u7a0e\u6cd5\u7684\u76f8\u5173\u89c4\u5b9a\uff0c\u4e0b\u5217\u4e0d\u5c5e\u4e8e\u89c6\u540c\u9500\u552e\u884c\u4e3a\u7684\u662f____\u3002\nA. \u5c06\u8d2d\u8fdb\u7684\u8d27\u7269\u65e0\u507f\u8d60\u9001\u7ed9\u707e\u6c11\nB. \u5355\u4f4d\u6548\u76ca\u4e0d\u597d\uff0c\u5c06\u81ea\u4ea7\u7684\u7535\u89c6\u673a\u53d1\u7ed9\u5458\u5de5\u505a\u798f\u5229\nC. \u5c06\u534a\u6210\u54c1\u4ece\u4e00\u4e2a\u8f66\u95f4\u8f6c\u79fb\u5230\u53e6\u4e00\u4e2a\u8f66\u95f4\u7ee7\u7eed\u52a0\u5de5\nD. \u5c06\u81ea\u4ea7\u7684\u8bbe\u5907\u7528\u4e8e\u6295\u8d44\u5165\u80a1\n",
        "output": "C. \u5c06\u534a\u6210\u54c1\u4ece\u4e00\u4e2a\u8f66\u95f4\u8f6c\u79fb\u5230\u53e6\u4e00\u4e2a\u8f66\u95f4\u7ee7\u7eed\u52a0\u5de5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "____\u662f\u4f20\u7edf\u4e1a\u7ee9\u8861\u91cf\u6307\u6807\u4f53\u7cfb\u7684\u91cd\u8981\u8865\u5145\u3002\nA. \u7ecf\u6d4e\u9644\u52a0\u503c\u6307\u6807\nB. \u8d44\u91d1\u6210\u672c\u6307\u6807\nC. \u51c0\u5229\u6da6\u6307\u6807\nD. \u73b0\u91d1\u6d41\u6307\u6807\n",
        "output": "A. \u7ecf\u6d4e\u9644\u52a0\u503c\u6307\u6807",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u6d89\u5916\u7ecf\u6d4e\u6cd5\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u6709\u6743\u4f5c\u51fa\u5f81\u6536\u53cd\u503e\u9500\u7a0e\u51b3\u5b9a\u7684\u673a\u6784\u662f____\u3002\nA. \u5546\u52a1\u90e8\nB. \u6d77\u5173\u603b\u7f72\nC. \u56fd\u5bb6\u7a0e\u52a1\u603b\u5c40\nD. \u56fd\u52a1\u9662\u5173\u7a0e\u7a0e\u5219\u59d4\u5458\u4f1a\n",
        "output": "D. \u56fd\u52a1\u9662\u5173\u7a0e\u7a0e\u5219\u59d4\u5458\u4f1a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u4f01\u4e1a\u7834\u4ea7\u6cd5\u5f8b\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u5173\u4e8e\u7834\u4ea7\u6848\u4ef6\u8bc9\u8bbc\u8d39\u7528\u627f\u62c5\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u7531\u7834\u4ea7\u7533\u8bf7\u4eba\u9884\u5148\u652f\u4ed8\nB. \u7531\u5168\u4f53\u503a\u6743\u4eba\u6309\u6bd4\u4f8b\u5206\u62c5\nC. \u4ece\u503a\u52a1\u4eba\u8d22\u4ea7\u4e2d\u968f\u65f6\u62e8\u4ed8\nD. \u7531\u503a\u6743\u4eba\u548c\u503a\u52a1\u4eba\u5206\u62c5\n",
        "output": "C. \u4ece\u503a\u52a1\u4eba\u8d22\u4ea7\u4e2d\u968f\u65f6\u62e8\u4ed8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u57fa\u5dee\u8d70\u5f3a\uff0c\u4e0b\u5217\u54ea\u79cd\u5957\u671f\u7ec4\u5408\u6536\u76ca\u589e\u5927____\u3002\nA. \u591a\u5934\nB. \u7a7a\u5934\nC. \u4ea4\u53c9\nD. \u5e73\u884c\n",
        "output": "B. \u7a7a\u5934",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5e02\u573a\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u63a7\u5236\u6743\u53d6\u5f97\u65e5\u540e\u7f16\u5236\u5408\u5e76\u4f1a\u8ba1\u62a5\u8868\u7684\u4e2d\u5fc3\u5185\u5bb9\u662f____\u3002\nA. \u8bd5\u7b97\u5e73\u8861\nB. \u7f16\u5236\u62b5\u6d88\u5206\u5f55\nC. \u5904\u7406\u4f01\u4e1a\u5185\u90e8\u7ecf\u6d4e\u4e1a\u52a1\u4e8b\u9879\nD. \u8fdb\u884c\u6bcd\u5b50\u516c\u53f8\u4f1a\u8ba1\u6570\u636e\u7684\u6c47\u603b\n",
        "output": "B. \u7f16\u5236\u62b5\u6d88\u5206\u5f55",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4f01\u4e1a\u7f34\u7eb3\u7684\u4e0b\u5217\u7a0e\u989d\u4e2d\uff0c\u5e94\u4f5c\u4e3a\u57ce\u5e02\u7ef4\u62a4\u5efa\u8bbe\u7a0e\u8ba1\u7a0e\u4f9d\u636e\u7684\u662f____\u3002\nA. \u6d88\u8d39\u7a0e\u7a0e\u989d\nB. \u623f\u4ea7\u7a0e\u7a0e\u989d\nC. \u57ce\u9547\u571f\u5730\u4f7f\u7528\u7a0e\u7a0e\u989d\nD. \u5173\u7a0e\u7a0e\u989d\n",
        "output": "A. \u6d88\u8d39\u7a0e\u7a0e\u989d",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u6709\u5173\u65e0\u5f62\u8d44\u4ea7\u644a\u9500\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u4f7f\u7528\u5bff\u547d\u786e\u5b9a\u7684\u65e0\u5f62\u8d44\u4ea7\u4e0d\u9700\u8981\u644a\u9500\uff0c\u5f53\u51fa\u73b0\u51cf\u503c\u8ff9\u8c61\u65f6\uff0c\u8fdb\u884c\u51cf\u503c\u6d4b\u8bd5\nB. \u5212\u5206\u4e3a\u6301\u6709\u5f85\u552e\u7684\u65e0\u5f62\u8d44\u4ea7\u5e94\u6309\u5c1a\u53ef\u4f7f\u7528\u5e74\u9650\u644a\u9500\nC. \u4f7f\u7528\u5bff\u547d\u6709\u9650\u7684\u65e0\u5f62\u8d44\u4ea7\uff0c\u5176\u6b8b\u503c\u4e00\u822c\u5e94\u5f53\u89c6\u4e3a\u96f6\nD. \u4e13\u95e8\u7528\u4e8e\u751f\u4ea7\u4ea7\u54c1\u7684\u65e0\u5f62\u8d44\u4ea7\uff0c\u6309\u671f\u644a\u9500\u8ba1\u5165\u7ba1\u7406\u8d39\u7528\n",
        "output": "C. \u4f7f\u7528\u5bff\u547d\u6709\u9650\u7684\u65e0\u5f62\u8d44\u4ea7\uff0c\u5176\u6b8b\u503c\u4e00\u822c\u5e94\u5f53\u89c6\u4e3a\u96f6",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5212\u5206\u4ea7\u54c1\u6210\u672c\u8ba1\u7b97\u7684\u57fa\u672c\u65b9\u6cd5\u548c\u8f85\u52a9\u65b9\u6cd5\u7684\u6807\u51c6\u662f____\u3002\nA. \u6210\u672c\u8ba1\u7b97\u5de5\u4f5c\u7684\u7b80\u7e41\nB. \u5bf9\u6210\u672c\u7ba1\u7406\u4f5c\u7528\u7684\u5927\u5c0f\nC. \u6210\u672c\u8ba1\u7b97\u662f\u5426\u53ca\u65f6\nD. \u5bf9\u8ba1\u7b97\u4ea7\u54c1\u5b9e\u9645\u6210\u672c\u662f\u5426\u5fc5\u4e0d\u53ef\u5c11\n",
        "output": "D. \u5bf9\u8ba1\u7b97\u4ea7\u54c1\u5b9e\u9645\u6210\u672c\u662f\u5426\u5fc5\u4e0d\u53ef\u5c11",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6210\u672c\u6838\u7b97\u7684\u57fa\u672c\u5047\u5b9a\u4e2d\u201c\u6750\u6599\u7269\u8d44\u8ba1\u4ef7\u5047\u5b9a\u201d\u7684\u57fa\u7840\u662f____\u3002\nA. \u56fd\u5bb6\u65b9\u9488\u653f\u7b56\nB. \u4f01\u4e1a\u4f1a\u8ba1\u51c6\u5219\nC. \u4f01\u4e1a\u7ecf\u8425\u7ba1\u7406\u89c4\u7ae0\nD. \u4f01\u4e1a\u6210\u672c\u5206\u914d\u6807\u51c6\n",
        "output": "B. \u4f01\u4e1a\u4f1a\u8ba1\u51c6\u5219",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u80a1\u6743\u6295\u8d44\u57fa\u91d1\u7ba1\u7406\u4eba\u5e94\u5f53\u4e8e\u6bcf\u4e2a\u4f1a\u8ba1\u5e74\u5ea6\u7ed3\u675f\u540e\u7684____\u4e2a\u6708\u5185\uff0c\u5411\u4e2d\u56fd\u8bc1\u5238\u6295\u8d44\u57fa\u91d1\u4e1a\u534f\u4f1a\u62a5\u9001\u7ecf\u4f1a\u8ba1\u5e08\u4e8b\u52a1\u6240\u5ba1\u8ba1\u7684\u5e74\u5ea6\u8d22\u52a1\u62a5\u544a\u548c\u6240\u7ba1\u7406\u80a1\u6743\u6295\u8d44\u57fa\u91d1\u5e74\u5ea6\u6295\u8d44\u8fd0\u4f5c\u57fa\u672c\u60c5\u51b5\u3002\nA. 1\nB. 2\nC. 3\nD. 4\n",
        "output": "D. 4",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u57fa\u91d1\u5229\u6da6\u662f\u6307\u57fa\u91d1\u5728\u4e00\u5b9a____\u7684\u7ecf\u8425\u6210\u679c\u3002\nA. \u4f1a\u8ba1\u65f6\u671f\nB. \u4f1a\u8ba1\u671f\u95f4\nC. \u4f1a\u8ba1\u95f4\u671f\nD. \u4f1a\u8ba1\u65f6\u95f4\n",
        "output": "B. \u4f1a\u8ba1\u671f\u95f4",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5c5e\u4e8e\u6269\u5f20\u6027\u8d27\u5e01\u653f\u7b56\u64cd\u4f5c\u7684\u662f____\u3002\nA. \u53d1\u884c\u592e\u884c\u7968\u636e\nB. \u964d\u4f4e\u6cd5\u5b9a\u5b58\u6b3e\u51c6\u5907\u91d1\u7387\nC. \u5728\u516c\u5f00\u5e02\u573a\u4e0a\u8fdb\u884c\u6b63\u56de\u8d2d\u64cd\u4f5c\nD. \u5728\u516c\u5f00\u5e02\u573a\u4e0a\u8fdb\u884c\u73b0\u5238\u5356\u65ad\u64cd\u4f5c\n",
        "output": "B. \u964d\u4f4e\u6cd5\u5b9a\u5b58\u6b3e\u51c6\u5907\u91d1\u7387",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d27\u5e01\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4f01\u4e1a\u884c\u653f\u7ba1\u7406\u90e8\u95e8\u8ba1\u63d0\u7684\u56fa\u5b9a\u8d44\u4ea7\u6298\u65e7\u8d39\uff0c\u5e94\u501f\u8bb0____\u3002\nA. \u201c\u9884\u63d0\u8d39\u7528\u201d\u79d1\u76ee\nB. \u201c\u8d22\u52a1\u8d39\u7528\u201d\u79d1\u76ee\nC. \u201c\u7ba1\u7406\u8d39\u7528\u201d\u79d1\u76ee\nD. \u201c\u5236\u9020\u8d39\u7528\u201d\u79d1\u76ee\n",
        "output": "C. \u201c\u7ba1\u7406\u8d39\u7528\u201d\u79d1\u76ee",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5404\u9879\u5173\u4e8e\u7eb3\u7a0e\u7533\u62a5\u7ba1\u7406\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u6263\u7f34\u4eba\u4e0d\u5f97\u91c7\u53d6\u90ae\u5bc4\u7533\u62a5\u7684\u65b9\u5f0f\nB. \u7eb3\u7a0e\u4eba\u5728\u7eb3\u7a0e\u671f\u5185\u6ca1\u6709\u5e94\u7eb3\u7a0e\u6b3e\u7684\uff0c\u4e0d\u5fc5\u529e\u7406\u7eb3\u7a0e\u7533\u62a5\nC. \u5b9e\u884c\u5b9a\u671f\u5b9a\u989d\u7f34\u7eb3\u7a0e\u6b3e\u7684\u7eb3\u7a0e\u4eba\u53ef\u4ee5\u5b9e\u884c\u7b80\u6613\u7533\u62a5\u3001\u7b80\u5e76\u5f81\u671f\u7b49\u7533\u62a5\u7eb3\u7a0e\u65b9\u5f0f\nD. \u4e3b\u7ba1\u7a0e\u52a1\u673a\u5173\u6839\u636e\u7eb3\u7a0e\u4eba\u5b9e\u9645\u60c5\u51b5\u53ca\u5176\u6240\u7eb3\u7a0e\u79cd\u786e\u5b9a\u7684\u7eb3\u7a0e\u7533\u62a5\u671f\u9650\u4e0d\u5177\u6709\u6cd5\u5f8b\u6548\u529b\n",
        "output": "C. \u5b9e\u884c\u5b9a\u671f\u5b9a\u989d\u7f34\u7eb3\u7a0e\u6b3e\u7684\u7eb3\u7a0e\u4eba\u53ef\u4ee5\u5b9e\u884c\u7b80\u6613\u7533\u62a5\u3001\u7b80\u5e76\u5f81\u671f\u7b49\u7533\u62a5\u7eb3\u7a0e\u65b9\u5f0f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e00\u822c\u60c5\u51b5\u4e0b\uff0c____\u4e0d\u7b97\u662f\u5c3d\u804c\u8c03\u67e5\u4e2d\u5fc5\u4e0d\u53ef\u5c11\u7684\u8c03\u67e5\u5185\u5bb9\u3002\nA. \u8d22\u52a1\u548c\u7a0e\u52a1\u5c3d\u804c\u8c03\u67e5\nB. \u6cd5\u5f8b\u5c3d\u804c\u8c03\u67e5\nC. \u4f01\u4e1a\u4e3b\u80cc\u666f\u5c3d\u804c\u8c03\u67e5\nD. \u8fd0\u8425\u5c3d\u804c\u8c03\u67e5\n",
        "output": "C. \u4f01\u4e1a\u4e3b\u80cc\u666f\u5c3d\u804c\u8c03\u67e5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u4e2a\u4eba\u72ec\u8d44\u4f01\u4e1a\u7684\u8868\u8ff0\u6b63\u786e\u7684\u662f____\u3002\nA. \u4e2a\u4eba\u72ec\u8d44\u4f01\u4e1a\u8bbe\u7acb\u65f6\uff0c\u4e0d\u9700\u8981\u6709\u6295\u8d44\u4eba\u7533\u62a5\u7684\u51fa\u8d44\nB. \u4e2a\u4eba\u72ec\u8d44\u4f01\u4e1a\u7684\u6295\u8d44\u4eba\u4e00\u822c\u662f\u81ea\u7136\u4eba\uff0c\u4f46\u4e5f\u53ef\u4ee5\u662f\u6cd5\u4eba\nC. \u4e2a\u4eba\u72ec\u8d44\u4f01\u4e1a\u7684\u6295\u8d44\u4eba\u5bf9\u4f01\u4e1a\u7684\u503a\u52a1\u627f\u62c5\u65e0\u9650\u8d23\u4efb\nD. \u4e2a\u4eba\u72ec\u8d44\u4f01\u4e1a\u4e0d\u9700\u8981\u56fa\u5b9a\u7684\u7ecf\u8425\u573a\u6240\n",
        "output": "C. \u4e2a\u4eba\u72ec\u8d44\u4f01\u4e1a\u7684\u6295\u8d44\u4eba\u5bf9\u4f01\u4e1a\u7684\u503a\u52a1\u627f\u62c5\u65e0\u9650\u8d23\u4efb",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u501f\u6b3e\u4eba\u4e3a\u53d7\u6559\u80b2\u4eba\u7684\uff0c\u53ef\u80fd\u88ab\u5b66\u6821\u5f00\u9664\uff0c\u56e0\u5b66\u4e60\u6210\u7ee9\u4e0d\u597d\u62ff\u4e0d\u5230\u6bd5\u4e1a\u8bc1\u548c\u5b66\u4f4d\u8bc1\u3002\u8fd9\u5c5e\u4e8e\u4e2a\u4eba\u6559\u80b2\u8d37\u6b3e\u4fe1\u7528\u98ce\u9669\u4e2d\u7684____\u3002\nA. \u6b3a\u8bc8\u98ce\u9669\nB. \u64cd\u4f5c\u98ce\u9669\nC. \u8fd8\u6b3e\u610f\u613f\u98ce\u9669\nD. \u8fd8\u6b3e\u80fd\u529b\u98ce\u9669\n",
        "output": "D. \u8fd8\u6b3e\u80fd\u529b\u98ce\u9669",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u4e0b\u54ea\u4e2a\u7406\u8bba\u6846\u67b6\u63cf\u8ff0\u4e86\u8d44\u672c\u5e02\u573a\u4e2d\u98ce\u9669\u4e0e\u9884\u671f\u56de\u62a5\u4e4b\u95f4\u7684\u5173\u7cfb____\u3002\nA. \u98ce\u9669\u5206\u6563\u6548\u5e94\nB. \u8d44\u672c\u8d44\u4ea7\u5b9a\u4ef7\u6a21\u578b(CAPM)\nC. \u5e02\u573a\u7ec4\u5408\nD. \u6709\u6548\u96c6\n",
        "output": "B. \u8d44\u672c\u8d44\u4ea7\u5b9a\u4ef7\u6a21\u578b(CAPM)",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u53e4\u8bfa\u6a21\u578b\u8ba8\u8bba\u7684\u662f____\u6761\u4ef6\u4e0b\u7684\u5382\u5546\u884c\u4e3a\u3002\nA. \u4ef7\u683c\u7ade\u4e89\u7684\u5e02\u573a\nB. \u4ea7\u91cf\u7ade\u4e89\u7684\u5e02\u573a\nC. \u4ea7\u91cf\u9886\u5bfc\u7684\u5e02\u573a\nD. \u4ef7\u683c\u9886\u5bfc\u7684\u5e02\u573a\n",
        "output": "B. \u4ea7\u91cf\u7ade\u4e89\u7684\u5e02\u573a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u80a1\u6307\u671f\u6743\u5e02\u573a\u4e0a\uff0c\u5982\u679c\u9884\u671f\u80a1\u5e02\u4f1a\u5728\u4ea4\u6613\u5b8c\u6210\u540e\u8fc5\u901f\u4e0a\u6da8\uff0c\u4ee5\u4e0b\u4ea4\u6613\u98ce\u9669\u6700\u5927\u7684\u662f____\u3002\nA. \u5356\u51fa\u770b\u6da8\u671f\u6743\nB. \u5356\u51fa\u770b\u8dcc\u671f\u6743\nC. \u4e70\u5165\u770b\u6da8\u671f\u6743\nD. \u4e70\u5165\u770b\u8dcc\u671f\u6743\n",
        "output": "A. \u5356\u51fa\u770b\u6da8\u671f\u6743",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5404\u9879\u7a0e\u6cd5\u539f\u5219\u4e2d\uff0c\u5c5e\u4e8e\u7a0e\u6cd5\u57fa\u672c\u539f\u5219\u6838\u5fc3\u7684\u662f____\u3002\nA. \u7a0e\u6536\u516c\u5e73\u539f\u5219\nB. \u7a0e\u6536\u6548\u7387\u539f\u5219\nC. \u5b9e\u8d28\u8bfe\u7a0e\u539f\u5219\nD. \u7a0e\u6536\u6cd5\u5b9a\u539f\u5219\n",
        "output": "D. \u7a0e\u6536\u6cd5\u5b9a\u539f\u5219",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5047\u8bbe\u4e00\u4e2a\u7ecf\u6d4e\u4e2d\u6d41\u901a\u4e2d\u73b0\u91d1\u670920\u4ebf\u5143\uff0c\u5b58\u6b3e\u6709100\u4ebf\u5143\uff0c\u51c6\u5907\u91d1\u670930\u4ebf\u5143\uff0c\u6cd5\u5b9a\u5b58\u6b3e\u51c6\u5907\u91d1\u7387\u662f2\u90a3\u4e48\u7ecf\u6d4e\u4e2d\u5546\u4e1a\u94f6\u884c\u6301\u6709\u8d85\u989d\u5b58\u6b3e\u51c6\u5907\u91d1\u548c\u8d27\u5e01\u4e58\u6570\u5206\u522b\u662f____\u3002\nA. 10\u4ebf\u5143\u548c3\nB. 20\u4ebf\u5143\u548c4\nC. 10\u4ebf\u5143\u548c2\nD. 10\u4ebf\u5143\u548c4\n",
        "output": "D. 10\u4ebf\u5143\u548c4",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u592e\u94f6\u884c\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u8fdc\u671f\u5408\u7ea6\u7684\u4e3b\u8981\u4f18\u70b9\u662f____\u3002\nA. \u53ef\u4ee5\u7075\u6d3b\u7684\u4f9d\u636e\u4ea4\u6613\u53cc\u65b9\u7684\u9700\u8981\u8ba2\u7acb\nB. \u6807\u51c6\u5316\u5408\u7ea6\uff0c\u53ef\u4ee5\u51cf\u5c11\u4ea4\u6613\u6210\u672c\nC. \u4e0d\u53d7\u91d1\u878d\u76d1\u7ba1\u673a\u6784\u76d1\u7ba1\nD. \u6ca1\u6709\u8fdd\u7ea6\u98ce\u9669\n",
        "output": "A. \u53ef\u4ee5\u7075\u6d3b\u7684\u4f9d\u636e\u4ea4\u6613\u53cc\u65b9\u7684\u9700\u8981\u8ba2\u7acb",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u671f\u8d27\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u4ea4\u6613\u6216\u4e8b\u9879\u5f62\u6210\u7684\u8d1f\u503a\u4e2d\uff0c\u5176\u8ba1\u7a0e\u57fa\u7840\u4e0d\u7b49\u4e8e\u8d26\u9762\u4ef7\u503c\u7684\u662f____\u3002\nA. \u4f01\u4e1a\u56e0\u9500\u552e\u5546\u54c1\u63d0\u4f9b\u552e\u540e\u670d\u52a1\u7b49\u539f\u56e0\u4e8e\u5f53\u671f\u786e\u8ba4\u4e86100\u4e07\u5143\u7684\u9884\u8ba1\u8d1f\u503a\nB. \u4f01\u4e1a\u4e3a\u5173\u8054\u65b9\u63d0\u4f9b\u503a\u52a1\u62c5\u4fdd\u786e\u8ba4\u4e86\u9884\u8ba1\u8d1f\u503a1000\u4e07\u5143\nC. \u4f01\u4e1a\u5f53\u671f\u786e\u8ba4\u5e94\u652f\u4ed8\u804c\u5de5\u85aa\u916c1000\u4e07\u5143\uff0c\u5c1a\u672a\u652f\u4ed8\u3002\u6309\u7167\u7a0e\u6cd5\u89c4\u5b9a\uff0c\u8be5\u4f01\u4e1a\u53ef\u4ee5\u4e8e\u5f53\u671f\u7a0e\u524d\u6263\u9664\u7684\u90e8\u5206\u4e3a800\u4e07\u5143\nD. \u7a0e\u6cd5\u89c4\u5b9a\u7684\u6536\u5165\u786e\u8ba4\u65f6\u70b9\u4e0e\u4f1a\u8ba1\u51c6\u5219\u4e00\u81f4\uff0c\u4f1a\u8ba1\u4e0a\u786e\u8ba4\u9884\u6536\u8d26\u6b3e500\u4e07\u5143\n",
        "output": "A. \u4f01\u4e1a\u56e0\u9500\u552e\u5546\u54c1\u63d0\u4f9b\u552e\u540e\u670d\u52a1\u7b49\u539f\u56e0\u4e8e\u5f53\u671f\u786e\u8ba4\u4e86100\u4e07\u5143\u7684\u9884\u8ba1\u8d1f\u503a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u76ee\u524d\u7edd\u5927\u591a\u6570\u56fd\u5bb6\u91c7\u7528\u7684\u5916\u6c47\u6807\u4ef7\u65b9\u6cd5\u662f____\u3002\nA. \u95f4\u63a5\u6807\u4ef7\u6cd5\nB. \u76f4\u63a5\u6807\u4ef7\u6cd5\nC. \u82f1\u9551\u6807\u4ef7\u6cd5\nD. \u6b27\u5143\u6807\u4ef7\u6cd5\n",
        "output": "B. \u76f4\u63a5\u6807\u4ef7\u6cd5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u671f\u8d27\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u589e\u52a0\u5ba1\u8ba1\u7a0b\u5e8f\u4e0d\u53ef\u9884\u89c1\u6027\u7684\u8bf4\u6cd5\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u6ce8\u518c\u4f1a\u8ba1\u5e08\u4e0d\u80fd\u63d0\u524d\u544a\u77e5\u88ab\u5ba1\u8ba1\u5355\u4f4d\u7ba1\u7406\u5c42\u4f1a\u5b9e\u65bd\u5177\u6709\u4e0d\u53ef\u9884\u89c1\u6027\u7684\u5ba1\u8ba1\u7a0b\u5e8f\nB. \u6ce8\u518c\u4f1a\u8ba1\u5e08\u53ef\u4ee5\u63d0\u524d\u544a\u77e5\u88ab\u5ba1\u8ba1\u5355\u4f4d\u7ba1\u7406\u5c42\u5177\u6709\u4e0d\u53ef\u9884\u89c1\u6027\u7684\u5ba1\u8ba1\u7a0b\u5e8f\u7684\u5177\u4f53\u5185\u5bb9\nC. \u9879\u76ee\u5408\u4f19\u4eba\u9700\u8981\u5b89\u6392\u9879\u76ee\u7ec4\u6210\u5458\u6709\u6548\u5730\u5b9e\u65bd\u5177\u6709\u4e0d\u53ef\u9884\u89c1\u6027\u7684\u5ba1\u8ba1\u7a0b\u5e8f\uff0c\u4f46\u540c\u5bf9\u8981\u907f\u514d\u4f7f\u9879\u76ee\u7ec4\u6210\u5458\u5904\u4e8e\u56f0\u96be\u7edd\u5883\nD. \u4e3a\u4e86\u907f\u514d\u635f\u5bb3\u5ba1\u8ba1\u7684\u4e0d\u53ef\u9884\u89c1\u6027\uff0c\u6ce8\u518c\u4f1a\u8ba1\u5e08\u4e0d\u80fd\u5728\u7b7e\u8ba2\u5ba1\u8ba1\u4e1a\u52a1\u7ea6\u5b9a\u4e66\u5bf9\u660e\u786e\u63d0\u51fa\u589e\u52a0\u5ba1\u8ba1\u7a0b\u5e8f\u4e0d\u53ef\u9884\u89c1\u6027\u7684\u8981\u6c42\n",
        "output": "C. \u9879\u76ee\u5408\u4f19\u4eba\u9700\u8981\u5b89\u6392\u9879\u76ee\u7ec4\u6210\u5458\u6709\u6548\u5730\u5b9e\u65bd\u5177\u6709\u4e0d\u53ef\u9884\u89c1\u6027\u7684\u5ba1\u8ba1\u7a0b\u5e8f\uff0c\u4f46\u540c\u5bf9\u8981\u907f\u514d\u4f7f\u9879\u76ee\u7ec4\u6210\u5458\u5904\u4e8e\u56f0\u96be\u7edd\u5883",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5ba1\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u519c\u6751\u91d1\u878d\u673a\u6784\u5bf9\u6309\u671f\u8fd8\u6b3e\u3001\u4fe1\u7528\u826f\u597d\u7684\u501f\u6b3e\u4eba\u91c7\u53d6\u7684\u5956\u52b1\u65b9\u5f0f\u4e0d\u5305\u62ec____\u3002\nA. \u4f18\u60e0\u5229\u7387\nB. \u5229\u606f\u8fd4\u8fd8\nC. \u4fe1\u7528\u7d2f\u79ef\nD. \u8fd4\u8fd8\u672c\u91d1\n",
        "output": "D. \u8fd4\u8fd8\u672c\u91d1",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u300a\u56fd\u9645\u6536\u652f\u624b\u518c\u300b\u7b2c\u4e94\u7248\u89c4\u5b9a\uff0c\u8bb0\u5728\u8d44\u672c\u4e0e\u91d1\u878d\u8d26\u6237\u7684\u662f____\u3002\nA. \u670d\u52a1\u6536\u5165\nB. \u80a1\u672c\u6536\u5165\nC. \u503a\u52a1\u6838\u9500\nD. \u503a\u52a1\u6536\u5165\n",
        "output": "C. \u503a\u52a1\u6838\u9500",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d27\u5e01\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6211\u56fd\u4e2d\u671f\u8d22\u52a1\u62a5\u544a\u7f16\u5236\u7684\u7406\u8bba\u57fa\u7840\u5e94\u4fa7\u91cd\u4e8e____\u3002\nA. \u72ec\u7acb\u89c2\nB. \u4e1a\u4e3b\u89c2\nC. \u5b9e\u4f53\u89c2\nD. \u4e00\u4f53\u89c2\n",
        "output": "A. \u72ec\u7acb\u89c2",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u4f01\u4e1a\u662f\u4e00\u5bb6\u5355\u4e00\u4e1a\u52a1\u4f01\u4e1a\uff0c\u91c7\u7528\u7684\u7ec4\u7ec7\u7ed3\u6784\u7279\u70b9\u662f\u4e0d\u540c\u7684\u90e8\u95e8\u6709\u4e0d\u540c\u7684\u4e1a\u52a1\u804c\u80fd\uff1a\u8425\u9500\u90e8\u95e8\u8d1f\u8d23\u4ea7\u54c1\u7684\u8425\u9500\u548c\u63a8\u5e7f\uff0c\u8d22\u52a1\u90e8\u8d1f\u8d23\u8bb0\u5f55\u6240\u6709\u4ea4\u6613\u5e76\u63a7\u5236\u6240\u6709\u4e0e\u7ecf\u8d39\u548c\u8d22\u52a1\u76f8\u5173\u7684\u6d3b\u52a8\u7b49\uff0c\u5404\u90e8\u95e8\u4e4b\u95f4\u76f8\u4e92\u72ec\u7acb\u3002\u8be5\u4f01\u4e1a\u9002\u5b9c\u91c7\u7528\u7684\u7ec4\u7ec7\u7ed3\u6784\u7684\u4f18\u70b9\u662f____\u3002\nA. \u4fbf\u4e8e\u4f01\u4e1a\u7684\u6301\u7eed\u6210\u957f\nB. \u6709\u5229\u4e8e\u57f9\u517b\u804c\u80fd\u4e13\u5bb6\nC. \u80fd\u66f4\u6709\u6548\u5730\u4f18\u5148\u8003\u8651\u5173\u952e\u9879\u76ee\nD. \u80fd\u5b9e\u73b0\u66f4\u597d\u66f4\u5feb\u7684\u5730\u533a\u51b3\u7b56\n",
        "output": "B. \u6709\u5229\u4e8e\u57f9\u517b\u804c\u80fd\u4e13\u5bb6",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u65b0\u51ef\u6069\u65af\u4e3b\u4e49\u6700\u91cd\u8981\u7684\u5047\u8bbe\u662f____\u3002\nA. \u975e\u5e02\u573a\u51fa\u6e05\nB. \u7ecf\u6d4e\u5f53\u4e8b\u4eba\u6700\u5927\u5316\u539f\u5219\nC. \u4fe1\u606f\u4e0d\u5b8c\u5168\nD. \u4ef7\u683c\u9ecf\u6027\n",
        "output": "D. \u4ef7\u683c\u9ecf\u6027",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6211\u56fd\u300a\u4fdd\u9669\u6cd5\u300b\u5c06\u4fdd\u9669\u516c\u53f8\u7ecf\u8425\u7684\u4e1a\u52a1\u5206\u4e3a____\u4e24\u5927\u7c7b\u3002\nA. \u8d22\u4ea7\u4fdd\u9669\u4e0e\u4eba\u5bff\u4fdd\u9669\nB. \u635f\u5931\u4fdd\u9669\u4e0e\u4eba\u8eab\u4fdd\u9669\nC. \u8d22\u4ea7\u4fdd\u9669\u4e0e\u4eba\u8eab\u4fdd\u9669\nD. \u666e\u901a\u4fdd\u9669\u4e0e\u6cd5\u5b9a\u4fdd\u9669\n",
        "output": "C. \u8d22\u4ea7\u4fdd\u9669\u4e0e\u4eba\u8eab\u4fdd\u9669",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4fdd\u9669\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u516c\u53f8\u80a1\u7968\u5347\u81f3\u8d85\u8fc7\u8f6c\u6362\u4ef7\u683c\u4e00\u5b9a\u500d\u6570\u65f6\uff0c\u516c\u53f8\u4e3a\u907f\u514d\u80a1\u672c\u88ab\u8fc7\u5ea6\u7a00\u91ca\uff0c\u4ee5\u53ca\u652f\u4ed8\u53ef\u8f6c\u6362\u503a\u5238\u6301\u6709\u8005\u8fc7\u591a\u7684\u76c8\u5229\u800c\u884c\u4f7f____\u6743\u5229\u3002\nA. \u8f6c\u6362\nB. \u6258\u7ba1\nC. \u8d4e\u56de\nD. \u56de\u552e\n",
        "output": "C. \u8d4e\u56de",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e00\u53ea\u80a1\u7968\u73b0\u5728\u7684\u4ef7\u683c\u662f100\u5143\uff0c\u5f53\u524d\u7684\u5206\u7ea2\u662f2\u5143\uff0c\u5206\u7ea2\u9884\u671f\u5728\u672a\u6765\u4ee5\u5e38\u6570\u589e\u957f\uff0c\u589e\u957f\u7387\u4e3a8$\\%$\u3002\u90a3\u4e48\uff0c\u8be5\u80a1\u7968\u7684\u5fc5\u8981\u6536\u76ca\u7387\u6700\u63a5\u8fd1\u4e8e____\u3002\nA. 11$\\%$\nB. 10.16$\\%$\nC. 5.8$\\%$\nD. 3$\\%$\n",
        "output": "B. 10.16$\\%$",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5e02\u573a\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "2022\u5e743 \u6708\uff0c\u7532\u5e02\u67d0\u70df\u8349\u516c\u53f8\u5411\u4e59\u53bf\u67d0\u70df\u8349\u79cd\u690d\u6237\u6536\u8d2d\u4e86\u4e00\u6279\u70df\u53f6\uff0c\u6536\u8d2d\u4ef7\u6b3e90 \u4e07\u5143\u3001\u4ef7\u5916\u8865\u8d349\u4e07\u5143\u3002\u4e0b\u5217\u5173\u4e8e\u8be5\u7b14\u70df\u53f6\u4ea4\u6613\u6d89\u53ca\u70df\u53f6\u7a0e\u5f81\u6536\u7ba1\u7406\u7684\u8868\u8ff0\u4e2d\uff0c\u7b26\u5408\u7a0e\u6cd5\u89c4\u5b9a\u7684\u4e0d\u5305\u62ec____\u3002\nA. \u7eb3\u7a0e\u4eba\u4e3a\u70df\u53f6\u79cd\u690d\u6237\nB. \u5e94\u7eb3\u7a0e\u989d\u4e3a19.8\u4e07\u5143\nC. \u5e94\u5728\u6b21\u670815\u65e5\u5185\u7533\u62a5\u7eb3\u7a0e\nD. \u5e94\u5411\u4e59\u53bf\u4e3b\u7ba1\u7a0e\u52a1\u673a\u5173\u7533\u62a5\u7eb3\u7a0e\n",
        "output": "A. \u7eb3\u7a0e\u4eba\u4e3a\u70df\u53f6\u79cd\u690d\u6237",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "2020\u5e744\u6708\uff0c\u67d0\u4f01\u4e1a\u5c06\u5176\u4e0e\u529e\u516c\u697c\u76f8\u8fde\u7684\u5730\u4e0b\u505c\u8f66\u573a\u548c\u53e6\u4e00\u72ec\u7acb\u7684\u5730\u4e0b\u5efa\u7b51\u7269\u6539\u4e3a\u5730\u4e0b\u751f\u4ea7\u8f66\u95f4\uff0c\u505c\u8f66\u573a\u539f\u503c100\u4e07\u5143\uff0c\u5730\u4e0b\u5efa\u7b51\u7269\u539f\u4ef7200\u4e07\u5143\uff0c\u8be5\u4f01\u4e1a\u6240\u5728\u7701\u8d22\u653f\u548c\u5730\u65b9\u7a0e\u52a1\u90e8\u95e8\u786e\u5b9a\u5730\u4e0b\u5efa\u7b51\u7269\u7684\u623f\u4ea7\u539f\u4ef7\u7684\u6298\u7b97\u6bd4\u4f8b\u4e3a50$\\%$\uff0c\u623f\u4ea7\u539f\u503c\u51cf\u9664\u6bd4\u4f8b\u4e3a30$\\%$\u3002\u8be5\u4f01\u4e1a\u4ee5\u4e0a\u4e24\u5904\u5730\u4e0b\u5efa\u7b51\u72692020\u5e744\u6708\u81f312\u6708\u4efd\u5e94\u7f34\u7eb3\u623f\u4ea7\u7a0e____\u4e07\u5143\u3002\nA. 0.95\nB. 1.15\nC. 1.26\nD. 1.89\n",
        "output": "C. 1.26",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5df2\u77e5\u5f53\u524d\u9ec4\u91d1\u73b0\u8d27\u7684\u4ef7\u683c\u4e3a$1200/\u76ce\u53f8\uff0c\u5e74\u50a8\u5b58\u6210\u672c\u7387\u4e3a\u73b0\u8d27\u4ef7\u683c\u76842$\\%$\uff08\u5047\u8bbe\u5e74\u672b\u652f\u4ed8\uff09\uff0c\u4e00\u5e74\u671f\u65e0\u98ce\u9669\u5229\u7387\u4e3a8$\\%$\u3002\u5982\u679c\u5f53\u524d\u5e02\u573a\u4e0a1\u5e74\u671f\u9ec4\u91d1\u671f\u8d27\u7684\u4ea4\u6613\u4ef7\u683c\u4e3a$1340/\u76ce\u53f8\uff0c\u90a3\u4e48\u4e0b\u5217\u5957\u5229\u7b56\u7565\u6b63\u786e\u7684\u662f____\u3002\nA. \u505a\u7a7a\u9ec4\u91d1\u671f\u8d27\u3001\u8d2d\u4e70\u9ec4\u91d1\u73b0\u8d27\u3001\u5356\u7a7a\u65e0\u98ce\u9669\u56fd\u503a\nB. \u505a\u591a\u9ec4\u91d1\u671f\u8d27\u3001\u8d2d\u4e70\u9ec4\u91d1\u73b0\u8d27\u3001\u5356\u7a7a\u65e0\u98ce\u9669\u56fd\u503a\nC. \u505a\u7a7a\u9ec4\u91d1\u671f\u8d27\u3001\u5356\u7a7a\u9ec4\u91d1\u73b0\u8d27\u3001\u8d2d\u4e70\u65e0\u98ce\u9669\u56fd\u503a\nD. \u505a\u591a\u9ec4\u91d1\u671f\u8d27\u3001\u5356\u7a7a\u9ec4\u91d1\u73b0\u8d27\u3001\u8d2d\u4e70\u65e0\u98ce\u9669\u56fd\u503a\n",
        "output": "A. \u505a\u7a7a\u9ec4\u91d1\u671f\u8d27\u3001\u8d2d\u4e70\u9ec4\u91d1\u73b0\u8d27\u3001\u5356\u7a7a\u65e0\u98ce\u9669\u56fd\u503a",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5e02\u573a\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6211\u56fd\u201c\u4e94\u4f4d\u4e00\u4f53\u201d\u7684\u671f\u8d27\u76d1\u7ba1\u534f\u8c03\u673a\u6784\u4e0d\u5305\u542b____\u3002\nA. \u4e2d\u56fd\u8bc1\u76d1\u4f1a\u5730\u65b9\u6d3e\u51fa\u673a\u6784\nB. \u671f\u8d27\u4ea4\u6613\u6240\nC. \u671f\u8d27\u516c\u53f8\nD. \u4e2d\u56fd\u671f\u8d27\u4e1a\u534f\u4f1a\n",
        "output": "C. \u671f\u8d27\u516c\u53f8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u671f\u8d27\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u4f01\u4e1a\u201c\u5e94\u6536\u8d26\u6b3e\u201d\u79d1\u76ee\u6708\u672b\u501f\u65b9\u91d1\u989d30000\u5143\uff0c\u5176\u4e2d\uff0c\u201c\u5e94\u6536A\u516c\u53f8\u8d26\u6b3e\u201d\u660e\u7ec6\u79d1\u76ee\u501f\u65b9\u91d1\u989d35000\u5143\uff0c\u201c\u5e94\u6536B\u516c\u53f8\u8d26\u6b3e\u201d\u660e\u7ec6\u79d1\u76ee\u8d37\u65b9\u91d1\u989d5000\u5143\uff1b\u201c\u9884\u6536\u8d26\u6b3e\u201d\u79d1\u76ee\u6708\u672b\u501f\u65b9\u91d1\u989d30000\u5143\uff0c\u5176\u4e2d\uff0c\u201c\u9884\u6536\u7532\u5de5\u5382\u8d26\u6b3e\u201d\u660e\u7ec6\u79d1\u76ee\u501f\u65b9\u91d1\u989d50000\u5143\uff0c\u201c\u9884\u6536\u4e59\u5de5\u5382\u8d26\u6b3e\u201d\u660e\u7ec6\u79d1\u76ee\u8d37\u65b9\u91d1\u989d20000\u5143\u3002\u5219\u8be5\u4f01\u4e1a\u6708\u672b\u8d44\u4ea7\u8d1f\u503a\u8868\u4e2d\u201c\u5e94\u6536\u8d26\u6b3e\u201d\u9879\u76ee\u7684\u91d1\u989d\u4e3a____\u5143\u3002\nA. 30000\nB. 60000\nC. 80000\nD. 85000\n",
        "output": "D. 85000",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u56fd\u7cbe\u7b97\u5e08\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u60c5\u5f62\u4e0d\u53ef\u4ee5\u7533\u8bf7\u516c\u79ef\u91d1\u4e2a\u4eba\u4f4f\u623f\u8d37\u6b3e\u7684____\u3002\nA. \u88c5\u4fee\u81ea\u6709\u4f4f\u623f\nB. \u5efa\u9020\u81ea\u6709\u4f4f\u623f\nC. \u8d2d\u4e70\u81ea\u6709\u4f4f\u623f\nD. \u7ffb\u5efa\u81ea\u6709\u4f4f\u623f\n",
        "output": "A. \u88c5\u4fee\u81ea\u6709\u4f4f\u623f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5546\u4e1a\u5229\u6da6\u662f\u901a\u8fc7\u5546\u54c1\u7684____\u5b9e\u73b0\u7684\u3002\nA. \u4ef7\u503c\u5dee\u989d\nB. \u4ef7\u683c\u5dee\u989d\nC. \u5e73\u5747\u5229\u6da6\nD. \u5269\u4f59\u4ef7\u503c\n",
        "output": "B. \u4ef7\u683c\u5dee\u989d",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u653f\u6cbb\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u82e5\u51c0\u73b0\u503c\u4e3a\u8d1f\u6570\uff0c\u8868\u660e\u8be5\u6295\u8d44\u9879\u76ee____\u3002\nA. \u5404\u5e74\u5229\u6da6\u5c0f\u4e8e0\uff0c\u4e0d\u53ef\u884c\nB. \u5b83\u7684\u6295\u8d44\u62a5\u916c\u7387\u5c0f\u4e8e0\uff0c\u4e0d\u53ef\u884c\nC. \u5b83\u7684\u6295\u8d44\u62a5\u916c\u7387\u6ca1\u6709\u8fbe\u5230\u9884\u5b9a\u7684\u6298\u73b0\u7387\uff0c\u4e0d\u53ef\u884c\nD. \u5b83\u7684\u6295\u8d44\u62a5\u916c\u7387\u8d85\u8fc7\u4e86\u9884\u5b9a\u7684\u6298\u73b0\u7387\uff0c\u4e0d\u53ef\u884c\n",
        "output": "C. \u5b83\u7684\u6295\u8d44\u62a5\u916c\u7387\u6ca1\u6709\u8fbe\u5230\u9884\u5b9a\u7684\u6298\u73b0\u7387\uff0c\u4e0d\u53ef\u884c",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u6295\u8d44\u65b9\u4e8e2019\u5e741\u67081\u65e5\u53d6\u5f97\u5bf9\u8054\u8425\u4f01\u4e1a30$\\%$\u7684\u80a1\u6743\uff0c\u80fd\u591f\u5bf9\u88ab\u6295\u8d44\u5355\u4f4d\u65bd\u52a0\u91cd\u5927\u5f71\u54cd\u3002\u53d6\u5f97\u6295\u8d44\u65f6\u88ab\u6295\u8d44\u5355\u4f4d\u7684\u67d0\u9879\u56fa\u5b9a\u8d44\u4ea7\u516c\u5141\u4ef7\u503c\u4e3a500\u4e07\u5143\uff0c\u8d26\u9762\u4ef7\u503c\u4e3a300\u4e07\u5143\uff0c\u5c1a\u53ef\u4f7f\u7528\u5e74\u9650\u4e3a10\u5e74\uff0c\u51c0\u6b8b\u503c\u4e3a\u96f6\uff0c\u6309\u7167\u5e74\u9650\u5e73\u5747\u6cd5\u8ba1\u63d0\u6298\u65e7\u3002\u88ab\u6295\u8d44\u5355\u4f4d2019\u5e74\u5ea6\u5229\u6da6\u8868\u4e2d\u51c0\u5229\u6da6\u4e3a1000\u4e07\u5143\u3002\u4e0d\u8003\u8651\u6240\u5f97\u7a0e\u548c\u5176\u4ed6\u56e0\u7d20\u7684\u5f71\u54cd\uff0c\u6295\u8d44\u65b9\u5bf9\u6b64\u6295\u8d44\u4e8e2019\u5e74\u5e94\u786e\u8ba4\u7684\u6295\u8d44\u6536\u76ca\u4e3a____\u4e07\u5143\u3002\nA. 300\nB. 291\nC. 294\nD. 240\n",
        "output": "C. 294",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4f01\u4e1a\u5185\u90e8\u96c6\u56e2\u4ea4\u6613\u7684\u56fa\u5b9a\u8d44\u4ea7\uff0c\u5230\u671f\u62a5\u5e9f\u6e05\u7406\u671f\u95f4\u9700\u8981\u62b5\u9500\u7684\u5185\u5bb9\u662f____\u3002\nA. \u4e0a\u671f\u591a\u8ba1\u63d0\u7684\u6298\u65e7\u8d39\u7528\nB. \u4e0a\u671f\u5c11\u8ba1\u63d0\u7684\u6298\u65e7\u8d39\u7528\nC. \u672c\u671f\u591a\u8ba1\u63d0\u7684\u6298\u65e7\u8d39\u7528\nD. \u4e0b\u671f\u5c11\u8ba1\u63d0\u7684\u6298\u65e7\u8d39\u7528\n",
        "output": "C. \u672c\u671f\u591a\u8ba1\u63d0\u7684\u6298\u65e7\u8d39\u7528",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ba1\u7406\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u4f1a\u8ba1\u8ba1\u91cf\u5c5e\u6027\u7684\u8868\u8ff0\u4e2d\uff0c\u4e0d\u6b63\u786e\u7684\u662f____\u3002\nA. \u5386\u53f2\u6210\u672c\u53cd\u6620\u7684\u662f\u8d44\u4ea7\u8fc7\u53bb\u7684\u4ef7\u503c\nB. \u91cd\u7f6e\u6210\u672c\u662f\u53d6\u5f97\u76f8\u540c\u6216\u76f8\u4f3c\u8d44\u4ea7\u7684\u73b0\u884c\u6210\u672c\nC. \u73b0\u503c\u662f\u53d6\u5f97\u67d0\u9879\u8d44\u4ea7\u5728\u5f53\u524d\u9700\u8981\u652f\u4ed8\u7684\u73b0\u91d1\u6216\u5176\u4ed6\u7b49\u4ef7\u7269\nD. \u516c\u5141\u4ef7\u503c\u662f\u6307\u5e02\u573a\u53c2\u4e0e\u8005\u5728\u8ba1\u91cf\u65e5\u53d1\u751f\u7684\u6709\u5e8f\u4ea4\u6613\u4e2d\uff0c\u51fa\u552e\u4e00\u9879\u8d44\u4ea7\u6240\u80fd\u6536\u5230\u6216\u8005\u8f6c\u79fb\u4e00\u9879\u8d1f\u503a\u6240\u9700\u652f\u4ed8\u7684\u4ef7\u683c\n",
        "output": "C. \u73b0\u503c\u662f\u53d6\u5f97\u67d0\u9879\u8d44\u4ea7\u5728\u5f53\u524d\u9700\u8981\u652f\u4ed8\u7684\u73b0\u91d1\u6216\u5176\u4ed6\u7b49\u4ef7\u7269",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u91d1\u878d\u5e02\u573a\u5206\u4e3a\u73b0\u8d27\u5e02\u573a\u4e0e\u671f\u8d27\u5e02\u573a\uff0c\u8fd9\u662f\u6309____\u6765\u5212\u5206\u7684\u3002\nA. \u4ea4\u6613\u7684\u9636\u6bb5\nB. \u4ea4\u6613\u573a\u6240\nC. \u4ea4\u5272\u65f6\u95f4\nD. \u671f\u9650\u957f\u77ed\n",
        "output": "C. \u4ea4\u5272\u65f6\u95f4",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5546\u4e1a\u94f6\u884c\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f8\u5411\u4e59\u516c\u53f8\u53d1\u884c\u80a1\u796810000\u4e07\u80a1\u53d6\u5f97\u4e59\u516c\u53f880$\\\uff05$\u7684\u80a1\u6743\uff0c\u7532\u516c\u53f8\u3001\u4e59\u516c\u53f8\u6cd5\u4eba\u8d44\u683c\u4fdd\u6301\u4e0d\u53d8\u3002\u8fd9\u79cd\u5408\u5e76\u65b9\u5f0f\u662f____\u3002\nA. \u6a2a\u5411\u5408\u5e76\nB. \u65b0\u8bbe\u5408\u5e76\nC. \u5438\u6536\u5408\u5e76\nD. \u63a7\u80a1\u5408\u5e76\n",
        "output": "D. \u63a7\u80a1\u5408\u5e76",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5173\u4e8e\u8bc1\u5238\u516c\u53f8\u5408\u89c4\u8d1f\u8d23\u4eba\u8fdb\u884c\u5408\u89c4\u7533\u67e5\u3001\u5408\u89c4\u68c0\u67e5\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u8bf4\u6cd5\u6b63\u786e\u7684\u662f____\u3002\nA. \u5408\u89c4\u8d1f\u8d23\u4eba\u5bf9\u7533\u8bf7\u6750\u6599\u6216\u62a5\u544a\u4e2d\u7684\u57fa\u672c\u4e8b\u5b9e\u548c\u4e1a\u52a1\u6570\u636e\u7684\u771f\u5b9e\u6027\u3001\u51c6\u786e\u6027\u53ca\u5b8c\u6574\u6027\u8d1f\u8d23\u3002\nB. \u8bc1\u5238\u516c\u53f8\u4e0d\u91c7\u7eb3\u5408\u89c4\u8d1f\u8d23\u4eba\u7684\u5408\u89c4\u5ba1\u67e5\u610f\u89c1\u7684\uff0c\u5e94\u5f53\u5c06\u6709\u5173\u4e8b\u9879\u63d0\u4ea4\u80a1\u4e1c(\u5927)\u4f1a\u51b3\u5b9a\nC. \u5408\u89c4\u8d1f\u8d23\u4eba\u548c\u5408\u89c4\u90e8\u95e8\u5e94\u5f53\u5bf9\u65b0\u4ea7\u54c1\u3001\u65b0\u4e1a\u52a1\u53d1\u8868\u5408\u89c4\u5ba1\u67e5\u610f\u89c1\nD. \u5408\u89c4\u68c0\u67e5\u5305\u62ec\u4f8b\u884c\u68c0\u67e5\u4e0e\u7a81\u51fb\u68c0\u67e5\n",
        "output": "C. \u5408\u89c4\u8d1f\u8d23\u4eba\u548c\u5408\u89c4\u90e8\u95e8\u5e94\u5f53\u5bf9\u65b0\u4ea7\u54c1\u3001\u65b0\u4e1a\u52a1\u53d1\u8868\u5408\u89c4\u5ba1\u67e5\u610f\u89c1",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8bc1\u5238\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u770b\u8dcc\u671f\u6743\u548c\u770b\u6da8\u671f\u6743\u7684\u884c\u6743\u4ef7\u4e3a55\u7f8e\u5143\u4e142\u4e2a\u6708\u5230\u671f\uff0c\u552e\u4ef7\u5206\u522b\u4e3a2.65\u7f8e\u5143\u548c5.32\u7f8e\u5143\uff0c\u5982\u679c\u8be5\u80a1\u76ee\u524d\u7684\u552e\u4ef7\u4e3a57.30\u7f8e\u5143\uff0c\u8fde\u7eed\u590d\u5229\u8ba1\u7b97\u6761\u4ef6\u4e0b\u7684\u5e74\u5229\u7387\u662f\u591a\u5c11____\u3002\nA. 0.02\nB. 0.03\nC. 0.04\nD. 0.05\n",
        "output": "C. 0.04",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f8\u662f\u4e00\u5bb6\u6a21\u5177\u5236\u9020\u4f01\u4e1a\uff0c\u6b63\u5728\u5236\u5b9a\u67d0\u6a21\u5177\u7684\u6807\u51c6\u6210\u672c\u3002\u52a0\u5de5\u4e00\u4ef6\u8be5\u6a21\u5177\u9700\u8981\u7684\u5fc5\u4e0d\u53ef\u5c11\u7684\u52a0\u5de5\u64cd\u4f5c\u65f6\u95f4\u4e3a90\u5c0f\u65f6\uff0c\u8bbe\u5907\u8c03\u6574\u65f6\u95f4\u4e3a1\u5c0f\u65f6\uff0c\u5fc5\u8981\u7684\u5de5\u95f4\u4f11\u606f\u4e3a5\u5c0f\u65f6\u3002\u6b63\u5e38\u7684\u5e9f\u54c1\u7387\u4e3a4$\\%$\u3002\u8be5\u6a21\u5177\u7684\u76f4\u63a5\u4eba\u5de5\u6807\u51c6\u5de5\u65f6\u662f____\u5c0f\u65f6\u3002\nA. 93.6\nB. 96\nC. 99.84\nD. 100\n",
        "output": "D. 100",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u8bc1\u5238\u516c\u53f8\u662f\u5185\u5730\u8bc1\u5238\u57fa\u91d1\u7ecf\u8425\u673a\u6784\uff0c\u5728\u4f7f\u7528\u6e2f\u80a1\u6295\u8d44\u987e\u95ee\u670d\u52a1\u7684\u8fc7\u7a0b\u4e2d\uff0c\u4e0d\u7b26\u5408\u4e1a\u52a1\u89c4\u8303\u7684\u662f____\u3002\nA. \u7532\u8bc1\u5238\u516c\u53f8\u59d4\u6258\u63d0\u4f9b\u6e2f\u80a1\u6295\u8d44\u987e\u95ee\u670d\u52a1\u7684\u9999\u6e2f\u673a\u6784\u76f4\u63a5\u6267\u884c\u6295\u8d44\u6307\u4ee4\nB. \u7532\u8bc1\u5238\u516c\u53f8\u4e0e\u63d0\u4f9b\u6e2f\u80a1\u6295\u8d44\u987e\u95ee\u670d\u52a1\u7684\u9999\u6e2f\u673a\u6784\u7b7e\u8ba2\u534f\u8bae\nC. \u7532\u8bc1\u5238\u516c\u53f8\u5728\u62db\u52df\u8bf4\u660e\u4e66\u4e2d\u5982\u5b9e\u62ab\u9732\u4f7f\u7528\u6e2f\u80a1\u6295\u8d44\u987e\u95ee\u670d\u52a1\u7684\u60c5\u6cc1\nD. \u7532\u8bc1\u5238\u516c\u53f8\u5bf9\u4f7f\u7528\u6e2f\u80a1\u901a\u6295\u8d44\u987e\u95ee\u670d\u52a1\u7684\u60c5\u51b5\u5b9e\u884c\u7559\u75d5\u7ba1\u7406\n",
        "output": "A. \u7532\u8bc1\u5238\u516c\u53f8\u59d4\u6258\u63d0\u4f9b\u6e2f\u80a1\u6295\u8d44\u987e\u95ee\u670d\u52a1\u7684\u9999\u6e2f\u673a\u6784\u76f4\u63a5\u6267\u884c\u6295\u8d44\u6307\u4ee4",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8bc1\u5238\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5173\u4e8e\u65e0\u5f62\u8d44\u4ea7\u7684\u540e\u7eed\u8ba1\u91cf\uff0c\u4e0b\u5217\u8bf4\u6cd5\u4e2d\u6b63\u786e\u7684\u662f____\u3002\nA. \u4f7f\u7528\u5bff\u547d\u4e0d\u786e\u5b9a\u7684\u65e0\u5f62\u8d44\u4ea7\u5e94\u8be5\u6309\u7cfb\u7edf\u5408\u7406\u7684\u65b9\u6cd5\u644a\u9500\nB. \u4f7f\u7528\u5bff\u547d\u4e0d\u786e\u5b9a\u7684\u65e0\u5f62\u8d44\u4ea7\uff0c\u5e94\u630910\u5e74\u644a\u9500\nC. \u4f01\u4e1a\u65e0\u5f62\u8d44\u4ea7\u7684\u644a\u9500\u65b9\u6cd5\uff0c\u5e94\u5f53\u53cd\u6620\u4e0e\u8be5\u9879\u65e0\u5f62\u8d44\u4ea7\u6709\u5173\u7684\u7ecf\u6d4e\u5229\u76ca\u7684\u9884\u671f\u5b9e\u73b0\u65b9\u5f0f\nD. \u65e0\u5f62\u8d44\u4ea7\u7684\u644a\u9500\u65b9\u6cd5\u53ea\u6709\u76f4\u7ebf\u6cd5\n",
        "output": "C. \u4f01\u4e1a\u65e0\u5f62\u8d44\u4ea7\u7684\u644a\u9500\u65b9\u6cd5\uff0c\u5e94\u5f53\u53cd\u6620\u4e0e\u8be5\u9879\u65e0\u5f62\u8d44\u4ea7\u6709\u5173\u7684\u7ecf\u6d4e\u5229\u76ca\u7684\u9884\u671f\u5b9e\u73b0\u65b9\u5f0f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5173\u4e8e\u671f\u6743\u6295\u8d44\u7b56\u7565\u7684\u8868\u8ff0\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u4fdd\u62a4\u6027\u770b\u8dcc\u671f\u6743\u53ef\u4ee5\u9501\u5b9a\u6700\u4f4e\u51c0\u6536\u5165\u548c\u6700\u4f4e\u51c0\u635f\u76ca\uff0c\u4f46\u4e0d\u6539\u53d8\u51c0\u635f\u76ca\u7684\u9884\u671f\u503c\nB. \u629b\u8865\u770b\u6da8\u671f\u6743\u53ef\u4ee5\u9501\u5b9a\u6700\u4f4e\u51c0\u6536\u5165\u548c\u6700\u4f4e\u51c0\u635f\u76ca\uff0c\u662f\u673a\u6784\u6295\u8d44\u8005\u5e38\u7528\u7684\u6295\u8d44\u7b56\u7565\nC. \u591a\u5934\u5bf9\u6572\u7ec4\u5408\u7b56\u7565\u53ef\u4ee5\u9501\u5b9a\u6700\u4f4e\u51c0\u6536\u5165\u548c\u6700\u4f4e\u51c0\u635f\u76ca\uff0c\u5176\u6700\u574f\u7684\u7ed3\u679c\u662f\u635f\u5931\u671f\u6743\u7684\u8d2d\u4e70\u6210\u672c\nD. \u7a7a\u5934\u5bf9\u6572\u7ec4\u5408\u7b56\u7565\u53ef\u4ee5\u9501\u5b9a\u6700\u4f4e\u51c0\u6536\u5165\u548c\u6700\u4f4e\u51c0\u635f\u76ca\uff0c\u5176\u6700\u4f4e\u6536\u76ca\u662f\u51fa\u552e\u671f\u6743\u6536\u53d6\u7684\u671f\u6743\u8d39\n",
        "output": "C. \u591a\u5934\u5bf9\u6572\u7ec4\u5408\u7b56\u7565\u53ef\u4ee5\u9501\u5b9a\u6700\u4f4e\u51c0\u6536\u5165\u548c\u6700\u4f4e\u51c0\u635f\u76ca\uff0c\u5176\u6700\u574f\u7684\u7ed3\u679c\u662f\u635f\u5931\u671f\u6743\u7684\u8d2d\u4e70\u6210\u672c",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u56fd\u503a\u4f9d\u5b58\u5ea6\u662f\u6307____\u3002\nA. \u5f53\u5e74\u56fd\u503a\u53d1\u884c\u989d\u5360\u5f53\u5e74\u8d22\u653f\u6536\u5165\u7684\u6bd4\u91cd\nB. \u5f53\u5e74\u56fd\u503a\u7d2f\u8ba1\u4f59\u989d\u5360\u5f53\u5e74\u8d22\u653f\u652f\u51fa\u7684\u6bd4\u91cd\nC. \u5f53\u5e74\u56fd\u503a\u53d1\u884c\u989d\u5360\u5f53\u5e74\u8d22\u653f\u652f\u51fa\u7684\u6bd4\u91cd\nD. \u5f53\u5e74\u56fd\u503a\u7d2f\u8ba1\u4f59\u989d\u5360\u5f53\u5e74GDP\u7684\u6bd4\u91cd\n",
        "output": "C. \u5f53\u5e74\u56fd\u503a\u53d1\u884c\u989d\u5360\u5f53\u5e74\u8d22\u653f\u652f\u51fa\u7684\u6bd4\u91cd",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u653f\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u80a1\u4efd\u6709\u9650\u516c\u53f8\u4e8e2014\u5e741\u67081\u65e5\u53d1\u884c3\u5e74\u671f\uff0c\u6bcf\u5e741\u67081\u65e5\u4ed8\u606f\u3001\u5230\u671f\u4e00\u6b21\u8fd8\u672c\u7684\u516c\u53f8\u503a\u5238\uff0c\u503a\u5238\u9762\u503c\u4e3a200\u4e07\u5143\uff0c\u7968\u9762\u5e74\u5229\u7387\u4e3a5$\\%$\uff0c\u5b9e\u9645\u5229\u7387\u4e3a6$\\%$\uff0c\u53d1\u884c\u4ef7\u683c\u4e3a194.65\u4e07\u5143\u3002\u6309\u5b9e\u9645\u5229\u7387\u6cd5\u786e\u8ba4\u5229\u606f\u8d39\u7528\u3002\u8be5\u503a\u5238\u5728\u4e09\u5e74\u5185\u7d2f\u8ba1\u786e\u8ba4\u7684\u5229\u606f\u8d39\u7528\u603b\u989d\u662f____\u4e07\u5143\u3002\nA. 30\nB. 35.34\nC. 35.35\nD. 5.35\n",
        "output": "C. 35.35",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7f8e\u5f0f\u671f\u6743\u662f\u6307\u671f\u6743\u7684\u6267\u884c\u65f6\u95f4____\u3002\nA. \u53ea\u80fd\u5728\u5230\u671f\u65e5\nB. \u53ef\u4ee5\u5728\u5230\u671f\u65e5\u4e4b\u524d\u7684\u4efb\u4f55\u65f6\u5019\nC. \u53ef\u4ee5\u5728\u5230\u671f\u65e5\u6216\u5230\u671f\u65e5\u4e4b\u524d\u7684\u4efb\u4f55\u65f6\u5019\nD. \u4e0d\u80fd\u968f\u610f\u6539\u53d8\n",
        "output": "C. \u53ef\u4ee5\u5728\u5230\u671f\u65e5\u6216\u5230\u671f\u65e5\u4e4b\u524d\u7684\u4efb\u4f55\u65f6\u5019",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u56fd\u9645\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5408\u5e76\u8d22\u52a1\u62a5\u8868\u4e2d\u7684\u975e\u63a7\u5236\u6743\u76ca\u662f\u6307\u4ec0\u4e48____\u3002\nA. \u63a7\u5236\u6743\u76ca\u4e4b\u5916\u7684\u80a1\u4efd\nB. \u975e\u5168\u8d44\u5b50\u516c\u53f8\u7684\u6743\u76ca\nC. \u88ab\u5408\u5e76\u65b9\u7684\u6743\u76ca\nD. \u5408\u5e76\u540e\u4f01\u4e1a\u7684\u6743\u76ca\n",
        "output": "B. \u975e\u5168\u8d44\u5b50\u516c\u53f8\u7684\u6743\u76ca",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u9ad8\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u4e00\u4e2a\u996d\u5e97\u95e8\u53e3\u7b49\u5f85\u51fa\u79df\u8f66\u7684\u65f6\u95f4\u662f\u5de6\u504f\u7684\uff0c\u5747\u503c\u4e3a12\u5206\u949f\uff0c\u6807\u51c6\u5dee\u4e3a3\u5206\u949f\u3002\u5982\u679c\u4ece\u996d\u5e97\u95e8\u53e3\u968f\u673a\u62bd\u53d6100\u540d\u987e\u5ba2\u5e76\u8bb0\u5f55\u4ed6\u4eec\u7b49\u5f85\u51fa\u79df\u8f66\u7684\u65f6\u95f4\uff0c\u5219\u8be5\u6837\u672c\u5747\u503c\u7684\u5206\u5e03\u670d\u4ece____\u3002\nA. \u6b63\u6001\u5206\u5e03\uff0c\u5747\u503c\u4e3a12\u5206\u949f\uff0c\u6807\u51c6\u5dee\u4e3a0.3\u5206\u949f\nB. \u6b63\u6001\u5206\u5e03\uff0c\u5747\u503c\u4e3a12\u5206\u949f\uff0c\u6807\u51c6\u5dee\u4e3a3\u5206\u949f\nC. \u5de6\u504f\u5206\u5e03\uff0c\u5747\u503c\u4e3a12\u5206\u949f\uff0c\u6807\u51c6\u5dee\u4e3a3\u5206\u949f\nD. \u5de6\u504f\u5206\u5e03\uff0c\u5747\u503c\u4e3a12\u5206\u949f\uff0c\u6807\u51c6\u5dee\u4e3a0.3\u5206\u949f\n",
        "output": "A. \u6b63\u6001\u5206\u5e03\uff0c\u5747\u503c\u4e3a12\u5206\u949f\uff0c\u6807\u51c6\u5dee\u4e3a0.3\u5206\u949f",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7edf\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4f7f\u7528\u80a1\u7968\u5e02\u4ef7\u6bd4\u7387\u6a21\u578b\u8fdb\u884c\u4f01\u4e1a\u4ef7\u503c\u8bc4\u4f30\u65f6\uff0c\u901a\u5e38\u9700\u8981\u786e\u5b9a\u4e00\u4e2a\u5173\u952e\u56e0\u7d20\uff0c\u5e76\u7528\u6b64\u56e0\u7d20\u7684\u53ef\u6bd4\u4f01\u4e1a\u5e73\u5747\u503c\u5bf9\u53ef\u6bd4\u4f01\u4e1a\u7684\u5e73\u5747\u5e02\u4ef7\u6bd4\u7387\u8fdb\u884c\u4fee\u6b63\u3002\u4e0b\u5217\u8bf4\u6cd5\u4e2d\uff0c\u6b63\u786e\u7684\u662f____\u3002\nA. \u4fee\u6b63\u5e02\u76c8\u7387\u7684\u5173\u952e\u56e0\u7d20\u662f\u6bcf\u80a1\u6536\u76ca\nB. \u4fee\u6b63\u5e02\u76c8\u7387\u7684\u5173\u952e\u56e0\u7d20\u662f\u80a1\u5229\u652f\u4ed8\u7387\nC. \u4fee\u6b63\u5e02\u51c0\u7387\u7684\u5173\u952e\u56e0\u7d20\u662f\u6743\u76ca\u51c0\u5229\u7387\nD. \u4fee\u6b63\u5e02\u9500\u7387\u7684\u5173\u952e\u56e0\u7d20\u662f\u589e\u957f\u7387\n",
        "output": "C. \u4fee\u6b63\u5e02\u51c0\u7387\u7684\u5173\u952e\u56e0\u7d20\u662f\u6743\u76ca\u51c0\u5229\u7387",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5df2\u77e5\u67d0\u7ecf\u6d4e\u67d0\u4e00\u5e74\u56fd\u6c11\u6536\u51651000\u4ebf\u5143\uff0c\u51c0\u6295\u8d44\u4e3a0\uff1b\u7b2c\u4e8c\u5e74\u56fd\u6c11\u6536\u5165\u589e\u81f31200\u4ebf\u5143\uff0c\u5728\u8d44\u672c\u2014\u4ea7\u51fa\u6bd4\u7387\u7b49\u4e8e2\u7684\u6761\u4ef6\u4e0b\uff0c\u7b2c\u4e8c\u5e74\u51c0\u6295\u8d44____\u3002\nA. \u589e\u52a0200\u4ebf\u5143\nB. \u589e\u52a0400\u4ebf\u5143\nC. \u7b49\u4e8e0\nD. \u589e\u52a0100\u4ebf\u5143\n",
        "output": "B. \u589e\u52a0400\u4ebf\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u5404\u9879\u4f1a\u8ba1\u4fe1\u606f\u8d28\u91cf\u8981\u6c42\u4e2d\uff0c\u5bf9\u76f8\u5173\u6027\u548c\u53ef\u9760\u6027\u8d77\u7740\u5236\u7ea6\u4f5c\u7528\u7684\u662f____\u3002\nA. \u53ca\u65f6\u6027\nB. \u8c28\u614e\u6027\nC. \u91cd\u8981\u6027\nD. \u5b9e\u8d28\u91cd\u4e8e\u5f62\u5f0f\n",
        "output": "A. \u53ca\u65f6\u6027",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u7ea7\u8d22\u52a1\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u4fdd\u9669\u76d1\u7ba1\u56fd\u9645\u5316\u4e2d\uff0c\u4ee5\u4e0b\u54ea\u9879\u4e0d\u5c5e\u4e8e\u56fd\u9645\u76d1\u7ba1\u7ec4\u7ec7____\u3002\nA. \u56fd\u9645\u8d27\u5e01\u57fa\u91d1\u7ec4\u7ec7\nB. \u91d1\u878d\u7a33\u5b9a\u7406\u4e8b\u4f1a\nC. \u56fd\u9645\u4fdd\u9669\u76d1\u7ba1\u534f\u4f1a\nD. \u56fd\u9645\u6807\u51c6\u5316\u7ec4\u7ec7\n",
        "output": "A. \u56fd\u9645\u8d27\u5e01\u57fa\u91d1\u7ec4\u7ec7",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4fdd\u9669\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5c06\u6c47\u603b\u7684\u8d27\u5e01\u5f53\u5c40\u8d44\u4ea7\u8d1f\u503a\u8868\u4e0e\u6c47\u603b\u7684\u5b58\u6b3e\u8d27\u5e01\u673a\u6784\u7684\u8d44\u4ea7\u8d1f\u503a\u8868\u5408\u5e76\u53ef\u4ee5\u7f16\u5236\u51fa____\u3002\nA. \u8d27\u5e01\u6982\u89c8\nB. \u91d1\u878d\u6982\u89c8\nC. \u94f6\u884c\u6982\u89c8\nD. \u56fd\u9645\u6536\u652f\u5e73\u8861\u8868\n",
        "output": "A. \u8d27\u5e01\u6982\u89c8",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4e2d\u592e\u94f6\u884c\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "____\u662f\u6307\u8d44\u4ea7\u88ab\u5f81\u7528\u3001\u7a0e\u6536\u653f\u7b56\u53d8\u5316\u548c\u5916\u6c47\u4ea4\u6613\u53ef\u80fd\u53d7\u5230\u7684\u9650\u5236\u3002\nA. \u8fdd\u7ea6\u98ce\u9669\nB. \u5916\u6c47\u98ce\u9669\nC. \u5e02\u573a\u98ce\u9669\nD. \u653f\u6cbb\u98ce\u9669\n",
        "output": "D. \u653f\u6cbb\u98ce\u9669",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6295\u8d44\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u88ab\u79f0\u4e3a\u5916\u90e8\u7ecf\u6d4e\u6548\u679c\u7684\u5e02\u573a\u5931\u7075\u53d1\u751f\u5728____\u3002\nA. \u5f53\u5e02\u573a\u4e0d\u80fd\u5b8c\u5168\u51fa\u6e05\u65f6\nB. \u5f53\u7ade\u4e89\u5efa\u7acb\u5728\u81ea\u8eab\u5229\u76ca\u6700\u5927\u5316\u7684\u524d\u63d0\u4e0a\u65f6\nC. \u5f53\u5382\u5546\u8ffd\u6c42\u5229\u6da6\u6700\u5927\u5316\u76ee\u6807\u65f6\nD. \u5f53\u5e02\u573a\u4ef7\u683c\u4e0d\u80fd\u53cd\u6620\u4e00\u9879\u4ea4\u6613\u7684\u6240\u6709\u6210\u672c\u548c\u6536\u76ca\u65f6\n",
        "output": "D. \u5f53\u5e02\u573a\u4ef7\u683c\u4e0d\u80fd\u53cd\u6620\u4e00\u9879\u4ea4\u6613\u7684\u6240\u6709\u6210\u672c\u548c\u6536\u76ca\u65f6",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u67d0\u516c\u53f8\u8fdb\u53e3\u4e00\u6279\u8d27\u7269\uff0c\u6d77\u5173\u4e8e2020\u5e743\u67081\u65e5\u586b\u53d1\u7a0e\u6b3e\u7f34\u6b3e\u4e66\uff0c\u4f46\u516c\u53f8\u8fdf\u81f33\u670827\u65e5\u624d\u7f34\u7eb3500\u4e07\u5143\u7684\u5173\u7a0e\u3002\u6d77\u5173\u5e94\u5f81\u6536\u5173\u7a0e\u6ede\u7eb3\u91d1____\u3002\nA. 2.75\u4e07\u5143\nB. 3\u4e07\u5143\nC. 6.5\u4e07\u5143\nD. 6\u4e07\u5143\n",
        "output": "B. 3\u4e07\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7a0e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e00\u822c\u8bf4\u6765\uff0c\u5b9e\u9645\u5de5\u4f5c\u4e2d\u7684\u6210\u672c\u5f00\u652f\u8303\u56f4\u4e0e\u7406\u8bba\u6210\u672c\u5305\u62ec\u7684\u5185\u5bb9____\u3002\nA. \u662f\u6709\u4e00\u5b9a\u5dee\u522b\u7684\nB. \u662f\u76f8\u4e92\u4e00\u81f4\u7684\nC. \u662f\u4e0d\u76f8\u5173\u7684\nD. \u662f\u76f8\u4e92\u53ef\u4ee5\u4ee3\u66ff\u7684\n",
        "output": "A. \u662f\u6709\u4e00\u5b9a\u5dee\u522b\u7684",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u6210\u672c\u4f1a\u8ba1\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5bf9\u4e8e\u591a\u4e2a\u6295\u8d44\u7ec4\u5408\u65b9\u6848\uff0c\u5f53\u8d44\u91d1\u603b\u91cf\u53d7\u5230\u9650\u5236\u65f6\uff0c\u5e94\u5728\u8d44\u91d1\u603b\u91cf\u8303\u56f4\u5185\u9009\u62e9____\u3002\nA. \u4f7f\u7d2f\u8ba1\u51c0\u73b0\u503c\u6700\u5927\u7684\u65b9\u6848\u8fdb\u884c\u7ec4\u5408\nB. \u7d2f\u8ba1\u4f1a\u8ba1\u6536\u76ca\u6700\u5927\u7684\u65b9\u6848\u8fdb\u884c\u7ec4\u5408\nC. \u7d2f\u8ba1\u73b0\u503c\u6307\u6570\u6700\u5927\u7684\u65b9\u6848\u8fdb\u884c\u7ec4\u5408\nD. \u7d2f\u8ba1\u5185\u542b\u62a5\u916c\u7387\u6700\u5927\u7684\u65b9\u6848\u8fdb\u884c\u7ec4\u5408\n",
        "output": "A. \u4f7f\u7d2f\u8ba1\u51c0\u73b0\u503c\u6700\u5927\u7684\u65b9\u6848\u8fdb\u884c\u7ec4\u5408",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4fe1\u7528\u5361\u900f\u652f\u5229\u7387\u5b9e\u884c\u4e0a\u9650\u548c\u4e0b\u9650\u7ba1\u7406\uff0c\u900f\u652f\u5229\u7387\u4e0a\u9650____\u3002\nA. \u65e5\u5229\u7387\u4e07\u5206\u4e4b\u4e94\nB. \u65e5\u5229\u7387\u5343\u5206\u4e4b\u4e00\nC. \u6708\u5229\u7387\u4e07\u5206\u4e4b\u4e94\nD. \u6708\u5229\u7387\u5343\u5206\u4e4b\u4e00\n",
        "output": "A. \u65e5\u5229\u7387\u4e07\u5206\u4e4b\u4e94",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u793e\u4f1a\u4e3b\u4e49\u653f\u5e9c\u4ee3\u8868____\u7684\u5229\u76ca\u3002\nA. \u5168\u4f53\u4eba\u6c11\nB. \u6709\u4ea7\u8005\nC. \u65e0\u4ea7\u8005\nD. \u5b98\u5458\n",
        "output": "A. \u5168\u4f53\u4eba\u6c11",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4ee5\u4e0b\u5bfc\u81f4\u4f01\u4e1a\u6d41\u52a8\u8d44\u4ea7\u589e\u52a0\u7684\u56e0\u7d20\u4e0d\u5305\u62ec____\u3002\nA. \u5b63\u8282\u6027\u9500\u552e\u589e\u957f\nB. \u957f\u671f\u9500\u552e\u589e\u957f\nC. \u8d44\u4ea7\u6548\u7387\u4e0b\u964d\nD. \u503a\u52a1\u91cd\u6784\n",
        "output": "D. \u503a\u52a1\u91cd\u6784",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u94f6\u884c\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u77ed\u671f\u53ef\u53d8\u6210\u672c\u66f2\u7ebf\u968f\u4ea7\u91cf\u589e\u52a0\u800c____\u3002\nA. \u4e0d\u65ad\u4e0a\u5347\nB. \u4e0d\u65ad\u4e0b\u964d\nC. \u5148\u4e0a\u5347\u540e\u4e0b\u964d\nD. \u5148\u4e0b\u964d\u540e\u4e0a\u5347\n",
        "output": "A. \u4e0d\u65ad\u4e0a\u5347",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u770b\u8dcc\u671f\u6743\u57286\u4e2a\u6708\u5185\u5230\u671f\uff0c\u884c\u6743\u4ef7\u4e3a75\u7f8e\u5143\uff0c\u552e\u4ef7\u4e3a4.89\u7f8e\u5143\uff0c\u8be5\u80a1\u76ee\u524d\u7684\u552e\u4ef7\u4e3a72\u7f8e\u5143\uff0c\u65e0\u98ce\u9669\u5229\u7387\u4e3a\u5e74\u606f3.6$\\%$\uff0c\u8fde\u7eed\u590d\u5229\u8ba1\u7b97\uff0c\u5177\u6709\u76f8\u540c\u884c\u6743\u4ef7\u7684\u770b\u6da8\u671f\u6743\u662f\u4ec0\u4e48\u4ef7\u683c____\u3002\nA. 3.2\u7f8e\u5143\nB. 4.2\u7f8e\u5143\nC. 5.2\u7f8e\u5143\nD. 6.2\u7f8e\u5143\n",
        "output": "A. 3.2\u7f8e\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u67d0\u5c01\u95ed\u7ecf\u6d4e\u4e2d\uff0c\u653f\u5e9c\u53ea\u5f81\u6536\u5b9a\u91cf\u7a0e\uff0c\u4e14\u5c06\u65b0\u5f81\u7a0e\u6536100\u4ebf\u7f8e\u5143\u5168\u90e8\u7528\u4e8e\u653f\u5e9c\u652f\u51fa\u3002\u8fd9\u4e00\u4e3e\u63aa\u7684\u51c0\u6548\u5e94\u662f____\u3002\nA. \u8be5\u7ecf\u6d4e\u7684GDP\u589e\u52a0100\u4ebf\u7f8e\u5143\nB. \u8be5\u7ecf\u6d4eGDP\u589e\u52a0\u91cf\u7b49\u4e8e100\u4ebf\u7f8e\u5143\u4e58\u4ee5\u8d22\u653f\u652f\u51fa\u4e58\u6570\nC. GDP\u589e\u52a0\u7684\u540c\u65f6\uff0c\u6d88\u8d39\u589e\u52a0\uff0c\u50a8\u84c4\u589e\u52a0\nD. \u4e0d\u80fd\u5224\u65adGDP\u589e\u52a0\u7a0b\u5ea6\n",
        "output": "A. \u8be5\u7ecf\u6d4e\u7684GDP\u589e\u52a0100\u4ebf\u7f8e\u5143",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5047\u5b9a\u653f\u5e9c\u6ca1\u6709\u5b9e\u884c\u8d22\u653f\u653f\u7b56\uff0c\u56fd\u6c11\u6536\u5165\u6c34\u5e73\u7684\u63d0\u9ad8\u53ef\u80fd\u5bfc\u81f4____\u3002\nA. \u653f\u5e9c\u652f\u51fa\u589e\u52a0\nB. \u653f\u5e9c\u7a0e\u6536\u589e\u52a0\nC. \u653f\u5e9c\u7a0e\u6536\u51cf\u5c11\nD. \u653f\u5e9c\u8d22\u653f\u8d64\u5b57\u589e\u52a0\n",
        "output": "B. \u653f\u5e9c\u7a0e\u6536\u589e\u52a0",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5b8f\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u4e0b\u5217\u4e0d\u662f\u589e\u503c\u670d\u52a1\u7684\u4ef7\u503c\u7684\u662f____\nA. \u901a\u8fc7\u589e\u503c\u670d\u52a1\u80fd\u534f\u52a9\u88ab\u6295\u8d44\u4f01\u4e1a\u5b9e\u73b0\u66f4\u597d\u66f4\u5feb\u7684\u53d1\u5c55\nB. \u53ef\u4ee5\u6709\u6548\u5730\u964d\u4f4e\u6295\u8d44\u98ce\u9669\nC. \u826f\u597d\u7684\u589e\u503c\u670d\u52a1\u80fd\u591f\u589e\u52a0\u6295\u8d44\u673a\u6784\u54c1\u724c\u5185\u6db5\u548c\u4ef7\u503c\uff0c\u6210\u4e3a\u6295\u8d44\u673a\u6784\u2018\u8f6f\u5b9e\u529b\u2019,\u7684\u91cd\u8981\u4f53\u73b0\nD. \u589e\u503c\u670d\u52a1\u7684\u4ef7\u503c\u80fd\u63d0\u9ad8\u7ecf\u8425\u98ce\u9669\u7684\u63a7\u5236\uff0c\u4ece\u800c\u63d0\u5347\u88ab\u6295\u8d44\u4f01\u4e1a\u81ea\u8eab\u4ef7\u503c\uff0c\u589e\u52a0\u6295\u8d44\u6536\u76ca\n",
        "output": "D. \u589e\u503c\u670d\u52a1\u7684\u4ef7\u503c\u80fd\u63d0\u9ad8\u7ecf\u8425\u98ce\u9669\u7684\u63a7\u5236\uff0c\u4ece\u800c\u63d0\u5347\u88ab\u6295\u8d44\u4f01\u4e1a\u81ea\u8eab\u4ef7\u503c\uff0c\u589e\u52a0\u6295\u8d44\u6536\u76ca",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u57fa\u91d1\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6211\u56fd\u300a\u671f\u8d27\u548c\u884d\u751f\u54c1\u6cd5\u300b\u4e8e2022\u5e744\u670820\u65e5\u7531\u4e2d\u534e\u4eba\u6c11\u5171\u548c\u56fd\u7b2c\u5341\u4e09\u5c4a\u5168\u56fd\u4eba\u6c11\u4ee3\u8868\u5927\u4f1a\u5e38\u52a1\u59d4\u5458\u4f1a\u7b2c\u4e09\u5341\u56db\u6b21\u4f1a\u8bae\u901a\u8fc7\uff0c\u81ea____\u8d77\u65bd\u884c\u3002\nA. 2022\u5e748\u67081\u65e5\nB. 2022\u5e744\u670821\u65e5\nC. 2022\u5e748\u670810\u65e5\nD. 2022\u5e7412\u670810\u65e5\n",
        "output": "A. 2022\u5e748\u67081\u65e5",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8bc1\u5238\u4ece\u4e1a\u8d44\u683c\u8bc1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u591a\u5473\u98df\u54c1\u516c\u53f8\u957f\u671f\u4ee5\u7ecf\u8425\u8c46\u5236\u54c1\u4e3a\u4e3b\u3002\u7531\u4e8e\u50a8\u5b58\u65b9\u5f0f\u4e0d\u5f53\uff0c\u516c\u53f8\u5185\u6709\u4e00\u6279\u9ec4\u8c46\u7565\u6709\u53d1\u9709\uff0c\u4f46\u56e0\u4e3a\u8d28\u91cf\u76d1\u7ba1\u7cfb\u7edf\u4e0d\u5b8c\u5584\uff0c\u8be5\u6279\u9ec4\u8c46\u4f9d\u7136\u88ab\u5236\u6210\u8c46\u76ae\u8fdb\u884c\u9500\u552e\u3002\u8d2d\u4e70\u8005\u98df\u7528\u4e86\u8fd9\u4e9b\u8c46\u76ae\u540e\uff0c\u51fa\u73b0\u4e86\u5934\u6655\u3001\u6076\u5fc3\u7b49\u4e0d\u826f\u53cd\u5e94\uff0c\u591a\u5473\u98df\u54c1\u516c\u53f8\u4e5f\u56e0\u6b64\u9762\u4e34\u5ba2\u6237\u7684\u8d77\u8bc9\u3002\u6839\u636e\u4e0a\u8ff0\u4fe1\u606f\u5224\u65ad\uff0c\u591a\u5473\u98df\u54c1\u516c\u53f8\u9762\u4e34\u7684\u4e3b\u8981\u98ce\u9669\u6709____\u3002\nA. \u8fd0\u8425\u98ce\u9669\nB. \u5e02\u573a\u98ce\u9669\nC. \u6280\u672f\u98ce\u9669\nD. \u91d1\u878d\u98ce\u9669\n",
        "output": "A. \u8fd0\u8425\u98ce\u9669",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u516c\u53f8\u6218\u7565\u4e0e\u98ce\u9669\u7ba1\u7406\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f8\u5e73\u4ef7\u53d1\u884c5\u5e74\u671f\u7684\u516c\u53f8\u503a\u5238\uff0c\u503a\u5238\u7968\u9762\u5229\u7387\u4e3a10$\\%$\uff0c\u6bcf\u534a\u5e74\u4ed8\u606f\u4e00\u6b21\uff0c\u5230\u671f\u4e00\u6b21\u507f\u8fd8\u672c\u91d1\u3002\u8be5\u503a\u5238\u7684\u6709\u6548\u5e74\u5229\u7387\u662f____\u3002\nA. 0.1\nB. 0.1025\nC. 0.105\nD. 0.095\n",
        "output": "B. 0.1025",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u52a1\u7ba1\u7406\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5546\u4e1a\u94f6\u884c\u6700\u57fa\u672c\u7684\u804c\u80fd\u662f____\u3002\nA. \u4fe1\u7528\u4e2d\u4ecb\nB. \u652f\u4ed8\u4e2d\u4ecb\nC. \u4fe1\u7528\u521b\u9020\nD. \u8d27\u5e01\u521b\u9020\n",
        "output": "A. \u4fe1\u7528\u4e2d\u4ecb",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u91d1\u878d\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u80fd\u6839\u636e\u7ecf\u6d4e\u7684\u6ce2\u52a8\u60c5\u51b5\u81ea\u52a8\u53d1\u751f\u7a33\u5b9a\u4f5c\u7528\uff0c\u65e0\u987b\u501f\u52a9\u5916\u529b\u5c31\u53ef\u76f4\u63a5\u4ea7\u751f\u8c03\u63a7\u6548\u679c\u7684\u8d22\u653f\u653f\u7b56\u662f____\u3002\nA. \u6269\u5f20\u6027\u8d22\u653f\u653f\u7b56\nB. \u7d27\u7f29\u6027\u8d22\u653f\u653f\u7b56\nC. \u81ea\u52a8\u7a33\u5b9a\u8d22\u653f\u653f\u7b56\nD. \u76f8\u673a\u6289\u62e9\u8d22\u653f\u653f\u7b56\n",
        "output": "C. \u81ea\u52a8\u7a33\u5b9a\u8d22\u653f\u653f\u7b56",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u8d22\u653f\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u5728\u5b8c\u5168\u7ade\u4e89\u7684\u5e02\u573a\u4e2d\uff0c\u884c\u4e1a\u7684\u957f\u671f\u4f9b\u7ed9\u66f2\u7ebf\u53d6\u51b3\u4e8e____\u3002\nA. SAC\u66f2\u7ebf\u6700\u4f4e\u70b9\u7684\u8f68\u8ff9\nB. SMC\u66f2\u7ebf\u6700\u4f4e\u70b9\u7684\u8f68\u8ff9\nC. LAC\u66f2\u7ebf\u6700\u4f4e\u70b9\u7684\u8f68\u8ff9\nD. LMC\u66f2\u7ebf\u6700\u4f4e\u70b9\u7684\u8f68\u8ff9\n",
        "output": "C. LAC\u66f2\u7ebf\u6700\u4f4e\u70b9\u7684\u8f68\u8ff9",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u5fae\u89c2\u7ecf\u6d4e\u5b66\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u6839\u636e\u7269\u6743\u6cd5\u5f8b\u5236\u5ea6\u7684\u89c4\u5b9a\uff0c\u4e0b\u5217\u5404\u9879\u4e2d\uff0c\u5c5e\u4e8e\u72ec\u7acb\u7269\u6743\u7684\u662f____\u3002\nA. \u5730\u5f79\u6743\nB. \u5efa\u8bbe\u7528\u5730\u4f7f\u7528\u6743\nC. \u8d28\u6743\nD. \u62b5\u62bc\u6743\n",
        "output": "B. \u5efa\u8bbe\u7528\u5730\u4f7f\u7528\u6743",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u7ecf\u6d4e\u6cd5\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    },
    {
        "input": "\u7532\u516c\u53f8\u4e3a\u4e59\u516c\u53f8\u7684\u6bcd\u516c\u53f8\u30022014\u5e741\u67081\u65e5\uff0c\u7532\u516c\u53f8\u4ece\u96c6\u56e2\u5916\u90e8\u7528\u94f6\u884c\u5b58\u6b3e3500\u4e07\u5143\u8d2d\u5165\u4e01\u516c\u53f880$\\%$\u80a1\u6743\uff08\u5c5e\u4e8e\u975e\u540c\u4e00\u63a7\u5236\u4e0b\u63a7\u80a1\u5408\u5e76\uff09\u5e76\u80fd\u591f\u63a7\u5236\u4e01\u516c\u53f8\u7684\u8d22\u52a1\u548c\u7ecf\u8425\u653f\u7b56\uff0c\u8d2d\u4e70\u65e5\uff0c\u4e01\u516c\u53f8\u53ef\u8fa8\u8ba4\u51c0\u8d44\u4ea7\u7684\u516c\u5141\u4ef7\u503c\u4e3a4000\u4e07\u5143\uff0c\u8d26\u9762\u4ef7\u503c\u4e3a3800\u4e07\u5143\uff0c\u9664\u4e00\u9879\u5b58\u8d27\u5916\uff0c\u5176\u4ed6\u8d44\u4ea7\u3001\u8d1f\u503a\u7684\u516c\u5141\u4ef7\u503c\u4e0e\u8d26\u9762\u4ef7\u503c\u76f8\u7b49\uff0c\u8be5\u9879\u5b58\u8d27\u7684\u516c\u5141\u4ef7\u503c\u4e3a500\u4e07\u5143\uff0c\u8d26\u9762\u4ef7\u503c\u4e3a300\u4e07\u5143\u3002\u81f32015\u5e747\u67081\u65e5\uff0c\u4e01\u516c\u53f8\u5c06\u4e0a\u8ff0\u5b58\u8d27\u5bf9\u5916\u9500\u552e60$\\%$\u30022015\u5e747\u67081\u65e5\uff0c\u4e59\u516c\u53f8\u8d2d\u5165\u7532\u516c\u53f8\u6240\u6301\u6709\u7684\u4e01\u516c\u53f880$\\%$\u80a1\u6743\uff0c\u5b9e\u9645\u652f\u4ed8\u6b3e\u98793000\u4e07\u5143\uff0c\u5f62\u6210\u540c\u4e00\u63a7\u5236\u4e0b\u7684\u63a7\u80a1\u5408\u5e76\u30022014\u5e741\u67081\u65e5\u81f32015\u5e747\u67081\u65e5\uff0c\u4e01\u516c\u53f8\u5b9e\u73b0\u7684\u51c0\u5229\u6da6\u4e3a800\u4e07\u5143\uff0c\u65e0\u5176\u4ed6\u6240\u6709\u8005\u6743\u76ca\u53d8\u52a8\u3002\u52192015\u5e747\u67081\u65e5\uff0c\u4e59\u516c\u53f8\u8d2d\u5165\u4e01\u516c\u53f880$\\%$\u80a1\u6743\u7684\u521d\u59cb\u6295\u8d44\u6210\u672c\u4e3a____\u4e07\u5143\u3002\nA. 3700\nB. 3744\nC. 3680\nD. 4044\n",
        "output": "D. 4044",
        "instruction": "\u4ee5\u4e0b\u662f\u4e2d\u56fd\u5173\u4e8e\u4f1a\u8ba1\u8003\u8bd5\u7684\u5355\u9879\u9009\u62e9\u9898\uff0c\u8bf7\u9009\u51fa\u5176\u4e2d\u7684\u6b63\u786e\u7b54\u6848\u3002",
        "domain": "fin",
        "task": "cmcq"
    }
]